<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />



<title>Covid-19 trials</title>

<meta property="og:title" content="Covid-19 trials" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script src="site_libs/header-attrs-2.1/header-attrs.js"></script>
<script src="site_libs/jquery-1.12.4/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<script src="site_libs/htmlwidgets-1.5.1/htmlwidgets.js"></script>
<link href="site_libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="site_libs/datatables-binding-0.13/datatables.js"></script>
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="site_libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<script src="site_libs/jszip-1.10.20/jszip.min.js"></script>
<link href="site_libs/dt-ext-buttons-1.10.20/css/buttons.dataTables.min.css" rel="stylesheet" />
<script src="site_libs/dt-ext-buttons-1.10.20/js/dataTables.buttons.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.flash.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.html5.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.colVis.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.print.min.js"></script>
<link href="site_libs/crosstalk-1.0.0/css/crosstalk.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.0.0/js/crosstalk.min.js"></script>
<link href="site_libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="site_libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="site_libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="site_libs/selectize-0.12.0/selectize.min.js"></script>
<style type="text/css">

/*
 Dashboard CSS from Keen IO Dashboards
 (https://github.com/keen/dashboards)
*/

body {
  background: #f2f2f2;
  padding: 60px 0 0 8px; /* padding-top overridden by theme */
}

body hr {
  border-color: #d7d7d7;
  margin: 10px 0;
}

.navbar-inverse .navbar-nav > li > a,
.navbar .navbar-brand {
  text-decoration: none;
}

.navbar-logo {
  margin-top: 1px;
}

.navbar-logo img {
  margin-right: 12px;
}

.navbar-author {
  margin-left: 10px;
  font-size: 15px;
}

.navbar .dropdown-menu .fa {
  min-width: 20px;
}

.navbar .dropdown-menu {
  min-width: 150px;
  max-height: 500px;
  overflow: auto;
}

.chart-wrapper,
.nav-tabs-custom,
.sbframe-commentary
{
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  margin-bottom: 8px;
  margin-right: 8px;
}

.chart-title {
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  padding: 7px 10px 4px;
}

.chart-wrapper .chart-title:empty {
  display: none;
}

.chart-wrapper .chart-stage {
  overflow: hidden;
  padding: 5px 10px;
  position: relative;
}

.chart-wrapper .chart-notes {
  background: #fbfbfb;
  border-top: 1px solid #e2e2e2;
  color: #808080;
  font-size: 12px;
  padding: 8px 10px 5px;
}

/*
 CSS for handling flexbox layout
*/

#dashboard-container {
  visibility: hidden;
}

.tab-content>.dashboard-page-wrapper.active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.dashboard-page-wrapper {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-row-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
}

.dashboard-column-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-column {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-wrapper-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-stage-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  position: relative;
}

.chart-shim {
  position: absolute;
  left: 8px; top: 8px; right: 8px; bottom: 8px;
}

.no-padding .chart-shim {
  left: 0; top: 0; right: 0; bottom: 0;
}

.flowing-content-shim {
  overflow: auto;
  left: 0; top: 0; right: 0; bottom: 0;
  padding-left: 8px;
  padding-right: 8px;
}

.flowing-content-container {
  padding-top: 8px;
  padding-bottom: 8px;
}

.chart-stage .table-bordered {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > th,
.chart-stage .table-bordered > tfoot > tr > th,
.chart-stage .table-bordered > tbody > tr > td,
.chart-stage .table-bordered > tfoot > tr > td {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > td {
  border-top: 1px solid #dddddd;
}

.chart-stage .table-bordered > thead > tr > th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.bootstrap-table table>thead {
  background-color: #fff;
}

.bootstrap-table table.data,
.bootstrap-table table.shiny-table {
  width: inherit !important;
}

.bootstrap-table table.data>tbody>tr>th,
.bootstrap-table table.shiny-table>tbody>tr>th {
  border-top: none;
  border-bottom: 2px solid #dddddd;
  padding: 5px;
}

.bootstrap-table .data td[align=right] {
  font-family: inherit;
}

.chart-wrapper form {
  padding-left: 5px;
  padding-right: 5px;
}

.shiny-input-container label {
  font-weight: normal;
}

.chart-stage .html-widget {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .html-widget-static-bound {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .shiny-bound-output {
  width: 100% !important;
  height: 100% !important;
}

/* Omit display of empty paragraphs */

.chart-shim>p:empty {
  display: none;
}

.chart-stage>p:empty {
  display: none;
}

/* Omit display of special knitr options div*/

.chart-stage .knitr-options {
  display: none;
}

/* Automatically resizing images */

.image-container {
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  margin: 0;
}

.image-container img {
  opacity: 0;
  overflow: hidden;
}

/* Value box */

.value-box {
  border-radius: 2px;
  position: relative;
  display: block;
  margin-right: 8px;
  margin-bottom: 8px;
  box-shadow: 0 1px 1px rgba(0, 0, 0, 0.1);
}

.value-box > .inner {
  padding: 10px;
  padding-left: 20px;
  padding-right: 20px;
}

.value-box .value {
  font-size: 38px;
  font-weight: bold;
  margin: 0 0 3px 0;
  white-space: nowrap;
  padding: 0;
}

.value-box .caption {
  font-size: 15px;
}
.value-box .caption > small {
  display: block;
  font-size: 13px;
  margin-top: 5px;
}

.value-box .icon i {
  position: absolute;
  top: 15px;
  right: 15px;
  font-size: 80px;
  color: rgba(0, 0, 0, 0.15);
}

.linked-value:hover {
  cursor: pointer;
}

.value-box.linked-value:hover {
  box-shadow: 0 2px 2px rgba(0, 0, 0, 0.3);
}

/* STORYBOARD */

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
  font-size: 50px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  color: #3a3c47;
  text-align: left;
  font-size: 14px;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.storyboard-nav .sbframelist ul li.active {
  color: #fff;
  background: #B8B8B8;
}

.sbframe-commentary {
  width: 300px;
  background: #fbfbfb;
  font-size: 14px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}

/* NAV TABS */

.nav-tabs-custom > .nav-tabs {
  margin: 0;
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  border-top-right-radius: 3px;
  border-top-left-radius: 3px;
}
.nav-tabs-custom > .nav-tabs > li {
  border-top: 3px solid transparent;
  margin-bottom: -1px;
  margin-right: 5px;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  color: #666;
  font-weight: 300;
  font-size: 14px;
  border-radius: 0;
  padding: 3px 10px 5px;
  text-transform: none;
}

.nav-tabs-custom > .nav-tabs > li:not(.active) > a {
  border-bottom-color: transparent;
}

.nav-tabs-custom > .nav-tabs > li > a.text-muted {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:hover {
  background: transparent;
  margin: 0;
}
.nav-tabs-custom > .nav-tabs > li > a:hover {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:hover,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:focus,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:active {
  border-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: #3c8dbc;
}
.nav-tabs-custom > .nav-tabs > li.active > a,
.nav-tabs-custom > .nav-tabs > li.active:hover > a {
  background-color: #fff;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.active > a {
  border-top-color: transparent;
  border-left-color: #d7d7d7;
  border-right-color: #d7d7d7;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type {
  margin-left: 0;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type.active > a {
  border-left-color: transparent;
}
.nav-tabs-custom > .nav-tabs.pull-right {
  float: none !important;
}
.nav-tabs-custom > .nav-tabs.pull-right > li {
  float: right;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type {
  margin-right: 0;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type > a {
  border-left-width: 1px;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type.active > a {
  border-left-color: #d7d7d7;
  border-right-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.header {
  line-height: 35px;
  padding: 0 10px;
  font-size: 20px;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.header > .fa,
.nav-tabs-custom > .nav-tabs > li.header > .glyphicon,
.nav-tabs-custom > .nav-tabs > li.header > .ion {
  margin-right: 5px;
}
.nav-tabs-custom > .tab-content {
  background: #fff;
  padding: 0;
  border-bottom-right-radius: 3px;
  border-bottom-left-radius: 3px;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom > .tab-content > .chart-wrapper {
  background: #fff;
  border: none;
  margin: 0;
}


.nav-tabs-custom > .tab-content > .active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom .dropdown.open > a:active,
.nav-tabs-custom .dropdown.open > a:focus {
  background: transparent;
  color: #999;
}


@media (max-width: 767px) {
  .value-box {
    text-align: center;
    margin-right: 8px;
  }
  .value-box .icon {
    display: none;
  }
}

/* Fixed position sidebar */

.section.sidebar {
  position: fixed;
  top: 51px; /* overridden by theme */
  left: 0;
  bottom: 0;
  border-right: 1px solid #e2e2e2;
  background-color: white; /* overridden by theme */
  padding-left: 10px;
  padding-right: 10px;
  visibility: hidden;
  overflow: auto;
}

.section.sidebar form p:first-child {
  margin-top: 10px;
}

/* Embedded source code */

#flexdashboard-source-code {
  display: none;
}

.featherlight-content #flexdashboard-source-code {
  display: inline-block;
}

.featherlight-content {
  width: 80%;
  max-width: 800px;
  padding: 0 !important;
  border-bottom: none !important;
}

.featherlight:last-of-type {
  background: rgba(0, 0, 0, 0.7);
}

.featherlight-inner {
  width: 100%;
}

.featherlight-content pre {
  margin: 0;
  border: 0;
  background: #fff;
  font-size: 12px;
}

.unselectable {
  -ms-user-select: none;
  -webkit-user-select: none;
  -khtml-user-select: none;
  -moz-user-select: -moz-none;
  -o-user-select: none;
  user-select: none;
}

#flexdashboard-source-code code {
  -ms-user-select: text;
  -webkit-user-select: text;
  -khtml-user-select: text;
  -moz-user-select: text;
  -o-user-select: text;
  user-select: text;
}

/* DataTables Tweaks */

.dataTables_filter input[type="search"] {
  -webkit-appearance: searchfield;
  outline: none;
}

.dataTables_wrapper.no-footer
.dataTables_info {
  padding-top: 0;
}


table.dataTable thead th {
  border-bottom: 1px solid #d7d7d7;
}

.dataTables_wrapper.no-footer .dataTables_scrollBody {
  border-bottom: 1px solid #d7d7d7;
}

/* Mobile phone only CSS */

.desktop-layout div.section.mobile {
  display: none;
}

.mobile-layout div.section.no-mobile {
  display: none;
}

.mobile-figure {
  display: none;
}



body {
  padding-top: 60px;
}

.section.sidebar {
  top: 51px;
  background-color: rgba(39, 128, 227, 0.1);
}

.value-box {
  color: #f9f9f9;
}

.bg-primary {
  background-color: rgba(39, 128, 227, 0.7);
}

.storyboard-nav .sbframelist ul li.active {
  background-color: rgba(39, 128, 227, 0.7);
}

.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: rgba(39, 128, 227, 0.7);
}

.bg-info {
  background-color: rgba(153, 84, 187, 0.7);
}

.bg-warning {
  background-color: rgba(255, 117, 24, 0.7);
}

.bg-danger {
  background-color: rgba(255, 0, 57, 0.7);
}

.bg-success {
  background-color: rgba(63, 182, 24, 0.7);
}

.chart-title {
  font-weight: 500;
}

.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  font-weight: 500;
}

@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<button id="navbar-button" type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  Covid-19 trials
  <span class="navbar-author">
        </span>
</span>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.html(h1.html());
        h3.insertBefore(h1);
        h1.remove();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    $(window).on('resize', function() {
      if (_options.isMobile !== isMobilePhone() ||
          _options.isPortrait !== isPortrait()) {
        window.location.reload();
      }
    });

    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          li.append(navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target));
          menu.append(li);
        }
      } else {
        var li = $('<li></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover it's id and title, then remove it
    var h1 = wrapper.find('h1').first();
    var title = h1.html();
    h1.remove();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      menu.append(li);
    } else {
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = icon.substring(0, dashPos);
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "google-plus": "https://plus.google.com/share?url="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.html(h2.html());
      h3.insertBefore(h2);
      h2.remove();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.html(h3.html());
      h3.remove();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.html(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var navClass = "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      if (i === 0)
        li.attr('class', 'active');
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');
      if (i === 0) {
        tab.addClass('active');
        if (fade)
          tab.addClass('in');
      }

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.html();
    h3.remove();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.html(blockquote.children('p:first-child').html());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.html(caption.html());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.location.hash;
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.location.hash;
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }


  // get theme color
  var themeColors = {
    bootstrap: {
      primary: "rgba(51, 122, 183, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cerulean: {
      primary: "rgb(47, 164, 231)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    journal: {
      primary: "rgba(235, 104, 100, 0.70)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    flatly: {
      primary: "rgba(44, 62, 80, 0.70)",
      info: "rgba(52, 152, 219, 0.70)",
      success: "rgba(24, 188, 156, 0.70)",
      warning: "rgba(243, 156, 18, 0.70)",
      danger: "rgba(231, 76, 60, 0.70)"
    },
    readable: {
      primary: "rgba(69, 130, 236, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    spacelab: {
      primary: "rgba(68, 110, 155, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    united: {
      primary: "rgba(221, 72, 20, 0.30)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cosmo: {
      primary: "rgba(39, 128, 227, 0.7)",
      info: "rgba(153, 84, 187, 0.7)",
      success: "rgba(63, 182, 24, 0.7)",
      warning: "rgba(255, 117, 24, 0.7)",
      danger: "rgba(255, 0, 57, 0.7)"
    },
    lumen: {
      primary: "rgba(21, 140, 186, 0.70)",
      info: "rgba(117, 202, 235, 0.90)",
      success: "rgba(40, 182, 44, 0.70)",
      warning: "rgba(255, 133, 27, 0.70)",
      danger: "rgba(255, 65, 54, 0.70)"
    },
    paper: {
      primary: "rgba(33, 150, 243, 0.35)",
      info: "rgb(225, 190, 231)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(255, 224, 178)",
      danger: "rgb(249, 189, 187)"
    },
    sandstone: {
      primary: "rgba(50, 93, 136, 0.3)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    simplex: {
      primary: "rgba(217, 35, 15, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    yeti: {
      primary: "rgba(0, 140, 186, 0.298039)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    }
  }
  function themeColor(color) {
    return themeColors[_options.theme][color];
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage,
    themeColor: themeColor
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from anyone currently active
    $('.navbar ul.nav').find('li').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").parents('li').addClass('active');
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// datatables
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.find('.datatables');
  },
  flex: function(fillPage) {
    return fillPage;
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.html(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var components = chartIcon.split("-");
      if (components.length > 1)
        iconLib = components[0];
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // set color based on data-background if necessary
    var dataBackground = valueBox.attr('data-background');
    if (dataBackground)
      valueBox.css('background-color', bgColor);
    else {
      // default to bg-primary if no other background is specified
      if (!valueBox.hasClass('bg-primary') &&
          !valueBox.hasClass('bg-info') &&
          !valueBox.hasClass('bg-warning') &&
          !valueBox.hasClass('bg-success') &&
          !valueBox.hasClass('bg-danger')) {
        valueBox.addClass('bg-primary');
      }
    }

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // color
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        if (dataColor.indexOf('bg-') === 0) {
          valueBox.css('background-color', '');
          if (!valueBox.hasClass(dataColor)) {
             valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
             valueBox.addClass(dataColor);
          }
        } else {
          valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
          valueBox.css('background-color', dataColor);
        }
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});


</script>

<div id="dashboard-container">

<div id="column" class="section level2 sidebar">
<h2 class="sidebar">Column</h2>
<div id="ltima-atualizao" class="section level3">
<h3>ltima atualizao</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">2020-04-23 16:42</span>
<hr />
</div>
<div id="trials-na-base-americana" class="section level3">
<h3>Trials na base americana</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">795</span>
<hr />
</div>
<div id="trials-na-base-da-oms" class="section level3">
<h3>Trials na base da OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">1528</span>
</div>
<div id="trials-na-base-da-china" class="section level3">
<h3>Trials na base da China</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">666</span>
<p>Extraidos da base da OMS + busca por outros mais recentes</p>
</div>
<div id="protocolos-na-base-da-unio-europeia" class="section level3">
<h3>Protocolos na base da Unio Europeia</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">174</span>
<p>Um trial pode ter protocolos diferentes em cada pas participante</p>
</div>
</div>
<div id="column-1" class="section level2 tabset tabset-fade">
<h2 class="tabset tabset-fade">Column</h2>
<div id="drogas-eua" class="section level3">
<h3>Drogas EUA</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-ef36f25b723ea0882b20" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-ef36f25b723ea0882b20">{"x":{"filter":"none","extensions":["Buttons"],"fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21"],["outros","Hidroxicloroquina","Placebo","Azitromicina","Convencional","Ritonavir","Cloroquina","Interferon","Metilprednisolona","Remdesivir","Sarilumab","Favipiravir","xido Ntrico","Imunoglobulina","Tamiflu","bloqueadores","DAS181","Dexametasona","Ivermectina","Amoxicilina","Levofloxacina"],[260,124,84,23,22,22,17,17,11,10,10,9,8,7,7,6,6,3,3,1,1],["Deferoxamine; Tocilizumab; Clevudine; Aspirin 75mg; Clopidogrel 75mg; Rivaroxaban 2.5 MG; Atorvastatin 40mg; Omeprazole 20mg; Huaier Granule; Losartan; Dapagliflozin 10 MG; Best supportive Care (BSC) + IFX-1; Best supportive care only;  Naproxen; Traditional Chinese Medicine Prescription; TCM prescriptions; Recombinant human angiotensin-converting enzyme 2 (rhACE2); Ruxolitinib; Baricitinib; Baricitinib (janus kinase inhibitor); Tocilizumab Injection; Acalabrutinib; Umifenovir; Ciclesonide Metered Dose Inhaler [Alvesco]; Anakinra; Siltuximab; Sildenafil citrate tablets; Sargramostim; Camostat Mesilate; Etoposide; Amiodarone; Verapamil; Chlorpromazine Injection; Sirolimus; Colchicine Tablets; Treatment and prophylaxis; RhACE2 APN01; Physiological saline solution; Methotrexate; Canakinumab 150 MG/ML [Ilaris]; Saline oral/nasal rinse; 0.5% Povidone/Iodine oral/nasal rinse; 0.12% Chlorhexidine oral/nasal rinse; HCQ &amp; AZ; PUL-042 Inhalation Solution; Nitazoxanide Tablets; Suspension of heat killed (autoclaved) Mycobacterium w; Clazakizumab 12.5 mg; Clazakizumab 25 mg; Povidone-Iodine 2%; Povidone-Iodine 0.5%; Isotonic saline 0.9%; HB-adMSCs; Vazegepant (BHV-3500); Tetrandrine; Bevacizumab; Levamisole Pill + Budesonide+Formoterol inhaler; Tocilizumab (TCZ); thalidomide; Thalidomide; Tranexamic acid tablets; Indomethacin; Zithromax Oral Product; chlorine dioxide 3000 ppm; Fingolimod 0.5 mg; Defibrotide Injection; Nitazoxanide; Ruxolitinib Oral Tablet; TJ003234; Imatinib tablets; Baricitinib Oral Tablet; BCG Vaccine;  ILT101; CD24Fc; LY3127804; Oral; Carrimycin; Gimsilumab; Piclidenoson; TD-0903; Gargle/Mouthwash; Tacrolimus; 50 mg/mL Virazole; 100 mg/mL Virazole; Galidesivir; Tinzaparin or unfractionated heparin; Bevacizumab Injection; Fluvoxamine; Patients with the treatment agains COVID19; Aspirin; Simvastatin; Clazakizumab; Prednisone; Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days; Nafamostat Mesilate; Nivolumab Injection; T3 solution for injection; Eculizumab; Tranexamic acid; Hydrocortisone; Sodium Chloride 9mg/mL; Dornase Alfa Inhalation Solution [Pulmozyme]; Pyridostigmine Bromide; Convalescent Serum; Ascorbic Acid and Folic Acid; Nivolumab; BLD-2660; Almitrine; Thiazide or Thiazide-like diuretics; ACE inhibitor; Treatment with Dexmedetomidine; Ascorbic Acid; L-ascorbic acid; Colchicine; Valsartan (Diovan); Enoxaparin; Best available treatment; Anluohuaxian; Imatinib; Telmisartan; YinHu QingWen Decoction; YinHu QingWen Decoction(low dose); Measles-Mumps-Rubella Vaccine; BMS-986253; Eicosapentaenoic acid gastro-resistant capsules; Bromhexine Hydrochloride Tablets; Arbidol Hydrochloride Granules; Yinhu Qingwen Granula; Yin Hu Qing Wen Granula(low does); trimethoprim/sulfamethoxazole; Leronlimab (700mg); T89; Sevoflurane; Intravenous drug; Angiotensin 1-7; Selinexor; Control group; Emtricitabine/tenofovir disoproxil; Melatonin 2mg; Abidol hydrochloride; Linagliptin; Insulin regimen; Tofacitinib; Aviptadil by intravenous infusion + maximal intensive care; Normal Saline Infusion + Maximal intensive care; Alteplase 50 MG [Activase]; Alteplase 100 MG [Activase]; Chemotherapy; Bromhexine 8 MG; Darunavir and Cobicistat; Fixed-duration Hydrocortisone; Shock-dependent hydrocortisone; Ceftriaxone; Piperacillin-tazobactam; Ceftaroline; Macrolide administered for 3-5 days; Macrolide administered for up to 14 days; Fixed-duration higher dose Hydrocortisone; Hyperbaric oxygen; Control arm; Ruxolitinib plus simvastatin; Honey; Nigella Sativa / Black Cumin; HCQ; HCQ+AZT; N-acetylcysteine+ Fuzheng Huayu Tablet; CM4620-Injectable Emulsion; Enoxaparin Prefilled Syringe [Lovenox]; captopril 25mg; Ibuprofen; Experimental drug; thymosin alpha 1; Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells; Nitazoxanide 500 MG; Plaquenil 200Mg Tablet; Liberase Enzyme (Roche); Sterile Normal Saline for Intravenous Use; Stem Cell Product; cholecalciferol 200,000 IU; cholecalciferol 50,000 IU; Group A HCQ; Group B Control; Arbidol; Tradipitant; ACEIs; Spironolactone 100mg; Nintedanib 150 MG; Escin; RoActemra iv; RoActemra sc; Kevzara sc; INO-4800; Niclosamide; Inhaled budesonide; Mefloquine; VC; Sterile Water for Injection; Xiyanping injection; nebulised recombinant tissue-Plasminogen Activator (rt-PA); Meplazumab for Injection; Rivaroxaban; Thromboprophylaxis; Candesartan; non-RAS blocking antihypertensives; Ribavirin; Vitamin C","Hydroxychloroquine; Hydroxychloroquine sulfate; Single Dose of Hydroxychloroquine; Placebo of Hydroxychloroquine; Hydroxychloroquine - Daily dosing; Hydroxychloroquine - Weekly Dosing; Hydroxychloroquine Sulfate 400 mg twice a day; Hydroxychloroquine Sulfate 600 mg twice a day; Hydroxychloroquine Sulfate 600 mg once a day; Hydroxychloroquine Sulfate; Hydroxychloroquine (HCQ); Hidroxicloroquine; Placebo for Hydroxychloroquine; Dexamethasone and Hydroxychloroquine; Bromhexine Oral Tablet and/or hydroxychloroquine tablet; Hydroxychloroquine 200 Mg Oral Tablet; Hydroxychloroquine as post exposure prophylaxis; Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline; Hydroxychloroquine, Clindamycin; Hydroxychloroquine, Clindamycin, Primaquine - low dose.; Hydroxychloroquine, Clindamycin, Primaquine - high dose.; Hydroxychloroquine Sulfate and Folic Acid; Hydroxychloroquine Sulfate and Azithromycin; Hydroxychloroquine Sulfate (HCQ); Hydroxychloroquine - Daily Dosing; Hydroxychloroquine Sulfate Regular dose; Hydroxychloroquine Sulfate Loading Dose; Low-dose chloroquine/hydroxychloroquine; Mid dose chloroquine or hydroxychloroquine; High does chloroquine or hydroxychloroquine; hydroxychloroquine sulfate 200 MG; Chloroquine or Hydroxychloroquine; Hydroxychloroquine Pre-Exposure Prophylaxis; hydroxychloroquine; hydroxychloroquine placebo; Hidroxicloroquina; Placebo: Hydroxychloroquine; Hydroxychloroquine + lopinavir/ritonavir; Hydroxychloroquine and azithromycin treatment arm.; Hydroxychloroquine Sulfate 200 milligram (mg) Tab; Hydroxychloroquine + placebo; hydroxychloroquine + azithromycin; Hydroxychloroquine + Azithromycin; Hydroxychloroquine + Placebo; Hydroxychloroquine SAR321068; Hydroxychloroquine Oral Product; Hydroxychloroquine + azithromycin; hydroxychloroquine in combination with camostat mesylate; Hydroxychloroquine in combination of Azithromycin","Placebo; Placebo of LPV/r Tablets; Placebo oral tablet; Placebos; placebo; Remdesivir placebo;  Placebo Comparator; Placebo 250 cc 24 hours continuous infusion for 15 days; Placebo: Emtricitabine/tenofovir disoproxil Placebo; N-acetylcysteine+Placebo; Placebo solution; placebo for clazakizumab","Azithromycin; Azithromycin Tablets; Azithromycin (Azithro); Placebo for Azithromycin; Atovaquone/Azithromycin; Azithromycin 500Mg Oral Tablet; azithromycin"," Standard of care; Standards of Care; Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.; Standard of Care; Standard therapy of COVID-19; Standard of care therapy; basic treatment; Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment; Standard treatment; Standard therapy for COVID-19 according to the stablished hospital protocols.;  Usual practice + SYMBICORT RAPIHALER; PD-1 blocking antibody+standard treatment; Thymosin+standard treatment; Conventional treatment; standard therapy; Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules; Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Lopinavir/ritonavir; Lopinavir / Ritonavir; Lopinavir and ritonavir; Danoprevir+Ritonavir; Ganovo+ritonavir+/-Interferon nebulization; Lopinavir / ritonavir tablets combined with Xiyanping injection; Lopinavir/ritonavir treatment; lopinavir/ritonavir; ASC09/ritonavir group; lopinavir/ritonavir group; Lopinavir / ritonavir, alpha-interferon nebulization; Lopinavir/Ritonavir","chloroquine; Lopinavir/Ritonavir + hydoxychloroquine; Chloroquine phosphate; lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate; Chloroquine; UNIKINON (Chloroquine phosphate) 200mg tablets; Chloroquine analog (GNS651); Chloroquine Diphosphate; Chloroquine diphosphate; Chloroquine Sulfate","Interferon Beta-1A; Interferon Beta-1B; Interferon- 1a; Peginterferon Lambda-1a; Pegylated interferon lambda; Interferon-Alpha2B; Recombinant Human Interferon 2b Spray; Peginterferon lambda alfa-1a subcutaneous injection; Abidol Hydrochloride combined with Interferon atomization; Interferon-1a; Peginterferon Lambda-1A; Recombinant human interferon 1; recombinant human interferon Alpha-1b","Methylprednisolone; methylprednisolone therapy; MethylPREDNISolone 80 Mg/mL Injectable Suspension; Methylprednisolone Sodium Succinate","Remdesivir","Sarilumab (anti-IL-6 receptor); Sarilumab; Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]; Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]; Sarilumab SAR153191","Favipiravir; favipiravir; Favipiravir Combined With Tocilizumab","Nitric Oxide Gas; Nitric Oxide; Inhaled nitric oxide gas; NORS (Nitric Oxide Releasing Solution); Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Transfusion of COVID-19 convalescent plasma; Human immunoglobulin; Plasma; Intravenous Immunoglobulin; Immunoglobulin of cured patients; -Globulin","Oseltamivir; ASC09F+Oseltamivir; Ritonavir+Oseltamivir; Five-days oseltamivir; Ten-days oseltamivir","Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB); ACE inhibitor, angiotensin receptor blocker; Calcium Channel Blockers; Angiotensin receptor blocker;  discontinuation of RAS blocker therapy;  continuation of RAS blocker therapy","DAS181; DAS181 COVID-19; DAS181 OL","Dexamethasone; Dexamethasone injection","Ivermectine; Ivermectin","Amoxicillin-clavulanate","Moxifloxacin or Levofloxacin"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Nome padronizado<\/th>\n      <th>freq<\/th>\n      <th>Nomes originais<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="nomes-de-substncias-ue" class="section level3">
<h3>Nomes de substncias UE</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-632ec3cd2e45c92f303f" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-632ec3cd2e45c92f303f">{"x":{"filter":"none","extensions":["Buttons"],"fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140"],["remdesivir","risankizumab","tocilizumab","hydroxychloroquine","hydroxychloroquine sulfate","lopinavir","azithromycin","hydrocortisone","ritonavir","sarilumab","clarithromycin","potassium clavulanate","anakinra","ceftriaxone","interferon beta-1a","piperacillin","ceftaroline fosamil","oseltamivir","roxithromycin","amoxicillin ","azithromycin monohydrate","tazobactam ","azithromycin dihydrate","chloroquine","dexamethasone","erythromycin ","levofloxacin ","moxifloxacin ","azithromycine","ixazomib citrate","lenalidomide","levofloxacin hemihydrate","moxifloxacin hydrochloride","amoxicillin sodium","apn01 / gsk2586881","baricitinib","bcg vaccine (bcg-vaccin ssi [nederlands vaccinstatens serum instituut]) danish strain 1331.","budesonide","chloroquine phosphate","ciclosporin","colchicine","darunavir","erythromycin lactobionate","imatinib","levofloxacin","methylprednisolone","moxifloxacin","nitric oxide","plaquenil","prednisone","remdesivir (active drug triphosphate)","ruxolitinib","siltuximab","tazobactam sodium","telmisartan","-","allogeneic adipose-derived mesenchymal stromal cells in vitro expanded","alteplase","amoxicillin","antimicrobial therapy (antibiotics)","antithrombin iii","azitromicina cinfa 500 mg comprimidos","azitrox","bevacizumab","bnt162a1","bnt162b1","bnt162b2","bnt162c2","camostat mesilate","candesartan","ceftaroline fosamil acetic acid solvate monohydrate ","ceftriaxone sodium ","clulas mesenquimales troncales adultas alognicas de mdula sea expandidas mediante procedimiento ibgm","chloroquine difosfato","circadin","clairyg 50mg/ml, solution for infusion","cobicistat","colchicina","curcumin","defibrotide","dolquine","dolquine 200 mg comprimidos recubiertos.","emtricitabine","erythromycin","favipiravir","for example \"gefrorenes frischplasma / apherese drk blutspendedienst\"","formoterol","hcr040","healing water","hydrocortisone sodium succinate","hydroxychloroquine sulfate 200 mg ","hydroxychloroquine sulphate","ibuprofen","imatinib mesilate","interferon beta-1b","itraconazole","kaletra","kevzara ","kineret 100 mg/0,67 ml (anakinra)","lopinavir/ritonavir","medicinal oxygen","mefloquine","metilprednisolona (como succinato de sodio)","naproxen","nivolumab","not available","olumiant 2mg (baricitinib)","osteltamivir","paracetamol","pembrolizumab","plaquenil","plaquenil 200 mg, comprim pellicul","prednisolone","propofol","pulmozyme 2500 u/2,5ml, solution pour inhalation par nbuliseur","quensyl","rebif","rivaroxaban","roactemra","roactemra 20mg/ml, 20 ml","sargramostim","secukinumab","selinexor","senicapoc","sevoflurane","simvastatin","sodium amoxicillin","soliris 300 mg (eculizumab)","solnatide","spironolactone","sulfamethoxazole and trimethoprim","sulfate d'hydroxychloroquine","tacrolimus","tazobactam","tenofovir disoproxil fumarate","valsartan","zithromax 250 mg","zithromax 250 mg, comprim pellicul","zymad 200 000 ui","zymad 50 000 ui"],[21,21,19,18,13,12,11,10,10,10,9,9,8,8,8,8,6,6,6,5,5,5,4,4,4,4,4,4,3,3,3,3,3,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>substance_name<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados-eua" class="section level3">
<h3>Dados EUA</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-e20e7993bb8cb6450d63" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-e20e7993bb8cb6450d63">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"1\" data-max=\"795\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"0\" data-max=\"10000000\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","extensions":["Buttons"],"fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621","622","623","624","625","626","627","628","629","630","631","632","633","634","635","636","637","638","639","640","641","642","643","644","645","646","647","648","649","650","651","652","653","654","655","656","657","658","659","660","661","662","663","664","665","666","667","668","669","670","671","672","673","674","675","676","677","678","679","680","681","682","683","684","685","686","687","688","689","690","691","692","693","694","695","696","697","698","699","700","701","702","703","704","705","706","707","708","709","710","711","712","713","714","715","716","717","718","719","720","721","722","723","724","725","726","727","728","729","730","731","732","733","734","735","736","737","738","739","740","741","742","743","744","745","746","747","748","749","750","751","752","753","754","755","756","757","758","759","760","761","762","763","764","765","766","767","768","769","770","771","772","773","774","775","776","777","778","779","780","781","782","783","784","785","786","787","788","789","790","791","792","793","794","795"],[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770,771,772,773,774,775,776,777,778,779,780,781,782,783,784,785,786,787,788,789,790,791,792,793,794,795],["NCT04333550","NCT04336904","NCT04351802","NCT04354831","NCT04345445","NCT04331509","NCT04355741","NCT04347915","NCT04343183","NCT04342637","NCT04333407","NCT04291053","NCT04336462","NCT04324489","NCT04347993","NCT04323228","NCT04335123","NCT04350593","NCT04333420","NCT04342689","NCT04343755","NCT04329611","NCT04321421","NCT04352582","NCT04325633","NCT04351659","NCT04323332","NCT04344015","NCT04352348","NCT04339660","NCT04306497","NCT04354857","NCT04354389","NCT04287686","NCT04344145","NCT04355338","NCT04324996","NCT04348071","NCT04340232","NCT04321993","NCT04355793","NCT04343768","NCT04329832","NCT04252118","NCT04317092","NCT04348396","NCT04346199","NCT04331171","NCT04354714","NCT04350671","NCT04350684","NCT04344587","NCT04330586","NCT04348656","NCT04350073","NCT04275947","NCT04328285","NCT04331899","NCT04337996","NCT04315298","NCT04352933","NCT04337762","NCT04330638","NCT04348942","NCT04343690","NCT04343677","NCT04332081","NCT04304313","NCT04326920","NCT04353284","NCT04337541","NCT04355936","NCT04338347","NCT04348422","NCT04356690","NCT04351763","NCT04354805","NCT04340544","NCT04334512","NCT04327674","NCT04341675","NCT04329923","NCT04330690","NCT04355143","NCT04318418","NCT04333628","NCT04330599","NCT04285801","NCT04351646","NCT04304053","NCT04333355","NCT04351620","NCT04319315","NCT04334382","NCT04357990","NCT04335136","NCT04331366","NCT04331795","NCT04333225","NCT04344444","NCT04344080","NCT04352465","NCT04348448","NCT04357535","NCT04344236","NCT04354597","NCT04307693","NCT04345692","NCT04323631","NCT04331834","NCT04336254","NCT04313023","NCT04332094","NCT04292899","NCT04312997","NCT04334980","NCT04348409","NCT04353518","NCT04343989","NCT04347954","NCT04348435","NCT04329572","NCT04292730","NCT04341506","NCT04345523","NCT04341168","NCT04345510","NCT04347850","NCT04344171","NCT04313322","NCT04346615","NCT04336956","NCT04347369","NCT04308317","NCT04346355","NCT04305106","NCT04315987","NCT04329650","NCT04331470","NCT04244591","NCT04320615","NCT04344925","NCT04273529","NCT04354870","NCT04273581","NCT04312464","NCT04339608","NCT04356560","NCT04353596","NCT04342221","NCT04347070","NCT04345679","NCT04355767","NCT04352608","NCT04338074","NCT04346017","NCT04344457","NCT04343742","NCT04345536","NCT04342182","NCT04325061","NCT04347174","NCT04315896","NCT04331600","NCT04280588","NCT04335201","NCT04350476","NCT04341389","NCT04346056","NCT04343248","NCT04329559","NCT04318301","NCT04355507","NCT04332107","NCT04337359","NCT04273646","NCT04355871","NCT04349241","NCT04345991","NCT04331106","NCT04334044","NCT04341116","NCT04346147","NCT04343781","NCT04252664","NCT04351152","NCT04328441","NCT04350931","NCT04346043","NCT04328493","NCT04348240","NCT04358068","NCT04347889","NCT04330521","NCT04348214","NCT04332913","NCT04357444","NCT04336332","NCT04344977","NCT04317040","NCT04356417","NCT04347876","NCT04351529","NCT04342897","NCT04338932","NCT04354701","NCT04346368","NCT04334005","NCT04353323","NCT04313127","NCT04288102","NCT04303299","NCT04286503","NCT04336657","NCT04329507","NCT04355533","NCT04351581","NCT04351243","NCT04339816","NCT04347980","NCT04343339","NCT04333472","NCT04350736","NCT04357808","NCT04293692","NCT04345315","NCT04344431","NCT04345276","NCT04291729","NCT04353336","NCT04341688","NCT04355247","NCT04353674","NCT04338828","NCT04335305","NCT04353180","NCT04273321","NCT04347538","NCT04355026","NCT04338360","NCT04355715","NCT04343976","NCT04341142","NCT04349631","NCT04334252","NCT04339426","NCT04353206","NCT04354584","NCT04343794","NCT04341103","NCT04341285","NCT04331665","NCT04352491","NCT04318444","NCT04344730","NCT04357574","NCT04352751","NCT04318015","NCT04341038","NCT04356677","NCT04350320","NCT04328272","NCT04352764","NCT04327531","NCT04348474","NCT04338568","NCT04350580","NCT03891420","NCT04336774","NCT04349202","NCT04323345","NCT04348877","NCT04355897","NCT04344756","NCT04344782","NCT04357327","NCT04335019","NCT04342663","NCT04354519","NCT04347278","NCT04351711","NCT04343001","NCT04348500","NCT04344288","NCT04356534","NCT04348383","NCT04334291","NCT04323644","NCT04341870","NCT04352400","NCT04352842","NCT04344951","NCT04358029","NCT04261517","NCT04251767","NCT04330144","NCT04347824","NCT04347681","NCT04354753","NCT04343144","NCT04348513","NCT04299724","NCT04342104","NCT04356586","NCT04346264","NCT04346797","NCT04338958","NCT04347928","NCT04257656","NCT04338126","NCT04343092","NCT04298814","NCT04335097","NCT04324190","NCT04354610","NCT04334850","NCT04348305","NCT04335071","NCT04355364","NCT04349540","NCT04333693","NCT04352803","NCT04276896","NCT04353011","NCT04351633","NCT04343963","NCT04349410","NCT04354428","NCT04351490","NCT04341415","NCT04333862","NCT04333953","NCT04358042","NCT04322188","NCT04323514","NCT04345653","NCT04304690","NCT04342195","NCT04356508","NCT04356937","NCT04316299","NCT04341207","NCT04336345","NCT04318431","NCT04329546","NCT04353271","NCT04344002","NCT04334460","NCT04355351","NCT04351919","NCT04341441","NCT04333914","NCT04357457","NCT04355494","NCT04344938","NCT04320017","NCT04336384","NCT04352959","NCT04357834","NCT04330300","NCT04350086","NCT04351191","NCT04347694","NCT04331574","NCT04321265","NCT04328961","NCT04357782","NCT04327206","NCT04333732","NCT04326790","NCT04345601","NCT04339712","NCT04331054","NCT04292964","NCT04344184","NCT04338698","NCT04337346","NCT04325646","NCT04346212","NCT04335786","NCT04342806","NCT04345848","NCT04335552","NCT04337320","NCT04357860","NCT04357106","NCT04341792","NCT04338009","NCT04334265","NCT04334148","NCT04333589","NCT04328480","NCT04311398","NCT04310228","NCT04302519","NCT04295551","NCT04356495","NCT04346667","NCT04278963","NCT04351854","NCT04357028","NCT04354441","NCT04303507","NCT04347941","NCT04347226","NCT04356482","NCT04328012","NCT04320472","NCT04272710","NCT04357418","NCT04335032","NCT04273763","NCT04352946","NCT04355611","NCT04331613","NCT04346810","NCT04310865","NCT04351789","NCT04351399","NCT04324021","NCT04344600","NCT04319445","NCT04357496","NCT04339998","NCT04323761","NCT04350450","NCT04319731","NCT04334967","NCT04321928","NCT04355481","NCT04342884","NCT04357366","NCT04349982","NCT04341766","NCT04336215","NCT04270383","NCT04298060","NCT04355728","NCT04348864","NCT04334954","NCT04332991","NCT04357275","NCT04340050","NCT04320511","NCT04352517","NCT04324528","NCT04336787","NCT04343651","NCT04285190","NCT04324606","NCT04325048","NCT04323878","NCT04356950","NCT04358003","NCT04351503","NCT04356443","NCT04344379","NCT04355962","NCT04354818","NCT04347239","NCT04349618","NCT04323800","NCT04321096","NCT04351139","NCT04332380","NCT04332666","NCT04268537","NCT04349098","NCT04330495","NCT04325412","NCT04339881","NCT04334928","NCT04355676","NCT04357639","NCT04346277","NCT04353128","NCT04329533","NCT04323787","NCT04332835","NCT04334876","NCT04352556","NCT04306705","NCT04337424","NCT04312100","NCT04312009","NCT04313946","NCT04315948","NCT04323839","NCT04311177","NCT04335084","NCT04353609","NCT04337788","NCT04261426","NCT04350099","NCT04332016","NCT04255017","NCT04354779","NCT04254874","NCT04340466","NCT04316949","NCT04348929","NCT04275414","NCT04357340","NCT04341935","NCT04339387","NCT04343053","NCT04261270","NCT04342169","NCT04357938","NCT04332042","NCT04353401","NCT04329195","NCT04316728","NCT04321616","NCT04311697","NCT04327349","NCT04357730","NCT04328129","NCT04263402","NCT04343261","NCT04341480","NCT04340349","NCT04252274","NCT02735707","NCT04327505","NCT03042143","NCT04256395","NCT04325919","NCT04345159","NCT04324866","NCT04305457","NCT04324463","NCT04347512","NCT04333368","NCT04327570","NCT04320277","NCT04348695","NCT04354259","NCT04339322","NCT04325867","NCT04342156","NCT04352634","NCT04347382","NCT04358081","NCT04355442","NCT04338100","NCT04349228","NCT04342650","NCT04339790","NCT04327401","NCT04356378","NCT04279197","NCT04284046","NCT04280705","NCT04345861","NCT04345614","NCT04349592","NCT04344210","NCT04322487","NCT04321174","NCT04318314","NCT04323592","NCT04354155","NCT04335747","NCT04335188","NCT04335773","NCT04355429","NCT04334629","NCT04354558","NCT04340219","NCT04357431","NCT04356885","NCT04264858","NCT04321811","NCT04339634","NCT04348227","NCT04344249","NCT04353583","NCT04351295","NCT04357769","NCT04337502","NCT04326452","NCT04356365","NCT04335162","NCT04312243","NCT04335279","NCT04322565","NCT04344197","NCT04357041","NCT04355624","NCT04341012","NCT04337047","NCT04306055","NCT04351516","NCT04357613","NCT04320732","NCT04340414","NCT04337008","NCT04331886","NCT04293887","NCT04340921","NCT04333654","NCT04320238","NCT04338945","NCT04346420","NCT04337489","NCT04296643","NCT04343898","NCT04351347","NCT04346342","NCT04319016","NCT04344561","NCT04346186","NCT04302688","NCT04316884","NCT04347408","NCT04357314","NCT04333849","NCT04348461","NCT04279899","NCT04290871","NCT04092478","NCT04337151","NCT03808922","NCT04341493","NCT04315480","NCT04340479","NCT04328454","NCT04346446","NCT04327804","NCT04345640","NCT04325906","NCT04344964","NCT04327388","NCT04346628","NCT04344535","NCT04338906","NCT04325893","NCT04326725","NCT04341714","NCT04321369","NCT04292340","NCT04346082","NCT04326114","NCT04326387","NCT04322123","NCT04346953","NCT04324047","NCT04346589","NCT04315870","NCT04342702","NCT04351906","NCT04337918","NCT04326036","NCT04344548","NCT04322396","NCT04346693","NCT04341610","NCT04352699","NCT04341519","NCT04274322","NCT04324073","NCT04343664","NCT04344041","NCT04345289","NCT04321278","NCT04353037","NCT04344912","NCT04320056","NCT04260594","NCT04314232","NCT04336748","NCT04330261","NCT04347460","NCT04326426","NCT04327180","NCT04338672","NCT04357847","NCT04345406","NCT04341922","NCT04334434","NCT04320862","NCT04355884","NCT04345549","NCT04344834","NCT04290858","NCT04324736","NCT04283461","NCT04344327","NCT04346160","NCT04354766","NCT04354792","NCT04355702","NCT04280224","NCT04290780","NCT04288713","NCT04343404","NCT04322513","NCT04318366","NCT04345887","NCT04320953","NCT04338802","NCT04299152","NCT04308187","NCT04322344","NCT04306393","NCT04322773","NCT04324684","NCT04337983","NCT04346329","NCT04336410","NCT04345419","NCT04354272","NCT04336761","NCT04355637","NCT04322786","NCT04351542","NCT04344119","NCT04342208","NCT04347798","NCT04344106","NCT04352985","NCT04349371","NCT04327479","NCT04305574","NCT04347031","NCT04279795","NCT04279782","NCT04350281","NCT04355234","NCT04343729","NCT04341584","NCT04292327","NCT04340557","NCT04269525","NCT04261907","NCT04325672","NCT04326075","NCT04337190","NCT04061382","NCT04264533","NCT04338841","NCT04323527","NCT04349163","NCT04275388","NCT04348370","NCT04302766","NCT04342728","NCT04245631","NCT04350710","NCT03331445","NCT04322682","NCT04335630","NCT04255940","NCT04281693","NCT04356833","NCT04344509","NCT04259892","NCT04251871","NCT04260308","NCT04275245","NCT04307459","NCT04322279","NCT04339686","NCT04355052","NCT04341727","NCT04335851","NCT04346927","NCT04319211","NCT04331808","NCT04353154","NCT04328467","NCT04351724","NCT04353245","NCT04280913","NCT04333251","NCT04357886","NCT04353141","NCT03852537","NCT04333875","NCT04316377","NCT04276688","NCT04356144","NCT04346940","NCT04319172","NCT03680274","NCT04326309","NCT04346966","NCT04308668","NCT04351880","NCT04262921","NCT04329897","NCT04346979","NCT04339842","NCT04276987"],["Application of Desferal to Treat COVID-19","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","COVID-19 Symptom Tracker","Gut Microbiota, \"Spark and Flame\" of COVID-19 Disease","The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","COVID-19 Endoscopy Survey","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","DAS181 for Severe COVID-19: Compassionate Use","A Prospective \"Universal\" Observational Database for COVID-19","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","Study of Open Label Losartan in COVID-19","Dapagliflozin in Respiratory Failure in Patients With COVID-19","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","The Role of Resistant Potato Starch in COVID-19 Infection","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","Hyperimmune Plasma for Critical Patients With COVID-19","COVID-19 and Vaccination Attitudes","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","Traditional Chinese Medicine for Severe COVID-19","COVID-19 Plasma Collection","Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection","DAS181 for STOP COVID-19","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population","Assessment of Seroprevalence and Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19","Safety and Efficacy of Ruxolitinib for COVID-19","Safety and Efficacy of Baricitinib for COVID-19","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","Clinical and Biological Predictors of COVID-19 Disease in Older Patients","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus)","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","Ruxolitinib to Combat COVID-19","Interferon Beta 1a in Hospitalized COVID-19 Patients","Umifenovir in Hospitalized COVID-19 Patients","COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning","A Trial of Ciclesonide in Adults With Mild COVID-19","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","The COVID-19 Mobile Health Study (CMHS)","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","Mild COVID-19 Peginterferon Lambda","Dynamic Evaluation of COVID-19 Diagnostic Tests","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","PROLIFIC ChemoprophylaxisTrial (COVID-19)","Beat COVID-19 - Observational Trial","Treatment of COVID-19 Patients With Anti-interleukin Drugs","A COVID-19 Symptom, Exposure and Immune Response Registry","COPING With COVID-19( CWC-19)","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","Hyperbaric Oxygen for COVID-19 Patients","A Pilot Study of Sildenafil in COVID-19","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","Camostat Mesylate in COVID-19 Outpatients","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","Telmisartan for Treatment of COVID-19 Patients","CAP-1002 in Severe COVID-19 Disease","Evaluating the Immune Response for COVID-19","Etoposide in Patients With COVID-19 Infection","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","Administration of Chloropromazine as a Treatment for COVID-19","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","A Study of Quintuple Therapy to Treat COVID-19 Infection","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","Colchicine to Reduce Myocardial Injury in COVID-19 (COLHEART-19)","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19","Longitudinal Population-based Observational Study of COVID-19 in the UK Population","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","Safety in Convalescent Plasma Transfusion to COVID-19","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19","Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19","Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","Non-contact ECG Sensor System for COVID19","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","Testing for COVID-19 Infection in Asymptomatic Persons","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","CovidDB: The Covid-19 Inpatient Database","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","Covid-19 Pediatric Observatory","A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease","Tetrandrine Tablets Used in the Treatment of COVID-19","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","COVID-19 PrEP HCW HCQ Study","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","Myocardial Damage in COVID-19","Max COVID19- Study","COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department","Stopping ACE-inhibitors in COVID-19","Hydroxychloroquine for COVID-19","Implementation of Physiotherapy on COVID-19 Patients in ICU","Anti COVID-19 Convalescent Plasma Therapy","Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19","Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19)","TXA and Corona Virus 2019 (COVID19) in Outpatients","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020","Fingolimod in COVID-19","Defibrotide in COVID-19 Pneumonia","COVID-19 Remote Monitoring","A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","Hypertension in Patients Hospitalized With COVID-19","Computed Tomography for COVID-19 Diagnosis","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain","Efficacy and Safety of Favipiravir in Management of COVID-19","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","Survey of the Anxiety Associated With the COVID-19 Pandemic","Treatment of SARS Caused by COVID-19 With Ruxolitinib","Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","A Trial of Remdesivir in Adults With Mild and Moderate COVID-19","Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database","The Vietnam Chloroquine Treatment on COVID-19","Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions","Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT","Impact of the Coronavirus (COVID-19) on Patients With Cancer","Screening &amp; Risk Assessment of Healthcare Workers &amp; Infection Control in University &amp; COVID-19 Quarantine Hospitals","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","COVID-19 Plasma Collection","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse","Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?","Austrian COVID-19 Registry","A Study of LY3127804 in Participants With COVID-19","COVID-19 and Deep Venous Thrombosis","COVID-19 and Cancer Consortium Registry","Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)","Vitamin D on Prevention and Treatment of COVID-19","COVID 19-Caregivers IGg Seroconversion","Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","The Clinical Study of Carrimycin on Treatment Patients With COVID-19","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","Immunity Against SARS-CoV2 in Children and Their Parents","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","A Study to Assess the Efficacy and Safety of of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment","Piclidenoson for Treatment of COVID-19","First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Evaluation of Ganovo Danoprevir  Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Efficacay of Chloroquine in COVID-19 Treatment","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients","Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm","Modulation of Hyperinflammation in COVID-19","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","Checkpoint Blockade in COVID-19 Pandemic","Assessment the Activity Value of Retinoic Acid in the Treatment of COVID-19","Efficacy and Safety of Corticosteroids in COVID-19","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","Combinaison of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia","Pegylated Interferon Lambda Treatment for COVID-19","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection","Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia","An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia","Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury","Study to Evaluate the Safety and Efficacy of VIRAZOLE in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19","Randomized Open-blind Controlled Trial to Study the Benefit of Colchicine in Patients With COVID-19","Effectiveness of Hydroxychloroquine in Covid-19 Patients","ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19","Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study","IgIV in COVID-19 Related ARds","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19","CAPTION AI to Minimize Risk of COVID Exposure","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","Plasma Rich Antibodies From Recovered Patients From COVID19","CoVID-19 Plasma in Treatment of COVID-19 Patients","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin/Zeribev) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","The United Kingdom Multiple Sclerosis Register Covid-19 Substudy","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","Immunological Profiling of Patients With COVID-19 in Respiratory Distress","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","Convalescent Plasma Trial in COVID -19 Patients","Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.","International COVID19 Clinical Evaluation Registry,","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)","Echocardiographic Manifestation in Patient With Coronavirus Disease 2019 (COVID-19)","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","Predict Adverse Events by Covid-19 Nephritis","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","AiM COVID for Covid 19 Tracking and Prediction","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection","Safety and Immunity of Covid-19 aAPC Vaccine","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms","CoVid-19 - Infection and Antibody Formation in the Viennese Population","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","A Trial of Remdesivir in Adults With Severe COVID-19","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","DIgital Online SuPport for COVID-19 StrEss","Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","Hydrocortisone for COVID-19 and Severe Hypoxia","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)","Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak","Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak","Pyridostigmine in Severe SARS-CoV-2 Infection","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","Treatment for SARS-CoV-2 in High-Risk Adult Outpatients","Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","COVID-19 in Patients With HIV","PSYCHIATRIC Disorders and Covid-19","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","Use of Ascorbic Acid in Patients With COVID 19","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers","COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Acquiring Convalescent Specimens for COVID-19 Antibodies","COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1","Efficacy of Tocilizumab on Patients With COVID-19","Acute Kidney Injury in Patients Hospitalized With COVID-19","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","Outcomes of Patients With COVID-19 in the Intensive Care Unit","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","Understanding COVID-19","Trial of Hydroxychloroquine In Covid-19 Kinetics","LunG canceR pAtients coVId19 Disease (GRAVID)","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects","Study of Immune Response During SARS-CoV-2 Infection","Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)","Will Hydroxychloroquine Impede or Prevent COVID-19","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia","SOLIRIS (Eculizumab) Treatment of Participants With COVID-19","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality","Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19","Impact of Covid-19 in Congenital Heart Disease","COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses","WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories","Coronavirus (COVID-19) ACEi/ARB Investigation","Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.","Renin-Angiotensin System Inhibitors and COVID-19","Outcomes and Prognostic Factors in COVID-19","Hydroxychloroquine for COVID-19 PEP","Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation","BCG Vaccination to Protect Healthcare Workers Against COVID-19","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)","Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","Protective Role of Inhaled Steroids for Covid-19 Infection","Prognostic Factors of Patients With COVID-19","Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","Evaluation of Covid 19 Anxiety in Endometriosis Patients","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Oropharyngeal Dysphagia in Patients With COVID-19","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns","Clinical Trial of Sarilumab in Adults With COVID-19","COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","The ECLA PHRI COLCOVID Trial","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)","Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19","Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room","Measles Vaccine in HCW","Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19","CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","Acute Encephalopathy in Critically Ill Patients With COVID-19","Prognositc Factors in COVID-19 Patients Complicated With Hypertension","Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives","EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial","Epidemiological Characteristics of COVID-19 in Patients With MS or NMO","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS","Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark","Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection","Mindfulness During COVID-19","COVID-19 Epidemic Response Study","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","Study of the Dissemination of SARS-COV-2 in the Environment of Infected Patients Admitted to Intensive Care Unit","COVID-19 Community Research Partnership","suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)","ICU Trial in Critical Ill COVID19 Patients","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19","Rutgers COVID-19 Cohort Study","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","Use of UC-MSCs for COVID-19 Patients","COVID-19 Antibody Self-testing Using Virtual Point-of-care","SARS-COV2 Pandemic Serosurvey and Blood Sampling","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","The RIsk Stratification in COVID-19 Patients in the ICU Registry","COVID-19 Convalescent Plasma","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Influence Physical Activity Psychological Responses COVID-19 Pandemic","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","A Study of a Candidate COVID-19 Vaccine (COV001)","Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","Analysis of the Coagulopathy Developed by COVID-19 Infected Patients","Plasma Adsorption in Patients With Confirmed COVID-19","A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City","Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","Sevoflurane in COVID-19 ARDS (SevCov)","Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)","Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","The Impact of Camostat Mesilate on COVID-19 Infection","Impact of the COVID-19 Pandemic in Gynecological Oncology","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Immunoregulatory Therapy for 2019-nCoV","Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","NOsocomial Dissemination Risk of SARS-Cov2","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19","Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )","Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","COVID19-hematological Malignancies: the Italian Hematology Alliance","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2","Sequential Oxygen Therapy Strategy for Patients With COVID-19","Losartan for Patients With COVID-19 Requiring Hospitalization","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","Trial of Treatments for COVID-19 in Hospitalized Adults","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","Losartan for Patients With COVID-19 Not Requiring Hospitalization","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","Emotional Burden of Healthcare Professionals and Covid Infection 19","COVID-19 Biological Samples Collection","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","Predictors of Respiratory Failure in SARS-Cov-2 Infection","Birth Experience During COVID-19 Confinement","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19","Effects of DPP4 Inhibition on COVID-19","COVID-19 Risk Stratification","Pro-thrombotic Status in Patients With SARS-Cov-2 Infection","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","University of Utah COVID-19 Hydrochloroquine Trial","Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections","TOFAcitinib in SARS-CoV2 Pneumonia","WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS","ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","STudy of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19)","Household Transmission Investigation Study for COVID-19 in French Guiana","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia","Convalescent Plasma in the Treatment of COVID 19","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong","Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","In-depth Immunological Investigation of COVID-19.","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis","Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19","The Covid-19 HEalth caRe wOrkErS (HEROES) Study","Efficacy of Nigella Sativa and Natural Honey Against COVID-19","Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease","Evolution of Facial Trauma During COVID Containment Measures","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals","Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Adaptive COVID-19 Treatment Trial (ACTT)","Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia","Qatar Prospective RCT Of Therapy Eliminating Covid Transmission","Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus","Simple, Safe, Same: Lung Ultrasound for COVID-19","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","COVID-19 Registry Rhineland-Palatinate (Germany)","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)","LIBA Trial in COVID-19","French Single Centre Experience of Critically Ill Patients With Covid 19","Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic","COVID-19 Among Egyptian Health Care Providers","COVID-19 and Psychotic Symptoms in France","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients","Behavior, Environment And Treatments for Covid-19","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","Renal Outcome in Patients With COVID-19","Efficacy of Faviprevir in COVID-19 Treatment","COVID-19 Pandemic Burden in Severe Mental Disease Patients","Clinical and Radiomic Model of COVID-19","Treating COVID-19 With a Bidirectional Oxygenation Valve","The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)","Cardiovascular Complications and COVID-19 (CovCardioVasc)","NO Prevention of COVID-19 for Healthcare Providers","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","Colchicine Counteracting Inflammation in COVID-19 Pneumonia","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being","Kidney Involvement in COVID-19 Disease (COVKID)","Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases","Assessment of Distress in Crisis Situations During COVID-19","Blood Donor Recruitment During Epidemic of COVID-19","Test and Treat COVID 65plus+","IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.","Risk Factors for Community- and Workplace Transmission of COVID-19","Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP","Renin Angiotesnin System - CoronaVirus","An Observational Study of Patients With Coronavirus Disease 2019","Efficacy and Safety of IFN-2 in the Treatment of Novel Coronavirus Patients","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","Hydroxychloroquine in Outpatient Adults With COVID-19","Experimental Trial of rhIFN Nasal Drops to Prevent 2019-nCOV in Medical Staff","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy","Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","Medical Masks vs N95 Respirators for COVID-19","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff","Accurate Classification System for Patients With COVID-19 Pneumonitis","Mechanisms for Organ Dysfunction in Covid-19","Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19","Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells","The Investigation of the Neonates With or With Risk of COVID-19","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","'' The Abdominal Crunch Position for COVID-19 Patients ''","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","Clinical Characteristics and Prognostic Factors of Patients With COVID-19","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research","The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS","Endoscopy-related Phone Consultation During the COVID-19 Outbreak","Sarilumab COVID-19","Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19","Convalescent Plasma vs. Standard Plasma for COVID-19","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19","Evaluation of Novel Diagnostic Tests for COVID-19","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19)","Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","A Study on the Prospective Cohort Library of COVID-19 in Southeran","Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19","ASC Therapy for Patients With Severe Respiratory COVID-19","Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?","Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)","Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)","PATCH 2&amp;3:Prevention &amp; Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine","Impact of COVID19 Outbreak in Cardiac Acute Care","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","Mechanisms to Morbidity and Mortality for Covid-19","HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers","Clinical Characteristics and Outcomes of Pediatric COVID-19","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients","Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)","COVID-19 Pandemic Response Network","Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors","Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak","Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","\"COVID-19 and Diabetes Outcomes\"","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)","COVID-19 in Cardiology Unit in France : Risk Factors for Mortality (CCF)","A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease","COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2","Asymptomatic COVID-19 Infection Among Healthcare Workers","Covid-19 in Lupus Patients","NK Cells Treatment for COVID-19","COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Eculizumab (Soliris) in Covid-19 Infected Patients","PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","Biomarkers for Identification of COVID-19 Infection","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Spironolactone in Covid-19 Induced ARDS","Non-contact Endoscopy at Covid-19 Outbreak","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19","Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19","Influence of the COvid-19 Epidemic on STRESS","Escin in Patients With Covid-19 Infection","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","Prognostic Factors Keeping Track for Covid-19 Pneumonia","Hemodynamic Characteristics of Patients With SARS-CoV-2","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","A Real-life Experience on Treatment of Patients With COVID 19","Evaluation of Dental Emergency Treatments During COVID19 Crisis","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","Ayurveda for Flu Like Illness During Covid-19 Outbreak","Assessment of Chilbains Occuring During Covid-19 Infection","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study","Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19","Saved From COVID-19","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","Social Media Use During COVID-19","An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","Double Therapy With IFN-beta 1b and Hydroxychloroquine","Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns","Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","Convalescent Plasma to Limit Coronavirus Associated Complications","Early CPAP in COVID Patients With Respiratory Failure.","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","Sero-epidemiological Survey of England in 2019/2020","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection","Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","BCG Vaccine for Health Care Workers as Defense Against SARS-COV2","Expanded Access Remdesivir (RDV; GS-5734)","Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Cardiovascular Manifestations of COVID-19","2019-nCoV Outbreak and Cardiovascular Diseases","A New Screening Strategy for 2019 Novel Coronavirus Infection","Nebulised Rt-PA for ARDS Due to COVID-19","Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)","Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.","Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","Video-Based Exercises and Well-Being During Social Isolation","Telerehabilitation for Patients Diagnosed With Coronavirus","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","The RAPID COVID TRIAGE Algorithm","Pre-exposure Prophylaxis for SARS-Coronavirus-2","Austrian CoronaVirus Adaptive Clinical Trial","Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System","Clinical Outcomes of Patients With COVID19","Study Testing Convalescent Plasma vs Best Supportive Care","Comparison of New Coronavirus (Covid-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey","International Lung UltraSound Analysis (ILUSA) Study","Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia","Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","Norwegian Coronavirus Disease 2019 Study","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections","The Effectiveness of Telerehabilitation-Based Exercises in Elderly People","Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","Lessening Organ Dysfunction With VITamin C","Audio Data Collection for Identification and Classification of Coughing","The Effectiveness of Video-Based Exercises in Young Adults","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge","Clinical Characterisation Protocol for Severe Emerging Infections","Acceptance and Commitment Therapy Delivered by Automated Software Messaging","Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation","Eating Habits of Adults During the Quarantine","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia"],[null,null,"COR-DLUS",null,null,null,null,null,null,"COVID-19 Endo","C-19-ACS",null,"COVID-19",null,null,"ONSCOVID19",null,"DARE-19","PANAMO",null,null,null,"COV19-PLASMA","VACAT","ENACOVID",null,null,null,"COVIDeF",null,"CTOROTSADTOC","Anosmie-COVID",null,null,null,null,null,null,null,null,null,"DIC","HAHPS",null,"TOCIVID-19",null,"ACE-ID-201","COVID CALL 15",null,"IB1aIC","UAIIC","CATNAP",null,"CONCOR-1",null,"CMHS","COVIDAXIS","COVID-Lambda","TRODVID-19",null,null,"JUPITER","COV-AID",null,null,null,null,null,"SARPAC",null,null,null,null,"COVIDIMMUNE",null,"ReCOVery-SIRIO",null,"COMIHY","HAZDpaC",null,"SCOPE","PATCH","CATCO","COLHEART-19","CODIV-ACE",null,"COVIDENCE",null,null,"HCQ4COV19",null,null,null,"HyAzOUT","KONS-COVID-19","APN01-COVID-19","GO2 PEEP","COVIDOSE",null,"RCT","CYTOCOV-19",null,null,null,null,"MOPHYDA",null,"OAHU-COVID19",null,"PrEP_COVID",null,null,"TOCOVID",null,null,null,null,null,null,null,null,null,null,null,"ConPlas-19",null,null,"COVIDothque",null,null,null,"PANDOR",null,"TT-NPC",null,"BEST-RCT","HOPE",null,null,null,"COVACTA",null,null,null,null,null,null,null,"ACEI-COVID","COV-HCQ","PHYSIO-COVID",null,null,null,"TCOutpatient",null,"COVID-19",null,"CovidRegOUH","ConCoVid-19","DEXA-COVID19",null,"HYDRA","QUARANTINE2020",null,"DEFI-VID19",null,"CTII-nCoV","Explore",null,null,"HT-COVID19","STOIC","ACTION",null,null,"COVID19@Spain","FAV-001","CORIPLASM","CORA",null,null,"Covid-19HUF","COVID19PUGG2",null,null,"BCG-CORONA",null,"Strain","VICO",null,null,null,null,null,"TOSCA","LILIADE-COVID",null,"NIAID","SAC-COVID","TRAPSAH",null,null,null,null,"CCC19",null,"COVITD-19","CoSigS","CTCOVID-19",null,"THDMS-COVID-19",null,null,null,"PED-COVID","RASCOVID-19",null,"AZIQUINE-ICU","DHYSCO","EPILOGUE",null,null,"SARCOVID",null,"CORSA","OHB10cov",null,null,null,"GARGLES",null,null,"NO COV-ED","COPERNICO","Isotretinoin",null,null,null,null,"COVID-Scan",null,"COVID-SER",null,null,null,null,"COV2ICU-DK",null,"Al-COVE","ECMO-VID",null,null,null,"COVIDICUS","CORONA-SHIELD",null,"PHYDRA","TACROVID",null,"COL-COVID","Covid",null,null,null,"SCOUT","ICAR",null,"CAPTION AI","BLAST COVID-19",null,"PRA-001",null,"CORIMMUNO-COAG","CORIMMUNO-BEVA",null,"eChoVid","STOP COVID","UKMSRCV19","RegCOVID19","ACTICOV-2","CRASH-19",null,"CORTI-Covid",null,"DEFACOVID","HOPE COVID 19","CovidSurg","CORIMUNO-VIRO","RACONA",null,"HOPE",null,null,null,null,null,null,null,"CORIMUNO-NIVO","Thy-Support",null,null,null,null,"CORIMUNO19-ECU","RuxCoFlam","PHYSIO-COVID",null,"TCInpatient",null,null,"HSC19","DISPOSE","Nancy-CovH-AKI","MultiCov","COVID STEROID","CORON-ACT","COVIDORNASE","(COVID19_BMT)","Covid-VAS",null,null,"DolPsyCOVID","OsPsyCOVID","PISCO","FMTVDM",null,"ZnD3-CoVici","SOS-COVID19","Covid-19",null,"PSYCHIC","SISCO",null,null,"SEROCOV",null,null,null,null,"ONCOVID","MexCOVID-19","COVILLE",null,"THICK","GRAVID",null,"CovImmune","COVID+PA","WHIP COVID-19","IMMUNONCOVID","AIRVM-COVID",null,null,"JOCOVID","COVID-CHD","BBCovid","WAVE","CORONACION","PRODEX","PRECISE","CONEC","SARS-RAS","COVIP",null,"AVoCaDO","BRACE","CROWN CORONA","GRECCO-19",null,"ESCAPE","INHASCO",null,null,"PROTECT",null,"CORSER",null,null,null,"COVID-HEP",null,null,"SARICOR","COPLA","BIOCOVU","REPLACECOVID",null,"HERO-HCQ",null,"COLCOVID",null,null,null,null,"COVERAGE","PEACE",null,"ReCovER","MV-COVID19","HyPreC","COPCOV","APPROVE-CARE",null,"COPLASCOV19","COVIDMED","NeuroCOVID19",null,"ICOS",null,null,"HERO","COVISEP",null,null,null,"PISCA","PRPsyCOVID",null,"PROTECT",null,"COVeR",null,null,null,null,null,"PROACTIVE-19","ENVIROREA",null,"SAVE","POINT-C",null,null,null,"STOP-Flu",null,null,null,"ORCHID","RISC-19-ICU",null,null,null,"CYCOV",null,null,null,null,null,"EC-COVID-PCS","COVID-TGT",null,null,null,"PREP-COVID",null,"CORIA",null,"VT4COVID","CSSC-001","CamoCO-19","COVID-GYN","CP-COVID-19","ATCO",null,"Coronavirus",null,"CAPACITY-COVID","NODS-Cov2","EPICOS",null,null,null,"MeCOVID",null,"COVID-19","CP-COVID-19","COVID-Antibody",null,"TACOS","EasyCoV","SOTSPC",null,"AI-COVID-Xr","DisCoVeRy","PRIORITY",null,"HELPCOVID-19","covid19 fai2r","COVIDeHPAD",null,"Emocovid","COLCOV19-BX",null,null,null,"FRENCH CORONA",null,"CONFINE","BEST-CP",null,null,null,"ATTAC-Co",null,null,"SCout",null,"CALYPSO","ACORES-2",null,null,"COVID-AIV",null,"STARS","EPI-COVID-19",null,null,null,"HCQINRLGII","DC-COVID-19","REMAP-CAP","COVID-19-HBO","REALIST","COVID-19",null,"COVCALL",null,"NoCovid","ACT COVID19","TEACHCOVID","STROMA-CoV2","COntAGIouS","BARI-COVID","Ruxo-Sim-20","ILIAD","COVID-19","eCardioCovid19","SHARP COVID-19","HEROES","WUHAN",null,"Traumax","POCUSCO","COVID_2Pro","CloroCOVID19II",null,"CoDEX","CAPACoV19",null,null,null,"COVIDOC",null,"Q-PROTECT",null,"LUSCOVID19","CORIPREV-LR","COVID19-HCW","MP-C19",null,null,null,null,"CAPTOCOVID","LIBA","CovidAmiens20","ONCOVID",null,"SCHIZOVID-19",null,"BEAT19",null,null,"IBD-COVID-19",null,null,"PsyCOVID",null,null,null,"CovCardioVasc","NOpreventCOVID","SPIN-CHAT","ColCOVID-19",null,"CoVS","COVKID",null,null,null,"COVID65plus","IMAGE-19",null,null,"SRA-COV","COVID-19",null,null,null,null,null,null,"REMOTE-COVID",null,"STOP-COVID",null,null,"COVID-preg","UPSAT",null,null,"UMODCOVID19","RAPID-19","MODIF","TOVID-49",null,null,"NOSARSCOVID",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"CLOCC","HYCOVID",null,null,null,null,null,null,"COVIDx","Coalition-I",null,"CORIMUNO-19",null,"I-COVID",null,null,"NOCOVID","GARM-COVID19",null,"ProPAC-COVID",null,"ASC COVID-19",null,"BURDENCOV",null,"CORIMUNO-SARI","New",null,"CCAP",null,null,"CCU-COVID19",null,null,"COVID MECH",null,"PERN-COVID-19","COVIDHLH",null,"PREDICT",null,"Covid-Thelium",null,null,null,null,null,null,null,"NoCovid","CORONADO",null,"CCF",null,"ANTI-COV-2",null,null,null,"NOSO-COR","SOLID-C19","ECMO-COVID-19","B-DT-COV2","COVID-BioB",null,null,null,null,"COVISTRESS","add-on-COV2","NOSARSCOVID","TOCIVID","NIKE_C19","PiCCOVID","Chloroquine UN",null,null,"URGDENTCOVID","INCOVPED",null,null,null,"ChilblainCOVID",null,"IMPACT","ProCov",null,null,null,null,null,null,null,null,"COVIPREG","MetCOVID","CORIMUNO-ANA","2019-nCoV",null,null,null,null,"EC-COVID-RCT","COVID-ARA2","STORY",null,"HOME-CoV","CloroCOVID19","Resi-CoV",null,null,null,"COVIDAtoZ",null,null,"NONTM","COVID-19",null,null,null,"PACA",null,"Cov-CONTACT",null,null,null,null,null,null,"COSTA","WU352",null,"COVID-19","COVID-19","CORIMUNO-TOC",null,null,"ACOVACT","PostCOVID19",null,null,null,"ILUSA",null,"AS DEFER","NO COVID-19",null,null,null,"COVIDSOT","LOVIT",null,null,"COVID-19 PEP",null,"CCP-nCoV",null,null,null,null],["Recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Active, not recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Withdrawn","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Available","Completed","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Available","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Completed","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Suspended","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Completed","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Available","Not yet recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Active, not recruiting","Completed","Suspended","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Withdrawn","Recruiting","Recruiting","Recruiting","Completed","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Suspended","Not yet recruiting","Recruiting","Available","Active, not recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Suspended","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Completed","Recruiting","Recruiting","Completed","Withdrawn","Not yet recruiting","Not yet recruiting","Recruiting","Completed","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Not yet recruiting","Terminated","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Completed","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Available","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Completed","Not yet recruiting","Not yet recruiting","Active, not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Withdrawn","Active, not recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Available","Not yet recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Available","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Completed","Recruiting","Recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Completed","Recruiting","Completed","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Recruiting","Recruiting","Enrolling by invitation","Completed","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Completed","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Withdrawn","Completed","Recruiting","Recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Recruiting","Recruiting","Completed","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Not yet recruiting","Active, not recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Completed","Not yet recruiting","Withdrawn","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Available","Recruiting","Recruiting","Recruiting","Not yet recruiting","Completed","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Completed","Recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Available","Recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Active, not recruiting","Recruiting","Recruiting","Not yet recruiting","Withdrawn","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Available","Enrolling by invitation","Recruiting","Recruiting","Active, not recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Withdrawn","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Completed","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Not yet recruiting"],["No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available"],["COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19 Drug Treatment","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19|SARS-CoV-2","COVID-19 Infection","SARS-CoV-2|COVID-19","COVID-19","Use of Stem Cells for COVID-19 Treatment","COVID-19 Infection","COVID-19","COVID-19 Disease","Corona Virus Disease 2019,COVID-19","COVID-19 Pneumonia","COVID-19 Pneumonia","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19 Infections","COVID-19 Pneumonia","COVID-19","COVID-19 Thalidomide","COVID-19","COVID-19 Thalidomide","COVID-19|Cardiovascular Diseases","COVID-19","COVID-19","SARS-CoV-2|COVID-19","COVID-19, Hydroxychloroquine Sulfate","Sars-CoV2|COVID-19","COVID 19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","Acute Respiratory Distress Syndrome Caused by COVID-19","COVID-19","COVID-19|Severe Acute Respiratory Syndrome","COVID-19","Coronavirus Disease (COVID-19)","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","COVID-19|Cardiac Arrhythmias","COVID-19","Coronavirus Disease (COVID-19)|COVID-19","COVID-19|Viral Respiratory Illnesses","COVID-19|Liver Cirrhosis","COVID-19|Hypertension","COVID-19","COVID-19|SARS-CoV-2","Severe/Very Severe COVID-19 Illness","2019 Novel Coronavirus Pneumonia|COVID-19","Covid19","Coronavirus Disease (COVID-19)","Covid19","Anxiety Related to the COVID-19 Pandemic","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","Coronavirus Disease 2019 COVID-19","COVID-19 Pneumonia","SARS-CoV-2|COVID-19","COVID-19|SARS-CoV-2","Coronavirus Disease 2019 (COVID-19) Pneumonia","COVID-19","Coronavirus Disease (COVID-19)","Coronavirus Disease (COVID-19)","SARS-CoV-2 Infection|COVID-19","COVID-19","COVID-19|SARS-CoV 2","Covid-19","Cancer|COVID-19","Coronavirus Disease (COVID-19)","COVID-19 Pneumonia","COVID 19","SARS-CoV-2|COVID-19","Coronavirus Disease 2019 (COVID-19)","Severe Coronavirus Disease (COVID-19)","AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection","COVID-19|BCG Vaccination","Infectious Disease|COVID-19","COVID-19|Pneumonia","COVID-19|Deep Vein Thrombosis (DVT)/Thrombophlebitis","COVID-19|Invasive Malignancy (Any Type)","Coronavirus Disease 2019 (COVID-19)","Patients Infected With COVID-19","Infection, COVID-19","COVID-19","Corona Virus Disease 2019(COVID-19)","SARS-COV-2 Infections|COVID-19","Novel Coronavirus Infectious Disease (COVID-19)","COVID-19","COVID-19|Respiratory Disease","COVID-19 Infection","Covid-19","Respiratory Distress Syndrome Due to COVID-19","COVID-19|Respiratory Failure","Respiratory Distress Syndrome, Adult|COVID-19","Addiction, Substance|COVID-19","COVID-19|Coronavirus Infection","Acute Lung Injury (ALI) Associated With COVID-19|Inflammatory Lung Conditions Associated With COVID-19","Covid-19","COVID-19","COVID-19|SARS-CoV-2","Covid-19","COVID-19","COVID-19","COVID-19|Coronavirus Infection","Covid-19","Covid-19","COVID-19|SARS","COVID19","COVID-19|Pneumonia, Viral","COVID19","COVID-19|Novel Coronavirus Pneumonia","COVID 19","Covid-19","COVID19","COVID 19|SARS-Cov-2","COVID-19|COVID","Covid19","COVID-19","COVID 19","Covid19","Covid-19|Sars-CoV2","COVID-19|Respiratory Failure","COVID19","Solid Organ Transplant Rejection|COVID-19","ARDS, Human|COVID-19","COVID-19|Pneumonia","COVID 19","COVID-19|Corona Virus Infection","Acute Hypoxemic Respiratory Failure|COVID-19","COVID-19|Cancer","Covid-19","COVID-19|Severe Acute Respiratory Syndrome","COVID-19|Lung Injury","COVID19","COVID19","COVID19","Covid19","COVID-19|Physician-Patient Relations","Covid-19","COVID-19 Pneumonia|Lung Ultrasound","Acute Respiratory Distress Syndrome|COVID-19","COVID-19|Yellow Fever","COVID-19","COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2","COVID-19","Coronavirus Disease (COVID-19)","COVID 19","COVID19 Pneumonia","COVID19 Pneumonia","COVID-19|SARS-CoV 2|Corona Virus Infection","2019-nCoV (COVID-19)|Interstitial Pneumonia","COVID 19|Coronavirus","Multiple Sclerosis|COVID-19","SARS-CoV-2","SARS-CoV-2|Covid-19","Covid-19","COVID19","Viral Pneumonia Human Coronavirus|COVID-19","SARS-CoV 2|COVID-19","COVID19","COVID 19","COVID-19|Coronavirus|Surgery","COVID19|SARS-CoV-2 Infection","COVID19","Covid19|Echocardiography","Pneumonia, Viral|Covid-19","COVID 19 Cardiac|COVID 16 Arrhythmia|COVID 19 Death","Pneumonia, Pneumocystis|Coronavirus|COVID-19","COVID-19 Complicated With Refractory Intestinal Infections","Contact Person From COVID-19 Confirmed Patient","Covid-19","Convalescent Plasma for COVID 19","COVID 19","COVID19- Infection With SARS-CoV-2 Virus","Pulmonary Infection|Covid-19","Treat and Prevent Covid-19 Infection","Respiratory Failure|Covid-19","COVID-19|Serology","Virus Diseases|COVID-19","SARS-CoV-2|COVID19","Covid-19","COVID-19|ARDS|Sars-CoV2","COVID-19|Remdesivir|SARS-CoV-2","COVID19","COVID 19","COVID-19|Endotracheal Intubation","COVID 19","COVID-19|Psychosocial Stress|Mental Health","COVID 19","Covid19|Pneumonia","Covid-19|Hypoxia","SARS-CoV-2 Infection","COVID-19|Acute Respiratory Distress Syndrome","COVID19","Vascular Surgical Procedures|COVID-19|Postoperative Complications","Covid-19 Pneumonia|Cyotokine Storm","Pathogen Infection Covid-19 Infection","Sars-CoV2|Chronic Pain","Sars-CoV2|Osteoporosis","COVID-19|SARS-CoV-2","CoVid 19 Positive","COVID-19|SARS-CoV-2","SARS-CoV 2","Covid19|SARS-CoV Infection","SARS-CoV-2","HIV/AIDS|COVID-19|SARS-CoV-2","Psychiatric Disorder|Covid19","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection","Hospitalized Patients With Covid-19 Pneumonia","COVID19","Sars-CoV2","COVID-19|Coronavirus Infection|Corona Virus Infection","COVID-19|SARS-CoV-2|2019-nCoV|Pneumonia, Viral","SARS-CoV 2","COVID-19|Acute Kidney Injury|Kidney Function","Cancer &amp; COVID 19","Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus","Covid19","SARS-CoV-2 Viral Kinetics and Host Immune Responses","Covid 19|Corona Virus Infection","Covid-19|Lung Cancer","Sars-CoV2","New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2","Patients With COVID19","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","Covid 19|Hypoxemic Respiratory Failure","COVID-19|Pneumonia, Viral|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","Covid 19 Pandemic From Ethical View","COVID-19|Myocardial Injury|Myocarditis","Congenital Heart Disease|Covid-19","COVID19|Mouthwash|Saliva","COVID|COVID 19|SARS-CoV 2","Hypertension|COVID-19","COVID-19 Infection|Sars-cov-2|Respiratory Failure|Palliative Situation","Sars-CoV2|Symptomatic Condition|Covid-19","SARS-CoV 2|Immunization; Infection","COVID-19|Hypertension|Cardiovascular Diseases","COVID-19|Elderly Patients|Critical Illness|Survival|Old Age","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2","COVID-19|Hypoxia","Coronavirus Disease 2019 (COVID-19)|Febrile Respiratory Illness|Corona Virus Infection|COVID-19","COVID 19","Corona Virus Disease 19 (Covid 19)","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection","Covid-19 Infection|Hospitalization in Respiratory Disease Department","SARS-CoV-2|Outcome, Fatal","COVID-19|Lung Injury, Acute","COVID 19","Endometriosis|Covid19","SARS (Severe Acute Respiratory Syndrome)|COVID-19","Oropharyngeal Dysphagia|COVID-19|Sars-CoV2|Nutrition","Respiratory Distress Syndrome, Adult|SARS-CoV-2","Health Care Worker (HCW)|COVID-19","COVID|Sars-CoV2","SARS-CoV-2","Covid19|Newborn Morbidity","SARS-CoV 2|SARS","COVID-19","Infection Viral|Coronavirus|COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","Corona Virus Infection|Sars-CoV2","SARS-CoV-2|Coronavirus Infection|Asymptomatic Condition|COVID-19","CoVID-19|Chinese Medicine","Corona Virus Infection|SARS-CoV 2","Covid19","COVID-19|SARS-CoV-2|Pregnant Women|Hydroxychloroquine","COVID19|Coronavirus|Acute Respiratory Illnesses","ARDS, Human|Mechanical Ventilation Complication|COVID19","Solid Tumor|Sars-CoV2|Hematological Malignancy","COVID-19|SARS-CoV 2|Convalescence|Plasma|Doses","SARS-CoV-2 Infection","COVID-19|Encephalopathy|Critically Ill","2019-nCoV","Anxiety State|COVID-19|Isolation, Social|Health Personnel Attitude","SARS-CoV-2","Novel Coronavirus Pneumonia|2019-nCoV","Prophylaxis|COVID-19|Health Care Worker|Hydroxychloroquine","Multiple Sclerosis|NMO Spectrum Disorder|COVID-19","COVID-19|Acute Respiratory Distress Syndrome|Virus; Pneumonia|Acute Lung Injury","COVID-19|Burnout, Caregiver|Intensive Care Unit|Stress, Psychological","COVID-19|Severe Pneumonia|Chinese Medicine","COVID-19|Mental Health|Psychoeducation|Anxiety","Sars-CoV2|Rheumatic Diseases|Rheumatoid Arthritis|Chronic Pain","SARS-CoV-2","Sars-CoV2","Migraine Disorders|Stress|Anxiety","Fever|Pneumonia|Cough","Coronavirus Infection|COVID|Covid-19|SARS-CoV-2","SARS-CoV2 Infection","COVID|Coronavirus|COVID-19","SARS CoV-2 Infection","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV","Covid-19|Viral Infection","Coronavirus|COVID","COVID-19|Virus Diseases|Corona Virus Infection|LRTI|Lower Respiratory Tract Infection Viral","Risk Factor, Cardiovascular|Covid19|Critical Illness|Course Illness","Pneumonia, Viral|COVID-19","Coronavirus|SARS-CoV-2","2019-nCoV","Influenza Infection|SAD-RV Infection and COVID-19","Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome","Communicable Disease|COVID-19|Sars-CoV2|Infectious Disease|Coronavirus|Virus Diseases","SARS-COV2 Virus","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Critical Illness|ARDS|Inflammatory Response|COVID-19|Circulatory Shock","Coronavirus","SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19","Sedentary Behavior|Mental Health Wellness 1","Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm","Covid-19|Coronavirus Infection|Pregnancy Related","Coronavirus Disease 2019","Coronavirus Disease 2019|Novel Coronavirus Pneumonia","Coronavirus","Coronavirus Infection","Early CPAP Ventilation in COVID-19 Patients","Sepsis|Blood Coagulation Disorders|Thrombin|Disseminated Intravascular Coagulation|COVID-19","Respiratory Failure","SARS Coronavirus (SARS-CoV-2) Infection","Respiratory Failure|Ventilatory Failure|COVID-19|Pneumonia|ARDS, Human","SARS-CoV-2 Infection","ARDS, Human|Coronavirus","HIV-1-infection|Cancer|Primary Immune Deficiency Disorder|Immunosuppression Disorders|COVID-19","Coronavirus Disease 2019","Acute Respiratory Distress Syndrome|COVID19|Sars-CoV2|Pneumonia","Coronavirus|Convalescence","Corona Virus Infection","Gynecologic Cancer|Breast Neoplasm Female|Uterine Neoplasms|Ovarian Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Vaginal Neoplasms","Coronavirus|Coronavirus Infection","Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2","2019 nCoV, PD-1","Coronavirus Infection","COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","COVID-19; Cardiovascular Diseases","Sars-CoV2","Coronavirus Infection","Coronavirus Infection","HIV Patients","COVID|ARDS, Human|Ards|Sars-CoV2","Covid19|SARS-CoV 2|Coronavirus Infection","Perceived Stress|Anxiety|Sleep Disturbance","Coronavirus","Coronavirus|Coronavirus Infection","SARS-CoV-2","SARS-CoV-2 Infection|Hematological Malignancies","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","SARS-CoV-2","Coronavirus Disease-2019","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical","Corona Virus Infection","Pregnancy|Coronavirus|COVID-19","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","COVID-19|Coronavirus Infection|Sars-CoV2|Corona Virus Infection|COVID|Coronavirus|Coronavirus-19|Coronavirus 19","Sars-CoV2|Chronic Inflammatory Rheumatism|Autoimmune Diseases","Coronavirus Infection","2019-nCoV","Emotionnal Distress; COVID-19","Infection Viral","2019-nCoV","Severe Acute Respiratory Syndrome Coronavirus 2|SARS-CoV 2|Coronavirus Infection|Covid19","2019-nCoV","Pneumonia, Viral|Critically Ill|Corona Virus Infection","SARS-CoV-2 Pneumonia","Postpartum Depression","Coronavirus Infections","Covid-19|Pneumonia|SARS Pneumonia","Coronavirus Infection|Type 2 Diabetes","Coronavirus|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere","Severe Acute Respiratory Syndrome Coronavirus 2","2019-nCoV Pneumonia","Coronavirus Infection|Coronavirus|Infectious Disease","Severe Acute Respiratory Syndrome Coronavirus 2","SARS-COv2 Related Interstitial Pneumonia","Coronavirus Infection|SARS-CoV-2","History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","Coronavirus Infections","SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS","Acute Respiratory Distress Syndrome|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection","Coronavirus Infections","Severe Acute Respiratory Syndrome|Respiratory Failure|Acute Respiratory Distress Syndrome","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","2019-nCoV Severe Pneumonia","SARS-CoV-2|COVID|Coronavirus","Gynecological Cancer","Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents","Pneumonia, Pneumocystis|Coronavirus","Community-acquired Pneumonia, Influenza, COVID-19","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Cytokine Storm|Infection Viral","Acute Respiratory Distress Syndrome","Susceptibility to Viral and Mycobacterial Infection","Coronavirus Infections","SARS-CoV-2|Systemic Lupus Erythematosus|Rheumatoid Arthritis|Sjogren's Syndrome|Psoriatic Arthritis","Coronavirus Infection","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Coronavirus|Severe Acute Respiratory Syndrome","Sars-CoV-2, Community-Acquired Pneumonia","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Coronavirus Infections","Pharmacological Action","Coronavirus Infection","Sars-CoV2","Characteristics Diseases|Outcome, Fatal","Angina Pectoris|Acute Coronary Syndrome|Coronary Syndrome|Coronary Artery Disease|Angioplasty|Stent Restenosis|Hypertension|Heart Failure, Systolic|Depression, Anxiety|Covid-19|Isolation, Social","Coronavirus Infection|Hydroxychloroquine Adverse Reaction","Covid-19|Mental Health Disorder|Stress Disorder|Anxiety|Depression|SARS-CoV-2","Coronavirus Infection|Sars-CoV2","Pneumonia","Maxillofacial Injuries|Skull Fractures|COVID-19","COVID|Coronavirus Infection","COVID19|Sars-CoV2|Hydroxychloroquine|Prophylaxis|Healthcare Worker","COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial","Healthy Volunteer|Mood Disorder|Anxiety Disorder|Preexisting Medical Condition","Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Infection With Coronavirus SARS-CoV2","Pulmonary Fibrosis Due to 2019-nCoV","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Corona Virus Infection","Coronavirus Infection|Pneumonia, Viral","Pneumonia","Covid19","COVID|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Coronavirus|Epidemic Disease|Pneumonia, Viral","Coronavirus Infections|Post-exposure Prophylaxis","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human","Infection Viral|Thromboses, Venous","Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis","COVID","Pediatric Respiratory Diseases|COVID|Fatigue Post Viral","Pneumonia|Coronavirus Infection","Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection","Epidemiology|Sars-CoV2|COVID 19|Critical Care|Prognostic|Survival","Cancer","COVID","Mental Disorder","2019-nCoV|Immunoglobulin of Cured Patients","Coronavirus","COVID|Drug Effect|Drug Interaction|Adverse Drug Event","Ventilator Associated Pneumonia","IBD|COVID","Acute Kidney Injury|Corona Virus Infection","COVID","Psychological Distress|COVID|Severe Mental Disorder","Coronavirus|Machine Learning","Coronavirus Infection","Depression|Generalized Anxiety|Adherence to Non-pharmacological Epidemiological Interventions (NPIs)","COVID|Acute Coronary Syndrome|Myocardial Infarction|Myocarditis|Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism","Coronavirus Infections|Healthcare Associated Infection","Scleroderma|Scleroderma, Systemic|Systemic Sclerosis","Coronavirus Infections|Pneumonia, Viral","Surgery|COVID|Asymptomatic Patient|Covid-19|Preventive Measures","ALL, Adult","COVID|Kidney Injury","Liver Diseases|Liver Cancer|COVID19","Stress, Psychological","Blood Donation","SARS-CoV 2","SARS Virus","Coronavirus","COVID-19|ECMO","COVID 19","COVID-19|Coronavirus","COVID-19|Recombinant Human Interferon 1","Cardiovascular Disease Acute|Cardiomyopathies|COVID","Coronavirus Infection","2019 Novel Coronavirus Infection","COVID","COVID|Hypoxemia","Coronavirus","Coronavirus|N95|Medical Mask","Coronavirus Infection","COVID","COVID|Mechanical Ventilation|Acute Respiratory Failure","Infection Viral","COVID|Hypoxic Respiratory Failure","COVID","Pneumonitis","COVID-19|Organ Dysfunction Syndrome Sepsis|Organ Dysfunction Syndrome, Multiple|Septic Shock|Acute Kidney Injury|Acute Respiratory Distress Syndrome","COVID","Myocardial Infarction","Coronavirus","COVID|Respiratory Distress Syndrome","Neonatal Infection|Perinatal Problems|Infectious Disease","Coronavirus|SARS (Severe Acute Respiratory Syndrome)","Anesthesia, Spinal","MAGEC Rod","Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19","Coronavirus Infection","SARS Pneumonia","COVID|Trauma|Ultrasound","Coronavirus","COVID","SARS-CoV Infection","Liver Cirrhoses","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Colon Polyp|Colon Disease|Reflux, Gastroesophageal|Varices, Esophageal","Corona Virus Infection","COVID","COVID","COVID","Coronavirus","Pneumonitis|Coronavirus Infection","Efficacy, Self|Satisfaction, Patient|Telemedicine","Infections, Respiratory|Fever|Cough","Coronavirus","Stress","Disease, Infectious|Respiratory Disease|Safety Issues|Effectiveness","Acute Disease|Coronavirus|Respiratory Viral Infection","Coronavirus Infections","Healthy Lifestyle","Corona Virus Infection","Pneumonia, Ventilator-Associated|Coronavirus Infection","Infection Viral","Follow-up|COVID-19|Infectious Diseases|Respiratory","ARDS|Hypercapnic Respiratory Failure|AKI","Corona Virus Infection","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","COVID","Virus Diseases|Infection Viral|Corona Virus Infection","Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia","Respiratory Tract Diseases","Surgery|Complication of Surgical Procedure|COVID","Corona Virus Infection|Post-traumatic Stress Disorder","Critically Ill|Coronavirus Infections","Corona Virus Infection","Mental Stress|Mental Health Wellness 1|Depression|Anxiety|Behavior Problem|Emotional Problem","Coronavirus","COVID|Corona Virus Infection|Viral Pneumonia","Coronavirus Infections|Pneumonia, Viral","Coronavirus|Corona Virus Infection","Acute Coronary Syndrome|Heart Failure|COVID","Coronavirus|Pneumonia|Oxygen Toxicity","2019-nCoV","Coronavirus|SARS","Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","COVID","Coronavirus Infection","Infection Viral|Coronavirus|ARDS|Pneumonia","Emergency Service, Hospital|General Surgery","Covid-19|Endothelial Dysfunction|Thrombosis|Critically Ill","COVID","Dysfunctional Worry","Telerehabilitation","COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection","COVID","Flu Like Symptom|Flu Like Illness","Mental Health Issue","Coronavirus Infections|Pneumonia, Viral|Dyspnea","Coronavirus|Diabetes","Corona Virus Infection|Immunisations","Infection Viral|Infection, Hospital|COVID","COVID|Conjunctivitis","COVID","Immunologic Activity Alteration","Systemic Lupus Erythematosus","Novel Coronavirus Pneumonia","Infection Viral","Coronavirus","Respiratory Distress Syndrome","Coronavirus","Coronavirus Infections","Respiratory Distress Syndrome, Adult","Gastrointestinal Disease|Infectious Disease","COVID-19|Nintedanib|Safety|Effect of Drugs","Severe Acute Respiratory Syndrome (SARS) Pneumonia","Stress, Psychological","Coronavirus Infections","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Corona Virus Disease","Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease","Coronavirus|SARS-CoV-2|COVID-19|Acute Respiratory Distress Syndrome|Shock|Acute Circulatory Failure|Left Ventricular Dysfunction|Fluid Overload","COVID","Coronavirus Infection","COVID","Orofacial Pain|Orofacial Edema|Dental Trauma|Oral Infection","Coronavirus|COVID|Infection Viral","Coronavirus Infection","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","Flu Like Illness","Skin Manifestations|COVID|Chilblains","Musculoskeletal Pain","Covid-19 Infection|Rheumatoid Arthritis|Psoriatic Arthritis|Hydroxychloroquine","Coronavirus Infection|Oxygen Deficiency","Septic Shock|Endotoxemia|COVID|Corona Virus Infection|Sepsis, Severe","COVID","Cardiovascular Diseases|Cardiovascular Risk Factor|SARS","Coronavirus|Depression|Anxiety|Stress","Pneumonia, Viral|Respiratory Failure","Coronavirus","Coronavirus","COVID","Pregnancy","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Corona Virus Infection","Pneumonia Caused by Human Coronavirus","SARS-CoV Infection","Pneumonia, Viral|Pneumonia, Ventilator-Associated","2019-nCoV","Coronavirus","CPAP Ventilation|COVID-19|Emergency Departments","COVID|Acute Respiratory Distress Syndrome","Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19","Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated","Coronavirus Infection","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Psychological","2019 Novel Coronavirus Pneumonia","Coronavirus|Coronavirus Infection|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|Coronavirus as the Cause of Diseases Classified Elsewhere","Coronavirus Disease 2019","COVID|Corona Virus Infection","New Coronavirus","Acute Respiratory Distress Syndrome|COVID","Respiratory Tract Infections|Corona Virus Infection","Corona Virus Infection","Cardiovascular Diseases|COVID","Cardiovascular Death; Major Adverse Cardiovascular Events","Novel Coronavirus Infection Pneumonia","COVID","Ventilator Associated Pneumonia","Coronavirus","Pneumonia Caused by Human Coronavirus (Disorder)","Virus; Pneumonia","2019-nCoVs Infection Pneumonia","Coronavirus Infections|Respiratory Failure|Ventilator Lung","Coronavirus","The Gold Standard for Current SARS CoV2 Detection is RT-PCR","COVID - 19","Coronavirus Infection","Social Isolation|Physical Inactivity|Well-Being","Telerehabilitation|Coronavirus","Healthy People","Corona Virus Infection","COVID","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","COVID","COVID19|Corona Virus Infection|Myocardial Injury|Pneumonia","Coronavirus Disease 2019","Pneumonia, Interstitial","Healthy","COVID|Pregnancy Complications, Infectious|Pregnancy Related|Pregnancy, High Risk|Pregnancy Disease|Pneumonia|Pneumonia, Viral|Diagnoses Disease","Pneumonia","Aortic Valve Stenosis","Corona Virus Infection","Novel Coronavirus Infection","Disseminated Intravascular Coagulation|Critical Illness|Sars-CoV2|Viral Infection|Coagulation Disorder, Blood|Covid19","Telerehabilitation|Elderly People|Social Isolation","Transplant Recipient|Infections, Coronavirus","Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus","COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy","Social Isolation|Exercise|Healthy","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Heart Failure|Copd|Liver Failure|Covid19|Diabetes Mellitus|Cancer|End Stage Renal Disease","Coronavirus Infections","Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus","Telerehabilitation","Health Behavior|Eating Behavior","Coronavirus"],["Drug: Deferoxamine","Drug: Favipiravir|Other: Placebo","Diagnostic Test: Lung ultrasound","Biological: anti-SARS-CoV-2 convalescent plasma","Drug: Tocilizumab|Drug: Methylprednisolone","Other: No Intervention","Other: Exposure","Drug: Clevudine|Drug: Hydroxychloroquine","Device: Hyperbaric Oxygen Therapy","Other: Practice details","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","Drug: Huaier Granule","Device: oxyhydrogen|Device: Oxygen","Drug: DAS181",null,"Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Drug: Losartan","Drug: Dapagliflozin 10 MG|Drug: Placebo","Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only","Dietary Supplement: Bob's Red Mill|Dietary Supplement: Control - Corn Starch","Biological: Convalescent Plasma","Drug: Hydroxychloroquine","Other: hyperimmune plasma","Other: Survey","Drug: 1: Naproxen|Drug: 2: Standard of care","Other: Blood donation from convalescent donor","Drug: Traditional Chinese Medicine Prescription","Other: Plasma Donation","Other: blood samples","Biological: UC-MSCs|Other: Placebo","Drug: TCM prescriptions","Other: olfactory and gustatory tests","Drug: DAS181|Drug: Placebo","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)",null,null,"Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Drug: Ruxolitinib","Drug: Baricitinib","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)|Drug: Sarilumab (anti-IL-6 receptor)","Drug: Ruxolitinib","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B","Drug: Hydroxychloroquine|Drug: Azithromycin","Biological: MSCs","Drug: Tocilizumab Injection",null,"Drug: Acalabrutinib","Device: Web application users","Drug: Ruxolitinib|Procedure: Peripheral blood draw","Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine","Drug: Umifenovir|Drug: Interferon- 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care","Other: Self-prone position recommendation|Other: Usual care","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Other: Convalescent plasma","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Other: nCapp, a cell phone-based auto-diagnosis system","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Drug: Peginterferon Lambda-1a|Other: Standard of Care Treatment","Diagnostic Test: COVID-19 diagnostic test","Drug: Sarilumab|Drug: Placebo","Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine",null,"Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab",null,"Behavioral: Crisis management coaching","Drug: Hydroxychloroquine|Dietary Supplement: Placebo","Device: hyperbaric oxygen therapy (HBOT)","Drug: Sildenafil citrate tablets","Drug: Sargramostim|Other: Control","Drug: Camostat Mesilate|Other: Placebo","Other: Surgical facial mask","Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare","Drug: Etoposide","Drug: Amiodarone|Drug: Verapamil","Drug: Chlorpromazine Injection","Drug: Hydroxychloroquine|Drug: Placebo","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc",null,"Drug: Sirolimus|Drug: Placebo","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Drug: Lopinavir/ritonavir","Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians",null,"Drug: chloroquine|Other: standard care",null,null,null,"Drug: Treatment and prophylaxis|Other: Standard Public Health measures","Biological: Convalescent Plasma","Drug: Hydroxychloroquine","Other: survey","Drug: Hydroxychloroquine|Drug: Azithromycin","Device: Kerecis Oral and Nasal Spray|Other: Placebo","Drug: RhACE2 APN01|Drug: Physiological saline solution","Device: GO2 PEEP MOUTHPIECE","Drug: Tocilizumab","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Azithromycin","Device: CytoSorb-Therapy","Drug: Methotrexate","Drug: Canakinumab 150 MG/ML [Ilaris]","Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)","Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse","Drug: HCQ &amp; AZ","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Placebos","Biological: allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC)|Other: Intravenous saline injection (Placebo)","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","Drug: Remdesivir|Drug: Standard of Care","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Biological: bacTRL-Spike|Other: Placebo","Drug: Nitazoxanide Tablets|Drug: Placebo","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Drug: Clazakizumab 12.5 mg|Drug: Clazakizumab 25 mg|Other: Placebo","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Drug: HB-adMSCs|Drug: Placebos","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Drug: Remdesivir|Drug: Standard of Care","Device: Non-contact ECG","Other: Blood and derivatives.|Drug: Standard of Care","Other: this study is non- interventional",null,"Other: blood sample",null,"Biological: WJ-MSCs","Drug: Vazegepant (BHV-3500)|Drug: Placebo","Other: hospitalized children with Covid19","Other: other","Drug: Tetrandrine","Drug: Tocilizumab","Drug: Bevacizumab","Biological: NestCell","Drug: Siltuximab|Drug: Methylprednisolone","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Drug: methylprednisolone therapy|Other: Standard care","Drug: Tocilizumab (TCZ)|Drug: Placebo","Device: Aerosol-reducing Mask|Device: Standard Mask","Drug: thalidomide|Drug: placebo","Drug: Hydroxychloroquine (HCQ)","Drug: placebo|Drug: Thalidomide","Other: non",null,"Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2","Drug: ACE inhibitor, angiotensin receptor blocker","Drug: Hydroxychloroquine Sulfate|Drug: Placebo","Other: Phsyiotherapy","Biological: anti-SARS-CoV-2 convalescent plasma","Biological: Convalescent Plasma|Biological: Standard Plasma","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Drug: chlorine dioxide 3000 ppm",null,"Biological: Convalescent plasma","Drug: Dexamethasone","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Chloroquine phosphate|Other: Telemedicine","Drug: Fingolimod 0.5 mg","Drug: Defibrotide Injection","Diagnostic Test: VitalConnect Vital Sign Patch","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo",null,"Drug: Nitazoxanide|Drug: Placebo",null,null,"Diagnostic Test: Chest computed tomography (CT)|Diagnostic Test: Reverse-transcription polymerase chain reaction (RT-PCR)","Drug: Azithromycin|Drug: Placebos","Drug: Ruxolitinib","Biological: UC-MSCs|Drug: Placebo",null,"Drug: favipiravir|Drug: Standard of care therapy","Drug: Transfusion of COVID-19 convalescent plasma","Diagnostic Test: Online Questionnaire","Drug: Ruxolitinib Oral Tablet","Drug: TJ003234|Drug: Placebo","Drug: Hidroxicloroquine|Drug: Lopinavir/ritonavir|Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet","Other: observation","Drug: Remdesivir|Drug: Remdesivir placebo","Biological: Lenzilumab|Drug: Standard of Care","Drug: BCG Vaccine|Drug: Placebo","Biological: intradermal injection of BCG Vaccine|Other: placebo",null,"Drug: Chloroquine phosphate",null,"Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin","Drug: Hydroxychloroquine|Other: Vitamin C",null,null,null,"Drug: 1: ILT101|Drug: 2: Placebo Comparator","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate",null,"Drug: CD24Fc|Drug: Placebo","Other: - Synthetic anti-malarial drugs","Diagnostic Test: Tuberculin test",null,"Drug: LY3127804|Drug: Placebo",null,"Other: Web-based REDCap survey","Biological: BM-MSCs|Biological: Placebo","Dietary Supplement: Vitamin D","Other: Blood sampling","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Biological: MSCs|Biological: Saline containing 1% Human serum albuminsolution of MSC","Drug: Oral","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment","Other: Questionnaire|Diagnostic Test: IgG","Diagnostic Test: Breath test","Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample","Other: Discontinuation of ACEi/ARB|Other: Continuation of ACEi/ARB","Drug: Gimsilumab|Drug: Placebo","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo","Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine",null,"Drug: Piclidenoson","Drug: TD-0903|Drug: Placebo","Drug: Sarilumab|Other: Standar of care","Biological: UC-MSCs|Other: Placebo","Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Drug: Danoprevir+Ritonavir","Drug: Ganovo+ritonavir+/-Interferon nebulization","Drug: Chloroquine","Drug: Gargle/Mouthwash","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","Device: Control group|Device: SLEDD with a L-MOD","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment","Drug: Methylprednisolone","Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation","Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet","Biological: COVID-19 convalescent plasma",null,"Drug: Pegylated interferon lambda","Diagnostic Test: Serological tests will be applied on patients blood sampling","Drug: HB-adMSCs","Other: Questionnaire","Drug: Atovaquone/Azithromycin","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma",null,"Device: BIOVITALS",null,"Procedure: ECMO Implantation","Drug: Ruxolitinib","Other: No intervention","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation","Other: Telehealth","Other: convalescent plasma","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Tacrolimus|Drug: Methylprednisolone","Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole","Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test","Behavioral: turkish physicians","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Diagnostic Test: Lung ultrasound","Drug: Human immunoglobulin|Drug: Placebo","Drug: Galidesivir|Drug: Placebo","Device: Caption AI","Diagnostic Test: EUROIMMUN assay","Dietary Supplement: Natural Honey|Other: Standard Care","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Biological: Convalescent COVID 19 Plasma","Drug: Tinzaparin or unfractionated heparin","Drug: Bevacizumab Injection","Diagnostic Test: rapid salivary test","Other: Pulmonary ultrasound","Drug: Fluvoxamine|Drug: Placebo",null,"Drug: Patients with the treatment agains COVID19","Other: Immunological profiling","Drug: Aspirin|Drug: Losartan|Drug: Simvastatin","Drug: Clazakizumab","Drug: Prednisone|Other: Control group","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","Combination Product: Observational (registry)","Procedure: Surgery","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","Drug: Nafamostat Mesilate|Drug: Placebo","Other: Echocardiography","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets",null,"Drug: Hydroxychloroquine","Other: washed microbiota transplantation|Other: placebo","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)",null,"Other: convalescent plasma from recovered COVID 19 donor","Other: No Intervention","Drug: Nivolumab Injection","Drug: T3 solution for injection|Drug: Placebo","Biological: Pathogen-specific aAPC","Other: Monitoring for aggravation|Other: Evaluate HACOR score effectivity in this patients",null,"Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing","Drug: Eculizumab","Drug: Ruxolitinib",null,"Drug: Remdesivir|Drug: Remdesivir placebo","Drug: Tranexamic acid|Drug: Placebo oral tablet","Drug: Ivermectine|Drug: Hydroxychloroquine Sulfate|Drug: Placebos","Other: severe covid-19 pneumonia with ET","Device: Biosensors","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment","Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL","Drug: Tocilizumab (TCZ)|Drug: Placebo","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure","Other: no intervention","Procedure: Vascular surgery","Biological: Autologous Adipose MSC's","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Other: questionnaire assesment","Other: questionnaire assesment","Drug: Pyridostigmine Bromide|Drug: Placebo","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Drug: Ascorbic Acid and Folic Acid|Drug: Hydroxychloroquine Sulfate and Folic Acid|Drug: Hydroxychloroquine Sulfate and Azithromycin","Dietary Supplement: Zinc gluconate|Dietary Supplement: 25-OH cholecalciferol","Procedure: Auricular neuromodulation|Procedure: Control",null,"Other: No intervention","Other: Brief Psychiatric Rating Scale|Other: Depression, Anxiety and Stress Scale|Other: Impact of Event Scale-Revised|Other: Connor-Davidson Resilience Scale 10 items (CD-RISC 10)",null,"Dietary Supplement: Vitamin C","Drug: Hydroxychloroquine Sulfate (HCQ)","Other: blood sample","Procedure: Blood draw","Drug: Nivolumab","Drug: Tocilizumab|Drug: Placebos",null,"Drug: Hydroxychloroquine|Drug: Azithromycin",null,"Diagnostic Test: Data collection and rhinopharyngeal swab","Other: NA (no intervention)","Drug: Hydroxychloroquine|Other: Placebo",null,"Drug: BLD-2660","Other: blood sampling|Other: additional blood tubes","Drug: Hydroxychloroquine|Drug: Azithromycin","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care","Drug: Almitrine|Drug: Placebo","Biological: eculizumab","Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality","Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care",null,"Device: mouthrinse with bta-cyclodextrin and citrox|Device: mouthrinse without bta-cyclodextrin and citrox","Other: Equipment with smartwatch throughout hospital stay on the general ward","Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","Drug: Treatment with Dexmedetomidine","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo",null,null,null,"Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Drug: L-ascorbic acid","Drug: BCG Vaccine","Drug: Low-dose chloroquine/hydroxychloroquine|Drug: Mid dose chloroquine or hydroxychloroquine|Drug: High does chloroquine or hydroxychloroquine|Drug: Placebo","Drug: Colchicine|Drug: Standard treatment","Genetic: Mesenchymal Stromal Cells","Drug: Anakinra|Drug: Tocilizumab","Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice",null,"Drug: L-ascorbic acid","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin",null,"Other: Human Biological samples","Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)","Drug: Valsartan (Diovan)|Drug: Placebo oral tablet",null,"Drug: Enoxaparin","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","Other: newborns from covid 19 positive mothers","Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment","Biological: Convalescent plasma",null,"Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","Drug: Anluohuaxian","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Favipiravir","Drug: Colchicine|Other: Local standard of care","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Biological: Dental pulp mesenchymal stem cells","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment","Dietary Supplement: Vitamins|Drug: Hydroxychloroquine|Drug: Imatinib|Drug: Favipiravir|Drug: Telmisartan","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment","Other: Retrospective data collection","Drug: Measles-Mumps-Rubella Vaccine","Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Procedure: Prone Positioning|Procedure: Standard of care.","Drug: BMS-986253","Biological: convalescent plasma","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","Other: Follow up",null,"Other: it is a survey","Drug: Eicosapentaenoic acid gastro-resistant capsules","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon 2b Spray","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet","Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)","Biological: CAStem","Other: Patient management suffering of coronavirus infection","Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment","Other: Psychoeducational intervention","Other: questionnaire assesment","Biological: Emapalumab|Biological: Anakinra","Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline","Behavioral: Mindfulness session(s)",null,"Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","Drug: Remdesivir","Drug: Hydroxychloroquine","Biological: Human Amniotic Fluid","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Behavioral: Personalized health education|Behavioral: General health education",null,null,"Drug: Anakinra|Drug: trimethoprim/sulfamethoxazole","Diagnostic Test: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)","Other: No special intervention","Other: Non-Interventional",null,"Drug: DAS181|Drug: Placebo","Biological: Umbilical Cord Mesenchymal Stem Cells|Other: Standard of Care","Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine",null,"Drug: Hydroxychloroquine|Drug: Placebo","Other: ICU treatment","Biological: anti-SARS-CoV-2 convalescent plasma","Device: CT-V","Other: Online Survey","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","Other: Survey","Drug: Placebos|Drug: Leronlimab (700mg)","Drug: T89","Biological: ChAdOx1 nCoV-19|Biological: MenACWY","Device: Cordio App",null,"Other: Thrombin generation test assay|Other: Fibrin generation markers assays","Device: Plasma Adsorption Cartridge","Other: Study A|Other: Study B|Other: Study C","Device: AirGo Respiratory Monitor","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","Drug: Sevoflurane|Drug: Intravenous drug",null,"Drug: Placebos|Drug: Leronlimab (700mg)","Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Other: modification of the planned therapeutic management","Drug: Plasma","Drug: Angiotensin 1-7|Drug: Placebos","Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment","Drug: Selinexor|Other: Placebo","Drug: Hidroxicloroquina|Drug: Control group",null,null,"Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Drug: Selinexor","Other: No intervention","Biological: IC14, a monoclonal antibody against CD14","Drug: Melatonin 2mg|Drug: Placebo oral tablet","Other: \"Calm\" is a mindfulness meditation mobile app","Other: observational","Drug: Plasma|Drug: Hydroxychloroquine|Drug: Azithromycin","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit",null,"Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Diagnostic Test: Sampling salivary","Other: oxygen treatment","Drug: Losartan|Other: Placebo","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Drug: Losartan|Other: Placebo","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc",null,"Other: telehealth applications","Drug: Intravenous Immunoglobulin|Other: Standard care","Other: quetionnary","Other: biological samples collection","Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir","Diagnostic Test: a specifically designed self-administered questionnaire","Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization","Other: No intervention",null,"Other: Self-administered questionnaires","Drug: Bevacizumab Injection","Other: Pulmonary Physiotherapy Techniques","Drug: Linagliptin|Drug: Insulin regimen",null,"Other: SARS-Cov-2 infection","Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Device: CT-imaging","Drug: Tofacitinib",null,"Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","Drug: Aviptadil by intravenous infusion + maximal intensive care|Drug: Normal Saline Infusion + Maximal intensive care","Biological: Convalescent Plasma","Drug: Alteplase 50 MG [Activase]|Drug: Alteplase 100 MG [Activase]","Procedure: Human biological samples","Drug: Methylprednisolone","Biological: Convalescent Plasma","Drug: Chemotherapy","Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG","Drug: Darunavir and Cobicistat","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab","Drug: Hyperbaric oxygen","Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148)","Other: mobile internet survey on self-test","Other: No intervention","Other: Questionnaire by phone call","Diagnostic Test: Nasopharyngeal swab","Drug: Nitric Oxide","Drug: Azithromycin|Drug: Chloroquine","Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Other: Patient sampling","Drug: Baricitinib","Drug: Ruxolitinib plus simvastatin|Other: Standard of Care","Drug: Peginterferon Lambda-1A","Other: Follow up","Other: Tele-medicine platform","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Other: Exposure to the SARS-CoV-2 and its consequences","Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos","Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo","Procedure: Facial fractures reduction or osteosynthesis","Procedure: Follow-up at 14 days","Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet","Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet",null,"Drug: Dexamethasone","Other: Data record","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo","Other: CT score","Other: Placebo|Drug: Remdesivir","Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin","Drug: CM4620-Injectable Emulsion","Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo","Behavioral: Tele-interventions related to diabetes management and mental well-being","Diagnostic Test: Lung ultrasound","Drug: Lopinavir/ritonavir","Diagnostic Test: COPAN swabbing and blood sample collection","Drug: Methylprednisolone|Other: standard care","Drug: Enoxaparin Prefilled Syringe [Lovenox]","Other: COVID-19 infection","Other: Prospective oberservational registry",null,"Drug: captopril 25mg","Drug: Ibuprofen",null,"Other: Survey administration","Other: self-administered questionnaire",null,"Drug: Immunoglobulin of cured patients|Drug: -Globulin","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Other: Simulation of Repurposed Drugs for COVID-19","Behavioral: Enhanced hygiene measures",null,null,"Drug: Favipiravir|Drug: Placebos","Other: PSS (Perceived Stress Scale)|Other: GAD-7 (7-item Generalized Anxiety Disorder)|Other: PHQ-9 (9-item Patient Health Questionnaire)|Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Other: Zaritt Burden Interview","Diagnostic Test: Machine learning model","Device: bidirectional oxygenation mouthpiece","Other: Cross-sectional study investigating the association of NPIs with mental health",null,"Drug: Inhaled nitric oxide gas","Other: SPIN-CHAT Program","Drug: Colchicine","Other: global survey",null,null,"Diagnostic Test: Collection of breath sample","Other: questionnaire assesment","Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information","Drug: Hydroxychloroquine|Other: Placebo","Drug: Experimental drug","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Device: Low flow ECMO driving by CVVH machine","Other: blood draw",null,"Drug: Recombinant human interferon 1","Biological: COVID-19 exposure","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","Behavioral: COVID-surgRES questionaire","Other: Standard interface|Device: Double-Trunk Mask","Device: SensiumVitals wearable sensor","Device: Medical Mask|Device: N95 respirator","Other: No intervention","Drug: Chloroquine|Drug: Nitazoxanide|Drug: Ivermectin",null,"Other: pregnant women with laboratory-confirmed 2019-n-CoV","Other: Postural Positioning","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2",null,null,"Diagnostic Test: Loop mediated isothermal amplification COVID-19|Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)|Diagnostic Test: Cytokine profile",null,null,"Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells",null,"Drug: Nitric Oxide Gas","Other: Spinal Anesthesia Position","Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine","Drug: Tocilizumab","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Other: retrospective analysis","Biological: Convalescent Plasma Transfusion|Other: Supportive Care","Diagnostic Test: Odd/Even birth year intervention groups","Other: no intervention","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Other: None - NA","Drug: Sarilumab SAR153191|Drug: Placebo","Drug: Favipiravir|Other: Standard of care treatment","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Placebo","Drug: Plaquenil 200Mg Tablet","Other: Satisfaction evaluation","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals",null,"Behavioral: online mindfulness group","Device: Inspiratory training device|Device: Expiratory training device","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Behavioral: Video based exercise",null,"Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","Other: pregnant women with laboratory-confirmed 2019-n-CoV",null,"Device: ECCO2R","Drug: NORS (Nitric Oxide Releasing Solution)","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Biological: Allogeneic NK transfer","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Drug: Stem Cell Product",null,"Behavioral: PTSD|Behavioral: Burnout","Other: Nutrition support","Drug: Sarilumab",null,"Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU","Biological: Convalescent anti-SARS-CoV-2 plasma|Drug: Sarilumab|Drug: Baricitinib|Drug: Hydroxychloroquine|Other: Injective placebo|Other: Oral placebo","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Drug: Group A HCQ|Drug: Group B Control","Other: Data collection","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","Drug: Arbidol|Other: basic treatment",null,"Drug: Hydroxychloroquine","Other: Exposure (not intervention) - SARS-CoV-2 infection",null,"Drug: Tradipitant|Drug: Placebo",null,"Other: COVID-19 Pandemic",null,"Drug: ACEIs|Drug: Conventional treatment","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","Other: Telerehabilitation",null,"Diagnostic Test: Standard 12-lead ECG, NT-proBNP, echocardiography","Other: Individualised Ayurveda","Diagnostic Test: Online questionnaire","Drug: Nitric Oxide","Other: no interventional study","Biological: mRNA-1273",null,"Diagnostic Test: Schirmer Test I","Other: Blood sample","Diagnostic Test: Serum SARs COV 2 IGg screening in health care workers",null,"Biological: NK Cells","Other: nosocomial infection/hospital acquired infection","Drug: Eculizumab",null,"Diagnostic Test: Biomarkers expression","Other: Observational Study","Drug: Spironolactone 100mg|Drug: Placebo oral tablet","Device: Non-contact MCE system","Drug: Nintedanib 150 MG|Other: Placebo","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis",null,"Drug: Escin|Drug: standard therapy","Drug: Nitric Oxide Gas","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care",null,"Device: Transpulmonary thermodilution|Device: Echocardiography","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: INO-4800|Device: CELLECTRA 2000","Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide","Other: Questionnaire","Diagnostic Test: nasopharyngeal swab","Drug: Inhaled budesonide","Drug: ACE inhibitor","Dietary Supplement: Ayurveda|Other: Usual Care",null,null,"Other: Hydroxychloroquine/Chloroquine","Procedure: Prone positioning","Device: Toraymyxin PMX-20R (PMX Cartridge)","Drug: Chloroquine|Drug: Placebo oral tablet","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","Behavioral: Use of social media during COVID-19","Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab",null,"Other: Comprehensive treatment","Drug: Interferon Beta-1B|Drug: Hydroxychloroquine","Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples","Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution","Drug: Anakinra",null,"Drug: Losartan","Biological: UC-MSCs","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group","Biological: Convalescent Plasma","Device: CPAP treatment","Biological: blood sampling","Procedure: venepuncture","Drug: VC|Drug: Sterile Water for Injection","Other: HOME-CoV rule implementation","Drug: Chloroquine diphosphate","Other: Questionnaire","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Biological: BCG Vaccine|Biological: Placebo Vaccine","Drug: Remdesivir","Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care","Diagnostic Test: Recombinase aided amplification (RAA) assay","Other: PEEP trial","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Drug: Colchicine|Drug: Placebo oral tablet","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values",null,"Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)","Other: Bacterial species isolated","Biological: 2019-nCoV PCR","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)",null,"Drug: Meplazumab for Injection","Other: standard operating procedures","Diagnostic Test: Serology|Genetic: Sequencing","Diagnostic Test: Thoracic CT Scan","Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Other: Video based aerobic exercise","Other: Telerehabilitation|Other: exercise brochure","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","Drug: Tocilizumab","Diagnostic Test: Spartan Cube Point-of Care Covid-19 test","Drug: Hydroxychloroquine|Other: Placebo","Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab","Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM","Other: retrospective analysis","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy",null,"Diagnostic Test: standardized Lung Ultrasound (LUS) examination","Drug: Methylprednisolone|Other: Usual Care","Device: TAVR or SAVR","Drug: Hydroxychloroquine Sulfate","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","Diagnostic Test: Thrombin Generation Assay (TGA)|Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)","Other: Telerehabilitation|Other: Exercise brochure",null,"Drug: Vitamin C|Other: Control",null,"Other: Study Group","Drug: Hydroxychloroquine|Other: Placebo","Other: Medically Tailored Meals",null,"Behavioral: Software Messaging","Other: Telerehabilitation-Based|Other: Video-Based","Other: Assessment of Dietary Changes in Adults in the Quarantine","Biological: MSCs-derived exosomes"],["Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay","Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality","Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19","Overall Mortality within 60 days|Length of ICU stay during current admission for COVID","The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay","Physical health symptoms|Lack of physical health symptoms|Fever","Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.","The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load","Decrease incidence of intubation by 30% or greater|Decrease renal injury","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number","All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate","Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function","Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Need for hospitalization|Duration of hospitalization|Need for ICU/Ventilator Support|Duration of ICU/Ventilator Support|Overall Survival","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor- concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:|Hierarchical composite outcome measures:|Time to hospital discharge|Total number of days alive, out of hospital, and/or free from mechanical ventilation|Total number of days alive, not in the ICU, and free from mechanical ventilation (as defined in the primary outcome measure)|Time to death from any cause|Time to new/worsened organ dysfunction|Time to acute kidney injury (defined as doubling of s-Creatinine compared to baseline)","Change in PaO2/FiO2|Patients achieving early response","Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score","For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased.","death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response","How vaccination and other attitudes are affected by COVID","Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)","Success rate in production of SARS-CoV-2 specific T cells from convalescent donor","Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures","Identification of prognostic factors for progression to a severe form of COVID-19 infection|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of clinical manifestations|Description of biological manifestations|Description of radiological manifestations|Description of physiological manifestations|Patient-related prognostic factors|Virus-related risk factors|Comparison of the results of different diagnosis tests","The immune function (TNF- IL-1IL-6TGF-IL-8PCTCRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time","The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score","SARS-CoV-2 infection status|Olfactory and gustatory loss|Ability to detect odor|Ability to detect salty taste|Ability to detect sweet taste|Severity of infection according to hospitalization rate","COVID-19 Clinical Status Scale (CCSS)|Clinical Status Scale|Return To Room Air (RTRA)|Death (all cause)|SARS-CoV-2 RNA undetectable|Percent of subjects discharged","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor- (TNF-) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations","Previous SARS-CoV-2 infection|Incidence of SARS-CoV-2 infection|Incidence of COVID-19|Incidence of hospitalization due to COVID-19|Level of neutralizing antibodies","Clinical response|Side effects in the treatment group","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS 2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS 2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events",null,"Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs","Treatment failure rate|Number of days alive free of assisted ventilation|Number of days with assisted ventilator use|Number of days hospitalized|Number of days in ICU|Number of days alive outside of hospital|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (AUC)","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure","Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|Transfusion-associated adverse events (AE)","Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency","Accuracy of nCapp COVID-19 risk diagnostic model","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Positive or negative character of the three tests|sensitivity and specificity of the tests according to the time elapsed since the first symptoms","Percent change in C-reactive protein (CRP) levels|Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of 2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate &gt;24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation 94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Change in serum CRP levels|Incidence of serious adverse events|Incidence of Grade 4 neutropenia (ANC &lt;500/mm3)|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Incidence of gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level","Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm","Health Outcomes","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score &lt;6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","Registry Data","Change in stress level as measured by survey|Change wellness as measured by survey","Incidence|Severity of Disease","Mortality|Days on invasive mechanical ventilation","Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature","Reduction in COVID-19 infection frequency|Antibody-screening","Need for supplementary oxygen|PAFI02 measure|Number of opacified quadrants on lung Rx",null,"Proportion of symptomatic patients with immune response (IgM/IgG/IgA)|Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)|Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement","Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)","Clinical improvement|Mean change in the 7-point ordinal scale|Mortality|Time to resolution of fever|Clinical improvement or fever resolution|Tachyarrhythmias|Mortality or tachyarrhythmias|Time to clinical improvement from admission using the 7-point ordinal scale|Change in NEWS2 score|Duration of hospitalization|PO2/FIO2","Lactate dehydrogenase (LDH)","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days","Successful treatment as determined by Negative Test and resolution of symptoms|Safety of Quintuple Therapy","FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.","Proportion of patients who progress to require advanced respiratory support","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Efficacy of Intervention|Time to improvement of one catergory from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","Maximum troponin level|Delta (baseline to peak) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (baseline to peak) C-Reactive protein (CRP) inflammatory biomarker level|Delta (baseline to peak) D-Dimer inflammatory biomarker level|Hospital length of stay|Number of participants requiring mechanical ventilation or ICU care|Re-hospitalization|All-cause mortality","Severe COVID-19|Death","change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease","Incidence of confirmed COVID-19|Incidence of probable or suspected COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of COVID-19 on participants' financial status|Incidence of physical complications of COVID-19|Impact of COVID-19 on participants' mental well-being","28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement","Antibody titres to SARS-CoV-2","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Lung infiltrates|Viral load of SARS-CoV-2","Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Number of days until complete resolution of symptoms per group|Number of hospital admissions per group|Number of days until a reduction in symptoms per group|Number of adverse events per group","Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline","Rate of COVID-19 positive conversion|Time-to-first clinical event","Most severe outcome","Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6 (IL6) level|Change of plasma Interleukin-10 (IL10) level|Change of plasma Procalcitonin (PCT) level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation","Change in clinical conditions|Change of Clinical symptoms - respiratory rate|Hypoxia|Changes of blood oxygen|Inflammatory parameters|Evolution of Acute Respiratory Syndrome|Hospital discharge|ICU discharge|Rate of mortality","intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event","Assess the rate of requirement of invasive mechanical ventilation|Mortality|Septic shock as defined by sepsis-3 criteria|Degree of severity of respiratory disease","Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient","Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate","Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine","i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality","Number patients developing severe infection or death","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events","Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 28 days|ICU admission|Mechanical Ventilation|Mortality","Frequency of Adverse Events|SARS-CoV-2 antibodies|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination|Seroconversion of circulating anti-Spike IgG antibodies &amp; stability of serum IgG titers|Effectiveness of intestinal colonization of the probiotic-based bacTRL-Spike oral vaccine","Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation","Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)|Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale","Incidence of serious adverse events associated with clazakizumab or placebo|Incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient survival","Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events","ECG changes associated with COVID-19","Category Changes in Ordinal Scale|Time to category 5, 6 or 7 of the ordinal scale|Mortality of any cause at 15 days|Mortality of any cause at 29 days|Oxygenation free days|Ventilator free days|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load","Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections","COVID-19 infection","Number of confirmed COVID-19|Number of severe COVID-19","Outcome comparison between different antiviral therapies|Outcome comparisons between ventilation types|Identification of risk factors|Number of days in hospital vs. clinical classification","Clinical outcome|CT Scan|RT-PCR results","To evaluate the safety and efficacy of vazegepant compared with placebo in patients hospitalized with COVID-19 infection requiring supplemental oxygen.|The number of unique subjects alive and off of oxygen. These are subjects in categories 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|A subject requiring initiation of mechanical ventilation, non-invasive ventilation, or a high flow nasal cannula is a subject that has any eCRF showing the use of any such device on any day.|The number of unique subjects admitted to an ICU verse those not admitted.|Subjects are alive and respiratory-failure free if they are categorized as being in categories 3, 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Subjects are alive and free of either mechanical ventilation or non-invasive ventilation if they are categorized as being in categories 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Efficacy on Day 29 will be evaluated using the same 6-point severity scales that is used at Day 15.|Time to improvement of one category on the 6-point severity scale will be determined as the number of days from baseline to the first day that an eCRF indicates a one category improvement in the scale.|A 48-hour improvement in SpO2/FiO2 consists of two consecutive days where the case report forms show a clinically meaningful increase from baseline.|The time to improvement in the in the NEWS2 scale will be determined as the number of days from baseline to the first eCRF that shows an improvement.|A score &lt; 2 for 24 hours on the NEWS2 scale consists of a day where all of the reported NEWS2 scores are &lt; 2.|The change in NEWS2 scores will be determined as the change from baseline at Day 15 and at Day 29.|The number of unique subjects alive and off of oxygen.|A day with a resting respiratory rate &gt; 24 is a day in which all eCRFs collected for a subject indicate observed respiratory rates &gt; 24 breaths per minute.|A day with supplemental oxygen is one in which any case report form collected on that day indicates the use of any amount of supplemental oxygen.|Time to saturation greater than or equal to 90% on room air is measured by the number of days from baseline to the first day on which an eCRF indicates saturation greater than or equal to 90% without any supplemental oxygenation.|A ventilator free day is a day in which all of the eCRFs collected indicate that the subject was not using a ventilator.|SOFA scores will be determined from eCRFs. Values will be determined for subjects at admission to an ICU and for all subjects still in an ICU at the end of the study (Day 29).|The number of days of hospitalization will be determined from eCRFs. A hospitalization day is any day that it is shown that a subject spent at least spent part of the day in a hospital.|Time to fever resolution, without antipyretics, during two contiguous days .|The number of deaths, SAEs, severe AEs and Grade 3 or 4 laboratory abnormalities will be tabulated as the number of unique subjects meeting those criteria.|The incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infections will be tabulated as the number of unique subjects, reported in eCRFs, as having these conditions at any point in the study|The incidence of intranasal administration reactions will be tabulated, from eCRFs, as the number of unique subjects having such a condition at any point in the study.|The percentage of subjects who develop significant renal disease.|The percentage of subjects discharged to home on supplemental oxygen will determined from the unique number of subjects have eCRF pages indicating they were discharged to home while still on supplemental oxygen.","Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days","discrimination|Calibration|Net benefit","Survival rate|body temperature","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count","The time from randomization to clinical improvement","Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;","Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary  36.6  C, oral  37.2  C, or rectal or tympanic  37.8  C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 &lt;93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute &lt;500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT 3 times ULN (for patients with initial values normal) or&gt; 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.","Clear chest CT-scan|PCR test|Physical statues of patient","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of &lt;/= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Organ Failure-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Total Leak Volume of Non Invasive Ventilation Mask|Glasgow Coma Scale(GCS)|Respiratory Rate|Heart Rate|Metabolic Data: Blood Gas Measurements|Metabolic Data: Bicarbonate (HC03)|Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)|Metabolic Data: Partial Pressure of Oxygen (Pa02)","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence","Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time","Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of  2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-, IL-1, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1 and other cytokine expression levels before and after treatment","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","COVID-19 positive case","Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways","Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic/diastolic blood pressure &gt; 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)","Effect of HCQ on in vivo viral clearance","Time of physiotherapy|Type of physiotherapy implemented","Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality","Time to disease progression|Change in symptom severity over time","Safety indexes of adverse reactions|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule day 0,14|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)|Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)|Safety indexes of serious adverse events (SAEs|Immunogenicity indexes of neutralizing-antibody seroconversion rates|Immunogenicity indexes of IgG antibody seropositivity rates|Immunogenicity indexes IgM antibody seropositivity rates|Immunogenicity indexes of GMT of neutralizing-antibody|Immunogenicity indexes of GMR of neutralizing-antibody","Hospitalization","IL6 concentration|IL6 concentration change from baseline value|Complement parameters|Complement parameters change from baseline values|Inflammatory cytokines baseline concentrations|Inflammatory cytokines change from baseline values|Concentration of markers of macrophage activation|Markers of macrophage activation change from baseline values","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","negative testing of covid19","Mortality|Severe disease","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways","60-day mortality|Ventilator-free days","Sequential Organ Failure Assessment (SOFA) scores|7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|All-cause mortality|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death","All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction","COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications","The change of pneumonia severity on X-ray images","to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival","Number of different arrhythmias|Temperature|Oxygen Saturation","Occurrence of adverse reactions|Anti SARS-CoV-2 S antibody response(ELISA)|Neutralizing antibody response to SARS-CoV-2|Occurrence of adverse events|Occurrence of serious adverse reaction|Neutralizing antibody response to Ad5-vector","Exploring the presence of COVID-19","Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI","All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Rate of Death|the severity of pneumonia","Predictive values of CT criteria|Accuracy of CT composite severity score|Accuracy of deep-learning based score|Predictive values of deep-learning based diagnostic algorithms|Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities","Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)",null,"Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Overall mortality|Mechanical ventilation","Viral clearance|Clinical improvement|Radiological Improvement","Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale 6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs","Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms","Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate","Proportion (%) of subjects experiencing deterioration in clinical status|Treatment Emergent Adverse Events|Clinical status|Improvement in clinical status|Sequential Organ Failure Assessment (SOFA) score|Change from baseline in PaO2/ FiO2|Length of time to normalization of oxygen saturation|Change from baseline in percentage of subjects requiring mechanical ventilation|Change from baseline in Glucocorticoid use|Mortality rate from any cause|Length of hospitalization|Change from baseline in D-dimer|Serum concentration of TJ003234|Incidence and titer of anti-drug antibodies (ADA)","time to clinical improvement|Safety of treatments|Tolerability of treatments","symptoms of COVID-19 in older patients","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events","Incidence of invasive mechanical ventilation (IMV) and/or Mortality|Incidence of acute respiratory distress syndrome (ARDS)|Duration of Hospitalization|Duration of Intensive Care Unit (ICU) Stay|Ventilator-free Days|Incidence of Non-invasive Ventilation|Proportion of Participants Alive and Off Oxygen|Percentage of Participants Experiencing Adverse Events|Percentage of Participants Experiencing Serious Adverse Events","Health Care Workers absenteeism|The cumulative incidence of documented SARS-CoV-2 infection|The number of days of unplanned absenteeism, because of documented SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS-CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (38 gr C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented SARS-CoV-2 infection|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection|The cumulative incidence of Hospital Admission for any reason|The cumulative incidence of Hospital Admission due to documented SARS-CoV-2 infection|The incidence and magnitude of SARS-CoV-2 antibodies at the end of the study period","incidence of confirmed COVID-19|Effectiveness of BCG vaccine","Dominant viral genome strain","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|Time to viral PCR negative from rectal swab|fever clearance time|Ordinal outcome scale|Development of ARDS","To determine SARS-CoV-2 viral load and infectivity insaliva that may contribute to asymptomatic transmission|Viral load of salivary droplets generated from speaking","Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve of total symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset","COVID-19 Seroconversion rate|Admission for Covid-19","Number of participants who fill out the survey and participate in the semi-structured interviews.","Risk categorization of healthcare workers|COVID-19 infection rate among health care workers|Risk factors for COVID-19 among health care workers|Adherence of health care workers to infection prevention|Validity of the available rapid serological test for detecting COVID-19 virus infection|Clinical spectrum of COVID-19|Effectiveness of infection prevention in the health care facility|Emergency infection prevention and control needs|Isolation rate and emergency health care worker replacement needs|Rate of seroconversion","Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score &lt;3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases","The PaO2/FiO2 ratio at D7|Changes in Tregs between Baseline and Day 7 (expressed in %)|Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time (in days) from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Use of antibiotics for respiratory (proved or suspected) infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma","Improvement of COVID-19 disease status|Disease progression of COVID-19|All cause of death|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of oxygen therapy|Length of hospital stay|Absolute lymphocyte count","Identification of serious COVID-19 infections|Pneumonia infections|ICU stay|Oro-tracheal intubation|Death","Pneumonia severity index|Need for ICU admission|COVID -19 test conversion|Mortality","Documentation of natural course and the therapeutic landscape of patients with COVID-19.","Number of Ventilator Free Days|Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment|Oxygen Saturation (SpO)|Oxygen Flow Rate|Mortality|Length of Hospitalization|Number of Participants with any Serious Adverse Event (SAE)|Number of Participants with any Treatment Emergent Adverse Event (TEAE)","to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.","Web-based REDCap survey","Changes of oxygenation index (PaO2/FiO2)|Side effects in the BM-MSCs treatment group|Clinical outcome|Hospital stay|CT Scan|Changes in viral load|Changes of CD4+, CD8+ cells count and concentration of cytokines|Rate of mortality within 28-days|Changes of C-reactive protein","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery","Seroconversion","Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune","Size of lesion area and severity of pulmonary fibrosis by chest CT|mMRC (Modified Medical Research Council) dyspnea scale|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Blood oxygen saturation|CD4+ T cell count and cytokine level|Side effects in the MSCs treatment group|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","Seroconversion against SARS-CoV2 in children of the Parisian area|Protective immunity|Measure of Ab antiN and Ab anti-S1|Neutralization activity|Positive qPCR|correlation between different Ab and qPCR and neutralization activity|correlation of the NGBiotech rapid test with the classical serological result|correlation of the NGBiotech rapid test with qPCR results|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|correlation of LIPS, the NGBiotech rapid test with the classical serological result|COVID-19 Symptom|seroconversion against SARS-CoV2 in parents of the Parisian area|Intra-family correlation of serological results|Measure of Ab antiN and Ab anti-S1 and neutralization activity|correlation between different Ab and qPCR","Days alive and out of hospital within 14 days after recruitment|Key-secondary composite endpoint: Occurrence of worsening of COVID-19|Occurrence and time to occurrence of each of the components of the key-secondary composite endpoint|Kidney function|Duration of index hospitalisation|30-day mortality|Number of days alive during the intervention period|Discharge beyond 30 days|Number of readmissions after 30 days.","Primary endpoint|Secondary endpoint","Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90","Day-28 mortality|Ventilator-free days|Intensive Care Unit mortality|Day-60 mortality|Nosocomial pneumonia|Bacteremia","Evolution of consumption|health care access","Duration of viral shedding in days|Time to clinical recovery (TTCR) in days|Treatment-emergent adverse events (AEs)|Requirement for non-invasive or mechanical ventilation|Length of hospital stay in days|Estimated PaO2/FiO2 ratio on day of discharge|All-cause mortality|Patients reaching undetectable COVID-19 virus levels in respiratory secretions|Duration of symptoms and signs of respiratory infection in days|Need for supportive respiratory management|Viral load|Treatment-emergent serious AEs (SAEs)|AEs leading to withdrawal|Treatment-emergent abnormalities in clinical laboratory parameters","Safety and Tolerability of SAD of TD-0903: Adverse Events|Safety and Tolerability of MAD of TD-0903: Adverse Events|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax","Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation","Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1, IL-6, IL-8,IL-10,TNF-)|Concentration of the myocardial enzymes","epidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells","Time to normalize the oxygen requirement (oxygeno-dependence)|Days of hospitalization between the HBO group and the control group.|Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.|Days on invasive mechanical ventilation|Mortality","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","Number of patients with virological cure","Intraoral viral load|Salivary cytokine profile","Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria","Efficacy of a L-MOD against controls receiving supportive care in ICU.|Mortality|Hospital Discharge|Leukocyte Monitoring|Sequential Organ Failure Assessment (SOFA) Score|Intubation length|Markers of Inflammation|Leukocytes and Macrophages|Myocardial damage|Renal recovery","Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality","Percentage of patients with normalization of SpO2 96%|Proportion of patients with temperature &lt; 37,5 C armpit.|Proportion of patients discharged from the emergency department and classified as low risk|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in SARS-CoV-2 RT-PCR test|Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)","lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days","the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days","Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment","Duration of hospitalization|Duration of disease|Hospital-aquired pneumonia|ICU stay duration|Oxygene therapy duration|Mechanical ventilatory support duration",null,"Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion","Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs standard of care with symptomatic improvement|Percentage of subjects on Lambda vs standard of care with improved clinical outcomes","The positivity (Yes/No) of the serological test.","Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity","Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.","White blood cell counts|Lymphocyte populations|Cytokines|Lectin complement pathway|Microorganisms|Respiratory pathogens|Ribosomal RNA in the airways|Levels of SARS-CoV-2 in the airways","Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality","Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19","28 day all cause mortality|90 day all cause mortality|Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days|duration of mechanical ventilation support|Ventilator Associated Pneumonia|Bleeding complications|Acute Renal Failure|Discharge Location","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay","Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score","Number of participants with symptomatic, lab-confirmed COVID-19.","The time-to-death from all causes|The time to need for mechanical ventilation (MV)|The viral load in the respiratory tract|Number of patient with at least one episode of healthcare-associated infections|Number of days alive without mechanical ventilation|Measure of SOFA score|Number of days alive without renal replacement therapy|Lengths of ICU-stay|Lengths of hospital-stay|Number of patients with severe hypoxemia,|Number of patients with cardiac arrest within 1 hour after intubation","Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19|Number of missed telehealth clinical evaluation visits during COVID-19|Number of unplanned emergency department visits or hospital admissions during COVID-19|Number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during COVID-19","Change in COVID-19 severity status","Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel","Time to reach clinical stability|Time to reach an afebrile state for 48 hours.|Time to reach PaO2 / FiO2&gt; 400 and / or SatO2 / FiO2&gt; 300|Time to reach FR  24 rpm for 48 hours|Time to normalization of D-dimer (&lt;250 ug / L)|Time until PCR normalization (&lt;5mg / L).|Time until normalization of ferritin (&lt;400ug / L)|Study the impact of immunosuppressive treatment on viral load using quantitative PCR|Time until hospital discharge|Need for ventilatory support devices|Duration that it is necessary to maintain ventilatory support.|COVID-19 mortality|all-cause mortality|Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.","Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2/FiO2 300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) &gt;94% for at least 24 hours.","Changes in the patients' clinical status through the 7 points ordinal scale WHO|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity","Accuracy of the diagnosis of interstitial syndrome by lung ultrasound|Inter-observer variability","Ventilator-free days|Mortality|Sequential Organ Failure Assessment Score|P/F ratio|Lung compliance|Radiological score|Biological efficacy endpoints - C-reactive protein|Biological efficacy endpoints - Procalcitonin|Immunological profile|Number of patients using other treatments for COVID-19 related ARDS|Occurrence of deep vein thrombosis or pulmonary embolism|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Kidney Disease: Improving Global Outcomes (KDIGO) score and need for dialysis|Occurrence of adverse event related to immunoglobulins|Occurrence of critical illness neuromyopathy|Occurrence of ventilator-acquired pneumonia","number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (YFV) titer (Group A)|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)|mortality","Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician","Prevalence COVID antibodies in employees of Beaumont Health","Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results","viral COVID-19 clearance|Decrease of radiological abnormalities|Clinical improvement","Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Safety and tolerability of convalescent plasma.","Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale 5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events","Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration","Sensibility|Specificity","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival","Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)","Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality|Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D (3l)","Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.","Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 (nave/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure|Mortality rate|Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress|Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure|Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization)","Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge","Evaluate the safety and efficacy of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay","Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 &lt;90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths","Requirement for invasive ventilation|Time to viral clearance|Radiological Improvement|Reduction in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate","1. Mortality rate|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale &lt;= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines","Time-to-clinical improvement|Responders|Critical or dead patients|pO2/FiO2 ratio|SOFA score over time|Hospitalization|Mechanical ventilation|Mechanical ventilation duration|Cardiovascular disease","Major adverse cardiovascular events(MACEs)|Death","50% reduction in symptom score for patients with lower respiratory tract infection|Lack of progression for patients with upper respiratory tract infection|Comparison of the primary endpoint with respective patients not receiving the treatment|Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.|Frequency of AEs and SAEs","Frequency of cardiac arrhythmias|Mode of death","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2","Number of participants with improvement from severe type to common type","The rate of COVID-19","Disease-Aggrevation|Complications","ICU length of stay|Safety of convalescent plasma &amp; Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .","Physical symptoms|Contact History|Travel History|Fever|Headache|Soar Throat|Runny nose|Cough|Shortness of breath|Nausea|Vomiting|Muscle pain|Joint pain|Diarrhoea|Other|Hospitalisation history|Co-morbid conditions","Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|World Health Organisation (WHO) progression scale","Assessment of weaning from cardiorespiratory support|Assessment of hemodynamic status|Assessment of pulmonary function|Assessment of hepatic function|Assessment of renal function|Assessment of cardiac function|Assessment of cardiac injury|Assessment of the course of COVID-19 infection|Assessment of clinical outcome and safety","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","HACOR score efficacy|HACOR score addaptation","Percentage of serological positive healthcare workers|Percentage of HCW with positive Saliva-sabs","Prevalence of SARS-CoV-2 antibody titres|Prevalence of SARS-CoV-2 antibody titres after 3 Months","Survival without needs of intubation at day 14|Change in organ failure at day 3|OMS progression scale 5 at day 4|OMS progression scale at days 4, 7 and 14|Survival at 14, 28 and 90 days|Time to discharge|Time to oxygen supply independency|Time to negative viral excretion|Incidence of secondary infections|Vasopressor-free survival|Ventilator-free survival|28-day ventilator-free days|Incidence of dialysis|PaO2/FiO2 ratio|Rate of respiratory acidosis at day 4|Time to ICU discharge","overall response rate in reversal of hyperinflammation","intrapulmonary shunt ratio|Evolution of respiratory variables|Evolution of hemodynamic stability variables","Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of  2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events","Admission to Intensive Care Unit","Number of cured patients|Number of participants with treatment-related adverse events","Success rate of intubation|Infection rate of Anesthesiologist|Extubation time","Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Allgemeine Selbstwirksamkeit Kurzskala (ASKU)|Screening Tool for Psychological Distress (STOP-D) - selected items","Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin&gt; 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation &gt;99th|Association with elevation of serum creatinine &gt;30%|With the onset of chronic renal failure (eDFG &lt;60 ml / min / 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital","Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life","Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year","Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)","Efficacy of intratracheal administration: occurrence of at least one grade improvement","Comparison of inflammatory/immunological biomarkers &lt;72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH (as defined by HS score)","30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events","Hospital Anxiety and Depression Scale questionnaire|Quality of life (SF36)|self-reported questionnaire for painful|qualitive questionnaire","percentage of patient with feeling of disabilities","Critical condition or death|IL-6","Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status","Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events","Survival rate in asymptomatic subjects at inclusion|Survival rate in symptomatic subjects at inclusion|Survival rate in overall subjects|Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion","Comparison of the percentage of clinically improved inpatients between D0 and D14","Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury","impact of the COVID-19 pandemic on psychiatric symptomatology","Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|\" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome \"","Number of antibodies against coronaviruses isolated and identified from patient samples","Viral clearance kinetics|Treatment-related adverse events of nivolumab (Intervention arm only)|Lymphocyte kinetics|Cytokine kinetics|Length of inpatient stay due to COVID-19","Proportion of patients that require mechanical ventilation|Requirement for inotropes and/or vasopressors|8-level Clinical improvement Scale|Duration of mechanical ventalition|Hospital discharge|Mortality|Duration of ICU stay|Duration of time on supplemental oxygen|The proportion of patients who require renal replacement therapy or have doubling of creatinine","Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Hospital mortality|Length of stay in the intensive care unit","Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","Percentage of virus free subjects|Disease severity|Incidence of hospitalization|Incidence of Death|Incidence of confirmed SARS-CoV-2 Detection|Incidence of all-cause study medication discontinuation or withdrawal|Immunity to Covid-19","Clinical data of lung cancer patients with COVID-19 diagnoses|Diagnosis data|Treatments received|Prognostic factors","Antiviral Activity|Improvement of oxygenation|Safety &amp; Tolerability: incidence of TEAEs and serious adverse events (SAEs)","Level of IFN-gamma after a non-specific stimulation of T lymphocytes","improvment or healing of clinical signs|Evolution of clinical signs","Reduction in the number of COVID-19 infections in healthcare workers.","28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)","Rate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatment",null,"Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes|Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival","Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths","Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days|Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days","Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC &gt; 0.85).|Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC &gt; 0.85).|Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve|Change of heart rate from baseline (hospitalization) to ICU admission|Change of heart rate variability from baseline (hospitalization) to ICU admission|Change of skin temperature from baseline (hospitalization) to ICU admission|Change of blood oxygen saturation from baseline (hospitalization) to ICU admission|Change of respiration rate from baseline (hospitalization) to ICU admission|Change of physical activity from baseline (hospitalization) to ICU admission|Change of stress level from baseline (hospitalization) to ICU admission|Change of sleep pattern from baseline (hospitalization) to ICU admission|Change of steps per day from baseline (hospitalization) to ICU admission|Change of blood pressure from baseline (hospitalization) to ICU admission|Change of body temperature from baseline (hospitalization) to ICU admission|Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission|Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission|Change of blood pH from baseline (hospitalization) to ICU admission|Change of bicarbonate from baseline (hospitalization) to ICU admission|Change of base excess from baseline (hospitalization) to ICU admission|Change of oxygen flow rate from baseline (hospitalization) to ICU admission","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring|All-cause mortality","Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.|Overall survival of patients on Dexmedetomidine|Daily analgesic effect of Dexmedetomidine|Other sedative pharmacological agents|Average dosage required for Dexmedetomidine to achieve mild to moderate sedation","RT-PCR negative status|Progression of symptoms|Mortality","Status of Immunization","Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity","Survival|Fragilty","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","Incidence of adverse events|Incidence of serious adverse reactions|Incidence of adverse reactions|Ventilator-free days|ICU-free days|Hospital-free days|All-cause mortality|Change in S/F ratio during HDIVC infusion|C-reactive protein (CRP)|Lactate dehydrogenase (LDH)|D-dimer|Lymphocyte count|Neutrophil to Lymphocyte ratio (NLR)|Serum Ferritin","COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Febrile respiratory illness|Episodes of febrile respiratory illness|Work absenteeism due to febrile respiratory illness|Bed confinement due to febrile respiratory illness|Symptom duration of febrile respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with febrile respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers","Symptomatic COVID-19|Peak severity of COVID-19 over the study period","CRP increase to 3 x upper limit of normal|Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&amp;D committee|Maximal concentration of cardiac troponin","Incidence of unexpected adverse events|Improved oxygen saturations 93%|Decrease in oxygen supplementation by non-invasive or invasive interventions|Frequency of progression to mechanical ventilation or ECMO|Duration of mechanical ventilation|Duration of ICU stay|Duration of hospital stay|All-cause mortality at day 28","Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function","Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.","all-cause mortality|Severe state","Number of ventilator-free days|All-cause-mortality|Acute-inflammation-free days|Organ-failure-free days","Laboratory Result|Clinical Outcome","Covid 19 Anxiety levels in Endometriosis Patients","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies","Prevalence of oropharyngeal dysphagia|Swallowing screening|Swallowing status.|Nutritonal status of study patient's.|Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).|Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).|Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions).|Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions).|Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department).|Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department).|Clinical complications at 6 months follow up from patient's medical history (respiratory complications).|Clinical complications at 6 months follow up from patient's medical history (mortality).","first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury","Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis|Distribution of COVID-19 risk factors by participant characteristics|Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)|Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study|Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment","Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Evaluation of apgar status of newborns from covid 19 positive mothers","Ventilation requirements|Crude mortality|Time to clinical improvement|Time until improvement in oxygenation|Patients requiring invasive mechanical ventilation|Patients having negative COVID-19 CRP at each visit|Mean of serum cytokine levels|Adverse events related to medication and its administration|Appearance of serious bacterial, fungal or opportunistic infections|Perforation of the gastrointestinal tract|Leukocyte and neutrophil count|Hemoglobin levels|Platelet count|Levels of creatinemia|Bilirubin levels|ALT and AST levels","Lung injury|Overall survival|Adverse reactions to plasma","Rate of secondary aggravation|Change of standart biological parameters|Change of Von willebrand factor (vWF) changes over time|Change of the Factor VIII (FVIII)|Prevalence of positivity of COVID-19 virus measured by PCR or serology","Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA","Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung","Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events","Viral nucleic acid test negative conversion rate|Clinical cure rate","All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.","Sensitivity spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time","Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen","Clinical recovery time","Proportion of participants with an occurrence of hospitalization|Death|Proportion of hospitalizations, overall and by cause, in each group|Death and causes of death|Proportion of intensive care hospitalizations, overall and by cause, in each group|Proportion of participants with negative nasopharyngeal SARS-CoV-2 RT-PCR|Proportion of participants with a loss of autonomy evaluated by the ADL and IADL scale|Haematological markers evolution|Biochemical markers evolution|Inflammatory markers evolution|Immunological markers evolution|Adverse events|Adverse reactions|Plasma concentration|Acceptability of the treatment","RT-PCR negative status|Progression of symptoms|Development of Symptoms|Adverse events","Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events","Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.|Determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ED|Identification of the ratio of patients with mild or moderate to severe disease","COVID-19 disease incidence|SARS-CoV-2 pneumonia|Critical care admission duration with SARS-CoV-2|Oxygen therapy with SARS-CoV-2","COVID-19-related hospital admissions|Symptoms related to COVID-19 infection|Adverse Events|Maternal outcomes|Newborn outcomes","Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses","The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.|Length of time tolerating prone positioning|PaO2/FiO2 measured before prone positioning|PaO2/FiO2 ratio after 1 hours of prone positioning|SpO2/FiO2 ratio measured before prone positioning|SpO2/FiO2 ratio after 1 hours of prone positioning|Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc)|Work of breathing assessment (Respiratory distress scale)|Changes in bioimpedance measures of lung edema in patients in PP|Use of awake prone positioning as a rescue intervention in control patients","Time to Improvement in the 7-point ordinal scale|Time to Death|Time to Intubation|Proportion of patients requiring ICU admission|Mortality at 1 month","Clinical improvement|improvement in tomographic image|test positivity for COVID-19|early and late complications associated to convalescent plasma|days at ICU","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival","prevalence|Favorable outcome","Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery","State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)|Visual numeric scales assessing anger and stress the ongoing week.|Beck Depression Inventory","Evaluation of EPA-FFA efficacy compared to standard of care|Increase in oxygen saturation|PaO2/FiO2 &gt;300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction","Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality","Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost","Clinical severity|EDSS (Expanded Disability Status Scale)","Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9/L)|Alanine aminotransferase (U/L)|Creatinine (umol/L)|Creatine kinase (U/L)|C-reactive protein (mg/L)|Procalcitonin (ng/L)|Lactate (mmol/L)|IL-1beta (pg/mL)|IL-2 (pg/mL)|IL-6 (pg/mL)|IL-8 (pg/mL)","Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit","changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events","Anxiety 1 month|Anxiety 3 months|Depression 3 months|Post Traumatic Stress Disorder (PTSD) symptoms 3 months|Anxiety 12 months|Post Traumatic Stress Disorder (PTSD) symptoms 12 months|Depression 12 months","Frequency of RA patients with emotional impact (feeling of isolation)|self-reported questionnaire for painful","Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge","Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples","Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference","Identification of prognostic parameters for SARS-CoV-2 infected participants.|Investigation of the kinetics of immune activation and antibody production against SARS-CoV-2 and correlation with clinical course","POCUS Score - Lungs|POCUS Score - Heart",null,"Time to resolution of symptoms|Number of days from onset of illness to symptom resolution|Number of days to return to work|Rate of hospital admission in treated and untreated healthcare workers|Adverse effect of HCQ during treatment","Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care","Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.","Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae","The ratio of patients who will not develop serious respiratory failure (SRF)|Comparison of the rate of patients who will not develop serious respiratory failure (SRF) until day 14 with historical comparators from Hellenic Sepsis Study Group Database|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14|Change of SOFA score in enrolled subjects between days 1 and 7|Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14|Cytokine of cytikine production between days 1 and 7|Change of plasma inflammatory mediators levels between days 1 and 7","ICU CV risk and Biomarker (e.g. Troponin)|CV risk and Outcome during ICU stay","Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients","Prevalence|Incidence","The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial","Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement","Incidence of pre-specified infusion associated adverse events|Incidence of Severe Adverse Events|Survival|Ventilator-Free Days|Change in Oxygenation Index (OI)|Plat-PEEP|Sequential Organ Failure Assessment (SOFA) Scores|Small Identification Test (SIT) scores|Troponin I levels|C-Reactive Protein levels|Arachidonic Acid (AA)/Eicosapentaenoic Acid (EPA) Ratio|D-dimer levels|25-Hydroxy Vitamin D levels|Alloantibodies levels|Blood white cell count|Platelets count","Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result|Clinical accuracy of the rapid tests based on Clinical diagnosis|Self-test interpretation of result vs expert clinical image interpretation of result|Ease of self-testing procedure","Number of people with detectable antibodies to SARS-COV2","COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28","ICU mortality|Hospital mortality|ICU length of stay","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)","Predictive association between CT-V, PBM score and disease progression","Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21|IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21","interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate","International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Perceived Stress Scale|Numerical Pain Rating Scale","Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|Time to clinical resolution (TTCR)|Change from baseline in National Early Warning Score 2 (NEWS2)|Change from baseline in pulse oxygen saturation (SpO2)|Change from baseline in the patient's health status on a 7-category ordinal scale|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity","The time to oxygen saturation recovery to normal level (97%)|The proportion of patients with normal level of oxygen saturation(97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19","Voice anaysis","Death or need of intubation|30-day mortality","Survival rate during hospitalization|Absolute thrombin generation test latent period|Relative thrombin generation test latent period compared to reference plasma|Absolute thrombin generation test initial velocity|Relative thrombin generation test initial velocity compared to reference plasma|Relative thrombin generation test peak thrombin compared to reference plasma|Absolute thrombin generation test peak thrombin|Absolute thrombin generation test peak thrombin time|Relative thrombin generation test peak thrombin time compared to reference plasma|Absolute thrombin generation test total thrombin generation time|Relative thrombin generation test total thrombin generation time compared to reference plasma|Absolute thrombin generation test endogenous thrombin potential|Relative thrombin generation test endogenous thrombin potential compared to reference plasma|Transfer to intensive care unit during hospitalization|Thrombotic complication during hospitalization|Plasma concentrations of D-dimers|Plasma concentrations of soluble fibrin monomers","All-cause mortality|Change in SOFA scores","Identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for ICU treatment (binary, yes/no)|duration of hospitalization (in days)|duration of Intensive Care Unit (ICU) stay (in days)|in-hospital mortality (binary, yes/no)|Number of infected cases within the city of Basel|whole genome sequencing to study pathogen evolution","Endotracheal intubation during present hospitalization, recorded through chart review|Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review|Premature need for removal of the band, recorded through investigator report|In-hospital mortality, recorded through chart review","To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events","Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28|Length of stay ICU|Plasma Inflammatory markers|Length of stay at hospital|Sex-related differences in complications","percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died","All-cause mortality at Day 28|All-cause mortality at Day 14|Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)|Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)|Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.","A composite score based on all-cause mortality and the number of ventilator free-days (VFD)|All-cause mortality (intention to treat)|Ventilator-free days (VFD)|All-cause mortality with per protocol analysis|Time to successful extubation|Length of hospital stay|Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|Daily sedation dose during the first 14 days of the study|Rate of use of rescue therapies|Incidence density rate of severe mixed acidosis|Incidence density rate of ventilator associated pneumonia|Incidence density rate of acute cor pulmonale|Incidence density rate of barotrauma|Incidence density rate of any serious adverse events|Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test|Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score|Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call|Cost-efficacy ratio of the innovative strategy compared to the reference strategy","Cumulative incidence of composite outcome of disease severity|Anti-SARS-CoV-2 titers|Rates of SARS-CoV-2 PCR positivity|Duration of SARS-CoV-2 PCR positivity|Peak quantity levels of SARS-CoV-2 RNA|Cumulative incidence of disease severity","Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Day 30 mortality|Change in NEW(2) score from baseline to day 30|Admission to ICU|Use of invasive mechanical ventilation or ECMO|Duration of supplemental oxygen (days)|Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30","percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)","Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings","lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days","Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Number of Participants with Overall Death Rate|Number of Participants With Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Change in Vienna Vaccine Safety Initiative (ViVI) Disease Severity Score|Time to Clinical Improvement in Participants  70 Years Old|Time to Clinical Improvement in Participants &gt; 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of &gt;1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE)","Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events","The incidence of cardiovascular complications in patients with COVID-19","Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days","Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged From Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants  70 Years Old|Time to Clinical Improvement in Participants &gt; 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of &gt;1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Number of Participants with Adverse Events (AE)","Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor|Determination of the seroprevalence of COVID-19 infection in both groups of the study|Comparison of the severity of COVID-19 infection symptoms in both groups of the study.|Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor",null,"SARS-CoV 2 infection rate","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire","ICU and hospital mortality of COVID-19 patients|30 days mortality","Change in Viral Load|Change in Immunoglobulin M COVID-19 Titers|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy","To evaluate admission to ICU requiring mechanical ventilation or death.|To evaluate potential predictive biochemical parameters of mortality.|To evaluate potential predictive HM-related parameters of mortality.|To evaluate COVID severity as predictive parameter of mortality.|Epidemiology of patients with HM infected by SARS-CoV-2with any spectrum of illness severity|Definition of complete clinical picture of COVID-19 in HM|Dynamic of HM evolution|To evaluate admission to ICU requiring mechanical ventilation or death per characteristics|Viral dynamics in infected HM patients","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1, IL-10, sIL-2R, IL-6, IL-8 and TNF-|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells","Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples","Incidence of respiratory failure|28 day mortality rate","Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15","COVID-19 positive X-Rays|COVID-19 negative X-Rays","Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of  2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19","Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days","Prevention of COVID-19 measured by negative testing with RT-PCR|Safety as determined by blood pressure readings|Safety as determined by presence of side effects","Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death|Proportion of patients who die from a severe form of covid-19|Proportion of patients who present an history of diabetes according to medical records|Proportion of patients who present obesity (validated by Body Mass Index value &gt; 30 kg/cm2)|Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records|Proportion of patients who present an history of Asthma according to medical records|Proportion of patients who present an history of Hypertension according to medical records|Proportion of patients who present an history of cardiac disease according to medical records|Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records|Proportion of patients who present an history of stroke according to medical records|Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records|Proportion of patients who present an history of cancer according to medical records","Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events","anxiety","COVID-19 desease description","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA","Antibody status in HCW|Active virus carriers in HCW|Incubation time|Background incidence rate|Occupation associated infection risk","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA","Mortality at day 28|severe complications|Imaging|Delay in Microbiological diagnosis|Antiviral therapy|Antibiotic therapy|Covid-19 treatments|Patients receiving renal replacement therapy|Patients receiving mechanical ventilation|Vital status","Respiratory failure|Occurence of bacterial superinfection","\"Labor Agentry Scale questionnaire\" score in immediate post-partum (duration of hospital stay)|\"Labor Agentry Scale questionnaire\" score at two months after birth|Edinburg Postnatale Depression Scale questionnaire\" score at two months after birth|\"Impact of Event Scale - Revised questionnaire\" score at two months after birth|Breastfeeding statement at two months after birth|\"SF-12 Quality of life questionnaire\" score at two months after birth|\"SF-12 Quality of life questionnaire\" score in immediate post-partum","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality","Mixed venous O2 pressure (PVO2)|Mixed venous CO2 pressure (PVCO2)|PH|HCO3|Oxygen saturation (O2 Sat) from VBG|Six minute walk test|O2 Sat after one minute walking|O2 Sat after two minutes use of Partial Rebreather|O2 Sat after two minutes free air breathing|O2 sat/ Fio2|breathlessness|Mortality rate|Number of participants with Rehospitalization|The Health-Related Quality of Life (HRQOL)","Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures","Suitable for discharge","on-treatment platelet reactivity|apoptosis rate in human umbilical vein endothelial cells (HUVEC)|Nitric oxide (NO) intracellular levels|reactive oxygen species (ROS) levels|coagulation factors levels|respiratory function|cardiac function|clinical outcome","Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery","Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition","Sensitivity and specificity of chest CT in detecting pneumonia in unspecific symptomatic patients who are to be admitted to hospital and who are rt-PCR negative for SARS-CoV-2.|Sensitivity and specificity of chest CT in patients with pulmonary comorbidities|Sensitivity and specificity of chest CT in patients with cardiovascular comorbidities|Sensitivity and specificity of chest CT in patients with malignancy|Sensitivity and specificity of chest CT in patients with immunodeficiency","need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events","Associations with severity and outcomes","Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge","Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients","In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction","Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days","Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization","PaO2/FiO2 improvement from pre-to-post intervention|Achievement of PaO2/FiO2  200 or 50% increase in PaO2/FiO2|48 hour in-hospital mortality|14 days in-hospital mortality|28 days in-hospital mortality|ICU-free days|In-hospital coagulation-related event-free (arterial and venous) days|Ventilator-free days|Successful extubation|Survival to discharge","Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases","Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA","Mortality|Viral Load|Serum Antibody Titers","SARS-CoV-2 infection|Tumor response|Safety and tolerability|Patient-reported outcomes","Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.|Polymerase chain reaction assay (PCR) negative at day 30.|Polymerase chain reaction assay (PCR) negative at day 60.","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2","All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome","PO2/FiO2 (Safety)|PO2/FiO2 (Efficacy)|Early Warning Score (NEWS) (Safety)|Early Warning Score (NEWS) (Efficacy)|Immunological response (Efficacy)|Mechanical ventilation (Efficacy)|SAE|Serious ADR|AE|Oxygen dose|Pulmonary CT (low-dose CT)|Chest X-ray|Chest ultrasound|Secondary infections|Mortality|ICU free days|ICU mortality|Hospital mortality|Micro RNA plasma (Biomarker)|MicroRNA/RNA PBMC (Explanatory)|Immunological response (Explanatory)|Viral load","Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality","positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient","Clinical|Virological|Microbiological","Adjusted Odds Ratio","Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery","Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality","Rate of patients reaching a significant hypoxemia, in each arms.","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 &gt; 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNF values at baseline and during the treatment course; the number of AEs.","Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs","Cohort A (Ambulatory) - Primary Efficacy Endpoint|Cohort A (Ambulatory) - Primary Safety Endpoint|Cohort B (Hospitalized) - Primary Efficacy Endpoint|Cohort B (Hospitalized) - Primary Safety Endpoint|Cohort A (Ambulatory) - Clinical Outcome #1|Cohort A (Ambulatory) - Clinical Outcome #2|Cohort A (Ambulatory) - Clinical Outcome #3|Cohort A (Ambulatory) - Clinical Outcome #4|Cohort A (Ambulatory) - Clinical Outcome #5|Cohort A (Ambulatory) - Clinical Outcome #6|Cohort A (Ambulatory) - Clinical Outcome #7|Cohort A (Ambulatory) - Virologic/Immunological Outcome #1|Cohort A (Ambulatory) - Virologic/Immunological Outcome #2|Cohort A (Ambulatory) - Virologic/Immunological Outcome #3|Cohort A (Ambulatory) - Virologic/Immunological Outcome #4|Cohort A (Ambulatory) - Virologic/Immunological Outcome #5|Cohort A (Ambulatory) - Virologic/Immunological Outcome #6|Cohort A (Ambulatory) - Transmission Outcome #1|Cohort A (Ambulatory) - Transmission Outcome #2|Cohort B (Hospitalized) - Clinical Outcome #1|Cohort B (Hospitalized) - Clinical Outcome #2|Cohort B (Hospitalized) - Clinical Outcome #3|Cohort B (Hospitalized) - Clinical Outcome #4|Cohort B (Hospitalized) - Clinical Outcome #5|Cohort B (Hospitalized) - Clinical Outcome #6|Cohort B (Hospitalized) - Clinical Outcome #7|Cohort B (Hospitalized) - Clinical Outcome #8|Cohort B (Hospitalized) - Clinical Outcome #9|Cohort B (Hospitalized) - Clinical Outcome #10|Cohort B (Hospitalized) - Clinical Outcome #11|Cohort B (Hospitalized) - Virologic/Immunological Outcome #1|Cohort B (Hospitalized) - Virologic/Immunological Outcome #2|Cohort B (Hospitalized) - Virologic/Immunological Outcome #3|Cohort B (Hospitalized) - Virologic/Immunological Outcome #4|Cohort B (Hospitalized) - Virologic/Immunological Outcome #5|Cohort B (Hospitalized) - Virologic/Immunological Outcome #6|Cohort B (Hospitalized) - Virologic/Immunological Outcome #7","Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group|Clinical manifestations of Coronavirus Disease 2019 (COVID-19)|Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort|Radiological features of Coronavirus Disease 2019 (COVID-19) cohort|outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group","Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given","positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.|Positive serology at day 28.|Symptoms of COVID-19.","Anxiety and depressive symptoms|Experiences, fears and concerns about the Covid-19|Training and resource prioritization|Suicide ideation (presence)|Suicide ideation (frequency)|Acute stress symptoms|Psycho/social support and network|Resilience","Days required to get a positive COVID-19 PCR to negative|HRCT/ X-ray findings of disease progression|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Oxygen Saturation at room air|Incidence of viral myocarditis|Incidence of Acute respiratory Distress Syndrome","Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo","evolution of number of maxillofacial trauma|variability in terms of type of trauma|the inter-regional variability of maxillofacial trauma","Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances","Symptomatic COVID(+) infection rate","Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity","NIMH COVID Study survey - adult responses|DSM XC and KS survey","Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score","Physical functional limitations","High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index","7-day mortality","Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of &lt;/= 2 and maintained for 24 hours, whichever occurs first","Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images","Improvement on a 7-point Ordinal Scale|Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability)|Change in estimated PaO2/FiO2|Number of days alive and free of mechanical ventilation|Time to discharge alive from hospital|Number of patients alive on day 30 and day 60|Change in interleukin (IL)-6 level|Change in IL-17 level|Change in tumor necrosis factor-alpha level|Change in cytokine levels|CM4620-IE serum concentration|Procalcitonin levels|Normalization of oxygen saturation|Time to first normalization of oxygen saturation","Proportion of virologically cured (no virus detected) cases at day 6|The dichotomous virologic shedding endpoint as assessed at two weeks after study entry|Quantitative viral load (assessed with each virology testing set)","Variation in HbA1c levels|COVID-19 infection|Variation in lipid profile|Variation in blood pressure levels|Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups|Comparison of eating disorders between groups|Comparison of adherence to the proposed clinical treatment between groups|Comparison of minor psychiatric disorders between groups|Comparison of sleep pattern changes between groups","Lung ultrasound grading system for COVID-19 pneumonia","Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life","Seroconversion to SARS-CoV-2 positivity","Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation","Safety of in-hospital thromboprophylaxis|Median twice-daily enoxaparin dose","Disease activity|Immune modulating treatments|Biomarkers","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","Risk Factors for severe infection|Immunulogical mechanisms|Long term outcome","Efficacy of captopril nebulization addition to standard of care compared to standard of care.","Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days","Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU","Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs  29).|Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21Depression); in terms of proportions (0-4 vs  5).|Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21Anxiety); in terms of proportions (0-3 vs  4).|Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21Stress); in terms of proportions (0-7 vs  8).|Distress measured at baseline by the CPDI; in terms of continuous values.|Depression at baseline measured by the DASS-21Depression; in terms of continuous values.|Anxiety at baseline measured by the DASS-21Anxiety; in terms of continuous values.|Stress at baseline measured by the DASS-21Stress; in terms of continuous values.|Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREFPhysical health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREFPsychological health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREFSocial relationships); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREFEnvironment); in terms of continuous values.|Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnairein terms of continuous values.|Change from baseline in distress measured by CDPI; in terms of continuous values.|Change from baseline in depression measured by the DASS-21Depression; in terms of continuous values.|Change from baseline in anxiety measured by the DASS-21Anxiety; in terms of continues values.|Change from baseline in stress measured by the DASS-21Stress; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREFPhysical health; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREFPsychological health; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREFSocial relationship; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREFEnvironment; in terms of continuous values.|Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.|The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics","The percentage of knowledge regarding COVID-19 information","Total score of the Cardiff Anomalous Perceptions Scale (CAPS)|Paranoia Scale","Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality","Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery","To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.|To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.","MDR pathogens in endotracheal aspirates|Microorganisms in endotracheal aspirates","IgG and IgM anti SARS-CoV-2|Clinical factors and severity of COVID-19 infection|demographic factors and severity of COVID-19 infection|pharmacologic factors and severity of COVID-19 infection","Incidence of AKI|Renal function changes during hospital stay|Incidence of chronic kidney disease","Number of patients with viral cure","Perceived Stress Scale (PSS) outcome|Generalized Anxiety Disorder (GAD-7) scale outcome|Patient Health Questionnaire (PHQ-9) scale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome|Caregiver Burden","Predictive performance","Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide","Patient Health Questionnaire 9|Generalized Anxiety Disorder 7|Measures of adherence","Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Stress: Perceived Stress Scale (PSS)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Frequency of social interactions|Adverse Effects","Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical ventilhation|Hospitalization|Time from treatment initiation to death|Time to Negativization COVID 19|Fever","overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.","Automated Self-Administered 24-Hour Dietary Recall (ASA24)|International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|State trait inventory for cognitive and somatic anxiety (STISA).|Beck Depression inventory (BDI)","Kidney involvement in COVID-19 disease|Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection|To identify risk factors for kidney involvement in in SARS-CoV-2 infection|To evaluate the impact of kidney involvement in SARS-CoV-2 infection|To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3","Breath volatile organic compound profiles|Utility of breath profiles for disease diagnosis or prognosis","quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.","Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks"," Rate of hospitalization or death at day 7 after study inclusion","To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.|To evaluate the feasibility of imatinib therapy.|To evaluate safety of imatinib therapy|To evaluate the clinical evolution|To evaluate the progression rate to severe COVID-19 disease|To evaluate mortality|To evaluate viral load|To evaluate plasmatic levels of imatinib","Rate of COVID-19 infection","PaCO2|Driving Pressure|Tidal volume","overactivity of the renin / aldosterone system","Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response","The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.","T-cell immunophenotype|Mortality|ITU admission|Myocardial injury","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events","new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect","Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents","Change in O2 output|Comfort with the interfaces|Changes in PaO2|Changes in PaCO2|Changes in pH|Changes in respiratory rate","Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression","RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death","14-Day Mortality|21-Day Mortality|28-Day Mortality|60-Day Mortality|90-Day Mortality|1-Year Mortality","Number of patients with virological cure","Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);|Level of pressure support above PEEP|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality","Maternal and perinatal outcomes","Incidence of Mechanical Ventilation|Percentage of time in the assigned position|Number of participants with supplemental oxygen requirements|Change in mean oxyhemoglobin saturation|Change in Nocturnal Oxyhemoglobin saturation|Change in Heart Rate|Change in Respiratory Rate","Positive IgM/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM/IgG positive participants on follow-up test","survival status","Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score","SARS-Cov2 positive molecular testing of throat/nasal swabs|Immunoglobulins (G and M) to SARS-Cov2 in plasma|Blood cytokine levels","Rates of patients presenting with acute myocardial infarction|Patient profile during admission for acute myocardial infarction|Rate of death due to myocardial infarction at home|Medical care times analysis|Proportion of patients who underwent systemic thrombolysis|Proportion of patients infected with COVID-19|Clinical evolution of patients","Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.","Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate","The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19","SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air","Inter spinal distance","Titanium level","Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)","Mechanical ventilation requirement","arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death","Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.","Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development","Spontaneous recovery or death in both groups|Severity of prior as well as present decompensation in both groups|Duration of prior as well as present decompensation in both groups|Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups|Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups|Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups|Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups|Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.","Treatment failure|Intubation rate|Efficacy of PP","Failed to attend patients|Patient satisfaction with the phone consult|Consultant satisfaction with the phone consult","Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner|Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale|Phase 2: The time to improvement in oxygenation|Phase 2: Mean change in 7-point ordinal scale from baseline to Day 15|Phase 2: Clinical status using the 7-point ordinal scale at Day 15|Phase 2: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3 : Time to resolution of fever|Phase 2 and 3 : Time to improvement in oxygenation|Phase 2 and 3: Time to resolution of fever and improvement in oxygenation|Phase 2 and 3:Time to change in NEWS2 from baseline|Phase 2 and 3: Time to NEWS2 of &lt;2 and maintained for 24 hours|Phase 2 and 3: Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2|Phase 2 and 3:Days with fever|Phase 2 and 3: Alive off supplemental oxygen at day 29|Phase 2 and 3: Days of resting respiratory rate &gt;24 breaths/min|Phase 2 and 3:Days of hypoxemia|Phase 2 and 3: Days of supplemental oxygen use|Phase 2 and 3: Time to saturation 94% on room air|Phase 2 and 3: Ventilator free days in the first 28 days (to day 29)|Phase 2 and 3: The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Phase 2 and 3: Proportion of patients requiring rescue medication during the 28-day period|Phase 2 and 3: The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Phase 2 and 3: Days of hospitalization among survivors|Phase 2 and 3: Incidence of death|Phase 3: Mean change in the 7-point ordinal scale from baseline to days 3, 5, 8, 11, 15, and 29 (or until discharge)|Phase 3: Clinical status using the 7-point ordinal scale at days 3, 5, 8, 11,15, and 29|Phase 3: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3: Incidence of serious adverse events|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|Phase 2 and 3: The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities","Time until cessation of oral shedding of SARS-CoV-2 virus|Count of participants with clinical worsening of COVID-19 disease|Sars-CoV-2 viral load|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Cmax of favipiravir|Cmin of favipiravir","28 day ventilator free days|90 day all-cause mortality","Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation &gt; 94% on room air for &gt;24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality","Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older","Protection against COVID-19","Efficiency of the telephone consultation|Satisfaction of the telephone consultation","Accuracy of patient administered tests","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","rate of recruitment|rate of attendence|Depression, Anxiety and Stress Scale (DASS-21)|Sense of Coherence Scale","COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects","SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity","Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Presence of virus at day 10 in subset of 180 patients","International Physical Activity Questionnaire - Short Form|Nottingham Health Profile|Beck Depression Inventory|Beck Anxiety Inventory|Pittsburgh Sleep Quality Index|Timed Get Up and Go Test|Flamingo Balance Test","Survival|WHO progression scale COVID 19","Number of mechanical ventilation days.|Survival|Shift to Continuous Positive Airway Pressure (CPAP) ventilation|Referral to a sub-intensive care unit or discharge","Maternal and perinatal outcomes","days to cure|Days of turning negative on RT-PCR test|36-Item Short Form Survey Instrument (SF-36)|C-reactive protein|number of cases returning to positive result in RT-PCR test|Number of positive outcome of IgG for antibody of COVID-19","Delta decrease in arterial partial pressure of carbon dioxide during ECCO2R treatment|Change in vasopressor use during ECCO2R|Assessment of changes in tidal volume during ECCO2R|Assessment of changes in pH during ECCO2R|Assessment of changes in Positive End-Expiratory Pressure during ECCO2R|Number of participants with adverse events directly related to ECCO2R|Technical adverse events directly related to ECCO2R|Delta decrease in venous partial pressure of carbon dioxide before and after ECCO2R membrane","Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms","Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry","Adverse effects and Safety|NK transfer Immunogenicity","Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement \"LTOT\")","The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study","Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization","Rate of UCI admission for surgery-related complication|Rate of surgery-specific death|Rate of coronaviruse positive serologies","PTSD Family members sup 22|PTSD Family members|PTSD Patients|PTSD healthcare providers|HADS Family members|HADS Patients|SF36 Patients|Questionnaire Family members|Questionnaire Patients|Questionnaire healthcare providers|MBI healthcare providers|Karasec instrument healthcare providers","28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation","Survival without needs of ventilator utilization at day 14.|WHO progression scale &lt;=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Depression|Anxiety symptoms|Stress related problems|Behavior and emotional problem among children and adolescents","Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)","All-cause mortality or need of invasive mechanical ventilation|Frequency of adverse events|Frequency of severe adverse events|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|Ventilator-free days|Organ failure-free days|Duration of ICU stay|Mortality rate|Length of hospital stay|Duration of supplemental oxygen","Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death","Sub Study 1: Patients|Sub Study 2: Health Care Workers|Sub Study 1: Patients: Rate of secondary infection of co-inhabitants|Sub Study 1: Patients: Adverse Events|Sub Study 1: Patients: Negative for COVID-19|Sub Study 2:Health Care Workers:Number of shifts missed|Sub Study 2:Health Care Workers:Rate of adverse events|Sub Study 2:Health Care Workers:Rate of hospitalization","Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization","The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay","Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count","Change in viral expression in association to organspecific biomarkers","Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave","Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies","Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin &gt; 10000 g/L) in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye","Time to improvement on a 7-point ordinal scale as compared to baseline|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours","Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance","Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity","Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality|Association of Endothelin-1 plasma level with 28 days mortality|Association of Vascular Endothelial Growth Factor A plasma level with 28 days mortality|Association of soluble Vascular Endothelial Growth Factor Receptor type 1 with 28 days mortality|Association of syndecan -1 plasma level with 28 days mortality|Association of D-dimers plasma levels with thrombotic events|Association of von Willebrandt Factor with thrombotic events|Association of Viscoelastic testing with thrombotic events","number of patients with virological cure","The self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)|Montgomery sberg Depression Rating Scale - Self report (MADRS-S)|Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)|Insomnia Severity Index (ISI)|Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)|Intolerance of uncertainty Scale (IUS)|Patient Satisfaction Questionnaire (PSQ)|Adverse events (AE)","Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly","Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants","New-onset cardiac arrhythmia|Elevation of NT-proBNP|Left ventricular dysfunction","Time to achieve afebrile|Severity of influenza symptom score","Depression|Anxiety|Obsessive compulsive disorder","Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery","Assess the prevalence of severe forms among hospitalized patients with diabtes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19","Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted","Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form","virus molecular analysis|host molecular analysis|Epidemiologic data","Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.","Number of IGg seropositive health care workers|Differentiation between low risk and high risk HCWs","prevalence and severity of Covid-19 infection in patients with SLE|prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine","Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging","nosocomial infection",null,"Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them","Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","p/f ratio|SOFA","Technical success|Clinical success|Adverse events","Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score","Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR","Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits","Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function","Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment","Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events","rate of recovery|time to improvement|efficacy of treatments|organ failure","Body temperature|Blood pressure|Pulse (heart rate)|Respiratory rate|Data provided by transpulmonary thermodilution-CI|Data provided by transpulmonary thermodilution-GEDV|Data provided by transpulmonary thermodilution-EVLW|Data provided by transpulmonary thermodilution-PVPI|Incidence of abnormal laboratory test results|Incidence of new-onset or reversible systolic left ventricular dysfunction|Changes of extravascular lung water measured by transpulmonary thermodilution|Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|Correlation between the hemodynamic characteristics and 90-day mortality","Adverse effects|Immune-score|COVID-19 prevention|Clinical response","Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-) Cellular Immune Response","Number of patients with decreased viral load","Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable|Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable|welcoming quality from hospital staff|anxiety score|perception of the technical quality of the emergency treatment","Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR","Proportion of patients in both arms fulfilling the criteria for treatment failure|ICU admission|ICU refusal|Occurrence of complications|lactate dehydrogenase (LDH)|C Reactive Protein (CRP)|ferritin|D-dimer|leukocyte counts","Incidence of influenza","Time to achieve afebrile|Severity of symptom score|Patient reported improvement","Clinical skin manifestations|Histology and biological data|Non invasive vascular examination","The Rapid Office Strain Assessment (ROSA)|The Standardised Nordic Questionnaries (NMQ)","Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action","Proportion of \"responder\" patients to prone position|proportion of \"persistent responders\" patients after prone position|Evolution of PaO2|Duration of prone positioning and PaO2 evolution|Evolution of Spo2|EVA Dyspnea|Intolerance to prone positioning|Tolerance to prone positioning",null,"Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance","All-cause mortality|30-day mortality|Major adverse cardiovascular events","Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic","1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2","Positive rate of 2019 Novel Coronavirus RNA|Survival rate","Survival rate|Chest computed tomography|Recovery Time|Depression evaluation","Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes","Seroprevalence of SARS-CoV-2 infection in parturient woman|Consequences of SARS-CoV-2 infection in pregnant women and their newborns|Assessment of the vertical transmission of SARS-CoV-2 and the possible routes of this transmission in women who are positive for SARS-CoV-2 during pregnancy|Assessment of susceptibility to infection during the 3 trimesters of pregnancy|Evaluation of the confinement on the risk of exposure to the virus during pregnancy .|collection of biological samples for new investigations in women who are positive for SARS-CoV-2 during pregnancy.|Assessment of the rate of SARS-CoV-2 infection in pregnant women and their newborns and the risk factors for the disease.","Mortality rate at day 28|Proportion of patients with SARS|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index","Survival without needs of ventilator utilization at day 14|WHO progression scale  5|Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) or withdrawal of NIV or high flow (for &gt; 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge","Mortality|The time interval of Nucleic acid detection become negative","Mechanical ventilation|ICU transfer|Oxygen therapy","Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-|-interferon(IFN)","The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal","RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support","Death or need of intubation|30-day mortality","ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment","Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection","Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores","the composite rate of adverse outcomes|The rate of hospitalization","Mortality rate reduction of 50% by day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)","compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.","Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia","incidence (measured by confirmed positive test) of SARS-CoV2 infection following BCG vaccination compared to placebo|COVID19-related disease severity (measured by ordinal severity scale) following BCG vaccination compared to placebo",null,"Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects","Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%","Recruitment-to Inflation ratio (R/I ratio)|PaO2/FiO2 (mmHg)|Lung volume recruited (VRec)|Plateau pressure (cm H2O)|Oesophagal pressure (cm H2O)|weight (Kg)|urine output (mL)|serum creatinine (Umo/L)|Mean arterial pressure (mmHg)|Peak Pressure (cm H2O)|PEEP total (cm H2O)|PEP Set (cm H2O)|Height (cm)|Airway pening pressure (cm H2O)|Expired volume in PEEP setted at 15 cmH2O (mL)|Expired volume in PEEP setted at 5 cmH2O (mL)","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score","Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications","Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety","Screening accuracy|Cost-effectiveness analysis","treatment efficacy - Percentage change in PaO2/FiO2 ratio|Safety as measured by bleeds|Safety as measured by other (non-bleed related) adverse events|Safety as measured by fibrinogen levels|Absolute change in PaO2/FiO2 ratio|Changes in respiratory compliance|Clinical status as determined by a 7 point ordinal scale|Sequential Organ Failure Assessment (SOFA) score|Follow up period - oxygen free days|Follow up period - ventilator free days|Follow up period - intensive care stay|New oxygen via ventilation use - incidence|New oxygen via ventilation use - duration|Incidence of new mechanical ventilation use|Duration of new mechanical ventilation use|In hospital mortality","Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2|Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever &gt; 38C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact","Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment","GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)","2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status","Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management","Number of Participants with positive serology in the 90 days following last contact|fever &gt; 38C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea","Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.|Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening).","clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death","Hours to recovery|Time fever resolution","World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale","Visual Analogue Scale|Modified Borg Scale|Leicester Cough Questionnaire|Timed Up and Go|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory","International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale","Survival without needs of ventilator utilization at day 14.|WHO progression scale &lt;=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Sensitivity","COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects","sustained improvement (&gt;48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) 2 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence and duration of new oxygen use during the trial|Ventilator free days until day 29|Incidence and duration of new mechanical ventilation use during the trial|Viral load/viral clearance|Duration of Hospitalization|Mortality|Obesity|Drug-drug interactions with lopinavir/ritonavir|Renin Angiotensin System (RAS) fingerprint","Fibrosis|Ergospirometers","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","reduction in oxygen and ventilation support","Covid-19 Awareness Survey","Diagnostic performance of LUS to predict poor outcome","Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection","Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure","Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status","Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens","ETP (AUC) without rhThrombomodulin (rhTM)|ETP (AUC) with rhThrombomodulin (rhTM)|ETP-ratio|ETP-Normalisation","Standardized Mini Mental Test|Mini Nutritional Assesment|Short Physical Performance Test|Single Leg Stance Test|Charlson Comorbidity Index|Clinic Fragility Scale|Pittsburgh Sleep Quality Index|Social Isolation Survey|Quality of life scale in the elderly|The Physical Activity Scale for the Elderly|Timed Up and Go Test|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory","Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing","Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration","Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application","International Physical Activity Questionnaire (Short Form)|Short Form-36 (SF-36)|The Pittsburgh Sleep Quality Index|Distress Tolerance Scale|Beck Anxiety Inventory|Nottingham Health Profile|Sit And Reach Test|Shoulder Flexibility Test|Curl-Up Test|Repetitive Squat Test|Side Plank Test|Timed Up and Go Test|Single Leg Stance Test","Incidence of COVID19 Disease among those who are asymptomatic at trial entry|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 day","Anxiety and Depression measured through the Hospital Anxiety and Depression Scale|Functional Status measured through the Katz Activities of Daily Living Scale|Re-hospitalization and Emergency Department Visits","Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants","Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","The Brief Resilience Scale|Nottingham Health Profile|Mindful Attention Awareness Scale|The Body Awareness Questionnaire|Richard-Campbell Sleep Questionnaire|Lateral bridge test|Functional reach test|Beck Depression Scale","Changes in the Eating Habits of Adults during the Quarantine","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality"],["Kermanshah University of Medical Sciences","Giuliano Rizzardini|ASST Fatebenefratelli Sacco","University Hospital Plymouth NHS Trust","Medical College of Wisconsin|Froedtert Hospital","University of Malaya","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","Universidade Nova de Lisboa|NOVA Medical School of Universidade NOVA de Lisboa|Hospital de So Francisco Xavier, Centro Hospitalar de Lisboa Ocidental|Centro Hospitalar Universitrio So Joo|CUF Academic and Research Medical Center|Hospital CUF Infante Santo, S.A.|Centro de Medicina Laboratorial Germano de Sousa, S.A.|CINTESIS - Center for Health Technology and Services Research","Bukwang Pharmaceutical","Ochsner Health System","Al-Azhar University","Imperial College London","Tongji Hospital","Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","Hackensack Meridian Health|Cota Inc.","King Saud University","University of Kansas Medical Center","Saint Luke's Health System|AstraZeneca|George Clinical Pty Ltd","InflaRx GmbH","Yale University|University of Michigan|University of Minnesota","Hackensack Meridian Health","Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of Alberta","Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA|OSPEDALE MAGGIORE LODI|OSPEDALE ASST CREMONA","University Hospital, Geneva|University of Zurich|University of Lausanne","Assistance Publique - Hpitaux de Paris","KK Women's and Children's Hospital|Singapore General Hospital|National University Hospital, Singapore","Xiyuan Hospital of China Academy of Chinese Medical Sciences","Thomas Jefferson University","Assistance Publique - Hpitaux de Paris","Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Basic Medical Sciences, Chinese Academy of Medical Sciences","Jiangsu Famous Medical Technology Co., Ltd.","Centre Hospitalier Universitaire de Nmes","Ansun Biopharma, Inc.","The First Affiliated Hospital of Guangzhou Medical University","Universit Libre de Bruxelles","Butantan Institute","Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.","University of Colorado, Denver","University of Colorado, Denver","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","Incyte Corporation","Shahid Beheshti University of Medical Sciences","Intermountain Health Care, Inc.|University of Utah","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL &amp; GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","National Cancer Institute, Naples","Istituto Nazionale di Ricovero e Cura per Anziani","AstraZeneca|Acerta Pharma B.V.","Weprom|Institut Pasteur|Assistance Publique - Hpitaux de Paris|DOCAPOST|Direction Gnrale de l'Offre de Soins","Washington University School of Medicine|Incyte Corporation","Shahid Beheshti University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Boston University","Korea University Guro Hospital","Hamilton Health Sciences Corporation|Canadian Blood Services|Hma-Qubec|University of Toronto|Universit de Montral|McMaster University","Duke University","Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","Stanford University","Tourcoing Hospital","Regeneron Pharmaceuticals|Sanofi","Cambridge University Hospitals NHS Foundation Trust","Beat COVID LLC","University Hospital, Ghent|Belgium Health Care Knowledge Centre","ObvioHealth","Duke University","United States Department of Defense","NYU Langone Health","Tongji Hospital","University Hospital, Ghent|Flanders Institute of Biotechnology","Yale University","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark","Laboratorio Elea S.A.C.I.F. y A.","Capricor Inc.","Assaf-Harofeh Medical Center","Boston Medical Center","Nicolaus Copernicus University","Cairo University","University Hospital Tuebingen|Robert Bosch Medical Center|Universittsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","ProgenaBiome","University of Aarhus","University of Cincinnati","Ravi Amaravadi, MD|University of Pennsylvania","Sunnybrook Health Sciences Centre|AbbVie","University of California, Los Angeles","Neuromed IRCCS","HaEmek Medical Center, Israel|T MAY BIOPHARMA LTD.","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine|University of Edinburgh|Swansea University|Queen's University, Belfast|Barts Charity","Chinese University of Hong Kong","St George's, University of London","Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubi|Institut Catala de Salut","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","University of Chicago","Assiut University","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","Kerecis Ltd.","Apeiron Biologics","Emory University","University of Chicago","Baylor Research Institute","LCMC Health","Universittsklinikum Hamburg-Eppendorf","Azidus Brasil|InCor Heart Institute|Hospital Santa Marcelina","AUSL Romagna Rimini","Hakeam Abdulaziz Hakeam|King Faisal Specialist Hospital &amp; Research Center","NYU Langone Health","Iyad Sultan|King Hussein Cancer Center","Asan Medical Center","Queen's Medical Centre","Rambam Health Care Campus|Rabin Medical Center","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubi","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","Pulmotect, Inc.","Fundaci Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","Gilead Sciences","Pulmotect, Inc.","Symvivo Corporation","Azidus Brasil|Farmoquimica S.A.|Hospital Vera Cruz|Hospital Casa de Sade - Vera Cruz - Campinas - SP - Brazil|Centro de Genomas - UNIFESP|Emilio Ribas Institute of Infectious Diseases","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","NYU Langone Health","Stanford University","Hope Biosciences|Hope Biosciences Stem Cell Research Foundation","Azidus Brasil","Gilead Sciences","Northwestern Medicine","Cristina Avendao Sol|Puerta de Hierro University Hospital","University Hospital of Cologne|Clinic for Internal Medicine I, University Hospital Cologne, Germany|Institute of Virology, University Hospital Cologne, Germany|Center for Molecular Medicine Cologne (CMMC) Cologne, Germany","German Cancer Research Center","University Hospital, Montpellier","ClarData","Stem Cells Arabia","Biohaven Pharmaceuticals, Inc.","Centre Hospitalier Intercommunal Creteil|ACTIV|GPIP|Socit Franaise de Pdiatrie|GFRUP","Xinqiao Hospital of Chongqing","Henan Provincial People's Hospital","Azienda Unit Sanitaria Locale Reggio Emilia","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital","Azidus Brasil|Cellavita Pesquisa Cientfica Ltda|Hospital Vera Cruz","Judit Pich Martnez|Fundacion Clinic per a la Recerca Biomdica","Fasa University of Medical Sciences","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","Hoffmann-La Roche","Lawson Health Research Institute","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","NYU Langone Health","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","Wuhan Union Hospital, China","Max Healthcare Insititute Limited","Rigshospitalet, Denmark","Medical University Innsbruck|Ludwig-Maximilians - University of Munich","University Hospital Tuebingen|Robert Bosch Medical Center|Universittsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","University Hospital, Montpellier|Socit espagnole de pneumologie (SEPAR)|Societe franaise de kinsithrapie en ranimation (SKR)","Orthosera Kft.|Semmelweis University|University of Pcs|Hungarian National Blood Service|Humn Bioplazma Kft - Kedrion","Stanford University","Sinovac Biotech Co., Ltd","University of Alabama at Birmingham","Francis Corazza|Brugmann University Hospital","Perseverance Research Center, LLC|Athena Medical Group","Genesis Foundation","Oslo University Hospital","Erasmus Medical Center|Maasstad Hospital","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigacin Biomdica en Red, M.P.","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","National Institute of Respiratory Diseases, Mexico|Sanofi","Wroclaw Medical University","First Affiliated Hospital of Fujian Medical University","IRCCS San Raffaele","Vivek Reddy|Icahn School of Medicine at Mount Sinai","Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China|CanSino Biologics Inc.|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Zhongnan Hospital","Ain Shams University","Romark Laboratories L.C.","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth Peoples Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth Peoples Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","Zhenhua Zen|Nanfang Hospital of Southern Medical University","Assistance Publique - Hpitaux de Paris|Institut National de la Sant Et de la Recherche Mdicale, France|GE Healthcare|Orange healthcare|TheraPanacea","University of California, San Francisco","Novartis Pharmaceuticals|Novartis","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","Fundacion SEIMC-GESIDA","Ain Shams University","Assistance Publique - Hpitaux de Paris|Etablissement Franais du Sang","Charite University, Berlin, Germany","Grupo Cooperativo de Hemopatas Malignas","I-Mab Biopharma Co. Ltd.","Hospital Universitario de Fuenlabrada|Centro Nacional de Investigaciones Oncologicas CARLOS III","University Hospital, Angers","Capital Medical University|Chinese Academy of Medical Sciences","Humanigen, Inc.","UMC Utrecht|Radboud University","Ain Shams University","Ain Shams University","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD","Stony Brook University","Stanford University","Ain Shams University","University of L'Aquila","Assistance Publique - Hpitaux de Paris|Iltoo Pharma","Rutgers, The State University of New Jersey","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","OncoImmune, Inc.","Assistance Publique - Hpitaux de Paris|GIS EPI-PHARE","Assiut University","Arbeitsgemeinschaft medikamentoese Tumortherapie","Eli Lilly and Company","Jessa Hospital","Vanderbilt-Ingram Cancer Center","Guangzhou Institute of Respiratory Disease|Guangzhou Eighth People's Hospital|Tongji Hospital, Huazhong University of Science &amp; Technology|Guangzhou Cellgenes Biotechnology Co.,Ltd","Universidad de Granada","University Hospital, Limoges","CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital","Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|General Hospital of Central Theater Command, Wuhan, China|VCANBIO CELL &amp; GENE ENGINEERING CORP.,LTD, China","Rajavithi Hospital","Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital","Assiut University","NHS Lothian","Assistance Publique - Hpitaux de Paris|Institut National de la Sant Et de la Recherche Mdicale, France|NG Biotech|Commissariat a lenergie atomique et aux energies alternatives|Institut Pasteur","University Hospital, Gentofte, Copenhagen","Kinevant Sciences GmbH","Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic","Centre Chirurgical Marie Lannelongue","University Hospital, Montpellier","Can-Fite BioPharma|Rabin Medical Center","Theravance Biopharma","Maria del Rosario Garcia de Vicua Pinedo|Instituto de Investigacin Sanitaria Hospital Universitario de la Princesa|Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa","Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|AUSL Romagna","Direction Centrale du Service de Sant des Armes","Huoshenshan Hospital|Ascletis Pharmaceuticals Co., Ltd.","The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.","Tanta University","Aga Khan University|University of Karachi","Auxilio Mutuo Cancer Center","Lawson Health Research Institute","Massachusetts General Hospital|Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital","MedSIR","Kafrelsheikh University","Beijing Chao Yang Hospital","Vanderbilt University Medical Center","General and Teaching Hospital Celje","Mayo Clinic","University Hospital, Montpellier","Raymond Chung|Eiger BioPharmaceuticals|Massachusetts General Hospital","Hospices Civils de Lyon","Hope Biosciences","Jessa Hospital","HonorHealth Research Institute","Noah Merin|Johns Hopkins University|University of Pittsburgh Medical Center|Cedars-Sinai Medical Center","Hvidovre University Hospital","The University of Hong Kong","CareDx","University Hospital Tuebingen|University Hospital Freiburg|RWTH Aachen University|University Hospital Muenster","University Health Network, Toronto","Institute of Liver and Biliary Sciences, India","Columbia University","Assistance Publique - Hpitaux de Paris","Duke University","Hilton Pharma","National Institute of Respiratory Diseases, Mexico|Sanofi","Hospital Universitari de Bellvitge|Institut d'Investigaci Biomdica de Bellvitge","Bausch Health Americas, Inc.","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","Texas Cardiac Arrhythmia Research Foundation","Kanuni Sultan Suleyman Training and Research Hospital","Azidus Brasil","Hasselt University|Ziekenhuis Oost-Limburg","Centre Hospitalier St Anne|Groupe Hospitalier Universitaire Paris psychiatrie &amp; neurosciences|Laboratoire franais de Fractionnement et de Biotechnologies","BioCryst Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)","Duke University|Caption Health, Inc.","William Beaumont Hospitals","Misr University for Science and Technology","Ain Shams University","The Christ Hospital","Assistance Publique - Hpitaux de Paris","Assistance Publique - Hpitaux de Paris","Universit degli Studi dell'Insubria","Assistance Publique - Hpitaux de Paris","Washington University School of Medicine","Swansea University","Instituto de Investigacin Marqus de Valdecilla","Centre Hospitalier Universitaire de Nmes|Institute of Human Genetics, Montpellier","London School of Hygiene and Tropical Medicine","Cedars-Sinai Medical Center","Hospices Civils de Lyon","Royal College of Surgeons in Ireland - Medical University of Bahrain|Salmaniya Medical Complex|Bahrain Defence Force Royal Medical Services, Military Hospital|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","IVAN J NUEZ GIL|St Carlos Hospital, Madrid, Spain","University of Birmingham","Assistance Publique - Hpitaux de Paris","University Hospital Padova|Yokohama City University|University of Zurich","RenJi Hospital","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|Athens General Hospital Hippokrateio|Athens General Hospital of Thoracic Diseases SOTIRIA|General Hospital of Athens Sismanoglio|Divine Providence Hospital Pammakaristos","Vivek Reddy|Icahn School of Medicine at Mount Sinai","Shanghai Public Health Clinical Center","The Second Hospital of Nanjing Medical University","Gangnam Severance Hospital","University Hospital Goettingen|Universittsklinikum Hamburg-Eppendorf|University Hospital, Aachen|Transplantationszentrum Kln-Merheim","King Fahad Specialist Hospital Dammam|King Fahad Medical City|King Faisal Specialist Hospital And Research Center|King Abdulaziz Medical City|King Fahad University Hospital|John Hopkins Aramco Healthcare|Taibah University|King Saud University|King Khaled University Hospital|King Fahad Military Medical Complex|Qatif Central Hospital","Aarogyam UK|University of Warwick|Igor Sikorsky Kyiv Polytechnic Institute|ClickMedix LLC","Assistance Publique - Hpitaux de Paris","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|ATTIKON University Hospital","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","Hospital General Universitario Morales Meseguer","Sciensano|Jessa Hospital","Ludwig Boltzmann Institute for Lung Health","Assistance Publique - Hpitaux de Paris","University of Jena","University Hospital, Lille","Capital Medical University","University of Alabama at Birmingham","University of Baghdad","Tongji Hospital","Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|Basque Country University","Gunther Meinlschmidt|Selfapy GmbH|International Psychoanalytic University Berlin","Central Hospital, Nancy, France","Assistance Publique - Hpitaux de Paris|BioMrieux","Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital","University Hospital Inselspital, Berne|Roche Pharma AG","Fondation Ophtalmologique Adolphe de Rothschild|University Hospital, Strasbourg, France","Great Ormond Street Hospital for Children NHS Foundation Trust","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","Regeneris Medical","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","University Hospital, Lille","University Hospital, Lille","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","The Camelot Foundation","University of Washington|Bill and Melinda Gates Foundation","University Hospital, Lille","Fondation Ophtalmologique Adolphe de Rothschild","University Hospital Inselspital, Berne","University of Missouri-Columbia","Nantes University Hospital","A.O. Ospedale Papa Giovanni XXIII","University of Palermo","Hackensack Meridian Health","Assistance Publique - Hpitaux de Paris","Columbia University","Dr Gerry Gin Wai Kwok|The University of Hong Kong|Queen Mary Hospital, Hong Kong","Massachusetts General Hospital|Genentech, Inc.","Zhenhua Zen|Nanfang Hospital of Southern Medical University","Gustave Roussy, Cancer Campus, Grand Paris","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Centre Hospitalier Intercommunal Creteil|ACTIV","University Hospital, Geneva|University of Geneva, Switzerland","University of South Alabama","Spanish Lung Cancer Group","Blade Therapeutics","Centre Hospitalier Universitaire de Nice","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting","Henry Ford Health System","Centre Leon Berard","Assistance Publique - Hpitaux de Paris|Centre Hospitalier de Chartres","Alexion Pharmaceuticals","Assiut University|Doaa M.EL Shehaby","Groupe Hospitalier Pitie-Salpetriere","University Hospital, Montpellier|Pr. Jean-Benot THAMBO, Bordeaux (prsident)|Dr. Cline GRUNENWALD GRONIER, Strasbourg|Dr. Sbastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier|Pr. Roland HENAINE, Lyon|Hamouda ABASSI, Montpellier","Claude Bernard University|University Hospital, Tours|University Hospital, Montpellier|Hospices Civils de Lyon","University Hospital Inselspital, Berne|ETH Zurich","National University of Ireland, Galway, Ireland","University Hospital, Limoges","Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Hospital, Lahore|Pakistan Kidney and Liver Institute","Medical University of Vienna","Societa Italiana dell'Ipertensione Arteriosa","Heinrich-Heine University, Duesseldorf","University of Washington|Bill and Melinda Gates Foundation","Hunter Holmes Mcguire Veteran Affairs Medical Center|McGuire Research Institute","Murdoch Childrens Research Institute|Royal Children's Hospital","Washington University School of Medicine|Bill and Melinda Gates Foundation","National and Kapodistrian University of Athens","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","Hellenic Institute for the Study of Sepsis","Assistance Publique - Hpitaux de Paris","Chongqing Medical University","Virginia Commonwealth University","Shehnoor Azhar|Federal Task Force on Science &amp; Technology notified by Government of Pakistan|University of Health Sciences Lahore","Kanuni Sultan Suleyman Training and Research Hospital","Institut Pasteur","Hospital de Matar|Centro Investigacin Biomdica en Red de Enfermedades Hepticas Digestivas","Radboud University","Duke University|Patient-Centered Outcomes Research Institute","University Hospital, Geneva","Duke University","Kanuni Sultan Suleyman Training and Research Hospital","Maimnides Biomedical Research Institute of Crdoba|Consejera de Salud y Familias - Junta de Andaluca|Red Andaluza de Ensayos Clnicos en Enfermedades Infecciosas (Red ANCRAID)","Centro de Hematologa y Medicina Interna|Laboratorios Clnicos de Puebla (Laboratorios Ruiz)","University Hospital, Lille","University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Vicente Corrales-Medina, MD, PhD|James Brian Byrd, MD|Roberto Viau Colindres","Peking University First Hospital","Duke University|Patient-Centered Outcomes Research Institute","Peking University First Hospital","Estudios Clnicos Latino Amrica|Population Health Research Institute","Huashan Hospital","Peking University First Hospital","CAR-T (Shanghai) Biotechnology Co., Ltd.","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","University Hospital, Bordeaux|University of Bordeaux","Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Institute of Medical Sciences, Pakistan|Pakistan Kidney and Liver Institute|Forman Christian College|Harvard School of Public Health","China Academy of Chinese Medical Sciences","University of Cologne","Kasr El Aini Hospital","Sir Mortimer B. Davis - Jewish General Hospital","University of Oxford","University College Hospital Galway","Matthew Dallos|Bristol-Myers Squibb|Columbia University","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado|SECRETARIA DE SALUD DEL ESTADO DE SONORA|Hospital General de Mexico|HOSPITAL CENTRAL NACIONAL PEMEX NORTE","Bassett Healthcare","Ictal Group","Chongqing Medical University","Centre hospitalier de Ville-Evrard, France","S.L.A. Pharma AG","Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.","GeoSentinel Foundation","Assistance Publique - Hpitaux de Paris","Chinese Academy of Sciences|Beijing YouAn Hospital","Hpital Raymond Poincar|Dominique FLETCHER MD-PhD|Guillaume GERI MD-PhD|Clement DURET MD","Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences","Copenhagen University Hospital, Hvidovre","University Hospital, Lille","Swedish Orphan Biovitrum","Johns Hopkins University|Eiger BioPharmaceuticals","Wake Forest University Health Sciences","Centogene AG Rostock","University of Minnesota","Gilead Sciences","Montefiore Medical Center","University of Utah","Providence Health &amp; Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute","University of Pecs","Assistance Publique - Hpitaux de Paris","Wake Forest University Health Sciences","Hellenic Institute for the Study of Sepsis","Medical University of Graz","Centre Hospitalier Intercommunal Creteil","Rutgers, The State University of New Jersey","Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Childrens Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University","Ansun Biopharma, Inc.","Camillo Ricordi|University of Miami","Neuroganics LLC","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","University of Zurich","University of Chicago","William Beaumont Hospitals","University of Extremadura","Dr. Alexander Supady|University Hospital Freiburg","Istanbul Kltr University|Istanbul University-Cerrahpasa","CytoDyn, Inc.","Tasly Pharmaceuticals, Inc.","University of Oxford","Cordio Medical","Mario Negri Institute for Pharmacological Research","Centre Hospitalier Universitaire de Nmes","Marker Therapeutics AG","University Hospital, Basel, Switzerland|sciCORE University of Basel|Leonhard Med IT ETH Zurich|Swiss Institute of Bioinformatics","Massachusetts General Hospital","Assistance Publique - Hpitaux de Paris","University of Zurich","Kirby Institute|St Vincent's Hospital, Sydney|Garvan Institute of Medical Research|Westmead Hospital, Sydney, Australia|Blacktown Hospital, Sydney, Australia|Holdsworth House Medical Practice|Royal North Shore Hospital|Melanoma Institute Australia|Prince of Wales Hospital, Sydney|Gilead Sciences|Cancer Institute NSW|Cancer Council New South Wales|Positive Life NSW","CytoDyn, Inc.","Hospices Civils de Lyon","Johns Hopkins University","University of Aarhus","Hospices Civils de Lyon","Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundacin Universitaria de Ciencias de la Salud","Erasme University Hospital|Fonds Erasme pour la Recherche Mdicale","Southeast University, China","Karyopharm Therapeutics Inc","Instituto de Investigacin Marqus de Valdecilla","UMC Utrecht","Assistance Publique - Hpitaux de Paris","Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.","Karyopharm Therapeutics Inc","Centre Hospitalier Intercommunal Creteil|Centre Hospitalier Intercommunal Villeneuve St Georges","Implicit Bioscience","Instituto de Investigacin Hospital Universitario La Paz","University of Arizona","Mayo Clinic","Universidad del Rosario|Fundacin Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnologa e Innovacion en Salud","Indiana University","Ospedale di Circolo - Fondazione Macchi","Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital","University Hospital, Montpellier|SkillCell|Sys2Diag (CNRS-Alcediag UMR9005)","Henan Provincial People's Hospital","University of Minnesota","Professor Adrian Covic|Falcon Trading Iasi|Grigore T. Popa University of Medicine and Pharmacy","Institut National de la Sant Et de la Recherche Mdicale, France","University of California, San Francisco|University of California, Los Angeles","University of Minnesota","ProgenaBiome","University Hospital, Lille|FAIR (Auto-immune and auto-inflammatory rare diseases French network)","University Hospital, Limoges","Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","University Hospital, Limoges","University Hospital, Bordeaux","Tongji Hospital","AUVA|Paracelsus Medical University","Tongji Hospital","Centre Hospitalier Universitaire de Nmes","University of Bologna","Central Hospital, Nancy, France","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital","Tehran University of Medical Sciences","University of Miami","Brigham and Women's Hospital","University Hospital of Ferrara","Tongji Hospital","University of Utah","Jena University Hospital","Universit Politecnica delle Marche","Vanda Pharmaceuticals","Assistance Publique - Hpitaux de Paris|Groupe Hospitalier Piti-Salptrire","Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.","Oslo University Hospital","NeuroRx, Inc.|Relief Therapeutics Holding SA|Target Health Inc.|Lavin Consulting, LLC","Mazandaran University of Medical Sciences","Denver Health and Hospital Authority|Genentech, Inc., University of Colorado Denver, National Jewish, Beth Israel Deaconess Medical Center, and Long Island Jewish Hospital","Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andre Rosemon de Cayenne","Tongji Hospital","Saint Francis Care","Tongji Hospital","Instituto Nacional de Rehabilitacion","Shanghai Public Health Clinical Center","MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht","Karolinska University Hospital|Karolinska Institutet|University of California, San Diego|Blekinge County Council Hospital","Belfast Health and Social Care Trust|Queen's University, Belfast|Northern Ireland Clinical Trials Unit|NHS Blood and Transplant","Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University","Chinese University of Hong Kong","Fondation Ophtalmologique Adolphe de Rothschild","Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Population Health Research Institute","University Hospital, Strasbourg, France","Assistance Publique - Hpitaux de Paris","Universitaire Ziekenhuizen Leuven","Hospital of Prato","Fundacin de investigacin HM|Apices Soluciones S.L.","University Health Network, Toronto","Assiut University","Professor Adrian Covic|Medical Sciences Academy - Romania|Victor Babes Clinical Hospital of Infectious Diseases - Bucharest|Grigore T. Popa University of Medicine and Pharmacy","Tan Tock Seng Hospital|National Center for Infectious Diseases|Singapore Clinical Research Institute|Singapore Eye Research Institute|Saw Swee Hock School of Public Health|Duke-NUS Graduate Medical School|Netherlands: Ministry of Health, Welfare and Sports","University of Chile","Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute","Novartis Pharmaceuticals|Novartis","University Hospital, Montpellier|Units de CMF des CHU de Paris (Dr Davrou - Piti salpetrire)|Amiens (Dr Dapke)|Nantes (Pr Corre)|Toulouse (Pr Lauwers - Purpan)|Marseille (Dr Foletti  La conception)|Nice (Dr Savoldelli)|Clermont Ferrand (Dr Sesque)|Perpignan (Dr Llobet)|Lyon (Dr Bourlet  Croix Rousse)","University Hospital, Angers","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Luiz F. L. Reis, Ph.D.|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.|Hospital Sirio-Libanes","CHU de Reims","ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 Peoples Hospital|Tongji Hospital","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","National Institute of Allergy and Infectious Diseases (NIAID)","University Hospital, Montpellier","CalciMedica, Inc.","Hamad Medical Corporation","Federal University of Rio Grande do Sul","Catholic University of the Sacred Heart|Valle del Serchio General Hospital, Lucca, Italy|University of Trento, Trento, Italy|Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy|Bresciamed, Brescia, Italy|118 USL Nordovest Toscana, Lucca, Italy|General Hospital, Voghera, Italy|Lodi General Hospital, Lodi, Italy","Darrell Tan|St. Michael's Hospital, Toronto","University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH","University of Trieste","Neil Goldenberg|Johns Hopkins All Children's Hospital","Salome Kristensen|Aalborg University Hospital","IHF GmbH - Institut fr Herzinfarktforschung|Ministerium fr Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","University Hospital, Akershus|St. Olavs Hospital|Helse Stavanger HF|Haukeland University Hospital|University Hospital of North Norway|Alesund Hospital|Norwegian Institute of Public Health|The University of New South Wales|University of Bristol|Sykehuset Ostfold|Nordlandssykehuset HF|Vestre Viken Hospital Trust|Helse Fonna|Levanger Hospital|Oslo University Hospital|Sykehuset Innlandet HF","Assistance Publique - Hpitaux de Paris","King's College London|Guy's &amp; St Thomas NHS Foundation Trust","Centre Hospitalier Universitaire, Amiens","University Hospital, Ghent","Assiut University","University Hospital, Montpellier|Epsylon Laboratory, EA 4556, University Paul Valry Montpellier 3, France|Laboratoy LIP/PC2S, University Grenobles-Alpes, Grenoble, France|Centre rfrent de rhabilitation psychosociale de Grenoble, Grenoble, France","Wuhan Union Hospital, China","xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud","Tabula Rasa HealthCare","Hpital Universitaire Fattouma Bourguiba","Nantes University Hospital","University of Giessen","Tanta University","Federico II University","Maastricht University|The Central Hospital of Wuhan","TMC HealthCare|PEEP Medical, LLC","University of Oslo|Modum Bad Psychiatric Hospital","Centre Hospitalier Universitaire de Nice","Massachusetts General Hospital","Lady Davis Institute","Azienda Ospedaliero-Universitaria di Parma","University of Rome Tor Vergata","Clinical Nutrition Research Center, Illinois Institute of Technology","Centre Hospitalier Universitaire de Nice","Mayo Clinic","Wefight","Guangzhou Blood Center","University Hospital Tuebingen","Versailles Hospital","Oslo University Hospital|Age Labs AS","Peking Union Medical College Hospital","Assistance Publique Hopitaux De Marseille","Target PharmaSolutions, Inc.","Tongji Hospital","Barts &amp; The London NHS Trust|Queen Mary University of London","Sanofi","Shanghai Jiao Tong University School of Medicine","Ospedale Policlinico San Martino","Cliniques universitaires Saint-Luc- Universit Catholique de Louvain","Imperial College London|CW+ Charity","McMaster University|Vancouver Coastal Health|University of Alberta|Dalhousie University","Brigham and Women's Hospital","Tanta University","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Federico II University","Johns Hopkins University","Herlev Hospital|Nordsjaellands Hospital|Hvidovre University Hospital|Rigshospitalet, Denmark|Mental Health Services in the Capital Region, Denmark|University Hospital Bispebjerg and Frederiksberg","Renmin Hospital of Wuhan University","Uppsala University","Queen's University, Belfast|Belfast Health and Social Care Trust","French Cardiology Society|Institut National de la Sant Et de la Recherche Mdicale, France","University Hospital, Angers","Instituto de Investigacin Sanitaria de la Fundacin Jimnez Daz|Instituto de Investigacin Sanitaria y Biomdica de Alicante|Hospital General Universitario Gregorio Maraon|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario de Salamanca|Hospital General Universitario de Alicante|Hospital Clnico Universitario Virgen de la Arrixaca","Children's Hospital of Fudan University","Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Konya Training and Research Hospital","Royal National Orthopaedic Hospital NHS Trust","Ansun Biopharma, Inc.","Hugo Mendieta Zeron|Materno-Perinatal Hospital of the State of Mexico","Universit Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord","University of Colorado, Denver","Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province","Institute of Liver and Biliary Sciences, India","Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group","Institute of Liver and Biliary Sciences, India","Rush University Medical Center","Austin Health","Sanofi|Regeneron Pharmaceuticals","Stanford University","Stony Brook University","Heinrich-Heine University, Duesseldorf|Universittsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany","University Hospital, Angers","Istinye University","Pierre and Marie Curie University","Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group","Shanghai Public Health Clinical Center","Chinese University of Hong Kong","Universidad Complutense de Madrid","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust","Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS","Istinye University","Assistance Publique - Hpitaux de Paris","A.O. Ospedale Papa Giovanni XXIII|Aferetica - Italy (BO)","Federico II University","Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Medical University|First Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital And Sixth People's Hospital of Wenzhou Medical University|Yueqing Hospital of Wenzhou Medical University|Ruian Hospital of Wenzhou Medical University|Cangnan Hospital of Wenzhou Medical University|Pingyang Hospital of Wenzhou Medical University|Yongjia People's Hospital","University of Giessen","Sanotize Research and Development corp.|The Emmes Company, LLC","Healeon Medical Inc|Robert W. Alexander, MD","Universidad Nacional de Colombia|Fundacin Salud de los Andes","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","Burnasyan Federal Medical Biophysical Center","Rigshospitalet, Denmark","Centre Hospitalier Universitaire de Nice","Assistance Publique - Hpitaux de Paris","Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada","Assistance Publique - Hpitaux de Paris","Tjhin Wiguna|Fakultas Kedokteran Universitas Indonesia|Dr Cipto Mangunkusumo General Hospital","University Hospital, Angers|Mylan Laboratories","Thomas Benfield|Hvidovre University Hospital","Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|Cristlia Produtos Qumicos Farmacuticos Ltda.","UnitedHealth Group|ProHealth Care Associates|University of Pennsylvania Perelman School of Medicine","Assistance Publique - Hpitaux de Paris|Action, France","Laval University","Jieming QU|Ruijin Hospital","University Hospital, Akershus","Medical University of Vienna","University of Calgary","Technische Universitt Mnchen","Vanda Pharmaceuticals","University Hospital, Lille","Sheba Medical Center","University Hospital, Rouen","Tanta University","Karolinska Institutet","Kubra Koce, MSc PT|Istanbul University-Cerrahpasa","Duke University","The University of Hong Kong","Aarogyam UK","Assiut University","Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Nantes University Hospital","National Institute of Allergy and Infectious Diseases (NIAID)","French Cardiology Society|Institut National de la Sant Et de la Recherche Mdicale, France","G. d'Annunzio University","Hospices Civils de Lyon|Eurobio Scientific","Kasr El Aini Hospital","University Hospital, Montpellier","Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University","Hospices Civils de Lyon","Hudson Medical","University Hospital, Strasbourg, France","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico \"Mater Domini\"","Universit Vita-Salute San Raffaele","Istanbul University-Cerrahpasa","Changhai Hospital","Huilan Zhang|Tongji Hospital","Tianhe Stem Cell Biotechnologies Inc.","University Hospital, Clermont-Ferrand|Faculty of Medicine, Clermont-Ferrand, France|UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France|Wittyfit, Paris, France","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico \"Mater Domini\"","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital","Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital","Catholic University of the Sacred Heart","Bicetre Hospital","Universidad Nacional de Colombia|Fundacin Salud de los Andes","Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)","Tanta University","Assistance Publique - Hpitaux de Paris","University Hospital, Lille","Sara Varea|Fundacion Clinic per a la Recerca Biomdica","University College, London","Aarogyam UK","Centre Hospitalier Universitaire de Nice","Istanbul University-Cerrahpasa","University of Alberta","ELHARRAR Xavier|Centre Hospitalier Intercommunal Aix-Pertuis","Spectral Diagnostics (US) Inc.","Columbia University","University Hospital, Essen","Jean Liu|Yale-NUS College","Burnasyan Federal Medical Biophysical Center","Third Affiliated Hospital, Sun Yat-Sen University","Third Affiliated Hospital, Sun Yat-Sen University","The University of Hong Kong","Assistance Publique - Hpitaux de Paris","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","Assistance Publique - Hpitaux de Paris","Fujian Provincial Hospital","Sharp HealthCare","ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital","First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.","Mayo Clinic","Mario Negri Institute for Pharmacological Research","University Hospital, Angers","University of Oxford","ZhiYong Peng|Zhongnan Hospital","University Hospital, Angers","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vincius Guimares de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mouro|Ludmila Abraho Hajjar|Jorge Souza Mendona","University Hospital, Angers","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","Andrew Dinardo|Radbound University Medical Center|M.D. Anderson Cancer Center|Harvard University|Baylor College of Medicine","U.S. Army Medical Research and Development Command","The Cleveland Clinic","Beijing Ditan Hospital","University Hospital, Angers","University of British Columbia|Mallinckrodt","Montreal Heart Institute|DACIMA Software","Memorial Hermann Health System","Qilu Hospital of Shandong University","Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital","University College, London","Poitiers University Hospital","Institut National de la Sant Et de la Recherche Mdicale, France","Beijing 302 Hospital","Huazhong University of Science and Technology","Tang-Du Hospital","University of Milan","Institut National de la Sant Et de la Recherche Mdicale, France","Poitiers University Hospital","Sheba Medical Center","Washington University School of Medicine","Biruni University|Istanbul University-Cerrahpasa","Yasemin rak|Istinye University","Istanbul University-Cerrahpasa","Assistance Publique - Hpitaux de Paris","Ottawa Heart Institute Research Corporation","University of Minnesota","Medical University of Vienna|Kaiser Franz Josef Hospital|SMZ-Ost Donauspital|Otto Wagner Hospital|Hospital Hietzing|Wilhelminenspital Vienna|Medical University Innsbruck","University of Sao Paulo General Hospital","Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital","Baylor Research Institute","Istanbul University-Cerrahpasa","KU Leuven","Mayo Clinic","University Hospital Inselspital, Berne","University Hospital, Akershus","The University of Hong Kong|Hospital Authority, Hong Kong","Medical University of Vienna|Medical Scientific Fund of the Mayor of Vienna","Istinye University","Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla|Spanish Network for Research in Infectious Diseases|GESITRA-IC","Universit de Sherbrooke|Lotte &amp; John Hecht Memorial Foundation","HealthMode Inc.","Istinye University","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","Kaiser Permanente","Institut National de la Sant Et de la Recherche Mdicale, France","University of Iowa","Istinye University","Eliz Arter|Cyprus Science University|Eastern Mediterranean University","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd."],["All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All"],["3 Years to 99 Years  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","30 Years to 70 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","21 Years to 65 Years  (Adult, Older Adult)","up to 85 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 89 Years  (Adult, Older Adult)","18 Years to 89 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","65 Years and older  (Older Adult)","18 Years to 130 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","50 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 64 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 110 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Months and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","25 Years to 65 Years  (Adult, Older Adult)","45 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","35 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 79 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","16 Years to 99 Years  (Child, Adult, Older Adult)","18 Years to 95 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years to 45 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","15 Years to 100 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 59 Years  (Adult)","19 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","1 Year to 80 Years  (Child, Adult, Older Adult)","65 Years to 120 Years  (Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Years and older  (Child, Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","40 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","18 Years to 75 Years  (Adult, Older Adult)","16 Years to 100 Years  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","8 Years to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 17 Years  (Child)","18 Years and older  (Adult, Older Adult)","18 Years to 79 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 95 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","Child, Adult, Older Adult","25 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","5 Years to 75 Years  (Child, Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","1 Year to 100 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","40 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","21 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 90 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","14 Years to 70 Years  (Child, Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 85 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Months to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","6 Years to 85 Years  (Child, Adult, Older Adult)","18 Years to 69 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","30 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","3 Months and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","6 Months to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","60 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","15 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Months to 15 Years  (Child)","Child, Adult, Older Adult","19 Years to 85 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","16 Years and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 120 Years  (Adult, Older Adult)","60 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","20 Years to 50 Years  (Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 120 Years  (Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 45 Years  (Adult)","5 Years and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 89 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","up to 15 Minutes  (Child)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","16 Years to 100 Years  (Child, Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","65 Years and older  (Older Adult)","20 Years to 50 Years  (Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 50 Years  (Adult)","18 Years to 50 Years  (Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","30 Years to 79 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","Child, Adult, Older Adult","60 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","45 Years and older  (Adult, Older Adult)","60 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 105 Years  (Adult, Older Adult)","20 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 45 Years  (Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 110 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 60 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","75 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","up to 100 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","15 Years to 90 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","30 Years to 70 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","5 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 99 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Months and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","up to 18 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","55 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","65 Years and older  (Older Adult)","70 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","14 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 95 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","up to 15 Years  (Child)","18 Years and older  (Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","up to 28 Days  (Child)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","5 Years and older  (Child, Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","20 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","40 Years to 60 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","4 Years and older  (Child, Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","50 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","16 Years and older  (Child, Adult, Older Adult)","65 Years and older  (Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","25 Years to 60 Years  (Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","14 Years to 75 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years to 79 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","up to 90 Years  (Child, Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","21 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 24 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 74 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","1 Year to 90 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","14 Years and older  (Child, Adult, Older Adult)","40 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","16 Years to 70 Years  (Child, Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","Child, Adult, Older Adult","14 Years to 80 Years  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 120 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 35 Years  (Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","15 Years and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","60 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 40 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","45 Years to 65 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)"],["Phase 1|Phase 2","Phase 3",null,"Phase 2","Phase 3",null,null,"Phase 2","Not Applicable",null,"Not Applicable","Phase 2|Phase 3","Not Applicable","Not Applicable",null,"Phase 4","Phase 1","Phase 3","Phase 2|Phase 3","Not Applicable","Phase 2","Phase 3","Not Applicable",null,"Phase 3",null,"Phase 3","Not Applicable","Not Applicable","Phase 1|Phase 2",null,null,"Phase 2|Phase 3","Not Applicable",null,null,"Phase 1|Phase 2","Phase 2|Phase 3","Phase 2|Phase 3","Phase 2",null,"Phase 4","Phase 2","Phase 1","Phase 2",null,"Phase 2",null,"Phase 2","Phase 4","Phase 4","Not Applicable","Phase 2","Phase 3","Not Applicable",null,"Phase 3","Phase 2","Not Applicable","Phase 2|Phase 3","Phase 3",null,"Phase 3",null,"Not Applicable","Phase 2","Not Applicable","Phase 3","Phase 4","Phase 2","Not Applicable","Phase 2",null,null,"Phase 2","Phase 2|Phase 3","Phase 1|Phase 2","Phase 3","Phase 2",null,"Phase 2","Phase 2","Phase 2","Phase 2",null,"Phase 2|Phase 3",null,null,null,"Phase 3","Phase 1","Phase 1",null,"Phase 3","Not Applicable","Phase 2","Not Applicable","Phase 2","Phase 2","Phase 3","Not Applicable","Phase 1|Phase 2",null,null,"Phase 2","Not Applicable","Phase 2","Phase 3","Early Phase 1","Phase 3","Phase 1|Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 1","Not Applicable","Phase 3","Phase 2","Phase 1|Phase 2","Phase 2","Early Phase 1","Phase 3",null,"Phase 2",null,null,null,null,"Phase 1","Phase 2|Phase 3",null,null,"Phase 4","Phase 2","Not Applicable","Phase 1","Phase 2","Phase 2|Phase 3","Phase 2|Phase 3","Phase 3",null,"Phase 2","Phase 2","Phase 2",null,null,null,"Phase 4","Phase 3",null,"Early Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Not Applicable","Phase 1|Phase 2",null,null,"Phase 2|Phase 3","Phase 4","Not Applicable","Phase 3","Phase 4","Phase 2","Phase 2","Not Applicable","Phase 2",null,"Phase 3",null,null,null,"Phase 3",null,"Not Applicable",null,"Phase 3","Phase 2",null,"Phase 1|Phase 2","Phase 1|Phase 2","Phase 2",null,"Phase 3","Phase 3","Phase 3","Phase 3",null,"Phase 2",null,"Phase 2","Phase 2",null,null,null,"Phase 2","Phase 2",null,"Phase 3",null,null,null,"Phase 2",null,null,"Phase 1|Phase 2","Not Applicable",null,"Phase 1","Phase 2","Phase 3","Phase 4",null,null,"Not Applicable","Not Applicable","Phase 2","Phase 3","Phase 3",null,"Phase 2","Phase 1","Phase 2","Not Applicable",null,"Phase 2|Phase 3","Phase 4","Phase 4","Phase 2|Phase 3","Not Applicable","Phase 2","Phase 1","Phase 2","Phase 2","Phase 3","Not Applicable","Not Applicable","Phase 4",null,null,"Phase 2","Not Applicable","Phase 2",null,"Phase 2","Early Phase 1",null,"Not Applicable",null,"Not Applicable","Not Applicable",null,"Phase 2|Phase 3","Not Applicable",null,"Not Applicable","Phase 3","Phase 3","Phase 1","Phase 3","Phase 3",null,null,"Early Phase 1","Not Applicable","Phase 3","Phase 1","Not Applicable",null,"Phase 3","Not Applicable","Early Phase 1","Phase 2","Phase 2","Not Applicable",null,"Phase 2",null,null,null,"Phase 3","Phase 2","Phase 2","Not Applicable","Phase 2",null,null,"Phase 2|Phase 3","Phase 2|Phase 3",null,"Phase 2",null,"Phase 3","Not Applicable","Phase 3",null,"Phase 2",null,"Phase 2","Phase 2","Phase 1",null,null,null,"Phase 2","Phase 2",null,"Phase 3","Phase 2","Phase 1",null,"Not Applicable","Not Applicable","Not Applicable","Not Applicable","Phase 3","Phase 2","Phase 3",null,null,"Phase 1","Phase 1|Phase 2",null,null,"Phase 2|Phase 3","Phase 2|Phase 3","Phase 2|Phase 3","Not Applicable","Not Applicable",null,null,null,null,"Not Applicable","Phase 2","Not Applicable",null,"Phase 2","Phase 3",null,"Phase 2",null,"Not Applicable",null,"Phase 2|Phase 3",null,"Phase 2","Not Applicable","Phase 4","Phase 3","Phase 2","Phase 3",null,null,null,null,"Not Applicable",null,"Phase 4","Phase 4","Phase 4",null,null,null,"Phase 2|Phase 3","Phase 1|Phase 2","Phase 3","Phase 3","Phase 2","Early Phase 1","Phase 2","Phase 3",null,"Phase 2","Phase 3",null,null,null,"Phase 4",null,"Phase 3","Phase 2",null,"Phase 2","Phase 2",null,"Not Applicable","Not Applicable","Phase 3","Not Applicable","Phase 3",null,"Not Applicable","Early Phase 1","Not Applicable","Phase 3","Phase 4","Phase 2|Phase 3",null,"Phase 3","Phase 2","Not Applicable","Not Applicable","Phase 2","Phase 1|Phase 2","Phase 2|Phase 3",null,null,null,"Phase 3","Not Applicable","Phase 3",null,"Phase 1|Phase 2",null,"Phase 2|Phase 3","Not Applicable",null,"Phase 2|Phase 3","Phase 2","Not Applicable",null,null,null,"Phase 2","Early Phase 1","Phase 4","Not Applicable",null,null,"Phase 2",null,null,null,null,"Phase 2","Phase 1|Phase 2","Not Applicable",null,"Phase 3",null,"Early Phase 1",null,null,"Not Applicable",null,"Phase 2","Not Applicable","Phase 1|Phase 2",null,null,null,"Not Applicable",null,null,"Phase 3","Phase 2",null,"Phase 2","Not Applicable","Phase 2","Phase 1|Phase 2",null,"Phase 2","Phase 2|Phase 3","Phase 2","Phase 2","Phase 4",null,null,"Phase 3","Phase 2",null,null,"Phase 2|Phase 3","Not Applicable",null,"Phase 2|Phase 3",null,null,null,null,null,"Phase 2",null,"Phase 3",null,"Phase 2","Phase 2",null,"Not Applicable","Phase 2|Phase 3",null,null,"Phase 4",null,"Phase 4",null,null,"Not Applicable","Phase 2|Phase 3","Not Applicable","Phase 4",null,"Not Applicable","Phase 3","Phase 2",null,"Phase 2",null,"Phase 3","Not Applicable","Phase 2|Phase 3","Phase 2","Not Applicable","Phase 2","Not Applicable","Phase 4","Phase 2",null,"Early Phase 1","Phase 3","Phase 4","Phase 2|Phase 3","Phase 1|Phase 2",null,null,null,null,"Phase 2","Phase 3","Phase 3","Phase 1|Phase 2",null,"Phase 2|Phase 3","Phase 2","Phase 2",null,"Not Applicable","Phase 3",null,"Phase 3","Phase 3",null,null,"Phase 3","Phase 2",null,"Phase 3",null,"Phase 2",null,"Phase 3","Phase 2|Phase 3","Phase 2","Not Applicable","Not Applicable",null,"Phase 3",null,"Phase 2|Phase 3","Phase 2",null,null,null,"Phase 2","Phase 4",null,null,null,null,"Not Applicable",null,null,null,null,null,"Phase 2|Phase 3",null,null,"Not Applicable",null,null,"Phase 2","Not Applicable","Phase 2",null,null,null,null,null,"Not Applicable","Phase 2|Phase 3","Phase 2",null,"Not Applicable","Not Applicable",null,"Early Phase 1",null,"Phase 1","Phase 3",null,"Not Applicable",null,"Not Applicable",null,"Phase 2|Phase 3",null,null,"Not Applicable",null,null,null,null,null,null,"Phase 2",null,"Phase 2",null,null,"Phase 3","Phase 4","Phase 2",null,null,"Phase 2",null,null,"Not Applicable",null,"Phase 2|Phase 3","Phase 2","Phase 1|Phase 2","Phase 4","Phase 3",null,null,null,null,"Not Applicable","Not Applicable",null,"Phase 3","Not Applicable",null,"Not Applicable",null,null,"Not Applicable","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 2","Phase 3","Phase 1|Phase 2",null,null,null,"Phase 2|Phase 3",null,"Phase 3","Phase 3","Phase 3","Phase 2",null,"Not Applicable","Phase 4",null,"Phase 3",null,null,"Phase 3",null,null,null,"Phase 3","Not Applicable","Not Applicable",null,null,"Not Applicable",null,"Phase 2",null,"Phase 1",null,null,null,null,null,"Phase 1",null,null,null,null,null,"Phase 4","Not Applicable","Phase 2","Phase 2",null,"Phase 2|Phase 3","Phase 2","Phase 2",null,null,"Phase 3","Phase 1","Phase 2|Phase 3",null,null,"Phase 4",null,"Not Applicable",null,null,null,"Not Applicable",null,"Phase 2",null,null,"Phase 2",null,null,"Phase 2","Not Applicable","Phase 2","Phase 2",null,"Phase 4","Phase 2","Not Applicable","Phase 2","Not Applicable",null,null,"Phase 2","Not Applicable","Phase 2",null,"Not Applicable","Phase 4",null,"Not Applicable",null,null,"Phase 2","Phase 3",null,null,"Not Applicable","Phase 2",null,null,"Not Applicable",null,"Phase 1|Phase 2",null,null,null,"Phase 3","Phase 3","Not Applicable","Not Applicable",null,"Phase 2",null,"Phase 3","Phase 2|Phase 3",null,null,"Phase 1",null,null,"Phase 2",null,"Phase 4","Phase 2",null,"Not Applicable",null,"Phase 3",null,"Not Applicable","Phase 3","Not Applicable",null,"Not Applicable","Not Applicable",null,"Phase 1"],[50,100,180,106,310,10000000,60,60,48,40,3170,550,100,4,5000,30,50,900,130,1300,55,1660,49,1000,584,8,50,2000,2000,30,340,454,82,0,200,4030,90,80,80,1000,null,60,300,20,400,300,428,3000000,25,40,40,380,141,1200,120,450,1200,120,176,400,1000,100000,342,10000,100,1450,40,10,80,114,6000,400,null,1000,134,804,60,2700,600,375,30,400,440,150,5000,210,12000,8,500,3040,20,20,400,1550,81,200,5,50,360,600,24,42,100,226,48,200,150,350,1116,440,20,200,276,6000,100,84,50,4000,90,45,100,400,1600,100,278,160,500,500,5000,5,120,250,1000,60,398,140,66,200,30,80,330,50,100,350,40,500,10000,300,208,220,150,20,206,744,100,200,80,20,400,426,200,40,500,400,30,50,1000,500,500,600,50,275,10000,2271,null,48,3000,100,120,6000,20,144,165,353,308,238,1500,900,100,250,30,2000,1212,50,3000,30,30,160,1500,230,6000000,100,1000,200,12,1000,20,200,130,108,90,320,520,100,200,1920,215,270,240,122,100,40,54,30,0,500,100,40,11,40,40,20,40,260,24,45,400,90,90,null,200,40,400,56,5000,25,90,20,200,500,200,64,1500,1600,550,1000,2000,400,84,50,102,75,1000,200,200,50,138,66,500,50000,1000,20,100,808,130,100,300,152,3000,100,60,10000,60,304,40,120,2500,1000,60,256,55,60,10000,30,0,2486,100,40,80,92,60,100,100,300,5500,120,200,15,237,60,50,120,214,600,57,194,1000,100,100,40,50,20,100,50,50,436,500,630,3140,60,500,500,250,50,500,45,1000,12,15,300,287,1000,150,600,250,58,200,120,400,400,3000,273,212,null,874,500,5000,178,100,2414,10,400,400,2000,4000,2000,20,4170,55000,180,30,40,436,201,200,500,80,1000,100,651,100000,200,500,70,120,10,1000,152,750,15000,210,2500,100,150,24,80,1057,400,300,500,200,600,40000,200,138,90,4000,250,0,1320,240,60,374,2000,9,100,116,66,100,54,164,200,400,500,null,100,10,1250,7576,150,150000,100,50,200,750,500,280,24,100,15000,510,10000,10,25,3500,30,100,75,120,510,5000,3000,175,2000,10000,500,900,64,1000,390,200,150,180,400,10,60,120,230,800,1000,100,4000,80,794,null,450,150,50000,80,340,250,120,180,30,200,200,3100,1000,580,600,13770,200,80,200,2000,400,4000,100,220,350,600,20,40,20,1500,60,60,400,145,50,5000,554,200,700,120,30,60,450,100,15,207,100,30,7100,200,75,300000,170,1500,300,240,1500,405,60,100,200,94,140,200,200,1200,2000,30,444,300,300,530,210,5000,290,300,136,39,572,150,120,456,149,100,1220,400,104,38,333,4000,350,230,230,200,180,600,600,10,100000,12123,120,850,40,40,400,300,15,10084,100,470,162,310,1200,500,80,120,2000,19491,350,99,50000,10,50,5000,328,140,210,2944,1200,15,200,576,2000,60,1000,20,70,30000,669,100,150,80,100,100,100,0,100,100,250,86,38,20,120,20,120,100,346,150,300,120,500,334,1300,80,400,533,15,30,240,200,630,128,1000,10,20,504,20,200,10,10,226,320,40,120,1464,117,239,10000,260,1500,440,850,500,216,380,200,440,12500,20,300,500,10000,100,60,670,30,200000,100,18,300,0,1000,45,500,25,10,1000,130,30,300,null,100,110,1000,60,5,96,20,50000,120,200,200,198,200,86,40,100,840,914,300,1302508,32,30,500,500,25,null,350,630,5000,320,20,100,80,2200,420,240,400,200,10,160,0,900,100,2300,140,4000,440,280,348,700,null,520,50,50,20,6000,500,12000,230,24,10000,300,150,30000,20,50,300,56000,250,500,30,30,200,240,20,3500,500,130,0,115,1000,1850,90,100,202,127,60,30,50,800,1000,128,3000,640,500,82,50,400,30],["Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Industry|Other","Other|Industry","Other|Industry","Other","Other","Other|Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Industry|Other","Other|Industry","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Industry","Other","Industry","Other","Industry","Other","U.S. Fed","Other","Other","Other","Other","Other","Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Industry","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Industry","Industry","Industry","Industry|Other","Industry|Other","Other","Other","Industry|Other","Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other|Industry","Other","Other","Other","Other","Other|Industry","Other","Industry","Other","Other","Other|Industry","Other","Industry","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Industry","Other","Other","Other","Other","NIH","NIH|Other","Other","Other","Other","Other","Other|Industry","Other","NIH","Industry","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other|Industry","Other","Industry","Other","Other","Other","Industry|Other","Industry","Other","Other","Other","Other","Other|Industry","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Industry","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Industry","Other|Industry","Other","Industry","Other","Other","Other","Other","Industry","Other","Other|Industry","Industry|NIH","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","U.S. Fed|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other|Industry","Other","Industry","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Industry","NIH","Other|NIH","Other","Other","Other","Other","Other","Other","Industry","Industry","Other","Industry","Other","Other","Industry","Other","Other","Other","Other","Other|Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other|Industry","Industry","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Industry|Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","NIH","Other|Industry","Other","Other","Other","NIH","Other","Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Industry","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other|Industry","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","NIH","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","U.S. Fed","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other|Industry"],["Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Expanded Access:Treatment IND/Protocol","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Expanded Access:Intermediate-size Population","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access:Intermediate-size Population","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access:Intermediate-size Population","Observational","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Expanded Access:Treatment IND/Protocol","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Expanded Access:Intermediate-size Population","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Expanded Access:Individual Patients|Treatment IND/Protocol","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Expanded Access:Intermediate-size Population","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional"],["Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",null,"Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Observational Model: Case-Only|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Cross-Sectional","Observational Model: Case-Control|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",null,"Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Ecologic or Community|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Other","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Retrospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Family-Based|Time Perspective: Cross-Sectional","Observational Model: Family-Based|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",null,"Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Other|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Family-Based|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective",null,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Other","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Other","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Other","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Cross-Sectional","Observational Model: Case-Only|Time Perspective: Other","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Retrospective","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective",null,"Observational Model: Case-Only|Time Perspective: Retrospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Other","Observational Model: Case-Control|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",null,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"],["1398.1224","HS216C17-PHASE III","282661","PRO00037712","TVCS-COVID19","COVID-19 Symptom tracker","COVID19_Microbiota","BK-CLV-201","STUDY00001051","WES-2","20HH5868","TJ-IRB20200205","JT202002LZ","DAS181-SARS-CoV-2","Pro2020-0342","ONS_COVID-19","STUDY00145514","D1690C00081|ESR-20-20653","IFX-1-P2.9","2000027887","Pro2020-0375","ABCOV-01 version 1.1","IRCCSSanMatteoH","VACAT","APHP200387","COVID-T 1.0","2020XLA015-1","20D.346","APHP200382|2020-A00754-35","Pr20200402","JSZYJ202001","IRB: 20.04.09","DAS181-3-02-EU|2020-001874-30","GIRH-APN01","PSY-ENCOVID19","COV-01-IB","ChongqingPublicHMC","20-0869","20-0738","SAIL-004","INCB 18424-MA-COVID-19-301","Different Interferons in COVID","1051355","2020003D","TOCIVID-19|2020-001110-38","INRCA_01_2020","D822FC00001","WP-2020-02","04-13-20-Dubberke","Interferon Beta 1a in COVID-19","Umifenovir in COVID-19","H-40070","KUMC-COVID-19","CONCOR-1","Pro00105221","CAALC-008-CMHS","20PH061|2020-001188-96","55619","RIPH_2020_6","6R88-COV-2040","PROLIFIC2020 (A095583)","20200835","COV-AID","OBVIO-OBV-001","Pro00105319","Pentagon 20-1","s20-00399","GST-G1","SARPAC","2000027971","2020-04-02","2020-001","CAP-1002-COVID-19","105-20-ASF","H-40102","NCU-COVID19","Medical","COMIHY","PRG-044","COVID-FLUS","2020-0337","842838","2114","20-000685","DEP_012020","EMC 0045-20","COVIDENCE","2020.059","2020.0075","HCQ4COV19|2020-001031-27","PC-TecSalud Fase I","IRB20-0572","AssiutU-3-2020","1051360","KS-0470","APN01-01-COVID19","STUDY00000381","IRB20-0515","020-132","COVID 2020-001","CYTOCOV-19|U1111-1250-2078|DRKS00021199","LDE-MTX_COVID19","CANASCOV","2210061","s20-00444","20 KHCC 67","S2020-0472-0001","RA-2020-018","0154-20-RMB","PrEP_COVID","2020K-G005|hDPSC-CoVID-2019-02-2020","PUL-042-501","IIBSP-COV-2020-23","GS-US-540-5773|2020-000841-15","PUL-042-502","bacTRL-Spike-1","NITFQM0320OR","CRSC20005","s20-00392","IRB-56134","Allogeneic COVID-19 Protection","HIAPRE0320OR","GS-US-540-5774|2020-000842-32","20-0407","ConPlas-19","KICC19","COVID-19-1.0-DKFZ","RECHMPL20_0185","CovidDB","COVID-19","BHV3500-203","PANDOR","XQonc-015","TT-NPC","RCT-TCZ-COVID-19|2020-001386-37","QLEmer","HOPE","SILCOR-COVID-19","97548","Glucocorticoid COVID-19","WA42380|2020-001154-22","137654","20200214-COVID-19-M-T","s20-00390","20200214-COVID-19-S-T","MD-COVID-19","Covid-19/MHC/2020","DT P-2020-353","EudraCT 2020-001206-35","COV-HCQ|2020-001224-33","RECHMPL20_0175","AntiCOVID19ORT","56249","PRO-nCOV-1001","TXACOVID1","CHUB-IL6-COVID-19","HIZ-PRC-COVID-19","Genesis AKCOVID- FG-1","CovidRegOUH","NL73489.078.20","2020-001278-31","CRSC20004","HidroxycloroquinaCOVID19","QUARANTINE2020","MRCTA, ECFAH of FMU [2020]027","DEFI-VID19","GCO 20-0932","JSVCT089","FMASU P17a/ 2020","RM08-3006","CHESS2002","HT-COVID19","APHP200434","20-30504","CINC424A2001M","202001","COVID-19/SEIMC-FSG","FMASU P14 / 2020","APHP200375-10|2020-001246-18","EA1/071/20","HAL 345/2020","TJ003234COV201","24032020","ar20-0031v1","CAP-China remdesivir 1","HGEN003-06","NL73249.041.20","FMASU P19a/ 2020","FMASU P16a/ 2020","COVID","200094|20-D-0094","ACTG A5395|38720","IRB2020-00222","55596","FMASU P18a/ 2020","0064468/20","APHP200406|2020-001571-32","002011|Pro2020000712","200081","CD24Fc-007|20200674","APHP200412","AssiutU12","AGMT_COVID-19","17824|I7W-MC-UDAA","JessaH_COVID19_DVT","VICC MD 2032","SC-2020-01","COVITD-19","87RI20_0016/CoSigS","JSVCT088","2020-013-D","TH-DMS-COVID19 study","BeijingYouan Hospital","AssiutU11","282014","APHP200467|2020-A00999-30","H-20026205|2020-001544-26","KIN-1901-2001","AZIQUINE-ICU-25032020|2020-001456-18","2037815010","RECHMPL20_0195","CAN-COR-1","0183|2020-000577-24","SARCOVID|2020-001634-36","Pr20200225","IRSTB113","2020PPRC03","ASC-CTP-HS-01","ASC-CTP-NC-01","chloroquine covid","2020-Sur-ERC-20","CCAM 20-01","115785","2019P00XXXX","MedOPP376",";Proposed by Mahmoud Elkazzaz","Methylprednisolone in COVID-19","200693","SBCebromhexinCovid-19","20-003312","RECHMPL20_0223","2020p00xxxx","69HCL20_0329","Protection Against COVID-19","JessaH_COVID19_prescreening","HRI-COVID-19-Anti-Malarial-001","Acute Care CP Consortium Trial","COV2ICU-DK|H-20023159|R349-2020-540","COVID19_Biovitals_Protocol_1","Al-COVE","ECMO-VID","U-DEPLOY: RUX-COVID|20-5315","ILBS-COVID-03","AAAS9676","APHP200388|2020-001457-43","Pro00105266","PIPK- 0000 /NIBD-0000/2020","ProfilaxisCOVID","TACRO-BELL-COVID|2020-001445-39","BHC-RIB-5401-HC","IMIB-COLVID-2020-03","Ath/ct101/22/3","TCAI_COVID-19","turkishcovid19","HIAPRE0420OR","CTU2020032","D20-P013|2020-001570-30","BCX4430-108|272201300017C-18-0-1|DMID18-0022","pro00105212","2020-134","MUST23032020","FMASU P15/ 2020","20-23","APHP200389-6","APHP200389-7","68/2020","APHP200390|2020-A00768-31","202004023","16SW0194","IDI-REM-2020-1","NIMAO/2020-01/PC-01","2020-KEP-420","00000644","69HCL20_0321|2020-001553-48","BDF/R&amp;REC/2020-423","IMIB-DFC-2020-02","20/241-E|EUPAS34399","CS-20200324","APHP200375-3","RACONA Nafamostat","COVID19-Echocardiography","UNIKINON-01/HOPE","GCO 20-0931","HC-COVID-19","WMT-YJ-202001","3-2020-0036","UMG_Co19-Nephritis","HAEM0321","AU12","APHP200389-5","T3inj-02/ThySupport","GIMI-IRB-20002","08-04-2020","Jessa300","LEAD CoVid-19","APHP200375-4","RuxCoFlam","2020_32|2020-A00957-32","CAP-China remdesivir 2","TXACOVID2","PRO20040001","COVEI","127157","IPUB_2020_01","2020PI072","APHP200392|2020-001324-33","RH-ITA-008|2020-001395-15","2020-00691|2020DR2044","CGE_2020_9","20BO08","RIV-2020-1","COVID-MSCIV","GIMI-IRB-20001","EQ_2020_02|2020-A00912-37","EQ_2020_03|2020-A00911-38","Inf-3323","FMTVDM2020","STUDY00009878","2020_30|2020-A00873-36","CRN_2020_8","2020-00563","262095","RC20_0165","v 0.9 16th March 2020","3143","Pro2020-0356","APHP200310","AAAS9517","UW20213","2020P001159","hkyy2020-005 AKI","2020-001250-21|2020/3078","3336","COVILLE|2020-A00724-35","2020-00516","[1582736-1]","GECP 20/02_GRAVID","B-2660-204","20-PP-09","ECC2020-04","1410401","ET20-076 - IMMUNONCOVID-20|2020-001373-70","APHP200461|2020-001909-22","ECU-COV-401","2020A10","CIC1421-20-05","RECHMPL20_0155","BBCovid","WAVE","C.A. 2348","87RI20_0011 (PRODEX)","NBC-COVID1902","1357/2020","SARS-RAS","20-004","STUDY00009750","Davis 001","62586","202004099","906295542","H-47561 MSC for COVID-19","ESCAPE|2020-001039-29","P 200394|2020-001306-35","2020-02-2","HM20018977","12(06)/2016-Coord","endocovid19","2020-007","COVID_OD","NL73547.091.20|2020-001320-34","Pro00105284","2020-00794","PRO00105339","covid19pregnancynewborn","SARICOR","CHMI-030420-01","2020_33|2020-A00906-33","842810","2020 research 110","Pro00105274","2020 research 112","COLCOVID version1.2","KY2020-COVID-19","2020YFC0844100","KT005HB001","QF-XYP1990-1","CHUBX 2020/12","NBC-COVID19-02","YHQW-V3.0","ReCovER","N-20-2020","1, March 30, 2020","VIR20001","APPROVE-CARE-2020","AAAS9881","TERAPLASCOV2","1581969","Neuro-COVID-19","2020-02","10477M-ICOS","EPA-COV-001","2019NCP1.0","GFICOVID-19-1","APHP200482","ChineseASZQ-006","CSC19APR","YHQW-Severe-V2.0","PISCA Study","EQ_2020_01|2020-A00907-32","Sobi.IMMUNO-101|2020-001167-93","IRB00248163","IRB00064587","COVER-2020","STUDY00009429","GS-US-540-5821|2020-001453-49","2020-11445","131618","2020000186","IV/2428- 2 /2020/EKU","APHP200411|2020-A00897-32","IRB00064912","SAVE|2020-001466-11","250320","COVID-ECHO","2020000679","BCH Lung 012","DAS181-2-07","20200370","2020/03/18","200083|20-I-0083","PETAL 05 Orchid","KEK-ZH-req-2020-00322","IRB20-0523","2020-087","3.954.038","CYCOV","FADP-2","CD10_COVID-19","T89-NCP-01","COV001","COV001","EC-COVID-PCS-Fenice","PHRC-I/2020/JCG-01","MH-007/B","2020-00769; qu20Egli2","2020P000881","APHP200386|2020-001273-73","2020-00719","2020-04-CORIA","CD12_COVID-19","69HCL20_0322","IRB00245634","2020-001200-42","69HCL20_0346|2020-A01036-33","ABN011-1","P2020/201","2020YFC0841300-03","XPORT-CoV-1001|2020-001411-25","EnCOVID-HidroxiCLOROQUINA","20-161/C","APHP200417","PrEP COVID-19","XPORT-CoV-1002","COVIP","COV02","MeCOVID","2003524869","20-002610","ABN011-2","2003973826","HM-COVID19-Italy","WHTJCOVID-19","RECHMPL20_0170","SOT-C","SURG-2020-28675","0110","C20-15","20-30410","SURG-2020-28683","PRG-042","NI_2020_03","87RI20_0013","IVIG-001","87RI20_0015/Emocovid","CHUBX 2020/11","TJ20200128","AUVA SARS-CoV-2 Studie","TJ20200131","2020-A00797-32","PREDI-CO","2020-A00881-38","QLEmer20200214","99-1-103-47429","20200384","2020P000944","250320","ASC09F-CTP-TJ-01","IRB_00131893","IDIR-001-2020","TOFACoV","VP-01-01 CALYPSO","APHP200409","VivaDiag-2020","118684","COVID-AIV","IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1","20-0880","2020-009","TJ20200201","SFH-20-23","2020-TJ-COVID-19","20/20","DC-COVID-19","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","K-2020-2611|2020-001349-37|4-1199/2020","16154DMcA-AS","RWS-BTCH-002","COVID-19 study 2020.076","GDE_2020_11","Gisondi 4","NOgas mildCOVID-19","PHRI.ACT.COVID19","7783","APHP200395|2020-001287-28","COntAGIouS","HPrato-3","Ruxo-Sim-20|2020-001405-23","JF-4-2020","COVID-19 in Egypt","GTP0032","2020/00402","HEROES Covid-19","1.6/M.Edu/141/2020","CJWT629A12301","RECHMPL20_0228","2020-A00782-37","ECC2020-03","CAAE: 30504220.5.0000.0005","999920085|20-M-N085","CAAE: 30227020.5.1001.0008","PO20055","Fzhy-ncp-2","CT2019-nCoV","20-0006","RECHMPL20_168","CM4620-204","MRC-05-001","2020241093","0013226/20","CORIPREV-1","130852","MP-19 023_2020","COVAC-TP","20200401","COVID-19 Registry","20/03794","APHP200410","282009","PI2020_843_0026","BC-07505-LGE","COVIDQ","RECHMPL20_0225","WuhanUH-2019 nCoV-Ig","XC-PCOR-COVID19","COVID-PACE-2020-001","KM2020-1","RC20_0150","AZ 58/20","faviprevir covid","152/20","UM_2020_GY_COVID-19","COVID19PEEP2020|GO2 PEEP Study","REK125510","20reamedcovid19","NOpreCOVID-19","SPIN-CHAT-001","ColCOVID-19","s-covid survey","IRB-2020-91","20reamedcovid.05","19-001971","WefightDistress20","Blood donor recruitment","COVID65plus","P20/05_IMAGE19","REK-124170","Low flow-ECMO by CVVH in NCP","2020-16|2020-A00795-34","TARGET-COVID-19","Zhaojp","282289","EFC16855|2020-001269-35|U1111-1249-6168","Interferon_prophylaxis","COVID-ItaliansurgRES-SPIGC","DTM-001","REMOTE-COVID","20006014","2007P000003","ivermecin covid","PRoVENT-COVID","145/20","IRB00246834","RegHCOVIDScreening","COVID-19 WU1","EPN 2017/043 Covid19","282617","2020-03","2020/29","BALMYS-19","CHFudanU_NNICU14","NO-SARS-COVID-19","YTire","RNOH MAGEC","DAS181-3-01|2018-004318-16","2020-03-681","TOCICOV-1","20-0751","HBCBH-IEC-2020-101","ILBS-COVID-02","20-002","ILBS-COVID-01","COVID-19-HFNC+PP","38839","EFC16844|U1111-1249-6021","56032","SBU-COVID19-ConvalescentPlasma","CLOCC-2020","49RC20_0071","2020-2/1","GREEN GRC01","20-001","Anti-SARS-CoV-2","online-mind","Covid_ISCIII 20/265-E_BS","COVIDx","Brazil COVID Coalition I Trial","002","APHP200375|2020-001246-18","DFPP COVID 19","5/20","SAHoWMU-CR2020-NCP-202","AZ 63/20","COVID-CTP-01","GARM COVID19","UNAL FSA COVID","KronLungesyg_COVID_19_protokol","DAL-05-04-2020","EudraCT number: 2020-001330-36","20urocovid.03","APHP200389","COV_NUTRIC","APHP200375-2","MH-Covid19","2020-001602-34","25032020|2020-001367-88","30155020.5.1001.0071","2020-0003","INDS 0522070420","21909","Abdrcspc202001","117589","HCQ prophylaxis for COVID19","REB18-0107_MOD9","161/20 S","VLY-686-3501","2020_20|2020-A00763-36","SMC-20-7078-YZ-CTIL","2020/097/OB","ACEIS COVID 19","Put in EPN","002","Pro00105189","COVID_LVD_SCREEN","AU08","Covid-19 mental health","COVID19 NOgas mild","RC20_0148","20-0003|1UM1AI148373-01","2020-02","UChieti03","69HCL20_0340|2020-A01038-31","N-18-2020","RECHMPL20_0219","xinxiangM","69HCL20_0214","COVID19","7772","covid-19 biomarkers","COVID-BioB/OSR","10042020","ncMCE1","huilanz Zhang","2020-TH-001","2020 COVISTRESS","covid-19 add-on therapy","NO-SARS-COVID-19","APPI2-CV-2020-01","20202503","2020-A00793-36","UNAL-COVID-CP","COVID19-001","COVID 19 treatment","APHP200464","2020_21|2020-A00811-38","TACTIC-COVID|2020-001616-18","ISAC17_205R","AU09","20dermatocovid.02","GPA1347","Pro00100000","20202703-2","SDI-PMX-013","AAAS9992","20-9213-BO","2020-CERC-001","FL-01/20","PL11","XWX3","UW 20-211","APHP 200448","CAEE: 30615920.2.0000.0005","APHP200375-5","KY-2020-24.01","COVID-ARB|2003902","2020002","ASC09F-CTP-ZY-01","20-002864","EC-COVID-RCT-Fenice","COVID-ARA2","ID 263097","2020001","2020-A00831-38","CAAE: 30152620.1.0000.0005","2020-A00831-39","QF-XYP2001-1","H-47454","S-20-01","IRB 20-361","DTXY022","2030/31","NTM-CTP-01: H17-02107","MHIPS-2020-001","HSC-MS-20-0286","2019nCoV-CVD","307-nCoV","132151","PAVM COVID","C20-06|2020-A00280-39","2020001D","IRBID:TJ-C 20200107","20200101","02-PNSNP-2020","C20-16|2020-A00609-30","POWER-COVID_CT","7092-20-SMC","202003188","Physical Activity Project","009","EAvcil|pek Yeldan","APHP200375-1","20200228-01H","STUDY00009414","ACOVACT","UAP107","GZHZ-COVID19","020-123","60350273-605.99-","COVID-19: ILUSA (S63988)","18-010925","2020-00672","REC 121446","UW-20-074","TGA-TM-Critical-2019","007","COVIDSOT","MP-31-2019-2945","HM070102","001","STUDY00009267","IRB-1556587","C20-05|2020-A00256-33","201412701-1","0001","Nutr2020","MEXCOVID"],["April 2020","March 25, 2020","April 20, 2020","May 1, 2020","April 15, 2020","March 23, 2020","April 2020","April 24, 2020","April 2020","April 10, 2020","April 3, 2020","April 1, 2020","February 15, 2020","March 6, 2020","March 27, 2020","May 1, 2020","March 25, 2020","April 15, 2020","March 31, 2020","May 1, 2020","April 9, 2020","April 13, 2020","March 17, 2020","April 14, 2020","April 13, 2020","April 2020","March 2020","April 13, 2020","March 31, 2020","February 1, 2020","March 2, 2020","March 27, 2020","April 25, 2020","February 2020","April 16, 2020","May 15, 2020","March 21, 2020","April 2020","April 2020","April 2020",null,"April 5, 2020","March 30, 2020","January 27, 2020","March 19, 2020","April 2020","April 24, 2020","March 17, 2020","June 30, 2020","April 15, 2020","April 15, 2020","April 2020","April 1, 2020","April 27, 2020","April 20, 2020","February 14, 2020","April 14, 2020","April 15, 2020","April 2020","March 18, 2020","April 2020","April 6, 2020","April 2020","April 20, 2020","April 13, 2020","April 2020","April 6, 2020","February 9, 2020","March 24, 2020","April 30, 2020","April 2, 2020","April 1, 2020",null,"April 20, 2020","April 2020","April 27, 2020","May 2020","April 10, 2020","April 2020","March 14, 2020","April 15, 2020","April 9, 2020","March 18, 2020","April 25, 2020","March 23, 2020","April 2020","May 5, 2020","February 14, 2020","April 15, 2020","March 18, 2020","April 15, 2020","April 2020","March 11, 2020","April 2, 2020","April 2020","April 2020","April 8, 2020","April 4, 2020","April 3, 2020","April 10, 2020","April 1, 2020","May 1, 2020","April 2020","April 12, 2020","April 9, 2020","April 15, 2020","March 11, 2020","March 26, 2020","March 2020","April 3, 2020","April 6, 2020","April 2020","April 2, 2020","March 6, 2020","April 2020","April 30, 2020","April 12, 2020","April 30, 2020","March 31, 2020","May 2020","April 23, 2020","April 23, 2020","March 15, 2020","April 15, 2020","April 3, 2020","April 2020","April 20, 2020","February 1, 2020","March 30, 2020","March 16, 2020","April 2020","April 7, 2020","January 17, 2020","March 5, 2020","March 31, 2020","March 17, 2020","April 2020","April 15, 2020","April 4, 2020","January 26, 2020","April 3, 2020","April 2020","February 20, 2020","April 3, 2020","February 18, 2020","January 1, 2020","April 2, 2020","March 23, 2020","April 15, 2020","March 29, 2020","April 1, 2017","April 14, 2020","May 2020","April 13, 2020","April 15, 2020","March 20, 2020","April 16, 2020","April 1, 2020","March 15, 2020","April 8, 2020","April 3, 2020","April 20, 2020","April 14, 2020","April 6, 2020","February 22, 2020","April 6, 2020","April 2020","April 12, 2020","April 14, 2020","April 30, 2020","March 30, 2020","March 21, 2020","April 2020","April 1, 2020",null,"April 20, 2020","March 18, 2020","April 20, 2020","April 14, 2020","March 27, 2020","April 15, 2020","April 11, 2020","April 13, 2020","March 22, 2020","February 12, 2020","May 2020","March 25, 2020","April 20, 2020","April 20, 2020","April 7, 2020","April 16, 2020","May 1, 2020","April 20, 2020","April 2020","April 20, 2020","April 1, 2020","April 2020","April 1, 2020","April 15, 2020","April 8, 2020","April 2020","April 11, 2020","April 1, 2020","April 20, 2020","April 17, 2020","March 17, 2020","April 2020","April 10, 2020","April 25, 2020","March 16, 2020","March 5, 2020","April 15, 2020","February 23, 2020","April 2020","March 25, 2020","April 2020","April 2020","April 2020","April 20, 2020","April 2020","April 8, 2020","April 6, 2020","April 2020","April 13, 2020","February 24, 2020","March 27, 2020","April 14, 2020","March 18, 2020","February 17, 2020","April 17, 2020","July 1, 2020","April 14, 2020","April 20, 2020","April 2020","April 14, 2020","April 2020","February 14, 2020","May 2020","April 10, 2020",null,"April 1, 2019","May 1, 2020","April 9, 2020","April 16, 2020","April 17, 2020","April 20, 2020","May 2020","April 6, 2020","April 1, 2020","April 1, 2020","June 1, 2020","April 20, 2020","April 22, 2020","March 2020","April 10, 2020","April 14, 2020","April 2020","April 14, 2020","April 1, 2020","April 2020","April 20, 2020","March 28, 2020","March 27, 2020","March 26, 2020","April 20, 2020","April 13, 2020","April 2020","April 9, 2020","April 2020","April 2020","April 15, 2020","April 20, 2020","April 2020","April 20, 2020","April 15, 2020","April 16, 2020","April 2020","April 10, 2020","March 14, 2020","April 15, 2020","April 2020","April 2020","April 21, 2020","April 2020","April 19, 2020","April 8, 2020","March 23, 2020","March 31, 2020","April 11, 2020","April 2020","February 19, 2020","April 6, 2020","April 9, 2020","February 6, 2020","February 5, 2020","April 1, 2020","April 13, 2020","April 12, 2020","March 28, 2020","April 15, 2020","May 2, 2020","February 15, 2020","April 1, 2020","April 30, 2020","April 27, 2020","April 2020","May 1, 2020","April 2020","February 6, 2020","April 15, 2020","April 8, 2020","March 7, 2020","April 7, 2020","April 8, 2020","April 15, 2020","April 2020","April 15, 2020","April 2020","April 15, 2020","April 15, 2020","April 1, 2020","April 2020","March 24, 2020","April 2020","April 2020","April 4, 2020","April 11, 2020","April 16, 2020","April 2020","April 2020","March 19, 2020","April 1, 2020","April 25, 2020","March 19, 2020","March 13, 2020","April 14, 2020","March 16, 2020","March 25, 2020","April 14, 2020","April 27, 2020","February 26, 2020","April 3, 2020","April 1, 2020","April 14, 2020","March 27, 2020","April 17, 2020","May 15, 2020","May 2020","April 22, 2020","April 15, 2020","April 7, 2020","April 15, 2020","April 2020",null,"April 2020","March 20, 2020","March 1, 2020","April 27, 2020","May 1, 2020","March 30, 2020","April 20, 2020","April 15, 2020","April 11, 2020","March 10, 2020","March 19, 2020","March 31, 2020","April 16, 2020","March 30, 2020","April 2020","April 6, 2020","May 2020","April 2, 2020","April 13, 2020","March 1, 2020","April 22, 2020","April 7, 2020","April 5, 2020","March 13, 2020","April 14, 2020","April 2020","April 10, 2020","April 14, 2020","April 2020","April 1, 2020","April 27, 2020","April 13, 2020","April 2020","March 31, 2020","April 1, 2020","April 2020","April 1, 2020","March 2020","March 14, 2020","March 8, 2020","March 5, 2020","March 14, 2020","April 15, 2020","April 14, 2020","February 27, 2020","April 20, 2020","May 1, 2020","May 2020","April 2020","April 11, 2020","April 16, 2020","May 2020","April 6, 2020","March 23, 2020","January 25, 2020","April 1, 2020","April 13, 2020","February 16, 2020","April 24, 2020","April 20, 2020","January 27, 2020","April 15, 2020","March 20, 2020","April 2020","April 2020","April 2, 2020","April 2020","March 22, 2020","April 20, 2020","April 15, 2020",null,"April 2020","March 20, 2020","March 30, 2020","April 1, 2020","April 2020","April 2020","April 15, 2020","April 8, 2020","March 31, 2020","April 7, 2020","February 15, 2020","April 2020","April 17, 2020","April 16, 2020","April 27, 2020","April 2, 2020","March 13, 2020","April 10, 2020","April 2020","March 16, 2020","March 27, 2020","April 12, 2020","April 1, 2020","February 26, 2020","April 2020","April 2020","April 6, 2020","April 2020","April 27, 2020","April 9, 2020","April 15, 2020","April 15, 2020","April 15, 2020","April 27, 2020","April 15, 2020","April 14, 2020","May 1, 2020","March 31, 2020","April 2020","April 1, 2020","March 31, 2020","February 10, 2020","April 17, 2020","April 6, 2020","March 23, 2020","April 13, 2020","April 15, 2020","April 30, 2020","April 30, 2020",null,"April 2020","April 13, 2020","March 30, 2020","April 1, 2020","April 1, 2020","April 7, 2020","February 20, 2020","April 7, 2020","February 1, 2020","April 13, 2020","March 18, 2020","March 22, 2020","March 20, 2020","April 9, 2020","April 2020","April 18, 2020","April 2020","February 10, 2020","April 15, 2020","April 2, 2020","February 1, 2020","April 2020","February 1, 2020","April 3, 2020","March 20, 2020","April 16, 2020","February 15, 2020","April 20, 2020","April 30, 2020","March 1, 2020","April 8, 2020","February 1, 2020","April 14, 2020","April 15, 2020","April 10, 2020","April 2020","April 9, 2020","March 2020","March 28, 2020","April 2020","March 28, 2020","April 2020","March 23, 2020","February 1, 2020","April 10, 2020","April 10, 2020","April 10, 2020","January 30, 2020","April 11, 2016","April 25, 2020","January 7, 2019","February 1, 2020","February 24, 2020","April 2020","April 1, 2020","March 21, 2020","April 1, 2020","May 1, 2020","April 1, 2020","March 27, 2020","May 16, 2020","April 12, 2020","April 21, 2020","May 1, 2020","March 31, 2020","April 2020","April 15, 2020","April 20, 2020","April 30, 2020","April 1, 2020","April 6, 2020","April 15, 2020","April 8, 2020","April 27, 2020","April 13, 2020","May 1, 2020","February 15, 2020","January 31, 2020","February 21, 2020","April 11, 2020","April 8, 2020","April 14, 2020","April 17, 2020","April 8, 2020","April 17, 2020","March 18, 2020","March 23, 2020","May 15, 2020","April 8, 2020","April 6, 2020","April 3, 2020","April 13, 2020","April 6, 2020","April 2020","March 30, 2020","April 2020","April 1, 2020","March 17, 2020","March 21, 2020","April 7, 2020","January 1, 2019","April 15, 2020","April 2020","April 17, 2020","April 10, 2020","December 23, 2019","March 27, 2020","March 31, 2020","February 28, 2020","April 2, 2020","April 15, 2020","April 20, 2020","April 2, 2020","April 17, 2020","April 15, 2020","September 10, 2019","March 31, 2020","March 13, 2020","May 1, 2020","May 1, 2020","March 27, 2020","March 3, 2020","April 3, 2020","April 2020","March 1, 2020","April 10, 2020","April 12, 2020","January 21, 2020","March 15, 2020","April 9, 2020","April 1, 2020","April 1, 2020","April 1, 2020","April 17, 2020","March 6, 2020","January 1, 2020","April 20, 2020","April 15, 2020","December 10, 2019","March 12, 2020","April 13, 2020","April 27, 2020","March 27, 2020","April 6, 2020","February 1, 2020","March 23, 2020","October 23, 2019","April 2020","May 23, 2019","April 6, 2020","March 12, 2020","May 1, 2020","January 30, 2020","April 14, 2020","March 25, 2020","April 14, 2020","April 2, 2020","April 15, 2020","March 29, 2020","April 2020","April 8, 2020","June 1, 2020","April 2020","March 20, 2020","March 16, 2020","March 9, 2020","February 1, 2020","May 1, 2020","April 26, 2020","April 6, 2020","April 1, 2020","April 20, 2020","March 27, 2020","April 2020","January 1, 2020","March 16, 2020","April 2020","April 6, 2020","March 25, 2020","April 13, 2020","April 6, 2020","April 8, 2020","April 20, 2020","March 15, 2020","April 9, 2020","February 19, 2020","March 27, 2020","April 12, 2020","April 15, 2020","April 20, 2020","March 28, 2020","April 7, 2020","March 20, 2020","April 20, 2020","February 7, 2020","March 23, 2020","April 2020","March 18, 2020","March 27, 2020","April 13, 2020","March 30, 2020","April 5, 2020","April 9, 2020","April 15, 2020","April 10, 2020","April 20, 2020","April 3, 2020","April 20, 2020","February 26, 2020","May 2020","March 1, 2020","March 10, 2020","March 3, 2020","April 10, 2020","April 14, 2020","April 27, 2020","April 25, 2020","March 1, 2020","February 15, 2020","March 9, 2020",null,"April 1, 2020","March 24, 2020","March 19, 2020","April 21, 2020","March 16, 2020","April 2, 2020","May 10, 2020","March 11, 2020","March 23, 2020","March 21, 2020","April 5, 2020","March 31, 2020","April 15, 2020","April 20, 2020","April 3, 2020","April 15, 2020","April 13, 2020","April 2020","April 18, 2020","January 1, 1998","March 6, 2020","April 9, 2020","April 10, 2020","April 15, 2020","April 1, 2020",null,"April 2020","March 26, 2020","March 8, 2020","April 8, 2020","January 20, 2020","January 20, 2020","April 9, 2020","April 16, 2020","April 18, 2020","April 2020","January 1, 2020","March 27, 2020","February 6, 2020","February 7, 2020","April 1, 2020","April 6, 2020","April 3, 2020","October 15, 2019","February 14, 2020","April 9, 2020","March 23, 2020","April 15, 2020","February 14, 2020","April 2020",null,"April 8, 2020","January 1, 2020","March 18, 2020","October 24, 2017","March 23, 2020","March 30, 2020","January 20, 2020","February 2020","April 14, 2020","April 2020","February 4, 2020","January 22, 2020","February 3, 2020","February 3, 2020","March 19, 2020","March 9, 2020","April 2020","April 11, 2020","April 4, 2020","April 6, 2020","April 10, 2020","March 25, 2020","March 31, 2020","April 15, 2020","April 6, 2020","April 16, 2020","June 1, 2020","February 22, 2020","April 1, 2020","May 2020","April 20, 2020","December 2, 2019","March 20, 2020","March 25, 2020","February 10, 2020","April 17, 2020","April 10, 2020","March 2020","November 8, 2018","March 25, 2020","April 20, 2020","March 17, 2020","April 15, 2020","February 7, 2020","April 5, 2020","May 1, 2020","April 10, 2020","February 15, 2020"],["September 2020","July 2020","January 20, 2021","May 1, 2022","October 31, 2020","March 23, 2022","July 2020","September 30, 2020","June 2020","October 10, 2020","March 30, 2021","August 1, 2020","February 21, 2020","April 25, 2020","April 2021","October 1, 2020","September 2020","October 2020","October 31, 2020","October 1, 2020","April 2021","August 31, 2020","May 31, 2020","April 30, 2020","May 13, 2021","August 2020","March 2020","April 12, 2021","May 31, 2021","June 30, 2020","May 2020","July 2020","June 30, 2020","April 2020","June 15, 2020","November 30, 2020","May 31, 2020","August 2020","August 2020","February 2021",null,"April 19, 2020","December 31, 2020","December 2020","December 19, 2020","December 2020","September 1, 2020","March 31, 2020","July 31, 2021","April 20, 2020","April 22, 2020","July 2020","June 30, 2020","October 31, 2020","October 1, 2020","April 30, 2020","November 30, 2020","May 31, 2021","July 2020","March 9, 2021","October 31, 2020","December 2020","September 2020","May 1, 2021","June 30, 2020","June 2020","July 2020","March 1, 2020","October 31, 2020","May 31, 2021","July 1, 2020","October 1, 2020",null,"December 1, 2020","December 2020","March 2, 2021","August 2020","November 30, 2021","April 2021","May 15, 2020","July 2020","April 1, 2021","March 18, 2022","April 25, 2021","April 10, 2020","April 2021","April 1, 2025","February 25, 2020","April 15, 2022","June 15, 2020","December 20, 2020","June 2020","April 1, 2020","December 31, 2020","July 2020","September 2020","May 2020","July 2020","July 30, 2020","April 10, 2021","December 2020","June 30, 2020","July 2020","July 31, 2020","May 1, 2020","August 15, 2020","May 2020","December 31, 2021","December 2020","October 3, 2020","December 31, 2020","September 2020","September 2020","May 2020","September 2020","August 31, 2021","May 31, 2020","March 30, 2021","July 1, 2020","July 2020","December 31, 2020","May 31, 2020","May 2020","July 15, 2020","July 2020","October 2020","May 31, 2020","December 1, 2022","December 31, 2022","June 30, 2020","July 2020","June 30, 2021","April 30, 2020","March 1, 2021","May 30, 2020","June 30, 2020","May 2020","May 20, 2020","April 20, 2020","April 13, 2020","August 31, 2021","June 2020","May 30, 2020","August 1, 2020","April 30, 2020","March 15, 2020","May 30, 2020","September 30, 2020","May 15, 2021","March 2021","September 1, 2020","June 1, 2020","December 2022","August 13, 2020","October 15, 2020","December 2020","June 20, 2020","April 7, 2020","January 1, 2021","July 1, 2020","October 30, 2020","June 30, 2020","October 31, 2020","September 30, 2020","July 1, 2020","September 30, 2020","April 2021","January 31, 2021","October 1, 2020","August 31, 2020","June 29, 2020","March 28, 2020","May 2020","July 30, 2020",null,"June 30, 2020","April 15, 2020","October 1, 2020","May 15, 2020","September 2020","June 1, 2020","September 2020","August 2020","April 5, 2020","April 10, 2020","September 2020","October 25, 2020","October 1, 2020","October 1, 2020","April 1, 2021","July 1, 2020","October 9, 2020","December 30, 2020","May 2022","October 1, 2020","December 31, 2020","May 2020","April 30, 2021","July 1, 2024","May 2021","June 2020","June 16, 2020","December 2021","July 10, 2020","September 30, 2020","December 2021","December 2020","June 30, 2020","June 25, 2020","December 30, 2020","July 15, 2020","October 31, 2020","February 28, 2021","May 2020","March 25, 2020","April 2020","December 2020","July 2020","December 31, 2021","June 2020","July 30, 2020","June 6, 2020","June 2020","June 2020","February 25, 2020","March 2021","April 2021","April 30, 2020","March 19, 2020","December 1, 2030","December 31, 2020","July 31, 2020","July 20, 2020","April 2021","May 15, 2020","May 2020","May 1, 2020","June 2021","June 30, 2020",null,"October 1, 2020","October 1, 2020","September 9, 2020","December 31, 2020","December 20, 2022","October 2020","May 2021","April 6, 2021","December 31, 2021","December 1, 2020","June 1, 2024","October 30, 2020","April 30, 2020","March 2021","December 31, 2020","April 2021","April 2021","December 31, 2020","June 1, 2020","April 2021","October 20, 2020","May 28, 2020","December 31, 2020","April 26, 2020","June 30, 2020","April 30, 2020","June 2020","May 31, 2021","November 1, 2020","June 2021","December 15, 2020","October 2020","July 2020","July 31, 2020","September 30, 2020","May 31, 2020","April 2020","June 1, 2020","July 14, 2021","October 15, 2020","October 2020","April 2021","December 31, 2020","November 2020","May 3, 2020","July 8, 2020","May 1, 2020","September 30, 2020","May 2020","December 2021","April 4, 2020","April 1, 2021","May 2021","February 25, 2020","April 30, 2020","March 30, 2021","December 31, 2020","December 31, 2020","April 14, 2020","July 31, 2020","May 2, 2021","July 31, 2023","June 1, 2020","July 30, 2020","June 1, 2020","May 2020","January 31, 2021","September 2020","March 30, 2020","October 15, 2020","August 1, 2020","May 30, 2020","April 8, 2021","June 2020","July 18, 2020","July 2020","March 30, 2021","October 2020","April 15, 2020","October 15, 2020","October 1, 2020","April 2024","July 31, 2023","December 2020","December 2020","September 30, 2020","October 11, 2020","July 2020","July 2020","June 2020","June 30, 2020","October 1, 2020","January 1, 2022","May 19, 2020","March 13, 2021","April 8, 2021","July 16, 2020","March 2021","June 30, 2020","June 30, 2020","February 28, 2020","April 2022","April 30, 2020","June 2020","January 31, 2022","July 1, 2020","May 15, 2021","August 2020","October 22, 2020","July 15, 2020","June 30, 2020","June 2020","June 2020",null,"June 2020","May 20, 2020","December 1, 2020","May 20, 2020","July 31, 2020","January 31, 2021","November 20, 2020","April 30, 2020","April 11, 2021","April 10, 2020","September 2020","September 30, 2020","June 1, 2020","October 30, 2020","February 2021","August 31, 2020","February 2022","April 1, 2022","July 13, 2020","March 13, 2020","April 2021","September 1, 2020","April 20, 2020","February 28, 2021","July 2020","July 2020","December 31, 2099","November 30, 2020","August 1, 2020","June 15, 2020","July 27, 2020","July 2020","August 2020","December 31, 2020","June 1, 2020","July 2020","June 1, 2020","May 30, 2020","June 1, 2020","May 2020","June 30, 2021","July 14, 2020","July 31, 2020","April 28, 2020","January 2021","December 31, 2025","October 1, 2020","November 2020","April 2021","March 11, 2021","September 2021","November 2020","January 1, 2021","December 2020","March 31, 2020","June 30, 2020","July 13, 2020","April 15, 2020","June 24, 2020","April 20, 2022","December 2020","August 15, 2020","March 30, 2021","April 2023","December 2020","July 2020","December 2020","December 2020","October 30, 2020","October 2020",null,"August 2020","March 20, 2021","September 30, 2021","April 21, 2021","October 2020","December 2021","April 15, 2022","June 30, 2020","May 1, 2020","September 1, 2020","December 31, 2020","March 2021","December 31, 2020","April 2021","March 31, 2022","April 2021","March 2021","December 31, 2020","March 2021","August 31, 2020","September 26, 2020","May 10, 2020","December 4, 2020","June 15, 2020","May 2021","June 2021","October 5, 2020","January 2021","August 1, 2020","April 2022","December 31, 2020","July 31, 2020","March 31, 2021","April 27, 2022","December 31, 2020","July 14, 2021","December 31, 2022","December 31, 2020","May 2020","August 31, 2020","May 30, 2020","April 30, 2020","August 31, 2020","November 6, 2020","March 23, 2021","May 15, 2020","June 30, 2020","August 30, 2020","May 31, 2020",null,"April 2021","June 30, 2020","April 30, 2021","August 31, 2020","November 1, 2020","April 30, 2021","May 30, 2020","April 17, 2020","October 2020","April 1, 2021","August 16, 2020","March 2023","March 31, 2024","April 1, 2021","April 2021","December 2020","July 2020","April 30, 2020","December 15, 2020","March 2023","June 1, 2020","July 2020","June 1, 2020","June 30, 2020","April 30, 2020","August 16, 2021","April 2020","June 20, 2020","June 30, 2020","April 15, 2020","June 30, 2020","May 1, 2020","April 2022","April 20, 2020","June 20, 2020","November 2020","May 9, 2020","September 2020","August 2020","August 2020","May 20, 2020","August 2020","March 23, 2022","June 1, 2020","December 1, 2020","July 10, 2020","June 9, 2020","August 31, 2020","December 2021","October 31, 2021","September 2020","July 31, 2020","February 28, 2021","October 2020","November 2020","April 1, 2021","September 30, 2020","August 1, 2021","June 30, 2020","September 30, 2020","June 30, 2020","May 13, 2020","August 1, 2020","July 30, 2020","October 1, 2020","August 2020","April 14, 2021","May 25, 2020","July 21, 2020","May 1, 2020","December 29, 2020","July 15, 2020","September 2020","March 1, 2022","August 30, 2020","September 1, 2021","December 2022","February 18, 2020","April 1, 2023","September 6, 2020","July 2020","May 14, 2020","August 20, 2020","December 31, 2020","March 31, 2021","December 31, 2020","May 20, 2020","September 15, 2022","August 1, 2021","July 31, 2021","December 31, 2030","July 2020","August 5, 2020","April 2021","April 2020","May 2020","July 30, 2020","April 30, 2020","March 20, 2021","July 7, 2020","January 1, 2020","September 30, 2020","July 2020","December 1, 2030","April 20, 2020","January 20, 2020","May 1, 2020","April 7, 2020","August 28, 2020","March 20, 2021","June 3, 2020","June 20, 2020","April 8, 2020","December 2020","April 30, 2020","December 31, 2021","April 30, 2020","March 13, 2020","December 31, 2020","November 1, 2020","March 27, 2022","August 15, 2020","June 3, 2020","March 2021","May 30, 2020","April 10, 2020","May 2020","May 2020","April 15, 2020","June 30, 2020","April 1, 2021","December 1, 2020","April 15, 2020","December 1, 2030","May 2020","April 30, 2020","May 2021","October 1, 2020","February 10, 2020","December 31, 2020","October 13, 2020","June 30, 2020","September 2020","September 15, 2020","November 30, 2020","March 1, 2021","January 8, 2020","January 2021","April 30, 2021","August 30, 2020","April 9, 2020","May 1, 2021","April 2, 2020","June 30, 2020","April 3, 2020","June 30, 2020","May 31, 2020","June 15, 2020","July 2020","April 2021","April 30, 2021","June 1, 2021","September 2020","July 1, 2020","May 30, 2020","March 23, 2020","July 31, 2020","April 30, 2021","September 26, 2020","April 7, 2021","August 30, 2020","June 1, 2020","March 27, 2021","July 2020","April 20, 2020","March 2021","April 2020","July 31, 2020","November 1, 2021","June 10, 2020","October 31, 2020","December 2020","January 30, 2021","April 17, 2020","November 30, 2020","April 4, 2020","March 27, 2021","June 30, 2020","July 2020","June 15, 2021","August 30, 2020","April 2021","June 2020","April 30, 2021","July 1, 2020","December 31, 2021","July 2020","March 17, 2021","July 1, 2020","August 1, 2020","September 2021","April 1, 2021","July 31, 2020","December 1, 2029","June 10, 2021","June 1, 2020","December 31, 2021","May 1, 2020","March 30, 2020","October 2020","March 1, 2021","April 10, 2020","June 1, 2021","April 19, 2020","April 30, 2020","July 2020","June 30, 2020","May 1, 2020","September 30, 2020","October 10, 2020",null,"April 15, 2020","June 30, 2020","March 19, 2022","July 21, 2020","March 26, 2020","May 4, 2020","October 9, 2020","March 2022","June 30, 2020","March 21, 2021","June 1, 2021","May 5, 2020","October 2020","June 1, 2020","November 2020","December 2029","June 20, 2020","December 2020","August 31, 2020","May 31, 2016","April 6, 2020","June 30, 2020","June 1, 2020","April 2021","April 15, 2020",null,"April 2021","March 25, 2026","May 31, 2020","August 1, 2020","January 31, 2021","January 31, 2021","March 31, 2022","August 31, 2021","September 2020","May 2020","April 30, 2020","October 6, 2020","April 30, 2020","May 31, 2020","December 31, 2022","October 5, 2020","October 6, 2020","April 30, 2020","September 30, 2020","June 1, 2020","August 31, 2020","May 15, 2020","May 14, 2020","May 2021",null,"September 30, 2020","December 31, 2020","April 20, 2020","December 31, 2020","September 2020","March 2021","April 30, 2020","March 2020","January 14, 2021","September 2020","October 4, 2020","January 22, 2021","April 15, 2020","December 31, 2020","April 19, 2020","May 1, 2020","September 2020","October 11, 2020","April 1, 2021","May 13, 2020","June 10, 2020","May 15, 2020","March 31, 2021","August 31, 2020","August 2020","December 1, 2020","September 30, 2021","March 31, 2020","December 31, 2022","May 2020","May 31, 2020","July 2021","December 2020","April 1, 2021","March 30, 2020","October 1, 2020","June 10, 2020","March 2022","December 31, 2021","September 25, 2022","June 20, 2020","April 21, 2020","February 2021","August 7, 2020","May 30, 2020","July 1, 2020","May 31, 2020","May 31, 2020"],["March 2021","July 2020","January 20, 2021","May 1, 2023","October 31, 2020","March 23, 2022","December 2020","December 31, 2020","June 2020","December 10, 2020","March 30, 2021","September 1, 2020","August 1, 2020","April 30, 2020","April 2021","October 30, 2020","October 2020","December 2020","December 31, 2020","May 1, 2021","April 2021","September 30, 2020","May 31, 2020","April 30, 2020","July 13, 2021","August 2020","April 2020","April 12, 2021","March 31, 2022","June 30, 2020","May 2020","November 2020","July 31, 2020","April 2020","July 15, 2020","May 15, 2022","September 30, 2020","October 2020","October 2020","July 2021",null,"April 19, 2020","December 31, 2021","December 2021","December 19, 2022","December 2020","September 1, 2020","July 31, 2020","December 31, 2021","April 24, 2020","April 24, 2020","July 2020","September 30, 2020","December 31, 2020","December 1, 2020","May 31, 2020","November 30, 2020","May 31, 2022","October 2020","April 1, 2021","April 2021","July 2021","December 2020","May 1, 2021","June 30, 2020","August 2020","July 2020","November 9, 2020","December 31, 2020","May 31, 2021","July 1, 2020","October 1, 2020",null,"December 31, 2020","December 2021","April 10, 2021","September 2020","September 30, 2022","July 2021","May 15, 2020","September 2020","December 1, 2021","May 18, 2022","April 25, 2021","April 30, 2020","December 2021","April 1, 2025","February 25, 2020","April 15, 2022","June 15, 2020","April 30, 2021","June 2020","April 16, 2020","December 31, 2021","July 2020","November 2020","May 2020","December 2020","July 30, 2020","December 10, 2021","February 2021","November 30, 2020","September 2020","September 30, 2020","May 9, 2020","October 15, 2020","May 2020","December 31, 2021","December 2020","October 30, 2020","March 31, 2021","October 2020","October 2020","May 2020","October 2020","December 31, 2021","June 30, 2020","May 30, 2021","July 1, 2020","August 2020","April 30, 2021","June 30, 2020","May 2020","September 15, 2020","July 2020","October 2020","December 31, 2020","December 30, 2022","June 30, 2023","September 30, 2020","July 2020","June 30, 2021","May 31, 2020","May 1, 2021","May 30, 2020","July 31, 2020","June 2020","May 20, 2020","May 20, 2020","April 13, 2020","September 30, 2021","August 2020","June 30, 2020","September 1, 2020","May 30, 2020","March 18, 2020","June 30, 2020","December 31, 2020","May 15, 2022","February 2022","December 1, 2022","April 1, 2021","December 2022","December 13, 2020","October 30, 2020","December 2020","September 30, 2020","June 1, 2020","May 1, 2021","July 1, 2020","October 30, 2020","July 30, 2020","March 22, 2021","December 31, 2020","July 1, 2020","December 31, 2020","April 2021","January 31, 2021","December 1, 2020","August 31, 2020","June 29, 2021","March 30, 2020","July 2020","July 30, 2021",null,"February 15, 2022","April 17, 2020","December 1, 2020","June 1, 2020","September 2021","June 1, 2020","September 2020","September 2020","April 5, 2020","April 27, 2020","September 2020","December 25, 2020","December 1, 2020","December 1, 2020","April 1, 2022","July 1, 2020","March 5, 2021","December 30, 2020","May 2022","December 1, 2020","March 31, 2021","July 2020","April 30, 2021","April 1, 2025","May 2022","June 2020","June 30, 2020","December 2021","July 10, 2020","December 30, 2020","December 2022","December 2020","June 30, 2020","December 25, 2020","December 20, 2022","July 31, 2020","November 30, 2020","February 28, 2021","May 2020","March 25, 2020","July 2021","December 2020","October 2020","June 30, 2022","August 2020","September 30, 2020","July 6, 2020","June 2020","June 2020","February 25, 2020","March 2022","May 2021","May 31, 2020","March 19, 2020","December 1, 2030","March 31, 2021","April 30, 2021","January 1, 2021","April 2022","May 15, 2020","June 2020","May 30, 2020","June 2022","July 31, 2020",null,"October 20, 2020","December 31, 2021","September 9, 2020","December 31, 2020","December 20, 2023","April 2021","May 2021","April 6, 2021","January 31, 2022","March 1, 2021","December 1, 2025","January 31, 2021","April 30, 2020","March 2022","December 31, 2020","April 2021","April 2021","March 31, 2021","July 1, 2020","April 2021","November 20, 2020","June 28, 2020","January 31, 2021","April 28, 2020","July 31, 2020","April 30, 2020","August 2020","May 31, 2021","November 9, 2020","June 2021","January 15, 2021","December 2020","August 2020","September 30, 2020","November 30, 2020","July 31, 2020","May 2020","July 1, 2020","July 14, 2022","January 1, 2021","October 2020","August 2021","March 31, 2021","November 2020","June 30, 2020","August 8, 2020","May 5, 2020","September 30, 2020","July 2020","December 2021","April 6, 2020","April 30, 2021","December 2021","February 25, 2020","April 30, 2020","March 30, 2022","December 31, 2021","April 11, 2021","April 17, 2020","September 30, 2020","May 31, 2021","December 31, 2024","July 1, 2020","July 30, 2020","September 30, 2020","August 2020","August 31, 2021","September 2020","April 10, 2020","December 15, 2020","August 1, 2020","July 30, 2020","December 20, 2025","December 2021","October 18, 2020","August 2020","December 30, 2021","October 2020","August 15, 2020","January 15, 2021","November 1, 2020","April 2026","December 31, 2024","December 2020","December 2020","April 30, 2021","November 11, 2020","October 2020","July 2020","June 2020","December 31, 2021","October 1, 2020","January 1, 2023","May 19, 2020","March 13, 2021","April 8, 2022","October 16, 2020","March 2021","August 31, 2021","August 30, 2020","March 8, 2020","April 2022","May 30, 2020","June 2020","March 31, 2022","December 1, 2020","May 15, 2022","September 2020","October 22, 2020","July 15, 2020","April 30, 2021","August 2020","July 2020",null,"July 2020","May 20, 2020","December 30, 2020","June 20, 2020","July 31, 2020","March 1, 2021","November 20, 2020","May 30, 2020","April 11, 2021","April 30, 2020","December 2020","October 31, 2020","August 1, 2020","March 30, 2022","February 2021","September 30, 2020","February 2022","April 1, 2022","July 13, 2020","March 13, 2020","May 2021","November 30, 2020","April 25, 2020","February 28, 2023","August 2020","August 2021","December 31, 2099","November 30, 2020","August 1, 2020","June 20, 2020","July 27, 2020","August 2020","August 2020","December 31, 2020","December 1, 2020","July 2020","September 15, 2020","June 30, 2020","December 1, 2020","May 2020","July 30, 2021","April 14, 2021","August 15, 2020","May 28, 2021","January 2021","August 31, 2026","November 1, 2020","November 2020","April 2021","May 11, 2021","September 2022","December 2020","April 1, 2021","December 2020","April 30, 2020","June 30, 2020","July 31, 2020","April 30, 2020","August 24, 2020","April 20, 2022","December 2020","September 1, 2020","June 30, 2021","April 2023","December 2020","September 2020","June 2021","December 2020","October 30, 2020","October 2020",null,"August 2020","March 20, 2021","September 30, 2023","August 21, 2021","December 2020","December 2021","April 15, 2022","July 31, 2020","September 30, 2020","October 21, 2021","December 31, 2020","September 2022","May 1, 2021","April 2021","March 31, 2022","July 2021","March 2022","December 31, 2021","March 2022","September 30, 2020","November 26, 2020","June 10, 2020","April 4, 2021","September 15, 2020","May 2021","September 2021","November 9, 2020","January 2021","December 1, 2020","April 2022","December 31, 2020","August 31, 2020","March 31, 2021","April 27, 2022","April 1, 2021","April 14, 2022","January 2023","May 1, 2021","May 2020","December 31, 2020","June 15, 2020","October 31, 2020","August 31, 2020","November 6, 2020","June 23, 2021","June 15, 2020","July 31, 2020","August 30, 2020","October 31, 2020",null,"July 2021","July 30, 2020","April 30, 2021","December 31, 2020","January 1, 2021","April 30, 2021","June 20, 2020","April 17, 2020","February 2021","April 1, 2021","August 18, 2020","March 2023","March 31, 2024","April 1, 2021","July 2021","December 2020","September 2020","June 30, 2020","June 15, 2021","March 2023","July 1, 2020","October 2020","July 1, 2020","April 30, 2021","May 31, 2020","November 1, 2021","May 2020","August 1, 2020","September 30, 2020","April 15, 2020","June 30, 2021","July 1, 2020","April 2023","April 30, 2020","July 10, 2020","December 2020","May 9, 2020","November 2020","November 2020","September 2020","September 30, 2020","October 2020","March 23, 2022","July 1, 2020","April 1, 2021","July 10, 2020","July 10, 2020","December 31, 2020","December 2023","December 31, 2022","October 2022","July 31, 2020","June 17, 2021","October 2020","December 2020","April 1, 2022","December 31, 2020","August 1, 2021","May 31, 2021","September 30, 2020","July 30, 2020","May 13, 2020","November 30, 2020","July 30, 2020","October 1, 2020","October 2020","April 14, 2021","May 30, 2020","July 21, 2020","May 30, 2020","January 29, 2021","July 15, 2020","September 2020","April 1, 2022","August 30, 2020","February 1, 2022","December 2022","February 18, 2020","April 1, 2023","April 6, 2021","September 2020","May 30, 2020","August 30, 2020","January 15, 2021","March 31, 2022","December 31, 2021","May 30, 2020","October 15, 2022","September 1, 2021","September 30, 2021","December 31, 2030","August 2020","November 5, 2020","April 2021","September 2020","May 2020","August 1, 2020","May 31, 2020","March 20, 2022","April 6, 2021","February 4, 2021","September 1, 2021","July 2020","December 1, 2030","April 25, 2020","March 3, 2020","June 1, 2020","April 7, 2020","August 28, 2020","March 20, 2022","June 3, 2020","July 20, 2020","April 15, 2020","April 2021","July 30, 2020","December 31, 2021","May 31, 2020","April 3, 2020","May 1, 2021","December 1, 2020","March 20, 2030","October 15, 2020","July 31, 2020","March 2021","June 30, 2020","June 10, 2020","May 2020","June 2020","May 1, 2020","June 30, 2020","April 1, 2021","January 1, 2021","June 1, 2022","December 1, 2030","August 2020","May 1, 2020","May 2021","August 1, 2021","March 4, 2020","December 31, 2021","October 13, 2020","July 31, 2020","September 2020","September 30, 2020","December 31, 2020","March 1, 2022","January 31, 2020","March 2021","December 28, 2021","December 30, 2020","May 2020","May 1, 2021","April 15, 2020","June 30, 2020","April 10, 2020","June 30, 2020","June 30, 2020","June 15, 2020","June 2021","April 2021","August 31, 2021","December 31, 2021","September 2020","September 1, 2020","June 15, 2020","March 23, 2020","December 31, 2020","April 30, 2021","October 12, 2020","October 7, 2021","August 30, 2020","July 31, 2020","December 31, 2021","July 2020","April 30, 2020","March 2021","May 2020","September 30, 2020","December 31, 2021","November 10, 2020","March 31, 2021","December 2020","April 30, 2021","May 1, 2020","December 31, 2021","July 2020","December 31, 2021","December 31, 2020","July 2020","June 15, 2021","August 30, 2020","June 15, 2021","August 2020","October 31, 2021","December 30, 2020","December 31, 2021","August 2020","March 17, 2022","August 31, 2020","August 31, 2020","September 2021","April 1, 2022","August 31, 2020","December 1, 2029","June 10, 2021","July 31, 2020","December 31, 2021","May 1, 2020","March 30, 2020","October 2020","February 1, 2022","May 8, 2020","June 1, 2021","July 9, 2020","April 30, 2020","July 2020","July 10, 2020","May 30, 2020","December 30, 2020","October 30, 2020",null,"April 15, 2020","August 30, 2020","March 19, 2022","October 21, 2020","April 9, 2020","August 1, 2020","November 10, 2020","March 2022","August 30, 2020","March 21, 2022","June 1, 2021","May 30, 2020","April 2021","October 1, 2020","November 2020","December 2029","June 20, 2020","December 2020","October 18, 2020","March 31, 2020","April 12, 2020","June 30, 2020","July 1, 2020","April 2021","May 1, 2020",null,"April 2021","March 25, 2026","May 31, 2020","August 1, 2020","February 28, 2021","February 28, 2021","July 31, 2022","August 31, 2021","September 2020","December 31, 2020","July 31, 2020","December 31, 2020","September 30, 2020","June 30, 2020","December 31, 2022","November 9, 2020","December 6, 2020","November 30, 2020","September 30, 2020","June 1, 2020","August 31, 2020","May 25, 2020","December 14, 2021","November 2021",null,"April 30, 2021","December 31, 2020","December 31, 2020","March 31, 2021","September 2020","March 2022","April 30, 2020","March 2020","January 14, 2021","December 2020","February 4, 2021","January 22, 2021","April 20, 2020","December 31, 2020","December 31, 2020","May 1, 2020","November 2020","December 11, 2020","August 1, 2021","June 30, 2020","July 31, 2020","July 20, 2020","December 31, 2021","February 28, 2021","August 2020","December 31, 2020","September 30, 2021","March 31, 2020","December 31, 2022","June 2020","December 31, 2020","July 2022","December 2020","March 3, 2025","March 31, 2020","December 1, 2020","July 31, 2020","April 2022","December 31, 2022","September 25, 2022","October 20, 2020","May 12, 2020","July 2021","August 7, 2023","June 30, 2020","August 1, 2020","May 31, 2020","July 31, 2020"],["April 3, 2020","April 7, 2020","April 17, 2020","April 21, 2020","April 14, 2020","April 2, 2020","April 21, 2020","April 15, 2020","April 13, 2020","April 13, 2020","April 3, 2020","March 2, 2020","April 7, 2020","March 27, 2020","April 15, 2020","March 26, 2020","April 6, 2020","April 17, 2020","April 3, 2020","April 13, 2020","April 13, 2020","April 1, 2020","March 25, 2020","April 20, 2020","March 27, 2020","April 17, 2020","March 26, 2020","April 14, 2020","April 20, 2020","April 9, 2020","March 13, 2020","April 21, 2020","April 21, 2020","February 27, 2020","April 14, 2020","April 21, 2020","March 27, 2020","April 15, 2020","April 9, 2020","March 26, 2020","April 21, 2020","April 13, 2020","April 1, 2020","February 5, 2020","March 20, 2020","April 16, 2020","April 15, 2020","April 2, 2020","April 21, 2020","April 17, 2020","April 17, 2020","April 14, 2020","April 1, 2020","April 16, 2020","April 16, 2020","February 19, 2020","March 31, 2020","April 2, 2020","April 8, 2020","March 19, 2020","April 20, 2020","April 8, 2020","April 1, 2020","April 16, 2020","April 13, 2020","April 13, 2020","April 2, 2020","March 11, 2020","March 30, 2020","April 20, 2020","April 7, 2020","April 21, 2020","April 8, 2020","April 16, 2020","April 22, 2020","April 17, 2020","April 21, 2020","April 9, 2020","April 6, 2020","March 31, 2020","April 10, 2020","April 1, 2020","April 1, 2020","April 21, 2020","March 24, 2020","April 3, 2020","April 1, 2020","February 26, 2020","April 17, 2020","March 11, 2020","April 3, 2020","April 17, 2020","March 24, 2020","April 6, 2020","April 22, 2020","April 6, 2020","April 2, 2020","April 2, 2020","April 3, 2020","April 14, 2020","April 14, 2020","April 20, 2020","April 16, 2020","April 22, 2020","April 14, 2020","April 21, 2020","March 13, 2020","April 14, 2020","March 26, 2020","April 2, 2020","April 7, 2020","March 18, 2020","April 2, 2020","March 3, 2020","March 18, 2020","April 6, 2020","April 16, 2020","April 20, 2020","April 14, 2020","April 15, 2020","April 16, 2020","April 1, 2020","March 3, 2020","April 10, 2020","April 14, 2020","April 10, 2020","April 14, 2020","April 15, 2020","April 14, 2020","March 18, 2020","April 15, 2020","April 7, 2020","April 15, 2020","March 16, 2020","April 15, 2020","March 12, 2020","March 20, 2020","April 1, 2020","April 2, 2020","January 28, 2020","March 25, 2020","April 14, 2020","February 18, 2020","April 21, 2020","February 18, 2020","March 18, 2020","April 9, 2020","April 22, 2020","April 20, 2020","April 10, 2020","April 15, 2020","April 14, 2020","April 21, 2020","April 20, 2020","April 8, 2020","April 15, 2020","April 14, 2020","April 13, 2020","April 14, 2020","April 10, 2020","March 27, 2020","April 15, 2020","March 20, 2020","April 2, 2020","February 21, 2020","April 6, 2020","April 17, 2020","April 10, 2020","April 15, 2020","April 13, 2020","April 1, 2020","March 23, 2020","April 21, 2020","April 2, 2020","April 7, 2020","February 18, 2020","April 21, 2020","April 16, 2020","April 15, 2020","April 2, 2020","April 3, 2020","April 10, 2020","April 15, 2020","April 13, 2020","February 5, 2020","April 17, 2020","March 31, 2020","April 17, 2020","April 15, 2020","March 31, 2020","April 16, 2020","April 22, 2020","April 15, 2020","April 1, 2020","April 16, 2020","April 3, 2020","April 22, 2020","April 7, 2020","April 14, 2020","March 20, 2020","April 22, 2020","April 15, 2020","April 17, 2020","April 13, 2020","April 8, 2020","April 21, 2020","April 15, 2020","April 3, 2020","April 20, 2020","March 18, 2020","February 28, 2020","March 11, 2020","February 27, 2020","April 7, 2020","April 1, 2020","April 21, 2020","April 17, 2020","April 17, 2020","April 9, 2020","April 15, 2020","April 13, 2020","April 3, 2020","April 17, 2020","April 22, 2020","March 3, 2020","April 14, 2020","April 14, 2020","April 14, 2020","March 2, 2020","April 20, 2020","April 10, 2020","April 21, 2020","April 20, 2020","April 8, 2020","April 6, 2020","April 20, 2020","February 18, 2020","April 15, 2020","April 21, 2020","April 8, 2020","April 21, 2020","April 14, 2020","April 10, 2020","April 16, 2020","April 6, 2020","April 9, 2020","April 20, 2020","April 21, 2020","April 13, 2020","April 10, 2020","April 10, 2020","April 2, 2020","April 20, 2020","March 24, 2020","April 14, 2020","April 22, 2020","April 20, 2020","March 23, 2020","April 10, 2020","April 22, 2020","April 17, 2020","March 31, 2020","April 20, 2020","March 31, 2020","April 16, 2020","April 8, 2020","April 17, 2020","March 27, 2019","April 7, 2020","April 16, 2020","March 26, 2020","April 16, 2020","April 21, 2020","April 14, 2020","April 14, 2020","April 22, 2020","April 6, 2020","April 13, 2020","April 21, 2020","April 15, 2020","April 17, 2020","April 13, 2020","April 16, 2020","April 14, 2020","April 22, 2020","April 16, 2020","April 6, 2020","March 26, 2020","April 10, 2020","April 20, 2020","April 20, 2020","April 14, 2020","April 22, 2020","February 7, 2020","February 5, 2020","April 1, 2020","April 15, 2020","April 15, 2020","April 21, 2020","April 13, 2020","April 16, 2020","March 9, 2020","April 10, 2020","April 22, 2020","April 15, 2020","April 15, 2020","April 8, 2020","April 15, 2020","February 6, 2020","April 8, 2020","April 13, 2020","March 6, 2020","April 6, 2020","March 27, 2020","April 21, 2020","April 6, 2020","April 16, 2020","April 6, 2020","April 21, 2020","April 16, 2020","April 3, 2020","April 20, 2020","February 19, 2020","April 20, 2020","April 17, 2020","April 14, 2020","April 16, 2020","April 21, 2020","April 17, 2020","April 10, 2020","April 3, 2020","April 3, 2020","April 22, 2020","March 26, 2020","March 26, 2020","April 14, 2020","March 11, 2020","April 10, 2020","April 22, 2020","April 22, 2020","March 20, 2020","April 10, 2020","April 7, 2020","March 24, 2020","April 1, 2020","April 20, 2020","April 14, 2020","April 6, 2020","April 21, 2020","April 17, 2020","April 10, 2020","April 3, 2020","April 22, 2020","April 21, 2020","April 14, 2020","March 24, 2020","April 7, 2020","April 20, 2020","April 22, 2020","April 1, 2020","April 16, 2020","April 17, 2020","April 15, 2020","April 2, 2020","March 25, 2020","April 1, 2020","April 22, 2020","March 31, 2020","April 3, 2020","March 30, 2020","April 14, 2020","April 9, 2020","April 2, 2020","March 3, 2020","April 14, 2020","April 8, 2020","April 7, 2020","March 27, 2020","April 15, 2020","April 6, 2020","April 13, 2020","April 15, 2020","April 6, 2020","April 7, 2020","April 22, 2020","April 22, 2020","April 10, 2020","April 8, 2020","April 6, 2020","April 6, 2020","April 3, 2020","March 31, 2020","March 17, 2020","March 17, 2020","March 10, 2020","March 4, 2020","April 22, 2020","April 15, 2020","February 20, 2020","April 17, 2020","April 22, 2020","April 21, 2020","March 11, 2020","April 15, 2020","April 15, 2020","April 22, 2020","March 31, 2020","March 25, 2020","February 17, 2020","April 22, 2020","April 6, 2020","February 18, 2020","April 20, 2020","April 21, 2020","April 2, 2020","April 15, 2020","March 17, 2020","April 17, 2020","April 17, 2020","March 27, 2020","April 14, 2020","March 24, 2020","April 22, 2020","April 9, 2020","March 27, 2020","April 17, 2020","March 24, 2020","April 6, 2020","March 25, 2020","April 21, 2020","April 13, 2020","April 22, 2020","April 16, 2020","April 10, 2020","April 7, 2020","February 17, 2020","March 6, 2020","April 21, 2020","April 16, 2020","April 6, 2020","April 3, 2020","April 22, 2020","April 9, 2020","March 25, 2020","April 20, 2020","March 27, 2020","April 7, 2020","April 13, 2020","February 26, 2020","March 27, 2020","March 27, 2020","March 27, 2020","April 22, 2020","April 22, 2020","April 17, 2020","April 22, 2020","April 14, 2020","April 21, 2020","April 21, 2020","April 15, 2020","April 16, 2020","March 27, 2020","March 25, 2020","April 17, 2020","April 2, 2020","April 3, 2020","February 13, 2020","April 16, 2020","April 1, 2020","March 27, 2020","April 9, 2020","April 6, 2020","April 21, 2020","April 22, 2020","April 15, 2020","April 20, 2020","April 1, 2020","March 27, 2020","April 3, 2020","April 6, 2020","April 20, 2020","March 13, 2020","April 7, 2020","March 18, 2020","March 17, 2020","March 18, 2020","March 20, 2020","March 27, 2020","March 17, 2020","April 6, 2020","April 20, 2020","April 8, 2020","February 7, 2020","April 16, 2020","April 2, 2020","February 5, 2020","April 21, 2020","February 5, 2020","April 9, 2020","March 20, 2020","April 16, 2020","February 19, 2020","April 22, 2020","April 10, 2020","April 9, 2020","April 13, 2020","February 7, 2020","April 10, 2020","April 22, 2020","April 2, 2020","April 20, 2020","April 1, 2020","March 20, 2020","March 25, 2020","March 17, 2020","March 31, 2020","April 22, 2020","March 31, 2020","February 10, 2020","April 13, 2020","April 10, 2020","April 9, 2020","February 5, 2020","April 13, 2016","March 31, 2020","February 3, 2017","February 5, 2020","March 30, 2020","April 14, 2020","March 27, 2020","March 12, 2020","March 27, 2020","April 15, 2020","April 3, 2020","March 31, 2020","March 24, 2020","April 16, 2020","April 21, 2020","April 9, 2020","March 30, 2020","April 10, 2020","April 20, 2020","April 15, 2020","April 22, 2020","April 21, 2020","April 8, 2020","April 16, 2020","April 13, 2020","April 9, 2020","March 31, 2020","April 22, 2020","February 21, 2020","February 25, 2020","February 21, 2020","April 15, 2020","April 14, 2020","April 16, 2020","April 14, 2020","March 26, 2020","March 25, 2020","March 23, 2020","March 26, 2020","April 21, 2020","April 6, 2020","April 6, 2020","April 6, 2020","April 21, 2020","April 6, 2020","April 21, 2020","April 9, 2020","April 22, 2020","April 22, 2020","February 11, 2020","March 25, 2020","April 9, 2020","April 16, 2020","April 14, 2020","April 20, 2020","April 17, 2020","April 22, 2020","April 7, 2020","March 30, 2020","April 22, 2020","April 6, 2020","March 18, 2020","April 6, 2020","March 26, 2020","April 14, 2020","April 22, 2020","April 21, 2020","April 10, 2020","April 7, 2020","March 12, 2020","April 17, 2020","April 22, 2020","March 25, 2020","April 9, 2020","April 7, 2020","April 2, 2020","March 3, 2020","April 10, 2020","April 3, 2020","March 24, 2020","April 8, 2020","April 15, 2020","April 7, 2020","March 5, 2020","April 13, 2020","April 17, 2020","April 15, 2020","March 24, 2020","April 14, 2020","April 15, 2020","March 10, 2020","March 20, 2020","April 15, 2020","April 22, 2020","April 3, 2020","April 16, 2020","February 21, 2020","March 2, 2020","September 17, 2019","April 7, 2020","January 18, 2019","April 10, 2020","March 19, 2020","April 9, 2020","March 31, 2020","April 15, 2020","March 31, 2020","April 14, 2020","March 30, 2020","April 14, 2020","March 31, 2020","April 15, 2020","April 14, 2020","April 8, 2020","March 30, 2020","March 30, 2020","April 10, 2020","March 25, 2020","March 3, 2020","April 15, 2020","March 30, 2020","March 30, 2020","March 26, 2020","April 15, 2020","March 27, 2020","April 15, 2020","March 20, 2020","April 13, 2020","April 17, 2020","April 8, 2020","March 30, 2020","April 14, 2020","March 26, 2020","April 15, 2020","April 10, 2020","April 20, 2020","April 10, 2020","February 18, 2020","March 27, 2020","April 13, 2020","April 14, 2020","April 14, 2020","March 25, 2020","April 20, 2020","April 14, 2020","March 24, 2020","February 7, 2020","March 19, 2020","April 7, 2020","April 1, 2020","April 15, 2020","March 30, 2020","March 30, 2020","April 8, 2020","April 22, 2020","April 14, 2020","April 10, 2020","April 6, 2020","March 25, 2020","April 21, 2020","April 14, 2020","April 14, 2020","March 2, 2020","March 27, 2020","February 25, 2020","April 14, 2020","April 15, 2020","April 21, 2020","April 21, 2020","April 21, 2020","February 21, 2020","March 2, 2020","February 28, 2020","April 13, 2020","March 26, 2020","March 24, 2020","April 15, 2020","March 25, 2020","April 8, 2020","March 6, 2020","March 13, 2020","March 26, 2020","March 12, 2020","March 26, 2020","March 27, 2020","April 8, 2020","April 15, 2020","April 7, 2020","April 14, 2020","April 21, 2020","April 7, 2020","April 21, 2020","March 26, 2020","April 17, 2020","April 14, 2020","April 10, 2020","April 15, 2020","April 14, 2020","April 20, 2020","April 16, 2020","March 31, 2020","March 12, 2020","April 15, 2020","February 21, 2020","February 21, 2020","April 17, 2020","April 21, 2020","April 13, 2020","April 10, 2020","March 3, 2020","April 9, 2020","February 13, 2020","February 10, 2020","March 27, 2020","March 30, 2020","April 7, 2020","August 19, 2019","February 11, 2020","April 8, 2020","March 26, 2020","April 16, 2020","February 19, 2020","April 16, 2020","March 10, 2020","April 13, 2020","January 29, 2020","April 17, 2020","November 6, 2017","March 26, 2020","April 6, 2020","February 5, 2020","February 24, 2020","April 22, 2020","April 14, 2020","February 7, 2020","February 5, 2020","February 7, 2020","February 19, 2020","March 13, 2020","March 26, 2020","April 9, 2020","April 21, 2020","April 10, 2020","April 6, 2020","April 15, 2020","March 24, 2020","April 2, 2020","April 20, 2020","March 31, 2020","April 17, 2020","April 20, 2020","February 21, 2020","April 3, 2020","April 22, 2020","April 20, 2020","February 25, 2019","April 3, 2020","March 20, 2020","February 19, 2020","April 22, 2020","April 15, 2020","March 24, 2020","September 21, 2018","March 30, 2020","April 15, 2020","March 16, 2020","April 17, 2020","February 10, 2020","April 1, 2020","April 15, 2020","April 9, 2020","February 19, 2020"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["April 6, 2020","April 8, 2020","April 17, 2020","April 21, 2020","April 14, 2020","April 7, 2020","April 21, 2020","April 17, 2020","April 13, 2020","April 21, 2020","April 9, 2020","March 17, 2020","April 7, 2020","April 2, 2020","April 15, 2020","April 15, 2020","April 14, 2020","April 17, 2020","April 16, 2020","April 16, 2020","April 17, 2020","April 21, 2020","March 25, 2020","April 20, 2020","April 14, 2020","April 17, 2020","March 26, 2020","April 16, 2020","April 22, 2020","April 9, 2020","March 17, 2020","April 21, 2020","April 22, 2020","March 17, 2020","April 20, 2020","April 22, 2020","March 27, 2020","April 17, 2020","April 9, 2020","April 7, 2020","April 21, 2020","April 21, 2020","April 9, 2020","April 15, 2020","April 7, 2020","April 16, 2020","April 17, 2020","April 17, 2020","April 21, 2020","April 20, 2020","April 20, 2020","April 14, 2020","April 1, 2020","April 21, 2020","April 22, 2020","February 19, 2020","April 16, 2020","April 2, 2020","April 8, 2020","April 6, 2020","April 20, 2020","April 9, 2020","April 8, 2020","April 17, 2020","April 13, 2020","April 13, 2020","April 9, 2020","March 17, 2020","April 22, 2020","April 20, 2020","April 7, 2020","April 21, 2020","April 8, 2020","April 21, 2020","April 22, 2020","April 17, 2020","April 21, 2020","April 9, 2020","April 13, 2020","March 31, 2020","April 21, 2020","April 13, 2020","April 22, 2020","April 22, 2020","March 24, 2020","April 14, 2020","April 22, 2020","March 10, 2020","April 17, 2020","April 16, 2020","April 3, 2020","April 17, 2020","April 7, 2020","April 9, 2020","April 22, 2020","April 6, 2020","April 14, 2020","April 20, 2020","April 10, 2020","April 14, 2020","April 14, 2020","April 22, 2020","April 16, 2020","April 22, 2020","April 14, 2020","April 21, 2020","March 13, 2020","April 14, 2020","March 26, 2020","April 7, 2020","April 7, 2020","April 14, 2020","April 7, 2020","April 22, 2020","April 14, 2020","April 22, 2020","April 22, 2020","April 22, 2020","April 20, 2020","April 15, 2020","April 21, 2020","April 22, 2020","April 21, 2020","April 10, 2020","April 15, 2020","April 14, 2020","April 14, 2020","April 16, 2020","April 21, 2020","March 18, 2020","April 22, 2020","April 21, 2020","April 15, 2020","March 16, 2020","April 15, 2020","March 26, 2020","April 15, 2020","April 17, 2020","April 13, 2020","April 15, 2020","April 22, 2020","April 14, 2020","February 21, 2020","April 22, 2020","February 21, 2020","March 18, 2020","April 9, 2020","April 22, 2020","April 20, 2020","April 10, 2020","April 16, 2020","April 21, 2020","April 21, 2020","April 20, 2020","April 8, 2020","April 15, 2020","April 16, 2020","April 13, 2020","April 14, 2020","April 17, 2020","April 17, 2020","April 17, 2020","April 17, 2020","April 2, 2020","February 21, 2020","April 6, 2020","April 17, 2020","April 21, 2020","April 20, 2020","April 16, 2020","April 1, 2020","April 7, 2020","April 22, 2020","April 8, 2020","April 7, 2020","April 14, 2020","April 21, 2020","April 20, 2020","April 15, 2020","April 13, 2020","April 17, 2020","April 21, 2020","April 16, 2020","April 14, 2020","April 15, 2020","April 17, 2020","April 3, 2020","April 20, 2020","April 20, 2020","April 21, 2020","April 22, 2020","April 22, 2020","April 17, 2020","April 1, 2020","April 20, 2020","April 13, 2020","April 22, 2020","April 13, 2020","April 21, 2020","April 22, 2020","April 22, 2020","April 15, 2020","April 20, 2020","April 22, 2020","April 8, 2020","April 21, 2020","April 15, 2020","April 7, 2020","April 20, 2020","April 14, 2020","April 7, 2020","April 10, 2020","February 27, 2020","April 7, 2020","April 1, 2020","April 21, 2020","April 17, 2020","April 21, 2020","April 13, 2020","April 17, 2020","April 15, 2020","April 3, 2020","April 20, 2020","April 22, 2020","March 18, 2020","April 15, 2020","April 21, 2020","April 14, 2020","April 13, 2020","April 20, 2020","April 16, 2020","April 21, 2020","April 20, 2020","April 8, 2020","April 22, 2020","April 20, 2020","April 17, 2020","April 20, 2020","April 21, 2020","April 8, 2020","April 21, 2020","April 14, 2020","April 20, 2020","April 17, 2020","April 20, 2020","April 21, 2020","April 21, 2020","April 21, 2020","April 15, 2020","April 10, 2020","April 16, 2020","April 13, 2020","April 22, 2020","March 25, 2020","April 14, 2020","April 22, 2020","April 20, 2020","April 17, 2020","April 10, 2020","April 22, 2020","April 17, 2020","April 2, 2020","April 22, 2020","April 2, 2020","April 22, 2020","April 15, 2020","April 17, 2020","April 15, 2020","April 7, 2020","April 16, 2020","April 21, 2020","April 20, 2020","April 21, 2020","April 15, 2020","April 17, 2020","April 22, 2020","April 6, 2020","April 15, 2020","April 21, 2020","April 15, 2020","April 17, 2020","April 20, 2020","April 16, 2020","April 20, 2020","April 22, 2020","April 17, 2020","April 6, 2020","March 26, 2020","April 14, 2020","April 20, 2020","April 21, 2020","April 14, 2020","April 22, 2020","April 13, 2020","March 17, 2020","April 1, 2020","April 15, 2020","April 21, 2020","April 21, 2020","April 14, 2020","April 16, 2020","March 9, 2020","April 13, 2020","April 22, 2020","April 16, 2020","April 15, 2020","April 22, 2020","April 15, 2020","April 15, 2020","April 8, 2020","April 13, 2020","March 6, 2020","April 16, 2020","April 14, 2020","April 21, 2020","April 6, 2020","April 21, 2020","April 8, 2020","April 22, 2020","April 16, 2020","April 3, 2020","April 21, 2020","March 19, 2020","April 20, 2020","April 21, 2020","April 15, 2020","April 17, 2020","April 21, 2020","April 21, 2020","April 10, 2020","April 3, 2020","April 7, 2020","April 22, 2020","March 31, 2020","March 26, 2020","April 16, 2020","April 13, 2020","April 13, 2020","April 22, 2020","April 22, 2020","March 30, 2020","April 10, 2020","April 22, 2020","April 21, 2020","April 13, 2020","April 22, 2020","April 15, 2020","April 6, 2020","April 21, 2020","April 21, 2020","April 15, 2020","April 21, 2020","April 22, 2020","April 21, 2020","April 17, 2020","April 22, 2020","April 14, 2020","April 20, 2020","April 22, 2020","April 13, 2020","April 20, 2020","April 17, 2020","April 22, 2020","April 2, 2020","April 8, 2020","April 20, 2020","April 22, 2020","April 7, 2020","April 15, 2020","April 2, 2020","April 22, 2020","April 22, 2020","April 17, 2020","March 17, 2020","April 14, 2020","April 10, 2020","April 7, 2020","March 31, 2020","April 22, 2020","April 22, 2020","April 15, 2020","April 15, 2020","April 13, 2020","April 7, 2020","April 22, 2020","April 22, 2020","April 10, 2020","April 8, 2020","April 6, 2020","April 17, 2020","April 10, 2020","March 31, 2020","March 17, 2020","April 10, 2020","March 10, 2020","March 4, 2020","April 22, 2020","April 15, 2020","March 17, 2020","April 22, 2020","April 22, 2020","April 21, 2020","March 27, 2020","April 15, 2020","April 20, 2020","April 22, 2020","April 8, 2020","April 22, 2020","March 17, 2020","April 22, 2020","April 13, 2020","March 23, 2020","April 22, 2020","April 22, 2020","April 2, 2020","April 17, 2020","March 17, 2020","April 17, 2020","April 21, 2020","April 9, 2020","April 14, 2020","April 8, 2020","April 22, 2020","April 9, 2020","April 21, 2020","April 17, 2020","April 17, 2020","April 6, 2020","March 27, 2020","April 21, 2020","April 13, 2020","April 22, 2020","April 16, 2020","April 10, 2020","April 15, 2020","February 17, 2020","April 2, 2020","April 21, 2020","April 20, 2020","April 22, 2020","April 7, 2020","April 22, 2020","April 14, 2020","March 31, 2020","April 21, 2020","March 31, 2020","April 13, 2020","April 14, 2020","February 26, 2020","April 20, 2020","April 14, 2020","March 31, 2020","April 22, 2020","April 22, 2020","April 17, 2020","April 22, 2020","April 17, 2020","April 21, 2020","April 22, 2020","April 15, 2020","April 16, 2020","April 8, 2020","April 6, 2020","April 22, 2020","April 2, 2020","April 6, 2020","February 13, 2020","April 21, 2020","April 13, 2020","March 27, 2020","April 9, 2020","April 22, 2020","April 21, 2020","April 22, 2020","April 16, 2020","April 22, 2020","April 21, 2020","April 14, 2020","April 3, 2020","April 6, 2020","April 20, 2020","March 17, 2020","April 7, 2020","March 18, 2020","April 22, 2020","April 2, 2020","March 25, 2020","April 21, 2020","April 21, 2020","April 22, 2020","April 22, 2020","April 8, 2020","February 7, 2020","April 16, 2020","April 3, 2020","March 17, 2020","April 21, 2020","March 17, 2020","April 14, 2020","April 7, 2020","April 22, 2020","April 3, 2020","April 22, 2020","April 10, 2020","April 9, 2020","April 13, 2020","March 17, 2020","April 16, 2020","April 22, 2020","April 2, 2020","April 20, 2020","April 14, 2020","March 20, 2020","April 14, 2020","April 10, 2020","March 31, 2020","April 22, 2020","April 16, 2020","March 17, 2020","April 14, 2020","April 10, 2020","April 9, 2020","April 13, 2020","April 16, 2020","March 31, 2020","April 15, 2020","April 22, 2020","March 30, 2020","April 21, 2020","March 27, 2020","April 9, 2020","March 27, 2020","April 15, 2020","April 3, 2020","March 31, 2020","April 22, 2020","April 17, 2020","April 21, 2020","April 9, 2020","April 1, 2020","April 20, 2020","April 20, 2020","April 21, 2020","April 22, 2020","April 21, 2020","April 8, 2020","April 21, 2020","April 14, 2020","April 22, 2020","April 15, 2020","April 22, 2020","February 21, 2020","February 25, 2020","April 20, 2020","April 21, 2020","April 17, 2020","April 16, 2020","April 14, 2020","April 17, 2020","April 21, 2020","March 26, 2020","March 27, 2020","April 21, 2020","April 7, 2020","April 8, 2020","April 17, 2020","April 21, 2020","April 6, 2020","April 21, 2020","April 9, 2020","April 22, 2020","April 22, 2020","March 17, 2020","April 2, 2020","April 14, 2020","April 17, 2020","April 14, 2020","April 20, 2020","April 17, 2020","April 22, 2020","April 7, 2020","April 1, 2020","April 22, 2020","April 6, 2020","April 3, 2020","April 20, 2020","April 15, 2020","April 14, 2020","April 22, 2020","April 21, 2020","April 13, 2020","April 7, 2020","April 13, 2020","April 20, 2020","April 22, 2020","March 31, 2020","April 9, 2020","April 7, 2020","April 17, 2020","March 3, 2020","April 10, 2020","April 20, 2020","March 31, 2020","April 10, 2020","April 15, 2020","April 7, 2020","March 5, 2020","April 16, 2020","April 17, 2020","April 15, 2020","April 10, 2020","April 14, 2020","April 15, 2020","March 10, 2020","March 20, 2020","April 16, 2020","April 22, 2020","April 8, 2020","April 16, 2020","February 21, 2020","March 24, 2020","April 21, 2020","April 7, 2020","April 17, 2020","April 21, 2020","April 13, 2020","April 10, 2020","March 31, 2020","April 17, 2020","April 14, 2020","April 15, 2020","April 22, 2020","April 15, 2020","April 17, 2020","April 15, 2020","April 17, 2020","April 8, 2020","April 8, 2020","April 10, 2020","April 10, 2020","April 13, 2020","March 3, 2020","April 15, 2020","March 30, 2020","April 10, 2020","April 13, 2020","April 15, 2020","April 1, 2020","April 17, 2020","March 20, 2020","April 13, 2020","April 17, 2020","April 9, 2020","March 31, 2020","April 14, 2020","April 13, 2020","April 15, 2020","April 10, 2020","April 20, 2020","April 10, 2020","April 8, 2020","April 15, 2020","April 14, 2020","April 21, 2020","April 14, 2020","April 22, 2020","April 20, 2020","April 14, 2020","April 21, 2020","February 7, 2020","March 19, 2020","April 7, 2020","April 1, 2020","April 15, 2020","April 20, 2020","April 6, 2020","April 21, 2020","April 22, 2020","April 14, 2020","April 10, 2020","April 16, 2020","April 13, 2020","April 21, 2020","April 14, 2020","April 15, 2020","March 24, 2020","April 14, 2020","April 13, 2020","April 14, 2020","April 20, 2020","April 21, 2020","April 22, 2020","April 21, 2020","April 14, 2020","April 13, 2020","March 30, 2020","April 13, 2020","April 13, 2020","March 31, 2020","April 15, 2020","April 17, 2020","April 8, 2020","April 14, 2020","March 13, 2020","March 27, 2020","April 7, 2020","April 7, 2020","April 13, 2020","April 8, 2020","April 15, 2020","April 9, 2020","April 14, 2020","April 21, 2020","April 7, 2020","April 21, 2020","March 26, 2020","April 17, 2020","April 14, 2020","April 10, 2020","April 20, 2020","April 14, 2020","April 20, 2020","April 21, 2020","April 15, 2020","March 17, 2020","April 15, 2020","February 21, 2020","February 24, 2020","April 17, 2020","April 21, 2020","April 21, 2020","April 14, 2020","March 3, 2020","April 9, 2020","February 17, 2020","February 10, 2020","April 8, 2020","March 31, 2020","April 10, 2020","March 24, 2020","March 10, 2020","April 13, 2020","April 15, 2020","April 17, 2020","February 19, 2020","April 16, 2020","April 10, 2020","April 17, 2020","April 10, 2020","April 17, 2020","March 31, 2020","April 21, 2020","April 7, 2020","February 5, 2020","February 24, 2020","April 22, 2020","April 14, 2020","February 17, 2020","February 5, 2020","February 7, 2020","February 19, 2020","March 17, 2020","March 26, 2020","April 13, 2020","April 21, 2020","April 10, 2020","April 6, 2020","April 15, 2020","March 24, 2020","April 8, 2020","April 20, 2020","April 10, 2020","April 17, 2020","April 20, 2020","March 19, 2020","April 6, 2020","April 22, 2020","April 20, 2020","April 22, 2020","April 7, 2020","April 3, 2020","April 15, 2020","April 22, 2020","April 15, 2020","March 24, 2020","April 10, 2020","March 30, 2020","April 15, 2020","April 8, 2020","April 17, 2020","February 11, 2020","April 8, 2020","April 15, 2020","April 15, 2020","February 25, 2020"],["Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of","Asst Fatebenefratelli Sacco, Milano, Italy",null,null,"University Malaya Medical Centre, Kuala Lumpur, Malaysia","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom","Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de So Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitrio So Joo, Oporto, Portugal",null,"Ochsner Medical Center, New Orleans, Louisiana, United States","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of","Charing Cross Hospital, London, United Kingdom",null,"First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",null,"University of Kansas Medical Center, Kansas City, Kansas, United States","Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States","University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands",null,"Hackensack University Medical Center, Hackensack, New Jersey, United States","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada","Catherine Klersy, Pavia, PV, Italy","Survey, London, United Kingdom",null,"National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore","Hao Li, Beijing, Beijing, China","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","GH Piti-Salptrire / Service d'Accueil des Urgences, Paris, Ile-de-France, France","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China","Huai'an fourth people's Hospital, Huaian, Jiangsu, China","CHU de Nimes, Nmes, France","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","Erasme Hospital CUB, Brussels, Belgium",null,"Chongqing Public Health Medical Center, Chongqing, China",null,"University of Colorado, Denver, Aurora, Colorado, United States","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",null,"Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States","Beijing 302 Military Hospital of China, Beijing, China","Azienda Ospedaliera \"SS. Antonio e Biagio e C. Arrigo\" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialit Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialit Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy","IRCCS INRCA Hospital, Ancona, Italy","Research Site, Barcelona, Spain","All French Emergency services, Le Mans, France","Washington University School of Medicine, Saint Louis, Missouri, United States","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",null,null,"University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Jospeh's Healthcare Hamtilon, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre - Cancer Centre, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health Toronto, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Hpital de la Cit-de-la-Sant, Laval, Quebec, Canada|Hpital Maisonneuve-Rosemont, Montral, Quebec, Canada|Centre hospitalier de l'Universit de Montral, Montral, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montral, Quebec, Canada|Jewish General Hospital, Montral, Quebec, Canada|McGill University Health Centre, Montral, Quebec, Canada|Hpital du Sacr-Coeur de Montreal, Montral, Quebec, Canada|Centre hospitalier universitaire de Qubec, Quebec City, Quebec, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre hospitalier affili universitaire rgional de Trois-Rivires, Trois-Rivires, Quebec, Canada","Duke University Medial Center, Durham, North Carolina, United States","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","CHU d'Angers, Angers, France|AP-HP - Hpital Bichat, Paris, France|CHU de Saint-Etienne, Saint-tienne, France",null,null,"Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Facility 2, Manhasset, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States",null,"Beat COIVD, LLC, Chicago, Illinois, United States","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|University Hospital Ghent, Gent, Belgium|University Hospital Brussels, Jette, Belgium|University Hospital Lige, Lige, Belgium",null,"Duke University, Durham, North Carolina, United States","Pentagon, Arlington, Virginia, United States","NYU Winthrop Hospital, Mineola, New York, United States","Department and Institute of Infectious Disease, Wuhan, Hubei, China","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium",null,"Rigshospitalet, Copenhagen, Denmark","Hospital de Clnicas 'Jos de San Martn', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina","Cedars-Sinai Medical Center, Los Angeles, California, United States",null,null,"Nicolaus Copernicus University, Bydgoszcz, Poland","Cairo University, Cairo, Egypt","Institute for Tropical Medicine, Tbingen, Germany","ProgenaBiome, Ventura, California, United States","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark","University of Cincinnati, Cincinnati, Ohio, United States","University of Pennsylvania, Philadelphia, Pennsylvania, United States","University of Alberta Hopsital, Edmonton, Alberty, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montral, Quebec, Canada|CHU de Qubec - Universit Laval, Qubec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Qubec- Universit Laval, Qubec, Quebec, Canada|Centre Intgr Universitaire de Sant et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",null,"IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",null,null,"Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong","St. Georges Hospital Foundation Trust, London, United Kingdom","Departament de Salut, Barcelona, Spain","Hospital San Jos, Monterrey, Nuevo Leon, Mexico","University of Chicago, Chicago, Illinois, United States","Assiut University Hospitals, Assiut, Egypt","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",null,"Medizinische Universitt Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universitt Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjllands Hospital, Hillerd, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universittsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universitt Mnchen, Mnchen, Germany","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States","University of Chicago Medicine, Chicago, Illinois, United States","Baylor University Medical Center, Dallas, Texas, United States","University Medical Center New Orleans, New Orleans, Louisiana, United States","University Medical Center Hamburg-Eppendorf, Hamburg, Germany",null,null,"King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia","NYU Langone Health, New York, New York, United States","King Hussein Cancer Center, Amman, Jordan","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of","Queen's Medical Center, Honolulu, Hawaii, United States",null,"ISGlobal, Barcelona, Spain","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",null,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham &amp; Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, 270-05 76th Ave, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Dsseldorf, WA, Germany|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universittsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik fr Hmatologie, Onkologie, Immunologie, Mnchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcal De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Corua, A Corua, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Hospital Universitario Fundacin Jimnez Daz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Mlaga, Mlaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genve, Genve 14, Switzerland|Ospedale Regionale di Locarno La Carit, Lugano, Switzerland|Universittsspital Zrich, Zrich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",null,"Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada","Hospital Vera Cruz, Campinas, So Paulo, Brazil|Centro de Genomas, So Paulo, Brazil|Hospital Emlio Ribas, So Paulo, Brazil",null,"New York University School of Medicine, New York, New York, United States","Stanford Health Care, Stanford, California, United States","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States","Prevent Senior Private Operadora de Sade LTDA., So Paulo, Brazil","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente-Oakland/San Francisco, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente-Oakland/San Francisco, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente-Oakland/San Francisco, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente-Oakland/San Francisco, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham &amp; Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UTSW Medical Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Dsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universittsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik fr Hmatologie, Onkologie, Immunologie, Mnchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcal De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Corua, A Corua, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Hospital Universitario Fundacin Jimnez Daz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Mlaga, Mlaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genve, Genve 14, Switzerland|Ospedale Regionale di Locarno La Carit, Lugano, Switzerland|Universittsspital Zrich, Zrich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, M13 9wl, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",null,"Hospital Clnico Universitario Lozano Blesa, Zaragoza, Aragn, Spain|Hospital Universitario Severo Ochoa, Legans, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Prncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Maran, Madrid, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Hospital Clnico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","University Hospital Cologne, Cologne, NRW, Germany",null,"Uh Montpellier, Montpellier, France","RoMed - Klinikum Bad Aibling, Bad Aibling, Germany|DONAUISAR Klinikum Deggendorf, Deggendorf, Germany|DONAUISAR Klinikum Dingolfing, Dingolfing, Germany|RoMed - Klinikum Prien am Chiemsee, Prien, Germany|RoMed - Klinikum Rosenheim, Rosenheim, Germany|Universittsklinikum Ulm, Ulm, Germany|RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany|Klinikum Altmhlfranken, Weienburg, Germany|Timi County Emergency Clinical Hospital, Timisoara, Romania","Stem Cells Arabia, Amman, Jordan","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","Chu Felix Guyon, Saint Denis, La Runion, France|Ch St Esprit, Agen, France|Ch General Aix En Provence -, Aix-en-Provence, France|CHU Angers, Angers, France|CH d'ANGOULEME, Angoulme, France|Pringy - Ch D'Annecy, Annecy, France|Ch Armentieres, Armentires, France|CH Arpajon, Arpajon, France|Ch Auxerre, Auxerre, France|CH GENERAL Henri Duffaut, Avignon, France|CHU de BESANCON, Besanon, France|Hopital Femme Enfant, Caen, France|Ch de Pontoise, Cergy-Pontoise, France|Ch W. Morey, Chalon-sur-Sane, France|CH de CHAMBERY, Chambry, France|Ch Hotel Dieu, Chartres, France|Centre Hospitalier intercommunal de Creteil, Creteil, France|Ch de Dax, Dax, France|Hopital D'Enfants Chu Dijon, Dijon, France|CH Louviers Val de Reuil, Elbeuf, France|CH Gonesse, Gonesse, France|CH d'HYERES, Hyres, France|Ch de Marne La Vallee, Jossigny, France|Chru de Grenoble, La Tronche, France|CHGnral du HAVRE, Le Havre, France|Hopital Saint Vincent de Paul, Lille, France|Ch de Longjumeau, Longjumeau, France|Hopital Femme Mere Enfant-Bron, Lyon, France|Hopital Nord Enfants, Marseille, France|Hopital de Meaux, Meaux, France|CH de Montargis, Montargis, France|CH de MONTBRISON, Montbrison, France|CHRU de Nancy, Nancy, France|Nantes - Hopital Mere Enfant, Nantes, France|Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France|Hopital Lenval, Nice, France|Assistance Publique Hpitaux de Paris, Paris, France|POISSY - CH de POISSY, Poissy, France|QUIMPER - CH de Cornouaille, Quimper, France|RANG du FLIERS - C.H.A.M., RANG du FLIERS, France|Hopital Amricain CHU REIMS, Reims, France|CH RODEZ, Rodez, France|Chu Rouen, Rouen, France|Hopital Charles-Nicolle, Rouen, France|Chu St Etienne, Saint Etienne, France|Ch de Saint Malo, Saint-Malo, France|Ch Du Pays Du Mont Blanc, Sallanches, France|Chg Salon de Provence, Salon de Provence, France|CH Bel Air, Thionville, France|Hopital Sainte Musse, Toulon, France|CHU Toulouse-hpital des Enfants, Toulouse, France|CH de TROYES, Troyes, France|Ch Le Chesnay, Versailles, France","Xinqiao Hospital of Chongqing, Chongqing, China","Tetrandrine Tablets, Jinhua, Zhejiang, China","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria \"Maggiore della Carit\" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unit Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale \"Dell'Angelo\", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy","Qilu Hospital of Shandong University, Jinan, Shandong, China","Hospital Vera Cruz, Campina Grande, So Paulo, Brazil","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clnic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Mtua de Terrassa, Terrassa, Spain","Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|New York University Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Baylor University Medical Center; Valdez/ Rhone, Dallas, Texas, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|McMaster University Medical Centre, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjllands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Kln, Kln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",null,null,"NYU Langone Health, New York, New York, United States",null,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India","Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark","Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tlz, Bad Tlz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum Mnchen, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|Mnchen Klinik Bogenhausen und Schwabing, Munich, Germany|Universittsklinik der Paracelsus Medizinischen Privatuniversitt, Nrnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik fr Innere Medizin Weilheim, Weilheim, Germany","Institute for Tropical Medicine, Tbingen, Germany","Uhmontpellier, Montpellier, France",null,"Stanford University, Stanford, California, United States","Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China","University of Alabama at Birmingham, Birmingham, Alabama, United States","CHU Brugmann, Brussels, Belgium","Perseverance Research Center, Scottsdale, Arizona, United States","San Carlos Hospital, Bogota, Cundinamarca, Colombia","Oslo University Hospital, Oslo, Norway","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands","ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clnic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundacin Jimnez Daz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clnico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Ro Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Ro Hortega, Valladolid, Spain","Postgraduate Institute of Medical Education and Research, Chandigarh, India","Instituto Nacional de Enfermedades Respiratorias, \"Ismael Coso Villegas\", Mexico, City, Mexico",null,"Wan-Jin Chen, Fuzhou, China",null,"Icahn School of Medicine at Mount Sinai, New York, New York, United States","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China","Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",null,"Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China","Hankou Hospital, Hankou, Hubei, China","Cochin Hospital, Paris, France","University of California San Francisco, San Francisco, California, United States",null,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","H. Univ. de Bellvitge, Barcelona, Spain|H. Univ. Gregorio Maraon, Madrid, Spain|H. Univ. INfanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","SMIT, Saint Antoine hospital, Paris, France","Charit-Universittsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany","Grupo Cooperativo de Hemopatas Malignas, Huixquilucan, Estado De Mxico, Mexico","OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Oschner Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain","Angers University Hospital, Angers, France","Jin Yin-tan hospital, Wuhan, Hubei, China",null,"Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",null,null,null,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","Ospedale San Salvatore, L'Aquila, Italy","Service Anesthsie Ranimation - Groupe Hospitalier Piti-Salptrire, Paris, France","Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States",null,"Baptist Health Research Institute, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Cooper University Hospital, Camden, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States|University of Vermont Medical Center, Burlington, Vermont, United States","Assistance Publique Hpitaux de Paris - CHU Henri Mondor, Crteil, France","AssiutU, Assiut, Egypt","IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria","Franciscan St. Francis Health, Indianapolis, Indiana, United States",null,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain","CHU de Limoges, Limoges, France","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China","Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",null,"AssiutU, Assiut, Egypt",null,"Hpital necker Enfants-Malades, Paris, France","Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Capital Region, Denmark","Mount Sinai, New York, New York, United States|Temple, Philadelphia, Pennsylvania, United States",null,"Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France","Uhmontpellier, Montpellier, France","Rabin Medical Center, Petah tikva, Israel","Theravance Biopharma Investigational Site, Manchester, United Kingdom","Hospital Universitario de la Princesa, Madrid, Spain","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy","Sainte Anne Military Teaching Hospital, Toulon, France","Huoshenshan Hostipal, Wuhan, Hubei, China","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China","Tanta University, Tanta, Egypt",null,"San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico",null,"Massachusetts General Hospital, Boston, Massachusetts, United States","Hospital Quirnsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain","Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt","Hubei province hospital of integrated Chinese &amp; Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China","Vanderblt University Medical Center, Nashville, Tennessee, United States","SB Celje, Celje, Slovenia","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States","Uh Montpellier, Montpellier, France","Massachusetts General Hospital, Boston, Massachusetts, United States","Hpital Lyon Sud,Sainte Eugnie bat 4M,5, Chemin du Grand Revoyet, Pierre-Bnite cedex, France","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",null,"HonorHealth, Scottsdale, Arizona, United States","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","Dept. of Intensive Care 542, University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",null,"University Hospital Tuebingen, Tuebingen, Germany","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","Columbia University Irving Medical Center, New York, New York, United States","Hopital Bichat - Aphp, Paris, France","Duke Cancer Center, Durham, North Carolina, United States","Hilton Pharma Pvt. Ltd., Karachi, Sindh, Pakistan","Instituto Nacional de Enfermedades Respiratorias, \"Ismael Coso Villegas\", Mexico, City, Mexico","Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain",null,null,"Ayub Teaching Institution, Abbottbd, K.p.k, Pakistan","St. David's Medical Center, Austin, Texas, United States","Pinar Yalcin Bahat, Istanbul, stanbul, Turkey","Prevent Senior Private Operadora de Sade LTDA., So Paulo, Brazil","Ziekenhuis Oost Limburg, Genk, Limburg, Belgium",null,"Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clnicas, School of Medicine, USP, So Paulo, SP, Brazil","Duke University Medical Center, Durham, North Carolina, United States","Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States","Mahmoud Tantawy, Cairo, Egypt","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",null,"Ranimation hpital Louis Mourier, Colombes, Hauts De Seine, France|ranimation hpital Cochin, Paris, France|Mdecine vasculaire, Hpital Europen Georges Pompidou, Paris, France",null,"ASST dei Sette Laghi, Varese, VA, Italy",null,"BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","Swansea Univeristy, Swansea, United Kingdom",null,"CHU de Nimes, Nmes, France","University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan",null,"Hpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Groupement Hospitalier Nord, Lyon, France|Hpital Edouard Herriot, Lyon, France|Hpital St Joseph Saint Luc, Lyon, France|Hpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Bnite, France|Centre hospitalier Lyon Sud, Pierre-Bnite, France|CHU St Etienne, Saint-tienne, France|Clinique Charcot, Sainte-Foy-ls-Lyon, France|CHG Vienne, Vienne, France|Mdiple, Villeurbanne, France|Clinique des Portes du Sud, Vnissieux, France|CH Annecy-Genevois, pagny, France","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain","Hospital Lclinico San Carlos, Madrid, Spain",null,"AP-HP Hpital Europen George Pompidou, Paris, France|AP-HP Hpital Lariboisire, Paris, France|AP-HP Hpital Piti Salptrire, Paris, France|AP-HP Hpital Saint Antoine, Paris, France",null,"Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China","Divine Providence Hospital \"Pammakaristos\", Athens, Greece|Athens General Hospital \"Hippokrateio\", Athens, Greece|Athens General Hospital of Thoracic Diseases \"SOTIRIA\", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases \"SOTIRIA\", 3rd University Pathology Clinic, Athens, Greece|General Hospital of Athens \"Sismanoglio\", Marosi, Greece","Icahn School of Medicine at Mount Sinai, New York, New York, United States","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",null,"University Medical Center Goettingen, Gttingen, Germany","John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|Taibah University, Madinah, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital &amp; Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia","Aarogyam (UK), Leicester, United Kingdom","Pneumologie hpital Tenon, Paris, France","Attikon University General Hospital, Haidari/Athens, Greece","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China","Hospital General Universitario Morales Meseguer, Murcia, Spain","Sciensano, Brussels, Belgium","The LEAD Study Center, Vienna, Austria",null,"University Hospital Jena, Jena, Germany",null,"Bin Cao, Beijing, Beijing, China","University of Alabama at Birmingham, Birmingham, Alabama, United States",null,null,null,"Selfapy GmbH, Berlin, Germany","CHRU de Nancy, Vanduvre-ls-Nancy, France","Intensive care department-Hospital Tenon, Paris, France","Rigshospitalet, Copenhagen, Denmark","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland","Hpital Fondation A. de Rotschhild, Paris, France","Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain",null,"Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",null,null,"Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn, Ciudad de Mxico, Tlalpan, Mexico","FHHI-OI-Camelot; QME, Los Angeles, California, United States","University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",null,"Fondation Adolphe de Rothschild, Paris, France","Guido Beldi, Bern, Switzerland","University of Missouri-Columbia, Columbia, Missouri, United States","Nantes University Hospital - IFAC, Nantes, France","ASST - Papa Giovanni XXIII, Bergamo, Italy","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States","Hopital Piti Salpetrire, Paris, France","Columbia University Irving Medical Center/NYP, New York, New York, United States",null,"Massachusetts General Hospital, Boston, Massachusetts, United States","Hankou Hospital, Wuhan, Hubei, China","Gustave Roussy, Villejuif, Val De Marne, France","Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevires-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|157 Avenue du Gnral Leclerc, Maisons-Alfort, France|Cabinet du Dr Bodin, Montgeron, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fosss, France|Cabinet de Pdiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beausjour, Vincennes, France|Cabinet Zouari, tampes, France","University Hospitals of Geneva, Geneva, Switzerland","University of South Alabama, Mobile, Alabama, United States","H. Universitario Quirn Dexeus, Barcelona, Spain|H.U. Puerta de Hierro, Madrid, Spain",null,"Antibes Hospital, Antibes, France|Cannes Hospital, Cannes, France|Nice Hospital, Nice, France","Eshmoun Clinical Research Centre/ Hpital Abderrahmen Mami-Ariana, Tunis, Tunisia","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department &amp; Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States","Centre Lon Brard, Lyon, Rhne, France|AP-HP Hpital Saint Antoine, Paris, France|AP-HP La Piti Salptrire, Paris, France|Hpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hpital Bichat Claude Bernard, Paris, France|Gustave Roussy, Villejuif, France","Hospital Piti-Salptrire, Paris, France","Hpital Henri Mondor, Creteil, France|Hpital Garches Raymond Poincar, Garches, France|Hpital de Bictre, Le Kremlin Bictre, France|Hpital Saint Louis, Paris, France|Hpital Paul Brousse, Villejuif, France",null,"Clinical Investigation Center Piti-Salptrire, Paris, France","Uh Montpellier, Montpellier, France",null,"Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland","University Hospital Galway, Galway, Ireland","University Hospital, Limoges, France",null,"Medical University of Vienna, Division for Nephrology and Dialysis, Vienna, Austria","Spedali Civili di Brescia, Brescia, Italy","Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|Hpitaux de Paris, Hpital Saint-Antoine, service de ranimation mdicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France|Sorbonne Universits, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States","Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia","Washington University School of Medicine, Saint Louis, Missouri, United States|Melbourne Medical School, Melbourne, Victoria, Australia|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|University College London, London, United Kingdom|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia",null,"Houston Methodist Hospital, Houston, Texas, United States","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ionnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, \"Latsio\", Thriasio Elefsis General Hospital, Elefsna, Greece|Intensive Care Unit, \"Koutlimbaneio &amp; Triantafylleio\" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece","Hpital Bichat - Service de Pneumologie, Paris, France","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",null,"Pinar Yalcin Bahat, Istanbul, stanbul, Turkey","CHU Amiens-Picardie, Amiens, France|CHU Franois Mitterand, Dijon, France|CHU Limoges, Limoges, France|Hpital de la Croix Rousse, Lyon, France|Hpitaux de Brabois, Nancy, France|CHR Orlans, Orlans, France|Institut Pasteur, Paris, France|CHU Poitiers, Poitiers, France|Hpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-tienne, France|CH de Tourcoing, Tourcoing, France|Hpital Bretonneau, Tours, France","Consorci Sanitari del Maresme (Hospital de Matar), Matar, Barcelona, Spain","Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands","Duke Clinical Research Institute, Durham, North Carolina, United States","Geneva University Hospitals, Geneva, Switzerland","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States","Pinar Yalcin Bahat, Istanbul, stanbul, Turkey","Hospital Universitario Reina Sofa, Crdoba, Spain","Centro de Hematologa y Medicina Interna, Puebla, Mexico",null,null,"The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",null,"The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",null,"Huashan Hospital of Fudan University, Shanghai, Shanghai, China","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China",null,null,"Bordeaux university Hospital, Bordeaux, France",null,"Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China","University Hospital of Cologne, Cologne, Germany","Cairo University Hospital, Cairo, Egypt",null,null,"Galway University Hospital, Galway, Ireland","Columbia University Irving Medical Center, New York, New York, United States","Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico|Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico|Hospital Central Norte Pemex, Mexico City, Mexico|hospital general de Mexico, Mexico City, Mexico","Bassett Medical Center, Cooperstown, New York, United States","Centre Hospitalier d'Argenteuil, Argenteuil, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Universitaire Ambroise Par, Boulogne, France|Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France|Centre Hospitalier Rgional Universitaire de Brest, Brest, France|Centre Hospitalier de Brives, Brive-la-Gaillarde, France|Centre Hospitalier Universitaire Beaujon, Clichy, France|Centre Hospitalier Universitaire Louis Mourier, Colombes, France|Centre Hospitalier Universitaire Henri Mondor, Crteil, France|Centre hospitalier de Dieppe, Dieppe, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier d'Etampes, Etampes, France|Grand Hpital de l'Est Francilien - Site de Marne-la-Valle, Jossigny, France|Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire Hpital Edouard Herriot, Lyon, France|Hpital priv Jacques Cartier, Massy, France|Groupe Hospitalier Sud Ile-de-France, Melun, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier Rgional d'Orlans, Orlans, France|Centre Hospitalier Universitaire Cochin, Paris, France|Groupe hospitalier Paris Saint-Joseph, Paris, France|Hpital Fondation Adolphe de Rothschild, Paris, France|Hopital Priv Claude Galien, Quincy-sous-Snart, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Centre Hospitalier de Roanne, Roanne, France|Hopital Foch, Suresnes, France|Centre Hospitalier de Toulon, Toulon, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours, France|Gustave-Roussy, Villejuif, France|Hospital Clinic Universitari, Valencia, Spain","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China","URC Ville Evrard, Neuilly-sur-Marne, France",null,"The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China","The New York Center for Travel and Tropical Medicine, New York, New York, United States",null,"Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China",null,"Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China",null,null,"ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensit di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy","Johns Hopkins Hospital, Baltimore, Maryland, United States","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States",null,"University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States","Community Medical Centers, Fresno, California, United States|MemorialCare Medical Group Long Beach, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|California Pacific Medical Center, San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo County Medical Center Foundation, San Mateo, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Massachusetts, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital Health System, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States|St. Michael's Medical Center, Newark, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|New York Presbyterian Hospital, Flushing, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hopsital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|St. David's Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Hpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hpital Raymond Poincar, Garches, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hpital Charles-Nicolle, Rouen, France|Universitatsklinikum, Essen, Germany|Universittsklinikum Freiburg, Freiburg, Germany|Universitatsklinikum Regensburg, Regensburg, Germany|Klinikum Wrzburg Mitte, Wrzburg, Germany|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom","Montefiore Medical Center, Bronx, New York, United States","University of Utah Health, Salt Lake City, Utah, United States","Portland Providence Medical Center, Portland, Oregon, United States",null,"Service de ranimation Hpital Avicenne, Bobigny, France|Service de ranimation Hpital Bichat, Paris, France|Service de ranimation Hpital Tenon, Paris, France","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ionnina, Greece|Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessalonki, Greece","Medical University of Graz, Graz, Styria, Austria","CHG de Chambery, Chambry, France|Centre Hospitalier Intercommunal de Crteil, Crteil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|Hopital priv de la Loire, Saint-tienne, France|CHU de Tours, Tours, France","Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States","Beijing Children's Hospital,, Beijing, China","Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States","Neuroganics, Northglenn, Colorado, United States","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States","University Hospital of Zurich, Zurich, Switzerland","University of Chicago Medicine, Chicago, Illinois, United States","Beaumont Health, Royal Oak, Michigan, United States","Universidade da Sao Paulo, Ribeiro Preto, Sao Paulo, Brazil|Universidad Autonoma de Chile, Santiago, Regin Metropolitana, Chile|Universidad de la Repblica, Rivera, Uruguay","University Clinic Freiburg, Freiburg, Germany","Istanbul University - Cerrahpaa, Istanbul, Turkey","Montefiore Medical Center, Bronx, New York, United States",null,"NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",null,null,"CHU de Bordeaux, Bordeaux, France|CHU de Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|CHU de Nimes, Nmes, France",null,"Viollier AG, Allschwil, Switzerland|University Hospital Basel, Basel, Switzerland|Biozentrum University of Basel, Basel, Switzerland|sciCore University of Basel, Basel, Switzerland|Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland|Swiss Institute of Bioinformatics, Geneva, Switzerland","Massachusetts General Hospital, Boston, Massachusetts, United States","Hpital GHU Paris Saclay, Boulogne-Billancourt, France|Hpital Saint Antoine, Paris, France|Hpital Broca, Paris, France|Hpital La Piti-Salptrire, Paris, France|Hpital Cochin, Paris, France|Hpital europen Georges Pompidou, Paris, France|Hpital Necker, Paris, France",null,null,"Montefiore Medical Center, Bronx, New York, United States","Service de Mdecine Intensive Ranimation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de Mdecine Intensive Ranimation Hpital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de Mdecine Intensive Ranimation Hpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Ranimation Chirurgicale Hpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Mdecine Intensive Ranimation Hpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de Ranimation Chirurgicale Hpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de ranimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de Ranimation Clinique de la Sauvegarde, Lyon, France|Service de Ranimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bnite, France|Service de Ranimation Centre hospitalier Annecy Genevois, Pringy, France|Service de Mdecine Intensive Ranimation Hpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France",null,"Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerd, Hillerd, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, Kbenhavn, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark","Service de Gyncologie, HFME, Hospices Civils de Lyon, Bron, France|Service de Gyncologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service Gyncologie, CHLS, Hospices Civils de Lyon, Pierre-Bnite, France","Universidad del Rosario, Bogota, Cundinamarca, Colombia",null,null,"UCLA, Los Angeles, California, United States|Norton Healthcare, Louisville, Kentucky, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott &amp; White Dallas, Dallas, Texas, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|Hadassah MC, Jerusalem, Israel|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain",null,"University Medical Center Utrecht, Utrecht, Netherlands",null,"Hospital Universitario de Ferrol, Ferrol, A Corua, Spain|Hospital Clnico Universitario de Santiago, Santiago De Compostela, A Corua, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Du de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Crdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastin, Guipuzcoa, Spain|Hospital San Pedro, Logroo, La Rioja, Spain|Hospital Principe de Asturias, Alcal De Henares, Madrid, Spain|Hospital Fundacin de Alcorcn, Alcorcn, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital Severo Ochoa, Legans, Madrid, Spain|Hospital Rey Juan Carlos, Mstoles, Madrid, Spain|Hospital Quirn Pozuelo, Pozuelo De Alarcn, Madrid, Spain|Hospital de Torrejn, Torrejn De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Mlaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Arnau de Vilanova, Llria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Mdico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirn Barcelona, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clnico San Cecilio, Granada, Spain|Hospital Universitario de Len, Len, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Fundacin Jimnez Daz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Maraon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofa, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Mlaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Seora de Sonsoles, vila, Spain",null,"CHI Crteil, Crteil, France|CHU Henri Mondor, Crteil, France|Centre hospitalier de Melun (GHSIF), Melun, France|Hpital universitaire de Htel Dieu, Paris, France|CHI Villeneuve St Georges, Villeneuve-Saint-Georges, France","IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy",null,"Banner University Medicine Women's Institute, Phoenix, Arizona, United States","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States","Universidad del Rosario, Bogota, Cundinamarca, Colombia",null,"SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|UOC Ematologia, Ospedali Riuniti, Ancona, Italy|UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy|SC Oncologia Medica, CRO, Aviano, Italy|SC Ematologia, Policlinico Bari, Bari, Italy|UOC Ematologia, I.R.C.C.S Istituto Tumori Giovanni Paolo II, Bari, Italy|SSD Ematologia, Ospedale degli Infermi, Biella, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,, Bologna, Italy|Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Bolzano, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UOC Onco-Ematologia ASST Valle Olona, Busto Arsizio, Italy|SC Ematologia e CTMO AZIENDA OSPEDALIERA \"G. BROTZU\" - OSPEDALE ONCOLOGICO BUSINCO, Cagliari, Italy|UOC Ematologia, AOU Policlinico Vittorio Emanuele, Catania, Italy|Ematologia, Ospedale Valduce, Como, Italy|UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy|UO Ematologia e CTMO, ASST Cremona, Cremona, Italy|SC Ematologia Ospedale S. Croce, Cuneo, Italy|UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy|S.O.D. Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOC Ematologia, Policlinico Ospedali Riuniti, Foggia, Italy|UO Ematologia, Ospedale Policlinico S.Martino IRCCS, Genova, Italy|UO Ematologia, Ospedale Policlinico San Martino, Genova, Italy|UOC di Ematologia e Trapianto di Cellule Staminali, P.O. Vito Fazzi, Lecce, Italy|UOC di Ematologia, Ospedale di Legnano, Legnano, Italy|UOC Oncologia ASST Lodi, Lodi, Italy|UOC Ematologia Azienda Ospedaliera Universitaria \"G.Martino\", Messina, Italy|UO Ematologia, Ospedale dell'Angelo di Mestre, Mestre, Italy|Ematologia, IEO, Milano, Italy|SC Ematologia, Istituto Nazionale dei Tumori, Milano, Italy|SC Ematologia, Ospedale Niguarda, Milano, Italy|UO Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy|UO Servizio di Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Milano, Italy|UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|UO Ematologia Policlinico di Modena, Modena, Italy|UOC Ematologia, Ospedale S. Gerardo, Monza, Italy|SC Ematologia Istituto Nazionale Tumori - IRCCS \"Fondazione G. Pascale\",, Napoli, Italy|UOC Ematologia e Trapianti di Midollo, AOU Federico II, Napoli, Italy|UOC Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Maggiore della Carit, Novara, Italy|Ospedale san Luigi Gonzaga, Orbassano, Italy|Ematologia Azienda Ospedaliera di Padova, Padova, Italy|UO Ematologia, Policlinico Paolo Giaccone, Palermo, Italy|UOC Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|SC Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera di Perugia, Perugia, Italy|UO Ematologia e CTMO, Azienda Ospedaliera Ospedali Riuniti, Pesaro, Italy|UOC di Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy|UO Ematologia e CTMO, Presidio Ospedaliero di Piacenza, Piacenza, Italy|UO Ematologia, AOU Pisana- Santa Chiara, Pisa, Italy|UO Ematologia dell'Ospedale Santa Maria delle Croci, Ravenna, Italy|UOC Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|SC Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|UO Ematologia, Ospedale Infermi, Rimini, Italy|SC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UO Ematologia e Trapianti di Cellule Staminali, A.O. S. Camillo-Forlanini, Roma, Italy|UO Ematologia, Policlinico Tor Vergata, Roma, Italy|UOC Ematologia e trapianto di cellule staminali, Policlinico Universitario Campus Bio-Medico, Roma, Italy|UOC Ematologia Policlinico Umberto I, Roma, Italy|UOC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UO Ematologia, Istituto Clinico Humanitas, Rozzano, Italy|UOC Ematologia e centro trapianti cellule staminali emopoietiche, AOU San Giovanni Di Dio e Ruggi D'aragona, Salerno, Italy|UOC Ematologia, Policlinico Santa Maria alle Scotte, Siena, Italy|UOC Ematologia e Trapianto Midollo Osseo, Ospedale S. G. Moscati, Taranto, Italy|SCDU Ematologia e terapie cellulari, Ospedale Mauriziano Umberto I, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Civili Ca' Foncello, Treviso, Italy|SC Ematologia, Azienda sanitaria universitaria Giuliano Isontina, Trieste, Italy|Clinica Ematologia, Azienda Ospedaliera-Universitaria Santa Maria della Misericordia, Udine, Italy|UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi, Varese, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Ospedale San Bortolo, Vicenza, Italy","Tongji Hospital, Wuhan, Hubei, China",null,"Henan Provincial People's Hospital, Zhengzhou, Henan, China","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Universit degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iai, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom","CHRU Lille, Lille, France|CHU Nantes, Nantes, France|APHP - Bichat Claude Bernard, Paris, France","University of California, San Francisco, San Francisco, California, United States","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States","ProgenaBiome, Ventura, California, United States","Hpital Huriez, Lille, France",null,null,"CH Esquirol, Limoges, France|CHU de Limoges, Limoges, France","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France","Department and Institute of Infectious Disease, Wuhan, Hubei, China",null,"Department and Institute of Infectious Disease, Wuhan, Hubei, China","CHU Nimes, Nmes, France","University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy","Centre Hospitalier Rgional Universitaire de Nancy, Nancy, France","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy","Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of","University of Miami, Miami, Florida, United States","Brigham and Women's Hospital, Boston, Massachusetts, United States","Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy","Department and Institute of Infectious Disease, Wuhan, Hubei, China","University of Utah, Salt Lake City, Utah, United States","Jena University Hospital, Jena, Thuringia, Germany","Ospedali Riuniti di Ancona, Ancona, Marche, Italy","Vanda Pharmaceuticals, Inc., Washington, District of Columbia, United States","Cardiologie, Groupe Hospitalier Piti-Salptrire, Paris, France","Unit' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy","Andreas Barratt-Due, Oslo, Norway","Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Rambam Health Care Campus, Haifa, Israel","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of",null,"Centre Hospitalier Andre Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana","Department and Institute of Infectious Disease, Wuhan, Hubei, China","Trinity Health Of New England, Hartford, Connecticut, United States","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","National Institute of Rehabilitation, Mexico City, Cdmx, Mexico","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Universit de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Poega, Poega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charit - Universittsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charit - Universittsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neuklln, Berlin, Germany|Universittsklinikum Kln, Cologne, Germany|Universittsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universittsklinikum Jena, Jena, Germany|Universittsklinikum Leipzig, Leipzig, Germany|Universitts Klinikum Tbingen, Tbingen, Germany|Universittsklinikum Wrzburg, Wrzburg, Germany|Jsa Andrs County Hospital, Nyregyhza, Hungary|Csolnoky Ferenc Krhz - Veszprem County Hospital, Veszprm, Hungary|Almsi Balogh Pl Krhz, zd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases \"Dr. Victor Babes\", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Crdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",null,"Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China","Prince of Wales Hospital, Sha Tin, Hong Kong","Fondation Adolphe de Rothschild, Paris, France",null,"Massachusetts General Hospital, Boston, Massachusetts, United States","Hamilton Health Sciences, Hamilton, Ontario, Canada",null,"Hpital Piti-Salptrire - APHP, Paris, France|Hpital Europen Georges Pompidou - APHP, Paris, France",null,"Fabrizio Cantini, Prato, Tuscany, Italy","Hospital Universitario Madrid Sanchinarro, Madrid, Spain","Toronto General Hospital, Toronto, Ontario, Canada",null,"Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania",null,"Columbia University, New York, New York, United States|University of Chile, Santiago, Chile|University of Cagliari, Cagliari, Italy|Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain","Mayo Hospital, Kingedward Medical University, Lahore, Punjab, Pakistan",null,"Uh Montpellier, Montpellier, France",null,"Eshmoun Clinical Research Centre/ Hpital Abderrahmane Mami-Ariana, Tunis, Tunisia","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Braslia, Distrito Federal, Brazil|Fundao Social Rural de Colatina, Colatina, Esorito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poos De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paran, Brazil|Eurolatino Natal Pesquisas Mdicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Cricima, Santa Catarina, Brazil|Fundao Pio XII, Barretos, So Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, So Paulo, Brazil|Associacao Beneficente Siria, So Paulo, Brazil|Hospital das Clnicas da Faculdade de Medicina de Ribeiro Preto da USP - HCFMRP, So Paulo, Brazil|Hospital Israelita Albert Einstein, So Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, So Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficncia/SP, So Paulo, Brazil|Santa Casa de Misericrdia, So Paulo, Brazil|Secretaria de Sade do Estado de So Paulo, So Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Srio-Libans, So Paulo, Brazil|Universidade Federal de So Paulo, So Paulo, Brazil","Damien JOLLY, Reims, France","Shuguang Hospital, Shanghai, Shanghai, China","Wuhan third hospital, Wuhan, Hubei, China","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universittsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutricin Salvador Zubirn - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Coso Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|Singapore General Hospital - Department of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Khoo Teck Puat Hospital - Clinical Research Unit, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Catalua, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Catalua, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom","Montpellier University hospital, Montpellier, France","Henry Ford Hospital, Detroit, Michigan, United States|Regions Hospital, Saint Paul, Minnesota, United States",null,"Hospital de Clnicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy","St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom","Marco Confalonieri, Trieste, TS, Italy","Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States","Aalborg University Hospital, Aalborg, Denmark","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik fr Herzchirurgie, Ludwigshafen, RLP, Germany","Akershus universistetssykehus, Lrenskog, Norway","CH Victor Dupuy- Argenteuil, Argenteuil, France|Hpital Avicenne,, Bobigny, France|Hpital Avicenne, Bobigny, France|Hpital Avicenne, Bobigny, France|Hpital Antoine Bclre, Clamart, France|CH de Compigne-Noyon, Compigne, France|Groupe hospitalier Sud Ile de France, Melun, France|Hpital de la Piti- Salptrire, Paris, France|Hpital Tenon, Paris, France|CHRU de Tours, Hpital Bretonneau, Tours, France|Hpital de Tours, Tours, France",null,"CHU Amiens, Amiens, France","University Hospital Gent, Gent, Belgium",null,"UH Montpellier, Montpellier, France","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","BEAT19.org, San Francisco, California, United States","Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States","Department of anesthesia and intensive care, Fattouma Bourguiba Hospital, Monastir, Tunisia","Chu Nantes, Nantes, France","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany","Tanta University, Tanta, Egypt","University of Naples \"Federico II\", Napoli, Italy","The central hospital of Wuhan, Wuhan, Hubei, China","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States","University of Oslo, Oslo, Norway","CHU de Nice, Nice, France|Hpitaux Universitaires Paris Centre - Hpital Cochin, Paris, France",null,null,null,"Tor Vergata Hospital, Rome, Italy","Clinical Nutrition Research Center, Chicago, Illinois, United States","Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France","Mayo Clinic Florida, Jacksonville, Florida, United States","Wefight, Montpellier, France","Guangzhou Blood Center, Guangzhou, Guangdong, China","Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany","CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France","Oslo University Hospital, Oslo, Norway","Yun Long, Beijing, Beijing, China","ASSISTANCE PUBLIQUE HPITAUX de MARSEILLE, Marseille, France","University of Washington, Seattle, Washington, United States",null,null,"Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 2501001, Bordeaux Cedex, France","Taihe Hospital, Shiyan, Hubei, China","U.O.C. Chirurgia Generale Universitaria \"V. Bonomo\", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Universit di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy","Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium",null,null,"Brigham and Women's Hospital, Boston, Massachusetts, United States","Tanta University, Tanta, Egypt","Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre hospitals, Apeldoorn, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Haga Hospital, Den Haag, Netherlands|Medical Center Haaglanden, Den Haag, Netherlands|Gelderse Vallei Hospital, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Medical Centre Leeuwarden, Leeuwarden, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medical Centre, Sittard, Netherlands|UMC Utrecht, Utrecht, Netherlands","Gabriele Saccone, Napoli, Italy",null,"Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, Kbenhavn NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center Kbenhavn, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|Brne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hillerd, Denmark|Psykiatrisk Center Nordsjlland, Hillerd, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, Rnne, Denmark|Psykiatrisk Center Bornholm, Rnne, Denmark","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","Uppsala University Hospital, Uppsala, Sweden","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom",null,"Angers University Hospital, Angers, France",null,"Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China",null,"Yasin Tire, Konya, Meram, Turkey","Royal National Orthopaedic Hospital, Stanmore, United Kingdom","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health &amp; Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan","Materno-Perinatal Hospital \"Mnica Pretelini\", Toluca, Mexico","Universit Politecnica delle Marche, Ancona, AN, Italy","Children's Hospital Colorado, Aurora, Colorado, United States","Shanghai 10th People's Hospital, Shanghai, Shanghai, China","Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","Everett Clinic, Seattle, Washington, United States","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","Rush University Medical Center, Chicago, Illinois, United States",null,"Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760004, Kln, Germany|Investigational Site Number 2760001, Mnster, Germany|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain","Stanford University, Stanford, California, United States","Stony Brook University Hospital, Stony Brook, New York, United States",null,"CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|APHP Henri Mondor, Crteil, France|CHU Dijon, Dijon, France|CHD Vende, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hpital Priv du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orlans, Orlans, France|APHP Saint-Antoine, Paris, France|La Piti-Salptrire, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-tienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco","Istinye University Medical School, Istanbul, Turkey","Department of Neuro- Urology, Hpital Tenon, Paris, France","Everett Clinic, Seattle, Washington, United States","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","School of public health and primary care, Hong Kong, Hong Kong",null,"Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom","Hospital Geral Clriston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitria Da Conquista, BA, Brazil|Hospital Geral de Vitria da Conquista, Vitria Da Conquista, BA, Brazil|Hospital de Braslia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Braslia, DF, Brazil|Hospital Maternidade So Jos - UNESC - Fundao Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericrdia de So Joo Del Rei, So Joo Del Rei, MG, Brazil|Associao Evanglica Beneficente de Londrina - Hospital Evanglico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Crebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital So Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital So Jos, Criciuma, SC, Brazil|Hospital Baa Sul - Baa Sul Medical Center, Florianpolis, SC, Brazil|Hospital Nereu Ramos, Florianpolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundao PIO XII), Barretos, SP, Brazil|Casa de Sade Santa Marcelina, So Paulo, SP, Brazil|Hospital Albert Einstein, So Paulo, SP, Brazil|Hospital Beneficncia Portuguesa - Real e Benemrita Associao Portuguesa de Beneficncia, So Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemrita, So Paulo, SP, Brazil|Hospital das Clnicas da FMUSP, So Paulo, SP, Brazil|Hospital do Servidor Pblico Estadual - HSPE - IAMSPE, So Paulo, SP, Brazil|Hospital So Paulo - UNIFESP, So Paulo, SP, Brazil|Hospital Srio-Libans, So Paulo, SP, Brazil|Hospital SEPACO, So Paulo, S, Brazil",null,"Kremlin Bictre APHP, Le Kremlin-Bictre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France","IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italy","University of Naples Federico II, Napoli, Italy","Wenzhou Medical University, Wenzhou, Zhejiang, China|The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany",null,"Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States","Fundacion Salud De Los Andes, Bogot, Bogot Distrito Capital, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjllands Hospital, Hillerd, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark","CHU de Nice, Nice, France","Saint-Louis Hospital, Paris, Ile De France, France","Peking University Third Hospital, Beijing, China","Kremlin Bicetre hospital APHP, Le Kremlin-Bictre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France","dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia","CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Arhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsjllands Hospital, Hillerd, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark","Instituto de Cardiologia do Distrito Federal, Braslia, Distrito Federal, Brazil|Fundao Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poos De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paran, Brazil|Hospital Adventista de Belm, Belm, Par, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Universitrio Onofre Lopes, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Cricima, Santa Catarina, Brazil|Fundao Pio XII, Barretos, So Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, So Paulo, Brazil|Hospital Israelita Albert Einstein, So Paulo, Brazil|AMICO Saude LTDA, So Paulo, Brazil|Associacao Beneficente Siria, So Paulo, Brazil|Hospital Vila Santa Catarina, So Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, So Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficncia/SP, So Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficncia/SP, So Paulo, Brazil|Santa Casa de Misericrdia, So Paulo, Brazil|Secretaria de Sade do Estado de So Paulo, So Paulo, Brazil|Serv Social da Industria do papel, papelo e cortia do estado de SP, So Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Srio-Libans, So Paulo, Brazil|Universidade Federal de So Paulo, So Paulo, Brazil","ProHealth New York, New York, New York, United States","Unit de Soins Intensifs de Cardiologie, Piti Salptrire Hospital, AP-HP, Paris, France","Institut universitaire de cardiologie et de pneumologie de Qubec - Universit Laval, Quebec, Canada",null,null,null,"University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada","Department of nephrology, Klinikum rechts der Isar, Mnchen, Bavaria, Germany","Lenox Hill Hospital Northwell Health, New York, New York, United States","Hpital Roger Salengro, ICU, CHU Lille, Lille, France","Sheba Medical Center, Ramat Gan, Israel","Rouen University Hospital, Rouen, France","Tanta University, Tanta, Egypt","Karolinska Institutet, Stockholm, Sweden","Istanbul university Cerrahpasa, Istanbul, Turkey","Duke University Medical Center, Durham, North Carolina, United States","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong","Aarogyam, Leicester, United Kingdom",null,null,"CHU Nantes, Nantes, France","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States","CHU de Lille, Lille, France|APHM, Marseille, France|CHU de Massy, Massy, France|APHP - Bichat, Paris, France|Aphp - Hegp, Paris, France|IMM, Paris, France|CHU de Rouen, Rouen, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|CHU de Nancy, Vanduvre-ls-Nancy, France","Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy","Hpital de la Croix-Rousse, Lyon, France",null,"Uhmontpellier, Montpellier, France","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China","Service Hygine, Epidmiologie et Prvention, Lyon, France|Service Hygine, Epidmiologie et Prvention, Lyon, France",null,"Service de Chirurgie Thoracique Nouvel Hpital Civil Hpitaux Universitaires de Strasbourg, Strasbourg, France","Luca Gallelli, Catanzaro, Italy","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Universit Vita-Salute San Raffaele, Milano, Mi, Italy","Istanbul University-Cerrahpaa, Istanbul, Turkey","Changhai Hospital, Shanghai, China",null,null,"University Hospital, Clermont-Ferrand, Clermont-Ferrand, France","Luca Gallelli, Catanzaro, Italy","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerd Hospital, Hillerd, Denmark","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy","Bicetre Hospital, Paris, Val-de-Marne, France","Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia","Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","Tanta university hospital, Tanta, Egypt",null,"CH Louis MOURIER, Colombes, France|Hpital Mre Enfant CHU, Nantes, France|Hpitaux Pdiatriques de Nice CHU-Lenval, Nice, France|Hpital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",null,"Aarogyam, Leicester, United Kingdom","CHU de Nice, Nice, France",null,"University of Alberta, Edmonton, Alberta, Canada","CHI Aix-Pertuis, Aix-en-Provence, France",null,"Columbia University Irving Medical Center/NYP, New York, New York, United States","University Hospital Essen, Essen, NRW, Germany","Yale-NUS College, Singapore, Singapore","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",null,"Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",null,"Fujian Provincial Hospital, Fuzhou, Fujian, China","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",null,null,null,"University Hospital Angers, Angers, France","Centre for Clinical Vaccinology &amp; Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Lige, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CHU Brest, Brest, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hpital Bichat, Paris, France|Hpital Lariboisire, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",null,null,"Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",null,"Cleveland Clinic, Cleveland, Ohio, United States","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China","CHU, Angers, France","Diamond Centre, Vancouver, British Columbia, Canada","University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|New York University School of Medecine, New York, New York, United States|Montreal Heart Institute, Montreal, Quebec, Canada","Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States","Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China",null,null,"CIC 1425, Paris, France","The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China","Tongji HospitalTongji Medical College AffiliatedHuazhong University of Science  Technology, Wuhan, Hubei, China","Tangdu Hospital, Xi'an, Shaanxi, China","Luigi Sacco University Hospital, Milan, Lombardia, Italy","CIC 1425, Paris, France",null,"Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",null,"Istanbul University Cerrahpasa, Istanbul, Turkey",null,null,"Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Sd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Hhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria","Instituto do Corao - Hospital das Clnicas - Faculdade de Medicina da Universidade de So Paulo, So Paulo, SP, Brazil","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China",null,"Istanbul University-Cerrahpasa, Istanbul, Turkey","University Hospitals Leuven, Leuven, Belgium|University of Brescia, Brescia, Italy|University of Foggia, Foggia, Italy|University of Milan, Milan, Italy|University of Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Queen Charlotte's &amp; Chelsea Hospital, London, United Kingdom","Mayo Clinic in Rochester, Rochester, Minnesota, United States","Department of Cardiology, Bern University Hospital, Bern, Switzerland","Akershus University Hospital, Lrenskog, Norway","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong","Medical University Vienna, Vienna, Austria",null,null,"Research Center of the CHUS, Sherbrooke, Quebec, Canada","Virtual Facility, Bronx, New York, United States",null,"Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montral, Quebec, Canada",null,"CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France|APHP La Piti Salptrire, service des Maladies Infectieuses et Tropicales, Paris, France|APHP Bichat, Service de ranimation mdicale et infectieuse, Paris, France|APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",null,"Online, Nicosia, Cyprus",null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04354519/Prot_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04352517/Prot_SAP_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf",null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf",null],["https://ClinicalTrials.gov/show/NCT04333550","https://ClinicalTrials.gov/show/NCT04336904","https://ClinicalTrials.gov/show/NCT04351802","https://ClinicalTrials.gov/show/NCT04354831","https://ClinicalTrials.gov/show/NCT04345445","https://ClinicalTrials.gov/show/NCT04331509","https://ClinicalTrials.gov/show/NCT04355741","https://ClinicalTrials.gov/show/NCT04347915","https://ClinicalTrials.gov/show/NCT04343183","https://ClinicalTrials.gov/show/NCT04342637","https://ClinicalTrials.gov/show/NCT04333407","https://ClinicalTrials.gov/show/NCT04291053","https://ClinicalTrials.gov/show/NCT04336462","https://ClinicalTrials.gov/show/NCT04324489","https://ClinicalTrials.gov/show/NCT04347993","https://ClinicalTrials.gov/show/NCT04323228","https://ClinicalTrials.gov/show/NCT04335123","https://ClinicalTrials.gov/show/NCT04350593","https://ClinicalTrials.gov/show/NCT04333420","https://ClinicalTrials.gov/show/NCT04342689","https://ClinicalTrials.gov/show/NCT04343755","https://ClinicalTrials.gov/show/NCT04329611","https://ClinicalTrials.gov/show/NCT04321421","https://ClinicalTrials.gov/show/NCT04352582","https://ClinicalTrials.gov/show/NCT04325633","https://ClinicalTrials.gov/show/NCT04351659","https://ClinicalTrials.gov/show/NCT04323332","https://ClinicalTrials.gov/show/NCT04344015","https://ClinicalTrials.gov/show/NCT04352348","https://ClinicalTrials.gov/show/NCT04339660","https://ClinicalTrials.gov/show/NCT04306497","https://ClinicalTrials.gov/show/NCT04354857","https://ClinicalTrials.gov/show/NCT04354389","https://ClinicalTrials.gov/show/NCT04287686","https://ClinicalTrials.gov/show/NCT04344145","https://ClinicalTrials.gov/show/NCT04355338","https://ClinicalTrials.gov/show/NCT04324996","https://ClinicalTrials.gov/show/NCT04348071","https://ClinicalTrials.gov/show/NCT04340232","https://ClinicalTrials.gov/show/NCT04321993","https://ClinicalTrials.gov/show/NCT04355793","https://ClinicalTrials.gov/show/NCT04343768","https://ClinicalTrials.gov/show/NCT04329832","https://ClinicalTrials.gov/show/NCT04252118","https://ClinicalTrials.gov/show/NCT04317092","https://ClinicalTrials.gov/show/NCT04348396","https://ClinicalTrials.gov/show/NCT04346199","https://ClinicalTrials.gov/show/NCT04331171","https://ClinicalTrials.gov/show/NCT04354714","https://ClinicalTrials.gov/show/NCT04350671","https://ClinicalTrials.gov/show/NCT04350684","https://ClinicalTrials.gov/show/NCT04344587","https://ClinicalTrials.gov/show/NCT04330586","https://ClinicalTrials.gov/show/NCT04348656","https://ClinicalTrials.gov/show/NCT04350073","https://ClinicalTrials.gov/show/NCT04275947","https://ClinicalTrials.gov/show/NCT04328285","https://ClinicalTrials.gov/show/NCT04331899","https://ClinicalTrials.gov/show/NCT04337996","https://ClinicalTrials.gov/show/NCT04315298","https://ClinicalTrials.gov/show/NCT04352933","https://ClinicalTrials.gov/show/NCT04337762","https://ClinicalTrials.gov/show/NCT04330638","https://ClinicalTrials.gov/show/NCT04348942","https://ClinicalTrials.gov/show/NCT04343690","https://ClinicalTrials.gov/show/NCT04343677","https://ClinicalTrials.gov/show/NCT04332081","https://ClinicalTrials.gov/show/NCT04304313","https://ClinicalTrials.gov/show/NCT04326920","https://ClinicalTrials.gov/show/NCT04353284","https://ClinicalTrials.gov/show/NCT04337541","https://ClinicalTrials.gov/show/NCT04355936","https://ClinicalTrials.gov/show/NCT04338347","https://ClinicalTrials.gov/show/NCT04348422","https://ClinicalTrials.gov/show/NCT04356690","https://ClinicalTrials.gov/show/NCT04351763","https://ClinicalTrials.gov/show/NCT04354805","https://ClinicalTrials.gov/show/NCT04340544","https://ClinicalTrials.gov/show/NCT04334512","https://ClinicalTrials.gov/show/NCT04327674","https://ClinicalTrials.gov/show/NCT04341675","https://ClinicalTrials.gov/show/NCT04329923","https://ClinicalTrials.gov/show/NCT04330690","https://ClinicalTrials.gov/show/NCT04355143","https://ClinicalTrials.gov/show/NCT04318418","https://ClinicalTrials.gov/show/NCT04333628","https://ClinicalTrials.gov/show/NCT04330599","https://ClinicalTrials.gov/show/NCT04285801","https://ClinicalTrials.gov/show/NCT04351646","https://ClinicalTrials.gov/show/NCT04304053","https://ClinicalTrials.gov/show/NCT04333355","https://ClinicalTrials.gov/show/NCT04351620","https://ClinicalTrials.gov/show/NCT04319315","https://ClinicalTrials.gov/show/NCT04334382","https://ClinicalTrials.gov/show/NCT04357990","https://ClinicalTrials.gov/show/NCT04335136","https://ClinicalTrials.gov/show/NCT04331366","https://ClinicalTrials.gov/show/NCT04331795","https://ClinicalTrials.gov/show/NCT04333225","https://ClinicalTrials.gov/show/NCT04344444","https://ClinicalTrials.gov/show/NCT04344080","https://ClinicalTrials.gov/show/NCT04352465","https://ClinicalTrials.gov/show/NCT04348448","https://ClinicalTrials.gov/show/NCT04357535","https://ClinicalTrials.gov/show/NCT04344236","https://ClinicalTrials.gov/show/NCT04354597","https://ClinicalTrials.gov/show/NCT04307693","https://ClinicalTrials.gov/show/NCT04345692","https://ClinicalTrials.gov/show/NCT04323631","https://ClinicalTrials.gov/show/NCT04331834","https://ClinicalTrials.gov/show/NCT04336254","https://ClinicalTrials.gov/show/NCT04313023","https://ClinicalTrials.gov/show/NCT04332094","https://ClinicalTrials.gov/show/NCT04292899","https://ClinicalTrials.gov/show/NCT04312997","https://ClinicalTrials.gov/show/NCT04334980","https://ClinicalTrials.gov/show/NCT04348409","https://ClinicalTrials.gov/show/NCT04353518","https://ClinicalTrials.gov/show/NCT04343989","https://ClinicalTrials.gov/show/NCT04347954","https://ClinicalTrials.gov/show/NCT04348435","https://ClinicalTrials.gov/show/NCT04329572","https://ClinicalTrials.gov/show/NCT04292730","https://ClinicalTrials.gov/show/NCT04341506","https://ClinicalTrials.gov/show/NCT04345523","https://ClinicalTrials.gov/show/NCT04341168","https://ClinicalTrials.gov/show/NCT04345510","https://ClinicalTrials.gov/show/NCT04347850","https://ClinicalTrials.gov/show/NCT04344171","https://ClinicalTrials.gov/show/NCT04313322","https://ClinicalTrials.gov/show/NCT04346615","https://ClinicalTrials.gov/show/NCT04336956","https://ClinicalTrials.gov/show/NCT04347369","https://ClinicalTrials.gov/show/NCT04308317","https://ClinicalTrials.gov/show/NCT04346355","https://ClinicalTrials.gov/show/NCT04305106","https://ClinicalTrials.gov/show/NCT04315987","https://ClinicalTrials.gov/show/NCT04329650","https://ClinicalTrials.gov/show/NCT04331470","https://ClinicalTrials.gov/show/NCT04244591","https://ClinicalTrials.gov/show/NCT04320615","https://ClinicalTrials.gov/show/NCT04344925","https://ClinicalTrials.gov/show/NCT04273529","https://ClinicalTrials.gov/show/NCT04354870","https://ClinicalTrials.gov/show/NCT04273581","https://ClinicalTrials.gov/show/NCT04312464","https://ClinicalTrials.gov/show/NCT04339608","https://ClinicalTrials.gov/show/NCT04356560","https://ClinicalTrials.gov/show/NCT04353596","https://ClinicalTrials.gov/show/NCT04342221","https://ClinicalTrials.gov/show/NCT04347070","https://ClinicalTrials.gov/show/NCT04345679","https://ClinicalTrials.gov/show/NCT04355767","https://ClinicalTrials.gov/show/NCT04352608","https://ClinicalTrials.gov/show/NCT04338074","https://ClinicalTrials.gov/show/NCT04346017","https://ClinicalTrials.gov/show/NCT04344457","https://ClinicalTrials.gov/show/NCT04343742","https://ClinicalTrials.gov/show/NCT04345536","https://ClinicalTrials.gov/show/NCT04342182","https://ClinicalTrials.gov/show/NCT04325061","https://ClinicalTrials.gov/show/NCT04347174","https://ClinicalTrials.gov/show/NCT04315896","https://ClinicalTrials.gov/show/NCT04331600","https://ClinicalTrials.gov/show/NCT04280588","https://ClinicalTrials.gov/show/NCT04335201","https://ClinicalTrials.gov/show/NCT04350476","https://ClinicalTrials.gov/show/NCT04341389","https://ClinicalTrials.gov/show/NCT04346056","https://ClinicalTrials.gov/show/NCT04343248","https://ClinicalTrials.gov/show/NCT04329559","https://ClinicalTrials.gov/show/NCT04318301","https://ClinicalTrials.gov/show/NCT04355507","https://ClinicalTrials.gov/show/NCT04332107","https://ClinicalTrials.gov/show/NCT04337359","https://ClinicalTrials.gov/show/NCT04273646","https://ClinicalTrials.gov/show/NCT04355871","https://ClinicalTrials.gov/show/NCT04349241","https://ClinicalTrials.gov/show/NCT04345991","https://ClinicalTrials.gov/show/NCT04331106","https://ClinicalTrials.gov/show/NCT04334044","https://ClinicalTrials.gov/show/NCT04341116","https://ClinicalTrials.gov/show/NCT04346147","https://ClinicalTrials.gov/show/NCT04343781","https://ClinicalTrials.gov/show/NCT04252664","https://ClinicalTrials.gov/show/NCT04351152","https://ClinicalTrials.gov/show/NCT04328441","https://ClinicalTrials.gov/show/NCT04350931","https://ClinicalTrials.gov/show/NCT04346043","https://ClinicalTrials.gov/show/NCT04328493","https://ClinicalTrials.gov/show/NCT04348240","https://ClinicalTrials.gov/show/NCT04358068","https://ClinicalTrials.gov/show/NCT04347889","https://ClinicalTrials.gov/show/NCT04330521","https://ClinicalTrials.gov/show/NCT04348214","https://ClinicalTrials.gov/show/NCT04332913","https://ClinicalTrials.gov/show/NCT04357444","https://ClinicalTrials.gov/show/NCT04336332","https://ClinicalTrials.gov/show/NCT04344977","https://ClinicalTrials.gov/show/NCT04317040","https://ClinicalTrials.gov/show/NCT04356417","https://ClinicalTrials.gov/show/NCT04347876","https://ClinicalTrials.gov/show/NCT04351529","https://ClinicalTrials.gov/show/NCT04342897","https://ClinicalTrials.gov/show/NCT04338932","https://ClinicalTrials.gov/show/NCT04354701","https://ClinicalTrials.gov/show/NCT04346368","https://ClinicalTrials.gov/show/NCT04334005","https://ClinicalTrials.gov/show/NCT04353323","https://ClinicalTrials.gov/show/NCT04313127","https://ClinicalTrials.gov/show/NCT04288102","https://ClinicalTrials.gov/show/NCT04303299","https://ClinicalTrials.gov/show/NCT04286503","https://ClinicalTrials.gov/show/NCT04336657","https://ClinicalTrials.gov/show/NCT04329507","https://ClinicalTrials.gov/show/NCT04355533","https://ClinicalTrials.gov/show/NCT04351581","https://ClinicalTrials.gov/show/NCT04351243","https://ClinicalTrials.gov/show/NCT04339816","https://ClinicalTrials.gov/show/NCT04347980","https://ClinicalTrials.gov/show/NCT04343339","https://ClinicalTrials.gov/show/NCT04333472","https://ClinicalTrials.gov/show/NCT04350736","https://ClinicalTrials.gov/show/NCT04357808","https://ClinicalTrials.gov/show/NCT04293692","https://ClinicalTrials.gov/show/NCT04345315","https://ClinicalTrials.gov/show/NCT04344431","https://ClinicalTrials.gov/show/NCT04345276","https://ClinicalTrials.gov/show/NCT04291729","https://ClinicalTrials.gov/show/NCT04353336","https://ClinicalTrials.gov/show/NCT04341688","https://ClinicalTrials.gov/show/NCT04355247","https://ClinicalTrials.gov/show/NCT04353674","https://ClinicalTrials.gov/show/NCT04338828","https://ClinicalTrials.gov/show/NCT04335305","https://ClinicalTrials.gov/show/NCT04353180","https://ClinicalTrials.gov/show/NCT04273321","https://ClinicalTrials.gov/show/NCT04347538","https://ClinicalTrials.gov/show/NCT04355026","https://ClinicalTrials.gov/show/NCT04338360","https://ClinicalTrials.gov/show/NCT04355715","https://ClinicalTrials.gov/show/NCT04343976","https://ClinicalTrials.gov/show/NCT04341142","https://ClinicalTrials.gov/show/NCT04349631","https://ClinicalTrials.gov/show/NCT04334252","https://ClinicalTrials.gov/show/NCT04339426","https://ClinicalTrials.gov/show/NCT04353206","https://ClinicalTrials.gov/show/NCT04354584","https://ClinicalTrials.gov/show/NCT04343794","https://ClinicalTrials.gov/show/NCT04341103","https://ClinicalTrials.gov/show/NCT04341285","https://ClinicalTrials.gov/show/NCT04331665","https://ClinicalTrials.gov/show/NCT04352491","https://ClinicalTrials.gov/show/NCT04318444","https://ClinicalTrials.gov/show/NCT04344730","https://ClinicalTrials.gov/show/NCT04357574","https://ClinicalTrials.gov/show/NCT04352751","https://ClinicalTrials.gov/show/NCT04318015","https://ClinicalTrials.gov/show/NCT04341038","https://ClinicalTrials.gov/show/NCT04356677","https://ClinicalTrials.gov/show/NCT04350320","https://ClinicalTrials.gov/show/NCT04328272","https://ClinicalTrials.gov/show/NCT04352764","https://ClinicalTrials.gov/show/NCT04327531","https://ClinicalTrials.gov/show/NCT04348474","https://ClinicalTrials.gov/show/NCT04338568","https://ClinicalTrials.gov/show/NCT04350580","https://ClinicalTrials.gov/show/NCT03891420","https://ClinicalTrials.gov/show/NCT04336774","https://ClinicalTrials.gov/show/NCT04349202","https://ClinicalTrials.gov/show/NCT04323345","https://ClinicalTrials.gov/show/NCT04348877","https://ClinicalTrials.gov/show/NCT04355897","https://ClinicalTrials.gov/show/NCT04344756","https://ClinicalTrials.gov/show/NCT04344782","https://ClinicalTrials.gov/show/NCT04357327","https://ClinicalTrials.gov/show/NCT04335019","https://ClinicalTrials.gov/show/NCT04342663","https://ClinicalTrials.gov/show/NCT04354519","https://ClinicalTrials.gov/show/NCT04347278","https://ClinicalTrials.gov/show/NCT04351711","https://ClinicalTrials.gov/show/NCT04343001","https://ClinicalTrials.gov/show/NCT04348500","https://ClinicalTrials.gov/show/NCT04344288","https://ClinicalTrials.gov/show/NCT04356534","https://ClinicalTrials.gov/show/NCT04348383","https://ClinicalTrials.gov/show/NCT04334291","https://ClinicalTrials.gov/show/NCT04323644","https://ClinicalTrials.gov/show/NCT04341870","https://ClinicalTrials.gov/show/NCT04352400","https://ClinicalTrials.gov/show/NCT04352842","https://ClinicalTrials.gov/show/NCT04344951","https://ClinicalTrials.gov/show/NCT04358029","https://ClinicalTrials.gov/show/NCT04261517","https://ClinicalTrials.gov/show/NCT04251767","https://ClinicalTrials.gov/show/NCT04330144","https://ClinicalTrials.gov/show/NCT04347824","https://ClinicalTrials.gov/show/NCT04347681","https://ClinicalTrials.gov/show/NCT04354753","https://ClinicalTrials.gov/show/NCT04343144","https://ClinicalTrials.gov/show/NCT04348513","https://ClinicalTrials.gov/show/NCT04299724","https://ClinicalTrials.gov/show/NCT04342104","https://ClinicalTrials.gov/show/NCT04356586","https://ClinicalTrials.gov/show/NCT04346264","https://ClinicalTrials.gov/show/NCT04346797","https://ClinicalTrials.gov/show/NCT04338958","https://ClinicalTrials.gov/show/NCT04347928","https://ClinicalTrials.gov/show/NCT04257656","https://ClinicalTrials.gov/show/NCT04338126","https://ClinicalTrials.gov/show/NCT04343092","https://ClinicalTrials.gov/show/NCT04298814","https://ClinicalTrials.gov/show/NCT04335097","https://ClinicalTrials.gov/show/NCT04324190","https://ClinicalTrials.gov/show/NCT04354610","https://ClinicalTrials.gov/show/NCT04334850","https://ClinicalTrials.gov/show/NCT04348305","https://ClinicalTrials.gov/show/NCT04335071","https://ClinicalTrials.gov/show/NCT04355364","https://ClinicalTrials.gov/show/NCT04349540","https://ClinicalTrials.gov/show/NCT04333693","https://ClinicalTrials.gov/show/NCT04352803","https://ClinicalTrials.gov/show/NCT04276896","https://ClinicalTrials.gov/show/NCT04353011","https://ClinicalTrials.gov/show/NCT04351633","https://ClinicalTrials.gov/show/NCT04343963","https://ClinicalTrials.gov/show/NCT04349410","https://ClinicalTrials.gov/show/NCT04354428","https://ClinicalTrials.gov/show/NCT04351490","https://ClinicalTrials.gov/show/NCT04341415","https://ClinicalTrials.gov/show/NCT04333862","https://ClinicalTrials.gov/show/NCT04333953","https://ClinicalTrials.gov/show/NCT04358042","https://ClinicalTrials.gov/show/NCT04322188","https://ClinicalTrials.gov/show/NCT04323514","https://ClinicalTrials.gov/show/NCT04345653","https://ClinicalTrials.gov/show/NCT04304690","https://ClinicalTrials.gov/show/NCT04342195","https://ClinicalTrials.gov/show/NCT04356508","https://ClinicalTrials.gov/show/NCT04356937","https://ClinicalTrials.gov/show/NCT04316299","https://ClinicalTrials.gov/show/NCT04341207","https://ClinicalTrials.gov/show/NCT04336345","https://ClinicalTrials.gov/show/NCT04318431","https://ClinicalTrials.gov/show/NCT04329546","https://ClinicalTrials.gov/show/NCT04353271","https://ClinicalTrials.gov/show/NCT04344002","https://ClinicalTrials.gov/show/NCT04334460","https://ClinicalTrials.gov/show/NCT04355351","https://ClinicalTrials.gov/show/NCT04351919","https://ClinicalTrials.gov/show/NCT04341441","https://ClinicalTrials.gov/show/NCT04333914","https://ClinicalTrials.gov/show/NCT04357457","https://ClinicalTrials.gov/show/NCT04355494","https://ClinicalTrials.gov/show/NCT04344938","https://ClinicalTrials.gov/show/NCT04320017","https://ClinicalTrials.gov/show/NCT04336384","https://ClinicalTrials.gov/show/NCT04352959","https://ClinicalTrials.gov/show/NCT04357834","https://ClinicalTrials.gov/show/NCT04330300","https://ClinicalTrials.gov/show/NCT04350086","https://ClinicalTrials.gov/show/NCT04351191","https://ClinicalTrials.gov/show/NCT04347694","https://ClinicalTrials.gov/show/NCT04331574","https://ClinicalTrials.gov/show/NCT04321265","https://ClinicalTrials.gov/show/NCT04328961","https://ClinicalTrials.gov/show/NCT04357782","https://ClinicalTrials.gov/show/NCT04327206","https://ClinicalTrials.gov/show/NCT04333732","https://ClinicalTrials.gov/show/NCT04326790","https://ClinicalTrials.gov/show/NCT04345601","https://ClinicalTrials.gov/show/NCT04339712","https://ClinicalTrials.gov/show/NCT04331054","https://ClinicalTrials.gov/show/NCT04292964","https://ClinicalTrials.gov/show/NCT04344184","https://ClinicalTrials.gov/show/NCT04338698","https://ClinicalTrials.gov/show/NCT04337346","https://ClinicalTrials.gov/show/NCT04325646","https://ClinicalTrials.gov/show/NCT04346212","https://ClinicalTrials.gov/show/NCT04335786","https://ClinicalTrials.gov/show/NCT04342806","https://ClinicalTrials.gov/show/NCT04345848","https://ClinicalTrials.gov/show/NCT04335552","https://ClinicalTrials.gov/show/NCT04337320","https://ClinicalTrials.gov/show/NCT04357860","https://ClinicalTrials.gov/show/NCT04357106","https://ClinicalTrials.gov/show/NCT04341792","https://ClinicalTrials.gov/show/NCT04338009","https://ClinicalTrials.gov/show/NCT04334265","https://ClinicalTrials.gov/show/NCT04334148","https://ClinicalTrials.gov/show/NCT04333589","https://ClinicalTrials.gov/show/NCT04328480","https://ClinicalTrials.gov/show/NCT04311398","https://ClinicalTrials.gov/show/NCT04310228","https://ClinicalTrials.gov/show/NCT04302519","https://ClinicalTrials.gov/show/NCT04295551","https://ClinicalTrials.gov/show/NCT04356495","https://ClinicalTrials.gov/show/NCT04346667","https://ClinicalTrials.gov/show/NCT04278963","https://ClinicalTrials.gov/show/NCT04351854","https://ClinicalTrials.gov/show/NCT04357028","https://ClinicalTrials.gov/show/NCT04354441","https://ClinicalTrials.gov/show/NCT04303507","https://ClinicalTrials.gov/show/NCT04347941","https://ClinicalTrials.gov/show/NCT04347226","https://ClinicalTrials.gov/show/NCT04356482","https://ClinicalTrials.gov/show/NCT04328012","https://ClinicalTrials.gov/show/NCT04320472","https://ClinicalTrials.gov/show/NCT04272710","https://ClinicalTrials.gov/show/NCT04357418","https://ClinicalTrials.gov/show/NCT04335032","https://ClinicalTrials.gov/show/NCT04273763","https://ClinicalTrials.gov/show/NCT04352946","https://ClinicalTrials.gov/show/NCT04355611","https://ClinicalTrials.gov/show/NCT04331613","https://ClinicalTrials.gov/show/NCT04346810","https://ClinicalTrials.gov/show/NCT04310865","https://ClinicalTrials.gov/show/NCT04351789","https://ClinicalTrials.gov/show/NCT04351399","https://ClinicalTrials.gov/show/NCT04324021","https://ClinicalTrials.gov/show/NCT04344600","https://ClinicalTrials.gov/show/NCT04319445","https://ClinicalTrials.gov/show/NCT04357496","https://ClinicalTrials.gov/show/NCT04339998","https://ClinicalTrials.gov/show/NCT04323761","https://ClinicalTrials.gov/show/NCT04350450","https://ClinicalTrials.gov/show/NCT04319731","https://ClinicalTrials.gov/show/NCT04334967","https://ClinicalTrials.gov/show/NCT04321928","https://ClinicalTrials.gov/show/NCT04355481","https://ClinicalTrials.gov/show/NCT04342884","https://ClinicalTrials.gov/show/NCT04357366","https://ClinicalTrials.gov/show/NCT04349982","https://ClinicalTrials.gov/show/NCT04341766","https://ClinicalTrials.gov/show/NCT04336215","https://ClinicalTrials.gov/show/NCT04270383","https://ClinicalTrials.gov/show/NCT04298060","https://ClinicalTrials.gov/show/NCT04355728","https://ClinicalTrials.gov/show/NCT04348864","https://ClinicalTrials.gov/show/NCT04334954","https://ClinicalTrials.gov/show/NCT04332991","https://ClinicalTrials.gov/show/NCT04357275","https://ClinicalTrials.gov/show/NCT04340050","https://ClinicalTrials.gov/show/NCT04320511","https://ClinicalTrials.gov/show/NCT04352517","https://ClinicalTrials.gov/show/NCT04324528","https://ClinicalTrials.gov/show/NCT04336787","https://ClinicalTrials.gov/show/NCT04343651","https://ClinicalTrials.gov/show/NCT04285190","https://ClinicalTrials.gov/show/NCT04324606","https://ClinicalTrials.gov/show/NCT04325048","https://ClinicalTrials.gov/show/NCT04323878","https://ClinicalTrials.gov/show/NCT04356950","https://ClinicalTrials.gov/show/NCT04358003","https://ClinicalTrials.gov/show/NCT04351503","https://ClinicalTrials.gov/show/NCT04356443","https://ClinicalTrials.gov/show/NCT04344379","https://ClinicalTrials.gov/show/NCT04355962","https://ClinicalTrials.gov/show/NCT04354818","https://ClinicalTrials.gov/show/NCT04347239","https://ClinicalTrials.gov/show/NCT04349618","https://ClinicalTrials.gov/show/NCT04323800","https://ClinicalTrials.gov/show/NCT04321096","https://ClinicalTrials.gov/show/NCT04351139","https://ClinicalTrials.gov/show/NCT04332380","https://ClinicalTrials.gov/show/NCT04332666","https://ClinicalTrials.gov/show/NCT04268537","https://ClinicalTrials.gov/show/NCT04349098","https://ClinicalTrials.gov/show/NCT04330495","https://ClinicalTrials.gov/show/NCT04325412","https://ClinicalTrials.gov/show/NCT04339881","https://ClinicalTrials.gov/show/NCT04334928","https://ClinicalTrials.gov/show/NCT04355676","https://ClinicalTrials.gov/show/NCT04357639","https://ClinicalTrials.gov/show/NCT04346277","https://ClinicalTrials.gov/show/NCT04353128","https://ClinicalTrials.gov/show/NCT04329533","https://ClinicalTrials.gov/show/NCT04323787","https://ClinicalTrials.gov/show/NCT04332835","https://ClinicalTrials.gov/show/NCT04334876","https://ClinicalTrials.gov/show/NCT04352556","https://ClinicalTrials.gov/show/NCT04306705","https://ClinicalTrials.gov/show/NCT04337424","https://ClinicalTrials.gov/show/NCT04312100","https://ClinicalTrials.gov/show/NCT04312009","https://ClinicalTrials.gov/show/NCT04313946","https://ClinicalTrials.gov/show/NCT04315948","https://ClinicalTrials.gov/show/NCT04323839","https://ClinicalTrials.gov/show/NCT04311177","https://ClinicalTrials.gov/show/NCT04335084","https://ClinicalTrials.gov/show/NCT04353609","https://ClinicalTrials.gov/show/NCT04337788","https://ClinicalTrials.gov/show/NCT04261426","https://ClinicalTrials.gov/show/NCT04350099","https://ClinicalTrials.gov/show/NCT04332016","https://ClinicalTrials.gov/show/NCT04255017","https://ClinicalTrials.gov/show/NCT04354779","https://ClinicalTrials.gov/show/NCT04254874","https://ClinicalTrials.gov/show/NCT04340466","https://ClinicalTrials.gov/show/NCT04316949","https://ClinicalTrials.gov/show/NCT04348929","https://ClinicalTrials.gov/show/NCT04275414","https://ClinicalTrials.gov/show/NCT04357340","https://ClinicalTrials.gov/show/NCT04341935","https://ClinicalTrials.gov/show/NCT04339387","https://ClinicalTrials.gov/show/NCT04343053","https://ClinicalTrials.gov/show/NCT04261270","https://ClinicalTrials.gov/show/NCT04342169","https://ClinicalTrials.gov/show/NCT04357938","https://ClinicalTrials.gov/show/NCT04332042","https://ClinicalTrials.gov/show/NCT04353401","https://ClinicalTrials.gov/show/NCT04329195","https://ClinicalTrials.gov/show/NCT04316728","https://ClinicalTrials.gov/show/NCT04321616","https://ClinicalTrials.gov/show/NCT04311697","https://ClinicalTrials.gov/show/NCT04327349","https://ClinicalTrials.gov/show/NCT04357730","https://ClinicalTrials.gov/show/NCT04328129","https://ClinicalTrials.gov/show/NCT04263402","https://ClinicalTrials.gov/show/NCT04343261","https://ClinicalTrials.gov/show/NCT04341480","https://ClinicalTrials.gov/show/NCT04340349","https://ClinicalTrials.gov/show/NCT04252274","https://ClinicalTrials.gov/show/NCT02735707","https://ClinicalTrials.gov/show/NCT04327505","https://ClinicalTrials.gov/show/NCT03042143","https://ClinicalTrials.gov/show/NCT04256395","https://ClinicalTrials.gov/show/NCT04325919","https://ClinicalTrials.gov/show/NCT04345159","https://ClinicalTrials.gov/show/NCT04324866","https://ClinicalTrials.gov/show/NCT04305457","https://ClinicalTrials.gov/show/NCT04324463","https://ClinicalTrials.gov/show/NCT04347512","https://ClinicalTrials.gov/show/NCT04333368","https://ClinicalTrials.gov/show/NCT04327570","https://ClinicalTrials.gov/show/NCT04320277","https://ClinicalTrials.gov/show/NCT04348695","https://ClinicalTrials.gov/show/NCT04354259","https://ClinicalTrials.gov/show/NCT04339322","https://ClinicalTrials.gov/show/NCT04325867","https://ClinicalTrials.gov/show/NCT04342156","https://ClinicalTrials.gov/show/NCT04352634","https://ClinicalTrials.gov/show/NCT04347382","https://ClinicalTrials.gov/show/NCT04358081","https://ClinicalTrials.gov/show/NCT04355442","https://ClinicalTrials.gov/show/NCT04338100","https://ClinicalTrials.gov/show/NCT04349228","https://ClinicalTrials.gov/show/NCT04342650","https://ClinicalTrials.gov/show/NCT04339790","https://ClinicalTrials.gov/show/NCT04327401","https://ClinicalTrials.gov/show/NCT04356378","https://ClinicalTrials.gov/show/NCT04279197","https://ClinicalTrials.gov/show/NCT04284046","https://ClinicalTrials.gov/show/NCT04280705","https://ClinicalTrials.gov/show/NCT04345861","https://ClinicalTrials.gov/show/NCT04345614","https://ClinicalTrials.gov/show/NCT04349592","https://ClinicalTrials.gov/show/NCT04344210","https://ClinicalTrials.gov/show/NCT04322487","https://ClinicalTrials.gov/show/NCT04321174","https://ClinicalTrials.gov/show/NCT04318314","https://ClinicalTrials.gov/show/NCT04323592","https://ClinicalTrials.gov/show/NCT04354155","https://ClinicalTrials.gov/show/NCT04335747","https://ClinicalTrials.gov/show/NCT04335188","https://ClinicalTrials.gov/show/NCT04335773","https://ClinicalTrials.gov/show/NCT04355429","https://ClinicalTrials.gov/show/NCT04334629","https://ClinicalTrials.gov/show/NCT04354558","https://ClinicalTrials.gov/show/NCT04340219","https://ClinicalTrials.gov/show/NCT04357431","https://ClinicalTrials.gov/show/NCT04356885","https://ClinicalTrials.gov/show/NCT04264858","https://ClinicalTrials.gov/show/NCT04321811","https://ClinicalTrials.gov/show/NCT04339634","https://ClinicalTrials.gov/show/NCT04348227","https://ClinicalTrials.gov/show/NCT04344249","https://ClinicalTrials.gov/show/NCT04353583","https://ClinicalTrials.gov/show/NCT04351295","https://ClinicalTrials.gov/show/NCT04357769","https://ClinicalTrials.gov/show/NCT04337502","https://ClinicalTrials.gov/show/NCT04326452","https://ClinicalTrials.gov/show/NCT04356365","https://ClinicalTrials.gov/show/NCT04335162","https://ClinicalTrials.gov/show/NCT04312243","https://ClinicalTrials.gov/show/NCT04335279","https://ClinicalTrials.gov/show/NCT04322565","https://ClinicalTrials.gov/show/NCT04344197","https://ClinicalTrials.gov/show/NCT04357041","https://ClinicalTrials.gov/show/NCT04355624","https://ClinicalTrials.gov/show/NCT04341012","https://ClinicalTrials.gov/show/NCT04337047","https://ClinicalTrials.gov/show/NCT04306055","https://ClinicalTrials.gov/show/NCT04351516","https://ClinicalTrials.gov/show/NCT04357613","https://ClinicalTrials.gov/show/NCT04320732","https://ClinicalTrials.gov/show/NCT04340414","https://ClinicalTrials.gov/show/NCT04337008","https://ClinicalTrials.gov/show/NCT04331886","https://ClinicalTrials.gov/show/NCT04293887","https://ClinicalTrials.gov/show/NCT04340921","https://ClinicalTrials.gov/show/NCT04333654","https://ClinicalTrials.gov/show/NCT04320238","https://ClinicalTrials.gov/show/NCT04338945","https://ClinicalTrials.gov/show/NCT04346420","https://ClinicalTrials.gov/show/NCT04337489","https://ClinicalTrials.gov/show/NCT04296643","https://ClinicalTrials.gov/show/NCT04343898","https://ClinicalTrials.gov/show/NCT04351347","https://ClinicalTrials.gov/show/NCT04346342","https://ClinicalTrials.gov/show/NCT04319016","https://ClinicalTrials.gov/show/NCT04344561","https://ClinicalTrials.gov/show/NCT04346186","https://ClinicalTrials.gov/show/NCT04302688","https://ClinicalTrials.gov/show/NCT04316884","https://ClinicalTrials.gov/show/NCT04347408","https://ClinicalTrials.gov/show/NCT04357314","https://ClinicalTrials.gov/show/NCT04333849","https://ClinicalTrials.gov/show/NCT04348461","https://ClinicalTrials.gov/show/NCT04279899","https://ClinicalTrials.gov/show/NCT04290871","https://ClinicalTrials.gov/show/NCT04092478","https://ClinicalTrials.gov/show/NCT04337151","https://ClinicalTrials.gov/show/NCT03808922","https://ClinicalTrials.gov/show/NCT04341493","https://ClinicalTrials.gov/show/NCT04315480","https://ClinicalTrials.gov/show/NCT04340479","https://ClinicalTrials.gov/show/NCT04328454","https://ClinicalTrials.gov/show/NCT04346446","https://ClinicalTrials.gov/show/NCT04327804","https://ClinicalTrials.gov/show/NCT04345640","https://ClinicalTrials.gov/show/NCT04325906","https://ClinicalTrials.gov/show/NCT04344964","https://ClinicalTrials.gov/show/NCT04327388","https://ClinicalTrials.gov/show/NCT04346628","https://ClinicalTrials.gov/show/NCT04344535","https://ClinicalTrials.gov/show/NCT04338906","https://ClinicalTrials.gov/show/NCT04325893","https://ClinicalTrials.gov/show/NCT04326725","https://ClinicalTrials.gov/show/NCT04341714","https://ClinicalTrials.gov/show/NCT04321369","https://ClinicalTrials.gov/show/NCT04292340","https://ClinicalTrials.gov/show/NCT04346082","https://ClinicalTrials.gov/show/NCT04326114","https://ClinicalTrials.gov/show/NCT04326387","https://ClinicalTrials.gov/show/NCT04322123","https://ClinicalTrials.gov/show/NCT04346953","https://ClinicalTrials.gov/show/NCT04324047","https://ClinicalTrials.gov/show/NCT04346589","https://ClinicalTrials.gov/show/NCT04315870","https://ClinicalTrials.gov/show/NCT04342702","https://ClinicalTrials.gov/show/NCT04351906","https://ClinicalTrials.gov/show/NCT04337918","https://ClinicalTrials.gov/show/NCT04326036","https://ClinicalTrials.gov/show/NCT04344548","https://ClinicalTrials.gov/show/NCT04322396","https://ClinicalTrials.gov/show/NCT04346693","https://ClinicalTrials.gov/show/NCT04341610","https://ClinicalTrials.gov/show/NCT04352699","https://ClinicalTrials.gov/show/NCT04341519","https://ClinicalTrials.gov/show/NCT04274322","https://ClinicalTrials.gov/show/NCT04324073","https://ClinicalTrials.gov/show/NCT04343664","https://ClinicalTrials.gov/show/NCT04344041","https://ClinicalTrials.gov/show/NCT04345289","https://ClinicalTrials.gov/show/NCT04321278","https://ClinicalTrials.gov/show/NCT04353037","https://ClinicalTrials.gov/show/NCT04344912","https://ClinicalTrials.gov/show/NCT04320056","https://ClinicalTrials.gov/show/NCT04260594","https://ClinicalTrials.gov/show/NCT04314232","https://ClinicalTrials.gov/show/NCT04336748","https://ClinicalTrials.gov/show/NCT04330261","https://ClinicalTrials.gov/show/NCT04347460","https://ClinicalTrials.gov/show/NCT04326426","https://ClinicalTrials.gov/show/NCT04327180","https://ClinicalTrials.gov/show/NCT04338672","https://ClinicalTrials.gov/show/NCT04357847","https://ClinicalTrials.gov/show/NCT04345406","https://ClinicalTrials.gov/show/NCT04341922","https://ClinicalTrials.gov/show/NCT04334434","https://ClinicalTrials.gov/show/NCT04320862","https://ClinicalTrials.gov/show/NCT04355884","https://ClinicalTrials.gov/show/NCT04345549","https://ClinicalTrials.gov/show/NCT04344834","https://ClinicalTrials.gov/show/NCT04290858","https://ClinicalTrials.gov/show/NCT04324736","https://ClinicalTrials.gov/show/NCT04283461","https://ClinicalTrials.gov/show/NCT04344327","https://ClinicalTrials.gov/show/NCT04346160","https://ClinicalTrials.gov/show/NCT04354766","https://ClinicalTrials.gov/show/NCT04354792","https://ClinicalTrials.gov/show/NCT04355702","https://ClinicalTrials.gov/show/NCT04280224","https://ClinicalTrials.gov/show/NCT04290780","https://ClinicalTrials.gov/show/NCT04288713","https://ClinicalTrials.gov/show/NCT04343404","https://ClinicalTrials.gov/show/NCT04322513","https://ClinicalTrials.gov/show/NCT04318366","https://ClinicalTrials.gov/show/NCT04345887","https://ClinicalTrials.gov/show/NCT04320953","https://ClinicalTrials.gov/show/NCT04338802","https://ClinicalTrials.gov/show/NCT04299152","https://ClinicalTrials.gov/show/NCT04308187","https://ClinicalTrials.gov/show/NCT04322344","https://ClinicalTrials.gov/show/NCT04306393","https://ClinicalTrials.gov/show/NCT04322773","https://ClinicalTrials.gov/show/NCT04324684","https://ClinicalTrials.gov/show/NCT04337983","https://ClinicalTrials.gov/show/NCT04346329","https://ClinicalTrials.gov/show/NCT04336410","https://ClinicalTrials.gov/show/NCT04345419","https://ClinicalTrials.gov/show/NCT04354272","https://ClinicalTrials.gov/show/NCT04336761","https://ClinicalTrials.gov/show/NCT04355637","https://ClinicalTrials.gov/show/NCT04322786","https://ClinicalTrials.gov/show/NCT04351542","https://ClinicalTrials.gov/show/NCT04344119","https://ClinicalTrials.gov/show/NCT04342208","https://ClinicalTrials.gov/show/NCT04347798","https://ClinicalTrials.gov/show/NCT04344106","https://ClinicalTrials.gov/show/NCT04352985","https://ClinicalTrials.gov/show/NCT04349371","https://ClinicalTrials.gov/show/NCT04327479","https://ClinicalTrials.gov/show/NCT04305574","https://ClinicalTrials.gov/show/NCT04347031","https://ClinicalTrials.gov/show/NCT04279795","https://ClinicalTrials.gov/show/NCT04279782","https://ClinicalTrials.gov/show/NCT04350281","https://ClinicalTrials.gov/show/NCT04355234","https://ClinicalTrials.gov/show/NCT04343729","https://ClinicalTrials.gov/show/NCT04341584","https://ClinicalTrials.gov/show/NCT04292327","https://ClinicalTrials.gov/show/NCT04340557","https://ClinicalTrials.gov/show/NCT04269525","https://ClinicalTrials.gov/show/NCT04261907","https://ClinicalTrials.gov/show/NCT04325672","https://ClinicalTrials.gov/show/NCT04326075","https://ClinicalTrials.gov/show/NCT04337190","https://ClinicalTrials.gov/show/NCT04061382","https://ClinicalTrials.gov/show/NCT04264533","https://ClinicalTrials.gov/show/NCT04338841","https://ClinicalTrials.gov/show/NCT04323527","https://ClinicalTrials.gov/show/NCT04349163","https://ClinicalTrials.gov/show/NCT04275388","https://ClinicalTrials.gov/show/NCT04348370","https://ClinicalTrials.gov/show/NCT04302766","https://ClinicalTrials.gov/show/NCT04342728","https://ClinicalTrials.gov/show/NCT04245631","https://ClinicalTrials.gov/show/NCT04350710","https://ClinicalTrials.gov/show/NCT03331445","https://ClinicalTrials.gov/show/NCT04322682","https://ClinicalTrials.gov/show/NCT04335630","https://ClinicalTrials.gov/show/NCT04255940","https://ClinicalTrials.gov/show/NCT04281693","https://ClinicalTrials.gov/show/NCT04356833","https://ClinicalTrials.gov/show/NCT04344509","https://ClinicalTrials.gov/show/NCT04259892","https://ClinicalTrials.gov/show/NCT04251871","https://ClinicalTrials.gov/show/NCT04260308","https://ClinicalTrials.gov/show/NCT04275245","https://ClinicalTrials.gov/show/NCT04307459","https://ClinicalTrials.gov/show/NCT04322279","https://ClinicalTrials.gov/show/NCT04339686","https://ClinicalTrials.gov/show/NCT04355052","https://ClinicalTrials.gov/show/NCT04341727","https://ClinicalTrials.gov/show/NCT04335851","https://ClinicalTrials.gov/show/NCT04346927","https://ClinicalTrials.gov/show/NCT04319211","https://ClinicalTrials.gov/show/NCT04331808","https://ClinicalTrials.gov/show/NCT04353154","https://ClinicalTrials.gov/show/NCT04328467","https://ClinicalTrials.gov/show/NCT04351724","https://ClinicalTrials.gov/show/NCT04353245","https://ClinicalTrials.gov/show/NCT04280913","https://ClinicalTrials.gov/show/NCT04333251","https://ClinicalTrials.gov/show/NCT04357886","https://ClinicalTrials.gov/show/NCT04353141","https://ClinicalTrials.gov/show/NCT03852537","https://ClinicalTrials.gov/show/NCT04333875","https://ClinicalTrials.gov/show/NCT04316377","https://ClinicalTrials.gov/show/NCT04276688","https://ClinicalTrials.gov/show/NCT04356144","https://ClinicalTrials.gov/show/NCT04346940","https://ClinicalTrials.gov/show/NCT04319172","https://ClinicalTrials.gov/show/NCT03680274","https://ClinicalTrials.gov/show/NCT04326309","https://ClinicalTrials.gov/show/NCT04346966","https://ClinicalTrials.gov/show/NCT04308668","https://ClinicalTrials.gov/show/NCT04351880","https://ClinicalTrials.gov/show/NCT04262921","https://ClinicalTrials.gov/show/NCT04329897","https://ClinicalTrials.gov/show/NCT04346979","https://ClinicalTrials.gov/show/NCT04339842","https://ClinicalTrials.gov/show/NCT04276987"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Rank<\/th>\n      <th>NCT Number<\/th>\n      <th>Title<\/th>\n      <th>Acronym<\/th>\n      <th>Status<\/th>\n      <th>Study Results<\/th>\n      <th>Conditions<\/th>\n      <th>Interventions<\/th>\n      <th>Outcome Measures<\/th>\n      <th>Sponsor/Collaborators<\/th>\n      <th>Gender<\/th>\n      <th>Age<\/th>\n      <th>Phases<\/th>\n      <th>Enrollment<\/th>\n      <th>Funded Bys<\/th>\n      <th>Study Type<\/th>\n      <th>Study Designs<\/th>\n      <th>Other IDs<\/th>\n      <th>Start Date<\/th>\n      <th>Primary Completion Date<\/th>\n      <th>Completion Date<\/th>\n      <th>First Posted<\/th>\n      <th>Results First Posted<\/th>\n      <th>Last Update Posted<\/th>\n      <th>Locations<\/th>\n      <th>Study Documents<\/th>\n      <th>URL<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"columnDefs":[{"className":"dt-right","targets":[1,14]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados-china" class="section level3">
<h3>Dados China</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-05dde889b8d38df96458" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-05dde889b8d38df96458">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"date\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"1579737600000\" data-max=\"1587686400000\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","extensions":["Buttons"],"fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621","622","623","624","625","626","627","628","629","630","631","632","633","634","635","636","637","638","639","640","641","642","643","644","645","646","647","648","649","650","651","652","653","654","655","656","657","658","659","660","661","662","663","664","665","666"],["ChiCTR2000032242","ChiCTR2000032239","ChiCTR2000032237","ChiCTR2000032233","ChiCTR2000032214","ChiCTR2000032213","ChiCTR2000032205","ChiCTR2000032165","ChiCTR2000032162","ChiCTR2000032161","ChiCTR2000032165","ChiCTR2000032162","ChiCTR2000032161","ChiCTR2000032165","ChiCTR2000032162","ChiCTR2000032161","ChiCTR2000032135","ChiCTR2000032135","ChiCTR2000032135","ChiCTR2000032098","ChiCTR2000032098","ChiCTR2000032098","ChiCTR2000032040","ChiCTR2000032040","ChiCTR2000032040","ChiCTR2000032013","ChiCTR2000032011","ChiCTR2000032010","ChiCTR2000032009","ChiCTR2000032013","ChiCTR2000032011","ChiCTR2000032010","ChiCTR2000032009","ChiCTR2000032013","ChiCTR2000032011","ChiCTR2000032010","ChiCTR2000032009","ChiCTR2000031982","ChiCTR2000031955","ChiCTR2000031954","ChiCTR2000031982","ChiCTR2000031955","ChiCTR2000031954","ChiCTR2000031982","ChiCTR2000031955","ChiCTR2000031954","ChiCTR2000031944","ChiCTR2000031930","ChiCTR2000031944","ChiCTR2000031930","ChiCTR2000031944","ChiCTR2000031930","ChiCTR2000031928","ChiCTR2000031896","ChiCTR2000031928","ChiCTR2000031896","ChiCTR2000031928","ChiCTR2000031896","ChiCTR2000031888","ChiCTR2000031888","ChiCTR2000031888","ChiCTR2000031860","ChiCTR2000031834","ChiCTR2000031836","ChiCTR2000031809","ChiCTR2000031809","ChiCTR2000031809","ChiCTR2000031794","ChiCTR2000031783","ChiCTR2000031782","ChiCTR2000031781","ChiCTR2000031779","ChiCTR2000031772","ChiCTR2000031770","ChiCTR2000031752","ChiCTR2000031751","ChiCTR2000031735","ChiCTR2000031734","ChiCTR2000031712","ChiCTR2000031707","ChiCTR2000031705","ChiCTR2000031700","ChiCTR2000031699","ChiCTR2000031672","ChiCTR2000031675","ChiCTR2000031630","ChiCTR2000031589","ChiCTR2000031627","ChiCTR2000031639","ChiCTR2000031587","ChiCTR2000031533","ChiCTR2000031539","ChiCTR2000031540","ChiCTR2000031538","ChiCTR2000031504","ChiCTR2000031503","ChiCTR2000031499","ChiCTR2000031494","ChiCTR2000031465","ChiCTR2000031501","ChiCTR2000031500","ChiCTR2000031453","ChiCTR2000031438","ChiCTR2000031454","ChiCTR2000031439","ChiCTR2000031429","ChiCTR2000031427","ChiCTR2000031428","ChiCTR2000031432","ChiCTR2000031430","ChiCTR2000031366","ChiCTR2000031365","ChiCTR2000031376","ChiCTR2000031356","ChiCTR2000031361","ChiCTR2000031336","ChiCTR2000031337","ChiCTR2000031330","ChiCTR2000031329","ChiCTR2000031319","ChiCTR2000031324","ChiCTR2000031328","ChiCTR2000031327","ChiCTR2000031301","ChiCTR2000031296","ChiCTR2000031293","ChiCTR2000031272","ChiCTR2000031271","ChiCTR2000031252","ChiCTR2000031245","ChiCTR2000031247","ChiCTR2000031246","ChiCTR2000031244","ChiCTR2000031227","ChiCTR2000031204","ChiCTR2000031203","ChiCTR2000031214","ChiCTR2000031163","ChiCTR2000031150","ChiCTR2000031187","ChiCTR2000031176","ChiCTR2000031198","ChiCTR2000031196","ChiCTR2000031199","ChiCTR2000031115","ChiCTR2000031140","ChiCTR2000031138","ChiCTR2000031104","ChiCTR2000031088","ChiCTR2000031090","ChiCTR2000031139","ChiCTR2000031089","ChiCTR2000031023","ChiCTR2000031014","ChiCTR2000030992","ChiCTR2000030989","ChiCTR2000030996","ChiCTR2000030986","ChiCTR2000030961","ChiCTR2000030993","ChiCTR2000030987","ChiCTR2000030985","ChiCTR2000030962","ChiCTR2000030988","ChiCTR2000030947","ChiCTR2000030946","ChiCTR2000030952","ChiCTR2000030950","ChiCTR2000030951","ChiCTR2000030941","ChiCTR2000030939","ChiCTR2000030933","ChiCTR2000030932","ChiCTR2000030943","ChiCTR2000030934","ChiCTR2000030931","ChiCTR2000030944","ChiCTR2000030942","ChiCTR2000030940","ChiCTR2000030938","ChiCTR2000030936","ChiCTR2000030937","ChiCTR2000030922","ChiCTR2000030906","ChiCTR2000030929","ChiCTR2000030920","ChiCTR2000030919","ChiCTR2000030923","ChiCTR2000030896","ChiCTR2000030895","ChiCTR2000030894","ChiCTR2000030902","ChiCTR2000030893","ChiCTR2000030863","ChiCTR2000030897","ChiCTR2000030862","ChiCTR2000030861","ChiCTR2000030901","ChiCTR2000030854","ChiCTR2000030853","ChiCTR2000030852","ChiCTR2000030892","ChiCTR2000030883","ChiCTR2000030860","ChiCTR2000030865","ChiCTR2000030858","ChiCTR2000030856","ChiCTR2000030898","ChiCTR2000030866","ChiCTR2000030864","ChiCTR2000030859","ChiCTR2000030857","ChiCTR2000030855","ChiCTR2000030812","ChiCTR2000030810","ChiCTR2000030809","ChiCTR2000030838","ChiCTR2000030836","ChiCTR2000030849","ChiCTR2000030835","ChiCTR2000030834","ChiCTR2000030833","ChiCTR2000030831","ChiCTR2000030819","ChiCTR2000030818","ChiCTR2000030816","ChiCTR2000030814","ChiCTR2000030795","ChiCTR2000030807","ChiCTR2000030805","ChiCTR2000030803","ChiCTR2000030802","ChiCTR2000030798","ChiCTR2000030796","ChiCTR2000030801","ChiCTR2000030800","ChiCTR2000030850","ChiCTR2000030841","ChiCTR2000030839","ChiCTR2000030832","ChiCTR2000030830","ChiCTR2000030806","ChiCTR2000030804","ChiCTR2000030799","ChiCTR2000030797","ChiCTR2000030817","ChiCTR2000030778","ChiCTR2000030782","ChiCTR2000030773","ChiCTR2000030784","ChiCTR2000030768","ChiCTR2000030779","ChiCTR2000030771","ChiCTR2000030759","ChiCTR2000030758","ChiCTR2000030757","ChiCTR2000030756","ChiCTR2000030764","ChiCTR2000030762","ChiCTR2000030760","ChiCTR2000030755","ChiCTR2000030751","ChiCTR2000030753","ChiCTR2000030744","ChiCTR2000030742","ChiCTR2000030741","ChiCTR2000030740","ChiCTR2000030739","ChiCTR2000030763","ChiCTR2000030761","ChiCTR2000030754","ChiCTR2000030752","ChiCTR2000030747","ChiCTR2000030765","ChiCTR2000030750","ChiCTR2000030721","ChiCTR2000030722","ChiCTR2000030718","ChiCTR2000030717","ChiCTR2000030716","ChiCTR2000030708","ChiCTR2000030707","ChiCTR2000030706","ChiCTR2000030719","ChiCTR2000030720","ChiCTR2000030703","ChiCTR2000030690","ChiCTR2000030701","ChiCTR2000030700","ChiCTR2000030702","ChiCTR2000030697","ChiCTR2000030704","ChiCTR2000030687","ChiCTR2000030683","ChiCTR2000030681","ChiCTR2000030686","ChiCTR2000030679","ChiCTR2000030593","ChiCTR2000030627","ChiCTR2000030581","ChiCTR2000030579","ChiCTR2000030578","ChiCTR2000030580","ChiCTR2000030619","ChiCTR2000030606","ChiCTR2000030597","ChiCTR2000030552","ChiCTR2000030559","ChiCTR2000030557","ChiCTR2000030574","ChiCTR2000030564","ChiCTR2000030556","ChiCTR2000030558","ChiCTR2000030535","ChiCTR2000030522","ChiCTR2000030544","ChiCTR2000030543","ChiCTR2000030541","ChiCTR2000030542","ChiCTR2000030540","ChiCTR2000030545","ChiCTR2000030528","ChiCTR2000030539","ChiCTR2000030503","ChiCTR2000030518","ChiCTR2000030509","ChiCTR2000030519","ChiCTR2000030494","ChiCTR2000030487","ChiCTR2000030493","ChiCTR2000030492","ChiCTR2000030491","ChiCTR2000030490","ChiCTR2000030489","ChiCTR2000030485","ChiCTR2000030472","ChiCTR2000030480","ChiCTR2000030479","ChiCTR2000030477","ChiCTR2000030481","ChiCTR2000030484","ChiCTR2000030482","ChiCTR2000030475","ChiCTR2000030483","ChiCTR2000030478","ChiCTR2000030476","ChiCTR2000030442","ChiCTR2000030471","ChiCTR2000030469","ChiCTR2000030468","ChiCTR2000030453","ChiCTR2000030467","ChiCTR2000030465","ChiCTR2000030464","ChiCTR2000030466","ChiCTR2000030433","ChiCTR2000030418","ChiCTR2000030420","ChiCTR2000030390","ChiCTR2000030432","ChiCTR2000030398","ChiCTR2000030389","ChiCTR2000030424","ChiCTR2000030391","ChiCTR2000030387","ChiCTR2000030436","ChiCTR2000030388","ChiCTR2000030417","ChiCTR2000030363","ChiCTR2000030381","ChiCTR2000030322","ChiCTR2000030314","ChiCTR2000030334","ChiCTR2000030333","ChiCTR2000030305","ChiCTR2000030317","ChiCTR2000030315","ChiCTR2000030327","ChiCTR2000030325","ChiCTR2000030300","ChiCTR2000030324","ChiCTR2000030312","ChiCTR2000030304","ChiCTR2000030329","ChiCTR2000030306","ChiCTR2000030330","ChiCTR2000030328","ChiCTR2000030331","ChiCTR2000030283","ChiCTR2000030293","ChiCTR2000030290","ChiCTR2000030288","ChiCTR2000030262","ChiCTR2000030263","ChiCTR2000030265","ChiCTR2000030264","ChiCTR2000030259","ChiCTR2000030258","ChiCTR2000030257","ChiCTR2000030260","ChiCTR2000030255","ChiCTR2000030261","ChiCTR2000030253","ChiCTR2000030226","ChiCTR2000030225","ChiCTR2000030223","ChiCTR2000030254","ChiCTR2000030224","ChiCTR2000030256","ChiCTR2000030222","ChiCTR2000030219","ChiCTR2000030215","ChiCTR2000030196","ChiCTR2000030218","ChiCTR2000030221","ChiCTR2000030198","ChiCTR2000030173","ChiCTR2000030166","ChiCTR2000030179","ChiCTR2000030164","ChiCTR2000030185","ChiCTR2000030167","ChiCTR2000030165","ChiCTR2000030188","ChiCTR2000030170","ChiCTR2000030138","ChiCTR2000030137","ChiCTR2000030136","ChiCTR2000030162","ChiCTR2000030163","ChiCTR2000030187","ChiCTR2000030135","ChiCTR2000030168","ChiCTR2000030118","ChiCTR2000030116","ChiCTR2000030093","ChiCTR2000030113","ChiCTR2000030096","ChiCTR2000030094","ChiCTR2000030117","ChiCTR2000030115","ChiCTR2000030092","ChiCTR2000030102","ChiCTR2000030091","ChiCTR2000030114","ChiCTR2000030095","ChiCTR2000030084","ChiCTR2000030090","ChiCTR2000030058","ChiCTR2000030056","ChiCTR2000030089","ChiCTR2000030088","ChiCTR2000030087","ChiCTR2000030086","ChiCTR2000030054","ChiCTR2000030082","ChiCTR2000030055","ChiCTR2000030085","ChiCTR2000030043","ChiCTR2000030041","ChiCTR2000030034","ChiCTR2000030032","ChiCTR2000030046","ChiCTR2000030029","ChiCTR2000030033","ChiCTR2000030039","ChiCTR2000030042","ChiCTR2000030031","ChiCTR2000030030","ChiCTR2000030027","ChiCTR2000030017","ChiCTR2000030015","ChiCTR2000029996","ChiCTR2000030021","ChiCTR2000030020","ChiCTR2000030019","ChiCTR2000030022","ChiCTR2000030014","ChiCTR2000030028","ChiCTR2000030016","ChiCTR2000030007","ChiCTR2000030012","ChiCTR2000030010","ChiCTR2000030008","ChiCTR2000030006","ChiCTR2000030000","ChiCTR2000029995","ChiCTR2000030001","ChiCTR2000029999","ChiCTR2000030004","ChiCTR2000030003","ChiCTR2000030002","ChiCTR2000030013","ChiCTR2000030005","ChiCTR2000029994","ChiCTR2000029978","ChiCTR2000029992","ChiCTR2000029990","ChiCTR2000029989","ChiCTR2000029988","ChiCTR2000029985","ChiCTR2000029981","ChiCTR2000029974","ChiCTR2000030386","ChiCTR2000029975","ChiCTR2000029991","ChiCTR2000029993","ChiCTR2000029984","ChiCTR2000029982","ChiCTR2000029976","ChiCTR2000029953","ChiCTR2000029956","ChiCTR2000029960","ChiCTR2000029959","ChiCTR2000029972","ChiCTR2000029954","ChiCTR2000030382","ChiCTR2000029952","ChiCTR2000029958","ChiCTR2000029957","ChiCTR2000029955","ChiCTR2000029935","ChiCTR2000029949","ChiCTR2000029947","ChiCTR2000029896","ChiCTR2000029883","ChiCTR2000029941","ChiCTR2000029939","ChiCTR2000029907","ChiCTR2000029905","ChiCTR2000029899","ChiCTR2000029898","ChiCTR2000029900","ChiCTR2000029895","ChiCTR2000029850","ChiCTR2000029869","ChiCTR2000029867","ChiCTR2000029849","ChiCTR2000029870","ChiCTR2000029855","ChiCTR2000029853","ChiCTR2000029839","ChiCTR2000029866","ChiCTR2000029865","ChiCTR2000029851","ChiCTR2000029829","ChiCTR2000029837","ChiCTR2000029830","ChiCTR2000029868","ChiCTR2000029814","ChiCTR2000029811","ChiCTR2000029810","ChiCTR2000029805","ChiCTR2000029822","ChiCTR2000029815","ChiCTR2000029813","ChiCTR2000029806","ChiCTR2000029821","ChiCTR2000029819","ChiCTR2000029804","ChiCTR2000029803","ChiCTR2000029817","ChiCTR2000029812","ChiCTR2000029826","ChiCTR2000029820","ChiCTR2000029818","ChiCTR2000029816","ChiCTR2000029789","ChiCTR2000029779","ChiCTR2000029778","ChiCTR2000029777","ChiCTR2000029776","ChiCTR2000029782","ChiCTR2000029764","ChiCTR2000029790","ChiCTR2000029788","ChiCTR2000029765","ChiCTR2000029769","ChiCTR2000029768","ChiCTR2000029781","ChiCTR2000029780","ChiCTR2000029770","ChiCTR2000029763","ChiCTR2000029758","ChiCTR2000029756","ChiCTR2000029754","ChiCTR2000029751","ChiCTR2000029762","ChiCTR2000029755","ChiCTR2000029761","ChiCTR2000029759","ChiCTR2000029760","ChiCTR2000029757","ChiCTR2000029742","ChiCTR2000029741","ChiCTR2000029747","ChiCTR2000029739","ChiCTR2000029740","ChiCTR2000029695","ChiCTR2000029735","ChiCTR2000029732","ChiCTR2000029734","ChiCTR2000029728","ChiCTR2000029656","ChiCTR2000029658","ChiCTR2000029637","ChiCTR2000029636","ChiCTR2000029639","ChiCTR2000029638","ChiCTR2000029626","ChiCTR2000029624","ChiCTR2000029628","ChiCTR2000029621","ChiCTR2000029625","ChiCTR2000029606","ChiCTR2000029605","ChiCTR2000029601","ChiCTR2000029602","ChiCTR2000029609","ChiCTR2000029600","ChiCTR2000029603","ChiCTR2000029589","ChiCTR2000029578","ChiCTR2000029572","ChiCTR2000029580","ChiCTR2000029579","ChiCTR2000029592","ChiCTR2000029573","ChiCTR2000029569","ChiCTR2000029559","ChiCTR2000029558","ChiCTR2000029548","ChiCTR2000029550","ChiCTR2000029549","ChiCTR2000029542","ChiCTR2000029539","ChiCTR2000029518","ChiCTR2000029517","ChiCTR2000029544","ChiCTR2000029541","ChiCTR2000029496","ChiCTR2000029495","ChiCTR2000029493","ChiCTR2000029462","ChiCTR2000029487","ChiCTR2000029468","ChiCTR2000029461","ChiCTR2000029460","ChiCTR2000029459","ChiCTR2000029479","ChiCTR2000029438","ChiCTR2000029432","ChiCTR2000029431","ChiCTR2000029436","ChiCTR2000029437","ChiCTR2000029439","ChiCTR2000029435","ChiCTR2000029430","ChiCTR2000029433","ChiCTR2000029434","ChiCTR2000029418","ChiCTR2000029400","ChiCTR2000029387","ChiCTR2000029386","ChiCTR2000029381","ChiCTR2000029308"],["2020-04-24","2020-04-23","2020-04-23","2020-04-23","2020-04-23","2020-04-23","2020-04-23","2020-04-21","2020-04-21","2020-04-21","2020-04-21","2020-04-21","2020-04-21","2020-04-21","2020-04-21","2020-04-21","2020-04-20","2020-04-20","2020-04-20","2020-04-19","2020-04-19","2020-04-19","2020-04-18","2020-04-18","2020-04-18","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-17","2020-04-16","2020-04-16","2020-04-16","2020-04-16","2020-04-16","2020-04-16","2020-04-16","2020-04-16","2020-04-16","2020-04-15","2020-04-15","2020-04-15","2020-04-15","2020-04-15","2020-04-15","2020-04-14","2020-04-14","2020-04-14","2020-04-14","2020-04-14","2020-04-14","2020-04-13","2020-04-13","2020-04-13","2020-04-12","2020-04-11","2020-04-11","2020-04-11","2020-04-11","2020-04-11","2020-04-10","2020-04-10","2020-04-10","2020-04-10","2020-04-10","2020-04-09","2020-04-09","2020-04-09","2020-04-08","2020-04-08","2020-04-08","2020-04-07","2020-04-07","2020-04-07","2020-04-07","2020-04-07","2020-04-06","2020-04-06","2020-04-05","2020-04-05","2020-04-05","2020-04-05","2020-04-04","2020-04-03","2020-04-03","2020-04-03","2020-04-03","2020-04-03","2020-04-03","2020-04-02","2020-04-02","2020-04-02","2020-04-02","2020-04-02","2020-04-01","2020-04-01","2020-04-01","2020-04-01","2020-03-31","2020-03-31","2020-03-31","2020-03-31","2020-03-31","2020-03-29","2020-03-29","2020-03-29","2020-03-28","2020-03-28","2020-03-28","2020-03-28","2020-03-27","2020-03-27","2020-03-27","2020-03-27","2020-03-27","2020-03-27","2020-03-27","2020-03-27","2020-03-27","2020-03-26","2020-03-26","2020-03-25","2020-03-25","2020-03-25","2020-03-25","2020-03-25","2020-03-25","2020-03-24","2020-03-24","2020-03-24","2020-03-23","2020-03-23","2020-03-23","2020-03-23","2020-03-23","2020-03-23","2020-03-23","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-21","2020-03-21","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-20","2020-03-19","2020-03-19","2020-03-19","2020-03-19","2020-03-19","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-18","2020-03-17","2020-03-17","2020-03-17","2020-03-17","2020-03-17","2020-03-17","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-14","2020-03-14","2020-03-14","2020-03-14","2020-03-14","2020-03-14","2020-03-14","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-12","2020-03-12","2020-03-11","2020-03-11","2020-03-11","2020-03-11","2020-03-11","2020-03-11","2020-03-11","2020-03-11","2020-03-10","2020-03-10","2020-03-10","2020-03-10","2020-03-10","2020-03-10","2020-03-10","2020-03-09","2020-03-09","2020-03-09","2020-03-09","2020-03-09","2020-03-08","2020-03-08","2020-03-08","2020-03-08","2020-03-08","2020-03-08","2020-03-08","2020-03-08","2020-03-08","2020-03-07","2020-03-07","2020-03-07","2020-03-07","2020-03-07","2020-03-07","2020-03-07","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-06","2020-03-05","2020-03-05","2020-03-05","2020-03-05","2020-03-05","2020-03-04","2020-03-04","2020-03-04","2020-03-04","2020-03-04","2020-03-04","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-03","2020-03-02","2020-03-02","2020-03-02","2020-03-02","2020-03-02","2020-03-02","2020-03-02","2020-03-02","2020-03-02","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-02-29","2020-02-29","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-27","2020-02-27","2020-02-27","2020-02-27","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-25","2020-02-25","2020-02-25","2020-02-25","2020-02-25","2020-02-25","2020-02-25","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-24","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-23","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-22","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-21","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-20","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-17","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-16","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-15","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-14","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-13","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-12","2020-02-11","2020-02-11","2020-02-11","2020-02-11","2020-02-11","2020-02-10","2020-02-10","2020-02-10","2020-02-10","2020-02-10","2020-02-09","2020-02-09","2020-02-08","2020-02-08","2020-02-08","2020-02-08","2020-02-07","2020-02-07","2020-02-07","2020-02-07","2020-02-07","2020-02-07","2020-02-07","2020-02-06","2020-02-06","2020-02-06","2020-02-06","2020-02-06","2020-02-05","2020-02-05","2020-02-05","2020-02-05","2020-02-05","2020-02-05","2020-02-05","2020-02-04","2020-02-04","2020-02-04","2020-02-04","2020-02-04","2020-02-04","2020-02-03","2020-02-03","2020-02-03","2020-02-03","2020-02-03","2020-02-03","2020-02-03","2020-02-02","2020-02-02","2020-02-02","2020-02-02","2020-02-02","2020-02-02","2020-02-02","2020-02-02","2020-02-02","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-02-01","2020-01-30","2020-01-29","2020-01-29","2020-01-29","2020-01-27","2020-01-23"],["A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)","Epidemiological characteristics of 88 patients with new coronavirus pneumonia (COVID-19) and its impact on severe disease","A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence","Clinical study for the potential impact of novel coronavirus pneumonia (COVID-19) on endocrine system","A randomized, double-blind, placebo-controlled, multicentre clinical study on the improvement of novel coronavirus pneumonia (COVID-19) convalescent sleep mood disorder with shumian capsule","The impact of wearing medical masks on oxygen saturation in adult surgical patients after general anaesthesia during novel coronavirus pneumonia (COVID-19) pandemic: a retrospective, single-centre, observational cohort study","A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia","A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period","A cohort retrospective study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients","A retrospective study for evolution and clinical outcomes of novel coronavirus pneumonia (COVID-19) patients","A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period","A cohort retrospective study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients","A retrospective study for evolution and clinical outcomes of novel coronavirus pneumonia (COVID-19) patients","A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period","A cohort retrospective study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients","A retrospective study for evolution and clinical outcomes of novel coronavirus pneumonia (COVID-19) patients","Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19) ","Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19","Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19","Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19","Observation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","Observation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","Observation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","The design of a modifed N95 respirator and its protective effects against facial pressure injuries","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease","The design of a modifed N95 respirator and its protective effects against facial pressure injuries","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease","The design of a modifed N95 respirator and its protective effects against facial pressure injuries","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease","Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people","Study on the prevention of COVID-19 with Chinese medicine regulating constitution","Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19): a multicenter retrospective cohort study","Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people","Study on the prevention of COVID-19 with Chinese medicine regulating constitution","Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19): a multicenter retrospective cohort study","Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people","Study on the prevention of COVID-19 with Chinese medicine regulating constitution","Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19): a multicenter retrospective cohort study","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19) for Returning Workers in Wuhan: a Randomized Controlled Trial","Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19) for Returning Workers in Wuhan: a Randomized Controlled Trial","Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19) for Returning Workers in Wuhan: a Randomized Controlled Trial","Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)","Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community","Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs","Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community","Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs","Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community","Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs","Clinical Research on Treatment of Novel Coronavirus Pneumonia  with ''Guangdong Pneumonia NO.1''","Clinical Research on Treatment of Novel Coronavirus Pneumonia  with ''Guangdong Pneumonia NO.1''","Clinical Research on Treatment of Novel Coronavirus Pneumonia  with ''Guangdong Pneumonia NO.1''","Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","Clinical Characteristics Of 45 Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome: A Single-Centered, Retrospective, Observational Study","Evaluation of the safety and immunogenicity of inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) in healthy population aged 6 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial","Evaluation of the safety and immunogenicity of inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) in healthy population aged 6 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial","Evaluation of the safety and immunogenicity of inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) in healthy population aged 6 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial","Clinical features and outcomes of critically ill adult patients with COVID-19 admitted to ICUs of non-Wuhan city, China: a medical records based retrospective study","The impact of Information Sources over behaviors and preventive measures against COVID-19","A questionnaire investigation of hydroxychloroquine for its potential protective effect against Severe Acute Respiratory Syndromes-coronavirus-2 infection","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years","Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","Public health emergencies of hospital emergency nursing human resource database to development and construction","Observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","A cross-sectional observation study to delineate the degree of environmental contamination by SARS-CoV-2 in the clinical environment","Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic","Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)","Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent","Serum, faeces and sputum proteins and metabolomic markers in patients with novel coronavirus pneumonia (COVID-19)","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","Retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","What happens to non-health care workers' sleep of China during the pandemic of novel coronavirus pneumonia (COVID-19)","Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","A paired clinical study of novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital","Survey of psychological status and related factors of emergency medical staff in the country during the COVID-19 pandemic","A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and  the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic","A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","Clinical experience of 59 novel coronavirus pneumonia patients with intensive endotracheal intubation: a single center, retrospective, descriptive study","The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study","Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial","Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)","A clinical study evaluating the safety and tolerability of microRNA2911 plasmids in healthy adults","Evaluation of  the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis","Serum and urine proteins and metabolomic markers in patients with COVID-19","Safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy","Altered brain structure and function in patients with COVID-19 after rehabilitation","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation","Influence of COVID-19 on disease activity, medical and mental condition of patients with rheumatic diseases","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of COVID-19","The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)","Clinical characteristics and death risk factors in COVID-19 patients","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a cohort study","Clinical features and prognosis of  invasive mechanicalventilation patients  with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis","The correlation between Vitamin D deficient and severe status of novel coronavirus pneumonia (COVID-19) patients","Application of radiology in the prevention and control system of emergency respiratory infectious diseases","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)","Study on home pharmaceutical care for chronic patients over the new coronavirus pneumonia epidemic","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)","Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)","Study on the impact on fetus and neonates of vertical transmission of 2019-nCoV","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)","The Cohotr of COVID-19","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)","Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","Detection of SARS-COV-2 RNA Level in Blood and Excrement of Patients Infected with 2019-nCOV in Recovery Period","The Diagnosis and prognosis prediction of novel coronavirus pneumonia (COVID-19) based on AI and Radiomics","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.","association of T lymphocytes level and clinical severity in patients of NCP: a single-center retrospective data","The Retrospective Study about Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia in WuHan","Upper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patients","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Psychological Responses of Medical Staff during the Metaphase of Coronavirus Disease 2019 Outbreak in Hubei, China","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study","Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial","Clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia","Myocardial injury and arrythmias in the COVID-19 patients","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggang.","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)","Venous Thrombosis Risk of 2019-nCoV Pneumonia(COVID-19) Patients: A Prospective Study","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of  Coronavirus SARS-CoV-2","Clinical Characteristic and Outcomes of Hospitalized Patients With Coronavirus Disease 2019","An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia","Combined diagnostic value of novel coronavirus infection detected by NLR and CRP","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","Clinical investigation and reseach on TCM syndrome of COVID-19","Hospital of Chengdu University of Traditional Chinese Medicine jointly launched a real-world study on the clinical efficacy evaluation of the Inner hospital preparation","Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection","A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","An observational study of cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","Retrospective and Prospective Study on Nosocomial infection in Stomatology Department under the Background of COVID-19","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors","Study of effects of crisis intervention on medical staff based on positive psychology","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19)9: An Multicenter Cohort Study","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Correlation analysis of blood eosinophil cell levels and clinical novel coronavirus pneumonia type: a single-center, retrospective study","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong","A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection","Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia","Factors associated with death patients with novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)","Investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital","An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-1","Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Analysis of influencing factors of death of COVID-19 patients in wuhan third hospital","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Clinical outcomes and follow-up study of COVID-19 patients","Development of warning system with clinical differential diagnosis and prediction for severe type of SARS-Cov-2 patients based on artificial intelligence and CT images","Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies","Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Epidemiological Characteristics and Antibody Levels of COVID-19 Infection of Pediatric Medical Staff working in Quarantine Area","Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia: a single center and descriptive study in Wuhan","Retrospective analysis of digestive system symptoms in 600 cases of 2019-ncov pneumonia in Guanggu district, Wuhan","The value of Lymphocyte subsets in Coronavirus Disease 2019","Nutritional risk assessment and outcome prediction of critically ill COVID-19 patients","Ocular dectection of SARS-CoV-2 in 114 cases of COVID-19 pneumonia in Wuhan, China: an observational study","A multicenter retrospective study of rheumatic  patients with COVID-19","Screening and Identification of SARS-CoV-2 Infection and Progression in Cancer Patients Based on Bioinformatics Analysis","Quantitative CT characteristic estimate the severity of 2019-nCoV","Clinical characteristics of severe or critically ill patients infected with 2019-nCoV","A retrospective study of clinical drug therapy in patients with COVID-19","Clinical characteristics of COVID-19","Clinical characteristics and treatment of COVID-19","Analysis of risk factors affecting prognosis of elderly patients infected with COVID-19 pneumonia: a single-center retrospective observational study","Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value","Study for the physical and mental health status of medical workers under the situation of COVID-19","Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients","Preliminary screening of Coronavirus Disease (COVID-19) by special laboratory examination and CT imaging before surgery","Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Development and application of COVID-19 intelligent image classification system based on deep learning","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia patients","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound","Epidemiologic and Clinical features of COVID-19 in Ningbo","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi","Risk Factors for Anxiety of Otolaryngology Workers in Hubei Province Fighting Against novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)","Research for the influence of epidemic of  novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''","Clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China","Characteristics, prognosis of  ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area: a dual-center, retrospective, cohort study","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19): a dual-center, retrospective, cohort study","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19)","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS","Analysis of Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19","Analysis of risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)","A prospective cohort  study on recovering patients with novel coronavirus pneumonia (COVID-19) by comprehensive treatment of Chinese medicine","Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection","Risk assessment and treatment timing of invasive fungal infection in critically ill covid-19 patients: medical records based study","Shedding of SARS-CoV-2 in human semen and reproductive health evaluation of ever infected males","Cross sectional study of dialysis treatment and mental status under the outbreak of COVID-2019 in China","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau","Application of cas13a-mediated RNA detection in the detection of novel coronavirus nucleic acid","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Study on immune cell subsets in convalescent patients with SARS-CoV-2 infection","A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)","An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)","Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","COVID-19 infection associated kidney injury in children","The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS): a retrospective observational study","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room","The effects of  prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study","Study on the application of convalescent plasma therapy in severe COVID-19","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial","Analysis of the characteristics of traditional Chinese medicine combined with western medicine and its correlation mechanism based on real-world patients with  novel coronavirus pneumonia (COVID-19)","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)","Retrospective study to assess the safety of in vitro blood purification treatment in critically ill patients with novel coronavirus pneumonia COVID-19","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)","Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country","A clinical study about the diagnosis and prognosis of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)","Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)","Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia COVID-19","Early risk stratification of the novel coronavirus disease 2019 (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)","Retrospective studyfor integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Comparative Study for Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients in Sichuan Province and Wuhan","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A case records based retrospective Cohort study","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","SARS-CoV-2 Infection on Myocardial Injury and Prognosis: a Multicenter, Long- term Follow-up and Registration Study","The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study","A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Key techniques of combination therapy of Novel Coronavirus Pneumonia (COVID-19) - Study on TCM symptoms and treatment law","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)","Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)","The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)","Application of flash glucose monitoring to evaluate the effect of hyperglycemia and glycemic variability on prognosis in patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome","A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang","Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)","Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) in asymptomatic patients: a single center, prospective, open clinical study","the effects of 6-minute walk training on walking distance, oxygen saturation, heart rate and global rating of change of normal or critial novel coronavirus pneumonia (COVID-19)","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus infection (COVID-19) from two hospitals in China","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic","Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients","The coagulation function of novel coronavirus pneumonia (COVID-19) patients","Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China","Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)","Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)","Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","The Real World Study to Evaluate the Added Treatment Effectiveness of Comprehensive Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","A prospective real world study on Compound Houttuyniae Mixture used in people of the observation period in close contact with novel coronavirus pneumonia (COVID-19)","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)","Optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients","A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)","Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","The risk factor and prognosis of acute kidney injury in novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)","Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","Development of 2019-nCoV  therapeutic antibody","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","Study on anxiety of different populations under novel coronavirus (COVID-19) infection","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","Effect of New Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students","Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)","Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)","A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Study on mental health status and influencing factors of nurses during epidemic prevention of Novel coronavirus pneumonia (COVID-19)","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study","Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism","Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine","Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Clinical observation of the novel coronavirus pneumonia (COVID-19) in neonatal","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet","Epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department","An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients","Co-infection of novel coronavirus pneumonia (COVID-19) and influenza virus: a single-center, two-phase, observational study","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy","Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics","Clinical characteristics and outcomes of cardiovascular disease patients infected by COVID-19 in Wuhan, China: a descriptive study","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19)  based on CRISPR-cas protein","Optimization of treatment and diagnosis plan for critically ill patients","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation","Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network","Optimization of treatment and diagnosis plan for critically ill patients","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Volatile Organic Compounds in Exhaled Breath","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)","Impact of vitamin D deficiency on prognosis of patients novel coronavirus pneumonia (COVID-19)","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia ((COVID-19)","Observational study of Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)","The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","An epidemiology study for TCM syndrome  of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","A study on treatment strategies of novel coronavirus pnueumonia patients","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection"],["http://www.chictr.org.cn/showproj.aspx?proj=52824","http://www.chictr.org.cn/showproj.aspx?proj=52507","http://www.chictr.org.cn/showproj.aspx?proj=52699","http://www.chictr.org.cn/showproj.aspx?proj=52796","http://www.chictr.org.cn/showproj.aspx?proj=52781","http://www.chictr.org.cn/showproj.aspx?proj=52788","http://www.chictr.org.cn/showproj.aspx?proj=52662","http://www.chictr.org.cn/showproj.aspx?proj=52679","http://www.chictr.org.cn/showproj.aspx?proj=52694","http://www.chictr.org.cn/showproj.aspx?proj=52561","http://www.chictr.org.cn/showproj.aspx?proj=52679","http://www.chictr.org.cn/showproj.aspx?proj=52694","http://www.chictr.org.cn/showproj.aspx?proj=52561","http://www.chictr.org.cn/showproj.aspx?proj=52679","http://www.chictr.org.cn/showproj.aspx?proj=52694","http://www.chictr.org.cn/showproj.aspx?proj=52561","http://www.chictr.org.cn/showproj.aspx?proj=52506","http://www.chictr.org.cn/showproj.aspx?proj=52506","http://www.chictr.org.cn/showproj.aspx?proj=52506","http://www.chictr.org.cn/showproj.aspx?proj=52477","http://www.chictr.org.cn/showproj.aspx?proj=52477","http://www.chictr.org.cn/showproj.aspx?proj=52477","http://www.chictr.org.cn/showproj.aspx?proj=52529","http://www.chictr.org.cn/showproj.aspx?proj=52529","http://www.chictr.org.cn/showproj.aspx?proj=52529","http://www.chictr.org.cn/showproj.aspx?proj=52483","http://www.chictr.org.cn/showproj.aspx?proj=52142","http://www.chictr.org.cn/showproj.aspx?proj=52479","http://www.chictr.org.cn/showproj.aspx?proj=52490","http://www.chictr.org.cn/showproj.aspx?proj=52483","http://www.chictr.org.cn/showproj.aspx?proj=52142","http://www.chictr.org.cn/showproj.aspx?proj=52479","http://www.chictr.org.cn/showproj.aspx?proj=52490","http://www.chictr.org.cn/showproj.aspx?proj=52483","http://www.chictr.org.cn/showproj.aspx?proj=52142","http://www.chictr.org.cn/showproj.aspx?proj=52479","http://www.chictr.org.cn/showproj.aspx?proj=52490","http://www.chictr.org.cn/showproj.aspx?proj=52341","http://www.chictr.org.cn/showproj.aspx?proj=52364","http://www.chictr.org.cn/showproj.aspx?proj=52365","http://www.chictr.org.cn/showproj.aspx?proj=52341","http://www.chictr.org.cn/showproj.aspx?proj=52364","http://www.chictr.org.cn/showproj.aspx?proj=52365","http://www.chictr.org.cn/showproj.aspx?proj=52341","http://www.chictr.org.cn/showproj.aspx?proj=52364","http://www.chictr.org.cn/showproj.aspx?proj=52365","http://www.chictr.org.cn/showproj.aspx?proj=52414","http://www.chictr.org.cn/showproj.aspx?proj=51602","http://www.chictr.org.cn/showproj.aspx?proj=52414","http://www.chictr.org.cn/showproj.aspx?proj=51602","http://www.chictr.org.cn/showproj.aspx?proj=52414","http://www.chictr.org.cn/showproj.aspx?proj=51602","http://www.chictr.org.cn/showproj.aspx?proj=52353","http://www.chictr.org.cn/showproj.aspx?proj=52332","http://www.chictr.org.cn/showproj.aspx?proj=52353","http://www.chictr.org.cn/showproj.aspx?proj=52332","http://www.chictr.org.cn/showproj.aspx?proj=52353","http://www.chictr.org.cn/showproj.aspx?proj=52332","http://www.chictr.org.cn/showproj.aspx?proj=52106","http://www.chictr.org.cn/showproj.aspx?proj=52106","http://www.chictr.org.cn/showproj.aspx?proj=52106","http://www.chictr.org.cn/showprojen.aspx?proj=52198","http://www.chictr.org.cn/showprojen.aspx?proj=52216","http://www.chictr.org.cn/showprojen.aspx?proj=52213","http://www.chictr.org.cn/showproj.aspx?proj=52227","http://www.chictr.org.cn/showproj.aspx?proj=52227","http://www.chictr.org.cn/showproj.aspx?proj=52227","http://www.chictr.org.cn/showprojen.aspx?proj=52193","http://www.chictr.org.cn/showprojen.aspx?proj=51832","http://www.chictr.org.cn/showprojen.aspx?proj=51934","http://www.chictr.org.cn/showprojen.aspx?proj=52006","http://www.chictr.org.cn/showprojen.aspx?proj=52051","http://www.chictr.org.cn/showprojen.aspx?proj=52165","http://www.chictr.org.cn/showprojen.aspx?proj=52148","http://www.chictr.org.cn/showprojen.aspx?proj=52135","http://www.chictr.org.cn/showprojen.aspx?proj=52130","http://www.chictr.org.cn/showprojen.aspx?proj=50613","http://www.chictr.org.cn/showprojen.aspx?proj=52103","http://www.chictr.org.cn/showprojen.aspx?proj=51650","http://www.chictr.org.cn/showprojen.aspx?proj=52079","http://www.chictr.org.cn/showprojen.aspx?proj=51793","http://www.chictr.org.cn/showprojen.aspx?proj=52052","http://www.chictr.org.cn/showprojen.aspx?proj=51924","http://www.chictr.org.cn/showprojen.aspx?proj=51940","http://www.chictr.org.cn/showprojen.aspx?proj=52037","http://www.chictr.org.cn/showprojen.aspx?proj=50474","http://www.chictr.org.cn/showprojen.aspx?proj=51969","http://www.chictr.org.cn/showprojen.aspx?proj=51865","http://www.chictr.org.cn/showprojen.aspx?proj=51119","http://www.chictr.org.cn/showprojen.aspx?proj=51952","http://www.chictr.org.cn/showprojen.aspx?proj=51835","http://www.chictr.org.cn/showprojen.aspx?proj=51893","http://www.chictr.org.cn/showprojen.aspx?proj=51684","http://www.chictr.org.cn/showprojen.aspx?proj=51938","http://www.chictr.org.cn/showprojen.aspx?proj=51781","http://www.chictr.org.cn/showprojen.aspx?proj=51911","http://www.chictr.org.cn/showprojen.aspx?proj=51915","http://www.chictr.org.cn/showprojen.aspx?proj=51904","http://www.chictr.org.cn/showprojen.aspx?proj=51538","http://www.chictr.org.cn/showprojen.aspx?proj=50254","http://www.chictr.org.cn/showprojen.aspx?proj=51897","http://www.chictr.org.cn/showprojen.aspx?proj=51859","http://www.chictr.org.cn/showprojen.aspx?proj=51815","http://www.chictr.org.cn/showprojen.aspx?proj=51693","http://www.chictr.org.cn/showprojen.aspx?proj=51837","http://www.chictr.org.cn/showprojen.aspx?proj=51816","http://www.chictr.org.cn/showprojen.aspx?proj=51809","http://www.chictr.org.cn/showprojen.aspx?proj=51813","http://www.chictr.org.cn/showprojen.aspx?proj=51646","http://www.chictr.org.cn/showprojen.aspx?proj=49254","http://www.chictr.org.cn/showprojen.aspx?proj=51692","http://www.chictr.org.cn/showprojen.aspx?proj=51694","http://www.chictr.org.cn/showprojen.aspx?proj=51724","http://www.chictr.org.cn/showprojen.aspx?proj=51499","http://www.chictr.org.cn/showprojen.aspx?proj=51385","http://www.chictr.org.cn/showprojen.aspx?proj=51517","http://www.chictr.org.cn/showprojen.aspx?proj=51170","http://www.chictr.org.cn/showprojen.aspx?proj=51504","http://www.chictr.org.cn/showprojen.aspx?proj=51667","http://www.chictr.org.cn/showprojen.aspx?proj=51647","http://www.chictr.org.cn/showprojen.aspx?proj=51668","http://www.chictr.org.cn/showprojen.aspx?proj=51425","http://www.chictr.org.cn/showprojen.aspx?proj=51669","http://www.chictr.org.cn/showprojen.aspx?proj=51603","http://www.chictr.org.cn/showprojen.aspx?proj=51584","http://www.chictr.org.cn/showprojen.aspx?proj=51629","http://www.chictr.org.cn/showprojen.aspx?proj=51455","http://www.chictr.org.cn/showprojen.aspx?proj=51194","http://www.chictr.org.cn/showprojen.aspx?proj=51559","http://www.chictr.org.cn/showprojen.aspx?proj=51518","http://www.chictr.org.cn/showprojen.aspx?proj=51540","http://www.chictr.org.cn/showprojen.aspx?proj=51535","http://www.chictr.org.cn/showprojen.aspx?proj=51486","http://www.chictr.org.cn/showprojen.aspx?proj=51473","http://www.chictr.org.cn/showprojen.aspx?proj=49420","http://www.chictr.org.cn/showprojen.aspx?proj=51030","http://www.chictr.org.cn/showprojen.aspx?proj=51509","http://www.chictr.org.cn/showprojen.aspx?proj=51390","http://www.chictr.org.cn/showprojen.aspx?proj=51021","http://www.chictr.org.cn/showprojen.aspx?proj=51442","http://www.chictr.org.cn/showprojen.aspx?proj=51443","http://www.chictr.org.cn/showprojen.aspx?proj=51488","http://www.chictr.org.cn/showprojen.aspx?proj=51112","http://www.chictr.org.cn/showprojen.aspx?proj=51478","http://www.chictr.org.cn/showprojen.aspx?proj=51032","http://www.chictr.org.cn/showprojen.aspx?proj=50605","http://www.chictr.org.cn/showprojen.aspx?proj=51416","http://www.chictr.org.cn/showprojen.aspx?proj=51185","http://www.chictr.org.cn/showprojen.aspx?proj=51132","http://www.chictr.org.cn/showprojen.aspx?proj=51148","http://www.chictr.org.cn/showprojen.aspx?proj=51404","http://www.chictr.org.cn/showprojen.aspx?proj=51136","http://www.chictr.org.cn/showprojen.aspx?proj=50984","http://www.chictr.org.cn/showprojen.aspx?proj=51348","http://www.chictr.org.cn/showprojen.aspx?proj=51338","http://www.chictr.org.cn/showprojen.aspx?proj=51331","http://www.chictr.org.cn/showprojen.aspx?proj=51349","http://www.chictr.org.cn/showprojen.aspx?proj=51316","http://www.chictr.org.cn/showprojen.aspx?proj=51291","http://www.chictr.org.cn/showprojen.aspx?proj=51342","http://www.chictr.org.cn/showprojen.aspx?proj=51329","http://www.chictr.org.cn/showprojen.aspx?proj=51311","http://www.chictr.org.cn/showprojen.aspx?proj=51254","http://www.chictr.org.cn/showprojen.aspx?proj=51317","http://www.chictr.org.cn/showprojen.aspx?proj=51267","http://www.chictr.org.cn/showprojen.aspx?proj=51265","http://www.chictr.org.cn/showprojen.aspx?proj=51278","http://www.chictr.org.cn/showprojen.aspx?proj=51272","http://www.chictr.org.cn/showprojen.aspx?proj=51283","http://www.chictr.org.cn/showprojen.aspx?proj=51000","http://www.chictr.org.cn/showprojen.aspx?proj=51059","http://www.chictr.org.cn/showprojen.aspx?proj=51184","http://www.chictr.org.cn/showprojen.aspx?proj=51230","http://www.chictr.org.cn/showprojen.aspx?proj=50898","http://www.chictr.org.cn/showprojen.aspx?proj=51160","http://www.chictr.org.cn/showprojen.aspx?proj=51212","http://www.chictr.org.cn/showprojen.aspx?proj=50199","http://www.chictr.org.cn/showprojen.aspx?proj=50981","http://www.chictr.org.cn/showprojen.aspx?proj=51061","http://www.chictr.org.cn/showprojen.aspx?proj=51239","http://www.chictr.org.cn/showprojen.aspx?proj=51100","http://www.chictr.org.cn/showprojen.aspx?proj=51240","http://www.chictr.org.cn/showprojen.aspx?proj=51141","http://www.chictr.org.cn/showprojen.aspx?proj=51154","http://www.chictr.org.cn/showprojen.aspx?proj=50696","http://www.chictr.org.cn/showprojen.aspx?proj=50476","http://www.chictr.org.cn/showprojen.aspx?proj=51149","http://www.chictr.org.cn/showprojen.aspx?proj=51139","http://www.chictr.org.cn/showprojen.aspx?proj=51028","http://www.chictr.org.cn/showprojen.aspx?proj=51034","http://www.chictr.org.cn/showprojen.aspx?proj=51126","http://www.chictr.org.cn/showprojen.aspx?proj=51130","http://www.chictr.org.cn/showprojen.aspx?proj=51073","http://www.chictr.org.cn/showprojen.aspx?proj=50767","http://www.chictr.org.cn/showprojen.aspx?proj=50462","http://www.chictr.org.cn/showprojen.aspx?proj=51107","http://www.chictr.org.cn/showprojen.aspx?proj=51103","http://www.chictr.org.cn/showprojen.aspx?proj=51064","http://www.chictr.org.cn/showprojen.aspx?proj=51083","http://www.chictr.org.cn/showprojen.aspx?proj=51081","http://www.chictr.org.cn/showprojen.aspx?proj=51077","http://www.chictr.org.cn/showprojen.aspx?proj=51118","http://www.chictr.org.cn/showprojen.aspx?proj=50960","http://www.chictr.org.cn/showprojen.aspx?proj=51102","http://www.chictr.org.cn/showprojen.aspx?proj=49933","http://www.chictr.org.cn/showprojen.aspx?proj=51097","http://www.chictr.org.cn/showprojen.aspx?proj=51091","http://www.chictr.org.cn/showprojen.aspx?proj=50780","http://www.chictr.org.cn/showprojen.aspx?proj=50299","http://www.chictr.org.cn/showprojen.aspx?proj=50662","http://www.chictr.org.cn/showprojen.aspx?proj=51025","http://www.chictr.org.cn/showprojen.aspx?proj=51040","http://www.chictr.org.cn/showprojen.aspx?proj=51090","http://www.chictr.org.cn/showprojen.aspx?proj=50947","http://www.chictr.org.cn/showprojen.aspx?proj=50986","http://www.chictr.org.cn/showprojen.aspx?proj=51015","http://www.chictr.org.cn/showprojen.aspx?proj=51071","http://www.chictr.org.cn/showprojen.aspx?proj=51054","http://www.chictr.org.cn/showprojen.aspx?proj=51086","http://www.chictr.org.cn/showprojen.aspx?proj=51050","http://www.chictr.org.cn/showprojen.aspx?proj=51047","http://www.chictr.org.cn/showprojen.aspx?proj=51035","http://www.chictr.org.cn/showprojen.aspx?proj=51036","http://www.chictr.org.cn/showprojen.aspx?proj=51039","http://www.chictr.org.cn/showprojen.aspx?proj=51037","http://www.chictr.org.cn/showprojen.aspx?proj=51048","http://www.chictr.org.cn/showprojen.aspx?proj=51042","http://www.chictr.org.cn/showprojen.aspx?proj=50982","http://www.chictr.org.cn/showprojen.aspx?proj=51019","http://www.chictr.org.cn/showprojen.aspx?proj=51026","http://www.chictr.org.cn/showprojen.aspx?proj=51007","http://www.chictr.org.cn/showprojen.aspx?proj=51004","http://www.chictr.org.cn/showprojen.aspx?proj=50994","http://www.chictr.org.cn/showprojen.aspx?proj=50991","http://www.chictr.org.cn/showprojen.aspx?proj=50998","http://www.chictr.org.cn/showprojen.aspx?proj=50997","http://www.chictr.org.cn/showprojen.aspx?proj=51056","http://www.chictr.org.cn/showprojen.aspx?proj=51072","http://www.chictr.org.cn/showprojen.aspx?proj=50904","http://www.chictr.org.cn/showprojen.aspx?proj=51044","http://www.chictr.org.cn/showprojen.aspx?proj=51009","http://www.chictr.org.cn/showprojen.aspx?proj=51029","http://www.chictr.org.cn/showprojen.aspx?proj=51018","http://www.chictr.org.cn/showprojen.aspx?proj=50995","http://www.chictr.org.cn/showprojen.aspx?proj=50988","http://www.chictr.org.cn/showprojen.aspx?proj=50631","http://www.chictr.org.cn/showprojen.aspx?proj=50987","http://www.chictr.org.cn/showprojen.aspx?proj=50976","http://www.chictr.org.cn/showprojen.aspx?proj=50934","http://www.chictr.org.cn/showprojen.aspx?proj=50307","http://www.chictr.org.cn/showprojen.aspx?proj=50968","http://www.chictr.org.cn/showprojen.aspx?proj=50973","http://www.chictr.org.cn/showprojen.aspx?proj=50961","http://www.chictr.org.cn/showprojen.aspx?proj=49284","http://www.chictr.org.cn/showprojen.aspx?proj=50590","http://www.chictr.org.cn/showprojen.aspx?proj=50648","http://www.chictr.org.cn/showprojen.aspx?proj=50705","http://www.chictr.org.cn/showprojen.aspx?proj=50852","http://www.chictr.org.cn/showprojen.aspx?proj=50950","http://www.chictr.org.cn/showprojen.aspx?proj=50955","http://www.chictr.org.cn/showprojen.aspx?proj=50945","http://www.chictr.org.cn/showprojen.aspx?proj=50941","http://www.chictr.org.cn/showprojen.aspx?proj=50901","http://www.chictr.org.cn/showprojen.aspx?proj=50910","http://www.chictr.org.cn/showprojen.aspx?proj=50857","http://www.chictr.org.cn/showprojen.aspx?proj=50907","http://www.chictr.org.cn/showprojen.aspx?proj=50900","http://www.chictr.org.cn/showprojen.aspx?proj=50896","http://www.chictr.org.cn/showprojen.aspx?proj=50921","http://www.chictr.org.cn/showprojen.aspx?proj=50956","http://www.chictr.org.cn/showprojen.aspx?proj=50824","http://www.chictr.org.cn/showprojen.aspx?proj=50925","http://www.chictr.org.cn/showprojen.aspx?proj=50000","http://www.chictr.org.cn/showprojen.aspx?proj=50964","http://www.chictr.org.cn/showprojen.aspx?proj=50928","http://www.chictr.org.cn/showprojen.aspx?proj=50759","http://www.chictr.org.cn/showprojen.aspx?proj=50338","http://www.chictr.org.cn/showprojen.aspx?proj=50843","http://www.chictr.org.cn/showprojen.aspx?proj=50860","http://www.chictr.org.cn/showprojen.aspx?proj=50850","http://www.chictr.org.cn/showprojen.aspx?proj=50083","http://www.chictr.org.cn/showprojen.aspx?proj=50160","http://www.chictr.org.cn/showprojen.aspx?proj=50001","http://www.chictr.org.cn/showprojen.aspx?proj=50867","http://www.chictr.org.cn/showprojen.aspx?proj=50793","http://www.chictr.org.cn/showprojen.aspx?proj=50251","http://www.chictr.org.cn/showprojen.aspx?proj=50261","http://www.chictr.org.cn/showprojen.aspx?proj=50795","http://www.chictr.org.cn/showprojen.aspx?proj=50786","http://www.chictr.org.cn/showprojen.aspx?proj=50537","http://www.chictr.org.cn/showprojen.aspx?proj=50781","http://www.chictr.org.cn/showprojen.aspx?proj=50778","http://www.chictr.org.cn/showprojen.aspx?proj=50572","http://www.chictr.org.cn/showprojen.aspx?proj=50633","http://www.chictr.org.cn/showprojen.aspx?proj=50763","http://www.chictr.org.cn/showprojen.aspx?proj=50714","http://www.chictr.org.cn/showprojen.aspx?proj=50730","http://www.chictr.org.cn/showprojen.aspx?proj=50228","http://www.chictr.org.cn/showprojen.aspx?proj=50727","http://www.chictr.org.cn/showprojen.aspx?proj=50394","http://www.chictr.org.cn/showprojen.aspx?proj=50692","http://www.chictr.org.cn/showprojen.aspx?proj=50690","http://www.chictr.org.cn/showprojen.aspx?proj=50693","http://www.chictr.org.cn/showprojen.aspx?proj=50656","http://www.chictr.org.cn/showprojen.aspx?proj=50713","http://www.chictr.org.cn/showprojen.aspx?proj=50702","http://www.chictr.org.cn/showprojen.aspx?proj=49708","http://www.chictr.org.cn/showprojen.aspx?proj=50583","http://www.chictr.org.cn/showprojen.aspx?proj=50667","http://www.chictr.org.cn/showprojen.aspx?proj=49953","http://www.chictr.org.cn/showprojen.aspx?proj=50653","http://www.chictr.org.cn/showprojen.aspx?proj=50672","http://www.chictr.org.cn/showprojen.aspx?proj=50678","http://www.chictr.org.cn/showprojen.aspx?proj=49790","http://www.chictr.org.cn/showprojen.aspx?proj=44213","http://www.chictr.org.cn/showprojen.aspx?proj=50134","http://www.chictr.org.cn/showprojen.aspx?proj=50541","http://www.chictr.org.cn/showprojen.aspx?proj=50623","http://www.chictr.org.cn/showprojen.aspx?proj=50608","http://www.chictr.org.cn/showprojen.aspx?proj=50658","http://www.chictr.org.cn/showprojen.aspx?proj=50126","http://www.chictr.org.cn/showprojen.aspx?proj=50641","http://www.chictr.org.cn/showprojen.aspx?proj=50660","http://www.chictr.org.cn/showprojen.aspx?proj=49632","http://www.chictr.org.cn/showprojen.aspx?proj=50586","http://www.chictr.org.cn/showprojen.aspx?proj=49956","http://www.chictr.org.cn/showprojen.aspx?proj=50604","http://www.chictr.org.cn/showprojen.aspx?proj=50077","http://www.chictr.org.cn/showprojen.aspx?proj=50507","http://www.chictr.org.cn/showprojen.aspx?proj=50547","http://www.chictr.org.cn/showprojen.aspx?proj=50549","http://www.chictr.org.cn/showprojen.aspx?proj=50552","http://www.chictr.org.cn/showprojen.aspx?proj=50487","http://www.chictr.org.cn/showprojen.aspx?proj=50490","http://www.chictr.org.cn/showprojen.aspx?proj=50459","http://www.chictr.org.cn/showprojen.aspx?proj=49753","http://www.chictr.org.cn/showprojen.aspx?proj=50470","http://www.chictr.org.cn/showprojen.aspx?proj=50450","http://www.chictr.org.cn/showprojen.aspx?proj=50458","http://www.chictr.org.cn/showprojen.aspx?proj=50453","http://www.chictr.org.cn/showprojen.aspx?proj=50263","http://www.chictr.org.cn/showprojen.aspx?proj=50353","http://www.chictr.org.cn/showprojen.aspx?proj=50452","http://www.chictr.org.cn/showprojen.aspx?proj=50495","http://www.chictr.org.cn/showprojen.aspx?proj=50460","http://www.chictr.org.cn/showprojen.aspx?proj=50455","http://www.chictr.org.cn/showprojen.aspx?proj=50380","http://www.chictr.org.cn/showprojen.aspx?proj=50421","http://www.chictr.org.cn/showprojen.aspx?proj=50082","http://www.chictr.org.cn/showprojen.aspx?proj=50390","http://www.chictr.org.cn/showprojen.aspx?proj=50381","http://www.chictr.org.cn/showprojen.aspx?proj=50378","http://www.chictr.org.cn/showprojen.aspx?proj=50388","http://www.chictr.org.cn/showprojen.aspx?proj=50382","http://www.chictr.org.cn/showprojen.aspx?proj=50387","http://www.chictr.org.cn/showprojen.aspx?proj=50273","http://www.chictr.org.cn/showprojen.aspx?proj=50341","http://www.chictr.org.cn/showprojen.aspx?proj=50286","http://www.chictr.org.cn/showprojen.aspx?proj=50224","http://www.chictr.org.cn/showprojen.aspx?proj=50268","http://www.chictr.org.cn/showprojen.aspx?proj=50173","http://www.chictr.org.cn/showprojen.aspx?proj=50278","http://www.chictr.org.cn/showprojen.aspx?proj=50174","http://www.chictr.org.cn/showprojen.aspx?proj=30796","http://www.chictr.org.cn/showprojen.aspx?proj=50329","http://www.chictr.org.cn/showprojen.aspx?proj=50297","http://www.chictr.org.cn/showprojen.aspx?proj=50306","http://www.chictr.org.cn/showprojen.aspx?proj=50279","http://www.chictr.org.cn/showprojen.aspx?proj=49984","http://www.chictr.org.cn/showprojen.aspx?proj=50290","http://www.chictr.org.cn/showprojen.aspx?proj=50240","http://www.chictr.org.cn/showprojen.aspx?proj=50248","http://www.chictr.org.cn/showprojen.aspx?proj=49491","http://www.chictr.org.cn/showprojen.aspx?proj=48801","http://www.chictr.org.cn/showprojen.aspx?proj=50223","http://www.chictr.org.cn/showprojen.aspx?proj=50247","http://www.chictr.org.cn/showprojen.aspx?proj=50255","http://www.chictr.org.cn/showprojen.aspx?proj=50214","http://www.chictr.org.cn/showprojen.aspx?proj=50227","http://www.chictr.org.cn/showprojen.aspx?proj=50022","http://www.chictr.org.cn/showprojen.aspx?proj=50231","http://www.chictr.org.cn/showprojen.aspx?proj=50258","http://www.chictr.org.cn/showprojen.aspx?proj=49653","http://www.chictr.org.cn/showprojen.aspx?proj=49779","http://www.chictr.org.cn/showprojen.aspx?proj=50222","http://www.chictr.org.cn/showprojen.aspx?proj=50274","http://www.chictr.org.cn/showprojen.aspx?proj=50241","http://www.chictr.org.cn/showprojen.aspx?proj=50271","http://www.chictr.org.cn/showprojen.aspx?proj=50119","http://www.chictr.org.cn/showprojen.aspx?proj=50195","http://www.chictr.org.cn/showprojen.aspx?proj=50175","http://www.chictr.org.cn/showprojen.aspx?proj=50202","http://www.chictr.org.cn/showprojen.aspx?proj=50136","http://www.chictr.org.cn/showprojen.aspx?proj=50140","http://www.chictr.org.cn/showprojen.aspx?proj=49691","http://www.chictr.org.cn/showprojen.aspx?proj=50161","http://www.chictr.org.cn/showprojen.aspx?proj=49918","http://www.chictr.org.cn/showprojen.aspx?proj=49887","http://www.chictr.org.cn/showprojen.aspx?proj=50006","http://www.chictr.org.cn/showprojen.aspx?proj=50130","http://www.chictr.org.cn/showprojen.aspx?proj=50089","http://www.chictr.org.cn/showprojen.aspx?proj=49963","http://www.chictr.org.cn/showprojen.aspx?proj=50143","http://www.chictr.org.cn/showprojen.aspx?proj=49855","http://www.chictr.org.cn/showprojen.aspx?proj=49945","http://www.chictr.org.cn/showprojen.aspx?proj=50026","http://www.chictr.org.cn/showprojen.aspx?proj=50137","http://www.chictr.org.cn/showprojen.aspx?proj=49968","http://www.chictr.org.cn/showprojen.aspx?proj=50078","http://www.chictr.org.cn/showprojen.aspx?proj=50048","http://www.chictr.org.cn/showprojen.aspx?proj=50110","http://www.chictr.org.cn/showprojen.aspx?proj=50107","http://www.chictr.org.cn/showprojen.aspx?proj=49883","http://www.chictr.org.cn/showprojen.aspx?proj=50115","http://www.chictr.org.cn/showprojen.aspx?proj=50071","http://www.chictr.org.cn/showprojen.aspx?proj=50066","http://www.chictr.org.cn/showprojen.aspx?proj=49229","http://www.chictr.org.cn/showprojen.aspx?proj=49696","http://www.chictr.org.cn/showprojen.aspx?proj=50059","http://www.chictr.org.cn/showprojen.aspx?proj=49983","http://www.chictr.org.cn/showprojen.aspx?proj=50058","http://www.chictr.org.cn/showprojen.aspx?proj=49567","http://www.chictr.org.cn/showprojen.aspx?proj=49947","http://www.chictr.org.cn/showprojen.aspx?proj=50025","http://www.chictr.org.cn/showprojen.aspx?proj=50017","http://www.chictr.org.cn/showprojen.aspx?proj=50004","http://www.chictr.org.cn/showprojen.aspx?proj=50007","http://www.chictr.org.cn/showprojen.aspx?proj=50005","http://www.chictr.org.cn/showprojen.aspx?proj=49570","http://www.chictr.org.cn/showprojen.aspx?proj=50031","http://www.chictr.org.cn/showprojen.aspx?proj=50057","http://www.chictr.org.cn/showprojen.aspx?proj=50002","http://www.chictr.org.cn/showprojen.aspx?proj=49433","http://www.chictr.org.cn/showprojen.aspx?proj=49594","http://www.chictr.org.cn/showprojen.aspx?proj=49901","http://www.chictr.org.cn/showprojen.aspx?proj=49932","http://www.chictr.org.cn/showprojen.aspx?proj=49988","http://www.chictr.org.cn/showprojen.aspx?proj=49794","http://www.chictr.org.cn/showprojen.aspx?proj=49970","http://www.chictr.org.cn/showprojen.aspx?proj=49762","http://www.chictr.org.cn/showprojen.aspx?proj=49964","http://www.chictr.org.cn/showprojen.aspx?proj=49880","http://www.chictr.org.cn/showprojen.aspx?proj=49747","http://www.chictr.org.cn/showprojen.aspx?proj=49914","http://www.chictr.org.cn/showprojen.aspx?proj=49987","http://www.chictr.org.cn/showprojen.aspx?proj=49845","http://www.chictr.org.cn/showprojen.aspx?proj=49952","http://www.chictr.org.cn/showprojen.aspx?proj=49910","http://www.chictr.org.cn/showprojen.aspx?proj=49831","http://www.chictr.org.cn/showprojen.aspx?proj=49904","http://www.chictr.org.cn/showprojen.aspx?proj=49889","http://www.chictr.org.cn/showprojen.aspx?proj=49902","http://www.chictr.org.cn/showprojen.aspx?proj=49919","http://www.chictr.org.cn/showprojen.aspx?proj=49934","http://www.chictr.org.cn/showprojen.aspx?proj=49869","http://www.chictr.org.cn/showprojen.aspx?proj=49915","http://www.chictr.org.cn/showprojen.aspx?proj=49864","http://www.chictr.org.cn/showprojen.aspx?proj=49948","http://www.chictr.org.cn/showprojen.aspx?proj=49866","http://www.chictr.org.cn/showprojen.aspx?proj=49891","http://www.chictr.org.cn/showprojen.aspx?proj=49647","http://www.chictr.org.cn/showprojen.aspx?proj=49816","http://www.chictr.org.cn/showprojen.aspx?proj=49861","http://www.chictr.org.cn/showprojen.aspx?proj=49824","http://www.chictr.org.cn/showprojen.aspx?proj=49703","http://www.chictr.org.cn/showprojen.aspx?proj=49544","http://www.chictr.org.cn/showprojen.aspx?proj=49899","http://www.chictr.org.cn/showprojen.aspx?proj=49806","http://www.chictr.org.cn/showprojen.aspx?proj=49841","http://www.chictr.org.cn/showprojen.aspx?proj=49852","http://www.chictr.org.cn/showprojen.aspx?proj=49798","http://www.chictr.org.cn/showprojen.aspx?proj=49800","http://www.chictr.org.cn/showprojen.aspx?proj=49510","http://www.chictr.org.cn/showprojen.aspx?proj=49690","http://www.chictr.org.cn/showprojen.aspx?proj=49812","http://www.chictr.org.cn/showprojen.aspx?proj=49768","http://www.chictr.org.cn/showprojen.aspx?proj=49797","http://www.chictr.org.cn/showprojen.aspx?proj=49802","http://www.chictr.org.cn/showprojen.aspx?proj=49840","http://www.chictr.org.cn/showprojen.aspx?proj=49799","http://www.chictr.org.cn/showprojen.aspx?proj=49619","http://www.chictr.org.cn/showprojen.aspx?proj=49718","http://www.chictr.org.cn/showprojen.aspx?proj=49777","http://www.chictr.org.cn/showprojen.aspx?proj=49426","http://www.chictr.org.cn/showprojen.aspx?proj=49737","http://www.chictr.org.cn/showprojen.aspx?proj=49748","http://www.chictr.org.cn/showprojen.aspx?proj=49418","http://www.chictr.org.cn/showprojen.aspx?proj=49723","http://www.chictr.org.cn/showprojen.aspx?proj=49717","http://www.chictr.org.cn/showprojen.aspx?proj=49783","http://www.chictr.org.cn/showprojen.aspx?proj=49770","http://www.chictr.org.cn/showprojen.aspx?proj=49738","http://www.chictr.org.cn/showprojen.aspx?proj=49796","http://www.chictr.org.cn/showprojen.aspx?proj=49669","http://www.chictr.org.cn/showprojen.aspx?proj=49309","http://www.chictr.org.cn/showprojen.aspx?proj=49702","http://www.chictr.org.cn/showprojen.aspx?proj=49574","http://www.chictr.org.cn/showprojen.aspx?proj=49674","http://www.chictr.org.cn/showprojen.aspx?proj=49720","http://www.chictr.org.cn/showprojen.aspx?proj=49218","http://www.chictr.org.cn/showprojen.aspx?proj=49711","http://www.chictr.org.cn/showprojen.aspx?proj=49692","http://www.chictr.org.cn/showprojen.aspx?proj=49321","http://www.chictr.org.cn/showprojen.aspx?proj=50323","http://www.chictr.org.cn/showprojen.aspx?proj=49592","http://www.chictr.org.cn/showprojen.aspx?proj=49666","http://www.chictr.org.cn/showprojen.aspx?proj=49435","http://www.chictr.org.cn/showprojen.aspx?proj=49712","http://www.chictr.org.cn/showprojen.aspx?proj=49724","http://www.chictr.org.cn/showprojen.aspx?proj=49631","http://www.chictr.org.cn/showprojen.aspx?proj=49217","http://www.chictr.org.cn/showprojen.aspx?proj=49618","http://www.chictr.org.cn/showprojen.aspx?proj=49639","http://www.chictr.org.cn/showprojen.aspx?proj=49636","http://www.chictr.org.cn/showprojen.aspx?proj=49664","http://www.chictr.org.cn/showprojen.aspx?proj=49402","http://www.chictr.org.cn/showprojen.aspx?proj=50325","http://www.chictr.org.cn/showprojen.aspx?proj=49630","http://www.chictr.org.cn/showprojen.aspx?proj=49635","http://www.chictr.org.cn/showprojen.aspx?proj=49633","http://www.chictr.org.cn/showprojen.aspx?proj=49531","http://www.chictr.org.cn/showprojen.aspx?proj=49607","http://www.chictr.org.cn/showprojen.aspx?proj=49181","http://www.chictr.org.cn/showprojen.aspx?proj=49599","http://www.chictr.org.cn/showprojen.aspx?proj=49432","http://www.chictr.org.cn/showprojen.aspx?proj=49549","http://www.chictr.org.cn/showprojen.aspx?proj=49596","http://www.chictr.org.cn/showprojen.aspx?proj=49612","http://www.chictr.org.cn/showprojen.aspx?proj=49587","http://www.chictr.org.cn/showprojen.aspx?proj=49595","http://www.chictr.org.cn/showprojen.aspx?proj=49536","http://www.chictr.org.cn/showprojen.aspx?proj=49482","http://www.chictr.org.cn/showprojen.aspx?proj=49377","http://www.chictr.org.cn/showprojen.aspx?proj=49569","http://www.chictr.org.cn/showprojen.aspx?proj=49533","http://www.chictr.org.cn/showprojen.aspx?proj=49486","http://www.chictr.org.cn/showprojen.aspx?proj=49514","http://www.chictr.org.cn/showprojen.aspx?proj=49530","http://www.chictr.org.cn/showprojen.aspx?proj=49563","http://www.chictr.org.cn/showprojen.aspx?proj=49543","http://www.chictr.org.cn/showprojen.aspx?proj=49532","http://www.chictr.org.cn/showprojen.aspx?proj=49439","http://www.chictr.org.cn/showprojen.aspx?proj=49519","http://www.chictr.org.cn/showprojen.aspx?proj=49545","http://www.chictr.org.cn/showprojen.aspx?proj=49534","http://www.chictr.org.cn/showprojen.aspx?proj=49520","http://www.chictr.org.cn/showprojen.aspx?proj=49495","http://www.chictr.org.cn/showprojen.aspx?proj=49511","http://www.chictr.org.cn/showprojen.aspx?proj=49524","http://www.chictr.org.cn/showprojen.aspx?proj=49387","http://www.chictr.org.cn/showprojen.aspx?proj=49355","http://www.chictr.org.cn/showprojen.aspx?proj=49407","http://www.chictr.org.cn/showprojen.aspx?proj=49188","http://www.chictr.org.cn/showprojen.aspx?proj=49502","http://www.chictr.org.cn/showprojen.aspx?proj=49346","http://www.chictr.org.cn/showprojen.aspx?proj=49425","http://www.chictr.org.cn/showprojen.aspx?proj=49161","http://www.chictr.org.cn/showprojen.aspx?proj=49306","http://www.chictr.org.cn/showprojen.aspx?proj=49490","http://www.chictr.org.cn/showprojen.aspx?proj=49178","http://www.chictr.org.cn/showprojen.aspx?proj=49428","http://www.chictr.org.cn/showprojen.aspx?proj=49384","http://www.chictr.org.cn/showprojen.aspx?proj=49374","http://www.chictr.org.cn/showprojen.aspx?proj=49481","http://www.chictr.org.cn/showprojen.aspx?proj=49492","http://www.chictr.org.cn/showprojen.aspx?proj=49382","http://www.chictr.org.cn/showprojen.aspx?proj=49389","http://www.chictr.org.cn/showprojen.aspx?proj=49348","http://www.chictr.org.cn/showprojen.aspx?proj=49378","http://www.chictr.org.cn/showprojen.aspx?proj=49422","http://www.chictr.org.cn/showprojen.aspx?proj=49380","http://www.chictr.org.cn/showprojen.aspx?proj=49342","http://www.chictr.org.cn/showprojen.aspx?proj=49445","http://www.chictr.org.cn/showprojen.aspx?proj=49388","http://www.chictr.org.cn/showprojen.aspx?proj=49453","http://www.chictr.org.cn/showprojen.aspx?proj=49452","http://www.chictr.org.cn/showprojen.aspx?proj=49409","http://www.chictr.org.cn/showprojen.aspx?proj=49415","http://www.chictr.org.cn/showprojen.aspx?proj=49131","http://www.chictr.org.cn/showprojen.aspx?proj=49138","http://www.chictr.org.cn/showprojen.aspx?proj=49220","http://www.chictr.org.cn/showprojen.aspx?proj=49412","http://www.chictr.org.cn/showprojen.aspx?proj=49408","http://www.chictr.org.cn/showprojen.aspx?proj=49295","http://www.chictr.org.cn/showprojen.aspx?proj=49222","http://www.chictr.org.cn/showprojen.aspx?proj=49370","http://www.chictr.org.cn/showprojen.aspx?proj=49354","http://www.chictr.org.cn/showprojen.aspx?proj=49404","http://www.chictr.org.cn/showprojen.aspx?proj=49301","http://www.chictr.org.cn/showprojen.aspx?proj=49400","http://www.chictr.org.cn/showprojen.aspx?proj=49352","http://www.chictr.org.cn/showprojen.aspx?proj=49369","http://www.chictr.org.cn/showprojen.aspx?proj=49081","http://www.chictr.org.cn/showprojen.aspx?proj=49297","http://www.chictr.org.cn/showprojen.aspx?proj=49263","http://www.chictr.org.cn/showprojen.aspx?proj=49287","http://www.chictr.org.cn/showprojen.aspx?proj=49283","http://www.chictr.org.cn/showprojen.aspx?proj=49317","http://www.chictr.org.cn/showprojen.aspx?proj=49219","http://www.chictr.org.cn/showprojen.aspx?proj=49279","http://www.chictr.org.cn/showprojen.aspx?proj=49302","http://www.chictr.org.cn/showprojen.aspx?proj=48868","http://www.chictr.org.cn/showprojen.aspx?proj=49250","http://www.chictr.org.cn/showprojen.aspx?proj=49086","http://www.chictr.org.cn/showprojen.aspx?proj=49074","http://www.chictr.org.cn/showprojen.aspx?proj=49127","http://www.chictr.org.cn/showprojen.aspx?proj=49215","http://www.chictr.org.cn/showprojen.aspx?proj=49187","http://www.chictr.org.cn/showprojen.aspx?proj=49224","http://www.chictr.org.cn/showprojen.aspx?proj=49170","http://www.chictr.org.cn/showprojen.aspx?proj=49132","http://www.chictr.org.cn/showprojen.aspx?proj=49155","http://www.chictr.org.cn/showprojen.aspx?proj=49165","http://www.chictr.org.cn/showprojen.aspx?proj=49177","http://www.chictr.org.cn/showprojen.aspx?proj=49146","http://www.chictr.org.cn/showprojen.aspx?proj=49051","http://www.chictr.org.cn/showprojen.aspx?proj=48988","http://www.chictr.org.cn/showprojen.aspx?proj=48985","http://www.chictr.org.cn/showprojen.aspx?proj=49145","http://www.chictr.org.cn/showprojen.aspx?proj=49042","http://www.chictr.org.cn/showprojen.aspx?proj=49075","http://www.chictr.org.cn/showprojen.aspx?proj=49104","http://www.chictr.org.cn/showprojen.aspx?proj=49080","http://www.chictr.org.cn/showprojen.aspx?proj=41760","http://www.chictr.org.cn/showprojen.aspx?proj=49088","http://www.chictr.org.cn/showprojen.aspx?proj=49045","http://www.chictr.org.cn/showprojen.aspx?proj=49069","http://www.chictr.org.cn/showprojen.aspx?proj=49065","http://www.chictr.org.cn/showprojen.aspx?proj=49062","http://www.chictr.org.cn/showprojen.aspx?proj=48880","http://www.chictr.org.cn/showprojen.aspx?proj=48792","http://www.chictr.org.cn/showprojen.aspx?proj=49015","http://www.chictr.org.cn/showprojen.aspx?proj=48775","http://www.chictr.org.cn/showprojen.aspx?proj=49014","http://www.chictr.org.cn/showprojen.aspx?proj=48968","http://www.chictr.org.cn/showprojen.aspx?proj=48991","http://www.chictr.org.cn/showprojen.aspx?proj=48860","http://www.chictr.org.cn/showprojen.aspx?proj=48861","http://www.chictr.org.cn/showprojen.aspx?proj=49013","http://www.chictr.org.cn/showprojen.aspx?proj=48992","http://www.chictr.org.cn/showprojen.aspx?proj=48809","http://www.chictr.org.cn/showprojen.aspx?proj=48971","http://www.chictr.org.cn/showprojen.aspx?proj=48931","http://www.chictr.org.cn/showprojen.aspx?proj=48922","http://www.chictr.org.cn/showprojen.aspx?proj=48965","http://www.chictr.org.cn/showprojen.aspx?proj=48919","http://www.chictr.org.cn/showprojen.aspx?proj=48927","http://www.chictr.org.cn/showprojen.aspx?proj=48930","http://www.chictr.org.cn/showprojen.aspx?proj=48929","http://www.chictr.org.cn/showprojen.aspx?proj=48773","http://www.chictr.org.cn/showprojen.aspx?proj=48911","http://www.chictr.org.cn/showprojen.aspx?proj=48881","http://www.chictr.org.cn/showprojen.aspx?proj=48907","http://www.chictr.org.cn/showprojen.aspx?proj=48884","http://www.chictr.org.cn/showprojen.aspx?proj=48913","http://www.chictr.org.cn/showprojen.aspx?proj=48904","http://www.chictr.org.cn/showprojen.aspx?proj=48827","http://www.chictr.org.cn/showprojen.aspx?proj=48902","http://www.chictr.org.cn/showprojen.aspx?proj=48898","http://www.chictr.org.cn/showprojen.aspx?proj=48889","http://www.chictr.org.cn/showprojen.aspx?proj=48886","http://www.chictr.org.cn/showprojen.aspx?proj=48824","http://www.chictr.org.cn/showprojen.aspx?proj=48782","http://www.chictr.org.cn/showprojen.aspx?proj=48777","http://www.chictr.org.cn/showprojen.aspx?proj=48768","http://www.chictr.org.cn/showprojen.aspx?proj=48684"],["Interventional study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Interventional study",null,null,null,"Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study",null,"Interventional study","Interventional study",null,"Interventional study","Interventional study",null,"Observational study","Observational study",null,null,null,null,"Interventional study","Interventional study","Diagnostic test","Observational study","Interventional study","Interventional study","Diagnostic test","Observational study",null,null,null,"Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study",null,null,"Interventional study","Observational study","Interventional study","Observational study",null,null,"Observational study","Observational study","Observational study","Observational study",null,"Interventional study","Interventional study","Observational study","Interventional study","Observational study",null,"Interventional study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Diagnostic test","Diagnostic test","Interventional study","Observational study","Interventional study","Observational study","Basic Science","Interventional study","Observational study","Health Services Research","Observational study","Interventional study","Health Services Research","Observational study","Interventional study","Observational study","Interventional study","Diagnostic test","Interventional study","Health Services Research","Interventional study","Observational study","Interventional study","Observational study","Observational study","Diagnostic test","Diagnostic test","Basic Science","Interventional study","Observational study","Diagnostic test","Observational study","Observational study","Observational study","Diagnostic test","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Health services reaserch","Epidemilogical research","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Diagnostic test","Interventional study","Interventional study","Observational study","Observational study","Diagnostic test","Interventional study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Basic Science","Diagnostic test","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Treatment study","Interventional study","Interventional study","Prevention","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Health services reaserch","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Diagnostic test","Interventional study","Interventional study","Interventional study","Observational study","Diagnostic test","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Observational study","Interventional study","Screening","Interventional study","Observational study","Observational study","Interventional study","Diagnostic test","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Epidemilogical research","Interventional study","Diagnostic test","Interventional study","Observational study","Observational study","Observational study","Observational study","Epidemilogical research","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Interventional study","Diagnostic test","Observational study","Observational study","Epidemilogical research","Interventional study","Diagnostic test","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Observational study","Interventional study","Interventional study","Basic Science","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Basic Science","Diagnostic test","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Epidemilogical research","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Epidemilogical research","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Epidemilogical research","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Diagnostic test","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Epidemilogical research","Observational study","Observational study","Observational study","Interventional study","Interventional study","Epidemilogical research","Interventional study","Observational study","Interventional study","Treatment study","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Observational study","Interventional study","Health services reaserch","Interventional study","Interventional study","Epidemilogical research","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Health services reaserch","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Diagnostic test","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Prognosis study","Diagnostic test","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Basic Science","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Treatment study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Interventional study","Observational study","Interventional study","Observational study","Diagnostic test","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Interventional study","Observational study","Diagnostic test","Observational study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Prevention","Interventional study","Prognosis study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Diagnostic test","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Basic Science","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Prevention","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study"],["Experimental group:Basic treatment + kolimycin;Control group:Basic treatment;","Group A:none;Group B:no;","experimental group:Xiangsha Liujun Pill;Control group:Placebo;"," COVID-19 critically ill patients;:NA;Non-COVID-19 critically ill patients.:NA;Normal tissue:NA;","Experimental group:Shumian capsule;Control group:Shumian capsule placebo;","Case series:wearing medical mask after extubation in PACU;","Experimental group:Shengmai Decoction;Control group:Shengmai Decoction simulant;","Control Group:Qimaifeiluoping Mixture Simulator + Respiratory Training + Rehabilitation Education Guidance;Experimental group:Qimaifeiluoping Mixture  + Respiratory Training + Rehabilitation Education Guidance;","ECMO group:ECMO;mechanic ventilation:mechanic ventilation;","Case series:N/A;","Control Group:Qimaifeiluoping Mixture Simulator + Respiratory Training + Rehabilitation Education Guidance;Experimental group:Qimaifeiluoping Mixture  + Respiratory Training + Rehabilitation Education Guidance;","ECMO group:ECMO;mechanic ventilation:mechanic ventilation;","Case series:N/A;","Control Group:Qimaifeiluoping Mixture Simulator + Respiratory Training + Rehabilitation Education Guidance;Experimental group:Qimaifeiluoping Mixture  + Respiratory Training + Rehabilitation Education Guidance;","ECMO group:ECMO;mechanic ventilation:mechanic ventilation;","Case series:N/A;","Experimental group: mild cases:Ulinastatin 300,000 IU, Q12H;Experimental group: severe or critical cases:Severe cases: 1 million IU of ulinastatin, Q8H; Critical cases: ulinastatin 1.6 million IU, Q8H;Control group: mild cases:conventional therapy;Control group: severe or critical cases :conventional therapy;","Experimental group: mild cases:Ulinastatin 300,000 IU, Q12H;Experimental group: severe or critical cases:Severe cases: 1 million IU of ulinastatin, Q8H; Critical cases: ulinastatin 1.6 million IU, Q8H;Control group: mild cases:conventional therapy;Control group: severe or critical cases :conventional therapy;","Experimental group: mild cases:Ulinastatin 300,000 IU, Q12H;Experimental group: severe or critical cases:Severe cases: 1 million IU of ulinastatin, Q8H; Critical cases: ulinastatin 1.6 million IU, Q8H;Control group: mild cases:conventional therapy;Control group: severe or critical cases :conventional therapy;","Case series :Western medicine plus Danggui Shaoyao Power ;","Case series :Western medicine plus Danggui Shaoyao Power ;","Case series :Western medicine plus Danggui Shaoyao Power ;","Case series:Subcutaneous injection of thymosin a1, take Ma-Xing-Shi-Gan tang and Yin-Qiao powder plus or minus;","Case series:Subcutaneous injection of thymosin a1, take Ma-Xing-Shi-Gan tang and Yin-Qiao powder plus or minus;","Case series:Subcutaneous injection of thymosin a1, take Ma-Xing-Shi-Gan tang and Yin-Qiao powder plus or minus;","Two groups:modified respirator versus conventional respirator;","1.5ATA:1.5ATA HBO;2.5ATA:2.5ATA HBO;Control group:Routine treatment;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:COVID-19&amp;#32;Intelligent&amp;#32;Assistant&amp;#32;Analysis&amp;#32;System;","Case series:No;","Two groups:modified respirator versus conventional respirator;","1.5ATA:1.5ATA HBO;2.5ATA:2.5ATA HBO;Control group:Routine treatment;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:COVID-19&amp;#32;Intelligent&amp;#32;Assistant&amp;#32;Analysis&amp;#32;System;","Case series:No;","Two groups:modified respirator versus conventional respirator;","1.5ATA:1.5ATA HBO;2.5ATA:2.5ATA HBO;Control group:Routine treatment;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:COVID-19&amp;#32;Intelligent&amp;#32;Assistant&amp;#32;Analysis&amp;#32;System;","Case series:No;","Case series:Ke-Gan-Li-Yan oral liquid;","control group:General basic epidemic prevention measures;sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet;Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray;Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups;","Case series:Nil;","Case series:Ke-Gan-Li-Yan oral liquid;","control group:General basic epidemic prevention measures;sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet;Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray;Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups;","Case series:Nil;","Case series:Ke-Gan-Li-Yan oral liquid;","control group:General basic epidemic prevention measures;sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet;Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray;Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups;","Case series:Nil;","experimental group:Chinese herbal tea;control group:drinking water;","Case series:Nil;","experimental group:Chinese herbal tea;control group:drinking water;","Case series:Nil;","experimental group:Chinese herbal tea;control group:drinking water;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","experimental group:''Guangdong Pneumonia NO.1''+basic treatment;\t control group:basic treatment and(or) antiviral therapy;","experimental group:''Guangdong Pneumonia NO.1''+basic treatment;\t control group:basic treatment and(or) antiviral therapy;","experimental group:''Guangdong Pneumonia NO.1''+basic treatment;\t control group:basic treatment and(or) antiviral therapy;","intervention group:exercise;Control group:Blank;","Experimental group:exercise rehabilitation under remote monitoring;Control group:patient education;","mild, moderate, severe ARDS:Nil;","phase I A1:Low dose;phase I A2:Placebo;phase I A3:Middle dose;phase I A4:Placebo;phase I A5:High dose;phase I A6:Placebo;phase I E1:Low dose;phase I E2:Placebo;phase I E3:Middle dose;phase I E4:Placebo;phase I E5:High dose;phase I E6:Placebo;phase I F1:Low dose;phase I F2:Placebo;phase I F3:Middle dose;phase I F4:Placebo;phase I F5:High dose;phase I F6:Placebo;phase II A1:Low dose;phase II A2:Placebo;phase II A3:Middle dose;phase II A4:Placebo;phase II A5:High dose;phase II A6:Placebo;phase II B1:Middle dose;phase II B2:Placebo;phase II C1:Middle dose;phase II C2:Placebo;phase II G1:Middle dose;phase II G2:Placebo;phase II D1:High dose;phase II D2:Placebo;phase II E1:Low dose;phase II E2:Placebo;phase II E3:Middle dose;phase II E4:Placebo;phase II E5:High dose;phase II E6:Placebo;phase II F1:Low dose;phase II F2:Placebo;phase II F3:Middle dose;phase II F4:Placebo;phase II F5:High dose;phase II F6:Placebo;","phase I A1:Low dose;phase I A2:Placebo;phase I A3:Middle dose;phase I A4:Placebo;phase I A5:High dose;phase I A6:Placebo;phase I E1:Low dose;phase I E2:Placebo;phase I E3:Middle dose;phase I E4:Placebo;phase I E5:High dose;phase I E6:Placebo;phase I F1:Low dose;phase I F2:Placebo;phase I F3:Middle dose;phase I F4:Placebo;phase I F5:High dose;phase I F6:Placebo;phase II A1:Low dose;phase II A2:Placebo;phase II A3:Middle dose;phase II A4:Placebo;phase II A5:High dose;phase II A6:Placebo;phase II B1:Middle dose;phase II B2:Placebo;phase II C1:Middle dose;phase II C2:Placebo;phase II G1:Middle dose;phase II G2:Placebo;phase II D1:High dose;phase II D2:Placebo;phase II E1:Low dose;phase II E2:Placebo;phase II E3:Middle dose;phase II E4:Placebo;phase II E5:High dose;phase II E6:Placebo;phase II F1:Low dose;phase II F2:Placebo;phase II F3:Middle dose;phase II F4:Placebo;phase II F5:High dose;phase II F6:Placebo;","phase I A1:Low dose;phase I A2:Placebo;phase I A3:Middle dose;phase I A4:Placebo;phase I A5:High dose;phase I A6:Placebo;phase I E1:Low dose;phase I E2:Placebo;phase I E3:Middle dose;phase I E4:Placebo;phase I E5:High dose;phase I E6:Placebo;phase I F1:Low dose;phase I F2:Placebo;phase I F3:Middle dose;phase I F4:Placebo;phase I F5:High dose;phase I F6:Placebo;phase II A1:Low dose;phase II A2:Placebo;phase II A3:Middle dose;phase II A4:Placebo;phase II A5:High dose;phase II A6:Placebo;phase II B1:Middle dose;phase II B2:Placebo;phase II C1:Middle dose;phase II C2:Placebo;phase II G1:Middle dose;phase II G2:Placebo;phase II D1:High dose;phase II D2:Placebo;phase II E1:Low dose;phase II E2:Placebo;phase II E3:Middle dose;phase II E4:Placebo;phase II E5:High dose;phase II E6:Placebo;phase II F1:Low dose;phase II F2:Placebo;phase II F3:Middle dose;phase II F4:Placebo;phase II F5:High dose;phase II F6:Placebo;","Case series:Nil;","Case series:None;","Patients with LE and are taking hydroxychloroquine:N/A;Patients with LE and are not taking hydroxychloroquine:N/A;Patients with dermatomyositis and are taking hydroxychloroquine:N/A;Patients with dermatomyositis and are not taking hydroxychloroquine:N/A;Patients with RA and are taking hydroxychloroquine:N/A;Patients with RA and are not taking hydroxychloroquine:N/A;Patients with rosacea and are taking hydroxychloroquine:N/A;Patients with rosacea and are not taking hydroxychloroquine:N/A;","1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;","1:none;","Experimental group:WeChat-based parenting education;Control groop:Electronic Manual + Teaching Plan;","Case series:Nursing care;","survival group:none;death group:none;","Case group:N/A;control group:N/A;","NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension;Control group:100ml normal saline intravenous drip;","Case series:Danorevir sodium tablets,/ritonavir oral;","Patient:Surface swab and air sample collection;Healthcare providers:Surface swab from personal protective equipment;","For the mild new coronary pneumonia: General Ward Group:Nil;For the severe new coronary pneumonia: ICU Group:Nil;Support staff: Logistics group:Nil;","Case series:no intervention;","Gold Standard:clinical outcome; nucleic acid test;Index test:antigen reagent;","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&amp;#32;metabolomics&amp;#32;and&amp;#32;other&amp;#32;markers,&amp;#32;mass&amp;#32;spectrometer;","Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);","Case series:cesarean section;","Experimental group:Celebrex capsules 200mg / time twice a day for 7 days;control group:routine treatment;","cross-sectional study:no;","Control group :Isolate PBMC to extract tRNA ;normal group:Isolate PBMC to extract tRNA;severe group:Isolate PBMC to extract tRNA;","Group 1:single-shot CBT-I;Group 2:Sleep Hygiene;","ordinary group versus severe group versus critical group versus deceased patients group:no;","Case series:N/A;","ARBs Group:Treatment of ARBs;non-ARBs Group:other treatments;","Experimental group:Rehabilitation Nursing Program;Control group:Routine rehabilitation care;","Medical personnel group:N/A;","Rheumatic disease with COVID-19:N/A;Rheumatic disease without COVID-19:N/A;","Control:NA;Noninvasive cardiopulmonary monitoring group:Wear non-invasive multi-channel cardiopulmonary monitor;","eye patch and earplugs:Nil;eye patch:Nil;","Experimental group:Conventional medication + Infusion of mesenchymal stem cells;Control group:Conventional medication;","Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgG;","Group 1:Routine treatment + Infusion of convalescent plasma;Group 2:Routine treatment;","experiment group:Cold outdoor environment;experiment group :temperature measuring distance;","Nintedanib group:Nintedanib;Control group:Placebo;","Case series:Questionnaire survey without intervention;","experimental group:Rabeprazole plus chloroquine;control group :Lopinavir + rabeprazole;",null,"COVID-19 with risk factors:N/A;COVID-19 without risk factors:N/A;","Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgM;","Gold Standard:Viral nucleic acid detection;Index test:specific&amp;#32;serological&amp;#32;detection;","Different dose groups:Injection dose;","Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;","Case series:no;","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&amp;#32;metabolomics&amp;#32;and&amp;#32;other&amp;#32;markers,&amp;#32;mass&amp;#32;spectrometer;","Mild:No;severe:No;","mild recovery:none;severe recovery:none;control:none;","Cesarean section:Case Series;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:new&amp;#32;artificial&amp;#32;intelligence-based&amp;#32;prognosis&amp;#32;assessment&amp;#32;system;","Case series:Nil;","Case series:orthokeratology lens;","Case series:None.;","hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;","Case series:none;","Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in accordance with the \"new coronavirus infection pneumonia diagnosis and treatment program\" trial fifth, sixth, seventh version of the provisions of the implementation.;","Case series:Nil;","Case series:Nil;","Survival and D:none;","Case series:Nil;","mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;","Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:NO;","Case series:Nil;","Case series:Nil;","Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);","1:Blank;2:Moxibustion treatment;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:?;","Homeopathic patient:The popular science education;","Case series:none;","treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;","Case series:Nil;","Case series:Nil;","Case series:none;","Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","Diagnosed Group:Nil;Suspending Group:Nil;","COVID-19  patients:no;","Group 1:psychological support;Group 2:cognitive behavioral therapy;","Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion interval 1 week (+/-2 days) from the last time.;","experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","Group 2:thymosin;Group 1:BaZhen soup;","SARS-COV-2 RNA Positive group:None;SARS-COV-2 RNA Negative group:None;","Gold Standard:Clinical outcomes;Index test:the&amp;#32;diagnosis&amp;#32;and&amp;#32;prognosis&amp;#32;prediction&amp;#32;AI&amp;#32;model;","SFBT group:Internet based SFBT;Waiting Group:Wait ;","Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","Critical group/ Ordinary group:no;","Case series:Nil;","Gold Standard:Other parts samples or other methods for virus detection;Index test:Upper&amp;#32;Respiratory&amp;#32;Tract&amp;#32;Virus&amp;#32;Detection;","Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","cross-sectional study:Nil;","Case series:standard treatment + syndrome differentiation and treatment of TCM;","Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","Case series:Nil;","1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","Case series:Nil;","the patients of 2019 new coronavirus pneumonia:None;","Gold Standard:RT-PCR test;Index test:artificial&amp;#32;intelligence&amp;#32;triage&amp;#32;system;","Case series:Nil;","Case series:oral CSA0001;","Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","COVID-19 patients:Nil;","Case series:Nil;","Case series:Nil;","COVID-19 patients:Retrospective analysis;","Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","Case series:no;","Experimental group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment;","confirmed group:none;control group:none;","CM group:Xinguan No. 2 / Xinguan No. 3 alone or + regular treatment;WM group:Regular Ttreatment;","Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;","1:Low dose (5E10vp);2:Middle dose (1E11vp);3:High dose (1E11vp);","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;","observational:Ultrasonic monitoring;","Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medicine;","Case series:traditional Chinese medicine and Western medicine treatment;","Case series:Nil;","Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;","Case series:None;","Observation group:Positive Psychological Guidance Group Counseling;","Case series:None;","Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","Ordinary COVID-19 patients:Nil;Heavy COVID-19 patients:Nil;","Case series:Nil;","Case series:Not applicable;","The triple combination antiviral therapy:abidor,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);The dual combination antiviral therapy:,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);","Case series:dexmedetomidine;","Case series:Nil;","Experimental group:Pirfenidone;Control group:Blank;","Case series:qingfei detoxification decoction (mixture);","Case series:N/A;","Case series:Nil;","Case series:none;","Gold Standard:RT-PCR test results;Index test:Artificial&amp;#32;intelligence&amp;#32;model;","Population under risk:Chushifangyi prescription;","MSC group:Intravenous infusion of MSC based on conventional treatments;","Case series:Western medicine plus Qingfei Paidu decoction;","Group 1:Traditional Chinese medicine and routine treatment of western medicine;Group 2:Routine treatment of western medicine;","Case series:The use of fiberoptic bronchoscopy;","Case series:external diaphragmatic pacing;","Case series:none;","Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","Case series:Nil;","Gold Standard:RT-PCR test results;Index test:Typing&amp;#32;and&amp;#32;prediction&amp;#32;accuracy&amp;#32;of&amp;#32;artificial&amp;#32;intelligence&amp;#32;models;","Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","Case series:Psychological intervention;","High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","Case series:Nil;","Gold Standard:PCR Nucleic acid detection;Index test:high-throughput&amp;#32;novel&amp;#32;coronavirus&amp;#32;(2019-nCoV)&amp;#32;screening&amp;#32;detection&amp;#32;kit;","Case series:Nil;","Case series:Nil;","\t Case series:none;","Case series:none;","Case series:N/A;","Case series:Nil;","non-cancer COVID-19 versus cancer with COVID-19:none;","Case series:Nil;","severe patients:none;","Case series:Nil;","Case series:Nil;","Case series:Nil;","discharge group:no;","Gold Standard:Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive;Index test:Elisa&amp;#32;analysis&amp;#32;of&amp;#32;validation&amp;#32;factors,&amp;#32;inflammatory&amp;#32;factors,&amp;#32;adhesion&amp;#32;factors;","Observation group:Medical workers in Hubei province;Control group:Non-Hubei medical staffNon-Hubei medical staff;","Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","Case series:Laboratory examination and pulmonary CT;","Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","Case series:Nil;","experimental group:Oral Chinese medicine \"qingfei detoxification soup\" + intravenous injection of ulinastatin 200000 U Bid.;","Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","Gold Standard:Clinical outcome;Index test:artificial&amp;#32;intelligence&amp;#32;prediction&amp;#32;model;","Case series:Noninvasive hemodynamic monitoring;","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","Case series:No;","Case series:none;","Case series:Early initiation of blood purification;","Case series:No;","Case series:no;","Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","Gold Standard:Clinical outcome;Index test:Based&amp;#32;on&amp;#32;proteomics,&amp;#32;genomics,&amp;#32;and&amp;#32;epigenomics&amp;#32;to&amp;#32;detect&amp;#32;molecular&amp;#32;markers&amp;#32;in&amp;#32;peripheral&amp;#32;blood&amp;#32;of&amp;#32;patients&amp;#32;with&amp;#32;mild&amp;#32;and&amp;#32;severe&amp;#32;COVID-19&amp;#32;infection,&amp;#32;in&amp;#32;order&amp;#32;to&amp;#32;establish&amp;#32;an&amp;#32;early&amp;#32;molecular&amp;#32;marker&amp;#32;prediction&amp;#32;model&amp;#32;to&amp;#32;predict&amp;#32;the&amp;#32;prognosis&amp;#32;of&amp;#32;patients.;","control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","NIV group:no;MV group:no;","Case series:Nil;","Case series:Nil;","4 groups:N/A;","Case series:Nil;","two groups:no intervention;","Case series:no;","Case series:Traditional Mongolian Medicine;","case series:no;","ECMO group:ECMO therapy;the conventional treatment group:no;","Case series:no;","transnasal high-flow oxygen therapy:prone position ventilation;noninvasive mechanical ventilation:prone position ventilation ;invasive mechanical ventilation:prone position ventilation;","case series:no;","case series:no;","case series:no;","Case series:CRRT;","Gold Standard:2019 nCOV detection;Index test:SARS-CoV-2 IgM;","case series:Nil;","Control group :Health education and   symptomatic treatment;Comprehensive treatment group:Health education+Comprehensive TCM treatment;",null,"common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;Index test:1.&amp;#32;throat&amp;#32;swab&lt;br&gt;2.&amp;#32;induced&amp;#32;sputum;","Case series:Nil;","Experimental group:chloroquine phosphate ;Control group:none;","Exposed group:Prophylactic antifungal therapy;Control group:Diagnostic antifungal therapy;","in hospital:Virus detection in semen;Recovered:Hormones and sperm quality;","Case series:filling in the  scale;","Case series:Nil;","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;","Integrated traditional Chinese and western medicine group:Traditional Chinese medicine and routine treatment of western medicine;Western medicine group:Routine treatment of western medicine;","Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","Two groups:Nil;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","Case series:NA;","Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;","Infection without renal injury group:none;Infection with proteinuria group:Bailing Capsule;Infection with hematuria group:Bailing Capsule;Infection with impaired renal function group:Bailing Capsule, Renal replacement therapy;","Gold Standard:Clinical outcomes;Index test:MEWS&amp;#32;and&amp;#32;other&amp;#32;scores;","Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common extubation;Group D:Propofol anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;","tumor patients group:no;","case series:N/A;","Case series:None;","Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","Case series:observation;","Case series:Nil;","Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","Case series:Nil;","Chinese medicine treatment cohort:traditional Chinese medicine;Integrated Chinese and western medicine treatment cohort:Chinese medicine and western medicine;Western medicine treatment cohort:western medicine;","Case series:N/A;","Case series:N/A;","Case series:clustering nusing progremm;","Case series:Nil;","case series:N/A;","monitor cases, suspected cases and diagnosed cases:Provide psychological intervention for children with severe stress response;","Gold Standard:Nucleic acid test;Index test:Nano-nasal&amp;#32;COVID-19&amp;#32;diagnostic&amp;#32;screening&amp;#32;model;","1:Throat swab virus nucleic acid test combined with low-dose chest CT;2:Throat swab virus nucleic acid test combined with low-dose chest CT;","experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","Case series:no;","Case series:reverse transcription polymerase chain reaction;","Medical students group; Non-medical students group:None;","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:None;","CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&amp;#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;","Group 1:Baduanjin;Group 2:Auricular acupressure;","control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug;","experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","Case series:Nil;","Novel coronavirus pneumonia:none;","Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment&amp;#32;","cross-sectional study:no;","Control group:Western medicine treatment;Experimental group:integrate Chinese and conventional medicine  treatment;","Patients in Wuhan versus Sichuan:none;","Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","COVID-2019 patients in Tongji Hospital:none;COVID-2019 patients in Mobile field hospital:none;Medical staff in Tongji Hospital:none;Control:none;","Group 2:conservation mechanical ventilation group;Group 1:aggressive mechanical ventilation;","Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","Control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan.;Experimental group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + Yiqi Huashi Jiedu Fang (same as above), decoction of decoction machine, 300mL;","Case series:oXiris membrane;","Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intravenous administration, 180mg / time, 1 time / day, 7 days / course, 2 courses in total;control group:The control group was given the same amount of placebo (stem cell solvent);","Case series:NA;","Case series:cytokine removal therapy with Cytosorb;","treatment group :Ba duanjin;","Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.;","1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","Case series:Combination of Tocilizumab, IVIG and CRRT;","Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","PRE-GROUP1:Taking Chinese medicine preventive decoction;PRE-GROUP2:General prevention methods;TRE-GROUP1:TCM syndrome differentiation treatment+ Western medicine treatment;TRE-GROUP2:Western medicine treatment;","ACEIs/ARBs:NA;","Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological intervention;","Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","Case series:Nil;","Case series:Psychological counseling;","one group:Rehabilitation Lung Health Eight - Stage Exercise ;","Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;","Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy;","Gold Standard:Postive result of SARS-CoV-2 nucleic acid examination;Index test:Diagnostic&amp;#32;Assistance&amp;#32;Decision&amp;#32;Support&amp;#32;System;","Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;","Exposure group:Western medicine routine treatment+triple energizer treatment;Control group:Conventional medicine routine treatment;","Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment;","Case series:NA;","Mild group:Conventional treatment;Serere group:intensive care;","Case series:Nil;","Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","Monitor cases, suspected cases and diagnosed cases:No;","Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","Light and common type group:Conventional treatment;Severe group:Conventional treatment;Western medicine treatment group:Give routine western medicine treatment;Chinese and western medicine combined treatment group:Traditional Chinese medicine is combined with conventional western medicine treatment.;Non-invasive mechanical ventilation group:Give noninvasive mechanical ventilation and respiratory support;Nasal high flow oxygen therapy group:Give nasal high flow oxygen therapy respiratory support;","Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","Gold Standard:COVID-19 viral PCR;Index test:MicroRNA;","Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","Case series:traditional Chinese medicine;","The experimental group:Wear a self-made \"gastroscope mask\" during gastroscopy;Control group:Without self-made \"gastroscope mask\" during gastroscopy;","Case series: Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Case series:Nil;","Intervention group:Psychological intervention;","Case series:mesenchymal stem cells therapy;","Two groups:Chinese massage versus control;","Case series:Anti-SARS-CoV-2 virus inactivated plasma;","Case series:Nil;","Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;","Case series:no;","Case series:6-minute walk training;","Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;","Case series:NA;","case series:N/A;","Case series:Retrospective analysis;","Case series:Nil;","experimental group:TCM formula and general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);control group:general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);","Group 2:Once for two days;Group 3:Once for one day;Group 1:Control Group;","Case series:N/A;","High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","Burnout positive group versus burnout negative group:NO;","Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","Experimental group:Conventional drug therapy plus hydrogen inhalation;Control group:Conventional drug therapy;","Case series:Nil;","Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day \t;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","Gold Standard:Detection of novel coronavirus by fluorescence RT-PCR;Index test:Detection&amp;#32;of&amp;#32;viral&amp;#32;nucleic&amp;#32;acids&amp;#32;in&amp;#32;eye&amp;#32;swabs,&amp;#32;throat&amp;#32;swabs,&amp;#32;oral&amp;#32;saliva,&amp;#32;feces,&amp;#32;urine&amp;#32;and&amp;#32;plasma;","Case series:Nil;","Experimental group:Conventional treatment &amp; Acupuncture;Control Group:Conventional treatment;","General population:Health Advice based on survey results;","Experimental group:Farpiravir tablets;Control group:Abidole tablets;","1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","Case series:Nil;","the elderly population:none;","Case series:Integration of traditional Chinese and Western Medicine;","Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kanguan No. 3;Control group (severe patients):Routine treatment;","Case series:conventional therapy+tocilizumab;","Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;","Case series:Nil;","experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;","Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules;","Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;","Case series:N/A;","Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical&amp;#32;care&amp;#32;ultrasound&amp;#32;examination;","Experimental Group:Conventional Treatment &amp; Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks);","control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;","Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","Case series:Humanistic care;","Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;",null,"Case series:NA;","Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","Experimental group:High-dose Vitamin C;Control group:Routine treatment;","Experimental group:Increased Compound Houttuynia Mixture in real world situations;Control group:None(People who do not receive Compound Houttuynia Mixture in real world situations);","Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;","Two groups:Different stem cell doses;","1:Simplify cognitive behavior;2:Supportive psychotherapy;","Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","Case series:Nil;","Adolescent group:NA;Childbearing group:NA;Climacterium group:NA;","Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","Case series:Basic symptomatic therapy combined with glucocorticoid therapy;","Severe group:None;Critical group:none;Light group:None;Common group:None;","control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:conventional treatment;experimental group with critical NCP:conventional treatment combined with ozone therapy;control group with critical NCP:conventional treatment;","Experimental group:Exercise prescription;Control group:none;","Gold Standard:Chest CT examination;Index test:Lung&amp;#32;ultrasound&amp;#32;examination;","Case series:Nil;","Psychological Intervention Group:\"Intelligent Psychosomatic Regulation System\" Intervention;Control Group :General Treatment ;","Exercise prescription group:Exercise prescription;Control group:None;","Experimental group :Oral leflunomide;Control group:Oral placebo;","case series:none;","Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","general anesthesia group vs. intraspinal anesthesia group:N/A;Health care goup:N/A;","Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan ;","experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","Routine treatment group:Conventional treatment of 2019-nCoV pneumonia;Dipyridamole treatment group:Conventional treatment of 2019-nCoV pneumonia and Dipyridamole;","Gold Standard:Nucleic acid detection method of COVID-19;Index test:IgM/IgG&amp;#32;detection&amp;#32;method&amp;#32;of&amp;#32;COVID-19;","Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;","Case series:FNC;","Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","Case series:Nil;","Case series:Anti-2019-nCoV virus inactivated plasma;","Case series:Suramin( IV.);","Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral \"Wu-Zhi-Fang-Guan-Fang\" decoction;Control group:Routine quarantine measures;","Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","Case series:Nil;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Case series:Nil;","Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Severe group:None;Non-severe group:None;","Case series:Nil;","Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;","Case series:Nil;","Case series:mesenchymal stem cells therapy;","Training:None;Vaidation:None;","Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","Experimental group:pulmonary training;control group:Conventional medication;","Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","Case series:NA;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Case series:Nil;","Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","pneumonia patients group:N/A;medical staff group:N/A;","Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","Mild Group:probiotics;Severe Group:probiotics;","college students:none;","Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","control group:conventional therapy;Experience group:conventional therapy and Tranilast;","Experimental group:recombinant human interferon a1b spray;Control group:Blank;","Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: 1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-Cov-2; 2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-Cov-2. ;Index test:SARS-Cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.morning&amp;#32;sputum&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples&amp;#32;;","Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel coronavirus pneumonia severe and critical cases;","experimental group:mesenchymal stem cells;control group:saline;","experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","Experimental group:Chloroquine Phosphate;Control group:No;","Case series:Nil;","Gold Standard:Pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and Pathogenic nucleic acid test of pharynx swab.;Index test:expression&amp;#32;of&amp;#32;sars-cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;in&amp;#32;vaginal&amp;#32;secretions;","Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","Case series:moxibustion;","Experimental group:Chloroquine phosphate;","Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","COVID-19 group:NA;Healthy people:NA;","experimental group:Fitness Qigong Yangfei prescription;control group:general advice and related psychological comfort.;","survival group:none;died:none;","Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","COVID-19 pregnant women and normal pregnant women and infants born to them:None;","Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group 2:Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid;","Case series:routine treatment+indirect moxibustion;","Case series:Nil;","patient group:Under surgical and anesthesia;Health care team:Anesthesiologists for NCP patients;","Case series:high-dose Vitamin C+Standard treatment;","Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.;Index test:First&amp;#32;pass&amp;#32;perfusion&amp;#32;imaging&amp;#32;parameters&amp;#32;(slope,&amp;#32;tip,&amp;#32;PT)&amp;#32;and&amp;#32;delayed&amp;#32;enhancement&amp;#32;ratio&amp;#32;(%);&amp;#32;quantitative&amp;#32;T1&amp;#32;\\&amp;#32;T2&amp;#32;values,&amp;#32;ECV&amp;#32;and&amp;#32;pseudocolor&amp;#32;images&amp;#32;were&amp;#32;obtained&amp;#32;by&amp;#32;t1mapping&amp;#32;\\&amp;#32;T2&amp;#32;mapping.&amp;#32;Meanwhile,&amp;#32;the&amp;#32;degree&amp;#32;of&amp;#32;myocardial&amp;#32;edema&amp;#32;and&amp;#32;fat&amp;#32;replacement&amp;#32;was&amp;#32;analyzed.&amp;#32;Myocardial&amp;#32;creatine&amp;#32;metabolism&amp;#32;was&amp;#32;analyzed&amp;#32;by&amp;#32;MRS,;","Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","Case series:Extracorporeal Membrane Oxygenation;","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;","Case series:Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: &lt;br&gt;1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-CoV-2; &lt;br&gt;2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-CoV-2.;Index test:SARS-CoV-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.&amp;#32;nasopharyngeal&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples;","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;","Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined with Chloroquine Phosphate.;","Case series:Nil;","Case series:Nil;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","Case series:Nil;","Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;","experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;","Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;","Gold Standard:Nucleic acid detection method of novel Coronavirus pneumonia ;Index test:IgM/IgG;","Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional treatment;","Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the \"Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)\" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.;","Case series:variety treatments;","Gold Standard:Diagnostic criteria for severe novel coronavirus pneumonia.;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system.;","common group:N/A;severe group:N/A;critical group:N/A;","control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","Case series:No;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","tumor patients group:N/A;non tumor patients group:N/A;","Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;","Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;","case series:N/A;","Experimental group:honeysuckle decoction;Control group:placebo;","Case series:Nil;","Experimental group:Conventional Treatment &amp; Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;","Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;","Observation  group:TCM prevention;Health  education unit:Health  education;","Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;","Case series:NA;","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","High dose group:High-dose NK cells (&gt;5x10^9)and mesenchymal stem cells(&gt;5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every week for a total of one time;","Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";Placebo:2 tablets placebo BID;","Case series:Nil;","Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;","Gold Standard:Guidelines for novel coronavirus pneumonia (fifth edition);Index test:Diagnosis&amp;#32;model&amp;#32;based&amp;#32;on&amp;#32;Artificial&amp;#32;Intelligence&amp;#32;(Epidemiological&amp;#32;history,&amp;#32;clinical&amp;#32;information,&amp;#32;laboratory&amp;#32;examination,&amp;#32;hospitalization&amp;#32;profile,&amp;#32;pulmonary&amp;#32;function&amp;#32;examination,&amp;#32;blood&amp;#32;gas&amp;#32;test,&amp;#32;chest&amp;#32;plain&amp;#32;film,&amp;#32;chest&amp;#32;CT,&amp;#32;complications,&amp;#32;final&amp;#32;classification,&amp;#32;disease&amp;#32;stage).;","TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;","experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;","Case series:Not applicable.;","case series:N/A;","Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;","Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;","Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;","experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;","experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","Case series:NA;","experimental group:TCM and general treatment;control group:general treatment;","Case series:Nil;","experimental group:Xiyanping injection;control group:alpha-interferon;","Epilepsy group:N/A;Health Control group:N/A;","Suspected patient control group:Routine respiratory disease treatment;Suspected patient Treatment group:Oral Chinese medicine treatment based on control group;Common NCP patient control group:treatment according to the guideline;Common NCP patient Treatment group:Oral Chinese medicine treatment based on control group;Severe NCP patient:Oral Chinese medicine treatment and treatment according to the guideline;","Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;","experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;","General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;","experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;","Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;","Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;","hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","Gold Standard:RT-PCR of the novel coronavirus;Index test:Exhaled&amp;#32;breath&amp;#32;detection&amp;#32;by&amp;#32;mass&amp;#32;spectrometry;","non-severe group and severe gorup:N/A;","Vitamin D deficiency group:N/A;Vitamin D normal group:N/A;","Case series:N/A;","Case series:Nil;","control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;","experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","Experimental group:Xinguan-1 formula+Standard treatment;Control group:Standard treatment;","Case series:Conventional standardized treatment and vMIP atomized inhalation;","doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;","Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;","Normal group:No;Severe group:No;","Case series:Traditional Chinese Medicine;","Experimental group:Xinguan-2 formula+Standard treatment;Control group:Standard treatment;","Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;","Gold Standard:Clinical outcome;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system;","experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental Group B2:Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment;Control Gorup A:Conventional treatment;","Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Control group:Routine treatment;","Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;","Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;","mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate  ;severe- Lopinavir/ritonavir group:oral Lopinavir/ritonavir;","Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;","Treatment group:Integrated Traditional Chinese and Western Medicine;","control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;","Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","Case series:Nil;","Two cohorts:Arbidol cohort versus without Arbidol cohort;","Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy Type Group C:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;","control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;","single arm:Chinese medicine treatment combined with western medicine treatment;","A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.;C:Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.;","Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","Experimental group:chloroquine;control group:conventional management;","experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;","(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Western Medicine Group:Use the (ordinary)   TCM clinical prescription combined with the western medicine  treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;","treament group:Chinese medicine decoction;placebo group:placebo;","Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;","DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 mg SC QOD) ;","Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / ritonavir tablets (Kaletra) twice a day, twice each time, 7-14 days.;intervention C:On the basis of routine medical treatment, combined with Novafron and Kaletra, the usage and course of treatment are the same as above.;","experimental group:Traditional Chinese Medicine+psychological intervention;\t Control group:Traditional Chinese Medicine;Control group:psychological intervention;","experimental group \t:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;","Case series:NA;","Experimental group:Isolation and oral  Gubiao Jiedu Ling Chinese medicine;Control group:Isolated observation;","experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;","control group:western medical therapies;Experimental group:Conventional medicine + TCM;","Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.;","A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;","Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;","Case series:according to guidelines;","control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;","Case series:Nil;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;","Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;","Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>trial_id<\/th>\n      <th>date_registration<\/th>\n      <th>scientific_title<\/th>\n      <th>url<\/th>\n      <th>study_type<\/th>\n      <th>intervention<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados-ue" class="section level3">
<h3>Dados UE</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-88325dfab2b978f69fba" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-88325dfab2b978f69fba">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","extensions":["Buttons"],"fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174"],["2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-002340-14","2015-004863-35","2015-004863-35","2015-004863-35","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2016-003191-50","2017-001100-30","2019-002688-89","2020-000841-15","2020-000841-15","2020-000841-15","2020-000841-15","2020-000841-15","2020-000841-15","2020-000841-15","2020-000842-32","2020-000842-32","2020-000842-32","2020-000842-32","2020-000842-32","2020-000842-32","2020-000842-32","2020-000890-25","2020-000919-69","2020-000936-23","2020-000982-18","2020-001010-38","2020-001023-14","2020-001031-27","2020-001038-36","2020-001039-29","2020-001052-18","2020-001052-18","2020-001052-18","2020-001052-18","2020-001110-38","2020-001113-21","2020-001154-22","2020-001154-22","2020-001154-22","2020-001154-22","2020-001154-22","2020-001154-22","2020-001154-22","2020-001156-18","2020-001160-28","2020-001162-12","2020-001162-12","2020-001162-12","2020-001162-12","2020-001172-15","2020-001172-15","2020-001188-96","2020-001194-69","2020-001200-42","2020-001209-22","2020-001224-33","2020-001236-10","2020-001243-15","2020-001244-26","2020-001246-18","2020-001250-21","2020-001254-22","2020-001255-40","2020-001257-51","2020-001262-11","2020-001266-11","2020-001270-29","2020-001270-29","2020-001270-29","2020-001270-29","2020-001271-33","2020-001273-73","2020-001275-32","2020-001278-31","2020-001281-11","2020-001290-74","2020-001301-23","2020-001302-30","2020-001303-16","2020-001306-35","2020-001307-16","2020-001310-38","2020-001320-34","2020-001321-31","2020-001324-33","2020-001327-13","2020-001329-30","2020-001331-26","2020-001333-13","2020-001335-28","2020-001345-38","2020-001366-11","2020-001366-11","2020-001367-88","2020-001373-70","2020-001375-32","2020-001379-34","2020-001385-11","2020-001386-37","2020-001405-23","2020-001406-27","2020-001408-41","2020-001409-21","2020-001411-25","2020-001413-20","2020-001420-34","2020-001421-31","2020-001435-27","2020-001437-12","2020-001440-26","2020-001442-19","2020-001445-39","2020-001448-24","2020-001453-49","2020-001455-40","2020-001456-18","2020-001457-43","2020-001466-11","2020-001469-35","2020-001490-68","2020-001492-33","2020-001500-41","2020-001511-25","2020-001527-14","2020-001530-35","2020-001531-27","2020-001536-98","2020-001553-48","2020-001565-37","2020-001570-30","2020-001587-29","2020-001591-15","2020-001602-34","2020-001606-33","2020-001614-38","2020-001616-18","2020-001622-64","2020-001634-36","2020-001640-26","2020-001659-42","2020-001662-11","2020-001682-36","2020-001689-12","2020-001765-37"],["BE","DE","ES","FI","FR","GB","HR","HU","IE","NL","PT","FI","LT","SE","AT","BE","BG","CZ","DE","DK","EE","ES","FR","GB","GR","HR","IE","LT","LV","NL","NO","PL","PT","SE","SK","DE","ES","DE","ES","FR","GB","IT","NL","SE","DE","ES","FR","GB","IT","NL","SE","FR","NL","FR","NO","NO","GB","ES","DE","GR","DK","ES","GB","GR","IT","GB","DE","DK","ES","FR","GB","IT","NL","ES","ES","DE","ES","FR","IT","AT","DK","FR","ES","DK","GB","DE","NL","BE","AT","FR","FR","BE","ES","DK","ES","ES","CZ","DK","FR","GB","FR","FR","DK","ES","FR","ES","FR","AT","FR","FR","ES","DE","NL","ES","FR","AT","AT","GB","FR","NL","GR","ES","IT","DK","FR","NL","ES","ES","IT","ES","FR","DE","ES","ES","ES","DK","ES","FR","ES","ES","ES","ES","GB","ES","GR","CZ","FR","GR","PL","SE","FR","BE","ES","NL","ES","ES","ES","FR","ES","FR","ES","NL","FR","ES","BE","ES","ES","ES","GB","ES","DE","ES","ES","ES"],["2018-11-19","2018-11-20","2020-02-24","2020-04-06","2020-03-27","2018-07-04","2020-01-20","2018-10-29","2018-03-08","2015-07-13","2018-04-18","2016-06-17","2018-01-04","2017-02-16","2017-07-31","2018-02-14","2017-07-27","2017-07-21","2017-07-20","2017-07-18","2017-08-10","2017-10-20","2019-01-28","2017-07-24","2017-11-16","2018-05-29","2017-07-25","2018-02-01","2017-07-25","2017-08-08","2017-11-16","2017-08-03","2017-07-21","2017-09-14","2017-05-31","2018-07-19","2019-07-26","2020-03-10","2020-03-11","2020-03-12","2020-03-20","2020-03-16","2020-03-20","2020-03-20","2020-03-10","2020-03-11","2020-03-12","2020-03-20","2020-03-16","2020-03-20","2020-03-23","2020-03-10","2020-03-17","2020-03-09","2020-03-24","2020-03-16","2020-03-17","2020-04-03","2020-04-14","2020-03-31","2020-03-20","2020-04-07","2020-03-23","2020-04-02","2020-03-23","2020-03-19","2020-03-26","2020-03-25","2020-04-03","2020-03-26","2020-03-31","2020-03-31","2020-03-27","2020-04-03","2020-04-13","2020-03-20","2020-04-03","2020-03-20","2020-03-31","2020-03-26","2020-03-23","2020-03-24","2020-04-07","2020-03-24","2020-03-25","2020-03-24","2020-03-31","2020-03-27","2020-03-31","2020-03-25","2020-03-24","2020-03-24","2020-04-20","2020-03-26","2020-04-13","2020-04-16","2020-03-30","2020-03-30","2020-04-06","2020-03-30","2020-03-24","2020-03-24","2020-03-24","2020-04-01","2020-03-26","2020-04-13","2020-03-26","2020-04-09","2020-03-29","2020-03-27","2020-04-08","2020-03-31","2020-03-30","2020-04-13","2020-03-29","2020-03-30","2020-04-03","2020-04-14","2020-04-02","2020-03-27","2020-03-31","2020-03-26","2020-04-20","2020-04-01","2020-03-29","2020-04-03","2020-04-14","2020-04-03","2020-04-02","2020-04-13","2020-04-03","2020-04-07","2020-04-03","2020-04-17","2020-04-13","2020-04-01","2020-04-07","2020-04-01","2020-04-13","2020-04-20","2020-04-03","2020-04-03","2020-04-17","2020-04-13","2020-04-01","2020-04-08","2020-04-02","2020-04-14","2020-04-08","2020-04-01","2020-04-01","2020-04-04","2020-04-15","2020-04-06","2020-04-13","2020-04-20","2020-04-20","2020-04-03","2020-04-07","2020-04-06","2020-04-13","2020-04-06","2020-04-03","2020-04-07","2020-04-06","2020-04-20","2020-04-20","2020-04-13","2020-04-09","2020-04-20","2020-04-15","2020-04-14","2020-04-13","2020-04-13"],["Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia Coronavirus COVID-19 (REMAP-CAP-COVID-19)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia ","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (COVID-19)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)","A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients","A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients","A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991;  or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; ; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; ; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; ; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991;  or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991;  or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; ; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; ; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991;  or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; ; or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991;  or Completed M15-989","A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991 or completed M15-989","Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo","Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19)","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment","Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine","Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gurin vaccination, a randomized controlled trial (COVID-19). ","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults ","The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).","NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION","A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) ","Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy:  a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults","EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL","A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European Union/United Kingdom Sites","A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European Union/United Kingdom Sites","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults","Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia","Randomised Evaluation of COVID-19 Therapy (RECOVERY)","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.","Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization","A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care","An adaptive phase 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19)","The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial","Platform Randomised trial of INterventions against COVID-19 In older peoPLE","Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19  a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.","COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS","Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients ","A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure.","Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.","The Danish Pre-HCQ Dialysis Study:","Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19","Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19.","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle","COVID-19+","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial ","A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients affected by COVID-19 with Acute Respiratory Distress Syndrome","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.","Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care","Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study","A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2)","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study ","Protective role of inhaled steroids for COVID-19 infection","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19.","A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19","A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (COVID-19)","Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF)","Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized controlled trial","A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC  ","Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19","ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial)","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\"","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care","Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform","IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection","Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with placebo","Uno studio randomizzato multicentrico in aperto per valutare lefficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19.","Randomized phase II clinical trial of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19.Ruxo-Sim-20 clinical trial.","Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19 ","A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia","A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19.","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection","Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia","Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency","Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety","Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs","Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel.","Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19)","PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19","Expanded Access Treatment Protocol: Remdesivir (RDV;GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection- COVID-19","The Greek study in the Effects of Colchicine in Covid-19 complications prevention","Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase III","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia","suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL","A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.","Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19","Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19","A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome.","Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19","COVID-19: addition of azithromycin to chloroquine treatment","Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19","Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome","Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare","Corticodes au cours de la pneumonie virale Covid-19 lie  linfection par le SARS-Cov-2","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL.","Interest of early treatment with polyvalent immunoglobulins in the management of respiratory distress syndrome associated with SARS-CoV-2 infections_COVID-19","Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy","Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Gurin vaccination, a randomized controlled trial. (COVID-19)","COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection.","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.","Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia","OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE","Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.","A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rt-PA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial","Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19","Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm","Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV-allo) in acute respiratory failure in patients with COVID-19 pneumonia.","COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)","Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alteration"],["https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/BE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/FI/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/HR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/HU/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/IE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/PT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/FI/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/LT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/SE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/AT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/BE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/BG/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/CZ/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/EE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/GR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/HR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/IE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/LT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/LV/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/NO/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/PL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/PT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/SE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003191-50/SK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001100-30/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002688-89/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/SE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/SE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001031-27/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001039-29/GR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/GR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001110-38/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001156-18/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001160-28/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001172-15/AT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001172-15/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001188-96/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001194-69/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001200-42/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001224-33/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001244-26/AT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001246-18/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001250-21/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001255-40/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001257-51/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001262-11/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001266-11/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/CZ/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001271-33/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001273-73/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001278-31/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001281-11/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001290-74/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001301-23/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001302-30/AT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001303-16/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001306-35/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001307-16/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001310-38/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001320-34/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001321-31/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001324-33/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001327-13/AT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001329-30/AT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001331-26/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001333-13/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001335-28/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001345-38/GR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001366-11/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001366-11/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001367-88/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001373-70/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001375-32/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001379-34/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001385-11/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001386-37/IT/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001405-23/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001406-27/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001408-41/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001409-21/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001411-25/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001413-20/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001420-34/DK/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001421-31/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001435-27/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001437-12/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001440-26/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001442-19/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001445-39/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001448-24/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001455-40/GR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001456-18/CZ/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001457-43/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001466-11/GR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001469-35/PL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001490-68/SE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001492-33/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001500-41/BE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001511-25/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001527-14/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001530-35/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001531-27/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001536-98/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001553-48/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001565-37/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001570-30/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001587-29/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001591-15/NL/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001602-34/FR/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001606-33/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001614-38/BE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001616-18/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001622-64/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001634-36/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001640-26/GB/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001659-42/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/DE/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001682-36/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001689-12/ES/","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001765-37/ES/"],["levofloxacin hemihydrate; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin lactobionate; amoxicillin sodium; potassium clavulanate; azithromycin monohydrate; piperacillin; tazobactam sodium; roxithromycin; ceftaroline fosamil; moxifloxacin hydrochloride; osteltamivir; lopinavir; ritonavir; anakinra; interferon beta-1a","levofloxacin ; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin ; amoxicillin ; potassium clavulanate; piperacillin; tazobactam ; roxithromycin; ceftaroline fosamil; moxifloxacin ; oseltamivir; ritonavir; lopinavir; anakinra; interferon beta-1a","levofloxacin; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin; amoxicillin; potassium clavulanate; moxifloxacin; oseltamivir","anakinra; interferon beta-1a","hydrocortisone","ceftriaxone sodium ; moxifloxacin hydrochloride; levofloxacin hemihydrate; piperacillin; tazobactam; ceftaroline fosamil acetic acid solvate monohydrate ; sodium amoxicillin; potassium clavulanate; azithromycin dihydrate; clarithromycin; hydrocortisone sodium succinate","levofloxacin; hydrocortisone; ceftriaxone; amoxicillin ; potassium clavulanate; azithromycin; clarithromycin; piperacillin; tazobactam ; moxifloxacin; oseltamivir","levofloxacin ; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin ; amoxicillin ; potassium clavulanate; azithromycin monohydrate; piperacillin; tazobactam ; roxithromycin; ceftaroline fosamil; moxifloxacin ; oseltamivir; ritonavir; lopinavir; anakinra; interferon beta-1a","levofloxacin ; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin ; amoxicillin ; potassium clavulanate; azithromycin monohydrate; piperacillin; tazobactam ; roxithromycin; ceftaroline fosamil; moxifloxacin ; oseltamivir; ritonavir; lopinavir; anakinra; interferon beta-1a","levofloxacin ; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin ; amoxicillin ; potassium clavulanate; azithromycin monohydrate; piperacillin; tazobactam ; roxithromycin; ceftaroline fosamil; moxifloxacin ; oseltamivir","levofloxacin hemihydrate; hydrocortisone; ceftriaxone; azithromycin; clarithromycin; erythromycin lactobionate; amoxicillin sodium; potassium clavulanate; azithromycin monohydrate; piperacillin; tazobactam sodium; roxithromycin; ceftaroline fosamil; moxifloxacin hydrochloride","ixazomib citrate; lenalidomide","ixazomib citrate; lenalidomide","ixazomib citrate; lenalidomide","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","risankizumab","healing water","hcr040","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","remdesivir","plaquenil 200 mg, comprim pellicul","bcg vaccine (bcg-vaccin ssi [nederlands vaccinstatens serum instituut]) danish strain 1331.","lopinavir; ritonavir; rebif; remdesivir; hydroxychloroquine","hydroxychloroquine sulphate; remdesivir","hydroxychloroquine sulfate","interferon beta-1a","darunavir; cobicistat; hydroxychloroquine","bnt162a1; bnt162b1; bnt162b2; bnt162c2","anakinra; tocilizumab","remdesivir","remdesivir","remdesivir (active drug triphosphate)","remdesivir (active drug triphosphate)","tocilizumab","lopinavir; ritonavir; dexamethasone; hydroxychloroquine; azithromycin; prednisolone; hydrocortisone; tocilizumab","tocilizumab","tocilizumab","tocilizumab","tocilizumab","tocilizumab","tocilizumab","tocilizumab","dolquine 200 mg comprimidos recubiertos.; azitromicina cinfa 500 mg comprimidos; kaletra","pembrolizumab; tocilizumab","sarilumab","sarilumab","sarilumab","sarilumab","apn01 / gsk2586881","apn01 / gsk2586881","lopinavir/ritonavir; hydroxychloroquine","mefloquine","camostat mesilate","hydroxychloroquine sulfate 200 mg ","quensyl","imatinib mesilate","itraconazole","solnatide","kevzara ; roactemra 20mg/ml, 20 ml; kineret 100 mg/0,67 ml (anakinra); plaquenil; zithromax 250 mg; soliris 300 mg (eculizumab); olumiant 2mg (baricitinib); secukinumab; bevacizumab","hydroxychloroquine; azithromycine","sargramostim","sarilumab","hydroxychloroquine","ciclosporin; lopinavir; ritonavir; darunavir; chloroquine; spironolactone; interferon beta-1b; tocilizumab","allogeneic adipose-derived mesenchymal stromal cells in vitro expanded","hydroxychloroquine sulfate","hydroxychloroquine sulfate","hydroxychloroquine sulfate","hydroxychloroquine sulfate","plaquenil","zithromax 250 mg, comprim pellicul; hydroxychloroquine","tocilizumab; sarilumab","dexamethasone","sulfate d'hydroxychloroquine","sarilumab; azithromycin dihydrate; hydroxychloroquine","naproxen","chloroquine; hydroxychloroquine; lopinavir; ritonavir; rivaroxaban; candesartan","hydroxychloroquine; telmisartan; azithromycine; curcumin","budesonide; formoterol","metilprednisolona (como succinato de sodio)","for example \"gefrorenes frischplasma / apherese drk blutspendedienst\"","valsartan","dolquine; ritonavir; lopinavir; imatinib; baricitinib","antimicrobial therapy (antibiotics)","azithromycin dihydrate","nitric oxide","hydroxychloroquine","dexamethasone; hydroxychloroquine","-","chloroquine phosphate","remdesivir; chloroquine; hydroxychloroquine sulfate; lopinavir; interferon beta-1a","remdesivir; chloroquine difosfato; hydroxychloroquine sulfate; lopinavir; interferon beta-1a","plaquenil; baricitinib; sarilumab","not available; nivolumab; tocilizumab","tocilizumab","sevoflurane; propofol","tenofovir disoproxil fumarate; emtricitabine; hydroxychloroquine","tocilizumab","ruxolitinib; simvastatin","hydroxychloroquine sulfate; azithromycine","roactemra","defibrotide","selinexor","siltuximab; methylprednisolone","senicapoc","hydroxychloroquine sulfate","hydroxychloroquine; imatinib; favipiravir; telmisartan","ciclosporin; tocilizumab","hydroxychloroquine","tocilizumab","methylprednisolone; tacrolimus","lopinavir; ritonavir; hydroxychloroquine sulfate","remdesivir","colchicine","hydroxychloroquine sulfate; azitrox","dexamethasone; medicinal oxygen","anakinra; sulfamethoxazole and trimethoprim","chloroquine phosphate","nitric oxide","pulmozyme 2500 u/2,5ml, solution pour inhalation par nbuliseur","anakinra; tocilizumab; siltuximab","colchicina","chloroquine; azithromycin","circadin","sarilumab","hydroxychloroquine","prednisone","hydroxychloroquine sulfate","clairyg 50mg/ml, solution for infusion","hydroxychloroquine sulfate","bcg vaccine (bcg-vaccin ssi [nederlands vaccinstatens serum instituut]) danish strain 1331.","zymad 200 000 ui; zymad 50 000 ui","ibuprofen; hydroxychloroquine; azithromycin; paracetamol","azithromycin dihydrate","budesonide","prednisone","sarilumab","alteplase","antithrombin iii","ruxolitinib","clulas mesenquimales troncales adultas alognicas de mdula sea expandidas mediante procedimiento ibgm","colchicine","hydroxychloroquine"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>eudract_number<\/th>\n      <th>country<\/th>\n      <th>date_entered<\/th>\n      <th>title<\/th>\n      <th>link<\/th>\n      <th>substances<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados-oms" class="section level3">
<h3>Dados OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-15ba6a249947779f01c9" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-15ba6a249947779f01c9">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"20150713\" data-max=\"20200420\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","extensions":["Buttons"],"fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621","622","623","624","625","626","627","628","629","630","631","632","633","634","635","636","637","638","639","640","641","642","643","644","645","646","647","648","649","650","651","652","653","654","655","656","657","658","659","660","661","662","663","664","665","666","667","668","669","670","671","672","673","674","675","676","677","678","679","680","681","682","683","684","685","686","687","688","689","690","691","692","693","694","695","696","697","698","699","700","701","702","703","704","705","706","707","708","709","710","711","712","713","714","715","716","717","718","719","720","721","722","723","724","725","726","727","728","729","730","731","732","733","734","735","736","737","738","739","740","741","742","743","744","745","746","747","748","749","750","751","752","753","754","755","756","757","758","759","760","761","762","763","764","765","766","767","768","769","770","771","772","773","774","775","776","777","778","779","780","781","782","783","784","785","786","787","788","789","790","791","792","793","794","795","796","797","798","799","800","801","802","803","804","805","806","807","808","809","810","811","812","813","814","815","816","817","818","819","820","821","822","823","824","825","826","827","828","829","830","831","832","833","834","835","836","837","838","839","840","841","842","843","844","845","846","847","848","849","850","851","852","853","854","855","856","857","858","859","860","861","862","863","864","865","866","867","868","869","870","871","872","873","874","875","876","877","878","879","880","881","882","883","884","885","886","887","888","889","890","891","892","893","894","895","896","897","898","899","900","901","902","903","904","905","906","907","908","909","910","911","912","913","914","915","916","917","918","919","920","921","922","923","924","925","926","927","928","929","930","931","932","933","934","935","936","937","938","939","940","941","942","943","944","945","946","947","948","949","950","951","952","953","954","955","956","957","958","959","960","961","962","963","964","965","966","967","968","969","970","971","972","973","974","975","976","977","978","979","980","981","982","983","984","985","986","987","988","989","990","991","992","993","994","995","996","997","998","999","1000","1001","1002","1003","1004","1005","1006","1007","1008","1009","1010","1011","1012","1013","1014","1015","1016","1017","1018","1019","1020","1021","1022","1023","1024","1025","1026","1027","1028","1029","1030","1031","1032","1033","1034","1035","1036","1037","1038","1039","1040","1041","1042","1043","1044","1045","1046","1047","1048","1049","1050","1051","1052","1053","1054","1055","1056","1057","1058","1059","1060","1061","1062","1063","1064","1065","1066","1067","1068","1069","1070","1071","1072","1073","1074","1075","1076","1077","1078","1079","1080","1081","1082","1083","1084","1085","1086","1087","1088","1089","1090","1091","1092","1093","1094","1095","1096","1097","1098","1099","1100","1101","1102","1103","1104","1105","1106","1107","1108","1109","1110","1111","1112","1113","1114","1115","1116","1117","1118","1119","1120","1121","1122","1123","1124","1125","1126","1127","1128","1129","1130","1131","1132","1133","1134","1135","1136","1137","1138","1139","1140","1141","1142","1143","1144","1145","1146","1147","1148","1149","1150","1151","1152","1153","1154","1155","1156","1157","1158","1159","1160","1161","1162","1163","1164","1165","1166","1167","1168","1169","1170","1171","1172","1173","1174","1175","1176","1177","1178","1179","1180","1181","1182","1183","1184","1185","1186","1187","1188","1189","1190","1191","1192","1193","1194","1195","1196","1197","1198","1199","1200","1201","1202","1203","1204","1205","1206","1207","1208","1209","1210","1211","1212","1213","1214","1215","1216","1217","1218","1219","1220","1221","1222","1223","1224","1225","1226","1227","1228","1229","1230","1231","1232","1233","1234","1235","1236","1237","1238","1239","1240","1241","1242","1243","1244","1245","1246","1247","1248","1249","1250","1251","1252","1253","1254","1255","1256","1257","1258","1259","1260","1261","1262","1263","1264","1265","1266","1267","1268","1269","1270","1271","1272","1273","1274","1275","1276","1277","1278","1279","1280","1281","1282","1283","1284","1285","1286","1287","1288","1289","1290","1291","1292","1293","1294","1295","1296","1297","1298","1299","1300","1301","1302","1303","1304","1305","1306","1307","1308","1309","1310","1311","1312","1313","1314","1315","1316","1317","1318","1319","1320","1321","1322","1323","1324","1325","1326","1327","1328","1329","1330","1331","1332","1333","1334","1335","1336","1337","1338","1339","1340","1341","1342","1343","1344","1345","1346","1347","1348","1349","1350","1351","1352","1353","1354","1355","1356","1357","1358","1359","1360","1361","1362","1363","1364","1365","1366","1367","1368","1369","1370","1371","1372","1373","1374","1375","1376","1377","1378","1379","1380","1381","1382","1383","1384","1385","1386","1387","1388","1389","1390","1391","1392","1393","1394","1395","1396","1397","1398","1399","1400","1401","1402","1403","1404","1405","1406","1407","1408","1409","1410","1411","1412","1413","1414","1415","1416","1417","1418","1419","1420","1421","1422","1423","1424","1425","1426","1427","1428","1429","1430","1431","1432","1433","1434","1435","1436","1437","1438","1439","1440","1441","1442","1443","1444","1445","1446","1447","1448","1449","1450","1451","1452","1453","1454","1455","1456","1457","1458","1459","1460","1461","1462","1463","1464","1465","1466","1467","1468","1469","1470","1471","1472","1473","1474","1475","1476","1477","1478","1479","1480","1481","1482","1483","1484","1485","1486","1487","1488","1489","1490","1491","1492","1493","1494","1495","1496","1497","1498","1499","1500","1501","1502","1503","1504","1505","1506","1507","1508","1509","1510","1511","1512","1513","1514","1515","1516","1517","1518","1519","1520","1521","1522","1523","1524","1525","1526","1527","1528"],["ChiCTR2000029953","ChiCTR2000029935","ChiCTR2000029850","ChiCTR2000029814","ChiCTR2000029805","NCT04246242","ChiCTR2000029949","ChiCTR2000029947","NCT04252885","NCT04255940","ChiCTR2000029789","ChiCTR2000029782","ChiCTR2000029896","ChiCTR2000029811","ChiCTR2000029810","ChiCTR2000029764","ChiCTR2000029779","ChiCTR2000029695","ChiCTR2000029778","NCT04251871","NCT04260594","ChiCTR2000029777","ChiCTR2000029776","NCT04260308","ChiCTR2000029883","ChiCTR2000029656","ChiCTR2000029869","ChiCTR2000029742","ChiCTR2000029741","ChiCTR2000029867","ChiCTR2000029849","ChiCTR2000029626","ChiCTR2000029637","ChiCTR2000029636","ChiCTR2000029624","ChiCTR2000029822","ChiCTR2000029815","ChiCTR2000029813","ChiCTR2000029806","NCT04261426","NCT04261907","ChiCTR2000029941","ChiCTR2000029939","ChiCTR2000029790","ChiCTR2000029788","ChiCTR2000029765","ChiCTR2000029601","ChiCTR2000029589","ChiCTR2000029763","ChiCTR2000029758","ChiCTR2000029756","ChiCTR2000029569","ChiCTR2000029747","ChiCTR2000029542","ChiCTR2000029539","ChiCTR2000029462","ChiCTR2000029438","ChiCTR2000029436","ChiCTR2000029578","ChiCTR2000029418","ChiCTR2000029907","ChiCTR2000029905","ChiCTR2000029518","ChiCTR2000029739","ChiCTR2000030173","ChiCTR2000029517","ChiCTR2000029495","ChiCTR2000029493","ChiCTR2000029732","ChiCTR2000029639","ChiCTR2000029628","ChiCTR2000029625","ChiCTR2000030166","ChiCTR2000029870","ChiCTR2000030118","ChiCTR2000030116","ChiCTR2000029602","ChiCTR2000029855","ChiCTR2000029600","ChiCTR2000029853","ChiCTR2000029572","ChiCTR2000029559","ChiCTR2000029544","ChiCTR2000029541","ChiCTR2000029487","ChiCTR2000029468","ChiCTR2000029437","ChiCTR2000029435","ChiCTR2000029430","ChiCTR2000029839","ChiCTR2000029400","ChiCTR2000029821","ChiCTR2000030185","ChiCTR2000029819","ChiCTR2000029804","ChiCTR2000030167","ChiCTR2000029769","ChiCTR2000030165","ChiCTR2000030117","ChiCTR2000030115","ChiCTR2000029432","ChiCTR2000030092","ChiCTR2000029431","ChiCTR2000030090","ChiCTR2000030093","ChiCTR2000029768","ChiCTR2000029754","ChiCTR2000030084","ChiCTR2000029751","ChiCTR2000029735","ChiCTR2000029734","ChiCTR2000029621","ChiCTR2000029609","ChiCTR2000029606","ChiCTR2000029605","ChiCTR2000030043","ChiCTR2000030058","ChiCTR2000029603","ChiCTR2000030041","ChiCTR2000030056","ChiCTR2000029558","ChiCTR2000030034","ChiCTR2000030033","ChiCTR2000029548","ChiCTR2000029461","ChiCTR2000029460","ChiCTR2000029459","ChiCTR2000029439","ChiCTR2000029381","NCT04259892","NCT04268537","ChiCTR2000030032","ChiCTR2000030179","ChiCTR2000030164","ChiCTR2000030113","ChiCTR2000030096","ChiCTR2000030094","ChiCTR2000030017","ChiCTR2000030016","ChiCTR2000030046","ChiCTR2000030015","ChiCTR2000030030","ChiCTR2000030008","ChiCTR2000030007","ChiCTR2000030029","ChiCTR2000030006","ChiCTR2000030027","NCT04269525","ChiCTR2000030188","ChiCTR2000030012","ChiCTR2000030000","ChiCTR2000030001","ChiCTR2000030010","ChiCTR2000029999","ChiCTR2000029956","ChiCTR2000030170","ChiCTR2000030138","ChiCTR2000030137","ChiCTR2000029996","ChiCTR2000029995","ChiCTR2000029994","ChiCTR2000029992","ChiCTR2000029990","ChiCTR2000029978","ChiCTR2000029960","ChiCTR2000029959","ChiCTR2000029981","ChiCTR2000029866","ChiCTR2000029865","ChiCTR2000030136","ChiCTR2000029851","ChiCTR2000029974","ChiCTR2000030102","ChiCTR2000030089","ChiCTR2000029781","ChiCTR2000029803","ChiCTR2000030088","ChiCTR2000030087","ChiCTR2000030086","ChiCTR2000029740","ChiCTR2000029780","ChiCTR2000030054","ChiCTR2000030039","ChiCTR2000030021","ChiCTR2000030020","ChiCTR2000030019","ChiCTR2000030004","NCT04256395","NCT04273529","NCT04270383","NCT04275947","ChiCTR2000030003","ChiCTR2000030002","ChiCTR2000029989","NCT04275245","NCT04275388","ChiCTR2000029988","ChiCTR2000030420","ChiCTR2000029985","NCT04273581","NCT04279782","ChiCTR2000029972","ChiCTR2000030390","ChiCTR2000029954","NCT04279795","ChiCTR2000030442","ChiCTR2000030363","NCT04279899","ChiCTR2000030433","ChiCTR2000030418","ChiCTR2000030424","ChiCTR2000030391","ChiCTR2000030386","ChiCTR2000030382","NCT04279197","NCT04280588","ChiCTR2000030432","ChiCTR2000030322","ChiCTR2000030327","ChiCTR2000030325","ChiCTR2000030314","ChiCTR2000030334","ChiCTR2000030324","ChiCTR2000030398","ChiCTR2000030389","ChiCTR2000030333","ChiCTR2000030305","ChiCTR2000030317","ChiCTR2000030387","ChiCTR2000030315","ChiCTR2000030262","ChiCTR2000030263","ChiCTR2000030283","ChiCTR2000030265","ChiCTR2000030264","ChiCTR2000030261","ChiCTR2000030260","ChiCTR2000030255","ChiCTR2000030253","ChiCTR2000030293","ChiCTR2000030215","ChiCTR2000030290","ChiCTR2000030196","ChiCTR2000030259","ChiCTR2000030258","ChiCTR2000030219","ChiCTR2000030257","ChiCTR2000030222","ChiCTR2000030022","ChiCTR2000030013","ChiCTR2000030218","ChiCTR2000029991","ChiCTR2000030226","ChiCTR2000029755","ChiCTR2000030225","ChiCTR2000029728","ChiCTR2000030223","ChiCTR2000029952","ChiCTR2000029900","ChiCTR2000030091","ChiCTR2000030042","ChiCTR2000029975","ChiCTR2000029761","ChiCTR2000029762","ChiCTR2000030162","ChiCTR2000029759","ChiCTR2000029387","ChiCTR2000029899","ChiCTR2000029386","ChiCTR2000029760","ChiCTR2000029898","ChiCTR2000029829","ChiCTR2000030552","ChiCTR2000030535","NCT04286503","ChiCTR2000030581","ChiCTR2000030574","ChiCTR2000030522","ChiCTR2000030556","ChiCTR2000030503","ChiCTR2000030542","ChiCTR2000030540","NCT04276987","ChiCTR2000030593","NCT04281693","NCT04282902","ChiCTR2000030492","ChiCTR2000030487","ChiCTR2000030559","ChiCTR2000030485","ChiCTR2000030490","ChiCTR2000030557","ChiCTR2000030472","ChiCTR2000030481","ChiCTR2000030543","ChiCTR2000030471","ChiCTR2000030541","NCT04284046","NCT04285190","ChiCTR2000030467","ChiCTR2000030627","ChiCTR2000030469","ChiCTR2000030518","ChiCTR2000030468","ChiCTR2000030579","ChiCTR2000030491","ChiCTR2000030465","ChiCTR2000030578","ChiCTR2000030453","ChiCTR2000030489","ChiCTR2000030014","ChiCTR2000030564","ChiCTR2000030312","ChiCTR2000030484","ChiCTR2000029580","ChiCTR2000030304","ChiCTR2000030544","ChiCTR2000030482","ChiCTR2000030493","ChiCTR2000029550","ChiCTR2000030475","ChiCTR2000030480","ChiCTR2000029549","ChiCTR2000030464","ChiCTR2000030163","ChiCTR2000030479","ChiCTR2000029479","ChiCTR2000030477","ChiCTR2000029993","ChiCTR2000030436","ChiCTR2000030896","ChiCTR2000029638","ChiCTR2000029958","ChiCTR2000030895","NCT04292327","NCT04295551","ChiCTR2000029579","ChiCTR2000030894","ChiCTR2000029757","ChiCTR2000029308","ChiCTR2000030893","ChiCTR2000030863","ChiCTR2000030862","NCT04296643","NCT04299711","NCT04298814","ChiCTR2000030898","NCT04292340","NCT04293887","ChiCTR2000030897","ChiCTR2000030866","ChiCTR2000030861","ChiCTR2000030902","ChiCTR2000030860","ChiCTR2000030901","ChiCTR2000030864","ChiCTR2000030892","ChiCTR2000030854","ChiCTR2000030812","ChiCTR2000030859","ChiCTR2000030853","ChiCTR2000030883","ChiCTR2000030810","ChiCTR2000030865","ChiCTR2000030852","ChiCTR2000030857","ChiCTR2000030858","ChiCTR2000030855","ChiCTR2000030838","ChiCTR2000030809","ChiCTR2000030856","ChiCTR2000030836","ChiCTR2000030850","ChiCTR2000030835","ChiCTR2000030849","ChiCTR2000030833","ChiCTR2000030834","ChiCTR2000030795","ChiCTR2000030841","ChiCTR2000030839","ChiCTR2000030831","ChiCTR2000030778","ChiCTR2000030819","ChiCTR2000030832","ChiCTR2000030816","ChiCTR2000030818","ChiCTR2000030759","ChiCTR2000030814","ChiCTR2000030830","ChiCTR2000030807","ChiCTR2000030806","ChiCTR2000030758","ChiCTR2000030805","ChiCTR2000030803","ChiCTR2000030804","ChiCTR2000030757","ChiCTR2000030798","ChiCTR2000030802","ChiCTR2000030756","ChiCTR2000030796","ChiCTR2000030801","ChiCTR2000030799","ChiCTR2000030800","ChiCTR2000030782","ChiCTR2000030797","ChiCTR2000030742","ChiCTR2000030784","ChiCTR2000030773","ChiCTR2000030779","ChiCTR2000030764","ChiCTR2000030768","ChiCTR2000030763","ChiCTR2000030741","ChiCTR2000030762","ChiCTR2000030751","ChiCTR2000030761","ChiCTR2000030760","ChiCTR2000030740","ChiCTR2000030755","ChiCTR2000030753","ChiCTR2000030718","ChiCTR2000030708","ChiCTR2000030754","ChiCTR2000030744","ChiCTR2000030717","ChiCTR2000030707","ChiCTR2000030752","ChiCTR2000030739","ChiCTR2000030716","ChiCTR2000030721","ChiCTR2000030706","ChiCTR2000030719","ChiCTR2000030701","ChiCTR2000030747","ChiCTR2000030703","ChiCTR2000030690","ChiCTR2000030700","ChiCTR2000030722","ChiCTR2000030580","ChiCTR2000030687","ChiCTR2000030683","ChiCTR2000030720","ChiCTR2000030558","ChiCTR2000030545","ChiCTR2000030681","ChiCTR2000030466","ChiCTR2000030329","ChiCTR2000030702","ChiCTR2000030388","ChiCTR2000030619","ChiCTR2000030483","ChiCTR2000030306","ChiCTR2000030697","ChiCTR2000030114","ChiCTR2000030478","ChiCTR2000030221","ChiCTR2000030082","ChiCTR2000030055","ChiCTR2000029984","ChiCTR2000030187","ChiCTR2000030686","ChiCTR2000030031","ChiCTR2000029957","ChiCTR2000030005","ChiCTR2000029895","ChiCTR2000029592","ChiCTR2000029817","ChiCTR2000029837","ChiCTR2000029812","ChiCTR2000030679","ChiCTR2000029826","ChiCTR2000030606","ChiCTR2000030597","ChiCTR2000029820","ChiCTR2000030528","ChiCTR2000030509","ChiCTR2000030476","ChiCTR2000030417","NCT04302519","ChiCTR2000031163","NCT04264533","NCT04308187","NCT04307693","ChiCTR2000031104","ChiCTR2000030381","ChiCTR2000030135","ChiCTR2000031140","ChiCTR2000030085","ChiCTR2000031138","ChiCTR2000031115","ChiCTR2000031088","ChiCTR2000031090","ChiCTR2000030992","ChiCTR2000029818","ChiCTR2000029816","ChiCTR2000030989","ChiCTR2000030996","ChiCTR2000029770","ChiCTR2000031023","ChiCTR2000030941","ChiCTR2000030986","ChiCTR2000031014","ChiCTR2000030939","ChiCTR2000030947","ChiCTR2000030961","ChiCTR2000030922","NCT04285801","NCT04299724","ChiCTR2000030946","ChiCTR2000030952","ChiCTR2000030950","ChiCTR2000030933","ChiCTR2000030943","ChiCTR2000030906","NCT04302688","ChiCTR2000031150","ChiCTR2000030932","ChiCTR2000030934","ChiCTR2000030519","ChiCTR2000031139","ChiCTR2000030931","ChiCTR2000030929","ChiCTR2000030254","ChiCTR2000031089","ChiCTR2000030224","ChiCTR2000030993","ChiCTR2000030771","ChiCTR2000030920","ChiCTR2000030765","ChiCTR2000030168","ChiCTR2000029955","ChiCTR2000030987","ChiCTR2000029658","ChiCTR2000029830","ChiCTR2000030985","ChiCTR2000029573","ChiCTR2000030951","ChiCTR2000029496","ChiCTR2000030944","ChiCTR2000030942","NCT04263402","NCT04273763","EUCTR2020-000890-25-FR","ChiCTR2000030919","NCT04251767","NCT04254874","ChiCTR2000030539","ChiCTR2000030095","JPRN-UMIN000039686","ChiCTR2000029868","NCT04283396","NCT04287686","NCT04255017","NCT04261270","JPRN-jRCTs041190120","NCT04276896","NCT04291053","NCT04264858","NCT04278963","JPRN-UMIN000039873","NCT04293692","NCT04305574","NCT04308317","NCT04312464","NCT04313322","NCT04272710","NCT04304313","NCT04306705","NCT04292964","NCT04306497","NCT04312100","NCT04310865","NCT04311398","ChiCTR2000031366","ChiCTR2000031365","NCT04314232","NCT04314817","NCT04316884","NCT04318418","ChiCTR2000031356","NCT04314271","NCT04315870","ChiCTR2000031361","ChiCTR2000031319","ChiCTR2000031330","ChiCTR2000031336","ChiCTR2000031329","ChiCTR2000031324","ChiCTR2000031328","NCT04316728","ChiCTR2000031337","ChiCTR2000031296","ChiCTR2000031327","ChiCTR2000031293","ChiCTR2000031272","ChiCTR2000031271","ChiCTR2000031301","ChiCTR2000031252","ChiCTR2000031247","ChiCTR2000031245","ChiCTR2000031204","ChiCTR2000031246","ChiCTR2000031187","ChiCTR2000031227","ChiCTR2000031214","ChiCTR2000031244","ChiCTR2000031198","ChiCTR2000031203","ChiCTR2000030936","ChiCTR2000031196","ChiCTR2000030940","ChiCTR2000030923","ChiCTR2000030937","ChiCTR2000031176","ChiCTR2000030988","ChiCTR2000030704","ChiCTR2000030962","EUCTR2020-001162-12-FR","ChiCTR2000030330","ChiCTR2000030028","ChiCTR2000030288","ChiCTR2000030256","ChiCTR2000030938","NCT04319211","NCT04320056","ChiCTR2000030198","EUCTR2020-001243-15-BE","EUCTR2020-000919-69-NL","NCT04320277","NCT04321174","NCT04315948","NCT04319900","EUCTR2020-001224-33-DE","ChiCTR2000030817","EUCTR2020-001023-14-GB","ChiCTR2000029982","NCT04321421","NCT04323332","NCT04320017","NCT04323514","NCT04305106","NCT04321928","NCT04323345","NCT04323592","NCT04323631","NCT04325919","NCT04061382","NCT04288713","NCT04322786","NCT04324996","NCT04324463","NCT04324866","NCT04290871","NCT04303507","NCT04325412","NCT04326309","NCT04331860","ISRCTN14966673","NCT04327570","ChiCTR2000031539","ChiCTR2000031627","NCT04316299","NCT04318314","ChiCTR2000031639","ChiCTR2000031533","ChiCTR2000031494","ChiCTR2000031503","ChiCTR2000031501","ChiCTR2000031199","NCT04318444","NCT04322344","ChiCTR2000031465","ChiCTR2000031500","NCT04323644","ChiCTR2000031630","ChiCTR2000031454","ChiCTR2000031432","ChiCTR2000031439","ChiCTR2000031430","ChiCTR2000031589","ChiCTR2000031428","EUCTR2020-000936-23-FR","ChiCTR2000031587","ChiCTR2000031376","EUCTR2020-001386-37-IT","ChiCTR2000031540","ChiCTR2000031538","EUCTR2020-001345-38-GR","ChiCTR2000031504","ChiCTR2000031499","EUCTR2020-001271-33-FR","ChiCTR2000031453","ACTRN12620000417987","ChiCTR2000031438","ChiCTR2000031429","EUCTR2020-001281-11-FR","ChiCTR2000031427","EUCTR2020-001275-32-DK","NCT03331445","NCT04298060","NCT04275414","NCT04315298","EUCTR2020-001236-10-NL","NCT04318366","NCT04321811","NCT04320238","NCT04321278","NCT04312243","NCT04316377","EUCTR2020-001010-38-NO","ACTRN12620000421932","NCT04322188","NCT04326452","NCT04321096","NCT04324489","NCT04324047","NCT04325867","NCT04326075","NCT04326114","NCT04324528","NCT04328272","NCT04328480","NCT04328493","NCT04326426","NCT04326920","NCT04280705","NCT04313946","NCT04326790","NCT04327505","NCT04327531","NCT04328441","NCT04320511","NCT04320732","NCT04329507","NCT04330144","NCT04328961","NCT04330261","NCT04330586","NCT04330599","NCT04323878","NCT04325646","NCT04330521","NCT04331613","NCT04331574","NCT04332016","NCT04325906","NCT04326036","NCT04332835","NCT04333251","NCT04327180","NCT04327349","NCT04331899","NCT04333862","NCT04332666","NCT04333550","NCT04327674","NCT04328454","NCT04333693","NCT04334967","NCT04334629","NCT04334850","ACTRN12620000438954","NCT04329559","NCT04331600","ACTRN12620000449932","ACTRN12620000457943","NCT04335019","NCT04335084","NCT04335279","ACTRN12620000443998","ACTRN12620000454976","NCT04335201","ACTRN12620000448943","NCT04332380","NCT04333355","ChiCTR2000031836","ChiCTR2000031794","ChiCTR2000031772","NCT04333472","ACTRN12620000444987","ACTRN12620000447954","ChiCTR2000031770","ChiCTR2000031782","ChiCTR2000031783","ChiCTR2000031781","ChiCTR2000031752","ChiCTR2000031860","ChiCTR2000031734","ChiCTR2000031751","ChiCTR2000031779","ChiCTR2000031707","ChiCTR2000031705","ChiCTR2000031834","ChiCTR2000031700","ChiCTR2000030328","ChiCTR2000031735","ChiCTR2000031699","ChiCTR2000031672","ChiCTR2000031675","ChiCTR2000030750","ChiCTR2000030494","ChiCTR2000030331","EUCTR2020-001250-21-FR","EUCTR2020-001381-11-FR","EUCTR2020-001301-23-FR","EUCTR2020-001310-38-DE","EUCTR2020-001335-28-NL","EUCTR2020-001500-41-BE","EUCTR2020-001435-27-FR","EUCTR2020-001333-13-FR","EUCTR2020-001188-96-FR","EUCTR2020-001366-11-ES","EUCTR2020-001373-70-FR","EUCTR2020-001409-21-ES","EUCTR2020-001039-29-GR","EUCTR2020-001457-43-FR","EUCTR2020-001492-33-FR","EUCTR2020-001445-39-ES","EUCTR2020-001442-19-ES","EUCTR2020-001194-69-ES","EUCTR2020-001385-11-ES","EUCTR2020-001421-31-ES","EUCTR2020-001565-37-ES","EUCTR2020-001270-29-GB","EUCTR2020-001606-33-ES","EUCTR2020-001307-16-ES","NCT03680274","NCT03808922","NCT04244591","NCT04252274","NCT03042143","NCT04274322","NCT04252664","NCT04261517","NCT04252118","NCT04273321","NCT03891420","NCT04245631","NCT04276688","NCT04291729","NCT04273646","NCT04304690","NCT04257656","NCT04280224","NCT04283461","NCT04288102","NCT04299152","NCT04303299","NCT04312997","NCT04313127","NCT04290780","NCT04302766","NCT04292730","NCT04292899","NCT04305457","NCT04306393","NCT04311177","NCT04311697","NCT04317092","NCT04318301","NCT04308668","NCT04310228","NCT04304053","NCT04306055","NCT04312009","NCT04313023","NCT04315987","NCT04319016","NCT04320472","NCT04322123","NCT04319315","NCT04320953","NCT04315480","NCT04315896","NCT04319445","NCT04321616","NCT04322396","NCT04323761","NCT04317040","NCT04318015","NCT04323787","NCT04323800","NCT04320615","NCT04320862","NCT04322487","NCT04322565","NCT04321265","NCT04322682","NCT04323839","NCT04325061","NCT04321369","NCT04321993","NCT04324073","NCT04324190","NCT04322773","NCT04323228","NCT04322513","NCT04324021","NCT04324736","NCT04325672","NCT04327388","NCT04327401","NCT04324606","NCT04324684","NCT04325048","NCT04325633","NCT04326725","NCT04327206","NCT04325893","NCT04327804","NCT04328285","NCT04328467","NCT04326387","NCT04328129","NCT04327479","NCT04328012","NCT04329572","NCT04329650","NCT04329533","NCT04330300","NCT04329832","NCT04331054","NCT04329546","NCT04329611","NCT04331106","NCT04331171","NCT04329923","NCT04331470","NCT04330495","NCT04330638","NCT04330690","NCT04331366","NCT04331509","NCT04331834","NCT04331665","NCT04331795","NCT04332107","NCT04333420","NCT04331808","NCT04332913","NCT04332094","NCT04333407","NCT04331886","NCT04332081","NCT04333732","NCT04333849","NCT04333589","NCT04333654","NCT04332991","NCT04333225","NCT04334148","NCT04334460","NCT04334252","NCT04334265","NCT04333628","NCT04333953","NCT04333914","NCT04334005","NCT04334291","NCT04335162","NCT04334044","NCT04334382","NCT04334512","NCT04334980","NCT04334928","NCT04335123","NCT04335188","NCT04335305","NCT04335032","NCT04335071","NCT04335630","NCT04335773","NCT04335851","NCT04336462","NCT04335747","NCT04336254","NCT04334434","NCT04335097","NCT04336215","NCT04336774","NCT04336332","NCT04337008","NCT04336657","NCT04336904","NCT04336956","NCT04337216","NCT04337151","NCT04337190","NCT04337047","NCT04337320","NCT04337502","NCT04335136","NCT04336345","NCT04337359","NCT04337996","NCT04337541","NCT04337762","NCT04336384","NCT04336410","NCT04338074","NCT04338100","NCT04337983","NCT04338828","NCT04336761","NCT04336787","NCT04338347","NCT04338672","NCT04339712","NCT04340349","NCT04338932","NCT04338945","NCT04338958","NCT04338698","NCT04338906","NCT04337346","NCT04337489","NCT04337788","NCT04341012","NCT04341038","NCT04337918","NCT04338009","NCT04339387","NCT04339608","NCT04339322","NCT04339660","NCT04338360","NCT04338568","NCT04339634","NCT04339816","NCT04341441","NCT04341480","NCT04338802","NCT04339426","NCT04340219","NCT04340544","NCT04340050","NCT04340466","NCT04341675","NCT04341688","NCT04339790","NCT04339998","NCT04340479","NCT04340921","NCT04341103","NCT04341168","NCT04340232","NCT04340414","NCT04341870","NCT04342104","NCT04341285","NCT04341493","NCT04341116","NCT04341142","NCT04341519","NCT04341610","NCT04341584","NCT04341766","NCT04343001","NCT04343183","NCT04341207","NCT04341389","NCT04341935","NCT04342169","NCT04341792","NCT04342195","NCT04341415","NCT04341506","NCT04342208","NCT04342221","NCT04341714","NCT04341922","NCT04343404","NCT04343651","NCT04342156","NCT04342182","NCT04342702","NCT04342728","NCT04342637","NCT04342650","NCT04342689","NCT04342806","NCT04343144","NCT04343261","NCT04344080","NCT04344730","NCT04342663","NCT04342884","NCT04342897","NCT04343248","NCT04343677","NCT04343768","NCT04343092","NCT04343729","NCT04344925","NCT04344938","NCT04344951","NCT04343742","NCT04343755","NCT04343794","NCT04344002","NCT04343339","NCT04343664","NCT04343963","NCT04343976","NCT04345159","NCT04345601","NCT04343690","NCT04343781","NCT04344171","NCT04344184","NCT04346017","NCT04346043","NCT04344119","NCT04344145","NCT04344210","NCT04344236","NCT04343898","NCT04343989","NCT04344197","NCT04344587","NCT04346212","NCT04346446","NCT04344015","NCT04344106","NCT04344327","NCT04344444","NCT04344834","NCT04345276","NCT04344249","NCT04344431","NCT04344535","NCT04344561","NCT04346667","NCT04346693","NCT04345679","NCT04345692","NCT04344457","NCT04344548","NCT04345887","NCT04346121","NCT04344977","NCT04345419","NCT04345445","NCT04344756","NCT04344782","NCT04347538","NCT04347954","NCT04344964","NCT04345315","NCT04345510","NCT04345536","NCT04345653","NCT04347980","NCT04347993","NCT04345406","NCT04345523","NCT04345861","NCT04346160","NCT04346147","NCT04346329","NCT04345549","NCT04345614","NCT04346186","NCT04346277","NCT04348214","NCT04348383","NCT04346342","NCT04346355","NCT04345640","NCT04345848","NCT04346420","NCT04346628","NCT04345991","NCT04346056","NCT04348396","NCT04348409","NCT04346368","NCT04346589","NCT04346810","NCT04346927","NCT04348422","NCT04348435","NCT04346082","NCT04346199","NCT04346953","NCT04347070","NCT04346797","NCT04347226","NCT04348864","NCT04350593","NCT04346264","NCT04346615","NCT04347239","NCT04347408","NCT04347278","NCT04347369","NCT04347174","NCT04347382","NCT04351646","NCT04351659","NCT04347850","NCT04347876","NCT04347460","NCT04347694","NCT04347681","NCT04347798","NCT04347928","NCT04348227","NCT04347889","NCT04348071","NCT04347824","NCT04347915","NCT04351906","ACTRN12620000468921","NCT04348461","NCT04348552","NCT04348305","NCT04348500","NCT04347941","NCT04348240","ACTRN12620000480987","NCT04348695","NCT04348877","NCT04348448","NCT04348474","ACTRN12620000482965","NCT04348513","NCT04348929","ACTRN12620000493943","NCT04348656","NCT04349098","NCT04348942","NCT04349371","NCT04349202","NCT04350086","ISRCTN18348009","NCT04349241","NCT04349982","NCT04349410","NCT04349618","ISRCTN10077335","NCT04350073","NCT04350099","NCT04350320","NCT04350736","NCT04349631","NCT04350281","NCT04350450","NCT04350476","NCT04351191","NCT04351399","NCT04351295","NCT04351529","ISRCTN40092247","NCT04351620","NCT04351711","NCT04350671","NCT04350684","ACTRN12620000486921","ACTRN12620000473965","ACTRN12620000474954","NCT04351633","NCT04351724","NCT04350931","NCT04351139","ACTRN12620000445976","ISRCTN83971151","ACTRN12620000492954","ISRCTN51255782","ACTRN12620000478910","ISRCTN86534580","ISRCTN50189673","ISRCTN51287266","ISRCTN14326006","ISRCTN13694948","ChiCTR2000032009","ISRCTN15281137","NCT04351152","NCT04351347","NCT04351542","NCT04351581","ISRCTN16912075","ChiCTR2000031982","ChiCTR2000031896","NCT04351763","NCT04351789","ChiCTR2000032098","NCT04351802","ACTRN12620000477921","ACTRN12620000472976","ACTRN12620000487910","ACTRN12620000479909","ACTRN12620000470998","ChiCTR2000032095","ChiCTR2000031955","ISRCTN80453162","ChiCTR2000031944","ChiCTR2000031928","ChiCTR2000031954","NL8498","ISRCTN43900695","ISRCTN77353041","ChiCTR2000029976","ChiCTR2000030300","ChiCTR2000032040","ChiCTR2000032013","NL8512","ChiCTR2000032011","ChiCTR2000032010","EUCTR2020-001324-33-FR","ChiCTR2000031930","ChiCTR2000031888","EUCTR2020-001257-51-DK","NL8513","NL8473","NL8485","ChiCTR2000031712","NL8490","ChiCTR2000029434","EUCTR2020-001320-34-NL","ChiCTR2000029433","EUCTR2020-001420-34-DK","NL8501","NL8521","EUCTR2019-002688-89-ES","EUCTR2020-001290-74-ES","NL8460","NL8483","EUCTR2020-001262-11-ES","NL8497","EUCTR2020-001406-27-FR","NL8491","NL8504","EUCTR2020-001553-48-FR","EUCTR2020-001156-18-ES","EUCTR2020-001530-35-ES","EUCTR2020-001303-16-FR","EUCTR2020-001437-12-ES","EUCTR2020-001160-28-ES","EUCTR2020-001602-34-FR","EUCTR2020-001587-29-ES","EUCTR2020-001367-88-DK","EUCTR2020-001321-31-ES","EUCTR2020-001682-36-ES","EUCTR2020-001172-15-DK","EUCTR2020-001331-26-GB","EUCTR2020-001634-36-ES","EUCTR2020-001413-20-ES","EUCTR2020-001266-11-ES","EUCTR2020-001689-12-ES","EUCTR2020-001765-37-ES","EUCTR2020-001448-24-GB","EUCTR2020-000982-18-NO","EUCTR2020-001511-25-ES","EUCTR2020-001570-30-FR","EUCTR2020-001466-11-GR","EUCTR2020-001379-34-ES","EUCTR2015-002340-14-NL","EUCTR2020-001254-22-BE","DRKS00021214","DRKS00021225","DRKS00021220","DRKS00021395","DRKS00021420","DRKS00021166","DRKS00021231","DRKS00021254","DRKS00021206","DRKS00021161","DRKS00021208","DRKS00021164","DRKS00021306","DRKS00021153","DRKS00021186","DRKS00021145","CTRI/2020/04/024442","DRKS00021300","DRKS00021152","IRCT20170117032004N3","DRKS00021289","DRKS00021301","IRCT20200310046736N1","IRCT20100228003449N29","DRKS00021268","DRKS00021270","IRCT20151113025025N3","DRKS00021276","IRCT20131113015393N6","IRCT20100228003449N30","CTRI/2020/04/024413","IRCT20200312046749N1","IRCT20200316046792N1","DRKS00021134","CTRI/2020/04/024479","IRCT20140911019125N6","CTRI/2020/03/024402","CTRI/2020/04/024636","IRCT20160316027081N1","CTRI/2020/04/024659","IRCT20200317046797N1","IRCT20120826010664N6","CTRI/2020/04/024473","IRCT20100228003449N28","IRCT20100228003449N27","IRCT20150303021315N17","IRCT20140528017891N8","IRCT20190727044343N1","IRCT20200128046294N2","IRCT20200324046850N3","IRCT20200314046764N1","IRCT20200324046847N1","IRCT20140617018126N2","IRCT20150914024017N1","IRCT20151227025726N12","IRCT20180923041093N3","IRCT20190727044343N2","IRCT20160625028622N1","IRCT20160310026998N10","IRCT20200321046828N1","IRCT20180610040049N3","IRCT20200325046860N1","IRCT20200324046850N2","IRCT20200324046852N1","IRCT20171122037571N2","IRCT20151227025726N13","IRCT20140907019073N4","IRCT20200324046850N1","IRCT20170611034452N11","IRCT20160310026998N11","IRCT20190804044429N1","IRCT20200323046841N1","IRCT20200324046850N5","IRCT20200204046369N1","IRCT20190917044805N2","IRCT20180712040449N2","IRCT20160313027033N2","IRCT20120225009124N4","IRCT20200317046797N2","IRCT20200318046812N1","IRCT20200325046859N1","IRCT20151228025732N51","IRCT20200325046860N2","IRCT20180923041093N4","IRCT20150704023055N2","IRCT20200328046886N1","IRCT20081019001369N2","IRCT20200319046819N1","IRCT20200322046833N1","IRCT20130917014693N10","IRCT20200404046933N1","IRCT20200404046934N1","IRCT20160131026298N2","IRCT20200401046909N1","IRCT20101219005416N2","IRCT20200402046923N1","IRCT20130306012728N8","IRCT20200405046960N1","IRCT20130812014333N145","IRCT20180429039463N2","IRCT20200404046935N1","IRCT20200404046937N1","IRCT20200318046812N2","IRCT20080901001157N16","IRCT20151227025726N14","IRCT20200317046797N4","IRCT20150808023559N20","IRCT20200405046953N1","IRCT20161204031229N3","IRCT20180802040678N4","IRCT20200405046958N1","IRCT20200217046526N1","IRCT20180610040049N4","IRCT20200401046909N2","IRCT20180725040596N2","IRCT20180129038542N1","IRCT20180520039738N2","IRCT20200317046797N3","IRCT20200413047053N1","IRCT20200404046947N1","IRCT20081019001369N3","IRCT20200403046926N1","IRCT20200408046990N1","IRCT20151228025732N53","IRCT20200317046797N5","IRCT20200406046965N1","IRCT20200217046526N2","IRCT20200404046948N1","IRCT20180923041093N5","IRCT20081019001369N4","IRCT20200411047025N1","LBCTR2020043459","IRCT20080901001165N46","IRCT20200415047089N1","IRCT20200408046992N1","IRCT20200415047092N1","IRCT20200404046937N2","IRCT20191125045492N2","IRCT20200406046968N1","IRCT20200409047007N1","IRCT20190122042450N4","PACTR202004693933092","JPRN-jRCT2031190264","JPRN-JapicCTI-205238","IRCT20200411047030N1","IRCT20200413047056N1","PACTR202004761408382","JPRN-jRCTs031190269","JPRN-jRCTs031190226","JPRN-jRCTs031190227","JPRN-UMIN000039997","RBR-3cbs3w","JPRN-UMIN000040162","RBR-9d8z6m","JPRN-UMIN000039986","TCTR20200409006","PACTR202004801273802","JPRN-UMIN000040185","TCTR20200405001","TCTR20200404004","RBR-6m69fc","JPRN-UMIN000040188","TCTR20200324001","RBR-9pgwfc","RPCEC00000306","PER-010-20","TCTR20200321001","RBR-8969zg","TCTR20200401002"],["17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","3 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","17 February 2020","17 February 2020","25 February 2020","17 February 2020","25 February 2020","25 February 2020","25 February 2020","17 February 2020","25 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","17 February 2020","25 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","24 February 2020","24 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","24 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","25 February 2020","25 February 2020","25 February 2020","2 March 2020","2 March 2020","25 February 2020","2 March 2020","25 February 2020","2 March 2020","2 March 2020","25 February 2020","2 March 2020","25 February 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","16 March 2020","9 March 2020","9 March 2020","16 March 2020","16 March 2020","16 March 2020","9 March 2020","16 March 2020","9 March 2020","9 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","16 March 2020","16 March 2020","23 March 2020","16 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","16 March 2020","16 March 2020","23 March 2020","23 March 2020","16 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","30 March 2020","30 March 2020","23 March 2020","23 March 2020","30 March 2020","30 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","23 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","23 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","6 April 2020","6 April 2020","30 March 2020","30 March 2020","30 March 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","6 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","21 April 2020","20 April 2020","20 April 2020","21 April 2020","21 April 2020","20 April 2020","20 April 2020","21 April 2020","20 April 2020","21 April 2020","21 April 2020","20 April 2020","21 April 2020","21 April 2020","20 April 2020","20 April 2020","21 April 2020","20 April 2020","20 April 2020","21 April 2020","20 April 2020","21 April 2020","21 April 2020","20 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","20 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","21 April 2020","20 April 2020","20 April 2020","20 April 2020","21 April 2020","21 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","20 April 2020","21 April 2020","20 April 2020","21 April 2020","20 April 2020","21 April 2020","20 April 2020","20 April 2020","21 April 2020","21 April 2020","21 April 2020","20 April 2020","21 April 2020","21 April 2020","20 April 2020","20 April 2020","21 April 2020","21 April 2020","21 April 2020"],["Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","2019-nCoV Outbreak and Cardiovascular Diseases","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Exhaled Breath","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19)","The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients","A medical records based study of novel coronavirus pneumonia (COVID-19) and influenza virus co-infection","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19)","Study for Mental health and psychological status of doctors, nurses and patients in novel coronavirus pneumonia (COVID-19) designated hospital and effect of interventions","A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children","A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)","Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)","Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients","Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients","A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques","Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)","Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Immunoregulatory Therapy for 2019-nCoV","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU","Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)","Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women","A medical records based study for acute kidney injury in novel coronavirus pneumonia (COVID-19)","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Study on anxiety of different populations under novel coronavirus (COVID-19) infection","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Clinical observation and research of  Severe acute respiratory syndrome coronavirus 2(COVID-19) infection in perinatal newborns","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics","Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients","Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","The COVID-19 Mobile Health Study (CMHS)","Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19)","Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Study for mental health status and influencing factors of nurses during epidemic prevention of novel coronavirus pneumonia (COVID-19)","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome","The Investigation of the Neonates With or With Risk of COVID-19","Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu","Fingolimod in COVID-19","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)","A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus pneumonia (COVID-19)","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)","Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)","Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","The coagulation function of novel coronavirus pneumonia (COVID-19) patients","Cancelled due to lack of participants                                        Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey","Cancelled due to lack of patient                         Medical records based study for epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","Cancelled due to lack of patient                                                                A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive&amp;","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","Cancelled due to lack of patient                Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Cancelled due to lack of patient                                                                              Clinical study for the effect and","Cancelled by the investigator                     Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Retracted due to lack of patient                               A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial","Cancelled due to lack of patient                              A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Cancelled due to lack of patient                                 Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","The Clinical Study of Carrimycin on Treatment Patients With COVID-19","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)","Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient","A clinical study about the diagnosis and prognosis evaluation of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study","A New Screening Strategy for 2019 Novel Coronavirus Infection","A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","Retrospective study for integrate Chinese and conventional medicine  treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19)","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country","CT Scores Predict Mortality in 2019-nCoV Pneumonia","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)","A medical records based study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City","Cancelled by the investigator                        Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases","Cancelled due to lack of patient                               Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)","Cancelled, due to modify the protocol                                          A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&amp;","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)","A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19)","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)","A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)","A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19)","Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)","Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department","Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Study for effects of crisis intervention based on positive psychology for medical staffs working in the novel coronavirus pneumonia (COVID-19) field","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter Cohort Study","Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study","Medical Masks vs N95 Respirators for COVID-19","Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","Efficacy and Safety of IFN-a2 in the Treatment of Novel Coronavirus Patients","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors","A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong","Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study","A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients","A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital","Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection","Factors associated with death in patients with novel coronavirus pneumonia (COVID-19)","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19)","Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images","A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients","An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT","Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","Study for the physical and mental health status of medical workers under the novel coronavirus pneumonia (COVID-19) epidemic","Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies","Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit","Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area","A multicenter retrospective study of rheumatic  patients with novel coronavirus pneumonia (COVID-19)","Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)","Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single center and descriptive study in Wuhan","A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital","Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan","Study for the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients","A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19)","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route","Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning","Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19)","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based study for sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)","Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19)","Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19)","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers","A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19)","A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19)","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)","Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)","Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center retrospective observational study","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19)","Cancelled by the investigator                Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia (COVID-19)","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19)","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations","Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19)","A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19).","A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area","A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)","Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China","Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19)","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau","A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS","Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of novel coronavirus pneumonia (COVID-19) male patients","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                       Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19)","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan","A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19)","A prospective cohort  study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19)","Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) associated kidney injury in children","The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Cancelled by the investigator             Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room","Cancelled due to lack of patients                                       Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator                          Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator         A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                               Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                                    Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator               Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator             Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator              Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak","Cancelled by the investigator                              A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COV","Cancelled by the investigator                         An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test","Cancelled by investigator                Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff","Cancelled by the investigator                    Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator          A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator               Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children","Cancelled by the investigator            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Cancelled by investigator                                      A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator           Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Cancelled by the investigator                               Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","The relationship between Vitamin D andnovel coronavirus pneumonia (COVID-19)","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","Influence of the COvid-19 Epidemic on STRESS","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)","Cancelled by investigator           A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Cancelled by the investigator                  A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","Study for the impact on fetus and neonates of vertical transmission of 2019-nCoV","Cancelled by the investigator               Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)","A prognosis study of novel coronavirus pneumonia (COVID-19)","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","A medical records based study for the diagnosis and prognosis prediction AI model of novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator            Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator                      Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial.","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggan, Hubei in Huanggang.","Correlation of T lymphocytes level and clinical severity in novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study","A Study for SARS-COV-2 RNA Level in Blood and Excrement of Novel Coronavirus Pneumonia (COVID-19) Convalescent Patients","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based study for clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia (COVID-19)","A Medical Records Based Retrospective Study for Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19) in WuHan","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with novel coronavirus pneumonia (COVID-19)","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Safety and Immunity of Covid-19 aAPC Vaccine","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19)","Myocardial injury and arrythmias in the novel coronavirus pneumonia (COVID-19) patients","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial","Venous Thrombosis Risk of novel coronavirus pneumonia (COVID-19) Patients: A Prospective Study","A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)","Accurate Classification System for Patients With COVID-19 Pneumonitis","Application of radiology in the prevention and control system of emergency respiratory infectious diseases","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of Novel Coronavirus (2019-COV)","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia (COVID-19)","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)","A Medical Records Based Study for Clinical Characteristic and Outcomes of Hospitalized Patients With Novel Coronavirus Pneumonia (COVID-19)","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","A medical records based study for the value of Upper Respiratory Tract Virus Detection in the assessment of rehabilitation of novel coronavirus pneumonia (COVID-19) patient","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","Cancelled by the investigator                 Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''","Cancelled by the investigator                   A real world study for Compound Houttuyniae Mixture for prevention of novel coronavirus pneumonia (COVID-19)","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging","A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak","Psychological Responses of Medical Staff during the Metaphase of novel coronavirus pneumonia (COVID-19) Outbreak in Hubei, China","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study","A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19)","Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR and CRP","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Hydroxychloroquine as a treatment for coronavirus disease COVID-19","An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus","A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Study for Novel Coronavirus Pneumonia (NCP)","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","Favipiravir for SARS-CoV-infected patients","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19","COVID-19 Registry","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","Social Media Use During COVID-19","Tetrandrine Tablets Used in the Treatment of COVID-19","Myocardial Damage in COVID-19","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Prognositc Factors in COVID-19 Patients Complicated With Hypertension","A Pilot Study of Sildenafil in COVID-19","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","Prognostic Factors of Patients With COVID-19","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","Sequential Oxygen Therapy Strategy for Patients With COVID-19","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis","To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients","Mechanisms to Morbidity and Mortality for Covid-19","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","Mechanisms for Organ Dysfunction in Covid-19","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19)","The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)","Influence of novel coronavirus pneumonia (COVID-19) on disease activity, medical and mental condition of patients with rheumatic diseases","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of novel coronavirus pneumonia (COVID-19)","The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death","Clinical characteristics and death risk factors in severe novel coronavirus pneumonia (COVID-19) patients: a single-center respective analysis based on medical records","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients: a medical records based retrospective study","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)","Clinical features and prognosis of invasive echanicalventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a medical records based study","A medical records based study for clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen","Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic","A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study","Sarilumab COVID-19","Cancelled by the investigator                               Clinical research of 6-minute walk training on motor function of novel coronavirus pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China","Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia (COVID-19)","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia","Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.","Reducing health care workers absenteeism in Coronavirus 2019 pandemic nu enhancement of the immune system through vaccination with Bacillus Calmette-Gurin","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Trial of Treatments for COVID-19 in Hospitalized Adults","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Systematic study of the medicine hydroxychloroquine against placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound","a trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in patients with COVID-19","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism","Hyperimmune Plasma for Critical Patients With COVID-19","Traditional Chinese Medicine for Severe COVID-19","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","Use of Ascorbic Acid in Patients With COVID 19","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong","Sero-epidemiological Survey of England in 2019/2020","Eculizumab (Soliris) in Covid-19 Infected Patients","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Audio Data Collection for Identification and Classification of Coughing","COVID-19 Public Image Registry","Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing?","In-depth Immunological Investigation of COVID-19.","A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and  the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)","Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune","Acute Kidney Injury in Patients Hospitalized With COVID-19","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","Survey of psychological status and related factors of emergency medical staff in the country during the novel coronavirus pneumonia (COVID-19) pandemic","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","Escin in Patients With Covid-19 Infection","Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial","Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adults","A medical records based study for novel coronavirus pneumonia (COVID-19) patients undergoing endotracheal intubation","Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis","Investigation for the sleep quality in non-health care workers during the pandemic of novel coronavirus pneumonia (COVID-19)","Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy","A paired clinical study for novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital","A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy","Efficacy of Tocilizumab - COVID-19","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS","A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province","Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","Chloroquine Chemorophylaxis Countermeasure against COVID-19","Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic","The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit..","Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial","Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failure","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","Countering Lung Damage in COVID-19 infection: the CounterCovid Study","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Behavior, Environment And Treatments for Covid-19","Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)","NO Prevention of COVID-19 for Healthcare Providers","Norwegian Coronavirus Disease 2019 Study","NORWEGIAN CORONAVIRUS DISEASE 2019 [NO-COVID-19] STUDY: A TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","Treating COVID-19 With a Bidirectional Oxygenation Valve","The Impact of Camostat Mesilate on COVID-19 Infection","DAS181 for Severe COVID-19: Compassionate Use","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","Early CPAP in COVID Patients With Respiratory Failure.","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Effectiveness of Hydroxychloroquine in Covid-19 Patients","The ECLA PHRI COLCOVID Trial","The Vietnam Chloroquine Treatment on COVID-19","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","Adaptive COVID-19 Treatment Trial (ACTT)","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Risk Factors for Community- and Workplace Transmission of COVID-19","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","Hydroxychloroquine for COVID-19 PEP","Clinical Characteristics and Outcomes of Pediatric COVID-19","A Trial of Ciclesonide in Adults With Mild COVID-19","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Impact of the Coronavirus (COVID-19) on Patients With Cancer","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS","Renin-Angiotensin System Inhibitors and COVID-19","COVID-19 Biological Samples Collection","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Study Testing Convalescent Plasma vs Best Supportive Care","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","Mild COVID-19 Peginterferon Lambda","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Application of Desferal to Treat COVID-19","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","Clinical Characteristics and Prognostic Factors of Patients With COVID-19","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","LIBA Trial in COVID-19","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","Utilizing lung ultrasound in COVID-19 patients in ICU  comparison of management strategies on survival and time on ventilation.","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020","Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy","Hydroxychloroquine for the Community-Based Treatment of COVID-19","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care","Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection?","Defibrotide in COVID-19 Pneumonia","Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Safety in Convalescent Plasma Transfusion to COVID-19","A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome","A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19)","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","Piclidenoson for Treatment of COVID-19","COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial)","Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19","Experiences in nursing care for patients with suspected novel coronavirus pneumonia (COVID-19) in Shanghai","A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19)","Investigation for Prevention Awareness against COVID-19","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)","A medical records based observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)","Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function","Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system","Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic","Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent","Cancelled by the investigator                            Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19)","Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","A medical records based retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","Early risk stratification of the novel coronavirus infected diseases (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients","COVID-19 - ACORES-2 study: ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection","Efficacy of Addition of Naproxen for COVID-19 Infection / Enacovid Study","Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection","An open label phase II/III study of IFX-1 in patients with severe COVID-19 Pneumonia","Treatment of COVID-19 patients with anti-interleukin drugs","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial)","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care","Study comparing the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection","DEFIBROTIDE AS PREVENTION AND TREATMENT OF RESPIRATORY DISTRESS AND CYTOKINE RELEASE SYNDROME OF COVID-19","MANAGEMENT OF NOVEL SARS CORONAVIRUS","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia","Interest in the administration of Dornase alpha aerosol in Acute Respiratory Distress Syndrome secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19","CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19)","EPICOS - Experimental clinical trial for PreventIon or COronavirus in health Care professionalS","Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","Prevention of novel Coronavirus infection with hydroxychloroquine","Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection.","Lessening Organ Dysfunction With VITamin C","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","A Trial of Remdesivir in Adults With Mild and Moderate COVID-19","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19","Efficacy and Safety of Corticosteroids in COVID-19","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","A Trial of Remdesivir in Adults With Severe COVID-19","NK Cells Treatment for COVID-19","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)","Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults","COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Expanded Access Remdesivir (RDV; GS-5734)","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","Losartan for Patients With COVID-19 Not Requiring Hospitalization","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","Hypertension in Patients Hospitalized With COVID-19","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","Blood Donor Recruitment During Epidemic of COVID-19","Losartan for Patients With COVID-19 Requiring Hospitalization","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","Acute Encephalopathy in Critically Ill Patients With COVID-19","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19)","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak","Non-contact Endoscopy at Covid-19 Outbreak","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","Mindfulness During COVID-19","The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVID-19 Pandemic Response Network","Simple, Safe, Same: Lung Ultrasound for COVID-19","Colchicine Counteracting Inflammation in COVID-19 Pneumonia","Outcomes and Prognostic Factors in COVID-19","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","DIgital Online SuPport for COVID-19 StrEss","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","Biomarkers for Identification of COVID-19 Infection","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","\"COVID-19 and Diabetes Outcomes\"","Convalescent Plasma to Limit Coronavirus Associated Complications","Sarilumab COVID-19","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","A Study of a Candidate COVID-19 Vaccine (COV001)","Prognostic Factors Keeping Track for Covid-19 Pneumonia","Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","BCG Vaccination to Protect Healthcare Workers Against COVID-19","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","Pre-exposure Prophylaxis for SARS-Coronavirus-2","Evaluation of Novel Diagnostic Tests for COVID-19","Household Transmission Investigation Study for COVID-19 in French Guiana","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic","Coronavirus (COVID-19) ACEi/ARB Investigation","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","Protective Role of Inhaled Steroids for Covid-19 Infection","Understanding COVID-19","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","Survey of the Anxiety Associated With the COVID-19 Pandemic","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Treatment of COVID-19 Patients With Anti-interleukin Drugs","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","COVID-19 Symptom Tracker","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","An Observational Study of Patients With Coronavirus Disease 2019","Hyperbaric Oxygen for COVID-19 Patients","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","Hydroxychloroquine in Outpatient Adults With COVID-19","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19","COVID-19 in Patients With HIV","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","Vitamin D on Prevention and Treatment of COVID-19","International COVID19 Clinical Evaluation Registry,","Cardiovascular Complications and COVID-19 (CovCardioVasc)","Treatment of SARS Caused by COVID-19 With Ruxolitinib","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","A Study of Quintuple Therapy to Treat COVID-19 Infection","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","Study of Open Label Losartan in COVID-19","COVID-19 Registry Rhineland-Palatinate (Germany)","Checkpoint Blockade in COVID-19 Pandemic","EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Cardiovascular Manifestations of COVID-19","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","Video-Based Exercises and Well-Being During Social Isolation","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","Rutgers COVID-19 Cohort Study","CAPTION AI to Minimize Risk of COVID Exposure","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","Renin Angiotesnin System - CoronaVirus","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","Covid-19 Pediatric Observatory","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","Assessment of Distress in Crisis Situations During COVID-19","Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns","Clinical and Radiomic Model of COVID-19","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Outcomes of Patients With COVID-19 in the Intensive Care Unit","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","Dynamic Evaluation of COVID-19 Diagnostic Tests","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","Beat COVID-19 - Observational Trial","Impact of Covid-19 in Congenital Heart Disease","Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","TXA and Corona Virus 2019 (COVID19) in Outpatients","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","Hemodynamic Characteristics of Patients With SARS-CoV-2","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","CAP-1002 in Severe COVID-19 Disease","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients","Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","COVID-19 and Deep Venous Thrombosis","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","Evaluation of Covid 19 Anxiety in Endometriosis Patients","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases","Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","COVID-19 Risk Stratification","Max COVID19- Study","Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","Will Hydroxychloroquine Impede or Prevent COVID-19","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection","Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","COVID-19 Convalescent Plasma","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","Safety and Efficacy of Baricitinib for COVID-19","Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","ASC Therapy for Patients With Severe Respiratory COVID-19","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)","Effects of DPP4 Inhibition on COVID-19","University of Utah COVID-19 Hydrochloroquine Trial","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","Acquiring Convalescent Specimens for COVID-19 Antibodies","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","Non-contact ECG Sensor System for COVID19","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","Hydroxychloroquine for COVID-19","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic","PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","A Study on the Prospective Cohort Library of COVID-19 in Southeran","Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation","COVID-19 Endoscopy Survey","Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","The Role of Resistant Potato Starch in COVID-19 Infection","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","Convalescent Plasma in the Treatment of COVID 19","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","COVID-19 Community Research Partnership","A Study of LY3127804 in Participants With COVID-19","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients","Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","LunG canceR pAtients coVId19 Disease (GRAVID)","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","Pyridostigmine in Severe SARS-CoV-2 Infection","Pegylated Interferon Lambda Treatment for COVID-19","Prevalence of COVID-19 Symptoms History in Patients With Autoimmune Diseases","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)","COPING With COVID-19( CWC-19)","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","CovidDB: The Covid-19 Inpatient Database","Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome","To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database","Assessment of Chilbains Occuring During Covid-19 Infection","Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population","Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning","Oropharyngeal Dysphagia in Patients With COVID-19","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","COVID-19 Plasma Collection","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study","COVID-19 in Cardiology Unit in France : Risk Factors for Mortality (CCF)","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health","Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","Convalescent Plasma vs. Standard Plasma for COVID-19","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19","Anti COVID-19 Convalescent Plasma Therapy","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","Spironolactone in Covid-19 Induced ARDS","Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis","COVID-19 Plasma Collection","A Real-life Experience on Treatment of Patients With COVID 19","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin/Zeribev) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)","Endoscopy-related Phone Consultation During the COVID-19 Outbreak","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","Testing for COVID-19 Infection in Asymptomatic Persons","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers","Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19","A Prospective \"Universal\" Observational Database for COVID-19","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","A Study to Assess the Virus, RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease","Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak","A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff","Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","Screening &amp; Risk Assessment of Healthcare Workers &amp; Infection Control in University &amp; COVID-19 Quarantine Hospitals","Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients","The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19","Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Clinical and Biological Predictors of COVID-19 Disease in Older Patients","Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19","Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)","Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients","Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit","Telerehabilitation for Patients Diagnosed With Coronavirus","Evaluating the Immune Response for COVID-19","Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19","Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus)","Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)","Implementation of Physiotherapy on COVID-19 Patients in ICU","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19","COVID-19 Antibody Self-testing Using Virtual Point-of-care","Dapagliflozin in Respiratory Failure in Patients With COVID-19","CoVid-19 - Infection and Antibody Formation in the Viennese Population","Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients","Efficacy of Nigella Sativa and Natural Honey Against COVID-19: an RCT","Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","IMPACT: IMPact of Antimalarials on Covid Infections in RAPPORT","Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT","Safety and Efficacy of Ruxolitinib for COVID-19","Predict Adverse Events by Covid-19 Nephritis","The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome","Effect of a Brief Problem Management Intervention on Covid 19-Related Anxiety and Depression","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells","Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study","Hydrocortisone for COVID-19 and Severe Hypoxia","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions","Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers (SUPPORT COVID-19 Healthcare Workers)","Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.","Plasma Rich Antibodies From Recovered Patients From COVID19","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19","Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection","Birth Experience During COVID-19 Confinement","Study evaluating Front-line health care workers serial blood COVID-19 antibody results in relation to symptom presentation","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","A COVID-19 Symptom, Exposure and Immune Response Registry","Saved From COVID-19","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","Occupational health and safety among health care personnel in a COVID-19 pandemic","Efficacy and Safety of Favipiravir in Management of COVID-19","ICU Trial in Critical Ill COVID-19 Patients","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","Emotional Burden of Healthcare Professionals and Covid Infection 19","Randomized Open-blind Controlled Trial to Study the Benefit of Colchicine in Patients With COVID-19","First in Human Study SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","Double Therapy With IFN-beta 1b and Hydroxychloroquine","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore","COVID-19 Remote Monitoring","PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak","Efficacy of Faviprevir in COVID-19 Treatment","Austrian COVID-19 Registry","UKOSS: Pandemic COVID-19 in pregnancy","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19","Immunological Profiling of Patients With COVID-19 in Respiratory Distress","Interferon Beta 1a in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","Umifenovir in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","AUSTRALIAN CARDIOVASCULAR COVID-19 REGISTRY (AUS-COVID) \r\n","Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85","Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study","Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak","Austrian CoronaVirus Adaptive Clinical Trial","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","Impact of the COVID-19 Pandemic in Gynecological Oncology","To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care\r\n\r\n","Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients","A Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic","Can the Ava fertility tracker device detect early signs of COVID-19?","Cord Blood Therapy to prevent progression of COVID-19 related pneumonia","A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above","A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)","Aspergillosis in patients with severe influenza or coronavirus","Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus?","Distress and resilience of healthcare professionals during the COVID-19 (coronavirus) pandemic","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease","A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers","Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia","The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment","Ayurveda for Flu Like Illness During Covid-19 Outbreak","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19  CPAP, high-flow nasal oxygen, and standard care","Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people","Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark","Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19)","CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable.","Adapting the Decathlon Group Easybreathe snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection.","Study evaluating Coronavirus (COVID-19) nasal/oral swab results compared to blood antibody results in COVID-19 clinic patients.","Mental health and wellbeing on general population during the COVID-19 outbreak","Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.","Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19)","Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine","The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial","Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community","Medical Records Based Study for Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19)","Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients","Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic","Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center","The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator             Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients","A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","The prevention and treatment strategy of the protective respirator related facial pressure injuries among healthcare professionals fighting novel coronavirus pneumonia (COVID-19)","The use of ACE2 receptor increasing medication at hospital admission and\nmortality rates in COVID-19 patints \n","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research","Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia","Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)","A medical records based study for ''Guangdong Pneumonia NO.1'' in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Hydroxychloroquine for prevention of COVID-19 in patients on chronic dialysis","COVID-19 in rheumatic patients: a prospective cohort study","Immunity against SARS-CoV-2 in Dutch population","COVID-19 during pregnancy: a prospective observational cohort","Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment","An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","A clinicial trial to investigate te effect of valsartan compared to placebo on acute respiratory failure in hospitalized SARS-CoV-2-infected patients","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Senicapoc treatment of COVID-19 positive patients in intensive care","Using eHealth to support COVID-19 education, self-assessment and symptom tracking.","Continuous positive airway pressure in severe Covid-19 pneumonia","Clinical study to assess the safety and preliminary efficacy of HCR040, a drug based on mesenchymal stem cells, in patients with acute respiratory distress syndrome. (included patients COVID-19)","Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care","Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study","A weapon against COVID-19: (Social) media and influencers","Clinical trial to assess the efficacy and safety of cyclosporin A treatment associated with standard treatment versus standard treatment only in hospitalized patients with confirmed coronavirus infection","Lung ultrasound vs CT scan in COVID-19 disease","efficacy and safety of a bitherapy by hydroxychloroquine + azythromycin vs monotherapy by hydroxychoroquine in adult patients with documentated infection by covid19","Countering Lung Damage in COVID-19 infection (CounterCovid) study","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","Corticodes au cours de la pneumonie virale Covid-19 lie  linfection par le SARS-Cov-2","Efficacy of different treatments in patients infected with COVID-19","Clinical trial to avoid infection by SARS-CoV-2 in high-risk population. COVID-19","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study","Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs","Tocilizumab plus Pembrolizumab in COVID-19","COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients","Preventing SARS-CoV-2 virus infection and severity of COVID-19 diseases during pregnancy with hydroxychloroquine","Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia","Clinical trial phase II to evaluate the efficacy of  3 types of treatment in patients with pneumonia by COVID-19","Treatment of COVID-19 with allogeneic mesenchymal cells (MSV).","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19","Preventative Drug Treatment for COVID-19 Infectious Disease","Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.","Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia","Clinical trial of administration of MSC to patients with respiratory distress type COVID-19","COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)","Pragmatic clinical trial of hydroxychloroquine in the treatment of oncohematological patients and health professionals with COVID-19 infection without radiological alteration.","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19","A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).","Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19","ICAR (IgIV in Covid-related ARds)","Prevention of severe respiratory failure in Covid-19","Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection","Adaptive trial in severe pneumonia (REMAP-CAP)","Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19","Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease","COVID-19 Registry of the LMU Hospital Munich","Evaluation of the performance of novel rapid diagnostics for COVID-19 at point-of-care","The effects of the COVID-19 pandemic on mental health","Observational clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients","Development of a test to measure the immune response in patients with Covid-19","Accompanying monitoring of primary care in GP practices during the COVID-19 pandemic","Investigation of the influence of the new coronavirus pandemic (COVID-19) on pain, mood and everyday life of patients with painful polyneuropathy","COVID-19 Registry Freiburg","Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course","COVID-19 related obstetric and neonatal outcome study (CRONOS)","Psychological distress of the COVID-19 pandemic: A comparison between cancer patients and healthy controls","Covid-19 Case-Cluster-Study","get.calm and move.on  tackling worries and finding strength for the crisis (COVID-19) in 10 steps","prospective observational study to evaluate transpulmonary pressure, end expiratory lung volume and intraabdominal pressure in mechanical ventilated patients with Covid-19","Lean European Open Survey on \nSARS-CoV-2 (COVID-19)","Screening for symptoms of COVID-19","Cytokine adsorption in severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation","COVID-19 Contact Study - Immunoreaction after possible SARS-CoV-2 / COVID-19 contact","Effect of vitamin A in patients with COVID19","Study on SARS-CoV-2-Serology (COVID-19) in Bremen's public sector","An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic: CoPE It","Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients","?Effect of sofosbuvir/ ledipasvir on COVID-19","VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic","Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in Germany","Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020","Dynamics of regional lung aeration non-invasive determined by electrical impedance tomography in patients with COVID 19","Effect of Benson Relaxation on Quality of Life and job stress  in nurses","Combination therapy in COVID 19","Knowledge, attitude and fear of COVID-19 in Bangladesh","Efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19","Effect of herbal syrup and solution in treatment of COVID-19","Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection (COVID-19)","Study of the effect of Chloroquine in addition to standard therapy in COVID-19 patients","The effect of dental pulp mesenchymal stem cells in treatment of  corona disease","Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection -A Tertiary Hospital based study","Assessment of Objective clinical scoring system to rule out COVID-19 with high sensitivity","Effect of Licorice in COVID-19","Study of Shreepad Shree Vallabh SSV Formulation to improve immunity in quarantine patients of COVID-19","Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia","Effect of hydroxychloroquine on prevention of covid-19 virus","Viral Infection and Respiratory illness Universal Study","Interferon in treatment of COVID-19","Interferon  in treatment  of COVID-19","Tocilizumab in COVID-19","The effect of stem cell transplantation in the treatment of COVID-19","?Effect of febuxostat against coronavirus","Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19)","The effect of naproxen on the healing process of patients with COVID-19","Pirfenidine in SARS-COV2","Treatment of patients with Corona virus infection","Persian Medicine Products in Covid-19","ReciGen for treatment of Covid-19","Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)","Efficacy of the myrtle syrup in the treatment of novel corona","Atorvastatin effect on COVID-19","The effect of Noscapine  on clinical and pulmonary manifestations of COVID-19 patients","Study of the metformin effect on the survival and recovery rate of patients with COVID-19","Remedy of human coroviruse infection with genetic nanocomposit drug","The effect of Trachyspermum copticum syrup on clinical manifestations of patients with COVID-19","Convalescent Plasma therapy for COVID-19 Patients","Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19","Comparison of efficacy of oral Levamisole and  Formoterol+Budesonide inhaler with standard treatment of Corona infection.","Remdesivir in treatment of COVID-19","Evaluation the Efficacy and Safety of Tocilizumab in COVID-19","Evaluation of the effectiveness of Ipecac homeopathic remedy  in control of Clinical manifestations of COVID-19","Comparison of vitamin D3 and N-acetylcysteine prescription in COVID-19 patients   and their effect on recovery process","Investigating the effectiveness of psychological interventions on mental health","Effect of metformin in COVID-19  symptom improvement and death","Interferon beta 1b in COVID-19","Efficacy evaluation of an herbal compound in COVID-19","Study of the effect of vitamin C in patients with Covid-19","Effect of Methylprednisolone in treatment of COVID-19 patients","Effects of High-dose Vitamin C on COVID-19","Effect of oral multi-herbal preparation on COVID-19","The effect of MCT Oil on COVID-19","Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19","Effect of Fingolimod for treatment of COVID-19-induced cytokine storm","Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19","The efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 who have not responded to standard three-drug protocol","Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19)","Mesenchymal Stem Cell therapy in COVID19","Efficacy of the barley-based remedy in the treatment of novel corona","Hemoperfusion in patients with COVID-19","The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients","Effect of berberine on COVID-19","supplementation in COVID-19","Umifenovir effectiveness in the treatment of COVID-19","Evaluation the effects of Hydroxychloroquine administration for COVID-19 prophylaxis","Evaluation the effect of licorice for treatment of coronavirus","Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected Corona (COVID-19)","The effect of PHR spray on patients with coronavirus-19","Evaluation of the  efficacy of oral 25-hydroxyvitamin D3 on COVID-19","Evaluation of  the effect of traditional  Iranian medicine product on improvement of clinical menifestation of COVID -19","Effect of herbal capsule, Viroherb, and herbal syrup, Fenugreek in treatment of COVID-19","Post-exposure hydroxycloroquine prophylaxis for Covid 19","Efficacy of Kelofan syrup on COVID-19","Comparative assessment of the efficacy and safety of add ontreatment with Sofosbuvir standard of care therapeutic regimenVelpatasvir to standard of caretherapeutic regimen in patients with COVID-19","The Impact of Family-Based Empowerment Model on Stress, Anxiety and Satisfaction","Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients","Evaluating the effect of Marshmallow and Licorice on COVID 19 patients","evaluation of Safety and efficacy of anti inflammatory regimens in COVID-19","Effect of IMFLUNA herbal compound on covid-19 pneumonia symptoms","Evaluation the effects of Favipiravir in COVID-19 patients","Effect of Bromhexine Hydrochloride on patients with COVID-19","Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in  hospitalized patients with COVID-19","Comparison of therapies for COVID-19","Evaluation the Effect of Ticoplanin  in Patients With Coronavirus Disease","Evaluation of the effects of Losartan in patients with corona virus disease 2019","Prevention of Novel Coronavirus Disease by Hydroxychloroquine in cancer patients.","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection","The effect of Tanacetum parthenium (L) Sch syrup on clinical manifestations of patients with COVID-19","Evaluation of the efficacy of oral 25-hydroxyvitamin D3 on COVID-19","Effect of Arbidol in treatment of COVID-19","Early tracheostomy in COVID-19","Evaluation and comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients","Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm","Evaluation the effect of asafoetida in the treatment of coronavirus infection","Effect of Methylprednisolone on treatment of COVID-19","Effect of crocetin on COVID-19","The effect of SOVODAK in the treatment of COVID-19 patients","Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad","Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease","Treatment of COVID-19-induced cytokine storm by hemoperfusion","The effect of elderberry syrup against COVID-19 symptoms","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection","Efficacy and safety of convalescent plasma in the treatment of COVID-19","Evaluation the efficacy of hot foot-bath on COVID-19","Effect of minocycline on COVID-19","Effect of Intravenous vitamin c in Patients with COVID-19","The effect of confinement on the mental health of individuals during the COVID-19 pandemic: an online survey","Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19","The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases","Effect of Trifluoperazine in treatment of COVID-19","The effect of azithromycin in treatment of COVID19","Evaluating the effect of Phyllanthus Emblica on COVID 19 patients","Effect of Ozone therapy in treatment of COVID-19","The  effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in Tabriz","Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS","The effect of hydroxychloroquine to prevent coronavirus disease","Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia","The effect of melatonin on the quality of sleep in COVID-19 patients","Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19","Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial","A multicenter, open-label, randomized controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19","Favipiravir in patients infected with COVID-19","Triple combination therapy in patients infected with COVID-19","Prevention of COVID-19 infection in a medical institution \nand maintenance of medical system","Evaluation of Hydroxychloroquine for prevention of hospitalization and respiratory complications in patients with confirmed diagnosis or suspected infection by (COVID-19)","Multicenter observational study to examine the efficacy of protection during endoscopy examination for Covid-19 infection","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus","Risk factors of death from coronavirus disease 2019","Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19","Lagos COVID-19 Chloroquine Treatment Trial (LACCTT)\r\n","Multicenter prospective cohort study evaluating outcome of COVID-19 in patients with hepatobiliary-pancreatic disease","Use of Covid-19 Rapid Test for Hospital Care: GI Procedure","Comparative effectiveness of Chloroquine and Vitamin C prophylaxis in household contacts of confirmed COVID-19 patients","Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes","Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized controlled trial","Covid-19 preparedness among Emergency Departments: a cross-sectional study in France.","Psychological effects of social isolation in the coronavirus pandemic","CIGB 2020 in contacts and SARS-CoV-2 infection suspects","SOLIDARITY","ED Response against Covid-19 pandemic","Treatment of 2019-nCoV Pneumonia with N-acetylcysteine","Social, ethical and behavioural aspects of the novel coronavirus pandemic"],["Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection","Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19)  based on CRISPR-cas protein","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Volatile Organic Compounds in Exhaled Breath","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial","Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia in Wuhan, China","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia ((COVID-19)","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients","A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia","A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients","Co-infection of novel coronavirus pneumonia (COVID-19) and influenza virus: a single-center, two-phase, observational study","A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","Impact of vitamin D deficiency on prognosis of patients novel coronavirus pneumonia (COVID-19)","Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study","Observational study of Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","An epidemiology study for TCM syndrome  of novel coronavirus pneumonia (COVID-19)","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)","Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)","Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network","Optimization of treatment and diagnosis plan for critically ill patients","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients","A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques","Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)","Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women","The risk factor and prognosis of acute kidney injury in novel coronavirus pneumonia (COVID-19)","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","Development of 2019-nCoV  therapeutic antibody","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Study on anxiety of different populations under novel coronavirus (COVID-19) infection","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Clinical observation of the novel coronavirus pneumonia (COVID-19) in neonatal","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics","Clinical characteristics and outcomes of cardiovascular disease patients infected by COVID-19 in Wuhan, China: a descriptive study","The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp","Effect of New Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students","Registry Study on the Efficacy of a Self-test and Self-alert Applet in Detecting Susceptible Infection of COVID-19 a Population Based Mobile Internet Survey","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp","Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)","Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Study on mental health status and influencing factors of nurses during epidemic prevention of Novel coronavirus pneumonia (COVID-19)","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients","The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome","A Multicenter Observational Study of the Perinatal-neonatal Population With or With Risk of COVID-19 in China","The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet","A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV","Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)","Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus infection (COVID-19) from two hospitals in China","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","The coagulation function of novel coronavirus pneumonia (COVID-19) patients","Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey","Epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","A study on treatment strategies of novel coronavirus pnueumonia patients","A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)","Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study","A clinical study about the diagnosis and prognosis of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study","Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection","A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection","Retrospective studyfor integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Retrospective study to assess the safety of in vitro blood purification treatment in critically ill patients with novel coronavirus pneumonia COVID-19","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A case records based retrospective Cohort study","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country","CT Scores Predict Mortality in 2019-nCoV Pneumonia","A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Study on the application of convalescent plasma therapy in severe COVID-19","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Key techniques of combination therapy of Novel Coronavirus Pneumonia (COVID-19) - Study on TCM symptoms and treatment law","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)","Comparative Study for Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients in Sichuan Province and Wuhan","Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases","Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)","A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)","SARS-CoV-2 Infection on Myocardial Injury and Prognosis: a Multicenter, Long- term Follow-up and Registration Study","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)","The Real World Study to Evaluate the Added Treatment Effectiveness of Comprehensive Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19)","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study","A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study","Application of flash glucose monitoring to evaluate the effect of hyperglycemia and glycemic variability on prognosis in patients with novel coronavirus pneumonia (COVID-19)","Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department","Retrospective and Prospective Study on Nosocomial infection in Stomatology Department under the Background of COVID-19","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV)","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection","Study of effects of crisis intervention on medical staff based on positive psychology","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19)9: An Multicenter Cohort Study","Correlation analysis of blood eosinophil cell levels and clinical novel coronavirus pneumonia type: a single-center, retrospective study","Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial","Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019: A Longitudinal Study Protocol","Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)","The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study","Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1 in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-1","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors","Investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong","Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study","A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients","Analysis of influencing factors of death of COVID-19 patients in wuhan third hospital","Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection","Factors associated with death patients with novel coronavirus pneumonia (COVID-19)","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia","Development of warning system with clinical differential diagnosis and prediction for severe type of SARS-Cov-2 patients based on artificial intelligence and CT images","Clinical outcomes and follow-up study of COVID-19 patients","An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT","Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","Study for the physical and mental health status of medical workers under the situation of COVID-19","Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies","Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit","Epidemiological Characteristics and Antibody Levels of COVID-19 Infection of Pediatric Medical Staff working in Quarantine Area","A multicenter retrospective study of rheumatic  patients with COVID-19","Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients","Preliminary screening of Coronavirus Disease (COVID-19) by special laboratory examination and CT imaging before surgery","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia: a single center and descriptive study in Wuhan","Epidemiologic and Clinical features of COVID-19 in Ningbo","Retrospective analysis of digestive system symptoms in 600 cases of 2019-ncov pneumonia in Guanggu district, Wuhan","Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Nutritional risk assessment and outcome prediction of critically ill COVID-19 patients","The value of Lymphocyte subsets in Coronavirus Disease 2019","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Ocular dectection of SARS-CoV-2 in 114 cases of COVID-19 pneumonia in Wuhan, China: an observational study","Development and application of COVID-19 intelligent image classification system based on deep learning","Screening and Identification of SARS-CoV-2 Infection and Progression in Cancer Patients Based on Bioinformatics Analysis","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)","Sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)","Quantitative CT characteristic estimate the severity of 2019-nCoV","Clinical characteristics of severe or critically ill patients infected with 2019-nCoV","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers","Clinical characteristics of COVID-19","A retrospective study of clinical drug therapy in patients with COVID-19","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)","Clinical characteristics and treatment of COVID-19","Analysis of risk factors affecting prognosis of elderly patients infected with COVID-19 pneumonia: a single-center retrospective observational study","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia","Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia patients","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19): a dual-center, retrospective, cohort study","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Research for the influence of epidemic of  novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations","Risk Factors for Anxiety of Otolaryngology Workers in Hubei Province Fighting Against novel coronavirus pneumonia (COVID-19)","Analysis of Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","Clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19)","Characteristics, prognosis of  ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area: a dual-center, retrospective, cohort study","Analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection","Cross sectional study of dialysis treatment and mental status under the outbreak of COVID-2019 in China","Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","Risk assessment and treatment timing of invasive fungal infection in critically ill covid-19 patients: medical records based study","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau","Analysis of risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS","Shedding of SARS-CoV-2 in human semen and reproductive health evaluation of ever infected males","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)","Application of cas13a-mediated RNA detection in the detection of novel coronavirus nucleic acid","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan","A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)","A prospective cohort  study on recovering patients with novel coronavirus pneumonia (COVID-19) by comprehensive treatment of Chinese medicine","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Study on immune cell subsets in convalescent patients with SARS-CoV-2 infection","An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)","Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial","COVID-19 infection associated kidney injury in children","The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS): a retrospective observational study","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room","Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","Analysis of the characteristics of traditional Chinese medicine combined with western medicine and its correlation mechanism based on real-world patients with  novel coronavirus pneumonia (COVID-19)","A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) in asymptomatic patients: a single center, prospective, open clinical study","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)","Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)","Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)","Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","The effects of  prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test","Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff","Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia","Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","The correlation between Vitamin D deficient and severe status of novel coronavirus pneumonia (COVID-19) patients","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial","The COVISTRESS Study: Influence of the COvid-19 Epidemic on STRESS","Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","Study on the impact on fetus and neonates of vertical transmission of 2019-nCoV","Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)","The Cohotr of COVID-19","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","The Diagnosis and prognosis prediction of novel coronavirus pneumonia (COVID-19) based on AI and Radiomics","Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggang.","association of T lymphocytes level and clinical severity in patients of NCP: a single-center retrospective data","Detection of SARS-COV-2 RNA Level in Blood and Excrement of Patients Infected with 2019-nCOV in Recovery Period","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia","Clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia","The Retrospective Study about Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia in WuHan","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia","Myocardial injury and arrythmias in the COVID-19 patients","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques","Venous Thrombosis Risk of 2019-nCoV Pneumonia(COVID-19) Patients: A Prospective Study","A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years","Accurate Classification System for Patients With COVID-19 Based on Prognostic Nomogram","Application of radiology in the prevention and control system of emergency respiratory infectious diseases","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of  Coronavirus SARS-CoV-2","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia COVID-19","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)","Clinical Characteristic and Outcomes of Hospitalized Patients With Coronavirus Disease 2019","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules","Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","Upper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patients","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''","A prospective real world study on Compound Houttuyniae Mixture used in people of the observation period in close contact with novel coronavirus pneumonia (COVID-19)","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak","Psychological Responses of Medical Staff during the Metaphase of Coronavirus Disease 2019 Outbreak in Hubei, China","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study","A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia","Combined diagnostic value of novel coronavirus infection detected by NLR and CRP","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine","An observational study of cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.","Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)","Optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease - ECMOCARD Study","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP)","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia","Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction","Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study","An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients","Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","COVID-19 Registry - COVID-19 Registry","Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus","Getting it Right: Towards Responsible Social Media Use During a Pandemic","Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19","Retrospective Study of Myocardial Damage in COVID-19","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China","A Pilot Study of Sildenafi in the Treatment of COVID-19","A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19","Prognostic Factors of Patients With COVID-19","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province","Sequential Oxygen Therapy Strategy for Patients With COVID-19","An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis","Serum and urine proteins and metabolomic markers in patients with COVID-19","Changes in Organ Specific Biomarkers, Virus Expression and Prognosis for Covid-19","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","Altered brain structure and function in patients with COVID-19 after rehabilitation","The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)","Influence of COVID-19 on disease activity, medical and mental condition of patients with rheumatic diseases","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of COVID-19","The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death","Clinical characteristics and death risk factors in COVID-19 patients","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)","Clinical features and prognosis of  invasive mechanicalventilation patients  with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a cohort study","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","Hospital of Chengdu University of Traditional Chinese Medicine jointly launched a real-world study on the clinical efficacy evaluation of the Inner hospital preparation","Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial","Study on home pharmaceutical care for chronic patients over the new coronavirus pneumonia epidemic","Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19","the effects of 6-minute walk training on walking distance, oxygen saturation, heart rate and global rating of change of normal or critial novel coronavirus pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China","Clinical investigation and reseach on TCM syndrome of COVID-19","Investigation of Physical Activity, Quality of Life and Stress Levels of Individuals Who Live in Their Homes Isolated Because of Coronavirus (COVID-19) Disease","Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)","Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19","Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gurin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound","A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG001) for SARS-CoV-2 infection","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism","Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19","A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","Use of Ascorbic Acid in Patients With COVID 19","The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial","Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)","The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial","Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)","Serum Testing of Representative Youngsters: Sero- Epidemiological Survey of England in 2019/2020","Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19","Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Audio Data Collection for Identification and Classification of Coughing","COVID-19 Public Image Registry","Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)","In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2","A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and  the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)","Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune","Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","Survey of psychological status and related factors of emergency medical staff in the country during the COVID-19 pandemic","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)","Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial","Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients","Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial","Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","A clinical study evaluating the safety and tolerability of microRNA2911 plasmids in healthy adults","Clinical experience of 59 novel coronavirus pneumonia patients with intensive endotracheal intubation: a single center, retrospective, descriptive study","Evaluation of  the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis","What happens to non-health care workers' sleep of China during the pandemic of novel coronavirus pneumonia (COVID-19)","Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy","A paired clinical study of novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital","Safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy","Uno studio randomizzato multicentrico in aperto per valutare lefficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RE","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPE","A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province","Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle - HYCOVID","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure","Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic","The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.","Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial","An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections","A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection","A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)","An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19  a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid Study","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19)","An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area","Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients","Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers","Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection","NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)","An Observational Case-control Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications","The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection","The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial","DAS181 for Severe COVID-19: Compassionate Use","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic","EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial","Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study","The ECLA PHRI COLCOVID Trial","A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam","ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection","A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","Safety and Efficacy of Hyperbaric Oxygen for Improvement of Acute Respiratory Distress Syndrome in Adult Patients With COVID-19; a Randomized, Controlled, Open Label, Multicentre Clinical Trial","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Reducing Health Care Workers Absenteeism in SARS-CoV-2 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Gurin Vaccination, a Randomized Controlled Trial.","COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Risk Factors for Community- and Workplace Transmission of COVID-19","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study","Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments","A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Impact of the Coronavirus (COVID-19) on Patients With Cancer","Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)","Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19","Biological Samples Collection From Patients and Caregivers Treated at Bordeaux University Hospital for Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Infection (COVID-19).","Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS","Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19","PCR-COVID-19 Predictors of Positivity in Patients Admitted to ICU for Respiratory Infection: A Prospective Observational Cohort Study","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","A Phase 2 Randomized, Open Label Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study (Covid-VAS)","Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment","Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial","Utilizing lung ultrasound in COVID-19 patients in ICU  comparison of management strategies on survival and time on ventilation.","Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Effectiveness and Safety of Chloroquine Phosphate in Combination With Telemedicine in the Reduction of Risk of Disease-related Hospitalization or Death, in Ambulatory Patients With COVID-19 at Particular Risk of Serious Complications","Prospective registry of maternal, perinatal and neonatal outcomes from pregnancies infected with SARS-COV2 (COVID-19)","A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19\r\n","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","An Open Label Phase II Pilot Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients","Home telerehabilitation for people with COVID-19: Implementing telehealth approaches to care and its effect on reintegration into the community","High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients: A pilot randomized controlled trial","Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia","Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection","Clinical Characteristics Of 45 Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome: A Single-Centered, Retrospective, Observational Study","Clinical features and outcomes of critically ill adult patients with COVID-19 admitted to ICUs of non-Wuhan city, China: a medical records based retrospective study","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial","ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial","Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19","Public health emergencies of hospital emergency nursing human resource database to development and construction","A questionnaire investigation of hydroxychloroquine for its potential protective effect against Severe Acute Respiratory Syndromes-coronavirus-2 infection","The impact of Information Sources over behaviors and preventive measures against COVID-19","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years","Observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)","Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function","Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system","Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic","Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)","Serum, faeces and sputum proteins and metabolomic markers in patients with novel coronavirus pneumonia (COVID-19)","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","Retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","Early risk stratification of the novel coronavirus disease 2019 (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID","COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: the randomized ACORES-2 study - ACORES-2","Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVID","A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo","A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial) - COVERAGE","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial - COVIDAXIS","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection\r\n\r\n - IMMUNONCOVID-20","A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVID","EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS","Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase","PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVID","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19","Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with placebo - EPICOS","Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVID","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)","Lessening Organ Dysfunction With VITamin C (LOVIT)","A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects","Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19)","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC)","A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19","Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails","A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19","Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection","An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.","Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus","Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence","Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734)","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19","Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial","Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.","Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia","Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study","Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China","Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection","An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients","Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak","Non-contact Endoscopy at Covid-19 Outbreak","Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia","Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)","Mindfulness During COVID-19 - Remote Mindfulness Sessions","The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection","A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)","Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","Pandemic Response Network: Duke Community Health Watch","Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method","COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA","Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","PRIORITY (Pregnancy Coronavirus Outcomes Registry)","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial","Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection","A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.","\"Coronavirus SARS-CoV2 and Diabetes Outcomes\" : CORONADO","Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19","An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19","COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)","A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Time of Recovery and Prognostic Factors of Covid19 Pneumonia","Single-Arm Observational Study Designed to Clinically Evaluate Cordio Application in Adult Patients Positive to COVID-19","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study","BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial","Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study","A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial","Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","Evaluation of Novel Diagnostic Tests for 2019-nCOV","Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)","Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia","Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial","The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial","Protective Role of Inhaled Steroids for Covid-19 Infection","How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study","A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.","Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome","A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients","GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","COVID-19 Symptom Tracker","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial","A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia","Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis","Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19","A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)","Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","An Observational Study of Patients With Coronavirus Disease 2019","Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19","An International, Multi-site, Bayesian Platform Adaptive,Randomised, Double-blind, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial","Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2","A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19","International COVID19 Clinical Evaluation Registry: HOPECOVID19. (Health Outcome Predictive Evaluation for COVID19)","Screening of Cardiovascular Complications in Patients With COVID-19","Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial","A Phase II Pilot Study of Quintuple Therapy to Treat COVID-19 Infection","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo","An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19","COVID-19 Registry Rhineland-Palatinate (Germany) - COVID-19 Disease Registry a National, Multicentre, Non-interventional, Prospective Observational Study","A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy","A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2","CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation","A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic","Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study","Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers","Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","Renin Angiotesnin System - CoronaVirus","COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Covid-19 Pediatric Observatory","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","Impact of Previous Treatment With Angiotensin II Receptor Blockers in Patients With SARS-Cov2 Infection Admitted to the Intensive Care Unit on Survival and Severity of the Disease (COVID-ARA2)","Assessment of Distress in Crisis Situations During COVID-19","Postnatal Outcomes of Covid 19 Positive Mothers Newborns","A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study)","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","Dynamic Evaluation of COVID-19 Diagnostic Tests","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression","Impact of Covid-19 in Congenital Heart Disease - COVID-CHD","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients","Point Of Care UltraSonography to Perform Risk-stratification of Patients With Suspected or Confirmed COVID-19 - POCUSCO Study","Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The Covid-19 Quarantine Period","CAP-1002 Treatment in Patients With Severe COVID-19 and in Critical Condition as Indicated by Life Support Measurements","The Impact of the Coronavirus Disease 2019 (Covid-19) Outbreak on Emergency Room Attendances of Surgical Patients at a Tertiary Medical Center","Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","COVID-19 and Deep Venous Thrombosis: a Cross-sectional Study","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy: an Italian Polispecialistic Society of Young Surgeons (S.P.I.G.C.) Survey","A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation","Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment","Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection","Endometriosis Patients Covid 19 Anxiety","REmote MOniToring usE in Suspected Cases of COVID-19 (Coronavirus): REMOTE-COVID Trial","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease","Development of a Breath Analysis Test for Disease Diagnosis and Prognosis","Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19","Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection","The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019","COVID-19 Risk Stratification","A Prospective, Longitudinal, Observational Study of Healthcare Workers and the General Population to Watch for Flu-like Symptoms in Suspicion of COVID 19","Characteristics and Outcome of COVID-19 Among Egyptian Patients","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial","Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study","Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study","Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection","A Prospective Cohort Study Investigating Oncology-patient-reported Anxiety, Mood, and Quality of Life During the COVID-19 Pandemic (ONCOVID Trial)","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)","A Double Blind, Randomized Controlled Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed Coronavirus (COVID-19) Patients: GARGLES STUDY","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","Safety and Efficacy of Baricitinib for COVID-19","Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenation(CO2 Removal) Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP)","Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome","A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","\"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers\" \"Impact Psychologique de l'pidmie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation\" \"BURDENCOV\"","Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19","Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19","Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes","Hydroxychloroquine for Outpatients With Confirmed COVID-19","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic","Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19","Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.","Evaluating Non-contact ECG Sensor System for Early Detection of COVID19","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial","STUDY ECMO-COVID-19 : PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial","Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19","A Study on the Prospective Cohort Library of Novel Coronavirus Pneumonia in Southeran","Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study","Gastrointestinal Endoscopy in the Era of COVID-19: a Multinational Survey","Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial","The Role of Resistant Potato Starch in COVID-19 Infection","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial","Convalescent Plasma in the Treatment of COVID 19","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records","A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19","A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Adjuvant Use of Ivermectin To Hydroxychloroquine in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study","Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.","Non-invasive Positive Pressure Ventilation Mask to Minimize Mask Leak and Potential Aerosolization Leading to Spread of Virus Such as COVID-19: A Non-inferiority Trial","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","Observational Retrospective Register of Spanish Lung Cancer Patients With COVID19 Disease","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection","A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Standard Supportive Care in Subjects Infected With COVID-19","Prevalence of COVID-19 Symptoms History in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome or Psoriatic Arthritis, With or Without Hydroxychloroquine Long-term Treatment","Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure: A Pilot Study","Effectiveness of Crisis Management Coaching on Faculty and Trainee Wellness During COVID-19 Crisis","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","CovidDB: The Covid-19 Inpatient Database","Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI)","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome","Strain Study: To Access the Egyptian COVID-19 Whole Genome (Dominant Strain) by Next Generation Sequencing (NGS) and Compare to the International Worldwide Database","Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains","Burnout, Emotional Distress and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population","Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial","A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning","Oropharyngeal Dysphagia in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment of Patients Admitted by COVID-19 in the Consorci Sanitari Del Maresme","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial","Collection of COVID-19 Convalescent Plasma","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)","SARS-CoV2 in Cardiology Unit in France : Risk Factors for Mortality","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial","Impact of Covid-19 on Egyptian Population Mental Health","An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection","UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)","Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate","An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)","Anti COVID-19 Convalescent Plasma Therapy","A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms in Maricopa County","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients","Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.","A Pilot Study for Collection of Anti-SARS-CoV-2 Immune Plasma","The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19","An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers","Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to SARS-CoV-2 Infection","Testing for COVID-19 Infection in Asymptomatic Persons","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers","Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial","Real World Observational Database for COVID-19 Treatment and Outcomes","Randomized Trial of ACEIs in Treatment of COVID-19","Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients","Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia","Tear Fluid miRNA Analysis in Sars-Cov2 Conjunctivitis","Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2","Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak","A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients With Severe COVID-19 Pneumonia","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff","Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","Screening and Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals Using Real-time Geospatial Mapping for Emergency Healthcare Resource Mobilization and Management","Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID) - an Observational Study of Invasively Ventilated Patients in the Netherlands","An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia","The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver - The Pan Asia-Pacific Prospective Multi-centre Observational Study (APCOLIS STUDY)","Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Randomized, Open-label Clinical Trial","Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19","A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS","Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR","ReportAge-COVID Project: Clinical and Biological Predictors of COVID-19 Disease in Older Patients","Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.","Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial","A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)","Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit","Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home","Evaluation of the Immune Response in Symptomatic and Asymptomatic Patients' Diagnosed Witih COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19","Feasibility and Acceptability of Online Based Mindfulness Interventions to Relieve Distress During COVID-19 Outbreak in a Chinese Population: a Proof-of-concept Trial","A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","Investigation Of The Effectiveness Of Video-Based Exercise Program Applied To Adult Individuals Who Experience Social Isolation At Houses Due To The Coronavirus (COVID-19) Pandemic","Implementation of Physiotherapy on COVID-19 Patients in Intensive Care Units : a Retrospective, Multicentric, International Study","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Cancer Patients With Severe COVID-19","Assessment of COVID-19 IgM/IgG Self-testing Using Virtual Point-of-care","An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19","CoVid-19 - Infection and Antibody Formation in the Viennese Population - Data From the Vienna Health Study LEAD","BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","a Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease","A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection","With Uncontroversial Honey And Nigella Sativa (WUHAN) Treatment for Noval Coronavirus Infection; Randomized, Controlled, Double Blind, Investigator Initiated Trial","Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak (DARTS)","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19) Infection, From Diagnosis to Long-term Follow-up","Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis?","Establishing a Covid-19 Prospective Cohort to Document Cases of Secondary Hemophagocytic Lymphohistiocytosis (sHLH, Synonoums to Macrophage Activation Syndrome)","COVID-19 Serology in Nephrology Health Care Workers","A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","IMPACT RAPPORT: IMPact of Antimalarials on Covid Infections: a Case Control sTudy of RAPPORT","Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?","Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT","Safety and Efficacy of Ruxolitinib for COVID-19","Covid-19 Associated Nephritis as Early Predictor for Complicated Course of Disease","The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome","Randomised Controlled Trial of Problem Management Plus versus Enhanced Treatment as Usual on Anxiety and Depression in People Distressed by Covid 19","Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19","Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study","Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial","A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions","Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers: A randomised placebo-controlled trial","Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.","Plasma Rich Antibodies From Recovered Patients From COVID19","Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia","Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Impact of high intensity interval training and aerobic training in on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain: a randomized controlled trial.","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)","Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care)","Prospective study evaluating the proportion of SARS-CoV-2 (COVID-19) antibody seroconversion in frontline health care workers on serial evaluation in comparison to symptom presentation.","A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection","COVID-19 Study - A Primarily Prospective Observational Study of COVID-19 Clinical Characteristics and Acquired Immune Response Within the General Population","Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","Predictive value of biological, physiological and analytical biomarkers with the use of personal protection equipment in COVID-19: observational, prospective, analytical, intervention and multicenter study","Efficacy and Safety of Favipiravir in Management of COVID-19","Prospective Observational ICU Trial in Critical Ill COVID-19 Patients (POINT-C) Cardiovascular Risk and the Effects on Myocardial Events in Critical Ill COVID-19 Patients","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS","EVALUATION: Extravascular lung water index in patients with COVID-19: A prospective comparison to a recent cohort with non-COVID-19 ARDS","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","Emotional Burden of Healthcare Professionals and the Epidemic Related to Covid Infection 19 -","Phase III, Prospective, Randomized, Controlled, Open-label and Pragmatic Trial, Comparing the Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria","Ph1, Dbl-blind, Rndmzd, Plcbo-controlled, Sponsor-open, Sgl Asc Dose(SAD) and Mltpl Asc Dose(MAD) Stdy in Healthy Subjs to Eval the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Trtmnt for Acute Lung Injury Assoc w COVID-19","A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease","An Open-label Randomized Controlled Trial on Interferon -1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes","Remote Monitoring in Patients With Coronavirus Disease (COVID-19)","Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate","Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak","Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment","Austrian COVID-19 Registry (AGMT_COVID-19)","Maternal and perinatal outcomes of pandemic COVID-19 in pregnancy","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19","Immunological Profiling of Patients With COVID-19 in Respiratory Distress","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","AUSTRALIAN CARDIOVASCULAR COVID-19 REGISTRY (AUS-COVID) \r\n","Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85","West Australian Airway Pressure Release Ventilation Study in COVID-19: evaluation of ventilation free survival days","Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak","A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology","Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care","\n                An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care\n","Feasibility of a Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic","Defining the role of a fertility bracelet for early recognition and monitoring of COVID-19 in Liechtenstein: an observational study (COVI-GAPP)","Cord Blood Therapy to prevent progression of COVID-19 related pneumonia","Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)","Randomized evaluation of COVID-19 therapy","Incidence and pathogenesis of invasive aspergillosis in intensive care patients with severe influenza or COVID-19 (AspiFlu)","Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled multi-site trial in Toronto, Canada","Distress And Resilience of healthcare professionals during the COVID-19 pandemic","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease","A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers","A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia","Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment","Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","In adult patients with known or suspected COVID-19, does the use of Continuous Positive Airway Pressure (CPAP) or high-flow nasal oxygen (HFNO), compared with standard care reduce mortality or need for tracheal intubation?","Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people","Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial","Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19)","CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","The use of a simplified negative pressure cuirass style ventilator under COVID-19 pandemic conditions in support of critically overwhelmed healthcare systems","Adapting the Decathlon Group Easybreathe snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection.","Retrospective and prospective study evaluating the sensitivity of upper respiratory swabs for SARS-CoV-2(COVID-19) NAT by determining the prevalence of SARS-CoV-2 antibody seroconversion following an initial negative swab in participants that have presented to the COVID-19 clinic","Impact of Social Isolation on Mental Health during the COVID-19 Pandemic: a large international multi-centre cohort study","Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.","Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19)","Study on the prevention of COVID-19 with Chinese medicine regulating constitution","The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery. An international cohort study (COVER)","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19) for Returning Workers in Wuhan: a Randomized Controlled Trial","Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community","Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19): a multicenter retrospective cohort study","Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients","Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19)","Predicting hospitalization and poor clinical outcomes in patients presenting for SARS-CoV-2 testing in an outpatient testing center in Switzerland - a prospective cohort study","Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine","Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study","Observation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","The design of a modifed N95 respirator and its protective effects against facial pressure injuries","The use of ACE2 receptor increasing medication at hospital admission and\nmortality rates in COVID-19 patints \n","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research","Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized controlled trial - MULTI-COV","Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)","Clinical Research on Treatment of Novel Coronavirus Pneumonia  with ''Guangdong Pneumonia NO.1''","The Danish Pre-HCQ Dialysis Study:\r\n Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease -\r\nA multicenter parallel-group open randomized clinical trial\r\n - The Danish Pre-HCQ COVID19 Dialysis Study","COVID-19 in rheumatic patients: a prospective cohort study","Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2","COVID-19 during pregnancy: a prospective observational cohort","A cross-sectional observation study to delineate the degree of environmental contamination by SARS-CoV-2 in the clinical environment","An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (COVID-19) - PRAETORIAN-COVID","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency\n A Randomized, Open-Label, Phase II Trial - COVIPOC","Using eHealth to support COVID-19 education, self-assessment and symptom tracking. An observational study in The Netherlands.","Continuous positive airway pressure in severe Covid-19 pneumonia: a feasibility and physiological end-point study","Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19)","Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care - SARICOVID","Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study","The use of (social) media","Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01","A prospective observational multi-center trial assessingthe diagnostic value of lungultrasound (LUS) vs CT-scan in patientswith COVID-19Infection","Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19","Countering Lung Damage in COVID-19 infection (CounterCovid) study","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","Corticodes au cours de la pneumonie virale Covid-19 lie  linfection par le SARS-Cov-2 - CORTI-Covid","Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19","Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-Aging","Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs","A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19  (COPERNICO Study)","COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients - CoVitTrial","Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy","Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCT","Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF","Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV-allo) in acute respiratory failure in patients with COVID-19 pneumonia.\r\n - Treatment of COVID.19 with allogeneic mesenchymal cells  (MSV).","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19","ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) - PROLIFIC Trial (COVID-19)","Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.","Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia","Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19.","COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)","Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alteration","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19\n - COVIDSurgRCT_v1.0_20200330","The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19","Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVID","Interest of early treatment with polyvalent immunoglobulins in the management of respiratory distress syndrome associated with SARS-CoV-2 infections_COVID-19 - ICAR (IgIV in Covid-related ARds)","suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL","Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (COVID-19) - REMAP-CAP","A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC","Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease - COVit","COVID-19 Registry of the LMU Hospital Munich - CORKUM","Evaluation of the performance of novel rapid diagnostics for COVID-19 at point-of-care - Novel rapid diagnostics for COVID-19","The effects of the COVID-19 pandemic on mental health - NA","Observational clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients - SR-NOCS","Development of a test to measure the immune response in patients with Covid-19 - CoV-Ak-Test","Accompanying monitoring of primary care in GP practices during the COVID-19 pandemic - COVIPRIM","Investigation of the influence of the new coronavirus pandemic (COVID-19) on pain, mood and everyday life of patients with painful polyneuropathy","COVID-19 Registry Freiburg - COVID-19-FR","Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course","COVID-19 related obstetric and neonatal outcome study (CRONOS) - CRONOS","Psychological distress of the COVID-19 pandemic: A comparison between cancer patients and healthy controls","Covid-19 Case-Cluster-Study","get.calm and move.on  tackling worries and finding strength for the crisis (COVID-19) in 10 steps - get.calm_move.on","prospective observational study to evaluate transpulmonary pressure, end expiratory lung volume and intraabdominal pressure in mechanical ventilated patients with Covid-19 - EELV and TPP in Covid-19","Lean European Open Survey on \nSARS-CoV-2 (COVID-19) - LEOSS","Max COVID Study","Cytokine adsorption in severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation - CYCOV","COVID-19 Contact Study - Immunoreaction after possible SARS-CoV-2 / COVID-19 contact - CoCo Study","evaluation the effect of vitamin A on respiratory signs and hospitalization in patients with COVID-19","Study on SARS-CoV-2-Serology (COVID-19) in Bremen's public sector","An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic: CoPE It","Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients: A Clinical Trial Study","Evaluating efficacy and safety of sofosbuvir/ ledipasvir in  treatment of COVID-19","VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic - VOICE","Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in Germany - ProCoV","Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020","Dynamics of regional lung aeration non-invasive determined by electrical impedance tomography in patients with COVID 19","Effect of Benson Relaxation on Quality of Life and job stress in nurses in intensive care units  with Covid-19 pationts","Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir/ritonavir combination  in patients with COVID-19","Knowledge, attitudes, and fear of COVID-19 during the rapid rise period in Bangladesh","Evaluation the efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19 outcomes: a prospective clinical trial study.","Formulation of two natural products (syrup and solution) and evaluation of their effects in patients with coronavirus disease 2019 (COVID-19): A randomized controlled trial","Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection (COVID-19) - SC2","Open labelled Randomised controlled trial to study the effect of Chloroquine in addition to standard therapy in COVID-19 patients","Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia","Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study - CORONA study","Outbreak of Respiratory Tract Infection Score (ORTIS): Objective Screening for Children to Rule Out COVID-19 and Prevent Nosocomial Spread - ORTIS","Comparison of the Effectiveness of Standard Treatment with Standard Treatment plus licorice extract in Improving Respiratory Symptoms and Survival Rate in COVID-19 Patients","An open labelled trial to evaluate safety and efficacy of SSV Formulation to boost immunity in quarantine patients of COVID-19","Effect of Camostate mesylate on clinical improvement and outcome of  Coronavirus (COVID-19)-induced pneumonia","Effect of hydroxychloroquine on prevention of covid-19 virus infection among treatment staff in Arash hospital-A double-blind clinical trial","Viral Infection and Respiratory illness Universal Study:\nCOVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)","Evaluating efficacy and safety of interferone -1a in the treatment COVID-19 infection","Evaluating efficacy and safety of interferone -1b (IFN -1b) in the treatment of COVID-19","Evaluation of the safety and efficacy of Tocilizumab (AryoGen ?pharmed Co. Iran) in patients with COVID-19?","Evaluation of the efficacy and safety of cord-derived mesenchymal stem cell transplantation in the treatment of COVID-19","The effect of febuxostat against lung injury induced by COVID-19 virus in infected patients: A clinical trial study","A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment","The effect of naproxen on the healing process of patients with COVID-19","The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19","Study the Efficacy and Safety of SeptimebTM in the Treatment of COVID-19   Infection in Iranian Patients: A Clinical Trial (Case Series)","The Effect of Persian Medicine Products on the Clinical and Laboratory Symptoms of Patients With or Suspected of Covid-19","the efficacy of Interferon beta 1 a (ReciGen)  in treatment of patients with Covid-19 in Sina Hospital Emergency Department","Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)","Efficacy of the myrtle (Myrtus Communis) syrup in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Atorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State: A Randomized Clinical Trial","The effect of  NOSCOVID on pulmonary &amp; other clinical manifestations of COVID-19 patients","Study of the metformin effect on the survival and recovery rate of COVID-19 patients","The effect of genetical nanocomposit drug with cell imunity level on human coronavirus (COVID-19)","The effect of Trachyspermum copticum-based traditional medicine product on clinical manifestations and Para clinical features in patients with COVID-19: A Randomized clinical trial","Evaluation of Convalescent Plasma as a Potential Therapy for COVID-19 infected patients","Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms","Evaluation of efficacy of pharmacotherapy treatment of COVID- 19  infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease","A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)","Double blind clinical trial study on Evaluation of the effectiveness of Ipecac homeopathic remedy  in control of Clinical manifestations of COVID-19","Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients   and their effect on recovery process","Investigating the effectiveness of psychological interventions on mental health of Kerman University of Medical Sciencess mental health in hospitals and reference clinics","Effect of metformin in COVID-19 mortality rate and symptom improvement","Efficacy and safety evaluation of therapeutic regimen of lopinavir/ritonavir and interferon beta 1b in patients with COVID-19","Efficacy evaluation of an herbal compound Fluherb on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients: a controlled randomized clinical trial.","Study of the effect of Vitamin C on duration of hospital stay in patients with Covid-19","Evaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19): A Non-Randomized Controlled Study","Effects of High-dose Vitamin C on Treatment, Clinical Symptoms and Laboratory Signs of Iranian COVID-19 Patients: A Double Blind Randomized Clinical Trial","Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.","Evaluation of the effect of oral intermediate chain triglyceride on prognosis and course of disease in suspected outpatients with COVID-19","Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19: a randomized controlled trial","Effect of Fingolimod for treatment of COVID-19-induced cytokine storm","Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study","Evaluation of the efficacy of intravenous immunoglobulin (IVIg) in patients with severe  COVID-19 (Before intubation phase) who have not responded to treatment with the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin)","Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19)","Mesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing  in patients infected with 2019-nCoV (phase I clinical trial)","Efficacy of the barley-based remedy in the treatment of suspected novel coronavirus  (COVID-19) pneumonia","To evaluate the effectiveness of hemoperfusion in patients with severe coronavirus disease 2019 (COVID-19)","Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial)","Clinical trial of berberine against COVID-19","Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit","Evaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19: A randomized clinical trial","Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis","Evaluation the effect of aqueous extract of licorice on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial","Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected  Corona(COVID-19)","Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in  pulmonary problems of the patients with Covid-19","The efficacy of oral 25-hydroxyvitamin D3 on  COVID-19 treatment in adults: A Randomized, Controlled Double-Blind Clinical Trial.","Evaluation of  the effect of Traditional medicine product incorporated in the base of  Astragalus gossypinus  with food  spice on improvement of clinical menifestation of COVID -19 patients with conventional protocol","Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences","Prospective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19)","Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19","Comparative assessment of the efficacy and safety of add ontreatment with Sofosbuvir plus Velpatasvir to standard of care therapeutic regimen in patients with COVID-19","The effect of family-centered empowerment model on stress, anxiety and family satisfaction in patients with Covid-19","Evaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients: a clinical trial","Evaluating the therapeutic effect of a mixed herbal drink of Marshmallow and Licorice on COVID 19 patients, A double blind clinical trial","Safety and efficacy of Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone and Hydroxychloroquine + Azithromycin + Naproxen regimens in comparison with Hydroxychloroquine + kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study","Evaluation of the effect of IMFLUNA herbal compound on the improvement of covid-19 pneumonia symptoms in patients referred to Baqiyatallah Hospital","Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients","Effect of Bromhexine Hydrochloride on clinical improvement and outcome of  COVID-19-induced pneumonia","Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in  hospitalized patients with COVID-19","Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial","Study of the Efficacy of Teicoplanin on mortality rate of patients with  COVID-19 Infection: A randomized clinical trial","Evaluation of the effects of Losartan in patients with corona virus disease 2019","Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 1 and 2 clinical trial","The comparison of effectiveness of Tanacetum parthenium (L) Sch. syrups on clinical and paraclinical features of inpatients infected with 2019 novel coronavirus COVID-19, Parallel randomized trial","Investigating preventive effects of oral 25-hydroxyvitamin D3 on COVID-19 in adults: A  Randomized, Controlled Double-Blind Clinical Trial.","Evaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19","The comparison between early tracheostomy and orotracheal intubation in critically ill COVID-19 patients.","Comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients","To evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine storm","Evaluation the effect of  asafoetida on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial","Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian ?COVID-19 patients: a clinical trial study","Clinical trial of the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19","The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study","Evaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19: An open label non-randomized clinical trial","Evaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patients","Treatment of COVID-19-induced cytokine storm with filter hemoperfusion HA330","A comparison of Elderberry (Sambucus nigra) extract syrup and placebo against COVID-19 symptoms in outpatients and home quarantined patients: A randomized double-blind clinical trial","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial","Randomized, parallel-controlled and multi-center clinical study evaluating the efficacy and safety of convalescent  plasma, in the treatment of patients with severe SARS-CoV-2 infection (COVID-19)","Investigating the effect of hot foot-bath on controlling the symptoms of hospitalized patients with COVID-19 and accelerating the recovery process","Clinical trial of minocycline against COVID-19","Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital: a clinical trial ?","The effect of confinement on the mental health of individuals during the COVID-19 pandemic: an online survey","Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19","The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases","Evaluation of the Effect  of  Trifluoperazin in Treatment of   Patients with Confirmed 2019 Novel Coronavirus(COVID- 19): An Open-Label Randomized Clinical Trial","Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study","Evaluating the therapeutic effect of Phyllanthus Emblica on COVID 19 patients, A double blind clinical trial","Comparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patients","The  effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure","The effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19","Prevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the community","Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT)","Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia","Evaluation of adding melatonin to routine treatment on outcomes and quality of sleep in COVID-19 patients","Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19: A randomized clinical trial","Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial","A multicenter, open-label, randomized controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 - RACCO trial","A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.","A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of  lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.","Prevention of COVID-19 infection in a medical institution \nand maintenance of medical system - Prevention of COVID-19 infection in a medical institution \nand maintenance of medical system","Randomized, pragmatic, open study evaluating Hydroxychloroquine for prevention of Hospitalization and Respiratory Complications in outpatients with confirmed or presumptive diagnosis of Infection by (COVID-19)","Multicenter observational study to examine the efficacy of protection during endoscopy examination for Covid-19 infection - Protection for Covid-19","Open and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19): a randomized controlled trial - Brazil COVID Coalition I Trial","Risk factors of death from coronavirus disease 2019 - Risk factors of death from coronavirus disease 2019","Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate and Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients in Lagos State","Multicenter prospective cohort study evaluating outcome of COVID-19 in patients with hepatobiliary-pancreatic disease - COVID-19 in patients with hepatobiliary-pancreatic disease","Use of Covid-19 Rapid Test for Hospital Care: GI Procedure","Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients","Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes: Randomized Control Trial","Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized controlled trial - Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized controlled trial","Preparedness and Responsiveness among Emergency Department against Covid-19 during a rapid growth epidemic phase.","Psychological effects of preventive isolation in the COVID-19 pandemic","Randomized control clinical trial of CIGB 2020 in contacts and SARS-CoV-2 infection suspects (COVID-19)","SOLIDARITY: AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS","Response adjustment of emergency deparytment against Covid-19 pandemic: experience of 5-French academic hospitals.","Clinical Trial using N-acetylcysteine for treatment of 2019-nCoV Pneumonia","Social, ethical and behavioural aspects of the novel coronavirus pandemic"],[null,null,null,null,null,null,null,null,"ELACOI",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Cov-CONTACT",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"COVID-19",null,null,"CMHS",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"2019-nCoV",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"COVISTRESS",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"TT-NPC",null,null,null,null,"TACOS",null,"CTOROTSADTOC","SOTSPC",null,null,null,null,"COVID MECH","CovidTox","UMODCOVID19","CODIV-ACE",null,null,"I-COVID",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"COVID-19",null,null,null,null,"BARI-COVID","CORIPREV-LR","DisCoVeRy",null,null,null,null,null,"COV19-PLASMA",null,"JOCOVID",null,"BEST-RCT","PROACTIVE-19",null,"MP-C19",null,null,"STORY","SOLID-C19",null,null,"ACT COVID19",null,"NOSARSCOVID","COPCOV","CAPACITY-COVID",null,"C19REG",null,"COntAGIouS",null,null,null,"COVID19-HCW",null,null,null,null,null,null,null,"add-on-COV2",null,null,"CovidSurg",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"NONTM","STOP-Flu","BEST-CP",null,null,"COVID-BioB","BEAT19",null,null,"NOpreventCOVID","NO COVID-19",null,null,"SISCO",null,"CamoCO-19",null,"CORIMUNO-19","eCardioCovid19","EC-COVID-RCT",null,"CYCOV","Covid","COLCOVID","VICO",null,"SARPAC",null,"AI-COVID-Xr","GRECCO-19","COVID-19-HBO",null,"BCG-CORONA",null,null,null,null,null,"PERN-COVID-19",null,"COVIDENCE","EC-COVID-PCS","CORSER",null,null,"SARS-RAS","COLCOV19-BX",null,"GARM-COVID19","CP-COVID-19",null,"PREDICT",null,"COVID-Lambda","Covid-19","ATCO",null,null,null,"Covid-VAS",null,"LIBA","MultiCov",null,null,"QUARANTINE2020",null,null,"eChoVid","HELPCOVID-19","SPIN-CHAT",null,null,"DEFI-VID19",null,"CP-COVID-19",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"LOVIT",null,null,"DC-COVID-19","REALIST",null,null,null,null,null,null,null,null,null,null,"SEROCOV",null,null,null,null,null,"THDMS-COVID-19",null,"CTCOVID-19","NOSO-COR",null,null,null,"NoCovid","NOSARSCOVID",null,"COVID-AIV","TOCIVID-19","HT-COVID19","COVID-19 PEP",null,"HCQ4COV19",null,null,null,"HOPE","COVID-preg","NeuroCOVID19","Coalition-I",null,null,null,"HYDRA",null,null,"ProPAC-COVID",null,"SAC-COVID","PHYDRA","COVID-19","CSSC-001","COVACTA",null,"LUSCOVID19","ColCOVID-19","COVIP","COVID-19","PRIORITY","DEXA-COVID19",null,null,"CORIMUNO-SARI","DISPOSE","TOCIVID","ONSCOVID19","B-DT-COV2",null,"CORONADO",null,null,"CoDEX",null,"NIKE_C19",null,"ENACOVID",null,"BRACE","HYCOVID",null,"COVIDAXIS",null,"COVIDx","EPI-COVID-19",null,"COVIDMED",null,null,null,"CORONACION","HAHPS","INHASCO",null,null,"CORA","COVID CALL 15","PATCH",null,null,"COV-AID","CATCO","GO2 PEEP",null,"PrEP_COVID",null,"COVIDOSE","ACTION","PANAMO","CORIMUNO-TOC","TOSCA","TOCOVID","C-19-ACS","COVID-19",null,"CROWN CORONA","TOVID-49",null,null,"ORCHID",null,"HERO-HCQ",null,null,null,null,null,"IMMUNONCOVID","COVITD-19","HOPE COVID 19","CovCardioVasc",null,"HyAzOUT","HAZDpaC",null,"EPICOS",null,null,"COPERNICO",null,"CORON-ACT",null,null,null,"COVID-19",null,null,null,"HSC19",null,"CAPTION AI",null,"SRA-COV",null,null,"PANDOR",null,null,"COVID-ARA2",null,null,null,"APN01-COVID-19","MexCOVID-19",null,"TRODVID-19",null,"JUPITER","COVID-CHD",null,"TCOutpatient","POCUSCO","PiCCOVID","NO COV-ED","INCOVPED",null,null,null,"ESCAPE","HCQINRLGII",null,null,"RuxCoFlam","PROTECT","CLOCC",null,"REMOTE-COVID","COVIDeHPAD",null,"TACROVID","NOCOVID","REPLACECOVID",null,null,"COVID-19",null,null,"SCOUT",null,"AZIQUINE-ICU","WHIP COVID-19",null,null,null,"ONCOVID","COMIHY",null,"FRENCH CORONA","SCOPE","GARGLES",null,null,null,null,"Al-COVE",null,null,null,"CORIMUNO-VIRO",null,"ECMO-VID",null,null,"COVID-SER","BURDENCOV","ASC COVID-19","CORIMUNO-ANA",null,"CRASH-19",null,"ONCOVID","CTII-nCoV",null,null,"BIOCOVU",null,"SOS-COVID19",null,null,"COV-HCQ",null,null,"ECMO-COVID-19",null,"SHARP COVID-19","ConCoVid-19",null,"COVIDAtoZ","COVID-19 Endo","CloroCOVID19II",null,null,"CORIMUNO-NIVO",null,"CYTOCOV-19","COVIDICUS","STOP COVID",null,null,null,null,"DIC",null,"MetCOVID",null,null,"HOPE",null,null,null,"GRAVID","EPILOGUE","New","PISCO",null,"COVCALL",null,null,"COVID19PUGG2",null,null,null,"Strain","ChilblainCOVID",null,null,null,"STOP-COVID",null,null,"CATNAP",null,null,null,"ProCov","CCF","RCT",null,null,"IBD-COVID-19","OHB10cov",null,"UPSAT","PEACE",null,null,"OAHU-COVID19","COVID-19",null,null,"PSI RECORd-GP","NIAID",null,null,"CORIMMUNO-COAG","CORIMMUNO-BEVA",null,null,null,"CORSA",null,"CovidRegOUH",null,"DHYSCO",null,null,"ConPlas-19","COVIDOC",null,"Covid-19HUF","Chloroquine UN",null,null,null,null,null,"DEFACOVID",null,null,null,"COVID-HEP",null,null,"CORIPLASM","Explore",null,null,null,null,null,"COVID-19","COVIDIMMUNE",null,null,"ACE-ID-201",null,"PHYSIO-COVID","CORIMUNO19-ECU",null,null,"DARE-19",null,null,null,"RAPID-19","RegCOVID19",null,null,"WUHAN Trail",null,null,"COVIDothque",null,"COVIDHLH","CONEC",null,"IMPACT","PHYSIO-COVID",null,null,null,null,null,null,null,null,"PSI RECORd-XP","COVID STEROID",null,"APPROVE-CARE",null,null,"Ruxo-Sim-20","PRA-001",null,null,null,"Thy-Support","CONFINE",null,"CONCOR-1","Coronavirus",null,null,"BLAST COVID-19","PRODEX",null,"FAV-001","POINT-C","FMTVDM","VT4COVID",null,null,"Emocovid","COL-COVID",null,null,null,null,null,"PRECISE","PRPsyCOVID",null,null,null,null,"ACTICOV-2","IB1aIC","UAIIC",null,null,null,"OslPsyCOVID","ACOVACT",null,"COVID-GYN",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"RASCOVID-19",null,null,null,"ReCOVery-SIRIO","PISCA",null,"COR-DLUS",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["Zhongnan Hospital of Wuhan University","HwaMei Hospital, University of Chinese Academy of Sciences","The First Affiliated Hospital of Zhejiang University School of Medicine","Children's Hospital of Fudan University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Xiangya Hospital of Central South University","Emergency Department of Zhongnan hospital of Wuhan University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","Guangzhou 8th People's Hospital","Qilu Hospital of Shandong University","The First Affiliated Hospital of He'nan University of Chinese Medicine","Zhejiang Provincial People's Hospital","Affiliated Hospital of Changchun University of traditional Chinese Medicine","Guangzhou reborn health management consultation co., LTD","Shenzhen Second People's Hospital","West China Hospital, Sichuan University","Wuxi People's Hospital","Shenzhen Third People's Hospital","Shanghai University of TCM","Beijing 302 Hospital","Jieming QU","Huangshi Hospital of Traditional Chinese Medicine","The First Affiliated of Wenzhou Medical University","Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Pulmonary Hosptial","Huangshi Hospital of Traditional Chinese Medicine","Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology","The Fifth Affiliated Hospital Sun Yat-Sen University","Beijing You'an Hospital, Capital Medical University","The First Affiliated Hospital of Zhengzhou University","The First Affiliated Hospital of Zhejiang University School of Medicine","Guangdong Provincial Hospital of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Public Health Clinical Center","Nanjing Second Hospital","Guangdong Provincial Hospital of Chinese Medicine","Shanghai Public Health Clinical Center","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Peking Union Medical College Hospital","First Affiliated Hospital of Zhejiang University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","HwaMei Hospital, University of Chinese Academy of Sciences","Shanghai Pulmonary Hospital","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Hubei Provincial Hospital of TCM","Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital","China Academy of Chinese Medical Sciences; Zhongnan Hospital of Wuhan University","Department of Critical Care Medicine, West China Hospital of Sichuan University","Renmin Hospital of Wuhan University","Xiangyang 1st People's Hospital","The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","Sun Yat sen Memorial Hospital of Sun Yat sen University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of He'nan University of Chinese Medicine","Beijing hospital of Traditional Chinese medicine; Hubei integrated traditional Chinese and Western Medicine Hospital","The First Hospital of He'nan University of Chinese Medicine","Zhejiang Chinese Medical University","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","West China Hospital, Sichuan University","Zhongnan Hospital of Wuhan University","Zhejiang Chinese Medical University","The First Affiliated Hospital of Guangzhou Medical University","Hunan yuanpin Cell Biotechnology Co., Ltd","Zhejiang Chinese Medical University","1. Xinhua Affiliated Hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","West China Hospital, Sichuan University","The Fifth Affiliated Hospital Sun Yat-Sen University","Guangdong Provincial Hospital of Chinese Medicine","The First Affiliated Hospital of Zhejiang University School of Medicine","The 5th Medical Center Chinese PLA General Hospital","Jiangsu Institute of Parasitic Diseases","Shenzhen national medicine inheritance medical research institute co. LTD","The First Affiliated Hospital of Nanchang University","Hubei Provincial Hospital of TCM","The First Affiliated Hospital of Medical College of Zhejiang University","The Third People's Hospital of Shenzhen","People's Hospital of Guangshan County","Xiangyang First People's Hospital","Renmin Hospital of Wuhan University","The First Hospital Affiliated to Zhejiang University's Medical School","Zhongnan Hospital of Wuhan University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences","Hubei Provincial Integrated Hospital of traditional Chinese and Western Medicine","Wuhan 1st Hospital","Hubei Integrated Hospital of Traditional Chinese and Western Medicine","Ningbo First Hospital","China Academy of Chinese Medical Sciences","Deyang Integrated Traditional Chinese and Western Medicine Hospital","West China Hospital of Sichuan University","Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Renmin Hospital of Wuhan University","Enze Hospital of Taizhou Enze Medical Center (Group)","Tianjin University","Shanghai Public Health Clinical Center","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Afflicated Hospital of Guangzhou University of Chinese Medicine","Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Zhongshan Hospital of Dalian University","West China Hospital, Sichuan University","The Second Hospital of Shanxi Medical University","Zhongnan Hospital of Wuhan University","West China Hospital, Sichuan University","The First Hospital of Shanxi Medical University","The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First People's Hospital of Huaihua","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital, College of Medicine, Zhejiang University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University Third Hospital","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Zhejiang University School of Medicine","Zhongnan Hospital of Wuhan University","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Hospital of Chengdu University of Traditional Chinese Medicine","Tongde Hospital of Zhejiang Province","The First Affiliated Hospital of Guangzhou Medical University","The First Affiliated Hospital, Zhejiang University School of Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese MedHubei integrated traditional Chinese and Western Medicine Hospital","The First Affiliated Hospital of Guangzhou Medical University","Institut National de la Sant Et de la Recherche Mdicale, France","Southeast University, China","Xi'an Chest Hospital","The First Affiliated Hospital of Nanchang University","Wuhan Jin Yin-tan hospital","The Third People's Hospital of Shenzhen","Peking University First Hospital","Chengdu University of Traditional Chinese Medicine","Department of Ultrasound Imaging, Renmin Hospital of Wuhan University","Guangxi medical uniwresity","First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital of Guangzhou Medical University","The First Affiliated Hospital of Zhejiang University School of Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","ZhiYong Peng","Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital","The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China","Nanchang Ninth Hospital","Health commission of Heilongjiang province","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Shanghai 10th people's hospital","Hospital of Chengdu University of Traditional Chinese Medicine","Shanghai Public Health Clinical Center","Chinese PLA General Hospital","The Second Affiliated Hospital of Xi'an Jiaotong University","Beijing Chaoyang Hospital, Capital Medical University","Shanghai General Hospital of Shanghai Jiaotong University","Shanghai University of TCM","Zhongshan Hospital Affiliated to Xiamen University","Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine,","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","West China Second Hospital, Sichuan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Enze Hospital of Taizhou Enze Medical Center (Group)","Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","the Second Affiliated hospital of Xi'an Jiaotong University","Zhongshan Hospital, Fudan University","Qingdao East Sea Pharmaceutical Co., Ltd.","Tianjin Huanhu Hospital","Shanghai Changzheng Hospital","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Renmin Hospital of Wuhan University","The Sixth Medical Center of PLA General Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","The First Hospital of Peking University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Zhongshan Hospital Affiliated to Xiamen University","Affiliated Hospital of Xuzhou Medical University","Department of respiratory and critical care medicine, Tongji Hospital, Tongji Medical College, Huazhong University of science and technology","Second Hospital of University of South China, Hengyang","Zhongshan Hospital Fudan University","West China Hospital, Sichuan University","Beijing Tsinghua Chang Gung Hospital","First Affiliated Hospital of Wenzhou Medical University","Beijing Children's Hospital","Chinese Alliance Against Lung Cancer","Hospital of Chengdu University of Traditional Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Chinese PLA General Hospital","Tang-Du Hospital","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","Zhongnan Hospital of Wuhan University","Institute of Integrative Medicine of Dalian Medical University, Dalian, China.","Sichuan Academy of Medical Sciences &amp; Sichuan Provincial Peoples Hospital","First Affiliated Hospital of Wenzhou Medical University","Third Affiliated Hospital, Sun Yat-Sen University","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine","Hubei Hospital of Traditional Chinese Medicine","Third Affiliated Hospital, Sun Yat-Sen University","the Second Affiliated hospital of Xi'an Jiaotong University","Tongji Hospital, Tongji Medical College, Huazhong University of science and technology","Children's Hospital of Fudan University","The First Affiliated Hospital of Fujian Medical University","The First Affiliated Hospital of Fujian Medical University","Henan Provincial People's Hospital","Lishui Central Hospital","Hu'nan university of chinese medicine","Hubei Provincial Hospital of TCM","ShuGuang Hospital","First Affiliated Hospital of Fujian Medical University","The First Affiliated Hospital of Fujian Medical University","Xinyang Central Hospital","The Second Affiliated hospital of Anhui Medical University","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Nanjing Second Hospital","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Hubei Provincial Hospital Of TCM","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","Li Caixia","West China Hospital of Sichuan University","Tongji Hospital of Tongji University","Affiliated Hospital of Changchun University of traditional Chinese Medicine","Shanghai Public Health Clinical Center","Beijing Geriatric Hospital","Xianning Central Hospital","The First Affiliated Hospital of Harbin Medical University","Department of critical care, Zhongnan Hospital of Wuhan University","Wuxi Fifth People's Hospital","Ganzi Hospital of West China Hospital, Sichuan University","Shanghai University of Traditional Chinese Medicine","Ganzi Hospital of West China Hospital, Sichuan University","Shanghai Public Health Clinical Center","The First Affiliated Hospital of Nanchang University, Ten layers pulse Research Institute of traditional Chinese medicine, Nanchang University","Xiamen University","Central South Hospital of Wuhan University","Shanghai Changzheng Hospital","The Fourth Affiliated Hospital of Harbin Medical University","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Puren Hospital of Wuhan City","The Thirteenth People's Hospital of Chongqing","First Affiliated Hospital of Anhui Medical University","Chinese PLA General Hospital","Fifth People's Hospital of Ganzhou","The First Affiliated Hospital of Nanchang University","The Fourth Hospital of Hebei Medical University","Tongji Hospital, Tongji Medical College of HUST","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","Tongji Hospital affiliated to Tongji medical college of HUST",null,"Chongqing Three Gorges Central Hospital(Chongqing University Three Gorges Hospital  )","Renmin Hospital of Wuhan University","West China Hospital, Sichuan University","Chongqing Liangjiang New Area first people's Hospital","The First Hospital of Jilin University","The First Affiliated Hospital of Chongqing Medical University","The First Affiliated Hospital of Chongqing Medical University","Cancelled","The Second Affiliated Hospital of Chongqing Medical University","Chongqing Public Health Medical Center","Peking University Third Hospital","Chongqing Public Health Medical Center","The Second Affiliated Hospital of Chongqing Medical University","Peking University Third Hospital","Chongqing Three Gorges Central Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Red Cross Hospital","Beijing YouAn Hospital","West China Hospital, Sichuan University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","Anhui Cancer Hospital","The First Affiliated Hospital of Zhejiang University School of Medicine","West China Hospital of Sichuan University","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","Ruijin Hospital","The First Affiliated Hospital, College of Medicine of Zhejiang University","Affiliated Hospital to Academy of Military Medical Sciences","Huilan Zhang","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","The First Affiliated Hospital of HeNan University of CM","The First Affiliated Hospital of Zhejiang University School of Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Huo-Shen-Shan Hospital","The Third Affiliated Hospital of the Second Military Medical University","Shenyang Sixth People's Hospita","Zhongnan Hospital of Wuhan University","Central Theater General Hospital of PLA","Maoming People's Hospital","Xiamen Medical College,Shijiazhuang Medical College","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","Tasly Pharmaceuticals, Inc.","Dalian Medical University, Dalian, China.","The First Affiliated Hospital of Zhengzhou University","Shanghai University of TCM","The Second Affiliated Hospital of Wenzhou Medical University","Affiliated Hospital of Shandong University of Traditional Chinese Medicine","Shandong Provincial Hospital","West China Hospital of Sichuan University","The First Affiliated Hospital of Guangzhou University of TCM","Shandong Provincial Hospital","The First Affiliated Hospital of Wenzhou Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Fourth Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","First people's hospital of Jiangxi district,Wuhan","Hubei Shiyan Taihe hospital","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Third Affiliated Hospital of Sun Yat-sen University","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Peking University First Hospital","Renmin Hospital of Wuhan University","Hospital of Chengdu University of Traditional Chinese Medicine","Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Hospital of Chengdu University of Traditional Chinese Medicine","The Third Xiangya Hospital, Central South University","Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Hospital of Chengdu University of Traditional Chinese Medicine","Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.","The First Affiliated Hospital of Guangzhou Medical University","Shanghai Sixth People's Hospital","Zhengzhou People's Hospital","West China Hospital, Sichuan University","Department of Anesthesiology, Zhongnan Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Fujian Provincial Hospital","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University First Hospital","China-Japan friendship hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Zhengzhou People's Hospital","Jinling Hospital, Medical School of Nanjing University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","McMaster University","University of Macau","Tongji Hospital","The affiliated Hospital to Changchun University of Traditional Chinese Medicine","Shanghai Public Health Clinical Center","Tongji Hospital","HwaMei Hospital, University of Chinese Academy of Sciences","The First Hospital of Changsha","The First Affiliated Hospital of the Guangzhou Medical University","Jingzhou Mental Health Center","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Chinese University of Hong Kong","Xiangyang 1st people's Hospital","State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University","Li Lanjuan","Shanghai Ninth People's Hospital","Wuhan Third Hospital","Department of critical care medicine, the third affiliated hospital of zunyi medical university","Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University","Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Tongji Hospital, Huazhong university of science and technology","Beijing An Zhen Hospital, Capital Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hubei Cancer Hospital","Department of Critical Care Medicine, the Third Affiliated Hospital of Zunyi Medical University","Zhongnan Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine","the First Affiliated Hospital of Xinxiang Medical University","Zhengzhou People's Hospital","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongren Hospital, Shanghai Jiao Tong University School of Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Ningbo First Hospital","Wuhan Third Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Department of Critical Care Medicine, The First Affiliated Hospital, Henan Traditional Chinese Medicine University","The First Affiliated Hospital of Wenzhou Medical University","Tongji hospital, Tongji medical College, Huazhong University of Science and Technology","Hwa Mei Hospital, University of Chinese Academy of Sciences","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Third Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Maoming People's Hospital","Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science &amp; Technology Medical Center","Wuhan 3rd Hospital","Tongji Hospital, Tongji medical college of HUST","Shenzhen Hospital of Southern Medical University","The Second Hospital of Hebei Medical University","The Third Hospital of Wuhan","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Third Affiliated Hospital of Zunyi Medical University","Cangzhou People's Hospital","Shanghai Fifth People's Hospital, Fudan University","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","The People's Hospital of Guangxi Zhuang Autonomous Region","Huashan Hospital Fudan Universtiy","Shanghai Changzheng Hospital","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Zhongnan Hospital of Wuhan University","Shandong Provincial Chest hospital","Shandong Provincial Chest hospital","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Affiliated Hospital of Inner Mongolia University for the Nationalities","Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","Zhejiang Hospital","Shandong Provincial Chest hospital","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Shandong Provincial Chest hospital","Zhongnan Hospital of Wuhan University","West China Hospital, Sichuan University","The Third Affiliated Hospital of Sun Yat-sen University","Shandong Provincial Chest Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China","Ganzi Hospital of West China Hospital, Sichuan University","Shandong Provincial Chest hospital","Shandong Provincial Chest hospital","Tongji Medical College, HUST","Affiliated Hospital of Guangdong Medical University","Affiliated Hospital of Zunyi Medical University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","The Third People's Hospital of Shenzhen","Hubei Provincial Hospital of TCM","Xiangya Hospital of Central South University","The Third Affiliated Hospital of the Second Military Medical University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Shanghai First People's Hospital","Shanghai General Hospital","Department of Nephrology, Wuhan children's Hospital","The Sixth Affiliated Hospital of Sun Yat-sen University","Hubei Provincial Hospital of TCM","Guangzhou Panyu Central Hospital","Hubei Hospital of Traditional Chinese Medicine","Liaocheng People's Hospital","Yongchuan Hospital,Chongqing Medical University","The Second Affiliated Hospital of Xi'an Medical University","China-Japan friendship hospital","Jingzhou First People's Hospital","The First Affiliated Hospital of Bengbu Medical College","The first affiliated hospital of guangzhou university of Chinese medicine","Luohu hospital group medical center of Shenzhen University","Ningbo First Hospital, Ningbo Hospital of Zhejiang University","Peking University People's Hospital","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Guangzhou Panyu Central Hospital","The First Affiliated Hospital of Nanchang University","The First Affiliated Hospital of Guangzhou Medical University","Guangzhou reborn health management consultation co., LTD","Jingzhou First People's Hospital","Peking University Third Hospital","The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)","The Second Affiliated Hospital Of Xi'an Jiaotong University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangzhou Eighth People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangzhou reborn health management consultation co., LTD","Jingzhou Central Hospital","Guangzhou reborn health management consultation co., LTD","Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Jingzhou Central Hospital","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","China Academy of Chinese Medical Science","Wuhan Asia General Hospital","The Second Clinical College of Guangzhou University of Chinese Medicine","The First Hospital of Harbin Medical University","Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","Harbin infectious diseases hospital","CAR-T (Shanghai) Biotechnology Co., Ltd.","The People's Hospital of GuangXi Zhuang Autonomous Region","ZhiYong Peng","University Hospital, Clermont-Ferrand","Asan Medical Center","The Fifth Affiliated Hospital of Sun Yat-Sen University","First people's hospital of Jiangxi district,Wuhan","The Second Affiliated Hospital Of Xi'an Jiaotong University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University","The third xiangya hospital of Central South University","Zhengzhou People's Hospital","Xiangyang 1st People's Hospital","Ningbo Kangning Hospital","Changzheng Hospital, Naval Military Medical University, Shanghai","Guangzhou reborn health management consultation co., LTD","Guangzhou reborn health management consultation co., LTD","Beijing Normal University","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hu'nan Cancer Hospital","Hu'nan Provincial People's Hospital, Hu'nan Normal University","Shenzhen Third People's Hospital","HwaMei Hospital, University of Chinese Academy of Sciences","PLA General Hospital","Beijing Chaoyang Hospital, Capital Medical University","Changzheng Hospital, Naval Military Medical University, Shanghai","Foshan First People's Hospital","Chinese University of Hong Kong","Shenzhen Geno-Immune Medical Institute","The First Affiliated Hospital of Guangzhou Medical University","The Fifth Hospital Affiliated to Sun Yat-sen University","West China Hospital of Sichuan University","The First Affiliated Hospital of Nanchang University","Shandong Provincial Hospital","Jiangsu Provincial Center for Disease Control and Prevention","Renmin Hospital of Wuhan University","Hwa Mei Hospital, University of Chinese Academy of Sciences","Anqing Municipal Hospital","The Fifth Affiliated Hospital of Sun Yat-sen University","Guangzhou Eighth People's Hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","HuiZhou Municipal Central Hospital","Renmin Hospital of Wuhan University","Zhongnan Hospital of Wuhan University","Guangzhou Eighth People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Renmin Hospital of Wuhan University","The Second Xiangya Hospital of CSU","HwaMei Hospital, University of Chinese Academy of Sciences","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","West China Second University Hospital, Sichuan University","Beijing Chao-yang Hospital, Capital Medical University","Central Theater General Hospital of PLA","The Fifth Affiliated Hospital of Sun Yat-Sen University","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Medical College of Zhejiang University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Hospital of Changsha; The Second Xiangya Hospital of Central South University","The Second Affiliated Hospital of Nanchang University","Shanghai Kongjiang Hospital","Tongji Hospital","Second Affiliated Hospital of Wenzhou Medical University","Fondation Mditerrane Infection (FMI) - IHU Mditerrane Infection","Xiangya Hospital, Central South University (West Campus of Wuhan Union Hospital)","The Second Hospital of Nanjing Medical University","Tongji Hospital","Guangzhou Eighth People's Hospital","The First Affiliated Hospital of Nanchang University","Critical Care Research Group\nThe Prince Charles Hospital","Ruijin Hospital, Shanghai Jiaotong University School of Medicine","Wuhan Union Hospital, China","The First Affiliated Hospital of Guangzhou Medical University","Tongji Hospital","Tongji Hospital","Doi Yohei","Shenzhen Geno-Immune Medical Institute","Tongji Hospital","Wuhan Union Hospital, China","China Academy of Chinese Medical Sciences","National Center for Global Health and Medicine","Puren Hospital Affiliated to Wuhan University of Science and Technology","Jean Liu","Henan Provincial People's Hospital","Wuhan Union Hospital, China","Stem Cells Arabia","Chongqing Medical University","Tongji Hospital","Tongji Hospital","Chongqing Medical University","Jiangsu Famous Medical Technology Co., Ltd.","Henan Provincial People's Hospital","Zhong Wang","Huashan Hospital","Chinese PLA General Hospital","WESTLAKE UNIVERSITY","University Hospital, Akershus","Groupe Hospitalier Pitie-Salpetriere","Uppsala University","Neuromed IRCCS","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Xiangya Hospital of Central South University","Federico II University","Hubei Maternal and Child Health Care Hospital","Renmin Hospital of Wuhan University","Shandong Eye Institute","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangdong Second Provincial General Hospital","Nanjing University Medical College Affiliated Drum Tower Hospital","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Centro Studi Internazionali, Italy","Shandong Eye Institute","Yichang Central people's Hospital","Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","China European International Business School (CEIBS)","The Third Affiliated Hospital of Sun Yat-sen University","China-Japan Union Hospital of Jilin Unversity","Chongqing Medical University","West China Hospital, Sichuan University","Renmin Hospital of Wuhan University","Beijing you'an Hospital, Capital Medical University","School of Public Health and Management, Chongqing Medical University","Wuhan Third Hospital &amp; Tongren Hospital of Wuhan University","Renmin Hospital of Wuhan University","Wuhan Third Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Nothern Jiangsu People's Hospital","Zhengzhou People's Hospital","Hospital of Chengdu University of Traditional Chinese Medicine.","Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine","The First Affiliated Hospital of Guangzhou Medical University","People's hospital of Zhengzhou","Guangdong Provincial Hospital of Chinese Medicine","The First People's Hospital of Jiangxia District, Wuhan","Hospital of Chengdu University of Traditional Chinese Medicine","Sanofi-aventis Recherche et Dveloppement","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","West China Hospital","China Academy of Chinese Medical Sciences","Daping Hospital,Army Medical University","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Istanbul University-Cerrahpasa","Laval University","West China Hospital of Sichuan University","UZLeuven","University Medical Center","Hospital of Prato","Darrell Tan","Institut National de la Sant Et de la Recherche Mdicale, France","Beijing Chao Yang Hospital","Universittsklinikum Tbingen","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Synairgen Research Limited","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Foundation IRCCS San Matteo Hospital","Xiyuan Hospital of China Academy of Chinese Medical Sciences","Groupe Hospitalier Pitie-Salpetriere","University of Palermo","Qilu Hospital of Shandong University","University of Pecs","Misr University for Science and Technology","University of Trieste","Rambam Health Care Campus","Chinese University of Hong Kong","University of Oxford","Hudson Medical","University College, London","Chongqing Public Health Medical Center","Population Health Research Institute","Universita di Verona","Xijing Hospital","University of Oxford","UMC Utrecht","HealthMode Inc.","RAD-AID International","University Hospital Southampton NHS Foundation Trust","Universitaire Ziekenhuizen Leuven","Wuhan Women and Children's Health Care Center","N0.2 People's Hospital of Fuyang City","Zhenhua Zen","University College, London","Peking University Sixth Hospital","Peking Union Medical College Hospital","Huangshi Hospital of Traditional Chinese Medicine (Municipal Infectious Disease Hospital)","Shanghai Sixth People's Hospital","Eastern theater General Hospital","Xiangya Hospital, Central South University (West Campus of Wuhan Union Hospital)","Columbia University","University of Catanzaro","The First People's Hospital of Jiangxia District, Wuhan","Dermatology Department of Peking University First Hosptal","University of Birmingham","Guangzhou Eighth People's Hospital","Infection prevention and treatment center of The Fifth Affiliated Hospital of Sun Yat-Sen University","Nanjing University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Fifth Medical Center of PLA General Hospital","Renmin Hospital of Wuhan University","Wuhan Asia heart Hospital","INSERM","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University Third Hospital","Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia","Affiliated Hospital of Zunyi Medical University","Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Oriental Hospital","CHU Angers","Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University","Australian Defence Force Malaria and Infectious Disease Institute","Affiliated Hospital of Southwest Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","CHU de Saint Etienne","The First People's Hospital of Jiangxia District, Wuhan","The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark","University of British Columbia","Ansun Biopharma, Inc.","Qilu Hospital of Shandong University","Regeneron Pharmaceuticals","Amsterdam UMC","Universit Vita-Salute San Raffaele","xCures","Shanghai Jiao Tong University School of Medicine","Hospital Israelita Albert Einstein","Massachusetts General Hospital","University Hospital, Akershus","Akershus University Hospital","The Prince Charles Hospital","A.O. Ospedale Papa Giovanni XXIII","TMC HealthCare","University of Aarhus","Renmin Hospital of Wuhan University","Assistance Publique - Hpitaux de Paris","Professor Adrian Covic","Mario Negri Institute for Pharmacological Research","Universidad Complutense de Madrid","Dr. Alexander Supady","Prof. Dr. Umar Farooq","Estudios Clnicos Latino Amrica","Oxford University Clinical Research Unit, Vietnam","Vanda Pharmaceuticals","University Hospital, Ghent","National Institute of Allergy and Infectious Diseases (NIAID)","Professor Adrian Covic","National and Kapodistrian University of Athens","Karolinska University Hospital","Kanuni Sultan Suleyman Training and Research Hospital","UMC Utrecht","William Beaumont Hospitals","Oslo University Hospital","NHS Lothian","Gangnam Severance Hospital","University of Washington","University of Calgary","Korea University Guro Hospital","Queen Mary University of London","Mario Negri Institute for Pharmacological Research","Institut Pasteur","Stanford University","Chinese Academy of Sciences","Societa Italiana dell'Ipertensione Arteriosa","University Hospital, Bordeaux","Rush University Medical Center","Healeon Medical Inc","Universidad del Rosario","Baylor Research Institute","University Hospital, Lille","Mazandaran University of Medical Sciences","Stanford University","University Hospital Inselspital, Berne","Erasme University Hospital","Kermanshah University of Medical Sciences","University of Aarhus","Shanghai 10th People's Hospital","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","Providence Health &amp; Services","King's College London","Assistance Publique - Hpitaux de Paris","Griffith University","Hepatopancreatobiliary Surgery Institute of Gansu Province","Wroclaw Medical University","University of Melbourne","Medical Research Institute of New Zealand","Assistance Publique - Hpitaux de Paris","ProgenaBiome","Lady Davis Institute","Flinders Medical Centre","Austin Health","IRCCS San Raffaele","Deakin University","Universidad del Rosario","Hospital San Jose Tec de Monterrey","The First Affiliated Hospital of Yangtze University","Huanggang Central Hospital","Fujian Provincial Maternity and Child Health Hospital","Can-Fite BioPharma","South Metropolitan Health Service","Royal Brisbane &amp; Women's Hospital","Shanghai Jiao Tong University Affiliated Sixth People's Hospital","The 2nd Xiangya Hospital of Central South Uinvercity","N/A","Jiangsu Provincial Center for Disease Control and Prevention","the First Affiliated Hospital of Nanjing Medical University","Beijing Sports University","Huoshenshan Hospital","Wuhan Fourth Hospital","Shandong Provincial Hospital","Shanghai Orient Hospital","Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Jiangsu Province Hospital","Chinese PLA General Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Huzhou Central Hospital","Wenzhou Central Hospital","Beijing University of Chinese Medicine","Women's Hospital, Medical School of Zhejiang University","Shenzhen Third People's Hospital","West China Hospital, Sichuan University","the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China","GUSTAVE ROUSSY","ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)","Assistance Publique - Hpitaux de Paris","DRK-Bluspendedienst Baden-Wrttemberg - Hessen gGmbH","InflaRx GmbH","University Hospital Ghent","CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC","Groupe Hospitalier Paris Saint-Joseph","CHU de Saint Etienne","FIB-HCSC","Centre Lon Brard","FFIS","HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS","APHP","Hpital Fondation Adolphe de Rothschild","Dr. Xavier Solanich Moreno. Servei Medicina Interna. Hospital de Bellvitge","INSTITUT DE RECERCA H. SANTA CREU I SANT PAU","Flix Gutirrez Rodero","Plan Nacional  Sobre SIDA","Sociedad Espaola de Farmacia Hospitalaria","ISGlobal","sanofi-aventis recherche &amp; dveloppement","Instituto Investigacin Sanitario Biocruces Bizkaia","Fundacin para la Investigacin Biomdica Hospital Ramn y Cajal","Universit de Sherbrooke","Ansun Biopharma, Inc.","Peking Union Medical College Hospital","Shanghai Public Health Clinical Center","Belfast Health and Social Care Trust","Peking University Third Hospital","Capital Medical University","Shanghai Public Health Clinical Center","Beijing 302 Hospital","Beijing Chao Yang Hospital","BioCryst Pharmaceuticals","Beijing Ditan Hospital","The University of Hong Kong","The Ninth Hospital of Nanchang","Wuhan Union Hospital, China","Assistance Publique - Hpitaux de Paris","Capital Medical University","Xinxiang medical university","National Institute of Allergy and Infectious Diseases (NIAID)","Beijing 302 Hospital","Tianhe Stem Cell Biotechnologies Inc.","Rajavithi Hospital","Pulmotect, Inc.","CanSino Biologics Inc.","Hospices Civils de Lyon","U.S. Army Medical Research and Development Command","Gilead Sciences","Gilead Sciences","Massachusetts General Hospital","Massachusetts General Hospital","University of Minnesota","NeuroRx, Inc.","National Cancer Institute, Naples","Zhenhua Zen","University of Minnesota","Peking University First Hospital","Fundacio Lluita Contra la SIDA","Guangzhou Blood Center","University of Minnesota","Pulmotect, Inc.","Azidus Brasil","Federico II University","Ictal Group","Hospital do Coracao","Assiut University","Changhai Hospital","Universit Politecnica delle Marche","National Institute of Respiratory Diseases, Mexico","Wake Forest University Health Sciences","Oslo University Hospital","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","Gilead Sciences","OncoImmune, Inc.","National Institute of Respiratory Diseases, Mexico","Mayo Clinic","Johns Hopkins University","Hoffmann-La Roche","Duke University","Catholic University of the Sacred Heart","Azienda Ospedaliero-Universitaria di Parma","Heinrich-Heine University, Duesseldorf","Montreal Heart Institute","University of California, San Francisco","Dr. Negrin University Hospital","Dr. Deneen Vojta","Lisa Barrett","Assistance Publique - Hpitaux de Paris","Gunther Meinlschmidt","Marius Henriksen","King Saud University","University of Catanzaro","Swedish Orphan Biovitrum","Nantes University Hospital","Mayo Clinic","Sanofi","Luiz F. L. Reis, Ph.D.","University of Oxford","Catholic University of the Sacred Heart","Cordio Medical","Assistance Publique - Hpitaux de Paris","Istinye University","Murdoch Childrens Research Institute","University Hospital, Angers","Dr. Deneen Vojta","Centre Hospitalier Universitaire de Saint Etienne","University of Minnesota","CCTU- Cancer Theme","Institut Pasteur","University Hospital, Essen","Bassett Healthcare","Azidus Brasil","Judit Pich Martnez","University of Arizona","National University of Ireland, Galway, Ireland","Intermountain Health Care, Inc.","Assistance Publique - Hpitaux de Paris","University Hospital, Geneva","Dr. Michael Hill","Charite University, Berlin, Germany","Weprom","Ravi Amaravadi, MD","Fasa University of Medical Sciences","Instituto de Investigacin Marqus de Valdecilla","University Hospital, Ghent","Sunnybrook Health Sciences Centre","Emory University","King's College London","Barcelona Institute for Global Health","University Health Network, Toronto","University of Chicago","University of California, San Francisco","InflaRx GmbH","Assistance Publique - Hpitaux de Paris","University of L'Aquila","Fundaci Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","Imperial College London","Target PharmaSolutions, Inc.","NYU Langone Health","Washington University School of Medicine","University Hospital, Angers","Peking University First Hospital","Sanofi","Massachusetts General Hospital","Baylor Research Institute","Duke University","Blade Therapeutics","Jessa Hospital","Peking University First Hospital","HaEmek Medical Center, Israel","University of Missouri-Columbia","Centre Leon Berard","Universidad de Granada","IVAN J NUEZ GIL","Centre Hospitalier Universitaire de Nice","Grupo Cooperativo de Hemopatas Malignas","Intermountain Health Care, Inc.","ProgenaBiome","Symvivo Corporation","Plan Nacional sobre el Sida (PNS)","University of Kansas Medical Center","IHF GmbH - Institut fr Herzinfarktforschung","MedSIR","S.L.A. Pharma AG","University Hospital Inselspital, Berne","Memorial Hermann Health System","University Hospital, Akershus","Biruni University","Shanghai Asclepius Meditec Inc.","Salome Kristensen","Renmin Hospital of Wuhan University","Kubra Koce, MSc PT","Lars Wik","Rutgers, The State University of New Jersey","Duke University","Rutgers, The State University of New Jersey","Assistance Publique Hopitaux De Marseille","Assiut University","Giuliano Rizzardini","Centre Hospitalier Intercommunal Creteil","Virginia Commonwealth University","Royal National Orthopaedic Hospital NHS Trust","University Hospital, Angers","Wefight","Kanuni Sultan Suleyman Training and Research Hospital","Maastricht University","Apeiron Biologics","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Novartis Pharmaceuticals","Tourcoing Hospital","Rigshospitalet, Denmark","Beat COVID LLC","University Hospital, Montpellier","Inovio Pharmaceuticals","University of Alabama at Birmingham","University Hospital, Angers","Bicetre Hospital","Massachusetts General Hospital","University Hospital, Lille","Istanbul Kltr University","Capricor Inc.","Sheba Medical Center","Hellenic Institute for the Study of Sepsis","Instituto Nacional de Rehabilitacion","Jessa Hospital","Ospedale Policlinico San Martino","Prof. Dr. med. Andreas Hochhaus","Shehnoor Azhar","Heinrich-Heine University, Duesseldorf","Kanuni Sultan Suleyman Training and Research Hospital","Imperial College London","University Hospital, Limoges","Mayo Clinic","Hospital Universitari de Bellvitge","Sanotize Research and Development corp.","University of Pennsylvania","Brigham and Women's Hospital","Max Healthcare Insititute Limited","Assiut University","Puren Hospital Affiliated to Wuhan University of Science and Technology","Mayo Clinic","Hasselt University","Tabula Rasa HealthCare","Frantisek Duska, MD, PhD","Henry Ford Health System","Tongji Hospital","Huilan Zhang","HonorHealth Research Institute","University Hospital, Ghent","University Hospital Tuebingen","University of Chicago","Centre Hospitalier Universitaire de Nimes","University of Cincinnati","Aga Khan University","National Institute of Mental Health (NIMH)","University of Minnesota","University of Colorado, Denver","Barts &amp; The London NHS Trust","CareDx","University Hospital of Cologne","University of Colorado, Denver","Peking Union Medical College Hospital","Assistance Publique - Hpitaux de Paris","Hospital General Universitario Morales Meseguer","University Hospital Tuebingen","Hugo Mendieta Zeron","I-Mab Biopharma Co. Ltd.","Hospices Civils de Lyon","Assistance Publique - Hpitaux de Paris","Rigshospitalet, Denmark","Assistance Publique - Hpitaux de Paris","Centre Hospitalier Intercommunal Creteil","London School of Hygiene and Tropical Medicine","Ochsner Health System","Gustave Roussy, Cancer Campus, Grand Paris","Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China","University of Miami","University of Utah","University Hospital, Lille","Columbia University","Fondation Ophtalmologique Adolphe de Rothschild","Northwestern Medicine","Istanbul University-Cerrahpasa","University Hospital Tuebingen","Pierre and Marie Curie University","Karolinska Institutet","University Hospital, Strasbourg, France","CytoDyn, Inc.","Tan Tock Seng Hospital","Erasmus Medical Center","Second Affiliated Hospital of Wenzhou Medical University","The Cleveland Clinic","Al-Azhar University","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","Yale University","Duke University","Assistance Publique - Hpitaux de Paris","Saint Francis Care","Universittsklinikum Hamburg-Eppendorf","Assistance Publique - Hpitaux de Paris","Washington University School of Medicine","Wake Forest University Health Sciences","Eli Lilly and Company","Romark Laboratories L.C.","United States Department of Defense","Shahid Beheshti University of Medical Sciences","University of Baghdad","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","Lawson Health Research Institute","Assiut University","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.","Genesis Foundation","Hackensack Meridian Health","The University of Hong Kong","Spanish Lung Cancer Group","University Hospital, Montpellier","Tjhin Wiguna","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Raymond Chung","Fondation Ophtalmologique Adolphe de Rothschild","Baylor College of Medicine","Duke University","University Hospital, Angers","ClarData","Virginia Commonwealth University","Francis Corazza","Ain Shams University","Centre Hospitalier Universitaire de Nice","Universit Libre de Bruxelles","Federal University of Rio Grande do Sul","NYU Langone Health","Brigham and Women's Hospital","NYU Langone Health","University of Rome Tor Vergata","Boston University","Hospital de Matar","Institute of Liver and Biliary Sciences, India","Thomas Jefferson University","ELHARRAR Xavier","French Cardiology Society","LCMC Health","Assiut University","Huoshenshan Hospital","Nantes University Hospital","Direction Centrale du Service de Sant des Armes","Stony Brook University","Johns Hopkins University","Government of Punjab, Specialized Healthcare and Medical Education Department","Burnasyan Federal Medical Biophysical Center","Orthosera Kft.","Queen's Medical Centre","Perseverance Research Center, LLC","Universidad Nacional de Colombia","Istanbul University-Cerrahpasa","Nantes University Hospital","National Institutes of Health Clinical Center (CC)","Tanta University","University of Malaya","Assistance Publique - Hpitaux de Paris","Assistance Publique - Hpitaux de Paris","Vanderbilt University Medical Center","Stanford University","Austin Health","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","German Cancer Research Center","Oslo University Hospital","Hackensack Meridian Health","Centre Chirurgical Marie Lannelongue","Hackensack Meridian Health","Tanta University","Cristina Avendao Sol","University Hospital, Montpellier","G. d'Annunzio University","Hospital Universitario de Fuenlabrada","Universidad Nacional de Colombia","Aarogyam UK","CalciMedica, Inc.","Herlev Hospital","Implicit Bioscience","Ain Shams University","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Azienda Unit Sanitaria Locale Reggio Emilia","Institute of Liver and Biliary Sciences, India","University Hospital, Geneva","Cliniques universitaires Saint-Luc- Universit Catholique de Louvain","Stanford University","Assistance Publique - Hpitaux de Paris","Ain Shams University","Istituto Nazionale di Ricovero e Cura per Anziani","Azidus Brasil","Guangzhou Institute of Respiratory Disease","A.O. Ospedale Papa Giovanni XXIII","Hpital Raymond Poincar","Yasemin irak","Assaf-Harofeh Medical Center","Hope Biosciences","Chinese University of Hong Kong","AstraZeneca","Istinye University","University Hospital, Montpellier","Assistance Publique - Hpitaux de Paris","Matthew Dallos","Neuroganics LLC","Saint Luke's Health System","Ludwig Boltzmann Institute for Lung Health","Biohaven Pharmaceuticals, Inc.","CytoDyn, Inc.","Queen's University, Belfast","Instituto de Investigacin Marqus de Valdecilla","Xinqiao Hospital of Chongqing","Cadila Pharnmaceuticals","Sheikh Zayed Federal Postgraduate Medical Institute","St George's, University of London","KK Women's and Children's Hospital","University Hospital, Montpellier","Assiut University","Technische Universitt Mnchen","Medical University of Vienna","King Fahad Specialist Hospital Dammam","University of Alberta","University Hospital, Lille","Hpital Universitaire Fattouma Bourguiba","Stony Brook University","University of Colorado, Denver","University Hospital Goettingen","Bukwang Pharmaceutical","University of Giessen","UNSW Sydney","Instituto de Investigacin Sanitaria de la Fundacin Jimnez Daz","Nantes University Hospital","Scandinavian Critical Care Trials Group","Cedars-Sinai Medical Center","University College Hospital Galway","National Institute of Dental and Craniofacial Research (NIDCR)","University of Auckland","Fundacin de investigacin HM","Ain Shams University","AUSL Romagna Rimini","Azidus Brasil","Juan P. Fuentes-Garca","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.","Central Hospital, Nancy, France","Albury Wodonga Health","Hamilton Health Sciences Corporation","Karyopharm Therapeutics Inc","ObvioHealth","Columbia University","William Beaumont Hospitals","University Hospital, Limoges","University of Valladolid","Ain Shams University","Medical University of Graz","The Camelot Foundation","Hospices Civils de Lyon","Klinikum der Universitt Mnchen","Duke University","University Hospital, Limoges","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","Theravance Biopharma","Hope Biosciences","The University of Hong Kong","Montefiore Medical Center","Vivek Reddy","Government of Punjab, Specialized Healthcare and Medical Education Department","University Hospital, Lille","Tanta University","Arbeitsgemeinschaft medikamentoese Tumortherapie","University of Oxford","University of Chicago","Centre Hospitalier Universitaire de Nimes","Shahid Beheshti University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Royal North Shore Hospital","The University of Queensland","Sir Charles Gairdner Hospital","University Hospital, Lille","Medical University of Vienna","Ain Shams University","Hospices Civils de Lyon","University of Melbourne","World Health Organization","University of New South Wales","labormedizinisches zentrum Dr. Risch","Monash Health","University of Oxford","University of Oxford","St George's University Hospitals NHS Foundation Trust","University Health Network","University Hospital of Bern","Renji Hospital, Shanghai Jiaotong University School of Medicine","University of Oxford","Humanigen, Inc.","Tanta University","Aarogyam UK","University Hospital, Gentofte, Copenhagen","University of Warwick","The Fifth Affiliated Hospital of Sun Yat-Sen University","Fujian Provincial Hospital","Nicolaus Copernicus University","Copenhagen University Hospital, Hvidovre","Union Hospital of Tongji Medical College, Huazhong University of Science and Technology","University Hospital Plymouth NHS Trust","Dr Michael Soares","Dr Simon Joosten","Albury Wodonga Health","The George Institute for Global Health","Firebrick Pharma Pty Ltd","The Third Affiliated Hospital of Sun Yat-sen University","Beijing University of traditional Chinese Medicine","University Hospitals Coventry and Warwickshire NHS Trust","China Academy of Chinese Medical Sciences","The Chinese University of Hong Kong","International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University","Radboudumc","Northumbria University","University of Zurich","Shanghai University of Traditional Chinese Medicine","Nanjing Second Hospital","Affiliated Hospital of Guangdong Medical University","The Fourth Medical Center of Chinese PLA General Hospital","nonen","Sixth Medical Center of PLA General Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","ASSISTANCE PUBLIQUE - HPITAUX DE PARIS (APHP)","Affiliated Hospital of Zunyi Medical University","Guangzhou Eighth People's Hospital","Rigshospitalet","Reade Research BV","National Institute for Public Health and the Environment (RIVM)","Mxima MC","The Chinese University of Hong Kong","UMC Utrecht","Hebei Yiling Hospital, Renmin Hospital of Wuhan University","Radboudumc","Hebei Yiling Hospital?Renmin Hospital of Wuhan University","Aarhus University","Interactive Studios","Raad van Bestuur van het AMC (Amsterdam)","Histocell S.L.","Consorci Parc de Salut Mar (PSMAR)","none","Fred Foundation ; Noaber Foundation","Instituto de Investigacin Sanitaria Fundacin Jimnez Daz","Radboudumc","University Hospital of Montpellier","Amsterdam UMC","UMCG, Roche","Hospices Civils de Lyon","Fundacin para la investigacin Biomedica Hospital Universitario La Paz","Fundacin para la Investigacin Biomdica del Hospital La Paz (FIBHULP)","Hpitaux Universitaires de Strasbourg","Fundaci Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)","Medica Scientia Innovation Research S.L. (MEDSIR)","CHU Angers","Barcelona Institute for Global Health (ISGlobal)","Department of Infectious diseases","Hospital Universitario de Fuenlabrada","CITOSPIN S.L.","APEIRON Biologics AG","Cambridge University Hospitals NHS Foundation Trust","Rosario Garca de Vicua","Fundaci Clnic per a la Recerca Biomdica","Fundacin Instituto de Investigacin Sanitaria Fundacin Jimnez Diaz","MONTREAL HEART INSTITUTE","Institut Catal dOncologia","University of Birmingham","Oslo University Hospital","FFIS","GHU PARIS PSYCHIATRIE ET NEUROSCIENCES","Hellenic Institute for the Study of Sepsis","Instituto de Investigacin Sanitaria INCLIVA","University Medical Center Utrecht","University Hospital Ghent","Klinik fr Innere Medizin I (UKSH Campus Kiel)","Klinikum der Universitt Mnchen, Campus Grohadern","Universittsklinikum Heidelberg Sektion Klinische Tropenmedizin","Universittsklinikum Freiburg","Klinikum rechts der Isar der TU Mnchen","Institut fr Virologie, Universittsklinikum Leipzig","Paracelsus Medizinische Privatuniversitt Institut fr Allgemeinmedizin","Leiter der Sektion Neurologische Schmerzforschung und -Therapie Universittsklinikum Schleswig-Holstein, Campus Kiel","Universitts-Herzzentrum Freiburg Bad Krozingen","Abteilung fr Krankenhaushygiene","Vorstand der Deutschen Gesellschaft fr Perinatale Medizin (DGPM) e.V.c/o Conventus Congressmanagement &amp; Marketing GmbH","Klinik fr Psychosomatische Medizin und Psychotherapie, LVR-Klinikum Essen, Kliniken und Institut der Universitt Duisburg-Essen","Institut fr Virologie/ Universittklinikum Bonn","Leuphana Universitt Professur fr Gesundheitspsychologie und Angewandte Biologische PsychologieInstitut fr Psychologie","KKH BergstrasseAbteilung Ansthesie/Intensivmedizin","Deutsches Zentrum fr Infektionsforschung (DZIF) e. V.","Max Super Speciality Hospital A Unit of Devki Devi Foundation","Universittsklinikum Freiburg","Medizinische Hochschule Hannover","Tabriz University of Medical Sciences","Performa Nord Zentrum fr Gesunde Arbeit Arbeitsmedizinischer Dienst","Klinik fr Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen, Universitt Duisburg-Essen","Ahvaz University of Medical Sciences","Tehran University of Medical Sciences","Universittsklinikum Erlangen Psychosomatische und Psychotherapeutische Abteilung","Krankenhaus Reinbek St. Adolf-Stift","Tehran University of Medical Sciences","Universittsklinikum Rostock","Sabzevar University of Medical Sciences","Tehran University of Medical Sciences","K M Amran Hossain","Tehran University of Medical Sciences","Iran University of Medical Sciences","Klinik fr Ansthesiologie und Intensivtherapie; Universittsklinikum Leipzig","COMMAND HOSPITAL AIRFORCE","Kerman University of Medical Sciences","Dr Remesh Bhasi","DACH Jaipur","Artesh University of Medical Sciences","SSV Phytopharmaceuticals","Tabriz University of Medical Sciences","Tehran University of Medical Sciences","Discovery the Critical Care Research Network","Tehran University of Medical Sciences","Tehran University of Medical Sciences","Aryogen Pharmed","MOM research and innovation center","Mazandaran University of Medical Sceinces","Digestive Disease Research Institute","Abadan University of Medical Sciences","Kermanshah University of Medical Sciences","Tehran University of Medical Sciences","Tabriz University of Medical Sciences","Tehran University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Kerman University of Medical Sciences","Mazandaran University of Medical Sceinces","Qazvin University of Medical Sciences","Tabriz University of Medical Sciences","RNA biotechnology, Science base company","Arak University of Medical Sciences","Darmanara .Co","Abadan University of Medical Sciences","Fasa University of Medical Sciences","Tehran University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Iran University of Medical Sciences","Abadan University of Medical Sciences","Kerman University of Medical Sciences","Tabriz University of Medical Sciences","Mazandaran University of Medical Sciences","Mashhad University of Medical Sciences","Abadan University of Medical Sciences","Shiraz University of Medical Sciences","Tehran University of Medical Sciences","Tehran University of Medical Sciences","Kerman University of Medical Sciences","Gorgan University of Medical Sciences","Tabriz University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Mashhad University of Medical Sciences","Semnan University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Kerman University of Medical Sciences","Babol University of Medical Sciences","Mazandaran University of Medical Sciences","Mashhad University of Medical Sciences","Tehran University of Medical Sciences","Center for Progress and Development of Iran","Shahid Beheshti University of Medical Sciences","Mashhad University of Medical Sciences","Deouty of Research &amp; Technology Qom University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Tehran University of Medical Sciences","Kerman University of Medical Sciences","Tehran University of Medical Sciences","Tabriz University of Medical Sciences","Ardabil University of Medical Sciences","Kermanshah University of Medical Sciences","Torbate-Heidaria University of Medical Sciences","Mazandaran University of Medical Sciences","Ahvaz University of Medical Sciences","Bagheiat-allah University of Medical Sciences","HomaPharmed  Company","Shahid Beheshti University of Medical Sciences","Tabriz University of Medical Sciences","Ardabil University of Medical Sciences","Iranian Ministry of Health and Medical Education, Deputy of Research and Technology","Iran University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Iranian academic center for education culture and research","Ghoum University of Medical Sciences","Tehran University of Medical Sciences","Iran University of Medical Sciences","The University of Baqiyatallah","Saveh University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Tehran University of Medical Sciences","Mashhad University of Medical Sciences","Mazandaran University of Medical Sciences","Mashhad University of Medical Sciences","Semnan University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Iranian academic center for education culture and research","Artesh University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Mashhad University of Medical Sciences","Tehran University of Medical Sciences","Hotel Dieu de France hospital","Center for Progress and Development of Iran","Saveh University of Medical Sciences","Birjand University of Medical Sciences","Tehran University of Medical Sciences","Ahvaz University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Iran University of Medical Sciences","Misr University for Science and Technology","Ohmagari Norio","FUJIFILM Toyama Chemical Co., Ltd.","Mazandaran University of Medical Sciences","Birjand University of Medical Sciences","Neimeth International Pharmaceuticals Plc.","Sugiyama Haruhito","Tokue Yutaka","Tokue Yutaka","Jichi Medical University\nDivision of Gastroenterology","EMS Farmacutica  - Hortolndia, SP, Brazil","Tokyo University","Hospital do Corao - So Paulo, SP, Brazil","Yokohama City University","Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital","LAGOS STATE GOVERNMENT","Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine","Liver Research Unit, Faculty of Medicine, Chulalongkorn University","Health Systems Research Institute (HSRI)","Universidad de Sevilla - Sevilla, Spain","Yokohama City University School of Medicine","Study Group for Efficiency and Quality of Emergency Departments and Non-Scheduled Activities Departm","Hospital Universitrio Bettina Ferro de Souza - Belm, PA, Brazil","Center for Genetic Engineering and Biotechnology (CIGB), in Havana","OMS/OPS,","Study Group for Efficiency and Quality of Emergency Departments and Non-Scheduled Activities Departm","Universidade de So Paulo - So Paulo, SP, Brazil","Wellcome Trust"],["2020-02-17","2020-02-16","2020-02-15","2020-02-14","2020-02-14","27/01/2020","2020-02-16","2020-02-16","30/01/2020","03/02/2020","2020-02-13","2020-02-13","2020-02-16","2020-02-14","2020-02-14","2020-02-13","2020-02-13","2020-02-10","2020-02-13","28/01/2020","06/02/2020","2020-02-13","2020-02-13","03/02/2020","2020-02-16","2020-02-09","2020-02-15","2020-02-11","2020-02-11","2020-02-15","2020-02-15","2020-02-07","2020-02-08","2020-02-08","2020-02-07","2020-02-14","2020-02-14","2020-02-14","2020-02-14","06/02/2020","06/02/2020","2020-02-16","2020-02-16","2020-02-13","2020-02-13","2020-02-13","2020-02-06","2020-02-05","2020-02-12","2020-02-12","2020-02-12","2020-02-04","2020-02-11","2020-02-03","2020-02-03","2020-02-02","2020-02-01","2020-02-01","2020-02-05","2020-01-30","2020-02-16","2020-02-16","2020-02-03","2020-02-11","2020-02-24","2020-02-03","2020-02-02","2020-02-02","2020-02-10","2020-02-08","2020-02-07","2020-02-07","2020-02-24","2020-02-15","2020-02-23","2020-02-23","2020-02-06","2020-02-15","2020-02-06","2020-02-15","2020-02-05","2020-02-04","2020-02-03","2020-02-03","2020-02-02","2020-02-02","2020-02-01","2020-02-01","2020-02-01","2020-02-15","2020-01-29","2020-02-14","2020-02-24","2020-02-14","2020-02-14","2020-02-24","2020-02-13","2020-02-24","2020-02-23","2020-02-23","2020-02-01","2020-02-23","2020-02-01","2020-02-22","2020-02-23","2020-02-13","2020-02-12","2020-02-22","2020-02-12","2020-02-10","2020-02-10","2020-02-07","2020-02-06","2020-02-07","2020-02-07","2020-02-21","2020-02-22","2020-02-06","2020-02-21","2020-02-22","2020-02-04","2020-02-21","2020-02-21","2020-02-04","2020-02-02","2020-02-02","2020-02-02","2020-02-01","2020-01-27","05/02/2020","08/02/2020","2020-02-21","2020-02-24","2020-02-24","2020-02-23","2020-02-23","2020-02-23","2020-02-20","2020-02-19","2020-02-21","2020-02-20","2020-02-20","2020-02-19","2020-02-19","2020-02-21","2020-02-19","2020-02-20","07/02/2020","2020-02-24","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-19","2020-02-17","2020-02-24","2020-02-24","2020-02-24","2020-02-20","2020-02-19","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-17","2020-02-17","2020-02-18","2020-02-15","2020-02-15","2020-02-24","2020-02-15","2020-02-18","2020-02-23","2020-02-22","2020-02-13","2020-02-14","2020-02-22","2020-02-22","2020-02-22","2020-02-11","2020-02-13","2020-02-22","2020-02-21","2020-02-20","2020-02-20","2020-02-20","2020-02-19","01/02/2020","14/02/2020","11/02/2020","17/02/2020","2020-02-19","2020-02-19","2020-02-18","06/02/2020","17/02/2020","2020-02-18","2020-03-01","2020-02-18","14/02/2020","15/02/2020","2020-02-17","2020-03-01","2020-02-17","19/02/2020","2020-03-02","2020-02-29","18/02/2020","2020-03-01","2020-03-01","2020-03-01","2020-03-01","2020-02-18","2020-02-17","15/02/2020","20/02/2020","2020-03-01","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-03-01","2020-03-01","2020-02-28","2020-02-28","2020-02-28","2020-03-01","2020-02-28","2020-02-26","2020-02-26","2020-02-27","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-27","2020-02-25","2020-02-27","2020-02-25","2020-02-26","2020-02-26","2020-02-25","2020-02-26","2020-02-25","2020-02-20","2020-02-19","2020-02-25","2020-02-18","2020-02-26","2020-02-12","2020-02-26","2020-02-10","2020-02-26","2020-02-17","2020-02-16","2020-02-23","2020-02-21","2020-02-18","2020-02-12","2020-02-12","2020-02-24","2020-02-12","2020-01-29","2020-02-16","2020-01-29","2020-02-12","2020-02-16","2020-02-15","2020-03-07","2020-03-06","25/02/2020","2020-03-08","2020-03-07","2020-03-06","2020-03-07","2020-03-05","2020-03-06","2020-03-06","16/02/2020","2020-03-08","20/02/2020","10/02/2020","2020-03-04","2020-03-04","2020-03-07","2020-03-03","2020-03-04","2020-03-07","2020-03-03","2020-03-03","2020-03-06","2020-03-02","2020-03-06","22/02/2020","19/02/2020","2020-03-02","2020-03-08","2020-03-02","2020-03-05","2020-03-02","2020-03-08","2020-03-04","2020-03-02","2020-03-08","2020-03-02","2020-03-04","2020-02-20","2020-03-07","2020-02-28","2020-03-03","2020-02-05","2020-02-28","2020-03-06","2020-03-03","2020-03-04","2020-02-04","2020-03-03","2020-03-03","2020-02-04","2020-03-02","2020-02-24","2020-03-03","2020-02-02","2020-03-03","2020-02-18","2020-03-01","2020-03-16","2020-02-08","2020-02-17","2020-03-16","23/02/2020","03/03/2020","2020-02-05","2020-03-16","2020-02-12","2020-01-23","2020-03-16","2020-03-16","2020-03-16","03/03/2020","04/03/2020","26/02/2020","2020-03-16","25/02/2020","15/02/2020","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-15","2020-03-16","2020-03-16","2020-03-16","2020-03-15","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-15","2020-03-15","2020-03-16","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-14","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-13","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-13","2020-03-15","2020-03-15","2020-03-15","2020-03-13","2020-03-15","2020-03-15","2020-03-13","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-14","2020-03-15","2020-03-13","2020-03-14","2020-03-14","2020-03-14","2020-03-13","2020-03-14","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-11","2020-03-11","2020-03-13","2020-03-13","2020-03-11","2020-03-11","2020-03-13","2020-03-13","2020-03-11","2020-03-12","2020-03-11","2020-03-11","2020-03-10","2020-03-13","2020-03-10","2020-03-10","2020-03-10","2020-03-12","2020-03-08","2020-03-09","2020-03-09","2020-03-11","2020-03-07","2020-03-06","2020-03-09","2020-03-02","2020-02-28","2020-03-10","2020-03-01","2020-03-08","2020-03-03","2020-02-28","2020-03-10","2020-02-23","2020-03-03","2020-02-25","2020-02-22","2020-02-22","2020-02-18","2020-02-24","2020-03-09","2020-02-21","2020-02-17","2020-02-19","2020-02-16","2020-02-05","2020-02-14","2020-02-15","2020-02-14","2020-03-09","2020-02-14","2020-03-08","2020-03-08","2020-02-14","2020-03-06","2020-03-05","2020-03-03","2020-03-01","27/02/2020","2020-03-23","04/02/2020","12/03/2020","10/03/2020","2020-03-22","2020-02-29","2020-02-24","2020-03-22","2020-02-22","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-20","2020-02-14","2020-02-14","2020-03-20","2020-03-20","2020-02-13","2020-03-21","2020-03-18","2020-03-20","2020-03-21","2020-03-18","2020-03-19","2020-03-20","2020-03-17","24/02/2020","05/03/2020","2020-03-19","2020-03-19","2020-03-19","2020-03-18","2020-03-18","2020-03-17","07/03/2020","2020-03-23","2020-03-18","2020-03-18","2020-03-05","2020-03-22","2020-03-18","2020-03-17","2020-02-26","2020-03-22","2020-02-26","2020-03-20","2020-03-14","2020-03-17","2020-03-13","2020-02-24","2020-02-17","2020-03-20","2020-02-09","2020-02-15","2020-03-20","2020-02-05","2020-03-19","2020-02-03","2020-03-18","2020-03-18","02/02/2020","14/02/2020","10/03/2020","2020-03-17","30/01/2020","02/02/2020","2020-03-06","2020-02-23","06/03/2020","2020-02-15","13/02/2020","21/02/2020","02/02/2020","04/02/2020","02/03/2020","17/02/2020","27/02/2020","08/02/2020","19/02/2020","19/03/2020","24/02/2020","08/03/2020","04/03/2020","04/03/2020","15/03/2020","12/02/2020","14/02/2020","08/03/2020","01/03/2020","01/03/2020","13/03/2020","15/03/2020","14/03/2020","2020-03-29","2020-03-29","17/03/2020","17/03/2020","13/03/2020","19/03/2020","2020-03-28","16/03/2020","18/03/2020","2020-03-28","2020-03-27","2020-03-27","2020-03-28","2020-03-27","2020-03-27","2020-03-27","14/03/2020","2020-03-28","2020-03-27","2020-03-27","2020-03-27","2020-03-26","2020-03-26","2020-03-27","2020-03-25","2020-03-25","2020-03-25","2020-03-24","2020-03-25","2020-03-23","2020-03-25","2020-03-24","2020-03-25","2020-03-23","2020-03-24","2020-03-18","2020-03-23","2020-03-18","2020-03-17","2020-03-18","2020-03-23","2020-03-20","2020-03-10","2020-03-20","20/03/2020","2020-02-28","2020-02-20","2020-02-27","2020-02-26","2020-03-18","20/03/2020","19/03/2020","2020-02-25","27/03/2020","17/03/2020","20/03/2020","18/03/2020","13/03/2020","20/03/2020","24/03/2020","2020-03-15","17/03/2020","2020-02-18","23/03/2020","08/03/2020","20/03/2020","18/03/2020","09/03/2020","20/03/2020","23/03/2020","19/03/2020","25/03/2020","24/03/2020","30/07/2019","27/02/2020","23/03/2020","25/03/2020","25/03/2020","24/03/2020","27/02/2020","06/03/2020","25/03/2020","26/03/2020","30/03/2020","18/03/2020","26/03/2020","2020-04-03","2020-04-05","17/03/2020","17/03/2020","2020-04-05","2020-04-03","2020-04-02","2020-04-03","2020-04-02","2020-03-23","20/03/2020","23/03/2020","2020-04-02","2020-04-02","25/03/2020","2020-04-05","2020-04-01","2020-03-31","2020-04-01","2020-03-31","2020-04-05","2020-03-31","09/03/2020","2020-04-04","2020-03-29","02/04/2020","2020-04-03","2020-04-03","31/03/2020","2020-04-03","2020-04-02","24/03/2020","2020-04-01","30/03/2020","2020-04-01","2020-03-31","26/03/2020","2020-03-31","24/03/2020","25/10/2017","28/02/2020","14/02/2020","15/03/2020","31/03/2020","19/03/2020","23/03/2020","21/03/2020","23/03/2020","15/03/2020","13/03/2020","16/03/2020","30/03/2020","24/03/2020","25/03/2020","23/03/2020","25/03/2020","25/03/2020","21/03/2020","26/03/2020","26/03/2020","25/03/2020","25/03/2020","30/03/2020","27/03/2020","26/03/2020","24/03/2020","20/02/2020","17/03/2020","26/03/2020","25/03/2020","27/03/2020","27/03/2020","23/03/2020","23/03/2020","26/03/2020","30/03/2020","23/03/2020","30/03/2020","31/03/2020","31/03/2020","25/03/2020","26/03/2020","30/03/2020","06/02/2020","30/03/2020","30/03/2020","26/03/2020","26/03/2020","31/03/2020","27/03/2020","25/03/2020","24/03/2020","27/03/2020","01/04/2020","27/03/2020","01/04/2020","27/03/2020","27/03/2020","31/03/2020","02/04/2020","02/04/2020","02/04/2020","06/04/2020","29/03/2020","30/03/2020","06/04/2020","08/04/2020","02/04/2020","02/04/2020","01/04/2020","06/04/2020","08/04/2020","31/03/2020","06/04/2020","30/03/2020","31/03/2020","2020-04-11","2020-04-10","2020-04-09","01/04/2020","06/04/2020","06/04/2020","2020-04-09","2020-04-10","2020-04-10","2020-04-10","2020-04-09","2020-04-12","2020-04-08","2020-04-08","2020-04-10","2020-04-07","2020-04-07","2020-04-11","2020-04-07","2020-02-28","2020-04-08","2020-04-07","2020-04-06","2020-04-06","2020-03-13","2020-03-05","2020-02-28","24/03/2020","29/03/2020","26/03/2020","31/03/2020","27/03/2020","04/04/2020","01/04/2020","02/04/2020","24/03/2020","26/03/2020","29/03/2020","03/04/2020","31/03/2020","02/04/2020","01/04/2020","03/04/2020","03/04/2020","07/04/2020","03/04/2020","07/04/2020","07/04/2020","30/03/2020","07/04/2020","08/04/2020","19/09/2018","16/01/2019","23/01/2020","29/01/2020","01/02/2017","16/02/2020","31/01/2020","06/02/2020","27/01/2020","15/02/2020","15/03/2019","26/01/2020","11/02/2020","27/02/2020","14/02/2020","09/03/2020","31/01/2020","13/02/2020","21/02/2020","24/02/2020","28/02/2020","24/02/2020","16/03/2020","15/03/2020","27/02/2020","02/03/2020","28/02/2020","28/02/2020","09/03/2020","10/03/2020","13/03/2020","14/03/2020","19/03/2020","20/03/2020","11/03/2020","09/03/2020","05/03/2020","08/03/2020","13/03/2020","16/03/2020","18/03/2020","20/03/2020","22/03/2020","24/03/2020","16/03/2020","21/03/2020","14/03/2020","18/03/2020","20/03/2020","23/03/2020","23/03/2020","24/03/2020","19/03/2020","19/03/2020","24/03/2020","24/03/2020","23/03/2020","23/03/2020","23/03/2020","24/03/2020","19/03/2020","23/03/2020","24/03/2020","25/03/2020","23/03/2020","24/03/2020","25/03/2020","26/03/2020","24/03/2020","23/03/2020","23/03/2020","25/03/2020","25/03/2020","26/03/2020","26/03/2020","26/03/2020","20/03/2020","25/03/2020","25/03/2020","26/03/2020","26/03/2020","25/03/2020","25/03/2020","26/03/2020","25/03/2020","27/03/2020","26/03/2020","23/03/2020","26/03/2020","27/03/2020","29/03/2020","31/03/2020","26/03/2020","30/03/2020","30/03/2020","29/03/2020","29/03/2020","29/03/2020","27/03/2020","30/03/2020","30/03/2020","30/03/2020","31/03/2020","31/03/2020","23/03/2020","31/03/2020","31/03/2020","01/04/2020","01/04/2020","01/04/2020","30/03/2020","01/04/2020","31/03/2020","26/03/2020","31/03/2020","01/04/2020","31/03/2020","30/03/2020","31/03/2020","01/04/2020","01/04/2020","01/04/2020","31/03/2020","01/04/2020","02/04/2020","02/04/2020","02/04/2020","01/04/2020","01/04/2020","31/03/2020","01/04/2020","29/03/2020","01/04/2020","03/04/2020","01/04/2020","02/04/2020","02/04/2020","31/03/2020","02/04/2020","31/03/2020","31/03/2020","31/03/2020","01/04/2020","02/04/2020","02/04/2020","03/04/2020","02/04/2020","25/03/2020","03/04/2020","28/03/2020","02/04/2020","01/04/2020","02/04/2020","03/04/2020","31/03/2020","03/04/2020","03/04/2020","03/04/2020","30/03/2020","01/04/2020","03/04/2020","03/04/2020","03/04/2020","05/04/2020","06/04/2020","01/04/2020","02/04/2020","03/04/2020","01/04/2020","02/04/2020","06/04/2020","30/03/2020","03/04/2020","06/04/2020","31/03/2020","30/03/2020","05/04/2020","03/04/2020","03/04/2020","31/03/2020","04/04/2020","01/04/2020","02/04/2020","07/04/2020","07/04/2020","07/04/2020","04/04/2020","03/04/2020","05/04/2020","01/04/2020","03/04/2020","07/04/2020","07/04/2020","06/04/2020","01/04/2020","06/04/2020","07/04/2020","07/04/2020","02/04/2020","03/04/2020","04/04/2020","07/04/2020","06/04/2020","07/04/2020","07/04/2020","01/04/2020","07/04/2020","31/03/2020","03/04/2020","07/04/2020","07/04/2020","05/04/2020","06/04/2020","08/04/2020","06/04/2020","06/04/2020","03/04/2020","16/03/2020","03/04/2020","03/04/2020","03/03/2020","06/04/2020","08/04/2020","30/03/2020","07/04/2020","04/04/2020","08/04/2020","07/04/2020","07/04/2020","07/04/2020","01/04/2020","08/04/2020","07/04/2020","08/04/2020","07/04/2020","06/04/2020","07/04/2020","07/04/2020","08/04/2020","07/04/2020","07/04/2020","07/04/2020","08/04/2020","08/04/2020","07/04/2020","08/04/2020","31/03/2020","08/04/2020","31/03/2020","04/04/2020","08/04/2020","07/04/2020","04/04/2020","08/04/2020","08/04/2020","09/04/2020","08/04/2020","09/04/2020","09/04/2020","08/04/2020","08/04/2020","10/04/2020","08/04/2020","09/04/2020","08/04/2020","05/04/2020","09/04/2020","03/04/2020","10/04/2020","06/04/2020","07/04/2020","08/04/2020","20/02/2020","09/04/2020","08/04/2020","09/04/2020","09/04/2020","09/04/2020","10/04/2020","10/04/2020","09/04/2020","09/04/2020","10/04/2020","09/04/2020","13/04/2020","13/04/2020","09/04/2020","09/04/2020","07/04/2020","08/04/2020","09/04/2020","09/04/2020","09/04/2020","08/04/2020","10/04/2020","14/04/2020","09/04/2020","08/04/2020","09/04/2020","10/04/2020","11/04/2020","10/04/2020","08/04/2020","09/04/2020","10/04/2020","10/04/2020","13/04/2020","08/04/2020","11/04/2020","09/04/2020","08/04/2020","10/04/2020","10/04/2020","10/04/2020","13/04/2020","11/04/2020","08/04/2020","09/04/2020","09/04/2020","11/04/2020","13/04/2020","10/04/2020","10/04/2020","12/04/2020","05/04/2020","08/04/2020","09/04/2020","13/04/2020","11/04/2020","02/04/2020","05/04/2020","10/04/2020","07/04/2020","10/04/2020","10/04/2020","07/04/2020","11/04/2020","13/04/2020","13/04/2020","08/04/2020","09/04/2020","12/04/2020","10/04/2020","07/04/2020","08/04/2020","10/04/2020","10/04/2020","13/04/2020","10/04/2020","03/04/2020","23/03/2020","09/04/2020","08/04/2020","13/04/2020","13/04/2020","14/04/2020","07/04/2020","09/04/2020","13/04/2020","10/04/2020","06/04/2020","02/04/2020","13/04/2020","14/04/2020","13/04/2020","09/04/2020","13/04/2020","07/04/2020","03/04/2020","18/03/2020","31/03/2020","11/04/2020","07/04/2020","16/04/2020","09/04/2020","14/04/2020","08/04/2020","12/04/2020","08/04/2020","13/04/2020","08/04/2020","10/04/2020","13/04/2020","13/04/2020","09/04/2020","14/04/2020","09/04/2020","14/04/2020","10/04/2020","13/04/2020","11/04/2020","13/04/2020","08/04/2020","15/04/2020","16/04/2020","13/04/2020","13/04/2020","13/04/2020","13/04/2020","17/04/2020","09/04/2020","10/04/2020","20/04/2020","13/04/2020","14/04/2020","13/04/2020","12/04/2020","13/04/2020","13/04/2020","15/04/2020","13/04/2020","10/04/2020","11/04/2020","08/04/2020","07/04/2020","14/04/2020","11/04/2020","14/04/2020","14/04/2020","06/04/2020","13/04/2020","14/04/2020","14/04/2020","14/04/2020","14/04/2020","15/04/2020","16/04/2020","01/04/2020","14/04/2020","10/04/2020","14/04/2020","14/04/2020","17/04/2020","15/04/2020","15/04/2020","15/04/2020","10/04/2020","13/04/2020","15/04/2020","06/04/2020","25/03/2020","20/04/2020","14/04/2020","16/04/2020","22/03/2020","02/04/2020","06/12/2019","14/04/2020","01/04/2020","2020-04-17","06/04/2020","15/04/2020","15/04/2020","14/04/2020","14/04/2020","06/04/2020","2020-04-16","2020-04-14","14/04/2020","11/04/2020","2020-04-19","16/04/2020","16/04/2020","15/04/2020","20/04/2020","16/04/2020","14/04/2020","2020-04-19","2020-04-16","14/04/2020","2020-04-15","2020-04-14","2020-04-16","31/03/2020","08/04/2020","07/04/2020","2020-02-18","2020-02-28","2020-04-18","2020-04-17","02/04/2020","2020-04-17","2020-04-17","29/03/2020","2020-04-15","2020-04-13","26/03/2020","07/04/2020","23/03/2020","27/03/2020","2020-04-07","31/03/2020","2020-02-01","30/03/2020","2020-02-01","01/04/2020","01/04/2020","13/04/2020","26/07/2019","13/04/2020","16/03/2020","26/03/2020","13/04/2020","31/03/2020","03/04/2020","31/03/2020","03/04/2020","03/04/2020","03/04/2020","13/04/2020","29/03/2020","13/04/2020","13/04/2020","03/04/2020","13/04/2020","01/04/2020","13/04/2020","14/04/2020","23/03/2020","14/04/2020","13/04/2020","13/04/2020","16/04/2020","13/04/2020","13/04/2020","17/04/2020","24/03/2020","15/04/2020","06/04/2020","14/04/2020","14/04/2020","13/07/2015","24/03/2020","01/04/2020","01/04/2020","01/04/2020","17/04/2020","16/04/2020","27/03/2020","02/04/2020","03/04/2020","30/03/2020","07/04/2020","31/03/2020","27/03/2020","14/04/2020","06/04/2020","26/03/2020","08/04/2020","01-04-2020","08/04/2020","07/04/2020","2020-03-29","14/04/2020","16/04/2020","2020-04-01","2020-03-19","09/04/2020","15/04/2020","2020-03-29","06/04/2020","2020-03-30","2020-03-22","01-04-2020","2020-03-28","2020-03-17","19/03/2020","07-04-2020","2020-04-04","31-03-2020","15-04-2020","2020-03-31","15-04-2020","2020-04-03","2020-04-05","03-04-2020","2020-03-19","2020-03-16","2020-04-12","2020-03-28","2020-04-05","2020-03-14","2020-03-30","2020-04-20","2020-03-31","2020-03-29","2020-04-03","2020-03-23","2020-03-28","2020-04-19","2020-03-22","2020-03-26","2020-03-26","2020-03-29","2020-03-30","2020-03-29","2020-04-05","2020-04-12","2020-03-26","2020-03-29","2020-03-29","2020-03-31","2020-03-27","2020-04-11","2020-03-28","2020-04-04","2020-04-08","2020-03-31","2020-04-01","2020-04-16","2020-04-02","2020-04-03","2020-04-01","2020-04-02","2020-04-08","2020-04-01","2020-03-28","2020-04-03","2020-04-12","2020-04-07","2020-04-04","2020-04-03","2020-04-08","2020-04-12","2020-04-13","2020-04-20","2020-04-09","2020-04-03","2020-04-09","2020-04-12","2020-04-08","2020-03-30","2020-04-10","2020-04-20","2020-04-09","2020-04-08","2020-04-08","2020-04-10","2020-04-14","2020-04-11","2020-04-06","2020-04-08","2020-04-01","2020-04-14","2020-04-13","2020-04-03","2020-04-11","2020-04-18","2020-04-13","2020-04-10","2020-04-11","2020-04-15","2020-04-15","2020-04-11","2020-04-11","2020-04-18","2020-04-10","2020-04-19","2020-04-12","2020-04-13","2020-04-15","2020-04-10","2020-04-11","2020-04-14","16/04/2020","2020-04-15","2020-04-19","2020-04-14","2020-04-20","2020-04-13","2020-04-18","2020-04-14","2020-04-12","2020-04-16","12/04/2020","24/03/2020","27/03/2020","2020-04-17","2020-04-17","13/04/2020","27/03/2020","27/02/2020","27/02/2020","01/04/2020","08/04/2020","15/04/2020","27/03/2020","31/03/2020","03/04/2020","02/04/2020","17/04/2020","05/04/2020","31/03/2020","02/04/2020","17/04/2020","21/03/2020","09/04/2020","13/04/2020","16/04/2020","20/03/2020","13/04/2020","31/03/2020"],[20200217,20200216,20200215,20200214,20200214,20200127,20200216,20200216,20200130,20200203,20200213,20200213,20200216,20200214,20200214,20200213,20200213,20200210,20200213,20200128,20200206,20200213,20200213,20200203,20200216,20200209,20200215,20200211,20200211,20200215,20200215,20200207,20200208,20200208,20200207,20200214,20200214,20200214,20200214,20200206,20200206,20200216,20200216,20200213,20200213,20200213,20200206,20200205,20200212,20200212,20200212,20200204,20200211,20200203,20200203,20200202,20200201,20200201,20200205,20200130,20200216,20200216,20200203,20200211,20200224,20200203,20200202,20200202,20200210,20200208,20200207,20200207,20200224,20200215,20200223,20200223,20200206,20200215,20200206,20200215,20200205,20200204,20200203,20200203,20200202,20200202,20200201,20200201,20200201,20200215,20200129,20200214,20200224,20200214,20200214,20200224,20200213,20200224,20200223,20200223,20200201,20200223,20200201,20200222,20200223,20200213,20200212,20200222,20200212,20200210,20200210,20200207,20200206,20200207,20200207,20200221,20200222,20200206,20200221,20200222,20200204,20200221,20200221,20200204,20200202,20200202,20200202,20200201,20200127,20200205,20200208,20200221,20200224,20200224,20200223,20200223,20200223,20200220,20200219,20200221,20200220,20200220,20200219,20200219,20200221,20200219,20200220,20200207,20200224,20200219,20200219,20200219,20200219,20200219,20200217,20200224,20200224,20200224,20200220,20200219,20200218,20200218,20200218,20200218,20200217,20200217,20200218,20200215,20200215,20200224,20200215,20200218,20200223,20200222,20200213,20200214,20200222,20200222,20200222,20200211,20200213,20200222,20200221,20200220,20200220,20200220,20200219,20200201,20200214,20200211,20200217,20200219,20200219,20200218,20200206,20200217,20200218,20200301,20200218,20200214,20200215,20200217,20200301,20200217,20200219,20200302,20200229,20200218,20200301,20200301,20200301,20200301,20200218,20200217,20200215,20200220,20200301,20200228,20200228,20200228,20200228,20200228,20200228,20200301,20200301,20200228,20200228,20200228,20200301,20200228,20200226,20200226,20200227,20200226,20200226,20200226,20200226,20200226,20200226,20200227,20200225,20200227,20200225,20200226,20200226,20200225,20200226,20200225,20200220,20200219,20200225,20200218,20200226,20200212,20200226,20200210,20200226,20200217,20200216,20200223,20200221,20200218,20200212,20200212,20200224,20200212,20200129,20200216,20200129,20200212,20200216,20200215,20200307,20200306,20200225,20200308,20200307,20200306,20200307,20200305,20200306,20200306,20200216,20200308,20200220,20200210,20200304,20200304,20200307,20200303,20200304,20200307,20200303,20200303,20200306,20200302,20200306,20200222,20200219,20200302,20200308,20200302,20200305,20200302,20200308,20200304,20200302,20200308,20200302,20200304,20200220,20200307,20200228,20200303,20200205,20200228,20200306,20200303,20200304,20200204,20200303,20200303,20200204,20200302,20200224,20200303,20200202,20200303,20200218,20200301,20200316,20200208,20200217,20200316,20200223,20200303,20200205,20200316,20200212,20200123,20200316,20200316,20200316,20200303,20200304,20200226,20200316,20200225,20200215,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200315,20200316,20200316,20200316,20200315,20200316,20200316,20200316,20200316,20200316,20200315,20200315,20200316,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200314,20200315,20200315,20200315,20200315,20200313,20200315,20200315,20200315,20200315,20200313,20200315,20200315,20200315,20200313,20200315,20200315,20200313,20200315,20200315,20200315,20200315,20200314,20200315,20200313,20200314,20200314,20200314,20200313,20200314,20200313,20200313,20200313,20200313,20200313,20200313,20200313,20200313,20200313,20200311,20200311,20200313,20200313,20200311,20200311,20200313,20200313,20200311,20200312,20200311,20200311,20200310,20200313,20200310,20200310,20200310,20200312,20200308,20200309,20200309,20200311,20200307,20200306,20200309,20200302,20200228,20200310,20200301,20200308,20200303,20200228,20200310,20200223,20200303,20200225,20200222,20200222,20200218,20200224,20200309,20200221,20200217,20200219,20200216,20200205,20200214,20200215,20200214,20200309,20200214,20200308,20200308,20200214,20200306,20200305,20200303,20200301,20200227,20200323,20200204,20200312,20200310,20200322,20200229,20200224,20200322,20200222,20200322,20200322,20200322,20200322,20200320,20200214,20200214,20200320,20200320,20200213,20200321,20200318,20200320,20200321,20200318,20200319,20200320,20200317,20200224,20200305,20200319,20200319,20200319,20200318,20200318,20200317,20200307,20200323,20200318,20200318,20200305,20200322,20200318,20200317,20200226,20200322,20200226,20200320,20200314,20200317,20200313,20200224,20200217,20200320,20200209,20200215,20200320,20200205,20200319,20200203,20200318,20200318,20200202,20200214,20200310,20200317,20200130,20200202,20200306,20200223,20200306,20200215,20200213,20200221,20200202,20200204,20200302,20200217,20200227,20200208,20200219,20200319,20200224,20200308,20200304,20200304,20200315,20200212,20200214,20200308,20200301,20200301,20200313,20200315,20200314,20200329,20200329,20200317,20200317,20200313,20200319,20200328,20200316,20200318,20200328,20200327,20200327,20200328,20200327,20200327,20200327,20200314,20200328,20200327,20200327,20200327,20200326,20200326,20200327,20200325,20200325,20200325,20200324,20200325,20200323,20200325,20200324,20200325,20200323,20200324,20200318,20200323,20200318,20200317,20200318,20200323,20200320,20200310,20200320,20200320,20200228,20200220,20200227,20200226,20200318,20200320,20200319,20200225,20200327,20200317,20200320,20200318,20200313,20200320,20200324,20200315,20200317,20200218,20200323,20200308,20200320,20200318,20200309,20200320,20200323,20200319,20200325,20200324,20190730,20200227,20200323,20200325,20200325,20200324,20200227,20200306,20200325,20200326,20200330,20200318,20200326,20200403,20200405,20200317,20200317,20200405,20200403,20200402,20200403,20200402,20200323,20200320,20200323,20200402,20200402,20200325,20200405,20200401,20200331,20200401,20200331,20200405,20200331,20200309,20200404,20200329,20200402,20200403,20200403,20200331,20200403,20200402,20200324,20200401,20200330,20200401,20200331,20200326,20200331,20200324,20171025,20200228,20200214,20200315,20200331,20200319,20200323,20200321,20200323,20200315,20200313,20200316,20200330,20200324,20200325,20200323,20200325,20200325,20200321,20200326,20200326,20200325,20200325,20200330,20200327,20200326,20200324,20200220,20200317,20200326,20200325,20200327,20200327,20200323,20200323,20200326,20200330,20200323,20200330,20200331,20200331,20200325,20200326,20200330,20200206,20200330,20200330,20200326,20200326,20200331,20200327,20200325,20200324,20200327,20200401,20200327,20200401,20200327,20200327,20200331,20200402,20200402,20200402,20200406,20200329,20200330,20200406,20200408,20200402,20200402,20200401,20200406,20200408,20200331,20200406,20200330,20200331,20200411,20200410,20200409,20200401,20200406,20200406,20200409,20200410,20200410,20200410,20200409,20200412,20200408,20200408,20200410,20200407,20200407,20200411,20200407,20200228,20200408,20200407,20200406,20200406,20200313,20200305,20200228,20200324,20200329,20200326,20200331,20200327,20200404,20200401,20200402,20200324,20200326,20200329,20200403,20200331,20200402,20200401,20200403,20200403,20200407,20200403,20200407,20200407,20200330,20200407,20200408,20180919,20190116,20200123,20200129,20170201,20200216,20200131,20200206,20200127,20200215,20190315,20200126,20200211,20200227,20200214,20200309,20200131,20200213,20200221,20200224,20200228,20200224,20200316,20200315,20200227,20200302,20200228,20200228,20200309,20200310,20200313,20200314,20200319,20200320,20200311,20200309,20200305,20200308,20200313,20200316,20200318,20200320,20200322,20200324,20200316,20200321,20200314,20200318,20200320,20200323,20200323,20200324,20200319,20200319,20200324,20200324,20200323,20200323,20200323,20200324,20200319,20200323,20200324,20200325,20200323,20200324,20200325,20200326,20200324,20200323,20200323,20200325,20200325,20200326,20200326,20200326,20200320,20200325,20200325,20200326,20200326,20200325,20200325,20200326,20200325,20200327,20200326,20200323,20200326,20200327,20200329,20200331,20200326,20200330,20200330,20200329,20200329,20200329,20200327,20200330,20200330,20200330,20200331,20200331,20200323,20200331,20200331,20200401,20200401,20200401,20200330,20200401,20200331,20200326,20200331,20200401,20200331,20200330,20200331,20200401,20200401,20200401,20200331,20200401,20200402,20200402,20200402,20200401,20200401,20200331,20200401,20200329,20200401,20200403,20200401,20200402,20200402,20200331,20200402,20200331,20200331,20200331,20200401,20200402,20200402,20200403,20200402,20200325,20200403,20200328,20200402,20200401,20200402,20200403,20200331,20200403,20200403,20200403,20200330,20200401,20200403,20200403,20200403,20200405,20200406,20200401,20200402,20200403,20200401,20200402,20200406,20200330,20200403,20200406,20200331,20200330,20200405,20200403,20200403,20200331,20200404,20200401,20200402,20200407,20200407,20200407,20200404,20200403,20200405,20200401,20200403,20200407,20200407,20200406,20200401,20200406,20200407,20200407,20200402,20200403,20200404,20200407,20200406,20200407,20200407,20200401,20200407,20200331,20200403,20200407,20200407,20200405,20200406,20200408,20200406,20200406,20200403,20200316,20200403,20200403,20200303,20200406,20200408,20200330,20200407,20200404,20200408,20200407,20200407,20200407,20200401,20200408,20200407,20200408,20200407,20200406,20200407,20200407,20200408,20200407,20200407,20200407,20200408,20200408,20200407,20200408,20200331,20200408,20200331,20200404,20200408,20200407,20200404,20200408,20200408,20200409,20200408,20200409,20200409,20200408,20200408,20200410,20200408,20200409,20200408,20200405,20200409,20200403,20200410,20200406,20200407,20200408,20200220,20200409,20200408,20200409,20200409,20200409,20200410,20200410,20200409,20200409,20200410,20200409,20200413,20200413,20200409,20200409,20200407,20200408,20200409,20200409,20200409,20200408,20200410,20200414,20200409,20200408,20200409,20200410,20200411,20200410,20200408,20200409,20200410,20200410,20200413,20200408,20200411,20200409,20200408,20200410,20200410,20200410,20200413,20200411,20200408,20200409,20200409,20200411,20200413,20200410,20200410,20200412,20200405,20200408,20200409,20200413,20200411,20200402,20200405,20200410,20200407,20200410,20200410,20200407,20200411,20200413,20200413,20200408,20200409,20200412,20200410,20200407,20200408,20200410,20200410,20200413,20200410,20200403,20200323,20200409,20200408,20200413,20200413,20200414,20200407,20200409,20200413,20200410,20200406,20200402,20200413,20200414,20200413,20200409,20200413,20200407,20200403,20200318,20200331,20200411,20200407,20200416,20200409,20200414,20200408,20200412,20200408,20200413,20200408,20200410,20200413,20200413,20200409,20200414,20200409,20200414,20200410,20200413,20200411,20200413,20200408,20200415,20200416,20200413,20200413,20200413,20200413,20200417,20200409,20200410,20200420,20200413,20200414,20200413,20200412,20200413,20200413,20200415,20200413,20200410,20200411,20200408,20200407,20200414,20200411,20200414,20200414,20200406,20200413,20200414,20200414,20200414,20200414,20200415,20200416,20200401,20200414,20200410,20200414,20200414,20200417,20200415,20200415,20200415,20200410,20200413,20200415,20200406,20200325,20200420,20200414,20200416,20200322,20200402,20191206,20200414,20200401,20200417,20200406,20200415,20200415,20200414,20200414,20200406,20200416,20200414,20200414,20200411,20200419,20200416,20200416,20200415,20200420,20200416,20200414,20200419,20200416,20200414,20200415,20200414,20200416,20200331,20200408,20200407,20200218,20200228,20200418,20200417,20200402,20200417,20200417,20200329,20200415,20200413,20200326,20200407,20200323,20200327,20200407,20200331,20200201,20200330,20200201,20200401,20200401,20200413,20190726,20200413,20200316,20200326,20200413,20200331,20200403,20200331,20200403,20200403,20200403,20200413,20200329,20200413,20200413,20200403,20200413,20200401,20200413,20200414,20200323,20200414,20200413,20200413,20200416,20200413,20200413,20200417,20200324,20200415,20200406,20200414,20200414,20150713,20200324,20200401,20200401,20200401,20200417,20200416,20200327,20200402,20200403,20200330,20200407,20200331,20200327,20200414,20200406,20200326,20200408,20200401,20200408,20200407,20200329,20200414,20200416,20200401,20200319,20200409,20200415,20200329,20200406,20200330,20200322,20200401,20200328,20200317,20200319,20200407,20200404,20200331,20200415,20200331,20200415,20200403,20200405,20200403,20200319,20200316,20200412,20200328,20200405,20200314,20200330,20200420,20200331,20200329,20200403,20200323,20200328,20200419,20200322,20200326,20200326,20200329,20200330,20200329,20200405,20200412,20200326,20200329,20200329,20200331,20200327,20200411,20200328,20200404,20200408,20200331,20200401,20200416,20200402,20200403,20200401,20200402,20200408,20200401,20200328,20200403,20200412,20200407,20200404,20200403,20200408,20200412,20200413,20200420,20200409,20200403,20200409,20200412,20200408,20200330,20200410,20200420,20200409,20200408,20200408,20200410,20200414,20200411,20200406,20200408,20200401,20200414,20200413,20200403,20200411,20200418,20200413,20200410,20200411,20200415,20200415,20200411,20200411,20200418,20200410,20200419,20200412,20200413,20200415,20200410,20200411,20200414,20200416,20200415,20200419,20200414,20200420,20200413,20200418,20200414,20200412,20200416,20200412,20200324,20200327,20200417,20200417,20200413,20200327,20200227,20200227,20200401,20200408,20200415,20200327,20200331,20200403,20200402,20200417,20200405,20200331,20200402,20200417,20200321,20200409,20200413,20200416,20200320,20200413,20200331],["4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM","4/22/2020 12:57:03 PM"],["ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","JPRN","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","JPRN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","JPRN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","EU Clinical Trials Register","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","ChiCTR","EU Clinical Trials Register","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ANZCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ANZCTR","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ANZCTR","ANZCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ANZCTR","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ISRCTN","ANZCTR","ISRCTN","ANZCTR","ISRCTN","ISRCTN","ISRCTN","ISRCTN","ISRCTN","ChiCTR","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ANZCTR","ANZCTR","ANZCTR","ANZCTR","ANZCTR","ChiCTR","ChiCTR","ISRCTN","ChiCTR","ChiCTR","ChiCTR","Netherlands Trial Register","ISRCTN","ISRCTN","ChiCTR","ChiCTR","ChiCTR","ChiCTR","Netherlands Trial Register","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","EU Clinical Trials Register","Netherlands Trial Register","Netherlands Trial Register","Netherlands Trial Register","ChiCTR","Netherlands Trial Register","ChiCTR","EU Clinical Trials Register","ChiCTR","EU Clinical Trials Register","Netherlands Trial Register","Netherlands Trial Register","EU Clinical Trials Register","EU Clinical Trials Register","Netherlands Trial Register","Netherlands Trial Register","EU Clinical Trials Register","Netherlands Trial Register","EU Clinical Trials Register","Netherlands Trial Register","Netherlands Trial Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","German Clinical Trials Register","CTRI","German Clinical Trials Register","German Clinical Trials Register","IRCT","German Clinical Trials Register","German Clinical Trials Register","IRCT","IRCT","German Clinical Trials Register","German Clinical Trials Register","IRCT","German Clinical Trials Register","IRCT","IRCT","CTRI","IRCT","IRCT","German Clinical Trials Register","CTRI","IRCT","CTRI","CTRI","IRCT","CTRI","IRCT","IRCT","CTRI","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","LBCTR","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","PACTR","JPRN","JPRN","IRCT","IRCT","PACTR","JPRN","JPRN","JPRN","JPRN","REBEC","JPRN","REBEC","JPRN","TCTR","PACTR","JPRN","TCTR","TCTR","REBEC","JPRN","TCTR","REBEC","RPCEC","REPEC","TCTR","REBEC","TCTR"],["http://www.chictr.org.cn/showproj.aspx?proj=49217","http://www.chictr.org.cn/showproj.aspx?proj=49607","http://www.chictr.org.cn/showproj.aspx?proj=49533","http://www.chictr.org.cn/showproj.aspx?proj=49387","http://www.chictr.org.cn/showproj.aspx?proj=49188","https://clinicaltrials.gov/show/NCT04246242","http://www.chictr.org.cn/showproj.aspx?proj=49181","http://www.chictr.org.cn/showproj.aspx?proj=49599","https://clinicaltrials.gov/show/NCT04252885","https://clinicaltrials.gov/show/NCT04255940","http://www.chictr.org.cn/showproj.aspx?proj=49348","http://www.chictr.org.cn/showproj.aspx?proj=49445","http://www.chictr.org.cn/showproj.aspx?proj=49432","http://www.chictr.org.cn/showproj.aspx?proj=49355","http://www.chictr.org.cn/showproj.aspx?proj=49407","http://www.chictr.org.cn/showproj.aspx?proj=49388","http://www.chictr.org.cn/showproj.aspx?proj=49378","http://www.chictr.org.cn/showproj.aspx?proj=49219","http://www.chictr.org.cn/showproj.aspx?proj=49422","https://clinicaltrials.gov/show/NCT04251871","https://clinicaltrials.gov/show/NCT04260594","http://www.chictr.org.cn/showproj.aspx?proj=49380","http://www.chictr.org.cn/showproj.aspx?proj=49342","https://clinicaltrials.gov/show/NCT04260308","http://www.chictr.org.cn/showproj.aspx?proj=49549","http://www.chictr.org.cn/showproj.aspx?proj=49086","http://www.chictr.org.cn/showproj.aspx?proj=49486","http://www.chictr.org.cn/showproj.aspx?proj=49297","http://www.chictr.org.cn/showproj.aspx?proj=49263","http://www.chictr.org.cn/showproj.aspx?proj=49514","http://www.chictr.org.cn/showproj.aspx?proj=49530","http://www.chictr.org.cn/showproj.aspx?proj=49170","http://www.chictr.org.cn/showproj.aspx?proj=49127","http://www.chictr.org.cn/showproj.aspx?proj=49215","http://www.chictr.org.cn/showproj.aspx?proj=49132","http://www.chictr.org.cn/showproj.aspx?proj=49502","http://www.chictr.org.cn/showproj.aspx?proj=49346","http://www.chictr.org.cn/showproj.aspx?proj=49425","http://www.chictr.org.cn/showproj.aspx?proj=49161","https://clinicaltrials.gov/show/NCT04261426","https://clinicaltrials.gov/show/NCT04261907","http://www.chictr.org.cn/showproj.aspx?proj=49596","http://www.chictr.org.cn/showproj.aspx?proj=49612","http://www.chictr.org.cn/showproj.aspx?proj=49453","http://www.chictr.org.cn/showproj.aspx?proj=49452","http://www.chictr.org.cn/showproj.aspx?proj=49409","http://www.chictr.org.cn/showproj.aspx?proj=48988","http://www.chictr.org.cn/showproj.aspx?proj=49104","http://www.chictr.org.cn/showproj.aspx?proj=49408","http://www.chictr.org.cn/showproj.aspx?proj=49295","http://www.chictr.org.cn/showproj.aspx?proj=49222","http://www.chictr.org.cn/showproj.aspx?proj=49062","http://www.chictr.org.cn/showproj.aspx?proj=49287","http://www.chictr.org.cn/showproj.aspx?proj=48968","http://www.chictr.org.cn/showproj.aspx?proj=48991","http://www.chictr.org.cn/showproj.aspx?proj=48922","http://www.chictr.org.cn/showproj.aspx?proj=48911","http://www.chictr.org.cn/showproj.aspx?proj=48884","http://www.chictr.org.cn/showproj.aspx?proj=49080","http://www.chictr.org.cn/showproj.aspx?proj=48886","http://www.chictr.org.cn/showproj.aspx?proj=49587","http://www.chictr.org.cn/showproj.aspx?proj=49595","http://www.chictr.org.cn/showproj.aspx?proj=48860","http://www.chictr.org.cn/showproj.aspx?proj=49283","http://www.chictr.org.cn/showproj.aspx?proj=49229","http://www.chictr.org.cn/showproj.aspx?proj=48861","http://www.chictr.org.cn/showproj.aspx?proj=48971","http://www.chictr.org.cn/showproj.aspx?proj=48931","http://www.chictr.org.cn/showproj.aspx?proj=49302","http://www.chictr.org.cn/showproj.aspx?proj=49187","http://www.chictr.org.cn/showproj.aspx?proj=49155","http://www.chictr.org.cn/showproj.aspx?proj=49177","http://www.chictr.org.cn/showproj.aspx?proj=49696","http://www.chictr.org.cn/showproj.aspx?proj=49563","http://www.chictr.org.cn/showproj.aspx?proj=49594","http://www.chictr.org.cn/showproj.aspx?proj=49901","http://www.chictr.org.cn/showproj.aspx?proj=48985","http://www.chictr.org.cn/showproj.aspx?proj=49543","http://www.chictr.org.cn/showproj.aspx?proj=49042","http://www.chictr.org.cn/showproj.aspx?proj=49532","http://www.chictr.org.cn/showproj.aspx?proj=41760","http://www.chictr.org.cn/showproj.aspx?proj=48880","http://www.chictr.org.cn/showproj.aspx?proj=49013","http://www.chictr.org.cn/showproj.aspx?proj=48992","http://www.chictr.org.cn/showproj.aspx?proj=48965","http://www.chictr.org.cn/showproj.aspx?proj=48919","http://www.chictr.org.cn/showproj.aspx?proj=48913","http://www.chictr.org.cn/showproj.aspx?proj=48827","http://www.chictr.org.cn/showproj.aspx?proj=48902","http://www.chictr.org.cn/showproj.aspx?proj=49439","http://www.chictr.org.cn/showproj.aspx?proj=48824","http://www.chictr.org.cn/showproj.aspx?proj=49306","http://www.chictr.org.cn/showproj.aspx?proj=50058","http://www.chictr.org.cn/showproj.aspx?proj=49490","http://www.chictr.org.cn/showproj.aspx?proj=49178","http://www.chictr.org.cn/showproj.aspx?proj=49567","http://www.chictr.org.cn/showproj.aspx?proj=49415","http://www.chictr.org.cn/showproj.aspx?proj=49947","http://www.chictr.org.cn/showproj.aspx?proj=49762","http://www.chictr.org.cn/showproj.aspx?proj=49964","http://www.chictr.org.cn/showproj.aspx?proj=48881","http://www.chictr.org.cn/showproj.aspx?proj=49880","http://www.chictr.org.cn/showproj.aspx?proj=48907","http://www.chictr.org.cn/showproj.aspx?proj=49910","http://www.chictr.org.cn/showproj.aspx?proj=49932","http://www.chictr.org.cn/showproj.aspx?proj=49131","http://www.chictr.org.cn/showproj.aspx?proj=49370","http://www.chictr.org.cn/showproj.aspx?proj=49952","http://www.chictr.org.cn/showproj.aspx?proj=49354","http://www.chictr.org.cn/showproj.aspx?proj=49279","http://www.chictr.org.cn/showproj.aspx?proj=48868","http://www.chictr.org.cn/showproj.aspx?proj=49165","http://www.chictr.org.cn/showproj.aspx?proj=49145","http://www.chictr.org.cn/showproj.aspx?proj=49146","http://www.chictr.org.cn/showproj.aspx?proj=49051","http://www.chictr.org.cn/showproj.aspx?proj=49866","http://www.chictr.org.cn/showproj.aspx?proj=49831","http://www.chictr.org.cn/showproj.aspx?proj=49075","http://www.chictr.org.cn/showproj.aspx?proj=49891","http://www.chictr.org.cn/showproj.aspx?proj=49904","http://www.chictr.org.cn/showproj.aspx?proj=48792","http://www.chictr.org.cn/showproj.aspx?proj=49647","http://www.chictr.org.cn/showproj.aspx?proj=49703","http://www.chictr.org.cn/showproj.aspx?proj=49015","http://www.chictr.org.cn/showproj.aspx?proj=48927","http://www.chictr.org.cn/showproj.aspx?proj=48930","http://www.chictr.org.cn/showproj.aspx?proj=48929","http://www.chictr.org.cn/showproj.aspx?proj=48904","http://www.chictr.org.cn/showproj.aspx?proj=48768","https://clinicaltrials.gov/show/NCT04259892","https://clinicaltrials.gov/show/NCT04268537","http://www.chictr.org.cn/showproj.aspx?proj=49816","http://www.chictr.org.cn/showproj.aspx?proj=50059","http://www.chictr.org.cn/showproj.aspx?proj=49983","http://www.chictr.org.cn/showproj.aspx?proj=49988","http://www.chictr.org.cn/showproj.aspx?proj=49794","http://www.chictr.org.cn/showproj.aspx?proj=49970","http://www.chictr.org.cn/showproj.aspx?proj=49798","http://www.chictr.org.cn/showproj.aspx?proj=49799","http://www.chictr.org.cn/showproj.aspx?proj=49861","http://www.chictr.org.cn/showproj.aspx?proj=49800","http://www.chictr.org.cn/showproj.aspx?proj=49841","http://www.chictr.org.cn/showproj.aspx?proj=49426","http://www.chictr.org.cn/showproj.aspx?proj=49619","http://www.chictr.org.cn/showproj.aspx?proj=49824","http://www.chictr.org.cn/showproj.aspx?proj=49737","http://www.chictr.org.cn/showproj.aspx?proj=49852","https://clinicaltrials.gov/show/NCT04269525","http://www.chictr.org.cn/showproj.aspx?proj=50025","http://www.chictr.org.cn/showproj.aspx?proj=49718","http://www.chictr.org.cn/showproj.aspx?proj=49748","http://www.chictr.org.cn/showproj.aspx?proj=49723","http://www.chictr.org.cn/showproj.aspx?proj=49777","http://www.chictr.org.cn/showproj.aspx?proj=49717","http://www.chictr.org.cn/showproj.aspx?proj=49618","http://www.chictr.org.cn/showproj.aspx?proj=50017","http://www.chictr.org.cn/showproj.aspx?proj=50004","http://www.chictr.org.cn/showproj.aspx?proj=50007","http://www.chictr.org.cn/showproj.aspx?proj=49510","http://www.chictr.org.cn/showproj.aspx?proj=49418","http://www.chictr.org.cn/showproj.aspx?proj=49309","http://www.chictr.org.cn/showproj.aspx?proj=49574","http://www.chictr.org.cn/showproj.aspx?proj=49674","http://www.chictr.org.cn/showproj.aspx?proj=49702","http://www.chictr.org.cn/showproj.aspx?proj=49639","http://www.chictr.org.cn/showproj.aspx?proj=49636","http://www.chictr.org.cn/showproj.aspx?proj=49692","http://www.chictr.org.cn/showproj.aspx?proj=49519","http://www.chictr.org.cn/showproj.aspx?proj=49545","http://www.chictr.org.cn/showproj.aspx?proj=50005","http://www.chictr.org.cn/showproj.aspx?proj=49534","http://www.chictr.org.cn/showproj.aspx?proj=49321","http://www.chictr.org.cn/showproj.aspx?proj=49747","http://www.chictr.org.cn/showproj.aspx?proj=49889","http://www.chictr.org.cn/showproj.aspx?proj=49138","http://www.chictr.org.cn/showproj.aspx?proj=49428","http://www.chictr.org.cn/showproj.aspx?proj=49902","http://www.chictr.org.cn/showproj.aspx?proj=49919","http://www.chictr.org.cn/showproj.aspx?proj=49934","http://www.chictr.org.cn/showproj.aspx?proj=49317","http://www.chictr.org.cn/showproj.aspx?proj=49220","http://www.chictr.org.cn/showproj.aspx?proj=49869","http://www.chictr.org.cn/showproj.aspx?proj=49544","http://www.chictr.org.cn/showproj.aspx?proj=49690","http://www.chictr.org.cn/showproj.aspx?proj=49812","http://www.chictr.org.cn/showproj.aspx?proj=49768","http://www.chictr.org.cn/showproj.aspx?proj=49783","https://clinicaltrials.gov/show/NCT04256395","https://clinicaltrials.gov/show/NCT04273529","https://clinicaltrials.gov/show/NCT04270383","https://clinicaltrials.gov/show/NCT04275947","http://www.chictr.org.cn/showproj.aspx?proj=49770","http://www.chictr.org.cn/showproj.aspx?proj=49738","http://www.chictr.org.cn/showproj.aspx?proj=49720","https://clinicaltrials.gov/show/NCT04275245","https://clinicaltrials.gov/show/NCT04275388","http://www.chictr.org.cn/showproj.aspx?proj=49218","http://www.chictr.org.cn/showproj.aspx?proj=50286","http://www.chictr.org.cn/showproj.aspx?proj=49711","https://clinicaltrials.gov/show/NCT04273581","https://clinicaltrials.gov/show/NCT04279782","http://www.chictr.org.cn/showproj.aspx?proj=49664","http://www.chictr.org.cn/showproj.aspx?proj=50224","http://www.chictr.org.cn/showproj.aspx?proj=49402","https://clinicaltrials.gov/show/NCT04279795","http://www.chictr.org.cn/showproj.aspx?proj=50380","http://www.chictr.org.cn/showproj.aspx?proj=49984","https://clinicaltrials.gov/show/NCT04279899","http://www.chictr.org.cn/showproj.aspx?proj=50273","http://www.chictr.org.cn/showproj.aspx?proj=50341","http://www.chictr.org.cn/showproj.aspx?proj=50174","http://www.chictr.org.cn/showproj.aspx?proj=30796","http://www.chictr.org.cn/showproj.aspx?proj=50323","http://www.chictr.org.cn/showproj.aspx?proj=50325","https://clinicaltrials.gov/show/NCT04279197","https://clinicaltrials.gov/show/NCT04280588","http://www.chictr.org.cn/showproj.aspx?proj=50268","http://www.chictr.org.cn/showproj.aspx?proj=50240","http://www.chictr.org.cn/showproj.aspx?proj=50214","http://www.chictr.org.cn/showproj.aspx?proj=50227","http://www.chictr.org.cn/showproj.aspx?proj=50248","http://www.chictr.org.cn/showproj.aspx?proj=49491","http://www.chictr.org.cn/showproj.aspx?proj=50231","http://www.chictr.org.cn/showproj.aspx?proj=50173","http://www.chictr.org.cn/showproj.aspx?proj=50278","http://www.chictr.org.cn/showproj.aspx?proj=48801","http://www.chictr.org.cn/showproj.aspx?proj=50223","http://www.chictr.org.cn/showproj.aspx?proj=50247","http://www.chictr.org.cn/showproj.aspx?proj=50329","http://www.chictr.org.cn/showproj.aspx?proj=50255","http://www.chictr.org.cn/showproj.aspx?proj=50136","http://www.chictr.org.cn/showproj.aspx?proj=50140","http://www.chictr.org.cn/showproj.aspx?proj=50119","http://www.chictr.org.cn/showproj.aspx?proj=49691","http://www.chictr.org.cn/showproj.aspx?proj=50161","http://www.chictr.org.cn/showproj.aspx?proj=49963","http://www.chictr.org.cn/showproj.aspx?proj=50130","http://www.chictr.org.cn/showproj.aspx?proj=50089","http://www.chictr.org.cn/showproj.aspx?proj=50143","http://www.chictr.org.cn/showproj.aspx?proj=50195","http://www.chictr.org.cn/showproj.aspx?proj=50107","http://www.chictr.org.cn/showproj.aspx?proj=50175","http://www.chictr.org.cn/showproj.aspx?proj=49883","http://www.chictr.org.cn/showproj.aspx?proj=49918","http://www.chictr.org.cn/showproj.aspx?proj=49887","http://www.chictr.org.cn/showproj.aspx?proj=50110","http://www.chictr.org.cn/showproj.aspx?proj=50006","http://www.chictr.org.cn/showproj.aspx?proj=50048","http://www.chictr.org.cn/showproj.aspx?proj=49797","http://www.chictr.org.cn/showproj.aspx?proj=49796","http://www.chictr.org.cn/showproj.aspx?proj=50115","http://www.chictr.org.cn/showproj.aspx?proj=49666","http://www.chictr.org.cn/showproj.aspx?proj=49855","http://www.chictr.org.cn/showproj.aspx?proj=49301","http://www.chictr.org.cn/showproj.aspx?proj=49945","http://www.chictr.org.cn/showproj.aspx?proj=49250","http://www.chictr.org.cn/showproj.aspx?proj=50026","http://www.chictr.org.cn/showproj.aspx?proj=49630","http://www.chictr.org.cn/showproj.aspx?proj=49377","http://www.chictr.org.cn/showproj.aspx?proj=49914","http://www.chictr.org.cn/showproj.aspx?proj=49899","http://www.chictr.org.cn/showproj.aspx?proj=49592","http://www.chictr.org.cn/showproj.aspx?proj=49400","http://www.chictr.org.cn/showproj.aspx?proj=49404","http://www.chictr.org.cn/showproj.aspx?proj=49570","http://www.chictr.org.cn/showproj.aspx?proj=49352","http://www.chictr.org.cn/showproj.aspx?proj=48782","http://www.chictr.org.cn/showproj.aspx?proj=49536","http://www.chictr.org.cn/showproj.aspx?proj=48777","http://www.chictr.org.cn/showproj.aspx?proj=49369","http://www.chictr.org.cn/showproj.aspx?proj=49482","http://www.chictr.org.cn/showproj.aspx?proj=49520","http://www.chictr.org.cn/showproj.aspx?proj=49708","http://www.chictr.org.cn/showproj.aspx?proj=49790","https://clinicaltrials.gov/show/NCT04286503","http://www.chictr.org.cn/showproj.aspx?proj=50394","http://www.chictr.org.cn/showproj.aspx?proj=49953","http://www.chictr.org.cn/showproj.aspx?proj=44213","http://www.chictr.org.cn/showproj.aspx?proj=50672","http://www.chictr.org.cn/showproj.aspx?proj=49632","http://www.chictr.org.cn/showproj.aspx?proj=50608","http://www.chictr.org.cn/showproj.aspx?proj=50658","https://clinicaltrials.gov/show/NCT04276987","http://www.chictr.org.cn/showproj.aspx?proj=50228","https://clinicaltrials.gov/show/NCT04281693","https://clinicaltrials.gov/show/NCT04282902","http://www.chictr.org.cn/showproj.aspx?proj=50549","http://www.chictr.org.cn/showproj.aspx?proj=50507","http://www.chictr.org.cn/showproj.aspx?proj=50583","http://www.chictr.org.cn/showproj.aspx?proj=50459","http://www.chictr.org.cn/showproj.aspx?proj=50487","http://www.chictr.org.cn/showproj.aspx?proj=50667","http://www.chictr.org.cn/showproj.aspx?proj=49753","http://www.chictr.org.cn/showproj.aspx?proj=50453","http://www.chictr.org.cn/showproj.aspx?proj=50541","http://www.chictr.org.cn/showproj.aspx?proj=50421","http://www.chictr.org.cn/showproj.aspx?proj=50623","https://clinicaltrials.gov/show/NCT04284046","https://clinicaltrials.gov/show/NCT04285190","http://www.chictr.org.cn/showproj.aspx?proj=50378","http://www.chictr.org.cn/showproj.aspx?proj=50727","http://www.chictr.org.cn/showproj.aspx?proj=50082","http://www.chictr.org.cn/showproj.aspx?proj=50586","http://www.chictr.org.cn/showproj.aspx?proj=50390","http://www.chictr.org.cn/showproj.aspx?proj=50692","http://www.chictr.org.cn/showproj.aspx?proj=50552","http://www.chictr.org.cn/showproj.aspx?proj=50388","http://www.chictr.org.cn/showproj.aspx?proj=50690","http://www.chictr.org.cn/showproj.aspx?proj=50381","http://www.chictr.org.cn/showproj.aspx?proj=50490","http://www.chictr.org.cn/showproj.aspx?proj=49802","http://www.chictr.org.cn/showproj.aspx?proj=50653","http://www.chictr.org.cn/showproj.aspx?proj=50258","http://www.chictr.org.cn/showproj.aspx?proj=50263","http://www.chictr.org.cn/showproj.aspx?proj=49088","http://www.chictr.org.cn/showproj.aspx?proj=49653","http://www.chictr.org.cn/showproj.aspx?proj=50134","http://www.chictr.org.cn/showproj.aspx?proj=50353","http://www.chictr.org.cn/showproj.aspx?proj=50547","http://www.chictr.org.cn/showproj.aspx?proj=48775","http://www.chictr.org.cn/showproj.aspx?proj=50452","http://www.chictr.org.cn/showproj.aspx?proj=50470","http://www.chictr.org.cn/showproj.aspx?proj=49014","http://www.chictr.org.cn/showproj.aspx?proj=50382","http://www.chictr.org.cn/showproj.aspx?proj=50031","http://www.chictr.org.cn/showproj.aspx?proj=50450","http://www.chictr.org.cn/showproj.aspx?proj=48773","http://www.chictr.org.cn/showproj.aspx?proj=50458","http://www.chictr.org.cn/showproj.aspx?proj=49435","http://www.chictr.org.cn/showproj.aspx?proj=50297","http://www.chictr.org.cn/showproj.aspx?proj=51028","http://www.chictr.org.cn/showproj.aspx?proj=49224","http://www.chictr.org.cn/showproj.aspx?proj=49635","http://www.chictr.org.cn/showproj.aspx?proj=51034","https://clinicaltrials.gov/show/NCT04292327","https://clinicaltrials.gov/show/NCT04295551","http://www.chictr.org.cn/showproj.aspx?proj=49045","http://www.chictr.org.cn/showproj.aspx?proj=51126","http://www.chictr.org.cn/showproj.aspx?proj=49081","http://www.chictr.org.cn/showproj.aspx?proj=48684","http://www.chictr.org.cn/showproj.aspx?proj=51073","http://www.chictr.org.cn/showproj.aspx?proj=50767","http://www.chictr.org.cn/showproj.aspx?proj=51107","https://clinicaltrials.gov/show/NCT04296643","https://clinicaltrials.gov/show/NCT04299711","https://clinicaltrials.gov/show/NCT04298814","http://www.chictr.org.cn/showproj.aspx?proj=50780","https://clinicaltrials.gov/show/NCT04292340","https://clinicaltrials.gov/show/NCT04293887","http://www.chictr.org.cn/showproj.aspx?proj=50462","http://www.chictr.org.cn/showproj.aspx?proj=50299","http://www.chictr.org.cn/showproj.aspx?proj=51103","http://www.chictr.org.cn/showproj.aspx?proj=51130","http://www.chictr.org.cn/showproj.aspx?proj=51102","http://www.chictr.org.cn/showproj.aspx?proj=51064","http://www.chictr.org.cn/showproj.aspx?proj=50662","http://www.chictr.org.cn/showproj.aspx?proj=51118","http://www.chictr.org.cn/showproj.aspx?proj=51083","http://www.chictr.org.cn/showproj.aspx?proj=50947","http://www.chictr.org.cn/showproj.aspx?proj=51025","http://www.chictr.org.cn/showproj.aspx?proj=51081","http://www.chictr.org.cn/showproj.aspx?proj=50960","http://www.chictr.org.cn/showproj.aspx?proj=50986","http://www.chictr.org.cn/showproj.aspx?proj=49933","http://www.chictr.org.cn/showproj.aspx?proj=51077","http://www.chictr.org.cn/showproj.aspx?proj=51040","http://www.chictr.org.cn/showproj.aspx?proj=51097","http://www.chictr.org.cn/showproj.aspx?proj=51090","http://www.chictr.org.cn/showproj.aspx?proj=51071","http://www.chictr.org.cn/showproj.aspx?proj=51015","http://www.chictr.org.cn/showproj.aspx?proj=51091","http://www.chictr.org.cn/showproj.aspx?proj=51054","http://www.chictr.org.cn/showproj.aspx?proj=51056","http://www.chictr.org.cn/showproj.aspx?proj=51050","http://www.chictr.org.cn/showproj.aspx?proj=51086","http://www.chictr.org.cn/showproj.aspx?proj=51035","http://www.chictr.org.cn/showproj.aspx?proj=51047","http://www.chictr.org.cn/showproj.aspx?proj=50982","http://www.chictr.org.cn/showproj.aspx?proj=51072","http://www.chictr.org.cn/showproj.aspx?proj=50904","http://www.chictr.org.cn/showproj.aspx?proj=51036","http://www.chictr.org.cn/showproj.aspx?proj=50987","http://www.chictr.org.cn/showproj.aspx?proj=51039","http://www.chictr.org.cn/showproj.aspx?proj=51044","http://www.chictr.org.cn/showproj.aspx?proj=51048","http://www.chictr.org.cn/showproj.aspx?proj=51037","http://www.chictr.org.cn/showproj.aspx?proj=49284","http://www.chictr.org.cn/showproj.aspx?proj=51042","http://www.chictr.org.cn/showproj.aspx?proj=51009","http://www.chictr.org.cn/showproj.aspx?proj=51019","http://www.chictr.org.cn/showproj.aspx?proj=51029","http://www.chictr.org.cn/showproj.aspx?proj=50590","http://www.chictr.org.cn/showproj.aspx?proj=51026","http://www.chictr.org.cn/showproj.aspx?proj=51007","http://www.chictr.org.cn/showproj.aspx?proj=51018","http://www.chictr.org.cn/showproj.aspx?proj=50648","http://www.chictr.org.cn/showproj.aspx?proj=50994","http://www.chictr.org.cn/showproj.aspx?proj=51004","http://www.chictr.org.cn/showproj.aspx?proj=50705","http://www.chictr.org.cn/showproj.aspx?proj=50991","http://www.chictr.org.cn/showproj.aspx?proj=50998","http://www.chictr.org.cn/showproj.aspx?proj=50995","http://www.chictr.org.cn/showproj.aspx?proj=50997","http://www.chictr.org.cn/showproj.aspx?proj=50976","http://www.chictr.org.cn/showproj.aspx?proj=50988","http://www.chictr.org.cn/showproj.aspx?proj=50857","http://www.chictr.org.cn/showproj.aspx?proj=50307","http://www.chictr.org.cn/showproj.aspx?proj=50934","http://www.chictr.org.cn/showproj.aspx?proj=50973","http://www.chictr.org.cn/showproj.aspx?proj=50852","http://www.chictr.org.cn/showproj.aspx?proj=50968","http://www.chictr.org.cn/showproj.aspx?proj=50921","http://www.chictr.org.cn/showproj.aspx?proj=50907","http://www.chictr.org.cn/showproj.aspx?proj=50950","http://www.chictr.org.cn/showproj.aspx?proj=50941","http://www.chictr.org.cn/showproj.aspx?proj=50956","http://www.chictr.org.cn/showproj.aspx?proj=50955","http://www.chictr.org.cn/showproj.aspx?proj=50900","http://www.chictr.org.cn/showproj.aspx?proj=50945","http://www.chictr.org.cn/showproj.aspx?proj=50901","http://www.chictr.org.cn/showproj.aspx?proj=50843","http://www.chictr.org.cn/showproj.aspx?proj=50083","http://www.chictr.org.cn/showproj.aspx?proj=50824","http://www.chictr.org.cn/showproj.aspx?proj=50910","http://www.chictr.org.cn/showproj.aspx?proj=50860","http://www.chictr.org.cn/showproj.aspx?proj=50160","http://www.chictr.org.cn/showproj.aspx?proj=50925","http://www.chictr.org.cn/showproj.aspx?proj=50896","http://www.chictr.org.cn/showproj.aspx?proj=50850","http://www.chictr.org.cn/showproj.aspx?proj=50759","http://www.chictr.org.cn/showproj.aspx?proj=50001","http://www.chictr.org.cn/showproj.aspx?proj=50867","http://www.chictr.org.cn/showproj.aspx?proj=50795","http://www.chictr.org.cn/showproj.aspx?proj=50000","http://www.chictr.org.cn/showproj.aspx?proj=50251","http://www.chictr.org.cn/showproj.aspx?proj=50261","http://www.chictr.org.cn/showproj.aspx?proj=50786","http://www.chictr.org.cn/showproj.aspx?proj=50338","http://www.chictr.org.cn/showproj.aspx?proj=50693","http://www.chictr.org.cn/showproj.aspx?proj=50572","http://www.chictr.org.cn/showproj.aspx?proj=50633","http://www.chictr.org.cn/showproj.aspx?proj=50793","http://www.chictr.org.cn/showproj.aspx?proj=50678","http://www.chictr.org.cn/showproj.aspx?proj=50126","http://www.chictr.org.cn/showproj.aspx?proj=50763","http://www.chictr.org.cn/showproj.aspx?proj=50387","http://www.chictr.org.cn/showproj.aspx?proj=49779","http://www.chictr.org.cn/showproj.aspx?proj=50537","http://www.chictr.org.cn/showproj.aspx?proj=50306","http://www.chictr.org.cn/showproj.aspx?proj=50656","http://www.chictr.org.cn/showproj.aspx?proj=50495","http://www.chictr.org.cn/showproj.aspx?proj=50222","http://www.chictr.org.cn/showproj.aspx?proj=50781","http://www.chictr.org.cn/showproj.aspx?proj=49987","http://www.chictr.org.cn/showproj.aspx?proj=50460","http://www.chictr.org.cn/showproj.aspx?proj=50071","http://www.chictr.org.cn/showproj.aspx?proj=49915","http://www.chictr.org.cn/showproj.aspx?proj=49864","http://www.chictr.org.cn/showproj.aspx?proj=49712","http://www.chictr.org.cn/showproj.aspx?proj=50057","http://www.chictr.org.cn/showproj.aspx?proj=50714","http://www.chictr.org.cn/showproj.aspx?proj=49806","http://www.chictr.org.cn/showproj.aspx?proj=49633","http://www.chictr.org.cn/showproj.aspx?proj=49669","http://www.chictr.org.cn/showproj.aspx?proj=49569","http://www.chictr.org.cn/showproj.aspx?proj=49069","http://www.chictr.org.cn/showproj.aspx?proj=49384","http://www.chictr.org.cn/showproj.aspx?proj=49495","http://www.chictr.org.cn/showproj.aspx?proj=49374","http://www.chictr.org.cn/showproj.aspx?proj=50730","http://www.chictr.org.cn/showproj.aspx?proj=49481","http://www.chictr.org.cn/showproj.aspx?proj=50713","http://www.chictr.org.cn/showproj.aspx?proj=50702","http://www.chictr.org.cn/showproj.aspx?proj=49492","http://www.chictr.org.cn/showproj.aspx?proj=50641","http://www.chictr.org.cn/showproj.aspx?proj=49956","http://www.chictr.org.cn/showproj.aspx?proj=50455","http://www.chictr.org.cn/showproj.aspx?proj=50279","https://clinicaltrials.gov/show/NCT04302519","http://www.chictr.org.cn/showproj.aspx?proj=51390","https://clinicaltrials.gov/show/NCT04264533","https://clinicaltrials.gov/show/NCT04308187","https://clinicaltrials.gov/show/NCT04307693","http://www.chictr.org.cn/showproj.aspx?proj=51185","http://www.chictr.org.cn/showproj.aspx?proj=50290","http://www.chictr.org.cn/showproj.aspx?proj=50002","http://www.chictr.org.cn/showproj.aspx?proj=50605","http://www.chictr.org.cn/showproj.aspx?proj=49948","http://www.chictr.org.cn/showproj.aspx?proj=51416","http://www.chictr.org.cn/showproj.aspx?proj=51032","http://www.chictr.org.cn/showproj.aspx?proj=51132","http://www.chictr.org.cn/showproj.aspx?proj=51148","http://www.chictr.org.cn/showproj.aspx?proj=51338","http://www.chictr.org.cn/showproj.aspx?proj=49382","http://www.chictr.org.cn/showproj.aspx?proj=49389","http://www.chictr.org.cn/showproj.aspx?proj=51331","http://www.chictr.org.cn/showproj.aspx?proj=51349","http://www.chictr.org.cn/showproj.aspx?proj=49412","http://www.chictr.org.cn/showproj.aspx?proj=50984","http://www.chictr.org.cn/showproj.aspx?proj=51000","http://www.chictr.org.cn/showproj.aspx?proj=51316","http://www.chictr.org.cn/showproj.aspx?proj=51348","http://www.chictr.org.cn/showproj.aspx?proj=51059","http://www.chictr.org.cn/showproj.aspx?proj=51267","http://www.chictr.org.cn/showproj.aspx?proj=51291","http://www.chictr.org.cn/showproj.aspx?proj=51141","https://clinicaltrials.gov/show/NCT04285801","https://clinicaltrials.gov/show/NCT04299724","http://www.chictr.org.cn/showproj.aspx?proj=51265","http://www.chictr.org.cn/showproj.aspx?proj=51278","http://www.chictr.org.cn/showproj.aspx?proj=51272","http://www.chictr.org.cn/showproj.aspx?proj=51184","http://www.chictr.org.cn/showproj.aspx?proj=50898","http://www.chictr.org.cn/showproj.aspx?proj=51154","https://clinicaltrials.gov/show/NCT04302688","http://www.chictr.org.cn/showproj.aspx?proj=51021","http://www.chictr.org.cn/showproj.aspx?proj=51230","http://www.chictr.org.cn/showproj.aspx?proj=51160","http://www.chictr.org.cn/showproj.aspx?proj=50604","http://www.chictr.org.cn/showproj.aspx?proj=51404","http://www.chictr.org.cn/showproj.aspx?proj=51212","http://www.chictr.org.cn/showproj.aspx?proj=50696","http://www.chictr.org.cn/showproj.aspx?proj=50137","http://www.chictr.org.cn/showproj.aspx?proj=51136","http://www.chictr.org.cn/showproj.aspx?proj=49968","http://www.chictr.org.cn/showproj.aspx?proj=51342","http://www.chictr.org.cn/showproj.aspx?proj=50961","http://www.chictr.org.cn/showproj.aspx?proj=50476","http://www.chictr.org.cn/showproj.aspx?proj=50964","http://www.chictr.org.cn/showproj.aspx?proj=49433","http://www.chictr.org.cn/showproj.aspx?proj=49531","http://www.chictr.org.cn/showproj.aspx?proj=51329","http://www.chictr.org.cn/showproj.aspx?proj=49074","http://www.chictr.org.cn/showproj.aspx?proj=49511","http://www.chictr.org.cn/showproj.aspx?proj=51311","http://www.chictr.org.cn/showproj.aspx?proj=49065","http://www.chictr.org.cn/showproj.aspx?proj=51283","http://www.chictr.org.cn/showproj.aspx?proj=48809","http://www.chictr.org.cn/showproj.aspx?proj=50199","http://www.chictr.org.cn/showproj.aspx?proj=50981","https://clinicaltrials.gov/show/NCT04263402","https://clinicaltrials.gov/show/NCT04273763","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25","http://www.chictr.org.cn/showproj.aspx?proj=51149","https://clinicaltrials.gov/show/NCT04251767","https://clinicaltrials.gov/show/NCT04254874","http://www.chictr.org.cn/showproj.aspx?proj=50660","http://www.chictr.org.cn/showproj.aspx?proj=49845","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045268","http://www.chictr.org.cn/showproj.aspx?proj=49524","https://clinicaltrials.gov/show/NCT04283396","https://clinicaltrials.gov/show/NCT04287686","https://clinicaltrials.gov/show/NCT04255017","https://clinicaltrials.gov/show/NCT04261270","https://jrct.niph.go.jp/latest-detail/jRCTs041190120","https://clinicaltrials.gov/show/NCT04276896","https://clinicaltrials.gov/show/NCT04291053","https://clinicaltrials.gov/show/NCT04264858","https://clinicaltrials.gov/show/NCT04278963","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045453","https://clinicaltrials.gov/show/NCT04293692","https://clinicaltrials.gov/show/NCT04305574","https://clinicaltrials.gov/show/NCT04308317","https://clinicaltrials.gov/show/NCT04312464","https://clinicaltrials.gov/show/NCT04313322","https://clinicaltrials.gov/show/NCT04272710","https://clinicaltrials.gov/show/NCT04304313","https://clinicaltrials.gov/show/NCT04306705","https://clinicaltrials.gov/show/NCT04292964","https://clinicaltrials.gov/show/NCT04306497","https://clinicaltrials.gov/show/NCT04312100","https://clinicaltrials.gov/show/NCT04310865","https://clinicaltrials.gov/show/NCT04311398","http://www.chictr.org.cn/showproj.aspx?proj=51692","http://www.chictr.org.cn/showproj.aspx?proj=51694","https://clinicaltrials.gov/show/NCT04314232","https://clinicaltrials.gov/show/NCT04314817","https://clinicaltrials.gov/show/NCT04316884","https://clinicaltrials.gov/show/NCT04318418","http://www.chictr.org.cn/showproj.aspx?proj=51499","https://clinicaltrials.gov/show/NCT04314271","https://clinicaltrials.gov/show/NCT04315870","http://www.chictr.org.cn/showproj.aspx?proj=51385","http://www.chictr.org.cn/showproj.aspx?proj=51647","http://www.chictr.org.cn/showproj.aspx?proj=51504","http://www.chictr.org.cn/showproj.aspx?proj=51517","http://www.chictr.org.cn/showproj.aspx?proj=51667","http://www.chictr.org.cn/showproj.aspx?proj=51668","http://www.chictr.org.cn/showproj.aspx?proj=51425","https://clinicaltrials.gov/show/NCT04316728","http://www.chictr.org.cn/showproj.aspx?proj=51170","http://www.chictr.org.cn/showproj.aspx?proj=51584","http://www.chictr.org.cn/showproj.aspx?proj=51669","http://www.chictr.org.cn/showproj.aspx?proj=51629","http://www.chictr.org.cn/showproj.aspx?proj=51455","http://www.chictr.org.cn/showproj.aspx?proj=51194","http://www.chictr.org.cn/showproj.aspx?proj=51603","http://www.chictr.org.cn/showproj.aspx?proj=51559","http://www.chictr.org.cn/showproj.aspx?proj=51540","http://www.chictr.org.cn/showproj.aspx?proj=51518","http://www.chictr.org.cn/showproj.aspx?proj=49420","http://www.chictr.org.cn/showproj.aspx?proj=51535","http://www.chictr.org.cn/showproj.aspx?proj=51442","http://www.chictr.org.cn/showproj.aspx?proj=51473","http://www.chictr.org.cn/showproj.aspx?proj=51509","http://www.chictr.org.cn/showproj.aspx?proj=51486","http://www.chictr.org.cn/showproj.aspx?proj=51488","http://www.chictr.org.cn/showproj.aspx?proj=51030","http://www.chictr.org.cn/showproj.aspx?proj=51100","http://www.chictr.org.cn/showproj.aspx?proj=51112","http://www.chictr.org.cn/showproj.aspx?proj=51061","http://www.chictr.org.cn/showproj.aspx?proj=51139","http://www.chictr.org.cn/showproj.aspx?proj=51240","http://www.chictr.org.cn/showproj.aspx?proj=51443","http://www.chictr.org.cn/showproj.aspx?proj=51317","http://www.chictr.org.cn/showproj.aspx?proj=50778","http://www.chictr.org.cn/showproj.aspx?proj=51254","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12","http://www.chictr.org.cn/showproj.aspx?proj=50274","http://www.chictr.org.cn/showproj.aspx?proj=49840","http://www.chictr.org.cn/showproj.aspx?proj=50202","http://www.chictr.org.cn/showproj.aspx?proj=50078","http://www.chictr.org.cn/showproj.aspx?proj=51239","https://clinicaltrials.gov/show/NCT04319211","https://clinicaltrials.gov/show/NCT04320056","http://www.chictr.org.cn/showproj.aspx?proj=50066","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001243-15","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000919-69","https://clinicaltrials.gov/show/NCT04320277","https://clinicaltrials.gov/show/NCT04321174","https://clinicaltrials.gov/show/NCT04315948","https://clinicaltrials.gov/show/NCT04319900","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33","http://www.chictr.org.cn/showproj.aspx?proj=50631","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14","http://www.chictr.org.cn/showproj.aspx?proj=49724","https://clinicaltrials.gov/show/NCT04321421","https://clinicaltrials.gov/show/NCT04323332","https://clinicaltrials.gov/show/NCT04320017","https://clinicaltrials.gov/show/NCT04323514","https://clinicaltrials.gov/show/NCT04305106","https://clinicaltrials.gov/show/NCT04321928","https://clinicaltrials.gov/show/NCT04323345","https://clinicaltrials.gov/show/NCT04323592","https://clinicaltrials.gov/show/NCT04323631","https://clinicaltrials.gov/show/NCT04325919","https://clinicaltrials.gov/show/NCT04061382","https://clinicaltrials.gov/show/NCT04288713","https://clinicaltrials.gov/show/NCT04322786","https://clinicaltrials.gov/show/NCT04324996","https://clinicaltrials.gov/show/NCT04324463","https://clinicaltrials.gov/show/NCT04324866","https://clinicaltrials.gov/show/NCT04290871","https://clinicaltrials.gov/show/NCT04303507","https://clinicaltrials.gov/show/NCT04325412","https://clinicaltrials.gov/show/NCT04326309","https://clinicaltrials.gov/show/NCT04331860","http://isrctn.com/ISRCTN14966673","https://clinicaltrials.gov/show/NCT04327570","http://www.chictr.org.cn/showproj.aspx?proj=51893","http://www.chictr.org.cn/showproj.aspx?proj=51865","https://clinicaltrials.gov/show/NCT04316299","https://clinicaltrials.gov/show/NCT04318314","http://www.chictr.org.cn/showproj.aspx?proj=51119","http://www.chictr.org.cn/showproj.aspx?proj=51835","http://www.chictr.org.cn/showproj.aspx?proj=51904","http://www.chictr.org.cn/showproj.aspx?proj=51911","http://www.chictr.org.cn/showproj.aspx?proj=50254","http://www.chictr.org.cn/showproj.aspx?proj=51478","https://clinicaltrials.gov/show/NCT04318444","https://clinicaltrials.gov/show/NCT04322344","http://www.chictr.org.cn/showproj.aspx?proj=51538","http://www.chictr.org.cn/showproj.aspx?proj=51897","https://clinicaltrials.gov/show/NCT04323644","http://www.chictr.org.cn/showproj.aspx?proj=50474","http://www.chictr.org.cn/showproj.aspx?proj=51693","http://www.chictr.org.cn/showproj.aspx?proj=51646","http://www.chictr.org.cn/showproj.aspx?proj=51837","http://www.chictr.org.cn/showproj.aspx?proj=49254","http://www.chictr.org.cn/showproj.aspx?proj=51969","http://www.chictr.org.cn/showproj.aspx?proj=51813","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23","http://www.chictr.org.cn/showproj.aspx?proj=51952","http://www.chictr.org.cn/showproj.aspx?proj=51724","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001386-37","http://www.chictr.org.cn/showproj.aspx?proj=51684","http://www.chictr.org.cn/showproj.aspx?proj=51938","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001345-38","http://www.chictr.org.cn/showproj.aspx?proj=51781","http://www.chictr.org.cn/showproj.aspx?proj=51915","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001271-33","http://www.chictr.org.cn/showproj.aspx?proj=51859","https://anzctr.org.au/ACTRN12620000417987.aspx","http://www.chictr.org.cn/showproj.aspx?proj=51815","http://www.chictr.org.cn/showproj.aspx?proj=51816","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001281-11","http://www.chictr.org.cn/showproj.aspx?proj=51809","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001275-32","https://clinicaltrials.gov/show/NCT03331445","https://clinicaltrials.gov/show/NCT04298060","https://clinicaltrials.gov/show/NCT04275414","https://clinicaltrials.gov/show/NCT04315298","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001236-10","https://clinicaltrials.gov/show/NCT04318366","https://clinicaltrials.gov/show/NCT04321811","https://clinicaltrials.gov/show/NCT04320238","https://clinicaltrials.gov/show/NCT04321278","https://clinicaltrials.gov/show/NCT04312243","https://clinicaltrials.gov/show/NCT04316377","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001010-38","https://anzctr.org.au/ACTRN12620000421932.aspx","https://clinicaltrials.gov/show/NCT04322188","https://clinicaltrials.gov/show/NCT04326452","https://clinicaltrials.gov/show/NCT04321096","https://clinicaltrials.gov/show/NCT04324489","https://clinicaltrials.gov/show/NCT04324047","https://clinicaltrials.gov/show/NCT04325867","https://clinicaltrials.gov/show/NCT04326075","https://clinicaltrials.gov/show/NCT04326114","https://clinicaltrials.gov/show/NCT04324528","https://clinicaltrials.gov/show/NCT04328272","https://clinicaltrials.gov/show/NCT04328480","https://clinicaltrials.gov/show/NCT04328493","https://clinicaltrials.gov/show/NCT04326426","https://clinicaltrials.gov/show/NCT04326920","https://clinicaltrials.gov/show/NCT04280705","https://clinicaltrials.gov/show/NCT04313946","https://clinicaltrials.gov/show/NCT04326790","https://clinicaltrials.gov/show/NCT04327505","https://clinicaltrials.gov/show/NCT04327531","https://clinicaltrials.gov/show/NCT04328441","https://clinicaltrials.gov/show/NCT04320511","https://clinicaltrials.gov/show/NCT04320732","https://clinicaltrials.gov/show/NCT04329507","https://clinicaltrials.gov/show/NCT04330144","https://clinicaltrials.gov/show/NCT04328961","https://clinicaltrials.gov/show/NCT04330261","https://clinicaltrials.gov/show/NCT04330586","https://clinicaltrials.gov/show/NCT04330599","https://clinicaltrials.gov/show/NCT04323878","https://clinicaltrials.gov/show/NCT04325646","https://clinicaltrials.gov/show/NCT04330521","https://clinicaltrials.gov/show/NCT04331613","https://clinicaltrials.gov/show/NCT04331574","https://clinicaltrials.gov/show/NCT04332016","https://clinicaltrials.gov/show/NCT04325906","https://clinicaltrials.gov/show/NCT04326036","https://clinicaltrials.gov/show/NCT04332835","https://clinicaltrials.gov/show/NCT04333251","https://clinicaltrials.gov/show/NCT04327180","https://clinicaltrials.gov/show/NCT04327349","https://clinicaltrials.gov/show/NCT04331899","https://clinicaltrials.gov/show/NCT04333862","https://clinicaltrials.gov/show/NCT04332666","https://clinicaltrials.gov/show/NCT04333550","https://clinicaltrials.gov/show/NCT04327674","https://clinicaltrials.gov/show/NCT04328454","https://clinicaltrials.gov/show/NCT04333693","https://clinicaltrials.gov/show/NCT04334967","https://clinicaltrials.gov/show/NCT04334629","https://clinicaltrials.gov/show/NCT04334850","https://anzctr.org.au/ACTRN12620000438954.aspx","https://clinicaltrials.gov/show/NCT04329559","https://clinicaltrials.gov/show/NCT04331600","https://anzctr.org.au/ACTRN12620000449932.aspx","https://anzctr.org.au/ACTRN12620000457943.aspx","https://clinicaltrials.gov/show/NCT04335019","https://clinicaltrials.gov/show/NCT04335084","https://clinicaltrials.gov/show/NCT04335279","https://anzctr.org.au/ACTRN12620000443998.aspx","https://anzctr.org.au/ACTRN12620000454976.aspx","https://clinicaltrials.gov/show/NCT04335201","https://anzctr.org.au/ACTRN12620000448943.aspx","https://clinicaltrials.gov/show/NCT04332380","https://clinicaltrials.gov/show/NCT04333355","http://www.chictr.org.cn/showproj.aspx?proj=52213","http://www.chictr.org.cn/showproj.aspx?proj=52193","http://www.chictr.org.cn/showproj.aspx?proj=52165","https://clinicaltrials.gov/show/NCT04333472","https://anzctr.org.au/ACTRN12620000444987.aspx","https://anzctr.org.au/ACTRN12620000447954.aspx","http://www.chictr.org.cn/showproj.aspx?proj=52148","http://www.chictr.org.cn/showproj.aspx?proj=51934","http://www.chictr.org.cn/showproj.aspx?proj=51832","http://www.chictr.org.cn/showproj.aspx?proj=52006","http://www.chictr.org.cn/showproj.aspx?proj=52135","http://www.chictr.org.cn/showproj.aspx?proj=52198","http://www.chictr.org.cn/showproj.aspx?proj=52103","http://www.chictr.org.cn/showproj.aspx?proj=52130","http://www.chictr.org.cn/showproj.aspx?proj=52051","http://www.chictr.org.cn/showproj.aspx?proj=52079","http://www.chictr.org.cn/showproj.aspx?proj=51793","http://www.chictr.org.cn/showproj.aspx?proj=52216","http://www.chictr.org.cn/showproj.aspx?proj=52052","http://www.chictr.org.cn/showproj.aspx?proj=50241","http://www.chictr.org.cn/showproj.aspx?proj=50613","http://www.chictr.org.cn/showproj.aspx?proj=51924","http://www.chictr.org.cn/showproj.aspx?proj=51940","http://www.chictr.org.cn/showproj.aspx?proj=52037","http://www.chictr.org.cn/showproj.aspx?proj=50928","http://www.chictr.org.cn/showproj.aspx?proj=50077","http://www.chictr.org.cn/showproj.aspx?proj=50271","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001250-21","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001381-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001301-23","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001335-28","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001373-70","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001409-21","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001492-33","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001442-19","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001194-69","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001421-31","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001565-37","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001606-33","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16","https://clinicaltrials.gov/show/NCT03680274","https://clinicaltrials.gov/show/NCT03808922","https://clinicaltrials.gov/show/NCT04244591","https://clinicaltrials.gov/show/NCT04252274","https://clinicaltrials.gov/show/NCT03042143","https://clinicaltrials.gov/show/NCT04274322","https://clinicaltrials.gov/show/NCT04252664","https://clinicaltrials.gov/show/NCT04261517","https://clinicaltrials.gov/show/NCT04252118","https://clinicaltrials.gov/show/NCT04273321","https://clinicaltrials.gov/show/NCT03891420","https://clinicaltrials.gov/show/NCT04245631","https://clinicaltrials.gov/show/NCT04276688","https://clinicaltrials.gov/show/NCT04291729","https://clinicaltrials.gov/show/NCT04273646","https://clinicaltrials.gov/show/NCT04304690","https://clinicaltrials.gov/show/NCT04257656","https://clinicaltrials.gov/show/NCT04280224","https://clinicaltrials.gov/show/NCT04283461","https://clinicaltrials.gov/show/NCT04288102","https://clinicaltrials.gov/show/NCT04299152","https://clinicaltrials.gov/show/NCT04303299","https://clinicaltrials.gov/show/NCT04312997","https://clinicaltrials.gov/show/NCT04313127","https://clinicaltrials.gov/show/NCT04290780","https://clinicaltrials.gov/show/NCT04302766","https://clinicaltrials.gov/show/NCT04292730","https://clinicaltrials.gov/show/NCT04292899","https://clinicaltrials.gov/show/NCT04305457","https://clinicaltrials.gov/show/NCT04306393","https://clinicaltrials.gov/show/NCT04311177","https://clinicaltrials.gov/show/NCT04311697","https://clinicaltrials.gov/show/NCT04317092","https://clinicaltrials.gov/show/NCT04318301","https://clinicaltrials.gov/show/NCT04308668","https://clinicaltrials.gov/show/NCT04310228","https://clinicaltrials.gov/show/NCT04304053","https://clinicaltrials.gov/show/NCT04306055","https://clinicaltrials.gov/show/NCT04312009","https://clinicaltrials.gov/show/NCT04313023","https://clinicaltrials.gov/show/NCT04315987","https://clinicaltrials.gov/show/NCT04319016","https://clinicaltrials.gov/show/NCT04320472","https://clinicaltrials.gov/show/NCT04322123","https://clinicaltrials.gov/show/NCT04319315","https://clinicaltrials.gov/show/NCT04320953","https://clinicaltrials.gov/show/NCT04315480","https://clinicaltrials.gov/show/NCT04315896","https://clinicaltrials.gov/show/NCT04319445","https://clinicaltrials.gov/show/NCT04321616","https://clinicaltrials.gov/show/NCT04322396","https://clinicaltrials.gov/show/NCT04323761","https://clinicaltrials.gov/show/NCT04317040","https://clinicaltrials.gov/show/NCT04318015","https://clinicaltrials.gov/show/NCT04323787","https://clinicaltrials.gov/show/NCT04323800","https://clinicaltrials.gov/show/NCT04320615","https://clinicaltrials.gov/show/NCT04320862","https://clinicaltrials.gov/show/NCT04322487","https://clinicaltrials.gov/show/NCT04322565","https://clinicaltrials.gov/show/NCT04321265","https://clinicaltrials.gov/show/NCT04322682","https://clinicaltrials.gov/show/NCT04323839","https://clinicaltrials.gov/show/NCT04325061","https://clinicaltrials.gov/show/NCT04321369","https://clinicaltrials.gov/show/NCT04321993","https://clinicaltrials.gov/show/NCT04324073","https://clinicaltrials.gov/show/NCT04324190","https://clinicaltrials.gov/show/NCT04322773","https://clinicaltrials.gov/show/NCT04323228","https://clinicaltrials.gov/show/NCT04322513","https://clinicaltrials.gov/show/NCT04324021","https://clinicaltrials.gov/show/NCT04324736","https://clinicaltrials.gov/show/NCT04325672","https://clinicaltrials.gov/show/NCT04327388","https://clinicaltrials.gov/show/NCT04327401","https://clinicaltrials.gov/show/NCT04324606","https://clinicaltrials.gov/show/NCT04324684","https://clinicaltrials.gov/show/NCT04325048","https://clinicaltrials.gov/show/NCT04325633","https://clinicaltrials.gov/show/NCT04326725","https://clinicaltrials.gov/show/NCT04327206","https://clinicaltrials.gov/show/NCT04325893","https://clinicaltrials.gov/show/NCT04327804","https://clinicaltrials.gov/show/NCT04328285","https://clinicaltrials.gov/show/NCT04328467","https://clinicaltrials.gov/show/NCT04326387","https://clinicaltrials.gov/show/NCT04328129","https://clinicaltrials.gov/show/NCT04327479","https://clinicaltrials.gov/show/NCT04328012","https://clinicaltrials.gov/show/NCT04329572","https://clinicaltrials.gov/show/NCT04329650","https://clinicaltrials.gov/show/NCT04329533","https://clinicaltrials.gov/show/NCT04330300","https://clinicaltrials.gov/show/NCT04329832","https://clinicaltrials.gov/show/NCT04331054","https://clinicaltrials.gov/show/NCT04329546","https://clinicaltrials.gov/show/NCT04329611","https://clinicaltrials.gov/show/NCT04331106","https://clinicaltrials.gov/show/NCT04331171","https://clinicaltrials.gov/show/NCT04329923","https://clinicaltrials.gov/show/NCT04331470","https://clinicaltrials.gov/show/NCT04330495","https://clinicaltrials.gov/show/NCT04330638","https://clinicaltrials.gov/show/NCT04330690","https://clinicaltrials.gov/show/NCT04331366","https://clinicaltrials.gov/show/NCT04331509","https://clinicaltrials.gov/show/NCT04331834","https://clinicaltrials.gov/show/NCT04331665","https://clinicaltrials.gov/show/NCT04331795","https://clinicaltrials.gov/show/NCT04332107","https://clinicaltrials.gov/show/NCT04333420","https://clinicaltrials.gov/show/NCT04331808","https://clinicaltrials.gov/show/NCT04332913","https://clinicaltrials.gov/show/NCT04332094","https://clinicaltrials.gov/show/NCT04333407","https://clinicaltrials.gov/show/NCT04331886","https://clinicaltrials.gov/show/NCT04332081","https://clinicaltrials.gov/show/NCT04333732","https://clinicaltrials.gov/show/NCT04333849","https://clinicaltrials.gov/show/NCT04333589","https://clinicaltrials.gov/show/NCT04333654","https://clinicaltrials.gov/show/NCT04332991","https://clinicaltrials.gov/show/NCT04333225","https://clinicaltrials.gov/show/NCT04334148","https://clinicaltrials.gov/show/NCT04334460","https://clinicaltrials.gov/show/NCT04334252","https://clinicaltrials.gov/show/NCT04334265","https://clinicaltrials.gov/show/NCT04333628","https://clinicaltrials.gov/show/NCT04333953","https://clinicaltrials.gov/show/NCT04333914","https://clinicaltrials.gov/show/NCT04334005","https://clinicaltrials.gov/show/NCT04334291","https://clinicaltrials.gov/show/NCT04335162","https://clinicaltrials.gov/show/NCT04334044","https://clinicaltrials.gov/show/NCT04334382","https://clinicaltrials.gov/show/NCT04334512","https://clinicaltrials.gov/show/NCT04334980","https://clinicaltrials.gov/show/NCT04334928","https://clinicaltrials.gov/show/NCT04335123","https://clinicaltrials.gov/show/NCT04335188","https://clinicaltrials.gov/show/NCT04335305","https://clinicaltrials.gov/show/NCT04335032","https://clinicaltrials.gov/show/NCT04335071","https://clinicaltrials.gov/show/NCT04335630","https://clinicaltrials.gov/show/NCT04335773","https://clinicaltrials.gov/show/NCT04335851","https://clinicaltrials.gov/show/NCT04336462","https://clinicaltrials.gov/show/NCT04335747","https://clinicaltrials.gov/show/NCT04336254","https://clinicaltrials.gov/show/NCT04334434","https://clinicaltrials.gov/show/NCT04335097","https://clinicaltrials.gov/show/NCT04336215","https://clinicaltrials.gov/show/NCT04336774","https://clinicaltrials.gov/show/NCT04336332","https://clinicaltrials.gov/show/NCT04337008","https://clinicaltrials.gov/show/NCT04336657","https://clinicaltrials.gov/show/NCT04336904","https://clinicaltrials.gov/show/NCT04336956","https://clinicaltrials.gov/show/NCT04337216","https://clinicaltrials.gov/show/NCT04337151","https://clinicaltrials.gov/show/NCT04337190","https://clinicaltrials.gov/show/NCT04337047","https://clinicaltrials.gov/show/NCT04337320","https://clinicaltrials.gov/show/NCT04337502","https://clinicaltrials.gov/show/NCT04335136","https://clinicaltrials.gov/show/NCT04336345","https://clinicaltrials.gov/show/NCT04337359","https://clinicaltrials.gov/show/NCT04337996","https://clinicaltrials.gov/show/NCT04337541","https://clinicaltrials.gov/show/NCT04337762","https://clinicaltrials.gov/show/NCT04336384","https://clinicaltrials.gov/show/NCT04336410","https://clinicaltrials.gov/show/NCT04338074","https://clinicaltrials.gov/show/NCT04338100","https://clinicaltrials.gov/show/NCT04337983","https://clinicaltrials.gov/show/NCT04338828","https://clinicaltrials.gov/show/NCT04336761","https://clinicaltrials.gov/show/NCT04336787","https://clinicaltrials.gov/show/NCT04338347","https://clinicaltrials.gov/show/NCT04338672","https://clinicaltrials.gov/show/NCT04339712","https://clinicaltrials.gov/show/NCT04340349","https://clinicaltrials.gov/show/NCT04338932","https://clinicaltrials.gov/show/NCT04338945","https://clinicaltrials.gov/show/NCT04338958","https://clinicaltrials.gov/show/NCT04338698","https://clinicaltrials.gov/show/NCT04338906","https://clinicaltrials.gov/show/NCT04337346","https://clinicaltrials.gov/show/NCT04337489","https://clinicaltrials.gov/show/NCT04337788","https://clinicaltrials.gov/show/NCT04341012","https://clinicaltrials.gov/show/NCT04341038","https://clinicaltrials.gov/show/NCT04337918","https://clinicaltrials.gov/show/NCT04338009","https://clinicaltrials.gov/show/NCT04339387","https://clinicaltrials.gov/show/NCT04339608","https://clinicaltrials.gov/show/NCT04339322","https://clinicaltrials.gov/show/NCT04339660","https://clinicaltrials.gov/show/NCT04338360","https://clinicaltrials.gov/show/NCT04338568","https://clinicaltrials.gov/show/NCT04339634","https://clinicaltrials.gov/show/NCT04339816","https://clinicaltrials.gov/show/NCT04341441","https://clinicaltrials.gov/show/NCT04341480","https://clinicaltrials.gov/show/NCT04338802","https://clinicaltrials.gov/show/NCT04339426","https://clinicaltrials.gov/show/NCT04340219","https://clinicaltrials.gov/show/NCT04340544","https://clinicaltrials.gov/show/NCT04340050","https://clinicaltrials.gov/show/NCT04340466","https://clinicaltrials.gov/show/NCT04341675","https://clinicaltrials.gov/show/NCT04341688","https://clinicaltrials.gov/show/NCT04339790","https://clinicaltrials.gov/show/NCT04339998","https://clinicaltrials.gov/show/NCT04340479","https://clinicaltrials.gov/show/NCT04340921","https://clinicaltrials.gov/show/NCT04341103","https://clinicaltrials.gov/show/NCT04341168","https://clinicaltrials.gov/show/NCT04340232","https://clinicaltrials.gov/show/NCT04340414","https://clinicaltrials.gov/show/NCT04341870","https://clinicaltrials.gov/show/NCT04342104","https://clinicaltrials.gov/show/NCT04341285","https://clinicaltrials.gov/show/NCT04341493","https://clinicaltrials.gov/show/NCT04341116","https://clinicaltrials.gov/show/NCT04341142","https://clinicaltrials.gov/show/NCT04341519","https://clinicaltrials.gov/show/NCT04341610","https://clinicaltrials.gov/show/NCT04341584","https://clinicaltrials.gov/show/NCT04341766","https://clinicaltrials.gov/show/NCT04343001","https://clinicaltrials.gov/show/NCT04343183","https://clinicaltrials.gov/show/NCT04341207","https://clinicaltrials.gov/show/NCT04341389","https://clinicaltrials.gov/show/NCT04341935","https://clinicaltrials.gov/show/NCT04342169","https://clinicaltrials.gov/show/NCT04341792","https://clinicaltrials.gov/show/NCT04342195","https://clinicaltrials.gov/show/NCT04341415","https://clinicaltrials.gov/show/NCT04341506","https://clinicaltrials.gov/show/NCT04342208","https://clinicaltrials.gov/show/NCT04342221","https://clinicaltrials.gov/show/NCT04341714","https://clinicaltrials.gov/show/NCT04341922","https://clinicaltrials.gov/show/NCT04343404","https://clinicaltrials.gov/show/NCT04343651","https://clinicaltrials.gov/show/NCT04342156","https://clinicaltrials.gov/show/NCT04342182","https://clinicaltrials.gov/show/NCT04342702","https://clinicaltrials.gov/show/NCT04342728","https://clinicaltrials.gov/show/NCT04342637","https://clinicaltrials.gov/show/NCT04342650","https://clinicaltrials.gov/show/NCT04342689","https://clinicaltrials.gov/show/NCT04342806","https://clinicaltrials.gov/show/NCT04343144","https://clinicaltrials.gov/show/NCT04343261","https://clinicaltrials.gov/show/NCT04344080","https://clinicaltrials.gov/show/NCT04344730","https://clinicaltrials.gov/show/NCT04342663","https://clinicaltrials.gov/show/NCT04342884","https://clinicaltrials.gov/show/NCT04342897","https://clinicaltrials.gov/show/NCT04343248","https://clinicaltrials.gov/show/NCT04343677","https://clinicaltrials.gov/show/NCT04343768","https://clinicaltrials.gov/show/NCT04343092","https://clinicaltrials.gov/show/NCT04343729","https://clinicaltrials.gov/show/NCT04344925","https://clinicaltrials.gov/show/NCT04344938","https://clinicaltrials.gov/show/NCT04344951","https://clinicaltrials.gov/show/NCT04343742","https://clinicaltrials.gov/show/NCT04343755","https://clinicaltrials.gov/show/NCT04343794","https://clinicaltrials.gov/show/NCT04344002","https://clinicaltrials.gov/show/NCT04343339","https://clinicaltrials.gov/show/NCT04343664","https://clinicaltrials.gov/show/NCT04343963","https://clinicaltrials.gov/show/NCT04343976","https://clinicaltrials.gov/show/NCT04345159","https://clinicaltrials.gov/show/NCT04345601","https://clinicaltrials.gov/show/NCT04343690","https://clinicaltrials.gov/show/NCT04343781","https://clinicaltrials.gov/show/NCT04344171","https://clinicaltrials.gov/show/NCT04344184","https://clinicaltrials.gov/show/NCT04346017","https://clinicaltrials.gov/show/NCT04346043","https://clinicaltrials.gov/show/NCT04344119","https://clinicaltrials.gov/show/NCT04344145","https://clinicaltrials.gov/show/NCT04344210","https://clinicaltrials.gov/show/NCT04344236","https://clinicaltrials.gov/show/NCT04343898","https://clinicaltrials.gov/show/NCT04343989","https://clinicaltrials.gov/show/NCT04344197","https://clinicaltrials.gov/show/NCT04344587","https://clinicaltrials.gov/show/NCT04346212","https://clinicaltrials.gov/show/NCT04346446","https://clinicaltrials.gov/show/NCT04344015","https://clinicaltrials.gov/show/NCT04344106","https://clinicaltrials.gov/show/NCT04344327","https://clinicaltrials.gov/show/NCT04344444","https://clinicaltrials.gov/show/NCT04344834","https://clinicaltrials.gov/show/NCT04345276","https://clinicaltrials.gov/show/NCT04344249","https://clinicaltrials.gov/show/NCT04344431","https://clinicaltrials.gov/show/NCT04344535","https://clinicaltrials.gov/show/NCT04344561","https://clinicaltrials.gov/show/NCT04346667","https://clinicaltrials.gov/show/NCT04346693","https://clinicaltrials.gov/show/NCT04345679","https://clinicaltrials.gov/show/NCT04345692","https://clinicaltrials.gov/show/NCT04344457","https://clinicaltrials.gov/show/NCT04344548","https://clinicaltrials.gov/show/NCT04345887","https://clinicaltrials.gov/show/NCT04346121","https://clinicaltrials.gov/show/NCT04344977","https://clinicaltrials.gov/show/NCT04345419","https://clinicaltrials.gov/show/NCT04345445","https://clinicaltrials.gov/show/NCT04344756","https://clinicaltrials.gov/show/NCT04344782","https://clinicaltrials.gov/show/NCT04347538","https://clinicaltrials.gov/show/NCT04347954","https://clinicaltrials.gov/show/NCT04344964","https://clinicaltrials.gov/show/NCT04345315","https://clinicaltrials.gov/show/NCT04345510","https://clinicaltrials.gov/show/NCT04345536","https://clinicaltrials.gov/show/NCT04345653","https://clinicaltrials.gov/show/NCT04347980","https://clinicaltrials.gov/show/NCT04347993","https://clinicaltrials.gov/show/NCT04345406","https://clinicaltrials.gov/show/NCT04345523","https://clinicaltrials.gov/show/NCT04345861","https://clinicaltrials.gov/show/NCT04346160","https://clinicaltrials.gov/show/NCT04346147","https://clinicaltrials.gov/show/NCT04346329","https://clinicaltrials.gov/show/NCT04345549","https://clinicaltrials.gov/show/NCT04345614","https://clinicaltrials.gov/show/NCT04346186","https://clinicaltrials.gov/show/NCT04346277","https://clinicaltrials.gov/show/NCT04348214","https://clinicaltrials.gov/show/NCT04348383","https://clinicaltrials.gov/show/NCT04346342","https://clinicaltrials.gov/show/NCT04346355","https://clinicaltrials.gov/show/NCT04345640","https://clinicaltrials.gov/show/NCT04345848","https://clinicaltrials.gov/show/NCT04346420","https://clinicaltrials.gov/show/NCT04346628","https://clinicaltrials.gov/show/NCT04345991","https://clinicaltrials.gov/show/NCT04346056","https://clinicaltrials.gov/show/NCT04348396","https://clinicaltrials.gov/show/NCT04348409","https://clinicaltrials.gov/show/NCT04346368","https://clinicaltrials.gov/show/NCT04346589","https://clinicaltrials.gov/show/NCT04346810","https://clinicaltrials.gov/show/NCT04346927","https://clinicaltrials.gov/show/NCT04348422","https://clinicaltrials.gov/show/NCT04348435","https://clinicaltrials.gov/show/NCT04346082","https://clinicaltrials.gov/show/NCT04346199","https://clinicaltrials.gov/show/NCT04346953","https://clinicaltrials.gov/show/NCT04347070","https://clinicaltrials.gov/show/NCT04346797","https://clinicaltrials.gov/show/NCT04347226","https://clinicaltrials.gov/show/NCT04348864","https://clinicaltrials.gov/show/NCT04350593","https://clinicaltrials.gov/show/NCT04346264","https://clinicaltrials.gov/show/NCT04346615","https://clinicaltrials.gov/show/NCT04347239","https://clinicaltrials.gov/show/NCT04347408","https://clinicaltrials.gov/show/NCT04347278","https://clinicaltrials.gov/show/NCT04347369","https://clinicaltrials.gov/show/NCT04347174","https://clinicaltrials.gov/show/NCT04347382","https://clinicaltrials.gov/show/NCT04351646","https://clinicaltrials.gov/show/NCT04351659","https://clinicaltrials.gov/show/NCT04347850","https://clinicaltrials.gov/show/NCT04347876","https://clinicaltrials.gov/show/NCT04347460","https://clinicaltrials.gov/show/NCT04347694","https://clinicaltrials.gov/show/NCT04347681","https://clinicaltrials.gov/show/NCT04347798","https://clinicaltrials.gov/show/NCT04347928","https://clinicaltrials.gov/show/NCT04348227","https://clinicaltrials.gov/show/NCT04347889","https://clinicaltrials.gov/show/NCT04348071","https://clinicaltrials.gov/show/NCT04347824","https://clinicaltrials.gov/show/NCT04347915","https://clinicaltrials.gov/show/NCT04351906","https://anzctr.org.au/ACTRN12620000468921.aspx","https://clinicaltrials.gov/show/NCT04348461","https://clinicaltrials.gov/show/NCT04348552","https://clinicaltrials.gov/show/NCT04348305","https://clinicaltrials.gov/show/NCT04348500","https://clinicaltrials.gov/show/NCT04347941","https://clinicaltrials.gov/show/NCT04348240","https://anzctr.org.au/ACTRN12620000480987.aspx","https://clinicaltrials.gov/show/NCT04348695","https://clinicaltrials.gov/show/NCT04348877","https://clinicaltrials.gov/show/NCT04348448","https://clinicaltrials.gov/show/NCT04348474","https://anzctr.org.au/ACTRN12620000482965.aspx","https://clinicaltrials.gov/show/NCT04348513","https://clinicaltrials.gov/show/NCT04348929","https://anzctr.org.au/ACTRN12620000493943.aspx","https://clinicaltrials.gov/show/NCT04348656","https://clinicaltrials.gov/show/NCT04349098","https://clinicaltrials.gov/show/NCT04348942","https://clinicaltrials.gov/show/NCT04349371","https://clinicaltrials.gov/show/NCT04349202","https://clinicaltrials.gov/show/NCT04350086","http://isrctn.com/ISRCTN18348009","https://clinicaltrials.gov/show/NCT04349241","https://clinicaltrials.gov/show/NCT04349982","https://clinicaltrials.gov/show/NCT04349410","https://clinicaltrials.gov/show/NCT04349618","http://isrctn.com/ISRCTN10077335","https://clinicaltrials.gov/show/NCT04350073","https://clinicaltrials.gov/show/NCT04350099","https://clinicaltrials.gov/show/NCT04350320","https://clinicaltrials.gov/show/NCT04350736","https://clinicaltrials.gov/show/NCT04349631","https://clinicaltrials.gov/show/NCT04350281","https://clinicaltrials.gov/show/NCT04350450","https://clinicaltrials.gov/show/NCT04350476","https://clinicaltrials.gov/show/NCT04351191","https://clinicaltrials.gov/show/NCT04351399","https://clinicaltrials.gov/show/NCT04351295","https://clinicaltrials.gov/show/NCT04351529","http://isrctn.com/ISRCTN40092247","https://clinicaltrials.gov/show/NCT04351620","https://clinicaltrials.gov/show/NCT04351711","https://clinicaltrials.gov/show/NCT04350671","https://clinicaltrials.gov/show/NCT04350684","https://anzctr.org.au/ACTRN12620000486921.aspx","https://anzctr.org.au/ACTRN12620000473965.aspx","https://anzctr.org.au/ACTRN12620000474954.aspx","https://clinicaltrials.gov/show/NCT04351633","https://clinicaltrials.gov/show/NCT04351724","https://clinicaltrials.gov/show/NCT04350931","https://clinicaltrials.gov/show/NCT04351139","https://anzctr.org.au/ACTRN12620000445976.aspx","http://isrctn.com/ISRCTN83971151","https://anzctr.org.au/ACTRN12620000492954.aspx","http://isrctn.com/ISRCTN51255782","https://anzctr.org.au/ACTRN12620000478910.aspx","http://isrctn.com/ISRCTN86534580","http://isrctn.com/ISRCTN50189673","http://isrctn.com/ISRCTN51287266","http://isrctn.com/ISRCTN14326006","http://isrctn.com/ISRCTN13694948","http://www.chictr.org.cn/showproj.aspx?proj=52490","http://isrctn.com/ISRCTN15281137","https://clinicaltrials.gov/show/NCT04351152","https://clinicaltrials.gov/show/NCT04351347","https://clinicaltrials.gov/show/NCT04351542","https://clinicaltrials.gov/show/NCT04351581","http://isrctn.com/ISRCTN16912075","http://www.chictr.org.cn/showproj.aspx?proj=52341","http://www.chictr.org.cn/showproj.aspx?proj=52332","https://clinicaltrials.gov/show/NCT04351763","https://clinicaltrials.gov/show/NCT04351789","http://www.chictr.org.cn/showproj.aspx?proj=52477","https://clinicaltrials.gov/show/NCT04351802","https://anzctr.org.au/ACTRN12620000477921.aspx","https://anzctr.org.au/ACTRN12620000472976.aspx","https://anzctr.org.au/ACTRN12620000487910.aspx","https://anzctr.org.au/ACTRN12620000479909.aspx","https://anzctr.org.au/ACTRN12620000470998.aspx","http://www.chictr.org.cn/showproj.aspx?proj=52565","http://www.chictr.org.cn/showproj.aspx?proj=52364","http://isrctn.com/ISRCTN80453162","http://www.chictr.org.cn/showproj.aspx?proj=52414","http://www.chictr.org.cn/showproj.aspx?proj=52353","http://www.chictr.org.cn/showproj.aspx?proj=52365","https://trialregister.nl/trial/8498","http://isrctn.com/ISRCTN43900695","http://isrctn.com/ISRCTN77353041","http://www.chictr.org.cn/showproj.aspx?proj=49631","http://www.chictr.org.cn/showproj.aspx?proj=50022","http://www.chictr.org.cn/showproj.aspx?proj=52529","http://www.chictr.org.cn/showproj.aspx?proj=52483","https://trialregister.nl/trial/8512","http://www.chictr.org.cn/showproj.aspx?proj=52142","http://www.chictr.org.cn/showproj.aspx?proj=52479","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001324-33","http://www.chictr.org.cn/showproj.aspx?proj=51602","http://www.chictr.org.cn/showproj.aspx?proj=52106","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001257-51","https://trialregister.nl/trial/8513","https://trialregister.nl/trial/8473","https://trialregister.nl/trial/8485","http://www.chictr.org.cn/showproj.aspx?proj=51650","https://trialregister.nl/trial/8490","http://www.chictr.org.cn/showproj.aspx?proj=48889","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001320-34","http://www.chictr.org.cn/showproj.aspx?proj=48898","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001420-34","https://trialregister.nl/trial/8501","https://trialregister.nl/trial/8521","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002688-89","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001290-74","https://trialregister.nl/trial/8460","https://trialregister.nl/trial/8483","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11","https://trialregister.nl/trial/8497","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001406-27","https://trialregister.nl/trial/8491","https://trialregister.nl/trial/8504","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001553-48","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001530-35","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001437-12","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001160-28","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001602-34","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001587-29","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001682-36","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001331-26","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001634-36","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001266-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001765-37","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001511-25","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001570-30","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001379-34","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22","http://www.drks.de/DRKS00021214","http://www.drks.de/DRKS00021225","http://www.drks.de/DRKS00021220","http://www.drks.de/DRKS00021395","http://www.drks.de/DRKS00021420","http://www.drks.de/DRKS00021166","http://www.drks.de/DRKS00021231","http://www.drks.de/DRKS00021254","http://www.drks.de/DRKS00021206","http://www.drks.de/DRKS00021161","http://www.drks.de/DRKS00021208","http://www.drks.de/DRKS00021164","http://www.drks.de/DRKS00021306","http://www.drks.de/DRKS00021153","http://www.drks.de/DRKS00021186","http://www.drks.de/DRKS00021145","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42687","http://www.drks.de/DRKS00021300","http://www.drks.de/DRKS00021152","http://en.irct.ir/trial/46564","http://www.drks.de/DRKS00021289","http://www.drks.de/DRKS00021301","http://en.irct.ir/trial/46424","http://en.irct.ir/trial/46567","http://www.drks.de/DRKS00021268","http://www.drks.de/DRKS00021270","http://en.irct.ir/trial/46531","http://www.drks.de/DRKS00021276","http://en.irct.ir/trial/46609","http://en.irct.ir/trial/46536","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42718","http://en.irct.ir/trial/46551","http://en.irct.ir/trial/46554","http://www.drks.de/DRKS00021134","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42713","http://en.irct.ir/trial/46668","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42638","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42961","http://en.irct.ir/trial/46678","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42967","http://en.irct.ir/trial/46573","http://en.irct.ir/trial/46603","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42684","http://en.irct.ir/trial/46538","http://en.irct.ir/trial/46545","http://en.irct.ir/trial/46550","http://en.irct.ir/trial/46623","http://en.irct.ir/trial/46629","http://en.irct.ir/trial/46463","http://en.irct.ir/trial/46718","http://en.irct.ir/trial/46533","http://en.irct.ir/trial/46720","http://en.irct.ir/trial/46637","http://en.irct.ir/trial/46665","http://en.irct.ir/trial/46561","http://en.irct.ir/trial/46721","http://en.irct.ir/trial/46639","http://en.irct.ir/trial/46576","http://en.irct.ir/trial/46693","http://en.irct.ir/trial/46624","http://en.irct.ir/trial/46697","http://en.irct.ir/trial/46759","http://en.irct.ir/trial/46713","http://en.irct.ir/trial/46706","http://en.irct.ir/trial/46660","http://en.irct.ir/trial/46681","http://en.irct.ir/trial/46736","http://en.irct.ir/trial/46732","http://en.irct.ir/trial/46803","http://en.irct.ir/trial/46690","http://en.irct.ir/trial/46741","http://en.irct.ir/trial/46715","http://en.irct.ir/trial/46751","http://en.irct.ir/trial/46776","http://en.irct.ir/trial/46804","http://en.irct.ir/trial/46782","http://en.irct.ir/trial/46762","http://en.irct.ir/trial/46810","http://en.irct.ir/trial/46786","http://en.irct.ir/trial/46783","http://en.irct.ir/trial/46811","http://en.irct.ir/trial/46828","http://en.irct.ir/trial/46789","http://en.irct.ir/trial/46728","http://en.irct.ir/trial/46837","http://en.irct.ir/trial/46885","http://en.irct.ir/trial/46868","http://en.irct.ir/trial/46838","http://en.irct.ir/trial/46731","http://en.irct.ir/trial/46849","http://en.irct.ir/trial/46893","http://en.irct.ir/trial/46913","http://en.irct.ir/trial/46733","http://en.irct.ir/trial/46875","http://en.irct.ir/trial/46775","http://en.irct.ir/trial/46879","http://en.irct.ir/trial/46932","http://en.irct.ir/trial/46961","http://en.irct.ir/trial/46790","http://en.irct.ir/trial/46933","http://en.irct.ir/trial/46940","http://en.irct.ir/trial/46903","http://en.irct.ir/trial/46968","http://en.irct.ir/trial/46907","http://en.irct.ir/trial/46942","http://en.irct.ir/trial/46969","http://en.irct.ir/trial/47022","http://en.irct.ir/trial/46930","http://en.irct.ir/trial/46814","http://en.irct.ir/trial/46824","http://en.irct.ir/trial/46946","http://en.irct.ir/trial/47030","http://en.irct.ir/trial/46850","http://en.irct.ir/trial/47010","http://en.irct.ir/trial/46897","http://en.irct.ir/trial/47013","http://en.irct.ir/trial/46974","http://en.irct.ir/trial/47014","http://en.irct.ir/trial/47139","http://en.irct.ir/trial/46904","http://en.irct.ir/trial/46978","http://en.irct.ir/trial/46926","http://en.irct.ir/trial/47061","http://en.irct.ir/trial/46931","http://en.irct.ir/trial/47015","http://en.irct.ir/trial/46958","http://en.irct.ir/trial/47073","http://en.irct.ir/trial/46973","http://en.irct.ir/trial/47018","http://en.irct.ir/trial/46977","http://en.irct.ir/trial/47078","http://lbctr.emro.who.int/Trials/Details/3459","http://en.irct.ir/trial/47087","http://en.irct.ir/trial/47234","http://en.irct.ir/trial/47006","http://en.irct.ir/trial/47244","http://en.irct.ir/trial/47016","http://en.irct.ir/trial/47149","http://en.irct.ir/trial/47021","http://en.irct.ir/trial/47058","http://en.irct.ir/trial/47090","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953","https://jrct.niph.go.jp/latest-detail/jRCT2031190264","https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238","http://en.irct.ir/trial/47099","http://en.irct.ir/trial/47212","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10957","https://jrct.niph.go.jp/latest-detail/jRCTs031190269","https://jrct.niph.go.jp/latest-detail/jRCTs031190226","https://jrct.niph.go.jp/latest-detail/jRCTs031190227","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045600","http://www.ensaiosclinicos.gov.br/rg/RBR-3cbs3w/","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045790","http://www.ensaiosclinicos.gov.br/rg/RBR-9d8z6m/","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045582","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=6016","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045820","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=6023","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5995","http://www.ensaiosclinicos.gov.br/rg/RBR-6m69fc/","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045825","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5976","http://www.ensaiosclinicos.gov.br/rg/RBR-9pgwfc/","http://rpcec.sld.cu/en/trials/RPCEC00000306-En","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=010-20","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5975","http://www.ensaiosclinicos.gov.br/rg/RBR-8969zg/","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5997"],["Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not recruiting","Not Recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting",null,"Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting",null,"Recruiting","Not Recruiting",null,"Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting",null,"Not Recruiting","Not Recruiting","Not Recruiting","Recruiting",null,"Recruiting","Not Recruiting","Recruiting","Recruiting",null,"Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting",null,"Not Recruiting","Not Recruiting","Recruiting",null,"Not recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting",null,"Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting",null,"Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Authorised","Not Recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting",null,"Not Recruiting","Authorised",null,"Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Authorised","Authorised","Recruiting","Not recruiting","Recruiting","Recruiting","Authorised","Recruiting","Authorised","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not Recruiting","Not Recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Authorised","Recruiting","Recruiting","Authorised","Recruiting","Not Recruiting","Authorised","Not Recruiting","Not Recruiting","Authorised","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Authorised","Not Recruiting","Authorised","Not recruiting","Not recruiting","Recruiting","Recruiting","Authorised","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Authorised","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not recruiting","Not Recruiting","Not Recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Not Recruiting","Not recruiting","Not Recruiting","Not recruiting","Not recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Authorised","Not Recruiting","Recruiting","Authorised","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Authorised","Not Recruiting","Authorised","Recruiting","Not Recruiting","Authorised","Authorised","Recruiting","Recruiting","Authorised","Recruiting","Authorised","Recruiting","Recruiting","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting",null,"Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting"],["No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","Yes","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","No","No","Yes","No","No","No","No","No","Yes","No","No","Yes","Yes","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","Yes","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","Yes","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","Yes","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No"],[null,null,"16","0",null,"N/A","18","18","18 Years","N/A","18","18",null,"18","1",null,null,"1","15","14 Years","18 Years","18",null,"N/A","18","18","18","18",null,"18","18","18",null,"18",null,"0","18","18","18","18 Years","18 Years","18",null,"18","18","18","18",null,"18",null,"18","18","12","18","18","18",null,null,null,"18","0",null,"14","18","18","14","18","18",null,"14",null,"18","18",null,null,"18","18","18","16","18","18","30","18","18",null,"18",null,"18","18","18","18","3",null,"18",null,"18","18","18","18","18",null,null,null,"15","18","18",null,"18",null,null,null,"18","18","1","18","18","18","18","18",null,null,"18","18","18","18","18","18",null,"18","N/A","18 Years","1","18",null,"16","16","16",null,"18","18",null,null,"18","15","18",null,"18","18 Years","18","18","18","18","18","18",null,"50","16","15","18",null,"18","18",null,"18",null,"0","18","18",null,"0","35","18","18",null,"18","18","18",null,null,"16","18","18","18",null,"18","18","16","N/A","18 Years","N/A","18 Years",null,"18","60","18 Years","18 Years","18",null,"22","18 Years","N/A","18",null,null,"N/A","20","0","N/A",null,"18","18",null,"0","18","18 Years","18 Years","20","18",null,null,"1","0",null,"18","18","18","18","18",null,"18","18",null,null,null,"18",null,null,"18",null,"16","18","18",null,"18","18","8",null,"60","18",null,"18","18",null,"18","18","18","18","0","18","15","14","18","18","18",null,"18","18","18","18",null,"18","0","18",null,"18 Years","18","18","18","18","18",null,"18","18 Years","18","N/A","18 Years",null,"18","18","14","18","18","18","18",null,"18","16","N/A","18 Years",null,null,"18","18",null,null,null,"18",null,null,"18","18","0","18",null,"18","20","14",null,"18",null,"18","18",null,null,"0","18",null,"18","18","18","18","18","18",null,"18 Years","18 Years","18","18","18","18","18",null,"0","18 Years","10 Years","18 Years","18","N/A","18 Years",null,"18","18","16","18","0",null,"18",null,"18",null,"18","10","18",null,"18",null,"18",null,"18","13","20","18","18","16","7",null,null,"12","18","12","18",null,"1",null,"14","0",null,"10",null,"23","18","14",null,"18","18",null,"30",null,"20",null,"65",null,"0","2","18","18",null,"18",null,"18",null,"14","14","1","18","16","18","14","65","14","18","24","18","14","14",null,"14","14","22",null,"1",null,"18",null,"18","18","18","18","18","0","60","18","1","18","2","18","18","18","18",null,null,"18","18","18","18","18","18","18",null,"18","18","18","18","18","18","18","18","18","18","0","18","18","18","1","18","18","14","18","18 Years","0.1","18 Years","N/A","16 Years","0","18","18","20","12",null,"18","0","18",null,"18","18","11","33",null,null,null,null,null,"14","38",null,"18","18 Years","6 Months","18","15",null,"18",null,"18","N/A",null,"16",null,"18","18",null,"18","18","18","18","18","0",null,"1","18",null,"18","18",null,"18",null,"0","18","4","20","18 Years","18 Years",null,"18","14 Years","18 Years","18",null,"1years-old","18","18 Years","18 Years","18 Years","18 Years","&gt;= 16age old","6 Months","18 Years","18 Years","18 Years","Not applicable","18 Years","21 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years",null,"1","18 Years","N/A","18 Years","N/A","18","18 Years","18 Years","18","18","8","18","18",null,"18","18 Years","8","18","18","0","22","18","18",null,null,"25",null,null,"7","0","18","18","18","18","18","16","18","0","18","45","18","7",null,null,"18","18","18",null,"18","18 Years","18 Years",null,null,null,"18 Years","18 Months","18 Years","18 Years",null,null,null,null,"18 Years","N/A","16 Years","N/A","18 Years","60 Years","5 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18 Years","18 Years","18 Years",null,"18 Years","18","10","18 Years","18 Years","18","18","18","18","18","18","18 Years","18 Years","/","20","N/A","18","18","18","30","18","18","1",null,"18","18",null,"18","20",null,"18",null,null,"18","18 Years","18","13",null,"/",null,"14 Years","18 Years","18 Years","18 Years",null,"18 Years","18 Years","18 Years","18 Years","18 Years","18 Years",null,"No limit","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","25 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","16 Years","18 Years","5 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","30 Years","18 Years","18 Years","18 Years","3 Years","18 Years","18 Years","18 Years","45 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18","18","2","18 Years","18 Years","18 Years","17",null,"17","18","29","18","18","18","18","28","14","18","10","18",null,"6","18","18","25","18","0",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"18 Years","N/A","18 Years","N/A","16 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","1 Year","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18 Years","18 Years","N/A","N/A","12 Years","12 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","25 Years","18 Years","18 Years","18 Years","N/A","18 Years","N/A","12 Years","18 Years","18 Years","N/A","18 Years","18 Years","N/A","N/A","18 Years","70 Years","40 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","14 Years","30 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","20 Years","18 Years","18 Years","N/A","18 Years","18 Years","16 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","60 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","15 Years","18 Years","18 Years","6 Months","18 Years","18 Years","18 Years","12 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","70 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","40 Years","N/A","18 Years","18 Years","45 Years","18 Years","19 Years","18 Years","18 Years","N/A","18 Years","18 Years","30 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","65 Years","18 Years","20 Years","18 Years","18 Years","18 Years","8 Years","18 Years","N/A","18 Years","N/A","18 Years","18 Years","N/A","N/A","35 Years","18 Years","6 Years","18 Years","18 Years","18 Years","N/A","18 Years","19 Years","18 Years","N/A","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","75 Years","18 Years","18 Years","19 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","55 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","N/A","N/A","18 Years","14 Years","18 Years","18 Years","18 Years","5 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","50 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","30 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","65 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","N/A","18 Years","4 Years","18 Years","18 Years","18 Years","18 Years","18 Years","70 Years","N/A","18 Years","N/A","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","20 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","N/A","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","1 Year","65 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","N/A","18 Years","18 Years","40 Years","18 Years","18 Years","18 Years","18 Years","18 Years","6 Years","18 Years","18 Years","N/A","1 Year","18 Years","18 Years","5 Years","18 Years","21 Years","N/A","12 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","N/A","19 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18 Years","18 Years","18 Years","18 Years","18 Years",null,"18 Years","18 Years","N/A","18 Years",null,"18 Years","N/A","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","20 Years","18 Years","N/A","18 Years",null,"18 Years","18 Years","50 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years",null,"60 Years",null,"18 Years",null,null,null,null,null,"18",null,"18 Years","N/A","18 Years","18 Years",null,"18",null,"18 Years","18 Years",null,"18 Years","35 Years","18 Years","18 Years","18 Years","18 Years","7","18",null,"18","0",null,null,null,null,"25","18","18","25",null,"18","18",null,null,"18",null,null,null,null,"0",null,"18",null,"18",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","24 Years","18 Years","18 Years","no minimum age","14 Years","18 Years","no minimum age","18 Years","18 Years","no minimum age",null,"18 Years","18 Years","18 years","16 Years","18 Years","20 years","18 years","18 Years","16 Years","18 years","18 Years","22 years","no limit",null,"18 years","18 years","18 Years",null,"18 years",null,null,"no limit",null,"18 years","18 years",null,"18 years","18 years","18 years","18 years","18 years","18 years","15 years","18 years","18 years","18 years","18 years","18 years","18 years","20 years","2 years","18 years","no limit","20 years","no limit","14 years","no limit","18 years","18 years","no limit","no limit","no limit","18 years","18 years","no limit","no limit","18 years","18 years","18 years","18 years","18 years","18 years","16 years","18 years","no limit","18 years","18 years","18 years","18 years","18 years","20 years","18 years","18 years","18 years","20 years","18 years","18 years","no limit","18 years","18 years","18 years","18 years","no limit","18 years","18 years","16 years","20 years","18 years","18 years","16 years","18 years","no limit","18 years","15 years","18 years","20 years","18 years","18 years","no limit","1 year","18 years","18 years","18 years","18 years","no limit","18 years","25 years","18 years","18 years","18 years","18 years","no limit","18 years","18 years","18","18 years","18 years","12 years","18 years","18 years","no limit","18 years","50 years","40 years","19 Year(s)","&gt;= 20age old","20","no limit","18 years","19 Year(s)","&gt;= 20age old","&gt;= 20age old","&gt;= 20age old","18years-old","18","20years-old","18Y","Not applicable","18 Years","19 Year(s)","Not applicable","18 Years","18 Years","18Y","Not applicable","30 Years","18Y","60 years",null,"18 Years","18Y","18 Years"],[null,null,"99","18",null,"N/A",null,"75","80 Years","N/A","90","80",null,null,"100",null,null,"100","85","80 Years","75 Years","80",null,"N/A","75",null,"80","70",null,"75","75","90",null,null,null,"100","75","75",null,"N/A","75 Years","75",null,"80","80","85","65",null,"75",null,"60",null,"80","80",null,"90",null,null,null,null,"100",null,"80","85","70","80","70","70",null,"??",null,"90",null,null,null,"75","65","75","75",null,null,"65","75","65",null,"80",null,"60","90",null,null,"85",null,"90",null,"75","80","80","70",null,null,null,null,"35","65","75",null,"75",null,null,null,null,"80","99",null,"75","70","75",null,null,null,"85","80","75","70","70","70",null,"75","N/A","N/A","90","65",null,"75",null,"50",null,"80","80",null,null,"65","80","75",null,null,"75 Years",null,"60","75",null,"70","100",null,"100","75","60",null,null,"80","75",null,"60",null,"1",null,"85",null,"90","74",null,"80",null,null,"60","80",null,null,"99",null,"75","60",null,"70","90","30","N/A","N/A","18 Years","90 Years",null,"85",null,"75 Years","70 Years","70",null,"55","N/A","N/A","65",null,null,"N/A","90","18","28 Days",null,"80",null,null,"0","65","65 Years","80 Years","45","90",null,null,"15","100",null,"75",null,null,"90","79",null,null,"70",null,null,null,null,null,null,"75",null,"92","65","60",null,"75","70","91",null,null,"80",null,null,"75",null,null,"80",null,"100","79",null,"35","99",null,"80","80",null,"80","65",null,null,null,"75","90","90",null,"75 Years","35","90","75","-",null,null,"90","75 Years","100","N/A","N/A",null,null,null,"90","75","80","75",null,null,"75","30","N/A","85 Years",null,null,"65",null,null,null,null,"90",null,null,"70","65","18","70",null,"75","55","90",null,"65",null,null,"110",null,null,"100","75",null,null,null,"80","75","75","99",null,"75 Years","100 Years","75","65","-",null,"70",null,"99","N/A","19 Years","90 Years","80","N/A","N/A",null,"85","85","65","85","100",null,"80",null,"100",null,null,"75",null,null,"100",null,"82",null,"80","90","88","80","??","75","70",null,null,null,null,"85","99",null,"100",null,"90","86",null,"88",null,"94","75","90",null,null,"75",null,"85",null,"80",null,"100",null,"86","89","80","90",null,"80",null,null,null,"90","90","99","70",null,"74","90","90","90",null,"89","70","90","90",null,"90","90","55",null,"100",null,null,null,"75","80",null,null,"80","18","110","65","80","75","65","55","65","-","80",null,null,"60","96",null,"75","60","80","70",null,"80",null,"65",null,"85",null,"65",null,"65",null,"18","75","ND","ND","90",null,"80","70","65","75 Years","85","N/A","N/A","99 Years","90","70",null,"50",null,null,"80","100","65",null,null,null,"18","75",null,null,null,null,null,null,"70",null,"65","N/A","80 Years","80","80",null,"75",null,"60","N/A",null,"90",null,"85","80",null,"70","100","80","100","100","100",null,"99","??",null,"75","80",null,"65",null,"99","70","80","90","N/A","80 Years",null,"-","70 Years","N/A","85",null,"100years-old",null,"90 Years","80 Years","N/A","55 Years","Not applicable","80 Years","75 Years","N/A","N/A","Not applicable","75 Years","N/A","75 Years","N/A","N/A","100 Years","N/A","80 Years","N/A","75 Years","75 Years","N/A","100 Years",null,"80","N/A","N/A","N/A","N/A","80","N/A","50 Years","50","65","25","90","100",null,null,"N/A","25","98","100","18","47","65","100",null,null,"77",null,null,"101","100","80","99","90","75","75","85","80","??",null,"80","85","90",null,null,null,null,"75",null,"??","55 Years","N/A",null,null,null,"85 Years","N/A","N/A","75 Years",null,null,null,null,"N/A","85 Years","N/A","N/A","80 Years","N/A","75 Years","80 Years","N/A","N/A","24 Years","N/A","N/A","N/A","N/A","75 Years","N/A","N/A","N/A","N/A","100 Years",null,"N/A","80","85","N/A","N/A","60","80","90","80","85","100","N/A","75 Years","/","30","N/A",null,"75","70","90","80","65","90",null,"100","?",null,"80","65",null,"N/A",null,null,"70","64 Years","70","N/A",null,"/",null,"N/A","N/A","80 Years","N/A",null,"N/A","N/A","65 Years","N/A","99 Years","N/A",null,"No limit","N/A","N/A","110 Years","70 Years","N/A","N/A","70 Years","N/A","100 Years","50 Years","N/A","N/A","90 Years","80 Years","99 Years","N/A","N/A","90 Years","55 Years","N/A","N/A","N/A","N/A","99 Years","80 Years","18 Years","80 Years","N/A","N/A","N/A","99 Years","70 Years","120 Years","100 Years","N/A","90 Years","60 Years","N/A","N/A","70 Years","64 Years","N/A","N/A","99 Years","N/A","N/A","N/A","N/A","N/A","N/A","80 Years","N/A","N/A","60 Years","75 Years","N/A","N/A","N/A","No limit","No limit","N/A","No limit","60 Years","N/A","88","100","7","N/A","No limit","No limit","80",null,"35",null,"91","80","75","45","80","54","75","75","90",null,null,"61","70","50","65","100","120",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","70 Years","N/A","N/A","90 Years","N/A","75 Years","65 Years","N/A","N/A","65 Years","55 Years","75 Years","60 Years","100 Years","N/A","60 Years","N/A","N/A","N/A","N/A","N/A","99 Years","N/A","100 Years","N/A","100 Years","N/A","65 Years","N/A","60 Years","N/A","N/A","N/A","N/A","N/A","N/A","65 Years","80 Years","90 Years","80 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","100 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","65 Years","75 Years","79 Years","N/A","N/A","N/A","N/A","55 Years","100 Years","N/A","N/A","90 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","99 Years","N/A","N/A","75 Years","N/A","N/A","N/A","N/A","N/A","100 Years","75 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","85 Years","N/A","N/A","N/A","N/A","80 Years","N/A","N/A","75 Years","N/A","65 Years","N/A","80 Years","N/A","N/A","N/A","70 Years","N/A","N/A","N/A","N/A","N/A","55 Years","65 Years","N/A","N/A","N/A","80 Years","80 Years","N/A","18 Years","35 Years","85 Years","N/A","65 Years","N/A","N/A","N/A","N/A","N/A","N/A","80 Years","75 Years","18 Years","N/A","N/A","N/A","N/A","15 Minutes","N/A","80 Years","N/A","N/A","N/A","N/A","110 Years","N/A","50 Years","N/A","N/A","N/A","N/A","18 Years","45 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","45 Years","95 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","75 Years","N/A","N/A","N/A","N/A","75 Years","80 Years","70 Years","95 Years","N/A","99 Years","N/A","N/A","N/A","65 Years","N/A","N/A","N/A","N/A","N/A","N/A","89 Years","N/A","80 Years","N/A","N/A","N/A","N/A","N/A","N/A","80 Years","N/A","105 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","65 Years","N/A","N/A","65 Years","99 Years","N/A","N/A","N/A","99 Years","80 Years","N/A","N/A","N/A","70 Years","N/A","N/A","89 Years","N/A","90 Years","90 Years","N/A","N/A","N/A","N/A","120 Years","N/A","N/A","N/A","N/A","N/A","60 Years","90 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","80 Years","90 Years","N/A","N/A","79 Years","N/A","N/A","N/A","N/A","N/A","65 Years","N/A","N/A","N/A","100 Years","N/A","75 Years","100 Years","90 Years","N/A","N/A","50 Years","80 Years","N/A","95 Years","N/A","N/A","N/A","N/A","70 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","99 Years","80 Years","N/A","N/A","N/A","75 Years","N/A","N/A","N/A","60 Years","N/A","N/A","70 Years","N/A","N/A","N/A","N/A","70 Years","N/A","N/A","N/A","N/A","80 Years","N/A","N/A","75 Years","N/A","N/A","70 Years","N/A","N/A","N/A","130 Years","60 Years","N/A","69 Years","N/A","99 Years","N/A","85 Years","N/A","65 Years","15 Years","100 Years","80 Years","N/A","N/A","N/A","65 Years","N/A","80 Years","N/A","100 Years","85 Years","N/A","N/A","N/A","N/A","89 Years","N/A","N/A","N/A","No limit","N/A","N/A","N/A","100 Years","N/A","N/A","70 Years","N/A","80 Years","100 Years","N/A","65 Years","N/A","N/A","No limit","N/A","N/A","N/A","N/A","N/A","N/A",null,"80 Years","N/A","N/A","N/A",null,"N/A","N/A","N/A","50 Years","N/A","N/A","99 Years","N/A","50 Years","N/A","N/A","N/A",null,"N/A","N/A","N/A","N/A","No limit","No limit","No limit","N/A","99 Years","N/A","N/A","No limit",null,"No limit",null,"No limit",null,null,null,null,null,"90",null,"85 Years","N/A","60 Years","N/A",null,"65",null,"99 Years","N/A",null,"N/A","45 Years","No limit","No limit","No limit","65 Years","25","70",null,"75","100",null,null,null,null,"65","75","75","33",null,null,"90",null,null,"80",null,null,null,null,"100",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"no maximum age","no maximum age","no maximum age","80 Years","70 Years","99 Years","no maximum age","no maximum age","no maximum age","no maximum age","no maximum age","no maximum age","no maximum age","no maximum age","no maximum age","no maximum age",null,"100 Years","no maximum age","no limit","67 Years","no maximum age","45 years","75 years","no maximum age","no maximum age","no limit","no maximum age","60 years","no limit",null,"no limit","65 years","no maximum age",null,"95 years",null,null,"no limit",null,"80 years","60 years",null,"75 years","65 years","no limit","95 years","no limit","no limit","no limit","no limit","65 years","85 years","no limit","no limit","65 years","50 years","no limit","no limit","no limit","70 years","no limit","no limit","no limit","no limit","no limit","no limit","no limit","no limit","no limit","no limit","70 years","no limit","no limit","no limit","75 years","65 years","70 years","80 years","100 years","65 years","no limit","70 years","65 years","no limit","65 years","65 years","60 years","no limit","no limit","65 years","70 years","65 years","75 years","no limit","no limit","no limit","no limit","no limit","no limit","no limit","no limit","100 years","70 years","no limit","80 years","100 years","no limit","no limit","no limit","no limit","65 years","70 years","75 years","no limit","no limit","75 years","65 years","65 years","no limit","65 years","no limit","65 years","55 years","65 years","65 years","65 years","70 years","no limit","65 years","no limit","85","no limit","65 years","no limit","no limit","no limit","no limit","70 years","75 years","no limit","44 Year(s)","Not applicable","74","no limit","50 years","44 Year(s)","Not applicable","Not applicable","Not applicable","Not applicable","0","Not applicable","0","Not applicable","0 N/A (No limit)","44 Year(s)","Not applicable","0 N/A (No limit)","100 Years","75Y","Not applicable","70 Years","90Y","None",null,"95 Years","0","0 N/A (No limit)"],["Both","Both","Male","Both","Both","All","Both","Both","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","Both","Both","Both","Both","Both","Female","Both","Both","Both","Female","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Male","Both","Both","Both","Both","Both","Both","Female","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","All","All","Both","Both","Both","All","All","Both","Both","Both","All","All","Both","Both","Both","All","Male","Both","All","Both","Male","Both","Both","Both","Both","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","All","Both","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","All","All","Both","Both","Both","Both","Both","Both","Both","All","All","All","Both","All","All","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","All","Male","All","All","All","Both","Both","Both","Female","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","All","All","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","All","All","Both","Both","Male and Female","Both","All","All","All","All","Both","All","All","All","All","Male and Female","All","All","All","All","All","All","All","All","All","All","All","All","All","Both","Both","All","All","All","All","Both","All","Female","Female","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","Both","Both","Both","All","All","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Both","All","Both","Both","All","All","Both","Both","Both","Both","Both","Both","All","All","Both","Both","All","Both","Both","Both","Male","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both males and females","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both males and females","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Both males and females","All","All","Females","Both males and females","All","All","All","Both males and females","Both males and females","All","Both males and females","All","All","Both","Both","Both","All","Both males and females","Both males and females","Both","Both","Both","Both","Both","Both","Both","Both","Male","Male","Both","Both","Both","Both","Both","Both","Both","Female","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Both males and females","All","All","All","All","All","All","Both males and females","All","All","All","All","Both males and females","All","Female","Both males and females","All","All","All","All","All","All","Both","All","All","All","All","Both","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","Both males and females","Both males and females","Both males and females","All","All","All","Female","Both males and females","Both","Both males and females","Both","Both males and females","Both","Both","Both","Both","Both","Both","Both","All","All","All","All","Both","Both","Both","All","All","Both","All","Males","Both males and females","Both males and females","Both males and females","Both males and females","Both","Both","Both","Both","Male","Female",null,"Both","Both","Both","Both","Both","Both",null,"Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;",null,null,null,"Both",null,"Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;",null,null,"&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;",null,null,"&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;",null,"&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;",null,null,"&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: no&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female","Both, male and female",null,"Both, male and female","Both, male and female","Both","Both, male and female","Both, male and female","Both","Both","Both, male and female","Both, male and female","Both","Both, male and female","Both","Both",null,"Both","Both","Both, male and female",null,"Both",null,null,"Both",null,"Both","Both",null,"Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","BOTH","Both","Both","Both","Both","Both","Both","Male and Female","-","Male and Female","-","Male and Female","Both","Both","Male and Female","Both","Both","-","Male and Female","Both","-","Male/Female",null,"Both","-","Both"],["2020-02-01","2020-02-06","2020-02-15","2020-02-14","2020-02-12","January 25, 2020","2020-02-16","2020-03-01","January 28, 2020","January 20, 2020","2020-02-15","2020-01-30","2020-01-31","2020-02-20","2020-02-16","2020-02-16","2020-02-14","2020-03-01","2020-02-14","January 22, 2020","February 7, 2020","2020-02-05","2020-02-11","February 3, 2020","2020-02-17","2020-02-14","2020-02-10","2020-02-10","2020-02-12","2020-02-15","2020-02-01","2020-02-17","2020-02-07","2020-02-09","2020-02-08","2020-02-07","2020-02-01","2020-02-14","2020-02-12","February 10, 2020","February 7, 2020","2020-03-01","2020-02-10","2020-02-17","2020-03-01","2020-02-10","2020-02-01","2020-02-06","2020-02-13","2020-02-03","2020-02-15","2020-02-05","2020-02-11","2020-02-03","2020-02-04","2020-02-01","2020-02-04","2020-02-01","2020-02-06","2020-02-03","2020-02-16","2020-02-10","2020-02-04","2020-02-12","2020-02-17","2020-02-04","2020-02-03","2020-02-03","2020-02-10","2020-02-10","2020-02-07","2020-02-17","2020-02-25","2020-02-15","2020-02-24","2020-02-01","2020-02-01","2020-02-15","2020-01-30","2020-02-16","2020-02-05","2020-01-31","2020-02-04","2020-02-10","2020-02-10","2020-02-01","2020-02-03","2020-02-01","2020-02-03","2020-02-10","2020-01-29","2020-02-14","2020-02-24","2020-02-11","2020-02-12","2020-03-02","2020-02-15","2020-02-24","2020-02-15","2020-02-27","2020-02-01","2020-02-12","2020-01-29","2020-02-22","2020-03-01","2020-02-12","2020-02-10","2020-02-24","2020-02-01","2020-01-26","2020-02-08","2020-02-07","2020-02-10","2020-01-25","2020-02-06","2020-02-21","2020-03-10","2020-02-06","2020-02-25","2020-02-23","2020-01-29","2020-02-07","2020-02-24","2020-02-04","2020-02-03","2020-02-02","2020-02-03","2020-02-02","2020-01-24","February 4, 2020","February 10, 2020","2020-02-10","2020-02-24","2020-02-24","2020-02-22","2020-02-17","2020-03-01","2020-02-17","2020-02-04","2020-02-07","2020-02-19","2020-02-20","2020-02-12","2020-02-03","2020-02-20","2020-02-19","2020-02-20","February 6, 2020","2020-02-15","2020-02-19","2020-02-16","2020-02-15","2020-02-19","2020-02-20","2020-02-18","2020-02-15","2020-02-24","2020-02-24","2020-02-20","2020-02-20","2020-02-19","2020-02-17","2020-01-30","2020-02-21","2020-02-28","2020-01-25","2020-02-18","2020-02-17","2020-02-20","2020-02-24","2020-02-19","2020-02-09","2020-02-24","2020-02-28","2020-02-14","2020-02-20","2020-03-01","2020-02-12","2020-02-24","2020-02-11","2020-02-14","2020-02-22","2020-05-31","2020-02-20","2020-02-06","2020-02-28","2020-02-20","February 1, 2020","February 20, 2020","February 15, 2020","February 14, 2020","2020-02-19","2020-02-15","2020-02-20","February 3, 2020","February 14, 2020","2020-02-13","2020-03-01","2020-02-10","February 18, 2020","January 20, 2020","2020-02-17","2020-01-01","2020-04-30","January 20, 2020","2020-03-05","2020-02-23","February 1, 2020","2020-03-01","2020-03-01","2020-03-02","2020-03-01","2020-03-01","2020-03-01","February 15, 2020","February 22, 2020","2020-03-02","2020-02-01","2020-01-21","2020-02-28","2020-02-28","2020-02-19","2020-02-28","2020-02-27","2020-02-29","2020-03-04","2020-03-09","2020-03-01","2020-03-01","2020-01-01","2020-02-01","2020-02-20","2020-02-27","2020-02-24","2020-02-28","2020-03-01","2020-02-27","2020-03-01","2020-02-27","2020-03-01","2020-02-26","2020-02-11","2020-02-20","2020-02-22","2020-02-21","2020-01-21","2020-03-09","2020-02-21","2020-02-22","2020-02-20","2020-01-22","2020-02-18","2020-02-01","2020-02-15","2020-02-22","2020-02-15","2020-02-20","2020-02-17","2020-02-17","2020-02-22","2020-02-21","2020-02-24","2020-02-13","2020-02-12","2020-03-01","2020-02-15","2020-01-25","2020-02-17","2020-01-29","2020-02-12","2020-02-17","2020-02-15","2020-03-08","2020-02-20","February 23, 2020","2020-02-02","2020-03-08","2020-03-09","2020-03-15","2020-01-20","2020-03-09","2020-03-08","February 15, 2020","2020-03-10","February 2020","February 4, 2020","2020-03-04","2020-03-04","2020-03-07","2020-03-03","2020-02-01","2020-03-10","2020-02-25","2020-03-01","2020-02-14","2020-03-02","2020-03-06","January 31, 2020","February 26, 2020","2020-03-01","2020-02-01","2020-02-27","2020-02-29","2020-02-28","2020-02-15","2020-03-03","2020-03-02","2020-03-07","2020-03-02","2020-02-01","2020-02-19","2020-03-15","2020-02-29","2020-02-02","2020-01-31","2020-03-10","2020-02-24","2020-03-06","2020-03-04","2020-01-29","2020-03-04","2020-03-03","2020-02-03","2020-03-03","2020-02-25","2020-02-26","2020-01-30","2020-03-04","2020-02-20","2020-03-06","2020-02-06","2020-02-03","2020-02-17","2020-03-14","January 1, 2020","March 14, 2020","2020-01-31","2020-03-01","2020-02-14","2020-01-10","2020-03-19","2020-01-22","2020-01-24","April 1, 2020","October 15, 2020","March 7, 2020","2020-01-27","February 1, 2020","March 1, 2020","2020-02-10","2020-02-01","2019-02-27","2020-02-10","2020-03-16","2020-03-09","2020-02-01","2020-03-06","2020-01-22","2020-01-31","2020-03-01","2020-02-01","2020-02-18","2020-02-23","2020-02-01","2020-01-27","2020-03-01","2020-02-06","2020-02-01","2020-01-20","2020-02-22","2020-02-15","2020-02-01","2020-03-15","2020-02-14","2020-03-16","2020-03-22","2020-03-16","2020-03-20","2020-02-17","2020-03-01","2020-01-01","2020-01-20","2020-03-01","2020-03-16","2020-02-24","2020-01-31","2020-02-15","2020-02-20","2020-01-01","2020-02-15","2020-02-01","2020-03-10","2020-02-15","2020-01-31","2020-02-01","2020-03-13","2020-02-10","2020-01-27","2020-02-20","2020-01-29","2020-01-23","2020-01-20","2020-02-01","2020-02-01","2020-03-07","2020-03-15","2020-01-17","2020-02-12","2020-03-16","2020-03-07","2020-02-01","2020-02-01","2020-02-01","2019-12-01","2020-01-25","2020-05-31","2020-03-13","2020-02-01","2020-03-15","2020-02-01","2020-02-12","2020-03-10","2020-03-11","2020-02-01","2020-04-01","2020-03-20","2020-02-01","2020-02-01","2020-03-05","2020-03-16","2020-02-09","2020-03-01","2020-03-10","2020-02-22","2020-03-10","2020-02-10","2020-03-09","2020-03-09","2020-02-01","2020-02-01","2020-03-09","2020-03-01","2020-03-07","2020-02-04","2020-03-16","2020-02-26","2020-03-05","2020-02-15","2020-02-18","2020-02-01","2020-03-01","2020-03-19","2020-03-10","2020-02-24","2020-02-26","2020-01-31","2020-02-23","2020-02-10","2020-03-01","2020-02-25","2020-03-03","2020-02-20","2020-02-24","2020-02-21","2020-02-16","2020-02-07","2020-02-20","2020-02-17","2020-02-20","2020-01-28","2020-02-17","2020-03-09","2020-03-09","2020-02-01","2020-03-06","2020-03-13","2020-03-03","2020-03-01","March 5, 2020","2020-02-16","February 14, 2020","March 11, 2020","March 11, 2020","2020-02-05","2020-02-29","2020-02-25","2020-02-01","2020-02-22","2020-02-26","2020-05-01","2020-02-09","2020-03-23","2020-03-10","2020-02-20","2020-02-20","2020-03-20","2020-03-18","2020-02-13","2020-03-16","2020-01-28","2020-03-20","2020-03-19","2020-03-16","2020-02-11","2020-01-01","2020-02-26","February 14, 2020","February 15, 2020","2020-02-10","2020-01-18","2020-02-10","2020-03-31","2020-03-31","2020-03-10","December 10, 2019","2020-04-01","2020-02-01","2020-03-01","2020-03-06","2020-03-20","2020-03-23","2020-03-17","2020-02-20","2020-03-13","2020-02-26","2020-03-12","2020-03-01","2020-02-20","2019-12-01","2020-02-29","2020-03-01","2020-03-05","2020-02-10","2020-02-14","2020-03-04","2020-02-06","2020-03-20","2020-01-29","2020-09-01","2020-01-20","February 1, 2020","February 16, 2020","05/03/2020","2020-03-20","February 5, 2020","February 1, 2020","2020-03-06","2020-02-23","2020/02/01","2020-02-11","February 21, 2020","February 2020","February 1, 2020","February 1, 2020","02/03/2020","March 24, 2020","April 1, 2020","March 17, 2020","February 27, 2020","2020/03/19","February 24, 2020","March 8, 2020","March 5, 2020","January 1, 2020","March 16, 2020","January 25, 2020","February 9, 2020","February 20, 2020","March 1, 2020","March 2, 2020","February 1, 2020","March 20, 2020","March 14, 2020","2020-04-01","2020-01-17","March 23, 2020","March 17, 2020","March 12, 2020","March 23, 2020","2020-04-12","March 20, 2020","January 1, 2020","2020-03-31","2020-04-01","2020-03-18","2020-04-12","2020-03-11","2020-04-10","2020-03-13","March 2020","2020-03-18","2020-01-14","2020-04-01","2020-03-16","2020-02-18","2020-04-01","2020-02-01","2020-02-10","2020-03-01","2020-01-25","2020-01-30","2020-02-01","2020-03-23","2020-03-26","2020-03-31","2020-03-25","2020-04-01","2020-03-16","2020-03-10","2020-01-10","2020-02-01","2020-02-15","2020-03-19","2020-02-20","2020-03-23","2020-02-10","2020-03-01","26/03/2020","2020-02-28","2020-02-24","2020-02-27","2020-02-01","2020-02-28","March 25, 2020","April 6, 2020","2020-02-24","26/03/2020","17/03/2020","March 16, 2020","March 30, 2020","March 22, 2020","March 5, 2020","25/03/2020","2020-02-28","17/03/2020","2020-03-26","March 17, 2020","March 2020","March 20, 2020","March 13, 2020","March 17, 2020","April 1, 2020","March 25, 2020","March 23, 2020","March 2020","February 24, 2020","October 15, 2019","February 25, 2020","January 1, 1998","March 21, 2020","April 1, 2020","April 1, 2020","March 23, 2020","April 2020","March 23, 2020","March 25, 2020","March 30, 2020","20/03/2020","March 27, 2020","2020-03-15","2020-04-20","February 26, 2020","March 18, 2020","2020-03-27","2020-04-10","2020-02-01","2020-04-01","2020-03-17","2020-02-04","March 2020","March 23, 2020","2020-03-25","2020-03-05","March 31, 2020","2020-02-17","2020-01-25","2020-05-01","2020-03-20","2020-03-20","2020-03-06","2020-02-05","09/03/2020","2020-01-27","2020-03-28","27/03/2020","2020-02-05","2020-04-03","02/04/2020","2019-12-01","2020-02-10","31/03/2020","2020-04-01","30/03/2020","2020-04-01","2020-04-01","30/03/2020","2020-03-25","03/04/2020","October 24, 2017","April 2020","February 15, 2020","March 18, 2020","31/03/2020","March 19, 2020","March 21, 2020","January 21, 2020","March 28, 2020","April 2, 2020","March 25, 2020","23/03/2020","05/03/2020","March 19, 2020","March 27, 2020","March 31, 2020","March 6, 2020","March 27, 2020","March 31, 2020","April 6, 2020","April 26, 2020","March 27, 2020","March 28, 2020","March 2020","April 1, 2020","April 1, 2020","March 24, 2020","February 21, 2020","March 18, 2020","April 6, 2020","April 25, 2020","March 26, 2020","March 25, 2020","April 2020","March 27, 2020","March 25, 2020","April 1, 2020","March 2020","March 18, 2020","April 1, 2020","April 2, 2020","April 6, 2020","March 13, 2020","April 2020","January 27, 2020","March 10, 2020","April 2, 2020","April 6, 2020","March 25, 2020","April 1, 2020","April 1, 2020","March 30, 2020","March 28, 2020","April 15, 2020","March 19, 2020","March 31, 2020","April 2020","March 14, 2020","January 30, 2020","April 1, 2020","March 30, 2020","April 6, 2020","April 2020","20/04/2020","March 30, 2020","April 6, 2020","10/04/2020","14/04/2020","April 2020","April 2020","April 15, 2020","01/05/2020","09/04/2020","April 6, 2020","01/06/2020","April 1, 2020","April 15, 2020","2020-01-23","2020-04-08","2020-01-10","April 6, 2020","07/04/2020","31/03/2020","2020-01-22","2020-04-13","2020-03-24","2020-04-09","2020-01-01","2020-04-27","2020-03-19","2020-04-01","2020-01-01","2020-03-01","2020-03-10","2020-04-20","2020-04-21","2020-03-02","2020-03-01","2020-02-01","2020-04-01","2020-04-06","2020-03-01","2020-03-01","2020-02-01","03/04/2020","08/04/2020","10/04/2020","06/04/2020","29/03/2020","03/04/2020","10/04/2020","09/04/2020","07/04/2020","27/03/2020","01/04/2020","01/04/2020","01/04/2020","10/04/2020","10/04/2020","31/03/2020","02/04/2020","30/03/2020","28/03/2020","06/04/2020","03/04/2020","02/04/2020","07/04/2020","01/04/2020","November 8, 2018","May 23, 2019","January 26, 2020","January 30, 2020","January 7, 2019","February 19, 2020","February 12, 2020","February 6, 2020","January 27, 2020","February 14, 2020","April 9, 2020","January 1, 2020","February 10, 2020","February 17, 2020","April 20, 2020","March 16, 2020","February 6, 2020","February 15, 2020","March 3, 2020","March 5, 2020","May 10, 2020","April 15, 2020","April 2020","March 16, 2020","March 9, 2020","April 2020","March 15, 2020","March 6, 2020","March 21, 2020","March 21, 2020","April 9, 2020","April 2020","March 19, 2020","March 21, 2020","March 17, 2020","March 8, 2020","March 18, 2020","March 13, 2020","April 13, 2020","April 2020","April 2020","January 1, 2020","March 23, 2020","April 1, 2020","March 11, 2020","March 16, 2020","March 12, 2020","April 14, 2020","March 22, 2020","March 28, 2020","April 6, 2020","April 2020","April 8, 2020","April 14, 2020","March 30, 2020","May 1, 2020","April 3, 2020","April 3, 2020","April 8, 2020","April 20, 2020","March 19, 2020","March 23, 2020","March 20, 2020","April 3, 2020","March 9, 2020","April 2020","March 27, 2020","April 8, 2020","April 5, 2020","May 1, 2020","March 24, 2020","April 2, 2020","March 10, 2020","April 1, 2020","March 29, 2020","April 13, 2020","April 2020","March 31, 2020","April 2020","April 13, 2020","March 20, 2020","March 30, 2020","April 2020","March 25, 2020","April 14, 2020","April 6, 2020","April 6, 2020","March 23, 2020","March 26, 2020","April 6, 2020","April 23, 2020","April 15, 2020","April 1, 2020","March 30, 2020","March 30, 2020","April 13, 2020","March 27, 2020","April 13, 2020","March 27, 2020","March 17, 2020","April 9, 2020","April 4, 2020","April 6, 2020","April 2020","March 18, 2020","April 8, 2020","March 23, 2020","April 3, 2020","April 20, 2020","April 4, 2020","April 1, 2020","March 31, 2020","March 31, 2020","April 1, 2020","April 2, 2020","April 3, 2020","April 2020","April 6, 2020","April 2020","March 27, 2020","April 1, 2020","March 31, 2020","April 2, 2020","April 3, 2020","April 2020","May 2020","April 17, 2020","April 1, 2020","April 2020","April 1, 2020","April 15, 2020","April 10, 2020","March 23, 2020","February 28, 2020","April 15, 2020","April 2, 2020","April 2020","April 30, 2020","April 1, 2020","March 25, 2020","April 6, 2020","April 14, 2020","April 13, 2020","April 2020","March 30, 2020","April 3, 2020","April 6, 2020","February 15, 2020","April 8, 2020","April 6, 2020","April 20, 2020","April 7, 2020","April 7, 2020","April 2020","April 1, 2020","April 3, 2020","April 2020","March 25, 2020","April 7, 2020","May 2020","April 2020","April 3, 2020","March 31, 2020","April 1, 2020","December 23, 2019","April 2020","April 1, 2020","April 5, 2020","April 2020","April 2, 2020","April 6, 2020","March 1, 2020","April 3, 2020","April 15, 2020","April 6, 2020","April 15, 2020","April 2020","April 2020","April 12, 2020","January 10, 2019","April 5, 2020","April 2, 2020","April 10, 2020","April 17, 2020","March 15, 2020","May 1, 2020","April 7, 2020","June 1, 2020","April 5, 2020","April 1, 2020","April 2020","September 10, 2019","April 1, 2020","April 6, 2020","March 31, 2020","March 1, 2020","April 2, 2020","May 1, 2020","February 1, 2020","January 10, 2019","April 13, 2020","April 7, 2020","April 20, 2020","April 7, 2020","April 10, 2020","April 2, 2020","April 2020","March 30, 2020","April 10, 2020","April 10, 2020","April 3, 2020","April 15, 2020","July 1, 2020","April 20, 2020","April 15, 2020","May 1, 2020","April 10, 2020","April 1, 2020","April 2020","April 2020","March 3, 2020","April 11, 2020","April 1, 2020","June 1, 2020","April 6, 2020","April 11, 2020","April 9, 2020","April 9, 2020","April 20, 2020","April 2020","March 31, 2020","April 2020","April 2020","April 3, 2020","April 12, 2020","April 30, 2020","April 14, 2020","April 2020","March 25, 2020","April 2020","April 15, 2020","April 10, 2020","March 29, 2020","March 16, 2020","April 10, 2020","April 1, 2020","April 1, 2020","April 2020","April 8, 2020","March 16, 2020","April 8, 2020","April 10, 2020","April 8, 2020","May 1, 2020","April 10, 2020","April 15, 2020","April 10, 2020","April 1, 2020","April 10, 2020","April 10, 2020","April 2020","April 18, 2020","April 30, 2020","April 2020","April 10, 2020","April 8, 2020","April 2020","April 2020","April 2020","April 6, 2020","April 1, 2020","April 9, 2020","April 1, 2020","May 15, 2020","April 8, 2020","April 12, 2020","April 4, 2020","May 1, 2020","April 2020","May 2020","April 13, 2020","March 22, 2020","March 30, 2020","April 22, 2020","March 20, 2020","April 20, 2020","April 9, 2020","April 15, 2020","April 17, 2020","April 9, 2020","April 1, 2020","March 31, 2020","April 2, 2020","April 2020","April 2020","April 14, 2020","April 13, 2020","April 1, 2020","April 10, 2020","April 10, 2020","May 2020","March 18, 2020","April 15, 2020","April 2020","April 8, 2020","April 20, 2020","April 14, 2020","April 8, 2020","April 14, 2020","March 26, 2020","April 16, 2020","April 13, 2020","April 21, 2020","April 15, 2020","April 15, 2020","April 15, 2020","April 15, 2020","April 20, 2020","April 15, 2020","May 2020","May 2020","April 15, 2020","March 27, 2020","April 20, 2020","March 15, 2020","April 14, 2020","April 2020","March 27, 2020","April 15, 2020","April 3, 2020","April 10, 2020","April 14, 2020","April 13, 2020","April 20, 2020","February 26, 2020","April 8, 2020","April 15, 2020","April 27, 2020","April 20, 2020","April 8, 2020","March 6, 2020","March 31, 2020","April 14, 2020","April 14, 2020","April 9, 2020","April 2020","April 14, 2020","April 20, 2020","April 2020","April 12, 2020","April 2020","April 2020","April 15, 2020","April 10, 2020","April 20, 2020","April 23, 2020","May 1, 2020","April 24, 2020","April 20, 2020","April 1, 2017","April 2020","April 2020","April 2020","April 15, 2020","April 27, 2020","April 2020","April 15, 2020","April 13, 2020","April 15, 2020","January 17, 2020","April 20, 2020","April 15, 2020","April 15, 2020","April 2020","February 1, 2020","April 11, 2020","March 27, 2020","April 11, 2020","April 12, 2020","April 15, 2020","April 2020","January 1, 2019","April 20, 2020","April 2020","April 13, 2020","April 24, 2020","April 2020","20/04/2020","April 6, 2020","April 15, 2020","April 15, 2020","April 21, 2020","April 11, 2020","April 22, 2020","01/06/2020","April 12, 2020","April 20, 2020","April 2020","April 20, 2020","17/03/2020","May 2, 2020","April 16, 2020","07/04/2020","April 27, 2020","April 30, 2020","April 20, 2020","April 2020","April 2020","April 20, 2020","16/04/2020","April 20, 2020","April 8, 2020","April 11, 2020","April 14, 2020","19/03/2020","April 17, 2020","April 15, 2020","April 20, 2020","April 2020","April 16, 2020","April 9, 2020","April 2020","April 2020","April 15, 2020","April 2020","April 17, 2020","April 1, 2020","20/03/2020","April 2020","April 2020","April 15, 2020","April 15, 2020","20/04/2020","01/06/2020","27/04/2020","April 2020","April 16, 2020","April 20, 2020","April 2020","10/04/2020","26/03/2020","01/05/2020","14/04/2020","01/06/2020","25/03/2020","19/03/2020","13/12/2019","13/04/2020","02/04/2020","2020-02-08","26/03/2020","May 2020","April 17, 2020","March 6, 2020","April 2020","06/04/2020","2020-04-01","2020-02-05","April 27, 2020","April 2020","2020-01-20","April 20, 2020","20/04/2020","27/04/2020","07/04/2020","01/05/2020","20/04/2020","2020-03-18","2020-04-01","09/04/2020","2020-04-16","2020-06-01","2020-04-15","15/03/2020","06/04/2020","08/04/2020","2020-02-18","2020-02-20","2020-04-01","2020-02-02","18/03/2020","2020-04-17","2020-05-01","09/04/2020","2020-01-31","2020-02-11","15/04/2020","13/04/2020","23/03/2020","27/03/2020","2020-04-01","12/04/2020","2020-02-01","10/04/2020","2020-02-01","14/04/2020","23/03/2020","18/04/2020","10/12/2019","11/04/2020","16/03/2020","16/03/2020","09/04/2020","15/03/2020","07/04/2020","31/03/2020","06/04/2020","13/04/2020","27/03/2020","09/04/2020","11/04/2020","09/04/2020","09/04/2020","10/04/2020","08/04/2020","14/04/2020","11/04/2020","13/04/2020","03/04/2020","14/04/2020","09/04/2020","07/04/2020","16/04/2020","11/04/2020","11/04/2020","15/04/2020","26/03/2020","14/04/2020","09/04/2020","15/04/2020","14/04/2020","16/09/2015","24/03/2020","06/04/2020","02/04/2020","05/04/2020","20/04/2020","01/04/2020","30/03/2020","03/04/2020","05/04/2020","26/03/2020","15/02/2020","01/04/2020","16/03/2020","31/03/2020","07/04/2020","26/03/2020","16/03/2020","08-04-2020","29/03/2020","05/04/2020","2020-04-03","31/03/2020","23/04/2020","2641-06-14","2020-03-18","20/04/2020","14/04/2020","2020-04-05","12/04/2020","2020-02-28","2020-03-15","09-04-2020","2020-03-27","2020-03-16","20/03/2020","13-04-2020","2020-04-04","08-04-2020","01-05-2020","2020-03-23","27-04-2020","2020-04-08","2020-03-29","15-04-2020","2020-03-15","2020-03-15","2020-03-15","2020-03-24","2020-03-16","2020-03-26","2020-03-28","2020-04-26","2020-03-28","2020-04-03","2020-03-27","2020-03-03","2020-04-02","2020-04-05","2020-03-19","2020-03-20","2020-03-22","2020-04-08","2020-03-15","2020-03-18","2020-04-01","2020-03-20","2020-03-11","2020-04-03","2020-03-29","2020-03-30","2020-03-20","2020-03-25","2020-03-28","2020-04-19","2020-04-14","2020-04-03","2020-03-23","2020-04-02","2020-04-18","2020-04-08","2020-04-01","2020-04-04","2020-03-18","2020-03-28","2020-04-02","2020-03-24","2020-03-05","2020-04-20","2020-04-02","2020-03-28","2020-04-07","2020-04-20","2020-03-10","2020-03-10","2020-04-15","2020-03-24","2020-04-05","2020-04-20","2020-04-09","2020-04-08","2020-03-20","2020-04-18","2020-04-09","2020-04-10","2020-03-30","2020-04-05","2020-04-18","2020-04-29","2020-04-08","2020-03-30","2020-03-31","2020-04-13","2020-03-15","2020-04-07","2020-04-14","2020-04-29","2020-04-06","2020-04-07","2020-04-20","2020-04-20","2020-03-28","2020-04-20","2020-04-08","2020-05-19","2020-04-20","2020-04-20","2020-04-20","2020-04-05","2020-04-13","2020-04-15","2020-04-20","2020-04-18","14/04/2020","2020-03-30","2020-04-18","2020-04-16","2020-04-24","2020-04-13","2020-04-23","2020-04-21","2020-04-13","2020-04-20","15/04/2020","26/03/2020","31/3/2020","2020-04-14","2020-04-18","01/05/2020","27/03/2020","14/03/2020","01/04/2020","2020/04/01","10/04/2020","2020/04/14","30/03/2020","2020/03/28","01/05/2020","17/04/2020","2020/04/17","19/03/2020","27/04/2020","01/04/2020","2020/04/17","24/03/2020","07/04/2020","27/03/2020","03/04/2020","20/03/2020","14/04/2020","01/06/2020"],["survival group:200;died:200;","Case series:100;","experimental group:10;control group:10;","control group:15;experimental group:15;","case series:100;","500","Case series:40;","experimental group :100;control group :100;","125","12000","Experimental group:50;Control group:50;","Case series:27;","Case series:100;","Experimental group:30;Control group:30;","Target condition:10000;Difficult condition:300","case series:100;","Target condition:0;Difficult condition:0","Target condition:300;Difficult condition:300","TCM Group:150;QFPD decoction group:150;SFJD capsuale group:150;control group:150;","150","380","experimental group:80;control group:80;","experimental group:20;control group:20;","30000","Target condition:200;Difficult condition:0","control group:50;experimental group:50;","experimental group:150;control group:150;","General patients treated with normal treatment:30;General patients experimental group:30;Severe patients control group 1:10;Severe patients control group 2:10;Severe patients experimental group:10;","experimental group:56;control group:56;","Experimental group:260;Control group:260;","Experimental group:30;Control group:30;","Normal group:10;Severe group:10;","Experimental group:50;Control group:50;","Case series:40;","Case series:500;","Experimental group:70;Control group:40;","Case series:800;","Experimental group:36;Control Group:36;","Thymosin treatment group:40;PD-1 treatment group:40;Conventional treatment group:40;","80","160","experimental group :100;control group:100;","Conventional treatment group:50;Experimental group:50;","Control group:60;Experimental group:60;","Control group :30;Intervention group :30;","control group:94;Experience group:94;","Control group:200;Experimental group:200;","control group:30;experimental group:30;","experimental group:204;control group:204;","Case series:100;","experimental group:119;control group:119;","control group :15;Experimental group :15;","Experimental group:100;control group:100;","Experimental group:10;control group:10;","experimental group:164;control group:164;","Case series:200;","control group:50;Experimental group:50;","Group 1:50;Group 2:50;","Treatment group:1000;","Experimental Group:28;Control Group:14;","Case series:1000;","Case series:271;","(ordinary) Western medicine group:40;(ordinary) Chinese and Western Medicine Group:40;(severe) Western medicine group:30;(severe) Chinese and Western Medicine Group:30;","Experimental group:220;Control group:220;","Experimental group:30;control group:30;","treament group:50;placebo group:50;","experimental group:30;\t Control group:30;Control group:30;","experimental group \t:50;control group :50;","Vitamin D deficiency group:104;Vitamin D normal group:52;","doctors group:48;nurses group:48;suspected cases group:48;cases group:48;","Experimental group:50;Control group:50;","Target condition:80;Difficult condition:0","Control group:10;Investigation group:10;","Target condition:500;Difficult condition:100","Experimental group:60;Control group:60;","Two groups:16;","Experimental group:300;Control group:300;","Chinese traditional medicine group 1:60;Chinese traditional medicine group 2:60;Control group:60;","Group A:30;Group B:30;Group C:30;","Experimental group:10;Control group:10;","control group:15;experimental group:15;","experimental group 1:100;experimental group 2:100;Placebo control group:100;","Experimental group 1:10;Experimental group 2:10;Control group:10;","DRV/c group:40;LPV/r group:40;other group:20;","Experimental group:100;Control group:100;","experimental group:60;Historical Control:60;","Case series:300;","Community exposure TCM intervention group:20;Community exposure control group:20;Hospital exposure TCM intervention group:20;Hospital exposure control group:20;Community suspected TCM intervention group:20;Community suspected control group:20;Hospital su","Case series:600;","Case series:100;","Group A:20;Group B:20;Group C:20;","Observation  group:300;Health  education unit:100;","Target condition:40;Difficult condition:0","Experimental group:40;Control group:40;","Case series:100;","Experimental Group:40;Control Group:40;","Experimental group:20;Control group:20;","control group:30;mild ill patients:15;severe/critical ill patients:15;","Combination therapy group:232;Conventional treatment group:116;","Case series:50;","Case series:72;","Severe group:200;Critical group:200;Light group:200;Common group:200;","A:15;B:15;C:15;","Exercise prescription group:200;Control group:200;","1:30;2:30;","experimental group:30;control group:30;","Epilepsy group:500;Health Control group:1000;","Psychological Intervention Group:90;Control Group :90;","Suspected patient control group:100;Suspected patient Treatment group:100;Common NCP patient control group:50;Common NCP patient Treatment group:50;Severe NCP patient:50;","non-severe group and severe gorup:500;","Case series:40;","Experimental group:190;Control group:190;","mild-moderate chloroquine group:59;mild-moderate Lopinavir/ritonavir group:59;mild-moderate combination group:59;severe-chloroquine group :14;severe- Lopinavir/ritonavir group:14;","experimental group A:18;control gorup A:15;Experimental Group B1:10;Experimental Group B2:10;Control Gorup A:10;","Low dose group:100;Medium dose of group:100;High dose of group:100;Control group:100;","Experimental:150;control:150;","Experimental group :100;Control group:100;","Experimental group:80;Control group:80;","Case series:40;","case series:100;","single arm:200;","Experimental group:88;Control group:44;","Intervention group 1:276;Intervention group 2:276;Control group:276;","A:10;B:10;C:10;","experimental group:50;Control group:50;","experimental group:50;Control group:50;","experimental group:50;control group:50;","control group:60;experimental group:60;","Group 1:200;Group 2:200;","300","120","Case series:20;","Experimental group:50;Control group:50;","Case series:10;","Control group:15;Experimental group:15;","Case series:120;","Adolescent group:50;Childbearing group:100;Climacterium group:50;","Severe group:100;Non-severe group:100;","1:30;2:30;","Case series:10;","Case series:300;","Case series:2000;","Case series:100;","Experimental group:100;Control group:100;","Case series:20;","Experimental group:30;Control group:30;","Case series:60;","10","Experimental group:80;Control group:40;","Case series:20;","Ganovo / ritonavir group:10;Pegasys group:10;Novaferon group:10;Coriolus group:10;Comparator:10;","Experimental group:120;Control group:120;","Experimental group:50;Control group:50;","Mild Group:30;Severe Group:30;","Experimental group:60;Control group:60;","severe NCP group:8;Acute exacerbation NCP group:8;","Experimental group:30;Control group:30;","Case series:130;","Low-dose group:20;Middle-dose group:20;High-dose group:20;","pneumonia patients group:100;medical staff group:100;","Control group:100;Experimental group:100;","Chloroquine phosphate gloup:40; Hydroxychloroquine sulfate gloup:40;Routine treatment group:20;","experimental group:60;control group:60;","Control group:93;Experimental group:93;","Control group:30;Experimental group:70;","COVID-19 pregnant women and normal pregnant women and infants born to them:30;","Target condition:60;Difficult condition:0","Target condition:120;Difficult condition:0","common group:400;severe group:400;critical group:400;","Humanistic care:100;Control group:30;","control group:34;Experience group:34;","Experimental group:150;Control group:150;","control group with common NCP:30;experimental group with common NCP:30;experimental group with severe NCP:30;control group with severe NCP:30;experimental group with critical NCP:30;control group with critical NCP:30;","Experimental group:30;Control group:30;","experimental group:80;control group:80;","A1:80;A2:80;B1:80;B2:80;","Experimental group:20;Control group:20;","Light group:200;Common group:200;Severe group:200;Critical group:200;","general anesthesia group vs. intraspinal anesthesia group:30;Health care goup:180;","hydroxychloroquine group:54;control group:24;","experimental group:80;control group:80;","Hydroxychloroquine sulfate gloup:40;Chloroquine phosphate gloup:40;Control group:20;","Experimental group:30;control group:60;","Case series:10;","Case series:20;","Training:150;Vaidation:450;","college students:150000;","300000","100","500","450","Group 1:120;Group 2:240;Group 3:120;","control group:30;Experience group:30;","experimental group.:150;Control group:150;","20","348","Experimental group:40;Control group:40;","Control group:30;Experimental group:30;","Case series:1853;","40","100","Experimental group:20;control:20;","Target condition:3000;Difficult condition:0","Control group:100;Experimental group 1:100;Experimental group 2:100;","20","Case series:100;","Monitor cases, suspected cases and diagnosed cases:120;","100","one group:80;","Group 1:40;Group 2:40;","Case series:30;","Case series:100;","Case series:1000;","Case series:50;","136","30","Case series:40;Control group:40;","Light and common type group:80;Severe group:40;Western medicine treatment group:30;Chinese and western medicine combined treatment group:30;Non-invasive mechanical ventilation group:15;Nasal high flow oxygen therapy group:15;","Case series:200;","Intervention group:500;","Case series:40;","Target condition:25;Difficult condition:25","Two groups:40;","Experimental group:170;Control group:170;","Exposure group:60;Control group:60;","Pirfenidone group:147;Control group:145;","Case series:20;","The experimental group:150;Control group:150;","Mild group:100;Serere group:30;","Case series:120;","Group 2:10;Group 3:10;Group 1:10;","Case series:200;","case series:100;","High inflammation oXiris CRRT treatment group:10;High inflammation Conventional treatment group:10;Low inflammation conventional treatment group:10;","Burnout positive group versus burnout negative group:1000;","Exocrine group:13;Control group:13;","Experimental group:10;Control group:10;","Routine treatment +  Jing-Yin Granule:200;Routine treatment :100;","Target condition:30;Difficult condition:30","Case series:300;","Experimental group 1:20;Control group (Mild patients):20;Experimental group 2:20;Control group (general patient):20;Experimental group 3:20;Control group (severe patients):20;","Case series:2000;","Case series:60;","Experimental group:30;Control group:30;","Experimental group:30;Control group:30;","Case series:120;","Case series:100;","the elderly population:658;","Experimental group:50;Control group:50;","Experimental group:300;Control group:150;","Experimental group of ordinary COVID-19:30;Control group of ordinary COVID-19:30;Experimental group of severe COVID-19:20;","Kesuting syrup group:24;Keqing capsule group:24;control group:24;","Case series:40;","experimental group:60;control group:60;","Experimental group:93;Control Group:93;","Case series:500;","General population:5000;","Case series:0;","Case series:200;","Experimental group:100;Control group:100;","Case series:240;","Experimental group:10;","Low-dose group:60;Medium-dose group:60;High-dose group:60;control group:60;","Experimental group:30;Control group:30;",null,"control group 1:20;control group 2:20;Experimental group:20;","arm A:36;arm B:36;arm C:36;","hydroxychloroquine sulfate:50;phosphate chloroquine:50;","Experimental group:24;Control group:24;","Experimental group:120;Control group:120;","hydroxychloroquine sulfate:50;phosphate chloroquine:50;","Case series:40;","Case series:70;","experimental group:50;control group:50;","520","Case series:192;","case series:500;","experimental group:50;control group:50;","Target condition:200;Difficult condition:200","Experimental group:30;Control group:30;","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:600;","CRRT group:76;Control group:76;","30","Case series:150;","230","294","Control group:30;Experimental group:170;","Azvudine Plus Symptomatic treatment:10;","Case series:12;","Group 2:50;Group 1:40;","Case series:100;","Case series:1030;","Experimental group:10;Control group:10;","Early corticosteroid intervention group:75;Middle-late corticosteroid intervention group:75;Control group:50;","Case series:35;","Lipoic acid group:197;Blank control group:197;","Medical students group; Non-medical students group:1300;","39","120","Control group:30;Experimental group:30;","Experimental group:15;Control group:15;","Control group:48;Experimental group:48;","Experimental group:30;Control group:30;","PRE-GROUP1:400;PRE-GROUP2:400;TRE-GROUP1:100;TRE-GROUP2:50;","Case series:200;","Patients in Wuhan versus Sichuan:100;","Group 2:35;Group 1:35;","Experimental group:20;Control group:20;","ACEIs/ARBs:100;","COVID-2019 patients in Tongji Hospital:250;COVID-2019 patients in Mobile field hospital:250;Medical staff in Tongji Hospital:250;Control:250;","Experimental group:150;control group:150;","monitor cases, suspected cases and diagnosed cases:120;","Case series:24;","treatment group1:30;treatment group 2:30;control group:30;","Experimental group:35;control group:35;","Case series:300;","Case series:1500;","Case series:8000;","cross-sectional study:1300;","Experimental group 1 (mild):150;Experimental group 1 (moderate):150;","Case series:19;","Interferon Therapy Group:164;Control group:164;","Experimental group:200;Control group:200;","Case series:200;","Case series:256;","Control group:50;Experimental group:50;","Experimental group:10000;blank cntrol group:10000;","Case series:19;","group A:20;control group:20;","Case series:100;","Case series:24;","Treatment group:50;Control group:50;","patient group:200;Health care team:60;","Case series:1000;","400","80","Case series:200;","Group 1:90;Group 2:30;Group 3:30;","Experimental group:100;Control group:100;","intervention group:80;Control group:80;","Observation group:50;","Case series:5000;","Ordinary COVID-19 patients:100;Heavy COVID-19 patients:50;","576","3428","120","Population under risk:1000;","15","328","Control group:10;Experimental group:10;","MSC group:30;","Case series:90;","Case series:1000;","Case series:100;","Case series:100;","Case series:50;","Experimental group:20;Control group:20;","The triple combination antiviral therapy:196;The dual combination antiviral therapy:41;","Case series:50;","Group 1:700;Group 2:605;","Case series:200;","Case series:100;","Experimental group:50;control group:50;","Case series:200;","Case series:150;","Case series:30;","Case series:483;","Case series:200;","Target condition:1000;Difficult condition:0","Case series:1000;","Target condition:600;Difficult condition:100","Group 2:150;Group 1:150;","Observation group:113;Control group:113;","High dose group:10;Low dose group:10;","Case series:81;","Target condition:400;Difficult condition:0","Case series:500;","Case series:90;","Experimental group:5;Control group:5;","Case series:100;","Case series:75;","Case series:40;","Case series:600;","Group 1:200;Group 2:200;Group 3:200;Group 4:200;","Case series:200;","\t Case series:10;","control group:14;experimental group:56;","Case series:100;","Case series:150;","non-cancer COVID-19 versus cancer with COVID-19:100;","experimental group:20;","NIV group:150;MV group:50;","Case series:200;","severe patients:400;","Exocarpium Citri Grandis Group:64;Placebo Group:64;","Case series:100;","Case series:100;","Case series:2000;","Case series:60;","Case series:500;","discharge group:100;","Target condition:1000;Difficult condition:0","Target condition:22;Difficult condition:57","Case series:20;","Case series:100;","Case series:200;","Case series:150;","Case series:20;","Experimental group:50;Control group:50;","4 groups:2800;","Case series:450;","case series:100;","transnasal high-flow oxygen therapy:50;noninvasive mechanical ventilation:30;invasive mechanical ventilation:20;","Case series:100;","Case series:60;","Case series:20;","two groups:74;","case series:100;","Case series:400;","case series:100;","Experimental group:40;Control group:40;","Case series:1000;","Target condition:30;Difficult condition:0","ECMO group:10;the conventional treatment group:20;","Exposed group:130;Control group:130;","Case series:78;","case series:500;","case series:100;","in hospital:50;Recovered:100;","Target condition:50;Difficult condition:0","Target condition:300;Difficult condition:200","Integrated traditional Chinese and western medicine group:771;Western medicine group:300;","experimental group:30;control group:30;","Control group :750;Comprehensive treatment group:750;","experimental group:20;control group:20;","Two groups:30;","experimental group:30;control group:30;","Case series:30;","experimental group:30;control group:30;","Infection without renal injury group:30;Infection with proteinuria group:30;Infection with hematuria group:30;Infection with impaired renal function group:30;","Target condition:234;Difficult condition:0","Group 2:60;Group 1:60;","1:132;2:132;","Control group:100;Experimental group 1:100;Experimental group 2:100;","Group A:60;Group B:60;Group C:60;Group D:60;","Case series:50;","Control group:30;CIK group:30;NK group:30;","eperimental group:25;control group:25;","Experimental group:30;Control group:30;","Case series:160;","treatment group :16;","Case series:15;","Case series:1500;","Target condition:150;Difficult condition:0","Positive drug control group:60;Compound Yuxingcao Mixture Group:60;","Case series:960;","experimental group:20;control group:20;","Routine treatment group:230;Dipyridamole treatment group:230;","Experimental group:30;Control group:30;","Experimental group:30;control group:30;","tumor patients group:300;","Phosphoric chloroquine:80;Placebo:40;","Case series:66;","Target condition:200;Difficult condition:0","Case series:160;","Two cohorts:1000;","High dose group:20;Conventional dose group:20;Preventive dose group:20;","Phosphoric chloroquine:80;Placebo:40;","Experimental group:30;Control group:30;","case series:500;","Phosphoric chloroquine:30;Placebo:15;","Chinese medicine treatment cohort:40;Integrated Chinese and western medicine treatment cohort:40;Western medicine treatment cohort:40;","Case series:150;","Case series:410;","Group 1:30;Group 2:30;","experimental group:20;control group:20;","1:100;2:100;","Experimental group:15;control group:15;","24","Case series:80;","140","50000","150","Diagnosed Group:98;Suspending Group:102;","Experimental group:20;Control group:20;","Experimental group:26;Control group:13;","Case series:300;","Target condition:400;Difficult condition:100","Pirfenidone group:20;Support treatment group:20;","Case series:30;","COVID-19  patients:314;","Group 1:30;Group 2:30;","Target condition:1000;Difficult condition:0","Experimental group :30;Control group:30;","Experimental group:30;Control group :30;","SFBT group:38;Waiting Group:38;","Experimental group:30;control group:30;","Case series:500;","Group 2:160;Group 1:160;","Case series:200;","Critical group/ Ordinary group:200;","SARS-COV-2 RNA Positive group:50;SARS-COV-2 RNA Negative group:50;","Case series:10;","Case series:34;","Case series:2000;","A:15;B:15;","8","100","1:80;2:40;","Case series:93;","the patients of 2019 new coronavirus pneumonia:50;","Group 1:36;Group 2:36;Group 3:36;","Case series:200;","1:36;2:36;3:36;","669","Case series:150;","COVID-19 patients:100;","Case series:90;","Case series:40;","Case series:20;","COVID-19 patients:60;","Experimental group:30;Control group:30;","Experimental group:120;Control group:120;","experimental group:150;control group:150;","1 the critical group :8;2 the severe group:8;3 the control group of the critical group:8;4 the control group of the severe group:8;","Target condition:300;Difficult condition:0","Target condition:30;Difficult condition:0","Tricholoma matsutake group:25;Cannabis sativa capsule group:25;Dendrobium candidum group:25;Routine treatment group:25;",null,"Experimental group:1000;Control group:1000;","Target condition:80;Difficult condition:20","Experimental group 1:50;Experimental group 2:50;Control group:50;","experimental group:30;control group:30;","tumor patients group:200;non tumor patients group:200;","cross-sectional study:1300;","Mild Type Group A:80;Mild Type Group B:80;Common and Heavy Type Group C:160;Common and Heavy Type Group C:160;","Target condition:2500;Difficult condition:500","Intervention A:30;intervention B:30;intervention C:30;","Experimental group:10;Control group:10;","Case series:191;","100","60","25","observational:80;","0","100","control group:20;Experimental group (mild and normal type in patients with new coronavirus pneumonia):20;","Case series:94;","500","Experimental group:180;Control group:180;","2000","0","400","60","86","100","550","10","300","9999","0","5000","60","500","5","0","10","120","201","340","30","116","100","Case series:5000;","Target condition:0;Difficult condition:0","200","1000","100","5000","mild recovery:200;severe recovery:200;control:200;","80","20","Cesarean section:2000;","hDPSCs group:10;Control group:10;","Case series:160;","Target condition:1000;Difficult condition:0","Case series:120;","Case series:300;","Group M:30;Group C:30;","200","Case series:400;","Survival and D:200;","Case series:120;","Case series:240;","mindfulness intervention group:60;control group:50;","Control group:40;Experimental group:40;","Case series:100;","Case series:60;","Case series:500;","Case series:2000;","Experimental treatment group:150;control group:150;","Case series:68;","Case series:1292;","Case series:40;","Case series:60;","Case series:200;","Case series:150;","1:14;2:14;","CM group:2130;WM group:710;","treatment group:60;control group:30;","Experimental group:38;control group:38;","Suspected case treatment group:150;Suspected case control group:150;Confirmed case  treatment group:50;Confirmed case control group:50;","Experimental group:72;Control group:72;","Homeopathic patient:100;","Experimental group:102;control group:102;","Experimental group:25;Control group:25;","Case series:60;","460","Case series:10;","Experimental group:20;Control group:20;","experimental group:102;control group:102;","Case series:1000;","confirmed group:100;control group:60;","200","216","experimental group:30;control group:30;","200","1000","60","1220","3100","150","220","Light group:200;Common group:200;Severe group:200;Critical group:200;","400","COVID-19 group:100;Healthy people:50;","49","50","500","500","140","7576","1000","104","1116","170","2300",null,"1302508","90","1500","300","0","40000","1000","1000","500000","500","100","ARBs Group:60;non-ARBs Group:120;","Control group :20;normal group:20;severe group:20;","287","400","Group 1:96;Group 2:96;","Case series:7000;","Experimental group:18;Control group:18;","Control:50;Noninvasive cardiopulmonary monitoring group:50;","Group 1:10;Group 2:10;","Case series:120;","1600","120","Target condition:200;Difficult condition:0","experiment group:29;experiment group :29;","1000","Experimental group:30;control group:30;","experimental group:28;control group :28;","Different dose groups:15;",null,"Experimental group:100;Control group:100;","cross-sectional study:462;","Target condition:500;Difficult condition:0","3100","ordinary group versus severe group versus critical group versus deceased patients group:2000;","Mild:400;severe:200;",null,"Experimental group:50;Control group:50;","Medical personnel group:123;","60","Rheumatic disease with COVID-19:1000;Rheumatic disease without COVID-19:1000;","eye patch and earplugs:16;eye patch:39;","1300","Nintedanib group:40;Control group:40;","680","Case series:820;","COVID-19 with risk factors:800;COVID-19 without risk factors:1200;","50","Target condition:200;Difficult condition:0","200","20","280","20","400","304","1000","100000","2944","440","470","202","200","400","50","15","180","4","1000","200","900","240","30","75","2500","250","300","80","440","200","180","200","200","1500","25","50000","200","2486","2000","12500","141","12000","3000","1000","50","9","2000","2000","346","10","80","115","500","30","120","500","60","50","375","120","50","1250","230","194","60","50","400","200","70","300","600","162","58","160","50","154","10","20","mild, moderate, severe ARDS:45;","Case series:130;","Experimental group:45;Control groop:60;","40","100000","150","Case series:119;","Patients with LE and are taking hydroxychloroquine:200;Patients with LE and are not taking hydroxychloroquine:50;Patients with dermatomyositis and are taking hydroxychloroquine:200;Patients with dermatomyositis and are not taking hydroxychloroquine:100;P","Case series:883;","1:250;2:125;3:125;","survival group:39;death group:36;","intervention group:72;Control group:78;","Case series:40;","Case group:30;control group:30;","1:50;","For the mild new coronary pneumonia: General Ward Group:20;For the severe new coronary pneumonia: ICU Group:17;Support staff: Logistics group:10;","Case series:200;","Experimental group:60;Control group:60;","Target condition:600;Difficult condition:0","Experimental group:30;Control group:30;","NK cell group:10;Control group:10;","Target condition:33;Difficult condition:30","Experimental Group:75;Control Group:75;","Case series:2000;","common type :30;Latent period group:30;Normal control group:30;Blank vaccine control group:30;","Novel coronavirus pneumonia:600;","Case series:498;","1000","554","584","106","130","342","1057","122","1200","100000","273","120","40","550","100","84","276","200","4000","1530","440","350","132","104","800","250","80","30","75","117","308","30","20","400","66","50","127","11","48","1000","237","30","45","90","20","320","100","108","300",null,"1600","6000","240","200","580","120","400","275","3000","150","3040","19491","200","200","66","20","250","630","400","5","38","500","200","700","226",null,"230","400","50000","150","330","200000","100","310","4000","6000","1000","200","533","1000","239","600","200","30","110","54","1000","0","300","290","510","198","5000","584","80","4170","1300","120","1200","3500","200","450","630","4000","400","200","150","2414","300","436","250","1660","6000","3000000","400","30","800","342","440","5","10000000","440","64","50","2271","130","240","30","276","3170","5000","40","55000","100","210","210","510","360","15000","120","5000","750","210","500","273","200","2500","100","20","1550","600","84","4000","50","4000","24","240","100","500","350","30","100","333","20","30","214","750","500","160","50","100","100","250","10","100","100","2000","70","300","200","150",null,"176","6000","100000","5000","40","100","300","200","260","914","100",null,"1000000","20","100","12","1200","200","500","334","80","200","200","120","84","200","152","1500","10000","200","30",null,"50","12123","240","3000","207","96","25","180","2700","10","220","30","40","5000","500","20","140","500","160","80","10","60","100","200","86","144","400","1464","40","240","200","10000","48","1000","500","20","400","1000","12","60","100","500","220","400","670","100","75","3000","426","504","520","40","210","1300","100000","92","15","24","550","152","150000","200","600","1450","60","50","420","50","874","60","20","55","200","200","100","10000","436","40","1500","30","100","353","5000","200","200","100","30","200","149","48","2000","30","1200","380","100","20","2000","25","500","600","300","40","850","100","500","70","400","320","20","350","80","10","60","1000","2800","100","310","808","130","90","45","150","500","500","400","45","122","5000","60","278","150","25","165","86","18","120","30000",null,"3000","120","1000","398","100","200","15","120","120","500","300","50","20","10","100","30","1000","100","30","428","128","150","120","138","100","900","5500","120","390","150","100","1000","40","30","500","8","500","100","20","400","40","500","15","120","1212","80","100","60","20","140","100","1000","1000","60","200","30","507","94","20","100","200","34","60","600","50","1200","230","10000","350","50000","10","80","100","50","500","200","25","120","200","102","54","56","80","100","1000","400","100","40","1000","500","20","60","40","40","865","1000","100","50","500","900","200","2500","10000","20","2170","24","3000","5000","70","988","400","Case series:30;","510","238","60","32","215","4002","Case series:240;","Case series:923;","804","66","Case series :300;","180","1","100","500","3000","20","Group 1:65;Group 2:65;","control group:2380;sachet group:476;Oral and nasal spray group:476;Oral Chinese medicine group:476;","200","experimental group:1000;control group:1000;","Case series:3000;","Case series:30;","20","75","2000","In-hospital rehabilitation group:60;Discharge follow-up rehabilitation group:100;","Case series:9;","Case series:30;","Two groups:8;","400","1.5ATA:15;2.5ATA:15;Control group:15;","Target condition:3000;Difficult condition:3000","194","Case series:9;","experimental group:150;\t control group:150;","568","8000","4000","20","Patient:30;Healthcare providers:30;","950","Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;","641","Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;","46","2000","13","26","216","100","17000","120","200","120","386","354","304","1000","450","1600","290","24","260","714","1500","165","24","200","1000","30","100","100","1000","103","6400","1218","102","126","100","50","4000","80","1300","1500","2000","60","30","15","2000","50","400","1000","100","220","1400","352","45","20000","5000","30","1000","30","100","90","45","50","2000","800","60","24","62","50","1000","80","150","60","32","10","500","1000","374","30","40","310","50000","30","30","500","10","60","70","40","40","30","60","40","20","100","100","125","200","30","60","200","60","30","120","40","60","100","60","200","70","60","40","48","60","68","120","105","40","324","50","60","5","100","10","48","40","60","100","100","40","130","64","260","80","110","500","15","80","30","40","60","906","60","84","60","100","3000","40","100","60","6","60","540","100","30","140","100","60","40","40","60","60","12","10","40","60","60","60","40","110","500","200","100","70","110","60","80","10","32","1000","200","100","96","82","15","72","100","50","50","3700","1300","1000","630",null,"206","600","600","20","400","99",null,"650","2300","80","1000","5000","200","2640"],["Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional","Observational study","Interventional study","Interventional","Observational","Interventional study","Observational study","Observational study","Interventional study","Diagnostic test","Observational study","Diagnostic test","Diagnostic test","Interventional study","Interventional","Interventional","Interventional study","Interventional study","Observational","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Basic Science","Observational study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional","Interventional","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Diagnostic test","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Prevention","Interventional study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Prevention","Diagnostic test","Interventional study","Prognosis study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational","Interventional","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Basic Science","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional","Interventional study","Treatment study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Diagnostic test","Diagnostic test","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational","Interventional","Observational","Observational","Interventional study","Interventional study","Interventional study","Interventional","Interventional","Interventional study","Interventional study","Observational study","Interventional","Observational","Interventional study","Diagnostic test","Interventional study","Observational","Interventional study","Observational study","Observational","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional","Interventional","Interventional study","Observational study","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Epidemilogical research","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Treatment study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Health services reaserch","Observational study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Observational study","Interventional study","Interventional","Observational study","Interventional","Interventional","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational","Interventional","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Epidemilogical research","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Epidemilogical research","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational","Interventional","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Interventional","Observational","Observational","Observational study","Observational","Interventional","Interventional study","Observational study","Health services reaserch","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Diagnostic test","Observational study","Diagnostic test","Interventional study","Observational study","Interventional study","Interventional study","Diagnostic test","Observational study","Observational study","Interventional study","Screening","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Diagnostic test","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Epidemilogical research","Observational study","Observational study","Epidemilogical research","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Diagnostic test","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Diagnostic test","Observational study","Interventional study","Observational study","Interventional study","Basic Science","Interventional study","Observational study","Interventional study","Basic Science","Diagnostic test","Interventional study","Epidemilogical research","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Diagnostic test","Interventional study","Health services reaserch","Interventional study","Prognosis study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Diagnostic test","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional","Observational study","Interventional","Observational [Patient Registry]","Interventional","Observational study","Interventional study","Interventional study","Observational study","Diagnostic test","Interventional study","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational","Interventional","Interventional study","Observational study","Basic Science","Interventional study","Observational study","Prevention","Observational","Health services reaserch","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Diagnostic test","Diagnostic test","Interventional study","Epidemilogical research","Observational study","Diagnostic test","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Observational study","Interventional","Interventional","Interventional clinical trial of medicinal product","Observational study","Interventional","Interventional","Interventional study","Observational study","Observational","Interventional study","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Observational","Interventional","Observational","Observational study","Diagnostic test","Observational","Observational","Observational","Observational","Observational study","Observational [Patient Registry]","Observational [Patient Registry]","Observational study","Interventional study","Observational study","Diagnostic test","Observational study","Observational study","Interventional study","Interventional","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Epidemilogical research","Observational study","Observational study","Observational study","Observational study","Interventional study","Treatment study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional clinical trial of medicinal product","Observational study","Interventional study","Interventional study","Epidemilogical research","Observational study","Observational","Interventional","Interventional study","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Interventional","Interventional clinical trial of medicinal product","Observational study","Interventional clinical trial of medicinal product","Observational study","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Expanded Access","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Observational","Observational [Patient Registry]","Interventional","Observational [Patient Registry]","Observational study","Basic Science","Observational","Observational [Patient Registry]","Interventional study","Health Services Research","Interventional study","Interventional study","Interventional study","Observational study","Interventional","Interventional","Diagnostic test","Health Services Research","Observational","Interventional study","Interventional study","Basic Science","Observational study","Interventional study","Observational study","Diagnostic test","Interventional clinical trial of medicinal product","Observational study","Observational study","Interventional clinical trial of medicinal product","Interventional study","Health Services Research","Interventional clinical trial of medicinal product","Observational study","Observational study","Interventional clinical trial of medicinal product","Interventional study","Interventional","Observational study","Observational study","Interventional clinical trial of medicinal product","Diagnostic test","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Interventional","Interventional clinical trial of medicinal product","Observational","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional clinical trial of medicinal product","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational [Patient Registry]","Observational","Observational","Interventional","Observational [Patient Registry]","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Observational","Observational [Patient Registry]","Interventional","Interventional","Interventional","Observational","Observational [Patient Registry]","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational study","Observational study","Interventional study","Interventional","Observational","Interventional","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Diagnostic test","Interventional study","Observational study","Interventional study","Observational study","Epidemilogical research","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Expanded Access","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational [Patient Registry]","Observational [Patient Registry]","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational [Patient Registry]","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational [Patient Registry]","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Observational [Patient Registry]","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational [Patient Registry]","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational [Patient Registry]","Interventional","Observational","Observational","Observational","Observational [Patient Registry]","Observational","Interventional","Observational [Patient Registry]","Expanded Access","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Expanded Access","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational [Patient Registry]","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Expanded Access","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Observational","Observational","Observational [Patient Registry]","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Observational","Observational [Patient Registry]","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational [Patient Registry]","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Expanded Access","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational [Patient Registry]","Observational","Interventional","Interventional","Observational","Observational","Observational","Observational","Observational","Observational","Interventional","Observational [Patient Registry]","Observational","Observational [Patient Registry]","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Observational","Interventional","Observational","Interventional","Observational [Patient Registry]","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational [Patient Registry]","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational study","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational study","Observational study","Interventional","Interventional","Interventional study","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational study","Interventional study","Observational","Interventional study","Observational study","Observational study","Observational","Interventional","Observational","Interventional study","Interventional study","Observational study","Interventional study","Observational","Interventional study","Diagnostic test","Interventional clinical trial of medicinal product","Observational study","Interventional study","Interventional clinical trial of medicinal product","Observational","Observational","Observational","Observational study","Interventional","Interventional study","Interventional clinical trial of medicinal product","Interventional study","Interventional clinical trial of medicinal product","Observational","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Observational","Interventional","Interventional clinical trial of medicinal product","Observational","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","interventional","observational","observational","observational","interventional","observational","observational","observational","observational","observational","observational","observational","observational","interventional","observational","observational","Observational","interventional","observational","interventional","observational","interventional","interventional","interventional","observational","observational","interventional","observational","interventional","interventional","Observational","interventional","interventional","observational","Interventional","interventional","Interventional","Observational","interventional","Interventional","interventional","interventional","Observational","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","Observational","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","interventional","Interventional","Interventional","INTERVENTIONAL","interventional","interventional","Interventional","Interventional","Interventional","Interventional","Observational","Intervention","Observational","Intervention","Others,meta-analysis etc","Interventional","Interventional","Observational","Observational","Interventional","Intervention","Others,meta-analysis etc","Observational","Observational","Interventional","Interventional","Observational","Intervention","Observational"],["Factorial","Single arm","Non randomized control","Non randomized control","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Sequential","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Parallel","Sequential","Sequential","Parallel","Factorial","Sequential","Factorial","Sequential","Non randomized control","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel",null,"Sequential","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Factorial","Sequential","Single arm","Sequential","Parallel","Sequential","Parallel","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Non randomized control","Parallel","Sequential","Parallel","Parallel","Parallel","Non randomized control","Parallel","Sequential","Parallel","Non randomized control","Single arm","Parallel","Sequential","Factorial","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Factorial","Factorial","Non randomized control","Sequential","Parallel","Sequential","Parallel","Dose comparison","Parallel","Parallel","Non randomized control","Parallel","Parallel","Parallel","Parallel","Parallel","Case-Control study","Non randomized control","Single arm","Parallel","Sequential","Sequential","Non randomized control","Non randomized control","Sequential","Non randomized control","Cohort study","Parallel","Parallel","Factorial","Parallel","Single arm","Sequential","Factorial","Parallel","Parallel","Non randomized control","Parallel","Factorial","Parallel","Non randomized control","Factorial","Sequential","Parallel","Non randomized control","Parallel","Parallel","Parallel","Parallel","Parallel","Single arm","Sequential","Single arm","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Non randomized control",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Sequential","Parallel","Sequential","Parallel","Sequential","Factorial","Factorial","Parallel","Single arm","Sequential","Sequential","Sequential","Parallel","Single arm","Parallel","Single arm","Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Parallel","Sequential","Non randomized control","Parallel","Parallel","Factorial","Parallel","Factorial","Parallel","Single arm","Parallel","Factorial","Parallel","Parallel","Parallel","Parallel","Non randomized control","Factorial","Sequential","Factorial","Factorial","Non randomized control","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Factorial","Factorial","Parallel","Parallel","Parallel","Non randomized control","Sequential","Sequential","Factorial","Sequential",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Parallel","Parallel","Parallel","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Parallel","Sequential","Parallel",null,"Non randomized control","Sequential",null,"Single arm","Parallel","Single arm","Sequential","Sequential","Single arm","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Factorial","Sequential","Sequential","Single arm","Factorial","Non randomized control","Parallel","Non randomized control","Parallel","Single arm","Parallel","Factorial","Sequential","Sequential","Sequential","Single arm","Parallel","Sequential","Parallel","Parallel","Parallel","Cross-sectional","Sequential","Parallel","Sequential","Single arm","Parallel","Single arm","Sequential","Sequential","Sequential","Parallel","Non randomized control","Parallel","Parallel","Sequential","Parallel","Parallel","Sequential","Sequential","Sequential","Sequential","Parallel","Sequential","Single arm","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Sequential","Sequential","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Sequential","Parallel","Sequential","Non randomized control","Factorial","Parallel","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Single arm","Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Non randomized control","Single arm","Sequential","Factorial","Single arm","Sequential","Non randomized control","Parallel","Sequential","Parallel","Sequential",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel","Parallel","Parallel","Non randomized control","Sequential","Cross-sectional","Parallel","Parallel","Sequential","Sequential","Parallel","Sequential","Single arm","Parallel","Parallel","Sequential","Sequential","Sequential","Sequential","Factorial","Single arm","Parallel","Parallel","Sequential","Sequential","Parallel","Cluster randomization","Single arm","Parallel","Single arm","Single arm","Parallel","Factorial","Sequential",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Parallel","Parallel","Parallel","Single arm","Sequential","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).",null,null,"Sequential",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Single arm","Sequential","Sequential","Sequential","Sequential","Non randomized control","Parallel","Cohort study","Cohort study","Factorial","Sequential","Sequential","Cross-sectional","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Non randomized control","Factorial","Single arm","Sequential","Sequential","Sequential","Factorial","Non randomized control","Sequential","Sequential","Sequential","Sequential","Parallel","Sequential","Sequential","Parallel","Sequential","Sequential","Factorial","Sequential","Factorial","Sequential","Sequential","Parallel","Sequential","Sequential","Case study","Sequential","Sequential","Case study","Sequential","Sequential","Case-Control study","Sequential","Sequential","Sequential","Cohort study","Parallel","Factorial","Sequential","Sequential","Sequential","Single arm","Sequential","Single arm","Case-Control study","Sequential","Sequential","Sequential","Parallel","Sequential","Sequential","Non randomized control","Factorial","Sequential","Sequential","Case study","Sequential","Sequential","Sequential","Cohort study","Parallel","Non randomized control","Parallel","Factorial","Parallel","Sequential","Parallel","Factorial","Sequential","Parallel","Sequential","Parallel","Parallel","Sequential","Parallel","Parallel","Parallel","Sequential","Parallel","Sequential","Non randomized control","Sequential","Parallel","Sequential","Parallel","Parallel","Parallel","Parallel","Sequential","Parallel","Sequential","Sequential","Single arm","Factorial","Parallel","Parallel","Parallel","Sequential","Parallel","Factorial","Sequential","Sequential","Non randomized control","Parallel","Parallel","Parallel","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Parallel","Parallel","Sequential","Factorial","Parallel","Sequential","Cohort study","Parallel","Sequential","Parallel","Parallel","Parallel","Parallel","Sequential","Historical control","Sequential","Factorial","Factorial","Non randomized control","Cohort study","Sequential","Parallel",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Non randomized control","Sequential","Sequential","Parallel","Sequential","Non randomized control",null,"Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Parallel","Parallel","Non randomized control","Parallel","Sequential","Sequential","Parallel","Sequential","Non randomized control","Sequential","Parallel","Parallel","Factorial","Sequential","Parallel","Sequential","Parallel","Parallel","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Controlled: no\nRandomised: no\nOpen: no\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: no\n","Single arm","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Case-Control study","Sequential","Not selected Not selected","Parallel",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","randomized controlled trial, open(masking not used), no treatment control, parallel assignment, treatment purpose","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).","Not selected Not selected","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Sequential","Sequential",null,null,null,null,"Factorial",null,null,"Sequential","Parallel","Sequential","Sequential","Sequential","Sequential","Parallel","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Sequential","Sequential","Sequential","Sequential","Quasi-randomized controlled","Parallel","Sequential","Cohort study","Sequential","Sequential","Parallel","Sequential","Case-Control study","Case-Control study","Sequential","Sequential","Sequential","Parallel","Quasi-randomized controlled","Non randomized control","Non randomized control","Parallel","Parallel","Sequential","Parallel","Cross-over","Single arm","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 3\n","Sequential","Parallel","Parallel","Sequential","Factorial",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).","Parallel","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: Best clinical practice\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Factorial","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Factorial","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator).","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",null,null,null,"Prospective interventional non-randomised pre and post implementation study (Diagnostic)",null,"Factorial","Factorial",null,null,"Parallel","Sequential","Single arm","Parallel","Non randomized control","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Care Provider).","Sequential","Diagnostic test for accuracy",null,"Non randomized control","Parallel","Dose comparison","Sequential","Case-Control study","Sequential","Sequential","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Factorial","Factorial","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Case-Control study","Sequential","Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Prospective, multicenter, open, phase 2 study, one arm-non randomized&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;","Factorial","Factorial","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Parallel","Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy;","Sequential","Factorial","Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;","Sequential","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Usual care&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;",null,null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Both;",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Health Services Research. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;",null,"Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy;","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Sequential","Non randomized control","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;","Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Pharmacokinetics;","Sequential","Factorial","Sequential","Parallel","Factorial","Non randomized control","Single arm","Factorial","Sequential","Cross-sectional","Factorial","Parallel","Sequential","Sequential","Parallel","Sequential","Parallel","Sequential","Parallel","Sequential","Sequential","Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: standard treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: discontinuation&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Cross-over allowed for patients with progressive COVID-19&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Best supportive care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Best Supportive Care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of Care&lt;br&gt;Number of treatment arms in the trial: 6&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: AZINC FORME ET VITALITE (vitamins supplements)&lt;br&gt;Number of treatment arms in the trial: 5&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Dexamethasone associated with hydroxychloroquine will be compared to hydroxychloroquine alone&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Local standard of care&lt;br&gt;Number of treatment arms in the trial: 5&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: conventional treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 8&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: usual treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: antiviral standard treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Other doses regimen&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: IBUPROFEN, PARACETAMOL&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Care Provider).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Care Provider).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Care Provider).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).",null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,null,"Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,null,"Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",null,null,null,null,"Allocation: Non-Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",null,"Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,null,null,null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).","Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,null,null,null,"Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Care Provider).","Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,null,null,null,null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).",null,"Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: None (Open Label).","Purpose: Screening;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Observational prospective cross-sectional cohort analytical intervention and multicenter study (Prevention)","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Single (Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Observational single-centre cohort study; comparison to a recent cohort of non-COVID-19 patients with ARDS (see ISRCTN32938630) (Diagnostic)","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Observational cohort study (Other)","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Purpose: Natural history;Duration: Cross-sectional;Selection: Defined population;Timing: Both;","Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy;","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Both;",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).",null,"Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Factorial;Type of endpoint: Efficacy;","Open-label randomized multicountry clinical trial  (Treatment)","Purpose: Prevention; Allocation: Non-randomised trial;","Single-center observational study  (Diagnostic)","Purpose: Treatment; Allocation: Randomised controlled trial;","Pragmatic open prospective individually randomised platform randomised controlled clinical trial in community care (Treatment)","Randomised adaptive trial (Treatment)","Observational; Design type: Cohort study (Other)","Multicentre double-blinded randomized placebo-controlled trial (Prevention)","Mixed-methods observational (Other)","Cohort study","Interventional randomized controlled trial (Prevention)","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Care Provider).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Adaptive (group-sequential), pragmatic, randomised controlled, open-label, multi-centre, effectiveness trial (Treatment)","Sequential","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Single arm",null,"Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Other;Type of endpoint: Efficacy;","Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy;","Purpose: Screening;Duration: Longitudinal;Selection: Defined population;Timing: Both;","Purpose: Psychosocial;Duration: Cross-sectional;Timing: Prospective;","Purpose: Prevention; Allocation: Non-randomised trial;","Non randomized control","Cohort study","Observational longitudinal study (Other)","Parallel","Cross-sectional","Cohort study","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Not applicable\n","Interventional cluster randomized trial (Treatment)","Single-center, prospective cohort study (Diagnostic)","Non randomized control","Non randomized control","Sequential","Cross-over","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Not applicable\n","Parallel","Diagnostic test for accuracy","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: Conventional strategy\nNumber of treatment arms in the trial: 2\n","Case study","Parallel","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: No treatment\nNumber of treatment arms in the trial: 2\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Not applicable\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Single arm\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Single arm\n","Sequential","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: 2 or more arms, randomized\n","Parallel","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Parallel","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: Standard treatment\nNumber of treatment arms in the trial: 1\n","\n                        Randomized: No, \n                        Masking: Unknown, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Not applicable\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Single arm\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Single arm\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Active, \n                        Group: undefined, \n                        Type: 2 or more arms, non-randomized\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Not applicable, \n                        Group: undefined, \n                        Type: Not applicable\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","\n                        Randomized: No, \n                        Masking: Double, \n                        Control: Placebo, \n                        Group: undefined, \n                        Type: 2 or more arms, randomized\n","\n                        Randomized: No, \n                        Masking: None, \n                        Control: Active, \n                        Group: undefined, \n                        Type: 2 or more arms, randomized\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: current practice\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 3\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: yes\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: yes\nOther trial design description: Adaptive\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: Herbal Medicine\nNumber of treatment arms in the trial: 4\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 4\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 6\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: yes\nOther trial design description: Multi-stage, adaptive\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 6\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: No comparator\nNumber of treatment arms in the trial: 3\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nOther specify the comparator: The same medicinal product at a different (lower) dosage will be used as a comparator.\nNumber of treatment arms in the trial: 3\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: yes\nOther trial design description: Low-level intervention trial\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: yes\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: no\nRandomised: no\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 1\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: yes\nOther specify the comparator: Control (normal practice)\nNumber of treatment arms in the trial: 4\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: yes\nOther specify the comparator: Standard of care\nNumber of treatment arms in the trial: 3\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: no\nRandomised: no\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 1\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: no\nNumber of treatment arms in the trial: 20\n","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: standard of care\nNumber of treatment arms in the trial: 2\n","Allocation: Randomized controlled trial;. Masking: Blinded (patient/subject, investigator/therapist). Control: Placebo. Assignment: Parallel. Study design purpose: Treatment;","Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Treatment;","Allocation: Other;. Masking: . Control: Other. Assignment: Other. Study design purpose: Diagnostic;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Supportive care;","Allocation: Non-randomized controlled trial;. Masking: Open (masking not used). Control: Active control (effective treament of control group). Assignment: Other. Study design purpose: Basic research/physiological study;","Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Diagnostic;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Health care system;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Other;","Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Prognosis;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Health care system;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Prognosis;","Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Supportive care;","Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Parallel. Study design purpose: Prevention;","Allocation: Randomized controlled trial;. Masking: Open (masking not used). Control: Control group receives no treatment. Assignment: Parallel. Study design purpose: Prevention;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Diagnostic;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Other;","Other\n  Method of generating randomization sequence:  Method of allocation concealment:  Blinding and masking:","Allocation: Randomized controlled trial;. Masking: Open (masking not used). Control: Active control (effective treament of control group). Assignment: Parallel. Study design purpose: Treatment;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Screening;","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: simple random allocation using computer by a person who is not one of researcher of the study and based on the numbers allocated to each patients.","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Prevention;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Other;","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple randomization with a random digit table, Blinding description: _ Participants are blinded to the details of the treatment process.\n_ Investigators (including Outcome assessor and Data analyzer) are blinded to knowing who is being given the treatment and who is not, and only receive the Patient's data and lab results from a physician as three subgroups A &amp; B &amp; C. But they don't know which are controls and or intervention groups!   \n_ The care provider (an expert physician) will randomly divide patients into 2 groups [controls, and 2 subgroups], and then do the intervention treatment. Only he knows which subgroup belongs to controls, or intervention.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done according to the blocks randomization method. Regarding to the sample size, 5 patients will be include in each block. SAS procedure PROC PLAN will be applied to generate the randomization schedule. \nThis is a non-blinded randomized clinical trial.","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Health care system;","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Screening;","Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients consuming renin-angiotensin-aldosterone system inhibitors are recruited in the study using computerized-sequence random codes in 2 groups, Blinding description: The physicians recruiting patients' data and the statistician are blinded whether the antihypertensive medication will be continued or withheld. \nA pharmacotherapist will consult with a cardiologist for the patient group whose antihypertensive medication should be changed. At the time of discharge, this medication will be prescribed by the cardiologist who is not blinded and not responsible for data gathering.","Allocation: Single arm study;. Masking: Open (masking not used). Control: Uncontrolled/Single arm. Assignment: Single (group). Study design purpose: Diagnostic;","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, patients will have numbers after entering the order of inclusion in the study. These numbers will be selected using a random number table. Randomly place your hand on a point in the random table and then divide the numbers in pairs from left to right. Numbers are selected to fit the sample size. After the numbers of a group are assigned the numbers of the opposite group are also assigned.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Other\n  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using computer generated randomization plan. The date and time of randomization will be recorded. Allocation concealment will be done with the sealed envelope method, Blinding description: The treatment assignment will remain unknown until the patient is randomized. Physicians who treat patients and the patients will not be blinded. Radiologists, physicians who assess outcomes and the statistician analyzing the data all will be blinded.","Allocation: Non-randomized controlled trial;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Prognosis;","Randomized, Parallel Group Trial\n  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomized, Parallel Group, Active Controlled Trial\n  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label","Single Arm Trial\n  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, permuted block randomization will be used for randomization. For this purpose six blocks consisting of AABB, ABAB, ABBA, BBAA, BABA, and BAAB are designated and then for each of four patients, one of these blocks will be assigned using the random digit table. In fact, according to the order specified in each block, two patients will receive protocol A (standard treatment of COVID) and two patients will receive protocol B (standard treatment of COVID plus licorice extract), Blinding description: Patients who have completed the informed consent form are not aware of their treatment protocol. Their physicians neither know which group is assigned to the patient at the beginning of the admission.","Single Arm Trial\n  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Simple randomization sequence will be generated with a computer from 1 to 40. The computer will divide the digits between the two groups. According to the sequence of admission, the patients will be allocated to the control or the Camostate mesylate groups regarding the sequence of computerized random list.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: The randomized block allocation method was developed using Stata version 15 software by an epidemiologist. The block size was six. Allocation to treatment groups was conducted by an independent researcher (The epidemiologist). To conceal the process of random assignment, it is written on paper labels (random 10-digit codes) with no sequences and no specific framework that identifies the relevant treatment number and only the methodologist will be aware of the code. The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according randomization list. When the physician declares a patient eligible, the methodologist will give him or her drug package. The person evaluating the outcomes is a third party who is unaware of the random allocation process and the type of treatment performed. The","Other\n  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done according to the blocks randomization method. Regarding to the sample size, 3 patients will be include in each block. Random sequences will be created  by SAS software. This is a non-blinded randomized clinical trial.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with inclusion criteria of the study will be recruited in the intervention or the control group according the permuted block randomization (5 blocks and 3 patients in each block).","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We will use a randomization method to minimize the researchers' opinion to select participation in study groups to control bias. After selection, participants will be assigned to the groups using a simple randomization method for received intervention and placebo in each participant. The randomization process will be performed using Random Allocation software, and since this study consists of two groups, the allocation outputs of the participants will be identified by A and B so the assign of each patient in each group is unpredictable to other members of the research team. We will notify the team manager after selecting each patient and they will send out each patient's intervention type based on the software output, without the known of other team members. But only the clinical care will be aware of any patient's intervention in cases where","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization with sealed envelope, Blinding description: The patient receives the medication (intervention or comparison) in sealed envelopes that are coded. The coding is done by a project colleague and the physician, assessor and patient are blind.","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using computer generated randomization plan. The date and time of randomization will be recorded. Allocation concealment will be done with the sealed envelope method, Blinding description: The treatment assignment will remain unknown until the patient is randomized. Physicians who treat patients and the patients will not be blinded. Radiologists, physicians who assess outcomes and the statistician analyzing the data all will be blinded.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, block randomization was performed using block size: 6. Allocation sequence and concealment codes are generated by www.sealedenvelope.com. The closed envelope method was used to hide the allocation sequence, Blinding description: Participants and researchers in this study are blind, and the placebo used in the control group is the pill, which is similar in appearance and color to naproxen.","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to prevent bias, a simple randomization method will be used in this study to perform random allocation. We will produce 40 cards , completely identical in appearance. \"Number 1\" will be written on  20 of them indicating the intervention and on the other 20 cards left, we will write \"number 2\" which indicates the control group. Each eligible participant then randomly picks one of these cards, which determines how the patients will be randomly assigned to each group. Without the trial participants being  informed of the nature of either 1 or 2 numbers, Blinding description: I this study the researcher, questionnaire data recorder, the radiologist evaluating imaging findings, outcome assessors, and data analyser are unaware of patients' affiliation to each group.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Samples will be randomly assigned to four blocks using Random Allocation Software. Blocking and allocation sequences for concealment will be done by the non-involved researcher (Allocation Concealment).The sample allocation ratio will be Allocation 1:1 and will be divided into two groups of receiving Iranian medicine products and control group (Assignment). Then based on blocks and allocation sequences medication will be given to patients. This is an open-label study and blinding will not happen.","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: a random sequence was generated by \"random.org\" , in which every subject in the study from number 1 to 40, is randomly assigned to one of the treatment groups A or B. based on this random sequence, patient 1 and 2 will be assigned to group A and patient number 3 will be assigned to other group and this goes on until 40 patients enroll in the study, Blinding description: the hospital pharmacist puts Recigen and Placebo (which produced by the same company and is exactly similar to Recigen without the active ingredient) in Groups A and B. he is the only person who knows which group has Recigen and which one has the placebo. the researcher injects the drug to the patients based on the  randomization chart in which each patient is assigned to groups A and B. The patient, the researcher, the clinicians who supervise the patient treatment and the statis","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be selected according to the inclusion criteria and then randomly assigned to the experimental and control groups according to the random sequence obtained through random allocation software.","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Blocked Randomization, Blinding description: Researcher is not aware of which patient will get Atorvastatin and drug will be given by nurse. Patients entry will be in order to admission time and randomly.","Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study  patients,  nurse , supervisor and researcher don't know which group of patients will use  the medicine.\nPhysician and clinicians team know about the drug and group who use the drug.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple randomization with computer generated digits.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method with 4, 6 and 8 block sizes will be used to assign people to the two groups. Concealment will also be observed by using this method. In this way, each individual is assigned a unique code and is attached to drug packages that will help the blind process, Blinding description: In this three-blind study , patient and therapeutic personnel and data analyst do not have any type of data and medications. The drugs are encoded and placed on the patient and medical personnel.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: Since convalescent plasma therapy in patients with COVID-19 disease has been approved by FDA as a investigational modality and being used in some other countries such as China and due to lack of curative medicine for the disease, this project will be performed in Iran as treatment for the patients.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: -.","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible patients  will be selected by the clinician. Each patient will be  assigned an alphabetical code, a list of codes will be sent to the researcher. The researcher coded the codes from the random number table and assigned a new numeric code to each patient for each test and control group. These numerical codes will be used to form patient records and place the patient in the designed group, Blinding description: All of the research team will be blind about the groups of study and position of patients in each group except of physician and main researcher. Files of patients which will be numbered using a random number table will be sent for analyzer of the study. Information about position of patients in the groups is masked from research team. Outcomes Assessor will receive the information of patients without any name in the file. Just w","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: Medicine used in study was provided by International donation as Compassionate use under the supervision of the Ministry of Health and Medical Education. The study was approved by the TUMS ethics committee and received a Clinical Trial Authorization- CTA from the Food and Drug Administration before the study began.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Firstly patients are divided into moderate and severe groups to match the severity of the disease then according to computerized block randomization division is performed, Blinding description: Bottles are numbered in each group and finally according to computerized block randomization division is performed , the remedies and placebo put on the numbered bottles by one of researchers who is only person that know about this concealment. Every patient admitted to the ward and who wants to participate this survey take this bottles respectively.\nPatients, therapist and evaluator does not know the true contents of the bottles(which have equal taste and odor) and the study is double-blinded.","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: Method of randomization is 6 unit block randomization. Unit of randomization is individual. Tools for randomization is a computer software. Sealed envelopes were used for allocation concealment, Blinding description: The participants in this study are blind and the drug used in both groups is similar in appearance. So patients do not understand which group they are in.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Simple.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization generated with computer from 1 to 200. Computer will divide digits between two groups. According to the sequences of admission they will go to control or metformin group regarding computerized random list.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Control group in this study is defined as patients who admitted in hospital and received national therapeutic regimen for COVID-19 before the approval of the study proposal compatible with inclusion criteria.","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balanced block randomization, Blinding description: In this study, patients will be informed by consent form that they would either be in the intervention group or the control group, but they won't be aware of the type of medication. Nurses who supply the drug are also unaware of its content because the appearance, taste, color, and prescription of the drug are similar, but the code on the drug will be different. The written codes on the drugs are random and only the pharmacist's partner is aware of the drug type and the inserted code on it. The patient data collector and the project statistical partner are also unaware of the type of intervention. As the control group uses placebo, which is similar in appearance, taste, color, and prescription, patients will be unaware of the type of drug being administered.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method is block randomization and block size if 4. Randomization sequence and concealment codes will de created by www.sealedenvelope.com website, Blinding description: Placebo will be produced with  a color and taste similar to  Vitamin C by Pharmacy school of Jundishapur University.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method of randomization is based on block randomization using random 4, 6 and 8 blocks.Table of patients number and block Randomization codes will be created by Online randomization web page and will be presented to pharmacist in-charged for serum content preparation. investigator informs patient inclusion number and serum ingredient will be determined by pharmacist based on randomization table, Blinding description: this study will be conducted as a double blind process. patients, investigator, health care workers including nurses and physicians, statistical analyzer will be blinded, by preparing serum content by pharmacist and allocating a code to each serum. pharmacist is the only one who knows the content and has no role in data gathering and result interpretation.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomly assign the patients to two groups of treatment and placebo by a third person and using a computer program with simple randomization method, the random sample number is generated and each patient will be assigned a number.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were randomly divided into intervention and control groups using Random Allocation Software.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be allocated into study groups using a simple randomization method. The allocation process will be concealed to the physician and researchers. Allocation concealment will be made using sealed envelope system.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Simple randomization will be generated with a computer from 1 to 40. The computer will divide the digits between the two groups. According to the sequences of admission, they will go to the control or the fingolimod group regarding the computerized random list.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use block randomization methods using variable block size of four and six stratified by center. We will use Excel software and rand() function to generate the random sequence. The master randomization list will be kept by the epidemiologist working wit the research team.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be selected according to the inclusion criteria and then randomly assigned to the experimental and control groups according to the random sequence obtained through random allocation software.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using computer generated randomization plan. The date and time of randomization will be recorded. Allocation concealment will be done with the sealed envelope method, Blinding description: clinical pharmacist who assess outcomes and the statistician analyzing the data will not be blinded.Physicians who treat patients and the patients will  be blinded.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages:\n1-\tRandom sequence generation: this step simple or limited randomization will be done based on a table of random numbers\n2-\tAllocation concealment: which is done in the form of coded boxes (numbered drug containers) with a random sequence. In this method, a number of boxes with the same shape and size are numbered based on random sequences and contain drugs or placebo that have a completely similar appearance.\n3-\tExecution of random allocation process:\nA: Identify the person who creates the random sequence\nB: A person who evaluates and registers researchers in terms of inclusion and exclusion criteria\nC: The person who assigned the participants to the groups: infectious diseases specialist\nThe main researcher of the project, who creates a random sequence, does not interfere in other stages of randomization, includin","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: blocking randomization, Blinding description: Patients are unaware of being placed in the intervention or control group after declaration of consent. All treatment staff are aware of the patients in which group due to the specific conditions of the ICU and the absence of placebo for control group.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use block randomization methods using four patents blocks that randomized by ( RAND) function in Excel .The patient code table is provided to the analyzer and will be used for analysis after completion of the study, Blinding description: In this study: The patient, the physician, the nurses, and the researchers are blind. The data analyst knows the details of the treatment regimen.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, simple randomization method will be used. A randomized list will be generated by online randomization site. Households will be allocated to case or control group according to the generated list. Then cluster sampling will be done in each group.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages: 1-  Generation simple or limited randomization will be done based on a table of random numbers\n2- Allocation concealment: which is done in the form of\ncoded boxes (numbered drug containers) with a random\nsequence. In this method, a number of boxes with the\nsame shape and size are numbered based on random\nsequences and contain drugs or placebo that have a\ncompletely similar appearance. 3- Execution of random\nallocation process: A: Identify the person who creates the\nrandom sequence B: A person who evaluates and\nregisters researchers in terms of inclusion and exclusion\ncriteria C: The person who assigned the participants to\nthe groups: infectious diseases specialist The main\nresearcher of the project, who creates a random\nsequence, does not interfere in other stages of\nrandomization, including registration and allocat","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The way to select groups is that they will be assigned to groups based on block randomization. Blocks of size 4 are considered. So we will have six blocks containing AABB, ABAB, BBAA, BABA, ABBA, BAAB. Each block will also be randomly selected using a dice throw. For example, if thrown dice is 3, the BBAA block is considered, and therefore the first two patients are assigned to treatment B and the next two patients to treatment A. The dice will be thrown 33 times to complete the assignment of patients to the treatment groups. Also, the allocation of treatment to groups A and B will be based on accident (coin toss), Blinding description: Zufa syrup and the Placebo syrup are inserted in the same-colored Bottles and the color of these two syrups is homogenized using the permitted pharmaceutical colors. Then, on each of the drugs, the same contents a","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method is cluster randomization.Randomization units are hospitalized wards. First, two inpatient wards (capacity of each ward is 32 patients) are selected with similar conditions and, as two clusters, are randomly assigned to the intervention and control group. Referral to departments in the intervention group and control group is based on the patient's turn and is not related to the patient's condition or severity of the disease. patients admitting method in two wards will cause approximately similarities between two clusters before randomization. This study has no concealment and patients in the intervention group will receive the intervention medication in addition to the routine treatment, but in the control group they will only receive the routine treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this clinical trial, 260 patients with positive COVID-19 will be recruited. Patients will be randomly allocated to the drug group (N=130) and placebo group (N=130). \nThe randomization method is \"restricted randomization\". It will be determined by a \"Random Allocation Software\". \nSubjects in the drug group will receive 1000 IUs of 25(OH)D daily for 8 wks and subjects in the placebo group will receive placebo daily for 8 wks, Blinding description: Participants, physicians, data collectors, and project executives are blind to the type of medication (medication and placebo).\nThe drug and placebo are coded by someone else. This person has no role in treatment, data collection and data analysis. The codes are randomly selected for each participant. Each patient has a specific code. Based on the drug coding, the physician or researcher will provide t","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done by permutation randomized block method in four-sided blocks. The construction of blocks is done with R version software 2, 3, 6, Blinding description: The treatment assignment will remain unknown until the patient is randomized. Physicians who treat patients and the patients will not be blinded. Radiologists, physicians who assess outcomes and the statistician analyzing the data all will be blinded.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Samples will be randomly assigned to four blocks using Random Allocation Software. Blocking and allocation sequences for concealment will be done by the non-involved researcher (Allocation Concealment).The sample allocation ratio will be Allocation 1:1 and will be divided into two groups of intervention and control (Assignment). Then based on blocks and allocation sequences medication will be given to patients.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Using a computerized random number table, taking into account blocks of size 4 and 6, with a 1: 1: 1 allocation ratio, Blinding description: Since the drugs (medications) will be prepared in similar shape; participant, researcher, and clinical caregiver will not be aware of the content of the tubes.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the random number table, patients are divided into two groups of 40. Each patient is assigned a 4-digit code based on the random number table, Based on the right number of patients code, the patients are divided into two groups. Patients whose last digit is 0, 2, 4, 6, 8 will be assigned to the intervention group and patients whose last digit is 1,3,5, 7, 9 will be assigned to the control group, Blinding description: In this study, patients will be kept blind to the type of treatment.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be enrollment after admission and then divided into two groups by odd and even number. Patients with even numbers will receive herbal medicine and patients with even numbers will assigned in control group. This study has no concealment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two Therapeutic groups by random method and used 6 blocks method.\nIndividuals are the randomization unit and randomization tools are statistical soft ware, make a random sequence is by using  statistical soft ware \nallocation concealment  is by assigning unique codes, Blinding description: double blind: Supervisor and the participants are blind to the prescription drug of the target group and the control group\nThe drugs of both groups are distinguished in the same form(aluminium package). Licorice and Marshmallow have no significant smell and placebo will be the same color as the medicine  by using  allowed color. Also there is no significant difference between drug and placebo taste. The package  are separated  by mentioning the number. The list of numbers will be provided to the statistical consultant and then the data","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use block randomization methods using variable block size of four and six strati?ed by center. We will use Excel software and rand() function to generate the random sequence. The master randomization list will be kept by the epidemiologist working wit the research team.","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: A random number table and block randomization method is used. In this method 60 eligible patients are assigned into 30 blocks of 2 patients. Then, each of the 2 patients in the block is randomly assigned to take herbal medicine or placebo, so that 30 patients assigned to each group, Blinding description: Package for herbal and placebo is labeled with code B or A. Other specifications on the labels are identical. Physicians, nurses, patients, data collectors and those who evaluate the outcome are unaware of the drug and placebo group. Only the expert who has done the capsules packaging is aware of the contents of the packages or what is code A or B. Patients are aware that they are either in the herbal drug or placebo groups, but they are not aware of the type of group they are in.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization method was used in this study. 21 blocks including 4 patients generated with online website. In each block, two patients will be assigned to Favipiravir group and two patients will be assigned to Lopinavir-ritonavir group.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Simple randomization will be generated with a computer from 1 to 60. The computer will divide the digits between the two groups. According to the sequences of admission, they will go to the control or the intervention group regarding the computerized random list.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use block randomization methods using variable block size of four  stratified .","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Given that this study is part of the SOLIDARITY Trial by the World Health Organization, the randomization method is only known by the Principal Investigators. \nPatients will be randomized through the study website equally between all the locally available treatment regimens (5 possibilities if all study drugs are locally available, fewer if not)\n\n\tLocal standard of care alone, \n\nOR local standard of care plus one of\n\n\tRemdesivir (daily infusion for 10 days) \n\tChloroquine or Hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)\n       [NB Some collaborating hospitals will study chloroquine, others hydroxychloroquine]\n\tLopinavir with Ritonavir (orally twice daily for 14 days) \n\tLopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days).","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Health service research, Randomization description: randomization to intervention and control groups. Simple randomization will be generated with a computer.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomizing by computer software.","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization will be performed using randomly permuted blocks. By using online website (www.randomization.com) the randomization sequence will be produced by quadruple blocks, Blinding description: The patient and the physician do not know whether the patient is in the intervention or the control group. The data analyser will also be blinded regarding the intervention and control groups.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method with 4, 6 and 8 block sizes will be used to assign people to the two groups. Concealment will also be observed by using this method. In this way, each individual is assigned a unique code and is attached to drug packages that will help the blind process, Blinding description: In this three-blind study , patient and therapeutic personnel and data analyst do not have any type of data and medications. The drugs are encoded and placed on the patient and medical personnel.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: in this study, the random allocation for intervention and placebo groups is based on a \"Random Allocation Software\".\nA simple randomized list will be produced by the software for a sample size of 540 subjects into two groups of the intervention and placebo with equal sample size and numeric sequential unique, Blinding description: It is a double-blind clinical trial. Participants, physicians, data collectors, and project executives are blind to the type of medication (medication and placebo). The drug and placebo are coded by someone else. This person has no role in treatment, data collection and data analysis. The codes are randomly selected for each participant. Each patient has a specific code. Based on the drug coding, the physician or researcher will provide the drug to the participants. medication: containing 25OHD soft gelatin capsular pl","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Method: Simple randomization.\nUnit: Individual.\nTools: Random blocks \nHow to build: Using 4 times Blocks (AABB, ABAB, ....) with random selection of block and reading from right to left\nAllocation concealment will be done by numbered drug cans that are numbered randomly. The cans will be the same weight and shape and will be prepared by an independent researcher.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The other similar studies are about the patients who required mechanical ventilation with many different conditions such as severe head trauma, acute respiratory distress syndrome, traumatic patients, etc. This is the first study about early tracheostomy and intubation in critically ill patients with COVID-19.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: At the beginning of the study, an evaluator examines the criteria for entering the study of patients, and if there are conditions for entering the study, using the table of random numbers, patients will be assigned to the experimental and control group. And this process will continue until the formation of two equal groups of 70 people, Blinding description: In this study, patients, laboratory technicians,  radiologists, and therapists who will be responsible for prescribing the drug, receiving the sample and completing the questionnaire, as well as the researcher responsible for evaluating the results and statistically analyzing the treatment group will blind patients. Were, and will not know the intervention group. The physicians responsible for prescribing medication will not be blind. vitamin A and placebo were purchased from the same factory","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization will be generated with a computer from 1 to 100. The computer will divide the digits between the two groups. According to the sequences of admission, they will go to the control or the IVIG group regarding the computerized random list.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages: 1- Generation simple or limited randomization will be done based on a table of random numbers 2- Allocation concealment: which is done in the form of coded boxes (numbered drug containers) with a random sequence. In this method, a number of boxes with the same shape and size are numbered based on random sequences and contain drugs or placebo that have a completely similar appearance. 3- Execution of random allocation process: A: Identify the person who creates the random sequence B: A person who evaluates and registers researchers in terms of inclusion and exclusion criteria C: The person who assigned the participants to the groups: infectious diseases specialist The main researcher of the project, who creates a random sequence, does not interfere in other stages of randomization, including registration and allocati","Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This study is double blinded clinical trial in phase 3 which will be carried out on 40 hospitalized ?COVID-19 patients. Patients randomly divided into two groups. Control group and treatment group ?which received of medicine (250 mg methylprednisolone pulse for 3 days). Clinical signs of patient including ?heart rate, blood pressure ? body temperature, O2 saturation, CT scan findings, laboratory tests result ??(CBC, ESR, CRP, VBG, IL-6, Ferritin, Troponin, D-dimer) will be recorded before and after treatment ??(at day 3, 7 and discharge time). In addition, dyspnea, cough, GI Symptom, myalgia, chest pain and ?BORG ?Score will be assessed before and after treatment (at day 3 and discharge time). Need an oxygen ?therapy (nasal Cannula, mask Oxygen, reserve Mask, NIV and invasive ventilation) will also be ?recorded before and after treatment (at","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages: 1- Random sequence\ngeneration: this step simple or limited randomization will\nbe done based on a table of random numbers 2-\nAllocation concealment: which is done in the form of\ncoded boxes (numbered drug containers) with a random\nsequence. In this method, a number of boxes with the\nsame shape and size are numbered based on random\nsequences and contain drugs or placebo that have a\ncompletely similar appearance. 3- Execution of random\nallocation process: A: Identify the person who creates the\nrandom sequence B: A person who evaluates and\nregisters researchers in terms of inclusion and exclusion\ncriteria C: The person who assigned the participants to\nthe groups: infectious diseases specialist The main\nresearcher of the project, who creates a random\nsequence, does not interfere in other stages of\nrandomization, includin","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be divided into two groups by Block Randomization. The block size is 4 people and a random list will be created by the sealedenvelope site. To hide the drugs, they are placed in the required number in the envelope. Then, according to the random codes created, one or two envelopes will be placed in a larger envelope.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization happens at three stages: \n1- Random sequence generation: Simple or limited randomization will be performed based on the table of random numbers.\n2- Allocation concealment: This step will be performed in the form of coded boxes (numbered drug containers) with a random sequence. In this method, a number of boxes with the same shape and size are numbered based on random sequences, containing either treatment drug or placebo with a completely similar appearance. \n3- Execution of random allocation process: \nA: To identify the person who creates the random sequence \nB: A person who evaluates and registers researchers in terms of inclusion and exclusion criteria.\nC: The person who has assigned the participants to the groups: Infectious diseases specialist who creates a random sequence, does not interfere in other stages of randomization, i","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The study will be done for the first ten of each intervention and then for the second ten of each intervention groups, Randomization description: Participants were randomly divided into three equal groups using a randomized tripled ABC blocking method based on a random number table.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: ??Simple randomization by computerized random number generation will be used. A list of sequentially number 1 to 60 will be created. This list will align numbers randomly by computer.  Patients are randomly assigned to the experimental group (conventional treatment combined with convalescent plasma treatment group) or the control group (conventional treatment group) according to the numbers of this list.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: By random blocking method with 4 blocks and using Random Allocation Software.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages: 1- Random sequence\ngeneration: this step simple or limited randomization will\nbe done based on a table of random numbers 2-\nAllocation concealment: which is done in the form of\ncoded boxes (numbered drug containers) with a random\nsequence. In this method, a number of boxes with the\nsame shape and size are numbered based on random\nsequences and contain drugs or placebo that have a\ncompletely similar appearance. 3- Execution of random\nallocation process: A: Identify the person who creates the\nrandom sequence B: A person who evaluates and\nregisters researchers in terms of inclusion and exclusion\ncriteria C: The person who assigned the participants to\nthe groups: infectious diseases specialist The main\nresearcher of the project, who creates a random\nsequence, does not interfere in other stages of\nrandomization, includin","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method is designed to randomize subjects into groups that result in equal sample sizes. This method is used to ensure a balance in sample size across groups over time. In this study we will be considered 4 patients in a block.","Allocation: N/A;Masking: N/A;Control: N/A;Assignment: Parallel;Purpose: Screening","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block Randomization method is used to randomized the patients.","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, patients will be randomly assigned to each of the two treatment groups using a 1: 1 block randomization method, Blinding description: Patients and physicians in charge of treating the patient will not go blind and will be aware of the intervention group. The researcher responsible for evaluating the results and the statistical analyst will be blind to the treatment group.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted block randomization.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients use randomized block-chain, which not only makes Randomization equal in two groups, but also allows patients to be assigned equally to both groups at each stage of the study. These small blocks keep the balance between the two groups and make the number of people in each group similar. In our study, considering that there are two groups, four patients are considered for each block.","Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two Therapeutic groups by random method and used 6 blocks method. Individuals are the randomization unit and randomization tools are statistical software, make a random sequence is by using statistical software. Allocation concealment is by assigning unique codes, Blinding description: Double blind: Supervisor and the participants are blind to the prescription drug of the target group and the control group. The drugs of both groups are distinguished in the same form (aluminium package). Phyllanthus Emblica have no significant smell and placebo will be the same color as the medicine by using allowed color. Also there is no significant difference between drug and placebo taste. The package are separated by mentioning the number. The list of numbers will be provided to the statistical consultant and then the data will be an","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the individuals will be randomly allocated into two groups (Treatment and Control) by using the block randomization method. The procedure of randomization will be carried out by using the SPSS software and the block size will be 4. Allocation concealment will be carried out.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 16 patients will be randomly assigned to each of the intervention and control arms. Randomization is that after making specific sequences for each group using specialized software, the assigned code (for example, even / odd) is written on separate sheets. Each sheet is folded and sealed so that it is not visible inside. After each eligible patient enters the ICU, a sheet is opened in order, and according to the code in it (even / odd), the patient is placed in the control or intervention group.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Randomization is done using random block method with variable block size. In this method, a number is randomly selected from the numbers 2, 4, 6, and 8. Then, according to the size of the selected block, a random combination of 2 studied treatments is selected. This process is repeated to the extent that a sequence of 1000 of 1 and 2 treatments is created, provided that the number of each of the two treatments is 500. At the time of performance, for each patient, by referring to this list, it is decided which of the two treatments to be assigned to him.","Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using by using procedures such as coin-tossing or dice-rolling,Sealed opaque envelopes","randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose","Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted block randomization.","Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes","randomized controlled trial, open(masking not used), no treatment control, parallel assignment, treatment purpose","single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose","single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose","Not selected Not selected","Treatment clinical trial, Phase III, prospective randomized-controlled, open, multicentre, national, parallel with two arms","Not selected Not selected","Randomized, open, controlled, three arms treatment clinical trial","Not selected Not selected","Randomized controlled trial","Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Numbered containers","Not selected Not selected","Non-randomized","Randomized controlled trial","double-blind, three arms, parerel, randomized, controlled clinical trial of treatment","Not selected Not selected","N/A","Retrospective observational analytical case-control study.","Randomization: Randomized controlled trial. Blinding: Open. Placebo: Active. Assignment: Parallel. Purpose: Other","The novel coronavirus that causes the disease COVID-19 is an international crisis that at the point of this request has caused more than 700,000 cases and 33,000 deaths worldwide. There are currently no vaccines or authorized treatments for COVID-19. Although treatments for other diseases may be of some help, they may not be. Therefore, the World Health Organization is organizing a study in many countries in which some of these treatments are compared  to see if they are useful for the treatment of COVID-19. A randomized controlled trial with the following 5 treatments is proposed.&lt;br&gt;1.Standard care that is given to all COVID patients who come to participating hospitals.&lt;br&gt;OR Standard care that is given to all COVID patients who come to participating hospitals plus one of the following:&lt;br&gt;2.Remdesivir (daily infusion for 10 days)&lt;br&gt;3. Hydroxychloroquine (two oral doses, then orally twice daily for 10 days)&lt;br&gt;4.Lopinavir with Ritonavir (orally twice daily for 14 days)&lt;br&gt;5.Lop","N/A","Clinical trial, single-center, randomized, placebo-controlled, double-blind.","N/A"],["N/A","N/A","0","0","N/A","Phase 4","Retrospective study","N/A","Phase 4",null,"0","N/A","N/A","0","0","0","0","0","0","N/A","Phase 4","0","4","N/A","0","0","4","4","4","4","0","0","0","0","N/A","0","N/A","0","N/A","Phase 2/Phase 3","N/A","N/A","N/A","N/A","N/A","4","0","0","N/A","0","0","0","0","4","0","N/A","4","0","0","0","0","N/A","0","N/A","0","0","0","0","0","0","0","0","0","0","0","N/A","0","N/A","0","0","0","4","0","N/A","N/A","N/A","N/A","0","N/A","4","0","N/A","0","4","Retrospective study","0","0","0","4","N/A","4","0","0","N/A","N/A","0","N/A","0","N/A","N/A","N/A","4","4","0","4","4","3","0","N/A","N/A","0","N/A","New Treatment Measure Clinical Study","0","0","0","0","0","4","N/A","Phase 2","0","New Treatment Measure Clinical Study","N/A","0","N/A","N/A","0","4","0","0","Retrospective study","N/A","0","0","N/A","N/A","Phase 2","N/A","0","4","3","N/A","0","N/A","0","2","0","2","N/A","0","4","1-2","0","0","N/A","0","Retrospective study","N/A","0","4","0","0","4","4","0","0","0","Retrospective study","4","4","0","N/A","Retrospective study","N/A","N/A","N/A","N/A","Phase 2",null,"N/A","N/A","4","4","Phase 1/Phase 2","N/A","4","N/A","N/A","Phase 2",null,"N/A","Retrospective study","4",null,"0","N/A","N/A","1","N/A","0","Retrospective study","0","0","Phase 2","Phase 2","0","0","Retrospective study","N/A","0","0","0","N/A","0","0","0","N/A","Retrospective study","0","0","N/A","Retrospective study","0","N/A","0","0","4","1","Retrospective study","0","N/A","2","N/A","0","New Treatment Measure Clinical Study","Retrospective study","N/A","4","4","N/A","4","Retrospective study","4","0","Retrospective study","N/A","Retrospective study","Retrospective study","N/A","Retrospective study","4","4","4","0","0","N/A","4","N/A","4","4","Retrospective study","0","4","Phase 4","N/A","0","0","0","0","Retrospective study","0","Phase 1","Retrospective study","N/A","Phase 3","Retrospective study","0","Retrospective study","Retrospective study","0","N/A","N/A","4","N/A","4","N/A","N/A","N/A","N/A","0","0","0","N/A","Retrospective study","0","N/A","N/A","Retrospective study","0","0","N/A","N/A","N/A","0","0","Retrospective study","N/A","N/A","N/A","0","4","N/A","Retrospective study","N/A","0","N/A","0","0","N/A","0","0","Retrospective study","1",null,"N/A","0","4","0","N/A","N/A","Retrospective study","Retrospective study","N/A","N/A","N/A","N/A",null,"Early Phase 1","N/A","0","0","N/A","0","Retrospective study","N/A","0","N/A","N/A","N/A","0","N/A","1","Retrospective study","Retrospective study","Retrospective study","N/A","1","N/A","N/A","0","4","N/A","New Treatment Measure Clinical Study","0","0","N/A","Retrospective study","0","0","Retrospective study","Retrospective study","N/A","0","Retrospective study","N/A","0","N/A","N/A","Retrospective study","1","Retrospective study","Retrospective study","Retrospective study","4","N/A","1","Retrospective study","0","Retrospective study","1","Retrospective study","0","N/A","N/A","Retrospective study","N/A","N/A","4","Retrospective study","N/A","Retrospective study","0","Retrospective study","N/A","N/A","Retrospective study","Retrospective study","Retrospective study","Retrospective study","4","N/A","Retrospective study","Retrospective study","Retrospective study","Retrospective study","Retrospective study","Retrospective study","N/A","0","0","Retrospective study","0","0","0","N/A","0","N/A","4","0","Retrospective study","0","Retrospective study","4","0","N/A","0","0","0","Retrospective study","1","0","Retrospective study","0","0","0","4","4","0","0","N/A","4","N/A","N/A","1-2","4","0","4","0","N/A","4","Retrospective study","Retrospective study","N/A","N/A","0","0","0","Early Phase 1","N/A","Phase 2",null,"Phase 2","N/A","N/A","N/A","0","0","0","0","Retrospective study","N/A","Retrospective study","0","0","N/A","0","N/A","N/A","N/A","Retrospective study","Retrospective study","0","N/A","Retrospective study","N/A","N/A","Phase 1","4","Retrospective study","0","0","0","1","N/A","N/A","Retrospective study","Retrospective study","0","0","Retrospective study","N/A","0","N/A","N/A","Retrospective study","0","N/A","Retrospective study","N/A","0","2-3","N/A","0","N/A","4","Retrospective study","4","1","Retrospective study","Phase 4","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","N/A","Phase 4","0","0","Not applicable","4","N/A","N/A","Phase 4","Phase 3","2","Phase 1/Phase 2","Phase 2/Phase 3","N/A","Phase 2/Phase 3","Not applicable","N/A",null,"Phase 4","N/A","Phase 1","N/A","Phase 3",null,"N/A",null,"N/A","Phase 2/Phase 3","N/A","Retrospective study","0",null,null,null,null,"N/A","N/A","N/A","Retrospective study","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","Retrospective study","Retrospective study","N/A","N/A","0","Retrospective study","N/A","N/A","Retrospective study","2","N/A","Retrospective study","Retrospective study","0","N/A","Retrospective study","0","N/A","Retrospective study","N/A","0","4","N/A","N/A","4","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","0","N/A","Retrospective study","0",null,"N/A","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","Phase 3","Phase 3","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","N/A","Phase 3","N/A","N/A","N/A","N/A","Phase 3","Phase 2/Phase 3","Early Phase 1","N/A",null,"Phase 2",null,"Phase 1/Phase 2","Phase 3",null,"Phase 2","N/A","N/A",null,null,"Not Applicable","N/A","Retrospective study","0",null,null,"N/A","N/A","1","N/A","0","Retrospective study","Phase 2/Phase 3","Phase 2/Phase 3","0","0",null,"0","0","1","N/A","2","N/A","Retrospective study","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","1","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Retrospective study","Retrospective study","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","4","Phase 4","N/A","Retrospective study","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2","Phase 2/Phase 3","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n",null,null,"Phase 3","Phase 3","Phase 2","Phase 4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Not Applicable","N/A","N/A","Phase 1/Phase 2","N/A",null,"N/A","N/A","N/A","N/A","Phase 3","Phase 3","Phase 2","Phase 3","Phase 4","Phase 3","N/A","Phase 2","Phase 2/Phase 3","N/A","Phase 3",null,"N/A",null,"Phase 3","Phase 1",null,"Phase 2",null,null,"N/A",null,"Phase 1/Phase 2","N/A","N/A","N/A","Early Phase 1","Phase 2/Phase 3","Phase 1","N/A","N/A","Phase 2","N/A","Phase 2/Phase 3","Phase 1/Phase 2","N/A",null,null,"Phase 4","Phase 4","N/A","Not Applicable","N/A","Phase 4","Not Applicable","Phase 2",null,"Phase 2","N/A","Not Applicable","Phase 1 / Phase 2","Phase 2","Not Applicable","Phase 2","Phase 1","Retrospective study","N/A","0","Phase 2","Not Applicable","Not Applicable","N/A","Retrospective study","N/A","2","Retrospective study","0","N/A","N/A","Retrospective study","N/A","N/A","N/A","N/A","4","0","0","0","Retrospective study","1-2","Retrospective study","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): \nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): \nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 3","Phase 2/Phase 3","Phase 3","Phase 1/Phase 2",null,"Phase 3","Phase 3","Phase 1","N/A","Phase 1","N/A","Phase 2","Phase 4","N/A","N/A","Phase 3","Phase 1","Phase 1","Phase 2","Phase 2","Phase 3","Phase 2","Phase 1",null,"Phase 1","Phase 3","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2",null,"Phase 3","N/A","Phase 3","N/A","Phase 2","Phase 2","Phase 1","N/A","N/A","Phase 3","N/A","N/A","Phase 2","Phase 3","N/A","Phase 2/Phase 3","Phase 2","Phase 3","Phase 3","Phase 3",null,"Phase 2","Phase 3","N/A",null,"Phase 2","N/A","Phase 3",null,"Phase 4",null,"Phase 2","Phase 2/Phase 3","N/A","Phase 2","Phase 4",null,"Phase 2/Phase 3",null,"Phase 2","Phase 2/Phase 3","Phase 3","Phase 1/Phase 2",null,null,"Phase 3",null,"Phase 3","Phase 3",null,"Phase 3","Phase 3",null,"N/A","N/A","Phase 2/Phase 3","Early Phase 1","Phase 2","N/A","Phase 4","Phase 2","Phase 3","N/A","Phase 3",null,null,"Phase 2","Phase 2/Phase 3","Phase 4","Phase 3","Phase 2","N/A","N/A","Phase 3","N/A","Phase 2","Phase 3","Phase 2/Phase 3","Phase 2",null,"Phase 2","N/A",null,"N/A","Phase 3",null,"N/A","Phase 1","Phase 3","Phase 2","Phase 3","Phase 2",null,"N/A","Phase 2/Phase 3",null,"Phase 2","N/A","N/A",null,"Phase 1/Phase 2","Phase 3","Phase 2","Phase 1","Phase 3","Phase 1",null,"Phase 2","Phase 3","Phase 2",null,null,"N/A","N/A",null,"Phase 1/Phase 2","N/A","N/A","N/A","N/A","Phase 2","N/A","N/A","Phase 3",null,"Phase 2","N/A","N/A","N/A","N/A","N/A","Phase 2",null,"N/A","N/A","N/A",null,null,"Phase 1","Phase 2",null,null,"Phase 2",null,"N/A","N/A",null,"Phase 2","Early Phase 1","N/A","N/A","Phase 2","Phase 3","Phase 4","N/A","N/A","N/A","N/A","Phase 3","Phase 2","N/A",null,null,"N/A","Phase 1/Phase 2","N/A","N/A",null,"Phase 3","Phase 3","N/A","Phase 2","N/A","N/A","Phase 3","Early Phase 1","N/A","Phase 2","N/A",null,null,"N/A",null,null,null,"Phase 2/Phase 3","N/A","Phase 2/Phase 3","N/A","N/A","Phase 4","Phase 1/Phase 2","N/A",null,"Phase 1/Phase 2","Phase 2","N/A","Phase 3","N/A","Phase 2","Phase 2","Phase 4","Phase 2","N/A",null,"N/A",null,null,"Phase 3","N/A","N/A","N/A","Phase 2","Phase 3","Phase 2/Phase 3","N/A","N/A","N/A","Phase 2","N/A",null,"Phase 2","Phase 2","N/A","N/A","Phase 2","N/A","Phase 2","Phase 3","Phase 2","Phase 4","Phase 1","Phase 2","N/A","N/A","Phase 2",null,"Phase 2","N/A",null,null,null,"Phase 2/Phase 3","Phase 2",null,"Early Phase 1","N/A",null,null,"Phase 2","N/A","N/A","N/A","N/A","N/A","Phase 2",null,"Phase 2",null,"N/A",null,"Phase 2","N/A","N/A","N/A","Phase 3","N/A","Phase 4",null,"Phase 2/Phase 3","Phase 1/Phase 2","N/A","Phase 4","Phase 3","Early Phase 1","Phase 3","Phase 1/Phase 2","Phase 1/Phase 2","Phase 4",null,null,"Phase 2/Phase 3","Phase 3","Phase 2","Phase 2","N/A","Phase 1/Phase 2",null,"N/A","N/A",null,"Phase 2","Phase 3",null,"Phase 3","Phase 2","Phase 2/Phase 3",null,"Phase 2","Phase 3","N/A","Phase 2","N/A","Phase 2","N/A","Phase 2",null,"Phase 2",null,"Phase 3","N/A","Phase 2","Phase 2","N/A",null,"N/A","Phase 1/Phase 2","N/A",null,"N/A","N/A","Phase 2","N/A","Phase 2","N/A","N/A","Phase 2","Phase 2","N/A","Phase 3",null,"Phase 2/Phase 3","Phase 2","N/A","N/A","N/A","N/A","Phase 3",null,null,null,"N/A","N/A",null,"Phase 2","N/A",null,"N/A","Phase 2","Phase 2/Phase 3","N/A","Phase 2","N/A","Not Applicable","Phase 2","N/A","Phase 3","Phase 2","N/A","N/A","Not Applicable","Phase 2","N/A",null,"Early Phase 1","Not Applicable","Phase 2","N/A","Not Applicable","Phase 3","Phase 2","N/A","Phase 2",null,"Phase 4","Not Applicable","Phase 3",null,"Phase 2/Phase 3","N/A","Not Applicable","N/A",null,"Phase 3","Phase 1","Phase 2","Phase 2","Phase 2","N/A","Phase 4",null,"Phase 2/Phase 3",null,"Not Applicable","Phase 1",null,"Phase 4","Phase 4","Not Applicable","Phase 3","Not Applicable",null,"Phase 2/Phase 3","Phase 3",null,"Phase 3","Phase III","Not Applicable","Not Applicable","Not Applicable","Phase III","Phase II/III","Not Applicable","Phase III","Not Applicable","Retrospective study","Phase I/II","Phase 3","Phase 2/Phase 3","N/A","N/A","Not Applicable","4","Retrospective study","Phase 2/Phase 3","N/A","N/A","N/A","Not Applicable","Not Applicable","Not Applicable","Not Applicable","Phase 0","0","0","Not Applicable","N/A","N/A","Retrospective study",null,"Not Applicable","Not Applicable","0","1","Retrospective study","0",null,"0","Diagnostic New Technique Clincal Study","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Retrospective study","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n",null,null,null,"N/A",null,"4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n",null,null,"Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n",null,null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n",null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n",null,null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","N/A","N/A",null,"N/A","I",null,"N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","II-III","N/A","N/A","N/A","N/A","2-3","2-3","N/A","N/A","4","IV","N/A","2-3","N/A","2-3","2-3","N/A","N/A","2","Phase 3","N/A","3","Phase 3","3","N/A","N/A","2-3","2-3","3","3","3","3","3","3","2","3","3","3","3","2-3","2","3","1-2","3","N/A","2","2-3","2-3","2","3","3","N/A","3","2-3","2-3","2","2-3","2-3","3","N/A","2-3","3","3","2","N/A","1","N/A","2","3","2","3","3","3","2","3","2-3","3","3","3","3","1-2","3","N/A","3","3","3","1-2","3","3","1-2","3","3","3","2-3","1-2","3","3","3","N/A","3","3","2","3","2","3","3","3","2","2","2-3","3","3","2","2-3","1","3","3","3","3","3","2-3","2-3","N/A","3","Not Applicable","3","3","3","3","Not Applicable","2","2","2","Not selected","3","Not applicable","3","Not selected","N/A","Phase-3","Not applicable","N/A","Phase 4","N/A","Not selected","N/A","N/A","1-2","0","N/A","N/A","N/A"],["China","China","China","China","China",null,"China","China","China","China","China","China","China",null,"China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China",null,null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","Wuhan","China","China","China","China","China","China","China","Chinese","China","China","China","China","China","China","France",null,"China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China",null,"China","China","China",null,"China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","china","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China",null,null,null,"China","China",null,"China","China",null,"China","China","China","China","China","China","China","Chian",null,"China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China",null,null,"China","China","China","China","China",null,"China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China?","China","China","China","China","China","China","China","China","China","China","China",null,"China","China",null,"China","China","China","China","China","China","China",null,"China",null,"China","China","China","China","China","China","China","China","China",null,"China","China","France","Korea, Republic of","China","China","China","China","China","China","China","China","China",null,null,null,"China","China","China","China","China","China","China","China","China",null,"China","Hong Kong","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","France","China","China","China","China","China","Japan,Asia(except Japan),Australia,Europe","China","China","China","China","China","Japan","China",null,"China","China","Japan","China","Singapore","China","China","Jordan","China","China","China","China","China","China","China","China","China","China",null,"France","Sweden","Italy","China","China","Italy","China","China","China","China",null,null,"China","Italy","China","China","China","China","China","China","China","China",null,"China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","France;Canada;Spain;Russian Federation;Israel;Germany;Japan;Italy","China","China","China","China","China","Turkey",null,"China","Belgium","Netherlands","Italy","Canada","France","China","Germany","China","United Kingdom","China","Italy","China","France","Italy","China",null,"Egypt","Italy",null,"Hong Kong","United Kingdom",null,null,"China","Canada",null,null,null,"Netherlands","United States","United States","United Kingdom",null,"China","China","China","United Kingdom","China","China","China","China","China","China","United States","Italy","China","China",null,"China","China","China",null,"China","China","China","France;Belgium;Luxembourg;Netherlands;Germany;United Kingdom;Spain","China","China","Italy","China","China","Greece","China","China","France","China","Australia","China","China","France","China","Denmark","Canada","China","China;Italy;China;Italy","United States","Netherlands","Italy","United States","China","Brazil",null,"Norway","Norway","Australia;Hong Kong;Taiwan, Province Of China;Indonesia;Korea, Republic Of;Japan;Italy;Singapore;Viet Nam;Thailand;United Kingdom;United States of America","Italy","United States","Denmark","China","France","Romania",null,null,"Germany","Pakistan",null,"Vietnam",null,"Belgium;Italy","United States;Denmark;Germany;Japan;Korea, Republic of;Mexico;Singapore;United Kingdom;Denmark;Germany;Japan;Korea, Republic of;Mexico;Singapore;United Kingdom;United States","Italy;Romania;United Kingdom;Italy;Romania;United Kingdom",null,null,"Turkey","Netherlands","United States","Norway",null,null,"United States","Canada",null,null,null,"France",null,"China","Italy","France","United States","United States","Colombia",null,"France","Iran, Islamic Republic of",null,"Switzerland",null,"Iran, Islamic Republic of","Denmark","China","Spain","United States",null,"France","Australia","China",null,"Australia","New Zealand",null,"United States",null,"Australia","Australia",null,"Australia","Colombia","Mexico","China","China",null,"Israel","Australia","Australia","China","China","Bolivia","China","China","China","China","China","??","China","China","China","China","China","China","China","China","China","China","China","China","France","France","France","Germany","Netherlands","Belgium","France","France","France","Spain","France","Spain","Greece","France","France","Spain","Spain","Spain","Spain","Spain","Spain","France;Hungary;Czech Republic;Denmark;Germany;United Kingdom","Spain","Spain","Canada","United States;Australia;Korea, Republic of;Taiwan;Australia;Korea, Republic of;Taiwan;United States","China","China","United Kingdom","China","China","China","China","China","Brazil","China","Hong Kong","China","China","France","China","China","United States","China",null,"Thailand","United States","China","France",null,"United States;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;Iran, Islamic Republic of","United States;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States","United States","United States","United States","United States;Israel;United States","Italy","China","United States;Canada;United States","China","Spain","China","United States",null,"Brazil","Italy","France;Spain;France;Spain","Brazil","Egypt","China","Italy","Mexico","United States","Norway","Denmark","United States;France;Germany;Italy;Spain;Switzerland;United Kingdom;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States","United States","Mexico","United States",null,"United States;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States","United States","Italy",null,"Denmark;France;Germany;Norway;Denmark;France;Germany;Norway","United States;Canada;United States","United States","Spain","United States","Canada","France","Germany","Denmark",null,"Italy","Italy","France","United States","Canada;France;Germany;Italy;Japan;Spain;Canada;France;Germany;Italy;Japan;Spain","Brazil","United Kingdom","Italy",null,null,"Turkey","Australia","France;Monaco;France;Monaco","United States","France","United States","United Kingdom","French Guiana","Germany","United States",null,"Spain",null,"Ireland","United States","France","Switzerland","Canada","Germany","France","United States","Iran, Islamic Republic of",null,"Belgium","Canada","United States","United States;United Kingdom;United States","Spain","Canada","United States","United States","Netherlands",null,"Italy","Spain","United Kingdom","United States","United States","United States;Australia;Canada;Ireland;South Africa;United Kingdom;Zambia;Australia;Canada;Ireland;South Africa;United Kingdom;United States;Zambia","France","China","United States;France;United States","United States","United States",null,null,null,"China",null,"United States","France","Spain","Spain","France","Mexico","United States","United States","Canada","Spain","United States","Germany","Spain",null,"Switzerland","United States","Norway","Turkey","China","Denmark","China","Turkey",null,"United States","United States","United States","France","Egypt","Italy","France","United States","United Kingdom","France","France","Turkey","China","Austria;Denmark;Germany;Austria;Denmark;Germany","Mexico",null,null,"Denmark","United States","France","United States","United States",null,"France","United States","France","Turkey","United States","Israel","Greece","Mexico",null,"Italy","Germany",null,null,"Turkey",null,null,"United States","Spain",null,null,"United States","India",null,"China","United States","Belgium","United States",null,"United States","China",null,null,"Belgium","Germany","United States","France","United States",null,"United States","United States","United States",null,null,"Germany","United States","China","France","Spain","Germany","Mexico","United States",null,"France","Denmark",null,"France","Nigeria;Pakistan;Nigeria;Pakistan","United States","France","China","United States","United States",null,"United States","France",null,null,"Germany","France","Sweden","France","United States",null,"Netherlands","China","United States","United States;Egypt;Iran, Islamic Republic of;Egypt;Iran, Islamic Republic of;United States","Brazil",null,"United States","France","United States","Germany","France","United States","United States",null,null,"United States","Iran, Islamic Republic of",null,"Brazil",null,null,"Greece","Colombia","United States","Hong Kong","Spain","France","Indonesia","Mexico","United States","France","United States","United States","France","Germany;Romania;Germany;Romania","United States","Belgium",null,"France",null,"Brazil","United States","United States","United States","Italy",null,"Spain","India","United States","France","France","United States",null,"China","France","France","United States",null,null,"Russian Federation",null,"United States","United States","Colombia","Turkey","France",null,"Egypt","Malaysia","France",null,"United States","United States",null,"Italy",null,"Norway","United States","France","United States","Egypt","Spain","France","Italy","Spain","Colombia","United Kingdom","United States","Denmark","Italy",null,"Spain","Netherlands","Italy","India","Switzerland","Belgium","United States","France",null,"Italy","Brazil","China","Italy",null,null,null,"United States","Hong Kong","Spain",null,"France",null,"United States","United States","United States","Austria",null,"United States","United Kingdom",null,"China","India","Pakistan","United Kingdom","Singapore","France","Egypt","Germany",null,"Saudi Arabia","Canada",null,"Tunisia",null,null,"Germany",null,"Germany","Australia",null,"France",null,null,"Ireland","United States","New Zealand","Spain",null,null,"Brazil","Spain","Greece","France","Australia","Canada",null,null,"United States","United States","France","Spain",null,"Austria","United States","France","Germany","United States","France",null,"United Kingdom","United States","Hong Kong","United States","United States",null,null,"Egypt","Austria","United Kingdom","United States","France","Iran, Islamic Republic of","Iran, Islamic Republic of","Australia","Australia","Australia",null,"Austria",null,"France","Australia;New Zealand","Argentina;Brazil;Canada;Germany;Indonesia;Iran;Norway;Peru;Qatar;South Africa;Spain;Switzerland;Thailand","Australia","Liechtenstein","Australia","United Kingdom","United Kingdom","United Kingdom","Canada","Australia;Austria;Belgium;Brazil;Bulgaria;Croatia;Cyprus;Czech Republic;Denmark;Finland;France;French Southern Territories;Germany;Greece;Ireland;Isle of Man;Israel;Italy;Lebanon;Liechtenstein;Lithuania;Luxembourg;Malta;Netherlands;New Zealand;Norway;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States of America","China","United Kingdom",null,"Egypt","United Kingdom","Denmark","United Kingdom","China","China","Poland",null,"China",null,"Australia","Australia","Australia","Australia;China;United States of America;Italy;Germany;Spain","Australia","China","The People's Republic of China","Afghanistan;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe","China","China","China","The Netherlands","United Kingdom","Switzerland","China","China","China","China","The Netherlands","China","China","France","China","China","Denmark","The Netherlands","The Netherlands","The Netherlands",null,"The Netherlands","China","Netherlands","China","Denmark","The Netherlands","The Netherlands","Spain","Spain","The Netherlands","The Netherlands","Spain","The Netherlands","France","The Netherlands","The Netherlands","France","Spain","Spain","France","Spain","Spain","France","Spain","Denmark","Spain","Spain","Austria;Denmark","United Kingdom","Spain","Spain","Spain","Spain","Spain","Ghana;Nigeria;South Africa;United Kingdom;India","Norway","Spain","France","Greece","Spain","Portugal;Greece;Finland;Spain;Ireland;United Kingdom;France;Czech Republic;Hungary;Belgium;Romania;Croatia;Australia;Denmark;Netherlands;Germany;New Zealand","Belgium","Germany","Germany","Germany","Germany","Germany","Germany","Germany;Austria","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Belgium;Germany;France;Italy;Ireland;Portugal;Spain;Austria;Iceland;Switzerland;United Kingdom","India","Germany","Germany","Iran (Islamic Republic of)","Germany","Germany","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Germany","Germany","Iran (Islamic Republic of)","Germany","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Bangladesh","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Germany","India","Iran (Islamic Republic of)","India","India","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","India","Iran (Islamic Republic of)","Iran (Islamic Republic of)","United Kingdom;India;Italy;United States of America","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Lebanon","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Egypt","USA;KOREA;Japan","Japan","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Nigeria;Nigeria","Japan","Japan","Japan","Japan","Brazil","Japan","Brazil","Japan","Thailand","Nigeria","Japan","Thailand","Thailand","Spain","Japan,North America","France","Brazil;Canada;Chile;Colombia;France;Portugal;Spain;United Kingdom;United States","Cuba","India;Iran;Thailand;Spain;Norway;Switzerland;South Africa;Argentina;Peru;Bahrain","France;France","Brazil","Thailand;Malaysia;Italy;England"],["Yan Zhao","Ting Cai","Xiaowei Xu","Zhai Xiaowen","Wu Wenjuan",null,"Yan, Zhao","LU Zhenhui",";",null,"Li Jiansheng","Yongshi Jia","Wang Tan","Chao Xu","Weiren Huang","Bin Song","Xiangming Fang","Deng Guofang","Wei Zhang","; ;",null,"Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang","Xiaoyin Huang",";","Xu Shuyun","Ronghui Du","Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang","Qin Ning, Meifang Han","Xia Jinyu","Ronghua Jin","Huaqi Wang","Fang Xueling","Zhang Zhongde","Hu bo, Li wei","Lu Hongzhou","Yongxiang Yi","Zhan Jie","Hongzhou Lu, Xiaorong Chen","Xia Jiaan",null,";","LU Zhenhui","Ting Cai","Lixin Wang","Yaosheng Zhang, Jianwei Shang","Xiaoling Xu","Tong Xiaolin","LIU QINGQUAN","Huang Luqi; Li Zhiqiang","Kang Yan","Zhan Zhang","Pei Bin","Nianzhi Zhang","Jiang Shanping","Jianping Zhao","Li Jiansheng","LIU QINGQUAN, MIAO QING, ZHANG BOLI","Li Jiansheng, Li Suyun","Chengping Wen","Tengxiao Liang, Tong Wang, Xuezeng Hao, Jingfeng Zhang, Yaosheng  Zhang","Yao, Rong","Zhao Yan","Wen Chengping","Nanshan Zhong, Zeguang Zheng","Xue Zhigang","Chengping Wen","Min Huang","Jixian Zhang","Jun Guo","Wen Shenglin, Xia Jinyu","Zhang Zhongde","Cai Hongliu","Yanling Zhao","Cao Jun","Yuan Yongming","Zhang Wei","Xiaolin Tong","Wu Guolin","Liu Yingxia","Pei Guangzhong","Pei Bei","Zhang Zhan","Qiu Yunqing","Wang Xinghuan/Ke Hengning","Su Wen","Jiang Hua","Xia Wenguang, An Changqing, Zhang Boli","Wei Li","ZHANG ZHONGDE, ZHANG BOLI","Chao Cao","Huang Luqi","Qiu Jun","Wanhong Yin","Ying Kejing","Wu Wenjuan","Qianxue Chen","Lv Dongqing","Yu Hongzhi","Hongzhou Lu","Wang Shaogang","Zhongqi Yang, Minyong Wen","Mingxing Xie","Dewei Zhao","XIONG YAN","Tian Feng","Jun Lin","Chen Lei","Xu Yong","Mao Wei","Min Xie","Chengfeng Qiu","Qu Jieming","Hong Shan","Lanjuan Li /Xiaowei Xu/Charile Xiang","Wang Daowen, Zhao Jianping","Ma Penglin","Ke Hu","Qiu Yunqing","Cheng Zhenshun","Qingping Wu","Xie Chunguang","Kequn Chai","Feng WANG","Yunqing Qiu","Wenguang Xia","Chanjuan Zheng","Wenguang Xia","WANG YUGUANG, LI XUCHENG, ZHANG BOLI","Zhong Nanshan / Song Yuanlin/Qiu Haibo/Li Yimin/Liu Xiaoqinqing","; ;",null,"Huang Yi","Le Aiping","You Shang","Liu Yingxia","Hong Zhao","Hua Lu","Qing Zhou","Chaoqian Li","Bende Liu","Shixuan Wang","Gang Xu","Jing Liu","Nanshan Zhong","Shentu Jianzhong?Wu Lihua","Chen Xiangdong","Yao-sheng Zhang/Ting-rong Huang/Chun-yan Ji/Jian-wei Shang","; ;","Donghui Huang","XiaoWang Qu","Hongyi Chen","Baofeng Yang","Zhang Dingyu","Peng Hu","Tang Jianyuan","Lu Hongzhou","Jian Bo and Chuanzhu Li","Gong Shouping","Zhaohui Tong","Jiang Hong","Fang Lei","Yin Zhenyu","Robert Chunhua Zhao/Ronghua Jin","Fang Min","CHEN Xinyu","Jun Tang","Shixuan Wang","Lyu Dongqing","Peng Yudong","Gong Shouping","Junbo Ge","Dong Liang","Xiaoguang Tong","Huji Xu","Xin Zheng","Zhan Zhang","Lianru Gao","Mingxing Xie","Haifa Xia, Xiangdong Chen","Zhuoli Zhang","Xin Zheng","Yin Zhenyu","Xuebing Yan","Zhou Min","Luo Zhigang","Chunxue Bai","Tao Li","; ;",";","; ; ; ;","; ;","Tang Jianyuan","Hongliang He","Feng Cao",";",null,"Zhao Yan","Dong Shang","Caixia Xie",";","; ;","Chen Hong","Kunlun He","Yang Yi","; ;","Ma Xiaorong","Yan Hao; Xiaoping Luo",null,"Nijun","Ni Jun","Shao Fengmin","Chuxiao Shao","Xiaorong Chang","Zhongyu Zhou",";",";","RongJin Lin","Lu Yibin","Zhenhua Zhang","Ming Chen","Rui Pan","Yongxiang Yi","Ming Chen","Zhang Dingyu","Jianzhong Liu","Huilan Zhang","Li Caixia","Hu Bing","Ziqiang Zhang","Wang Tan","Jianqing Xu","Jihui Lyu","Kaihu Yu","Kaijiang Yu","WANG Jing","Meiping Chu","Lijia Deng","Liu Hua/Wang Qian","Lijia Deng","Feng Li","Shao Yi","Jiemin Zhu","Zhiyong Peng","Junxue Wang","Wei Yang","Bi Ying-fei","Li Jiangping","Bin Zhan","Liangdan Sun","Feng Cao","Xie Liangdong","Wei Zhang","Zhenjie Hu","Liu Dong","Zhou Jia","Liu Dong","Daisy Dexing Zhang","Kaihu Xiao","Yu Jia","XIONG YAN","Chen Hao","Hua Shucheng","Wenxiang Huang","Wenxiang Huang","Cancelled","Peng Hu","Yaokai Chen","Shen Ning","Yaokai Chen","Huawei Mao","Shen Ning","Wang Hailong","Li Shusheng","Xu Zhihua",";","Yunxia Zuo","Mei Heng","Chuantao Zhang","Hu Liu","Xiaowei XU","Ying binwu","Li Shusheng",";","Xiaoyang Lu","; ;",";","CHEN Xinyu","Li Suyun","Zhang Huafen","Shusheng Li","Wang Hao","Wang Hongyang","Ye Gu","Chen Zhenshun","Chen Xiao","Chen Chunbo","Ye Wan",null,";","Wei Yao","Guojun Zhang","Xiuming Song","Yuanrong Dai","Zhang Wei","Jiang Shujuan","Kang Yan","Wu Caineng","Liu Yi","Yanling Shi","Xufang Sun","CAI YU","Yan Hao; Xiaoping Luo","Bende Liu","Jie Luo","Jianfeng Zhou","Pang Yong-li","Minghao Fang","Yong Huo","Zhongyuan Xia","Xie Chunguang","Xuemei Li","Huilan Zhang","Xie Chunguang","Chengxian Guo","Bin Li","Zhijun Fang","Tang Jianyuan","Xuemei Li","Ye Feng/ Yang Zifeng/ Xu Xuyan/ Zhu Jun/ Jiang Lihong/ Zhang Yunhui/ Yuan Bing/ Chen Shi/ Fan Jie","ZHOU JIAN","Wang Dazhong","Lunxu Liu","Zongze Zhang","Jingzhi Ma",null,null,"Jianfeng Zhou","Guiqiang Wang","Cao Bin","Zhang Dingyu","Wang He","Lu Guangming","Feng Gao",";",null,null,"Wang Tan","; ;",null,"Honghua Ye","Xie yuanlin","Shiyue Li","Deng Xiaopeng","Zhang Sheng","Prof. Christopher CK Lai","Zhu Bo","Qun Luo","Li Lanjuan","Xu Jie","Guoqin Sun","Wen Jianli","Yang Si-Jin","Li Xugui","Luo Xiaoping","Jiang Xie","Shusheng Li","Tiejun Wang","Wen Jianli","Xu Haibo","Xu Shuyun","Liming Xia","Bangjiang Fang","Fengbin Liu","Dou Qifeng","Yibin Hao","Ning Qin","Yan Hao, Xiaoping Luo","Lingli Dong","Xiang Cheng","Peng Sun","Ye Tu","Qian Guoqing","Xia Tian","Yuan Yang","Yi Bian","Zhengrong Mao","Jing-Guo Cheng","Junming Wang","Jingfeng Zhang","Zhihua Wang, Xianglin Yuan","JIAN PENG","Zhigang He","Liang Wang","Xin Li","Hu Linhui","Zhang Yue","Wang Hua-bing","LIU DONG","Qingyou Zheng","Yuan Yadong","Peng Jian","TAO WANG","Wu Kaifeng","Lihui Wang","Yingjia Xu","Hongyu Gao","Guo Zhang","Jing Chen","Zhaofen Lin,Wansheng Chen,Weifen Xie","Xia Hong","Xiong Chen","Fenglin Liu","Fenglin Liu","GuoLin Song","Burenbatu","Qin Wang","Hong Wang","Fenglin Liu","Cuntai Zhang","Fenglin Liu","Zhao Yan","Hui Zhong","Zhanlian Huang","Fenglin Liu","Minghao Fang","Lijia Demi","Fenglin Liu","Fenglin Liu","HONGGANG LI","Huanqin Han","Guangtao huang","Wei Li","Cai Qingxian","Li Xiaodong","Pinhua Pan, Yehong Kuang","Wang Hongyang","Zhang Yu","Zhi Zhang","Min Zhang","Wang Xiaowen","Chen Lei","Xiaodong Li","Hanwei Chen","Yang Yi","Zunyuan Liu","Song Ying","Gao Jun","Cao Bin","xiao wei","Qingping Shi","He jing","Bi Xiaohui","Zhongze Lou","Zhu Fengxue","Haibin Ni","Zhu Haibing","Hong tao","Qingling Zhang","Wei Wei","Wei Xiao","Baoshan Cao","Ying Deng","Gao Dengfeng","Jingzhi Ma","Weiping Cai","Xin Zheng","Chao Xu","Jinghua Mao","Chao Xu","Liu Zhisheng","Jinghua Mao","Miao Qing","Miao Qing","Huang Keqiang","Meizhen Lin","Kaijiang Yu","Jia Lijun","Jing Xu",";","Kun Ye","; ;","; ;",null,"Pengfei Pang","Bende Liu","Gao Dengfeng","CHEN Hui","Zairong Wei","Meng Jie","Jiao Xianfa","Pei Bin","Haihang Yu","Fan Li","Chao Xu","Chao Xu","Shitao Chen","Jing Li","Jin Yang","Yang Jinfeng","YY Chen","GAO Hong","Rengbin Ji","Gang Sun","Zhaohui Tong","Tang Hao","Bin Zhang/Yinong Ye",null,"; ;","Chunli Liu","Chen Jian","Liujie","Feng Zhen","Jiang Shujuan","Zhu Fengcai",null,"Jie Lin","Changqing Hu","Tian Lin","Chuo Li","Zhang Dingyu","Huang Hui","Binghong Zhang","Xinghuan Wang","Luping Lin","Chengyun Liu","Binru Wang","Qianjin Lu","Ting Cai","GuoLin  Song","Dawei Wang","Ying-kun Guo","Zhaohui Tong","Li Bixi","Hongmei Tao","Zhongyuan Xia","Li Lanjuan","Wei Wang","Gong Guozhong","Ye Xiaoqun","MINGLI LIU",";",null,"IHU Mditerrane Infection","Zhang Lina",null,";","Fan Zhong","Wei Zhang","Keibun","Guochao Shi",";",null,";",";","Masashi","; ;",null,null,"; ;","Junko",null,"; ;",null,null,";",null,";","; ;",null,";","; ;","; ; ; ;",";","Kun Xiao","Haixiao Chen",null,"; ;","; ;","; ;","Wenliang Fan","; ;",null,"Shen Chan","Prof. Qingsong Ye; Dr. Chenliang Zhou","Xianli Du","Fan Yang","Tianwang Li","Wei Min","Yuan-hao Wu","; ;","Xianli Du","Zhang Rong","Hong Qiu","Yan Hao, Xiaoping Luo","Zheng Xue","Zhuang-Gui Chen","Daoyuan Si","Qiuling Shi","Xiandong Meng","Zhongyuan Xia","Jin Ronghua","Xiaojun Tang","Pengcheng Luo","Qingta Meng","GAO Tian-lin","Wei Wang","Jun Shao","Fu Liran","Peiyang Gao","Zhe Xu","Wei Lu","Lei Genping","Li Shi-yue","Zhang Yi","Zhongde Zhang","Hu Xingxing","Peiyang Gao","Direction des Oprations Cliniques","Ming Wu","Yan Kang","Huang Luqi; Ruan Lianguo","Cao Guoqiang","Sun Hongyuan","; ;",null,"Chengqi He","Laurens Liesenborghs","Marc J. M. Bonten","; ;","; ;",";",";","Project management,Diane Egger-Adam","Mingxing Xie","Jody Brookes","Jin Yang",null,"; ;",";",";","; ; ;",";",";","; ;",";",";","; ;",null,null,"; ;","; ; ;",null,";",null,";",";","; ;",null,";","Zhang Hua-nian","Xiuyong Li",null,"; ; ; ; ; ; ; ;","Hongqiang Sun","Xuezhong Yu","Feng Ganzhu","Shen Chengxing","Weiqin Li","Fan Rong",";",";","Xiang Changgang","LI HANG",null,"Hong wenxin","Xiao Fei","Chenyu Zhang","Li Wan","Fu-Sheng Wang","Zhongyuan Xia","Zejin Liu","Christelle DELMAS","Xiaomei Guo","Dongyang Liu","Trial Information Support Line-TISL","Jiang ZhiXia","Yaqin Zhu","Regulatory Affairs department","Lingli Dong","Li Chen","chef de projets","Xianglin Yuan",null,"Ou Cehua","Lingli Dong","project manager","Xiang Changgang","Sponsor/Investigator",null,";",";",";","Jurjan Aman",null,"; ;",";",";",null,"; ;","Department of Infectious Diseases",null,"; ;",null,";","; ;",null,"; ;",";",null,"; ;","; ;",null,";",null,";",null,"; ;",null,";",null,null,"; ;",";",null,";","; ;","; ;",null,null,";",null,null,";","; ; ; ; ; ; ; ;",";",";",null,"; ;",null,"; ;",null,";","; ;","; ;","; ; ; ;",";",null,";",";",";","; ;",null,"; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;",null,null,null,";",";",";",null,null,null,null,"; ;",";","Jinzhi Lu","Liping Jia","Guihua Liu",";",null,null,"Sanlian Hu","Qianjin Lu","DIANA MARIA CESPEDES ARCANI","Zhu Fengcai","Yun Liu","Jinghua Qian","Junxue Wang","zhu pengfei","Shengtian Zhao","Chen Li","Ying Fan","Li Jianan","Zhang Chunyan","Yun Lin","Enhai Cui","Tangshaohua","Yingshuai Li","Bai Xiaoxia","Zhenlin Zhao","Rui Zeng","Weng Jianping",null,"Carla VANDENABELE","Eldoie SOLER","Sixten Krper","Clinical Research and Development","HIRUZ CTU","REC","Clinical research project manager","Project manager","SCREN-UICEC","Julien GAUTIER","LOLA SERNA GUIRAO","President of the Board","DRCI","Clinical Research Director","Xavier Solanich Moreno","UICEC Sant Pau","Unidad de Enfermedades Infecciosas","Clinical Trials Department","Emilio Garcia Cabrera","Jose Muoz Gutirrez","Medical Information","Epidemiologist","Anabel Snchez","; ; ;",";",null,null,"; ;",null,null,null,";",null,"; ;","; ;",null,null,null,null,null,";",null,";",";",null,";","; ;",";",null,";",";",";","; ;","; ;",";",";",null,";",";",";",null,"; ;",";",";",null,";","; ;","; ;",null,null,"; ; ; ; ; ; ; ;","; ;","; ; ; ; ; ; ; ;",null,";",";","; ; ; ; ; ; ; ; ;",null,";",";",";","; ; ; ;",null,null,"; ;","; ;",";",null,null,null,";",";",null,";",";",";",null,";",";",";","; ;",";",";",";",";",null,"; ; ;","; ;",";","; ;","; ;","; ;","; ;",";",";",";","; ;",";","; ;","; ;","; ;","; ; ;","; ;","; ;","; ;",null,";",";",";",";",";","; ; ;","; ;","; ; ;",";",null,";",";","; ;",";",";","; ; ;",null,";",";",";",null,";",null,null,";",";",null,";",";",";",";",null,";",";","; ; ;",";","; ;","; ;",";",null,";",";",";","; ; ;",";","; ;","; ;",";",";","; ;","; ;","; ;","; ;",";",null,null,null,null,"; ;",null,null,null,";","; ; ;",";","; ;","; ; ; ; ;",null,"; ;",";","; ;","; ; ; ; ; ; ; ; ;",null,";",";",";","; ;",";",";",null,null,null,"; ;",";",null,null,";",null,"; ;","; ;",";",null,";","; ;",null,";",";","; ;",null,null,"; ; ;",";",null,";","; ;",null,"; ;","; ;","; ;",";","; ;",";","; ;","; ;",null,"; ; ;",";","; ;",null,"; ; ;",";",";",";",null,"; ;",null,";",null,"; ;",";",";","; ;",";","; ;",";","; ;","; ;",null,null,"; ;","; ;","; ;","; ;",null,";",";",null,null,null,";",";","; ;",";",";","; ;","; ;",";",";",";",null,"; ; ; ; ;","; ; ; ;",null,null,null,null,"; ; ; ;","; ; ;","; ;","; ;","; ; ;","; ;","; ;","; ;","; ;","; ;","; ;","; ; ;",null,";","; ; ;",";",null,";",";",null,"; ;","; ;","; ;",null,";","; ;",";",";","; ; ; ; ; ; ; ; ;","; ;","; ;",null,"; ;",null,";",null,";",null,null,";","; ;","; ; ;",";","; ;",";",null,"; ; ;",";",null,null,"; ;",";",";","; ;",null,"; ;",null,"; ;","; ;",";","; ; ; ; ;","; ;",";",null,null,";",";","; ; ; ; ; ; ; ; ; ;",null,null,null,"; ; ; ; ; ; ;","; ;","; ;",null,";",";","; ;",null,";",null,";",null,null,null,";",null,";",null,null,"; ;",null,"; ;",";","; ;",null,null,null,"; ;",null,";",";","; ; ; ; ; ;",";",";","; ;",null,"; ;",";",";",";",";",null,null,";",null,";",";",null,null,";",";",null,null,"; ;",null,";",null,null,";",null,";","; ;",null,";",";",null,"; ;","; ;",";",null,null,";",null,null,null,"; ;",null,";","; ;",null,"; ;","; ;","; ; ;",null,";",";","; ;",null,"; ;","; ;","; ; ; ;","; ; ; ; ; ; ;",null,null,null,";",";",null,";",null,null,null,"Lorenz",null,"Emma;Julie","Michelle",null,"Julie",null,"Xiong Ma",null,";",";",";",";","Keith","Huang Mingxing","MiaoXing",";",";","Yang shenglan",";",null,null,null,null,null,"Xun Liu","Lingru Li","Ruth;Sandip","Lu Cheng","Prof. KS Chan Paul","He-Feng Huang","Frank","Greg","Jan","Shan Chunlei","Yongxiang Yi","Zhang Yuanli","Chuanan Shen","Diederik","Shuyi Pan","Fan Yang","Ple Promotion - DRCI","Chen Miao","Luping Lin","Department of Nephrology 2132","Femke","Alienke","Marion","Christopher KC Lai","Jesper","Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua","Cardiology Research Department","Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua","www.Clinicaltrials.gov","Thomas","Joost","Begoa Castro","Ana Aldea","JAH","Hamza","CLINICAL RESEARCH UNIT","Frank","Claire CHAUVETON","Harm Jan","Margriet","Regulatory Project Manager","Alberto Borobia","Alberto Borobia","Eric DEMONSANT","Salvador Augustin","Clinical Trial Unit","Chef de Projet","Clara Menndez","Charlotte Kastberg Levin","Comisin de Investigacin","CRO","Sponsor",null,"Rosario Garca de Vicua","Felipe Garca","Unidad de Investigacin Clnica","Alberto Borobia","Margarita Garca Martn","Donna Smith","Sect. Clin. Imm. &amp; Infect. Diseases","SPONSOR","AWASSI","President of the Board","Subdirectora Cientfica","W.W. van Bentum-Puijk","HIRUZ CTU","Stefan","Johannes","Claudia","Prisca","Dirk","Christian","Dagmar","Dilara","Achim","Michael","Ulrich","Venja","Hendrik","Hanna","Armin","Jrg Janne","DrSujeet Jha","Alexander","Georg","Zeinab Nikniaz","Jan","Alexander","Mandana Puladzadeh","Hossein Khalili","Andrea","Jonas","Maryam Bahreini","Sven","Narjes Heshmatifar","Hossein Khalili","Md. Shahoriar Ahmed","Vahid Ziaee","Amir Hossein Jamshidi","Sven","SALIL GUPTA","Alireza Farsinejad","Dr Remesh Bhasi","Varnit Shanker","Dr. Saeed Soleiman Meigooni","Dr Samadhan Patil","Dr Khalil Ansarin","Reihaneh Pirjani MD.","Dr Naresh Kumar","Hossein Khalili","Hossein Khalili","Nassim Anjidani","Nader Tavakoli","Lotfollah Davoodi","Dr Hossein Poustchi","Sara Mobarak","Bahareh Baghchi","Hamidreza Khorram Khorshid","Hojjat Pourfathi Nematabad","Pooya Payandemehr","Farzaneh Dastan","Maryam Azimi","Lotfollah Davoodi","Dr Ehsan Aali","Saba Ghaffary","Dr Mahdi Khozaei","Seied Amirhosein Latifi","Hassan Abolghasemi","Sara Mobark","Dr. Siamack Afazeli","Hamed Hosseini","Farzaneh Dastan","Farbod Rahnama Chitsaz","Sara Mobarak","Atefeh Ahmadi","Saba Ghaffary","Monireh Ghazaeian","Mahdi Yousefi","Sara Mobarak","Dr. Mohsen Moghadami","Kourosh Sadeghi","Mehrdad Karimi","Alireza Zahedi Neyestani","Dr Nafiseh Abdolahi","Dr Khalil Ansarin","Hossein Biganeh","Rozita Khodashahi","Rahimeh Eskandarian","Hasan Abolghasemi","Maryam Azimi","Masoumeh Asgharpour","Hamideh Abbaspour Kasgari","Hossein Hosseinzadeh","Sama Bitarafan","Bita Shahrami","Omidvar Rezaiemirghaed","Gholamreza Karimi","Razieh Borujerdi","Ahmad Reza Sharifi Olounabadi","Zhila Maghbooli","Haleh Tajadini","Roja Rahimi","Sakineh Hajebrahimi","Ramin Nasimi Doost Azgomi","Dr. Reza Khodarahmi","mohammad namazi nia","Farhang Babamahmoodi","Mehran Varnaseri Ghandali","Seyed Hassan Saadat","Fallah Huseini Hasan","Hossein Vahidi","Dr Khalil Ansarin","Somaieh Matin","Hossein Poustchi","Azadeh Eshraghi","Armin Sadeghi","Mohammad Moeini Nodeh","Morteza Zarrabi","Reza Shirvani","Zhila Maghbooli","?Dr. Mitra Ranjbar","Shahriar Najafizadeh","Mohammadreza Rouhani","Mohammadreza Ardalan","Mehrdad Iranshahi","Abdorahman Rostamian","Hossein Hosseinzadeh","Fatemeh Roozbeh","Sepideh Elyasi","Parviz Kokhaei","Ali Taghizadieh","Seyed Ahmad Emami","Morteza Zarrabi","Ramin Hamidi Farahani","Roshanak Mokaberinejad","Hossein Hosseinzadeh","Fereshteh Ghiasvand","Rami","Parisa Kianpour","mehdi mesri","Masood Ziaee","Ehsan Sekhavati Moghadam","Mehran Varnaseri Ghandali","Ali Sarrafzadeh","Mikaili, haleh","Dr Mohsen Seddigh Shamsi","Mohammad Ebrahim Khamseh","Mahmoud","Ayako","FUJIFILM Toyama Chemical Co., Ltd. Development Coordination Department","Seyed Abbas Mousavi","Malihe Zangoue","Jude","Terada","Tetsuya","Tetsuya","Hironori","Dayane","Ryota","Fernando","Nobuyuki","Nattachai","Hussein","Nobuhito","Tongluk","Suvimol","Carlos","Nobuyuki","Enrique","Janari","Zurina","Patricia","Enrique","Julio","Phaik"],[null,null,null,null,null,"Pinhua Pan, Medical PhD",null,null,"Yueping Li, MD, Master;Linghua Li, MD, PhD","Panpan Hao, MD",null,null,null,null,null,null,null,null,null,"Xiao-he Xiao, PD.;Rui-lin Wang, Dr.;Rui-lin Wang, Dr.",null,null,null,"Yuhong Dai;Yuhong Dai",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Taisheng Li","Yunqing Qiu, Master;Xiaowei Xu, Master",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Xavier Duval, MD;Xavier Duval, MD;Xavier Duval, MD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"XingHuan Wang, professor;XingHuan Wang, professor;XingHuan Wang, professor",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Jiahong Dong, M.D;Xiaobin Feng, M.D;Xiaobin Feng, M.D","Jinglin Xia, MD;Jinglin Xia, MD","Kunling Shen, MD,PhD;Tianyou Wang, MD,PhD;Baoping Xu, MD,PhD;Baoping Xu, MD,PhD;Lina Wang","Chunxue Bai;Chunxue Bai;Chunxue Bai",null,null,null,"Jianqi Lian, MD;Sicao Li","Hongzhou Lu, Master",null,null,null,"Jinglin Xia, MD;Jinglin Xia, MD","Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor",null,null,null,"Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor",null,null,null,null,null,null,null,null,null,"Chenghai Liu, PhD;Chenghai Liu, PhD","Ying Fu;Wan-Jin Chen, MD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Ronghua Jin;Huiguo Ding",null,null,null,null,null,null,null,"Jie-ming Qu, MD.,PhD.;Jie-ming Qu, MD.,PhD.",null,"Yan Liu;Xiaotian Sun;Yan Liu, Ph.D.","Huilan Zhang, PD;Huilan Zhang, PD",null,null,null,null,null,null,null,null,null,null,null,null,"Shuiping Zhou, PhD;Yi He, PhD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Xiuling Shang",null,null,null,null,null,null,null,null,"Mark B Loeb;Mark Loeb, MD",null,null,null,"Hongzhou Lu, Ph.D;Hongzhou Lu, Ph.D;Jun Chen","Jianping Zhao, Ph.D.",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Liwei cheng, doctor;Xiaoyang Zhou, doctor",null,"Zhiyong Peng, professor;Zhiyong Peng, professor;Zhiyong Peng, professor","Frderic DUTHEIL;Lise Laclautre;Lise Laclautre","Sung-Han Kim, MD.PhD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Lung-Ji Chang;Lung-Ji Chang;Lung-Ji Chang",null,null,null,null,null,null,"Qiong Gong, MD.",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Qing Ning, Professor;Qin Ning, professor","XIAN SHEN, phd",null,null,"Faming Zhang, MD; PHD","Qing Ning, Professor;Qin Ning, professor",null,null,"Liu",null,"Yang Jin;Yang Jin","Yimin Li, PhD, MD","Qing Ning, Professor;Qin Ning, professor","Qing Ning, Professor;Qin Ning, professor","Kondo","Lung-Ji Chang, PhD;Lung-Ji Chang, PhD;Lung-Ji Chang, PhD","Lin Chen",null,"Wei Zhang;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.","Terada",null,"Jean Liu, PhD;Jean Liu, PhD;Jean Liu, PhD",null,null,"Adeeb M AlZoubi, Ph.D.;Adeeb M Alzoubi, Ph.D.",null,"Qing Ning, Professor;Qin Ning, professor","SHAOXIAN HU, M.D;YIKAI YU, M.D;AIHUA DU, M.D",null,"Haibo Cheng, phD;Lei Cui, phD","Xiaoju Zhang, PhD;Ziqi Wang, MD;Li Li, Master","Dong Shang, M.D.;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.;Zhong Wang, M.D.;Jun Liu, M.D.","Wenhong Zhang, Doctor;Wenhong Zhang, PhD,MD",null,null,null,"Joe-Elie Salem, MD, PhD;Lee S Nguyen, MD, PhDc;Lee S Nguyen, MD, PhDc","Robert Frithiof, MD. PhD;Robert Frithiof, MD. PhD.;Robert Frithiof, MD. PhD.","Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo",null,"Zhang Li Na, MD;Zhao Ch Guang, MD;Xiao","Gabriele Saccone, MD",null,null,null,null,null,null,null,"Maurizio Cipolla, MD;Antonio V Gaddi, MD, MSc;Maurizio Cipolla, MD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Ipek Yeldan, Prof.;Eren Avcil, M.Sc,Pt;Eren Avcil, M.Sc,Pt","Franois Lellouche",null,null,null,"Fabrizio Cantini, MD;Fabrizio Cantini, MD;Fabrizio Cantini","Darrell Tan, MD FRCPC PhD;Attia Qamar, BEng;Adrienne Chan, MD MPH FRCPC","Florence Ader, MD;Florence Ader, MD","Shumin Wang, Phd.;Shumin Wang, Phd.",null,null,null,null,"Cesare Perotti, MD","Hao Li, Professor;Hao Li, Professor;Hao Li, Prof.","Joe-Elie Salem, MD-PhD;Joe-Elie Salem, MD-PhD","Salvatore Corrao, MD;Salvatore Corrao, MD","Yihai Cao, Dr;Yuguo Chen, Dr;Jiaojiao Pang, Dr;Jiaojiao Pang, Dr","Pter Hegyi, MD, PhD, DSc;Pter Hegyi, MD, PhD, DSc","Mahmoud Tantawy, MD;Mahmoud Tantawy, MD","Francesco Salton, MD;Francesco Salton, MD;marco confalonieri, MD","Paul;Paul","Paul CHAN;","Matthew Snape, Professor;Iason Vichos;Iason Vichos","Thomas C Pitts, M.D.",null,"Min Liu, A.B;Min Liu, A.B;Min Liu, A.B","Richard Whitlock, MD PhD;Emilie Belley-Cote, MD PhD;ACT COVID-19 Study Coordinator;ACT COVID-19 Study Coordinator","Paolo Gisondi","Chong Lei, MD, PhD;Lorenzo Berra, MD","William Schilling, MD","Folkert W. Asselbergs, MD, PhD;Marijke Linschoten, MD","Daniel R Karlin, MD, MA;Daniel R Karlin, MD, MA","Daniel Mollura, MD;Dan Gebow, PhD;TBD TBD",null,"Joost Wauters, MD PhD;Joost Wauters, MD PhD",null,null,null,"James C Moon;Gabriella Captur;Charlotte Manisty;Ben O'Brien;Hugh Montgomery;Steffen Petersen;Thomas Treibel;James C Moon, MD MBBS MRCP;James Moon",null,null,null,null,null,null,"Elizabeth Oelsner, MD, MPH;Elizabeth Oelsner, MD, MPH","LUCA GALLELLI;LUCA GALLELLI",null,null,"Aneel Bhangu",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Jeremy D Road, MD","Jennifer Ho, MD, PhD;Ivy Fan","Yuguo Chen, Dr;Jiaojiao Pang, Dr","Clinical Trial Management;Clinical Trials Administrator",null,"Giovanni Landoni, Professor","Mark Shapiro;BEAT19.org;BEAT19.org","Zhongji Meng;Zhongji Meng","Otvio Berwanger, PhD;ARO-HIAE Academic Research Organization HIAE","Lorenzo Berra, MD","Olav Dalgard, MD PhD;Olav Dalgard, MD PhD;Olav Dalgard, MD PhD",null,null,"Giuseppe GRITTI, MD;GIUSEPPE GRITTI, MD;Alessandro Rambaldi, MD",null,"Lars stergaard, Professor;Ole S Sgaard, MD PhD","Zuojiong Gong, MD;Zuojiong Gong, MD;Zuojiong Guong, MD","Olivier HERMINE, MD-PhD","Alexandru Burlacu, MD, PhD;Cristina Plesoianu, PhD;Alexandru Burlacu, MD, PhD","Guido Bertolini, MD;Guido Bertolini, MD","Csar Calvo Lobo, PhD","Alexander Supady, Dr., MPH;Alexander Supady, Dr., MPH;Alexander Supady, Dr., MPH","Umar Farooq, PhD;Umar Farooq, PhD;Umer Farooq, PhD","Andres Orlandini, MD","Guy Thwaites, PhD. MD;Jeremy Day, PhD. MD","Vasilios Polymeropoulos, MD","Bart Lambrecht;Anja Delporte","20-0006 Central Contact","Alexandru Burlacu, Lecturer;Radu Dabija, Lecturer;Alexandru Burlacu, MD, PhD","Spyridon Deftereos","Anders Kjellberg, MD;Anders Kjellberg, MD",null,"Thijs ten Doesschate, MD","Girish B Nair, MD;Joanne Gondert, RN, BSN;Joanne Gondert, RN, BSN","Arne Sraas, MD, PhD;Arne Sraas, PhD","Michael Eddleston","Yong Goo Song, Professor;Yong Goo Song, Professor","Ruanne V. Barnabas, MBChB, DPhil;Anna Bershteyn, PhD;Meighan Krows","Stephen Freedman, MD;Stephen Freedman, MDCM, MSc;Stephen Freedman, MDCM, MSc","Joon Young Song, MD, PhD","Adrian Martineau, PhD","Guido Bertolini, MD;Guido Bertolini, MD","Bruno HOEN, Pr",null,"Zhou Qi, Doctor;Wang Liu, Doctor","Guido Iaccarino, MD;Guido Grassi, MD;MariaLorenza Muiesan, MD;Claudio Borghi, MD;Claudio Ferri, MD;MASSIMO VOLPE, MD;Leonardo Sechi;Guido Iaccarino, MD, PhD;Marialorenza Muiesan","Isabelle PELLEGRIN;Isabelle PELLEGRIN","Jie Li, PhD;Jie Li, PhD","Robert W Alexander, MD","Juan M Anaya Cabrera, MD, PhD;Juan M Anaya Cabrera, MD, PhD;Gustavo Quintero, MD, MSc",null,"Julien Poissy, MD,PhD;Julien Poissy, MD,PhD;","Majid Saeedi, Ph.D.","Upinder Singh;Upinder Singh","Guido Beldi, Prof. Dr.;Guido Beldi;Guido Beldi","Filippo Annoni, MD;Robson AS Santos, MD,PhD;filippo annoni, MD","Alireza Ghaffarieh, MD;Yadollah Shakiba, MD, PhD;Amir Kiani, PhD;Alireza Ghaffarieh, MD;Yadollah Shakiba, MD, PhD","Sren H Skaarup;Sren H Skaarup","Ming Li, M.D.","Enrique M San Norberto, MD, PhD, MsC;Enrique M San Norberto, MD, PhD, MsC","Brian Kendal, MD;Trista Johnson, PhD, MPH","Manu Shankar-Hari, MBBS;Ndaba Mazibuko, MD","Muriel FARTOUKH, PU-PH MD PHD;Muriel FARTOUKH, PU-PH MD PHD;Muriel FARTOUKH, PU-PH MD PHD",null,"Mingkai Chen, MD;Xiaolong Qi, MD;Fengmei Wang, MD;Ye Gu, MD;Zicheng Jiang, MD;Guo Zhang, MD;Yong Zhang, MD;Dengxiang Liu, MD;Qing He, MD;Hua Yang, MD;Zhengyan Wang, MD;Bin Xiong, MD;Xiaodan Li, MD;Hongguang Zhang, MD;Chuxiao Shao, MD;Hongmei Yue, MD;Xiaolong Qi, MD","Marta Duda-Sikula, MBA",null,null,"Mehdi BENCHOUFI, MD;Mehdi BENCHOUFI, MD","Sabine Hazan, MD;Sabine Hazan, MD","Brett D Thombs, PhD;Marie-Eve Carrier, MSc",null,null,"Fabio Ciceri, MD",null,"Juan M Anaya Cabrera, MD, PhD;Juan M Anaya Cabrera, MD, PhD;Gustavo Quintero, MD, MSc","Jos Fe Castilleja-Leal, MD.;Servando Cardona-Huerta, MD., Ph. D.",null,null,null,"Zivit Harpaz;Zivit Harpaz",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Franois Lamontagne, MD FRCPC MSc;Neill Adhikari, MDCM FRCPC MSc;Marie-Helene Masse;Marie-Helene Masse","Stanley Lewis, M.D;Jennifer Ho, M.D",null,"Hongzhou Lu, Ph.D","Danny F McAuley, Professor;Danny F McAuley, MD;Danny F McAuley, MD",null,null,null,"Lei Shi, MD,PhD;Lei Shi, MD, PhD",null,"Esper Kallas, MD, PhD;Study Director;Esper Kallas, MD","Yao Xie, Doctor;Yao Xie, Doctor;Yao Xie, Doctor","Ivan FN Hung, MD FRCP","Yahong Chen, MD","Yang Jin, MD","Pierre HAUSFATER, MD PHD",null,"ZHU, Professor;GUO, Professor","20-0003 Central Contact","Fu-Sheng Wang, MD, PhD;Lei Shi, MD,PhD","Heng Li, MD,PhD;Johnny Itticheria","Subsai Kongsaengdao, M.D.","Colin Broom, MD;Colin Broom, MD","Zhu Fengcai;Guan Xuhua;Wang Wei","Philippe VANHEMS, MD, PhD;Philippe VANHEMS, MD, PhD","Sandi K Parriott","Gilead Study Director;Gilead Clinical Study Information Center","Gilead Study Director;Gilead Clinical Study Information Center","Lorenzo Berra;Lorenzo Berra, MD","Lorenzo Berra, MD;Lorenzo Berra, MD;Lorenzo Berra, MD","Christopher Tignanelli, MD;Michael Puskarich, MD, MS;Christopher Tignanelli, MD","Jonathan C Javitt, MD, MPH;Robert E Besthof, MIM","Francesco Perrone, MD, PhD;Francesco Perrone, MD, PhD",null,"David Boulware, MD, MPH;David Boulware (Please email), MD, MPH","Guiqiang Wang;Guiqiang Wang","oriol Mitja, PhD;Oriol Mitj",null,"Christopher Tignanelli, MD;Michael Puskarich, MD, MS;Christopher Tignanelli, MD","Colin Broom, MD;Colin Broom, MD","Florentino de Araujo Cardoso Filho;Florentino de Araujo Cardoso Filho, MD, PhD","Gabriele Saccone","Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD","Alexandre Biasi, PhD;Fernando G Zampieri;Fernando G Zampieri, PhD","Aliae Mohamed-Hussein;Aliae Mohamed-Hussein;Aliae Hussein, MD","Zhuan Liao, MD",null,"Carmen Hernandez-Crdenas, MD. MSc.;Luis-Felipe Jurado-Camacho, MD;Ireri Thirion-Romero, MD. MSc;Sebastian Rodriguez-Llamazares, MD.MPH;Rogelio Perez-Padilla, MD. PhD;Cristobal Guadarrama, MD MSc;Joel Vasquez-Prez, MD;Carmen Hernandez-Crdenas, MD. MSc;Aranxta Remigio, MD","Rebecca E Wells, MD, MPH;Rebecca E Wells, MD, MPH;Rebecca Wells, MD","Paul Aukrust, MD, Professor;Andreas Barratt-Due, MD, PhD;Trine Ksine, MD;Katerina Nezvalova-Henriksen, Pharm D, PhD;Anne Margarita Dyrhol Riise, MD, Professor;Marius Trseid, MD, PhD;Inge Christoffer Olsen, PhD;Paul Aukrust, MD, Professor;ANDREAS BARRATT-DUE, PhD","Jens-Ulrik Sthr Jensen, MD, PhD","Gilead Study Director;Gilead Clinical Study Information Center","Shyamasundaran Kottilil;Pan Zheng, MD, PhD","Jorge Rojas-Serrano, MD, PhD.;Rogelio Perez-Padilla, MD;Felipe Jurado-Camacho, MD. MSc;Ireri Thirion-Romero, MD, MSc;Sebastian Rodrguez-Llamazares, MD, MPH;Carmen Hernandez Crdenas, MD, MSc;Cristobal Guadarrama-Prez, MD;Alejandra Ramrez-Venegas, MD, MSc;Felipe Camacho-Jurado, MD;Aranxta Remigio, MD","Rahul Kashya, MBBS","Shmuel Shoham, MD;Shmuel Shoham, MD","Clinical Trials;Reference Study ID Number: WA42380 www.roche.com/about_roche/roche_worldwide.htm","Becky Smith, MD;Mark Sendak, MD, MPP","Riccardo Inchingolo, MD, PhD;Andrea Smargiassi, MD, PhD;Libertario Demi, PhD;Gino Soldati, MD;Libertario Demi, PhD","Umberto Maggiore, MD","Christian Jung, MD","Jean-Claude Tardif, MD;Zohar Bassevitch, B.SC.;Jean-Claude Tardif, MD","Vanessa Vacoby, MD, MAS;Ruth Gebrezghi;Study Coordinator","Jess Villar, MD;Jess Villar, MD","Ethan Berke, MD","Barbara Goodall",null,"Gunther Meinlschmidt, Prof. Dr.;Kati Bermbach","Lars Erik Kristensen, PhD;Lars Erik Kristensen, PhD","Mahmoud M.A. Abulmeaty, M.D., FACN","LUCA GALLELLI;LUCA GALLELLI","Emanuele Nicastri, MD;Cristina de Min, MD / CMO","Bertrand Cariou, Pr;Bertrand Cariou, PU-PH","Michael Joyner, MD","Clinical Sciences &amp; Operations;Trial Transparency email recommended (Toll free number for US &amp; Canada)","Luciano Cesar Pontes Azevedo, Ph.D;Luciano Cesar Pontes Azevedo, Ph.D","Andrew Pollard, Prof;Volunteer Recruitment Co-ordinator","Geltrude Mingrone, MD PhD;Anna Caprodossi;Anna Caprodossi","Zaher Azzam, Prof;Miri Yafee, MSc","Frdric ADNET, MD, PhD;Frdric ADNET, MD, PhD","Mahir M Ozmen, Professor;Istinye University M ozmen, Prof","Prof Nigel Curtis;Prof Nigel Curtis, MBBS PhD","Vincent DUBEE","Ethan Berke;Yuan Tu;Ethan Berke;Yuan Po Tu, MD","Elisabeth Botelho-Nevers, MD, PhD;Bruno Hoen, MD, PhD;Arnauld Garcin","Radha Rajasingham, MD;Radha Rajasingham (Please Email), MD","Ravindra Prof. Gupta, BMBCh;Richard D. Skells, BSc.;Ravi K Gupta, PhD","Claude Flamand, PhD;Claude Flamand, Phd;Claude Flamand, PhD","Tienush Rassaf, MD;Matthias Totzeck, MD;Amir A Mahabadi, MD","Daniel Freilich, MD;Jennifer Victory, RN;Kristin Pullyblank, RN, MS","Luciana Ferrara;Carla Morales Guerra Godoy, MD, PhD","Felipe Garca, MD;Felipe Garca, MD","Mike Foley;Rachael Smith, DO","John William McEvoy, MBBCh MHS;John William McEvoy, MBBCh MHS;John William McEvoy, MBBCh MHS","Samuel M Brown, MD MS;Valerie T Aston, MBA","Camille TAILLE, MD, PhD;Camille TAILLE, MD, PhD;Camille TAILLE, MD, PhD","Claire-Anne Siegrist, MD;Claire-Anne Siegrist, MD;Claire-Anne Siegrist, MD","Luanne Metz, MD;Michael D Hill, MD;Dr. L Metz, MD","Andreas Strhle, Prof.Dr.;Antonia Bendau, M.Sc.Psych.;Antonia Bendau, M.Sc.Psych.;","Fabrice DENIS, MD;Fabrice DENIS, MD;Fabrice DENIS, MD","Ravi Amaravadi, MD;Amelia Anderson;Amelia Anderson","Siamack Afazeli;Siamack Afazeli, Pharm.D;Jalal Karimi, PhD","Javier Crespo, MDPhD","Bart Lambrecht, MD, PhD;Anja Delporte","Vaseeharan Sathiyamoorthy;Srinivas Murthy, MD","Jeffrey Miller, MD;Jeffrey Miller, MD","Tim D Spector;Victoria Vazquez","Jose Muoz Gutirrez, MD, PhD;Jose F Muoz Gutirrez, MD, PhD","Steven Chan, M.D.;Vikas Gupta, M.D.;Steven Chan, M.D.;Steven Chan, M.D.","Pankti Reid, MD, MPH;Pankti Reid, MD, MPH;Pankti Reid, MD, MPH","Catherine Oldenburg, ScD, MPH;Thuy Doan, MD, PhD;Jessica M Brogdon, MPH;Jessica M Brogdon, MPH","A Vlaar, MD;Korinna Pilz, MD","Olivier HERMINE, MD-PhD","Roberto Giacomelli, MD, PhD;Roberto Giacomelli, MD","Pere Domingo, MD, PhD;Pere Domingo, MD, PhD","Prapa Kanagaratnam, FRCP, PhD;Alena Marynina, BSc, MSc;Alena Marynina, BSc, MSc","Chuck Moser;Peter Nguyen","Scott Gorenstein;David Lee, MD","Michael S. Avidan, MBBCh;Ramani Moonesinghe, MD;Helen Rees, MD;Linda Yun, BS","Cedric ANNWEILER, MD, PhD","Guiqiang Wang;Guiqiang Wang","Clinical Sciences &amp; Operations;Trial Transparency email recommended (Toll free number for US &amp; Canada)","Boyd Taylor Thompson, MD;Katie Oldmixon, RN","Peter A McCullough, MD, MPH","Adrian Hernandez, MD;Rachel Olson, RN",null,"Janneke Cox, Dr","Guiqiang Wang;Guiqiang Wang","Lee Goldstein, MD;Lee Goldstein, MD","Dima Dandachi, MD","Philippe CASSIER;Julien GAUTIER","Manuel J Castillo, MD, PhD;Manuel J Castillo, MD, PhD","IVAN J NUNEZ GIL, MD, PhD, MSc;IVAN J NUEZ J NUEZ GIL, MD","Denis DOYEN;Denis DOYEN","Roberto Ovilla-Martinez, MD","Brandon Webb, MD;Valerie T Aston, MBA","Sabine Hazan, MD;Sabine Hazan, MD","Eric L Sievers, MD;Manish Sadarangani, MRCPCH, DPHIL;Joanne Langley, MD, FRCPSC;Alexander Graves, PhD, MBA","Rosa Polo, MD,PhD;Miguel Hernn, MD,PhD","Matthias Salathe;Matthias Salathe, MD;Matthias Salathe, MD","Anselm Gitt, MD;Anselm Gitt, MD;Anselm Gitt, MD","Javier Corts;Alicia Garca","Justin Slagel","Peter M. Villiger, Prof. Dr. med.;Stephan Reichenbach, Prof. Dr.med.","Efstratios Koutroumpakis, MD;Efstratios Koutroumpakis, MD","Christopher Inchley, Phd;Lise Beier Havdal","Ayse Zengin Alpzgen, Assistant Professor, PhD;Begum Kara Kaya, MSc;Ayse Zengin Alpzgen, Assistant Professor, PhD;Ayse Zengin Alpozgen, Assistant Professor, PhD","Zhang Ze Guang, doctor;Zheng Z Guang, doctor","Salome Kristensen, MD, PhD;Line Uhrenholt, MD;Line Uhrenholt, MD","Prof. Qingsong Ye, PhD,DDS;Qingsong Ye, PhD,DDS;Chenliang Zhou, PhD","Ayse zengin alpozgen;Ayse Zengin Alpzgen, Ass.Prof.PhD","Lars Wik, MD;Lars Wik, MD","Jeffrey L Carson, MD;Reynold A Panettieri, MD;Jeffrey L Carson, MD","Sreekanth Vemulapallli, MD;Kristine Arges, BSN;Kristine Arges, BSN","Sabiha Hussain, MD;Steven K. Libutti, MD, FACS;Sabiha Hussain, MD","Emilie Garrido-Pradalie;Franois Silhol, MD;Francois Silhol, MD","Aliae Mohamed-Hussein;Aliae AR Mohamed-Hussein","Giuliano Rizzardini, Md","Corinne Levy, MD","Antonio Abbate, MD, PhD","Harry Hothi, PhD","Pierre Asfar, MD, PhD;Pierre Asfar, MD, PhD;Julien Demiselle, M.D.",null,null,null,"Sonja Hller, Dr.;Henning Bundgaard, Prof. Dr. med.","Silvio A. amendys-Silva, MD, MSc;Guillermo Dominguez-Cherit, MD;Eduardo Rivero-Sigarroa, MD;Silvio A. amendys-Silva, MD, MSc","Novartis Pharmaceuticals;Novartis Pharmaceuticals","Pierre PATOZ, PharmD;Barthelemy LAFONDESMURS, MD;Pierre PATOZ, PharmD","Henrik Ullum, Prof., DMSc;Kasper Karmark Iversen, Prof., DMSc;Thomas Benfield, Prof., DMSc;Christian Torp-Pedersen, Prof., DMSc;Henning Bundgaard, Prof., DMSc;Henning Bundgaard, Prof., DMSc","Rama Jager, M.D.","Pascal AMEDRO, MD-PhD;Pascal AMEDRO, MD-PhD;Pascal AMEDRO, MD-PHD","ShuPing Yang, MD, PhD;Inovio Call Center","Timothy J Ness, MD PhD;Timothy J Ness, MD PhD;Timothy J Ness","Philippe LE CONTE, Pr;Thomas FLAMENT, Dr;Louis SOULAT, Pr;Nicolas MARJANOVIC, Dr;Francis COUTURAUD, Dr;Laure BAUDIN, Dr;Karim TAZAROURTE, Pr;Thomas DELOMAS, Dr;Luc-Marie JOLY, Pr;Franois MORIN, Dr","Xavier Monnet, MD.PhD","N. Stuart Harris, MD, MFA;N. Stuart Harris, MD, MFA","Franois Dubos, MD,PhD;Franois DUBOS, MD,PhD","Ayse Zengin Alpzgen, assistant professor;Ayse Zengin Alpzgen, Assistant Professor","Raj Makkar, MD;Siegfried Rogy, PhD;Mitch Gheoghiu, MD","Roi Anteby, MD;Roi Anteby, MD","Apostolos Armaganidis, MD, PhD;Evangelos Giamarellos-Bourboulis, MD, PhD",null,"Bjorn Stessel, Dr",null,"Andreas Hochhaus, Prof. Dr.;Andreas Hochhaus, Prof. Dr.;Andreas Hochhaus, Prof. Dr.","Javed Akram, FRCP;Shehnoor Azhar, MPH",null,null,"Ara Darzi, Prof;Fahad M Iqbal, MBChB (hons)","Achille TCHALLA, MD","Tushar Patel;Robert Brannock;Robert Brannock","Xavier Corbella, MD, PhD;Xavier Solanich, MD;Xavier Solanich, MD","Jeremy Road, MD;Chris Miller, Ph.D.","Julio A Chirinos","David Levine, MD;David M Levine, MD MPH MA","Sujeet Jha, MRCP (U.K);Sujeet Jha, MRCP (U.K);Samreen Siddiqui, PhD",null,"Yan Liu, MD;Yan Liu, MD","Michael Joyner, MD;Michael Joyner, MD","Michiel Thomeer, MD,PhD;Michiel J Thomeer, MD,PhD;Michiel J Thomeer, MD, PhD","Veronique Michaud, PhD",null,"William W O'Neill, MD;Dee Dee Wang, MD;Dee Dee Wang, MD;Dee Dee Wang, MD","Qinglei Gao, Dr.;Qinglei Gao, Dr.","Huilan Zhang, PD","Michael Gordon, MD;Karen Lewandowski, RN","Hannelore Denys, MD, PhD;Heini Kanervo, RN;Hannelore Denys","Diane Egger-Adam, Dr.","Maria Lucia Madariaga, MD;Maria Lucia Madariaga, MD;Maria Lucia Madariaga","CLAIRE ROGER;CLAIRE ROGER, MD, PhD;Claire Roger, MD, PhD","Nishant Gupta, MD;Nishant Gupta, MD;Davis Alexandria","Syed MR Kazmi, FCPS;Farhan R Khan, MS, FCPS","Joyce Y Chung, M.D.;Alison Gibbons;Alison Gibbons","Matthew Yocum, MD;Matthew Yocum, MD","Jose L Diaz-Miron, MD;Jose L Diaz-Miron, MD;Jose L Diaz-Miron, MD","Sam (Saidi) Mohiddin, MD;Federica Marelli-Berg, PhD;Daniel E Harding, BM BCh","Alana Burns","Robert W Krner, Dr.;Miguel A Alejandre Alcazar, Prof. Dr. Dr.;Robert W Krner, Dr.;Robert W Koerner, Dr.","Joaquin Espinosa, PhD;Angela Rachubinski, PhD","Yun Long;Yun Long, MD;Yun Long","David Saadoun, MD PhD","Miguel Guia;Antonio Esquinas;Miguel Guia;Antonio Esquinas","Peter Rosenberger, Prof.;Peter Rosenberger, Prof.","Jos Meneses Caldern, MD;Hugo Mendieta Zern, PhD.","Claire Xu, MD, PhD;US Site Head","Jean-Baptiste Mr FASSIER, Dr","Elie AZOULAY, MD PhD;Nancy KENTISH-BARNES, PhD;Nancy KENTISH-BARNES, MD PHD","Jens Kastrup, Professor MD","Xavier Mariette, MD, PhD;Xavier Mariette, MD, PhD","Gilles MANGIAPAN, MD","Haleema Shakur-Still;Ian Roberts;Haleema Shakur-Still","Jeffery S Kuo, MD;John F Engle, MD","Lisa DEROSA, MD;Lisa DEROSA, MD","Fengcai Zhu, MD;Wenjuan Wang, MD;Zhao Wang, MD","Gianluca Iacobellis, MD PhD;Gianluca Iacobellis, MD PhD","Adam Spivak, MD;Christina Pacchia, PhD;Christina Pacchia, PhD","Delphine Garrigue, MD;Delphine Garrigue, MD","David Ho, M.D,;Yang Luo, PhD;Brett Gray","Claire-Marie RANGON;Amlie YAVCHITZ;Claire-Marie RANGON","Andrew Gostine, MD","Ayse Zengin Alpzgen","Benjamin Mordmller, Prof.;Diane Egger-Adam, Dr.;Diane Egger-Adam, Dr.","Grard Amarenco, PhD;Camille Chesnel, MD;Camille Chesnel, MD","Erik M Andersson, PhD;Erik M Andersson, PhD;Erik M Andersson, PhD","Pierre-Emmanuel FALCOZ, MD, PhD;Pierre-Emmanuel FALCOZ, MD, PhD;Pierre-Emmanuel FALCOZ, MD, PhD","Kush Dhody, MBBS, MS, CCRA","Rupesh Agrawal, MD;Rupesh Agrawal, MD","Bart Rijnders, MD, PhD;Bart Rijnders, MD, PhD",null,"Milind Desai, M. D.","Mohamed Alboraie, MD, MRCP(UK)","Marcus Lacerda, MD;Mayla Borba, MD","Sherry Mansour, MD, MS;Sherry Mansour, MD, MS","Emily O'Brien, PhD;Laura Webb;Laura Webb","Jacques Cadranel, MD PhD;Jacques Cadranel, MD PhD","Latha Dulipsingh, MD;Latha Dulipsingh, MD","Stefan Kluge, MD;Dominik Jarczak, MD;Dominik Jarczak, MD","Jean Franois TIMSIT, Pr;Jean Franois TIMSIT, Pr;LILA BOUADMA, Pr","Eric J Lenze, MD;Angela Stevens","John W Sanders, MD, MPH&amp;TM;Wake Forest Baptist Medical Center","Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST);There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or","Matthew Bardin, PharmD, BCPS","Angela Phillips, PhD;Scott A Wallace, MD;David S Robinson, MD;John S Baxter, MD, JD;Scott A Wallace, MD;Scott A Wallace, MD","Ilad Alavi Darazam, MD;Shervin Shokouhi, MD;Minoosh Shabani, MD;Mohammadreza Haji Esmaelie, MD;Seyed Sina Naghibi Irvani, MD, MPH, MBA",null,"Marcus Lacerda","Tarek Loubani, MD",null,"Helen Sambatakou, MD;Nikolaos Koulouris, MD;Garyfallia Poulakou, MD;Malvina Lada, MD;Ioannis Baraboutis, MD","yohanny andrade, researcher;oswaldo leyva, researcher;EDUARDO INSIGNARES-CARRIONE, Research Direc.;YOHANNY ANDRADE, INVESTIGATOR","Michele L Donato, MD;Mariefel Vendivil;Mariefel Vendivil","David Siu, MD FRCP;David Siu, MD FRCP;David Siu, MD","Mariano MD Provencio, MD;Cristina MD Avendao Sol, MD;Mara MD Gonzlez-Cao, MD;Eva Pereira","Hlne Donnadieu-Rigole, MD PhD;Hlne Donnadieu-Rigole, MD PhD;hlne Donnadieu-Rigole, doctor","Tjhin Wiguna, PhD;Tjhin Wiguna, PhD;Tjhin Wiguna, PhD","Sergio I Valds-Ferrer, MD, PhD;Sergio I Valds-Ferrer, MD, PhD;Sergio I Valds-Ferrer, MD, PhD","Raymond Chung, MD;Jenna Gustafson, MSc;Raymond Chung, MD","Guillaume DEBELLEMANIERE, MD;Amlie YAVCHITZ, MD;Guillaume DEBELLEMANIERE, MD","LaQuisa Hill, MD;LaQuisa Hill, MD;LaQuisa Hill, MD","Patty Lee, MD;Sangeeta Joshi, MD;Erika Ratcliffe;Erika Ratcliffe","Cdric Annweiler, M.D., Ph.D.","Julia Ferencz, MD;Julia Ferencz, MD","Markos G Kashiouris, MD MPH;Brian Davis, MD;Markos G Kashiouris, MD MPH;Brian Davis, MD","Francis Corazza, MD;Francis Corazza, MD",null,"Cynthia CAILLON;Thierry PASSERON","Julien Tiete, PhD;Julien Tiete, PhD",null,"Scott Rickert, MD;Scott Rickert, MD;Scott Rickert","David E Leaf, MD, MMSc;Shruti Gupta, MD, MPH;David E Leaf, MD, MMSc","Bonnie Lonze, MD;Bonnie Lonze, MD;Bonnie Lonze, MD",null,"Allan J Walkey, MD;Nicholas A Bosch, MD","Pere Clav, MD, PhD;Pere Clav, MD, PhD;Pere Clav, MD, PhD","Dr Shiv Kumar Sarin, DM;Dr Meenu Bajpai, MD","Julie Karp, MD;Julie Karp, MD","Xavier ELHARRAR, MD;Youssef Trigui, MD;Stephanie Martinez, MD;Laurence Maulin, MD;Marie Bernardi, MD;Laurent Lefebvre, MD;Thibaut Helbert, MD;Camille begne, MD;Xavier ELHARRAR, MD;Xavier ELHARRAR","Guillaume BONNET, MD;Orianne WEIZMAN, MD;Guillaume BONNET, MD","Meredith Clement, MD;Jeannine Ascani, MS;Jeannine Ascani",null,"Yahong Chen, MD;Junxue Wang, MD;Junxue Wang, MD","Arnaud Bourreille, Pr","Jean-Eric BLATTEAU, MD, PhD;Jean-Eric BLATTEAU, MD, PhD","Elliott Bennett-Guerrero, MD","Luu Pham, MD;Luu Pham, MD","Ammar Sarwar, MD",null,"Veronika Mller, MD, PhD;Eszter Fodor, medical doctor","Todd Seto, MD;Todd Seto, MD;Todd Seto, MD","Teresa Gaither, NP;Nicole C. Hank, PhD, MCR, MHSM;Nicole C Hank, PhD,MCR,MHSM;Brandon McCravey","David A Bernal E., MD PhD;David A Bernal-Estvez, MD PhD","Yalim Dikmen;Olcay Dilken;Olcay Dilken","Jean-Pascal FOURNIER, Doctor;Jean-Pascal FOURNIER, Doctor",null,"Sherief Abd-Elsalam, ass. prof.;Eslam Saber, ass. lect;Mai Khalaf, ass. lect.;Sherief Abd-Elsalam","Adeeba Kamarulzaman, MBBS;Reena Rajasuriar, PhD","Tristan Mirault","Jacques Cadranel, MD PhD","Kyle Kimura, MD;Justin H. Turner, MD, PhD;Kate Von Wahlde, MJ, CCRP","Peter H Hwang, MD;Peter H Hwang, MD","Sujievvan Chandran, MD;LEONARDO ZORRON CHENG TAO PU, MD, MSc","Giovanni Martinelli, Prof.;Giovanni Martinelli, Prof;Giovanni Martinelli, Prof",null,"Kristian Tonby, MD;Aleksander Holten, MD;Aleksander Holten, PhD","Jawad Kirmani, MD","Francois STEPHAN, MD, PhD;Francois STEPHAN, MD, PhD;Francois STEPHAN, MD, PhD","Andrew Ip, MD;Brittany Sinclaire;Brittany Sinclaire","Sherief Abd-Elsalam, ass. prof.;Sherief Abd-Elsalam","Cristina Avendao Sol, MD, PhD;Rafael Duarte Palomino, MD, PhD;Antonio Ramos, MD, PhD;Jos Luis Bueno, MD;Inmaculada Casas Flecha, PharmD, PhD;Cristina Avendao Sol, MD, PhD","Jacques REYNES, MD,PhD;Jacques REYNES, MD PhD;jacques REYNES, MD, PhD","Leonardo Mastropasqua, Professor;Manuela Lanzini, Doctor","David Bernal, Ph MD",null,"Neha Sharma;Jaydeep Joshi","Sudarshan Hebbar, MD;Sudarshan Hebbar, MD","Kasper Iversen, Prof.;Henning Bundgaard, Prof.;Henrik Ullum, Prof.;Thomas Benfield, Prof.;Susanne Dam Poulsen, Prof.;Jrgen Rungby, Prof.;Fredrik Folke, Associate prof.;Thea Klsen Fischer;Ove Andersen, Prof.;Ida Hageman;Rasmus Hasselbalch, MD","Lorenzo Dagna, MD",null,"Jos M. Moraleda, MD","Marcus Schultz, MD, PhD;Frederique Paulus, PhD;Ary Serpa Neto, MD, PhD;Anna Geke Algera, MD;Anissa Tsonas, MD;Michela Botta, MD;Michela Botta, MD;Michela Botta","Carlo Salvarani, M.D.;Massimo Costantini, Ph.D.;Massimo Costantini, Ph.D.","Dr Shiv Kumar Sarin, DM;Dr Ashok Choudhary, DM;Dr Ashok Choudhary, DM","Marc Blondon","William Poncin, PT, PhD;William Poncin","Yvonne (Bonnie) A Maldonado, MD;Study Team","Karine LACOMBE, PU-PH;Karine LACOMBE, PU-PH;Karine LACOMBE, PU-PH",null,"Silvia Bustacchini, MD;Antonio Cherubini, MD","Florentino de Araujo Cardoso Filho, MD, PhD","Shiyue Li, MD;Shiyue Li, MD","Piero Luigi Ruggenenti, MD","Hakim Harkouk, M.D.",null,"Shai Efrati, MD;Shai Efrati, MD","Thanh Cheng, MD","Kam Pui Lee, MSc;kam pui Lee, Msc","AstraZeneca Clinical Study Information Center",null,"Roberto Martinez-Alejos, MD, PhD;roberto Martinez-Alejos, Physiotherapis;Roberto Martinez-Alejos","Rgis Peffault de Latour, MD PhD","Matthew Dallos, MD;Lisa Olmos, RN;Lisa Olmos, RN","Donald Cooper, Ph.D.;Donald Cooper, Ph.D.","Mikhail Kosiborod, MD;Sheryl Windsor;Study Coordinator","Otto C Burghuber, Prof.MD",null,"Kush Dhody, MBBS, MS, CCRA","Thomas Waterfield, BMBCh;Thomas Waterfield, BMBCh;Thomas Waterfield, BMBCh","MARIA DEL MAR GARCIA SAIZ, MDPhD","Jianguo Sun;Sun JG","Sanjay Patel, MBBS;Inderpaul Singh Sehgal, MD, DM (Pulmonary Medicine)","Shoaib Ashraf, PhD;Muhammad Ashraf, PhD;Sohaib Ashraf, MBBS;Muhammad Ahmad Imran, MBBS;Ayesha Hamayun, PhD;Sohaib Ashraf, MBBS;Sohaib Ashraf, MBBS","Timothy D Planche, Dr.;Timothy D Planche, Dr.","Wing Hang Leung;Michaela Seng","Edouard TUAILLON, MD; PhD;Edouard TUAILLON, MD; PhD;Edouard TUAILLON, MD; PhD","Aliae AR Mohamed-Hussein","Christoph Schmaderer, M.D.;Christoph Schmaderer, M.D.;Christoph Schmaderer, M.D.","Thomas J Reiter, MD;Thomas J Reiter, MD","Hani Al-Hashmi, MD;Hani AL-Hashmi, MD","Stephanie O Keeling, MD;Walter P Maksymowych, MD","Thibault Duburcq, MD;Thibault Duburcq, MD","Malek Khemili, Resident",null,"Joaquin Espinosa, PhD;Angela Rachubinski, PhD","Oliver Gross, MD","Woo-Joo Kim, M.D.,Ph.D.;Bukwang Bukwang","Werner Seeger, MD;Faeq Husain-Syed, MD",null,"Barbara Juan, MD","Jean-Pascal FOURNIER, Doctor;Jean-Pascal FOURNIER, Doctor","Anders Perner, MD, PhD;Marie Warrer Petersen, MD, PhD, Professor","Noriko Ammerman, PharmD","Bairbre A McNicholas, MB BCh PhD","Blake M Warner, D.D.S.;Blake M Warner, D.D.S.;For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)",null,"Jess Garca Donas, MD;Jess Garca Donas, MD",null,null,"Rafael Souza, MD, PhD;Rafael Souza, MD, PhD",null,"Georgia Kostopanagiotou, MD;Georgia Kostopanagiotou, MD","Charline BERTHOLDT;Charline BERTHOLDT;Charline BERTHOLDT",null,"Donald M Arnold, MD;Donald M Arnold, MD","Dayana Michel;Jatin Shah, Chief Medical Officer","Kamalia Sazali, MS","Anca Askanase, MD, MPH;Anca D. Askanase, MD, MPH;Anca D. Askanase, MD, MPH","Matthew Sims, MD, PhD;Maureen Cooney, RN, BSN;Maureen Cooney, RN, BSN","Paul-Antoine QUESNEL, MD;Paul-Antoine QUESNEL, MD",null,null,"Martin Rief, Dr.;Martin Rief, Dr.","Richard M Fleming, PhD, MD, JD","Jean-Christophe RICHARD, Pr",null,"Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM;Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM;Paul Wischmeyer, MD, EDIC, FASPEN, FCCM","Anne-Laure FAUCHAIS, MD","Domingo A Pascual Figal, MD;Domingo A Pascual Figal, MD","Medical Monitor;Theravance Biopharma Call Center;Theravance Biopharma Call Center","Thanh Cheng, MD","Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP","Priya Nori, MD;Priya Nori, MD;Priya Nori, MD","Vivek Y Reddy, MD;Martin Goldman, MD;Sam Cammack;Betsy Ellsworth, ANP",null,"Ren-Marc FLIPO, MD,PhD;Ren-Marc FLIPO, MD,PhD","sherief Abd-Elsalam, Ass. Prof.;Sherief Abd-Elsalam, ass. prof.","Richard Greil, MD;Daniela Wolkersdorfer, Dr.;Richard Greil, MD",null,"Reem Jan;Reem Jan, MBBS BSc;Reem Jan","Pierre Corbeau;Pierre Corbeau;Anissa Megzari","Ilad Alavi Darazam, MD;Shervin Shokouhi, MD;Minoosh Shabani, MD;Mohammadreza Haji Esmaelie, MD;Seyed Sina Naghibi Irvani, MD, MPH, MBA","Shervin Shokouhi, MD;Ilad Alavi Darazam, MD;Minoosh Shabani, MD;Mohammadreza Haji Esmaelie, MD;Latif Gachkar, MD;Mahdi Amirdosara, MD;Masoud Mardani, MD;Seyed Sina Naghibi Irvani, MD, MPH, MBA",null,null,null,"Bernard Cortet, MD,PhD;Bernard Cortet, MD,PhD","Bernd Jilma, MD;Bernd Jilma, MD",null,"Gry LAMBLIN;Gry LAMBLIN, MD",null,null,null,"Risch",null,"Ogburn;Allen","Nunn",null,"Wright",null,null,null,"Cameron Durrant, MD;Omar Ahmed, PharmD","sherief Abd-Elsalam, Ass. Prof.;Sherief Abd-Elsalam, ass. prof.","Neha Sharma, PhD;Jaydeep Joshi, BAMS","Filip K Knop, MD, PhD;Filip K Knop, MD, PhD","Couper",null,null,"Prof. Eliano P Navarese, MD, PhD;Jacek Kubica, MD, PhD","Nina Weis, MD, PhD;Nina Weis, MD, PhD",null,"John P Corcoran, BMBCh MRCP;UHPNT Research &amp; Development Office",null,null,null,null,null,null,null,"Benson;Nandhra",null,null,null,"Bosch","Elder","Fehr",null,null,null,null,"van Wijk",null,null,null,null,null,null,"Hooijberg","Wijmenga-Monsuur","Frenken",null,"Weehuizen",null,null,null,null,"Timmers","van den Aardweg",null,null,"VAN Oers","Yousuf",null,"Bosch",null,"Bogaard","Dijkstra",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Schreiber","Hellmuth","Denkinger","Bauer","Wilhelm","Jassoy","Schaffler","Kersebaum","Lother","Hauptmann","Pecks","Musche","Streeck","Heckendorf","Kalenka","Vehreschild",null,"Supady","Behrens",null,"Neumann","Buerle",null,null,"Borho","Herzberg",null,"Pulletz",null,null,null,null,null,"Laudi",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Bou Khalil",null,null,null,null,null,null,null,null,null,"Nassar","Mikami",null,null,null,"Duru","Junko","Nakamura","Nakamura","Yamamoto","Vila Nova","Niikura","Zampieri","Horita","Srisawat","AbdurRazzaq","Taniki","Teerasarntipan","Niyomnaitham","Utrera","Horita","Casalino","Pedroso","Cinza Estevez","Garcia","Casalino","Alencar","Cheah"],["169 Donghu Road, Wuchang District, Wuhan, Hubei, China","41 Xibei Street, Ningbo, Zhejiang, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","399 Wanyuan Road, Minhang District, Shanghai","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China",null,"169 Donghu Road, Wuchang District, Wuhan, Hubei, China","725 Wanping Road South, Xuhui District, Shanghai, China",null,null,"156 Jinshui Road East, Zhengzhou, He'nan, China","158 Shangtang Road, Xiacheng District, Hangzhou, China","1478 Gongnong Road, Changchun, Jilin, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","3002 Sungang Road West, Futian District, Shenzhen","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","299 Qingyang Road, Liangxi District, Wuxi, Jiangsu","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","Pulmonary Department, 5A Ward, 528 Zhanghen Road, Pudong New Area District, Shanghai, China",null,null,"6 Guangchang Road, Huangshi, Hubei","Nanbaixiang, Ouhai District, Wenzhou, Zhejiang",null,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","28 Baofeng Road, Qiaokou District, Wuhan, Hubei, China","6 Guangchang Road, Huangshi, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","52 Meihua Road East, Xiangzhou District, Zhuhai, China","8 Xitoutou, You'anmen, Fengtai District, Beijing","1 Jianshe Road East, Zhengzhou, He'nan, China","79 Qingchun Road, Hangzhou, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","2901 Caolang Road, Jinshan District, Shanghai, China","1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","2901 Caolang Road, Jinshan District, Shanghai","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China",null,null,"725 Wanping Road South, Xuhui District, Shanghai, China","41 Xibei Street, Ningbo, Zhejiang, China","507 Zhengmin Road, Yangpu District, Shanghai, China","5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China","17 Lujiang Road, Luyang District, Hefei, Anhui, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","23 Art Gallery Back Street, Dongcheng District, Beijing, China","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","117 Meishan Road, Hefei, Anhui, China","102 Yanjiang Road West, Guangzhou, Guangdong, China","1095 Jiefang Avenue, Wuhan, Hubei","156 Jinshui East Road, Zhengzhou, He'nan, China","23 Back Street of Art Gallery, Dongcheng District, Beijing, China","19 Renmin Road, Zhengzhou, He'nan, China","548 Binwen Road, Hangzhou, Zhejiang, China","5 Haiyuncang Lane, Dongcheng District, Beijing","37 Guoxue Lane, Chengdu, Sichuan, China","169 Donghu Road, Wuhan, Hubei, China","548 Binwen Road, Binjiang District, Hangzhou, Zhejiang","151 Yanjing Road, Yuexiu District, Guangzhou, China","102 South Dongwu Road, Changsha Economic and Technological Development Zone, Changsha, Hu'nan, China","548 Binwen Road, Hangzhou, Zhejiang, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","52 Meihua Road East, Zhuhai, Guangdong, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","79 Qingchun Road, Hangzhou, Zhejiang, China","100 West Fourth Ring Road, Fengtai District, Beijing, China","117 Meiyuan Yangxiang, Wuxi, Jiangsu, China","Room 18A 03-2, Anlian Building, 4018 Jintian Road, Fuzhong Community, Lianhua Street, Futian District, Shenzhen, Guangdong, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","222 Zhengda Street, Guangshan County, He'nan, China","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","238 Jiefang Road, Wuchang District, Wuhan, Hubei, China","79 Qingchun Road, Hangzhou, Zhejiang, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","32 Second Section, First Ring Road West, Chengdu, Sichuan, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","10 Poyang Lake Road, Jinghai District, Tianjin, China","59 Liuting Road, Ningbo, Zhejiang, China","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","159 Tianshan Road South, Jingyang District, Deyang, Sichuan, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","3 Qingchun Road East, Jianggan District, Hangzhou, Zhejiang, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","99 Jiefang Road, Wuchang District, Wuhan, Hubei, China","1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang, China","890 Jin'gu Road, Jinnan District, Tianjin, China","9th Floor, Block 3, Lufthansa Center, 16 Xinyuanli Street, Chaoyang District, Beijing, China","1095 Jiefang Avenue, Wuhan, Hubei, China","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","6 Jiefang Street, Dalian, Liaoning, China","363 Furong Avenue, Wenjing District, Chengdu, Sichuan, China","382 Wuyi Road, Xinghualing District, Taiyuan, Shanxi, China","169 Donghu Road, Wuchang District, Wuhan, Hubei","37 Guoxuexiang, Wuhou District, Chengdu, Sichuan, China","85 Jiefang Road South, Yingze District, Taiyuan, Shanxi, China","54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang, China","1095 Jiefang Avenue, Wuhan, Hubei, China","144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China","197 Second Ruijin Road, Huangpu District, Shanghai, China","52 Meihua Road East, Zhuhai, Guangdong, China","79 Qingchun Road, Hangzhou, Zhejiang, China","1095 Jiefang Avenue, Wuhan, Hubei, China","49 North Huayuan Road, Haidian District, Beijing, China","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","79 Qingchun Road, Hangzhou, Zhejiang, China","169 Donghu Road, Wuhan, Hubei, China","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","234 Gucui Road, Xihu District, Hangzhou, Zhejiang, China","151 Yanjiang Road, Guangzhou, Guangdong, China","79 Qingchun Road, Hangzhou, Zhejiang, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","23 Back Street of Art Gallery, Dongcheng District, Beijing/11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China",null,null,"Xi'an Chest Hospital, East Section of Hangtian Avenue, Chang'an District, Xi'an, Shaanxi, China","17 Yongwai Main Street, Nanchang, Jiangxi, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","29 Bulan Road, Logngang District, Shenzhen, Guangdong, China","8 Xi-Shi-Ku Street, Xicheng District, Beijing, China","37 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","238 Jiefang Road, Wuhan, Hubei, China","6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China","1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China.","151 Yanjiang Road, Yuexiu District, Guangzhou","79 Qingchun Road, Hangzhou, Zhejiang, China","1277 Jiefang Avenue, Wuhan, Hubei, China","5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China",null,"53 Jidajingle Road, Zhuhai, Guangdong, China","102 Luo-Jia-Jing, Beihu District, Chenzhou, Hu'nan, China","167 Hongdu Middle Avenue, Qingshanhu District, Nanchang, Jiangxi, China","194 Xuefu Road, Nangang District, Harbin, Heilongjiang, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","301 Yanchang Middle Road, Shanghai, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","2901 Caolang Road, Jinshan District, Shanghai, China","28 Fuxing Road, Haidian Distract, Beijing, China","157 West 5th Road, Xi'an, Shaanxi, China","8 Workers Stadium Road South, Chaoyang District, Beijing","650 Xinsongjiang Road, Songjiang District, Shanghai, China","1200 Cailun Road, Pudong New District, Shanghai, China","201-209 Hubin Road South, Siming District, Xiamen, Fujian","5 Shantiao Street, Dongdan, Dongcheng District, Beijing, China","110 Ganhe Road, Hongkou District, Shanghai, China","95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China","20 Third Section, Renmin Road South, Chengdu, Sichuan, China","1095 Jiefang Avenue, Wuhan, Hubei, China","1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang","1277 Jiefang Avenue, Wuhan, Hubei, China","157 West 5th Road, Xi'an, Shaanxi, China","180 Fenglin Road, Xuhui District, Shanghai, China","1377 Jiao-Zhou-Wan Road West, Yinzhou Street, Huangdao District, Qingdao, Shandong, China","6 Jizhao Road, Jinnan District, Tianjin","415 Fengyang Road, Huangpu District, Shanghai, China","1277 Jiefang Avenue, Wuhan, Hubei","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","6 Fucheng Road, Haidian District, Beijing, China","1277 Jiefang Avenue, Wuhan, Hubei, China","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China","8 Xishiku Street, Beijing, China","1277 Jiefang Avenue, Wuhan, Hubei, China","Room 507, Xianyue Haijing Building, 195 Xianyue Road, Siming Square, Xiamen, Fujian, China","9 Kunpeng Road, Gulou District, Xuzhou, Jiangsu, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","35 Jiefang Avenue, Zhengxiang District, Hengyang, Hu'nan, China","180 Fenglin Road, Xuhui District, Shanghai, China","28 South Dianxin Street, Wuhou District, Chengdu, Sichuan, China",null,null,null,null,"39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","17 Lujiang Road, Luyang District, Hefei, Anhui, China","28 Fuxing Road, Haidian District, Beijing, China",null,null,"169 Donghu Road, Wuhan, Hubei, China","9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China","32 West Second Section, First Ring Road, Chengdu, Sichuan, China",null,null,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","28 Fuxing Road, Haidian District, Beijing, China","4 Garden Hill, Wuchang District, Wuhan, Hubei, China",null,"157 West 5th Road, Xi'an, Shaanxi, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",null,"20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China","20 Chazhong Road, Fuzhou, Fujian, China","7 Weiwu Road, Jinshui District, Zhengzhou, He'nan, China","289 Kuocang Road, Liandu District, Lishui, Zhejiang, China","Hanpu Science and Teaching Road, Yuelu District, Changsha, Hu'nan, China","4 Huayuan Hill, Wuchang District, Wuhan, Hubei, China",null,null,"20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China","1 Siyi Road, Shihe District, Xinyang, He'nan, China","678 Furong Road, Jingkai District, Hefei, Anhui, China","136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China","136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China","1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China","136 Jingzhou Street, Xiangcheng DIstrict, Xiangyang, Hubei, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","4 Garden Hill, Wuchang District, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","N1 Shangcheng Road, Yiwu, Zhejiang, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China.","389 Xincun Road, Putuo District, Shanghai, China","1478 Gongnong Road, Chaoyang  District, Changchun, Jilin, China","2901 Caolang Road, Jinshan District, Shanghai, China","118 Wenquan Road, Haidian District, Beijing, China","228 Jingui Road, Xianning, Hubei, China","23 Youzheng Street, Nangang District, Harbin, Heilongjiang, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","1215 Guangrui Road, Wuxi, Jiangsu, China","94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China","1200 Cailun Road, Zhangjiang Hi-TechPark, Pudong New Area, Shanghai, China","94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China","2901 Caolang Road, Jinshan District, Shanghai, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","Room 222, Alice Lee Building, Xiangan Campus, Xiamen University, Fujian, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","415 Fengyang Road, Huangpu District, Shanghai, China","37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China","88 Changling Road, Xiqing District, Tianjin, China","1 Benxi Street, Fouth Jianshe Road, Qinshan District, Wuhan, Hubei, China","16 Railway New Village, Jiulongpo Districts, Chongqing, China","218 Jixi Road, Hefei, Anhui, China","28 Fuxing Road, Haidian District, Beijing, China","Chizhuling Fifth People's Hospital, Shuixi Town, Ganzhou, Jiangxi, China","17 Yongwai Main Street, Nanchang, Jiangxi","12 Jiankang Road, Shi-Jia-Zhuang, Hebei, China","1095 Jiefang Avenue, Wuhan, Hubei","110 Ganhe Road, Hongkou District, Shanghai, China","1095 Jiefang Avenue, Wuhan, Hubei, China","4/F, School of Public Health and Primary Care","165 Xincheng Road, Wanzhou District, Chongqing, China","99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China","363 Furong Avenue, Wenjing District, Chengdu, Sichuan","116 North Street, Guixi Street, Dianjiang, Chongqing, China","71 Xinmin Street, Changchun, Jilin, China","1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing","1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China","Cancelled","74 Lingjiang Road, Yuzhong District, Chongqing, China","109 Baoyu Road, Shapingba District, Chongqing, China","49 Huayuan Road North, Haidian District, Beijing, China","109 Baoyu Road, Shapingba District, Chongqing, China","136 Second Zhongshan Road, Yuzhong District, Chongqing, China","49 Huayuan Road North, Haidian District, Beijing, China","165 Xincheng Road, Wanzhou, Chongqing, China","1095 Jiefang Avenue, Wuhan, Hubei.","Mianyang Central Hospital of Sichuan province",null,"37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei","39 Shi-Er-Qiao Road, Chengdu, Sichuan, China","107 Huanhu Road East, Hefei, Anhui, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","1095 Jiefang Avenue, Wuhan, Hubei, China",null,"79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China",null,null,"95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China","19 Renmin Road, Zhengzhou, He'nan, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","Zhiyin Aveneu, Caidian District, Wuhan, Hubei, China","225 Changhai Road, Yangpu District, Shanghai, China","85 Heping Street South, Heping District, Shenyang, Liaoning, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","627 Wuluo Road, Wuchang District, Wuhan, Hubei, China","101 Weimin Road, Maoming, Guangdong, China","1999 Guankou Middle Road, Jimei District, Xiamen, Fujian, China",null,null,"9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China","1 Jianshe Road East, Zhengzhou, He'nan, China","528 Zhanghen Road, Pudong New Area District, Shanghai, China","109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China","42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China",", Jinan, Shandong,Shandong,PR China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","16 Jichang Road, Guangzhou, Guangdong, China","324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China","Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","473 Hanzheng Street, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China","32 Renmin Road South, Shiyan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","1095 Jiefang Avenue, Wuhan, Hubei, China","No.8 Xishiku Street, West city District, Peking","238 Jiefang Road, 99 Zhangzhidong Raod, Wuchang, Hubei, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","1 Shuai-Fu-Yuan, Dongcheng District, Beijing, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China","110 Ganhe Road, Hongkou District, Shanghai, China","100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","1 Shuai-Fu-Yuan,  Dongdan, Dongcheng District, Beijing, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","600 Yishan Road, Xuhui District, Shanghai, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, 610041, P.R China","169 Donghu Road, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China",null,null,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","8 Xishiku Street, Xicheng District, Beijing, China","Cherry Blossom Garden East Street, Chaoyang District, Beijing","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","305 East Zhongshan Road, Nanjing, Jiangsu, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",null,null,null,"1478 Gongnong Road, Changchun, Jilin, China",null,null,"41 Xibei Street, Haisu District, Ningbo, Zhejiang, China","311 Yingpan Road, Kaifu District, Changsha, Hu'nan, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","47 Taqiao Road North, Shashi District, Jingzhou, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","Department of Microbiology Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin , NT, Hong Kong SAR","3 Yunxing Road, Fancheng District, Xiangyang, Hubei, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","280 Mohe Road, Baoshan District, Shanghai, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China","182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China","279 Luoyu Road, Hongshan District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","2 Anzhen Road, Chaoyang District, Beijing, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","116 Zhuodaoquan Road South, Hongshan District, Wuhan, Hubei, China","98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","725 Wanping Road South, Xuhui District, Shanghai, China","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","88 Jiankang Road, Weihui, Xinxiang, He'nan, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","1095 Jiefang Avenue, Hankou, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou DIstrict, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","1111 Xianxia Road, Changning District, Shangha","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","59 Liuting  Street, Ningbo, Zhejiang, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","19 Renmin Road, Jinshui District, Zhengzhou, He'nan, China","Wenzhou Medical University, Chashan Higher Education Park, Wenzhou, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","Room 711, Building 4, 41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","216 Guanshan Avenue, Hongshan District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1277 Jiefang Avenue, Wuhan, Hubei, China","101 Weimin Road, Maoming, Guangdong, China","1120 Lianhua Road, Futian District, Shenzhen, Guangdong, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1333 Xinhu Road, Bao'an District, Shenzhen, Guangdong, China","215 Heping Road West, Shijiazhuang, Hebei, China","241 Peng-Liu-Yang Road, Wuchang, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China","13 North Qingchi Avenue, Xinhua District, Cangzhou, Hebei, China","801 Heqing Road, Shanghai, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","6 Taoyuan Road, Nanning, Guangxi Zhuang Autonomous Region, China","12 Wulumuqi Road Middle, Jin'an District, Shanghai, China","415 Fengyang Road, Huangpu District, Shanghai, China","1 Xiyuan Playground, Haidian District, Beijing, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","32 Feishan Street, Guiyang, Guizhou, China","1742 Huolinhe Street, Keerqin District, Tongliao, Inner Mongolia Autonomous Region, China","1630 Dongfang Road, Pudong District, Shanghai, China","1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","12 Lieshishan Road East, Licheng District, Jinan, Shandong, China","169 Donghu Road, Wuhan, Hubei, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","1095 Jiefang Road, Wuhan, Hubei, China","94 West Street, Kangding, Ganzi Prefecture, Sichuan, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","13 Hangkong Road, Qiaokou District, Wuhan, Hubei, China","57 South Renmin Road, Zhanjiang, Guangdong, China","149 Dalian Road, Zunyi, Guizhou, China","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China","225 Changhai Road, Yangpu District, Shanghai, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","100 Haining Road, Hongkou District, Shanghai, China","NO.85 Wujin Road, Hongkou District, Shanghai, China","100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China","26 Yuancun Erheng Road, Tianhe District, Guangzhou, Guangdong, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","8 Fuyu Road East, Qiaonan Street, Panyu District ,Guangzhou, Guangdong, China","4 Garden Hill, Wuchang District, Wuhan, Hubei, China","67 Dongchang Road West, Liaocheng, Shandong, China","439 Xuanhua Road, Yongchuan District, Chongqing, China","167 Fangdong Street, Baqiao District, Xi'an, Shaanxi, China","2 Yinghua Street East, Chaoyang District, Beijing, China","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","287 Changhuai Road, Longzihu District, Bengbu, Anhui, China","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","33 Zhongyuan Road, Buji Town, Longgang District, Shenzhen, Guangdong, China","59 Liuting Street, Haishu, Ningbo, Zhejiang, China","11 Xizhimen Street South, Xicheng District, Beijing, China","100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China","8 East Fuyu Road, South Bridge Street, Panyu District, Guangzhou, Guangdong, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","49 North Garden Road, Haidian District, Beijing, China","22 Second Shuguang Road, Qingcheng District, Qingyuan, Guangdong, China","157 Xiwu Road, Xi'an, Shaanxi, China","1095 Jiefang Avenue, Wuhan, Hubei, China","627 Dongfeng Road East, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China","60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China","1 Xiyuan Playground, Haidian District, Beijing, China","1 Xiyuan Playground, Haidian District, Beijing, China","300 Taizihu north Road, Wuhan Economic and Technological Development Zone, Wuhan, Hubei, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","23 Youzheng Street, Harbin, Heilongjiang, China","725 Wanping Road South, Xuhui District, Shanghai, China","Room 319, life medicine venture building, Limin biomedical R &amp; D center, East Shenyang Street and South Zhuhai Road, Harbin, Heilongjiang, China",null,"6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China",null,null,null,"52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","157 Xiwu Road, Xi'an, Shaanxi, China","58 Shenlong Avenue, Wuhan, Hubei, China","149 Dalian Road, Huichuan District, Zunyi, Guizhou, China","138 Tong-Zi-Po Road, Yuelu District, Changsha, Hu'nan, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","Zhuangyu Road South, Zhenhai District, Ningbo, China","415 Fengyang Road, Huangpu District, Shanghai, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","85 Kefeng Road, Hi-Tech Development District, Guangzhou, Guangdong, China","19 Xin-Jie-Kou-Wai Street, Haidian District, Beijing, China","1 Xiyuan Playground, Haidian District, Beijing","1277 Jiefang Avenue, Wuhan, Hubei, China","283 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China","61 West Jiefang Road, Changsha, Hu'nan, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","41 Xibei Street, Ningbo, Zhejiang, China","28 Fuxing Road, Haidian District, Beijing, China","8 Worker Stadium Road South, Chaoyang District, Beijing, China","415 Fengyang Road, Huangpu District, Shanghai, China","81 Lingnan Avenue North, Foshan, Guangdong, China",null,null,"151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China","172 Jiangsu Road, Gulou District, Nanjing District, Jiangsu, China",null,"41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China","352 Renmin Road, Yingjiang District, Anqing, Anhui, China","52 Meihua Road, Xiangzhou District, Zhuhai, Guangdong, China","8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","41 Erling Road, Huizhou, Guangdong, China","99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","627 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Wuhan, Hubei, China","241 Pengliuyang Road, Wuchang District, Wuhan, Hubei, China","139 Renmin Middle Road, Furong District, Changsha, Hu'nan, China","41 Xibei Street, Ningbo, Zhejiang, China","32 Feishan Street, Guiyang, Guizhou, China","100 Shizhi Street, Hongshan Road, Nanjing, Jiangsu, China","20 South Renmin Road, Chengdu, Sichuan, China","8 Worker Stadium Road South, Chaoyang District, Beijing, China","627 Wuluo Road, Wuchang District, Wuhan, Hubei, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","238 Jiefang Road/99 Zhangzhidong Raod, Wuchang, Wuhan, Hubei, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","139 Renmin Road, Furong District, Changsha, Hu'nan, China","1 Minde Road, Donghu District, Nanchang, Jiangxi, China","480 Shuangyang Road, Yangpu District, Shanghai, China",null,null,"19-21 Boulevard Jean Moulin","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China",null,null,"8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","Takebayashi 911-1, Utsunomiya-shi, Tochigi","197 Second Ruijin Road, Huangpu District, Shanghai, China",null,null,null,null,"1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi 470-1192, Japan",null,null,null,null,"1-21-1, Toyama, Shinjuku-ku, Japan",null,null,null,null,null,null,null,null,null,null,null,null,null,"28 Fuxing Road, Beijing, China","150 Ximen Street, Linhai, Zhejiang, China",null,null,null,null,"1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China",null,null,"745 Wuluo Road, Hongshan District, Wuhan, Hubei, China","238 Jiefang Road, Wuchang District, Wuhan, Hubei, China","5 Yan-Er-Dao Road, Qingdao, Shandong, China","1277 Jiefang Avenue, Wuhan, Hubei, China","466 Xingang Middle Road, Guangzhou, Guangdong, China","321 Zhongshan Road, Gulou District, Nanjing, Jiangsu, China","314 West Anshan Road, Nankai District, Tianjin, China",null,"5 Yan-Er-Dao Road, Shi'nan District, Qingdao, Shandong, China","183 Yiling Road, Yichang, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","699 Hongfeng Road, Pudong New District, Shanghai, China","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","126 Xiantai Street, Erdao District, Changchun, Jilin, China","1 Yi-Xue-Yuan Road, Yuzhong District, Chongqing, China","28 Dianxin Road South, Wuhou District, Chengdu, Sichuan, China","99 Zhangzhidong Road, Wuhan, Hubei, China","8 Xi-Tou-Tiao Lane West, You'anmen Street, Fengtai District, Beijing, China","1 Yi-Xue-Yuan Road, Yuzhong District, Chongqing, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","238 Jiefang Road / 99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","349 Hangzhou Road, Yangpu District, Shanghai, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","98 Nantong Road West, Guangling District, Yangzhou, Jiangsu, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","39 Shi-er-qiao Road, Chengdu, Sichua, China","100 West 4th Ring Middle Road, Fengtai District, Beijing, China","725 Wanping Road South, Xuhui District, Shanghai, China","Plus 2 Weiyang Road West, Xianyang, Shaanxi, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","100 Shizi Street, Hongshan Road, Qixia District, Nanjing, Jiangsu, China","39 Shi-Er-Qiao Road, Chengdu, Sichuan, China","1 avenue Pierre Brossolette","17 Lujiang Road, Luyang District, Hefei, Anhui, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","10 Changjiang Branch Road, Yuzhong District, Chongqing, China","88 Changling Road, Xiqing District, Tianjin, China",null,null,"37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","Herestraat 49","Heidelberglaan 100",null,null,null,null,"Wilhelmstr. 27","1277 Jiefang Avenue, Wuhan, Hubei, China","Mailpoint 810, Level F, Southampton General Hospital, Tremona Road","1277 Jiefang Avenue, Wuhan, Hubei, China",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"100 Hong Kong Road, Jiang'an District, Wuhan, Hubei, China","1088 Yinghe Road West, Yinzhou District, Fuyang, Anhui, China",null,null,"51 Huayuan Road North, Haidian District, Beijing","1 Shuai-Fu-Yuan,  Dongdan, Dongcheng District, Beijing, China","12 Guangchang Road, Huangshigang District, Huangshi, Hubei, China","600 Yishan Road, Xuhui District, Shanghai, China","305 Zhongshandong road, Xuanwu district, Nanjing, Jiangsu, China.","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China",null,null,"1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","8 Cao-Lan-Zi hutong, Xi-Shi-Ku Street, Xicheng District, Beijing, China",null,"627 Dongfeng Road East, Yuexiu District, Guangzhou, Guangdong, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","163 Xianling Avenue, Qixia District, Nanjing, Jiangsu, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","100 West Fourth Ring Road Middle, Fengtai District, Beijing, China","238 Jiefang Road/99 Zhangzhidong Raod, Wuchang, Wuhan, Hubei, China","300 Taizi Lake Road North, Economic and Technological Development Zone, Wuhan, Hubei, China","8 rue de la Croix Jarry","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","49 North Huayuan Road, Haidian District, Beijing, China","Grenzacherstrasse 124","149 Dalian Road, Huichuan District, Zunyi, Guizhou, China","500 Quxi Road, Huangpu District, Shanghai, China","14th Km National Road 1","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","150 Jimo Road, Pudong New Area, Shanghai","4 rue Larrey","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",null,"25 Taiping Street, Jiangyang District, Chuzhou, Sichuan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","URCIP - Batiment Recherche - Hpital Nord","1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","Nordre Fasanvej 57, vej 8, Indg 19",null,null,null,null,"De Boelelaan 1117",null,null,null,null,null,null,"Sykehusveien 25",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","11 Kaopeng Street, Huangzhou District, Huanggang, Hubei, China","18 Daoshan Road, Gulou District, Fuzhou, Fujian, China",null,null,null,"600 Yishan Road, Xuhui District, Shanghai, China","139 Renmin Middle Road, Furong District, Changsha, Hu'nan, China","Suit 29, Unit 1, 2nd Building, Donghu Guoji, Wuchang, Wuhan, Hubei, China","172 Jiangsu Road, Gulou District, Nanjing District, Jiangsu, China","300 Guangzhou Road, Nanjing, Jiangsu, China","48 Xinxi Road, Haidian District, Beijing, China","Zhiyinhu Avenue, Caidian District, Wuhan, Hubei, China","473 Hanzheng Street, Qiaokou District, Wuhan, Hubei, China","324 Jing-Wu-Wei-Qi Road, Ji'nan, Shandong, China","149 Jimo Road, Pudong New District, Shanghai, China","600 Yishan Road, Xuhui District, Shanghai, China","300 Guangzhou Road, Nanjing, Jiangsu, China","28 Fuxing Road, Haidian District, Beijing, China","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China","198 Hongqi Road, Wuxing District, Huzhou, Zhejiang, China","Kang-Le-Fang-Kou, Jiangbin Road West, Lucheng District, Wenzhou, Zhejiang, China","11 Beisanhuan Road East, Chaoyang District, Beijing, China","1 Xueshi Road, Shangcheng District, Hangzhou, Zhejiang, China","Floor 10, Building 10, Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi street, Pingshan District, Shenzhen, Guangdong, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan","17 Lujiang Road, Luyang District, Hefei, Anhui, China",null,"DRCI Hpital St Louis, 1 av. Claude Vellefaux","DRCI, 1 avenue Claude Vellefaux","Helmholtzstr. 10","Winzerlaer Strasse 2","C. Heymanslaan 10","12 rue dubernat","133 Avenue de la rsistance","URCIP - Batiment Recherche - Hpital Nord","profesor martin lagos s/n","28 rue Laennec","LUIS FONTES PAGAN 9","88 Michalakopoulou Street","1, Avenues Claude Vellefaux","29 rue Manin","Feixa Llarga","Sant Quint 77-79","Camino de la Almazara 11","P Castellana 127-1D","Calle Castilla 135 2C","Calle Rossell 132 42","410 Thames Valley Park Drive","Plaza de Cruces N12 Edificio 1 Planta 0","Carretera de Colmenar Viejo Km 9,100",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Wuhrstrasse 14",null,"\n                    Nuffield Department of Primary Care Health Sciences, University of Oxford\n                    Radcliffe Observatory Quarter, Woodstock Road\n                ;\n                    Nuffield Department of Primary Care Health Sciences, University of Oxford\n                    Radcliffe Observatory Quarter, Woodstock Road\n","\n                    CTSU, Nuffield Department of Population Health\n                    University of Oxford\n                    Richard Doll Building\n                    Old Road Campus\n",null,"\n                    MaRS, Toronto Medical Discovery Tower\n                    101 College St, Ste 10-360A\n",null,"160 Pujian Road, Shanghai, China",null,null,null,null,null,"\n                    Clinical Trials Unit\n                    Warwick Medical School\n                    University of Warwick\n","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","134 East Street, Gulou District, Fuzhou, Fujian, China",null,null,"1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China",null,null,null,null,null,null,"600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","11 North Third Ring Road East, Chaoyang District, Beijing, China","Vascular and Endovascular Research Network (President);Vascular and Endovascular Research Network","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","Department of Microbiology Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin , NT, Hong Kong SAR, CHINA","910 Hengshan Road, Xuhui District, Shanghai, China",null,"\n                    Northumbria Sleep Research Laboratory\n                    Northumbria University\n","\n                    Epidemiology, Biostatistics and Prevention Institute (EBPI)\n                    University of Zurich\n                    Hirschengraben 84\n","1200 Cailun Road, Pudong New District, Shanghai, China","1-1 Zhongfu Road, Gulou District, Nanjingy, Jiangsu, China","57 Renmin Avenue South, Xiashan District, Zhanjiang, Guangdong, China","51 Fucheng Road, Haidian District, Beijing, China",null,"6 Fucheng Road, Haidian District, Beijing, China","1277 Jiefang Avenue, Wuhan, Hubei, China","Hpital St Louis, 1 av Claude Vellefaux","149 Dalian Road, Huichuan District, Zunyi, Guizhou, China","627 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong, China","Blegdamsbej 9",null,null,null,"1/F Lui Che Woo Clinical Science Building, Prince of Wales Hospital, N.T. Hong Kong",null,"385 Xinshi Road North, Qiaoxi District, Shijiazhuang, Hebei, China","Geert Grooteplein Zuid 10","385 North Xinshi Road, Qiaoxi District, Shijiazhuang, Hebei, China","Ole Worms All 4",null,null,"Parque Tecnolgico de Bizkaia, 801A, 2 planta","IMIM. Dr Aiguader",null,null,"Avenida reyes catlicos 2",null,"191 avenue du Doyen Gaston Giraud",null,null,"3 QUAI DES CELESTINS","Paseo de la Castellana 261","Paseo de la Castellana 261","1 place de l'hopital","Passeig Vall d'Hebron, 119","Torre Glries. Avenida Diagonal, 211, planta 27","4 Rue Larrey","Rossell","Kettegaard All 30","Calle Camino del Molino 2","Paseo de la Castellana 127-1d","Campus-Vienna-Biocenter 5","Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Hills Road, Coton House","Diego de Len 62","Villarroel 170","Avenida Reyes Catolicos 2","Paseo de la Castellana 261","Av Gran Via de l'Hospitalet 199-203","Public Health Building,","Sognsvannsveien 20","LUIS FONTES PAGAN 9","1 RUE CABANIS","88 Michalakopoulou Street","Avd. Mendez Pelayo 4 acc","Universiteitsweg 100","C. Heymanslaan 10","Arnold-Heller-Str 3","Marchioninistr. 15","Im Neuenheimer Feld 324","Hauptstrae 8","Ismaningerstr. 22","Johannisallee 30","Strubergasse 21","Arnold-Heller-Strae 3","Hugstetter Str. 55","Fehrbelliner Strae 38","Carl-Pulvrich-Str. 1","Virchowstr. 174","Venusberg-Campus 1","Universittsallee 1","Viernheimer Str. 2","Herderstrae 52-54","Institute of Endocrinology, Diabetes and Metabolism, Max Super Speciality Hospital, 2, Press Enclave Road, Saket","Hugstetter Str. 55","Carl-Neuberg-Str. 1","Liver and gastrointestinal diseases research center, Imam Reza Hospital, Tabriz University of medical sciences, Daneshgah street","Schillerstrae 1","Virchowstrae 174","Ahvaz Jundishapur University of Medical Sciences, Golestan Blv. Ahvaz, IR Iran","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","Schwabachanlage 6","Hamburger Strae 41","Sina Hospital, Imam-Khomeini Ave., Tehran, Iran","Schillingallee 35","School of Nursing and Midwifery; Shohadaye Hasteii Boulevard, Sabzevar","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","Bangladesh Physiotherapy Association, CRP, Savar, Dhaka-1343","Markaz Tebi Atfal hospital, Dr. Gharib street","No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran","Liebigstrasse 20","MEDICAL DIVISION\nCOMMAND HOSPITAL AIRFORCE\nAGRAM POST","Paramedical college, Kerman university of medical science, Haft Bagh Blvd, Kerman, Iran","Aster Malabar Institute of Medical Sciences (MIMS)\nP O Govindapuram\nKozhikode\nKerala\nIndia 673016","Dr. Atuls Child Hospital\nShastri Nagar Road\nJaipur 302016","No 29, 1th Niloufar, Sarv Av, east Farsad, St, Javanmardan Bolv, Shahr-e-Ziba","Department of Medicine,\nNiphad Sub district Hospital, Niphad, Maharashtra, India","Imam Reza Hospital; Golgasht street","Arash Hospital, Baghdarnia Street, Farjam Street, Tehranpars , Tehran","125 BL Taneja Block \nDepartment of Medicine \nMaulana Azad Medical College \nNew Delhi","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","No 42, Attar St., Vanak Sq.,","Rasoul Akram Hospital, Niyayesh St, Sattarkhan St.","Amirmazandarani","Shariati Hospital, Kargar Street, Tehran","Abadan School of Medical Sciences,Beginning of the  30 meters Ave, Zolfaghari street, Abadan city.","Baghabrisham Ave., Parastar Blvd., Medicine school","Kodakyar Ave., Daneshjo Blvd., Evin","Faculty of Medicine, Tabriz University of Medical Sciences, Golgasht Street","Imam Khomeini Ave., Hasan Abad Sq., Sina Hospital","Dr. Masih Daneshvari Hospital, Daar-Abad, Niavaran","Crossroad Amir kabir, Jomhuri eslami Blvd","Razi hospital","Bahonar","Department of Pharmacotherapy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, I","Bozorgmehr St","Arak University of Medical Sciences, Basij Square","Baqiyatallah University of Medical Sciences, Molla Sadra Ave","Deputy of Education in front of Ayatollah Jamie Airport","Unit704, No 372, Felestin Ave.","23rd Unit, 4th Floor, No. 1547, North Kargar St.,","Valieasr St., Intersection of Niyayesh Highway, Shahid Beheshti University of Medical Sciences, Faculty of Pharmacy","No. 119 Shahid Farshi Moqaddam street(16th)","Abadan School of Medical Sciences,Beginning of the 30 meters Ave, Zolfaghari street, Abadan city.","Pardis of Kerman University, First element of the Haft Bagh Allavi, Kerman","Shahid Ghazi hospital, Tabriz University of Medical Sciences, Daneshgah Street","Ibn Sina hospital, Pasdaran Blvd, Sari, Mazandaran province, Iran.","School of Persian and Complementary Medicine; University Campus; Azadi Square","-","Zand street","No. 226, Qods St., Keshavarz Blvd., Tehran, Iran","No. 27, Sarparast Ave, Taleghani Ave, Tehran, School of Persian medicine","Crossroad Amirkabir, Jomhuri eslami Blvd","Sayyad Shirazi boulevard, Sayyad Shirazi hospital","Immamreza Hospital-Golgasht Street","Vanak, Mulla Sadra Street, Sheikh Bahaee Street, Nosrat Alley","Imam Reza Hospital, next to Imam Reza square, Ibne Sina street","Street Amin, Semnan","Hemmat HW, sheikh bahaaei","Crossroad Amir kabir, Jomhuri eslami Blvd","Ganjafrooz avenue, Babol","Faculty of pharmacy, Payambar Azam academic complex, 18 km of Khazar Abad Ave, Sari","Blv. Vakilabad2-School of Pharmacy, 1365-91775","Floor 4, Iranian Center of Neurological Research biulding, Imam Khomeini Hospital, Keshavarz Blvd, Tehran","Sina hospital,  Hassan-abad square","Loghman Hakim Hospital, Kamali St, Makhsoos St","Vakil abad Blvd","Shahid Lavasani St. - Qom University of Medical Sciences","Vice-Chancellor for Research and Technology, Third Floor, Baqiyatallah University, Sheikh Bahaei St, Mulla Sadra St, Vanak Square","Emamkhomeini St., Sina hospital","No. 9, Jahad 19, Kerman","Corner of Tabriz Ally, North Sarparast St., Taleqani Ave.","Azadi street- Golgasht Ave, Tabriz, East Azarbaijan, Iran","Ardabil University of Medical Sciences; Daneshgah street","School of Pharmacy, Nursing Boulevard","Torbat Heydariyeh","Yousefreza","Razi hospital, Felestin Ave, Amanieh Ave","Tehran, Vanak Square, Mulla Sadra Street, Sheikh Bahai Street","Kavosh Blvd., Supa Blvd., Poleh Kordan","Valieasr St., Intersection of Niyayesh Highway, Shahid Beheshti University of Medical Sciences, Faculty of Pharmacy","Daneshgah Street, Tabriz University of Medical Sciences","Imam Khomeini Hospital, Shahid Jeddi street, Ardabil","Karegare Shomali St. Shariati Hospital","Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran","Golgasht Ave.","Internal medicine department, Ghaem hospital, Ahmadabad Ave, Shariati Sq.","No. 2, Hafez St., Banihashem St., Resalat Ave","Shahid Lavasani Street,Qom University of Medical Sciences","Emamkhomeini St., Sina hospital","Firoozgar hospital., Beh Afarin Ave., Karimkhan Ave., Valiasr Sq","No. 5, Mollasadra St., Vanak Sq., Baqiyatallah Hospital, Department of Surgery","No.4, Shahid Shiroodi St. - Alam Al-Huda St., Arak University of Medical Sciences, School of Medicine, Department of Internal Medicine","Tabriz University of Medical Sciences","Blvd vakilabad, school of pharmacy","Shariati Hospital, Jalal-e-Al-e-Ahmad Hwy","Blv. Vakilabad2-School of Pharmacy, 1365-91775","Miandrood, Surak, Imam Khomeini St., Ashouri Medical Clinic","Vakilabad Boulevard; Ferdowsi University; Faculty of Pharmacy","Semnan University of Medical Sciences, Basij boulevard, Semnan","Gholgasht Street, Tabriz University of Medical Sciences","School of Pharmacy, University Campus, VakilAbad boulvard","No. 2, Hafez St., Banihashem St., Resalat Ave","Etemadzadeh avenue; West Fatemi street","Faculty of Traditional Medicine, Shams Alley, opposite Tavanir St, above Saei Park, Valiasr Ave.","Blv. Vakilabad2-School of Pharmacy, 1365-91775","Keshavarz Blvd?","rami.boukhalil@usj.edu.lb","Pharmacy faculty, Tehran university of medical science, 16 Azar St., Enghelab Sq., Tehran, Iran","Saveh, at the beginning of Jomhouri Street, Saveh School of Medical Sciences","Ghafari Street,","Zeiaeian hospital , Abuzar Ave","Razi hospital, Felestin Ave, Amanieh Ave","Sarrafzadeh house, No. 21, in front of Mellat park, Ahmadzade avenue, Ansari boulevard","Valiasr St., Shariati St., East Kohanmooi St.","Department of Internal Medicine, Taqi abad Square, Mashhad","Firoozeh Alley, Vali-asr Sq, Tehran, Iran","Al-Motamayez District","1-21-1 Toyama, Shinjuku-ku, Tokyo Japan",null,"Imam Khomeini Hospital","Birjand university of medical sciences, Ghaffari st.,","Ishaga Rd, Idi-Araba","1-21-1, Toyama, Shinjuku-ku, Tokyo","3-39-15 Showa-mchi, Maebashi-shi, Gunma","3-39-15 Showa-mchi, Maebashi-shi,Gunma","3311-1, Yakushuji, Shimotsuke, Tochigi, Japan","Rua Joo Julio, 331","7-3-1 Hongo, Bunkyo-ku, Tokyo","Rua Abilio Soares 250, 12o. andar","3-9, Fukuura, Kanazawa, Yokohama, Jaapn","1873 Rama IV Road, Pathumwan Bangkok 10330","2, Jinadu Olusi Street","35 Shinanomachi Shinjuku-ku, Tokyo","1873 Rama 4 Rd., Lumphini, Pathumwan, Bangkok, Thailand Bangkok 10330","His Majesty the King's 80th Birthday Anniversary 5th December 2007 Building 10th floor, 2 Wang Lang  Bangkok 10700","Cefiro 14 5D","3-9 Fukuura Kanazawa Yokohama","46 rue Henri Huchard Paris 75018","Rua Augusto Corra, 01","Ave. 31 entre 158 y 190, Cubanacan, Playa.","Av. Salaverry 801","46 rue Henri Huchard Paris 75018","Av. Dr. Eneas de Carvalho Aguiar, 255","Mahidol-Oxford Tropical Medicine Research Unit (MORU) Faculty of Tropical Medicine Mahidol Universit Bangkok  10400"],["doctoryanzhao@whu.edu.cn","caiting@ucas.ac.cn","xxw69@126.com","zhaixiaowendy@163.com","88071718@qq.com","pinhuapan668@126.com","doctoryanzhao@whu.edu.cn","tcmdoctorlu@163.com","lipipi007@163.com;","panda.how@sdu.edu.cn","li_js8@163.com","jiayongshi@medmail.com.cn","Wangtan215@sina.com","164972769@qq.com","pony8980@163.com","songlab_radiology@163.com","xiangming_fang@njmu.edu.cn","jxxk1035@yeah.net","zhangw1190@sina.com",";wrl7905@163.com;wrl7905@163.com",null,"fangbji@163.com","zjwzhxy@126.com","eier_dai@163.com;eier_dai@163.com","sxu@hust.edu.cn","bluesearh006@sina.com","fangbji@163.com","31531955@qq.com","xiajinyu@mail.sysu.edu.cn","dinghuiguo@medmail.com.cn","wanghuaqi2004@126.com","13588867114@163.com","doctorzzd99@163.com","hubo@mail.hust.edu.cn","Luhongzhou@shphc.org.cn","ian0126@126.com","zhanjie34@126.com","luhongzhou@fudan.edu.cn","3131862959@qq.com","litsh@263.net",";xxw69@126.com","tcmdoctorlu@163.com","caiting@ucas.ac.cn","wlx1126@hotmail.com","zysjsgzs@163.com","xxlahh08@163.com","252417083@qq.com","Liuqingquan2003@126.com","huangluqi01@126.com","Kangyan@scu.edu.cn","doctorzhang2003@163.com","xyxzyxzh@163.com","13505615645@163.com","shanpingjiang@126.com","zhaojp@tjh.tjmu.edu.cn","li_js8@163.com","ZJHTCM@FOXMAIL.COM","lisuyun2000@126.com","wengcp@163.com","shanghongcai@126.com","1037070596@qq.com","doctoryanzhao@whu.edu.cn","wengcp@163.com","zheng862080@139.com","xuezg@tongji.edu.cn","wengcp@163.com","1025823309@qq.com","jxzhang1607@163.com","guojun@wchscu.cn","wenshl@mail.sysu.edu.cn","doctorzzd99@163.com","caiicu@163.com","zhaoyl2855@126.com","caojuncn@hotmail.com","64699629@qq.com","zhangweiliuxin@163.com","Xiaolintong66@sina.com","wuguolin28@163.com","yingxialiu@hotmail.com","503818505@qq.com","xyxzyxzh@163.com","doctorzhang2003@163.com","qiuyq@zju.edu.cn","wangxinghuan@whu.edu.cn","784404524@qq.com","cdjianghua@qq.com","DOCXWG@16.COM","whsdyyykjc@126.com","ZJHTCM@FOXMAIL.COM","caocdoctor@163.com","huangluqi01@126.com","973007530@qq.com","doctorwhy@126.com","yingsrrsh@163.com","1346801465@qq.com","chenqx666@whu.edu.cn","lvdq@enzemed.com","ykb@tju.edu.cn","luhongzhou@shphc.org.cn","lingqing1985@163.com","yang_zhongqi@163.com","xiemx@hust.edu.cn","zhaodewei2016@163.com","luyibingli@163.com","tflook@163.com","wdznyy@126.com","leilei_25@126.com","xuyongsmu@vip.163.com","maoweilw@163.com","xie_m@126.com","qiuchengfeng0721@163.com","jmqu0906@163.com","shanhong@mail.sysu.edu.cn","ljli@zju.edu.cn","dwwang@tjh.tjmu.edu.cn","mapenglin1@163.com","hukejx@163.com","qiuyq@zju.edu.cn","chzs1990@163.com","wqp1968@163.com","xcg718@aliyun.com","ckqmzygzs@163.com","412475734@qq.com","qiuyq@zju.edu.cn","docxwg@163.com","chanjuanzheng@163.com","docxwg@163.com","ZJHTCM@FOXMAIL.COM","ylsong70@163.com",";xavier.duval@aphp.fr;xavier.duval@aphp.fr",null,"huang-yi-1980@163.com","leaiping@126.com","you_shang@126.com","yingxialiu@hotmail.com","zhaohong_pufh@bjmu.edu.cn","1924238034@qq.com","qingzhou.wh.edu@hotmail.com","2534776680@qq.com","liubende99@outlook.com","sxwang@tjh.tjmu.edu.cn","xugang@tjh.tjmu.edu.cn","liujing25@mail.sysu.edu.cn","linling@gird.cn","stjz@zju.edu.cn","xiangdongchen2013@163.com","ysz3129@163.com",";znyylcsy@126.com;","13600001163@139.com","quxiaowang@163.com","Chenhongyi8660@163.com","yangbf@ems.hrbmu.edu.cn","1813886398@qq.com","18917683122@189.cn","tangjianyuan163@163.com","luhongzhou@shphc.org.cn","boj301@sina.com","shpingg@126.com","13910930309@163.com","jhong.pku@163.com","fanglei586@126.com","Yinzy@xmu.edu.cn","zhaochunhua@vip.163.com","fangmin19650510@163.com","chenxinyuchen@163.com","tj1234753@sina.com","sxwang@tjh.tjmu.edu.cn","lvdq@enzemed.com","am-penicillin@163.com","shpingg@126.com","jbge@zs-hospital.sh.cn","dl5506@126.com","Tongxg@yahoo.com","xuhuji@smmu.edu.cn","Xin11@hotmail.com","doctorzhang2003@163.com","lianru666@163.com","xiemx@hust.edu.cn","xiangdongchen2013@163.com","zhuoli.zhang@126.com","Xin11@hotmail.com","Yinzy@xmu.edu.cn","yxbxuzhou@126.com","minzhou@tjh.tjmu.edu.cn","706885399@qq.com","bai.chunxue@zs-hospital.sh.cn","xuntao26@hotmail.com",";fengxiaobin200708@aliyun.com;",";xiajinglin@fudan.edu.cn",";;;xubaopingbch@163.com;",";bai.chunxue@zs-hospital.sh.cn;","tangjianyuan163@163.com","44271370@qq.com","fengcao8828@163.com","liangjq@fmmu.edu.cn;","lunliweiyuanhui2009@126.com","doctoryanzhao@whu.edu.cn","shangdongdalian@163.com","8999578@qq.com",";xiajinglin@fudan.edu.cn",";xwx1983@163.com;pzp33@hotmail.com","chenhong1129@hotmail.com","hekl301@aliyun.com","153267742@qq.com",";xwx1983@163.com;pzp33@hotmail.com","maxr0910@163.com","haoyaner@163.com",null,"nijun1000@126.com","nijun1000@126.com","guyuesunny@163.com","scx1818@126.com","xrchang1956@163.com","2209447940@qq.com","chenghailiu@hotmail.com;","fuying1995@163.com;wanjinchen75@fjmu.edu.cn","nplrj@126.com","luyb6810@163.com","zzh1974cn@163.com","55815147@qq.com","55815147@qq.com","ian0126@126.com","55815147@qq.com","1813886398@qq.com","ljzwd@163.com","huillanz_76@163.com","li_caixia@zju.edu.cn","hubingnj@163.com","zzq1419@126.com","Wangtan215@sina.com","xujianqing@shphc.org.cn","lvjihui@139.com","2066255602@qq.com","drkaijiang@163.com","wangjing9279@163.com","chump1981@163.com","27216302@qq.com","yyliuhua@126.com","27216302@qq.com","dr_lif08@126.com","freebee99@163.com","jieminzhu@xmu.edu.cn","Pengzy5@hotmail.com","docd1@sina.com","hydyangwei@tom.com","yingfei1981@163.com","1078404424@qq.com","406302524@qq.com","ahmusld@163.com","fengcao8828@163.com","2590410004@qq.com","zhangweiliuxin@163.com","syicu@vip.sina.com","ld_2069@163.com","pdzhoujia@163.com","ld_2069@163.com","zhangdxdaisy@cuhk.edu.hk","xiaokh1@163.com","yogaqq116@whu.edu.cn","luyibingli@163.com","1041863309@qq.com","shuchenghua@126.com","wenxiang_huang@163.com","wenxiang_huang@163.com","wdxjy@whu.edu","hp_cq@163.com","yaokaichen@hotmail.com","shenning1972@126.com","yaokaichen@hotmail.com","maohwei@qq.com","shenning1972@126.com","wangjinlong2007666@163.com","shushengli16@sina.com","1121733818@qq.com",";dinghuiguo@medmail.com.cn","zuoyunxiahxa@qq.com","hmei@hust.edu.cn","1035788783@qq.com","drliuhu@gmail.com","xxw69@126.com","binwuying@126.com","shushengli16@sina.com",";jmqu0906@163.com","luxiaoyang@zju.edu.cn",";xiaotian-sun@hotmail.com;13911798288@163.com","huilanz_76@163.com;","chenxinyuchen@163.com","38797527@qq.com","zhanghuafen@zju.edu.cn","shushengli16@sina.com","wanghaohh@vip.126.com","hywangk@vip.sina.com","sylykjk@163.com","chzs1990@163.com","cxfn817@163.com","gghicu@163.com","417433835@qq.com",null,";heyi@tasly.com","411484335@qq.com","zlgj-001@126.com","Xiumingsong@sina.com","13968888872@163.com","zhagnweijinan@126.com","docjiangshujuan@163.com","Kangyan@scu.edu.cn","wucaineng861010@163.com","15168888626@163.com","akidney_doctor@hotmail.com","s_1862777@163.com","caiy_kf@163.com","haoyaner@163.com","liubende99@outlook.com","182190248@qq.com","zhougene@medmail.com.cn","pangi88@126.com","Fangmh@tjh.tjmu.edu.cn","drhuoyong@163.com","wenqin-1987@163.com","xcg718@aliyun.com","lixmpumch@126.com","huilanz_76@163.com","xcg718@aliyun.com","gchxyy@163.com","18930568129@163.com","fangzjnj@hotmail.com","tangjianyuan163@163.com","lixmpumch@126.com","yefeng@gird.cn","zhoujian@sjtu.edu.cn","13803818341@163.com","lunxu_liu@aliyun.com","zhangzz@whu.edu.cn","majingzhi2002@163.com",null,null,"zhougene@medmail.com.cn","john131212@126.com","caobin_ben@163.com","1813886398@qq.com","WH9400@163.com","cjr.luguangming@vip.163.com","13971587381@163.com",";loebm@mcmaster.ca",null,null,"Wangtan215@sina.com",";luhongzhou@fudan.edu.cn;","Zhaojp88@126.com","yehonghua@medmail.com.cn","1286779459@qq.com","lishiyue@188.com","49637569@qq.com","aloof3737@126.com","chris.kclai@cuhk.edu.hk","274770142@qq.com","luoqunx@163.com","ljli@zju.edu.cn","dr.xu@aliyun.com","707986890@qq.com","zywenjianli@163.com","lykyk3160823@126.com","spine672@163.com","xpluo@tjh.tjmu.edu.cn","frank782008@aliyun.com","Shushengli16@sina.com","tiejunwanghp@163.com","zywenjianli@163.com","xuhaibo1120@hotmail.com","sxu@hust.edu.cn","Lmxia@tjh.tjmu.edu.cn","fangbji@163.com","liufb163@163.com","douqifeng@126.com","haoyibin0506@126.com","qning@vip.sina.com","haoyaner@163.com","tjhdongll@163.com","nathancx@hust.edu.cn","SP2082@shtrhospital.com","whtuye@163.com","guoqing.qian@foxmail.com","hcwy100@163.com","yuanyang70@hotmail.com","bianyi2526@163.com","maozhengrong1971@163.com","wzwsjcjg@126.com","eyedrwjm@163.com","jingfengzhang73@163.com","zhwang_hust@hotmail.com","137585260@qq.com","1097685807@qq.com","wang6@tjh.tjmu.edu.cn","314440820@qq.com","hulinhui@live.cn","zyzy1933@163.com","273225540@qq.com","ld_2069@163.com","zhengqingyou@163.com","yuanyd1108@163.com","541163409@qq.com","wt7636@126.com","kiphoonwu@126.com","849614995@qq.com","xuyingjia@5thhospital.com","hygao@tjh.tjmu.edu.cn","zhangguogx@hotmail.com","money_0921@163.com","linzhaofen@sina.com","970236538@qq.com","zn_chenxiong@126.com","xkyylfl@163.com","xkyylfl@163.com","ant000999@126.com","nmbrbt8989@163.com","qinwang_1975@126.com","hongwang71@yahoo.com","xkyylfl@163.com","ctzhang0425@163.com","xkyylfl@163.com","doctoryanzhao@whu.edu.cn","zhonghui39@126.com","zhanlianh@163.com","xkyylfl@163.com","fangmh@tjh.tjmu.edu.cn","27216302@qq.com","xkyylfl@163.com","xkyylfl@163.com","lhgyx@hotmail.com","huanqinhan@126.com","haitao3140@sina.com","784404524@qq.com","41180423@qq.com","lixiaodong555@126.com","pinhuapan668@126.com","hywangk@vip.sina.com","whxhzy@163.com","16683890@qq.com","maggie_zhangmin@163.com","b5477@163.com","chenlei0nan@163.com","lixiaodong555@126.com","docterwei@sina.com","153267742@qq.com","ly29.love@163.com","164738059@qq.com","13816012151@163.com","caobin_ben@163.com","99xw@sina.com","sir_shi@126.com","sakeonel@126.com","524712958@qq.com","lorenzo_87@163.com","fxzhu72@163.com","nhb_2002@126.com","zhb-ck@163.com","ht2000@vip.sina.com","zqling68@hotmail.com","wwei@chinacord.org","99xw@sina.com","caobaoshan0711@aliyun.com","surewin001@126.com","gaomedic@163.com","majingzhi2002@163.com","gz8hcwp@126.com","xin11@hotmail.com","164972769@qq.com","hbjzyyywlc@163.com","164972769@qq.com","liuzsc@126.com","hbjzyyywlc@163.com","miaoqing55@sina.com","miaoqing55@sina.com","hkq123123@163.com","lmzmay@163.com","drkaijiang@163.com","ljjia@shutcm.edu.cn","18604501911@163.com",";xiaoyangzh@hotmail.com","yezi5729@163.com",";pengzy5@hotmail.com;",";promo_interne_drci@chu-clermontferrand.fr;","shkimmd@amc.seoul.kr","pangpf@mail.sysu.edu.cn","liubende99@outlook.com","gaomedic@163.com","chenhhust@126.com","188116999@qq.com","mengjie@csu.edu.cn","278353780@qq.com","xyxzyxzx@163.com","yuhaihang0414@sina.com","fanli0930@163.com","164972769@qq.com","164972769@qq.com","kittychen36@gmail.com","xyyylijing@sina.com","whuhjy@sina.com","315977705@qq.com","chenyinyin1212@hunnu.edu.cn","13603035264@139.com","rengbinji@163.com","sunok301@126.com","tongzhaohuicy@sina.com","tanghao_0921@126.com","FSYYN001@126.com",null,";c@szgimi.org;c@szgimi.org","chunli@gird.cn","chenjn@mail.sysu.edu.cn","liudr@outlook.com","fengzhenly@sina.com","docjiangshujuan@163.com","iszfc@sina.com",null,"linjie1992@zju.edu.cn","13966906638@139.com","tianlin@mail.sysu.edu.cn","gz8hlc@126.com","1813886398@qq.com","393406816@qq.com","zbhong6288@163.com","wangxinghuan@whu.edu.cn","13533550083@163.com","chengyunliu@hust.edu.cn","wanbr2000@sina.com","qianlu5860@gmail.com","caiting@ucas.ac.cn","ant000999@126.com","cleverwdw@126.com","gykpanda@163.com","tongzhaohuicy@sina.com","bxlee@sohu.com","13926946929@163.com","wenqin-1987@163.com","ljli@zju.edu.cn","wwang@vip.126.com","gongguozhong@csu.edu.cn","511201663@qq.com","395956184@qq.com","qning@vip.sina.com;qning@vip.sina.com",null,"line.meddeb@ap-hm.fr","zln7095@163.com",null,"qning@vip.sina.com;qning@vip.sina.com","gz8hzf@126.com","zhangweiliuxin@163.com","keiliu0406@gmail.com","shi_guochao2010@qq.com","whunjy@126.com;whuhjy@126.com",null,"qning@vip.sina.com;qning@vip.sina.com","qning@vip.sina.com;qning@vip.sina.com","mkond@fujita-hu.ac.jp",";c@szgimi.org;c@szgimi.org","chenlin_tj@126.com",null,";;","registry.covid@hosp.ncgm.go.jp",null,";jeanliu@yale-nus.edu.sg;jeanliu@yale-nus.edu.sg",null,null,"adeebalzoubi@stemcellsarabia.net;adeebalzoubi@stemcellsarabia.net",null,"qning@vip.sina.com;qning@vip.sina.com",";yuyikai@163.com;",null,"363994906@qq.com;houy@famousmed.net",";13781919609@163.com;sykyxmbgs@163.com",";;;;franlj1104@aliyun.com","zhangwenhong@fudan.edu.cn;zhangwenhong@fudan.edu.cn","455957898@qq.com","chenhx@enzemed.com",null,";nguyen.lee@icloud.com;",";robert.frithiof@surgsci.uu.se;robert.frithiof@surgsci.uu.se",";dicastel@ngi.it;","fwl@hust.edu.cn",";562122649@qq.com;xyyyllwyh@126.com","gabriele.saccone@unina.it","sunnyabs1215@163.com","20215851@qq.com","lilibestever@126.com","fyang@vip.163.com","litian-wang@163.com","824647903@qq.com","doctor.wuyh@gmail.com",";antonio.gaddi@ehealth.study;maurizio.cipolla@ehealth.study","lilibestever@126.com","13972046539@163.com","tjqiuhong@163.com","haoyaner@163.com","zhengxue.academic@gmail.com","chenzhuanggui@126.com","sidaoyuan1984@sina.com","qshi@cqmu.edu.cn","wchmhcmxd@163.com","wanzimili@sina.com","jin_eagle@sina.com","tangxiaoj0726@qq.com","pluo@whu.edu.cn","mengqt2013@hotmail.com","2235658154@qq.com","wwang@vip.126.com","sjun1982@163.com","fuliran@126.com","gaopy930@126.com","xuzhe302@139.com","icuwei@163.com","leigenping2006@163.com","lishiyue@188.com","nicole8611@163.com","doctorzzd99@163.com","huxingxing82@163.com","gaopy930@126.com","Public-Registry-MA-France@sanofi.com","ahslyywm@163.com","kangyan_hx@163.com","huangluqi01@126.com","cgq1963@163.com","sunhongyuan12@163.com",";erenavcil@gmail.com;erenavcil@gmail.com","francois.lellouche@criucpq.ulaval.ca","hxkfhcq@126.com","laurens.liesenborghs@uzleuven.be","M.J.M.Bonten@umcutrecht.nl",";fbrzcantini@gmail.com;fbrzcantini@gmail.com",";Attia.Qamar@unityhealth.to;adrienne.chan@sunnybrook.ca",";florence.ader@chu-lyon.fr","shuminwang7000@163.com;shuminwang7000@163.com","diane.egger-adam@uni-tuebingen.de","xiemx@hust.edu.cn","jody.brookes@synairgen.com","whuhjy@sina.com",null,";xyhplihao1965@126.com;xyhplihao1965@126.com","joe-elie.salem@aphp.fr;joe-elie.salem@aphp.fr","s.corrao@tiscali.it;s.corrao@tiscali.it",";;jiaojiaopang@126.com;jiaojiaopang@126.com",";hegyi2009@gmail.com",";drmtantaway@yahoo.com",";francesco.salton@gmail.com;mconfalonieri@units.it",";M_paul@rambam.health.gov.il","paulkschan@cuhk.edu.hk;",";info@ovg.ox.ac.uk;info@ovg.ox.ac.uk","Drpitts@hudsonmedical.com",null,";gwzxliumin@foxmail.com;gwzxliumin@foxmail.com",";;ACT.ProjectTeam@PHRI.ca;ACT.ProjectTeam@PHRI.ca","paolo.gisondi@univr.it",";","William@tropmedres.ac","f.w.asselbergs@umcutrecht.nl;m.p.m.linschoten@umcutrecht.nl",";",";dgebow@gmail.com;TBD@TBD.com",null,";joost.wauters@uzleuven.com","whet_ctr@163.com","lxy7111@126.com",null,";;;;;;;bartshealth.covid-hcw@nhs.net;","sunhq@bjmu.edu.cn","yxzpumch@126.com","zhu1635253@163.com","shencx@sjtu.edu.cn","liweiqindr@vip.163.com","fanrong3463@163.com",";eco7@cumc.columbia.edu","gallelli@unicz.it;gallelli@unicz.it","18971327286@163.com","drlihang@126.com","A.A.Bhangu@bham.ac.uk","winsonhong@126.com","xiaof35@sysu.edu.cn","cyzhang@nju.edu.cn","wanli0604@163.com","fswang302@163.com","wenqin-1987@163.com","zejinliu@163.com","rqrc.siege@inserm.fr","xmguo@tjh.tjmu.edu.cn","liudongyang@vip.sina.com","global.rochegenentechtrials@roche.com","jzxhl@126.com","zyq1590@163.com","soumelas@uni-pharma.gr","393176736@qq.com","leetangbaba@163.com","DRCI-Promotion-Interne@chu-angers.fr","yuanxianglin@hust.edu.cn",null,"oucehua@swmu.edu.cn","393176736@qq.com","carine.labruyere@chu-st-etienne.fr","18971327286@163.com","lars.erik.kristensen@regionh.dk",null,";ifan@ansunbiopharma.com",";jiaojiaopang@126.com",";clinicaltrials@regeneron.com","j.aman@amsterdamumc.nl","landoni.giovanni@hsr.it",";info@beat19.org;info@beat19.org","zhongji.meng@163.com;zhongji.meng@163.com",";aro.clinicaltrials@einstein.br","lberra@mgh.harvard.edu",";odalgard@uio.no;odalgard@uio.no","jan.erik.berdal@medisin.uio.no",null,";g.gritti@asst-pg23.it;arambaldi@asst-pg23.it",null,";olesoega@rm.dk",";zjgong@163.com;","ohermine@gmail.com",";;alexandru.burlacu@umfiasi.ro",";guido.bertolini@marionegri.it","cescalvo@ucm.es",";alexander.supady@universitaets-herzzentrum.de;",";dean@ayubmed.edu.pk;dean@ayubmed.edu.pk","aorlandinimd@eclainternational.org",";jday@oucru.org","vasilios.polymeropoulos@vandapharma.com",";anja.delporte@uzgent.be","DMIDClinicalTrials@niaid.nih.gov",";;alexandru.burlacu@umfiasi.ro","spdeftereos@gmail.com",";anders.kjellberg@ki.se",null,"t.tendoesschate@umcutrecht.nl",";joanne.gondert@beaumont.org;joanne.gondert@beaumont.org","Arne.Vasli.Lund.Soraas@rr-research.no;Arne.Vasli.Lund.Soraas@rr-research.no","m.eddleston@ed.ac.uk",";imfell@yuhs.ac",";;meigs@uw.edu",";stephen.freedman@ahs.ca;stephen.freedman@ahs.ca","infection@korea.ac.kr","a.martineau@qmul.ac.uk",";Guido.bertolini@marionegri.it","bruno.hoen@pasteur.fr",null,";wangliu@ioz.ac.cn",";;;;;;;guiaccar@unina.it;","isabelle.pellegrin@chu-bordeaux.fr;isabelle.pellegrin@chu-bordeaux.fr",";Jie_Li@rush.edu",null,";anayajm@gmail.com;gustavo.quintero@urosario.edu.co",null,";julien.poissy@chru-lille.fr;",null,";usingh@stanford.edu",";Guido.Beldi@insel.ch;Guido.Beldi@insel.ch",";;filippo.annoni@erasme.ulb.ac.be",";;;alireza_ghaffarieh@meei.harvard.edu;",";soeska@rm.dk","mlid163@163.com","esannorberto@hotmail.com;esannorberto@hotmail.com",";",";ndaba.mazibuko@nhs.net",";muriel.fartoukh@aphp.fr;muriel.fartoukh@aphp.fr",null,";;;;;;;;;;;;;;;;qixiaolong@vip.163.com","marta.duda-sikula@umed.wroc.pl",null,null,";mehdi.benchoufi@aphp.fr",";sabinehazan@aim.com",";carrier.marie.eve@gmail.com",null,null,"ciceri.clinicaltrials@hsr.it",null,";anayajm@gmail.com;gustavo.quintero@urosario.edu.co",";servandocardona@tec.mx","jinzhilu2015@163.com","41025513@qq.com","lgh19870628@126.com",";Zivit@canfite.co.il",null,null,"liuliu9027@163.com","qianlu5860@gmail.com","dicespedes2@hotmail.com","jszfc@sina.com","yanggang201301@163.com","ydkfedu@163.com","docd1@sina.com","happyzhupengfei@163.com","398139849@qq.com","leetangbaba@163.com","fanyingsh@126.com","lijianan@njmu.edu.cn","rebrcca@126.com","frank0130@126.com","kjkceh@126.com","tsh006@163.com","liyingshuai2013@163.com","baixiaoxia@zju.edu.cn","zhaozl2006@163.com","zengrui_0524@126.com","wengjp@ustc.edu.cn",null,"carla.vandenabele@aphp.fr","elodie.soler@aphp.fr","s.koerper@blutspende.de","korinna.pilz@inflarx.de","hiruz.ctu@uzgent.be","patrick.cassai@chu-bordeaux.fr","l.lamrani@hml.fr","arnauld.garcin@chu-st-etienne.fr","fibucicec.hcsc@salud.madrid.org","julien.gautier@lyon.unicancer.fr","lola.serna@carm.es","insepsis@otenet.gr","fadila.amerali@aphp.fr","pvachey@for.paris","xsolanich@bellvitgehospital.cat","epenag@santpau.cat","gutierrez_fel@gva.es",null,"secretaria@delosclinical.com","jose.munoz@isglobal.org","uk-medicalinformation@sanofi.com","eunate.aranaarri@osakidetza.eus","anabelsanchez.hrc@gmail.com",";;marie-helene.masse3@usherbrooke.ca;marie-helene.masse3@usherbrooke.ca",";jho@ansunbiopharma.com",null,"luhongzhou@fudan.edu.cn",";d.f.mcauley@qub.ac.uk;d.f.mcauley@qub.ac.uk",null,null,null,"shilei302@126.com;shilei302@126.com",null,";clinicaltrials@biocryst.com;",";xieyao00120184@sina.com;xieyao00120184@sina.com",null,null,"whuhjy@sina.com","pierre.hausfater@aphp.fr",null,"wulingzhu@xxmu.edu.cn;guomh@163.com","KPWA.vaccine@kp.org",";shilei302@126.com",";info@TianheCell.com","skhongsa@gmail.com",";clinicaltrials@pulmotect.com",";;",";philippe.vanhems@chu-lyon.fr","sandi.k.parriott.mil@mail.mil",";GileadClinicalTrials@gilead.com",";GileadClinicalTrials@gilead.com","lberra@mgh.harvard.edu;lberra@mgh.harvard.edu",";lberra@mgh.harvard.edu;",";;Covid19trial@umn.edu",";rbesthof@neurorxpharma.com",";f.perrone@istitutotumori.na.it",null,";covid19@umn.edu",";john131212@sina.com","oriolmitja@hotmail.com;omitja@flsida.org",null,";;Covid19trial@umn.edu",";clinicaltrials@pulmotect.com","florentino.cardoso@hospitalcare.com.br;florentino.cardoso@hospitalcare.com.br","gabriele.saccone@libero.it",";neurocovid19study@ictalgroup.org",";;fzampieri@hcor.com.br",";aliaehussein@aun.edu.eg;aliaehussein@aun.edu.eg",null,null,";;;;;;;cmhcar@hotmail.com;iner.hydra@gmail.com",";rewells@wakehealth.edu;rewells@wakehealth.edu",";;;;;;;paukrust@ous-hf.no;andreas.barrattdue@gmail.com","jens.ulrik.jensen@regionh.dk",";GileadClinicalTrials@gilead.com",";pzheng@oncoimmune.com",";;;;;;;;lfjcamacho@comunidad.unam.mx;iner.hydra@gmail.com",null,";TOID_CRC@jhmi.edu",";global-roche-genentech-trials@gene.com",";mark.sendak@duke.edu",";;;;libertario.demi@unitn.it","umberto.maggiore@unipr.it","contact@vipstudy.org",";;jean-claude.tardif@icm-mhi.org",";PRIORITYCOVID19@ucsf.edu;PRIORITYCOVID19@ucsf.edu",";jesus.villar54@gmail.com",null,"barbara.goodall@nshealth.ca",null,"gunther.meinlschmidt@ipu-berlin.de;contact@selfapy.com",";lars.erik.kristensen@regionh.dk","mabulmeaty@ksu.edu.sa","gallelli@unicz.it;gallelli@unicz.it",";sobi.immuno@sobi.com","bertrand.cariou@univ-nantes.fr;bertrand.cariou@univ-nantes.fr",null,";Contact-US@sanofi.com",";luciano.azevedo@hsl.org.br",";vaccinetrials@ndm.ox.ac.uk",";anna.caprodossi@policlinicogemelli.it;anna.caprodossi@policlinicogemelli.it",";miri@cordio-med.com",";frederic.adnet@aphp.fr","ozmenmm@gmail.com;mahir.ozmen@istinye.edu.tr",";nigel.curtis@rch.org.au","vincent.dubee@chu-angers.fr",";;ethan.berke@uhg.com;",";;Arnauld.Garcin@chu-st-etienne.fr",";covid19prep@umn.edu",";richard.skells@addenbrookes.nhs.uk;rkg20@cam.ac.uk",";cflamand@pasteur-cayenne.fr;cflamand@pasteur-cayenne.fr",";matthias.totzeck@uk-essen.de;amir-abbas.mahabadi@uk-essen.de",";jennifer.victory@bassett.org;kristin.pullyblank@bassett.org",";carla.ccih@gmail.com",";fgarcia@clinic.cat",";rachael.smith@bannerhealth.com",";johnwilliam.mcevoy@nuigalway.ie;johnwilliam.mcevoy@nuigalway.ie",";Valerie.Aston@imail.org",";camille.taille@aphp.fr;camille.taille@aphp.fr",";claire-anne.siegrist@unige.ch;",";;luanne.metz@ahs.ca",";;antonia.bendau@charite.de;corona-angst@charite.de",";f.denis@cjb72.org;",";amelia.anderson@pennmedicine.upenn.edu;amelia.anderson@pennmedicine.upenn.edu",";Dr.afazeli@gmail.com;info@fums.ac.ir","javiercrespo1991@gmail.com",";anja.delporte@uzgent.be",";srinivas.murthy@cw.bc.ca",";jeffrey.miller@emory.edu",";victoria.vazquez@kcl.ac.uk",";jose.munoz@isglobal.org",";;steven.chan@uhn.ca;steven.chan@uhn.ca",";pankti.reid@uchospitals.edu;",";;ACTIONTrial@ucsf.edu;ACTIONTrial@ucsf.edu",";korinna.pilz@inflarx.de","ohermine@gmail.com","roberto.giacomelli@univaq.it;roberto.giacomelli@univaq.it","pdomingo@santpau.cat;pdomingo@santpau.cat",";alena.marynina@nhs.net;alena.marynina@nhs.net","cmoser@targetpharmasolutions.com;phnmedic@uw.edu","Scott.Gorenstein@nyulangone.org;David.Lee@nyulangone.org",";;;lindayun@wustl.edu","ceannweiler@chu-angers.fr",";john131212@sina.com",";Contact-US@sanofi.com",";coldmixon@mgh.harvard.edu",null,";rachel.e.olson@duke.edu",null,"janneke.cox@jessazh.be",";john131212@sina.com",";goldstein_le@clalit.org.il","dandachid@health.missouri.edu",";julien.gautier@lyon.unicancer.fr",";mcgarzon@ugr.es","ibnsky@yahoo.es;ibnsky@yahoo.es",";doyen.d@chu-nice.fr","ovillarob@gmail.com",";Valerie.Aston@imail.org",";sabinehazan@aim.com",";;;bd@symvivo.com",";",";msalathe@kumc.edu;msalathe@kumc.edu",";gitta@klilu.de;gitta@klilu.de",";alicia.garcia@medsir.org","jslagel@slapharma.com",";stephan.reichenbach@ispm.unibe.ch","Efstratios.Koutroumpakis@uth.tmc.edu;Efstratios.Koutroumpakis@uth.tmc.edu","chris.inchley@gmail.com;lisebeierommen@gmail.com",";;azengin@istanbul.edu.tr;azengin@istanbul.edu.tr","zheng862080@139.com;zheng862080@139.com",";l.uhrenholt@rn.dk;l.uhrenholt@rn.dk",";qingsongye@foxmail.com;","azengin@istanbul.edu.tr;azengin@istanbul.edu.tr",";lars.wik@medisin.uio.no",";;jeffrey.carson@rutgers.edu",";kristine.arges@duke.edu;kristine.arges@duke.edu",";;hussaisa@rwjms.rutgers.edu",";francois.silhol@ap-hm.fr;francois.silhol@ap-hm.fr","aliaehussein@aun.edu.eg;aliaehussein@gmail.com",null,"corinne.levy@activ-france.fr",null,"harry.hothi@nhs.net",";piasfar@chu-angers.fr;julien.demiselle@chu-angers.fr",null,null,null,"sonja.hoeller@apeiron-biologics.com;",";;;snamendys@gmail.com",";novartis.email@novartis.com",";;ppatoz@ch-tourcoing.fr",";;;;henning.bundgaard@regionh.dk;henning.bundgaard@regionh.dk","rjager@beatcovidtrial.com",";p-amedro@chu-montpellier.fr;p-amedro@chu-montpellier.fr",";clinical.trials@inovio.com",";tness@uabmc.edu;tness@uabmc.edu",";;;;;;;;;Francois.Morin@chu-angers.fr","xavier.monnet@aphp.fr","nsharris@mgh.harvard.edu;nsharris@mgh.harvard.edu",";francois.dubos@chru-lille.fr","azengin@istanbul.edu.tr;",";srogy@capricor.com;Mitch.Gheorghiu@cshs.org","roi.anteby@sheba.health.gov.il;roi.anteby@sheba.health.gov.il",";egiamarel@med.uoa.gr",null,"bjorn.stessel@jessazh.be",null,";ruxcoflam@med.uni-jena.de;ruxcoflam@med.uni-jena.de",";shehnoor.azhar@gmail.com",null,null,";f.iqbal@imperial.ac.uk","achille.tchalla@chu-limoges.fr",";brannock.robert@mayo.edu;brannock.robert@mayo.edu",";xsolanich@bellvitgehospital.cat;xsolanich@bellvitgehospital.cat",";chris@sanotize.com","juliochi@pennmedicine.upenn.edu","dmlevine@bwh.harvard.edu;dmlevine@bwh.harvard.edu",";sujeet.jha@maxhealthcare.com;samreensiddiqui@maxhealthcare.com",null,"447822853@qq.com;447822853@qq.com",";USCOVIDplasma@mayo.edu",";michiel.thomeer@zol.be;michiel.thomeer@zol.be",null,null,";;whipcovid19@hfhs.org;whipcovid19@hfhs.org","qingleigao@hotmail.com;qingleigao@hotmail.com","Huilanz_76@163.com",";klewandowski@honorhealth.com",";heini.kanervo@uzgent.be;","diane.egger-adam@uni-tuebingen.de",";mlmadariaga@bsd.uchicago.edu;",";claire.roger@chu-nimes.fr;claire.roger@chu-nimes.fr",";guptans@ucmail.uc.edu;davis5ax@ucmail.uc.edu",";farhan.raza@aku.edu",";alison.gibbons@nih.gov;alison.gibbons@nih.gov",";yocum007@umn.edu",";jose.diaz-miron@childrenscolorado.org;jose.diaz-miron@childrenscolorado.org",";;d.harding@qmul.ac.uk","aburns@caredx.com",";;robert.koerner@uk-koeln.de;robert.koerner@uk-koeln.de",";bari-covid19@cuanschutz.edu",";ly_icu@aliyun.com;ly_icu@aliyun.com","david.saadoun@aphp.fr",";;miguelguia7@gmail.com;antmesquinas@gmail.com",";peter.rosenberger@med.uni-tuebingen.de",";drmendietaz@yahoo.com",";US.Info@I-MabBiopharma.com","jean-baptiste.fassier@chu-lyon.fr",";nancy.kentish@aphp.fr;nancy.kentish@aphp.fr","jens.kastrup@regionh.dk",";xavier.mariette@aphp.fr","gilles.mangiapan@chicreteil.fr",";;haleema.shakur-still@lshtm.ac.uk",";englemd94@gmail.com","lisa.derosa@gustaveroussy.fr;lisa.derosa@gustaveroussy.fr",";wangwj@jscdc.cn;markwangzhao@qq.com",";giacobellis@med.miami.edu",";christina.pacchia@hsc.utah.edu;christina.pacchia@hsc.utah.edu",";Delphine.garrigue@chru-lille.fr",";yl4459@cumc.columbia.edu;",";ayavchitz@for.paris;cmrangon@for.paris","andrew.gostine@nm.org","azengin@istanbul.edu.tr",";diane.egger-adam@uni-tuebingen.de;diane.egger-adam@uni-tuebingen.de",";greengrc01@gmail.com;greengrc01@gmail.com",";erik.m.andersson@ki.se;erik.m.andersson@ki.se",";pierre-emmanuel.falcoz@chru-strasbourg.fr;pierre-emmanuel.falcoz@chru-strasbourg.fr","kushd@amarexcro.com",";rupesh_agrawal@ttsh.com.sg",";b.rijnders@erasmusmc.nl",null,null,"alboraie@azhar.edu.eg","marcuslacerda.br@gmail.com;",";sherry.mansour@yale.edu",";heroesresearch@duke.edu;heroesresearch@duke.edu","jacques.cadranel@aphp.fr;jacques.cadranel@aphp.fr","Latha.Dulipsingh@trinityhealthofne.org;",";d.jarczak@uke.de;d.jarczak@uke.de",";jean-franois.timsit@aphp.fr;",";stevens.a@wustl.edu",";jwsander@wakehealth.edu",";ClinicalTrials.gov@lilly.com","matthew.bardin@romark.com",";;;;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil",";;;;",null,"marcuslacerda.br@gmail.com","tlouban@uwo.ca",null,";;;;",";;eduardoinsignarescarrione@gmail.com;yohanny.andrade2@gmail.com",";Mariefel.Vendivil@HackensackMeridian.org;Mariefel.Vendivil@HackensackMeridian.org",";cwdsiu@hku.hk;cwdsiu@hku.hk",";;;epereira@gecp.org",";h-donnadieu_rigole@chu-montpellier.fr;h-donnadieu_rigole@chu-montpellier.fr",";;twiga00@yahoo.com",";sergio.valdesf@incmnsz.mx;sergio.valdesf@incmnsz.mx",";JLGustafson@mgh.harvard.edu;Chung.Raymond@mgh.harvard.edu",";ayavchitz@for.paris;gdebellemaniere@for.paris",";LaQuisa.Hill@bcm.edu;LaQuisa.Hill@bcm.edu",";;erika.ratcliffe@duke.edu;erika.ratcliffe@duke.edu",null,";j.ferencz@clardata.com",";;mkashiouris@vcu.edu;brian.davis1@vcuhealth.org","francis.corazza@chu-brugmann.be;francis.corazza@chu-brugmann.be",null,"caillon.c@chu-nice.fr;",";julien.tiete@erasme.ulb.ac.be",null,";scott.rickert@nyulangone.org;scott.rickert@nyulangone.org",";;deleaf@bwh.harvard.edu",";bonnie.lonze@nyulangone.org;bonnie.lonze@nyulangone.org",null,";nabosch@bu.edu",";pere.clave@ciberehd.org;pere.clave@ciberehd.org",";meenubajpai@hotmail.com","CovidPlasma@jefferson.edu;CovidPlasma@jefferson.edu",";;;;;;;;rechercheclinique@ch-aix.fr;rechercheclinique@ch-aix.fr",";;guillaume.bonnetccf@gmail.com",";jeannine.ascani@lcmchealth.org;jeannine.ascani@lcmchealth.org",null,";docd1@sina.com;docd1@sina.com","arnaud.bourreille@chu-nantes.fr",";jean-eric.blatteau@intradef.gouv.fr",null,";luu.pham@jhmi.edu","asarwar@bidmc.harvard.edu",null,";eszter.fodor@orthosera.com",";tseto@queens.org;tseto@queens.org",";;nhank@prcresearcheducation.com;info@prcresearchaz.com","dbernal.investigacion@saluddelosandes.com;dbernal.investigacion@saluddelosandes.com",";olcaydilken@gmail.com;olcaydilken@gmail.com","jean-pascal.fournier@univ-nantes.fr;jean-pascal.fournier@univ-nantes.fr",null,";;;sheriefabdelsalam@yahoo.com","adeeba@um.edu.my;reena@um.edu.my","tristan.mirault@aphp.fr","jacques.cadranel@aphp.fr",";;kate.vonwahlde@vumc.org",";hwangph@stanford.edu",";leo.zorronchengtaopu@austin.org.au",";giovanni.martinelli@irst.emr.it;giovanni.martinelli@irst.emr.it",null,";aleksander.holten@gmail.com;",null,";f.stephan@hml.fr;f.stephan@hml.fr",";Brittany.Sinclaire@HackensackMeridian.org;Brittany.Sinclaire@HackensackMeridian.org",";sheriefabdelsalam@yahoo.com",";;;;;cavendano@salud.madrid.org",";j-reynes@chu-montpellier.fr;j-reynes@chu-montpellier.fr",";m.lanzini@unich.it",null,null,";",";sudarshan@calcimedica.com",";;;;;;;;;;rasmus.bo.hasselbalch@regionh.dk","dagna.lorenzo@unisr.it",null,"jmoraled@um.es",";;;;;;m.botta@amsterdamumc.nl;m.botta@amsterdamumc.nl",";;massimo.costantini@ausl.re.it",";doctor.ashokchoudhury@gmail.com;doctor.ashokchoudhury@gmail.com","marc.blondon@hcuge.ch","william.poncin@uclouvain.be;william.poncin@uclouvain.be",";altamira@stanford.edu",";karine.lacombe2@aphp.fr;karine.lacombe2@aphp.fr",null,"s.bustacchini@inrca.it;a.cherubini@inrca.it","florentino.cardoso@hospitalcare.com.br","lishiyue@188.com;lishiyue@188.com","pruggenenti@asst-pg23.it","hakim.harkouk@aphp.fr",null,";efratishai@outlook.com",null,"lkp032@cuhk.edu.hk;lkp032@cuhk.edu.hk","information.center@astrazeneca.com",null,";r-martinezalejos@chu-montpellier.fr;r-martinezalejos@chu-montpellier.fr","regis.peffaultdelatour@aphp.fr",";cancerclinicaltrials@cumc.columbia.edu;cancerclinicaltrials@cumc.columbia.edu","drdon@neuroganicslabs.com;drdon@neuroganicslabs.com",";swindsor@saint-lukes.org;",null,null,"kushd@amarexcro.com",";t.waterfield@qub.ac.uk;t.waterfield@qub.ac.uk","mmar.garcia@scsalud.es","sunjg09@aliyun.com;sunjg09@aliyun.com","sanjay.p@cadilapharma.co.in;inderpgi@outlook.com",";;;;;sohaib-ashraf@outlook.com;sohaib-ashraf@outlook.com","tim.planche@nhs.net;tim.planche@nhs.net",";childhoodcancer@kkh.com.sg",";e-tuaillon@chu-montpellier.fr;e-tuaillon@chu-montpellier.fr","aliaehussein@gmail.com",";christoph.schmaderer@mri.tum.de;christoph.schmaderer@mri.tum.de",";thomas.reiter@meduniwien.ac.at",";hanih.hashmi@kfsh.med.sa",";",";thibault.duburcq@chru-lille.fr",null,null,";rux-covid19@cuanschutz.edu",null,";bk.E106@bukwang.co.kr",";faeq.husain-syed@innere.med.uni-giessen.de",null,"barbara.soria@quironsalud.es","jean-pascal.fournier@univ-nantes.fr;jean-pascal.fournier@univ-nantes.fr",";marie.warrer.petersen.01@regionh.dk","noriko.ammerman@cshs.org","bairbre.nimhaille@hse.ie",";blake.warner@nih.gov;prpl@cc.nih.gov",null,"jgarciadonas@gmail.com;jgarciadonas@gmail.com",null,null,"dr.rafaelsouza@ig.com.br;dr.rafaelsouza@ig.com.br",null,";gkostopan@med.uoa.gr",";c.bertholdt@chru-nancy.fr;c.bertholdt@chru-nancy.fr",null,";arnold@mcmaster.ca",";jshah@karyopharm.com","kamalia.sazali@obviohealth.com",";ada20@cumc.columbia.edu;ada20@cumc.columbia.edu",";Maureen.Cooney@beaumont.org;Maureen.Cooney@beaumont.org","Paul-Antoine.QUESNEL@chu-limoges.fr;Paul-Antoine.QUESNEL@chu-limoges.fr",null,null,"martin.rief@medunigraz.at;",null,"j-christophe.richard@chu-lyon.fr",null,";paul.wischmeyer@duke.edu;paul.wischmeyer@duke.edu","alfauchais@orange.fr",";dpascual@um.es",";medinfo@theravance.com;medinfo@theravance.com",null,";ivanhung@hku.hk;ivanhung@hku.hk",";pnori@montefiore.org;pnori@montefiore.org",";;sam.cammack@mountsinai.org;betsy.ellsworth@mountsinai.org",null,";rene-marc.flipo@chru-lille.fr",";sheriefabdelsalam@yahoo.com",";d.wolkersdorfer@agmt.at;",null,";rjan@medicine.bsd.uchicago.edu;rjan@medicine.bsd.uchicago.edu",";pierre.corbeau@chu-nimes.fr;drc@chu-nimes.fr",";;;;",";;;;;;;",null,null,null,";OsPsyCovid@gmail.com",";klin-pharmakologie@meduniwien.ac.at",null,";gery.lamblin@chu-lyon.fr",null,null,null,"lorenz.risch@risch.ch",null,"principle@phc.ox.ac.uk;principle@phc.ox.ac.uk","recoverytrial@ndph.ox.ac.uk",null,"julie.wright@one-mail.on.ca",null,"maxiongmd@163.com",null,";oahmed@humanigen.com",";sheriefabdelsalam@yahoo.com",";",";filip.krag.knop.01@regionh.dk","k.couper@warwick.ac.uk","huangmx5@mail.sysu.edu.cn","miaoxing126@126.com","elianonavarese@gmail.com;jwkubica@gmail.com",";nina.weis@regionh.dk","yangshenglan@126.com",";plh-tr.RD-Office@nhs.net",null,null,null,null,null,"naturestyle@163.com","Lilingru912@163.com","vern.arterial.disease@gmail.com;vern.arterial.disease@gmail.com","lv_cheng0816@163.com","paulkschan@cuhk.edu.hk","huanghefg@sjtu.edu.cn","frank.bosch@radboudumc.nl","g.elder@northumbria.ac.uk","jan.fehr@uzh.ch","shanclhappy@163.com","hcm200702@163.com","zhangyuanly@126.com","shenchuanan@126.com","DF.van.Wijk@nwz.nl","psy9992011@163.com","fyang@vip.163.com","aurelie.zindjirdjian@aphp.fr","764590955@qq.com","13533550083@163.com",null,"f.hooijberg@reade.nl","alienke.wijmenga@rivm.nl","marion.frenken@mmc.nl","chris.kclai@cuhk.edu.hk","j.m.weehuizen-2@umcutrecht.nl","jiactm@163.com",null,"jiactm@163.com","us@biomed.au.dk","thomas@interactivestudios.nl","j.g.vandenaardweg@amsterdamumc.nl","bcastro@histocell.com","aaldea@imim.es","jah.vanoers@etz.nl","hamza@hamzayousuf.nl","mireia.arcas@fjd.es","frank.bosch@radboudumc.nl","depotAC@chu-montpellier.fr","hj.bogaard@amsterdamumc.nl","m.j.dijkstra-tiekstra@umcg.nl","drci_promo@chu-lyon.fr","a.borobia@gmail.com","alberto.borobia@salud.madrid.org","dpidrci@chru-strasbourg.fr",null,"regulatory@medsir.org","justine.gonsard@chu-angers.fr","clara.menendez@isglobal.org","charlotte.kastberg.levin.01@regionh.dk","fernando.bermejo@salud.madrid.org","enrique.conde@efficeresearch.com","sonja.hoeller@apeiron-biologics.com","ccturegulatory@addenbrookes.nhs.uk","mariadelrosario.garcia@salud.madrid.org","fgarcia@clinic.cat","mireia.arcas@fjd.es","alberto.borobia@salud.madrid.org","mgarciamartin@iconcologia.net","d.smith.6@bham.ac.uk","andreas.barrattdue@gmail.com","Lola.serna@carm.es","v.awassi@ghu-paris.fr","insepsis@otenet.gr","gestioncientifica@incliva.es","w.w.puijk-2@umcutrecht.nl","hiruz.ctu@uzgent.be","s.schreiber@mucosa.de","johannes.hellmuth@med.uni-muenchen.de","claudia.denkinger@uni-heidelberg.de","prisca.bauer@uniklinik-freiburg.de","dirk.wilhelm@tum.de","christian.jassoy@medizin.uni-leipzig.de","dagmar.schaffler@pmu.ac.at","dilara.kersebaum@uksh.de","achim.lother@universitaets-herzzentrum.de","michael.hauptmann@mhb-fontane.de","gs@dgpm-online.org","venja.musche@uni-due.de","Hendrik.Streeck@ukbonn.de","getcalm.moveon@leuphana.de","armin.kalenka@kkh-bergstrasse.de","janne.vehreschild@uk-koeln.de","sujeet.jha@maxhealthcare.com","alexander.supady@universitaets-herzzentrum.de","behrens.georg@mh-hannover.de","znikniaz@hotmail.com","jan.neumann@performanord.bremen.de","alexander.baeuerle@uni-due.de","parastoomoradi40@yahoo.com","khalilih@tums.ac.ir","andrea.borho@uk-erlangen.de","jonas.herzberg@krankenhaus-reinbek.de","bahreinimaryam@gmail.com","sven.pulletz@med.uni-rostock.de","nheshmatifar@yahoo.com","khalilih@tums.ac.ir","physiozahid@gmail.com","ziaee@tums.ac.ir","jamshidi.ah@iums.ac.ir","anaesthesie@medizin.uni-leipzig.de","chickusalil@yahoo.com","afarsinejad@kmu.ac.ir","remesh.bhasi@asterhospital.com","varnitshanker@gmail.com","dr.saeed.meigooni@gmail.com","yogesh_dound@yahoo.com","dr.ansarin@gmail.com","pirjani@razi.tums.ac.ir","drnareshmamc@gmail.com","khalilih@tums.ac.ir","khalilih@tums.ac.ir","anjidani.n@orchipharmed.com","tavakoli.n@iums.ac.ir","lotfdavoodi@yahoo.com","h.poustchi@gmail.com","s.mobarak@abadanums.ac.ir","bahareh.baghchi@kums.ac.ir","hrkk1@uswr.ac.ir","hojjatpourfathi@yahoo.com","p-payandemehr@sina.tums.ac.ir","f_dastan@sbmu.ac.ir","dr.azimm@gmail.com","Lotfdavoodi@yahoo.com","en.aali@gmail.com","ghaffarys@tbzmed.ac.ir","mahdi_khozaei@yahoo.com","seiedalatifi@yahoo.com","h.abolghasemi.ha@gmail.com","s.mobarak@abadanums.ac.ir","dr.afazeli@gmail.com","ctc@tums.ac.ir","f_dastan@sbmu.ac.ir","farbod.chitsaz@gmail.com","s.mobarak@abadanums.ac.ir","a.ahmadi@kmu.ac.ir","ghaffarys@tbzmed.ac.ir","ghazaeianm@gmail.com","yousefim@mums.ac.ir","S.mobarak@abadanums.ac.ir","moghadami@sums.ac.ir","kourosh.sadeghi@gmail.com","mehrdadkarimi@yahoo.com","ali.zahedi@kmu.ac.ir","n_abdolahi2002@yahoo.com","dr.ansarin@gmail.com","Biganeh75@gmail.com","khodashahir@mums.ac.ir","are20935@gmail.com","h.abolghasemi.ha@gmail.com","dr.azimm@gmail.com","masi9932002@yahoo.com","dr.abbaspour1@yahoo.com","hosseinzadehh@mums.ac.ir","Bitarafans@gmail.com","bita.shahrami@gmail.com","alisaffaei.ss@gmail.com","karimig@mums.ac.ir","borujerdi.teb@gmail.com","a-sharifi@shahed.ac.ir","zhilayas@gmail.com","drhalehtajadini@gmail.com","rojarahimi@gmail.com","Hajebrahimis@gmail.com","modir7060@yahoo.com","rkhodarahmi@mbrc.ac.ir","mnamazi99@gmail.com","farhang.baba@yahoo.com","Dr.varnaseri@gmail.com","saadat350@gmail.com","h.fallah@acecr.ac.ir","h.vahidi@sbmu.ac.ir","dr.ansarin@gmail.com","s.matin@arums.ac.ir","h.poustchi@gmail.com","aepharm@gmail.com","arm.sad@gmail.com","moeininm@mums.ac.ir","m.zarrabi@rsct.ir","bahramiazam26@gmail.com","zhilayas@gmail.com","mitrearanjbar@yahoo.com","dr.najafi73@gmail.com","mohamadreza.rohani@yahoo.com","ardalan34@yahoo.com","iranshahim@mums.ac.ir","arostamian@tums.ac.ir","hosseinzadehh@mums.ac.ir","roozbeh@mazums.ac.ir","elyasis@mums.ac.ir","p_kokha@yahoo.com","alitaghizadieh@yahoo.com","emamia@mums.ac.ir","m.zarrabi@rsct.ir","Amir.salarian@gmail.c0m","mokaberi@sbmu.ac.ir","hosseinzadehh@mums.ac.ir","ghiasvand_62@yahoo.com","rami.boukhalil@usj.edu.lb","parisa_kianpour@yahoo.com","mesrimd@gmail.com","dr.m.ziaee@gmail.com","Dr.esekhavati@gmail.com","Dr.varnaseri@gmail.com","ali_sarrafzadeh@yahoo.com","halehmikaeili@gmail.com","seddighshamsim@mums.ac.ir","khamseh.m@iums.ac.ir","dr.nassar@aucegypt.edu","amikami@hosp.ncgm.go.jp","https://www.fujifilm.co.jp/form/fftc/ja/general/input.php?id=FFTCClinicalEn","mmm89099@gmail.com","mzangoue@yahoo.com","jduruonweni2203@hotmail.com","jterada@hosp.ncgm.go.jp","nakamurt@gunma-u.ac.jp","nakamurt@gunma-u.ac.jp","ireef@jichi.ac.jp","dvilanova@haoc.com.br","rniikura@triton.ocn.ne.jp","fzampieri@hcor.com.br","horitano@yokohama-cu.ac.jp","drnattachai@yahoo.com","haderazz05@ymail.com","nobuhitotaniki@keio.jp","kulgnotb@hotmail.com","suvimol.niy@mahidol.edu","cbernal495@gmail.com","horitano@yokohama-cu.ac.jp","enrique.casalino@aphp.fr","pedrosoufpa@gmail.com","zurina.cinza@cigb.edu.cu","patricia.garcia@upch.pe","enrique.casalino@aphp.fr","julio.alencar@hc.fm.usp.br","phaikyeong@tropmedres.ac"],["+86 13995577963","+86 13738498188","+86 13605708066","+86 64931902","+86 13397192695","+86 13574810968","+86 13995577963","+86 13817729859","020- 36052117;","86-18560086593","+86 371-65676568","+86 13605813177","+86 13756858523","+86 15018720816","+86 13923781386","86 28 85423680","+86 13861779030","+86 13530027001","+86 13601733045",";+86 10 66933436;+86 66933323",null,"+86 0714-6224162","+86 13819711719","+86 13476229575;+86 13476229575","+86 13517248539","+86 15337110926","+86 0714-6224162","+86 27 83662688","+86 13823078064","+86 13811611118","+86 15890689220","+86 13588867114","+86 13903076359","+86 13707114863","+86 18930810088","+86 13338628626","+86 15818136908","+86 18930810088","+86 13871120171","010-69155086",";+86 13605708066","+86 13817729859","+86 13738498188","+86 18917962300","+86 18134048843","+86 18963789002","+86 18908628577","+86 010-52176520","+86 010-64089801","+86 18980601566","+86 18062567610","+86 18995678520","+86 13505615645","+86 13922738892","+86 13507138234","+86 371 65676568","+86 13902020873","+86 371 66248624","+86 571 86613587","+86 010 84012510","+86 18980601415","+86 13995577963","+86 13906514781","+86 18928868242","+86 15000285942","+86 13601331063","+86 13307161995","+86 13377897297","+86 15388178461","+86 13312883618","+86 13903076359","+86 13505811696","+86 13681208998","+86 0510-68781007","+86 18664556429","+86 13707089183","+86 13910662116","+86 13136150848","+86 755 61238922","+86 13839708181","+86 18995678520","+86 18962567610","+86 13588189339","+86 18971387168/+86 15729577635","+86 13659897175","+86 028 87393881","+86 13902020873","+86 13163283819","+86 13902020873","+86 574-87089878","+86 010-64089801","+86 13881070630","+86 13518106758","+86 13588706900","+86 13397192695","+86 027-88041911-82237","+86 13867622009","+86 22 58830026","+86 21-37990333","+86 15827257012","+86 13688867618","+86 13607108938","+86 0411-62893509","+86 18328737998","+86 13934570253","+86 13971156723","+86 18980605819","+86 18234016125","+86 0571-87068001","+86 18602724678","+86 14786531725","+86 21 64370045","+86 0756 2528573","+86 0571-87236426","+86 13971301060","+86 13810339898","+86 18971035988","+86 13588189339","+86 02767812787","+86 13971605283","+86 18980880132","+86 13906503739","+86 13710801606","+86 13588189339","+86 13377897278","+86 18971317115","+86 13377897278","+86 13902020873","+86 020 34294311",";01 40 25 71 48;01 40 25 71 48",null,"+86 13319184133","+86 13707089009","+86 15972127819","+86 755 61238922","+86 13810765943","+86 18980880525","+86 13971358226","+86 13807887867","+86 13907191851","+86 027-83663078","+86 13507181312","+86 13844021812","+86 13902233092","13957111817","+86 15071096621","+86 18610329658",";18971387168;","+86 0756-3325892","+86 15526272595","+86 13807088660","+86 133 0451 2381","+86 13507117929","+86 18917683122","+86 13910768464","+86 18930810088","+86 13801257802","+86 13709206398","+86 13910930309","+86 15301655562","+86 021-51323092","+86 13950120518","+86 010-65125311","+86 18930568005","+86 13807312410","+86 18180609287","+86 02783663078","+86 13867622009","+86 13886157176","+86 13709206398","+86-21-64041990","+86 18560082787","+86 13820088121","+86 13671609764","+86 18602724981","+86 18062567610","+86 18600310121","+86 13607108938","+86 15071096621","+86 13901094780","+86 18602724981","+86 13950120518","+86 15205215685","+86 15002749377","+86 13907342350","+86 18621170011","+86 18980601817",";+86 13228683243;",";0577-55578166",";;;861059616308;",";+8618621170011?;","+86 13910768464","+86 15956927046","+86 13911798280","+86-13571892829;+86-029-84777631","021-37990333","+86 13995577963","+86 18098875933","+86 13699093647",";0577-55578166",";+8613760783281;+8613533978874","+86 13296508243","+86 010 66939107","+86 18971163518",";+8613760783281;+8613533978874","+86 13992856156","+86 13971679960",null,"+86 19890572216","+86 19890572216","+86 15037167775","+86 0578 2285102","+86 0731 88458187","+86 18672308659","8621-20256521;","+86;+1386061359","+86 13809508580","+86 13937642780","+86 13215510411","+86 13797625096","+86 13986394739","+86 13338628626","+86 13797625096","+86 13507117929","+86 13307173928","+86 15391532171","+86 15268118258","+86 18980601278","+86 18721335536","+86 13756858523","+86 18964630206","+86 010 62402842","+86 13508649926","+86 13303608899","+86 18186161668","+86 15052103816","+86 17723451376","+86 18930568010","+86 17723451376","+86 18121150282","+86 13576955700","+86 15960212649","+86 18672396028","+86 18917387623","+86 13845099775","+86 13920648942","+86 18602764053","+86 13678494357","+86 13856985045","+86 13911798280","+86 13707077997","+86 0791-88693401","+86 13933856908","+86 13507183749","+86 18017306677","+86 13507183749","+852 22528451","+86 19923204040","+86 18062586860","+86 18328737998","+86 023 61103649","+86 13756661209","+86 13883533808","+86 13883533808","123","+86 13608338064","+86 023-65481658","+86 15611908958","+86 13638352995","+86 13928459556","+86 15611908958","+86 15923859880","+86 13971086498","+86 18508160990",";+86-13911683832","+86 18980601541","+86 13886160811","+86 13880336152","+86 13866175691","+86 13605708066","+86 18980601655","+86 13971086498",";+86-21-64370045","+86 13605715886",";+86-01066823480;010-66947473","15391532171;","+86 13807312410","13938415502","+86 13757120681","+86 13971086498","+86 13901883868","+86 13801955367","+86 18502468189","+86 13627288300","+86 13986156712","+86 13922745788","+86 13806086169",null,";86-022-86343860","+86 17709877386","+86 13673665268","+86 13817525012","+86 13857715778","+86 13505319899","+86 15168887199","+86 18980601566","+86 13580315308","+86 18660117915","+86 0577 55579261","+86 18627770651","+86 18702745799","+86 13971679960","+86 13907191851","+86 0719 8801713","+86 027 83665506","+86 15626235237","+86 15071157405","+86 13901333060","+86 13808628560","+86 18980880132","+86 13911467356","+86 15391532171","+86 18980880132","+86 0731-88618338","+86 18930568129","+86 13372018676","+86 13910768464","+86 13911467356","+86 13710494278; +86 13622273918","+86 18930172033","+86 13803818341","+86 18980601525","+86 13971687403","+86 13871257728",null,null,"+86 027-83665506","+86 13911405123","13911318339","13507117929","+86 15937129400","+86 13951608346","+86 13971587381",";9053340010",null,null,"+86 13756858523",";+86-021-37990333;008602137990333","13507138234","+86 13505743664","+86 13975137399","+86 13902233925","+86 13872250922","+86 18971201115","+852 3505 3333","+86 13995789500","+86 13710658121","+86 13906514210","+86 13501722091","+86 18971163158","+86 15186660001","+86 15228218357","+86 13807172756","+86 027-83662684","+86 13161985564","+86 13971086498","+86 13277914596","+86 15186660001","+86 13545009416","+86 13517248539","+86 13607176908","+86 18917763257","+86 020-36591782","+86 13503735556","+86 15903715671","+86 027-83662391","+86 13971679960","+86 18672912727","+86 15972061080","+86 18121225835","+86 18986152706","+86 15888193663","+86 13871480868","+86 13995561816","+86 15102710366","+86 18695808321","+86 13857797188","+86 13886169836","+86 15706855886","+86 13607195518","+86 13907105212","+86 18827001384","+86 13971625289","+86 13797062903","+86 13580013426","+86 18823361933","+86 15377628125","+86 13507183749","+86 18601085226","+86 15833119392","+86 18627151212","+86 13971477320","+86 13788989286","+86 13832102657","+86 18017321696","+86 13886188018","+86 13978839646","+86 13816108686","+86 13601605100, 13301833859, 13701682806","+86 13699207252","+86 13995599373","+86 13953116564","+86 13953116564","+86 13985004689","+86 18804758989","+86 13621964604","+86 0571 87377780","+86 13953116564","+86 15927668408","+86 13953116564","+86 13995577963","+86 18980601215","+86 13580584031","+86 13953116564","+86 15071157405","+86 17723451376","+86 13953116564","+86 13953116564","+86 13871402927","+86 13828291023","+86 18085287828","+86 18995598097","+86 13760857996","+86 13908658127","+86 13574171102","+86 13801955367","+86 13971292838","+86 13621759762","+86 18121288279","+86 15907190882","+86 13570236595","+86 13908658127","+86 18922238906","+86 18971163518","+86 18263511977","+86 13668077090","+86 13816012151","+86 13911318339","+86 071 68494565","+86 13855288331","+86 13760661654","+86 15618795225","+86 0574-87085111","+86 13911005275","+86 15312019183","+86 13826041759","+86 13803535961","+86 13609068871","+86 13729856651","+86 18972161798","+86 15611963362","+86 13500296796","+86 15091544672","+86 13871257728","+86 020-83710825","+86 027 85726732","+86 15018720816","+86 071 68497225","+86 15018720816","+86 027-82433145","+86 071 68497225","+86 13910812309","+86 13910812309","+86 15287110369","+86 18922108136","+86 0451-53602290","+86 13585779708","+86 18604501911",";18986033792","+86 18978817899",";+8618672396028;",";0473754963;0473754963","82-2-3010-3114","+86 18902536585","+86 13907191851","+86 15091544672","+86 13437171877","+86 15208660008","+86 13607492399","+86 13674950311","+86 18995678520","+8613605880185","+86 13564684699","+86 15018720816","+86 15018720816","+86 15967196694","+86 15901203883","+86 13554361146","+86 13875985950","+86 13637403483","+86 13603035264","+86 13989370664","+86 13501078679","+86 13910930309","+86 13816033045","+86 18038860666",null,";+86(755)8672 5195;86-755-86725195","+86 13560158649","+86 13926931713","+86 18980606533","+86 13970038111","+86 15168887199","+86 025 83759418",null,"+86 15258871484","+86 13966906638","+86 0756 2528222","+86 15989096626","+86 13507117929","+86 13825498648","+86 13886009855","+86 027 67813096","+86 13533550083","+86 18007117616","+86 13554260702","+86 731-85295860","+86 13738498188","+86 13985004689","+86 025-52362054","+86 18180609256","+86 13910930309","+86 13397192089","+86 13926946929","+86 13808628586","+86 13906514210","+86 13871143176","+86 13873104819","+86 0791 86300047","+86 13761153836","+8613971521450;",null,"00334 13 73 23 47","+86 15874875763",null,"+8613971521450;","+86 18122317900","+86 13707089183","028-626-5500","+86 13918462035","13554361146;13554361146",null,"+8613971521450;","+8613971521450;","+81-562-93-9407",";+86(755)8672 5195;86-755-86725195","+8613517260864",null,";;","0332027181",null,";66013694;",null,null,"+962795337575;+962795337575",null,"+8613971521450;",";+1 (484) 995-5917;+86 2783662886",null,"13815857118;13951266803",";+86-13781919609;+86-13619842879",";;;;8610-64093207","13801844344;+86 21 52889999","+86 13716608331","+86 13706760666",null,";0033158414143;",";0736563473;073-6563473",";3289035621;","+86 027 85726727",";+86136673520046;","0817462202","+86 18986161976","+86 027 88041919-83920","+86 15192552255","+86 027 85726309","+86 13710874687","+86 15850531741","+86 022 27986625",";+393920039246;","+86 15192552255","+86 13972046539","+86 13986296106","+86 13971679960, 13387522645","+86 17717830223","+86 13600009221","+86 13578949866","+86 023-68485008","+86 18980605046","+86 17762551726","+86 13901374552","+86 13668023656","+86 13507191363","+86 13995569560","+86 18930132792","+86 13871143176","+86 18051061365","+86 15837117112","+86 18980025566","+86 15001111836","+86 18917763194","+86 13609219205","+86 13902233925","+86 13837167212","+86 13903076359","+86 17327006987","+86 18980025566",null,"+86 18655106697","+86 18980601556","+86 010-64089801","+86 023 68757780","+86 18222521385",";+9005320683378;+9005320683378","418-656-8711","+86 18980601618",null,"00318875 503 50",";+393408075607;+39 3408075607",";416-864-6060;",";+33 (0)4 72 07 15 60","+86 13488760399;+86 13488760399","+4970712982191","+86 13607108938","02380512800","+86 13554361146",null,";+0086-133113382093;01062835088","01 42 17 85 31;01 42 17 85 31","+390916662717;+390916662717",";;18560089129;+86 18560089129",";+36703751031",";+201221865587",";3486986287;+393356895168",";+972-50-2062140","+852 35053339;+852 35053555",";01865611400;01865 611 400","6465967386",null,";13668072999;13668072999",";;905-297-3479;","+39 0458122547",";","+66 2 203-6333","+31 (0) 88 755 5555;+31 (0)88 755 5555","+1 (201) 212-6643;",";415-244-1481;415-244-1481",null,";003216344275","+86 027 82308909","+86 13505581239",null,";;;;;;;07570911438;","+86 10 82805960","+86 13601262164","+86 18951762691","+86 18501664545","+86 13951839654","+86 13808454319",";212-305-9056","3339245656;3339245656","+86 18971327286","+86 13693058190","+44 1216272949","+86 13729834533","+86 13380600018","+86 13913994223","+86 13638670601","+86 010-66933332","+86 27 88041911","+86 18963980043","33182533368","+86 13971518978","+86 18610966092",null,"+86 19385219073","+86 13817091896","3021080725121374","+86 02783665518","+86 13585808910","0241353342","+86 13667241722",null,"+86 15608089909","+86 027-83665518","33(0)477120469","+86 18971327286","4538164157",null,";+86 186 2190 9313",";(086)0531-82166843",";844-734-6643","+31610738910","+390226436151",";(415) 754-9290;","18971905757;+86-18971905757",";+55 (11) 2151-1233","+16176437733",";+47 92616800;+47 92 61 68 00","+4767960000",null,";+39.0352673684;+39 035 2673683",null,";+45 2499 4962",";027-88999120;","603707920",";;0040744488580",";+39 035 4554 313","91 394 1544",";+49761270;",";00923219111681;00929929311100","+ 54 341 4450210",";+84 8 39237954","2027343400",";+32-9-3320228","13017617948",";;0040744488580","00306944699901",";+46812375212",null,"+31621197660",";248-898-0343;248-898-0343","+4790652904;+4790652904","0131 242 3867",";82-2-2019-3310",";;206-520-3833",";4039557740;4039557740","82-2-2626-3052","+442078822551",";+39 035 4535 313","+33 1 40 61 37 60",null,";+86-01064807858",";;;;;;;+390817464717;","05 57 82 11 50;05 57 82 11 50",";312-947-0065",null,";+57 321 233 9828;+57 318 3606458",null,";0320444495;0320445962",null,";6507234045",";0316328275;0316328275",";;0032(0)483141483",";;;+1-608-698-7334;",";28911869","+8613524348108","0034686754618;0034686754618",";",";07961949717",";01 56 01 65 74;01 56 01 65 74",null,";;;;;;;;;;;;;;;;+86-18588602600","48 71 784 00 34",null,null,";+33(0) 6 30 37 11 00",";805-200-7426",";514-340-8222",null,null,"+39 02 2643",null,";+57 321 233 9828;+57 318 3606458",";+5218112121946","+86 18163138632","+86 15171346752","18359186153",";+972-3-9241114",null,null,"+86 18930177147","+86 13797097676","+86 15549450300","+86-025-83759418","+86 18601406982","+86 18600819602","18917387623","+8613720162185","+86 15153169567","+86 13585808910","+86 13918307508","+86 13705161766","+86 18810882866","+86 13986268403","+86 13857281688","+86 13858825280","+86 13681410020","+86 13957152365","+86 13828895409","+86 028-85423248","+86 0551-62286223",null,"+33140 27 57 27","+3301 44 84 17 35","0049731150519","+4989414 1897897","+3293320500","+33057820334","0033140942554","33(0)477120286","+349133030007360","+33426 55 68 29",null,"302107480662",null,"33148036433","0034932602324","34935537636","34966616234","+34912948910",null,"+349322754001825","+448450230441","0034946182646","+34913368825",";;819-346-1110;819-346-1110",";858-452-2631",null,"+86-021-37990333",";02890976385;",null,null,null,"86-10-66933333;86-10-66933333",null,";919-859-1302;",";8610-84322200;8610-84322200",null,null,"+8613554361146","33142177240",null,"00863733029089;00863734402517","12062872061",";86-10-66933333",";6308496657","66818180890",";713-579-9226",";;",";04 72 11 07 20","301-619-6824",";1-833-445-3230 (GILEAD-0)",";1-833-445-3230 (GILEAD-0)","+16176437733;",";+16176437733;",";;612-624-4373",";+14842546134",";+390815903571",null,";6126249996",";13911405123","0034 934651072;",null,";;612-624-4373",";713-579-9226","+55 19 991232882;+55 19 991232882","3394685179",";33139638839",";;+55 11 99882-9343",";01222302352;01222302352",null,null,";;;;;;;54871700;+52 5532 590125",";336-716-2357;",";;;;;;;0047 46778374;+47 98209974","004528938168",";1-833-445-3230 (GILEAD-0)",";(202) 7516823",";;;;;;;;+52 55871700;+52 5532 590125",null,";410-614-6702",";888-662-6728",";919-684-3234",";;;;00390461283942","00390521904760","+2118118800",";;514-376-3330",";(415) 754-3749;415-754-3749",";+34606860027",null,"(902) 292-0132",null,"+49 30 300117;+49 (0) 30 - 3982031",";0045 38164157","00966548155983","3339245656;3339245656",";+46 8 697 20 00","02 53 48 27 06;0253482706",null,";800-633-1610",";+5511992383611",";01865 611424",";+390630154395;",";97235467159",";+33 1-48-96-44-08","+905324246838;+905324246838",";+613 93456366","241353872",";;603/286-0376;",";;(0)477120285",";612-626-8171",";01223 349707;07500792984",";+33 5 94 29 26 15;+33 5 94 29 26 15",";+49201723;+49201723",";6075476965;607-547-6711",";+55 11 991893404",";+34932275400",";1-541-601-9106",";+353 9 154 4331;+353 9 154 4331",";8015074606",";+33 1 40 25 68 63;+33 1 40 25 68 63",";+41795533396;+4179 553 4676",";;403-944-4241",";;+4930450517274;+49 30 450 517 285",";241682940;",";215-509-5690;215-509-5690",";+989121392982;+987153314026","942202520",";+32-9-3320228",";(604) 875-2778",";404-778-7200",";02071886765",";608774071",";;416-946-2000;",";7737021220;",";;(415) 514-1582;415-514-1582",";+49 89 4141 89 78","603707920","0039 0862 434742;0862434742",";",";07776 224520;07776 224520","984-234-0268;206-744-3402","516-663-8498;212-562-6561",";;;314-273-2240","(+33)241354725",";13911405123",";800-633-1610",";617 726-4777",null,";919-668-5590",null,"03211 33 76 51",";13911405123",";972-4-6494143","573-884-8728",";+33 4.26.55.68.29",";+34 649440850","0034 913303002;913303002",";0033492035510","(55)5246-5000",";8015074606",";805-200-7436",";;;(604) 428-7474",";",";9135886000;913-588-6000",";+49 621 5032944;0621 - 5032944",";+34 611 261 467","01923681001",";+41 31 631 56 98","4123203161;412-320-3161","90069276;",";;+90 (212) 866 37 00;+90(212) 866 37 00","18928868242;86-20-83062843",";+45 21707727;+45 21707727",";+8615858242516;+86 027 88041919","+902128663700;+902128663700",";91728966",";;732-235-7122",";919-668-0927;919-668-0927",";;732-235-7840",";;","01222302352;+201222302352",null,"148850404",null,"+44 (0) 20 8909 5847?",";+33241355865;33 (0)241355865",null,null,null,"43 1 865 65 77 128;",";;;+52 55 54870900",";41613241111",";;0320694540",";;;;+4526112290;+4526112290","(708) 620-4608",";04 67 33 66 43;467336643",";(267) 440-4237",";2059079743;205-907-9743",";;;;;;;;;33 (0)2 41 35 00 81","+33 01 45 21 35 39","617-724-3290;617-724-3290",";020445982","(212) 866 37 00 43144;",";818-618-5774;310-423-6152","19293011120;+972545882207",";+302107480662",null,"003211222107",null,";+49 3641;+49 3641",";+92 321 4090221",null,null,";07588550244","+33 5 55 05 86 26",";904-953-2000;904-953-2000",";0034 932607500;0034 932607500",";778-899-0607","215-573-6606","617-732-7063;617-732-7063",";+919910609000;+919582865898",null,"+8613387517458;+8613387517458",";507-255-4288",";+3289327171;+3289327171",null,null,";;313-574-2651;313-574-2651","+86-13871127473;+86-13871127473","15391532171",";480-583-0760",";+32 9 332 26 19;","+4970712982191",";773-270-2004;",";0033466683050;+33466683331",";5135584831;513-558-2187",";03052225117",";(240) 665-0697;240-665-0697",";612-626-8015",";720-777-6571;720-777-6571",";;020 7377 7000","415.287.2420",";;+49 221 478;+49221478",";(720) 507-9107",";+8610169152300;+8610169152300","673081143",";;00351915774975;0034609321966",";+49707129",";+52-722-276-5540",";240-767-6981","04 78 86 12 05",";142499995;142499995","+4535452819",";145213751","0033157022087",";;+44 207 958 8113",";985-768-8918","0142114211;0142114211",";8625-83759911;13476011311",";3052433636",";8012138735;801-213-8735",";03 20 44 67 97",";2123046205;",";(0)1 48 03 64 54;(0)1 48 03 64 54","(312) 695-0061","+905526830479",";+4970712982191;+4970712982191",";0156017500;0156017500",";+46736716335;08-524 824 46",";33 3 69 55 11 34;33 3 69 55 11 34","301-956-2536",";6357100",";+31107033510",null,null,"00201155019700","+55 92 99114 7633;+5592981519122",";412 716 0497",";+1 919 668 8977;919-668-8977","1 56 01 66 73;01 56 01 66 73","860-714-4402;860-714-4402",";+49 40 741035315;+49 40 741035315",";1 40 25 77 03;",";(314)362-6291",";336-70-COVID",";1-317-615-4559","813-282-8544",";;;;703-697-3255;703-697-3255",";;;;",null,"+55 92 99114 7633","5194886475",null,";;;;",";;+573007191994;+573012629694",";551-996-5828;551-996-5828",";22554694;22554649",";;;+34934302006",";0467337020;0467337020",";;+628129005599",";+525554870900;+52(55)5487-0900",";6177243836;",";(0)148036454;",";(713) 441-1450;713-441-1450",";;919-681-5006;919-681-5006",null,";+4917687607223",";;804-305-7187;","024772506;32 2 477 25 06",null,"+33492034011;",";+3225555265",null,";646-501-7890;",";;617-525-7612",";212-263-8365;",null,";(617) 358-2800",";+34937417700;+34937417700",";01146300000","215-503-4838;215-503-4838",";;;;;;;;0442335650;0442335650",";;+33 6 22 70 15 01",";5047023141;504-702-3141",null,";8618917387623;8618917387623","0240083152",";483162189",null,";410-550-2118","+92-42-35302701-14",null,";+36306640494",";808 354-3533;808-354-3533",";;4804716132;480-471-6132","3105638254;3105638254",";+905547378709;+905547378709","2.40.41.28.28;2.40.41.28.28",null,";;;+201147773440","+603-79492050;","1 56 09 50 41","1 56 01 66 73",";;615-322-0333",";650-725-6500",";03 9496 3688",";+39 0543 739100;",null,";+4799275784;",null,";33140948580;0140948580",";551-996-8073;551-996-8073",";+201147773440",";;;;;+34 91 191 64 79",";0033467337220;0033 4 67 33 72 20",";+393703005156",null,null,";",";816-838-7105",";;;;;;;;;;+4538686405","+39-02-26434683",null,"+34 968369532",";;;;;;+31-20-5664432;",";;+39 0522 295360",";01146300000;01146300000","+41.22.372.92.92","+3227642316;+320470592032",";650-721-5805",";+33 149283196;+33 149283196",null,"00390718004613;00390718003537","+55 19 991232882","86-20-83062885;86-20-83062885","0039 035 267","0033149095422",null,";972549212866",null,"85260996560;85260996560","1-877-240-9479",null,";677952556;","1 42 49 96 39",";212.342.5162;212-342-5162","7204313495;720-431-3495",";816-932-9858;816-932-5989",null,null,"301-956-2536",";07872990521;07872990521","942203333","023-68774490;","+912714221481;9101722748215",";;;;;+923334474523;+923334474523","02087252683;02087252683",";82487085",";467 338 469;467 338 469","+201222302352",";0049-89-4140;0049-89-4140",";+43140400",";00966564773377",";",";3 20 44 44 95",null,null,";?(720) 515-2868",null,";+82-2-828-8114",";+4964198542351",null,"0034 915 50 48 00","2.40.41.28.28;2.40.41.28.28",";+45 3545 7237","310-248-8186","353838624777",";(301) 496-4486;800-411-1222",null,"+34 666383649;+34 666383649",null,null,"+55 11 98383-3256;+55 11 98383-3256",null,";+30 210 5831000",";+3383344312;",null,";9055259140",";(617) 658-0600","4074320809",";212-305-0856;212-305-0856",";248-551-0099;248-551-0099","+33 (0) 555 056 613;+33 (0) 555 056 613",null,null,"(+43)0316-385;",null,"04 26 10 92 72",null,";919-681-6437;919-681-6437","0555051640",";968369500",";1-855-633-8479;1-855-633-8479",null,";22554049;22554049",";(718) 920-4622;718-920-4622",";;212-824-8931;212-824-8902",null,";0320445962",";00201147773440",";+43 662 6404411;",null,";734-972-7953;734-972-7953",";06.07.23.16.35;04.66.68.42.36",";;;;",";;;;;;;",null,null,null,";0320446926",";+4314040029810",null,";472 35 58 71",null,null,null,"+41 585233000",null,"+44 (0)800 138 0880;+44 (0)800 138 0880","-",null,"+1 (0)416 340 4800",null,"+86 13636354001",null,";201-509-0713",";00201147773440",";",";38674266","+442476151179","+86 15989778816","+86 13763810443","+48 885 101 728;",";+45 3862 3514","+86 13995641276",";+44 (0)1752 432842",null,null,null,null,null,"+86 18922103768","+86 13426096071","+44 (0)121 4143344;+44 (0)191 2336161","+86 010-64093264","+852 35053333","+86 021 64070434","+31243619880","+44 (0)191 227 3241","+41 44 634 46 79","+86 18616974986","+86 13584010516","+86 13828223316","+86 010 66848772","088-085-7589","+86 18600310183","+86 027 85726309","+33144841764","+86 13595248166","+86 13533550083","+4535453545","0202421633",null,"040-8888380","+852 55696828","0887555678","+86 0311 83855881","+31621137538","+86 0311-83855881","+4560202613","0031650617047","020-5669111","0034946567900","+34933160490","0132213808","00 31 20 444 22 44","+00349155048003214","+31243619880","00330608492834","+31020 444 1896","+31 50 3610468","472406829+33","+34912071466","34912071466","0033388115266","0034934893000","34932214135","0241356329",null,"+4538622941","34916006000","+34912948910",null,"01223348158","0034915202473","+349322754002884","0034915 50 48 003214","34912071466","0034932607331",null,"+4723071916","34968359763","33145657401","+302107480662","0034961973536","+31(0)8875 55196","+3293320500","0431 500-22201","+49 89 4400 0","+49 6221 56-36637","0761 270-68050","+498941405036","0341 9714314","+43-662-2420","043150023911","0761-27073791","+493391 39-14580","036413116475","0201 438755 227","022828715522","+49 4131.677-2378","06252701217","+49 221 478-88794","9910609000","0761/270-73790","0511 532 5337","+98 41 3335 1688","0421-361-6743","0201 7227-323","+98 61 3373 8283","+98 21 6695 4715","09131-8544321","00494072803300","+98 21 6312 1413","+49 (0)381 494-2529","+98 51 4401 1000","+98 21 6695 4715","8801670962775","+98 21 6692 0981","+98 21 5563 9666","+49 341 97 17700","8197751281","+98 34 3132 5374","9447010634",null,"+98 21 4414 4939","91-9769057549","+98 41 3335 2898","+98 21 7788 3288","9953946064","0098216654715","+98 21 6695 4715","009843473000","+98 21 6653 9260","+98 11 3336 1700","+98 21 8241 5000","+98 61 5338 4004","+98 83 3427 4618","+98 21 2218 0138","+98 41 3336 4672","+98 21 6312 1413","+98 21 2610 9490","+98 34 3211 0860","+98 11 4221 8231","+98 28 3333 6001","+98 33266042","+98 31 3267 3139","+98 86 3417 3601","+98 21 81261","+98 61 5326 7800","+98 21 6647 5335","+98 21 8896 3546","+98 21 8820 0118","+98 21 8413 0001","+98 61 5338 4004","+98 34 3132 5700","+41 33365010","+98 11 3334 3011","0091 51 38848930","+98 61 5326 7800","+98 71 3230 5410","+98 21 8889 6696","+98 21 8897 6527","+98 34 3132 5856","+98 17 3225 1910","+98 41 3335 2898","+98 31 5472 3386","+98 51 385022406","+98 23 3345 1336","+98 21 8126 3799","+98 34 3211 0860","+98 11 3219 7667","+98 11 4203 1035","+98 51 3180 1193","+98 21 6694 8899","+98 21 2244 5566","+98 21 5541 9005","+98 51 3180 1191","+98 25 3612 2058","+98 21 8755 5250","+98 21 6670 6142","+98 34 3243 5539","+98 21 8899 0835","+98 41 3334 2219","+98 45 3142 2529","+98 83 3426 6780","+98 51 5222 6013","+98 11 4221 8231","+98 61 3333 7446","+98 21 8860 0067","+98 26 3476 4010","+98 21 8820 0118","+98 41 3335 2898","+98 45 3325 1410","+98 21 8241 5204","+98 21 6435 2564","+98 41 3335 7311","+98 51 3801 2742","+98 21 2233 9940","+98 25 3770 6470","+98 21 6670 6142","+98 21 8214 1201","+98 21 8216 2440","+98 86 3368 4615","+98 41 3336 9331","+98 51 3180 1256","+98 21 6119 2756","+98 51 3180 1193","+98 11 3388 4579","+98 51 3180 1588","+98 23 3345 1336","+98 41 1335 2078","+98 51 3180 1267","+98 21 2233 9940","+98 21 8609 6356","+98 21 8877 3521","+98 51 3180 1193","009861192811","01615300","+98 21 6695 4709","+98 86 4222 4414","+98 56 3238 1200","+98 21 5517 6810","+98 61 3333 7446","+98 13 3324 7683","+98 41 3329 6024","+98 51 3859 8818","+98 21 8894 5171","+201000037609","+81-3-3202-7181",null,"+98 11 3336 1700","+98 56 3239 5000","+2348037212638","+81-3-3202-7181","+81-27-220-8740","+81-27-220-8740","0285-58-7348","11 3549-0729","0338155411","+551130536611","0457872800","0818361891","+2348099355417","+81-3-3353-1211","0846434747","66824542896","+34627382889","0457872800","33140257761","+5591982893370","+53-72085887, 72087465","991886872","33140257761","+55-11-943960027","66 2 203 6333"],["Emergency Department of Zhongnan Hospital of Wuhan University","HwaMei Hospital, University of Chinese Academy of Sciences","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","Children's Hospital of Fudan University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)",null,"Emergency Department of Zhongnan hospital of Wuhan University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine",null,null,"He'nan University of Chinese Medicine","Zhejiang Provincial People's Hospital","Affiliated Hospital of Changchun University of traditional Chinese Medicine",null,"Shenzhen Second People's Hospital","West China Hospital, Sichuan University","Wuxi People's Hospital","Pulmonary Diseases Department, Shenzhen Third People's Hospital","Shuguang Hospital Affiliated to Shanghai University of TCM.","302 Military Hospital;",null,"Huangshi Hospital of Traditional Chinese Medicine","The First Affiliated of Wenzhou Medical University",null,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Pulmonary Hospital","Huangshi Hospital of Traditional Chinese Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Fifth Affiliated Hospital Sun Yat-Sen University","Beijing You'an Hospital, Capital Medical University","The First Affiliated Hospital of Zhengzhou University","The First Affiliated Hospital of Zhejiang University School of Medicine","Guangdong Provincial Hospital of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Public Health Clinical Center","Nanjing Second Hospital","Guangdong Provincial Hospital of Chinese Medicine","Shanghai Public Health Clinical Center","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)",null,"First Affiliated Hospital of Zhejiang University;","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","HwaMei Hospital, University of Chinese Academy of Sciences","Shanghai Pulmonary Hospital","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Hubei Provincial Hospital of TCM","Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital","China Academy of Chinese Medical Sciences","Department of Critical Care Medicine, West China Hospital of Sichuan University","Renmin Hospital of Wuhan University","Xiangyang 1st People's Hospital","The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","Sun Yat sen Memorial Hospital of Sun Yat sen University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of He'nan University of Chinese Medicine","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine","The First Hospital of He'nan University of Chinese Medicine","Zhejiang Chinese Medical University","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","West China Hospital, Sichuan University","Zhongnan Hospital of Wuhan University","Zhejiang Chinese Medical University","The First Affiliated Hospital of Guangzhou Medical University","Hu'nan Yuanpin Cell Biotechnology Co., Ltd","Zhejiang Chinese Medical University","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","West China Hospital, Sichuan University","Department of Psychology, the Fifth Affiliated Hospital Sun Yat-Sen University","Guangdong Provincial Hospital of Chinese Medicine","The First Affiliated Hospital of Zhejiang University School of Medicine","The 5th Medical Center Chinese PLA General Hospital","Jiangsu Institute of Parasitic Diseases","Shenzhen national medicine inheritance medical research institute co. LTD","The First Affiliated Hospital of Nanchang University","Hubei Provincial Hospital of TCM","The First Affiliated Hospital of Medical College of Zhejiang University","The Third People's Hospital of Shenzhen","People's Hospital of Guangshan County","Xiangyang First People's Hospital","Renmin Hospital of Wuhan University","The First Hospital Affiliated to Zhejiang University's Medical School","Zhongnan Hospital of Wuhan University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital","Hubei integrated hospital of traditional Chinese and Western Medicine","Wuhan 1st Hospital","Tianjin University of Traditional Chinese Medicine","Ningbo First Hospital","China Academy of Chinese Medical Sciences","Deyang integrative medicine hospital","Department of Critical Care Medicine, West China Hospital of Sichuan University","Sir Run Run Show Hospital, School of Medicine, Zhejiang University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Renmin Hospital of Wuhan University","Enze Hospital of Taizhou Enze Medical Center (Group)","Haihe hospital, Tianjin University","Jiangxi Qingfeng Pharmaceutical Co., Ltd.","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Afflicated Hospital of Guangzhou University of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Zhongshan Hospital of Dalian University","West China Hospital, Sichuan University","The Second Hospital of Shanxi Medical University","Zhongnan Hospital of Wuhan University","West China Hospital, Sichuan University","The First Hospital of Shanxi Medical University","The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First People's Hospital of Huaihua","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital, College of Medicine, Zhejiang University","Department of Cardiovascular Medicine, Tongji Hospital","Peking University Third Hospital","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Zhejiang University School of Medicine","Zhongnan Hospital of Wuhan University","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Hospital of Chengdu University of Traditional Chinese Medicine","Tongde Hospital of Zhejiang Province","The First Affiliated Hospital of Guangzhou Medical University","The First Affiliated Hospital, Zhejiang University School of Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine","The First Affiliated Hospital of Guangzhou Medical University","Institut National de la Sant Et de la Recherche Mdicale, France;",null,"Xi'an Chest Hospital","The First Affiliated Hospital of Nanchang University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shenzhen the 3rd People's Hospital","Peking University First Hospital","Chengdu University of Traditional Chinese Medicine","Renmin Hospital of Wuhan University","Department of respiratory medicine, the First Affiliated Hospital of Guangxi Medical University","First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)","Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital of Guangzhou Medical University","The First Affiliated Hospital of Zhejiang University School of Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing China","Wuhan University;","Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital","The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China","Nanchang Ninth Hospital","Heilongjiang Province hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Shanghai 10th People's Hospital, Tongji University","Hospital of Chengdu University of Traditional Chinese Medicine","Shanghai Public Health Clinical Center","Chinese PLA General Hospital","The Second Affiliated Hospital of Xi'an Jiaotong University","Beijing Chaoyang Hospital, Capital Medical University","Shanghai General hospital of Shanghai Jiaotong University","Faculty of Rehabilitation Medicine, Shanghai University of Chinese Medicine","Zhongshan Hospital Affiliated to Xiamen University","institute of basic medicine, Chinese Academy of medical sciences","Tuina Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","West China Second Hospital, Sichuan University, Chengdu, China","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Enze Hospital of Taizhou Enze Medical Center (Group)","Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology","the Second Affiliated hospital of Xi'an Jiaotong University","Zhongshan Hospital, Fudan University","Qilu Hospital of Shandong University","Tianjin Huanhu Hospital","Shanghai Changzheng Hospital","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Renmin Hospital of Wuhan University","The Sixth Medical Center of PLA General Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","The First hospital of Peking University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Zhongshan Hospital Affiliated to Xiamen University","Affiliated Hospital of Xuzhou Medical University","Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Second Hospital of University of South China, Hengyang","Zhongshan Hospital Fudan University","West China Hospital, Sichuan University","Beijing Tsinghua Changgung Hospital;","First Affiliated Hospital of Wenzhou Medical University;","Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;","Shanghai Respiratory Research Institution;","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Chinese PLA General Hospital",null,null,"Zhongnan Hospital of Wuhan University","Institute of Integrative Medicine of Dalian Medical University","Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital","First Affiliated Hospital of Wenzhou Medical University;","Third Affiliated Hospital of Sun Yat-sen University;","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine","Hubei Hospital of Traditional Chinese Medicine","Third Affiliated Hospital of Sun Yat-sen University;","the Second Affiliated hospital of Xi'an Jiaotong University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",null,"The First Affiliated Hospital of Fujian Medical University","The First Affiliated Hospital of Fujian Medical University","He'nan Provincial People's Hospital","Lishui Central Hospital","Hu'nan University of Chinese Medicine","Hubei Provincial Hospital of TCM",null,null,"The First Affiliated Hospital of Fujian Medical University","Xinyang Central Hospital","The Second Affiliated hospital of Anhui Medical University","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Nanjing Second Hospital","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Hubei Provincial Hospital of TCM","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","The Fourth Affiliated Hospital of Zhejiang University School of Medicine","West China Hospital of Sichuan University","Tongji Hospital of Tongji University","Affiliated Hospital of Changchun University of traditional Chinese Medicine","Shanghai Public Health Clinical Center","Beijing Geriatric Hospital","Xianning Central Hospital","The First Affiliated Hospital of Harbin Medical University","Department of critical care, Zhongnan Hospital of Wuhan University","Wuxi Fifth People's Hospital","Ganzi Hospital of West China Hospital, Sichuan University","Shanghai University of Traditional Chinese Medicine","Ganzi Hospital of West China Hospital, Sichuan University","Shanghai Public Health Clinical Center","The First Affiliated Hospital of Nanchang University","Xiamen University","Central South Hospital, Wuhan University","Shanghai Changzheng Hospital","The Fourth Affiliated Hospital of Harbin Medical University","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Puren Hospital of Wuhan City","The Thirteenth People's Hospital of Chongqing","First Affiliated Hospital of Anhui Medical University","Chinese PLA General Hospital","Fifth People's Hospital of Ganzhou","The First Affiliated Hospital of Nanchang University","The Fourth Hospital of Hebei Medical University","Institutional Review Board, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","Tongji Hospital affiliated to Tongji Medical College of HUST","JC School Of Public Health And Primary Care, The Chinese University Of Hong Kong","Chongqing Three Gorges Central Hospital","Renmin Hospital of Wuhan University","West China Hospital, Sichuan University","Chongqing Dianjiang County People's Hospital","The First Hospital of Jilin University","The First Affiliated Hospital of Chongqing Medical University","The First Affiliated Hospital of Chongqing Medical University","Cancelled","The Second Affiliated Hospital of Chongqing Medical University","Chongqing Public Health Medical Center","Peking University Third Hospital","Chongqing Public Health Medical Center","Chongqing Medical University","Peking University Third Hospital","Three Gorges Central Hospital","Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Mianyang Central Hospital","Beijing YouAn Hospital;","Department of Anesthesiology, West China School of Medicine, Sichuan University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","Anhui Cancer Hospital","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","West China Hospital, Sichuan University","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","Ruijin Hospital, Medical School of Shanghai Jiaotong University Shanghai, China;","The First Affiliated Hospital, College of Medicine of Zhejiang University","The Fifth Medical Center of Chinese PLA General Hospital;",null,"The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","The First Affiliated Hospital of HeNan University of CM","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","Eergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Huo-Shen-Shan Hospital","The Third Affiliated Hospital of the Second Military Medical University","Shenyang Sixth People's Hospital","Zhongnan Hospital of Wuhan University","Central Theater General Hospital of PLA","Maoming People's Hospital","Xiamen Medical College",null,"Tasly Pharmaceutical Group Co., Ltd.;","Dalian Medical University","The First Affiliated Hospital of Zhengzhou University","Shuguang Hospital Affiliated to Shanghai University of T.C.M.","the Second Affiliated Hospital of Wenzhou Medical University","Affiliated Hospital of Shandong University of Traditional Chinese Medicine","Department of Respiratory Medicine, Shandong Provincial Hospital","West China Hospital, Sichuan University","The First Affiliated Hospital of Guangzhou University of TCM","Shandong Provincial Hospital","The First Affiliated Hospital of Wenzhou Medical University","Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Fourth Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","First People's Hospital of Jiangxi District","Shiyan Taihe hospital","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Third Affiliated Hospital of Sun Yat-sen University","Emergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Peking University First Hospital","Renmin Hospital of Wuhan University","Hospital of Chengdu University of Traditional Chinese Medicine","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Hospital of Chengdu University of Traditional Chinese Medicine","The Third Xiangya Hospital, Central South University","Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Hospital of Chengdu University of Traditional Chinese Medicine","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","The First Affiliated Hospital of Guangzhou Medical University","Shanghai Sixth People's Hospital","Zhengzhou People's Hospital","West China Hospital, Sichuan University","Zhongnan Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Fujian Provincial Hospital",null,"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University First Hospital","China-Japan friendship hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Zhengzhou People's Hospital","Jinling Hospital, Medical School of Nanjing University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","McMaster University;",null,null,"Affiliated Hospital of Changchun University of Traditional Chinese Medicine","Shanghai Public Health Clinical Center;",null,"HwaMei Hospital, University of Chinese Academy of Sciences","The First Hospital of Changsha","The First Affiliated Hospital of the Guangzhou Medical University","Jingzhou Mental Health Center","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Chinese University of Hong Kong","Xiangyang 1st People's Hospital","State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University","The First Affiliated Hospital, College of Medicine,Zhejiang University","Shanghai Ninth People's Hospital","Wuhan Third Hospital","The Third Affiliated Hospital of Zunyi Medical University","Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University","Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Tongji Hospital, Huazhong University of Science and Technology","Beijing Anzhen Hospital, Capital Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Department of Breast Surgery, Hubei Cancer Hospital","The Third Affiliated Hospital of Zunyi Medical University","Wuhan University Central South Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","the First Affiliated Hospital, Guangzhou University of Chinese Medicine","the First Affiliated Hospital of Xinxiang Medical University","Zhengzhou people's hospital","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital","Union hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongren Hospital, Shanghai Jiao Tong University School of Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Ningbo First Hospital","Wuhan Third Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)","Eergency / Intensive Care Department of Tongji Hospital","The First Affiliated Hospital, He'nan Traditional Chinese Medicine University","WenZhou Medical University","Tongji hospital, Tongji medical College, Huazhong University of Science and Technology","Hwa Mei Hospital, University of Chinese Academy of Sciences","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)","Wuhan third hospital","Eergency / Intensive Care Department of Tongji Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Maoming People's Hospital","Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science &amp; Technology Medical Center","Wuhan 3rd Hospital","Tongji Hospital, Tongji Medical College of HUST","Shenzhen Hospital of Southern Medical University","The Second Hospital of Hebei Medical University","The Third Hospital of Wuhan","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Third Affiliated Hospital of Zunyi Medical University","Cangzhou People's Hospital","Shanghai Fifth People's Hospital, Fudan University","Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The People's Hospital of Guangxi Zhuang Autonomous Region","Huashan Hospital Fudan University","Shanghai Changzheng Hospital","Xiyuan Hospital of China Academy of Chinese Medical Sciences","Zhongnan Hospital of Wuhan University","Shandong Provincial Chest Hospital","Shandong Provincial Chest Hospital","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Affilated Hospital of Inner Mongolia University for the Nationalities","Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","Zhejiang Hospital","Shandong Provincial Chest Hospital","Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shandong Provincial Chest hospital","Zhongnan Hospital of Wuhan University","West China Hospital, Sichuan University","The Third Affiliated Hospital of Sun Yat-sen University","Shandong Provincial Chest Hospital","Department of Emergency, Tongji Hospital","Ganzi Hospital of West China Hospital, Sichuan University","Shandong Provincial Chest hospital","Shandong Provincial Chest hospital","Huazhong University of Science and Technology","Affiliated Hospital of Guangdong Medical University","Affiliated Hospital of Zunyi Medical University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","The Third People's Hospital of Shenzhen","Hubei Provincial Hospital of TCM","Xiangya Hospital of Central South University","The Third Affiliated Hospital of the Second Military Medical University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Shanghai First People's Hospital","Shanghai General Hospital","Department of Nephrology, Wuhan Children's Hospital","The Sixth Affiliated Hospital of Sun Yat-sen University","Hubei Provincial Hospital of TCM","Guangzhou Panyu central hospital","Hubei Hospital of Traditional Chinese Medicine","Liaocheng People's Hospital","Yongchuan Hospital, Chongqing Medical University","The Second Affiliated Hospital of Xi'an Medical University","China-Japan Friendship Hospital","Jingzhou First People's Hospital","The First Affiliated Hospital of Bengbu Medical College","The First Affiliated Hospital of Guangzhou University of Chinese Medicine","Luohu hospital group medical center of Shenzhen University","Ningbo First Hospital, Ningbo Hospital of Zhejiang University","Peking University People's Hospital","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Central Hospital of Panyu District, Guangzhou City","The First Affiliated Hospital of Nanchang University","The First Affiliated Hospital of Guangzhou Medical University","Guangzhou reborn health management consultation co., LTD","Jingzhou First People's Hospital","Peking University Third Hospital","The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)","The Second Affiliated Hospital of Xi'an Jiaotong University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangzhou Eighth People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangzhou reborn health management consultation co., LTD","Jingzhou Central Hospital","Guangzhou reborn health management consultation co., LTD","Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Jingzhou Central Hospital","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Wuhan Asia General Hospital","The Second Clinical College of Guangzhou University of Chinese Medicine","The First Hospital of Harbin Medical University","Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","Harbin Peiyou Jiandi Biotechnology Co., Ltd","Research office of wuhan renmin university;","The People's Hospital of GuangXi Zhuang Autonomous Region","Wuhan University;","University Hospital, Clermont-Ferrand;",null,"The Fifth Affiliated Hospital of Sun Yat-Sen University","First people's hospital of Jiangxi district, Wuhan","The Second Affiliated Hospital of Xi'an Jiaotong University","Union Hospital West Campus, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Hospital of Zunyi Medical University","The Third Xiangya Hospital of Central South University","Zhengzhou People's Hospital","Xiangyang 1st People's Hospital","Ningbo Kangning Hospital","Department of Respiratory Medicine, Changzheng Hospital, Naval Military Medical University","Guangzhou reborn health management consultation co., LTD","Guangzhou reborn health management consultation co., LTD","Mental Health Service Center, Beijing Normal University","Nursing Department of Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hu'nan Cancer Hospital","Hu'nan Provincial People's Hospital, Hu'nan Normal University","Shenzhen Third People's Hospital","HwaMei Hospital, University of Chinese Academy of Sciences","PLA General Hospital","Beijing Chaoyang Hospital","Department of Respiratory Medicine, Changzheng Hospital, Naval Military Medical University","Department of Infectious Diseases, Foshan First People's Hospital",null,"Shenzhen Geno-Immune Medical Institute;","The First Affiliated Hospital of Guangzhou Medical University","The Fifth Hospital Affiliated to Sun Yat-sen University","West China Hospital of Sichuan University","The First Affiliated Hospital of Nanchang University","Shandong Provincial Hospital","Jiangsu Provincial Center for Disease Control and Prevention","Renmin Hospital of Wuhan University","Hwa Mei Hospital, University of Chinese Academy of Sciences","Department of Infectious Diseases, Anqing Municipal Hospital","The Fifth Affiliated Hospital of Sun Yat-sen University","Guangzhou Eighth People's Hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","HuiZhou Municipal Central Hospital","Renmin Hospital of Wuhan University","Zhongnan Hospital of Wuhan University","Guangzhou Eighth People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Third Hospital","The 2nd Xiangya Hospital of CSU","HwaMei Hospital, University of Chinese Academy of Sciences","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","West China Second University Hospital, Sichuan University","Beijing Chao-yang Hospital, Capital Medical University","Central Theater General Hospital of PLA","The Fifth Affiliated Hospital of Sun Yat-Sen University","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Medical College of Zhejiang University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Second Xiangya Hospital of Cental South University","The Second Affiliated Hospital of Nanchang University","Shanghai Kongjiang Hospital",null,"The 2nd Affiliated Hospital of Wenzhou Medical University","Fondation Mditerrane Infection (FMI) - IHU Mditerrane Infection","Intensive Care Unit, XiangYa Hospital, Central South University","The Second Hospital of Nanjing Medical University",null,"Guangzhou Eighth People's Hospital","The First Affiliated Hospital of Nanchang University","Saiseikai Utsunomiya Hospital Department of emergency medicine and intensive care unit","Ruijin Hospital, Shanghai Jiaotong University School of Medicine",null,"The First Affiliated Hospital of Guangzhou Medical University",null,null,"Fujita Health University Hospital","Shenzhen Geno-Immune Medical Institute;",null,null,"Jingzhou Hospital of Traditional Chinese Medicine;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine","National Center for Global Health and Medicine Center for Clinical Sciences",null,"Yale-NUS College;",null,null,null,null,null,"Tongji Hospital;",null,null,"Henan Provincial People's Hospital;","Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine;China Academy of Chinese Medical Sciences;",null,null,"Taizhou Hospital of Zhejiang Province",null,"Clinical Investigations Center;","Uppsala University Hospital;","IRCCS Neuromed;","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Xiangya Hospital;",null,"Maternal and Child Health Hospital of Hubei Province","Center for Regenerative Medicine, Renmin Hospital of Wuhan University","Shandong Eye Institute","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangdong Second Provincial General Hospital","Nanjing University Medical College Affiliated Drum Tower Hospital","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Medical director of UCCP CATANZARO, Italy;","Shandong Eye Institute","Yichang Central People's Hospital","Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology",null,"China European International Business School (CEIBS)","Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-sen University","China-Japan Union hospital of Jilin University","Department of Public Health and Management, Chongqing Medical University","West China Hospital, Sichuan University","Renmin Hospital of Wuhan University","Beijing You'an Hospital, Capital Medical University","School of Public Health and Management, Chongqing Medical University","Wuhan Third Hospital &amp; Tongren Hospital of Wuhan University","Department of anesthesiology, Renmin Hospital of Wuhan University","The First Rehabilitation Hospital of Shanghai","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Nothern Jiangsu People's Hospital","Zhengzhou People's Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine","the First Affiliated Hospital of Guangzhou Medical University","People's hospital of Zhengzhou","Guangdong Provincial Hospital of Chinese Medicine","Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine","Hospital of Chengdu University of Traditional Chinese Medicine","Sanofi-aventis France","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","West China Hospital, Sichuan University","China Academy of Chinese Medical Sciences","Daping Hospital, Army Medical University","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Istanbul University-Cerrahpasa;",null,"West China Hospital, Sichuan University","UZ Leuven","University Medical Center Utrecht","Hospital of Prato, Italy;","St. Michael's Hospital, Toronto;","Hospices Civils de Lyon;",null,"Universittsklinikum Tbingen","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Synairgen Research Ltd","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Foundation IRCCS San Matteo Hospital","Xiyuan Hospital of China Academy of Chinese Medical Sciences;",null,null,"Qilu Hospital of Shandong University, Karolinska Institutet;Qilu Hospital of Shandong University;","Insitute for Translational Medicine, University of Pcs, HU;","Misr University for Science and Technology","University of Trieste;","Rambam MC;",null,"University of Oxford;",null,null,"Chongqing Public Health Center;","Population Health Research Institute;Population Health Research Institute;",null,"Fourth Military Medical University;Massachusetts General Hospital",null,null,null,"Rad-AID;",null,"UZ Leuven;","Wuhan Women and Children's Health Care Center","2nd People's Hospital of Fuyang City",null,"BHC &amp; UCL;RFH &amp; UCL;BHC &amp; UCL;BHC &amp; QMUL;UCL;BHC &amp; QMUL;Barts Heart Center;","Peking University Sixth Hospital","Peking Union Medical College Hospital","Huangshi Hospital of Traditional Chinese Medicine","Shanghai Sixth People's Hospital","Eastern theater General Hospital","Department of Integrated Traditional Chinese &amp; Western Medicine, Xiangya Hospital, Central South University","Columbia University Irving Medical Center;",null,"The First People's Hospital of Jiangxia District, Wuhan","Peking University First Hospital",null,"Guangzhou Eighth People's Hospital","The Fifth Affiliated Hospital of Sun Yat-Sen University","Nanjing University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Fifth Medical Center of PLA General Hospital","Wuhan University Renmin Hospital","Wuhan Asia General Hospital","INSERM","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University Third Hospital","F. Hoffmann-La Roche Ltd","Affiliated Hospital of Zunyi Medical University","Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories SA","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Oriental Hospital","CHU Angers","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University",null,"Affiliated Hospital of Southwest Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","URCIP- CHU Saint Etienne","the First People's Hospital of Jiangxia District","The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark","Professor","Ansun Biopharma, Inc.;","Qilu Hospital of Shandong University;","Regeneron Pharmaceuticals;","Amsterdam UMC",null,"xCures;",null,"Hospital Israelita Albert Einstein;",null,"Akerhus University Hospital;","Akershus University Hospital",null,"ASST PAPA GIOVANNI XXIII;",null,"Head of Department;","Renmin Hospital of Wuhan University;",null,"University of Medicine and Pharmacy \"Gr. T. Popa\" Iasi, Romania;Medical Sciences Academy from Romania;","Istituto di Ricerche Farmacologiche Mario Negri IRCCS;",null,"University Clinic Freiburg;","Khyber Medical University Peshawer;",null,"University of Oxford, UK;",null,"University Hospital, Ghent;",null,"University of Medicine and Pharmacy Gr T Popa - Iasi;University of Medicine and Pharmacy Gr T Popa - Iasi;",null,"Karolinska University Hospital (and karolinska Insitutet);",null,null,"William Beaumont Hospitals;",null,null,"Gangnam Severance Hospital;","University of Washington;NYU Langone Health;","University of Calgary;",null,null,"Istituto di Ricerche Farmacologiche Mario Negri IRCCS;",null,null,"Institute of zoology, Chinese Academy of Sciences;","Federico II University;Inversity of Milan, BICOCCA;Universit degli Studi di Brescia;University of Bologna;University of L'Aquila;Univerity of Rome \"La Sapienza\";University of Udine;",null,"Rush University Medical Center;","Global Alliance Regenerative Medicine","Universidad del Rosario;",null,"University Hospital, Lille;","Vice-Chancellor for Research, Mazandaran University of Medical Sciences","Professor (Medicine -Infectious Diseases);","University Hospital Inselspital, Berne;","Erasme hospital;Minas Gerais University;","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;","Aarhus Universitets Hospital;",null,null,"Providence Medical Group Infectious Disease;Providence Ambulatory Quality and Clinical Services","Guys and St Thomas' NHS Foundation Trust;","Assistance Publique - Hpitaux de Paris;",null,"Renmin Hospital of Wuhan University;LanZhou University;Tianjin Second People's Hospital;Sixth Peoples Hospital of Shenyang;Ankang Central Hospital;Guangxi Zhuang Autonomous Region;Dalian Sixth Peoples Hospital;Xingtai People's Hospital;Shenzhen Third People's Hospital;Minda Hospital Affiliated to Hubei University for Nationalities;Suizhou Hospital, Hubei University of Medicine;Wuhan Union Hospital, China;The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture;The Affiliated Third Hospital of Jiangsu University;The Central Hospital of Lishui City;LanZhou University;",null,null,null,"Assistance Publique - Hpitaux de Paris;","ProgenaBiome;","Lady Davis Institute for Medical Research, McGill University;",null,null,null,null,"Universidad del Rosario;","Hospital San Jos;","The First Affiliated Hospital of Yangtze University","Huanggang Central Hospital",null,"Can-Fite BioPharma Ltd;",null,null,"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","The Second Xiangya Hospital of Central South University","Wuhan University","Jiangsu Provincial Center for Disease Control and Prevention","the First Affiliated Hospital of Nanjing Medical University","Beijing Sports University","Huoshenshan Hospital","Wuhan Fourth Hospital","Shandong Provincial Hospital","Shanghai Orient Hospital","Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Jiangsu Provincial Hospital","Chinese PLA General Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Huzhou Central Hospital","Wenzhou Central Hospital","Beijing University of Chinese Medicine","Women's Hospital, Medical School of Zhejiang University","Shenzhen Ruipuxun Academy for Stem Cell &amp; Regenerative Medicine","West China Hospital, Sichuan University","the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China",null,"ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)","Assistance Publique - Hpitaux de Paris","IKT Ulm","InflaRX GmbH","University Hospital Ghent","CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC","Groupe Hospitalier Paris Saint Joseph - Hpital Marie Lannelongue","CHU Saint Etienne","FIB-HCSC","Centre Lon Brard","FFIS","HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS","APHP","Hpital Fondation Adolphe de Rothschild","Dr. Xavier Solanich Moreno. Servei Medicina Interna. Hospital de Bellvitge","INSTITUT DE RECERCA H. SANTA CREU I SANT PAU","FISABIO","Effice","Delos Clinical","ISGlobal","sanofi-aventis recherche &amp; dveloppement","Eunate Arana Arri (Instituto Investigacin Biocruces Bizkaia)","Fundacin para la Investigacin Biomdica Hospital Ramn y Cajal","Universit de Sherbrooke and CIUSSS de l'Estrie - CHUS;Sunnybrook Health Sciences Centre, University of Toronto;","Ansun Biopharma, Inc.;",null,null,"Belfast Health and Social Care Trust;",null,null,null,null,null,"University of Sao Paulo, Brazil;","Department of Hepatology, Division 2, Beijing Ditan Hospital;","The University of Hong Kong","Ascletis Pharmaceuticals Co., Ltd.",null,null,null,null,null,"The fifth medical center of PLA general hospital;","Tianhe Stem Cell Biotechnologies Inc.;",null,"Pulmotect, Inc.;","Jiangsu Province Centers for Disease Control and Prevention;Hubei Provincial Center for Disease Control and Prevention;Tongji Hospital","Service Hygine, Epidmiologie et Prvention;",null,"Gilead Sciences;","Gilead Sciences;",null,"Massachusetts General Hospital;","University of Minnesota;University of Minnesota;","NeuroRx, Inc.;","Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale;",null,"University of Minnesota;","Peking University First Hospital;",null,null,"University of Minnesota;University of Minnesota;","Pulmotect, Inc.;",null,null,"Ictal Group;","Hospital do Corao;Hospital do Corao;","Assiut University;","Changhai Hospital",null,"National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;","Wake Forest University Health Sciences;","Oslo University Hospital;Oslo University Hospital;Oslo University Hospital;Oslo Hospital Pharmacies;Oslo University Hospital;Oslo University Hospital;NorCRIN;",null,"Gilead Sciences;","Institute of Human Virology, University of Maryland Baltimore;","National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;","Mayo Clinic","Johns Hopkins University;","Hoffmann-La Roche;","Duke University;","Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy;Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy;Dept. of Information Engineering and Computer Science, University of Trento, Italy;Diagnostic and Interventional Ultrasound Unit, Valle del Serchio Hospital, Lucca, Italy;",null,null,"Montreal Heart Institute;Montreal Health Innovations Coordinating Center;","University of California, San Francisco;","Hospital Universitario Dr. Negrin;","UnitedHealth Group",null,null,null,"The Parker Institute;",null,null,"Direttore Dipartimento di Malattie Infettive;",null,"Mayo Clinic","Sanofi;","Teaching Director of Teaching &amp; Research Institute Srio-Libans Hospital;","University of Oxford;","Fondazione Policlinico Universitario A. Gemelli IRCCS;","Rambam Health Care Campus;","Assistance Publique - Hpitaux de Paris;",null,"Murdoch Children's Research Institute;",null,"UnitedHealth Group Research &amp; Development;OptumCare, Everett Clinic;","CHU de Saint-Etienne;Institut Pasteur;","University of Minnesota;","University of Cambridge &amp; Cambridge University Hospitals NHS Foundation Trust;","Institut Pasteur de la Guyane, Head of Epidemiology Unit;","University Hospital Essen, Deparment of Cardiology and Vascular Medicine;","Bassett Medical Center;","Azidus Brasil;","Hospital Clnic de Barcelona;","Director Department of Obstetrics and Gynecology BUMCP;","National University of Ireland, Galway, Ireland;","Intermountain Health Care, Inc.;","Assistance Publique - Hpitaux de Paris;","Professor of vaccinology;","University of Calgary;University of Calgary;","Charit-Universittsmedizin Berlin - Department of Psychiatry and Psychotherapy;Charit-Universittsmedizin Berlin - Department of Psychiatry and Psychotherapy;","Jean Bernard Center - LE MANS;","University of Pennsylvania;","Fasa University of Medical Sciences;",null,"University Hospital, Ghent;","World Health Organization;","Emory University;","King's College London;","Barcelona Institute for Global Health","Princess Margaret Cancer Centre;Princess Margaret Cancer Centre;","University of Chicago, Department of Medicine, Section of Rheumatology;","University of California, San Francisco;University of California, San Francisco;","University Amsterdam;",null,null,null,"Imperial College Healthcare NHS Trust;",null,null,"Washington Univeristy School of Medicine;University College, London;Wits University;",null,"Peking University First Hospital;","Sanofi;","Massachusetts General Hospital;","Baylor Health Care System","Duke University;",null,null,"Peking University First Hospital;","HaEmek Medical Center, Israel;",null,"Centre Leon Berard;","Universidad de Granada;",null,"CHU de NICE - Archet 1;",null,"Intermountain Health Care, Inc.;","ProgenaBiome;","Chief Medical Officer;Principal Investigator;Principal Investigator;","Plan Nacional sobre el Sida (PNS);Harvard School of Public Health","University of Kansas Medical Center;","Stiftung IHF and Klinikum der Stadt Ludwigshafen;","IOB Institute of Oncology, Vall dHebron Institute of Oncology (VHIO);",null,"University Hospital Bern (Inselspital);",null,null,"Istanbul University-Cerrahpasa;Biruni University;",null,"Department of Rheumatology, Aalborg University Hospital;","Center for Regenerative Medicine, Renmin Hospital of Wuhan University;",null,"Oslo University Hospital;","Rutgers Biomedical Health Sciences;Rutgers Institute for Translational Medicine and Science;","Duke University;","Rutgers, The State University of New Jersey;Rutgers Cancer Institute of New Jersey;","ASSISTANCE PUBLIQUE HPITAUX de MARSEILLE;",null,"ASST Fatebenefratelli Sacco",null,"Virginia Commonwealth University",null,"CHU Angers, service de mdecine intensive ranimation;",null,null,null,";The Capital Region's Unit of Inherited Cardiac Diseases Faculty of Health and Medical Sciences University of Copenhagen Rigshospitalet, University of Copenhagen","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;","Novartis Pharmaceuticals;","CH Tourcoing;CH Tourcoing;","Rigshospitalet, Denmark;Herlev Hospital;Hvidovre University Hospital;Nordsjllands Hospital;",null,"UH MONTPELLIER;","Inovio Pharmaceuticals;","University of Alabama at Birmingham;","University Hospital of Nantes;University Hospital of Tours;University Hospital of Rennes;University Hospital of Poitiers;University Hospital of Brest;Hospital of Cholet;Hospices Civils de Lyon (University Hospital of Lyon);Hospital of Saint-L;University Hospital, Rouen;",null,null,"University Hospital, Lille;",null,"Cedars-Sinai Medical Center, Los Angeles, CA 90048;",null,"National Kapodistrian University of Athens, Medical School;",null,null,null,"University Hospital Jena;","University of Health Sciences Lahore;",null,null,"Institute of Global Health Innovation;",null,"Mayo Clinic;","Hospital Universitari de Bellvige;","Vancouver Coastal Health;",null,null,"Max Healthcare;",null,null,"Mayo Clinic;","Ziekenhuis Oost-Limburg;","Tabula Rasa HealthCare",null,"Henry Ford Health System;Henry Ford Health System;",null,null,"HonorHealth Research Institute;","Medical Oncologist;",null,"University of Chicago Biological Sciences Division Department of Surgery;","Nimes University Hospital;","University of Cincinnati;","Aga Khan University;","National Institute of Mental Health (NIMH);","University of Minnesota;","University of Colorado/Children's Hospital Colorado;","Barts &amp; The London NHS Trust;Queen Mary University of London;",null,"Children's University Hospital Cologne;Children's University Hospital Cologne;","University of Colorado, Denver;","Peking Union Medical College Hospit;",null,"Hospital General Universitario Morales Meseguer;Hospital General Universitario Morales Meseguer;","+4970712986622;","Hospital Materno-Perinatal \"Mnica Pretelini Senz\";","I-Mab Biopharma US Limited;",null,"APHP;",null,"Hpital Bictre, Assistance Publique-Hpitaux de Paris;",null,"London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;","Ochsner Health System;",null,"Jiangsu Province Centers of Disease Control and Prevention;","University of Miami;","University of Utah;","University Hospital, Lille;","Columbia University Irving Medical Center;","Fondation Adolphe de Rothschild;",null,null,"University Hospital Tbingen;","Sorbonne Universit, GRC 001, GREEN Groupe de Recherche en Neuro-Urologie, AP-HP, Hpital Tenon, F-75020, Paris, France;","Karolinska Institutet;","Service de Chirurgie Thoracique Nouvel Hpital Civl Hpitaux Univesitaires de Strasbourg;",null,"Tan Tock Seng Hospital;","Erasmus Medical Center;",null,"The Cleveland Clinic",null,null,"Yale University;","Duke University;",null,null,"University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine;","Assistance Publique - Hpitaux de Paris;","Washington University School of Medicine;","Wake Forest University Health Sciences;","Eli Lilly and Company;",null,"11 MDG;NMRTC Bethesda;11 MDG;11 MDG;","Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences",null,null,null,null,"Athens General Hospital \"Hippokrateio\", 2nd department of Pathology;Athens General Hospital of Thoracic Diseases \"SOTIRIA\", 1st University Pulmonary Clinic;Athens General Hospital of Thoracic Diseases \"SOTIRIA\", 3rd University Pathology Clinic;General Hospital of Athens \"Sismanoglio\", 2nd Department of Pathology;Divine Providence Hospital \"Pammakaristos\", Pathology Department","Genesis Foundation;Genesis Foundation;","Hackensack Meridian Health;","HKU;","Hospital Puerta de Hierro de Majadahonda de Madrid;Hospital Puerta de Hierro de Majadahonda de Madrid;Hospital Universitario Dexeus de Barcelona.;","University Hospital, Montpellier;","Dr Cipto Mangunkusumo General Hospital;Fakultas Kedokteran Univeristas Indonesia;","Instituto Nacional De Ciencias Mdicas y Nutricin;","Massachusetts General Hospital;","Fondation Adolphe de Rothschild;","Baylor College of Medicine;","Duke University;Duke University;","University Hospital, Angers","ClarData;","Virginia Commonwealth University;Hunter Holmes McGuire VA Medical Center - Richmond, VA;",null,null,null,"Universit Libre de Bruxelles;",null,"NYU Langone Health;","Brigham and Women's Hospital;Brigham and Women's Hospital;","NYU Langone Health;",null,"Boston University;","Hospital de Matar;","Institute of Liver &amp; Biliary Sciences;",null,"Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;Centre Hospitalier Intercommunal Aix-Pertuis (CHIAP), France;","Hopital Europen Georges Pompidou;CHU de Nancy;","LSUHSC/UMCNO;",null,"Ascletis Pharmaceuticals Co., Ltd.;",null,"Sainte-Anne military hospital;","Stony Brook Hospital","Johns Hopkins University;",null,null,"Semmelweis University;","Queen's Medical Centre;","Athena Medical Group;Perseverance Research Center;",null,"Prof;",null,null,"Tanta University Faculty of medicine;Tanta University Faculty of medicine;Tanta University Faculty of medicine;",null,null,null,"Vanderbilt University Medical Center;Vanderbilt University Medical Center;","Stanford University;","Consultant Gastroenterologist;","IRST IRCCS;",null,"Oslo University Hospital;","Hackensack Meridian Health Corporation","Centre Chirurgical Marie Lannelongue;","Hackensack Meridian Health;","Tanta University Faculty of medicine;","Hospital Universitario Puerta de Hierro Majadahonda;Hospital Universitario Puerta de Hierro Majadahonda;Hospital Universitario Puerta de Hierro Majadahonda;Hospital Universitario Puerta de Hierro Majadahonda;Centro Nacional de Microbiologa, Instituto de Salud Carlos III;","Montpellier University Hospital;","Ophtalmology Clinic, G. d'Annunzio University;","Hospital Universitario de Fuenlabrada",null,"Aarogyam UK;Aarogyam UK","CalciMedica, Inc.;","Herlev-Gentofte Hospital;Rigshospitalet, Denmark;Rigshospitalet, Denmark;Hvidovre University Hospital;Rigshospitalet, Denmark;Bispebjerg Hospital;Akutberedskabet;Nordsjllands Hospital;Hvidovre University Hospital;Mental Health Services in the Capital Region, Denmark;",null,null,null,"Department of Intensive Care, Academic Medical Center, University of Amsterdam;Department of Intensive Care, Academic Medical Center, University of Amsterdam;Department of Intensive Care, Academic Medical Center, University of Amsterdam;Department of Intensive Care, Academic Medical Center, University of Amsterdam;Department of Intensive Care, Academic Medical Center, University of Amsterdam;Department of Intensive Care, Academic Medical Center, University of Amsterdam;","Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia;Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia;","Institute of Liver &amp; Biliary Sciences;",null,null,"Stanford University","Assistance Publique - Hpitaux de Paris;",null,null,null,null,null,null,null,"Head of Research and Development Unit;","Hope Biosciences Stem Cell Research Foundation",null,null,null,"University Hospital, Montpellier;",null,"Columbia University Irving Medical Center;",null,"Saint Luke's Mid America Heart Institute;","Ludwig Boltzmann Institute for Lung Health",null,null,"Queen's University, Belfast;",null,null,null,"Harvard University, Boston, USA;University Of Veterinary &amp; Animal Sciences, Lahore;Federal Post-Graduate Medical Institute, Lahore;Shaikh Zayed Hospital, Lahore;Shaikh Khalifa Bin Zayed Al-Nahyan Medical &amp; Dental College, Lahore;",null,"KK Hospital, SingHealth, Duke-NUS;","UH MONTPELLIER;",null,"Department of Nephrology, TUM Medical School, Klinikum rechts der Isar;","Medical University of Vienna;","King Fahad Specialist Hospital;","University of Alberta;University of Alberta","University Hospital, Lille;","Department of anesthesia and intensive care, Fattouma Bourguiba Hospital",null,"University of Colorado, Denver;",null,"Korea University Guro Hospital;","University Hospital Giessen and Marburg, Giessen;",null,null,null,"Rigshospitalet, Denmark;",null,null,"National Institute of Dental and Craniofacial Research (NIDCR);",null,null,null,null,null,null,"ATTIKON University General Hospital","Centre Hospitalier Rgional Universitaire de Nancy;",null,"McMaster University;","Karyopharm Therapeutics Inc;",null,"Columbia University;","William Beaumont Hospitals;",null,null,null,null,"FHHI-OI-Camelot;QME",null,null,"Duke University;",null,"HCUVA;","Theravance Biopharma;","Hope Biosciences Stem Cell Research Foundation","The University of Hong Kong;","Montefiore Medical Center;","Icahn School of Medicine at Mount Sinai;Icahn School of Medicine at Mount Sinai;",null,"University Hospital, Lille;","Tanta University - Faculty of Medicine;","IIIrd Medical Department, Private Medical University Hospital Salzburg;",null,"University of Chicago;","CHU Nimes;","Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences","Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences",null,null,null,"University Hospital, Lille;","Medical University of Vienna;",null,"Gynaecology Department, Hpital Femme Mre Enfant Hospices Civils de Lyon;",null,null,null,null,null,";",null,null,null,null,"Renji Hospital, Shanghai Jiaotong University School of Medicine",null,"Humanigen, Inc.;","Tanta University - Faculty of Medicine;","Aarogyam UK;Aarogyam UK","Center for Clinical Metabolic Research, Gentofte Hospital;",null,"The Fifth Affiliated Hospital of Sun Yat-Sen University","Fujian Provincial Hospital",null,"Copenhagen University Hospital, Hvidovre;","Union Hospital","University Hospitals Plymouth NHS Trust;",null,null,null,null,null,"The Third Affiliated Hospital of Sun Yat-sen University","Beijing University of traditional Chinese Medicine",";",null,"The Chinese University of Hong Kong","International Peace Maternity and Children Health Hospital, School of Medicine, Shanghai Jiao Tong University",null,null,null,"Shanghai University of Traditional Chinese Medicine","Nanjing Second Hospital","Affiliated Hospital of Guangdong Medical University","The Fourth Medical Center of Chinese PLA General Hospital",null,"Sixth Medical Center of PLA General Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","ASSISTANCE PUBLIQUE - HPITAUX DE PARIS (AP-HP)","Affiliated Hospital of Zunyi Medical University","Guangzhou Eighth People's Hospital","Rigshospitalet",null,null,null,"Chinese University of Hong Kong",null,"Hebei Yiling Hospital","Radboudumc","Shijiazhuang Yiling Pharmaceutical Co., Ltd.","Aarhus University",null,null,"Histocell S.L.","Consorci PSMAR",null,null,"FUNDACION JIMENEZ DIAZ HEALTH RESEARCH",null,"University hospital of Montpellier",null,null,"Hospices Civils de Lyon","Servicio de Farmacologa Clnica. Unidad de Ensayos Clnicos (UCICEC)","Fundacin para la Investigacin Biomdica del Hospital La Paz (FIBHULP)","Hpitaux Universitaires de Strasbourg","Fundaci Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)","Medica Scientia Innovation Research S.L. (MEDSIR)","CHU Angers","Barcelona Institute for Global Health (ISGlobal)","Department of infectious diseases","Hospital Universitario de Fuenlabrada","Effice spi S.L.","APEIRON Biologics AG","Carrie Bayliss","Rosario Garca de Vicua","Hospital Clnic","Fundacin Instituto de Investigacin Sanitaria Fundacin Jimnez Daz","Fundacin investigacin biomedica Hospital Universitario La Paz-UCICEC","Institut Catal dOncologia","University of Birmingham, Birmingham Clinical Trials Unit (BCTU)","Oslo university hospital","FFIS","GHU PARIS PSYCHIATRIE ET NEUROSCIENCES","Hellenic Institute for the Study of Sepsis","Instituto de Investigacin Sanitaria INCLIVA","University Medical Center Utrecht, Julius Centrum UMCU","University Hospital Ghent","Klinik fr Innere Medizin I, UKSH Campus Kiel","Medizinische Klinik III","Universittsklinikum Heidelberg Sektion Klinische Tropenmedizin","Universittsklinikum Freiburg, department fr psychische Erkrankungen, psychosomatische Medizin und Psychotherapie","Klinikum rechts der Isar, Technical University Munich","Institut fr Virologie, Universittsklinikum Leipzig","Paracelsus Medizinische Privatuniversitt Institut fr Allgemeinmedizin","Universittsklinikum Schleswig-Holstein, Campus KielKlinik fr Neurologie Sektion Neurologische Schmerzforschung und -therapie","Universitts-Herzzentrum Freiburg Bad Krozingen","Institut fr Biometrie und Registerforschung, Medizinische Hochschule Brandenburg, Neu-ruppin","Deutsche Gesellschaft fr Perinatale Medizinc/o Conventus Congressmanagement &amp; Marketing GmbH","Klinik fr Psychosomatische Medizin und Psychotherapie, LVR-Klinikum Essen, Kliniken und Institut der Universitt Duisburg-Essen","Institut fr Virologie/ Universittklinikum Bonn","Leuphana Universitt Lneburg","KKH BergstrasseAbt. Ansthesie und Intensivmedizin","University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany","Max Healthcare (A Unit of Devki Devi Foundation)","Universittsklinikum Freiburg","Medizinische Hochschule Hannover","Tabriz University of Medical Sciences","Performa Nord Zentrum fr Gesunde Arbeit Arbeitsmedizinischer Dienst","Klinik fr Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen, Universitt Duisburg-Essen","Ahvaz University of Medical Sciences","Tehran University of Medical Sciences","Psychosomatische und Psychotherapeutische Abteilung, Universittsklinikum Erlangen","Krankenhaus Reinbek St. Adolf-Stift","Tehran University of Medical Sciences","Klinik fr Ansthesiologie und Intensivtherapie Universittsmedizin Rostock","Sabzevar University of Medical Sciences","Tehran University of Medical Sciences","Bangladesh Health Professions Institute","Tehran University of Medical Sciences","Iran University of Medical Sciences","Klinik fr Ansthesiologie und Intensivtherapie; Universittsklinikum Leipzig","COMMAND HOSPITAL AIRFORCE","Kerman University of Medical Sciences","Aster Malabar Institute of Medical Sceinces","1. DACH Jaipur 2. Harvard University, USA","Artesh University of Medical Sciences","Shreepad Shree Vallabh SSV Phytopharmaceuticals","Tabriz University of Medical Sciences","Tehran University of Medical Sciences","Maulana Azad Medical College","Tehran University of Medical Sciences","Tehran University of Medical Sciences","OrchidPharmed Co.","Iran University of Medical Sciences","Mazandaran University of Medical Sciences","Tehran University of Medical Sciences","Abadan University of Medical Sciences","Kermanshah University of Medical Sciences","University of social welfare and rehabilitation sciences","Tabriz University of Medical Sciences","Tehran University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Kerman University of Medical Sciences","Mazandaran University of Medical Sciences","Qazvin University of Medical Sciences","Tabriz University of Medical Sciences","Islamic Azad University","Arak University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Abadan University of Medical Sciences","Fasa University of Medical Sciences","Tehran University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Medical Council of Iran","Abadan University of Medical Sciences","Kerman University of Medical Sciences","Tabriz University of Medical Sciences","Mazandaran University of Medical Sciences","Mashhad University of Medical Sciences","Abadan University of Medical Sciences","Shiraz University of Medical Sciences","Tehran University of Medical Sciences","Tehran University of Medical Sciences","Kerman University of Medical Sciences","Gorgan University of Medical Sciences","Tabriz University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Mashhad University of Medical Sciences","Semnan University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Kerman University of Medical Sciences","Babol University of Medical Sciences","Mazandaran University of Medical Sciences","Mashhad University of Medical Sciences","Tehran University of Medical Sciences","Tehran University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Mashhad University of Medical Sciences","Ghoum University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Tehran University of Medical Sciences","Kerman University of Medical Sciences","Tehran University of Medical Sciences","Tabriz University of Medical Sciences","Ardabil University of Medical Sciences","Kermanshah University of Medical Sciences","Torbate-Heidaria University of Medical Sciences","Mazandaran University of Medical Sciences","Ahvaz University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Institute of Medicinal Plants","Shahid Beheshti University of Medical Sciences","Tabriz University of Medical Sciences","Ardabil University of Medical Sciences","Tehran University of Medical Sciences","Iran University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Royan Institute","Ghoum University of Medical Sciences","Tehran University of Medical Sciences","Iran University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Saveh University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Tehran University of Medical Sciences","Mashhad University of Medical Sciences","Mazandaran University of Medical Sciences","Mashhad University of Medical Sciences","Semnan University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","Royan Institute","Artesh University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Mashhad University of Medical Sciences","Tehran University of Medical Sciences","Saint Joseph University","Tehran University of Medical Sciences","Saveh University of Medical Sciences","Birjand University of Medical Sciences","Tehran University of Medical Sciences","Ahvaz University of Medical Sciences","Bagheiat-allah University of Medical Sciences","Tabriz University of Medical Sciences","Mashhad University of Medical Sciences","The Institute of Endocrinology and Metabolism Research and Training Center","investigator","National Center for Global Health and Medicine",null,"Mazandaran University of Medical Sciences","Birjand University of Medical Sciences","Consultant","Center Hospital of the National Center for Global Health and Medicine","Gunma Universty Hospital","Gunma University Hospital","Jichi Medical University Division of Gastroenterology","Hospital Alemo Oswaldo Cruz","Tokyo University Department of Gastroenterology","Hospital do Corao","Yokohama City University Department of Pulmonology","Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Faculty of Med","Head of Health Research","Keio University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine","Chulalongkorn University","Faculty of Medicine Siriraj Hospital","Universidad de Sevilla","Yokohama City University School of Medicine Department of Pulmonology","Assistance Publique Hopitaux de Paris","Universidade Federal do Par","Center for Genetic Engineering and Biotechnology (CIGB).","MINISTERIO DE SALUD","APHP","Universidade de So Paulo","Mahidol-Oxford Tropical Medicine Research Unit"],["2019-nCoV Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 Novel Coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Infections","Cardiovascular Death; Major Adverse Cardiovascular Events","Novel Coronavirus Pneumonia  (COVID-19)","novel coronavirus pneumonia (COVID-19); mental health status","novel coronavirus pneumonia","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Pneumonia Caused by Human Coronavirus (Disorder)","2019-nCoV","severe novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Virus; Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 Novel Coronavirus Infection (CoVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Emotional  disorder","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019-nCoV","2019-nCoV","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","new coronavirus pneumonia","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia  (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19) in children","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Mental health; Novel coronavirues pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Epilepsy, Chronic diseases, Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19) with mild to moderate anxiety and depression","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","new coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus","2019 nCoV, PD-1","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","anxiety and depression; novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Pneumonia, Viral;Pneumonia, Ventilator-Associated","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Pneumonia caused by new coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Anxiety; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","pneumonitis caused by novel coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Coronavirus Disease 2019","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia(COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia","Susceptibility to Viral and Mycobacterial Infection","COVID-19 Thalidomide","2019-nCoV","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019-nCoVs Infection Pneumonia","2019 Novel Coronavirus Pneumonia","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","NO","COVID-19 Thalidomide","Coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus","Coronavirus Disease 2019","Novel Coronavirus Pneumonia (COVID-19)","Neonatal Infection;Perinatal Problems;Infectious Disease","2019-nCov pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Pulmonary Fibrosis Due to 2019-nCoV","Coronavirus Disease (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19);U07.100x001","Novel Coronavirus Pneumonia (COVID-19)","psychological health; Novel Coronavirus Pneumonia (COVID-19)","pediatric COVID19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); children","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Digestive endoscopy gastroscopy; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","psychological status","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","job burnout; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","cytokine release syndrome of new coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Geriatrics; Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Biopsychosocial health; novel coronavirus pneumonia (COVID19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Cancelled","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Infectious Disease (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Infection Pneumonia","Novel Coronavirus Pneumonia;Pneumonia;Pirfenidone","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Coronavirus Disease 2019;Novel Coronavirus Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Lung injury","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 novel coronavirus pneumonia(COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","sleep disorders","influenza","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Pneumonia Caused by Human Coronavirus","COVID-19","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","psychological well-being; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus;N95;Medical Mask","Mental Disorder","COVID-19;Endotracheal Intubation","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus","COVID-19;Recombinant Human Interferon a1","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Fibrosis after Severe Coronavirus Disease 2019 (COVID-19) Pneumonia","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Somatopsychic illness; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Rheumatic disease; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19); mental health status","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Corona Virus Disease 2019(COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); psychosomatic medicine","Anxiety; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","End-stage renal disease; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); Kidney disease in children","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Mental health; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel common type of coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)N; psychosomatic medicine","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Sleep; Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","2019-nCoV pneumonia","novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","malignant  tumor","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus (COVID-19) Infected Diseases","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Vitamin C;Pneumonia, Viral;Pneumonia, Ventilator-Associated","Stress, Psychological","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Severe COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); Anxiety Disorder","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","cancer","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019-nCOV Disease","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Treat and Prevent Covid-19 Infection","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); myocardial injury, arrythmias","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Pneumonitis","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","malignant tumor; Novel Coronavirus Pneumonia (COVID-19)","sleep disorders","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019-nCoV Severe Pneumonia","Novel Coronavirus Pneumonia;2019-nCoV","Patients with documented respiratory infection with coronavirus SARS COV 2;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 Complicated With Refractory Intestinal Infections","2019-nCoV","Novel Coronavirus Pneumonia (COVID-19)","2019 - nCoV pneumonia","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia","COVID-19","2019-nCoV","2019-nCoV Pneumonia","COVID-19 infection &lt;br&gt;COVID-19 infection","Pathogen Infection Covid-19 Infection","COVID-19","2019-nCoV;Immunoglobulin of Cured Patients","CoVID-19;Chinese Medicine","COVID-19","COVID-19","Coronavirus;Depression;Anxiety;Stress","Corona Virus Disease 2019,COVID-19","COVID-19;Cardiovascular Diseases","Use of Stem Cells for COVID-19 Treatment","2019-nCoV","COVID-19","Covid-19;SARS;Cytokine Storm;Cytokine Release Syndrome;Tocilizumab","SARS-CoV-2;Outcome, Fatal","COVID-19","Coronavirus Disease-2019","COVID-19;Severe Pneumonia;Chinese Medicine","COVID-19","fever; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus;SARS","Coronavirus;Iatrogenic Disease;Acute Kidney Injury;ARDS, Human","COVID-19;Organ Dysfunction Syndrome Sepsis;Organ Dysfunction Syndrome, Multiple;Septic Shock;Acute Kidney Injury;Acute Respiratory Distress Syndrome","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia","Infection Viral","Cesarean delivery","Novel Coronavirus Pneumonia (COVID-19)","Myopia","Novel Coronavirus Pneumonia (COVID-19)","Rheumatic diseases; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); medical adhesive-related skin injury","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Infections","Myopia; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Sleep, stress and anxiety","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Chronic diseases such as hypertension, diabetes, malignant tumor, immunosuppressive state, etc","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Corona virus infection &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus disease (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Healthy People","Coronavirus;Pneumonia;Oxygen Toxicity","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10038700\nTerm: Respiratory infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-CoV-2  infection &lt;br&gt;MedDRA version: 20.0\nLevel: HLT\nClassification code 10047490\nTerm: Virus identification and serology\nSystem Organ Class: 100000004848\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Pharmacological Action","Coronavirus Infections;Post-exposure Prophylaxis","Corona Virus Infection","Novel Coronavirus Pnuemonia","Acute coronavirus disease 2019 &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","novel coronavirus pneumonia (COVID-19)","COVID-19","COVID-19","COVID-19;Myocardial Injury;Myocarditis","Hospitalized Patients With Covid-19 Pneumonia","COVID-19 Pneumonia","SARS-CoV-2;Coronavirus;COVID-19;2019-nCoV;2019nCoV","COVID-19","Severe Acute Respiratory Syndrome (SARS) Pneumonia;Coronavirus Infections;ARDS, Human","COVID-19","Coronavirus Infections","Serogroup C Meningococcal Meningitis;Diphtheria;COVID-19","Coronavirus","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","COVID-19","Coronavirus;Severe Acute Respiratory Syndrome","Coronavirus Infection","Coronavirus;SARS (Severe Acute Respiratory Syndrome)","COVID19;Coronavirus;Acute Respiratory Illnesses","COVID-19; Cardiovascular Diseases","COVID-19;Coronavirus Infections;Hay Fever;Asthma;Chronic Obstructive Pulmonary Disease;Influenza;Common Cold;Respiratory Tract Infections;Healthy","COVID-19","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;Coronavirus infection, unspecified site","Coronavirus Infections","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Acute Kidney Injury;Kidney Function","Health Care Worker Patient Transmission;Coronavirus;Coronavirus Infections;Immunological Abnormality","Acute Insomnia","depression","Corona Virus Disease 2019","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Corona Virus Infection","Coronavirus Infections","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Coronavirus;Surgery","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","sleep disorders","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 \n\n- Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen &lt; 72 hours prior to randomization.\n- Illness of any duration, and at least one of the following:\nClinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, OR\nRequiring mechanical ventilation and/or supplemental oxygen.\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 infection;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Possible prevention of pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospital &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10035738\nTerm: Pneumonia viral NOS\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","rheumatic disease; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Patient atteint du Covid-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 Infection; &lt;br&gt;COVID-19 Infection;Infection - Other infectious diseases","Cervical spondylosis","Novel Coronavirus Pneumonia (COVID-19)","covid-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10070267\nTerm: SARS virus test positive\nSystem Organ Class: 100000004848\n &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10022519\nTerm: Intensive care\nSystem Organ Class: 10042613 - Surgical and medical procedures\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","SARS-CoV-2 infection &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10070267\nTerm: SARS virus test positive\nSystem Organ Class: 100000004848\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Respiratory Tract Infections;Corona Virus Infection","Influenza Infection;SAD-RV Infection and COVID-19","Coronavirus Infections","COVID-19","Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Coronavirus Infections","Coronavirus","2019 Novel Coronavirus Infection","Coronavirus Infections;Pneumonia, Viral","Coronavirus Infections;Healthcare Associated Infection","Corona Virus Infection","SARS-COV-2 infection &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10037373\nTerm: Pulmonary disorder\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19);Respiratory Infection; &lt;br&gt;2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19) &lt;br&gt;Respiratory Infection;Infection - Studies of infection and infectious agents;Respiratory - Other respiratory disorders / diseases","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection","Coronavirus Infection","Corona Virus Infection","COVID-19","Corona Virus Infection","Angina Pectoris;Acute Coronary Syndrome;Coronary Syndrome;Coronary Artery Disease;Angioplasty;Stent Restenosis;Hypertension;Heart Failure, Systolic;Depression, Anxiety;Covid-19;Isolation, Social","CPAP Ventilation;COVID-19;Emergency Departments","Disease, Infectious;Respiratory Disease;Safety Issues;Effectiveness","Coronavirus;COVID-19;SARS-CoV Infection;Respiratory Failure;Cytokine Storm","COVID19","COVID-19","SARS-CoV-2 Infection;COVID-19","Coronavirus Infection","COVID-19","Corona Virus Infection","COVID-19;Pneumonia, Viral;Influenza With Pneumonia;Flu Symptom;Flu Like Illness;Pneumonia, Interstitial;Pneumonia, Ventilator-Associated;Pneumonia Atypical","Corona Virus Disease 19 (Covid 19)","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS);Cytokine Storm;Infection Viral","COVID-19;Physician-Patient Relations","COVID-19","SARS-COV2;Severe Acute Respiratory Syndrome;COVID-19","Coronavirus","COVID-19;Respiratory Disease","Contact Person From COVID-19 Confirmed Patient","COVID-19;Corona Virus Infection;SARS (Severe Acute Respiratory Syndrome)","COVID-19;SARS-CoV-2 Infection;Pediatric ALL;Pneumonia, Viral;Pandemic Response","COVID-19","COVID-19","Early CPAP Ventilation in COVID-19 Patients","SARS (Severe Acute Respiratory Syndrome);COVID-19","Cancer;COVID-19","COVID-19;Acute Respiratory Distress Syndrome;Virus; Pneumonia;Acute Lung Injury","COVID-19;Hypertension;Cardiovascular Diseases","Infection Viral","Prone Positioning;High Flow Nasal Cannula;Acute Respiratory Distress Syndrome;Corona Virus Infection","Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infection;Interstitial Lung Disease","Coronavirus;Coronavirus Infection","Pneumonia, Interstitial","Infection Viral;Coronavirus;ARDS;Pneumonia","Coronavirus Infections","COVID-19","SARS-CoV-2","Coronavirus;Respiratory Failure;Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere;SARS-CoV-2","COVID-19","COVID-19","Coronavirus","Vascular Surgical Procedures;COVID-19;Postoperative Complications","COVID-19;Corona Virus Infection;SARS-CoV-2;2019-nCoV;2019 Novel Coronavirus","Coronavirus;Respiratory Distress Syndrome;SARS-CoV Infection","Covid19;Pneumonia","COVID-19;Acute respiratory distress syndrome;Pneumonia; &lt;br&gt;COVID-19 &lt;br&gt;Acute respiratory distress syndrome &lt;br&gt;Pneumonia;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","COVID-19;Liver Cirrhosis","COVID-19","Pregnancy;COVID-19 infection; &lt;br&gt;Pregnancy &lt;br&gt;COVID-19 infection;Reproductive Health and Childbirth - Childbirth and postnatal care;Reproductive Health and Childbirth - Complications of newborn;Reproductive Health and Childbirth - Fetal medicine and complications of pregnancy;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","COVID-19; &lt;br&gt;COVID-19;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","2019-nCoV (COVID-19);Interstitial Pneumonia","COVID-19","Scleroderma;Scleroderma, Systemic;Systemic Sclerosis","COVID-19;Requiring home rehabilitation service; &lt;br&gt;COVID-19 &lt;br&gt;Requiring home rehabilitation service;Public Health - Health service research;Physical Medicine / Rehabilitation - Other physical medicine / rehabilitation;Infection - Other infectious diseases","COVID-19 infection;Acute respiratory distress syndrome; &lt;br&gt;COVID-19 infection &lt;br&gt;Acute respiratory distress syndrome;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","inflammatory bowel disease;Crohn's disease;ulcerative colitis;indeterminate colitis;COVID-19; &lt;br&gt;inflammatory bowel disease &lt;br&gt;Crohn's disease &lt;br&gt;ulcerative colitis &lt;br&gt;indeterminate colitis &lt;br&gt;COVID-19;Oral and Gastrointestinal - Inflammatory bowel disease;Oral and Gastrointestinal - Crohn's disease;Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon;Mental Health - Anxiety;Mental Health - Depression;Infection - Other infectious diseases","Coronavirus;Coronavirus Infection","COVID-19","Novel Coronavirus Pneumonia (COVID-19); Acute respiratory distress syndrome (ARDS)","Novel Coronavirus Pneumonia (COVID-19)","Autism Spectrum Disorder","COVID-19;Coronavirus Infection","COVID-19 (known or suspected);serious acute respiratory infection (SARI), known or suspected; &lt;br&gt;COVID-19 (known or suspected) &lt;br&gt;serious acute respiratory infection (SARI), known or suspected;Respiratory - Other respiratory disorders / diseases;Infection - Other infectious diseases","COVID-19; &lt;br&gt;COVID-19;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","sleep disorder","renal injuries","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Cesarean management and maternal and","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia 2019 (COVID-19)","COVID-19","Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies.;Therapeutic area: Diseases [C] - Cancer [C04]","Adult patients with a diagnosis of COVID-19 requiring hospitalization in a non-ICU and on prior therapy with RAS blockers;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 Infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Patients with SARS-CoV-2 infection and:\r\n1.\tage = 18 years and = 75 years\r\n2.\tSARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal \r\n                    swap)\r\n3.\tsevere disease defined by at least one of the following:\r\n  a.\trespiratory rate = 30 breaths / minute under ambient air\r\n  b.\trequirement of any type of ventilation support\r\n  c.\tneeds ICU treatment\r\n &lt;br&gt;MedDRA version: 20.1\nLevel: LLT\nClassification code 10047475\nTerm: Viral pneumonia, unspecified\nSystem Organ Class: 100000004862\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10070267\nTerm: SARS virus test positive\nSystem Organ Class: 100000004848\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10021433\nTerm: Immunization\nSystem Organ Class: 100000004865\n &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10054540\nTerm: Passive immunization\nSystem Organ Class: 100000004865\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Severe pneumonia in context of COVID-19\r\n &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10035737\nTerm: Pneumonia viral\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome.;Therapeutic area: Diseases [C] - Virus Diseases [C02]","severe acute respiratory syndrome coronavirus 2(SARS-CoV 2);Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]","Acute Respiratory Distress Syndrome (ARDS) caused by SARS-Cov-2 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Healthcare workers &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10008434\nTerm: Chemoprophylaxis NOS\nSystem Organ Class: 100000004865\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10061986\nTerm: SARS\nSystem Organ Class: 100000004862\n;Therapeutic area: Not possible to specify","COVID-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit;Therapeutic area: Diseases [C] - Cancer [C04]","COVID-19;Therapeutic area: Body processes [G] - Immune system processes [G12]","Organ dysfunction by the novel SARS-Cov-2 virus &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10035738\nTerm: Pneumonia viral NOS\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","acute hypoxemic respiratory failure (AHRF);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Patients on mechanical ventilation, inpatient resuscitation for ARDS, secondary to COVID-19 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Hospitalized patients with severe pneumonia secondary  to COVID-19. &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10070255\nTerm: Coronavirus test positive\nSystem Organ Class: 10022891 - Investigations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection is being spread around the world with more than 400.000 cases. The spred of the disease is being a world health problem.;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-CoV-2 infection &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10049924\nTerm: Infection prophylaxis\nSystem Organ Class: 10042613 - Surgical and medical procedures\n;Therapeutic area: Health Care [N] - Environment and Public Health [N06]","COVID-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Coronavirus infection &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10070255\nTerm: Coronavirus test positive\nSystem Organ Class: 10022891 - Investigations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Adult respiratory distress syndrome (ARDS) secondary to SARS-CoV-2;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Sepsis;Vitamin C;Intensive Care Unit;COVID-19;Pandemic;Coronavirus","Lower Respiratory Tract Infection;Parainfluenza;Immunocompromised;COVID-19","COVID-19 Infections","Pneumonia, Pneumocystis;Coronavirus","Acute Respiratory Distress Syndrome","Critically Ill;Coronavirus Infections","COVID-19;SARS-CoV-2","Pneumonia, Pneumocystis;Coronavirus;COVID-19","COVID-19","COVID-19;Novel Coronavirus Pneumonia","COVID-19;Yellow Fever","New Coronavirus","Novel Coronavirus Infection","COVID-19","2019 Novel Coronavirus Pneumonia;COVID-19","Sars-CoV2","COVID-19;Remdesivir;SARS-CoV-2","Novel Coronavirus Pneumonia","Corona Virus Infection;Immunisations","Corona Virus Disease 2019(COVID-19)","Severe Acute Respiratory Syndrome (SARS) Pneumonia","SARS-COV-2 Infections;COVID-19","COVID-19","COVID-19","Infection Viral","Coronavirus Disease 2019","COVID-19","COVID-19","Coronavirus Infections;Pneumonia, Viral;Acute Respiratory Distress Syndrome","SARS (Severe Acute Respiratory Syndrome);Coronavirus","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection","Acute Respiratory Distress Syndrome;Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS);Corona Virus Infection","COVID-19 Pneumonia","COVID-19;Hypertension","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection;Coronavirus;Coronavirus Infections","COVID-19","COVID-19","Blood Donation","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection","COVID-19","COVID-19 Pneumonia","Infection Viral","COVID-19;Encephalopathy;Critically Ill","Coronavirus Infections","COVID-19","Gastrointestinal Disease;Infectious Disease","SARS Pneumonia","COVID-19;Severe Acute Respiratory Syndrome","Migraine Disorders;Stress;Anxiety","SARS-CoV Infection;COVID 19;Acute Respiratory Distress Syndrome ARDS","Virus Diseases;Infection Viral;Corona Virus Infection","SARS-CoV2 Infection","Severe Coronavirus Disease (COVID-19)","COVID-19;Severe Acute Respiratory Syndrome","Coronavirus","Coronavirus;Convalescence","COVID-19 Pneumonia","COVID-19;SARS-CoV-2;Coronavirus;Influenza -Like Illness;Lower Resp Tract Infection;Upper Resp Tract Infection","Coronavirus;Epidemic Disease;Pneumonia, Viral","Coronavirus Infections;Pneumonia, Viral","COVID-19;Elderly Patients;Critical Illness;Survival;Old Age","Corona Virus Infection","Pregnancy;Coronavirus;COVID-19","Acute Respiratory Distress Syndrome Caused by COVID-19","Infections, Respiratory;Fever;Cough","COVID-19","Corona Virus Infection","COVID-19;Psychosocial Stress;Mental Health","Corona Virus Disease","COVID-19","Coronavirus","SARS-CoV-2","Coronavirus;Diabetes","Coronavirus","Corona Virus Infection","Coronavirus Infection;Pneumonia, Viral;Acute Respiratory Distress Syndrome","Coronavirus","Pneumonia, Viral;Hypertension;Diabetes Mellitus;Obesity;Cardiovascular Diseases;Obstructive Lung Disease","Coronavirus Infection","COVID-19","Pneumonitis;Coronavirus Infection","Coronavirus Disease 2019 (COVID-19);Febrile Respiratory Illness;Corona Virus Infection;COVID-19","Coronavirus","SARS-CoV Infection","COVID-19","COVID-19;Corona Virus Infection;ARDS;Acute Respiratory Distress Syndrome","Acute Disease;Coronavirus;Respiratory Viral Infection","Coronavirus Infections;Severe Acute Respiratory Syndrome;SARS-CoV Infection","Cardiovascular Diseases;Cardiovascular Risk Factor;SARS","SARS-CoV-2 Infection","COVID-19","COVID-19","Perceived Stress;Anxiety;Sleep Disturbance","Hypertension;COVID-19","COVID-19","Covid-19 Infection;Hospitalization in Respiratory Disease Department","SARS-CoV-2 Viral Kinetics and Host Immune Responses","COVID-19","Anxiety Related to the COVID-19 Pandemic","COVID-19","COVID-19","COVID-19","COVID 19;Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19;Pneumonia","COVID-19","COVID-19;SARS-CoV-2","COVID-19 Pneumonia","Corona Virus Infection","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19;Coronavirus","COVID-19","COVID 19","Coronavirus","COVID-19","Coronavirus Infection","Coronavirus;Acute Respiratory Infection;SARS-CoV Infection","COVID-19","COVID-19","Sars-CoV2","COVID 19","COVID-19","COVID-19","HIV/AIDS;COVID-19;SARS-CoV-2","SARS-CoV-2 (COVID-19) Infection;Advanced or Metastatic Hematological or Solid Tumor","Patients Infected With COVID-19","COVID 19","COVID;Acute Coronary Syndrome;Myocardial Infarction;Myocarditis;Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","COVID-19;Severe Acute Respiratory Syndrome Coronavirus 2","COVID-19","COVID-19","COVID-19","Coronavirus Infection","COVID-19","COVID","COVID-19;Pneumonia, Viral","SARS-CoV-2","SARS-CoV-2 Infection","Cardiovascular Diseases;COVID","Pediatric Respiratory Diseases;COVID;Fatigue Post Viral","Social Isolation;Physical Inactivity;Well-Being","COVID-19","Rheumatoid Arthritis;Psoriatic Arthritis;Axial Spondyloarthritis;Systemic Lupus Erythematosus;Giant Cell Arteritis","COVID-19","Telerehabilitation","COVID 19","Coronavirus;SARS-CoV-2","COVID-19","SARS-CoV-2;COVID-19","COVID 19","COVID-19","COVID-19","COVID-19","COVID-19","MAGEC Rod","COVID;Acute Respiratory Distress Syndrome","Stress, Psychological","Covid19;Newborn Morbidity","Coronavirus;Machine Learning","COVID-19","Coronavirus Infections;COVID-19;Viral Pneumonia Human Coronavirus","Severe/Very Severe COVID-19 Illness","COVID-19","COVID-19","COVID-19","Congenital Heart Disease;Covid-19","Coronavirus Infection","COVID-19","COVID;Coronavirus Infection","Coronavirus;SARS-CoV-2;COVID-19;Acute Respiratory Distress Syndrome;Shock;Acute Circulatory Failure;Left Ventricular Dysfunction;Fluid Overload","COVID19","Coronavirus;COVID;Infection Viral","Covid-19;Coronavirus Infection;Pregnancy Related","COVID-19","Emergency Service, Hospital;General Surgery","COVID-19;Virus Diseases;Macrophage Activation Syndrome;Corona Virus Infection","Hydroxychloroquine;Antimalarials;Enzyme Inhibitors;Antirheumatic Agents","COVID-19;Deep Vein Thrombosis (DVT)/Thrombophlebitis","COVID","Covid-19","COVID 19","COVID","Endometriosis;Covid19","Coronavirus","Coronavirus Infection","Liver Diseases;Liver Cancer;COVID19","COVID-19;Lung Injury","Corona Virus Infection","COVID-19","Coronavirus;Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere","COVID-19","Characteristics Diseases;Outcome, Fatal","COVID-19","COVID19","COVID-19 Pneumonia;Lung Ultrasound","COVID;Drug Effect;Drug Interaction;Adverse Drug Event","COVID-19;Respiratory Failure","COVID-19;Coronavirus;Coronavirus Infections;SARS-CoV 2","Gynecological Cancer","COVID-19;Nintedanib;Safety;Effect of Drugs","Covid19","Cancer","COVID-19","Coronavirus","Pneumonia, Viral;Critically Ill;Corona Virus Infection","COVID-19","Covid-19","Healthy Volunteer;Mood Disorder;Anxiety Disorder;Preexisting Medical Condition","Coronavirus Infection;COVID;Covid-19;SARS-CoV-2","COVID;Trauma;Ultrasound","Cardiovascular Disease Acute;Cardiomyopathies;COVID","Solid Organ Transplant Rejection;COVID-19","COVID-19;SARS-CoV-2","COVID-19","COVID-19;ECMO","COVID19;SARS-CoV-2 Infection","Respiratory Failure;Covid-19","ARDS, Human;COVID-19","Coronavirus Infection","Coronavirus Disease 2019 COVID-19","Suspicion of Infection With SARS-CoV-2","Corona Virus Infection;Post-traumatic Stress Disorder","Respiratory Tract Diseases","Corona Virus Infection","Pneumonia, Viral;COVID-19","Covid-19","COVID-19","Cancer &amp; COVID 19","COVID-19","Coronavirus Infection;Type 2 Diabetes","Coronavirus Infection;Coronavirus;Infectious Disease","Infection Viral;Coronavirus;COVID-19","COVID-19;Coronavirus Infection;Corona Virus Infection","Covid19;SARS-CoV Infection","COVID-19","Musculoskeletal Pain","COVID-19, Hydroxychloroquine Sulfate","Efficacy, Self;Satisfaction, Patient;Telemedicine","Dysfunctional Worry","Respiratory Distress Syndrome","Coronavirus Disease 2019","Coronavirus Infection;Hydroxychloroquine Adverse Reaction","COVID-19","Follow-up;COVID-19;Infectious Diseases;Respiratory","COVID;Corona Virus Infection","COVID-19","COVID-19;SARS-CoV Infection;Severe Acute Respiratory Syndrome (SARS) Pneumonia;Clinical Trial","COVID-19","Health Care Worker (HCW);COVID-19","COVID19- Infection With SARS-CoV-2 Virus","SARS-CoV-2;COVID;Coronavirus","COVID-19","Acute Hypoxemic Respiratory Failure;COVID-19","COVID 19;Coronavirus","Coronavirus;COVID","COVID-19;Pneumonia","COVID-19;Viral Respiratory Illnesses","COVID-19","COVID-19","COVID 19","SARS-CoV Infection;Severe Acute Respiratory Syndrome (SARS) Pneumonia","COVID-19","Covid 19 Pandemic From Ethical View","Pneumonia, Viral;Covid-19","COVID-19","COVID-19","COVID19","Covid-19;Lung Cancer","Addiction, Substance;COVID-19","Mental Stress;Mental Health Wellness 1;Depression;Anxiety;Behavior Problem;Emotional Problem","COVID-19;SARS-CoV-2","COVID-19;COVID","SARS-CoV-2;Systemic Lupus Erythematosus;Rheumatoid Arthritis;Sjogren's Syndrome;Psoriatic Arthritis","Sars-CoV2;Acute Respiratory Distress Syndrome;COVID-19","COVID-19","SARS-CoV-2;COVID-19","COVID-19","COVID-19;Lung Injury, Acute","COVID-19","Coronavirus Disease (COVID-19)","Skin Manifestations;COVID;Chilblains","COVID-19","COVID;Diabetes Mellitus, Type 2;Diabetes Mellitus, Type 1","COVID-19","Coronavirus Infection","COVID-19","Surgery;COVID;Asymptomatic Patient;Covid-19;Preventive Measures","COVID-19","Oropharyngeal Dysphagia;COVID-19;Sars-CoV2;Nutrition","COVID","COVID-19","Coronavirus Infection;Oxygen Deficiency","Infection Viral;Infection, Hospital;COVID","COVID-19","Mental Health Issue","COVID-19","IBD;COVID","Covid-19","COVID","COVID;Hypoxic Respiratory Failure","SARS-CoV-2;Coronavirus Infection;Asymptomatic Condition;COVID-19","Acute Respiratory Tract Infection;Acute Respiratory Insufficiency;Pneumonia;Septic Shock;Hypoxemia","COVID 19","COVID-19","COVID-19","COVID","Respiratory Distress Syndrome, Adult","Patient Safety","Coronavirus Disease 2019 (COVID-19)","COVID","COVID-19","COVID19 Pneumonia","COVID19 Pneumonia","COVID 19","COVID-19","Colon Polyp;Colon Disease;Reflux, Gastroesophageal;Varices, Esophageal","COVID-19;SARS-CoV-2","COVID-19 Infection","COVID-19","COVID19","Respiratory Distress Syndrome, Adult;COVID-19","COVID-19","COVID","COVID-19","Coronavirus Infection;Pneumonia, Viral","COVID;Conjunctivitis","COVID-19 Pneumonia","COVID","Flu Like Symptom;Flu Like Illness","Pneumonia","COVID","COVID;ARDS, Human;Ards;Sars-CoV2","Coronavirus Disease (COVID-19)","COVID19","COVID;Mechanical Ventilation;Acute Respiratory Failure","COVID-19 Pneumonia","Liver Cirrhoses","COVID;Sars-CoV2","COVID;Hypoxemia","COVID","Covid19","Coronavirus Disease (COVID-19)","COVID-19","COVID-19","Coronavirus Disease 2019 (COVID-19)","Pneumonia, Ventilator-Associated;Coronavirus Infection","COVID-19;Burnout, Caregiver;Intensive Care Unit;Stress, Psychological","Telerehabilitation;Coronavirus","COVID-19","COVID-19","Stress","COVID-19","Healthy Lifestyle","Sars-CoV2;COVID-19","SARS-CoV-2;COVID19","Solid Tumor;Sars-CoV2;Hematological Malignancy","Communicable Disease;COVID-19;Sars-CoV2;Infectious Disease;Coronavirus;Virus Diseases","COVID-19","Virus Diseases;COVID-19","COVID-19 Infection","Coronavirus Disease 2019","COVID","SARS-CoV-2","COVID-19 Disease","COVID-19","Coronavirus Infection;Sars-CoV2","COVID-19","COVID-19","SARS-CoV-2;COVID-19","COVID-19;BCG Vaccination","COVID","SARS-CoV 2;Immunization; Infection","Convalescent Plasma for COVID 19","Covid-19 Infection;Rheumatoid Arthritis;Psoriatic Arthritis;Hydroxychloroquine","COVID-19;ARDS;Sars-CoV2","Ventilator Associated Pneumonia","Covid-19","COVID-19","Covid-19","COVID-19","ARDS;Hypercapnic Respiratory Failure;AKI","Anxiety;Depression;COVID-19; &lt;br&gt;Anxiety &lt;br&gt;Depression &lt;br&gt;COVID-19;Mental Health - Anxiety;Mental Health - Depression;Infection - Other infectious diseases","COVID;Respiratory Distress Syndrome","Patient Safety","Covid-19;Hypoxia","COVID19","ARDS, Human;Mechanical Ventilation Complication;COVID19","COVID-19","Psychological Stress;COVID19; &lt;br&gt;Psychological Stress &lt;br&gt;COVID19;Mental Health - Studies of normal psychology, cognitive function and behaviour;Public Health - Health service research","Coronavirus Infection","Coronavirus Disease (COVID-19)","COVID-19","Covid-19","Stress;Anxiety;Depression; &lt;br&gt;Stress &lt;br&gt;Anxiety &lt;br&gt;Depression;Mental Health - Anxiety;Mental Health - Depression;Mental Health - Other mental health disorders","Pulmonary Infection;Covid-19","Postpartum Depression","Coronavirus Disease 19 (COVID-19);SARS-CoV-2; &lt;br&gt;Coronavirus Disease 19 (COVID-19) &lt;br&gt;SARS-CoV-2;Infection - Other infectious diseases;Public Health - Other public health;Respiratory - Other respiratory disorders / diseases","COVID-19","Coronavirus Infection","COVID-19","COVID","COVID-19;Coronavirus Infection;Severe Acute Respiratory Syndrome Coronavirus 2","COVID-19 Infection;Sars-cov-2;Respiratory Failure;Palliative Situation","Complications or secondary effects derived from the use of personal protective equipment against biological risks &lt;br&gt;Not Applicable","Coronavirus Disease (COVID-19)","Risk Factor, Cardiovascular;Covid19;Critical Illness;Course Illness","CoVid 19 Positive","Acute Respiratory Distress Syndrome;COVID19;Sars-CoV2;Pneumonia","COVID-19 (SARS-CoV-2 infection) and acute respiratory distress syndrome (ARDS) &lt;br&gt;Infections and Infestations","COVID-19","Emotionnal Distress; COVID-19","COVID19","Acute Lung Injury (ALI) Associated With COVID-19;Inflammatory Lung Conditions Associated With COVID-19","COVID-19","COVID","COVID;Coronavirus;COVID-19","COVID-19;Cardiac Arrhythmias","Sars-CoV2;Symptomatic Condition;Covid-19","Covid-19;Rheumatic Diseases;Rheumatoid Arthritis;Chronic Pain","COVID","Infectious Disease","COVID-19 (SARS-CoV-2 infection) in pregnant women &lt;br&gt;Pregnancy and Childbirth","COVID-19","SARS-CoV-2;Covid-19","COVID-19","COVID-19","COVID-19;SARS-CoV-2 Infection; &lt;br&gt;COVID-19 &lt;br&gt;SARS-CoV-2 Infection;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Severe lower respiratory illness;Covid-19; &lt;br&gt;Severe lower respiratory illness &lt;br&gt;Covid-19;Respiratory - Other respiratory disorders / diseases;Infection - Other infectious diseases","COVID-19 (SARS-CoV2); &lt;br&gt;COVID-19 (SARS-CoV2);Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Sars-CoV2;Osteoporosis","COVID","Coronavirus Disease (COVID-19)","Gynecologic Cancer;Breast Neoplasm Female;Uterine Neoplasms;Ovarian Neoplasms;Uterine Cervical Neoplasms;Vulvar Neoplasms;Vaginal Neoplasms","COVID-19 (SARS-CoV-2); &lt;br&gt;COVID-19 (SARS-CoV-2);Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)","mental health\r\n;Physical inactivity; &lt;br&gt;mental health&lt;br&gt; &lt;br&gt;Physical inactivity;Physical Medicine / Rehabilitation - Other physical medicine / rehabilitation;Mental Health - Depression;Public Health - Health promotion/education","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations","COVID-19;Pneumonia; &lt;br&gt;COVID-19 &lt;br&gt;Pneumonia;Infection - Studies of infection and infectious agents;Respiratory - Other respiratory disorders / diseases","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;Coronavirus infection, unspecified site","Severe Acute Respiratory Syndrome, COVID-19 (SARS coronavirus 2 [SARS-CoV-2] infection) &lt;br&gt;Infections and Infestations","Aspergillosis &lt;br&gt;Infections and Infestations &lt;br&gt;Aspergillosis","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations","Individual resilience and work sense of coherence and the development of mental symptoms during a pandemic scenario &lt;br&gt;Not Applicable","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations","Coronavirus Disease 2019 (COVID-19) Pneumonia","COVID","Flu Like Illness","Covid-19","Respiratory failure in patients with known or suspected COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Respiratory &lt;br&gt;COVID-19 (SARS-CoV-2 infection)","Novel Coronavirus Pneumonia (COVID-19); Pharyngitis, laryngitis","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","COVID-19;Mental Health;Psychoeducation;Anxiety","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Ventilation;COVID-19;Coronavirus;Acute Respiratory Distress Syndrome; &lt;br&gt;Ventilation &lt;br&gt;COVID-19 &lt;br&gt;Coronavirus &lt;br&gt;Acute Respiratory Distress Syndrome;Respiratory - Other respiratory disorders / diseases;Emergency medicine - Resuscitation;Anaesthesiology - Other anaesthesiology;Infection - Other infectious diseases","COVID-19;Respiratory failure.;Safe inter- and intra- hospital transfer of patients suffering from suspected or confirmed COVID-19; &lt;br&gt;COVID-19 &lt;br&gt;Respiratory failure. &lt;br&gt;Safe inter- and intra- hospital transfer of patients suffering from suspected or confirmed COVID-19;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Coronavirus Disease 19 (COVID-19);SARS-CoV-2; &lt;br&gt;Coronavirus Disease 19 (COVID-19) &lt;br&gt;SARS-CoV-2;Infection - Other infectious diseases;Public Health - Other public health;Respiratory - Other respiratory disorders / diseases","Mental health;COVID19;Social isolation; &lt;br&gt;Mental health &lt;br&gt;COVID19 &lt;br&gt;Social isolation;Mental Health - Anxiety;Mental Health - Depression;Mental Health - Studies of normal psychology, cognitive function and behaviour;Public Health - Other public health","COVID-19 Positive; &lt;br&gt;COVID-19 Positive;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Mental illness","Novel Coronavirus Pneumonia (COVID-19)","Any vascular condition, including: aortic or other type of aneurysmal disease, peripheral arterial disease, venous disease, vascular malformations, trauma, major haemorrhage, access (for renal dialysis), carotid (and cerebrovascular) disease, any other type of pathology treated by vascular surgeons. &lt;br&gt;Circulatory System","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","SARS-CoV2 infection","Acute insomnia &lt;br&gt;Mental and Behavioural Disorders","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); skin adverse reaction","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Severe confirmed COVID-19 pneumonia &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10038695\nTerm: Respiratory failure\nSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10023420\nTerm: Kidney failure chronic\nSystem Organ Class: 100000004857\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis","COVID-19, SARS-CoV-2","COVID-19 during pregnancy","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia  (COVID-19)","SARS-CoV-2 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","suspected novel coronavirus pneumonia (COVID-19)","Infection with COVID19;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","COVID-19","Corona virus disease 2019 (Covid-19), proven with PCR on nasopharyngeal swab and with matching abnormalities on low-dose CT-scan","acute respiratory distress syndrome;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Patients with confirmed COVID-19 infection and criteria for mild-moderate pneumonia (CURB-65 =1 i SatO2 =90%, MEWS score less than 3) and IL6 values of 20 pg / ml, will be randomly assigned to a sarilumab treatment group or another group receiving treatment according to the current therapeutic protocol of the PSMAR. &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10035737\nTerm: Pneumonia viral\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Lower respiratory tract infections","SARS-CoV-2","COVID-19 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-CoV2 Infection","infection COVID 19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Covid19 positive pneumonitis with need for hospital admission","COVID-19 with Hypoxia","viral pneumonia &lt;br&gt;MedDRA version: 20.1\nLevel: LLT\nClassification code 10047474\nTerm: Viral pneumonia\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Patients infected with COVID19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-CoV-2 infection in high-risk contacts;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]","Severe COVID-19 pneumonia &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10035737\nTerm: Pneumonia viral\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Coronavirus Disease 2019 (COVID-19)-Pneumonia &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Patient atteint du Covid-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-SoV-2 infection and CoVid-19 disease &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Pneumonia due to SARS Cov2 (COVID-19);Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Severe COVID-19 POSITIVE hospitalized male or female, between 35 and = 80 years of age;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection requiring hospitalization;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Respiratory distress secondary to SARS-Cov-2 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion.;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SAR COV2 virus infection, without radiological affectation. &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10070255\nTerm: Coronavirus test positive\nSystem Organ Class: 10022891 - Investigations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10035664\nTerm: Pneumonia\nSystem Organ Class: 10021881 - Infections and infestations\n &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10003083\nTerm: ARDS\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-COV-2 infection &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10037373\nTerm: Pulmonary disorder\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID19;Therapeutic area: Body processes [G] - Immune system processes [G12]","Cov-2 SARS Disease &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Lower respiratory tract infection by Covid-19 at high risk for development of severe respiratory failure &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10035738\nTerm: Pneumonia viral NOS\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Acute Respiratory Distress Syndrome caused by COVID19 infection &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10001052\nTerm: Acute respiratory distress syndrome\nSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Severe Community Acquired Pneumonia &lt;br&gt;MedDRA version: 20.1\nLevel: LLT\nClassification code 10010120\nTerm: Community acquired pneumonia\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Acute hypoxic respiratory failure of COVID-19 patients &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10074615\nTerm: Hypoxic respiratory failure\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","ICD: U07.1: SARS-CoV-2;U07.1 - Emergency use of U07.1",";U07.1 - Emergency use of U07.1","COVID-19;U07.1 - Emergency use of U07.1","Adjustment disorder;F30-F39 - Mood [affective] disorders;F40-F48 - Neurotic, stress-related and somatoform disorders",";J12.8 - Other viral pneumonia;U07.1 - Emergency use of U07.1",";U07.1 - Emergency use of U07.1","Challenges of the Covid 19 pandemic in primary care","painful polyneuropathy;G60-G64 - Polyneuropathies and other disorders of the peripheral nervous system",";J12.8 - Other viral pneumonia","Covid-19 disease",";U07.1 - Emergency use of U07.1","oncological diagnosis","COVID-19;U07.1 - Emergency use of U07.1","Worry",";U04.9 - Severe acute respiratory syndrome [SARS], unspecified;J80.0 - [generalization J80: Adult respiratory distress syndrome]",";U07.1 - Emergency use of U07.1","Healthcare Workers of Max Hospital and general population","SARS-CoV-2-infection (COVID-19-disease) with severe pneumonia;U07.1 - Emergency use of U07.1",";U07.1 - Emergency use of U07.1","U07.1. &lt;br&gt;Confirmed cases;07.1",";U07.1 - Emergency use of U07.1","psychological burden caused by COVID-19;U07.1 - Emergency use of U07.1","COVIDE-19. &lt;br&gt;Other coronavirus as the cause of diseases classified elsewhere;B97.29","COVID-19 pneumonia.","Psychological Distress (Depression, anxiety, financial/Family Problems) and resources (coherence, self-efficacy, social support)",";U07.1 - Emergency use of U07.1","COVID-19. &lt;br&gt;corona virus disease 2019;U07.1",";U07.1 - Emergency use of U07.1;J80.03 - [generalization J80: Adult respiratory distress syndrome]","Job Stress. &lt;br&gt;Acute stress reaction;F43.0","COVID-19 pneumonia.","Not applicable","COVID-19. &lt;br&gt;COVID-19;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1",";J12.8 - Other viral pneumonia","Coronavirus as the cause of diseases classified elsewhere","Corona virus disease. &lt;br&gt;COVID19, virus identified;U07.1","COVID- 19 (Prevention of  infection)","Other specified viral diseases","Condition 1: Pneumonia. Condition 2: Acute bronchitis. Condition 3: Acute respiratory distress syndrome (ARDS). &lt;br&gt;Other viral pneumonia &lt;br&gt;Acute bronchitis due to other specified organisms &lt;br&gt;Acute respiratory distress syndrome;J12.89;J20.8","Coronavirus infection, unspecified","Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: COVID-19. &lt;br&gt;Other viral pneumonia &lt;br&gt;COVID-19, virus identified;J12.89;U07.1","Covid-19 prophylaxis.","Other viral pneumonia","COVID-19 pneumonia.","COVID-19 pneumonia.","COVID-19. &lt;br&gt;COVID-19;U07.1","COVID-19. &lt;br&gt;Severe Acute Respiratory Syndrome coronavirus;RA01.0","COVID-19. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19. &lt;br&gt;COVID-19;U07.1","corona virus disease. &lt;br&gt;COVID-19, virus not identified;U07.2","Pulmonary fibrosis and acute respiratory distress syndrome caused by novel corona-virus pneumonia (COVID-19). &lt;br&gt;Coronavirus infection, unspecified;B34.2","Infection caused by COVID-19. &lt;br&gt;COVID-19, virus identified is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing;U07.1","Covid-19. &lt;br&gt;Covid-19;RA01.0","Covid 19. &lt;br&gt;COVID-19, virus identified;U07.1","COVID-19 pneumonia. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19. &lt;br&gt;COVID-19;U07.1","Coronavirus Disease 2019 (COVID-19). &lt;br&gt;COVID-19;U07.1","Novel Cronavirus Disease (COVID-19). &lt;br&gt;?????? ?????? ?????;COVID-19","corona virus.","Infectious disease and respiratory of the Corona virus. &lt;br&gt;Coronavirus infection;B34.2","Patients with Corona Virus. &lt;br&gt;Coronavirus infection, unspecified;U07.1","COVID-19 Disease. &lt;br&gt;COVID-19 Disease;U07.02","COVID-19. &lt;br&gt;2019-nCOV disease;U07.1","Corona virus infection. &lt;br&gt;COVID-19, confirmed by laboratory testing;U07.1","COVID-19. &lt;br&gt;Clinically-epidemiologically diagnosed COVID-19, Probable COVID-19, Suspected COVID-19;U07.1","COVID-19 pneumonia. &lt;br&gt;Confirmed diagnosis of COVID-19;RA01.0","covid-19. &lt;br&gt;Covid-19;U07.1","Covid-19. &lt;br&gt;Other coronavirus as the cause of diseases classified elsewhere;U07.1","Condition 1: anxiety. Condition 2: Coronavirus disease (COVID-19). &lt;br&gt;Anxiety disorder, unspecified &lt;br&gt;Coronavirus infection, unspecified;F41.9;B34.2","corona virus or COVID-19. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19 pneumonia. &lt;br&gt;COVID-19, virus identified;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1","Covid-19. &lt;br&gt;Covid-19;U07.1","the 2019 novel Corona virus (COVID-19). &lt;br&gt;COVID-19 confirmed by laboratory testing.;U07.1","COVID-19. &lt;br&gt;COVID-19 confirmed by laboratory testing;U07.1","COVID-19. &lt;br&gt;Covid-19;U07.1","Coronavirus COVID-19. &lt;br&gt;COVID-19;U07.1","COVID-19. &lt;br&gt;COVID-19, virus identified;U07.1","Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: Coronavirus (COVID-19)-induced pneumonia. &lt;br&gt;COVID-19, virus identified;U07.1;J12.8","COVID-19. &lt;br&gt;U07.1 COVID-19;COVID-19","COVID-19 disease. &lt;br&gt;COVID-19, virus identified;U07.1","Coronavirus. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19 Disease. &lt;br&gt;COVID-19 Disease;U07.02","COVID-19. &lt;br&gt;COVID-19;U07.1","Condition 1: COVID-19. Condition 2: COVID-19. &lt;br&gt;U07.1: COVID-19, virus identified &lt;br&gt;U07.2: COVID-19, virus not identified;U07.1;U07.2","The effectiveness of Sovodak in patients with novel Corona Virus. &lt;br&gt;ICD-10 code of U07.1 COVID-19, virus identified is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing.;U07.1 COVI","Covid-19. &lt;br&gt;COVID-19 Disease;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1","Covid-19. &lt;br&gt;Covid-19;U07.1","COVID-19 pneumonia. &lt;br&gt;COVID-19, virus not identified;U07.2","Covid-19. &lt;br&gt;Covid-19 disease;U07.1","Coronavirus. &lt;br&gt;Coronavirus as the cause of diseases classified elsewhere;B97.2","COVID-19. &lt;br&gt;U07.2COVID-19, virus not identified, COVID-19;U07.2","COVID-19. &lt;br&gt;SARS-associated coronavirus as the cause of diseases classified elsewhere;U07.1","COVID-19. &lt;br&gt;Confirmed COVID-19;U07.1","COVID-19. &lt;br&gt;COVID-19, virus identified;U07.1","COVID-19. &lt;br&gt;U07.1;U07.1","Condition 1: COVID-19. Condition 2: COVID-19. &lt;br&gt;COVID19, virus identified &lt;br&gt;COVID19, virus not identified;U07.1;U07.2","COVID-19. &lt;br&gt;COVID-19 disease;U07.1","Stress.","COVID-19. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID 19. &lt;br&gt;Corona virus infection, unspecified;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1 COVI","COVID-19 pneumonia. &lt;br&gt;Confirmed diagnosis of COVID-19;RA01.0","COVID-19 pneumonia. &lt;br&gt;COVID-19, virus identified;U07.1","Condition 1: Patients with COVID-2019. Condition 2: . &lt;br&gt;COVID-19, virus identified;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1","COVID-19. &lt;br&gt;Coronavirus infection, unspecified;U07.1","Corona virus disease 2019 (COVID-19). &lt;br&gt;Coronavirus infection, unspecified;B34.2","Condition 1: COVID-19 disease. Condition 2: Acute myeloid leukemia. Condition 3: Acute lymphoblastic leukemia. Condition 4: Breast cancer. Condition 5: Colon cancer. Condition 6: Diffuse large B cell lymphoma. &lt;br&gt;Coronavirus infection, unspecified &lt;br&gt;Acute myeloblastic leukemia &lt;br&gt;Acute lymphoblastic leukemia [ALL] &lt;br&gt;Malignant neoplasm of breast &lt;br&gt;Malignant neoplasm of colon &lt;br&gt;Diffuse large B-cell lymphoma;B34.2;C92.0;C91.0;C83.3","Acute Respiratory Distress Syndrome of COVID-19. &lt;br&gt;COVID-19;U07.1","Patients with Corona Virus. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19. &lt;br&gt;SARS-associated coronavirus as the cause of diseases classified elsewhere;U07.1","COVID-19. &lt;br&gt;Coronavirus infection, unspecified;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1","Corona virus disease 2019 (COVID-19). &lt;br&gt;COVID-19, virus identified;U07.1","Condition 1: COVID-19. Condition 2: Coronavirus (COVID-19)-induced pneumonia. &lt;br&gt;U07.1: COVID-19, virus identified &lt;br&gt;Pneumonia due to SARS-associated coronavirus;U07.1;J12.81","Covid-19. &lt;br&gt;Covid-19;U07.1","COVID-19 disease. &lt;br&gt;COVID-19;U07.2, U07","Covid-19. &lt;br&gt;COVID-19 disease;U07.1","COVID-19. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19 pneumonia. &lt;br&gt;COVID-19, virus identified;U07.1","COVID-19. &lt;br&gt;COVID-19, virus identified;U07.1","Condition 1: COVID-19. Condition 2: COVID-19-induced pneumonia. &lt;br&gt;COVID-19, virus identified &lt;br&gt;Pneumonia due to SARS-associated coronavirus;U07.1;J12.81","COVID-19 disease. &lt;br&gt;COVID-19, virus identified;U07.1","Acute Respiratory Distress Syndrome of COVID-19. &lt;br&gt;COVID-19;U07.1","Novel Coronavirus Pneumonia (COVID-19)Coronavirus (COVID-19). &lt;br&gt;COVID-19, virus identified;U07.1","COVID-19. &lt;br&gt;COVID-19;U07.1","Covid-19. &lt;br&gt;COVID-19 Disease;U07.1","covid-19. &lt;br&gt;COVID-19, virus identified;U07.1","Mental Disorders &lt;br&gt;Depression &lt;br&gt;Anxiety;2568;2605;Depression;Anxiety","COVID-19. &lt;br&gt;Covid-19;U07.1","COVID 19. &lt;br&gt;U07.1;U07.1","COVID-19 disease. &lt;br&gt;Pneumonia due to SARS-associated coronavirus;U07.1","SARS-COV2 ASSOCIATED INFECTION. &lt;br&gt;COVID-19, virus identified;U07.1","COVID 19. &lt;br&gt;Corona virus infection, unspecified;U07.1","COVID-19. &lt;br&gt;COVID-19, virus not identified;U07.2","COVID-19 disease. &lt;br&gt;COVID-19 disease;U07.1","COVID-19 Disease. &lt;br&gt;COVID-19 Disease;U07.02","Covid-19. &lt;br&gt;COVID-19, Virus Identified;U07.1","&lt;br&gt;COVID-19;COVID-19","Novel Coronavirus Infectious Disease (COVID-19)","Patients with COVID-19 non-severe pneumonia","COVID-19. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19 disease.","&lt;br&gt;COVID-19;COVID-19","COVID-19 &lt;br&gt;COVID-19;D000073640","patients infected with COVID-19 &lt;br&gt;Coronavirus","patients infected with COVID-19 &lt;br&gt;Coronavirus","COVID-19 infection","Coronavirus infection &lt;br&gt;Coronavirus Infections;Coronavirus Infections","Covid-19","non specified coronavirus infection/ coronavirus &lt;br&gt;Coronavirus infection, unspecified ;A00-B99;Coronavirus infection, unspecified","COVID-19","COVID-19\r\nARDS &lt;br&gt;COVID-19&lt;br&gt;ARDS&lt;br&gt;Pneumonia&lt;br&gt;Hemoadsorption&lt;br&gt;IL-6;COVID-19&lt;br&gt;ARDS&lt;br&gt;Pneumonia&lt;br&gt;Hemoadsorption&lt;br&gt;IL-6","&lt;br&gt;Covid-19;Covid-19","COVID-19\nHepatobiliary-pancreatic disease","Health care personnel in the endoscopy unit\r\nPatients who will be performed endoscopy procedures &lt;br&gt;healthy&lt;br&gt;health care personnel&lt;br&gt;endoscopy&lt;br&gt;Covid-19&lt;br&gt;rapid test&lt;br&gt;antibody;healthy&lt;br&gt;health care personnel&lt;br&gt;endoscopy&lt;br&gt;Covid-19&lt;br&gt;rapid test&lt;br&gt;antibody","Household members of newly diagnosed COVID-19 patients &lt;br&gt;Household members&lt;br&gt;COVID-19&lt;br&gt;Prophylaxis;Household members&lt;br&gt;COVID-19&lt;br&gt;Prophylaxis","COVID19 &lt;br&gt;Coronaviridae;Coronaviridae","COVID-19","Preparedness and responsiveness of french Hospital and ED by electronic survey.\r\nHead of Emergency Department will be questionned. &lt;br&gt;Covid-19, Preparedness, Responsiveness, Emergency, Quality, Organization, Formation, Resources, Management, Interoperability;Covid-19, Preparedness, Responsiveness, Emergency, Quality, Organization, Formation, Resources, Management, Interoperability","Volunteers; pathological conditions, signs and symptoms &lt;br&gt;Volunteers;Volunteers","Contacts and SARS-CoV-2 infection suspects","-B342 Coronavirus infection, unspecified site\r\n &lt;br&gt;Coronavirus infection, unspecified site;B342;Coronavirus infection, unspecified site","Covid-19 cases management during epidemic phase &lt;br&gt;Covid-19; Emergency; Quality; ;Covid-19; Emergency; Quality;","Severe acute respiratory syndrome; Viral Pneumonia &lt;br&gt;Other viral pneumonia ;U00-U99;J00-J99;Other viral pneumonia","Illiterate\r\nSerious illness &lt;br&gt;Social, Ethical, Behavioural, Novel coronavirus, Pandemic  ;Social, Ethical, Behavioural, Novel coronavirus, Pandemic"],["survival group:none;died:none;","Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;","control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;","case series:N/A;","Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid","Case series:Extracorporeal Membrane Oxygenation;","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;","Drug: Lopinavir and Ritonavir Tablets;Drug: Arbidol",null,"Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;","Case series:Not applicable.;","Case series:Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;","case series:N/A;","Gold Standard:Guidelines for novel coronavirus pneumonia (fifth edition);Index test:Diagnosis&amp;#32;model&amp;#32;based&amp;#32;on&amp;#32;Artificial&amp;#32;Intelligence&amp;#32;(Epidemiological&amp;#32;history,&amp;#32;clinical&amp;#32;information,&amp;#32;laboratory&amp;#32;examination,&amp;#32;hospitalization&amp;#32;profile,&amp;#32;pulmonary&amp;#32;function&amp;#32;examination,&amp;#32;blood&amp;#32;gas&amp;#32;test,&amp;#32;chest&amp;#32;plain&amp;#32;film,&amp;#32;chest&amp;#32;CT,&amp;#32;complications,&amp;#32;final&amp;#32;classification,&amp;#32;disease&amp;#32;stage).;","Gold Standard:RT-PCR of the novel coronavirus;Index test:Exhaled&amp;#32;breath&amp;#32;detection&amp;#32;by&amp;#32;mass&amp;#32;spectrometry;","TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules;Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Drug: Arbidol;Other: basic treatment","experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;",null,"Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: &lt;br&gt;1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-CoV-2; &lt;br&gt;2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-CoV-2.;Index test:SARS-CoV-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.&amp;#32;nasopharyngeal&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples;","control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;","experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;","experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;","Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;","Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;","Normal group:No;Severe group:No;","Experimental group:Xinguan-1 formula+Standard treatment;Control group:Standard treatment;","Case series:Conventional standardized treatment and vMIP atomized inhalation;","Case series:Traditional Chinese Medicine;","Experimental group:honeysuckle decoction;Control group:placebo;","Case series:Nil;","Experimental group:Conventional Treatment &amp; Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;","Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;","Drug: Intravenous Immunoglobulin;Other: Standard care","Drug: ASC09/ritonavir group;Drug: lopinavir/ritonavir group","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;","Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined with Chloroquine Phosphate.;","Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;","Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;","Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;","control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;","experimental group:TCM and general treatment;control group:general treatment;","Case series:Nil;","experimental group:Xiyanping injection;control group:alpha-interferon;","control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;","Experimental group:chloroquine;control group:conventional management;","experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;","Case series:NA;","control group:western medical therapies;Experimental group:Conventional medicine + TCM;","Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;","Treatment group:Integrated Traditional Chinese and Western Medicine;","Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;","Case series:Nil;","Case series:Nil;","(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Western Medicine Group:Use the (ordinary)   TCM clinical prescription combined with the western medicine  treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;","Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;","Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;","treament group:Chinese medicine decoction;placebo group:placebo;","experimental group:Traditional Chinese Medicine+psychological intervention;\t Control group:Traditional Chinese Medicine;Control group:psychological intervention;","experimental group \t:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;","Vitamin D deficiency group:N/A;Vitamin D normal group:N/A;","doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;","Experimental group:Xinguan-2 formula+Standard treatment;Control group:Standard treatment;","Gold Standard:Clinical outcome;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system;","Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules;","Gold Standard:Nucleic acid detection method of novel Coronavirus pneumonia ;Index test:IgM/IgG;","Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;","Two groups:Different stem cell doses;","Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;","Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional treatment;","Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the \"Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)\" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.;","control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;","experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;","Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;","DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 mg SC QOD) ;","Experimental group:Isolation and oral  Gubiao Jiedu Ling Chinese medicine;Control group:Isolated observation;","experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","Case series:according to guidelines;","Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;","Case series:Nil;","Case series:variety treatments;","Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","Observation  group:TCM prevention;Health  education unit:Health  education;","Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical&amp;#32;care&amp;#32;ultrasound&amp;#32;examination;","Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;","Case series:NA;","Experimental Group:Conventional Treatment &amp; Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks);","Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;","control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","Case series:Basic symptomatic therapy combined with glucocorticoid therapy;","Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.;","Severe group:None;Critical group:none;Light group:None;Common group:None;","A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;","Exercise prescription group:Exercise prescription;Control group:None;","1:Simplify cognitive behavior;2:Supportive psychotherapy;","experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;","Epilepsy group:N/A;Health Control group:N/A;","Psychological Intervention Group:\"Intelligent Psychosomatic Regulation System\" Intervention;Control Group :General Treatment ;","Suspected patient control group:Routine respiratory disease treatment;Suspected patient Treatment group:Oral Chinese medicine treatment based on control group;Common NCP patient control group:treatment according to the guideline;Common NCP patient Treatment group:Oral Chinese medicine treatment based on control group;Severe NCP patient:Oral Chinese medicine treatment and treatment according to the guideline;","non-severe group and severe gorup:N/A;","Case series:N/A;","Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;","mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate  ;severe- Lopinavir/ritonavir group:oral Lopinavir/ritonavir;","experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental Group B2:Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment;Control Gorup A:Conventional treatment;","Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Control group:Routine treatment;","Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;","Experimental group :Oral leflunomide;Control group:Oral placebo;","Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","Case series:FNC;","case series:none;","single arm:Chinese medicine treatment combined with western medicine treatment;","Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral \"Wu-Zhi-Fang-Guan-Fang\" decoction;Control group:Routine quarantine measures;","A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.;C:Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.;","experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","Biological: 2019-nCoV PCR","Drug: PD-1 blocking antibody+standard treatment;Drug: Thymosin+standard treatment;Other: standard treatment","Case series:Nil;","Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;","Case series:N/A;","Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","Case series:Nil;","Adolescent group:NA;Childbearing group:NA;Climacterium group:NA;","Severe group:None;Non-severe group:None;","1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","Case series:Anti-2019-nCoV virus inactivated plasma;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","Case series:Suramin( IV.);","Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Biological: UC-MSCs","Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","Case series:NA;","Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Mild Group:probiotics;Severe Group:probiotics;","Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;","Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","Case series:Humanistic care;","Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;","pneumonia patients group:N/A;medical staff group:N/A;","Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel coronavirus pneumonia severe and critical cases;","experimental group:mesenchymal stem cells;control group:saline;","Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","COVID-19 pregnant women and normal pregnant women and infants born to them:None;","Gold Standard:Pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and Pathogenic nucleic acid test of pharynx swab.;Index test:expression&amp;#32;of&amp;#32;sars-cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;in&amp;#32;vaginal&amp;#32;secretions;","Gold Standard:Diagnostic criteria for severe novel coronavirus pneumonia.;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system.;","common group:N/A;severe group:N/A;critical group:N/A;","Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;","control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:conventional treatment;experimental group with critical NCP:conventional treatment combined with ozone therapy;control group with critical NCP:conventional treatment;","Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","general anesthesia group vs. intraspinal anesthesia group:N/A;Health care goup:N/A;","hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan ;","Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","Case series:Nil;","Case series:mesenchymal stem cells therapy;","Training:None;Vaidation:None;","college students:none;","Other: mobile internet survey on self-test","Drug: thalidomide;Drug: placebo",null,"Other: nCapp, a cell phone-based auto-diagnosis system","Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","control group:conventional therapy;Experience group:conventional therapy and Tranilast;","experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","Drug: Meplazumab for Injection","Drug: Xiyanping injection;Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Experimental group:Chloroquine Phosphate;Control group:No;","Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy;","Case series:Nil;","Drug: placebo;Drug: Thalidomide","Other: Comprehensive treatment","Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","Gold Standard:Postive result of SARS-CoV-2 nucleic acid examination;Index test:Diagnostic&amp;#32;Assistance&amp;#32;Decision&amp;#32;Support&amp;#32;System;","Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group 2:Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid;",null,"Case series:Combination of Tocilizumab, IVIG and CRRT;","Monitor cases, suspected cases and diagnosed cases:No;",null,"one group:Rehabilitation Lung Health Eight - Stage Exercise ;","Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;","Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment;","Case series:NA;","Case series:moxibustion;","Case series:routine treatment+indirect moxibustion;","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet;Drug: N-acetylcysteine+Placebo","Drug: Fingolimod 0.5 mg","Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","Light and common type group:Conventional treatment;Severe group:Conventional treatment;Western medicine treatment group:Give routine western medicine treatment;Chinese and western medicine combined treatment group:Traditional Chinese medicine is combined with conventional western medicine treatment.;Non-invasive mechanical ventilation group:Give noninvasive mechanical ventilation and respiratory support;Nasal high flow oxygen therapy group:Give nasal high flow oxygen therapy respiratory support;","Case series:Nil;","Intervention group:Psychological intervention;","Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","Gold Standard:COVID-19 viral PCR;Index test:MicroRNA;","Two groups:Chinese massage versus control;","Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;","Exposure group:Western medicine routine treatment+triple energizer treatment;Control group:Conventional medicine routine treatment;","Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","Case series:traditional Chinese medicine;","The experimental group:Wear a self-made \"gastroscope mask\" during gastroscopy;Control group:Without self-made \"gastroscope mask\" during gastroscopy;","Mild group:Conventional treatment;Serere group:intensive care;","Case series: Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Group 2:Once for two days;Group 3:Once for one day;Group 1:Control Group;","Case series:N/A;","case series:N/A;","High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","Burnout positive group versus burnout negative group:NO;","Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day \t;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Gold Standard:Detection of novel coronavirus by fluorescence RT-PCR;Index test:Detection&amp;#32;of&amp;#32;viral&amp;#32;nucleic&amp;#32;acids&amp;#32;in&amp;#32;eye&amp;#32;swabs,&amp;#32;throat&amp;#32;swabs,&amp;#32;oral&amp;#32;saliva,&amp;#32;feces,&amp;#32;urine&amp;#32;and&amp;#32;plasma;","Case series:Retrospective analysis;","Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kanguan No. 3;Control group (severe patients):Routine treatment;","Case series:Nil;","Case series:conventional therapy+tocilizumab;","Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","Experimental group:Conventional drug therapy plus hydrogen inhalation;Control group:Conventional drug therapy;","Case series:Integration of traditional Chinese and Western Medicine;","Case series:Nil;","the elderly population:none;","Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","Experimental group:recombinant human interferon a1b spray;Control group:Blank;","Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;","Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","Case series:Nil;","experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","Experimental group:Conventional treatment &amp; Acupuncture;Control Group:Conventional treatment;","Case series:Nil;","General population:Health Advice based on survey results;","Case series:Nil;","Case series:Nil;","Experimental group:Exercise prescription;Control group:none;","Case series:Nil;","Experimental group:Chloroquine phosphate;","Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;",null,"control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;","Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","Case series:No;","Case series:N/A;","experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","Drug: Carrimycin;Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;Drug: basic treatment","Case series:observation;","case series:N/A;","experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","Gold Standard:Nucleic acid test;Index test:Nano-nasal&amp;#32;COVID-19&amp;#32;diagnostic&amp;#32;screening&amp;#32;model;","Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:None;","CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","Biological: MSCs-derived exosomes","Case series:None;","Diagnostic Test: Standard screening strategy;Diagnostic Test: New screening strategy","Drug: pirfenidone","Control group:Western medicine treatment;Experimental group:integrate Chinese and conventional medicine  treatment;","Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment&amp;#32;","Case series:clustering nusing progremm;","Group 2:conservation mechanical ventilation group;Group 1:aggressive mechanical ventilation;","Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","Case series:Nil;","Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","Case series:reverse transcription polymerase chain reaction;","Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","Medical students group; Non-medical students group:None;","Other: CT score","Drug: T89","Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological intervention;","Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug;","PRE-GROUP1:Taking Chinese medicine preventive decoction;PRE-GROUP2:General prevention methods;TRE-GROUP1:TCM syndrome differentiation treatment+ Western medicine treatment;TRE-GROUP2:Western medicine treatment;","Case series:Nil;","Patients in Wuhan versus Sichuan:none;","Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","ACEIs/ARBs:NA;","COVID-2019 patients in Tongji Hospital:none;COVID-2019 patients in Mobile field hospital:none;Medical staff in Tongji Hospital:none;Control:none;","Experimental group:pulmonary training;control group:Conventional medication;","monitor cases, suspected cases and diagnosed cases:Provide psychological intervention for children with severe stress response;","Case series:Anti-SARS-CoV-2 virus inactivated plasma;","treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intravenous administration, 180mg / time, 1 time / day, 7 days / course, 2 courses in total;control group:The control group was given the same amount of placebo (stem cell solvent);","Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","Case series:Nil;","Case series:no;","Case series:NA;","cross-sectional study:no;","Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","Case series:cytokine removal therapy with Cytosorb;","Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","Case series:Nil;","Case series:NA;","Control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan.;Experimental group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + Yiqi Huashi Jiedu Fang (same as above), decoction of decoction machine, 300mL;","Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;","Case series:oXiris membrane;","group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","Case series:Nil;","Case series:traditional Chinese medicine and Western medicine treatment;","Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;","patient group:Under surgical and anesthesia;Health care team:Anesthesiologists for NCP patients;","Case series:Nil;",null,"Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection;Drug: Lopinavir/ritonavir treatment","Case series:Nil;","Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;","Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;","intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;","Observation group:Positive Psychological Guidance Group Counseling;","Case series:None;","Ordinary COVID-19 patients:Nil;Heavy COVID-19 patients:Nil;","Device: Medical Mask;Device: N95 respirator","Other: Exposed to the novel coronavirus disease 2019","Other: severe covid-19 pneumonia with ET","Population under risk:Chushifangyi prescription;",null,"Drug: Recombinant human interferon a1","Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","MSC group:Intravenous infusion of MSC based on conventional treatments;","Case series:Nil;","Case series:None;","Case series:N/A;","Case series:Not applicable;","Case series:Western medicine plus Qingfei Paidu decoction;","Experimental group:Pirfenidone;Control group:Blank;","The triple combination antiviral therapy:abidor,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);The dual combination antiviral therapy:,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);","Case series:none;","Group 1:Traditional Chinese medicine and routine treatment of western medicine;Group 2:Routine treatment of western medicine;","Case series:dexmedetomidine;","Case series:qingfei detoxification decoction (mixture);","Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","Case series:Nil;","Case series:Nil;","Case series:The use of fiberoptic bronchoscopy;","Case series:none;","Case series:external diaphragmatic pacing;","Gold Standard:RT-PCR test results;Index test:Typing&amp;#32;and&amp;#32;prediction&amp;#32;accuracy&amp;#32;of&amp;#32;artificial&amp;#32;intelligence&amp;#32;models;","Case series:Nil;","Gold Standard:RT-PCR test results;Index test:Artificial&amp;#32;intelligence&amp;#32;model;","Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","Observation group:Medical workers in Hubei province;Control group:Non-Hubei medical staffNon-Hubei medical staff;","High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","Case series:Psychological intervention;","Gold Standard:PCR Nucleic acid detection;Index test:high-throughput&amp;#32;novel&amp;#32;coronavirus&amp;#32;(2019-nCoV)&amp;#32;screening&amp;#32;detection&amp;#32;kit;","Case series:Nil;","Case series:Nil;","Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","Case series:Laboratory examination and pulmonary CT;","Case series:Nil;","Case series:No;","Case series:Nil;","Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","Case series:none;","\t Case series:none;","control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","Case series:N/A;","Case series:Nil;","non-cancer COVID-19 versus cancer with COVID-19:none;","experimental group:Oral Chinese medicine \"qingfei detoxification soup\" + intravenous injection of ulinastatin 200000 U Bid.;","NIV group:no;MV group:no;","Case series:Nil;","severe patients:none;","Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","discharge group:no;","Gold Standard:Clinical outcome;Index test:artificial&amp;#32;intelligence&amp;#32;prediction&amp;#32;model;","Gold Standard:Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive;Index test:Elisa&amp;#32;analysis&amp;#32;of&amp;#32;validation&amp;#32;factors,&amp;#32;inflammatory&amp;#32;factors,&amp;#32;adhesion&amp;#32;factors;","Case series:none;","Case series:Noninvasive hemodynamic monitoring;","Case series:no;","Case series:No;","Case series:Early initiation of blood purification;","Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","4 groups:N/A;","Case series:no;","case series:no;","transnasal high-flow oxygen therapy:prone position ventilation;noninvasive mechanical ventilation:prone position ventilation ;invasive mechanical ventilation:prone position ventilation;","Case series:Nil;","Case series:Traditional Mongolian Medicine;","Case series:CRRT;","two groups:no intervention;","case series:no;","Case series:no;","case series:no;","Experimental group:chloroquine phosphate ;Control group:none;","Case series:filling in the  scale;","Gold Standard:2019 nCOV detection;Index test:SARS-CoV-2 IgM;","ECMO group:ECMO therapy;the conventional treatment group:no;","Exposed group:Prophylactic antifungal therapy;Control group:Diagnostic antifungal therapy;","Case series:Nil;","case series:Nil;","case series:no;","in hospital:Virus detection in semen;Recovered:Hormones and sperm quality;","Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;Index test:1.&amp;#32;throat&amp;#32;swab&lt;br&gt;2.&amp;#32;induced&amp;#32;sputum;","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;","Integrated traditional Chinese and western medicine group:Traditional Chinese medicine and routine treatment of western medicine;Western medicine group:Routine treatment of western medicine;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Control group :Health education and   symptomatic treatment;Comprehensive treatment group:Health education+Comprehensive TCM treatment;","experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","Two groups:Nil;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Case series:Nil;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","Infection without renal injury group:none;Infection with proteinuria group:Bailing Capsule;Infection with hematuria group:Bailing Capsule;Infection with impaired renal function group:Bailing Capsule, Renal replacement therapy;","Gold Standard:Clinical outcomes;Index test:MEWS&amp;#32;and&amp;#32;other&amp;#32;scores;","Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","1:Throat swab virus nucleic acid test combined with low-dose chest CT;2:Throat swab virus nucleic acid test combined with low-dose chest CT;","Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&amp;#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;","Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common extubation;Group D:Propofol anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;","Case series:Psychological counseling;","Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;","eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","Case series:Nil;","treatment group :Ba duanjin;","Case series:no;","Case series:NA;","Gold Standard:Chest CT examination;Index test:Lung&amp;#32;ultrasound&amp;#32;examination;","Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.;","Case series:Nil;","experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","Routine treatment group:Conventional treatment of 2019-nCoV pneumonia;Dipyridamole treatment group:Conventional treatment of 2019-nCoV pneumonia and Dipyridamole;","Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","tumor patients group:no;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Case series:high-dose Vitamin C+Standard treatment;","Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: 1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-Cov-2; 2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-Cov-2. ;Index test:SARS-Cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.morning&amp;#32;sputum&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples&amp;#32;;","Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","Two cohorts:Arbidol cohort versus without Arbidol cohort;","High dose group:High-dose NK cells (&gt;5x10^9)and mesenchymal stem cells(&gt;5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every week for a total of one time;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","case series:N/A;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";Placebo:2 tablets placebo BID;","Chinese medicine treatment cohort:traditional Chinese medicine;Integrated Chinese and western medicine treatment cohort:Chinese medicine and western medicine;Western medicine treatment cohort:western medicine;","Case series:N/A;","Case series:Nil;","Group 1:Baduanjin;Group 2:Auricular acupressure;","experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","Biological: Dental pulp mesenchymal stem cells","Case series:Nil;","Drug: VC;Drug: Sterile Water for Injection",null,"Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate","Diagnosed Group:Nil;Suspending Group:Nil;","Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","Experimental group:High-dose Vitamin C;Control group:Routine treatment;","Case series:none;","Gold Standard:Nucleic acid detection method of COVID-19;Index test:IgM/IgG&amp;#32;detection&amp;#32;method&amp;#32;of&amp;#32;COVID-19;","Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","Case series:Nil;","COVID-19  patients:no;","Group 1:psychological support;Group 2:cognitive behavioral therapy;","Gold Standard:Clinical outcomes;Index test:the&amp;#32;diagnosis&amp;#32;and&amp;#32;prognosis&amp;#32;prediction&amp;#32;AI&amp;#32;model;","Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","SFBT group:Internet based SFBT;Waiting Group:Wait ;","Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","Case series:NA;","Group 2:thymosin;Group 1:BaZhen soup;","Case series:Nil;","Critical group/ Ordinary group:no;","SARS-COV-2 RNA Positive group:None;SARS-COV-2 RNA Negative group:None;","Case series:oral CSA0001;","Case series:Nil;","Case series:Nil;","A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;",null,"Biological: Pathogen-specific aAPC","1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","Case series:Nil;","the patients of 2019 new coronavirus pneumonia:None;","Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","Case series:Nil;","1:Low dose (5E10vp);2:Middle dose (1E11vp);3:High dose (1E11vp);",null,"Case series:Nil;","COVID-19 patients:Nil;","Case series:Nil;","Case series:Nil;","Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion interval 1 week (+/-2 days) from the last time.;","COVID-19 patients:Retrospective analysis;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Experimental group:Farpiravir tablets;Control group:Abidole tablets;","experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","Gold Standard:Other parts samples or other methods for virus detection;Index test:Upper&amp;#32;Respiratory&amp;#32;Tract&amp;#32;Virus&amp;#32;Detection;","Gold Standard:Clinical outcome;Index test:Based&amp;#32;on&amp;#32;proteomics,&amp;#32;genomics,&amp;#32;and&amp;#32;epigenomics&amp;#32;to&amp;#32;detect&amp;#32;molecular&amp;#32;markers&amp;#32;in&amp;#32;peripheral&amp;#32;blood&amp;#32;of&amp;#32;patients&amp;#32;with&amp;#32;mild&amp;#32;and&amp;#32;severe&amp;#32;COVID-19&amp;#32;infection,&amp;#32;in&amp;#32;order&amp;#32;to&amp;#32;establish&amp;#32;an&amp;#32;early&amp;#32;molecular&amp;#32;marker&amp;#32;prediction&amp;#32;model&amp;#32;to&amp;#32;predict&amp;#32;the&amp;#32;prognosis&amp;#32;of&amp;#32;patients.;","Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;",null,"Experimental group:Increased Compound Houttuynia Mixture in real world situations;Control group:None(People who do not receive Compound Houttuynia Mixture in real world situations);","Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.;Index test:First&amp;#32;pass&amp;#32;perfusion&amp;#32;imaging&amp;#32;parameters&amp;#32;(slope,&amp;#32;tip,&amp;#32;PT)&amp;#32;and&amp;#32;delayed&amp;#32;enhancement&amp;#32;ratio&amp;#32;(%);&amp;#32;quantitative&amp;#32;T1&amp;#32;\\&amp;#32;T2&amp;#32;values,&amp;#32;ECV&amp;#32;and&amp;#32;pseudocolor&amp;#32;images&amp;#32;were&amp;#32;obtained&amp;#32;by&amp;#32;t1mapping&amp;#32;\\&amp;#32;T2&amp;#32;mapping.&amp;#32;Meanwhile,&amp;#32;the&amp;#32;degree&amp;#32;of&amp;#32;myocardial&amp;#32;edema&amp;#32;and&amp;#32;fat&amp;#32;replacement&amp;#32;was&amp;#32;analyzed.&amp;#32;Myocardial&amp;#32;creatine&amp;#32;metabolism&amp;#32;was&amp;#32;analyzed&amp;#32;by&amp;#32;MRS,;","Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","tumor patients group:N/A;non tumor patients group:N/A;","cross-sectional study:Nil;","Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy Type Group C:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;","Gold Standard:RT-PCR test;Index test:artificial&amp;#32;intelligence&amp;#32;triage&amp;#32;system;","Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / ritonavir tablets (Kaletra) twice a day, twice each time, 7-14 days.;intervention C:On the basis of routine medical treatment, combined with Novafron and Kaletra, the usage and course of treatment are the same as above.;","Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","Case series:no;","Drug: Methylprednisolone;Drug: Methylprednisolone","Drug: Bromhexine Hydrochloride Tablets;Drug: Arbidol Hydrochloride Granules;Drug: Recombinant Human Interferon a2b Spray","&lt;br&gt;Trade Name: Plaquenil 200 mg, comprim pellicul&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","observational:Ultrasonic monitoring;","Other: washed microbiota transplantation;Other: placebo","Drug: Abidol hydrochloride;Drug: Abidol Hydrochloride combined with Interferon atomization","control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","Case series:Nil;",null,"Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","Combination Product: systemic treatment","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Drug: Abidol hydrochloride;Drug: Oseltamivir;Drug: Lopinavir/ritonavir","Drug: ASC09F+Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: Oseltamivir","Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2&lt;br&gt;Delayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15, 1800 mg twice a day on Day 6 followed by 800 mg twice a day from Day 7","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Drug: Huaier Granule","Drug: Immunoglobulin of cured patients;Drug: ?-Globulin","Drug: YinHu QingWen Decoction;Drug: YinHu QingWen Decoction(low dose);Other: Chinese medicine treatment;Other: standard western medicine treatment",null,"Biological: UC-MSCs;Other: Placebo","Behavioral: Use of social media during COVID-19","Drug: Tetrandrine","Other: non","Biological: WJ-MSCs",null,"Drug: Sildenafil citrate tablets","Drug: Tocilizumab;Other: Standard of care;Procedure: Continuous renal replacement therapy",null,"Drug: TCM prescriptions","Other: oxygen treatment","Drug: Yinhu Qingwen Granula;Drug: Yin Hu Qing Wen Granula(low does);Other: standard medical treatment","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Case series:no;","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&amp;#32;metabolomics&amp;#32;and&amp;#32;other&amp;#32;markers,&amp;#32;mass&amp;#32;spectrometer;",null,"Drug: Any drug used to treat Covid-19",null,null,"mild recovery:none;severe recovery:none;control:none;",null,"Other: pregnant women with laboratory-confirmed 2019-n-CoV","Cesarean section:Case Series;","hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;","Case series:orthokeratology lens;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:new&amp;#32;artificial&amp;#32;intelligence-based&amp;#32;prognosis&amp;#32;assessment&amp;#32;system;","Case series:None.;","Case series:none;","Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in accordance with the \"new coronavirus infection pneumonia diagnosis and treatment program\" trial fifth, sixth, seventh version of the provisions of the implementation.;","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Case series:Nil;","Survival and D:none;","Case series:Nil;","Case series:Nil;","mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;","Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);","Case series:NO;","Case series:?;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Case series:none;","1:Blank;2:Moxibustion treatment;","CM group:Xinguan No. 2 / Xinguan No. 3 alone or + regular treatment;WM group:Regular Ttreatment;","treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;","Experimental group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment;","Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medicine;","Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","Homeopathic patient:The popular science education;","Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;","Case series:standard treatment + syndrome differentiation and treatment of TCM;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Current Sponsor code: SAR153191&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Case series:6-minute walk training;","Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","experimental group:TCM formula and general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);control group:general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);","Case series:Nil;","confirmed group:none;control group:none;","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","Other: Standard administration of oxygen flow;Device: Automated oxygen administration - FreeO2","experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: BCG vaccine (BCG-Vaccin SSI [Nederlands VaccinStatens Serum Instituut]) Danish strain 1331.&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Concentrate and solvent for solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","Drug: Baricitinib","Drug: Lopinavir/ritonavir","Drug: Remdesivir;Drug: Lopinavir/ritonavir;Drug: Interferon Beta-1A;Drug: Hydroxychloroquine;Other: Standard of care","Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo","&lt;br&gt;Trade Name: Quensyl&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","&lt;br&gt;Product Name: Interferon beat-1a (IFN-1a)&lt;br&gt;Product Code: SNG001&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;Current Sponsor code: SNG001&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;Pharmaceutical form of the placebo: Nebulisation solution&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","COVID-19 group:NA;Healthy people:NA;","Other: hyperimmune plasma","Drug: Traditional Chinese Medicine Prescription","Diagnostic Test: Electrocardiogram and transthoracic echocardiography","Dietary Supplement: Vitamin C","Drug: Bevacizumab","Behavioral: Personalized health education;Behavioral: General health education","Dietary Supplement: Natural Honey;Other: Standard Care","Drug: Methylprednisolone;Other: standard care","Drug: Hydroxychloroquine;Other: The control group will not receive hydroxychloroquine","Other: No intervention","Procedure: venepuncture","Drug: Eculizumab","Drug: ACE inhibitor","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Drug: Azithromycin;Drug: Chloroquine","Diagnostic Test: Nasopharyngeal swab","Drug: Nitric Oxide Gas","Drug: Chloroquine or Hydroxychloroquine;Drug: Placebo",null,null,"Other: No intervention","Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient follow up but clinical outcome data are collected retrospectively from case notes and hospital information systems for the duration of hospitalisation, up to 30 days post-intervention.","Other: Patient sampling","ARBs Group:Treatment of ARBs;non-ARBs Group:other treatments;","Control group :Isolate PBMC to extract tRNA ;normal group:Isolate PBMC to extract tRNA;severe group:Isolate PBMC to extract tRNA;",null,"Diagnostic Test: COPAN swabbing and blood sample collection","Group 1:single-shot CBT-I;Group 2:Sleep Hygiene;","Case series:N/A;","Experimental group:Conventional medication + Infusion of mesenchymal stem cells;Control group:Conventional medication;","Control:NA;Noninvasive cardiopulmonary monitoring group:Wear non-invasive multi-channel cardiopulmonary monitor;","Group 1:Routine treatment + Infusion of convalescent plasma;Group 2:Routine treatment;","Case series:Nil;","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Escin;Drug: standard therapy","Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgG;","experiment group:Cold outdoor environment;experiment group :temperature measuring distance;","Procedure: Surgery","Experimental group:Celebrex capsules 200mg / time twice a day for 7 days;control group:routine treatment;","experimental group:Rabeprazole plus chloroquine;control group :Lopinavir + rabeprazole;","Different dose groups:Injection dose;",null,"Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;","cross-sectional study:no;","Gold Standard:Viral nucleic acid detection;Index test:specific&amp;#32;serological&amp;#32;detection;","&lt;br&gt;Trade Name: MYLAN&lt;br&gt;Product Name: lopinavir/ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;&lt;br&gt;Trade Name: REBIF&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Remdesivir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","ordinary group versus severe group versus critical group versus deceased patients group:no;","Mild:No;severe:No;","&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Experimental group:Rehabilitation Nursing Program;Control group:Routine rehabilitation care;","Medical personnel group:N/A;","&lt;br&gt;Trade Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Product Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CHLOROQUINE PHOSPHATE&lt;br&gt;Other descriptive name: CHLOROQUINE PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Rheumatic disease with COVID-19:N/A;Rheumatic disease without COVID-19:N/A;","eye patch and earplugs:Nil;eye patch:Nil;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Nintedanib group:Nintedanib;Control group:Placebo;","Oral 500mg chloroquine phosphate tablets prophylactic weekly regimen against COVID-19 over 10 week trial period followed with plasma chloroquine levels.","Case series:Questionnaire survey without intervention;","COVID-19 with risk factors:N/A;COVID-19 without risk factors:N/A;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Sulfate d'hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgM;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Sarilumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: Kevzara&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Drug: DAS181;Drug: Placebo","Drug: Bevacizumab Injection","Drug: Sarilumab;Drug: Placebo","&lt;br&gt;Trade Name: Imatinib mesilate &lt;br&gt;Product Name: Imatinib mesilate&lt;br&gt;Product Code: L01XE01&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Other: Observational Study","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Drug: recombinant human interferon Alpha-1b;Drug: thymosin alpha 1","Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine","Drug: Inhaled nitric oxide gas","Drug: Hydroxychloroquine Sulfate","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","In patients in patients with 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in effect a large-scale clinical audit during a global health emergency, as all data is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. Retrospective data will be sourced from all collaborating hospitals across Australia from January 2020 to March 2020. Whereas, international hospitals will provide their retrospective data between January 2019 and march 2020. Prospective data will be collected in Australian and International hospitals until completion of COVID-19 global epidemic, as judged by the World Health Organization. The total duration of observation per participant will be until hospital discharge or 28 days post intensive care unit admission, whichever comes first. The study will combine prospective observation, and retrospective observations sourced from clinical charts. &lt;br&gt;",null,"Device: bidirectional oxygenation mouthpiece","Drug: Camostat Mesilate;Drug: Placebo oral tablet","Drug: DAS181",null,"Other: Tele-medicine platform","Device: CPAP treatment","Device: Inspiratory training device;Device: Expiratory training device","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber);Device: vv-ECMO only (no cytokine adsorption)","Drug: Hydroxychloroquine 200 Mg Oral Tablet;Drug: Azithromycin 500Mg Oral Tablet;Dietary Supplement: Glucose tablets","Drug: Colchicine;Other: Local standard of care","Drug: Chloroquine phosphate","Drug: Tradipitant;Drug: Placebo","Drug: Sargramostim;Other: Control","Other: Placebo;Drug: Remdesivir","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","Drug: Colchicine;Drug: Standard treatment","Drug: Hyperbaric oxygen","Behavioral: turkish physicians","Drug: BCG Vaccine;Drug: Placebo","Device: CT-V","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Diagnostic Test: Breath test","Drug: Hydroxychloroquine as post exposure prophylaxis;Other: Others(No intervention)","Drug: Hydroxychloroquine Sulfate;Drug: Ascorbic Acid","Other: Exposure (not intervention) - SARS-CoV-2 infection","Drug: Ciclesonide Metered Dose Inhaler [Alvesco];Drug: Hydroxychloroquine",null,null,"Other: Human Biological samples",null,"Biological: CAStem",null,"Other: biological samples collection","Device: high flow nasal cannula (HFNC);Procedure: Prone positioning (PP)","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use","Drug: Plasma;Drug: Hydroxychloroquine;Drug: Azithromycin","Biological: high-titer anti-Sars-CoV-2 plasma;Other: oxygen therapy",null,"Biological: Convalescent Plasma","Drug: Peginterferon Lambda-1a;Other: Standard of Care Treatment",null,"Drug: Angiotensin 1-7;Drug: Placebos","Drug: Deferoxamine",null,"Other: retrospective analysis","Procedure: Vascular surgery","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C","Drug: Ibuprofen","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin;Other: Usual antibiotic treatment","Patients with pulmonary infection and COVID 19 will have their respiratory management during ICU admission decided in one of two ways&lt;br&gt;Method 1. Lung ultrasound will be used to make management decisions - this is a non-invasive way of ultrasounding the lungs &lt;br&gt;One hospital site will use method 1&lt;br&gt;Three hospitals will use method 2&lt;br&gt;Both methods are currently standard at the respective hospitals&lt;br&gt;The comparator treatment will be decided by the attending intensivist. The treatment will be different in every patient. Depending on the results of the auscultation and waveform analysis, a different method of mechanical ventilation or respiratory physiotherapy may be chosen. &lt;br&gt;&lt;br&gt;Respiratory physiotherapy may be different in each case but will consist of either ventilator hyperinflation, positioning or manual techniques. The senior respiratory physiotherapist will decide the type of physiotherapy treatment delivered based on COVI 19 guidelines. &lt;br&gt;This will be from admission to ICU to 28 days post hospital discharge",null,"Drug: Chloroquine phosphate;Other: Telemedicine","All women infected with SARS-CoV 2 (novel coronavirus) infection or who were diagnosed with COVID-19 during pregnancy. Observation will continue throughout pregnancy up until 6 weeks postpartum. In addition to standard care, women will be asked to complete a questionnaire after discharge to include postpartum and neonatal outcomes.","Oral administration of Hydroxychloroquine capsules for five days. &lt;br&gt;Day 1: 800mg (4 capsules) Hydroxychloroquine stat&lt;br&gt;Days 2 - 5: 400mg (2 capsules) Hydroxychloroquine once daily&lt;br&gt;Adherence to trial treatment will be assessed through the study diaries which will require the participant to complete the time of administration and number of tablets taken each day. Participants will not be required to return used study treatments to the research office but encouraged to dispose of any unused medication via their community pharmacy or general practice.","Other: Pulmonary ultrasound","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Other: SPIN-CHAT Program","The primary aim of this study is to evaluate the efficacy and efficiency of two telerehabilitation interventions. The intervention consists of a rehabilitation intervention which focuses more on participation in usual activities and is offered via a coaching model to a virtual group of people. The intervention components are: identifying patient goals with therapist (1:1); and participation in virtual groups (up to 4 participants per session) with physiotherapist and occupational therapists which focus on increasing participation in life roles and usual activities. &lt;br&gt;The 1:1 session will last for approximately 45 minutes and will be followed by commencement of group sessions within 5 days.&lt;br&gt;Groups adopt a coaching model where the therapist talks about common challenges, facilitates discussion and sharing of experiences and ideas and the group brainstorm and plan next steps together. The group sessions will last approximately 45 minutes and will be delivered 3 times per week for up to 4 weeks. &lt;br&gt;Adherence will be measured using attendance logs. &lt;br&gt;&lt;br&gt;","COVID-19 symptomatic confirmed hospitalized adult patients will be enrolled as soon as possible after fulfilling the criteria for randomisation. Patients will be allocated in a 1:1 ratio to either the treatment group receiving intravenous zinc chloride (0.5mg/kg/d) or to control group, receiving saline placebo alone. &lt;br&gt;Pharmaceutical grade Zinc Chloride stock solution obtained from an Australian company (Phebra Pty Ltd) will be diluted in 250ml of normal saline and infused, resulting in a final dosage of 0.5mg/kg/d. Patients will be administered zinc for seven days. To standardise administration time, zinc infusions will commence around 9am but anywhere between 8am to 12pm in the morning is adequate. Zinc chloride will be administered via central venous or peripheral access over 3-6 hrs.&lt;br&gt;We will monitor fidelity to the intervention by review of nursing documentation in the intravenous fluid given section of the electronic fluid balance chart. Note will be made of what was given, time commenced, volume given, time completed.&lt;br&gt;","Drug: Defibrotide Injection","Expressive/gratitude writing intervention  This group will participate in the adapted evidenced-based 4-day writing program (Pennebaker 1997). Participants will meet with the facilitator (a researcher with a Psychology degree) using Zoom in a group format four times in one week for approx. 30 minutes (25 minutes of writing time). Daily e-mail reminders will be sent during the 4 days of writing. Session structure  1 min to complete the distress VAS measure (before), 5 minutes write any reflection from last session, 15 minutes spent writing about your thoughts and feelings, 5 minutes writing about the things you are grateful for, 1 min to complete the distress VAS measure (after). The instruction each day will be (adapted from Pennebaker): &lt;br&gt;Please write about your thoughts and feelings about your IBD and the recent situation with COVID-19. Try to select something that you had a strong reaction to  perhaps this was a thought that was challenging or unpleasant. Feel free to really let go and explore your very deepest emotions and thoughts. You might tie your topic to your relationships with others, including parents, lovers, friends or relatives, to your past, your present, your future, or to who you have been, who you would like to be, or who you are now. All of your writing will be completely confidential. Please dont worry about spelling, sentence structure, or grammar. Feel free to type or write by hand. &lt;br&gt;Participants will not be asked to share their writing with the study investigators, to ensure free expression.&lt;br&gt;","Drug: Plasma","Biological: Convalescent Plasma","mild, moderate, severe ARDS:Nil;","Case series:Nil;","Experimental group:WeChat-based parenting education;Control groop:Electronic Manual + Teaching Plan;","Drug: Piclidenoson","Exposure to COVID-19.&lt;br&gt;&lt;br&gt;Participant involvement is required, including but not limited to extra nasopharyngeal swabs, blood draws, as well as possible surveys (local site intervention is bound to ISARIC protocol).&lt;br&gt;There may be follow-up after discharge, at 3 and 6 month timepoints (protocol is evolving).","Based on preclinical and non-randomised studies, the Royal Brisbane and Womens Hospital Intensive Care Unit clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all patients admitted to the ICU with COVID-19 infection should receive hydroxychloroquine as standard care. Therefore, hydroxychloroquine is NOT considered a trial intervention for the purpose of this study.&lt;br&gt;&lt;br&gt;The dose of hydroxychloroquine used for COVID-19 infection is extrapolated from that in common use for malaria and other approved indications. However, the organ dysfuction that accompanies critical illness suggests dosing is likely to require adjustment. This study will adjust the dose of hydroxychloroquine using therapeutic drug monitoring (TDM) to a goal concentration known to be safe. The observation period for TDM will be a total of up to 10 days or until the time of ICU discharge, which ever is sooner.&lt;br&gt;&lt;br&gt;As is routine practice at the RBWH ICU, TDM will be led by the senior ICU pharmacist after initiation of therapy. Trough venous blood samples (3 ml) will be taken via an indwelling arterial cannula. The first TDM should ideally occur before the administration of the FIRST MAINTENANCE DOSE, provided the appropriate loading dose schedule has been completed. Sampling thereafter can occur every 24-48 hours to confirm the appropriateness of ongoing dosing as guided by the Pharmacy and Medical Team. Blood samples will be transported to Queensland Pathology on the Herston Campus for drug analysis. Prescribing of initial and ongoing/revised dosing will remain the responsibility of medical officers, whilst fidelity of the intervention will be maintained through pharmacy dosing adjustment notes which are subjected to","Case series:Nursing care;","Patients with LE and are taking hydroxychloroquine:N/A;Patients with LE and are not taking hydroxychloroquine:N/A;Patients with dermatomyositis and are taking hydroxychloroquine:N/A;Patients with dermatomyositis and are not taking hydroxychloroquine:N/A;Patients with RA and are taking hydroxychloroquine:N/A;Patients with RA and are not taking hydroxychloroquine:N/A;Patients with rosacea and are taking hydroxychloroquine:N/A;Patients with rosacea and are not taking hydroxychloroquine:N/A;","Case series:None;","1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;","survival group:none;death group:none;","intervention group:exercise;Control group:Blank;","Case series:Danorevir sodium tablets,/ritonavir oral;","Case group:N/A;control group:N/A;","1:none;","For the mild new coronary pneumonia: General Ward Group:Nil;For the severe new coronary pneumonia: ICU Group:Nil;Support staff: Logistics group:Nil;","Case series:no intervention;","Experimental group:exercise rehabilitation under remote monitoring;Control group:patient education;","Gold Standard:clinical outcome; nucleic acid test;Index test:antigen reagent;","Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;","NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension;Control group:100ml normal saline intravenous drip;","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&amp;#32;metabolomics&amp;#32;and&amp;#32;other&amp;#32;markers,&amp;#32;mass&amp;#32;spectrometer;","Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);","Case series:cesarean section;","common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","Novel coronavirus pneumonia:none;","Case series:NA;","&lt;br&gt;Trade Name: Plaquenil 200mg&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: NAPROXEN&lt;br&gt;Other descriptive name: NAPROXEN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI&lt;br&gt;&lt;br&gt;Product Name: For example \"Gefrorenes Frischplasma / Apherese DRK Blutspendedienst\"&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: IFX-1&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: -&lt;br&gt;CAS Number: -&lt;br&gt;Current Sponsor code: IFX-1&lt;br&gt;Other descriptive name: -&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ANAKINRA&lt;br&gt;CAS Number: 143090-92-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: SYLVANT&lt;br&gt;Product Name: SYLVANT&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib Teva 400 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IMATINIB&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: AVIGAN 200mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FAVIPIRAVIR&lt;br&gt;Other descriptive name: FAVIPIRAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MICARDIS 20mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TELMISARTAN&lt;br&gt;CAS Number: 144701-48-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEXAMETHASONE MYLAN 20mg/5mL &lt;br&gt;Product Name: DEXAMETHASONE&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: PLAQUENIL 200MG&lt;br&gt;Product Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Product Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Current Sponsor code: REMDESIVIR&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Chloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Interfern b 1A&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: GNS561&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not available&lt;br&gt;CAS Number: 1914148-72-3&lt;br&gt;Current Sponsor code: GNS561&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50 - 200-&lt;br&gt;&lt;br&gt;Trade Name: Opdivo&lt;br&gt;Product Name: Nivolumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: NIVOLUMAB&lt;br&gt;CAS Number: NIVOLUMAB&lt;br&gt;Current Sponsor code: ET17-093&lt;br&gt;Other descriptive name: NIVOLUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEFITELIO&lt;br&gt;Product Name: DEFITELIO&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: DEFIBROTIDE&lt;br&gt;CAS Number: 83712-60-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dexamethasone 20 mg/5mL&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: DEXAMETHASONE&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Medicinal Oxygen&lt;br&gt;Product Name: Medicinal Oxygen&lt;br&gt;Pharmaceutical Form: Medicinal gas, liquefied&lt;br&gt;INN or Proposed INN: Medicinal Oxygen&lt;br&gt;Other descriptive name: Medicinal Oxygen&lt;br&gt;Concentration unit: % (V/V) percent volume/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Pulmozyme 2500 U/2,5ml, solution pour inhalation par nbuliseur&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Metilprednisolona&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-125&lt;br&gt;&lt;br&gt;Trade Name: Modigraf&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.1-0.2&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 648-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lariam&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: MEFLOQUINE&lt;br&gt;CAS Number: 53230-10-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Truvada&lt;br&gt;Product Name: Truvada&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE&lt;br&gt;CAS Number: 202138-50-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: EMTRICITABINE&lt;br&gt;CAS Number: 143491-57-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 245-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine Sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 mg, comprim pellicul&lt;br&gt;Product Code: SAR390530&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: SAR321068&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ibuprofen&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IBUPROFEN&lt;br&gt;CAS Number: 15687-27-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Other descriptive name: AZITHROMYCIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Paracetamol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Paracetamol&lt;br&gt;CAS Number: 103-90-2&lt;br&gt;Other descriptive name: PARACETAMOL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Solu-Modern 1 g polvo y disolvente para solucin inyectable&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Metilprednisolona (como succinato de sodio)&lt;br&gt;CAS Number: 2375-03-3&lt;br&gt;Current Sponsor code: Pfizer, SL&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;","Drug: Vitamin C;Other: Control","Drug: DAS181;Drug: Placebo;Drug: DAS181 COVID-19;Drug: DAS181 OL","Drug: methylprednisolone therapy;Other: Standard care","Drug: Darunavir and Cobicistat","Biological: Human umbilical cord derived CD362 enriched MSCs;Biological: Placebo (Plasma-Lyte 148)","Other: Nutrition support","Drug: Remdesivir;Drug: Remdesivir placebo","Drug: Hydroxychloroquine","Biological: MSCs","Drug: Methylprednisolone","Drug: Galidesivir;Drug: Placebo","Diagnostic Test: Recombinase aided amplification (RAA) assay","Drug: Lopinavir/ritonavir;Drug: Ribavirin;Drug: Interferon Beta-1B","Drug: Ganovo+ritonavir+/-Interferon nebulization","Biological: UC-MSCs;Drug: Placebo","Other: blood sample","Drug: Remdesivir;Drug: Remdesivir placebo","Biological: NK Cells","Biological: mRNA-1273","Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Drug: Oral","Drug: PUL-042 Inhalation Solution;Drug: Placebo","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Other: nosocomial infection/hospital acquired infection","Drug: Remdesivir","Drug: Remdesivir;Drug: Standard of Care","Drug: Remdesivir;Drug: Standard of Care","Drug: Nitric Oxide","Drug: Nitric Oxide Gas","Drug: Losartan;Other: Placebo","Drug: Aviptadil by intravenous infusion + maximal intensive care;Drug: Normal Saline Infusion + Maximal intensive care","Drug: Tocilizumab Injection",null,"Drug: Hydroxychloroquine;Other: Placebo","Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab","Drug: Treatment and prophylaxis;Other: Standard Public Health measures","Other: Questionnaire with precaution information;Other: Experimental: Questionnaire without precaution information","Drug: Losartan;Other: Placebo","Drug: PUL-042 Inhalation Solution;Drug: Placebo","Biological: NestCell","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Other: Follow up","Drug: Hydroxychloroquine Oral Product;Drug: Hydroxychloroquine + azithromycin","Other: survey","Device: Non-contact MCE system","Drug: Tocilizumab","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Behavioral: Mindfulness session(s)","Drug: Hydroxychloroquine;Drug: Remdesivir;Other: (Standard of Care) SoC","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo oral tablet;Drug: Placebo oral tablet","Drug: Remdesivir","Drug: CD24Fc;Drug: Placebo","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Other: observational","Biological: Anti- SARS-CoV-2 Plasma;Biological: SARS-CoV-2 non-immune Plasma","Drug: Tocilizumab (TCZ);Drug: Placebo",null,"Diagnostic Test: Lung ultrasound","Drug: Colchicine",null,"Drug: Colchicine;Drug: Placebo oral tablet","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19;Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Drug: Dexamethasone","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate;Drug: Baricitinib (janus kinase inhibitor);Drug: Sarilumab (anti-IL-6 receptor)","Drug: Sarilumab","Behavioral: Guided online support program;Behavioral: WHO recommendations (waiting condition)","Drug: RoActemra iv;Drug: RoActemra sc;Drug: Kevzara sc;Other: Standard medical care","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants;Dietary Supplement: isocaloric/isonutrigenous ONS","Diagnostic Test: Biomarkers expression","Biological: Emapalumab;Biological: Anakinra","Other: no interventional study","Biological: Convalescent Plasma","Drug: Sarilumab SAR153191;Drug: Placebo","Drug: Dexamethasone","Biological: ChAdOx1 nCoV-19;Biological: MenACWY Placebo",null,"Device: Cordio App","Drug: 1: Naproxen;Drug: 2: Standard of care","Drug: Plaquenil 200Mg Tablet","Drug: BCG Vaccine","Drug: Hydroxychloroquine;Drug: Placebo","Diagnostic Test: Odd/Even birth year intervention groups","Drug: Hydroxychloroquine;Drug: Placebo of Hydroxychloroquine;Drug: Lopinavir and ritonavir;Drug: Placebo of LPV/r Tablets","Drug: Hydroxychloroquine;Other: Placebo","Diagnostic Test: SAMBA II (Diagnostic for the Real World);Diagnostic Test: Public Health England Gold Standard;Diagnostic Test: Cambridge Validated Viral Detection Method;Diagnostic Test: Radiological Detection","Procedure: Human biological samples","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","Drug: lopinavir/ritonavir;Drug: Hydroxychloroquine Sulfate;Drug: Losartan;Drug: Placebos","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets","Drug: Siltuximab;Drug: Methylprednisolone","Other: \"Calm\" is a mindfulness meditation mobile app","Drug: Thiazide or Thiazide-like diuretics;Drug: Calcium Channel Blockers;Drug: ACE inhibitor;Drug: Angiotensin receptor blocker","Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: 2: Usual practice + SYMBICORT RAPIHALER;Other: 1: Usual practice","Other: NA (no intervention)","Drug: Hydroxychloroquine","Diagnostic Test: Online Questionnaire","Device: Web application users","Drug: Hydroxychloroquine Sulfate 400 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg once a day;Drug: Placebo oral tablet","Drug: Levamisole Pill + Budesonide+Formoterol inhaler;Drug: Lopinavir/Ritonavir + hydoxychloroquine","Drug: Hidroxicloroquina;Drug: Control group","Other: Usual Care;Drug: Anakinra;Drug: Siltuximab;Drug: Tocilizumab","Drug: Lopinavir/ritonavir","Device: GO2 PEEP MOUTHPIECE","Other: No Intervention","Drug: Hydroxychloroquine;Drug: Placebos","Drug: Ruxolitinib","Drug: Tocilizumab;Drug: Tocilizumab","Drug: Azithromycin;Drug: Placebos","Drug: Best supportive Care (BSC) + IFX-1;Drug: Best supportive care only","Drug: Tocilizumab",null,"Drug: Tocilizumab;Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Aspirin 75mg;Drug: Clopidogrel 75mg;Drug: Rivaroxaban 2.5 MG;Drug: Atorvastatin 40mg;Drug: Omeprazole 20mg",null,"Device: hyperbaric oxygen therapy (HBOT)","Drug: Low-dose chloroquine/hydroxychloroquine;Drug: Mid dose chloroquine or hydroxychloroquine;Drug: High does chloroquine or hydroxychloroquine;Drug: Placebo",null,"Drug: Favipiravir","Drug: Hydroxychloroquine SAR321068;Drug: Placebo","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: BLD-2660","Other: Questionnaire","Drug: Anluohuaxian","Drug: chloroquine;Other: standard care","Other: No intervention","Drug: Chloroquine analog (GNS651);Drug: Nivolumab;Drug: Tocilizumab;Other: Standard of care","Dietary Supplement: Vitamin D","Combination Product: Observational (registry)",null,"Drug: Ruxolitinib Oral Tablet","Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Hydroxychloroquine;Drug: Azithromycin;Dietary Supplement: vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Biological: bacTRL-Spike;Other: Placebo","Drug: Emtricitabine/tenofovir disoproxil;Drug: Hydroxychloroquine;Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo;Drug: Placebo: Hydroxychloroquine","Drug: Losartan","Other: Prospective oberservational registry","Drug: Tocilizumab;Biological: Pembrolizumab (MK-3475)","Drug: Eicosapentaenoic acid gastro-resistant capsules","Drug: Tocilizumab (TCZ);Drug: Placebo","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values",null,"Other: Video based aerobic exercise","Device: oxyhydrogen;Device: Oxygen","Other: COVID-19 infection","Biological: allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC);Other: Intravenous saline injection (Placebo)","Other: Telerehabilitation","Device: Biosensors","Other: Non-Interventional","Device: Caption AI","Combination Product: Hydroxychloroquine Sulfate + Azithromycin;Drug: Hydroxychloroquine Sulfate","Other: blood draw","Other: Questionnaire;Diagnostic Test: IgG","Drug: Favipiravir;Other: Placebo","Other: hospitalized children with Covid19","Drug: Mavrilimumab","Device: MAGEC Spine Rod;Diagnostic Test: Titanium blood test","Biological: blood sampling","Other: questionnaire assesment","Other: newborns from covid 19 positive mothers","Diagnostic Test: Machine learning model","Drug: RhACE2 APN01;Drug: Physiological saline solution",null,"Drug: Ruxolitinib","Diagnostic Test: COVID-19 diagnostic test","Other: Surgical facial mask",null,null,"Drug: INO-4800;Device: CELLECTRA 2000","Drug: Tranexamic acid tablets;Drug: Placebo oral tablet","Procedure: Follow-up at 14 days","Device: Transpulmonary thermodilution;Device: Echocardiography","Drug: Nitric Oxide Gas;Other: Inhaled Supplemental Oxygen","Diagnostic Test: nasopharyngeal swab","Other: Survey","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells","Other: COVID-19 Pandemic","Drug: Anakinra;Drug: Tocilizumab","Drug: Hydroxychloroquine Sulfate;Drug: Bromhexine 8 MG",null,"Behavioral: COVID-surgRES questionaire","Drug: Ruxolitinib 10 MG","Drug: Hydroxychloroquine;Drug: Oseltamivir;Drug: Azithromycin","Drug: Camostat Mesilate;Drug: Placebo;Drug: Hydroxychloroquine",null,"Device: SensiumVitals wearable sensor","Other: telehealth applications","Diagnostic Test: Collection of breath sample","Drug: Tacrolimus;Drug: Methylprednisolone","Drug: NORS (Nitric Oxide Releasing Solution);Drug: NORS (Nitric Oxide Releasing Solution)","Other: Discontinuation of ARB/ACEI;Other: Continuation of ARB/ACEI",null,null,"Other: Follow up","Biological: UC-MSCs;Other: Placebo","Biological: COVID-19 convalescent plasma","Diagnostic Test: Lung ultrasound","Other: Simulation of Repurposed Drugs for COVID-19","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo","Drug: Hydroxychloroquine - Daily Dosing;Drug: Hydroxychloroquine - Weekly Dosing;Other: Placebo oral tablet;Diagnostic Test: Monitoring Visit - Baseline;Diagnostic Test: Monitoring Visit - Week 4;Diagnostic Test: Monitoring Visit - Week 8;Other: Weekly Assessment","Drug: Chemotherapy","Drug: Nintedanib 150 MG;Other: Placebo","Drug: Atovaquone/Azithromycin","Other: Survey administration","Drug: Hydroxychloroquine;Drug: Placebo","Biological: anti-SARS-CoV-2 convalescent plasma","Other: No intervention","Drug: Sirolimus;Drug: Placebo","Drug: Gargle/Mouthwash",null,"Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Biological: COVID-19 exposure",null,"Other: this study is non- interventional","Drug: Baricitinib","Device: Low flow ECMO driving by CVVH machine","Drug: Sarilumab;Drug: Azithromycin;Drug: Hydroxychloroquine","Other: Monitoring for aggravation;Other: Evaluate HACOR score effectivity in this patients","Procedure: ECMO Implantation","Drug: Nitazoxanide 500 MG;Drug: Hydroxychloroquine","Drug: TJ003234;Drug: Placebo","Diagnostic Test: Serological tests will be applied on patients blood sampling","Behavioral: PTSD;Behavioral: Burnout","Drug: Stem Cell Product","Drug: Anakinra","Other: No special intervention","Drug: Aspirin;Drug: Losartan;Drug: Simvastatin","Device: Hyperbaric Oxygen Therapy","Drug: Hydroxychloroquine;Drug: Azithromycin","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);Other: Placebo","Drug: Linagliptin;Drug: Insulin regimen","Drug: Hydroxychloroquine;Drug: Placebo oral tablet",null,"Procedure: Blood draw","Procedure: Auricular neuromodulation;Procedure: Control","Device: Non-contact ECG",null,"Drug: Hydroxychloroquine Sulfate;Drug: Placebo","Other: Satisfaction evaluation","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic",null,"Drug: Placebos;Drug: Leronlimab (700mg)","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Biological: Convalescent plasma",null,"Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care","Other: Practice details","Drug: Chloroquine Diphosphate;Drug: Placebo oral tablet","Dietary Supplement: Bob's Red Mill;Dietary Supplement: Control - Corn Starch",null,"Drug: Nivolumab Injection","Biological: Convalescent Plasma","Device: CytoSorb-Therapy","Drug: Dexamethasone injection;Drug: placebo;Procedure: conventional oxygen;Procedure: CPAP;Procedure: HFNO;Procedure: mechanical ventilation","Drug: Fluvoxamine;Drug: Placebo",null,"Drug: LY3127804;Drug: Placebo","Drug: Nitazoxanide;Drug: Placebo","Drug: Hydroxychloroquine;Dietary Supplement: Placebo","Drug: Hydroxychloroquine;Drug: Lopinavir / Ritonavir;Drug: Interferon Beta-1A;Drug: Interferon Beta-1B","Drug: Ivermectine;Drug: Hydroxychloroquine Sulfate;Drug: Placebos","Drug: Methylprednisolone Sodium Succinate;Drug: Placebo solution","Device: Aerosol-reducing Mask;Device: Standard Mask","Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","Drug: chlorine dioxide 3000 ppm","Biological: Convalescent Plasma","Device: BIOVITALS",null,null,null,"Drug: Pyridostigmine Bromide;Drug: Placebo","Drug: Pegylated interferon lambda","Other: Questionnaire by phone call","Genetic: Mesenchymal Stromal Cells","Behavioral: Crisis management coaching","Other: observation",null,"Drug: L-ascorbic acid","Diagnostic Test: Cytokines dosage;Diagnostic Test: Complement dosage",null,null,null,"Behavioral: Tele-interventions related to diabetes management and mental well-being","Drug: Saline oral/nasal rinse;Drug: 0.5% Povidone/Iodine oral/nasal rinse;Drug: 0.12% Chlorhexidine oral/nasal rinse","Other: No intervention","Drug: Clazakizumab 12.5 mg;Drug: Clazakizumab 25 mg;Other: Placebo","Other: global survey","Other: Self-prone position recommendation;Other: Usual care","Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)","Biological: Convalescent Plasma Transfusion;Other: Supportive Care","Other: Plasma Donation","Procedure: Prone positioning",null,"Drug: Hydroxychloroquine;Drug: Azithromycin","Diagnostic Test: Online questionnaire","Drug: Danoprevir+Ritonavir",null,"Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Biological: Convalescent Plasma;Biological: Standard Donor Plasma","Other: Postural Positioning","Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Chloroquine;Drug: Placebo","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Biological: anti-SARS-CoV-2 convalescent plasma","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Indomethacin;Drug: Zithromax Oral Product","Biological: Allogeneic NK transfer","Drug: Spironolactone 100mg;Drug: Placebo oral tablet","Other: GPs reports of potential patient safety incidents, non-COVID-19 related",null,"Drug: Chloroquine;Drug: Favipiravir;Drug: Nitazoxanide;Drug: Ivermectin;Drug: Niclosamide","Drug: Tocilizumab;Drug: Methylprednisolone","Drug: Tinzaparin or unfractionated heparin","Drug: Bevacizumab Injection","Other: Saline Nasal Irrigation;Other: Saline with Baby Shampoo Nasal Irrigation","Drug: Povidone-Iodine 2%;Drug: Povidone-Iodine 0.5%;Drug: Isotonic saline 0.9%","Other: None - NA","Other: serological test;Other: Rapid molecular test;Genetic: Next generation Sequencing (NGS) analysis;Other: serum chemistry analysis",null,null,"Drug: Hydroxychloroquine Sulfate (HCQ)","Drug: Dexamethasone and Hydroxychloroquine;Drug: Hydroxychloroquine",null,"Drug: ACEIs;Drug: Conventional treatment","Other: Blood and derivatives.;Drug: Standard of Care","Drug: Hydroxychloroquine + placebo;Drug: hydroxychloroquine + azithromycin","Diagnostic Test: Schirmer Test I","Drug: Hidroxicloroquine;Drug: Lopinavir/ritonavir;Drug: Imatinib tablets;Drug: Baricitinib Oral Tablet","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Other: Individualised Ayurveda","Drug: CM4620-Injectable Emulsion","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2;Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2","Biological: IC14, a monoclonal antibody against CD14",null,"Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days;Drug: Placebo 250 cc 24 hours continuous infusion for 15 days",null,"Drug: Tocilizumab","Other: no intervention","Drug: Enoxaparin","Other: Standard interface;Device: Double-Trunk Mask","Drug: Favipiravir;Other: Standard of care treatment","Drug: Transfusion of COVID-19 convalescent plasma",null,null,"Drug: Nitazoxanide Tablets;Drug: Placebo","Biological: BM-MSCs;Biological: Placebo","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","Other: Patient management suffering of coronavirus infection","Other: Telerehabilitation;Other: exercise brochure","Diagnostic Test: COVID-19 RT-PCR;Diagnostic Test: COVID-19 Serology;Other: Symptoms questionnare","Drug: HB-adMSCs;Drug: Placebos","Behavioral: online mindfulness group","Drug: Acalabrutinib","Behavioral: Video based exercise","Other: Phsyiotherapy","Drug: Eculizumab","Drug: BMS-986253","Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support;Other: Telemedicine","Drug: Dapagliflozin 10 MG;Drug: Placebo","Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing","Drug: Vazegepant (BHV-3500);Drug: Placebo","Drug: Placebos;Drug: Leronlimab (700mg)","Diagnostic Test: Loop mediated isothermal amplification COVID-19;Diagnostic Test: Covid-19 Antibody testing (IgG and IgM);Diagnostic Test: Cytokine profile","Drug: Patients with the treatment agains COVID19","Other: other","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Drug: Standard therapy of COVID-19","Drug: Honey;Drug: Nigella Sativa / Black Cumin;Drug: Placebos",null,"Other: Blood donation from convalescent donor","Other: blood sample","Diagnostic Test: Tuberculin test",null,null,"Other: convalescent plasma from recovered COVID 19 donor","Other: Hydroxychloroquine/Chloroquine",null,"Behavioral: Enhanced hygiene measures","Drug: Hydroxychloroquine;Other: Vitamin C","Drug: Ruxolitinib",null,"Drug: Clevudine;Drug: Hydroxychloroquine","Device: ECCO2R","There are two arms to this trial. Arm 1: Problem Management Plus. Arm 2: Enhanced Treatment as Usual. Therapy is administered once-weekly 60 minute sessions by clinical psychologists over 6 weeks delivered via teleconferencing to groups of 4 people at a time. Problem Management Plus is a program developed by the World Health Organization. Across sessions the clinical psychologist will teach the following stress coping strategies: anxiety reduction, problem solving, behavioral activation, and accessing social support. This will occur will via educational sessions, group discussions via teleconference, and handouts. The duration of the study for any participant will conclude after a 2-month follow-up assessment, resulting in participation duration of 15 weeks.","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Other: Primary care professionals reports of potential patient safety incidents, non-COVID-19 related","Drug: Hydrocortisone;Drug: Sodium Chloride 9mg/mL","Drug: Clazakizumab","Procedure: Prone Positioning;Procedure: Standard of care.",null,"Participants who are randomly assigned to the intervention group will  receive capsules containing the probiotic Lactobacillus rhamnosus HN001 (6X109 colony forming units). &lt;br&gt;&lt;br&gt;Participants will be instructed to take one capsule a day for a period of 12 weeks.&lt;br&gt;&lt;br&gt;Adherence will be assessed by asking participants to enter the number of remaining capsules they have in the bottle at the post-intervention data collection phase.","Drug: Ruxolitinib plus simvastatin;Other: Standard of Care","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Drug: Canakinumab 150 MG/ML [Ilaris]","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets","A home-based intervention based on high-intensity interval training (HIIT). A physical therapist, with more than 5 years of experience, will provide a video session upload to YouTube. A WhatsApp message will individually send to each participant with a session link, that they will have to complete.&lt;br&gt;Frequency, duration of the sessions and overall duration of the intervention: 45 min of HIIT session, six days per week during all the self-isolation period (6 weeks estimated). &lt;br&gt;Each session will have: &lt;br&gt;1) A warm-up (10 min): Joint mobility exercises. &lt;br&gt;2) Main part: CORE, arms and legs exercises, with 10-12 sets of 30-90 seconds with 15-60 seconds of rest between sets (ie. push ups, squats, splits or dead lifts). All the exercises will be performed with their own weight. &lt;br&gt;3) Cold down: Flexibility exercises.&lt;br&gt;Adherences will daily be monitored through WhatsApp message.","Drug: T3 solution for injection;Drug: Placebo","Other: Self-administered questionnaires","Front-line Healthcare Workers&lt;br&gt;Participants will have serial (monthly) SARS-CoV-2 IgG, IgA and IgM antibody serum sample analysed for six months and Coronavirus symptom data collection. Front-line health care worker participants will be requested to records symptoms in a diary each day. This will be reviewed monthly by a research staff member.Front-line health care worker participants who develop symptoms consistent with COVID-19 will be assessed at the Coronavirus clinic as per standard practice. Any nasopharyngeal swabs collected and tested will be compared to the symptoms diary and serology results. Upon completion of 6 months, no further follow up is required.","Other: Convalescent plasma","Drug: Selinexor;Other: Placebo",null,"Drug: Chloroquine;Drug: Placebo oral tablet","Diagnostic Test: EUROIMMUN assay","Drug: Treatment with Dexmedetomidine","&lt;br&gt;                Volunteers (workers in a COVID19 treatment unit) undergo a structured and objective evaluation. Physiological variables (respiratory rate, saturation, heart rate, systolic and diastolic blood pressure and temperature) are collected, health variables are also collected (previous illnesses, taking medication, COVID19 symptoms, weight and height) and an analytical test is performed of blood (venous by extraction in the cephalic vein of the left arm) to obtain the following parameters: pH, PaCo2, PO2, HCO3, Na, K, Cl, Ca, Hematocrit, hemoglobin, lactate, glucose, urea, BUN and creatinine.&lt;br&gt;&lt;br&gt;                Volunteers are randomized, some wear N95 respirators and others wear an FFP2 mask with an exhalation valve, are fully equipped with personal protective equipment and enter the COVID19 area. At 4 hours of work they leave, are decontaminated and the same determinations that have been made on a basal basis are repeated. They are also asked if they have a headache (not due to the pressure of the glasses or face shield), wounds or chafing, and how they have felt at the level of tiredness.&lt;br&gt;                At this time, the observation will end.&lt;br&gt;","Drug: favipiravir;Drug: Standard of care therapy","Diagnostic Test: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)","Drug: Hydroxychloroquine, Azithromycin;Drug: Hydroxychloroquine, Doxycycline;Drug: Hydroxychloroquine, Clindamycin;Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.;Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.;Drug: Remdesivir;Drug: Tocilizumab;Drug: Methylprednisolone;Drug: Interferon-Alpha2B;Drug: Losartan;Drug: Convalescent Serum","Other: PROTECTIVE VENTILATION;Other: ULTRAPROTECTIVE VENTILATION","According to the standard of the ICU for COVID-19 and non-COVID-19 patients, routine data of patients with COVID-19 and ARDS including PiCCO-monitoring will be documented from the day of intubation until extubation. All measurements were repeated at least once per day.","Device: Q-NRG Metobolic Cart Device;Device: MuscleSound Ultrasound;Device: Multifrequency Bioimpedance Spectroscopy","Other: quetionnary","Drug: Colchicine Tablets;Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Drug: TD-0903;Drug: Placebo","Drug: HB-adMSCs","Drug: Interferon Beta-1B;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine","Diagnostic Test: VitalConnect Vital Sign Patch","Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Chloroquine;Drug: Placebo","Other: questionnaire assesment","Drug: Favipiravir;Drug: Placebos",null,"&lt;br&gt;                Research design:&lt;br&gt;                This cohort study will use the UK Obstetric Surveillance System (UKOSS) to identify women hospitalized with pandemic novel coronavirus infection in pregnancy throughout a 6-month period. Participants will receive their usual management and information will be collected subsequently, detailing their treatment and outcomes. Research participants will not be contacted directly and no personally identifiable information (names, addresses or dates of birth will be collected.&lt;br&gt;&lt;br&gt;                Cohort identification:&lt;br&gt;                Infected women will be identified through the UKOSS network of nominated reporting clinicians in each consultant-led maternity unit in the UK. Nominated reporting clinicians will be asked to report all pregnant women with confirmed pandemic novel coronavirus infection admitted to their unit. In view of the need for rapid and ongoing data analysis and production of guidance, we will use a specific web-based rapid reporting and data collection system for this study to enable UKOSS nominated clinicians to report cases as they occur. In addition, nominated clinicians will be sent a standard UKOSS reporting card each month to further enhance case ascertainment.&lt;br&gt;&lt;br&gt;                Comparison group identification:&lt;br&gt;                Information about comparison women will be obtained from previously conducted UKOSS studies. Previous UKOSS studies have collected detailed demographic, pregnancy and delivery information about a cohort of over 1200 women giving birth in the UK identified from the same hospitals as infected women. This pragmatic approach has been adopted to allow risk factors for severe outcomes of pandemic influenza or novel coronavirus to be identified while minimizing the data collection burden on","Drug: Hydroxychloroquine","Other: Immunological profiling","Drug: Interferon Beta-1A;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine","Drug: Umifenovir;Drug: Interferon- 1a;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine;Drug: Standards of Care","Patients who are hospitalised with acute SARS-CoV-2 infection. Patients will only be observed until discharge from hospital or termination of the study (whichever comes first). Data will be collected from hospital medical records. There will not be any follow up outside of hospital.","Study design: parallel group, wait list design, with treatment delayed by 3 months.&lt;br&gt;Open label OM85 one capsule (7.0mg) daily for 3 months with 3 months follow-up off treatment. &lt;br&gt;Adherence assessed by participant diary and blister pack return.","Airway pressure release ventilation has traditionally been used as a rescue  mode of mechanical ventilation for patients with ARDS (acute respiratory distress syndrome), however it  may also be beneficial early on in ARDS. It helps with recruitment (opening up) of lungs by having a continuous high level of positive pressure and timed pressure release. Spontaneous breathing is still possible. &lt;br&gt;The mode of ventilation provided to patients is chosen at the discretion of the treating clinician. Mode of mechanical ventilation received by intubated patients in ICU is being observed from intubation until extubated.","Other: questionnaire assesment","Drug: Chloroquine or Hydroxychloroquine;Drug: Lopinavir/Ritonavir;Other: Best standard of care;Drug: Rivaroxaban;Drug: Thromboprophylaxis;Drug: Candesartan;Drug: non-RAS blocking antihypertensives;Drug: Clazakizumab;Drug: placebo for clazakizumab","Biological: intradermal injection of BCG Vaccine;Other: placebo","Other: modification of the planned therapeutic management","Intervention 1&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir/ritonavir&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 2&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Hydroxychloroquine&lt;br&gt;Intervention Description: 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 3&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir / ritonavir plus hydroxychloroquine&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days plus hydroxychloroquine 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;","&lt;br&gt;                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups:&lt;br&gt;                1. Local standard of care alone&lt;br&gt;                OR local standard of care plus one of&lt;br&gt;                2. Remdesivir (daily infusion for 10 days)&lt;br&gt;                3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)&lt;br&gt;                4. Lopinavir + ritonavir (orally twice daily for 14 days)&lt;br&gt;                5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon-beta (daily injection for 6 days)&lt;br&gt;&lt;br&gt;                Follow-up is until death or discharge from hospital.&lt;br&gt;                Randomization is performed at one central global location through an online portal.&lt;br&gt;","This study will recruit older adults (aged 60 years and older) during the COVID-19 pandemic to a 6-week, group based physical activity promotion intervention delivered online through a private Facebook group. The group will allow members to receive information and contribute to weekly conversations on pre-specified topics related to physical activity eg. sedentary behaviour, goal setting, benefits of physical activity and support. Different topics will be covered each week with 2-3 Facebook posts on the topic each week. The content of each topic is designed specifically for this study but will also make use of existing videos, pictures and information sources. An exercise physiologists and dietitian will deliver the program. The purpose of the Facebook group is to facilitate social support and provide participants with a platform to exchange personal experiences including barriers and facilitators to commencing and maintaining a physical activity program. While discussion topics will be pre-determined, discussion will change weekly based on the participants posts for example someone may ask for examples of workouts or different ways overcome barriers. Participants will also be able to join a group video call via zoom two times per week. These calls will last for 20-30mins. The facilitator will lead the call and provide education on the topic for the week. This will also give the facilitator the chance to check in on participants and allow them to ask questions. The intervention itself will go for 6 weeks however there is the option for participants to remain in the Facebook group and continue to use it for support without the input from the facilitators. All 20 participants will be included in the one Facebook group and encouraged to check the Facebook weekly. The page","&lt;br&gt;                In a first phase, participants (n=2170) of the population-based GAPP study (https://doi.org/10.4414/smw.2013.13728)  will be contacted to be recruited for the COVI-GAPP study. After a first phase of including participants from the GAPP study, we eventually might attain a sample size of 5000 participant by opening the inclusion criteria  by onboarding additional participants residing in Liechtenstein. The second phase is depending on obtaining the funding.&lt;br&gt;                Participants will be asked to use a wearable device called the AVA bracelet (https://www.avawomen.com) during the night until the study is terminated. Temperature, breath rate, pulse rate and movements are recorded. Information on COVID-19-specific health status is collected at study start and symptomatic patients will be diagnosed for COVID-19, as recommended by national guidelines. At the end of the study blood will be drawn for serological analysis of anti-SARS-CoV2 antibodies.&lt;br&gt;","Cord blood therapy (expanded cord blood cells) + standard supportive management&lt;br&gt;5 million expanded umbilical cord blood cells (max -500 million cells) given intravenously over an hour by hospital staff under observation by research team&lt;br&gt;Single administration sourced from off the shelf CB units","&lt;br&gt;                The trial will initially be two-arm, comparing usual care to usual care with hydroxychloroquine treatment.&lt;br&gt;&lt;br&gt;                The trial will be implemented in the first instance in practices that are already part of the RCGP RSC Network. Currently, over 500 practices are part of this network, with 100 already offering a sentinel viral swabbing service which is being scaled up and due to the pandemic, all practices in the UK have been asked to join the RCGP RSC Network.&lt;br&gt;&lt;br&gt;                A platform trial, in contrast to say a  traditional two-arm design, allows multiple arms to be considered simultaneously, and interventions can be dropped and replaced as evidence emerges for effectiveness or lack of it. The intent is to establish an on-going trial infrastructure within a master protocol that uses all the data already accumulated for the assessment of current and subsequently introduced interventions. New interventions will only be added after submission to the appropriate approval bodies.&lt;br&gt;&lt;br&gt;                The PRINCIPLE trial will begin as a 1:1 randomised trial of usual care plus study-specific medication (in the first instance hydroxychloroquine) versus usual care alone but the study design has the capability to add additional interventions over time. The evaluation of any new interventions will be governed by the master protocol, including adaptive and decision criteria. In addition, the inclusion of any new interventions will require supplementary appendices to the protocol and SAP.&lt;br&gt;&lt;br&gt;                The initial drug is hydroxychloroquine sulphate 200 mg tablets. The tablets are for oral administration. One tablet (200 mg) hydroxychloroquine to be taken twice daily for 7 days by mouth (14 tablets in total). This is the standard therapeutic dose for its n","&lt;br&gt;                RECOVERY is a randomised trial among adults hospitalised for COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs lopinavir + ritonavir vs interferon 1 vs low-dose corticosteroids vs hydroxychloroquine. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.&lt;br&gt;&lt;br&gt;                RECOVERY has an adaptive trial design. The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The DMC will assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.&lt;br&gt;&lt;br&gt;                Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs Lopinavir-Ritonavir vs Interferon 1 vs Low-dose Corticosteroids vs Hydroxychloroquine.&lt;br&gt;                For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.&lt;br&gt;&lt;br&gt;                Drug dosage and duration:&lt;br&gt;                Lopinavir 400 mg + ritonavir 100 mg: by mouth (or nasogastric tube) every 12 hours for 10 days or unti","&lt;br&gt;                After consent and enrolment patients in the influenza cohort will undergo a single-draw set of baseline blood tests. This will include peripheral blood mononuclear cells and Paxgene DNA. Approximately 30-40 ml of blood will be taken. BAL will only be performed at the discretion of the treating team as per standard clinical care. Surplus BAL samples from participants will be stored for analysis after the influenza season. Leftover serum will also be stored.&lt;br&gt;&lt;br&gt;                Data Collection&lt;br&gt;                Clinical data will be collected from the electronic hospital records at baseline, during the patients ICU stay, and after ICU discharge - up to 90 days or hospital discharge (whichever is longer).&lt;br&gt;&lt;br&gt;                Data Analysis&lt;br&gt;                The researchers will use the collected clinical and microbiological data and BAL/blood galactomannan results to determine the primary and secondary outcome measures, with input from the study statistician for the multivariable analyses.&lt;br&gt;&lt;br&gt;                Retrospective Diagnostic Evaluation&lt;br&gt;                Once the prospective study is complete, stored BAL/blood samples will be tested retrospectively in parallel by two tests: galactomannan EIA (the current gold standard biomarker test for IA) and by the AspLFD (the new test we wish to validate). This will be done after the influenza season so results will have no implications for participants. The BAL/blood AspLFD results will be compared against the IA status of the patient to evaluate test performance against the AspICU definition.&lt;br&gt;&lt;br&gt;                Planned Sub-studies&lt;br&gt;                These will be subject to further funding and are laboratory studies to help us understand why certain patients with influenza might be at greater risk of developing IA. This will i","&lt;br&gt;                Intervention: Hydroxychloroquine 400 mg orally once a day as pre-exposure prophylaxis against COVID-19.&lt;br&gt;                Control: Placebo.&lt;br&gt;                Randomization details: Fixed 1:1 allocation ratio produced by a computer-based random number generator. Randomly permuted blocks of varying size will be used to ensure equal allocation to each group, stratified by site.&lt;br&gt;","&lt;br&gt;                Matched longitudinal internet-based survey with pre-existing, validated self-questionnaires (Work-SoC, PHQ-9, IES-6, PVD, SFI, CD-RISC 10), at 3 time periods of 2 weeks over 6 months, with the option to prolong depending on the development of the pandemic.&lt;br&gt;&lt;br&gt;                Semi-structured interviews with focus groups after the last period of the survey.&lt;br&gt;","Case series:No;","&lt;br&gt;                Current interventions as of 17/04/2020:&lt;br&gt;&lt;br&gt;                Volunteers will initially be required to complete an online screening. This is an initial confirmation of eligibility. Volunteers will initially be invited for a screening visit. Prior to attending they will have received written information about the study and had time to consider it. At the screening visit a doctor will explain about the study and answer any questions they may have. If the volunteer decides to take part, they will be asked to sign a consent form. The doctor will then check whether the volunteer is eligible to take part. This will involve taking a medical history, performing a physical examination, taking blood tests, urine tests, and measuring blood pressure and temperature.&lt;br&gt;                The doctor will then write to the volunteers own GP to enquire about their medical health. If all the inclusion criteria are met and none of the exclusion criteria are present then the volunteer is invited to return for vaccination. Due to the need for rapid delivery of this study, there will be minimal flexibility around appointment dates.&lt;br&gt;&lt;br&gt;                Before vaccination, volunteers will be asked about their recent health to ensure that they are still medically fit. They will have blood tests taken and participants in groups 1 and 2 will be randomised (1:1) to receive either ChAdOx1 nCoV-19 or MenACWY. Group 3 participants will not be randomised and therefore not blinded.&lt;br&gt;&lt;br&gt;                Participants from group 1 or 3 will be vaccinated first. The first volunteer to receive the IMP will be vaccinated ahead of any other participants. The investigators and/or chair of DSMB will assess there are no safety concerns within 48 hours (24h) post vaccination. The next 3 volunteers will be vacci","Biological: Lenzilumab;Drug: Standard of Care","Drug: Chloroquine;Drug: Nitazoxanide;Drug: Ivermectin","Dietary Supplement: Ayurveda;Other: Usual Care","Other: Discontinuation of ACEi/ARB;Other: Continuation of ACEi/ARB","&lt;br&gt;                Patients will be randomised in a 1:1:1 ratio to:&lt;br&gt;                Arm 1: Continuous positive airway pressure (CPAP), administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 2: High flow nasal oxygen (HFNO) will be administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 3: Standard care. Standard oxygen therapy according to local protocol/guidelines.&lt;br&gt;","Case series:Ke-Gan-Li-Yan oral liquid;","Case series:Nil;","Drug: Amiodarone;Drug: Verapamil","Other: Psychoeducational intervention","Case series :Western medicine plus Danggui Shaoyao Power ;","Diagnostic Test: Lung ultrasound","This study is an unblinded trial of a cuirass based negative pressure ventilator. &lt;br&gt;The device consists of a plastic casing (cuirass) placed over the thorax with negative pressure of -200cmH2O applied by a household vacuum cleaner.The negative pressure in the cuirass facilitates inspiration. The device cycles back to atmospheric pressure allowing expiration.&lt;br&gt;Following confirmation of fit by the research team, application of ANZCA standard monitoring (Australian and New Zealand College of Anaesthetists, 2017) and trial of the device in an awake volunteer, the study will use sedation to simulate an unwell patient.  &lt;br&gt;Baseline data before intervention will include AVPU level of consciousness, HR, SpO2 and Vt on room air, then HR and SpO2 on 4L/min via Hudson mask.  &lt;br&gt;The patient will be ventilated using the device with supplemental oxygen via Hudson face mask at 4L/min for one hour. Tidal volumes will be recorded every 15 minutes. The Hudson mask will be removed and a face mask connected to a GE Anaesthetic Machine running FiO2 at 30%, 4L/min will be used to record Vt for 3 consecutive breaths.  &lt;br&gt;Sedation will be provided by an accredited Consultant Anaesthetist and targeted to maintain an AVPU score of V, that is, rousable to command. The level of sedation will be targeted to not require direct airway intervention. Sedation will be provided using propofol and Total Intravenous Anaesthesia (TIVA) using the Marsh algorithm. An initial bolus of Lignocaine will be included with the propofol to minimise patient discomfort as per accepted practice. &lt;br&gt;An anaesthetic record will be maintained as per ANZCA Guidelines (Australian and New Zealand College of Anaesthetists, 2019). &lt;br&gt;The trial will be conducted in an operating theatre environment with full resuscitati","We are testing the feasibility and comfort of the use of a novel mask (the Decathlon group EasyBreathe snorkel mask) for the transport of patients between locations at our health service.&lt;br&gt;The Decathlon mask is a non-TGA approved device used for recreational snorkelling.  It has been adapted for use in COVID-19 patients by Italian engineers (see https://www.isinnova.it/easy-covid19-eng/)&lt;br&gt;In this trial we propose to apply the Decathlon mask in place of standard delivery systems for oxygen and positive airway pressure.  The Decathlon mask will be applied by clinicians in the hospital setting.&lt;br&gt;The mask is worn over the entire face and has advantages over conventional delivery methods in that it is thought to reduce the risk of virus aerosolization (a common problem with conventional delivery systems) and therefore increase safety for healthcare workers and other patients at the hospital.&lt;br&gt;We will test mask comfort and tolerability with daily questionnaires.&lt;br&gt;The mask will be applied to suspected or confirmed COVID-19 patients during transfer between the emergency department and other locations such as radiology department, ward and high dependency unit.&lt;br&gt;We anticipate the mask will be worn for several hours at a time depending on patient tolerability (early data from overseas suggests superior tolerability to conventional mask setups).  The mask may be used intermittently for the entire patient admission to hospital pending the clinical needs and preference of the patient. We anticipate, based on how conventional treatments are applied, that the patient will use the mask in 3 hour sessions with potential breaks in between to be determined by clinical need and patient tolerability.","Coronovirus Screening Clinic Participants&lt;br&gt;Participants have SARS-CoV-2 IgG, IgA and IgM antibody serum sample analysed approximately 14 days after developing Coronavirus symptoms. Upon completion of blood sampling, no further follow up is required. Data to be collected for the study will include general patient demographics, medical history, baseline SARS-CoV-2 NAT pathology results, SARS-CoV-2 Risk assessment and symptom assessment.&lt;br&gt;&lt;br&gt;","This is designed as a cross-sectional, community-based observational study assessing the impact of social isolation on mental health (depression, anxiety, insomnia) during the COVID-19 pandemic.&lt;br&gt;The duration of the study is one month.&lt;br&gt;The duration of observation in each participant will be single 15 min assessment","Intervention is an aqueous buffered solution of 0.5% povidone-iodine (PVP-I) contained in a 30 mL bottle closed with a traditional nasal spray pump.&lt;br&gt;Subjects will receive a single dose to their nasal passages, administered by the investigator. &lt;br&gt;The amount a subject receives consists of 6 x 140L pump actuations (3 into each nostril), being 0.84 mL total volume.","Group 1:phone consultation;Group 2:face-to-face consultation;","control group:General basic epidemic prevention measures;sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet;Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray;Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups;","&lt;br&gt;                This project is a three-tiered study designed to fully elucidate the impact of the COVID-19 pandemic on vascular surgery across the world.&lt;br&gt;&lt;br&gt;                The aim of Tier 1 is to document how the provision and availability of vascular services evolves over time per unit/region/country.&lt;br&gt;&lt;br&gt;                The aim of Tier 2  is to prospectively capture data on all vascular procedures performed during the pandemic and understand the impact on outcomes in the short and medium-term (up to 1 year).&lt;br&gt;&lt;br&gt;                The aim of Tier 3 is to document (prospectively) deviations from standards of care/practice during the pandemic in vascular patients.&lt;br&gt;&lt;br&gt;                The main objective of the COVER study is to understand and evaluate the impact of the COVID-19 pandemic on global vascular practice and the effect on outcomes for patients presenting/receiving treatment during the pandemic.&lt;br&gt;                Population (patients)  All patients with a vascular pathology.&lt;br&gt;                Outcome of interest  Tier 1: state of vascular services per centre weekly; Tier 2: procedures performed in each centre; Tier 3: assessment of longer-term outcomes.&lt;br&gt;                Time  end of study 12 months after the end of the COVID19 pandemic.&lt;br&gt;&lt;br&gt;                The study is formally supported by the Vascular Society of Great Britain and Ireland (VSGBI),  the British Society for Endovascular Therapy (BSET), the Rouleaux Club, the NIHR, SingVasc and several national vascular surgery societies in Europe, Asia, Australia, New Zealand, and the Americas.&lt;br&gt;","experimental group:Chinese herbal tea;control group:drinking water;","Case series:Nil;","Case series:Nil;","Lung Ultrasound","&lt;br&gt;                This is an interventional study where good sleepers will be recruited as a wait-list control, where they will receive the treatment after a delay of one week. An additional group of good sleeper participants will be recruited who will not receive the intervention. An equal number of participants will be recruited to each group and healthy good sleepers and individuals with sleep problems will be recruited at a 2:1 ratio (estimated n = 40:20 participants).&lt;br&gt;&lt;br&gt;                The study is single-centre and the study will be run entirely online.&lt;br&gt;&lt;br&gt;                Participants who are in the two intervention groups (poor sleep and wait-list control good sleepers) will be provided with an online version of a self-help leaflet. A printed version of this leaflet has been used in previous treatment studies conducted by our research group. Briefly, this self-help leaflet aims to improve sleep by identifying and addressing sleep-related dysfunctional thinking by providing education about sleep, providing techniques to distract from intrusive worrisome thoughts at night, and providing guidelines for sleep-related stimulus control.&lt;br&gt;&lt;br&gt;                The duration of treatment will be one week and the follow-up period is at the end of the treatment period. Participants will be randomised using online software (where good sleepers will be randomised to treatment or no treatment).&lt;br&gt;","&lt;br&gt;                Patients presenting to the UZH COVID-19 Testing Center for SARS-CoV-2 testing will be enrolled in the cohort study. All patients will undergo routine testing at the testing center. The cohort study-specific follow-up and prospective data collection will depend on the test result.&lt;br&gt;&lt;br&gt;                Patients tested positive for SARS-CoV-2 will receive three calls at 7, 14 and 60 days after their visit to the testing center. Information will be collected about the disease course and current health status, as well as further health care contacts. Further information about the disease course, hospitalization and patient outcomes will be collected from patient records obtained from general practitioners and treating physicians in hospitals.&lt;br&gt;&lt;br&gt;                Patients tested negative for SARS-CoV-2 will receive one call at 14 days after their visit to the testing center. Information will be collected about the disease course and current health status, as well as further health care contacts and retesting. If retested, further information about the second test result will be collected from general practitioners and treating physicians in hospitals. Biological samples obtained for viral testing will additionally be analyzed for further respiratory pathogens.&lt;br&gt;","In-hospital rehabilitation group: A. the patients took Qigong lung-nourishing exercise twice a day, once in the morning and afternoon, about 15 minutes each time. B, through online WeChat group patient communication, functional guidance, health counseling, psychological comfort.;Discharge follow-up rehabilitation group: A. the patients were given fitness Qigong lung-nourishing exercise twice a day, once in the morning and afternoon, about 15 minutes each time. B, through online one-to-one patient communication, functional guidance, health counseling, psychological comfort.;","Case series:mesenchymal stem cells therapy;","Case series:Subcutaneous injection of thymosin a1, take Ma-Xing-Shi-Gan tang and Yin-Qiao powder plus or minus;","Two groups:modified respirator versus conventional respirator;",null,"1.5ATA:1.5ATA HBO;2.5ATA:2.5ATA HBO;Control group:Routine treatment;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:COVID-19&amp;#32;Intelligent&amp;#32;Assistant&amp;#32;Analysis&amp;#32;System;","&lt;br&gt;Trade Name: Antimicrobial therapy (antibiotics)&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;","Case series:Nil;","experimental group:''Guangdong Pneumonia NO.1''+basic treatment;\t control group:basic treatment and(or) antiviral therapy;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;",null,"Not applicable","None","Patient:Surface swab and air sample collection;Healthcare providers:Surface swab from personal protective equipment;","All treatment arms contain standard supportive care during hospital and:&lt;br&gt;1.\tChloroquine arm: loading dose 600mg as chloroquine base followed by 300mg 12 hours later followed by 300mg twice a day; total treatment duration 5 days (same dose as LCI guideline) &lt;br&gt;2.\tHydroxychloroquine arm: loading dose 400mg bid followed by 200mg twice a day; total treatment duration 5 days (same dose as LCI guideline)&lt;br&gt;3.\tNo antiviral treatment arm","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","&lt;br&gt;Product Name: Valsartan or matched placebo&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: VALSARTAN&lt;br&gt;CAS Number: 137862-53-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 80-160&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","&lt;br&gt;Product Name: Senicapoc&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;",null,"Three conditions are tested (each lasting 30 min, the measurement period): &lt;br&gt;1. Oxygen delivery via a nonrebreathing mask (current standard of care) with sufficient inflow of O2 (which does not create PEEP).  &lt;br&gt;2. Oxygen delivery via the adapted face mask with zero PEEP in order to test the effect of the mask alone. &lt;br&gt;3. Oxygen delivery via the adapted face mask with PEEP of 7.5 cmH2O in order to test effect of moderate PEEP.","&lt;br&gt;Product Name: HCR040&lt;br&gt;Product Code: HCR040&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: HCR040&lt;br&gt;Current Sponsor code: HCR040&lt;br&gt;Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Kevzara&lt;br&gt;Product Code: 1171196003&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: EU/1/17/1196/012&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Product Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: hidroxicloroquina&lt;br&gt;Product Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","During routine daily laboratory rounds blood will be stored at -80 C until biomarkers will be assayed later.","Infotainment intervention with (social) media and influencers.","&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DARUNAVIR&lt;br&gt;CAS Number: 206361-99-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SPIRONOLACTONE&lt;br&gt;Other descriptive name: SPIRONOLACTONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: INTERFERON BETA-1B&lt;br&gt;CAS Number: 145155-23-3&lt;br&gt;Other descriptive name: INTERFERON BETA-1B&lt;br&gt;Concentration unit: g/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Lung Ultrasound and CT-scan","&lt;br&gt;Trade Name: plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: azithromycin&lt;br&gt;Product Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;Other descriptive name: AZITHROMYCIN MONOHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","Imatinib or placebo","Patients in this study are treated with intravenous tociluzumab: 8 mg/kg (maximum dose 800 mg), which can be repeated at the same dose after 8 hours if the hypoxia has not improved. This is the approved dose for cytokine release syndrome.","&lt;br&gt;Trade Name: prednisone&lt;br&gt;Product Name: prednisone&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: PREDNISONE&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos.&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Buccal use&lt;br&gt;&lt;br&gt;Trade Name: azitromicina cinfa 500 mg comprimidos&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;Trade Name: Kaletra&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: CIRCADIN 2 mg&lt;br&gt;Product Name: CIRCADIN 2mg&lt;br&gt;Product Code: EMEA/H/C/000695&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CIRCADIN&lt;br&gt;CAS Number: 73-31-4&lt;br&gt;Other descriptive name: MELATONIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Telmisartan EG&lt;br&gt;Product Name: Telmisartan&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine EG&lt;br&gt;Product Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Curcumin C3&lt;br&gt;Product Name: Curcumin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Sandimmun&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-15&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 800-1200&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: KEYTRUDA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Pembrolizumab&lt;br&gt;Current Sponsor code: MK3475&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: ZYMAD 200 000 UI&lt;br&gt;Product Name: ZYMAD 200 000 UI&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;&lt;br&gt;Trade Name: ZYMAD 50 000 UI&lt;br&gt;Product Name: ZYMAD 50 000 UI&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Product Name: Olumiant&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Kevzara&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Subcutaneous use&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Dolquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Kaletra versus Aluvia&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Imatinib&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-300&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Other descriptive name: Olumiant&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 4-2&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Clulas mesenquimales troncales adultas alognicas de mdula sea expandidas en suspensin&lt;br&gt;Product Code: MSV-allo&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: clulas mesenquimales troncales adultas alognicas de mdula sea expandidas mediante procedimiento IBGM&lt;br&gt;Current Sponsor code: MSV_allo&lt;br&gt;Concentration unit: U/ml unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;Pharmaceutical form of the placebo: Injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Recombinant human angiotensin-converting enzyme 2&lt;br&gt;Product Code: APN01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: APN01 / GSK2586881&lt;br&gt;Other descriptive name: GSK2586881&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Sylvant&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 11-&lt;br&gt;&lt;br&gt;Trade Name: Urbason&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Allogeneic mesenchymal stromal cells isolated from adipose tissue&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Allogeneic adipose-derived mesenchymal stromal cells in vitro expanded&lt;br&gt;Other descriptive name: Allogeneic adipose-derived mesenchymal stem cells in vitro expanded&lt;br&gt;Concentration unit: million organisms/ml million organisms/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINA SEID 0,5 mg comprimidos&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: COLCHICINE&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lopinavir-Ritonavir &lt;br&gt;Product Name: Lopinavir-Ritonavir &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Lopinavir&lt;br&gt;Other descriptive name: Antiretroviral&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: Ritonavir&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine (Plaquenil) &lt;br&gt;Product Name: Hydroxychloroquine (Plaquenil) &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine sulfate&lt;br&gt;Other descriptive name: Antimalarial, Aminoquinoline&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulphate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Other descriptive name: Remdesivir&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINE&lt;br&gt;Product Name: COLCHIMAX&lt;br&gt;Product Code: M04AX&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: COLCHICINA&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .5-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Clairyg 50mg/ml, Solution for infusion&lt;br&gt;Product Name: Clairyg 50mg/ml, Solution for infusion&lt;br&gt;Product Code: J06BA02&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;Pharmaceutical form of the placebo: Infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: Bactrimel&lt;br&gt;Product Name: Sulfamethoxazole and Trimethoprim&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: SEVOFLURANE&lt;br&gt;Pharmaceutical Form: Inhalation vapour, liquid&lt;br&gt;INN or Proposed INN: SEVOFLURANE&lt;br&gt;CAS Number: 28523-86-6&lt;br&gt;Other descriptive name: SEVOFLURANE&lt;br&gt;Concentration unit: ml millilitre(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Product Name: PROPOFOL&lt;br&gt;Pharmaceutical Form: Emulsion for suspension for injection&lt;br&gt;INN or Proposed INN: PROPOFOL&lt;br&gt;Other descriptive name: PROPOFOL&lt;br&gt;Concentration unit: mg/kg/h milligram(s)/kilogram/hour&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: LEVOFLOXACIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LEVOFLOXACIN &lt;br&gt;CAS Number: CAS 138199-7&lt;br&gt;&lt;br&gt;Product Name: HYDROCORTISONE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROCORTISONE&lt;br&gt;CAS Number: 50-23-7&lt;br&gt;&lt;br&gt;Product Name: CEFTRIAXONE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CEFTRIAXONE&lt;br&gt;CAS Number: 73384-59-5&lt;br&gt;&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AZITHROMYCIN&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;&lt;br&gt;Product Name: CLARITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;CAS Number: 81103-11-9&lt;br&gt;Other descriptive name: CLARITHROMYCIN LACTOBIONATE&lt;br&gt;&lt;br&gt;Product Name: ERYTHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ERYTHROMYCIN &lt;br&gt;CAS Number: 3847-29-8&lt;br&gt;&lt;br&gt;Product Name: AMOXICILLINE-CLAVULANTE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AMOXICILLIN &lt;br&gt;CAS Number: 34642-77-8&lt;br&gt;INN or Proposed INN: POTASSIUM CLAVULANATE&lt;br&gt;CAS Number: 61177-45-5&lt;br&gt;&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AZITHROMYCIN MONOHYDRATE&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;&lt;br&gt;Product Name: CLARITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;CAS Number: 81103-11-9&lt;br&gt;&lt;br&gt;Product Name: PIPERACILLIN-TAZOBACTAM&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: PIPERACILLIN&lt;br&gt;CAS Number: 66258-76-2&lt;br&gt;INN or Proposed INN: TAZOBACTAM &lt;br&gt;CAS Number: CAS 89785-84&lt;br&gt;&lt;br&gt;Product Name: ROXITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ROXITHROMYCIN&lt;br&gt;CAS Number: 80214-83-1&lt;br&gt;Other descriptive name: ROXITHROMYCIN&lt;br&gt;&lt;br&gt;Product Name: CEFTAROLINE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CEFTAROLINE FOSAMIL&lt;br&gt;CAS Number: 229016-73-3&lt;br&gt;Other descriptive name: CEFTAROLINE FOSAMIL&lt;br&gt;&lt;br&gt;Product Name: MOXIFLOXACIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: MOXIFLOXACIN &lt;br&gt;CAS Number: 186826-86-8&lt;br&gt;Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE&lt;br&gt;&lt;br&gt;Trade Name: Oseltamivir&lt;br&gt;Product Name: oselt","&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for nebuliser solution&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","Intervention 1: Nicotinamide, 1,000 mg/day p.o. (2 x 500-mg tablets), for 4 weeks Intervention 2: Silica, 245 mg/day p.o., for 4 weeks","Intervention 1: Confirmed SARS-CoV-2 infection Intervention 2: SARS-CoV-2 negative patients, which often showed symptoms of an infection but were tested negative","Intervention 1: Potential study participants will be invited through phone calls by the Rhine-Neckar Health Department if they are a suspect of a COVID-19 infection and will be tested in the drive-in. In the drive-in, potential study participants are asked whether they would be willing to participate voluntarily in the validation of a new antigen test in addition to the standard PCR test and if this is the case, a further swab is taken from the study participants after signing the consent form. This swab is not used for clinical diagnosis and is only used for validation of the antigen test.","Intervention 1: An interview will be conducted with patients who are undergoing (partial) inpatient or day-care psychosomatic treatment during the COVID-19 pandemic for mental or psychosomatic diseases, as well as with employees of the Department of Psychosomatic Medicine of the University Hospital of Freiburg who have patient contact during the pandemic (with or without COVID-19 infection), and with employees of the University Hospital of Freiburg who are working on so-called COVID-19 wards during the pandemic.","Intervention 1: robotic autonomous naso-oropharyngeal swab collection Intervention 2: manual naso-oropharyngeal swab collection","Intervention 1: Persons with previous SARS CoV-2 infection Intervention 2: Blood donors","Intervention 1: Questionnaire survey of general practitioners with panel practice Method: Based on semi-structured guideline interviews with general practitioners, nine subject areas were identified. Based on this structure a questionnaire was developed. The questionnaire contains items that are only given once (e.g. items relating to the beginning of the pandemic) and items that can be given weekly. This questionnaire was checked for comprehensibility by 3 - 5 family doctors. The recruitment of the participants is carried out via the email distribution list of professional associations and existing family doctor research and teaching networks. The survey is conducted via the open source online tool LimeSurvey. Persons who have agreed to participate in a weekly survey in the first survey will be contacted weekly. Since each participant chooses a code that only he/she knows, it is possible to summarize the surveys belonging to one person longitudinally, but it is not possible to assign these answers to a specific person. This guarantees the anonymity of the respondents. &lt;br&gt;Evaluation: The questionnaire is evaluated descriptively. Primarily, the extent of existing deficiencies and problems is to be recognized. Therefore, the items are evaluated individually and no summary of the items is planned. For this reason, the answers are displayed in frequencies. In order to obtain a conclusion on the population, 95% confidence intervals are calculated for the frequencies. Possible group differences (e.g. ordination in the country vs. ordination in the city) are analysed exploratively by means of chi-square methods. The sample size results from the e-mail addresses available in the distribution lists.","Intervention 1: patients with painful polyneuropathy&lt;br&gt;Evaluation of questionnaires (DN4, BPI, PainDETECT, PROMIS, EuroQol 5D, Pain catastrophizing scale, IPAQ, PGIC)","Intervention 1: Patients with suspected COVID19 will be asked for medical history and current medication and a biomarker profile will be generated. Course of disease will be evaluated on day 30.","Intervention 1: All clinical and radiological data were extracted from an electronic database, named iNOK, which is collecting medical records of all patients admitted to the Helios Hospitals since February, 15 2020 . For this study medical records such as epidemiological, demographic, clinical, laboratory, management and outcome data &lt;br&gt;are collected by using a CRF. These data are merged in real time","Intervention 1: Medical history, clinical data of Covid-19 positive pregnant women will be collected during pregnancy, delivery, of the neonate and during childbed.","Intervention 1: One assessment of psychological burden (e.g. anxiety, depressive symptoms) and behavioural changes due to the COVID-19 pandemic in oncological patients Intervention 2: One assessment of psychological burden (e.g. anxiety, depressive symptoms) and behavioural changes due to the COVID-19 pandemic in matched healthy controls","Intervention 1: Index persons of the Gangelt register as well as household or family members: Collection of biological samples for virus diagnostics from the study participants:&lt;br&gt;- adults: 3 EDTA tubes (10 ml), throat swab, spit (saliva)&lt;br&gt;- Children: 1 EDTA tube (1 ml), throat swab, spit (saliva), handing out a study questionnaire&lt;br&gt;In up to 50 selected households, further virological diagnostics, including the living environment, are to be used to evaluate the extent to which the virus can be transmitted to family members via air and the inanimate environment (surfaces, consumer goods, food, wastewater) and the living environment (pets) Intervention 2: Participants of the \"Kappenmeeting\" residing in the Heinsberg district as well as household or family members: virus diagnostics like observation group 1 and extended questionnaire","Intervention 1: Interventiongroup, direct access to the internet intervention Intervention 2: Waitlist controlgroup, delayed access to the internet intervention","Intervention 1: We will measure transpulmonary pressure, end expiratorisch lung volume and abdominal pressure in adult intensive care medicine patients. Through this parameter an individual approach for mechanical Ventilation should be implemented.","Intervention 1: Patients with confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx, oropharynx, stool, or blood. Rapid tests are an acceptable alternative.&lt;br&gt;Within the framework of LEOSS, data on the therapy and the course of treatment of patients infected with SARS-CoV-2 will be documented. The resulting registry will enable the analysis of important questions regarding SARS-CoV-2. Within the scope of the project, no study conditional interventions will be carried out.",null,"Intervention 1: vv-ECMO with cytokine adsorption using a CytoSorb adsorbers for 72 hours Intervention 2: vv-ECMO without cytokine adsorption","Intervention 1: This study has two phases. After informed consent phase 1 assesses longitudinally the seroconversion against SARS CoV-2 in departments with intensive patient contact, including COVID-19 patients, correlates to Symptoms and assesses the duration and kinetics of antibodyresponse in a limited cohort of health-care workers.&lt;br&gt;&lt;br&gt;In addition biomaterials will be stored for broader immunological Analysis (PBMCs, antibodies, cytokindes). &lt;br&gt;&lt;br&gt;The results of Phase 1 will enable an adaption of phase 2, if necessary. &lt;br&gt;&lt;br&gt;Phase two is a vertical study on more employes of the university hospial and assessed the prevalence of SARS-CoV-2-IgG. This prevalence will be correlated to exposure data of certain departments.","Intervention 1: Intervention group: 50000 Vitamin A daily for two weeks. Intervention 2: Control group: common treatment.","Intervention 1: One-time survey and blood collection of about 100 public servants in Bremen.","Intervention 1: All participating subjects conduct the web-based psychological CoPE It training over a period of two weeks. Every 48 hours a new session ( 30 minutes) is activated for the patients. The CoPE It training can be conducted on the PC, tablet or smartphone of the participating person.&lt;br&gt;&lt;br&gt;The four modules of the CoPE It training include stress-related sessions with instructional videos, audio files, interactive worksheets, personal skills box, and the resulting final material for everyday use.&lt;br&gt;&lt;br&gt;The contents of the modules are based on established elements and methods from cognitive behavioural therapy and the field of mindfulness teaching.","Intervention 1: In this  intervention group COVID-19 patients who do not reply to routine treatments and are in a critical stage and prolonged hospitalization  will be treated with convalescent plasma (obtained from fully recovered patients according to inclusion criteria) {200 cc/day intravenous (IV) administration for 1 to 4 hours} for 1-4 days. Intervention 2: The second intervention group will be treated with Plasma-derived Immunoglobulin-enriched solution {IV, 0.2 _0.4 g/kg/day based on the patient's physiological tolerance}. Intervention 3: The control group will only receive routine care without any new therapeutic interventions.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (Tab hydroxychloroquine 400 mg twice daily at day 1 then 200 mg twice daily plus Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 days), patients will receive one tablet of sofosbuvir/ledipasvir 400/100 mg (Danesh Pharmaceutical Development Company) daily for 10 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (Tab hydroxychloroquine 400 mg twice daily at day 1 then 200 mg twice daily plus  Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 days).","Intervention 1: Medial health care worker of the University Hosptials will receive a questionnaire package at 3 different measurement points.","Intervention 1: All employees at Reinbek Hospital are smeared weekly on COVID-19 and a blood sample is taken for the antibody test. At the same time, a daily online survey of the state of health takes place.","Intervention 1: Intervention group: Discontinuation of agents inhibiting renin-angiotensin-aldosterone system substituting by calcium channel blocker with or without beta-blocker. Intervention 2: Control group: Continuation of renin-angiotensin-aldosterone inhibiting agents.","Intervention 1: spontaneously breathing and ventilated patients with COVID 19","Intervention 1: Intervention group: experimental group will receive supportive intervention and get education of Benson relaxation with video tape and every nurse will get one CD and pamphlet for use in home. nurses in experimental group will do Benson relaxation for 15 minute, twice a day during one month. Job Stress and Quality of working life questionnaire will complete by experimental group before, and 4 week after intervention. Intervention 2: Control group: no intervention in control group.","Intervention group: Patients in this group will receive drug regimen including Tab hydroxychloroquine 400 mg twice daily on day 1 then 200 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablets twice daily or Tab atazanavir/ritonavir 300/100 mg daily for at least 5 days..","Intervention1: Not applicable: Not applicable&lt;br&gt;Control Intervention1: Not applicable: Not applicable&lt;br&gt;","Intervention 1: Intervention group: altebrel 50mg by aryogen company subcutaneously in two dose with2-3 days duration in one week. Intervention 2: Control group: In control group, supportive care and protocol without any injection.","Intervention 1: Intervention group: Hospitalized patients will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee. Intervention 2: Control group: Hospitalized patients will receive standard treatment according to the national guidelines for the treatment of COVID-19. Intervention 3: Intervention group:  Outpatients (self-quarantine at their home) will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee.","Intervention 1: no or mild symptoms of common cold, SARS-CoV-2 negative Intervention 2: mild COVID-19 Intervention 3: severe COVID-19 Intervention 4: severe viral pneumonia, SARS-CoV-2 negative","Intervention1: Chloroquine phosphate: Chloroquine phosphate tablets will be given in the dose of 500 mg twice daily for 10 days to the patients who meets the inclusion criteria&lt;br&gt;Control Intervention1: No drug: Chloroquine will not be given to control group. These patients will be managed as per standard protocol.&lt;br&gt;","Intervention group:  The extracted tooth is brought to the lab . After tooth extraction, it is enzymatically digested and cultured. After the cells have reached the required level, 40 million cells are injected intravenously at one time. Patients receive common medications at the same time..","Intervention1: HCQS -MIMS Regimen: 300 mg daily x 1 wk followed by 300 mg weekly&lt;br&gt;Intervention2: Hydroxychloroquine: 300 mg daily x 7 days followed by 300 mg weekly x 7 weeks&lt;br&gt;Control Intervention1: Hydro Chloroquine(HCQ)-ICMR regimen: Group 2 : &lt;br&gt;400 mg bd for one day followed by 400 mg weekly for 7 weeks to be taken with meals (or until the epidemic stops) (ICMR Regimen)&lt;br&gt;Both groups will be advised to follow strict measures of self hygiene, social distancing and other routine protocols issued by IMA and Government bodies to prevent transmission. &lt;br&gt;&lt;br&gt;&lt;br&gt;",null,"Intervention 1: Intervention group: In this group of patients with COVID-19, in addition to standard treatment introduced by the Ministry of Health, the second drug is also prescribed. It is a licorice-based herbal extract that contains licorice, Rheum palmatum, Rosa damascene, Crocus sativus, and Ziziphus jujube. In order to prepare this extract, simple substances of these herbal are first prepared from the pharmaceutical market and after identification in the herbarium of the Faculty of Pharmacy of Tehran University of Medical Sciences, a herbarium code is assigned to each one. Then, a herbal syrup is extracted from these herbs by the maceration method. The syrup is standardized based on glycerol content, the total phenolic, and flavonoids compounds by HPLC method. Microbial controls are performed on the syrup. The syrup is packaged in 240 cc dark pets and given to the patient and at a dose of 10 cc every 8 hours for up to 8 days. Intervention 2: Control group: Patients in this group receive only standard treatment provided by the Ministry of Health for COVID-9.","Intervention1: SSV Formulation Tablets: Each tablet of 500 mg to be consumed orally twice a day immediately after meals for 15 days.&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;","Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 mg three times daily). Intervention 2: Control group: they will receive standard regimen for COVID-19 patients.","Intervention 1: Intervention group:   Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical, 400 mg daily and once a week for one to three months. (Based on the duration of corona virus epidemic). Intervention 2: Control group: placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy)is given.The dosage is two tablet daily , once a week for one to three months (based on duration of Corona virus epidemic in Tehran).",null,"Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon beta, sub type 1a (CinnaGen Company) with dose of 44 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir) for at least 5 days.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon , sub-type 1b (Zist Daru Daneh Company) with dose of 250 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir) for at least 5 days.","Intervention group: Intravenous (4-8 mg/kg) or subcutaneous (two PFS injections of 162 mg Tocilizumab for ?patients &lt;100 kg and three PFS injections of 162 mg Tocilizumab for patients &gt;100 kg) in addition to the standard treatment. In case of inadequate response, Tocilizumab would be re-administered in either form with a 12-hour interval between injections..","Intervention 1: Intervention group: In this group, mesenchymal stem cells will be injected at an initial dose of 0.5-1 milion/ kg. This process will be performed on the first, third and sixth days. This intervention will be done along with other treatments for this type of patients, varying in severity of COVID Infectious, and in accordance with national and international guidelines. Mesenchymal Stem Cell is GMP-approved by SinaCell. Intervention 2: Control group:This group, like the intervention group, will receive all routine medication according to national and international guidelines, depending on the severity of COVID-19. But on the first, third and sixth day, placebo (normal saline) will be injected.","Intervention 1: Intervention group: Acetaminophen + Febuxostat. Intervention 2: Control group: Acetaminophen + Hydroxychloroquine.","Intervention 1: Control group: Standard of care treatment according to the national guidelines for the treatment of COVID-19. Intervention 2: Intervention group: Sovodak, Company: Rojan, Daily single oral tablet containing 400mg of Sofosbovir and 60mg of Daclatasvir plus Standard of care treatment.","Intervention 1: Control group: Standard drugs of the national protocol (hydroxychloroquine sulfate 200mg, two single-dose tablets (Tehran Daru) , two single-dose tablets (Pars), Kaletra tablets (Lupinavir / Ritonavir) every 12 hours 2 tablets 50/200)+ A placebo every 12 hours (in terms of appearance and color similar to 500 mg naproxen). Intervention 2: Intervention Group: Standard Protocol Drugs For 5 days (Hydroxychloroquine Sulfate 200mg Two Single Dose tablets (Tehran Daroo) , Kaletra tablets (Lupinavir / Ritonavir)  every 12 hours, 2 tablets 50/200) + Naproxen 500 mg every 12 hours (Pars Daru) For 5 days.","Intervention 1: Intervention group: Pirfenidone 200 mg ,three times daily in addition to standard treatment (according to the national protocol)  containing Coltra Lupinavir / Ritonavir twice daily, Chloroquine 250 mg twice daily, and Osiltamivir 75 mg twice daily, in critically ill patients with ribavirin 1200 twice daily. ). Intervention 2: Control group: In the control group, standard treatment according to the national protocol containing Coltra (Lupinavir / Ritonavir) 100mg/400mg twice daily, chloroquine 250 mg twice daily, and siltamivir 75 mg twice daily in critically ill patients with ribavirin 1200 twice daily.","Intervention group: Patients who suffer from sever (ARDS patients who are not admitted in ICU) or very severe (ARDS or related symptoms and signs who are admitted in ICU) complications of COVID-19, received 150 mg of SeptimebTM in 500 ml of DW 5%, infused over 1.5 hours on the first day. All hemodynamic data are monitored during the infusion and in case of any negative hemodynamic deterioration, dermal rash, urticaria or anaphylactic reaction, the infusion discontinued. In absence of the mentioned complications the treatment is continued by administration of 300 mg of the drug that will be infused in 500 ml of DW5%, every day for up to 14 days (the duration of treatment will be adjusted based on the severity of symptom and sign of the patients)..","Intervention 1: Intervention group: In the intervention group, in addition to the standard treatment, medicinal herbal products will be prescribed. The drug will be given in two combination forms. One in the form of a syrup containing the following medicinal herbs: Zattaria multiflora, Punicagranatum, Marticaria chamomilla, Zizyphus sativa and Mentha spp, and the other in the form of a capsule containing the following medicinal herbs: Rheum officinale, nigella Sativa andnepeta bracteata . In addition to the usual treatment, the intervention group, will receive a capsule every 8 hours and 10 cc of of Iranian medicine syrup every 8 hours for one week. The capsule will be taken at least half an hour after taking the syrup. Intervention 2: Control group: Get standard treatment.","Intervention 1: Intervention group: subcutaneous injection of Recigen (44mcg) daily until 5 days or the discharge day (which ever come sooner) in addition to standard treatment (based on the Ministry of Health protocol: chloroquine, etc .. ). Intervention 2: Control group: subcutaneous injection of placebo daily until 5 days or the discharge day (which ever come sooner) in addition to standard treatment (based on the Ministry of Health protocol: chloroquine, etc .. ).","Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Interferon beta-1a 44 mg every other day S.C for 10 days.","Intervention 1: Intervention group: Patients in this group receive medication for treatment of Covid-19 based on Fifth Edition of the Novel Corona Virus Guidelines, in addition they recieve myrtle syrup for 5 days  (Patients daily boil the contents of a pack containing 10 grams of myrtle fruit and 10 grams of sugar in 3 glasses of water gently to stay 2 glasses, then smooth it and drink one glass in the morning and one glass in the evening.). Intervention 2: Control group: Patients in this group receive medication according to the novel Corona virus country guideline version 5.","Intervention 1: Intervention group: Oral Atorvastatin 40 mg for 5 days. Intervention 2: Control group: Routine Care.","Intervention 1: Intervention group: Treatment group which received Noscapine   mg, tds. Intervention 2: Control group: Group receiving Placebo with no API.","Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID orally for 2 weeks. Intervention 2: Control group: standard regimen of covid-19 patients.","Intervention 1: Control group 1: Positive people with corona virus infection after laboratory tests are classified according to expert diagnosis and based on the patient's symptoms and history as well as laboratory results with primary infection in the first control group. This spectrum of patients is treated by the Ministry of Health's pharmacological and medical regimen, which is monitored by relevant specialists. Intervention 2: Intervention group 1: In this group, patients will be diagnosed with corona virus primary infection  after the corona virus infection is confirmed. The symptoms and level of virus infection is categorized with specialist. For this group the same dose of 2 puffs is used every 12 hours. An estimate of 400 ug / ml is considered for each dose of drug. The drug is given 8 days every two days for the patient to have optimal efficacy. The chemical formula is reserved for the RNA Biotechnology company, but according to the ethics committee, no harm can be expected to consumers. The new drug has FDA-approved components. Intervention 3: Intervention group 2: . Once the corona virus infection is confirmed positive and the clinical symptoms are diagnosed according to the specialist's diagnosis, the secondary level of corona virus infection is defined.  The application of drugs for this group is same as group 1.  the same dose of 2 puffs is used every 12 hours. An estimate of 400 ug / ml is considered for each dose of drug. The period  time for treatment of the drug is 8 days and the drug application is for every two days and a resting day for the patient to be optimal for effectiveness. The chemical formula for the RNA Biotechnology company is protected, but according to the ethics committee, there is no compensation for consumer users. The new drug h","Intervention 1: \"Intervention group:\" This group consumes the Trachyspermum copticum syrup. The Trachyspermum copticum plant is a member of the Umbrella family. The total extract of this plant is used.The concentration of this syrup is 10% of the aqueous extract of Trachyspermum copticum. This syrup is administered three times daily for two weeks, 5 ml each time, a total of 15 ml daily. The syrup is made by Shahid Beheshti School of Pharmacy. Intervention 2: \"Control group:\" This group is taking placebo. Placebo syrup have the same size and shape as the drug.The placebo syrup contains all the basic ingredients of a syrup without the addition of herbal medicine.  The placebo syrup is made by Shahid Beheshti School of Pharmacy.","Intervention 1: Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 500 Ml convalescent plasma in 4 hrs. Intervention 2: Control group: Patients hospitalized with COVID-19 disease who are receive routine treatment.","Intervention 1: Intervention group 1: Tablet Sovodak  (Sufbosvir 400mg + Daclatasvir 60mg) daily for 5 days. Intervention 2: Intervention group 2: Tablets Ribavirin 200 mg  every 12 hours 1200mg.","Intervention 1: Intervention group:In this group along with the standard drugs according to the national guideline of treatment for COVID-19, patients will take Levamisole 50 mg TDS for 3-7 days, made by Poursina pharmaceutical Company and Budesonide+Formoterol 1 Puff every 12 hours made by Astra Zenca Company for 3-7 days. Brand name of  Budesonide+Formoterol is Symbicort and it has two strength ; 160/4.5 and 320/9 mcg respectively. Decision about the used strength and dose of drug depends on the situation of the disease and will be made by physician. Intervention 2: Control group: This group just take standard drugs consist of Kaletra and Hydroxychloroquie. This national  protocol would be taken as below: 1- Hydroxychloroquine sulfate 200 mg as a single dose. 2- Kaletra tablet ( Lopinavir/ Ritonavir) 200/50 mg 2 tablets every 12 hoursfor atleast 5 days which can be extended to 14 days.","Intervention group: In addition to standard treatment:(two-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days or alternatively, atazanavir OR three-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days and ribavirin 1200 mg BID for at least 5 days)Remdesivir is also prescribed for 5 days (for patients over 40 kg or more: Amp Remdesivir 200 mg IV infusion over 30 minutes once-daily dose, followed by 100 mg iv infusion over 30 minutes once-daily maintenance doses for next 4 days.For patients weighing less than 40 kg: Amp Remdesivir 5 mg/kg IV infusion over 30 minutes loading dose on day 1, followed by 2.5 mg/kg iv infusion over 30 minutes once-daily maintenance doses for next 4 days).","Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Tocilizumab (Actemra) 400 mg I.V infusion as a single dose.","Intervention 1: The one globule of  (Ipecac)homeopathy remedy with C30 potency produced by Hellios homeopathy pharmacy distilled in 20 ml. 10 degree alcohol which will be administered at a dose of 15 drops every 2 hours for 6 hours and then every 6hours at 15 drops for 3 days. Intervention 2: The one placebo(Sac-lac) distilled in 20 ml. 10 degree alcohol which will be administered at a dose of 15 drops every 2 hours for 6 hours and then 15 drops every 6 hours  for 3 days. remedy and placebo have both common bases and are similar in taste, color, odor and taste.","Intervention 1: Group I: Receivers of standard national protocol drugs. Intervention 2: Intervention group: Group II: Drug recipients of National Medicines Standard Protocol + (Perl Vitamin D3 50,000 units) once a week. Intervention 3: Intervention group: Group III: National standard drug + N acetylcysteine (NAC) tablets receiving 600mg every 12 hours for 14 days. Intervention 4: Intervention group: Group IV: National standard protocol drug + (Perl vitamin D3 50,000 units) once a week + N acetylcysteine (NAC) tablet 600mg every 12 hours for 14 days.","Intervention 1: Intervention group:Intervention is used to Psychological counseling program consisting of 10 daily virtual sessions through virtual networks such as WhatsApp or Skype For 30 to 45 minutes. Intervention 2: Control group: There is no intervention for the control group.","Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID  orally for 2 weeks. Intervention 2: Control group: standard regimen of covid-19 patients.","Intervention 1: Intervention group: National therapeutic guideline including hydroxychloroquine 400 mg stat and lopinavir/ritonavir plus 250 mcg interferon beta 1 b subcutaneous injection every other day for at least 3 doses. Intervention 2: Control group: Patients with inclusion criteria and received national therapeutic guideline within two weeks before proposal approval.","Intervention 1: Intervention group: This group will receive routine treatments for COVID-19 disease and will receive a suspension of extract of five herbs. Patients will receive a combination consisted of aqueous extract of 10 grams of hyssop leaf, 5 grams of Plantain seed, 10 grams of purslane seed , 10 grams of licorice root and 5 grams of turmeric, orally, in three divided doses daily. The intervention duration is five days. Intervention 2: Control group: This group receive routine treatments for COVID-19 disease and placebo. Placebo will be given as an oral syrup, three servings a day. For the placebo syrup, a non-absorbable sweetened drop of stevia (a product from a pharmaceutical company), authorized oral dyes are used to make the color and taste relatively similar to the original drug.","Intervention 1: Control group: Standard Protocol Drugs (Hydroxychloroquine Sulfate Tablet 200mg Two Single Dose Pills  or Chloroquine Phosphate 150mg Pill Two Single Dose Pills, Coltra Pills (Lupinavir / Ritonavir)(50/ 200)+A placebo (in terms of appearance and color similar to vitamin C) every 12 hours. Intervention 2: Intervention group: Standard Protocol Drugs (Hydroxychloroquine Sulfate Tablet 200mg Two Single Dose Pills (Tehran Drug) or Chloroquine Phosphate 150mg Pill Two Single Dose Pills (Pars), Coltra Pills (Lupinavir / Ritonavir)) 200) + Vitamin C 500mg every 12 hours for 5 days.","Intervention 1: Intervention group: An initial dose of 1mg/kg will be started for all patients in the case group. The patients will receive the mentioned dose for 5 days, which will then be halved for 5 days and repeated until reached a dose of under 20mg/day, which will then be converted into oral tablet form of prednisolone. Also, patients will receive the national treatment protocol for COVID-19. Intervention 2: Control group: Patients in the control group will receive the standard treatment based on the National protocol.","Intervention 1: Intervention group: this group adjunct to standard treatment will receive intravenous infusion of 12 grams of vitamin C in Dextrose 5% serum to the total volume of 200 ml  over 24 hours for 4 days. Intervention 2: Control group: infusion of serum containing 120 ml distilled water in Dextrose 5% serum to the total volume of 200 ml over 24 hours for 4 days beside receiving standard treatment.","Intervention 1: Intervention group: 34 patients receive herbal treatment including 10 ml of decoction (Glycyrrhiza glabra L., Althaea officinalis L., Ziziphus jujuba Mill) 3 times a day and capsule (dried extract of Hyssopus officinalis L., Punica granatum L.) 2 times a day with routine interventions based on the instructions of the Ministry of Health for 2 weeks. Intervention 2: Control group:34 patients receive routine interventions according to the instructions of the Ministry of Health for 2 weeks.","Intervention 1: Intervention group: Patients in this group in addition to drug treatment according to the Ministry of Health protocol, take 2 tablespoons of medium-chain triglyceride (MCT) to cure fever with each meal. Both group are thought to take the following advice base on traditional medicine instructions:During this period, avoid consuming carbohydrate including sweet and eat less starch food.skim snacks and start eating when they're starving.avoid eating before satiating.eat slowly and chew well.walk for 15 minutes after eating. Intervention 2: Control group: Patients in this group receive medication according to the Ministry of Health protocol. Both group are thought to take the following advice base on traditional medicine instructions:During this period, avoid consuming carbohydrate including sweet and eat less starch food.skim snacks and start eating when they're starving.avoid eating before satiating.eat slowly and chew well.walk for 15 minutes after eating.","Intervention 1: Control group: Receive standard treatment for COVID19 according to the protocol of MOH of Iran (antiviral drugs and hydroxychloroquine). Intervention 2: Intervention group 1: Receive standard treatment for COVID19 and combination of dexamethadone, IV-IG and Interferon beta at admission. Intervention 3: Intervention group 2: Receive standard treatment for COVID19 and combination of dexamethasone, IV-IG and Interferon beta 48 hours after admission.","Intervention 1: Intervention group:  Twenty patients with Coronavirus (COVID-19)-induced pneumonia addition to standard regimen of covid-19? will receive Fingolimod for 1 day (50 mg one time). Intervention 2: Control group: standard regimen of covid-19 patients.","Intervention 1: Intervention group: Group receiving Favipiravir plus Hydroxychloroquine. Stat dose of eight 200 mg Favipiravir tablets (total 1600 mg) followed by Favipiravir 600 mg three times a day for 7 days plus Hydroxychloroquine 200mg two times per day for 7 days. This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups. Intervention 2: Control group: Group receiving Kaletra plus Hydroxychloroquine regimen. Stat dose of two 200 mg Hydroxychloroquine tablets (total 400 mg) followed by Kaletra(Lopinavir/Ritonavir) 200/50 mg two times a day for 7 days. This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups.","Intervention group: Patients with severe clinical symptoms for whom the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin) was not responsive receive intravenous immunoglobulin (IVIg) before entering the intubation phase. They will receive 0.4-0.5/g/kg/day of IVIg in 3-5 doses with each dose being equal to about 30g with a weight of 60 kg. Also patients under prophylaxis from thrombosis, in the case of the absence of contraindication, will receive heparin with prophylaxis dose..","Intervention 1: Intervention group: In addition to the treatment protocol, patients are given four daily doses of 300 mg of Vulgaris.C supplemented with Herbal tea (2g Pennyroyal; 2g chamomile, 1.4g Hollyhocks and 0.6g Mallow). Intervention 2: Control group: Treatment is according to the protocol and is for comparison only with the intervention group.","Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 70 million mesenchymal stem cell day 0, 3 6 , infusion time 30 min 4..","Intervention 1: Intervention group: Patients in this group receive the treatment according to the protocol of the Ministry of Health, in addition they should daily boil the contents of one drug pack with 8 glasses of water slowly to stay two glasses, then smooth and the content of the sachet will be added for 5 days. They drink a glass in the morning and a glass in the evening. Intervention 2: Control group: Patients in this group receive medication according to the Ministry of Health protocol.","Intervention group: Patients undergo extracorporeal blood purification on three sessions. Each session conducts in six hours per day, using hemoperfusion filters (HA280 and HA230) manufactured by the Jafron Company, China. The second course of hemoperfusion is performed 12-24 hours after the first and the third session 24 hours after the second time..","Intervention 1: Intervention group: sovodak+ribavirin. Intervention 2: Control group: standard care regimen.","Intervention 1: In addition to the standard treatment regimen for COVID-19, the berberine hydrochloride capsule (Pharmaceutical grade)  300 mg will be given three times a day for 2 weeks. Berberine capsule (300 mg) is formulated at the School of Pharmacy with the inert ingredients of aerosol and avicel. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo capsules three times a day for 2 weeks. The placebo is formulated in capsules of the same shape and size as the drug capsules and contains avicel and aerosil.","Intervention 1: Intervention group: Vitamin supplementation in order (ampoules): 25,000 international units of vitamin A daily, 600,000 international units of vitamin D once during the intervention time, 300 international units of vitamin E, 2 times a day, 500 mg of vitamin C, 4 times a day and B vitamins in the form of one Soluvit ampoule in a day. The control group does not receive any supplement or placebo. In this study, the duration of supplementation and evaluation of patients is one week .Except for Soluvit (Fresenius Kabi New Zealand) , all supplements are made in Iran. Soluvit: Thiamine nitrate 3.1 mg, Sodiumriboflavine phosphate 4.9 mg(corresponding to Vitamin B2 3.6mg), Nicotinamide 40 mg,Pyridoxine hydrochloride 4.9 mg(corresponding to Vitamin B6 4.0mg), Sodium pantothenate 16.5 mg(corresponding to Pantothenic acid15 mg), Sodium ascorbate 113 mg(corresponding to Vitamin C 100mg), Biotin 60 g, Folic acid 400 g,Cyanocobalamin 5 g,. Intervention 2: Control group: no placebo.","Intervention 1: Intervention group: Hydroxychloroquine 400 mg every 12 hours for the first day then 200 mg every 12 hours Atazanavir / ritonavir 300/100 mg once daily. Arbidol 100 mg(manufactured by Pharmstandard)2 capsules every 6 hours. Intervention 2: Control group: Hydroxychloroquine 400 mg every 12 hours for the first day then 200 mg every 12 hours Atazanavir / ritonavir 300/100 mg, two placebo capsules (hand made) every 6 hours.","Intervention 1: Intervention group: Participants receive Hydroxychloroquine (Amin Pharmaceutical company, Isfahan) at dose of 200 mg TDS up to 7 days. Intervention 2: Control group:  Participants receive no medicines.","Intervention 1: Intervention group: In addition to the standard treatment regimen  for covid-19,  capsules which have aqueous licorice extract  containing 80 mg of the active ingredient glycyrrhizin will be given three times a day for 2 weeks. Licorice capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. Intervention 2: Control group: ]n addition to general drugs for  treatment of corona, the patients take placebo capsule 3 times a day for 14 days.","Intervention 1: Intervention group: under treatment with Zufa syrup 6 times a day (every 4 hours) and 7.5 cc each time for 10 days made by Bouali Daru  Pharmaceutical Company. Intervention 2: Control group: under treatment with placebo syrup 6 times a day (every 4 hours) and 7.5 cc each time for 10 days made by Bouali Daru   Pharmaceutical Company.","Intervention 1: Intervention group:The group  uses the following herbal medicine in addition to the current medicine for Covid-19: Drug Name: Pinene-Hydronoplactone-Ribonucleoic-Abbreviation: PHR160 - Drug Form: Inhaler Spray --- Ingredients: Sineol Menthol Crocin Safranol Alpha Tojun Oleic Acid Linoleic Acid Linolenic AcidIt was extracted from natural products found in 7 plant species by steam distillation method. These herbs have previously had a single, double or triple human consumption history. Effectives per puff: 160 micrograms How to use PHR160: Determine the dosage approach for the above product based on the following: 1. Due to the volume of the nozzle output and pump MDIs and the presence of propylant (HFA gas) and alcohol in the product concentration of essential oils and herbal compounds in the total MDI is about 0.3%. Therefore, the total amount of soluble natural substances available per puff is less than 300 nL or 270 mg, which, of course, reaches a limited proportion in the lungs. 1-20 g / kg of human body weight and these compounds are considered very safe and high dosage is much lower than the toxic range indicated and is 1/100 toxic in the case of essential oils.3. Products available on the market such as Eucalyptus Barrage incense, Eucalyptus dyne incense Pulmonary doses of essential oils are similar to our product compounds in excess of 30mg. Of the amount in each puff investigated product is less than 1/100 of the amount above 0.4. External products mainly used in Aroma Therapy Ascents, MBC Aerosol, Primatene Mist are examples of those with higher doses of essential oil.5.Refruitment time to discuss the use or inhalation of the above product 30-45 In this case, the maximum time interval of 1 hour of awakening has been suggested for this product to","Intervention 1: Intervention group: containing 25OHD soft gelatin capsular 1000 IU , Producer: Dishmen. the case group will receive 1000 IUs of 25(OH)D daily for 8 wks. The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the 25(OH)D. The bottles will be returned to be checked at each visit. Intervention 2: Placebo: containing white to off white color suspension oil. Producer: Dishmen Company. The control group will receive placebo daily for 8 wks..The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the placebo. The bottles will be returned to be checked at each visit.","Intervention 1: Intervention group: Patients admitted to hospital in addition to receiving standard treatments of the Corona Country Committee, received a traditional  product based on Astragalus gossypinus  of 10 cc daily for 2 hours and food spice based on Ferula assa-foetida  of 2 grams once a day with apple juice. Traditional protocol duration is 5 days. Intervention 2: Control group:  Hospitalized patients are receiving standard corona treatment.","Intervention 1: Intervention group: Medications in national guideline+ Viroherb capsule 500 mg 2 caps every 12 h + Fenugreek syrup 10 cc every 6 h. Intervention 2: Control group: Medications in national guideline.","Intervention 1: Intervention group: Hydroxychloroquine200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days. Intervention 2: Control group: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days.","In the intervention group, in addition to the standard treatment, medicinal herbal products will be prescribed. The drug will be given in syrup form. The syrup will contain the following medicinal herbs: Nepeta bracteata?  Adiantum capillus veneris?  Glycyrrhi za glabra, Foeniculum vulgare? Viola odorata,  Ziziphus jujube,  Malva sylvestris, Nigella sativa . The intervention group will receive 7.5 cc of Kelofan syrup every 12 hours for one week..","Intervention 1: The intervention group in addition to standard treatment  (400 mg of hydroxychloroquine and 100 to 400 mg of Lupinavir-ritonavir at a time), will receive 100 to 400 mg of Sofosbuvir-Velpatasvir for 10 days. Intervention 2: The control group will receive standard treatment including 400 mg of hydroxychloroquine and 100 to 400 mg of lupinavir-ritonavir for 10 days at a time.","Intervention group: The Family-Based Empowerment Model, which will include four empowerment training sessions (2 45-minute sessions per week)..","Intervention 1: Intervention group: Kaletra 200 mg/50 mg tablet every 12 hours + hydroxychloroquine 200 mg tablets every 12 hours + herbal medicine containing sage, hofariqun and fennel (5 ml 3 times a day). Intervention 2: Control group: Kaletra 200 mg/50 mg tablet every 12 hours + hydroxychloroquine 200 mg tablets every 12 hours.","Intervention 1: Intervention group:After routine treatment , the main group will be received the drug of the study . drugs are in the sacher form. every sacher contain 2.5 gram of Marshmallow and 2.5 gram of Licorice. For 10 days Patients should infuse the contents of one packet with 250 cc of boiling water for 10 minutes every 12 hours, then strain and sip. Intervention 2: Control group: after routine treatment, the control group willl be received the placebo. they are in the sacher form. The contents of each package of placebo is 5 grams of starch powder. For 10 days,  patients should infuse the contents of one packet with 250 cc of boiling water for 12 minutes every 12 hours, then strain and sip.","Intervention 1: Intervention group: Intervention group: Group 1: Patients in this group will first receive hydroxychloroquine as two 200 mg tablets with a total of 400 mg of stat; then the following regimen will be continued for 5 days - azithromycin two 250 mg tablets on the first day. And then 250 mg daily for 5 days - 5 mg prednisolone tablets in the amount of 5 tablets (25 mg) daily for 5 days - 250 mg naproxen tablets twice a day for 5 days. Also, patients in this group to prevent complications. Digestive patients will receive 40 mg of pentoprazole tablets or capsules daily during treatment. According to the attending physician, this treatment protocol can be continued for 10 days, depending on the clinical symptoms, if necessary. The patient will be discharged from the protocol. In this case, all the patient's information will be collected until the end of the study. If treatment is needed in the intensive care unit, all treatment methods will be used according to the patient's clinical needs and the decision of the treating physician. Prednisolone in this group will continue to be cleared and gradually reduced to 5 mg each week to be discontinued. The weekly dose will be as follows: -First week after clearance: 20 mg per day -Second week after clearance: 15 mg per day- Third week after clearance: 10 mg per day -Fourth week after clearance 5 Mg per day and finally discontinued. Intervention 2: Intervention group: Patients in this group will first receive hydroxychloroquine in the form of two 200 mg tablets with a total of 400 mg of stat; then the following diet will be continued for 5 days.- Azithromycin two 250 mg tablets on the first day and then 250 mg daily for 5 days- Naproxen tablets 250 mg twice daily for 5 daysIn addition, patients in this group will rec","Intervention 1: Intervention group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the herbal compound three times a day after meals. The herbal capsule contains a mixture of medicinal plant extract powder and is manufactured by the HomaPharmed Pharmaceutical Company. The herbal capsule is given as a supplement to patients for two weeks along with standard medications. Intervention 2: Control group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the placebo three times a day after meals. The placebo capsule contains a toasted powder is manufactured by the HomaPharmed Pharmaceutical Company. The placebo capsule is given as a supplement to patients for two weeks along with standard medications.","Intervention 1: Intervention group: Favipiravir (Toliddaru-Sobhan Oncology company, Iran) at dose of 1600 mg BID for one day and then 600 mg BID for totally 7 days with the standard and supportive care. Intervention 2: Control group: Lopinavir-ritonavir (Heterd company, India) at dose of 200/50 mg two tablets BID for 7 days with the standard and supportive care.","Intervention 1: Intervention group:30 patients with COVID-19 in addition to a standard regimen will receive Bromhexine  8 mg tablets every 8 hours for 14 days from the beginning of hospitalization. Intervention 2: Control group: 30 patients will receive only standard regimen of COVID-2019.","Intervention 1: Intervention group: Group receiving Favipiravir (Nafas farmed Co, Iran) plus Hydroxychloroquine (Iran daroo Co, Iran). This group will receive stat dose of eight 200 mg Favipiravir tablets (total 1600 mg) followed by Favipiravir 600 mg three times a day for 7 days plus Hydroxychloroquine 200mg two times per day for 7 days.This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups. Intervention 2: Control group: Group receiving Kaletra (Bakhtar bioshimi Co, Iran) plus Hydroxychloroquine (Iran daroo Co, Iran) regimen. This group will receive Stat dose of two 200 mg Hydroxychloroquine tablets (total 400 mg) followed by Kaletra(Lopinavir/Ritonavir) 50/200 mg two times a day for 7 days,This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups.","Intervention 1: Intervention group: local standard of care plus Remdesivir (daily infusion for 10 days). Intervention 2: Intervention group: local standard of care plus Chloroquine or Hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days). Intervention 3: Intervention group: local standard of care plus Lopinavir with Ritonavir (orally twice daily for 14 days). Intervention 4: Intervention group: local standard of care plus Lopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days). Intervention 5: Control group: local standard of care.","Intervention 1: Intervention group:  Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven days or Tab atazabavir-ritonavir 100/300 mg P.O one tablet daily for seven days plus Teicoplanin IV 400 mg daily for 1 weeks. Intervention 2: Control group: Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven days or Tab atazabavir-ritonavir 100/300 mg P.O one tablet daily for seven days.","Intervention 1: Intervention group: In the case group, patients will receive 25 mg losartan tablets two times daily. Intervention 2: Intervention group: Patients will receive 5 mg amlodipine daily.","Intervention 1: Intervention arm: Patients in this group receive 200 mg of hydroxychloroquine tablets (manufactured by Amin Pharmaceutical Company, Isfahan) every other day for 2 months. At the same time, specific cancer treatments are given. Intervention 2: Control arm: Patients receive the placebo, which is similar to Amin's hydroxychloroquine tablets, one every other day. Cancer treatment of these patients is done according to the standard during this period.","Intervention group: (n=6). Patients will receive three doses of MSCs. Three doses of 20010e6 (10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0, day 2, day 4. The cells will inject in 50 ml saline containing 1% human serum albumin..","Intervention 1: \"Intervention group:\" This group consumes the Trachyspermum copticum syrup. The total extract of this plant is used.The concentration of this syrup is 10% of the aqueous extract of Tanacetum parthenium (L) Sch. This syrup is administered three times daily for two weeks, 7 ml each time, a total of 21 ml daily. The syrup is made by Shahid Beheshti School of Pharmacy. Intervention 2: \"Control group:\" This group is taking placebo. Placebo syrup have the same size and shape as the drug.The placebo syrup contains all the basic ingredients of a syrup without the addition of herbal medicine. The placebo syrup is made by Shahid Beheshti School of Pharmacy.","Intervention 1: Intervention group: containing 25OHD soft gelatin capsular 1000 IU , Producer: Dishmen. the case group will receive 1000 IUs of 25(OH)D daily for 8 wks. The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the 25(OH)D. The bottles will be returned to be checked at each visit. Intervention 2: Placebo: containing white to off white color suspension oil. Producer: Dishmen Company. The control group will receive placebo daily for 8 wks..The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the placebo. The bottles will be returned to be checked at each visit.","Intervention 1: Intervention group: 50 patients with COVID-19 will be included in this group and their treatment regimen includes oral Hydroxychloroquine 400 mg single dose and Arbidol orally at a dose of 50 mg 4 times a day for 5 to 10 days. Intervention 2: Control group: Sixty COVID-19 patients in the control group will be given a treatment regimen of two Kaletra 200/50 mg tablets every 12 hours and two Hydroxychloroquine sulfate 200 mg tablets as a single dose for 5 to 10 days.","Intervention 1: Intervention group: Patients in this group received medications for the treatment of COVID-19 based on the Fifth Edition of the Novel Corona Virus Guidelines, in addition they indicated for mechanical ventilation and the  airway management was selected using the tracheotomy tube within 3 days from intubation. Intervention 2: Control group: Patients in this group received medications for the treatment of COVID-19 based on the Fifth Edition of the Novel Corona Virus Guidelines, in addition they indicated for mechanical ventilation and the  airway management was selected using the Orotracheal tube.","Intervention 1: Intervention group:25000 IU vitamin A per day for ten days, the plus, the standard national treatment for COVID 19. Intervention 2: Control group: the standard national treatment for COVID19 ,and placebo.","Intervention 1: Intervention group: 50 patients with Coronavirus (COVID-19)-induced moderate or severe pneumonia in addition to the standard regimen of covid-19? will receive IVIG for 2 days (100-200 mg two-wise a day). Privigen, Behring company, Switzerland. Intervention 2: Control group: will receive a standard regimen of covid-19 based on national protocol including Hydroxychloroquine, Ribavirin and Kaletra).","Intervention 1: Intervention group1: In addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Khorasan asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention 2: Intervention group2: n addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Fars asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention 3: control group: this group receive placebo capsules exactly with similar characteristics to real drugs in intervention group. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine.","Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease who in addition to their standard treatment will be received 250mg/day Methylprednisolone? for 3 days. Intervention 2: Control group: Patients hospitalized with COVID-19 disease who are received standard treatment.","Intervention 1: Intervention group: In addition to the standard treatment regimen for COVID-19, the crocetin capsule 22.5 mg (7.5 mg, three times a day) will be given for 2 weeks. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo capsules 3 times a day for 2 weeks. The placebo is formulated in capsules of the same shape and size as the drug capsules and contains inert ingredients.","Intervention 1: Intervention group: COVID-19 Patients receiving hydroxychloroquine + SOVODAK. Intervention 2: Control group: COVID-19 Patients receiving hydroxychloroquine.","Intervention 1: Intervention group: nanocurcumin capsule 40mg, two capsule twice daily for two weeks then 1 capsule twice daily for 2 weeks. Intervention 2: Control group:all standard measures will be performed for patient.","Intervention 1: Intervention group: Administration of 2 units of CP (Convalescent Plasma obtained from COVID-19 recovered people thorough plasmapheresis) (IV). Each unit of plasma that is collected from one different donor will be given over 2h with an interval of 1h between the two units. Intervention 2: Control group: Patients with COVID-19 will receive conventional treatment.","Intervention group: Patients undergo hemodialysis on 2 sessions, each session will be conducted in 4 hours using hemoperfusion HA330 filter (JAFRON BIOMEDICAL.CO.LTD, China). The second round will be performed 18-24 hours after the first time. Protocol: a blood flow 150cc/minute, Heparin 10-12 unit per kg per hour..","Intervention 1: Intervention group:The patients will receive 10 ml of elderberry extract syrup 3 times daily (2.6 g of elderberry extract per day equivalent to 15.76 g of fresh elderberries) beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol. This treatment will continue for 2 weeks. The syrup is formulated according to the United States Pharmacopoeia description. This syrup is preservative-free and remains stable for up to 1 month. The syrups will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences. Intervention 2: Control group: The patients will receive the placebo syrup beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol with the same order as the intervention group.The placebo consists of USP syrup formula with food-grade coloring agents with the same shape and size containers as the elderberry syrup. This syrup is preservative-free and will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences.","Intervention 1: Intervention group: The intervention group 1, Patients will receive three doses of MSCs. Two doses of 10010e6 (10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2. Intervention 2: The intervention group 3, Patients will receive two doses of MSCs intravenously and EVs. Two doses of 10010e6 (10%) MSCs will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2. In days 4 and 6, the patients will receive two times the infusion of MSCs-EVs. Intervention 3: Control group: Patients will receive conventional therapy.","Intervention 1: Intervention group: patients in this group  (Laboratory confirmed COVID-19 by PCR), will receive conventional therapy with Infusion of convalescent plasma, 200-500ml, two IV infusions during two consecutive days. Intervention 2: Control group: Laboratory confirmed COVID-19 by PCR only receive conventional therapy.","Intervention 1: Intervention group: They receive both usual treatments and foot bath (warm water at 42 C for 20 minutes and then kept warm for 5 minutes once a day for 7 days). Intervention 2: Control group: They receive only usual treatments based on classical medicine.","Intervention 1: Intervention group: In addition to the standard treatment regimen forCOVID-19, the minocycline capsule 100 mg will be given two times a day for 2 weeks. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo capsules two times a day for 2 weeks. The placebo is formulated in capsules of the same shape and size as the drug capsules and contains avicel and aerosil.","Intervention 1: Intervention group: case group 55 patients treat with intravenous  vitamin c 1.5 gram 4 times a day  and   Hydroxychloroquine ??400 mg in the ?first day and then 200 mg BID plus Atazanavir / Ritonavir 300/100? daily  5 days. Every vitamin c vial content of 500 mg and is from Darou Pakhsh factory. The patients receive 3 vials slow infusion (1-2 hours)  with normalsaline.  Duration of treatment base of clinical response is 3-5 days. Renal function with BUN and CR monitor every other day. Intervention 2: Control group: control group 55 patients treat with    Hydroxychloroquine ??400 mg in the ?first day and then 200 mg BID plus Atazanavir / Ritonavir 300/100? daily  5 days.","Online survey dividing participants to three groups according to the level of influence of confinement on their lifestyle;Online survey assessing mental health during the last month;Mental Health; Online survey; Confinement","Intervention 1: Intervention group: Capsule Umnifenovir 100 mg, 2 capsuls every 6 hours, for 7 days. (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: routine treatment according to the latest national guideline for the treatment of new corona-virus.","Intervention group: In this study, 2 herbal medicines (in addition to standard treatment) will be used as follows. 1. Vomigone 500 tablets (containing ginger) 2 TDS a day (after meals) With drug registration number: 9406633051781240 Dineh Pharmaceutical Company        .2 Rucoldup tablets 750 (containing echinacea) 1 tablet TDS day with drug registration number: 6563916081842893 Company: Ghaem Daru.","Intervention 1: Intervention group:35 participants in the investigational treatment group will receive trifluoprazine at a dose of 5 mg twice daily for 14 days on admission in addition to standard treatment consisting of hydroxychloroquine. If necessary, according to the approved treatment protocol, kaletra and ribavirin would be added to the treatment. Intervention 2: Control group:35 participants in control group, would receive standard treatment protocol consisting hydroxychloroquine and , if necessary, according to the approved treatment protocol, kaletra and ribavirin would be added to the treatment.","Intervention 1: Intervention group: These patients receive daily azithromycin 500 mg, bi-daily oseltamivir 75, bi-daily lopinavir/ritonavir or in case of adverse gastrointestinal effects daily atazanavir (Kaletra) 400/100 mg and daily 400 mg of hydroxychloroquine; all for 5 days. Intervention 2: Control group: These patients receive bi-daily oseltamivir 75, bi-daily lopinavir/ritonavir or atazanavir (Kaletra) 400/100 mg and in case of adverse gasterointestinal effects, daily atazanavir (Kaletra) 400/100 mg and daily 400 mg of hydroxychloroquine; all drugs are administered for five days.","Intervention 1: Intervention group: After routine treatment, the main group will be received the drug of the study. Drugs are in the sacher form. Every sacher contain 2 gram of Phyllanthus Emblica powder. For 10 days Patients should infuse the contents of one packet with 250 cc of boiling water for 10 minutes every 12 hours, then strain and sip. Intervention 2: Control group: After routine treatment, the control group willl be received the placebo. They are in the sacher form. The contents of each package of placebo is 2 grams of starch powder. For 10 days, patients should infuse the contents of one packet with 250 cc of boiling water for 12 minutesevery 12 hours, then strain and sip.","Intervention 1: Intervention group:  In addition to the conventional treatments for Covid-19, patients will undergo a cycle of Ozone Major Autohemotherapy. In this method, a specific volume of patient's blood is drawn (100 to 200 cc in mild to moderate cases and 200 cc in severe cases). Then, a corresponding volume (100 to 200cc) of the oxygen-ozone gas mixture is added to the blood (initially with an ozone concentration of 35 micrograms/ml and gradually increasing it up to 45micrograms/ml in mild to moderate cases and up to 50micrograms/ml in severe cases). After mixing the blood with the gas mixture for at least 5 minutes with gentle rotating movements, the blood is reinfused to the patient. Mild to moderate cases will be treated daily for 4 days. Severe cases will be treated twice daily for at least 7 days. Intervention 2: Control group: Patients of this group, will just get the conventional treatments for COVID-19.","Intervention 1: Intervention group: Patients with COVID-19, in addition to the usual treatment, receive Tocilizumab IL-6 at a dose of 400 mg diluted in 155 cc of normal saline for one hour as a single dose, and monitoring is improved. Oxygenation status and subsequent complications will occur in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Intervention 2: Control group: Patients with COVID-19 disease who have not received the Tocilizumab IL-6 medication are routinely treated.","Intervention 1: Intervention group: In the intervention group, patients, in addition to the current standard treatments, also receive survivors plasma 500 cc each time. This treatment is started as soon as possible after the patient enters the ICU and within a week and is performed up to 3 times a day. For the preparation of fresh plasma products, survivors with 18 to 60 years old were contacted and tested for CRP, CBC, HBS Ag, HCV Ab, HIV Ab, HTLV1 Ab and COVID 19 PCR if they were without symptoms for at least 10 days.  If all tests are normal, 500 cc plasma will be taken from them and are prescribed to patients in the ICU in less than 12 hours. Survivors should have a positive initial PCR test for coronavirus, be male, or have no history of pregnancy if they are female. The donor and the patient must be the same in blood group and Rh. Intervention 2: Control group: In the control group, patients benefit from all available supportive and specific therapies based on existing standards. Survivors plasma is not prescribed in this group.","Intervention 1: Intervention group: hydroxychloroquine  Ruzdarou 200mg;  This group take 2 hydroxychloroquine tablet (400 mg) for the first day and From the second day, take one tablet (200 mg) daily for two weeks. Intervention 2: Control group: Domestic quarantine for 14 days.",";Placebo;Measles Mumps and Rubella vaccine","Dosing and Administration&lt;br&gt;Subjects will be randomized 1:1 to receive either active product or placebo. Initially, the trial will have 2 arms: &lt;br&gt;-Remdesivir will be administered as a 200 mg IV loading dose on Day 1, followed by a 100 mg once-daily IV maintenance dose for the duration of the hospitalization up to a 10 day total course. If a subject is no longer hospitalized, then infusions will no longer be given. &lt;br&gt;-A matching placebo will be given at an equal volume at the same schedule. &lt;br&gt;&lt;br&gt;Any dose that is delayed, but still the same study day, may be given. Any dose that is missed (not given that calendar day) is not made up.","Intervention name : Favipiravir (T-705)&lt;br&gt;INN of the intervention : Favipiravir&lt;br&gt;Dosage And administration of the intervention : Oral Multiple Dose&lt;br&gt;Control intervention name : -&lt;br&gt;INN of the control intervention : -&lt;br&gt;Dosage And administration of the control intervention : -","Intervention 1: Intervention group: COVID-19 patients receiving hydroxychloroquine (200 mg every 12 hours), azithromycin (500 mg daily) and melatonin tablets (3 mg every night before bedtime) for up to 7 days. Intervention 2: Control group: COVID-19 patients receiving hydroxychloroquine (200 mg every 12 hours) and azithromycin (500 mg daily)  for up to 7 days.","Intervention 1: Intervention group: In addition to the common national protocol, this group will receive convalescent plasma of recovered individuals twice and 200 cc each time. Intervention 2: Intervention group: In addition to the common national protocol, this group will receive intravenous immunoglobulin (400mg/kg/d). Intervention 3: Control group: This group will receive common national protocol.",";IHP Detox tea;Placebo","Ciclesonide is inhaled three times a day at a dose of 400 microgram once a day for seven consecutive days.","oral administration of favipiravir","oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir",null,"Group 1 - Hydroxychloroquine, 400 mg 12/12h, oral, on the first day followed by Hydroxychloroquine, 400 mg once daily, oral for  6 days, totaling 7 days of treatment - 650 patients &lt;br&gt;&lt;br&gt;Grupo 2 - Control - 650 patients;Drug;Hydroxychloroquine",null,"1. Control group - 210 participants&lt;br&gt;Control group will recieve proper COVID19 treatment but will not recieve hydroxychloroquine, chloroquine, azythromicyn or other macrolide.&lt;br&gt;&lt;br&gt;2. HCQA - 210 participants&lt;br&gt;HCQA group will recieve proper COVID19 treatment and hydroxychloroquine 400mg + azythromicyn 500mg once a day, oral, enteral or intravenous, for 7 days&lt;br&gt;&lt;br&gt;3. HCQ - 210 participants&lt;br&gt;HCQ group will recieve proper COVID19 treatment, and hydroxychloroquine 400mg once a day, oral, enteral or intravenous, for 7 days;Drug;Hydroxychloroquine;Azithromycin",null,"HA330 hemoperfusion&lt;br&gt;- HA330 hemoperfusion will be performed on a daily basis with a 6-hour duration per session until 1) 7 days, 2) IL-6 &lt;400 pg/mL, 3) clinically improved (defined by 3.1) PF ratio &gt;300 for at least 48 hours or 3.2) spontaneous respiration), whichever comes first.&lt;br&gt;, Usual care will be provided including antivirals, IV fluids, vasopressors, oxygenation and ventilatory support, steroid, antibiotics, IVIG","Chloroquine phosphate;Hydroxychloroquine sulphate;Placebo;",null,"Health care personnel in the endoscopy unit&lt;br&gt;Patients who will be performed endoscopy procedures","Chloroquine 10 mg base/kg once a day on Day 1 and Day 8, Vitamin C 1000 mg once a day from Day 1 to Day 14","Group 1: Respiratory Exercise Program (REP) (n=33)&lt;br&gt;\tThe REP will consist of 10 exercises based on the recommendations made by the official Physiotherapy organizations at the institutional level (College of Physiotherapists of the Community of Madrid, Spain), with scientific evidence, consisting of exhalation and inspiration exercises, diaphragmatic reeducation and rib cage mobility. The REP will be taught to patients telematically in the first session, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. The REP will be reinforced by a physical therapist daily, through telematic control by videoconference with each patient.&lt;br&gt;&lt;br&gt;Group 2: Non-specific Toning Exercise Program (NTEP) (n=33)&lt;br&gt;\tThe NTEP will consist of 10 exercises based on the recommendations about toning exercises, general and functional muscle work of the lower and upper limb and trunk muscles, made by the official Physiotherapy organizations at the institutional level (College of Physiotherapists of the Community of Madrid, Spain), with scientific evidence. The NTEP will be taught to patients in the first session, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. and 12 a.m. The NTEP will be reinforced by a physical therapist daily, through telematic control by videoconference with each patient.&lt;br&gt;&lt;br&gt;Group 3: Sham Program (SP) (n=33)&lt;br&gt;\tThe Sham Program consists of 10 sedentary exercises based on sophrology and meditation, with mental exercises of visualization, concentration and mental activity. The SP will be taught to patients in the first session telematically, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. and 12 a.m. The SP will be reinforced by a physical therapis;Other;Exercise Therapy;Placebo Effect",null,"Head of departmenet or nurse supervisor of all emergency departments in France","Initially, an online questionnaire (Portuguese, English, Spanish, French, Italian and German) will be applied to volunteer participants over 18 years old, selected by invitation on social media (Facebook, WhatsAPP). The questions will be on a platform on the internet. The participation of 2,300 participants is estimated. Filling takes an average of 10 minutes.;Other;Surveys and Questionnaires;Internet Access","- Control Group: Conventional treatment Basic (conventional) treatment planned in the hospital for the management of contacts and suspects of SARS-CoV-2 infection.   - Experimental Group: Conventional treatment + CIGB 2020 vaccine Basic (conventional) treatment planned in the hospital for the management of contacts and suspects of SARS-CoV-2 infection. In addition, patients will receive treatment with the CIGB 2020 vaccine nasal (scheme 0-7-14 days) and sublingually (one daily dose for 14 days).","Group name:Standard of care Type of group;2 N of participants:200 Intervention(s) description:Standard of care that all patients with COVID recieve at the hospital. &lt;br&gt;Group name:Standard of care plus lopinavir with ritonavir plus interferon beta 1a Type of group;1 N of participants:200 Intervention(s) description:Standard care that is given to all COVID patients who come to this hospital / clinic plus Lopinavir with Ritonavir (orally twice a day for 14 days) plus interferon beta 1a (daily injection for 6 days). Lopinavir / Ritonavir is available from multiple manufacturers as fixed-dose thermostable tablets for oral administration: Lopinavir 200mg with Ritonavir 50mg per tablet. The oral solution for patients who cannot swallow is a light yellow to orange liquid containing 400 mg Lopinavir and 100 mg Ritonavir per 5 ml (80 mg Lopinavir and 20 mg Ritonavir per ml). Interferon beta 1a is supplied as a sterile solution that does not contain any preservative available in a pre-filled syringe. It is provided as a single dose pre-filled graduated syringe available in two strengths; either 44 micrograms per 0.5 ml or 22 micrograms per 0.5 ml (allowing a convenient supply of 44 ug doses for subcutaneous use). The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe. Contains the following inactive ingredients: Albumin (Human), Mannitol, Sodium Acetate, Water for Injection.&lt;br&gt;","Patients suspected of Covid-19 infection with severity criteria","A total of 140 (one hundred and forty) patients diagnosed with severe acute respiratory syndrome will be invited to participate in the study, and, after signing the informed consent form, they will be randomized into two groups, which will be treated according to the protocol : Control Group (70 patients): will receive intravenous infusion in peripheral venous access of Placebo (Glucose 5% 100mL) in 20h (single dose). Intervention Group (70 patients): will receive intravenous infusion in peripheral venous access of N acetylcysteine in a total dose of 300 mg / kg, with the first dose being 200 mg / kg in 4 hours and the second dose 100 mg / kg in 16 hours ( Single dose). Serum tests (30mL of blood from peripheral venous access) and arterial blood gases will be collected from all patients. Patients will be monitored daily by reviewing medical records and clinical data will be recorded on a RedCap form.;Drug;Clinical Trial;Medical Examination","About 600 online surveys per country. , Online (via zoom, skype or other platforms) interviews and focus group discussions with 50-60 participants per country"],["duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;","Length of hospital stay;","Fatality rate;","Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;","28-day mortality and 90-day mortality.;","mortality","inhospital length;inhospital mortality;ECMO treatment length;28th day mortality after admission;","Lung function;","The rate of virus inhibition","Cardiovascular Death","St. George's Respiratory Questionnaire;","PSQI;","Conversion rate of mild and common type patients to severe type;Mortality Rate;","Time to disease recovery;","SEN, SPE, ACC, AUC of ROC;","imaging feature;","Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;","Sensitivity of detection of NCP;Specificity of detection of NCP;","Length of hospital stay;fever clearance time;","Time to complete remission of 2019-nCoV infection-associated symptoms","Virus negative conversion rate in the first week","14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","Time to Clinical recovery;","GHQ-12(general health questionnaire-12)","detection of SARS-CoV-2 nucleic acid;SEN;","ECG;Chest imaging;Complications;vital signs;NEWS2 score;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","Chest imaging (CT);","Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL-6, IL-10, TNF-a, etc.);Lymphocyte subsets and complement;Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count);Virus nucleic acid;","Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate;","Length of admission;mortality rate;","TCR sequencing;BCR sequencing;HLA sequencing;","Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;","2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;","Time for body temperature recovery;Chest CT absorption;Time of nucleic acid test turning negative;","rate of cure;","Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;","Time of viral nucleic acid turns negative;Antipyretic time;","Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;","Lower Murray lung injury score;Lower Murray lung injury score;Clinical improvement based on the 7-point scale","The incidence of composite adverse outcome","Number of worsening events;","Length of hospital stay;","TCM symptoms efficacy;","Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;","cure rate;","the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;","Antipyretic time;","Rate of conversion to severe or critical illness;","length of stay;length of stay in ICU;Antibiotic use;Hospital costs;Organ function support measures;Organ function;","vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;","PSI;","Chest CT;Routine blood test;liver and renal function;TCM syndrome;","viral negative-transforming time;30-day cause-specific mortality;","The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;","Clinical characteristics;TCM syndrome;","CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;","Duration of PCR normalization;Clinical symptom score;","Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;","Critically ill patients (%);","clinical features and risk factors;validity and reliability of the model;","Incidence of co-infection;","Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;","the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;","pulmonary function;Novel coronavirus pneumonic nucleic acid test;","Relief of clinical symptoms and duration;","Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;","pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;","ROX index;","Physical examination;Nucleic acid;Oxygenation index;GAD-7;PHQ-9;SASRQ;PSQI;Lymphocyte subsets;","Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;","Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;","CT scan of the lungs;Nucleic acid detection of throat secretion;","Positive/Negtive;SEN, SPE, ACC, AUC of ROC;","Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;","Time to leave ventilator on day 28 after receiving MSCs infusion;","Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;days of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;","TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;","Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;","time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pulmonary imaging improvement;time and rate of change to negative COVID-19 nucleic acid test;time and rate of improvement of oxygenation measurement;improvement time and rate of CD4 count;rate of mild/modorate type to severe type, rate of severe type to critical type;length of hospitalization;mortality;","PSI;","The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;","Time to viral negativity by RT-PCR;Time to clinical improvement;","Time to conversion of 2019-nCoV RNA result from RI sample;","body temperature;Whole blood count and five classifications;C-reactive protein;","Patient survival rate;","all available outcome;","Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;","TCM syndroms;","Time to clinical recovery;","the rate of remission;","CD4+;CD3+;HAMA;HAMD;STAI;","28day mortality;","Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;","Inpatient mortality;","CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;","28-day survival;Inflammatory factor levels;","Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;","Clinical recovery time;","Cortisol;ACTH;Form of Adrenal tissue;","Time for body temperature recovery;Chest X-ray absorption;","M mode echocardiography;two-dimensional echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;","CT of lung;CT and MRI of hip;","Mood index;","State anxiety;","Time to Clinical recovery;","Physical and mental health;","the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;","blood routine examination;CRP;PCT;Chest CT;Liver and kidney function;Etiology test;","incidence;mortality;","Epidemiological history;haematological;First symptom;blood glucose;blood glucose;prognosis;Blood gas analysis;complication;","Virus negative conversion rate in the first week;","virus nucleic acid negative-transforming time;","Mortality in patients;","Time to disease recovery;","pneumonia severity index (PSI);Incidence of new organ dysfunction;","The days from positive to negative for viral nucleic acid testing;","The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2&lt;= 93% without oxygen supplementation, PaO2/FiO2 &lt;= 300mmHg or RR &lt;=30 breaths per minute.;","The novel coronavirus nucleic acid negative rate;","ICU hospitalization days;Death rate;","blood routine;urine routines;CRP;PCT;ESR;creatase;troponin;myoglobin;D-Dimer;arterial blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;","Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;","Proportion of COVID-19 close contacts who have developed as confirmed cases;","Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2&lt;2 for 24 hours.;","pulmonary function;Antipyretic time;Time of virus turning negative;","pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;","pulmonary function;St Georges respiratory questionnaire, SGRQ;","Antipyretic time;Time of virus turning negative;","pneumonia severity index (PSI);","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab","lung injury score","Distribution of 'B' line around lungs of both lungs;Whether there is peripulmonary focus;","Cure rate;Mortality;","the daily treatment intensity;","Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;","SARS-CoV2 Nucleic Acid Quantification;","menstruation changes;TCM body constitution score;","Death;Recovered;Discharged;","viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme);","The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine aminotransferase) and ALT(aspartate aminotransferase);Neutralization antibody level;","menstruation changes;","Acute kidney injury;","psychological scale;Intestinal flora abundance, etc;Upper respiratory flora abundance, etc;","Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;","clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;","Recovery rate;","Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;","Oxygenation index","TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;","NA;","Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;","Time to Clinical recovery;","Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;2-microglobulin;IFN-gama;IL-6;TNF-beta;IL-10;IL-2;IL-4;IL-13;IL-12;chest CT;abdominal CT;ECG;Weight;height;body temperature;respiratory rate;Heart Rate;Blood Pressure;Defecate frequency;Bristol grading;","Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;","Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;","Clinical index;","Self-rating depression scale;","Time to Clinical Recovery;","Self-Rating Anxiety Scale;Self-Rating Depression Scale;Posttraumatic stress disorder checklist,;Questionnaire for Simple Responses;","lung function;ADL;6min walk;","Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;","Improved respiratory system function (blood oxygen saturation) recovery time;","Length of hospital stay;","TCM syndrome;","CoVID-19 Perinatal Outcomes;","SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;","Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;","blood cell count;C-reactive protein (CRP);arterial blood-gas analysis;markers of myocardial injury;coagulation profile;serum biochemical test;brain natriuretic peptide(BNP);blood lipid;fibrinogen(FIB), D-Dimer.;","recovery time;","SOFA;","Time to Clinical recovery;Butyrate in feces;","Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Blood oxygen saturation;Time to 2019-nCoV RT-PCR negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day);Liver, renal  and heart  function;","TTCI (Time to Clinical Improvement);","Disappearance rate of fever symptoms;","Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;","The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;","Three-dimensional ultrasound;Two-dimensional ultrasound;Respiration related parameters;Doppler ultrasound;","CT image of lung of close contact medical staff;Human body temperature of close contact medical staff;Anxiety Scale of of close contact medical staff;","oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;","Recovery time;","Clinical recovery time;","SARS-CoV-2 DNA;SARS-CoV-2  antibody levels;thoracic spiral CT;","Clinical characteristics;","Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);","Accuracy;","Mental health status;","positive number diagnosed by national guideline in the evaluated population","Time to Clinical recoveryTime to Clinical Recovery (TTCR)","The incidence of long-term adverse outcomes.;The improvement rate of 2019-nCoV.;The cure rate of 2019-nCoV.","Accuracy of nCapp COVID-19 risk diagnostic model","hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;","cure rate;","Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;","2019 nCoV nucleic acid detection","Clinical recovery time","Time to Clinical Recovery;","Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;","HSCS;SCSQ;GHQ-12;","Time to Clinical Improvement (TTCI)","Survival rate","the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;","CT;SEN, SPE, ACC, AUC of ROC;","Recovery time;Pneumonia psi score;","Positive rate of 2019 Novel Coronavirus RNA","Inhospital time;","Epidemiological characteristics;clinical features;Treatment outcome;","The death of newborns with COVID-19;The SARS-CoV-2 infection of neonates born to mothers with COVID-19","PCL;HRQL;IPAQ;PASE;","Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;","Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;","cure rate;virus negative rate;time of virus negative;","mood assessment;","pulmonary iconography;","High-resolution computed tomography (HRCT) score;Lung function including FVC, FVC as a percentage of projected value and DLco","The change of pneumonia severity on X-ray images","PCL;PSQI;FSI;","Epidemiological and clinical characteristics;","Blood Routine;Liver function;Blood electrolyte;Anticoagulation index;Lung CT;Viral RNA;","Psychological questionnaire;","temperature;respiratory symptoms;","SEN, SPE, ACC, AUC of ROC;","Temperature;Respiratory symptoms;","Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;","Lung CT;TCM symptoms;","K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;","blood RNA;","During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;","Epidemiological and clinical characteristics;","Critically ill patients (%);Mortality Rate;","Viral load;Clinical features;Inflammation;Pulmonary imaging;","GHQ-20;","imaging feature;","Inflammation factor;","no;","Lung CT;","NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;","Clearance rate and time of main symptoms (fever, fatigue, cough);","SEN, SPE, ACC, AUC of ROC;","Clinical indicators;","Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node imaging;Chest CT;Infectious disease test;","Quality of Life;Epidemic Prevention Medical Protective Equipment related Skin Lesion and Management Scale;","the relive of CRS;","Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;","temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;","Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;","INR;PT;TT;APTT;FIB;DD;","health status;Mental health status;","COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;","Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;","Clinical recovery time;Pneumonia Severity Index (PSI) score;","cough;","Clinical characteristics;","Validity observation index;","Length of hospital stay;Discharge time of general type;Discharge time of severe type;","The proportion of patients diagnosed with 2019-ncov viral pneumonia;","Quality of life;Socio-demographcis and others;","Clinical symptoms;Test result;Examination result;","exposed factors;latent period;preventive measures;","Mood index;","ROC;calibration curve;","viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;","Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;","Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;","Cancelled;","time to recovery.;","The time to 2019-nCoV RNA negativity in patients;","Time to Clinical Recovery, TTCR;","SOFA score;","Time to clinical recovery;","TTCI (Time to Clinical Improvement);","Worsening condition;Death;Heart fatty acid binding protein;","Lung ultrasound index;Right ventricular function ultrasound index;Left ventricular function ultrasound index;","Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);","Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment;Pulmonary inflammation resolution time (HRCT) (day);Fever to normal time (day)","intrusion;avoidance;","Immunity function;cytokines;viral load;","Time to Clinical Recovery (TTCR);","Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;","Mortality;","Pulmonary image findings;Relevant clinical manifestations of COVID-19;Oxygen saturation in resting state;Arterial partial pressure of oxygen/ Oxygen absorption concentration;Length of hospital stay;Viral genome information;Host genome information;Expression level of host cytokines;Conventional laboratory testing index;","Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;","Time to clinical improvement (TTIC);Adverse reaction (AE) and severe adverse reaction (SAE)","ALT;","Screening accuracy","chest CT;Finger pulse oxygen;blood gas;K-BILD","TCM syndrome;","Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;","Unplanned shutdowns;","28-day mortality;ICU 14-day mortality;","Cure rate;","viral load;virus genotyping;Classification of lymphocytes;","Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;","The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;","A cycle threshold value (Ct-value);","Progression rate from mild to critical/severe;","PSS-14;","7-day mortality","The proportion of patients with normal level of oxygen saturation(=97%);The time to oxygen saturation recovery to normal level (=97%)","Psychological status;","Tempreture;Virus nucleic acid detection;","fever clearance time;Effective rate of TCM symptoms;","Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs);Time to clinical improvement;Change in size of lesion area by chest CT;Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours;","disease incidence;Duration of PCR normalization;Distribution pattern of TCM syndromes;","clinic outcome;","length of stay;length of stay in ICU;Hospital costs;Hospital costs;Antibiotic use;Organ function support measures;","SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 &lt; 90%;","Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;","ratio of severe cases;","Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;","MRC breathlessness scale;6MWD;","Child Stress Disorders Checklist evaluation;Achenbach children's behavior checklist evaluation;children's severe emotional disorder and psychological crisis during inpatient treatment;","Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or absent;Time for dyspnea to become mild or no dyspnea;Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation;Inflammatory cytokines (CRP / PCT / SAA, etc.);Frequency of serious adverse events;","Safety;","Mental status;Social support;","in-ICU mortality;mortality of 28 days;","Cardiac injury;Death in hospital and/or Endotracheal Intubation Deaths during hospitalization;Admitted to the ICU;Composite end points of cardiovascular events( nonfatal heart failure, nonfatal myocardial infarction, nonfatal stroke or cardiovascular death);Stroke;Heart failure;Myocardial infarction;Other cardiovascular health related endpoints;","Pittsburgh sleep quality index;","CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine examination;chest CT;creatase;","28 day mortality;","Incidence of side effects;","Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;","Clinical characteristics;","cure rate;duration of hospitalization;days of treatment;","lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","Inccidence of 2019-nCoV pneumonia;","28 day mortality;","Main symptom relief time;","time in range;","Improvement of symptoms;","Clinical symptoms;Blood routine;Biochemical and myocardial enzymes;C-reactive protein;Erythrocyte sedimentation rate;Inflammatory cytokines;Chest CT;Etiology Inspection;Vital signs;","CT image of lung;","nosocomial infection ratio of SARS-Cov-2;","The time interval of Nucleic acid detection become negative;Mortality","Clinical recovery time","Cytokines;","Clinical cure rate;","the number of days between randomised grouping and clinical improvement;","Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospitalization for oxygen therapy;3 points: Hospitalization does not require oxygen therapy;2 points: discharged but not restored to normal functional status;1 point: discharged to normal function;","Symptom Checklist 90;","chest CT images;","Laboratory inspection index;Oxygen therapy case;Film degree exam;","RT-PCR confirmed COVID-19 infection","The prevalence and incidence changes of common mental disorders","Infection rate of Anesthesiologist;Success rate of intubation","Confirmed 2019-ncov pneumonia;","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;Numbers of participants with different Clinical outcomes","The incidence of side effects;The incidence of side effects;The incidence of side effects","serum albumin;siderophilin;prealbumin;lung CT scanning result;","Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients;","CT;","mental health status and influence factors;","RT-PCR test for SARS-CoV-2;","Transmission dynamics of COVID-19 in Hong Kong;Characteristics of super-spreading events;Effectiveness of public health measures;","2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;","HRCT pulmonary fibrosis score;","white blood cell;lymphocyte;creatinine;CRP;","Single cell sequencing;","Mortality rate;","CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;","temperature;Systemic symptom;Respiratory symptoms;Chest imaging changes;Detection of novel coronavirus nucleic acid two consecutive negative time;","Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;","Maternal and neonatal morbidity;","Death;","cytology;proteomics;chest X-ray;Oxygenation index;","Discharge rate;","Length of stay in ICU;Diaphragm movement;","Precision;SEN, SPE, ACC, AUC of ROC;","Clinical outcomes after discharge;","sensitivity;SPE;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;","Chinese health status scale;Self-rating Anxiety Scale;Self-rating Depression Scale;",null,"SCL-90 scale;","RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;","Epidemiological characteristics;SARS-CoV-2 IgM, IgG antibody titer test result;","Clinical features;","Time to Clinical Improvement (TTCI);","SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;","Laboratory inspection index;Imaging examination results(chest CT);performance of intubation;therapeutic schedule;prognosis;","Epidemiological features;","Liver function;","PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTH;cortisol;24-hour ECG;Magnetic resonance spectroscopy;","Mortality of ICU 28-day;","ymphocyte subsets;","The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;","Ocular  Symptoms;","Abnormalities on chest CT;Exposure to source of transmission within past 14 days;","lynphocyte;cytokine;cancer history;order of severity;","blood RT;ABG;blood clotting function;liver and kidney function;","Dose of analgesic and sedative drugs;28-day mortality rate;","Quantitative CT characteristic;","age;sex;comorbidities;chest-CT examination;standard blood counts;albumin;pre-albumin;hemoglobin;alanine transaminase;aspartate transaminase;creatinine;glucose;lipids;procalcitonin;C-reactive protein;coagulation function;nutritional risk screening;body weight;body height;prognosis;","Cough Score;Expectoration score;","Psychological assessment;","blood biochemistry;","time  and rate of cure; proportion and time of patients who progressed to severe disease;","SARS-CoV-2;","mortality;effective rate;","discharg time;","cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;",null,"28-day prognosis;","all-cause death;fatal arrhythmias;","in-ICU mortality;","Epidemiological characteristics;clinical features;Treatment outcome;","death;Number of failure organs;Length of hospital stay;","blood gas;SOFA score;","PSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian Version,PCL-C;","anxiety;","Pulmonary function;Cardiac function;neural function;","PaO2;PaCO2;","Clinical characteristics according to TCM;","nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;","CRP;IL-6;TNF-alpha;IL-8;","the clinical, laboratory and the radiologic characteristics;","mortality;ICU hospital stay;mechanical ventilation time;mortality of 28 days;","Critical illness ratio;","ICU hospitalization days;The recurrence rate of infection;","Time to Clinical Recovery;","Levels of anxiety, stress and depression;","false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;","Inpatient mortality;ICU hospital stay;","14-days mortality;28-days mortality;","Blood oxygen saturation;","Outcome;","Tempreture;cough;dyspnea;Blood Routine;Aterial Blood Gas;Chest CT Scan;","SARS-CoV-2 virus;sex hormones;sperm quality;","detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;","Sensitivity, specificity and accuracy;","Mortality rate;Common-severe conversion rate;Length of hospital stay.;","Time to Virus Eradication;","CT Scan-Chest;","Lung CT;","Lymphocyte grouping;","Time to Virus Eradication;","ascultation;","chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;","temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine analysis;microalbuminuria;COVID-19 nucleic acid;COVID-19 antibody;renal ultrasound;24-hour urine protein;Tc-DTPA renal dynamic imaging;eGFR;","In-hospital mortality;ACC, SEN, SPE, ROC;","Medical imaging improvement rate in patients during recovery period;","CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;","Recovery time;Pneumonia psi score;","cough;agitation;","Comprehensive psychological assessment;Mental toughness;Solution;","Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;","Time to clinical recovery after randomization;","The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;","treatment effect;",null,"Time to disease recovery;Time and rate of coronavirus become negative;","SDS;SAS;PSQI;","Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);","lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","sleep status and related factors of insomnia;","The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;","Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;","IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);","Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;","impact on the treatment of tumor patients;","Time of conversion to be negative of novel coronavirus nucleic acid;","Ventilation-free days;mortality;","detection of SARS-Cov-2 nucleic acid;SEN, ACC;","The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;","2019-nCoV RNA;2019-nCoV antibody;Chest CT;","Time to disease recovery;","Time of conversion to be negative of novel coronavirus  nucleic acid;","Time to disease recovery;","Clinical characteristics;Clinical outcomes;","Mortality rate;","Imaging;","Disease Severity;Imaging;Syndrome Features of TCM;","DEATH;","GAD-7;","Time and rate of novel coronavirus become negative.;","Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;","Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sampling interval at least 1 day);","Disppear time of ground-glass shadow in the lungs","25(OH)D;","Ventilation-free days","Stress","Viral load","Metagenomics Sequencing;","Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","Ventilation-free days;mortality;","Neonatal outcome;","Positive/Negtive;False positive of rate  ;","HRCT score;","T lymphocyte subsets;","demographic information;exposure history;clinical  symptoms;Laboratory examination;radiological  findings;treatment;disease progression;","Pittsburgh sleep quality index;Self-rating anxiety scale;Self-rating depression scale;CD-RISC scale;","SEN, SPE, ACC, AUC of ROC;","Time to disease recovery;","Time to disease recovery;","GAD-7;STAI-Y (C);","insomnia;anxiety;depression;comfort;","Patients general information: epidemiological indicators such as age, gender, address, telephone, exposure history, past medical history, and BMI;Clinical symptoms;Patients' signs;blood routine examination;Urine routine test;stool routine examination;Blood biochemistry;myocardial enzyme spectrum;full set of coagulation;blood gas analysis;cytokine profile;T lymphocyte subsets;ESR;CRP;PCT;complete set of self-immunity test;Etiology related inspections;Chest X-ray;lung CT;Patients' treatment history;Patients' Prognosis;the cause of death;Others;","postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;","clincical characteristics;","T lymphocyte count;","Serum SARS-COV-2 RNA;Swallow swab SARS-COV-2 RNA;feces SARS-COV-2 RNA;Sputum SARS-COV-2 RNA;Urine SARS-COV-2 RNA;","nuclear acid test of faeces;nuclear acid test of the upper respiratory tract;IgM;IgG;CT test of lung;glutamic oxalacetic transaminase;glutamic-pyruvic transaminase;total bilirubin;direct bilirubin;urea nitrogen;lactic dehydrogenase;creatinine;lymphocyte;C-reactive protein;procalcitonin;erythrocyte sedimentation rate;","hospital mortality;","Clinical Characteristics, Treatments and Prognosis;","COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality;","28 day mortality","Frequency of vaccine events;Frequency of serious vaccine events;Proportion of subjects with positive T cell response","The biochemical indicators;","Clinical characteristics and risk factors;","Nucleic acid;","Maximal inspiratory pressure;Respiratory muscle evaluation;","Venous Thrombosis;","adverse reactions 7 days post injection;","survival status","Abnormalities on chest CT;","Length of hospital stay;","Immune response multiomics;","RNA of  Coronavirus;","Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline;","Time to negative conversion of severe acute respiratory syndrome coronavirus 2;","Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","Clinical recovery rate of day 7;","syndrome;nucleic acid of nCoV-19;","SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;","PT-PCR test;SEN, SPE, ACC, AUC of ROC;","RNA;DNA;","Albumin;Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4));","prognosis;","Compared with the control group, the positive rate of NCP nucleic acid test on subjects used Compound Houttuynia Mixture.;","First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;","improvement or recovery of respiratory symptoms;viral nucleic acid shedding;","the lowest SpO2 during intubation;","psychological states;","Pittsburgh sleep quality index;hospital anxiety and depression scale;","The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups The difference of;","CT image;sensitivity;Specificity;Time efficiency;","novel coronavirus nucleic acid clearance rate;","Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;","Blood routine test;","Rate and time of entering the critical stage;Rate of disease remission","Rate of aggravation;Time to clinical recovery after treatment","Main Objective: To shorten the period of virus carrying and thus contagion;Secondary Objective: To evaluate the clinical effectiveness of treatment on time to apyrexia, normalization of respiratory rate, and average length of hospital stay and mortality.;Primary end point(s): Results of SARS-COV2 virus detection ;Timepoint(s) of evaluation of this end point: Day 1, Day 4, Day 7 and Day 14","auto B line method;Semi-automatic manual measurement of line B;CT image score;NEWS score;hospital time;ICU time;Critical time;Hospital costs;mechanical ventilation time;prognosis of the patient;","Number of participants with improvement from severe type to common type","Time for lung recovery;Rate of disease remission","novel coronavirus nucleic acid;","detection of virus nucleic acid;","1.\tDate of ECMO discontinuation&lt;br&gt;2.\tDate of invasive mechanical ventilation discontinuation&lt;br&gt;3.\tDate of ICU Discharge&lt;br&gt;4.\tDate of Hospital Discharge&lt;br&gt;5.\tMortality at 28 days&lt;br&gt;6.\tMain cause of death","Viral nucleic acid test;","recovery","Viral load over time;Time course of body temperature (fever)","Rate of disease remission;Time for lung recovery","Rate of comprehensive adverse outcome","Proportion of subjects with clearance of SARS-CoV2 in nasopharyngeal swab on Day 6","Clinical improvement based on the 7-point scale;Lower Murray lung injury score","Mortality rate","Time to Clinical Improvement (TTCI)","Mean clinical recovery time (hours)","none","Size of lesion area by chest imaging;Blood oxygen saturation","Depression, Anxiety and Stress Scale;Assessment of COVID-19 situation","Survival rate","The risk factors analysis for the death;The myocardial injury incidence","RT-PCR results;CT Scan;Clinical outcome","Occupancy rate in the intensive care unit (ICU);Mechanical Ventilation;Death","Rate of disease remission;Rate of entering the critical stage;Time of entering the critical stage","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14","all-cause mortality","Chest CT absorption;The relief / disappearance rate of main symptoms","Incidence of respiratory failure","changes in the ratio of PaO2 to FiO2 from baseline","Sensitivity, spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","temperature;novel coronavirus;Influenza virus;","proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;","Change in viral expression in association to organspecific biomarkers","Renal failure","Acute Kidney Injury","Severe COVID-19","brain volume;white matter;brain function;","characteristics of cardiopulmonary ultrasound","Maternal and perinatal outcomes","fever;Chest CT;cough;;Anesthesia during cesarean section;Adverse reactions;Apgar score for neonates; Intraoperative blood loss;diagnosis of COVID-19 during perioperative;the medical observations of anesthesiologists participating in anesthesia management;","TTCI;","Axle length;Visual acuity;corneal diopter;Tear film rupture time;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;","sensitivity;accuracy;specificity;","medication possession ratio;selfrating anxiety scale;selfrating depression scale;Disease activity score-28;Systemic lupus erythematosus disease activity index;Ankylosing spondylits disease activity score;Visual analogue scale;","Incidence of medical adhensive-related injury;","Self-assessment of sleep quality;Efficient of sleep improvement;","Number of patients with contrasting results;Overall Number of patients negative for COVID-19;Overall Number of patients positive for COVID-19;Number of patients with positive test with a positive PCR for COVID-19;Number of patients with constant negative results","eye axial length;corneal diopter;Tear film rupture time;Visual acuity;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;","clinical features of COVID-19 patients and risk factors of death;","Time of death;The hospitalization time;","Epidemiological characteristics;clinical features;Treatment outcome;","Anxiety level;Sleep;","Hospital stay or death ratio of experimental group / death ratio of control group;","ECG;","Demographic data;Epidemiological characteristics;Routine laboratory testing;Viral nucleic acid test;Patient reports symptoms daily;","mental state;","Rate of COVID-19, distribution, time of onset and outcome;","Clearance time of virus RNA;","IgG antibody;IgM antibody;Throat swab virus nucleic acid test;","PT-PCR test;","Clinical features and prognosis;","Modified dyspnea index scale;St.George's Respiratory Questionnaire;Self-Rating Depression Scale;","RT-PCR test for Covid-19;CT image;Covid-19 antibody test;","mortality;","TCM Syndrome Scale;","Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;","time till the SARS-CoV-2 clearance;","Quantitative table of main symptom grading;Quantitative table of lung physical signs grading;","Incidence of COVID-19 pneumonia;COVID-19 pneumonia rate of improvement;","The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;","Patient satisfaction;","Inflammation absorption on Chest CT;","PO2/FiO2;ROX INDEX;","fatality rate;the ratio of patients transforming from severe/critical to light;Non-invasive/invasive mechanical ventilation time;","Timepoint(s) of evaluation of this end point: Baseline to Day 29;Primary end point(s): Phase 2: time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner&lt;br&gt;Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale;Secondary Objective: Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity, changes in the National Early Warning Score 2, duration of predefined symptoms and signs, duration of supplemental oxygen dependency, incidence of new mechanical ventilation use, the duration of new mechanical ventilation use, need for admission into ICU, duration of hospitalization,  28-day mortality rate.&lt;br&gt;Secondary safety objectives are to evaluate the safety of sarilumab compared to the control arm as assessed by incidence of: SAEs, Grade 4 neutropenia (ANC&lt;500/mm3) with concurrent severe or life-threatening bacterial, invasive fungal, or opportunistic infection, Grade =2 infusion related reactions, Grade =2 hypersensitivity reactions, Increase in ALT =3X ULN (for patients with normal baseline) or &gt;3X ULN and at least 2-fold increase from baseline value (for patients with abnormal baseline), Invasive bacterial or fungal infections of clinical significance with confirmed diagnosis ;Main Objective: Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19&lt;br&gt;Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19  &lt;br&gt;","walking distance;oxygen saturation;heart rate;","Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lymphocyte count;CD4+ T lymphocyte count;CD8+ T lymphocyte count;B lymphocyte count;NK cell count;Proportion of navie CD4+ T lymphocytes to CD4+ T lymphocytes;Proportion of memory CD4+ T lymphocyte to CD4+ T lymphocytes;Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes;Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes;Activation ratio of CD8+ T lymphocytes;Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes;","The time to 2019-nCoV RNA negativity in patients;","Epidemiological and clinical characteristics;","traditional Chinese medicine symptom;","Beck Depression Scale;Health-Related Quality of Life SF-12 Scale;International Physical Activity Questionnaire (IPAQ)","Duration of interventions;The number of interventions","pulmonary function;","Timepoint(s) of evaluation of this end point: Day 15;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale): &lt;br&gt;1.\tNot hospitalized, no limitations on activities &lt;br&gt;2.\tNot hospitalized, limitation on activities; &lt;br&gt;3.\tHospitalized, not requiring supplemental oxygen; &lt;br&gt;4.\tHospitalized, requiring supplemental oxygen; &lt;br&gt;5.\tHospitalized, on non-invasive ventilation or high flow oxygen devices; &lt;br&gt;6.\tHospitalized, on invasive mechanical ventilation or ECMO; &lt;br&gt;7.\tDeath.;Secondary Objective: To evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by Clinical Severity, Oxygenation, Ventilation, Hospitalisation.;Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the standard of care in patients hospitalized with COVID-19.","Timepoint(s) of evaluation of this end point: Between day 0 up to day 180 after inclusion;Primary end point(s): Number of days of unplanned absenteeism for any reason ;Secondary Objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Main Objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.","Microbiologic evidence of infection","Percentage of subjects reporting each severity rating on a 7-point ordinal scale","Time of Improvement or recovery of respiratory symptoms;Number of days virus nucleic acid shedding;Frequency of Improvement or recovery of respiratory symptoms","Timepoint(s) of evaluation of this end point: One interim analysis for evaluating the primary efficacy endpoint is planned for this study. The interim analysis will be done when 40% of events have accrued.  In case the interim analysis shows a HR &gt; 1.93 (nominal p &lt; 0.0018), efficacy is shown and the trial may be stopped.  Final analysis upon completion of the trial and final database lock.;Primary end point(s): Primary efficacy endpoint: Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number =100, measured by real time reverse-transcription polymerase chain reaction in throat swabs&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: Exploratory objectives are to assess the effect of infection and HCQ treatment on clinical outcome, cardiac function, mucosal, humoral and cellular immune response including single cell phenotype and RNA expression, effect on anti-viral defense, assessment of chronic symptoms and quality of life. ;Main Objective: Primary objective: Effect of HCQ on in vivo viral clearance.","Two-dimensional ultrasound;M mode echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;","Timepoint(s) of evaluation of this end point: The dosing period is 14 days. Changes in the ordinal scale during the dosing period will be assessed.;Primary end point(s): Primary Endpoint:&lt;br&gt;Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period.&lt;br&gt;&lt;br&gt;The Ordinal Scale for Clinical Improvement is a World Health Organisation recommended scale for use in COVID-19 trials.&lt;br&gt;;Secondary Objective: To understand more about the biology of how SNG001 affects patients and the virus infection, this will be done by assessing changes in biomarkers in blood and sputum if they are available.;Main Objective: To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.","Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Metabolomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;","death","Length of hospital stay (days)","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay","In-hospital mortality","The time from randomization to clinical improvement","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases","Rate of recovery from positive to negative swaps;Fever to normal temperature in days;Resolution of lung inflammation in CT or X ray","Composite primary end-point;death;Admission to ICU;Endotracheal intubation (invasive mechanical ventilation)","Number patients developing severe infection or death","Microbiological;Virological;Clinical","Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds",null,"Incidence of influenza","Side effects in the treatment group;Clinical response","Inpatients: Invasive mechanical ventilation or mortality;Outpatients: Hospital Admission or Death","Point prevalence of COVID-19 infection","SARS-free patients at 14 days","Number of symptomatic COVID-19 infections;Symptoms severity of COVID-19","The incidence of cardiovascular complications in patients with COVID-19","Dataset size","CT or Xray images from COVID-19 patients","Time from COVID-19 test being requested to the result being available to clinical teams in minutes and hours, recorded during hospitalisation","Host genetic variation;Immune host response at local level;Immune host response at systemic level;Clinical Features","Incidence of ARDS;Mortality within 28 days;","CRP;SAA;IL-6;PCT;tRNA;","Rate of Acute Kidney Injury","Seroconversion to SARS-CoV-2 positivity","Sleep diary;The insomnia severity index;Sleep visual analogue scale;","The score of PHQ-9;","Chest Imaging;lung function;ADL;","Exposure time in the medical cabin;Hospitalization period;Detection rate of arrhythmia;","hospital mortality;","Cure rate;improvement rate;","Number of participants with symptomatic, lab-confirmed COVID-19.","Mortality rate;Clinical status evaluated in agreement with guidelines","2019-nCov IgG;","body surface temperature;","30-day mortality","Prostaglandin E2;","2019-ncov nucleic acid yin rate;Blood 2019-ncov nucleic acid positive;Positive 2019-ncov nucleic acid in feces;Nasopharyngeal swab positive for 2019-ncov nucleic acid;","Safety and tolerance;","Success rate of intubation;Exposure classification of glottis;","Electrocardiogram;St George's Respiratory Questionnaire Score;High resolution CT for chest;Blood gas analysis;Percutaneous blood oxygen saturation;6 min walking distance;Pulmonary function VCmax;Blood routine;Liver and kidney function;Cytokine analysis;Immunoglobulin;Lymphocyte subsets;Coagulation;Myocardial enzymes;Serum ferritin;Procalcitonin;IL-6;Lactic acid;D-Dimer;CRP;","PSQI;","SARS-CoV-2 antibody;SEN, SPE, ACC, AUC of ROC;","Timepoint(s) of evaluation of this end point: Day 15;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):&lt;br&gt;1.\tNot hospitalized, no limitations on activities&lt;br&gt;2.\tNot hospitalized, limitation on activities;&lt;br&gt;3.\tHospitalized, not requiring supplemental oxygen;&lt;br&gt;4.\tHospitalized, requiring supplemental oxygen;&lt;br&gt;5.\tHospitalized, on non-invasive ventilation or high flow oxygen devices;&lt;br&gt;6.\tHospitalized, on invasive mechanical ventilation or ECMO;&lt;br&gt;7.\tDeath.&lt;br&gt;&lt;br&gt;;Secondary Objective: Evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by:&lt;br&gt;&lt;br&gt;-Clinical Severity (Ordinal scale, National Early Warning Score (NEWS), Oxygenation, Mechanical Ventilation)&lt;br&gt;-Hospitalization : duration of hospitalization (days). &lt;br&gt;-Mortality&lt;br&gt;-Evaluate the safety of different investigational therapeutics through 28 days of follow-up as compared to the control arm&lt;br&gt;-Evaluate the virologic efficacy of different investigational therapeutics as compared to the control arm as assessed ;Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19.&lt;br&gt;\tThe primary endpoint is subject clinical status (on a 7-point ordinal scale) at day 15 &lt;br&gt;","Chest computed tomography (CT);","Safety;Effectiveness;","Primary end point(s): ;Secondary Objective: ;Main Objective:","6minu tewalkingtest,6MWT;mMRC;Rating of Perceived Exertion Scale;SAS;","ASDS;PSS;PHQ;GAD;","Timepoint(s) of evaluation of this end point: Days 1, 2-7, 8;Primary end point(s):  Recording of co-administered drugs, vital signs, absolute blood cell count (if any), biochemical markers (if any), microbiological tests and antibiotics (if any)&lt;br&gt; Pneumonia symptoms ratings for patients with lower respiratory infection (Appendix V)&lt;br&gt; Recording of adverse reactions (AEs) or serious adverse reactions (SAEs);Secondary Objective:  Comparison of the primary endpoint with respective patients not receiving the treatment&lt;br&gt; Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment&lt;br&gt; Frequency of AEs and SAEs;Main Objective: Achieving one of two goals on day 8 visit from study initiation:&lt;br&gt; 50% reduction in symptom score for patients with lower respiratory tract infection&lt;br&gt; Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection&lt;br&gt;&lt;br&gt;Patients leaving the hospital alive before day 8 visit are considered to have reached the primary endpoint. Patients who die before the day 8 visit are considered to have failed at the primary endpoint.","Infection;","Quality of sleep;","Timepoint(s) of evaluation of this end point: Le critre de jugement principal est le dcs quelle quen soit la cause ou le recours  une intubation et ventilation invasive dans les 14 jours (J14) suivant linclusion et le dbut du traitement (J0).;Primary end point(s): Le critre de jugement principal est le dcs quelle quen soit la cause ou le recours  une intubation et ventilation invasive dans les 14 jours (J14) suivant linclusion et le dbut du traitement (J0).;Secondary Objective: Les objectifs secondaires sont :&lt;br&gt;&lt;br&gt;1) valuer lefficacit de lhydroxychloroquine versus placebo chez les patients COVID-19 sur : &lt;br&gt;a- lvolution clinique via lchelle OSCI (Ordinal Scale for Clinical Improvement) pour COVID-19 de lOMS&lt;br&gt;b- la mortalit toute cause &lt;br&gt;c- le portage viral &lt;br&gt;d- lincidence des accidents thrombo-emboliques veineux &lt;br&gt;&lt;br&gt;2) valuer lefficacit de lhydroxychloroquine versus placebo dans le sous-groupe des personnes ges de 75 ans ou plus sur :&lt;br&gt;a- lvolution clinique via lchelle OSCI pour COVID-19 de lOMS &lt;br&gt;b- la mortalit toute cause&lt;br&gt;&lt;br&gt;3) valuer la tolrance de lhydroxychloroquine versus placebo sur la survenue dvnements indsirables graves&lt;br&gt;&lt;br&gt;Objectifs ancillaires &lt;br&gt;valuer, dans un sous-groupe de patients COVID-19, limpact de lhydroxychloroquine versus placebo sur lvolution des cytokines et des marqueurs biologiques de limmunit, de linflammation et de lhmostase&lt;br&gt;;Main Objective: Lobjectif principal est dvaluer lefficacit de lhydroxychloroquine versus placebo sur le taux de dcs ou de recours  une ventilation invasive chez les patients ayant une infection COVID-19  haut risque daggravation.","FVC;","Number of sick days (SDS) during the study period: The number of sick days will be obtained from participants medical records as defined as the number of days deemed 'not fit for duty/work' by their reviewing medical professional, and will be compared between participants randomised to chloroquine and vitamin C.[12 weeks post-commencement of the IMP. Study to commence Apr 2020.]","Phone time before and during the outbreak;Physical exercise time before and during the outbreak;Symptoms worsened in patients with previous cervical spondylosis since the outbreak;Symptoms in people with no previous symptoms of cervical spondylosis since the outbreak;","Blood cell number;Biochemical markers;Metabolic markers;","Timepoint(s) of evaluation of this end point: daily for 10 days;Primary end point(s): determination of the blood concentration of hydroxychloroquine by liquid chromatography coupled with mass spectrometry.;Secondary Objective:  - Describe the relationship between HCQ concentration and cardiac toxicity.&lt;br&gt;- To describe the pharmacokinetic (concentration) and pharmacodynamic (viral load) relationship of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.&lt;br&gt;- To define the best modalities of administration of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2  based on the PK/PD relationship.;Main Objective: to describe the pharmacokinetics of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.","SPE, SEN, ACC, AUC of ROC;","Timepoint(s) of evaluation of this end point: Up to 28 days;Primary end point(s): Time to independence from supplementary oxygen therapy in days ;Secondary Objective: Not applicable;Main Objective: To investigate  the effect of different types of IL-6 inhibition versus no adjuvant treatment compared to standard of care in patients with severe SARS-CoV-2 pneumonia.","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects","Percent change of subjects return to baseline oxygen requirement;Percent of subjects who have returned to room air","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio","Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal;Percent change in C-reactive protein (CRP) levels","Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Composite outcome of death / need for invasive ventilation / need for ECMO ;Secondary Objective: The secondary objective is to evaluate the pharmacokinetics of a 10-day course of oral imatinib in patients with severe Covid19 pneumonitis.;Main Objective: To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Define Natural Symptom Course","new-onset COVID-19","Evaluation of the clinical status","COVID-19 diagnosis","Rate of decline in SARS-CoV-2 viral load","Timepoint(s) of evaluation of this end point: 96 hours.;Primary end point(s): Rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR  in samples collected at baseline, 48 and 96 hours after randomization;Secondary Objective: \tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR from baseline to 96 hours&lt;br&gt;\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on changes in NEWS score&lt;br&gt;\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on admission rate to ICU&lt;br&gt;\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on in hospital mortality&lt;br&gt;;Main Objective: To assess whether early treatment with chloroquine in patients with established COVID-19 will significantly reduce replication rate of SARS-CoV-2.","Mortality&lt;br&gt;[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]","Cohort A: reduction of the need of invasive ventilation or 30-day mortality;Cohort B: reduction of mortality","Pulse oximetry level","Days to clinical improvement from study enrolment","Improved clinical status;Return to room air","WHO progression scale COVID 19;Survival","Number of patients included in this platform;Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients","Death or need of intubation","COVID-19 disease diagnosis","interleukin-6 (IL-6) level after 72 hours","National Early Warning Score equal to zero","All-cause mortality","Viral clearance time","Proportion of participants with normalization of fever and oxygen saturation by day 14","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure","Percentage of subjects reporting each severity rating on an 8-point ordinal scale","COVID-19 positive X-Rays;COVID-19 negative X-Rays","Maximal concentration of cardiac troponin;Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&amp;D committee;CRP increase to 3 x upper limit of normal","Mechanical ventilation (Efficacy);Immunological response (Efficacy);Early Warning Score (NEWS) (Efficacy);Early Warning Score (NEWS) (Safety);PO2/FiO2 (Efficacy);PO2/FiO2 (Safety)","Evaluation of covid-19 knowledge level of turkish physicians","Health Care Workers absenteeism","Predictive association between CT-V, PBM score and disease progression","Rate of COVID-19 infection","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.","The rate of COVID-19","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection;Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection","Factors associated with severe COVID-19 outcomes;Clinical characteristics of children with SARS-CoV-2","Rate of SARS-CoV-2 eradication at day 14 from study enrollment","Incidence of suspected, probable or confirmed COVID-19","Death or need of intubation","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.","Number of participants who fill out the survey and participate in the semi-structured interviews.","Changes of lung imaging examinations;Adverse reaction (AE) and severe adverse reaction (SAE)","Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents;Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents","COVID-19 desease description;COVID-19 desease description","Treatment failure;Intubation rate","Incidence of Treatment-Emergent Adverse Events","Change in Immunoglobulin G COVID-19 Titers;Change in Immunoglobulin M COVID-19 Titers;Change in Viral Load","reduction in oxygen and ventilation support","Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU","Mortality changes in day 10;Mortality changes in day 30;Changes of C-reactive protein;Changes of C-reactive protein;Changes of C-reactive protein;Changes of Interleukin 6;Changes of Interleukin 6;Changes of Interleukin 6;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Fraction of healthcare workers infected with SARS-CoV-2","ventilator free days","Mortality rate","FLUS findings and respiratory failure","Time to negative conversion of severe acute respiratory syndrome coronavirus 2","30-days mortality","Total Mechanical Ventilation;Total Hospitalization","Time to mechanical ventilation;Disease progression","Number of antibiotic free days","Length of stay intensive care unit from patient medical record[Discharge from intensive care];Mortality[28 day post discharge from ICU];Mortality[During Intensive care unit stay &lt; 14 days]","All-cause mortality of COVID-19 patients with liver cirrhosis","COVID-19-related hospitalization or all-cause death","Maternal mortality from COVID-19[During pregnancy until 6 weeks postpartum];Perinatal mortality (stillbirth, neonatal death)[During pregnancy and until day 28 in the neonate]","Efficacy of Hydroxychloroquine in the community-based management of COVID-19 assessed by the mean daily InFLUenza Patient-Reported Outcome (FLU-PRO) illness severity score[Day 5 of treatment administration]","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity","Safety as determined by presence of side effects;Safety as determined by blood pressure readings;Prevention of COVID-19 measured by negative testing with RT-PCR","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0","Integration to community as measured on the Reintegration to Normal Living Index (RNLI) -  A 11-item questionnaire-based instrument that measures the degree to which individuals achieve reintegration into normal social activities (such as recreation, movement in the community, and interaction in family or other relationships). [Baseline, &lt;br&gt;Three (3) months following baseline assessment. ]","In non-ventilated patients- Mean change in the worst (highest) level of oxygenation (oxygen flow in litres/min). This will be assessed by the nursing documentation in the participant's electronic record of the flow rate of oxygen delivered and the delivery method (ie nasal prongs, Hudson mask, or non-breather mask). &lt;br&gt;In ventilated patients- Mean change in the worst (lowest) PaO2 /FiO2 ratio (in mmHg). This will be assessed by nursing documented PaO2 and FiO2 levels in the patient chart.[Worst recorded level of oxygenation during the 7 days of intervention.];Feasibility will be assesses by the following measures:&lt;br&gt; The primary assessment of our ability to blind treatment of the HDIVZn in a 250-ml saline preparation&lt;br&gt; Drug availability from supplier, storage and timely delivery to a patient&lt;br&gt; Good clinical practice documentation of drug prescription on Cerner (an electronic medical record), delivery to ICU by project research officer, double signing by nursing staff&lt;br&gt; Appropriate preparation of drug- onsite refrigeration storage, preparation with SOPs, maintenance of sterile conditions, protocol compliance, breaches, and variation, documentation processes including patient retention and follow-up rates&lt;br&gt; Determine the per-patient cost to estimate subsequent pivotal trial costs&lt;br&gt; Assess the process for efficient and effective data entry and analysis&lt;br&gt;These will be assessed by our research investigators on a regular basis and data collected in the case report forms.[During 7 days of intervention]","to able to reduce the progression of acute respiratory failure","Distress measured on Kessler Psychological Distress Scale (K10)[Baseline, post-intervention (within one week since the completion of the intervention, primary endpoint), 3 months post-intervention]","Change in Immunoglobulin G COVID-19 antibodies Titers;Change in Immunoglobulin M COVID-19 antibodies Titers;Change in Viral Load","Side effects","partial pressure of arterial oxygen;","clinical characteristics and risk factors of death;inflammatory factors;","Psycho Educational Profile,PEP;Self-Rated Anxiety Scale,SAS;Self-Rated Depression Scale,SDS;Parenting Stress Index-Short Form,PSI-SF;","Duration of viral shedding in days;Time to clinical recovery (TTCR) in days;Treatment-emergent adverse events (AEs)","Describe the clinical features of COVID-19.&lt;br&gt;&lt;br&gt;(This is verbatim from submitted protocol)[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints. ];Describe the response to treatment, including supportive care and novel therapeutics, based on data linkage to medical records. (composite primary outcome)&lt;br&gt;&lt;br&gt;(This is verbatim from submitted protocol)&lt;br&gt;[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints.]","Dose adjustment required to attain a steady-state target trough hydroxychloroquine concentration of 0.24mg/L using TDM (proportion of patients / magnitude of adjustments)&lt;br&gt;&lt;br&gt;Dose adjustment data will be collected and maintained by the senior ICU clinical pharmacist.[Up to the point of ICU discharge, in the first 10 days after commencement of initial HCQ dose, ]","Fever;","Incidence of SARS-CoV-2 infection (including confirmed SARS-CoV-2 detection, but might asymptomatic);Incidence of COVID-19 pneumonia;","attitudes toward COVID-19;Consciousness awareness toward COVID-19;","Adverse reactions 0-14 days post vaccination;Anti-S antibody IgG titer on day 28 post vaccination;Anti-SARS-CoV-2 neutralizing antibody titer on day 28 post vaccination;","survival;","cardiopulmonary function;motor function;","Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;","Colour Sonography;electrocardiogram;Pulmonary function(TLC, FVC, FEV1, DLCO);","semen;feces;blood;urine;","PSQI;","NGAL;MAU;cystatin C;Beta 2-MG;","Total distances of 6 minutes walk test;","new coronavirus nucleocapsid (N) antigen;SEN, SPE, ACC, AUC of ROC;","Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;","Monitoring of adverse events within 24 hours after infusion (including infusion related events and severe adverse reactions associated with non-primary disease);","proteomics;metabonomics;S antibody IgG;S antibody IgM;S-RBD antibody IgG;S-RBD antibody IgM;N antibody IgG;N antibody IgM;SEN, SPE, ACC, AUC of ROC;","Lung CT Score;","Perioperative fever;Perioperative cough;Outcome of lung CT;Operative time;Volume of Postpartum hemorrhage;postoperative hospitalization;Stay in isolation ward;Apgar score of newborn;Neonatal admission to NICU;Medical observation of personnel involved in the operation;","Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;","mortality;",null,"Timepoint(s) of evaluation of this end point: 12 weeks and 12 month (mortality);Primary end point(s): The primary endpoints of the study are for the: &lt;br&gt;o\tPart A: prevalence at first visit and 12 weeks cumulative incidence (in a competing risk model with mortality) of SARS-CoV-2 positive subjects (RT-PCR)&lt;br&gt;o\tPart B: Covid-19 disease specific mortality;Secondary Objective: To evaluate the safety, Covid-19 disease severity, response to cancer treatment, Progression-free survival (PFS), cancer mortality, and Overall Survival (OS) of cancer patients infected by SARS-Cov2.&lt;br&gt;To follow the evolution of SARS-CoV-2 infection and viral load in different compartments (nasal epithelia, blood and urine) during the course of therapy.&lt;br&gt;To evaluate the impact of mutation shifts in SARS-CoV-2 genotype (in sever cases only).&lt;br&gt;To follow the humoral and cellular immune responses to the virus, to cancer and control antigens during infection with SARS-CoV-2.&lt;br&gt;To deconvolute SARS-CoV-2-specific MHC class I and II binding epitopes to follow T cell responses with tetramers and Elispot assays, as well as cancer antigens (NY-ESO-1, MAGEn, preprocalcitonin, actinin...)-specific responses.&lt;br&gt;;Main Objective: To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).&lt;br&gt;To evaluate the Covid-19 disease mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).&lt;br&gt;","Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Primary endpoint: &lt;br&gt;Time to clinical improvement from day 0 to day 28.&lt;br&gt;Clinical improvement is defined as an improvement of two points  on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first,  as recommended by the WHO R&amp;D Blueprint expert group (3).&lt;br&gt;&lt;br&gt;The seven-category ordinal scale consisted of the following categories: &lt;br&gt;1.\tnot hospitalized with resumption of normal activities &lt;br&gt;2.\tnot hospitalized, but unable to resume normal activities&lt;br&gt;3.\thospitalized, not requiring supplemental oxygen &lt;br&gt;4.\thospitalized, requiring supplemental oxygen&lt;br&gt;5.\thospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both&lt;br&gt;6.\thospitalized, requiring ECMO, invasive mechanical ventilation, or both&lt;br&gt;7. death. ;Secondary Objective: 1.\tEvaluate the cardiovascular safety of RAS blockers discontinuation in patients hospitalized for COVID-19 by a composite endpoint of MACE.&lt;br&gt;2.\tEvaluate the efficacy of RAS blockers discontinuation in patients hospitalized for COVID-19 by the secondary efficacy endpoints.&lt;br&gt;;Main Objective: To compare the effect of discontinuation versus continuation of RAS blockers on the clinical course of patients with confirmed COVID-19 infection leading to hospitalization","Timepoint(s) of evaluation of this end point: 30 days;Primary end point(s): 30-day mortality all causes;Secondary Objective: To demonstrate the effect of naproxen treatment to in-hospital mortality, morbidity, virus concentration;Main Objective: To demonstrate the superiority of naproxen treatment addition to standard of care compared to standard of care in term of 30-day mortality","Timepoint(s) of evaluation of this end point: Treatment group: Day 21&lt;br&gt;&lt;br&gt;Control group: Days 14 and 21;Primary end point(s): Composite endpoint of:&lt;br&gt;&lt;br&gt;- Survival &lt;br&gt;&lt;br&gt;AND&lt;br&gt;&lt;br&gt;- no longer fulfilling criteria of severe COVID-19 within 21 days after randomization&lt;br&gt;&lt;br&gt;All criteria must be met in order to fulfill the primary endpoint.&lt;br&gt;;Secondary Objective: - Time to clinical improvement on WHO R&amp;D Blueprint seven-category ordinal scale by 2 &lt;br&gt;- Adverse events &lt;br&gt;- Case fatality rate on days 21, 35 and 60&lt;br&gt;- Length of hospital stay&lt;br&gt;- Length of ICU stay &lt;br&gt;- Duration of ventilation Support / ECMO&lt;br&gt;- Time until negative SARS-CoV-2 PCR&lt;br&gt;- Predictive value of comorbidities and inflammation markers &lt;br&gt;- Feasibility of collection of plasma units &lt;br&gt;- Kinetics of anti-SARS-CoV-2 antibodies in plasma of patients = plasma donors who recovered &lt;br&gt;   from a SARS-CoV-2 infection&lt;br&gt;- Titer of anti-SARS-CoV-2 in transfused plasma units&lt;br&gt;- Impact of donor characteristics on anti-SARS-CoV-2 humoral response&lt;br&gt;- Course of anti-SARS-CoV-2 titer in patients &lt;br&gt;- Effect of timing of plasma transfusions on outcome&lt;br&gt;;Main Objective: To improve survival &lt;br&gt;&lt;br&gt;AND&lt;br&gt;&lt;br&gt;remove criteria of severe COVID-19 (CoV-2 infection) within 21 days after randomization","Main Objective: The primary objective of Phase II is:&lt;br&gt; To explore the effect of IFX-1 on COVID-19 related severe pneumonia (hypothesis generating)&lt;br&gt;&lt;br&gt;The primary objective of Phase III is&lt;br&gt; To demonstrate the efficacy of IFX-1 to improve of symptoms and outcome of severe COVID-19 pneumonia (confirmative)&lt;br&gt;;Secondary Objective: The secondary objectives of Phase II and Phase III are:&lt;br&gt; To assess and define other parameters of efficacy&lt;br&gt; To assess the safety of IFX-1&lt;br&gt;;Primary end point(s): Phase II: &lt;br&gt;The primary endpoint in Phase II is the relative change (%) from baseline (day 1 prior to study drug administration at  1h of randomization) in Oxygenation Index (PaO2 / FiO2) in supine position at day 3, 5, 9, and 15.&lt;br&gt;&lt;br&gt;Phase III: &lt;br&gt;The primary, secondary, and other endpoints for Phase III are the same as those for Phase II if not adjusted according to recommendations of the expert committee.&lt;br&gt;;Timepoint(s) of evaluation of this end point: Day 3, 5, 9 and 15","Main Objective: Study if blockade of IL-6 +/- IL-1 to block the cytokine storm and acute lung injury in comparison with usual care reduces time to clinical improvement as defined by an increase of more than 2 on the 6 point ordinal scale or discharge from the hospital;Secondary Objective: -to investigate whether treatment with either tocilizumab, siltuximab, anakinra or combinations thereof&lt;br&gt;-improves oxygenation&lt;br&gt;-causes defervescence, measured as time to first fever-free 48h period&lt;br&gt;-improves features of secondary haemophagocytic lymphohistiocytosis&lt;br&gt;-improves features of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6 and IL-1&lt;br&gt;-affects clinical outcome in relation to IL-6 and IL-1 levels&lt;br&gt;-affects the rate of nosocomial infection&lt;br&gt;-affects progression to mechanical ventilation, high oxygen delivery device, and/or ARDS in non-ventilated patients&lt;br&gt;-affects length of dependency of ventilation in ventilated patients&lt;br&gt;-affects all-cause mortality rate at 4 and 20 weeks post inclusion&lt;br&gt;-affects long term 10-20 week follow up clinical status and lung function&lt;br&gt;-is safe (number of AEs/SAEs)&lt;br&gt;-When there is a significant association between IL-6 blockade and time to clinical improvement, tocilizumab and siltuximab will be compared versus usual care ;Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Time to clinical improvement (defined as the time from randomization to either an improvement of two points on a six-category ordinal scale measured daily till day 28 or discharge from the hospital or death)&lt;br&gt;1. Death&lt;br&gt;2. Hospitalized, on invasive mechanical ventilation or ECMO;&lt;br&gt;3. Hospitalized, on non-invasive ventilation or high flow oxygen devices;&lt;br&gt;4. Hospitalized, requiring supplemental oxygen&lt;br&gt;5. Hospitalized, not requiring supplemental oxygen&lt;br&gt;6. Not hospitalized","Timepoint(s) of evaluation of this end point: day 14 after inclusion;Primary end point(s): Proportion of participants with an occurrence of hospitalization and/or death between D0 and D14 in each arm;Secondary Objective: To estimate :&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, to prevent death on D28&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, to prevent hospitalization on D28&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent hospitalization in intensive care on D28&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2 to suppress nasopharyngeal viral carriage, compared to standard care&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent a loss of autonomy on D14 and D28&lt;br&gt;- the tolerance of experimental treatments against SARS-CoV-2&lt;br&gt;- Study the factors associated with the worsening of the disease&lt;br&gt;- Evaluate the feasibility and acceptability of the trial and the care model implemented&lt;br&gt;- Assess the relationship between the concentration of each drug and the effectiveness of each treatment;Main Objective: The main objective of this trial is To estimate the efficacy of several specific experimental treatments, compared to standard care, to prevent hospitalization or death at D14 in adults over 65 years of age, with documented SARS-CoV-2 infection, with symptoms lasting less than 72 hours and not meeting any hospitalization criteria.","Timepoint(s) of evaluation of this end point: the 28th day after the start of treatment&lt;br&gt;;Primary end point(s): Mortality on D28&lt;br&gt;;Secondary Objective: Assess, in patients with ARDS causedd by COVID-19, the efficacy of DXM associated with HCQ compared to HCQ alone on :&lt;br&gt;- the ventilator-free days&lt;br&gt;- mortality in intensive care unit&lt;br&gt;- mortality on D60&lt;br&gt;- the occurrence of infectious complications ;Main Objective: Assess, in patients with ARDS caused by COVID-19, the efficacy of dexamethasone (DXM) associated with hydroxychloroquine (HCQ) compared to HCQ alone on mortality at 28 days","Main Objective: To explore whether a 2-month treatment with either LPV/r or hydroxychloroquine may reduce the incidence of symptomatic or asymptomatic infection by SARS-CoV-2, as compared to their placebo in healthcare workers exposed to SARS-CoV-2.;Timepoint(s) of evaluation of this end point: Day: 7, 14, 21, 28, 35, 42, 49, 57, 71 after the start of the drug;Primary end point(s): The primary endpoint is the occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs) &lt;br&gt;An infection by SARS-CoV-2 is defined by either:&lt;br&gt; a positive specific RT-PCR on periodic systematic nasopharyngeal swab during follow-up&lt;br&gt;OR&lt;br&gt; a positive specific RT-PCR on a respiratory sample in case of onset of symptoms consistent with COVID-19 during follow-up&lt;br&gt;OR&lt;br&gt; a seroconversion to SARS-CoV-2 after randomization.;Secondary Objective: 1. To evaluate the occurrence of adverse events in each arm,&lt;br&gt;2. To evaluate the discontinuation rates of the investigational drug in each arm,&lt;br&gt;3. To evaluate the adherence of participants to study drug,&lt;br&gt;4. To evaluate the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,&lt;br&gt;5. To evaluate the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm, at to 2,5 months after randomization,&lt;br&gt;6. To evaluate the incidence of severe cases of SARS-CoV-2 infection in each arm.","Main Objective: The aim of this core protocol is to compare the effects on major outcomes in hospital of the local standard of care alone versus the local standard of care plus one of four alternative anti-viral agents. &lt;br&gt;&lt;br&gt;The primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death.","Main Objective: The main objective is to compare versus standard of care short-term mortality rates in advanced or metastatic cancer patients who are positive for COVID-19 treated with a chloroquine analog (GNS561), an anti-PD1 (nivolumab) or an anti-IL-6R antibody (tocilizumab).;Secondary Objective: The secondary objectives will be to describe in each arm of the study:&lt;br&gt; Time to clinical improvement&lt;br&gt; Clinical status at days 7, 14 and 28&lt;br&gt; Mean change in clinical status from baseline to days 7, 14 and 28 &lt;br&gt; Overall survival &lt;br&gt; Length of stay in Intensive Care Unit and in Resuscitation Unit&lt;br&gt; Duration of mechanical ventilation or high flow oxygen devices&lt;br&gt; Duration of hospitalization&lt;br&gt; Rate of throat swab negativation at days 7, 14 and 28&lt;br&gt; Quantitative SARS-CoV-2 virus in throat swab at days 7, 14 and 28&lt;br&gt; Quantitative SARS-CoV-2 virus in blood at days 7, 14 and 28&lt;br&gt; Rate of secondary infection by other documented pathogens (bacteria, fungi)&lt;br&gt; Biological parameters (hematological parameters and markers of inflammation)&lt;br&gt; Safety of experimental treatments.&lt;br&gt;And to perform Cost-Effectiveness Analyses (CEA) with Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.&lt;br&gt;;Primary end point(s): The primary endpoint will be the 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization. &lt;br&gt;;Timepoint(s) of evaluation of this end point: 28-day","Main Objective: To determine the efficacy of the intravenous infusion of Defibrotide (Defitelio) to reduce mortality in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.;Secondary Objective: To assess the safety of intravenous Defibrotide (Defitelio) infusion in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.&lt;br&gt;? To analyze the effects of the intravenous infusion of Defibrotide (Defitelio) on the clinical state of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.&lt;br&gt;? Assess the capacity of intravenous infusion of Defibrotide (Defitelio) to improve the radiological response of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.&lt;br&gt;? Study the action of Defibrotide (Defitelio) on risk biomarkers in patients with SARS-CoV-2 infection with grade 4, 5 or 6 clinical status according to the WHO classification.;Primary end point(s): Mortality rate 30 days after starting treatment.;Timepoint(s) of evaluation of this end point: 15, 30 ,60 days","Timepoint(s) of evaluation of this end point: Visit study day 8;Primary end point(s): The study primary endpoint is composite and contains the achievement of at least one of the following goals or both goals after 7 days (study visit of day 8):&lt;br&gt; At least 25% decrease of baseline total SOFA score or increase of the pO2/FiO2 ratio by at least 50%&lt;br&gt; Clinical improvement of lung involvement&lt;br&gt;Patients discharged from hospital alive before study visit of day 8 are considered achieving the primary endpoint. Patients dying before study visit of day 8 are considered non-achieving the primary endpoint.;Secondary Objective: Not applicable;Main Objective: Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs.","Main Objective: The main objective is to assess the impact of dexamethasone on overall mortality at day-60 after randomization in patients admitted in ICU for severe COVID-19 infection.&lt;br&gt;In non mechanical ventilation (MV) patients, the additional objective is to assess whether oxygen support based on either HFNO or CPAP modality in COVID-19 related AHRF reduces the need for mechanical ventilation at day-28.&lt;br&gt;;Timepoint(s) of evaluation of this end point: october 2020;Primary end point(s): , the primary endpoint is the time-to-death from all causes within the first 60 days after randomization.and the  time to need for mechanical ventilation (MV);Secondary Objective: For the study of the effect of corticosteroids, secondary objectives include: &lt;br&gt;1.To compare the evolution of the viral load in the respiratory tract &lt;br&gt;2.To compare the occurrence of healthcare-associated infections &lt;br&gt;3.To compare the exposition to mechanical ventilation &lt;br&gt;4.To compare the evolution of SOFA score &lt;br&gt;5.To compare the exposition to renal replacement therapy &lt;br&gt;6.To compare the lengths of ICU and hospital-stay&lt;br&gt;&lt;br&gt;For the study of the effect of oxygen support modalities, secondary objectives are, to compare each of oxygen support group to the control group in terms of: &lt;br&gt;1.overall survival&lt;br&gt;2.occurrence of healthcare-associated infections &lt;br&gt;3.length of ICU and hospital-stay&lt;br&gt;","Timepoint(s) of evaluation of this end point: D7;Primary end point(s): Comparison between the two treatment arms of the evolution of the PaO2/FiO2 ratio between D0 (inclusion) and D7;Secondary Objective: 1) all-cause mortality at D28&lt;br&gt;2) the clinical evolution at D28 ;&lt;br&gt;3) the duration of mechanical ventilation;&lt;br&gt;4) the number of days without mechanical ventilation at D28;&lt;br&gt;5) the length of stay in intensive care ;&lt;br&gt;6) the concentrations of blood markers of inflammation over time;&lt;br&gt;7) NET concentrations in bronchial secretions over time&lt;br&gt;8) the occurrence of adverse events;Main Objective: To evaluate the efficacy of intratracheal administration of dornase alfa (Pulmozyme) on the evolution of ventilatory parameters at D7","Main Objective: Main objective: &lt;br&gt;- To study the time (days) to reach clinical stability after randomization in hospitalized patients with severe pneumonia secondary  to COVID-19, and elevated inflammatory parameters.;Secondary Objective: Clinical &lt;br&gt;-time to reach an afebrile state during 48 hours. &lt;br&gt;-time to reach PaO2/FiO2 &gt;400 and/or SatO2/FiO2 &gt;400 &lt;br&gt;-time until you reach a FR = 24 rpm for 48 hours &lt;br&gt;-time to D-dimer normalization (&lt;250 ug/L) &lt;br&gt;-time until PCR is normalized (&lt;5mg/L). &lt;br&gt;-time to normalisation of ferritin (&lt;400ug/L). &lt;br&gt;-impact of immunosuppressive treatment on viral dynamics using quantitative PCR. &lt;br&gt;-duration of treatment with tacrolimus. &lt;br&gt;-duration of the inpatient stay. &lt;br&gt;-Percentage of patients requiring artificial respiratory support&lt;br&gt;-duration of artificial respiratory support needs to be maintained. &lt;br&gt;-mortality Incidence COVID at 28 and 56 days&lt;br&gt;-mortality incidence all-cause at 28 and 56 days &lt;br&gt;-relapses of COVID-19 pneumonia at 28 and 56 days&lt;br&gt;-Analysis of expanded cytokine profile (day 0 and every 7 days)&lt;br&gt;Safety&lt;br&gt;-side effects according to the severity attributed to tacrolimus during its administration. &lt;br&gt;-side effects according to the severity attributed to other treatments administered;Primary end point(s): Primary endpoint  (for the main objective of effectiveness): &lt;br&gt;- Time (days) to clinical stability after initiation of trial treatment in hospitalised patients with severe pneumonia secondary to COVID-19 and elevated inflammatory parameters;Timepoint(s) of evaluation of this end point: Throughout the study until clinical stability","Main Objective: To evaluate in-hospital mortality or mechanical ventilation in the Intensive Care Unit (ICU), or need for a rescue dose of tocilizumab in patients with confirmed infection by COVID-19 in treatment with hydroxychloroquine and azithromycin combined or non-tocilizumab.;Secondary Objective: To assess the clinical efficacy of tocilizumab in COVID-19 infection compared to the control arm by:&lt;br&gt;&lt;br&gt;Clinical severity:&lt;br&gt;Patient score according to the WHO 7-point ordinal scale&lt;br&gt;National Early Warning Score (NEWS)&lt;br&gt;Oxygen therapy&lt;br&gt;Mechanic ventilation&lt;br&gt;Hospitalization&lt;br&gt;Mortality at 15, 30 and 90 days&lt;br&gt;&lt;br&gt;To assess the safety of the intervention 30 days after treatment compared to the control arm.&lt;br&gt;&lt;br&gt;To assess the safety of the intervention at 90 days of treatment compared to the control arm.&lt;br&gt;- Cumulative incidence of serious adverse effects (SAEs).&lt;br&gt;- Cumulative incidence of grade 3 and 4 adverse effects (AEs).&lt;br&gt;- Discontinuation or suspension of treatment for any reason.&lt;br&gt;- Changes in the white blood cell count, hemoglobin, platelets, creatinine, glucose, total bilirubin, AST, ALT, GGT, LDH, C-reactive protein, D-dimer, troponin, ferritin, fibrinogen, KL-6 during follow-up.;Primary end point(s): In-hospital mortality or need for mechanical ventilation in the Intensive Care Unit.;Timepoint(s) of evaluation of this end point: During hospitalization","Timepoint(s) of evaluation of this end point: The patient will be evaluated weekly for 30 days from enrollment in the study to rule out / confirm COVID-19 infection.;Primary end point(s): COVID-19 infection.;Secondary Objective: -Establish if the preventive administration of mefloquine attenuates the clinical manifestations of COVID-19 in people who become infected.&lt;br&gt;-Evaluate the safety of prophylactic mefloquine in this setting.;Main Objective: To determine the protective efficacy of mefloquine prophylaxis against placebo in close contacts of people with COVID-19.","Main Objective: To assess the efficacy of a daily single dose of TDF (300 mg)/FTC (200 mg), a daily single dose of HC (200 mg), daily single dose of TDF (300 mg)/FTC (200 mg) plus HC (200 mg) or placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing the clinical severity of the coronavirus infection (COVID-19) among hospital healthcare workers aged 18 to 65 years who are exposed to coronavirus infection (COVID-19) in Spain.;Secondary Objective: not applicable;Primary end point(s): number of symptomatic confirmed infections by SARS-CoV-2 (COVID-19);Timepoint(s) of evaluation of this end point: 12 weeks treatment + 4 weeks F/U","Timepoint(s) of evaluation of this end point: - At the end of prophylaxis treatment&lt;br&gt;- Fourteen days after the last dose of treatment;Primary end point(s): Diagnosis of SARS-CoV-2 COVID-19 infection;Secondary Objective: To assess the safety of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.&lt;br&gt;&lt;br&gt;To assess the efficacy of personal protective equipment against SARS-CoV-2 (COVID-19) infection in healthcare professionals;Main Objective: To assess the efficacy of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals by negative PCR.","Main Objective: To compare the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of COVID-19 disease during an epidemic period.;Secondary Objective: 1) To assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period.&lt;br&gt;&lt;br&gt;2) To evaluate the safety of PrEP with hydroxychloroquine in adults.&lt;br&gt;&lt;br&gt;3) To describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection.&lt;br&gt;&lt;br&gt;4) To identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection.&lt;br&gt;&lt;br&gt;5) To set up a repository (biobank) of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.;Primary end point(s): Confirmed cases of a COVID-19 (defined by symptoms compatible with COVID-19 and/or a positive PCR for SARS-CoV-2) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 at day 0.;Timepoint(s) of evaluation of this end point: 6 months","Timepoint(s) of evaluation of this end point: 1, 2. Baseline to Day 15;Primary end point(s): 1. Phase 2: Change in SpO2/FiO2 ratio from baseline  to  Day 15.&lt;br&gt;2. Phase 3 (may be reassessed after review of phase 2): Change in SpO2/FiO2 ratio from baseline to Day 15;Secondary Objective: Evaluate the clinical efficacy of HCQ + standard of care as compared to standard of care only in adult patients hospitalized with moderate to severe COVID-19&lt;br&gt;Evaluate the effect of HCQ + standard of care as compared to standard of care only on the virologic load in nasopharynx as assessed by quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) counts in adult patients hospitalized with moderate to severe COVID-19  &lt;br&gt;Evaluate the safety of HCQ + standard of care as compared to standard of care ;Main Objective: Evaluate the effect of hydroxychloroquine (HCQ) + standard of care as compared to standard of care only on oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio  in adult patients hospitalized with moderate to severe Coronavirus Disease 2019 (COVID-19)","Main Objective: Demonstrate the therapeutic effectiveness of Hydroxychloroquine associated with Azithromycin treatment for symptom control and negative viral load, in patients with comorbidities without pneumonia and COVID-19 infection.;Secondary Objective: - Evaluate the safety of the treatment&lt;br&gt;- Assess tolerance of treatment;Primary end point(s): Proportion of patients with negative viral load by CODV-19 [SARS-CoV-2 (PCR)] at 6 days after the start of treatment;Timepoint(s) of evaluation of this end point: 30 DAYS","Timepoint(s) of evaluation of this end point: The first 28 days after randomization.;Primary end point(s): The primary end point of efficacy will be death for any cause in the first 28 days after randomization.;Secondary Objective: To evaluate the safety of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary to SARS-CoV-2.;Main Objective: To evaluate the efficacy of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary tp SARS-CoV-2 .","Number of deceased participants or with persistent organ dysfunction","Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study);Percent of subjects who Return to Room Air (RTRA) (main study)","Lower Murray lung injury score;Lower Murray lung injury score","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7","Incidence of Serious Adverse Events (SAEs);Oxygenation index (OI)","28-day all cause mortality","Time to Clinical recoveryTime to Clinical Recovery (TTCR)","The mortality rate of subjects at weeks 2;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3","Size of lesion area by chest radiograph or CT;Side effects in the MSCs treatment group","the incidence of treatment failure in 14 days","exposure of galidesivir as measured by plasma concentrations;number of subjects with change in laboratory parameters;number of subjects with treatment emergent adverse events and serious adverse events","Detection sensitivity is greater than 95%;Detection specificity is greater than 95%","Time to negative NPS","Rate of composite adverse outcomes","Pneumonia severity index;Oxygenation index (PaO2/FiO2)","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff","Time to Clinical Improvement (TTCI) [Censored at Day 28]","Improvement of clinical symptoms including duration of fever;Improvement of clinical symptoms including respiratory frequency;Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0","Grade of solicited systemic reactogenicity adverse events (AEs);Grade of solicited local reactogenicity adverse events (AEs);Grade of any unsolicited adverse events (AEs);Frequency of solicited systemic reactogenicity adverse events (AEs);Frequency of any unsolicited adverse events (AEs);Frequency of any serious adverse events (SAEs);Frequency of any new-onset chronic medical conditions (NOCMCs);Frequency of any medically-attended adverse events (MAAEs);Frequency of solicited local reactogenicity adverse events (AEs)","Size of lesion area and severity of pulmonary fibrosis by chest CT","Determine the number of Covid-19 patients who were unable to complete SCE Therapy","SARS-CoV-2 eradication time","Severity of COVID-19","Safety indexes of adverse reactions","nosocomial infection",null,"The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation","Change of arterial oxygenation at 48 hours from enrollment","Hospital Admission","Mortality;PaO2:FiO2 ratio","One-month mortality rate","Rate of Death","Incidence of COVID19 Disease among those who are asymptomatic at trial entry;Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry","Clinical cure rate","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases","Differences of attitude about blood donation towards different questionnaires","Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days","Severity of COVID-19","Change in Clinical Condition","Maternal and perinatal outcomes","prevalence","Evaluation of the clinical status","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Technical success","arrest in deterioration of pulmonary function;improving in pulmonary function","All-cause hospital mortality","Helpfulness of the session;Platform effectiveness","In-hospital mortality","Number of days alive and discharged from hospital within 14 days",null,"Improvement of COVID-19 disease status","Symptomatic COVID-19 infection rate","ICU and hospital mortality of COVID-19 patients","Cumulative incidence of composite outcome of disease severity","Clinical Status Assessed Using a 7-Category Ordinal Scale","Number of participants who experience inpatient admission","Lung ultrasound grading system for COVID-19 pneumonia","Clinical improvement;Hospital discharge","Survival","Number of participants who die or require hospitalization due to COVID-19 infection","Clinical presentation;Disease prognosis outcomes;Pregnancy outcomes;Obstetric outcomes;Neonatal outcomes;Modes of transmission of COVID-19","60-day mortality","Accuracy of patient administered tests","Clinical status of subject at day 15 (on a 7 point ordinal scale).","Survival without needs of ventilator utilization at day 14.;WHO progression scale &lt;=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14;WHO progression scale at day 4","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score","Time to independence from supplementary oxygen therapy","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial;Change from baseline Serum ferritin level at end of the trial;Change from baseline serum Interleukin-6 concentration at end of the trial;Change from baseline serum C-reactive protein concentration at end of the trial;Change from baseline serum Tumor necrosis factor-a concentration at end of the trial;Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial","Biomarkers expression;Liver Biomarkers expression","Treatment success","Assess the prevalence of severe forms among hospitalized patients with diabtes and COVID-19","RNA in SARS-CoV-2;ICU Admissions;Hospital Mortality;Hospital Length of Stay (LOS)","Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale;Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner","Ventilator-free days","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases;Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)","rate of recovery","Voice anaysis","Mortality all causes at day30","Protection against COVID-19","COVID-19 disease incidence;Severe COVID-19 disease incidence","Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.","Detection of SARS-CoV-2 virus","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)","COVID-19-free survival","SAMBA COVID-19 POC PCR Test","Evaluation of the extent of the virus transmission within households","All-cause mortality","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability","Proportion of patients requiring ICU admission at any time within the study period.","Perceived Stress Scale;Perceived Stress Scale;Perceived Stress Scale","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)","COVID Ordinal Outcomes Scale at 14 days","Time (in days) to clinical improvement within 30 days after randomization","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days;Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","Composite of hospitalization, invasive mechanical ventilation or death within 30 days","Characteristics of COVID-19-related anxiety;COVID-19-related anxiety symptoms","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/;To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/","Median release from quarantine time;Rate of hospital discharge;Rate of infection","Clear chest CT-scan;PCR test","Incidence rate of new COVID-19 cases in both arms;Prevalence of COVID-19 cases in both arms;Mortality rate secondary to COVID-19 cases in both groups;Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups","Time to Clinical Improvement","Efficacy of Intervention","Change in Oxygen Saturation by Pulse Oximetry","Physical health symptoms;Lack of physical health symptoms","Confirmed cases of a COVID-19","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more);Number of adverse events","Clinical response;Biochemical response","Hospitalization","Change in PaO2/FiO2","Survival without needs of ventilator utilization at day 14.;WHO progression scale &lt;=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14;WHO progression scale at day 4","Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.","In-hospital mortality;Need for mechanical ventilation in the Intensive Care Unit","All-cause mortality at 30 days after admission","Natural history of COVID-19: Characteristics of COVID-19;Natural history of COVID-19: Participant demographics;Natural history of COVID-19: Treatment use;Time point of clinical response","Mortality","Symptomatic COVID-19;Peak severity of COVID-19 over the study period","Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).","Viral nucleic acid test negative conversion rate","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available);Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)","COVID Ordinal Outcomes Scale on Day 15","Rate of COVID-19 positive conversion","Number of participants with clinical infection with COVID-19 infection","Antiviral Activity;Improvement of oxygenation","Prevalence of symptoms;Prevalence of positive Sars CoV-2 PCR;Prevalence of positive radiological findings","Changes in high-resolution computer tomography of the lung;Change in 6-minute walking distance","change in virus duration (viral shedding);change in the number of patients going from asymptomatic to moderately disease","Mortality","28-day survival rate","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.","Death","Determine the incidence of cardiomyopathies and venous thromboembolism","Recovery of Pneumonia","Hospitalization within 14 days of enrollment","Successful treatment as determined by Negative Test and resolution of symptoms;Safety of Quintuple Therapy","Frequency of Adverse Events","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)","Number of participants with treatment-related adverse events as assessed by protocol definition of AE","Chest x-ray;Chest CT;Supportive care - ICU;Supportive care - oxygen therapy;Supportive care - ventilation;Medication;Therapeutic strategies;Lab parameters;Intra-hospital complications;Vital status at discharge","Percentage of patients with normalization of SpO2 =96%","Evaluation of EPA-FFA efficacy compared to standard of care","Number of patients with ICU admission;Number of patients with intubation;Number of patients with death","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.","Risk Factors for severe infection;Immunulogical mechanisms;Long term outcome","World Health Organization Quality of Life Questionnaire Bref","Recovery time","Disease activity","TTCI","Physical Activity Scale for the Elderly;Nottingham Health Profile;Loneliness Scale for the Elderly","Stop home isolation;NEWS score","Prevalence;Incidence","Time to acquire images as measured by time stamps;Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction);Percent of patient echos that are not interpretable","Changes in patients viral load;Second evaluation of changes in patients viral load","overactivity of the renin / aldosterone system","Measure frequency of people suffered from unusual flu-like symptoms before December 2019","Time from randomization to clinical recovery","Percentage of children with severe or critical form.","Time to resolution of fever","Titanium level","ACE2 level change over time","quantify and qualify distress over a large population in times of pandemic crisis.","Evaluation of apgar status of newborns from covid 19 positive mothers","Predictive performance","Cause of death or invasive mechanical ventilation","Hospital mortality",null,"Positive or negative character of the three tests;Positive or negative character of the three tests","Reduction in COVID-19 infection frequency","Health Outcomes","Prevalence of Covid-19 infection in the overall CHD population","Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events of Special Interest (AESIs);Change from Baseline in Antigen-Specific Binding Antibody Titers;Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-?) Cellular Immune Response","Hospitalization","Risk of unfavourable outcome at D14","Body temperature;Blood pressure;Pulse (heart rate);Respiratory rate;Data provided by transpulmonary thermodilution-CI;Data provided by transpulmonary thermodilution-GEDV;Data provided by transpulmonary thermodilution-EVLW;Data provided by transpulmonary thermodilution-PVPI;Incidence of abnormal laboratory test results","Rates of return visits to the ED","Prevalence of positivity of COVID-19 virus measured by rt-PCR","International Physical Activity Questionnaire;Pittsburgh Sleep Quality Index;Perceived Stress Scale;Numerical Pain Rating Scale",null,"Rates of emergency visits needing surgical consult;The ratio of severe presentations to non-severe presentations","Increase of pO2/FiO2 ratio;Improvement of lung involvement measurements;Change of baseline total sequential organ failure assessment (SOFA) score","Polymerase chain reaction assay (PCR) negative at day 60.;Polymerase chain reaction assay (PCR) negative at day 30.;Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.","to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.","Measure of the impact of COVID Emergency on surgical specialist training programs","overall response rate in reversal of hyperinflammation","Laboratory Result;Clinical Outcome","Not hospitalized","Covid 19 Anxiety levels in Endometriosis Patients","Deterioration resulting in healthcare review","Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).","Utility of breath profiles for disease diagnosis or prognosis;Breath volatile organic compound profiles","Time to reach clinical stability","Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19;Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19","Hierarchical composite endpoint","Suitable for discharge","COVID-19 positive case","Radiological features of Coronavirus Disease 2019 (COVID-19) cohort;Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort;Clinical manifestations of Coronavirus Disease 2019 (COVID-19);Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group","Blood oxygen saturation;The immune function (TNF-a ?IL-1?IL-6?TGF-?IL-8?PCT?CRP)",null,"Accuracy of the diagnosis of interstitial syndrome by lung ultrasound;Inter-observer variability","To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.;To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.;To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.;To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.","Proportion of alive patients free off mechanical ventilation","Reduction in the number of COVID-19 infections in healthcare workers.","SARS-CoV-2 infection","Changes in forced vital capacity (FVC)","Virology Cure Rate","Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21Stress); in terms of proportions (0-7 vs = 8).;Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21Anxiety); in terms of proportions (0-3 vs = 4).;Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21Depression); in terms of proportions (0-4 vs = 5).;Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs = 29).","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients;Type of respiratory support","Mortality at day 28","Progression to advanced respiratory support","Intraoral viral load","NIMH COVID Study survey - adult responses","POCUS Score - Lungs;POCUS Score - Heart","Correlation of FAST+ pulmonary findings with active COVID infection","T-cell immunophenotype","Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19","Clinical course of COVID-19;Analysis of development of antibodies to SARS-CoV-2;Estimation of viral load;Detection of viral coinfections;Measurement of cytokine and chemokine response;Characterisation of virus-host-interaction;Identification of disease patterns in proteome;Analysis of change in lymphocyte subtypes;Analysis of histological changes in severe lung disease;Detection of bacterial coinfections","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs);Phase 2: Cumulative incidence of serious adverse events (SAEs);Phase 2: Changes in white blood cell count (CBC) through Day 15;Phase 2: Changes in hemoglobin through Day 15;Phase 2: Changes in platelets through Day 15;Phase 2: Changes in creatinine through Day 15;Phase 2: Changes in glucose through Day 15;Phase 2: Changes in prothrombin time (PT) through Day 15;Phase 2: Changes in total bilirubin through Day 15;Phase 2: Changes in ALT through Day 15;Phase 2: Changes in AST through Day 15;Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS);Phase 2: Changes in hemoglobin through End of Study (EOS);Phase 2: Changes in platelets through End of Study (EOS);Phase 2: Changes in creatinine through End of Study (EOS);Phase 2: Changes in glucose through End of Study (EOS);Phase 2: Changes in prothrombin time (PT) though End of Study (EOS);Phase 2: Changes in total bilirubin through End of Study (EOS);Phase 2: Changes in ALT through End of Study (EOS);Phase 2: Changes in AST through End of Study (EOS);Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15","PaCO2;Driving Pressure;Tidal volume","Need for ventilation (including invasive and non invasive ventilation), intensive care or death","HACOR score addaptation;HACOR score efficacy","28 day all cause mortality","Mechanical ventilation requirement","Proportion (%) of subjects experiencing deterioration in clinical status;Treatment Emergent Adverse Events","The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.","PTSD Family members sup 22","Changes in clinical critical treatment index","Survival without needs of ventilator utilization at day 14;WHO progression scale = 5;Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) or withdrawal of NIV or high flow (for &gt; 48h), at day 14;Decrease of at least one point in WHO progression scale score","Characteristics of pulmonary ultrasound for Covid-19 patients","Death","Decrease incidence of intubation by 30% or greater","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients;Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Occurrence of adverse reactions;Anti SARS-CoV-2 S antibody response(ELISA);Neutralizing antibody response to SARS-CoV-2","Changes in Glucose Llevels","Duration of viral shedding","Rate of secondary aggravation","Number of antibodies against coronaviruses isolated and identified from patient samples","Comparison of the percentage of clinically improved inpatients between D0 and D14","ECG changes associated with COVID-19","The Rapid Office Strain Assessment (ROSA)","Effect of HCQ on in vivo viral clearance","Efficiency of the telephone consultation","The self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)","Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them","Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)","positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first","Days of turning negative on RT-PCR test;days to cure","Symptom Reduction","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection;To measure the percentage change in performed endoscopic procedure in response to COVID-19","Proportion of patients with onset of severe acute respiratory syndrome (SARS)","Rates of hospitalization for a COVID-19 related complication","Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis;Distribution of COVID-19 risk factors by participant characteristics;Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization);Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study;Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment","Time to clinical improvement","Mortality;Viral Load;Serum Antibody Titers","Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours","The time to need for mechanical ventilation (MV);The time-to-death from all causes","Time to clinical worsening","Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina;Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina","Number of Ventilator Free Days","Symptomatic laboratory-confirmed COVID-19;Symptomatic laboratory-confirmed VRI","Incidence","Time to clinical improvement","Number of cured patients","Mortality rate at day 28","Total Leak Volume of Non Invasive Ventilation Mask","Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic","50% reduction in symptom score for patients with lower respiratory tract infection;Lack of progression for patients with upper respiratory tract infection","negative testing of covid19","For patients hospitalized for COVID-19 but not intubated;Primary objective for patients with COVID-19 already intubated","Time to diagnosis of COVID-19 by RT-PCR in subjects","Clinical data of lung cancer patients with COVID-19 diagnoses;Diagnosis data;Treatments received;Prognostic factors","Evolution of consumption;Evolution of consumption","Depression;Anxiety symptoms;Stress related problems;Behavior and emotional problem among children and adolescents","Critical condition or death;IL-6","Undetectable COVID PCR at day 7","Adjusted Odds Ratio","Improved oxygen saturations =93%;Incidence of unexpected adverse events","Change in stress level as measured by survey","symptoms of COVID-19 in older patients","Outcome comparison between different antiviral therapies;Outcome comparisons between ventilation types;Identification of risk factors;Number of days in hospital vs. clinical classification","Number of ventilator-free days","Inflammatory cytokines change from baseline values;Inflammatory cytokines baseline concentrations;Complement parameters change from baseline values;Complement parameters;IL6 concentration change from baseline value;IL6 concentration","Dominant viral genome strain","Clinical skin manifestations","Burnout;Emotional Distress;Insomnia","Variation in HbA1c levels","Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx","14-Day Mortality","Incidence of serious adverse events associated with clazakizumab or placebo","overview of surgical management on preventive measures of hospital infection spread during covid 19","Change in respiratory status","Prevalence of oropharyngeal dysphagia","Proportion of patients remaining free of mechanical ventilation in both groups","Number of patients who screen eligible for donation;Number of patients who consent to plasma donation;Number of plasma donations received","Proportion of \"responder\" patients to prone position","Death rate;Transfer to intensive care unit;Ventilation analysis","Most severe outcome","Depression;Anxiety;Obsessive compulsive disorder","Rate of composite adverse outcomes","IgG and IgM anti SARS-CoV-2","Time to normalize the oxygen requirement (oxygeno-dependence)","28 day ventilator free days","Incidence of Mechanical Ventilation;Percentage of time in the assigned position","RT-PCR negative status","The change of viral load in patients with SARS-COVID-19.;The frequency of development of Acute Respiratory Distress Syndrome (ADRS);Duration of hospitalization;The frequency of early mortality;The frequency of late mortality;Clinical status at the time of completion of participation in the study","Changing of viral load of SARS-CoV2","i. Clinical status","Improvement of clinical status","Adverse effects and Safety","p/f ratio","Describe patient safety incidents (types, severity, contributing and correcting factors)","Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma","Number of patients with decreased viral load","The proportion of patients requiring mechanical ventilation;Mean days of ventilation","Survival without ventilation (VNI or mechanical ventilation);ventilator free survival","Proportion of surviving patients without need for intubation for respiratory support","Change in Viral Load in the nasopharynx over the course of COVID-19 infection;Change in microbial load in the nasopharynx;Change in SARS-CoV-2 mucosal immune response in the nasopharynx","Mean change in viral titers of SARS-CoV-2","Failed to attend patients","epidemiology","COVID-19 infection","Mortality;Severe disease","Recruitment Feasibility;Recourse utilization;Safety as reflected on the number and severity of adverse events and serious adverse events;Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.","Day-28 mortality","Need for hospitalization;Duration of hospitalization;Need for ICU/Ventilator Support;Duration of ICU/Ventilator Support;Overall Survival","number of patients with virological cure","Category Changes in Ordinal Scale","Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).","virus RNA and miRNA levels in tears;inflammatory response in tears","time to clinical improvement","Adverse effects","Time to achieve afebrile","Improvement on a 7-point Ordinal Scale;Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability)","Positive IgM/IgG tests;Positive IgM/IgG tests;Positive IgM/IgG tests;Comparison of the point of care test and Elisa;Comparison of the point of care test and Elisa;Comparison of the point of care test and Elisa;Re-infection rate;Re-infection rate;IgM/IgG positive participants on follow-up test;IgM/IgG positive participants on follow-up test",null,"Validity of the available rapid serological test for detecting COVID-19 virus infection;Adherence of health care workers to infection prevention;Risk factors for COVID-19 among health care workers;COVID-19 infection rate among health care workers;Risk categorization of healthcare workers","1. Mortality rate","Ventilation Mode;Tidal volume set;Expiratory tidal volume;Positive end-expiratory pressure;Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);;Level of pressure support above PEEP;Inspired fraction of oxygen;Set and measured respiratory rate;Inspiration to expiration ratio","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation","Spontaneous recovery or death in both groups","Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality","Change in O2 output","Time until cessation of oral shedding of SARS-CoV-2 virus","Survival without needs of ventilator utilization or use of immunomodulatory drugs;WHO progression scale =6","Exploring the presence of COVID-19","Descriptive-epidemiological analysis of health conditions","Viral load","Changes of oxygenation index (PaO2/FiO2);Side effects in the BM-MSCs treatment group","Number of mechanical ventilation days.","Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit","Visual Analogue Scale;Modified Borg Scale;Leicester Cough Questionnaire;Timed Up and Go;30 Second Chair Stand Test;The Beck Depression Inventory;The Beck Anxiety Inventory","Proportion of symptomatic patients with immune response (IgM/IgG/IgA);Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)","Incidence of hospitalization for COVID-19;Incidence of symptoms associated with COVID-19","rate of recruitment;rate of attendence","Treatment failure rate","International Physical Activity Questionnaire - Short Form;Nottingham Health Profile;Beck Depression Inventory;Beck Anxiety Inventory;Pittsburgh Sleep Quality Index;Timed Get Up and Go Test;Flamingo Balance Test","Time of physiotherapy;Time of physiotherapy;Time of physiotherapy","Survival without needs of intubation at day 14;Change in organ failure at day 3","Time to Improvement in the 7-point ordinal scale","Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result;Clinical accuracy of the rapid tests based on Clinical diagnosis;Self-test interpretation of result vs expert clinical image interpretation of result","Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:","Prevalence of SARS-CoV-2 antibody titres","To evaluate the safety and efficacy of vazegepant compared with placebo in patients hospitalized with COVID-19 infection requiring supplemental oxygen.","All-cause mortality at Day 28","SARS-Cov2 positive molecular testing of throat/nasal swabs;Immunoglobulins (G and M) to SARS-Cov2 in plasma;Blood cytokine levels","Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice;Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice;Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice","discrimination;Calibration;Net benefit","Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)","Days required to get a positive COVID-19 PCR to negative;HRCT/ X-ray findings of disease prgression;Severity of symptoms progression;Duration of Hospital Saty;30 day mortality","Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2","Success rate in production of SARS-CoV-2 specific T cells from convalescent donor","Number of confirmed COVID-19","Pneumonia severity index;Need for ICU admission","Presence of sHLH as determined by expert chart review by two independent reviewers;Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection;Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin &gt; 10000 g/L) in Covid 19 viral infection;Characterization and incidence of the hyper-inflammatory state in COVID-19","Status of Immunization","ICU length of stay;Safety of convalescent plasma &amp; Serious adverse reactions.","Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group","intrapulmonary shunt ratio","MDR pathogens in endotracheal aspirates","COVID-19 Seroconversion rate","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs);Phase 2: Cumulative incidence of serious adverse events (SAEs);Phase 2: Changes in white blood cell count (CBC) through Day 15;Phase 2: Changes in hemoglobin through Day 15;Phase 2: Changes in platelets through Day 15;Phase 2: Changes in creatinine through Day 15;Phase 2: Changes in glucose through Day 15;Phase 2: Changes in prothrombin time (PT) through Day 15;Phase 2: Changes in total bilirubin through Day 15;Phase 2: Changes in ALT through Day 15;Phase 2: Changes in AST through Day 15;Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS);Phase 2: Changes in hemoglobin through End of Study (EOS);Phase 2: Changes in platelets through End of Study (EOS);Phase 2: Changes in creatinine through End of Study (EOS);Phase 2: Changes in glucose through End of Study (EOS);Phase 2: Changes in prothrombin time (PT) though End of Study (EOS);Phase 2: Changes in total bilirubin through End of Study (EOS);Phase 2: Changes in ALT through End of Study (EOS);Phase 2: Changes in AST through End of Study (EOS);Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15","Disease-Aggrevation","The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)","Delta decrease in arterial partial pressure of carbon dioxide during ECCO2R treatment","Anxiety and depression represent a composite primary outcome, as measured by the Hospital Anxiety and Depression scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 15). ]","Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate);Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate","Describe patient safety incidents (types, severity, contributing and correcting factors)","Days alive without life support at day 28","Evaluate the safety and efficacy of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement","The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.","To determine SARS-CoV-2 viral load and infectivity insaliva that may contribute to asymptomatic transmission","Scores on the Perceived Stress Scale.  The PSS is a widely used measure of the appraisal of how stressful events over the previous month are.  Scores range from 0 to 40 with higher scores representing higher levels of stress. [Perceived Stress Scale scores will be measured at baseline and following a 12 week intervention period, with the primary time point of interest being scores post the 12 week intervention period.]","Percentage of patients who develop severe respiratory failure.","viral COVID-19 clearance","intensive care treatment","Change in Clinical Condition","Anxiety assessed by the State-Trait Anxiety Inventory (STAI)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement).];Depression symptoms by the the Beck Depression Inventory (BDI-13)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement)..];Stress by the Perceived Stress Scale (PPS-10)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement)..]","Assessment of weaning from cardiorespiratory support","\"Labor Agentry Scale questionnaire\" score in immediate post-partum (duration of hospital stay)","To determine the rate of front-line healthcare workers at Albury Wodonga Health who demonstrate SARS-CoV-2 antibody seroconversion [Monthly for six months following enrollment or until presentation of Coronavirus symptoms]","Intubation or death in hospital","Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale","Registry Data","Number of symptomatic illness in at risk healthcare workers;Number of healthcare workers with symptomatic COVID infections;Number of severe illness in at risk healthcare workers","Prevalence COVID antibodies in employees of Beaumont Health","Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.","&lt;br&gt;                1. Respiratory rate, assessed by clinical observation at baseline and at the end of the 4-hour workday&lt;br&gt;                2. Oxygen saturation, assessed using a Physio LifePAK 15 monitor at baseline and at the end of the 4-hour workday&lt;br&gt;                3. Heart rate, assessed using a Physio LifePAK 15 monitor at baseline and at the end of the 4-hour workday&lt;br&gt;                4. Blood pressure, assessed using a Physio LifePAK 15 monitor at the start of the study and at the end of the 4-hour workday&lt;br&gt;                5. Tympanic temperature evaluated using a Braun ThermoScan PRO 6000 model at baseline and at the end of the 4-hour workday&lt;br&gt;                6. Weight, with the TANITA BC 545-N scale at baseline&lt;br&gt;                8. Size, with the SECA 206 tape measure at baseline&lt;br&gt;                9. Analytical biomarkers: pH, pCO2, pO2, cHCO3-, BE (ecf), cSO2, Na +, K +, Ca ++, Cl-, TCO2, Agap, AGapK, Hct, Hb, BE (b), Glu , Lac, BUN, Urea and Crea, evaluated using COPD Siemens Healthcare at baseline and at the end of the 4-hour workday&lt;br&gt;                10. Medical history of interest, through a structured questionnaire at baseline&lt;br&gt;                11. Level of physical activity using the IPAQ questionnaire at baseline&lt;br&gt;","Viral clearance;Clinical improvement","ICU CV risk and Biomarker (e.g. Troponin)","Improvement in FMTVDM Measurement with nuclear imaging.","A composite score based on all-cause mortality and the number of ventilator free-days (VFD)","Extravascular lung water index EVLWI measured using TPTD (PiCCO; Pulsion Medical Systems; Feldkirechen Germany) daily from intubation until extubation","Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device;Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device;Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients","anxiety;anxiety;anxiety;anxiety","Changes in the patients' clinical status through the 7 points ordinal scale WHO;Changes in IL-6 concentrations","Safety and Tolerability of SAD of TD-0903: Adverse Events;Safety and Tolerability of MAD of TD-0903: Adverse Events","Incidence of hospitalization for COVID-19;Incidence of symptoms for COVID-19","Time to negative NPS viral load","Time to resolution of symptoms","Number of different arrhythmias;Temperature;Oxygen Saturation","RT-PCR negative status","Frequency of RA patients with emotional impact (feeling of isolation)","Number of patients with viral cure","To assess the clinical and treatment patterns of patients with COVID-19.","Incidence of pandemic COVID-19 in pregnancy assessed as proportion of pregnant women hospitalised with confirmed COVID-19 disease per 100,000 maternities during the study period","Tolerability of high dose HCQ as measured by HCQ dose modification;Tolerability of high dose HCQ as measured by discontinuation of HCQ;Tolerability of High Dose HCQ as measured by Adverse Events","Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 27 (nave/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled);Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled);Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled);Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled);Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).;Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).;Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)","Time to clinical improvement","Time to clinical improvement","Incidence of in-hospital cardiac complications. This data will be collected from hospital medical records.[Discharge from hospital]","Proportion of health care workers (HCW) contracting an lower respiratory illness necessitating workforce removal, assessed from workforce information including rosters and medical records.[Assessed at the end of month 3, prior to the wait-list control (WLC) commencing treatment.]","Ventilation free survival days  as assessed by reviewing medical records[At 90 days after initiation of mechanical ventilation]","percentage of patient with feeling of disabilities","sustained improvement (&gt;48h) of one point on the WHO Scale","incidence of confirmed COVID-19;Effectiveness of BCG vaccine","percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)","Proportion of participants alive and not having required intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen flow) at 15 days after enrolment.&lt;br&gt;&lt;br&gt;This outcome is assessed by the number of patients who are not admitted into the intensive care unit (ICU)&lt;br&gt;&lt;br&gt;[15 days after enrolment]","All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study","Feasibility. Measured by:&lt;br&gt;1. Participant retention (in program and completion of questionnaires).&lt;br&gt;2. Usage of the Facebook group (manual calculation of the sum of comments &amp; likes)&lt;br&gt;3. Feasibility and acceptability questionnaire (modified version of Naslund et al's (2016) Feasibility and Acceptability questionnaire) [Post intervention (week 6)];SIDAS- Suicidal Ideation Attributes Scale[Post intervention (week 6)]","Occurrence of COVID-19 infection, as assessed by clinical signs, serology and/or RT-PCR testing. Date of occurrence, clinical symptoms and laboratory results will be collected. The endpoints will be collected by periodic monthly reports obtained on questioning the study participants. Participants and the treating healthcare institutions will be contacted to obtain respective information.","Safety and tolerability of UCB cell administration (absence of immediate and short-term side effects, including allergic reactions, line related effects, infection)&lt;br&gt;This will be assessed based on partipant rports, and hospital charts and monitoring[24 hrs (collection of hourly vital monitoring data, examination at 24 hrs)];Clinical improvement, as documented by change of patient status on a seven-category ordinal scale (to be completed by hospital staff or researcher)&lt;br&gt;Seven-category ordinal scale:&lt;br&gt;1, not hospitalised with resumption of normal activities; 2, not hospitalised, but unable to resume normal activities; 3, hospitalised, not requiring supplemental oxygen; 4, hospitalised, requiring supplemental oxygen; 5, hospitalised, requiring humidified nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 6,hospitalised, requiring ECMO, invasive mechanical ventilation, ECMO or both; and 7, death.[ Assessed every day until resolution of symptoms or death]","The need for hospital admission or death, for patients aged =50 years with comorbidity, and aged =65 with or without comorbidity and suspected COVID-19 infection during time of prevalent COVID-19 infections, measured by hospital admission or mortality related to suspected COVID-19 within 28 days","Number of hospitalised patients who died within 28 days of randomisation, data collected via a secure web-based case report form","&lt;br&gt;                1. Incidence and risk factors for invasive aspergillosis (IA) in the study cohort (as per modified AspICU criteria):&lt;br&gt;                1.1. Diagnostic classification of Influenza-associated aspergillosis (IAA) during ICU admission as per modified AspICU criteria, determined at the end of ICU stay&lt;br&gt;                1.2. Risk factors to be elicited from baseline clinical data points collected at enrolment (within three days of ICU admission) and ICU therapeutics/interventions collected at the end of ICU stay&lt;br&gt;","Microbiologically confirmed COVID-19 (i.e. SARS-CoV-2 infection). This is a composite endpoint which includes any validated SARS-CoV-2 diagnostic assay, including detection of viral RNA and seroconversion, performed on participant viral detection samples throughout the study period or venous samples for serologic testing collected at day 0, 30, 60, 90 and 120.","COVID-19 Anxiety (adapted SARS-Anxiety-Scale) at 3 time periods of 2 weeks over 6 months","Critical event rate;Critical event rate;","&lt;br&gt;                1. Efficacy of candidate vaccine measured by virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 6 months&lt;br&gt;                2. Safety of candidate vaccine measured by the occurrence of serious adverse events (SAEs) over the course of 6 months&lt;br&gt;","Incidence of invasive mechanical ventilation (IMV) and/or Mortality","Number of patients with virological cure","Time to achieve afebrile;Severity of symptom score","Days alive and out of hospital within 14 days after recruitment","Composite outcome comprising tracheal intubation or mortality within 30 days. Mortality will be reported from hospital records up until discharge and tracked after discharge. Intubation will be obtained from hospital data.","Relief time and rate of symptoms of laryngeal discomfort, sore throat, dry and hot pharynx, and pharyngeal mucosal congestion;New fever, cough, muscle soreness, headache, the time it takes for symptoms to disappear or to subside;Symptom scores;Occurrence of adverse events/reactions;","Mental health index;","Clinical improvement","Anxiety 1 month","Blood routine;Blood biochemistry;C-reactive protein;chest CT;2019-ncov-RNA;TCM symptom;","Diagnosis of COVID-19 on lung ultrasound;Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray","Recorded tidal volumes whilst continuously using the pandemic cuirass ventilator for 60 minutes. Tidal volumes will be recorded using a face mask connected to an existing GE Anaesthetic Machine.[Tidal volumes will be assessed every 15 minutes. Total sedation time will be 60 minutes.]","Patient comfort and tolerability as assessed by a 6 point question item originally developed for CPAP use.  We will use a modified version of the 6 point scale developed by Balachandran et al JCSM 2013.  It is a 6 point Likert scale.[At 24 hours after initiation of therapy and every subsequent 24 hours of use of the mask until disposition from hospital.]","To determine proportion of people with nucleic acid test (NAT) negative nasopharyngeal swab for SARS-CoV-2 (nasopharyngeal NAT) while exhibiting symptoms consistent with COVID-19 disease who then develop SARS-CoV-2 antibody seroconversion prior to, and during, the development of widespread community transmission.[Approximately 14 to 28 days after developing Coronavirus symptoms]","the prevalence of depression which will be assessed by the 9-item Patient Health Questionnaire[Assessed at baseline];the prevalence of anxiety, which will be assessed by the 7-item Generalized Anxiety Disorder scale[Assessed at baseline];the prevalence of insomnia, which will be assessed by the 7-item Insomnia Severity Index. [Assessed at baseline]","Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus.  Virus concentration is  measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]","Changes in anxiety and depression scale scores;difference between two interventions;","SARS-CoV-2;IgM;IgG;","&lt;br&gt;                1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection&lt;br&gt;                2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:&lt;br&gt;                2.1. Type of procedure performed&lt;br&gt;                2.2. Time taken from presentation to the surgical team to intervention&lt;br&gt;                2.3. Mode of referral (primary vs. secondary care)&lt;br&gt;                2.4. Site of surgery  hub or spoke hospital&lt;br&gt;                2.5. Imaging modalities used and timings&lt;br&gt;                2.6. Emergency classification i.e. urgent/emergency/elective&lt;br&gt;                2.7. Operative technique(s) and device(s) used&lt;br&gt;                2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)&lt;br&gt;                2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)&lt;br&gt;                2.10. Documentation of changes to usual practice for this specific procedure as per surgeons standard protocol (type of procedure, type of anaesthetic, post-procedural destination)&lt;br&gt;                3. Management of all referred urgent vascular cases using the online survey, focusing on:&lt;br&gt;                3.1.  Chronic Limb Threatening Ischaemia (CLTI):&lt;br&gt;                3.1.1. Decision to discharge/admit/refer to a \"hot\"/emergency clinic&lt;br&gt;                3.1.2. Decision for endovascular or open surgery first&lt;br&gt;                3.1.3. Decision for best medical therapy or palliation or primary amputation&lt;br&gt;                3.2. Carotid disease:&lt;br&gt;                3.2.1. Number of patients managed with best medical therapy (BMT)&lt;br&gt;                3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)&lt;br&gt;                3.2.3. Delays to treatment due to lack of theatre/bed availability&lt;br&gt;                3.3. Abdominal Aortic Aneurysm (AAA)&lt;br&gt;                3.3.1. Increasing use of Endovascular repair (if applicable)&lt;br&gt;                3.3.2. Changes to criteria for intervention&lt;br&gt;                3.3.3. Decisions for palliation, i.e. turn down&lt;br&gt;                3.4. Acute Aortic syndrome (AAS)&lt;br&gt;                3.4.1. Decision to manage in non-critical care beds&lt;br&gt;                3.4.2. Changes to imaging protocol at unit level&lt;br&gt;                3.4.3. Decision to defer surgery&lt;br&gt;","the rate of 2019-nCoV RNA positive;","Delineate the true prevalence of SARS-CoV-2 infection in Hong Kong;Estimate the size of outbreak at different periods;Understand the epidemiology and characteristics of asymptomatic and mild infections;","pregnancy maternal complications;labor complications;mode of delivery;birth weight;Neonatal disease;Apgar score;neonatal infection;NICU admitting rate;neonates with COVID-19;","Patients will receive regular care as indicated by the treating physician. LUS is performed immediately in  the  Emergency  Department  or after  admissionto  the hospital. SARS-CoV-2  PCR testing  will  be performed along with standard laboratory testing and other microbiological tests to detect pathogens that cause respiratory tract infection.CT-scan during admission is only performed if this is clinically indicated or protocol during COVID outbreak.","Insomnia severity measured using the Insomnia Severity Index at one week post-intervention","Hospital admission for any reason among patients who tested positive for SARS-CoV-2 within 30 days following initial consultation for SARS-CoV-2 testing. Information will be collected from participants via follow-up phone calls at days 7, 14, and 60 after consultation, as well as via patient records from general practitioners and/or treating physicians in hospitals after 60 days.","cough;Degree of expiratory dyspnoea;","Time to disease recovery;Exacerbation (transfer to RICU) time;","28-day mortality;","temperature;area of facial indents;gray level of facial indents;pain;","mortality and end of mechanical respiratory support.","Oxygenation index;","sensitivity;specificity;accuracy;","Timepoint(s) of evaluation of this end point: D28;Primary end point(s): The primary assessment criterion is the number of antibiotic free days at D28, which corresponds to the number of days alive without any antibiotic at Day 28. The D28 time point is usual in studies assessing antibiotic use in ICU patients.;Secondary Objective: Mortality rates at 28 (D28) and 90 days (D90); &lt;br&gt;- Overall antibiotics use, including broad- and narrow-spectrum antibiotics;&lt;br&gt;- Total exposure to antibiotics at D28;&lt;br&gt;- Number of organ-failure free days at D28;&lt;br&gt;- Incidence rates of bacterial super-infections and colonization/infection with resistant pathogens at D28;&lt;br&gt;- ICU and hospital lengths of stay;&lt;br&gt; - Quality of life at D90.;Main Objective: To assess the efficacy of a management strategy combining a broad panel respiratory mPCR and an algorithm of early antibiotic de-escalation and discontinuation based on both the mPCR results and the procalcitonin, on antibiotics exposure, as compared with a conventional strategy, in severe confirmed COVID-19 pneumonia.","Blood routine tests;Liver function;Renal function;CK-MB;B-BNP;myoglobin;Hypersensitive troponin;Interleukin - 6;Tumor necrotizing factor-alpha;Interleukin - 10;","syndrome;nucleic acid of nCoV-19;blood count;liver and kidney function;cardiac enzymes;lung CT;","Timepoint(s) of evaluation of this end point: End of study as defined by 3 months following last inclusion;Primary end point(s): The primary efficacy outcome of hospitalization due to SAR-COV-2 infections will be compared between patients allocated hydroxychloroquine and no treatment.;Secondary Objective: Not applicable;Main Objective: The main objective of the following multicentre parallel-group open randomized clinical trial aims to investigate the benefit, tolerability, and safety of initiating prophylactic hydroxychloroquine versus no treatment in patients on chronic dialysis in Denmark. The anticipated results from this project will provide evidence as to the appropriateness of initiating prophylactic treatment for prevention of symptomatic SAR-COV-2 in dialysis populations with direct effects on clinical management and guidelines pertaining to these patients.","Our primary study parameter is the percentage of participants with a positive IgM or IgG response admitted to the hospital.","To assess achieved immunity against COVID-19 across the different age groups in The Netherlands by testing a representative part of&lt;br&gt;the Dutch population for the presence of SARS-Cov-2 specific antibodies in serum","-To describe the clinical presentation (symptoms) of pregnant women who tested positive on SARS-CoV-2&lt;br&gt;-To describe the clinical course of COVID-19 infection during pregnancy","Environment viral load;","-\tComposite endpoint with disease progression defined as a NEWS2score = 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.","Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","Main Objective: To investigate the effect of the ARB valsartan in comparison to placebo on the occurrence of one of the following items, within 14 days of randomization:1) ICU admission; 2) Mechanical ventilation; 3) Mortality.;Secondary Objective: \tDeath within 14 days, 30 days, 90 days and at 1 year, defined as all-cause mortality.&lt;br&gt;\tMechanical ventilation and ICU admission within 14 days.&lt;br&gt;\tTime to ICU admission, mechanical ventilation and death.&lt;br&gt;\tOccurrence of acute kidney injury within 14 days defined as a 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of &gt;30 ml/min/1.73m2 and to a value below 60 ml/min/1.73m2.&lt;br&gt;;Primary end point(s): The primary study endpoint is the occurrence within 14 days of randomization of either: 1) ICU admission; 2) Mechanical ventilation; 3) Death.  ;Timepoint(s) of evaluation of this end point: The occurrence of the main study endpoint will be assessed on a daily basis.","Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","Timepoint(s) of evaluation of this end point: The primary measure of the PaO2/FIO2 ratio will be done 72-hours after&lt;br&gt;randomization. This time point was chosen to allow adequate time for&lt;br&gt;the interventions to work while avoiding missing data due to deaths.;Primary end point(s): The primary outcome will be the PaO2/FiO2 ratio 72 hours after&lt;br&gt;randomization. The PaO2/FiO2 ratio will be calculated based on the&lt;br&gt;arterial gas closest to the time-point of 72 hours after randomization. If&lt;br&gt;no clinically-indicated arterial gas is performed or planned within  2&lt;br&gt;hours of the time-point, an arterial gas will be performed. The ratio will&lt;br&gt;be calculated based on the PaO2 from the arterial gas and the FiO2 at&lt;br&gt;the same time point. If the patient is receiving mechanical ventilation&lt;br&gt;(invasive or non-invasive) or is receiving oxygen through a high-flow&lt;br&gt;nasal cannula, the FiO2 will be obtained directly from the ventilator. If&lt;br&gt;the patient is receiving oxygen through a regular nasal cannula, the FiO2&lt;br&gt;will be calculated based on the following: FiO2 = 21% + 4%/(l/min) x&lt;br&gt;O2 flow in l/min. For face masks, with or without reservoir, the FiO2 will&lt;br&gt;be estimated based on the approach used in EPIC2.40,41 Patients who&lt;br&gt;dies prior to the 72-hour time point will be handled as described in&lt;br&gt;Section 6.2.3.&lt;br&gt;&lt;br&gt;The PaO2/FiO2 ratio is a commonly used measure of illness severity in&lt;br&gt;patients with acute lung injury and ARDS and is used to define these two&lt;br&gt;conditions.17 Furthermore, the PaO2/FiO2 ratio is associated with&lt;br&gt;mortality17,20 making it a potential useful surrogate outcome for phase&lt;br&gt;II trials. Although data is sparse, a lower PaO2/FiO2 ratio has also been&lt;br&gt;associated with worse outcomes in patients with COVID-19.10,42&lt;br&gt;Furthermore, animal studies in mice have shown that Senicapoc&lt;br&gt;improves the PaO2/FiO2 ratio in experimentally induced ARDS (Section&lt;br&gt;1.3.2). Based on these considerations, and the fact that hypoxemic&lt;br&gt;respiratory failure is the hallmark of severe COVID-19 infection, the&lt;br&gt;PaO2/FiO2 ratio is a reasonable primary outcome for a phase II trial.&lt;br&gt;The primary measure of the PaO2/FiO2 ratio will be done 72-hours after&lt;br&gt;randomization. This time-point was chosen to allow adequate time for&lt;br&gt;the intervention to work while avoiding missing data due to deaths.;Secondary Objective: Not applicable;Main Objective: To treat respiratory insufficiency due to COVID19","Number of people that download the app and choose to check their health, perform the self-assessment and use the 7 day self-reported symptoms diary for one or more days.","A change in the two-dimensional variable (SpO2, RR), the combination of oxygen saturation and respiratory rate.&lt;br&gt;SpO2 is measured with a pulse oximeter and RR is derived from the pressure changes in the mouth compartment of the mask. &lt;br&gt;","Timepoint(s) of evaluation of this end point: 7, 14, 21, 28, 90, 120 and  365 post-administratin.;Primary end point(s): \tAdverse events&lt;br&gt;\tAverage stay in the ICU &lt;br&gt;\tSOFA index &lt;br&gt;\tMechanical ventilation;Secondary Objective: To assess the preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome.;Main Objective: To assess the feasibility, safety and tolerability of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome.","Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Time to clinical improvement, defined as the time from randomization to a two-point improvement (from randomization status) on an ordinal scale of seven categories or hospital discharge, whichever occurs first.&lt;br&gt;&lt;br&gt;The seven-category ordinal scale consisted of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and 7, death.;Secondary Objective: To evaluate:&lt;br&gt;-Clinical status of patients on days 7 and 14 later than the treatment initiation.&lt;br&gt;-Proportion of patients discharged on day 14&lt;br&gt;-28-day mortality rate&lt;br&gt;-Proportion of patients who required mechanical ventilation and days of duration&lt;br&gt;-Days of hospital stay of patients who have survived to 28 days&lt;br&gt;-Time since start of treatment to death of the patient&lt;br&gt;-Possible serious adverse events related to sarilumab and possible causes of discontinuation of sarilumab treatment&lt;br&gt;to analyze:&lt;br&gt;-type of medications received during admission and days since onset of symptoms to starting glucocorticoids&lt;br&gt;-the evolution of prognostic factors: IL6, D-dimer, ferritin, calprotectin;Main Objective: To assess the efficacy and safety of early treatment of sarilumab, added to standard treatment, in patients hospitalized for mild-moderate COVID-19 pneumonia, with criteria of a CURB 65 less than or equal to 1, oxygen saturation equal to or greater than 90%, MEWS less than 3 and with IL6 greater than 20 pg / mL.","28-day mortality","Elevation of proper hygiene behaviour (behavioural change)","Main Objective: To assess the efficacy of the association of CsA with standard treatment in reducing the severity of COVID19-confirmed infection in hospitalized patients.;Secondary Objective: -To assess the efficacy of CsA in combination with standard treatment in reducing mortality, days in hospital, days in ICU beds, and FiO2.&lt;br&gt;- Compare the evolution of BP, plasma creatinine, lymphocyte count, lymphocyte activation markers and CD4 between both groups.&lt;br&gt;- To evaluate the safety of the association of CsA with the standard treatment of hospitalized patients with confirmed infection by COVID19.&lt;br&gt;- To study the possible differences in the modification in the viral load and the seroconversion parameters (IgM and IgG to the virus) throughout the process in both groups.&lt;br&gt;-To assess the incidence of the use of CsA in combination with standard treatment in the reduction of ferritin, LDH and PCR levels from admission, in the CPK and D-dimer peak, in the KL6 peak and in IL6 levels at the same time. throughout evolution.&lt;br&gt;- Evaluate the relationship between CsA doses (mean in mg / kg / day and accumulated) and improvement parameters.;Primary end point(s): Proportion of patients in a non-serious category at 12 days of treatment;Timepoint(s) of evaluation of this end point: At 12 days of treatment","Diagnostic accuracyof LUSand CT in COVID-19 patients","Timepoint(s) of evaluation of this end point: D11;Primary end point(s): At least 1 level improvement in clinical status assessed by a level ordinal scale (at least 1 level) between D1 and D11 :&lt;br&gt;1. Not hospitalized, no limitation of activities&lt;br&gt;2. Not hospitalized, limitation of activities;&lt;br&gt;3. Hospitalized, not requiring oxygen supplementation&lt;br&gt;4. Hospitalized, requiring oxygen supplementation&lt;br&gt;5. Hospitalized, non-invasive ventilation or high flow oxygen device&lt;br&gt;6. Hospitalized, under invasive mechanical ventilation or ECMO (extracorporeal membrane oxygenation)&lt;br&gt;7. Death;Secondary Objective: - Evaluation of the safety  of  a bitherapy  by hydroxychloroquine + azythromycin vs  monotherapy by hydroxychoroquine&lt;br&gt;- Need of oxygenotherapy&lt;br&gt;- virological, and pharmacokinetic assessment of each treatment&lt;br&gt;-PAtient transfer in ICU.&lt;br&gt;- hospitalization duration&lt;br&gt;Vital status&lt;br&gt;Adverses event;Main Objective: Evaluation of efficacy of a bitherapy  by hydroxychloroquine + azythromycin vs  monotherapy by hydroxychoroquine administered for 10 days, on patient infected with SarS COV 2 with either a moderate clinical form (level 3), or a severe non-resuscitative clinical form (level 4)","time to liberation from ventilation and supplemental oxygen and alive during a 28day period after randomization","30-day mortality (from randomization)","Main Objective: Rduire le nombre de patients prsentant une indication thorique de transfert en ranimation dindication respiratoire, value par une SpO2 &lt; 90% stabilise au repos et sous un dbit doxygne ne dpassant pas 5 L/min doxygne au masque  moyenne concentration  J7 de la randomisation (soit J14 des symptmes 5 jours). Ce critre permet de dterminer objectivement la gravit de ltat respiratoire du patient.;Secondary Objective: Evalus  la visite 3, J7 de la randomisation (soit J14 des symptmes 2jours) : &lt;br&gt;-\tRduire la gravit sur une chelle ordinale  7 niveaux &lt;br&gt;-\tRduire les besoins en oxygnothrapie&lt;br&gt;-\tRduire les signes radiologiques visibles sur limagerie thoracique&lt;br&gt;&lt;br&gt;Evalus  la visite 4, J21 de la randomisation (soit J28 des symptmes 2jours) : &lt;br&gt;-\tRduire le nombre de patients transfrs en ranimation ou soins intensifs&lt;br&gt;-\tRduire le nombre de patients ncessitant un recours  la ventilation invasive&lt;br&gt;-\tRduire la dure de loxygnothrapie&lt;br&gt;-\tRduire la dure dhospitalisation  partir de la randomisation&lt;br&gt;-\tEvaluer la tolrance de la corticothrapie et la frquence des complications induites par la corticothrapie&lt;br&gt;-\tEvaluer la frquence des infections autres que SARS-CoV-2&lt;br&gt;-\tEvaluer la mortalit globale  J21 (J28 des symptmes)&lt;br&gt;;Primary end point(s): Nombre de patients  J7 de la randomisation (soit J14 des symptmes 5 jours), prsentant une indication thorique de transfert en ranimation dindication respiratoire value par une SpO2 &lt; 90% stabilise au repos et sous 5 L/min doxygne au masque  moyenne concentration mesure deux fois  5-15 min dintervalle. La valeur moyenne des deux mesures sera retenue.;Timepoint(s) of evaluation of this end point: J14 des symptmes 5 jours","Primary end point(s): Discharge from the patient or death;Timepoint(s) of evaluation of this end point: The main result is all-cause mortality, subdivided by disease severity at the time of randomization.;Main Objective: Provide reliable estimates of the effects of these antiviral treatments on hospital mortality.;Secondary Objective: The secondary objectives are to evaluate the effects of these antiviral treatments on the length of the hospital stay and on the reception of ventilation or intensive care.","Timepoint(s) of evaluation of this end point: 16 weeks;Primary end point(s): Number of symptomatic infections confirmed by SARS-CoV-2 (COVID-19);Secondary Objective: o Evaluate the efficacy of melatonin in the prevention of asymptomatic SARS-CoV-2 infections (COVID-19).&lt;br&gt;o To evaluate the efficacy of melatonin in preventing the development of severe COVID-19 in participants who acquire the infection during the development of the study.&lt;br&gt;o Assess the duration of symptoms of COVID-19 infection in participants receiving melatonin.&lt;br&gt;o Assess IgM / IgG seroconversion from symptom detection;Main Objective: The main objective is to evaluate the efficacy of melatonin in the prevention of SARS-CoV-2 infection in healthcare personnel with high-risk contacts.","Main Objective: The main objective of this study is to evaluate the survival interest of Hydroxychloroquine 400 mg, Telmisartan 80 mg, Azithromycin 500 mg and Curcumin 800 mg daily on the survival of elderly patients with VIDOC-19 at 2 weeks from the start of treatment.;Secondary Objective: To evaluate adverse events, and particulary serious adverse avent.&lt;br&gt;ToEvaluate the effectiveness of different treatments on :&lt;br&gt;- SARS-Cov-2&lt;br&gt;- Survival to 4 weeks&lt;br&gt;- Inflammation&lt;br&gt;- The confusion &lt;br&gt;- Walking&lt;br&gt;- Functional capabilities&lt;br&gt;- Breathing rate&lt;br&gt;-Oxygen therapy&lt;br&gt;- Pulse rate&lt;br&gt;- Systolic and diastolic blood pressure &lt;br&gt;- Temperature&lt;br&gt;- Pneumonia&lt;br&gt;- Discharge&lt;br&gt;- Transfer to a convalescent hospital (SSR or equivalent)&lt;br&gt;- Necessity of add-on coritcosteroids or other immunomodulator or immunosuppressor&lt;br&gt;- Oxygen therapy&lt;br&gt;- The impulse rate&lt;br&gt;- Systolic and diastolic blood pressure&lt;br&gt;- The temperature&lt;br&gt;- Pneumonia&lt;br&gt;- The return home&lt;br&gt;- Disclaimer&lt;br&gt;- Transfer to a convalescent hospital (RHS or equivalent)&lt;br&gt;- The need for treatment with complementary, immonumodulating or immunosuppressive corticosteroids.;Primary end point(s): The primary endpoint will be two-weeks survival rate.;Timepoint(s) of evaluation of this end point: 14 days","Timepoint(s) of evaluation of this end point: Day 28 after treatment initiation;Primary end point(s): Mortality at day 28 after treatment initiation  (proportion of patient died that day);Secondary Objective: To assess the impact of this strategy on the following variables: premature mortality (48 hours, 7 days and at hospital), mortality at intensive care unit, days of mechanical ventilation, virus clearance (viral clearance / viral shedding), time to normalization of oxygen saturation , time to defervescence, improvement of inflammatory reaction, days of hospitalization, days of intubation, safety and tolerability of the intervention;Main Objective: To assess the mortality impact at 28 days of an immunomodulatory strategy with 2 treatment regimens stratified according to IL-6 plasma levels, administered in addition to standard treatment, in adult patients with severe COVID-19 pneumonia.","Main Objective: To assess the efficacy as determined by the proportion of patients with normalization of SpO2 =96% of continued standard care together with tocilizumab plus pembrolizumab (MK-3475) in patients with COVID-19 pneumonia who are nonresponsive to frontline therapy within 48 hours from treatment initiation.;Secondary Objective: To assess the efficacy as determined by:&lt;br&gt; the proportion of patients with normalization of fever of study drugs in this population.&lt;br&gt; the proportion of discharged patients of study drugs in this population.&lt;br&gt; the duration of hospitalization of study drugs in this population.&lt;br&gt; the Sequential Organ Failure Assessment (SOFA) of study drugs in this population.&lt;br&gt; the mortality rate of study drugs in this population.&lt;br&gt; the remission of respiratory symptoms of study drugs in this population in terms of:&lt;br&gt;      -Time to invasive mechanical ventilation;&lt;br&gt;      -Time to independence from oxygen therapy.&lt;br&gt; the radiological response of study drugs in this population.&lt;br&gt; the severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 negativization of study drugs in this population.&lt;br&gt;the change in laboratory parameters of study drugs in this population.&lt;br&gt;To evaluate the safety and tolerability of study drugs in this population.;Primary end point(s): Percentage of patients with normalization of SpO2 =96% through day 14 after study treatment initiation;Timepoint(s) of evaluation of this end point: through day 14 after study treatment initiation.","Main Objective: Evaluer lefficacit dune forte dose de cholecalciferol 400 000 UI per os en une fois versus une dose standard de 50 000 UI per os en une fois sur le taux de dcs  14 jours (J14) chez les patients gs ayant ;Secondary Objective: 1) Evaluer lefficacit de la forte dose de cholecalciferol versus la dose standard sur : &lt;br&gt;2) Evaluer la tolrance de la forte dose de cholecalciferol versus la dose standard sur la survenue dvnements indsirables graves&lt;br&gt;3) Evaluer lefficacit de la forte dose de cholecalciferol versus la dose standard dans le sous-groupe des participants ayant une hypovitaminose D svre  linclusion, cest--dire ayant une concentration srique de 25-OHD &lt;25 nmol/L  J1&lt;br&gt;4) Evaluer limpact de la concentration srique de 25-hydroxyvitamine D  J7 (&lt; 75 nmol/L versus = 75 nmol/L) sur le taux de dcs  J14 et J28 et lvolution clinique (chelle OSCI)  J14 et J28 &lt;br&gt;5) Dans le sous-groupe des participants prsentant une hypovitaminose D svre initiale (25-OHD &lt;25 nmol/L  J1), comparer le taux de dcs et lvolution clinique (chelle OSCI)  J14 et J28 en fonction de la concentration srique de 25-OHD atteinte  J7 (&lt; 75 nmol/L versus = 75 nmol/L).&lt;br&gt;;Primary end point(s): Le critre dvaluation principal est la survenue dun dcs quelle quen soit la cause dans les 14 jours (J14) suivant linclusion et le dbut du traitement (J1).;Timepoint(s) of evaluation of this end point: Le critre dvaluation principal est la survenue dun dcs quelle quen soit la cause dans les 14 jours (J14) suivant linclusion et le dbut du traitement (J1).","Timepoint(s) of evaluation of this end point: Day 14 after treatment initiation;Primary end point(s): - The mean reduction in viral load at day 14 after recruitment among those women infected by SARS-CoV-2, in the ITT and ATP cohorts, adjusted by age, gravidity, region(municipality) and other variables associated with the prevalence and viral load of SARS-CoV-2 infection. &lt;br&gt;- The comparison of the proportion of pregnant women who were close contacts of confirmed cases of SARS-CoV-2 infection, with a positive PCR for the infection at day 14, in the ITT and ATP cohorts, adjusted by adjusted by age, gravidity, region(municipality) and other variables associated with the prevalence of SARS-CoV-2 infection.;Secondary Objective: 1.\tTo determine the impact of HCQ on the clinical course and duration of the COVID-19 disease &lt;br&gt;2.\tTo evaluate the effect of HCQ in avoiding the development of the COVID-19 disease in asymptomatic-infected women&lt;br&gt;3.\tTo determine the safety and tolerability of HCQ in pregnant women &lt;br&gt;4.\tTo describe the clinical presentation of SARS-CoV-2 and the effects on pregnancy outcomes &lt;br&gt;5.\tTo determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2;Main Objective: 1.\tTo assess the effect of HCQ in reducing maternal viral load  &lt;br&gt;2.\tTo asses the efficacy of HCQ to prevent incident SARS-CoV-2 infection","Main Objective: The aim of this study is to evaluate the efficacy and safety of convalescent anti-SARS-CoV-2 plasma, hydroxychloroquine, sarilumab and baricitinib compared with placebo in combination with standard of care (SOC) for the treatment of moderate-to-severe COVID-19 pneumonia on the basis of the composite endpoint: All-cause mortality or need of invasive mechanical ventilation up to 28 days.;Secondary Objective: Not applicable;Primary end point(s): The primary outcome is a composite endpoint: All-cause mortality or need of invasive mechanical ventilation up to 28 days.;Timepoint(s) of evaluation of this end point: Day 28","Main Objective: To compare and evaluate the efficacy of 3 treatment regimens (Hydroxychloroquine in combination with baricitinib, imatinib or lopinavir / ritonavir) in SARS-CoV-2 patients with severe pneumonia requiring admission, considering primary efficacy as time to clinical improvement.;Primary end point(s): 8.1 Demographics&lt;br&gt;Age&lt;br&gt;Sex&lt;br&gt;Tobacco&lt;br&gt;Alcohol&lt;br&gt;Significant comorbidity&lt;br&gt;- HTA&lt;br&gt;- Cardiovascular disease&lt;br&gt;- DM&lt;br&gt;- COPD&lt;br&gt;- Cancer&lt;br&gt;- Chronic liver disease&lt;br&gt;- I kidney&lt;br&gt;- Known immunosuppression&lt;br&gt;&lt;br&gt;8.2 Laboratory parameters&lt;br&gt;COVID BIOMARKERS&lt;br&gt;- PCR&lt;br&gt;- Procalcitonin&lt;br&gt;- LDH&lt;br&gt;- Dimero D&lt;br&gt;-\tFerritin&lt;br&gt;- IL6&lt;br&gt;BIOCHEMICAL PARAMETERS&lt;br&gt;- Enzymatic creatinine&lt;br&gt;- ALT&lt;br&gt;- AST&lt;br&gt;- Bilirubin&lt;br&gt;- GGT&lt;br&gt;- F Alkaline&lt;br&gt;- Albumine&lt;br&gt;- Venous lactate&lt;br&gt;- Ultrasensitive Troponin I&lt;br&gt;- Creatin Kinasa (CK)&lt;br&gt;&lt;br&gt;HEMATOLOGICAL PARAMETERS&lt;br&gt;- White Series&lt;br&gt;- Leukocytes (in absolute value)&lt;br&gt;- Neutrophils (in absolute value)&lt;br&gt;- Lymphocytes (in absolute value)&lt;br&gt;- Neutrophil / lymphocyte ratio&lt;br&gt;- Platelet / lymphocyte ratio&lt;br&gt;- Red Series&lt;br&gt;- erythrocytes&lt;br&gt;- Hb&lt;br&gt;- Platelets&lt;br&gt;- Coagulation&lt;br&gt;- Fibrinogen&lt;br&gt;- Coagulation Study&lt;br&gt;&lt;br&gt;MICROBIOLOGICAL PARAMETERS&lt;br&gt;- SARS-Cov2 PCR in nasopharyngeal exudate&lt;br&gt;&lt;br&gt;8.3 Radiodiagnosis&lt;br&gt;- Unilateral, unilobar, bilobar pneumonia ...&lt;br&gt;- Bilateral pneumonia&lt;br&gt;- Resolution infiltrators&lt;br&gt;- Infiltration resolution days&lt;br&gt;- Stabilization&lt;br&gt;- Radiological progression&lt;br&gt;&lt;br&gt;8.4 Clinical variables&lt;br&gt;- Symptom onset days&lt;br&gt;- Days resolution symptoms&lt;br&gt;- Fever days&lt;br&gt;- Respiratory improvement (days)&lt;br&gt;- Temperature (&lt;38.4 / 38.4-39.4 /&gt; 39.4) * From The The Hscore11&lt;br&gt;- Organomegaly (No, liver or spleen, both) * From The Hscore11&lt;br&gt;-\tFever&lt;br&gt;-\tDry cough&lt;br&gt;- productive cough&lt;br&gt;- Hemoptysis&lt;br&gt;- dyspnea&lt;br&gt;- Asthenia&lt;br&gt;- Myalgia&lt;br&gt;- headache&lt;br&gt;- nausea&lt;br&gt;Vomiting&lt;br&gt;-\tDiarrhea&lt;br&gt;- Abdominal discomfort&lt;br&gt;- ARDS&lt;br&gt;- I cardiac&lt;br&gt;- FRA&lt;br&gt;- SHOCK&lt;br&gt;- death&lt;br&gt;- Secondary infection&lt;br&gt;- O2 saturation levels.&lt;br&gt;- Need O2, nasal goggles, liters VM non-invasive reservoir Intubation&lt;br&gt;&lt;br&gt;8.5 Clinical management variables&lt;br&gt;-\tHospital stay&lt;br&gt;- ICU admission&lt;br&gt;- No. of registrations;Timepoint(s) of evaluation of this end point: Baseline, 7 days during treatment, day 14, day 35+/-5 and day 70+/-5;Secondary Objective: To assess the safety (serious adverse effects, premature discontinuation of treatment), tolerability and secondary efficacy parameters of the 3 treatment guidelines, understood as: absence of progression to respiratory failure, absence of increased O2 requirements; need for mechanical ventilation; reduction of analytical parameters associated with poor prognosis; radiological progression of the disease on day + 7 of starting treatment; average hospital stay, intensification treatments, such as steroid boluses and tocilizumab, ICU admission,% mortality at the end of follow-up.&lt;br&gt;In addition, in those patients who consent and participate in an additional sub-study, possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 will be evaluated using high-performance techniques with serum DNA from the participants.","Timepoint(s) of evaluation of this end point: 7 days from treatment and 28 days from diagnosis;Primary end point(s): 1. Proportion of patients in whom removal of invasive mechanical ventilation has been achieved in less than 7 days after IMP administration.&lt;br&gt;2. Proportion of patients surviving on day 28 from diagnosis;Secondary Objective: 1. Time to recover from the symptoms and clinical signs after the MSV-allo administration&lt;br&gt;2. Time to reach the normalization of imaging tests, chest radiography and/or lung CT&lt;br&gt;3. Modification in the inflammatory response in terms of blood levels of cytokines and chemokines.&lt;br&gt;4. Modification in the number of leukocytes and lymphocyte populations.&lt;br&gt;5. Safety, tolerability and immunogenicity profiles of MSV-allo in patients with severe COVID-19;Main Objective: Assessing the safety and efficacy of MSV-allo in obtaining recovery from respiratory failure in patients with pneumonia due to severe / critical COVID-19 infection.","Main Objective: To assess clinical efficacy of APN01 using a composite outcome of all cause-death or need of invasive mechanical ventilation up to 28 days;Secondary Objective: To assess efficacy of APN01 using log transformed levels of Lactate dehydrogenase (LDH) as a surrogate marker for organ damage.&lt;br&gt;To evaluate the safety of APN01 in patients with severe COVID-19&lt;br&gt;To monitor other biomarker changes (e.g. IL-6, AngII) in patient with severe COVID-19 treated with APN01&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.;Timepoint(s) of evaluation of this end point: Continioulsy over the duration of the trial","Main Objective: The principle research objective is to determine whether giving the drug Hydroxychloroquine increases time to COVID-19 disease in healthy frontline healthcare workers compared to giving a placebo.;Secondary Objective: \tTo determine whether giving hydroxychloroquine daily versus weekly decreases time to COVID-19 disease in healthy frontline healthcare workers&lt;br&gt;\tTo compare the number of confirmed COVID-19 cases between each group on the basis of different testing methods&lt;br&gt;\tTo compare disease severity in each group&lt;br&gt;\tTo compare recovery time in each group;Primary end point(s): Time to positive COVID-19 disease &lt;br&gt;;Timepoint(s) of evaluation of this end point: Weekly over approximately 90 days","Main Objective: -To evaluate the efficacy of the early administration of sarilumab subcutaneously in patients with moderate-severe COVID-19 infection in early stages compared to the current treatment standard.&lt;br&gt;-To compare the baseline clinical and biological parameters, including serum IL-6, of the intervention population against historical controls, to search for possible markers that identify candidates for treatment with subcutaneous IL-6 inhibitors and attempt an approximation to the time frame of window of opportunity.;Secondary Objective: Not applicable;Primary end point(s): - Time to become afebrile for a minimum period of 48 hours, without antipyretics&lt;br&gt;- Average change in the ordinal scale of 7 points from the inclusion in the study until day 7 (after randomization):&lt;br&gt;1. Death&lt;br&gt;2. Hospitalized, with mechanical ventilation or extracorporeal membrane oxygenation (ECMO).&lt;br&gt;3. Hospitalized, with non-invasive mechanical ventilation, a mask with a reservoir or oxygen with high flow nasal goggles.&lt;br&gt;4. Hospitalized with oxygen supplement&lt;br&gt;5. Hospitalized, without oxygen supplement, but in need of continued medical care (related or not with COVID)&lt;br&gt;6. Hospitalized, without oxygen supplement and without the need for continued medical care&lt;br&gt;7. Not hospitalized&lt;br&gt;- Duration of hospitalization (days)&lt;br&gt;- Death&lt;br&gt;;Timepoint(s) of evaluation of this end point: The expected duration of subject participation in the trial is until resolution of the COVID-19 infection pattern, approximately 1 month. The overall duration of the study is estimated to be about 2 months, from the recruitment of the first patient to the end of the follow-up of the last patient included. The duration can be shortened if the current rate of income is maintained for at least one month.","Main Objective: To assess the efficacy of siltuximab vs corticosteroids in hospitalized patients with COVID19 pneumonia by evaluating the number of admissions in the unit intensive care (ICU);Secondary Objective: -Stay in the ICU&lt;br&gt;-Time to resolution of fever for at least 48 hours, without administration of antipyretics&lt;br&gt;-Incidence of worsening in the oxygen therapy requirement &lt;br&gt;-Duration of supplemental oxygen dependence&lt;br&gt;-Incidence of the use of mechanical ventilation &lt;br&gt;-Duration of the use of mechanical ventilation &lt;br&gt;-Time to start of mechanical ventilation, non-invasive ventilation&lt;br&gt;or use of high flow nasal cannula&lt;br&gt;-Days of hospitalization &lt;br&gt;-Mortality rate at 29 days&lt;br&gt;-Incidence of SAEs &lt;br&gt;-Incidence of invasive bacterial or fungal infections or opportunistic with grade 4 neutropenia&lt;br&gt;-Incidence of invasive bacterial or fungal infections or opportunistic &lt;br&gt;-Incidence of hypersensitivity reactions or reactions grade 2 related to the infusion&lt;br&gt;-Incidence of GI perforations &lt;br&gt;-Incidence of new serious secondary infections or worsening of existing infections &lt;br&gt;-Changes in leukocytes, Hb, platelets, creatinine, bilirubin, ALT&lt;br&gt;-Changes in inflammatory biomarkers&lt;br&gt;-Changes in chest X-ray;Primary end point(s): Proportion of patients requiring ICU admission at any time within the study period.;Timepoint(s) of evaluation of this end point: 29 days","Timepoint(s) of evaluation of this end point: Day 1, Day 3, Day 7, day 10, Third Month, Sixth Month;Primary end point(s): ?% survival at 28 days after treatment&lt;br&gt;? Days from the patient enters the study until the temperature normalizes: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;o Normalization of the temperature defined as: reaching a body temperature between 35C and 37C&lt;br&gt;? Days until patient was extuted: defined as&lt;br&gt;(Total days with mechanical ventilation) - (Total days without mechanical ventilation) Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;? Number of patients who abandoned mechanical ventilation, defined as: (Total of patients with mechanical ventilation at the time of inclusion) - (Total of patients who abandoned mechanical ventilation)&lt;br&gt;Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;? Number of patients that go from Mechanical Ventilation to oxygen therapy: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;? Duration of oxygen therapy (days), defined as: (Total days in the study) - (Total days of need for oxygen therapy). Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;? Days of stay in the Intensive Care Unit: defined as (Total days in the study) - (Total days in the Intensive Care Unit).&lt;br&gt;? Duration of hospitalization (days): defined as (Total days in the study) - (Total days hospitalized)&lt;br&gt;? Oxygen saturation: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month&lt;br&gt;Pa PaO2 / FiO2 ratio: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month, and 6th month.&lt;br&gt;Radi Radiological pattern on Chest Radiography: decrease in interstitial alveolar infiltrates: yes / no. Measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;FA SOFA score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.&lt;br&gt;? Murray score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month&lt;br&gt;? Analytical parameters: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month&lt;br&gt;o Hties, Hb, Hto, VCM, Leukocytes with leukocyte formula, platelets. procalcitonin&lt;br&gt;o Glucose, Glycosylated Hb, urea, uric acid, creatinine, total bilirubin, direct bilirubin, sodium, potassium, calcium, chlorine, total protein, C-reactive protein, AST, ALT, GGT, Cl Cr and FG.&lt;br&gt;o Coagulation: prothrombin time (TP), activated partial thromboplastin time (APTT), thrombin time (TT), Fibrinogen, INR.&lt;br&gt;o IL-6, IL-2, DD, lactate dehydrogenase, CK (Creatin Kinase), Alkaline Phosphatase&lt;br&gt;o Lymphocyte population: CD4 +, CD8 + T lymphocytes, B lymphocytes, NK cells&lt;br&gt;or C3, C4, IgG, IgA, IgM.&lt;br&gt;;Secondary Objective: -To evaluate the safety of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19.&lt;br&gt;-To evaluate preclincial variables;Main Objective: The main objective of this project is to evaluate the efficacy of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19.","Main Objective: The main objective of this study is to determine if short-term treatment with colchicine reduces the mortality rate and lung complications related to COVID-19.;Secondary Objective: The secondary objective is to determine the safety of colchicine treatment in this patient population.;Primary end point(s): The primary endpoint will be a composite endpoint of death or need for hospitalization from COVID-19 infection within 30 days of randomization.;Timepoint(s) of evaluation of this end point: 30 days","Main Objective: To determine the efficacy of hydroxychloroquine in the treatment of SARS-COV2 infection in oncohaematological patients without radiological alteration and SARS-COV2 positive professionals without radiological alteration.;Secondary Objective: Evaluate the toxicity profile of the treatment.;Primary end point(s): Percentage of patients (cohort A) and professionals (cohort B) who achieve control of the disease without symptoms in 14 days, assessed by chest radiography without pneumonia.;Timepoint(s) of evaluation of this end point: 14 days after treatment initiation","Timepoint(s) of evaluation of this end point: Up to 30 days following surgery;Primary end point(s): Trial outcomes will only be based on routinely available data. Patients will not undergo any additional investigations for trial purposes.&lt;br&gt;&lt;br&gt;Primary outcome measure&lt;br&gt;The primary outcome is any one of the following COVID-19 specific, inpatient, postoperative pulmonary complications  (definitions are given in an Appendix in the protocol and through brief online training):&lt;br&gt;\tPneumonia&lt;br&gt;\tAcute respiratory distress syndrome (ARDS)&lt;br&gt;\tDeath&lt;br&gt;&lt;br&gt;Definitions for each outcome are provided in the protocol. The components of the composite outcome have all been internationally validated. The feasibility of collecting these endpoints within routine care pathways has been demonstrated by our RECON cohort (11,500 patients, 4 countries).&lt;br&gt;&lt;br&gt;;Secondary Objective: To assess the effects of study treatments on:&lt;br&gt;-Post-operative proven COVID-19 pulmonary complications&lt;br&gt;-Overall SARS-CoV-2 infected rate&lt;br&gt;-Duration of intensive care and total hospital stay&lt;br&gt;-Pulmonary function in keeping with WHO Solidarity Trial outcome scale &lt;br&gt;-Safety and tolerability of study treatments&lt;br&gt;&lt;br&gt;;Main Objective: Primary Objective&lt;br&gt;&lt;br&gt;To provide reliable estimates of the effect of study treatments on postoperative pulmonary complications during the COVID-19 pandemic.","Timepoint(s) of evaluation of this end point: During hospitalisation.;Primary end point(s):  All-cause in-hospital mortality. ;Secondary Objective: - To assess the effect of Remdesivir and Hydroxychloroquine treatment on hospital duration, receipt of ventilation or intensive care, and to identify any serious adverse reactions.&lt;br&gt;- To assess the effect of Remdesivir and  Hydroxychloroquine treatment on 28 days mortality, viral clearance, kidney and myocardial failure, co-infections, organ dysfunction and health-related Quality of Life.&lt;br&gt;&lt;br&gt;Exploratory:&lt;br&gt;Assess the effect of Remdesivir and Hydroxychloroquine on biomarkers and safety. ;Main Objective: To investigate the effect of Remdesivir and Hydroxychloroquine on all-cause in-hospital mortality compared to standard of care.&lt;br&gt;&lt;br&gt;","Timepoint(s) of evaluation of this end point: END OF STUDY;Primary end point(s): 1. Ordinal 7-point clinical evaluation scale (WHO R&amp;D Blueprint expert group (31).&lt;br&gt;2. IL-6 concentrations, which together with the rest of the laboratory result variables will be measured together at the end of the study.;Secondary Objective: 1. Improvement of clinical status defined as time to reduction of at least 2 points on the WHO 7-point ordinal scale.&lt;br&gt;2. Changes in the Sequential Organ Failure Scale (SOFA,) during hospitalization and time to 50% reduction with respect to randomization.&lt;br&gt;3. Changes in NEWS severity scale score (33) during hospitalization and time to NEWS score =2 or 50% reduction from randomization.&lt;br&gt;4. Number of days in invasive mechanical ventilation or ECMO&lt;br&gt;5. Number of days with oxygen at high flow.&lt;br&gt;6. Changes of other inflammatory markers: C-reactive protein, TNF-alpha, GDF-15, IL-1 up to 28 days with respect to randomization.&lt;br&gt;7. Changes in severity markers: D-dimer, leukocytes, lymphocytes, platelets, LDH and ferritin up to 28 days with respect to randomization.&lt;br&gt;8. Changes in markers of myocardial damage: hsTnT and NT-proBNP up to 28 days with respect to randomization.&lt;br&gt;9. Time to viral negative by RT-PCR&lt;br&gt;10. Duration in days of hospital stay&lt;br&gt;11. ICU income&lt;br&gt;12. Mortality from causes;Main Objective: To study whether the administration of colchicine, compared to a control group, improves the clinical evolution of patients and prevents the inflammatory response.&lt;br&gt;1. Changes in the clinical status of patients on the 7-point ordinal scale (WHO R&amp;D Blueprint expert group) (34) at 7, 14 and 28 days:&lt;br&gt;2. Change in IL-6 concentrations up to 28 days.","Timepoint(s) of evaluation of this end point: 28 day delay;Primary end point(s): Survival without invasive ventilatory assistance (i.e. ventilator-free days) until D28. The score is calculated by summing the days on which the patient has not had a VM; but in the event of death before D28, the score is zero. The 28-day delay was recommended because the average duration of VM for post-SARS-CoV-2 ARDS patients is 20 days.;Secondary Objective: The secondary objectives are to assess the impact of IVIg on mortality, organ failure, complications of resuscitation and the functional and psychological sequelae at D28 as well as their side effects.;Main Objective: To determine if the administration of IVIG at a dose of 2 g / kg over 4 consecutive days (i.e. 0.5 g / Kg / D) started during the first 24 to 120 hours of invasive mechanical ventilation (VM) of a patient suffering from d 'A post-SARS-CoV-2 ARDS improves the number of days living without VM on D28.&lt;br&gt;","Timepoint(s) of evaluation of this end point: Day 14;Primary end point(s): This is defined on day 14 as the percentage of patients who will not experience SAIs (as defined in Annex V). Patients who die before the day 14 visit are considered to have failed at the primary endpoint.;Secondary Objective: Not applicable;Main Objective: Recent data coming from the Hellenic Sepsis Study Group reveal that suPAR levels =6 ng/ml are early found among patients who will eventually develop severe respiratory failure (SRF) by Covid-19 with positive predictive value more than 80%. This signifies that an early pro-inflammatory reaction has been started in the lung. It is postulated that early anakinra treatment in these patients may halt this reaction and prevent development of SRF.  In the SAVE study patients with sars-cov-2 infection with SARS-CoV-2 virus at high risk for progression to MSDs will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in SAA.","Secondary Objective: - to quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19 &lt;br&gt;- evaluate the 30-day mortality.;Primary end point(s): Efficacy will be assessed according to the defined objectives of oxygenation, reduction of inflammatory markers;Timepoint(s) of evaluation of this end point: 2 days -\tPaO2/FiO2 and TNF, IL-1b, IL-6 e IL-8 da 2.;Main Objective: To evaluate the effect of 48-hour treatment with inhaled sevoflurane on arterial oxygenation, assessed by PaO2/FiO2 on day two, in patients with ARDS-CoVid19","Main Objective: The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by the occurrence of death during the index hospital admission censored 90 days from the date of enrolment.&lt;br&gt;;Secondary Objective: The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months, health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS).;Primary end point(s): The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days.;Timepoint(s) of evaluation of this end point: 90 Days from the date of enrolment.","Main Objective: The primary objective is to investigate whether the administration of inhaled sargramostim (Leukine) at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure .;Secondary Objective: - to study if early intervention with sargramostim is safe (number of AEs/SAEs)&lt;br&gt;- to study if early intervention with inhaled sargramostim affects clinical outcome defined by&lt;br&gt;duration of hospital stay, 6-point ordinal scale, clinical sign score, SOFA score, NEWS2 score&lt;br&gt;- to study if early intervention with sargramostim affects the rate of nosocomial infection&lt;br&gt;- to study if early intervention with inhaled sargramostim affects progression to mechanical ventilation and/or ARDS&lt;br&gt;- to study if treatment with sargramostim affects all-cause mortality rate at 4 and 20 weeks post inclusion&lt;br&gt;-to study if treatment with sargramostim affects features of secondary haemophagocytic lymphohistiocytosis, defined by HS score&lt;br&gt;- to study if treatment with sargramostim has a favourable effect on long term 10-20 week follow up&lt;br&gt;;Primary end point(s): To measure the effectiveness of sargramostim on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation after 5 DAYS of inhaled (and intravenous) treatment through assessment of pretreatment (day 0) and post-treatment (day 5) ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID -19 ward or ICU COVID-19 unit. Preferentially, this measurement should be done in the upright position, while breathing room air for a minimum of 3 minutes.. If this is impossible due to need for supplemental oxygen, FiO2 and oxygen supplementation method should be recorded in patient record, so that A-a gradient can be normalized for age expected normal A-a gradient while on supplemental oxygen use.&lt;br&gt;During the 5 day treatment period, we will perform daily measurements of oxygen saturation (pulse oximetry) in relation to FiO2, and the slope of alterations in this parameters could also be an indicator that our hypothesis is correct.&lt;br&gt;If the patient leaves hospital prior to the day 6 analysis point, oxygenation at day of discharge will be used as value for measuring primary endpoint.&lt;br&gt;;Timepoint(s) of evaluation of this end point: day 5","Frequency of hospitalization with a continuous oxygen requirement of at least 24 hours.&lt;br&gt;&lt;br&gt;Control calls are scheduled for week 0, week 2, week 4 and week 6. In UKSH patients, as part of the Global Consent residual materials serum and stool are preserved for exploratory analyzes of the serum levels of tryptophan, tryptophan metabolites and neopterin and the composition of the stool microbiome.","The aim of this project is to characterize the etiology and clinical course of COVID-19 infections and identify biomarkers to predict morbidity and mortality of those patients.","Point estimates of sensitivity and specificity of index test, with 95% confidence intervals, using an RT-PCR reference standard","The primary goal criterion is the qualitative description of effects of the COVID-19 pandemic on mental health in the phenomenological interview. The interviews will take place during the pandemic while patients are admitted for psychological diseases. For employees, the interviews take place during the pandemic, outside working hours, the interview time is registered as overtime.","Equivalence of the method measured by correlation of the smear result","The study determines if the test identifies persons with previous infection by comparing with a gold standard test","The aim of this project is to conduct a regular survey among Austrian and German general practitioners working in GP practices during the Covid-19 pandemic regarding their role in this pandemic, their specific challenges in this setting and their strategies developed during the pandemic.","Pain development during the corona crisis.&lt;br&gt;End: as soon as the measures are cancelled and daily life can take place again as before&lt;br&gt;with which: the assessment is carried out using the questionnaires mentioned","Association of biomarkers with incidence and course of COVID 19 disease.","The primary endpoints are composed of admission to an intensive care unit (ICU), tracheal intubation or death.","Trying to identify the risk/risk factors for bad outcome of Covid-19 infection during pregnancy for mother and baby until the end of the puerperium (6 weeks postpartum).","Psychological distress and behavioural changes of oncology patients and matched healthy controls in the context of the COVID-19 pandemic","The primary endpoint is the prevalence of SARS/CoV-2 positive individuals in the study population, defined as the number of individuals with positive laboratory findings (from at least one of the sample media collected in the study) divided by the total number of study participants.","Worry: Penn State Worry Questionnaire: Meyer, T. J., Miller, M. L., Metzger, R. L. &amp; Borkovec, T. D. (1990). Development and validation of the Penn State Worry Questionnaire. Behaviour Research and Therapy, 28, 487-495. (t1, t2, t3, t4)","measurement of transpulmonary pressure, end expiratory lung volume and intraabdominal pressure at a PEEP Level of 15, 10 an 5 cm of water in mechanical ventilated intensive care patients","To identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2.","To identify suspected cases of COVID-19Timepoint: Weekly follow-up will be done","IL-6 at 72 hours after initiation of vv-ECMO","Seroconversion (IgG) with quantitiative ELISA","Hospitalization duration. Timepoint: until discharge from hospital. Method of measurement: Questionnaire.","The aim of the study is to identify the number of seropositive persons (SARS-CoV-2 serology) in public sector persons. For this, 100 study participants (laboratory results and questionnaires) are needed for this purpose.","The primary outcome is the changed experience of anxiety, measured with the Generalized Anxiety Disorder Scale [GAD-7] (Spitzer, Kroenke, Williams, &amp; Lwe, 2006) at measurement time T1.","Normal CT Scan. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Result of CT scan.;Negative result for COVID-19 RT-PCR test. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Results of qRT-PCR test.;Primary outcome: complete remission of clinical signs of disease. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.","Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Cutaneous complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Neurological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Renal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Hematological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.","Primary Outcomes are the working conditions and activities, in order to assess the current state during the COVID-19 Pandemic at the following 3 measurement points: April 2020, June 2020, April 2021","How many employees develop a COVID-19 positive test and how many develop antibodies in the sense of a seroconversion?","Death. Timepoint: 3 months. Method of measurement: Number of deceased patients.","regional distribution of ventilation","Job stress. Timepoint: Before the intervention, one month after intervention. Method of measurement: Job Stress Questionnaire Osipow.;Quality of working life. Timepoint: Before the intervention,  one month after intervention. Method of measurement: Work-Related Quality of Life questionnaire.","Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data.","Knowledge, attitude, practice, fear to COVID 19Timepoint: during answering the questionnaire","Improvement of pulmonary manifestations and the duration. Timepoint: One week, two weeks and 6 months after. Method of measurement: physical examination, labratory data and CT scan.;Improvement the radiologic parameters. Timepoint: after 7-10 days. Method of measurement: computed tomography.;Necessity and Duration to ICU admission and hospitalization. Timepoint: One to two weeks later. Method of measurement: Questionnaire.;Mortality. Timepoint: One month later. Method of measurement: Number.;The three months outcomes: complete improvement; improvement with transient complication; improvement with persistent complication. Timepoint: After three months. Method of measurement: Physical examination and history.","Complications of the treatment. Timepoint: Daily, until the tenth day. Method of measurement: Interview and patient's record.;Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2  C), respiratory rate (=24 breaths per minute), oxygen saturation (&gt; 94% at room temperature) and cough (zero or mild) that persist for at least 24 hours. Cough will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.","genetic and epigenetic risk profiles","number of days of hospitalizationTimepoint: discharge","Pulmonary Condition. Timepoint: Before intervention and 14, 28 days after intervention. Method of measurement: CT scan.;Expression of nucleic acid of virus. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: real time PCR.;Lymphocytes count. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: Flowcytometry.;Patients clinical signs. Timepoint: before intervention and 14 and 28 days after intervention. Method of measurement: Observation.","Infected  Non infectedTimepoint: Time to clinical improvement","100% sensitivity in ruling out COVID-19 cases through ORTIS system.Timepoint: 100% sensitivity in ruling out COVID-19 cases through ORTIS system.","Patient discharge. Timepoint: Daily. Method of measurement: Yes or no.;Increase or decrease of respiratory rates more than 25% of primary respiratory rate. Timepoint: Daily. Method of measurement: Respiratory rate in minute.;Myocardial Infarction or unstable angina. Timepoint: Daily. Method of measurement: Yes or no.;Rising of creatinine more than 25% primary creatinine. Timepoint: Daily. Method of measurement: milligram in deciliter.;Patient death. Timepoint: Daily. Method of measurement: Yes or no.","Improvement in ambulatory patients who are assessed daily for symptoms which include cough, fever with or without chills and difficulty in breathing for the period they are in quarantine.    &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;Timepoint: Baseline, telephonically everyday and day 15.","Lung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan.;Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation.;Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation.","Covid-19 infection. Timepoint: One, two and three months after starting the drug. Method of measurement: Covid-19 PCR test and clinical symptoms.","To create a real time COVID-19 registry of current ICU/hospital care patterns to allow evaluations of safety and observational effectiveness of COVID-19 practices &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;To determine the variations in practice across hospitals &lt;br/ &gt;&lt;br&gt;Hypothesis: The registry will be essential for near-real time observational comparative effectiveness studies to learn effective treatment strategies and/or provide meaningful hypotheses for clinical trialsTimepoint: 04/30/2021","Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.","Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.","The proportion of participants with clinical response (normalization of fever and oxygen saturation through day 14). Fever normalization: Temperature &lt;36.6 C armpit, &lt;37.2 C oral, or &lt;37.8 C rectal, sustained for at least 24 hours; Oxygen saturation normalization: peripheral capillary oxygen saturation (SpO2) &gt; 94% sustained for at least 24 hours. Timepoint: day 1 through 14. Method of measurement: Physical Examination.","Death. Timepoint: Up to 28 days after starting the study. Method of measurement: Patient observation and evaluation of vital signs.","CT-scan findings. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: CT-scan.","Clinical recovery (composite) within 14 days from initiation of study treatment until normalization of fever (=37.2 C oral), respiratory rate (=24/minute on room air), and oxygen saturation (=94% on room air),  sustained for at least 24 hours. Timepoint: daily up to 14 days after starting the trial. Method of measurement: Clinical examination.","Fever. Timepoint: At the time of positivetest and 14 days later. Method of measurement: Using oral thermometer.;Cough. Timepoint: At the time of positivetest and 14 days later. Method of measurement: Clinical observation and examination.;Chills. Timepoint: At the time of positivetest and 14 days later. Method of measurement: Clinical observation and examination.;Night sweats. Timepoint: At the time of positivetest and 14 days later. Method of measurement: Clinical observation and examination.","The scales of pulmonary involvement changes according to the scoring system defined, based on high resolution pulmonary computed tomography before and after the interventions. Timepoint: At visit 1 and then after 14 days. Method of measurement: Defined scoring system based on pulmonary involvement in high resolution pulmonary CT scan; score one: involvement in less than 5% of a lobe of a lung. Score two: Conflict about 25 percent of a lobe of a lung. Score three: Conflict about 26 to 49 percent of a lobe of a lung. Score four: Conflict about 50 to 75 percent of a lobe of a lung. Score Five: Conflict in more than 75% of a lobe of a lung.","Number of admission days. Timepoint: every day. Method of measurement: Number of days.;The mortality rate in COVID-19 patients. Timepoint: Everyday. Method of measurement: Number of death.;Assessment of potential side effects. Timepoint: Every day. Method of measurement: Inspection for potential side effects.","Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: respiratory Count.","Hospital stay. Timepoint: discharge date. Method of measurement: checklist.;Need for ICU admission. Timepoint: discharge date. Method of measurement: check list based on treating clinicians judgment.;Need for intubation. Timepoint: discharge date. Method of measurement: check list based on treating clinicians judgment.","Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.","Temperature. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Termometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Muscular pain. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.","CRP level in Blood. Timepoint: At the beginning of the study at after 5 consecutive days. Method of measurement: Blood sampling and CRP measuring.","Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.","Decreased mortality. Timepoint: 2 weeks. Method of measurement: observation.;Decreased need to hospitalization. Timepoint: 2 weeks. Method of measurement: obsevation.","The treatment of patients with corona infection. In healthy subjects the CT image of the lungs signs an improvement of the corona contamination. Timepoint: At the beginning of the test, positive people are determined based on who tests and then the severity of disease is classified through fever and CT-pulmonary image. Then, after 8-10, the initial cases including fever and CT lungs, as well as general individuals, were analyzed. Method of measurement: CT scan.;Fever. Timepoint: At the beginning of the test, then 8 - 10 days after taking the new drug and ensuring efficacy. Method of measurement: Thermometers.","Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.;The rate of lung inflammation. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: CT SCAN.","Improving Respiratory function of patients. Timepoint: Every 24 hours. Method of measurement: Clinical and, Para-clinical.","Number of people recovering from medication. Timepoint: 14 days. Method of measurement: Improve symptoms.","Response to treatment in Lymphocytes count. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Response to treatment for  COVID-19 specific PCR test. Timepoint: Days 0-3-7. Method of measurement: Using PCR apparatus.;Response to treatment in  O2 level and  CO2 level in ABG or VBG test. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Chest CT-Scan response to treatment including dispersion size of Ground Glass area,  bronchitis and consolidation. Timepoint: Days 0-3-7. Method of measurement: CT scan apparatus.","Time to Clinical Improvement (TTCI): TTCI is defined as the time (in days) from initiation of study treatment until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death).6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC therapy;3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC);2. Hospitalization, not requiring supplemental oxygen; 1. Hospital discharge.\tIMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation;HFNC, High-flow nasal cannula. Timepoint: Daily for 14 days. Method of measurement: Based on clinical evaluation.;Time to Clinical recovery (TTCR): TTCR is defined as the time (in hours) from initiation of study treatment until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough sustained for at least 72 hours.Normalization and alleviation criteria:\tFever - =36.9C or -axilla, =37.2 C oral,\tRespiratory rate - =24/minute on room air,\tOxygen saturation - &gt;94% on room air,\tCough - mild or absent on a patient-reported scale of severe, moderate, mild, absent. Timepoint: Daily for 14 days. Method of measurement: Based on clinical evaluation.","Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.","Serum CRP. Timepoint: The first day, the second day, the third day. Method of measurement: Blood test.;Number of lymphocytes. Timepoint: The first day, the second day, the third day. Method of measurement: Blood test.;O2 arterial blood saturation. Timepoint: The first day, the second day, the third day. Method of measurement: Pulse Oximeter Report.;Myalgia. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Chills. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Shortness of breath. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Cough. Timepoint: The first day, the second day, the third day. Method of measurement: Physician report.;Fever. Timepoint: The first day, the second day, the third day. Method of measurement: Check body temperature with thermometer.","Night sweats. Timepoint: Time to get the Corona test positive  _14 days after test positive. Method of measurement: Clinical observation and examination.;Chills. Timepoint: Time to get the Corona test positive  _14 days after test positive. Method of measurement: Clinical observation and examination.;Cough. Timepoint: Time to get the Corona test positive  _14 days after test. Method of measurement: Clinical observation and examination.;Shortness of breath. Timepoint: Time to get the Corona test positive  _14 days after test positive. Method of measurement: Using oral thermometer and Improve symptoms.","Anxiety,. Timepoint: Before the intervention, immediately after the intervention. Method of measurement: Health Anxiety Assessment Questionnaire.;Depression. Timepoint: Before the intervention, immediately after the intervention. Method of measurement: Hospital Anxiety-Depression Index Questionnaire.","Decreased hospitalization period. Timepoint: at baseline and discharge time. Method of measurement: counting the day.;Mortality rate. Timepoint: at baseline and discharge time. Method of measurement: observation.;Decreased need for intubation. Timepoint: at baseline and discharge time. Method of measurement: observation.","Clinical response to therapeutic regimen by respiratory rate. Timepoint: Daily. Method of measurement: physical exam.;Clinical response to therapeutic regimen by blood oxygen saturation. Timepoint: daily. Method of measurement: pulse oximeter.;Clinical response to therapeutic regimen by fever. Timepoint: daily. Method of measurement: thermometer.;Therapeutic regimen safety. Timepoint: daily. Method of measurement: patient tolerability.;Cough recovery. Timepoint: daily. Method of measurement: physical exam.;Lymphocyte count recovery. Timepoint: daily. Method of measurement: laboratory test.;CRP level reduction. Timepoint: three times weekly. Method of measurement: laboratory test.;LDH  level reduction. Timepoint: three times weekly. Method of measurement: laboratory test.","Changing the patient's clinical status in the COVID-19 clinical classification table. Timepoint: Before and after intervention. Method of measurement: Clinical and Paraclinical Indicators in COVID-19 Classification Table.","Number of hospital days. Timepoint: Daily since hospitalization time. Method of measurement: Based on patient's file.","PAO2/fio2. Timepoint: 5 days after intervention. Method of measurement: ABG.","Time to clinical improvement (TTIC). Timepoint: day 0, 5, at discharge. Method of measurement: assessing respiratory rate, blood oxygen saturation, fever.;Time to clinical improvement (TTIC) of NEWS2 (National Early Warning Score 2) of 0 maintained for 24 hours. Timepoint: day 0, 5, at discharge. Method of measurement: NEWS2 (National Early Warning Score 2) questionaire.","O2 saturation percentage. Timepoint: Clinical examination and pulse oximetry at baseline, days 3, 6, 9, 12 and 14. Method of measurement: Pulse Oximeter.;Lung inflammation. Timepoint: CT scan at baseline, days 7 and 14. Method of measurement: CT scan.","Temperature. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Thermometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.;Muscular pain. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Urine Ketone. Timepoint: Four hours after taking MCT oil. Method of measurement: It is checked with a urine test strip.","Improvement in SpO2 (increasing in level of SpO2 to levels higher than 90%). Timepoint: After finishing the intervetion. Method of measurement: By Pulse oximeter.","Improvement of the symptoms of lung, pulmonary  infiltrates. Timepoint: At baseline (before intervention) and 2 day after drug administration. Method of measurement: Lung CT scan.;Decreased hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: counting the hospitalization days.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: observation.;Need for intubation. Timepoint: period of hospitalization. Method of measurement: observation or reading of  hospitalized documents.","Admission to intensive care unit. Timepoint: Once (when admitted to intensive care unit). Method of measurement: Hospital records.","Fever. Timepoint: before and after treatment. Method of measurement: Thermometer.;Respiration rate. Timepoint: before and after treatment. Method of measurement: counting the number of breaths patients take per minute.;Findings of chest CT scan. Timepoint: before and after treatment. Method of measurement: CT scan machine.;Pulse. Timepoint: before, during and after treatment. Method of measurement: patient monitoring device.;SpO2. Timepoint: before, during and after treatment. Method of measurement: patient monitoring device.;WBC. Timepoint: before and after treatment. Method of measurement: biochemical tests.;Number of lymphocytes. Timepoint: before and after treatment. Method of measurement: biochemical tests.;Lactate dehydrogenase. Timepoint: before and after treatment. Method of measurement: biochemical tests.;Signal Recognition Particle (SRP). Timepoint: before and after treatment. Method of measurement: biochemical tests.","Clinical symptoms (Coronavirus infection). Timepoint: Before starting the study and daily until discharge. Method of measurement: Laboratory values and radiographic changes or CT scans.","Respiratory function of patients. Timepoint: Every 24 hours after MSC infusion. Method of measurement: Clinical, lab test , CT scan.","Temperature. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Termometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Muscular pain. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.","Improving the general condition of the patient. Timepoint: Before intervention and one week after the third session of hemoperfusion. Method of measurement: No need to receive any intensive respiratory care in the patient.","Need of invasive and non invasive mechanical ventilation ,need of oxygen supplement , the median time for recovery and well-being. Timepoint: daily in all duration of study. Method of measurement: By designed investigator checklist.","Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.","WBC, CRP, IL6,TNF-a, IFN-G ? ESR. Timepoint: Before and after intervention. Method of measurement: Laboratory blood test.;Intensity of pulmonary involvement. Timepoint: Before and after intervention. Method of measurement: CT scan.;Mortality. Timepoint: Before and after intervention. Method of measurement: Observation.","Clinical improvement includes fever rupture. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, thermometer, questionnaire.;Clinical improvement includes  SPO2 &gt;93%. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, pulse oxymetery,questionnaire.;Improvement of respiratory symptoms. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, ct scan,questionnaire.;Adverse effects. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Questionnaire, physical examination.","Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Questionnaire.;Dyspnea. Timepoint: Daily. Method of measurement: Questionnaire.;Sore throat. Timepoint: Daily. Method of measurement: Questionnaire.;Myalgia. Timepoint: Daily. Method of measurement: Questionnaire.","Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Time of recovery.;Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.;CRP level. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit.","Clinical signs Includes oxygen saturation, temperature, blood pressure, respiration rate, heart rate. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Individual profile and follow-up questionnaire.;Oxygen levels. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Oximeter.","Measurement of cough severity. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Standard cough questionnaire.;Severity of shortness of breath. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.","Infection duration. Timepoint: during study. Method of measurement: WHO criteria.","Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2  C), respiratory rate (=24 breaths per minute), oxygen saturation (&gt; 94% at room temperature) and cough  ; dyspnea ; headche and dirrhea that will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.","Body temperature. Timepoint: At the beginning of the study and on day 6. Method of measurement: thermometer.;Adverse events. Timepoint: whole duration of study. Method of measurement: type and number of adverse event.;Cough. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Dyspnea. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Myalgia. Timepoint: At the beginning of the study and on day 6. Method of measurement: Visual Analogue Scale.","Incidence of clinical symptoms of COVID-19 disease (especially pulmonary involvement) among people who are asymptomatic when entering the study. Timepoint: At the beginning of the study and 7, 14 and 21 days after the start of the intervention. Method of measurement: The number of cases with clinical symptoms, especially cases of pulmonary involvement in a period of 21 days among the participants in the studied groups and as needed using CT scan results.","Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: Respiratory Count.","Clinical status. Timepoint: Beginning of the study, 10 days later, or discharge time. Method of measurement: By a doctor.","Stress. Timepoint: Stress will be measured once before the first intervention and once after the last intervention session. Method of measurement: Doss Stress Questionnaire.","Fever. Timepoint: Every day for 7 days. Method of measurement: termometer.;Lymphocyte count. Timepoint: Before and 7 days after intervention. Method of measurement: Cell counter device.;Erythrocyte sedimentation rate. Timepoint: Before and 7 days after intervention. Method of measurement: ESR device.","Viral diagnostic test. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Polymerase chain reaction.","Admission to intensive care unit. Timepoint: Once (when admitted to intensive care unit). Method of measurement: Hospital records.","Blood oxygen saturation. Timepoint: At beginning and regularly during study. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: At beginning and regularly during study. Method of measurement: Respiratory Count.;Lung inflammation. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.","Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.","Hospitalization days. Timepoint: At baseline and discharge time. Method of measurement: Counting the  days.;Need for mechanical ventilation. Timepoint: From baseline to discharge time. Method of measurement: Observation and documents.;Condition of discharge (death or recovery). Timepoint: End of hospitalization. Method of measurement: Observation and documents.;Period of mechanical ventilation. Timepoint: End of hospitalization. Method of measurement: Documents of hospitalization.","Death. Timepoint: At the time of discharge from the hospital. Method of measurement: Patient medical records.","Primary Outcome: All-cause mortality. Timepoint: Any time death or discharge of patients occurs. Method of measurement: Death certificate signed by hospital clinicians or discharge documents.","Measurement of inflammatory markers (CRP). Timepoint: at baseline and discharge time. Method of measurement: ELISA.;WBC count. Timepoint: at baseline and discharge time. Method of measurement: Blood count.;Evaluation of lung CT scan. Timepoint: at baseline and discharge time. Method of measurement: Radiologic finding.;Evaluation of inflammatory marker ESR. Timepoint: at baseline and discharge time. Method of measurement: Blood count.","Mortality. Timepoint: 28 days. Method of measurement: Number of death.;Performance of patients. Timepoint: Primary and 14 days after. Method of measurement: Sequential Organ Failure Assessment (SOFA) Respiratory Score.;Length of hospitalization. Timepoint: 28 days. Method of measurement: Days between admission to discharge.;Laboratory Findings. Timepoint: Primary and 14 days after. Method of measurement: Laboratory methods.","COVID-19 incidence rate in cancer patients under treatment. Timepoint: Patients are examined and investigated if they become symptomatic during the 2 months of study. Method of measurement: First, a history and physical examination are performed for the symptoms of COVID-19, and if the test is positive, a computerized tomography scan of the lungs and a nucleic acid amplification test for the SARS-CoV-2 virus.","Adverse events assesment. Timepoint: At the same time of each intervention, 24 hours after each intervention, on days 6, 7, 14 and 28 after the first intervention. Method of measurement: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.","Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.","Affected by COVID-19. Timepoint: Sign of COVID-19 during study. Method of measurement: COVID-19 positive by PCR.","Improvement of patients fever. Timepoint: Measurement of patient's body temperature at the beginning of the study and 7 days after starting treatment. Method of measurement: Thermometer.;Improvement of complete blood count test. Timepoint: Performing a complete blood cell count test at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Improvement of C-reactive protein test. Timepoint: Measurement of C-reactive protein level at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Improvement of chest X-Ray symptoms. Timepoint: Examination of patient's chest x-ray at the beginning of the study and 7 days after starting treatment. Method of measurement: Taking a chest x-ray.;Improvement of blood oxygen saturation and no adjuvant oxygen therapy. Timepoint: Measurement of  oxygen saturation level at the beginning of the study and 7 days after starting treatment. Method of measurement: Pulse oximeter.","The oxygen blood saturation. Timepoint: Every 12 hours from the first day of hospitalization to the last day. Method of measurement: The pulse oximetry.;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.;The mortality rate. Timepoint: 10, 20 days after starting intervention. Method of measurement: Counting deaths.","Body temperature. Timepoint: before the start of the intervention and 10 days after the supplement Vitamin A. Method of measurement: Measureing body temperature with a thermometer through the mouth.;Blood oxygen saturation percentage. Timepoint: Before and ten days after starting treatment. Method of measurement: Pulse oximeter.;Cough rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Physical examination.;C-Reactive Protein (CRP) Test rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Complete blood count (CBC) Rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Creat. Rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Lymphocytes Rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Erythrocyte Sedimentation Rate (ESR) rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Number of breaths. Timepoint: Before and ten days after starting treatment. Method of measurement: Physical examination.;The pH of the blood. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Creatine phosphokinase (CPK) rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Lactate Dehydrogenase (LDH) rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Liver function tests rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.","Improving the general condition of the patient. Timepoint: Before and after intervention. Method of measurement: Lung CT scan; No need to receive any intensive respiratory care in the patient.;Mortality rate. Timepoint: At baseline and discharge time or patient death. Method of measurement: Observation.;Need for intubation. Timepoint: Period of hospitalization. Method of measurement: Observation or reading of hospitalized documents.","Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.","Radiographic features Findings. Timepoint: Before and after (at day 3, 7 and discharge time). Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after. Method of measurement: Observation.;O2 saturation. Timepoint: Before and after (at day 3, 7 and discharge time). Method of measurement: Pulse Oximeter.;Need an oxygen therapy ?. Timepoint: Before and after (at day 3 and discharge time). Method of measurement: clinical.","Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.","Symptoms ending. Timepoint: During the study. Method of measurement: Clinical examination.;Lymphopenic Status. Timepoint: Before the intervention and the seventh day. Method of measurement: Counting lymphocytes.;C-reactive protein Status. Timepoint: Before the intervention and the seventh day. Method of measurement: C-reactive protein serological test.;Saturation of Peripheral Oxygen. Timepoint: Before the intervention and the seventh day. Method of measurement: Pulseimetry.","Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on clinical, paraclinical and laboratory findings.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient interview and file.;Radiologic response. Timepoint: one month after the beginning of the treatment. Method of measurement: lung HRCT.","Checking the amount of ventilation. Timepoint: Before intervention, 30 minutes after each step of intervention and daily. Method of measurement: Artificial respirator or ventilator.;White blood cell count, CRP in patients with COVID-19. Timepoint: Every 24 hours (Before and after intervention). Method of measurement: Cell counter.;Percentage of T CD8 in peripheral blood. Timepoint: Before and after the intervention. Method of measurement: Evaluation of T CD8 percentage by Flow cytometry.;Percentage of T CD4 in peripheral blood. Timepoint: Before and after the intervention. Method of measurement: Evaluation of T CD4 percentage by Flow cytometry.;C-Reactive Protein (CRP) in patients with COVID-19. Timepoint: Every 24 hours (Before and after intervention). Method of measurement: Rapid test.","The general condition of the patient. Timepoint: Before intervention and 1 day after final intervention. Method of measurement: Lung CT scan; No need to receive any intensive respiratory care in the patient.;Mortality rate. Timepoint: At baseline and discharge time or patient death. Method of measurement: Observation.;Need for intubation. Timepoint: Period of hospitalization. Method of measurement: Observation or reading of hospitalized documents.;Period of hospitalization. Timepoint: At baseline and discharge time. Method of measurement: Number of hospitalized days.","Fever. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Thermometer.;Shortness of breath. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Autosaturation device, Counting the number of breaths in 1 minute.;Coughs. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.;Myalgia. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.","Adverse events assesment. Timepoint: At the same time of each intervention, 24 hours after each intervention, on days 6, 7, 14 and 28 after the first intervention. Method of measurement: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.;Blood oxygen saturation. Timepoint: At Baseline, simultaneously with each intervention and on days 5, 6, 7, 14 after the first intervention. Method of measurement: Evaluation of Pneumonia Improvement.","Clinical improvement within 14 days of admission. Timepoint: everyday. Method of measurement: Clinical improvement is defined as the patient's admission status of 6 grade scale score reduced by 2 points or patient discharge. (Clinical improvement was defined as a 2-point reduction or discharge of a 6-point scale for patient admission status. The 6-point scale includes: 6 points: death; 5 points: hospitalization for ECMO and / or mechanical ventilation; 4 points: non-invasive admission Ventilation and / or high-flow oxygen therapy; 3 points: hospitalization for oxygen therapy (but no high-flow or non-invasive ventilation is required); 2: points for hospitalization) Point1: discharge.","Temperature. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Fisman scale.;Respiratory rate. Timepoint: Daily. Method of measurement: Counting the number of breaths per minute.;Weakness. Timepoint: Daily. Method of measurement: Visual analog scale.;Muscular pain. Timepoint: Daily. Method of measurement: Visual analog scale.;C Reactive Protein (CRP). Timepoint: Daily. Method of measurement: Blood test.;Lymphocyte count. Timepoint: Daily. Method of measurement: Blood test.;O2 Saturation percentage  (SpO2). Timepoint: Daily. Method of measurement: Pulse oximetery.;Anxiety. Timepoint: Daily. Method of measurement: Beck questionnare.;Chest X Ray. Timepoint: Daily. Method of measurement: Analysis of radiography.","Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.","Improvement of SPO2 (stands for peripheral capillary oxygen saturation). Timepoint: Daily, until 3-5 days or discharge. Method of measurement: pulse oximetry.","Name: Mental disorders (Depression; anxiety; eating disorders; substance use disorders);Timepoints: one month;Measure: DASS-21; SCOFF; CAGE-AID","Respiratory symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Respiratory symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: pulse oxymetery device.;Respiratory symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.","Improvement of clinical symptoms. Timepoint: Start of study and 7 days after study. Method of measurement: Questionnaire - telephone follow-up and.","Determining the efficacy of trifluoprazine in improving the Clinical manifestations of patients with confirmed COVID-19 infection by recording the patient's clinical parameters including 7 clinical parameters of respiration number, Blood Oxigen Saturation, oxygen support, temperature, heart rate, systolic blood pressure and Awareness level, assessment of lung involvement with Chest CT-Scan, measurement of c-reactive protein on treatment days, measurement of CBC indicators and biochemical factors such as urea and creatinine. Timepoint: Check of the patient's clinical condition and blood sampling of patients on days 1-14 in the hospital and also on the 28th day after the onset of the disease. Method of measurement: Measuring CBC indicators and biochemical factors using an autoanalyzer and examining heart function using EKG,Measurement of other factors  using a thermometer and blood pressure monitor and patient bedside examinations.","Peripheral capillary oxygen saturation. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: pulse oximeter.;Admission duration. Timepoint: From the beginning of the hospital visit to the discharge. Method of measurement: Questionnaire.;Fever. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: Mercury thermometer.;Need to ICU admission. Timepoint: During admission. Method of measurement: Questionnaire.","Viral diagnostic test. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Polymerase chain reaction.","Quantitative CRP. Timepoint: Before and after the intervention. Method of measurement: Lab kit.;Oxygen Saturation. Timepoint: Before and after the intervention. Method of measurement: Pulse Oximetry.;Body's temperature. Timepoint: Before and after the intervention. Method of measurement: Thermometer.;Dyspnea. Timepoint: Before and after the intervention. Method of measurement: Subjective assessment of the patient and physical examination.;Cough. Timepoint: Before and after the intervention. Method of measurement: subjective assessment of the patient.;Diarrhea. Timepoint: before and after the intervention. Method of measurement: subjective assessment of the patient.;Headache. Timepoint: Before and after the intervention. Method of measurement: Subjective assessment of the patient.;Chills. Timepoint: Before and after the intervention. Method of measurement: Subjective assessment of the patient.","Percentage of effect of Tocilizumab on COVID-19 patients. Timepoint: Patients receive the drug in a single dose over an hour, and resorption monitoring will be performed to improve oxygenation status and subsequent complications in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Method of measurement: Clinical and laboratory testing.","Mortality rate in first month from the time of entry into the study. Timepoint: The first month of entering the study. Method of measurement: Continuous clinical evaluation.","Reduction of incubation time. Timepoint: Daily for 14 days. Method of measurement: Participants' clinical status.;Reducing the incidence of Symptomatic respiratory disease. Timepoint: 14 days after taking hydroxychloroquine. Method of measurement: CT-scan test.","Serologic evidence of infection","The overall objective of the study is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19.&lt;br&gt;-The primary objective will be determined by a pilot study of the first 100 subjects.&lt;br&gt;-Subject clinical status  (8-point ordinal scale) at Day 15 is the default primary endpoint.","efficacy&lt;br&gt;Time to alleviation of body temperature, SpO2, and chest image findings, and time to SARS-CoV-2 RT-PCR negativity.","Stop the fever. Timepoint: It will be reviewed for 7 days from the study onset. Method of measurement: It is recorded by a thermometer.;Transfer to ICU. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Mortality. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Sleep quality. Timepoint: Days 1, 2, 3, and 7. Method of measurement: The Leeds Sleep Evaluation questionnaire will be used.","Lung involvement in X-ray and CT-scan, SPO2, LDH enzyme, viral load, acute phase protein, white blood cell count, ESR, length of hospital stay, duration of mechanical ventilation. Timepoint: from the start of the intervention for 12 days. Method of measurement: Blood and biochemical factors are measured using laboratory tests by an autoanalyzer. Pulmonary function indicators are measured by pulse oximetry and ABG.","The mean time to negative test to COVID-19.;Presence of immune determinants.","Pneumonia incidence on day 8 of ciclesonide inhalation","expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","The positive rates of COVID-19-related markers in&lt;br&gt; medical workers.","Assess need for hospitalization due to a COVID-19 compatible cause within 30 days after hospitalization through telephone contact by a trained professional, as it is believed that 90% of hospital admissions due to SARS-Cov2 occur within the first 15 sick days. The outcome period of 30 days was chosen to capture the 10% of the remaining hospitalizations, which are outliers, which will happen between 15 and 30 days of illness.;Clinically assess efficacy for the presence of uncontrolled asthma after 5 or more days of medication initiation through telephone contact by trained staff","Incidence of COVID-19","Evaluate patient's health condition after 15 days. The primary outcome is based on six possible patient's health conditions whithin 15 days:&lt;br&gt;;Patient at home;Death;Patient in mechanical ventilation;Patient in hospital with non-invasive ventilation or high flow cannula;Patient in hospital, with oxygen;Patient in hospital, without oxygen","Odds ratio for death","28-day mortality [Timeframe day 28 after enrollment status of patient (alive/dead)]\t\t\t","Status on 7-point ordinal scale","mortality rate","Antibody to Covid-19 infection [Timeframe 30 minutes Observation]\t\t\t","Seroconversion of SARS-CoV2 [Timeframe Day 21 Rate of seroconversion ]\t\t\t","Visual Analog Scale Fatigue (VASF), for fatigue measurement. Patients participating in the study will indicate the intensity of their fatigue by means of the VAS through the Smartphone application called Visual Scale (Apple Store and Google Play). They will have to signal in a horizontal line where they would place their fatigue, being 0 \"no fatigue\" and the 10 would be \"the worst imaginable fatigue. VASF will be controlled telematically by the evaluators through the Smartphone application. The evaluator will ask the patient to indicate their level of VASF in the \"Visual Scale\" application, and to take a screenshot of the smartphone to obtain the established value for VASF, which is calculated as the average value of two attempts. The patient must send the VASF screenshot daily to the evaluator, via WhatsApp or email.;Multidimensional Dysphnoea-12 (MD12) Spanish version. The MD12 questionnaire will be self-administered and will be performed at the end of the 6MWT. Patients will send the results of MD12 screenshot daily to the evaluator, via WhatsApp or email. ;Peak Expiratory Flow (PEF).  The evaluator will ask the patient to indicate their level of PEF assessed by Piko-1 device, twice each time. After obtaining values, patients will send them to the evaluator, by WhatsApp or email. We will calculate means of each 2 measurements, assessed by patients every day. ;Forced Expiratory Volume in one second (FEV1). The Piko-1 spirometer device  will be sent to the home of each patient by post and a telematic control of its use will be carried out. The evaluator will ask the patient to indicate their level of FEV1 assessed by Piko-1 device, twice each time. FEV1 obtained values by patients must send to the evaluator, via WhatsApp or email. We will calculate means of each 2 measurements, assessed by patients every day. ;Six Minute Walk Test (6MWT).  The 6MWT will be performed by all patients in their home, under the telematically supervision of a physiotherapist. All patients will receive the same instructions before the walk, and will be encouraged by the physiotherapist who repeated set phrases every minute during the walk. The distance covered during the test will be recorded in meters telematically by patient smartphone. Patients will be allowed to stop and rest during the test but they will be instructed to resume walking as soon as they felt able to do so. Patients will send the results of 6MWT screenshot daily to the evaluator, via WhatsApp or email. ;hirty Seconds Sit-To-Stand Test (30STST). Evaluators will ask patients to place a straight-backed armless chair, with a hard seat , which will be stabilized by placing it against a wall, considering floor to seat height will be between 45 - 50 cm. Seated participants will asked to come forward on the seat until their feet will be flat on the floor, and to fold their upper limbs across the chest, without moving it during all test. Patients will be then instructed to stand up all the way and sit down once without using the upper limbs. Patients will start in the seated position on the chair and, upon command telematically, they will stand up, and then they will return to sitting as many times as they could, in a 30-second time period. The evaluators will control this test telematically by videoconference.;Borg Scale (BS). The Borg scale, of perceived effort, measures the entire range of effort that the individual perceives when exercising. This scale gives criteria to make adjustments to the intensity of exercise, that is, to the workload, and thus forecast and dictate the different intensities of exercise in sports and medical rehabilitation. The BS will be completed by patients at the beginning of each session, and after completing the exercise program, as well as at the end of the tests, every day (6MWT, 30STST). Patients will send the results of BS screenshot daily to the evaluator, via WhatsApp or email.","All cause death (odds ratio). Viral clearance on day 7","Prepredness measurement [Timeframe at response date electronic survey with electronic questionnaire]\t\t\t","It is expected that social isolation will have an effect on the psychological parameters of optimism and affection of the studied populations, in a way that depends on cultural aspects related to socioeconomic conditions.","Activation of markers of the innate immune system (in oropharyngeal scraping: relative concentration of dendritic cells; phenotypic analysis of leukocyte cells; transcriptional analysis of elements of molecules related to the immune response with expression at the level of epithelium and infiltrating leukocytes; quantification by ELISA of cytokines related to systemic inflammation such as IL-6, TNF alpha, IFN alpha and gamma, among other mediators of systemic inflammation, etc.). Measurement time: at baseline and, on days 4 and 8 post-treatment.","Outcome name:Ratio of the number of deaths among patients enrolled in the study&lt;br&gt;Measure:Provide reliable estimates of the effects of these antiviral treatments on hospital mortality in patients with moderate or severe COVID&lt;br&gt;Timepoints:5 months","ED time interval [Timeframe hospital exit Time between ED arrival and hospital admission]\t\t\t","Reduction in in-hospital mortality in 5%, verified by medical record analysis, in patients receiving N-acetylcysteine compared to the group receiving Placebo","Correlation between COVID-19 nonpharmaceutical interventions including communications, quarantine, t [Timeframe no time point  administering online questionnaire, in-dept interview and focus group discussion   ]\t\t\t"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"17/04/2020",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"30/07/2020",null,null,null,null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"31/08/2021",null,null,null,null,null,null,null,null,null,null,"31/01/2021",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"01/04/2021",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"22/04/2020",null,null,null,null,"30/04/2020",null,null,null,null,null,null,null,null,null,null,null,null,"31/12/2022",null,null,null,null,null,null,null,null,null,null,null,null,"25/03/2021",null,"31/12/2021",null,"24/03/2021","30/06/2021","05/08/2021","30/01/2022","01/01/2021",null,"31/12/2020",null,null,null,null,"05/05/2021",null,null,null,null,null,null,null,null,null,null,null,null,null,"01/04/2022",null,null,null,null,"06/04/2022","31/12/2020",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"31/12/2021",null,"31/03/2021",null,"28/03/2020","01/05/2022",null,"31/03/2023","24/07/2020","31/08/2020",null,"31/03/2021","30/04/2020",null,"15/07/2020",null,"30/04/2020",null,"31/05/2021"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","No","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","No","No","Yes","Yes","Yes","No","Yes","Yes","No","No","Yes","Yes","No","No","Yes","No","No","No","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","Yes","No","No","Yes","No","No","No","No","Yes","No","No","No","Yes","Yes","Yes","No","Yes","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","Yes","No","Yes","No","No","Yes","Yes","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","Yes","No","No","Yes","Yes","Yes","No","No","Yes","No","Yes","Yes","No","No","Yes","No","Yes","No","No","Yes","Yes","Yes","No","Yes","Yes","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","Yes","No","No","Yes","No","No","No","No","No","No","Yes","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","No","No","Yes","No","No","Yes","No","Yes","No","No","No","No","No","Yes","No","Yes","No","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","No","Yes","No","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","Yes","No","Yes","Yes","Yes","No","Yes","No","No","Yes","No","No","No","No","No","Yes","Yes","No","No","No","Yes","Yes","No","No","Yes","No","No","Yes","No","Yes","Yes","No","No","Yes","No","No","No","No","Yes","Yes","No","Yes","No","No","Yes","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","No","Yes","No","No","Yes","No","No","Yes","No","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","No","Yes","No","No","Yes","No","No","No","No","Yes","No","No","No","No","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","Yes","No","No","Yes","No","No","No","Yes","No","No","No","No","No","Yes","Yes","Yes","No","No","No","Yes","No","No","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","No","Yes","Yes","No","No","No","Yes","Yes","No","No","No","No","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","No","Yes","No","No","Yes","No","Yes","No","No","Yes","Yes","No","No","Yes","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","Yes","No","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","No","No","No","No","No","Yes","No","Yes","No","Yes","No","No","Yes","No","No","No","No","Yes","No","No","No","No","No","Yes","Yes","No","No","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","No","No","Yes","No","No","Yes","No","No","No","Yes","No","No","Yes","No","No","Yes","Yes","Yes","No","No","Yes","Yes","No","No","Yes","Yes","Yes","No","No","No","No","Yes","Yes","Yes","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","Yes","Yes","Yes"],["False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","True","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","True","False","True","False","True","False","False","True","False","False","False","False","False","True","False","False","True","True","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","True","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","True","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","True","False","False","False","False","True","False","False","False","False","False","False","False","False","True","False","False","False","False","False","True","False","True","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,"parent",null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,"parent",null,"parent",null,"parent",null,null,"parent",null,null,null,null,null,"parent",null,null,"parent","parent",null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent","parent",null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,"parent",null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,"parent",null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,"parent",null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>TrialID<\/th>\n      <th>Last Refreshed on<\/th>\n      <th>Public title<\/th>\n      <th>Scientific title<\/th>\n      <th>Acronym<\/th>\n      <th>Primary sponsor<\/th>\n      <th>Date registration<\/th>\n      <th>Date registration3<\/th>\n      <th>Export date<\/th>\n      <th>Source Register<\/th>\n      <th>web address<\/th>\n      <th>Recruitment Status<\/th>\n      <th>other records<\/th>\n      <th>Inclusion agemin<\/th>\n      <th>Inclusion agemax<\/th>\n      <th>Inclusion gender<\/th>\n      <th>Date enrollement<\/th>\n      <th>Target size<\/th>\n      <th>Study type<\/th>\n      <th>Study design<\/th>\n      <th>Phase<\/th>\n      <th>Countries<\/th>\n      <th>Contact Firstname<\/th>\n      <th>Contact Lastname<\/th>\n      <th>Contact Address<\/th>\n      <th>Contact Email<\/th>\n      <th>Contact Tel<\/th>\n      <th>Contact Affiliation<\/th>\n      <th>Condition<\/th>\n      <th>Intervention<\/th>\n      <th>Primary outcome<\/th>\n      <th>results date posted<\/th>\n      <th>results date completed<\/th>\n      <th>results url link<\/th>\n      <th>Retrospective flag<\/th>\n      <th>Bridging flag truefalse<\/th>\n      <th>Bridged type<\/th>\n      <th>results yes no<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"columnDefs":[{"className":"dt-right","targets":8},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="fontes-dos-trials-oms" class="section level3">
<h3>Fontes dos trials OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-5065c577dc265beeff70" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-5065c577dc265beeff70">{"x":{"filter":"none","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16"],["ChiCTR","ClinicalTrials.gov","IRCT","EU Clinical Trials Register","ANZCTR","German Clinical Trials Register","ISRCTN","JPRN","Netherlands Trial Register","CTRI","TCTR","REBEC","PACTR","LBCTR","REPEC","RPCEC"],[617,613,111,72,25,24,16,13,13,7,6,5,3,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Source Register<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
</div>

</div>

<script>

$(document).ready(function () {

  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');

  // initialize mathjax
  var script = document.createElement("script");
  script.type = "text/javascript";
  script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
  document.getElementsByTagName("head")[0].appendChild(script);

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    theme: "cosmo",
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460
  });
});
</script>

</body>
</html>
